<SEC-DOCUMENT>0000200406-22-000071.txt : 20220729
<SEC-HEADER>0000200406-22-000071.hdr.sgml : 20220729
<ACCEPTANCE-DATETIME>20220729161439
ACCESSION NUMBER:		0000200406-22-000071
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20220703
FILED AS OF DATE:		20220729
DATE AS OF CHANGE:		20220729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		221120998

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>jnj-20220703.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:a211293e-c516-4076-a852-d6c27f4cfad7,g:c2e9e48c-ca8c-4ec1-bfd7-8d90ecda38c0,d:01b5d6689adc4498bfe63be39e352060--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20220703" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20220703</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV80LTEtMS0xLTcwMDM0_d6eb2da0-026f-4021-891b-f5400f9ee9e0">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV81LTEtMS0xLTcwMDM0_55b6af1b-df68-4642-9507-d3c0c7629e46">1/1</ix:nonNumeric><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV85LTEtMS0xLTcwMDM0_9541b481-cade-4610-b6b3-322e34dcb3b0">2022</ix:nonNumeric><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV8xMC0xLTEtMS03MDAzNA_8ecd8193-ad3e-49d5-b4f4-a5412c7ff489">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV8xMS0xLTEtMS03MDAzNA_016152d0-d882-4d22-96d3-de0002383a66">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20220703.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i081646bd651e49ccbec8525d32cdd1ee_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbb124a5ccb24559ac685f2e90cbaea3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ef6f7979ef4744b07bd5c44033c0ed_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if661bb2f35c84737a9a48c16676d08af_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554ee5b5caea422aab835052a7bcd38f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391bd8bf57bd4482a4a2ddc2a79b27fc_I20220722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b78141263e14aa589db463e889e3571_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ea286cb593414bad834aaf21a6fcae_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id28888afdc0d41829f3f9c4f745b09bc_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd15db9229e94c4ab701152a505a8fd9_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef6b87b8da34c3ab39ea64cec57d1ab_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c985e9590a44414b4eb9c785af847ef_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63678c9b15dc4215981671d3417b1d43_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b106f4f9be47ecbdbf4494e08f368e_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f63c6c6b554f82a78ab56462752f26_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c44097a42f4c9b8d26741faed5e548_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i675f9b859a9642f9980e206847468603_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d913e7414246628af7b698ff38c727_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b538347dc21414a92b3853037648c53_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i116332ccca294d499f773d00109c050b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e44d359c554d62b5eb567fbe00c74f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d0890b94dec44eaa3b81bc34fb36d8c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d2dbba5d85c4a23b5fe98df37e5b2f0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cfb8860f4a14a0a800de5dab7ad09d3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30ab88c7a9b24105a98e4bce891e1382_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a7eb101ecd248fa8113d9b3f69f69e1_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0104c40629d42e2b32ea4a3608507a6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8978590cb1f45bbb5dd3354dd289e0e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e13fe78d9384d259e35ea7a933fd95b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id32639e6970348639d64a785e7a5ba93_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i447127aa6c664afab9dd53cc168aa3e2_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb8035da5ed0409392b2294beb7ff4d0_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd9d432f47f643658a371e3e1029702b_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b98f47b14654327afbb7932046478c8_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18c5660480c941a989748af1c5101066_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c49da8cee9448c0a2c883ab7e653b32_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d9822830ad463ba8ac40ab5c36dd39_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab458019d3d5460183663da5dd757b6a_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e3aba93759e44e6998ff20f017b0ca4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i207dad082de3463797edacf5f0aca4ae_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia260343fe6194304ba1526a976025d5d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb7154123a34d2fb4812c12d8a88644_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ae55af07ea46c6bc94c11db48a7393_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i286c70d01444493ebbeeaf534a382878_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc88aabe12454cb5a6b8b3e1ffc291ca_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b85e73978e94a6e9d40658f17f4dbba_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1e83abddf294b49862a285ff0526959_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4644c94cdbe54b26bcc9d703afd57af1_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a97a3c30ea42378cd8743fdde441fa_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fa373ac3b69447baa5db15e621348bc_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a8cf9ad2e7647399248ae1419508e0f_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f8bf96c98845fea1edfe19f545e830_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b304ee8aa140a588288dad04e0aaac_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id26a9c75b7c94e1085843fc1e74cf160_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4bbbe18d2594f8aad55ae35a3d252da_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id28638ba3e4b42e1a64486cf30194fd9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b72b1c234f43a3b95f3f25252e2da2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3057d1e214724cb89a838867914b6faf_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc23407245a4376af9e0430687579f6_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e542b5e6c24d51a5840e549f120d1c_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709b7cc74ca74a80a4840c6c2463936a_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf76b5399fa64aeda445faded52c1175_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48d21dab7e7140dc8981cd34ec5ca636_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17734f536a0942538d393c2a2be78a63_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic46b61746c914b54a3d85958237e5f97_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b760074bfcb4cc58e6a1ae3aac3d6e3_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f129fa36664a10963aba1c422e6f76_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd623d33cd684c54b9e101ccb633f27e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3634444be4ba4cf2985688254d252758_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9480099d643c4b7cb1462c5d2ac5ecd7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99d3df0e7ab74f219ef244be03b7433f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie88ebdcc2bcd40839c3f8784531db588_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97621d82be79453e9fa3553e70d1ca31_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc8308f7d14c4181a0ae28210ff4ad62_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dccbe17c2b340f59a7b489aff4bfbda_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65844a253fd240329a7e6e0a74622398_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3261c0c12c40feacb473910d1a2350_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22373e19eea64b96965159ae548a3427_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052c717f8d424999972ae78c20e442bb_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70aee3ac261c42958695f57ef7aa8d75_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ffbcc5181264051a6e74314d827dd4f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2f3ae164fc04ca49438e6a4347fa265_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i426ece422f5943a1808350edaeddda4a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e20365cb144535a9cedca9aed02546_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife68bcfafe314d1496be2149a6e924e8_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c9b9a50530a45588281a4cf80ddebf3_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aaee80239bc4e2e93981af33614099c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if188f2ad192d44daa74ba7278a4fcc3c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae48c65d3bab4e199e770a5fcfb0a80c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab75f9b509940dbbb2fb9dead6e12fe_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da8d593cb89443aa125dde02cbdc486_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c67b5fa2091465ab9dc2693e5093889_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d1e66f130e549638c38349732d6b9df_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada32f8e1c5a4cfc8679d5181aba3515_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c4df0b7052471c8b4beecb6802dc5e_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf52c3ab707d4713b81fa73f99e93487_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i928ceff46ed841a39f43bd28f651f09a_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad78c3349a7f48d6a0d49345aca00641_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c77b30de27d45df96a8104f4525f7d1_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf04012d40344529ab914fdd97d47466_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61321ab212a84d638148bcc2c0db2529_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87adb12b544400aabac91ac10b55d9d_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacaa73a24dc34f44ba74aee3094334f5_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee1a2a6de5a421fbaf2a6ac76876bc0_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4f90bd741f24c46bc4278b4e28f7162_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9177a536afa141448d3a25292e1296fd_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5df6c8fd44b4cfaa5405658069eea76_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328dd4d5d05a4285b0893246ff22ab9f_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dcc42285b6142869767f28bbda885e9_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb5735d577994517bf90dd973a568b70_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbfeb1c605d04a88a882e139f2fa2b4b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia993599e0574405f95aa489e16792d7a_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f85ff3cb4e8499d8c86fd7dc882efb7_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1c9a175a9fc4cbb8ad060ba18633dbc_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ea95b17407743509a8e35647b738929_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc5f6a5fc5d46d49d5760c3a3f39b2c_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05aa739fc5bf4fa59b3b001daa07a0b4_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f501bd038344088354f3932536f457_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5664b5dabfd740a3b6f4396883d2cda8_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i408e7c6bfbab44228e55381d1839fb61_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i580cc60e6cdf496389e8435cc5955c25_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e8d90fbd49d4704baf0c8e5c9ca228b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96fc5113393f459a8780e466f3ff2ea9_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf9543b34dd4f93b96f68a4ca25eae0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if53d09453c094af1b92a936cdfbacd94_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f2db1557b74173a9cac2b055ab75cf_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf0b9936cce44a77872c14571dd9ddf5_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6797e39b27654b74a22b814d372e8d12_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i326883f0b0fd4a0d825ea9cb59de5804_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a97916e3efb46e09815fb9d03aa504b_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide58dcad79ab45bfbe863ddffac83f2f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6facbdbd9a04803b321187e1f040e70_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2561de1bd5d4cfdb3e9f49ac0d0ffdb_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45661dbdcb9f4e8c8661b5da47b3b783_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21556e9074dd4a0f8288063ebf6e970a_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19c220c5c40240a4954cd7dae60f584b_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice3fdb84972d41ab9ba4bf47ef5ce854_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf3885343f54fc687fd890f151c63d7_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i710f2081b05d404f86c62f35feb19186_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8399be3fe8e44b1f94bca7aff8b41680_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic84064d0beba43568502fa51c3264dd4_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237ab2105da9479f82802abf0e650c17_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i208da50d0b9a48189368d6e10d6a4fb3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f1f944b894e40ceba89ce94e11c72d7_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd6b67f063a14008822cf81aae590318_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce50b6f31f149f3a70237f88868b0cd_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f6dad62d53466ea010085927c81451_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib81964c4791646ce966adfc8c90aa7a2_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5349dd1284b14193a5715e5b6427c992_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc891ef4689a4994ac1847e71f539d52_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f13601b97f4c86a0a2ee40c14abae9_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1785c3b63c8c4e48805730aed53c751b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d2d946886f14b34b8cec403cb9ceeb2_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d77d7df0fc245a083931c66c8432fda_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc5d938e6594db3a5592348cbdf14b0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4271111bb61a42b8bc92b5628a6fa89f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42c0a6a0ba542ba87e204f1f199172c_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id61c7ab12f0d40a5b1d148b50984a0ae_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b395b190b6c40bdb82d652a413b2417_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0558f0c929e482384449ccfff5a6c40_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id002bac7c1ae4826bb20f0839018ad2f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia57bf4d1498c4d5a8f38143d4bfab826_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07fd826f5b134e9fa417cd75e225e819_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2584883493814b06bf0ed930f4028c51_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10665768ac6c48af85f34ec614dbc6fc_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i455ed2b8001d4cb29c1bbe414bfe1b33_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8f70882583b47f7924e55453b7f672d_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ebb8454e231462c9e01ddd2a9cd640e_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b9bc17484844788bb099a867ad7081_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5585c30b729c45f9bf242ad075fd7e6e_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6ff307f7d004130a7fbc2c25929d6fb_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5174e789a11a483cb8a586d1a51f8af1_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee1a9681011c41fc91369cb2a262d523_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2bb14177b1543589f7e2d2b40f3ed99_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i974d845b8fdb4e7fa0bc0da100fcb02e_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d11cbf312f4920a063822b57fb4379_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie465262306f745bfa8f4d12d012583ba_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i820748c0ee614ffc85acb984e5a8fa84_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic45c5d30ba924db5a64a324285891798_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58070284d45c4b4b97413c70ea4b99ac_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c5ce1a5044744c98c6fc083f0e7beca_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb0e6ccd8a9348ec80a99cd8c4672572_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02c147ca24594e40a66c2a2f2b084eeb_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib39755d463f2405bacc970b45155df96_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9b36b292cb1493bb900a69e5bd34765_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2023f668e54901b44a7ca21bcc4c7b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616a8d8561e148bc93cfff8d5eaaf83b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b1386668dd451a99e7f7cab14f56c2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18ceca8d5a1842a6aa3fc80736183e3d_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i061f4c2dadcc48f6952c7a8571f88284_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c793d1a04514fca815ddcf0b0cbcff8_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbdeb75dc07c40a6aeaf91aa2cb9a764_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd657c60f1a24c10a33422ab5ee9af4a_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e49767d9045405dbabb0ebdd3457dc3_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab0ec69a90244ff8a111f44c89663546_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00d9e4015c714d518f4373cf0ad3530b_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7423beb705924764a8f4876d7d961b65_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808ec468ce6c44538860a6822a475fbf_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i437b71eb938a462080e32d083a962f86_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504a09c1cadb41b2bc01218b05dd9585_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i489821c51d7e4e6692905fc0dd2b650e_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf37690c3b94285af307610b22628e8_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35b52ff0f6ac42609c258100f987af3e_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if668327e01644d82befdc0a8ab72e2cb_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0412d7e68cd949e69dd56bb1f8ec4989_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida1ae3624a844b4f875208ff051c690e_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7607c810ff1d4ac3b1e1815bf6afca66_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if214bf0473764e41a84dd8791aadae18_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd688062d5f3442ab9e3d49a23df957b_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19bd93d4b6414d7c80050b05ab626367_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ac16b6eb33a475a8a71478faa2b6027_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ib5ad0d9d40c440198c4ccaebcefe7e24_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d8e76325af440aa71852c405d16386_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie265961801c14b649e4aec89b623b822_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="ic73c4fedbb644223a20f315d7dd9f3e7_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f34fca0ba04ca781f7befcff5614b3_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7397d924e2469bb389835fe06d5b23_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c0348a7bec543bbb40b652ecc155701_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaea24750d14422d8bb195caed4c0fa2_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i517d31de7560429e9f6447755677fcc3_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f8f438d45649aaa711cfeee70572f3_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i714604558c6448ceac87445bd3cbe601_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6080a0f3af3f49e9bc2edc00f7c218f5_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5eac34b27640f79085c03f81117a27_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d83f40eadc482f9785a1a1e73ae1fb_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2422ade4dd254785ba67cf1997145fef_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24356a7eaa814e15a526f1f4f1dbb4a3_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6fdac95f174a9db30f9dde4a867361_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i932f859fe5004fcab7d388c3ef37b01b_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8500a36cb2b404fb1495e3f0cd34b1b_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10cb7e790720410393c02b3b71132200_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a981ac377da4942bd8a08b6b8f69e74_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f8a9e2e7444c16b12a3c2edb6be775_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f60341d6ee24828ac150d7fb989724d_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85954b0bbfb747cba4560e6bbe91083a_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd3188721d3496bbfcb0a0a1fcdeeaa_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i247279ce24df4fc984684a77a1afc670_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dd4fb1b88c34db49fc66928580f5871_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b5a0c24ecf49209b2e36a4c3789ba6_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i687f005d14ed416ba74831b5b47b4555_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7501e1e2bb74a89922e7f7a201f16ce_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90a8017e0214944955fce66d917c85a_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idab876f881cb42b3b32ad3e26e9ec7ab_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c198d27655479abef21848a7bba761_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16ab0ee504eb41599816d24c2113bc1f_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d05ba815c654783b44178265f82de44_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7914f4f7746046df9a737d4fb8979c6b_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id275d71b261a432c89901abc9e36512b_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc1e5091506483785afd9d275795a46_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d838b361e1428f9af039eded3b682a_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60dba65131c1437481410132c5ea4df7_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9048cedccfb40ed8e4d52b8f5430ad1_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85efca72771a40499d8082f58202a3dd_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i350a972bfcfd4efdb72b431248967d66_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f46a77f7992478ea4128962d4c9f391_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d3fb3a791ca414fa77eaa67cc99a07f_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ccb7e446b348588dd2f9516636ffb7_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a17432bed1945c48370b5015ddb5642_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id65c4c72715349aba29bef207c5ed392_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bc27cc5ec494407a381cf8b2d1d893b_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9fca044219d42f0971fb8ef3a32a6c4_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b97c77efcb43fbab577c42a6fbfc7c_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc2e3c1f9254ffba88d55ca0c4ce058_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i915b24d83829484ebf50c108621501e4_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec88f4e48124475a9632ff20fb8edd5_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc6c33b6176b422483f5f3ef6becebff_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd4e43d48a4c4e21bcbe809be40eca70_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53a8feaecb4246bc9b98605730a15584_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3d3ef2ea8d84db099d215dfe535ddcb_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib006c54c03ed480e9b393694820c92c6_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575934a7cedc4cedbde5e430befc2365_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05004c0e3cfc490cac8c08c422000ba2_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7614f062f264a8fa4c4907f54853e94_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea66b619cb3443197db56a50a304a6c_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f17d6898c04d318d57f363e7c9bf98_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1058600fb83c4dd480871a0a2a908496_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616df737a6e04747b5272a1cef450ed1_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d3e3e61a244a51b1d33daefe6fe819_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd5f7853d0d4ffeab0ca0c4e2369e5d_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30c41e781ada48aebeffcd3857c0fabb_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f5b18cb544467e97c5f515dcf98586_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f4a61e1d17435cb3f75c415b7bedea_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie81ee28385e645de81a4923e2eb9efb4_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92f0cf689bb644bcb78bfd87f8b277ad_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0a95408bdaa4b3782748bb151cab603_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27effcd5f6a94b389235ad25b18e2bcd_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia18fac953b8141dabab3475985def187_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78494e54f3114f17a858e621c5e6752d_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d8d0c23c594dd8a278bdb58b5042b2_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07459c41a6f843978c00a7b71ef76e9c_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7afb6fc2c7ae48c8b09189c72a0dd118_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b91038961e64c0085d31120a376145e_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd7696abcc3b4b91843a6ef7190f4f06_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33b7a271cb844d789cdf3dad5b732c3a_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i702f71864f5046db87e856abadec5a61_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59e59e4d0e434ad28048bd9cc5ed9cf5_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143c1877fac245a1b05d14212b80d45f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2daa8a32f1fc4fdf8b188540df1f7766_D20220704-20220729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68813d26799a432b89daecc2918201f0_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c6a26c3964431798d06c23223c6509_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62384ef644a54697aca04106e3f0437b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc2f74ef18d4d33b92e9d7d64d48020_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9717a3a8ced548948d10ecbb0f33b8c3_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2601e00af4474b03b245711113cf2975_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d1e90be3564affb9df03eb62cc401e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a55a77208474cb0a1becbbd53ec82ca_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f7f5277eb57456983ec4fe69703fd6a_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f6f63f466324af9a0ba713c475af49a_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72370e9d3ef64afc8247235db2a6256a_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb20df11643a4db4a4501af374b8611c_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8195ff1841b44360849eba5718e01652_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa7ba884545448a83b114bcc5344580_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b4ebb79f86444c5878078484251d735_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e5385aae254b489b7e039a2183a902_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bbf0047aef3405eb9f261a53967efb1_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26d715418394045bf2d275669c0c2d5_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc6d07570ff45a8a24f52ea1dae3e62_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ee1eec7950c4ef78e937d2c4e3298f8_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e9c8dc44154c0889a38ce4ae1cfdee_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b746d1f6934a38b36cc2f177fd06bb_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ab60eec1f141039a0d797a3f451481_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id334e2622b5a43608b68569880f13d0a_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c500211bc040d4855e6035ad051bf5_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01784d325404849937b0a9daeb1c938_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2ebe5ae60c49b0a9fff97883e882ed_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6d906d8c3b44108349d0c7ae0c91ca_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0621cbfb3ca24c87b649251bb892364a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if398f47ba6cc4d43b6d90c700176240d_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33319c8b0e2844c1a78f06bc06b7301c_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13a2d7df3c942ba9306523693e96af2_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaddb3c97163a44a0a32251c19d5d0ff7_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b62bea6d6874162b043629fa713ac31_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68089e150f524c5abad75d4bc0930034_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9095543594314e21a7ed013540198140_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if13101093f5447d9bc000921069e8423_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40a4e77c23874d21a2804eff01168460_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f309ab7ce9e47f6a93a24b6c21f112f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff5349857aa4a3496da3c8d285390a8_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d9cb7fd4ddb4911b27d35f071fa8886_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09063562e0d4fd3a2f72663c512d14d_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd7a688a72f4a6d9787219e5e029a38_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de727b2f6144bfaa64c8a53dedb41bb_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce860b4fb8441f18fffa07dcef2a31b_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed64e30f1e54509a52b4ad3abd15f77_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53177aeb7e124a05bf7af2cd65156f97_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c9d35d1483442cdb89d4315ab87c195_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef348574e5b40b5951363c5761b57e0_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i944b4a698ea646128ec4f289fc31f5bb_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5876de3f5bd4a6fafa27ffe0d10a9da_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18cce1df7be41d3addfa2391156aebb_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f715131df5f4ce38b709e366c8634f8_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f9fa20297e84900a134c648c79ed724_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33a293dc78794b8c84941522d362b2b3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ed86e0bf67442ab4bdba01c26ab3ef_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102548ebfc714d89b200cb8801eada1d_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib041fceea7e145b69657ad998b398574_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a72fab377cd41989bd7cb664b052786_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7718b305fa4e98af05f13ccd09b117_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6651ef9c1ac4edbb8cf6a115bf220cc_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed1bfe39b4e4bb5bba8bbdce7bdaa1e_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie744fe7eb10840b59f191d4ebfb373d8_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43d92d32a1fb4d1fa4667d39d0165593_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67c37007b3dc425b849156d2b344eb7e_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e018caf3a44821b6b23d3804a73e3f_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd7be7ef01a442ea8668894c4d382fa_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1d7a7b9b2a4248887b77dba76f601f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e407cd47704992a0317255189675b7_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib867ef751de5492fa15d45f7bf794438_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb71611308d4b42a6e9f2cd42a75c82_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i693bf3820634476c859b68b815574d1d_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78dde3c6195f4c578643c83727dcad04_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb0aaffa7084f09810c1685730156ed_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10a3f80fd7e44589ec7f14f0a2f9fe8_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cccfe83ac064549a7486973cb800b07_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e1f5924669f4a169c42aa764613999a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81ccc7cb7a9415a99c7f89e84017979_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0812d79d0004274855fe19590ad7dd0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8781a8fbd8814cff8dcfd139cc582995_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ffbd0973fa444c9b15cf063be1c3066_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6d698eee9664f599005ef75c6f73674_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fee31f1267449d6b660c897312001ae_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7192a0ac28bf4f76aa87147c2805f776_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f670f752605441cb46a46a85c79ecf2_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i658570b4166140dfadfbeea24c17c0db_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f83165908d14fcdb9fa9d202e01a201_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74eb8c72df8240e79e32ce252be20ff1_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ea4eb5ba9a4f1c803077ceebb44e5f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie50ce2e3f0464c71a9c5b8e469a9fa78_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c19f4191b1d426ba5408a30686ae901_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf51f604ce94696a0c9e9f86c80dcbe_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i228867d760f145b882a88a1d618a76f8_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecaa039dee6d486891f8d14610b01fbe_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e3c97cc494f4d5bafd40b0e6898cdc8_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04a8138535574b2f8dd29e2d2ab984bc_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i435910ace8fa4896a65a5f676869084d_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf527b43e5c64384a1fe49225cbe7797_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f36da8c5bd4d708ddc21a066e32df1_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i429afaa0d03d45ef928c1df6565d72ea_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84783ba4704e45429e147e9d5dc289ac_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96db2fb32064dcc955371ae075882e9_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i901108f0a04f4af892226bc6740b5bfa_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f056f7919a4853bb535aacc4a0cf01_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be3651fc9014dafa9dde9d16bfb5921_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1cd05eff2ba4e3a9580f155f072c389_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72b5f1820f5c48d2af430c445889e0c3_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8848b6a4264e499ea3824a825f707e78_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia486efb8fecc4fc8934c3d17358c54d9_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2010cbe9958f446584500182486f8c58_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d43b5d1458c418aace6f6915a81d82b_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66216b2932674442903d1b7f700d5d93_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22058af4a4044d0083e435a04e70cdc7_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce6642f7a9645f58eeecaec17c3aaf3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaca44e36bd354228bdceed07ebdda5c4_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8375cf3203764f32b355e4b3f1eed776_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87013a0ff92c4beea595abb9a8da5946_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1b43f5e37d4e2abc94f7b4529f8f9b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic461d711f25c43cea2c56556fcad7ede_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54580f240f0f45e792175de738dd614b_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbfafce4ceb2468f82b2f231481f3145_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff5db7fcd89445889265894b5fcd908_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9bd678a6f6b45f49f1ad8f99d6732f4_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica430109af49463a9ccc4038a1739ff0_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie308e8e3be304525870ea855ce38d851_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119135a7bf4e4b77a3ab7bdd5088eaaa_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79cb5dafd17f46df9670ff1449263941_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7278c069afed4a878b544df06a8f6fa6_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68d3d93e645c47b28b4e7046d008ba26_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i856a0c7b52a545e79ff3fe227f8b6e96_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia11c3e051f3640f48ab85ea94a59bcf9_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e9ebb6fa3f46c0958ce4ca2ba73452_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f6d9bd9cfe420eb311754a66cd6704_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e7322aee8f94298875960a274d7d725_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19a11268216c41a0b8530633effddd01_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeec2de848b7400c8f1cbd655a32fef5_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f3484c640948dcb33be80e3ab6ce4a_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5608e9bbae904b85a2dc6cfcb6fb8128_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3768e1c0c0144fe18b8421760ec7e5e9_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b39afcb128845be8ace8181351523cc_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c0e26bb5d8c4e45980858e3929c5f05_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee6054821eb402795176964928243a9_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496bda2ebfc045e592996bab0207f6cb_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb85facac1f24b5493bbfd6b7352b778_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813a1577af2d4a23a4349732e1febc84_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a68313ab7b046478534719e89e2face_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f537f91aebd4a4286209578f7c5aa71_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2caa599d7e6c46479b011171a2725a0f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf7e16d1d0a41ecae80c957ca6cf057_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e94b02a54bf4dccb3fed8ad8526a6b3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8485fb4ed0e431fa60a21304c9940de_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4212c615c9141e8b1d901365e40d779_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d619e3e7e91444ea79bc47ca3e226eb_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644925d4826546d3be77503d471f03f9_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0383c0ed08a340a0a7e28475880e66ff_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37e987627024b6a9dc1bc0795ad8ce3_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7fd69b06f674ad1abfb09825949a8f1_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5fc362f083407ebc59e3ab3a9ba67f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57f215e7cc34af3b9e4ed202855fba3_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22768f5a2f114ce2ab20531d2853362f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a0d44953e7140198cf5743c8f9bf9fd_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia648fc74bae7454781dfef132266663b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df360f1333340c7b4588969e82c2f00_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i889a1f92c9a540c2bd4c73d5f7491f90_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf53305e3b644b48bece17159e61f8bd_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6a42cf1a5db49bc8a0351e6d0e34b93_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic810c0a48e8743a59ad02500a4aeecdd_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4edb2f147a48b09eddb23a0c7d5ce7_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac357a41dcce46b8bac2ce939cdb4918_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d140cebad34e369cd420d22831ce65_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i254bd81a5b934d1da8ed0bb423ffd265_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82df753eb9a14110a4457fc71fa570ca_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa982fc8c9040bd9afdbedde483a631_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b329b805e8241389b4b59c22a25fed0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b5a3356d9fd49bc8b3e5f75cc325bd4_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ff638816b949f49434427996afdf27_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa077604d394f2e9da2c45c7c1f570d_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba42deda339d4571bf02c560ebf58128_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb0c7aecba784a1ba368d125cf5ef87e_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecb92120191540b08b3e1547d87f071c_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i451bf253d3fe4d909fb3822b81e8b8e7_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131b62957aea4245a2e4f40e80b92785_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3edcdddf80a04d079d92e9eea316d11a_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b150cb6ff444a02936a3d237e2aac00_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ae1895ed4f4e7d8ffd5e113242fb46_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58cdc6aca3145fe9c3bcad7c0f6caa3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a04f60e80c410ea3de2b7af02a2047_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4eea102b0f843ce9148053725724350_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib21ebd581b69464f935e36c4077fcfe8_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68320c8fb7d9415da27ec1628fccc3a9_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied8c3beb651f493d825692e877822643_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a77ac5cc2f444fdbd37f54e3f3763e8_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477ed121b34f408288a548d3dd53cc95_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf65e5c0ea164fe9851e44a3c5176fea_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867589638fb74338a731e3ec601b44f7_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833b35d6c2414dada6f601d238feca65_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51cf983137194da19e1e0ee43f86f2e6_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a964d08b0e4123a5c734a55c08768b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0be555378cf4bc7b2c312db80e53e0c_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0703b43478466cb628ab8efd4070ff_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c83561616a848de8a12e6750c8eb1d4_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfe7e4eb68f4542a0694c4e9160e4f3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f9e9151965a452dbb603490e84ec8d3_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia064ab4c0e6f48f4be4e3fb8e412913d_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c4619bd414a4f4191ac0846d8ada2bd_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied852099577c4b06b69b158e06bdf30b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9748a1cfe0ae4be3ac0b1f755e7a71bd_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610bb1c1ae2941719016b00d983418c0_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i545c78bcf6864df7b8f8c7f3f1874047_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5687d376693949f995a3364dc24a36fb_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie177897f7a0e4cbb9fc1ae70b3de094c_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2d49cc4b5f4e3fb983e82500551388_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0743c16b76bc4a4eb2c7f09b19fb4d77_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5c01877918467fa667de5c4b5a1e4b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8432ba6c71b9494d954af4cdfc975370_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2e8ad7b5ad474990841305b1f44bf0_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e2297bbc16743a6af0a9162f757bafd_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63d56d230d06461fbbf797c27c6ebf04_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf382b886c2c4ddfb2e4f553d4f3aa6c_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ae5da5ecb6c40da849942dbc851b857_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i881a26ffb23941f7b130a2daf70e1cab_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b81754b34f1429a95dcde81ff323530_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ee23c86245486ca886b6aee57831eb_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i233aa02837fb4f0fbbc523316a35d3c5_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8c24d1d48d4f6490558a822b6c2921_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37807e01372a4baa8332eca83c82dcf5_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7989fc025b464111973e629161e2434e_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892c07bc3d55496bb0c411f6c4597f9b_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if533c4ba85374d80b615f4cc8c0ac77d_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350d006de9494081b89834d206e20b85_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c986ffb2bc4b73a03b90d4d1e6e058_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf2f6500b8d47f8bcd2e1f52815ef65_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e260586dedd4093a608d4f9e119e9f6_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d07ff2062fb400eab890cf3cde739a0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb100c8ad50b4c32a7486560779c59c7_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8eb6f559d024fe9867b516d3d470c90_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3128acda5249f7b1aa270169630b2e_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9bb08a5cb64471bdd5fa7215d3a890_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0939ae8630144f4986774c9e0e93db3f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ebcc5ce76814be69eea5e381ee927e1_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8cdb6868c7c4eaa83b08096e087411d_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70d8c0890db5470dabd162468412c872_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if270f92cc3864c79b2464cfd5f2f9ea0_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64083077365f4393b411e13a8d829ba5_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24bd17706c8045b28592622c702e9945_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2fa6af256364b8ba090796d8cef039e_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c7f3684e96430cb08ceb7f25e639b0_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i821e476b1e124c3da418c0da884873ec_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9867c33d4e041e39d64aeb94ca7220f_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e9055569824947bc8a8aa2e70f9c21_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa6b7234499430f8a3da6a879bb9820_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c551506a1274d12b61d0b0bb6a17e0e_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c0fbf4de99a4afdab1711dbfaae9849_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee16de5d59840c5bd123a9e5601d81d_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f474b0d055142afacf952c297331e99_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b1abcd0990401ca49e18dbeb437c17_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3ee672bbd7141948b03208867985b7c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f190476843b4d519e98652aff7a77fb_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36139166d5b482eb6fba5b9c7a5dff4_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc2adbb26c4f4169ac3ed1446c0047a5_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a8333f41594a4ea74e78b5265277e8_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33af160294004e19b207a7f75170082d_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dabd6e5fadb4ace892027521ea05718_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381a4444cf624dc6be2aa2fa0a0a3659_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9404903e6e74429b27dbbdf8d4ff248_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81967cf9960e417ca2396582624be8d5_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58cde252d1f4e799a3a302ee1c41607_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4616b6887b354b9e96c3d430604d3c42_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ef0d86dacf40c98cf4e5607785cedb_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c58a72b8a448dd98f5ac9d8f55ad47_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f4c25c27d346e28d79fffe1ec89849_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9db6a1f46624828bc4b33dcc757c82e_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabdebd8234af4a4b9621fb3ecb624d8b_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc179fa1a480426cb4fd0d3d966e2f9d_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i331342035f8849bab17b1dd2debe6771_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ed53bcf088487b9c9fb95699fb4684_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a8381b611d418cac230e38702d6256_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a732ecb6ddf466da949b0e4f1047c8c_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8467285a7fb842329b2d56b3c68bc6b2_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b0e21c3cb246bcbf7a18d3394d1fc3_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11e7b7ef58fc4d74b79a62f31f63b60a_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec84871b973443e4b3a3810d110bc6a9_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05deb876f009412dba8fee7b750b9a3f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae486921d8e2413a95e450c0a846f660_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084e1532e11242b9ab8e982e98cce345_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2eec65477c4cf6b0a2e012668bd440_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0bf55fd1f5940659534d3655320b2a8_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53cbe5667f104372ac5709b96be56d7b_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03d9b2307334d22bd42f69770c03cbe_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c787a1466bc48398971fdb66dccf821_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a6b0b9f19b4a3aa3d549fb91013f6b_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee8ceb7982104bb097677e4f08cf19c8_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic935596d94fb4f8cbc7662516ebd2337_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74032420b0d54f859aa6ac4ae4cb6092_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i628c3315204b4c819f5612c6ea0f76c9_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i489d0217d95349a09e3854a159fe1e20_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia852ccdace584ca893a3f9fb3926a08b_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ea038280ba420e8b3e85334bd010be_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0579266bf5fa431e86d0cc99966caf96_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf0ee75730ec4eaf8b49daa1a0982cbf_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9208998ddf664f808ab029146e8a7091_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93dc841f45e74baab367942431755f0d_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8abc2da8c3544d7a8631b23ee75d1876_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615f22ff6960415c94431ef20433e83c_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271d0e8006734cb381410cc5d646c7e5_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b08f5246c2483c8916b0d18a4cb899_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4137bbbedc454ce4a1e326ab7eddfed0_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46129e353ad84f39a366e43a8ac98e0a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7a134dff79c46c1bb7e1c0967197d54_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb851f7c092f4ee3bd18823be28d76ec_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f4755679550432890b18a7d35fbe2fe_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e47d07acf0a4b3bbe3c60a9e96bf4f3_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9f53949a41d46ef898ac80d318d4189_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2284a61a0db642eb9a40b3613d8594d2_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1379f0be014f4ea396ebb2effecec503_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i426a47a9bb5049e49edcb30d41af643d_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie71f54f5a529400e992bcff94dd82726_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i130828dd7fbb4e60887d19e7e530c789_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib90029a9516f4591902efe683175866b_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e7b1fc93c648b8b4e52538ecb02755_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea982946629432694550a8492f1df45_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba1c7b633bd48db874857a7afcde3a7_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5808bbc2a03c4b5bab9390a5f8f31033_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc0c50a7dcd74d0db255eeaf0c492416_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i387b27c79f194d799d0479f8a64250d9_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f7fbaf72f24eac8c150dc42468daee_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8419c61da6e9446b84344e772ddcae1f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bfa9586158743db9a0c50d35d5c3e89_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i592eccbed0a44157b77b90479b36ff12_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0339ec3d81486890f895801d2a05b3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c10bec547049118934a57af7d55e71_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30dd2aba0a4a4cd58d61a14fded9bf4e_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40056c4ceeb846b4811bce1524b88e28_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4acd16385e14790b4257cd1e30e36ad_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28e28b4687a6462d8f2d01ee02868bf2_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406d7f79310444cba9070d2c72c8ed3d_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f9ae73e21244184a996ccfa27a0e0d6_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe33b178b5f24c92919e80285cf6ce87_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a022bc19634f4291caec90e24c1e56_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8fbf93a0d984f74a4c18b8438d93705_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e590252c39f4b69acea8c278aaaa6f1_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d89ac93d3541048345e457b838050c_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a77e4ef832546f095278c7e2e4cdd06_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53abdb7bf8da48d28acfcb3784400145_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1508e902d9b44570a06c0b42a8e602df_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b50ec6523c84e019fd0db2f7ee816f9_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5d63678be1842828f166c73f3d5ae66_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia254c76d3f8f491097090592e479401a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14d651799574575bfd8abdfa9223117_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aaf1d0c5d9848a8b48f4bd785f69d6a_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fbc96ca92fb42cea0ec295a49f4dfc5_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb3058cd0a794324aafc2a3a3fb3d32c_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06149290e1044e6681818593b0e3b54a_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7665d8acf34544c7bc3d213e29a403a7_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b2aa9141884cdb897069ea96225219_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50642add27bf4a3c847f19d7dcc1fa55_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1878b6e06b6d4e8fbac6886000f181e7_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e1c777f67d469aa4c5d82eb4cac8d3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a597acb37e446f8a4c956653e8bab3_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c828becc5644f42afd048825810abaf_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fea4855dd1f4faabcb8e2d17b561470_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f53d151fe8347b498763fd23057410d_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be7291502c242fa9978dea11ad9818c_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc09d2d675884189bc0ba76a89d7113f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89dd98c72cc84fe1ba6b852522d18a83_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aa4bd06b9544485bda39398396ffcb0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaafcb61ea5b64eafb32a7afa38475c33_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d20d851bb704983b94a0bd5e2bf8063_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdee48ad66d84e4c821395f425508ec9_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29866d57d1454ab78e5a90bf77a1bd34_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d781877b74c43629248df91d29e0ac3_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i287ae97dc4bb452493b5178c62898f36_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffbcf7aa3c2d4150a651ef9642bdc10a_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc239cfb9ce0485982b4ed133c7bd657_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37914cd1dccc44c0996e33a397571801_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c955b2727464d82bdccca98ce299c54_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0328f187daa42cebf05b6bd3a2f5dae_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb153e375c54c7eafcbd065d7b6af94_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7f501d0f4a749579b31839d170e6acd_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53051d91ab824126b4235ef16cb6263a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i051a1f8ff4d040a5a7eb2d6081274333_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ef09cd80ce48528fd4e15b267fa581_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06739f6ca36d4acf8527637cfd8a8414_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2195e9ea8f74827888df91311e38634_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie560385a5b9746bfbc9ecf44f08e40b2_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c14ab77a3f4981856f2e47e937f928_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6e2da82b9524140bea1c1e3e0376373_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica029ef15f3c412ea7f79ededd61891e_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if38059bf51b94495b9e558db7253d6b7_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55223f8e057b44348303589fe6a6d634_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1da4c3fbf5a45588aa47da0d8af5515_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22eb4caafc674003b9ed0fe8faa1adfd_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa53a4d85235465fb23f952022ed2de3_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d1ebe756b1a4fdaba163f6226a73865_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib38c14e59526462aa00b9fdf01150b88_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ca4cedb5aa472d978a64ed56e29c3e_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50df75de55354d31977579bd740f47d0_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb8526f11d44a7285dcfe44fe83967c_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d92da1715d4466934af62c118acd2d_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0236b7aa74b24bf18b2ebaca9df2dfaa_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibebde257fe3c43c099d64ee47d4049de_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ff9ea6230d4739b53a98d08fe59cd1_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i557f42df940c4b5ab8401d631fbf9c50_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdf3bc11cf184431b734d51a51999f44_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05790066f2a14f93b4be920ebfa71d30_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f0430dcadf4801885432b12fc09d25_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b567ecf14d4468a81aeaabef24109b_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25a1a2d1f27b42d4804ea393d24ea74a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d46afbf8ebf4c85a615530f2f6ca89c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbfa29cbf57143ac90d54acbc629ab41_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b934d9eaccf40c292408c0121b1ab1f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6b191b04cb24993a324572ceed1a094_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd72d040762453daa0d7e628045ba1c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39d2198e5ec0432fa48695a07a06b16f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb17e60efe244f14be98a7b086a2993b_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic801c7ed779a4b89ab0b1c8ecda3f3c1_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2cf187fa1e34995ab2bc76d0f9990b1_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eefdcd0b36f4eab9f7efff9e9bbd8b4_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2207e1597d44adb9a60324bef5417b_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73303bef5d5d44fa9de21fa225eb70b0_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328e26ff5b614b91acdf8a791462b459_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be86e56935f49e082bc5a14e5f2756d_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fffd0e4936e44f9ab0a1b46f12c274f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic518c8578d7d45928e9c8d6d8f5afdb9_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11d6a998a194ce0abd3b90c4cac5da7_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d2a4965d144779a4ceefbf2e67dda8_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dbfb604e8334efcb004e1de36bbe2ba_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a5fe4bb174446db8453acdb52d0b8d_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5868064a491c4c21beda0fc35e2236f5_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcef923095ae403daa45a3cd38e272eb_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2e614016aa4c27b3a18c5a2bb1d03d_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d4961fbd434dfdb053a7619753dbb5_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5288342ca6544db84e6afa56ec57667_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f2490c0acc14641bd54b07d1a9dcba1_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8201a9664e94c64abb84f293366b311_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a145198034434d8c34cb328adb37ee_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa58911049db441c9be14900db7de10b_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92942d5c5a284320a4d0d4db266ef84b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13dbe9e6430447a283ce3f28d7a2cff3_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634a6971cc2c4ab4b880a9dc1245444c_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9198cff7a66447b9be7b837f342aaf9_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63e2dbe91cf1482c865a5ed7f20252ae_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280edb799a7541e4b978e766002ab0dd_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df7fc7846394d8cb6b3dfa190ddbeec_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4358b89737469c9a4a76ab01d38b21_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748c908553434318bab2f9e71aca0df3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d7d57cfef704ed4a19a72497cfd1cff_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07dc3cd22e6141a9b58734901b2bcca3_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib37d45622a2a4e2aaf861e5d5425dc36_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5736eee575b44f30b0528226c5b341e0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd466ee6375247868fb5aa1fe4cf6baf_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453e566b12f94b9ca1bf28f9a151ca35_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac7771dfc5043b3bc9fe3d75e90560b_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19b54aa8f21a4defb2e212647938d507_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0430efa680354f9cb2e7be97ad4bbd52_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01602ac9da834941912114e1dd805606_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2018aba666564bf1b4cbefc426636cd4_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica2b3030232242349c0d22aa237d5dd7_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10a4ac80eaa840618cb738116eeaed5d_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia46733e339864c9abf57c0d982aa4ce3_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic649a922ce584f0d9a52986e9dc716a2_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab330b638fb84af6abe1d5d6ece91457_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ba7b8ae8c0741bc955d90fcc7f5d900_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia03b1fe2f3c84cfcb0bb12f78e27dfd3_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1878e36b1da48ddb9bb5431f67577b0_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dfc5851d11944dbb13e597eb1fd2070_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62985e4313f041be8295862d52b0fc22_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i637eadc895304441993cdbadddd0035c_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a3c9a671634fbba070e5002be64b8d_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd716f176c54a4ab7a98be713399fc0_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ebdbfdd7008486e8f029ba89cadcf10_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6daaee3c30874bc79deda2eecad2dfd6_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75726cc4c32942e7a189dd026b7e9840_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78908a1d4be846b8a6aced964d30ae02_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ebc6f14333d4c1388255155e8187c1c_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia43954139ed84f7788fdfc46187abd9c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19a3f4ca28e54311a8fa6ffc5adf57e5_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f9cf052510468ba9fc81d28838fd23_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e9a42189a364282ad35f4fd9c4a7727_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9144df0a32e4cb08d0e4aa2404166d7_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb3c8f804914aacbb20f2e7f625263a_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c37042917f440519d1e8bc9992f2fec_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2629a235c24645959df36f899307dc_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e55ed4369874656b82f600d8374ab35_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c61d257b050413a9a5a10d395f54aae_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda8eac58b0944c9aab3bf2cde640d22_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc7392d00fe4b7db44b1ba0ad3f51fd_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9843005d574706b3acbf5b7281d78f_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab78a1c95a9c4ab192a4c1a1d997c9ca_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776c543649cb40e19afd5abe8d84c755_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08070e9deccd401188eddde752dc796b_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i097c8aa852634e928b7afcda7183e13c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i574c9d60d2e44b9cb58117accbb26f8e_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i288b2f784c3e4914ac7711b5f2478340_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d97ec6f67842ab9cadf89c6fe46eda_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84032433ba9a4c7ba7a5e2b0546f0df0_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a6d6bc6ec434449b8d91b39d96f7fdd_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4db29bb20ad146c98f52bdefa9efc026_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id86625d8b1c144f6a7fcb9b8153032b9_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia123fa54d1184c2aad6e71ad4bae91a2_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65c45e5237224a03a593f86fb93b0f6e_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if310cab52cc8487192e4cee2584a6967_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da796b8ae144afaa39da1574f7ee62f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3333c58c0224485a25259a31b39760c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d0ef2500d684d2499aa554260f71a9a_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af9ca056caa4bd992cb4135170e25b6_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief64ee8dccfd4858bca89783721cee84_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i535b8d9ff9b64a70bf52d430da04038b_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7b0bfbd8d946e583f91bdff7c13a2f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d06f779d4c344b5a71fc394e5493ba1_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i488ea6d5e23043b399c268075239f4e0_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d8db5b819f845cfa20287368a74625f_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i308a3a88c11043999761321424b73595_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68b8bbd849704bb8a3082cf7ddf04d68_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib50f737a17604260939c66ca049ac180_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff780826f8d4410fb949c193f8b1f46c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7919279ca65c431e8605adcfc55e133c_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic304b1ad72744238ab93ae9de9dbbf07_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9722068a2d428f869481dca29dbdfd_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6fccf214b6547379cc0f5be19a827a5_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcb2ac2edd4547409e4873be0e8e70d0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34444c4d5b245d6882f29099655768f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0963689bca64f6898d7b2bf22ef5fc4_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6077b503ac1a407ca0aa969ab1a53c71_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc182ac674a40cda02a21659912b0ac_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1100853d86db4419993b4d34aeecc26f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d2f83c9f3cf4e93b4ab482d7b240b68_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff83048ffc448809d919aa3cc1cdbf0_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0000c4d098c643cda7e8da1a1ce56862_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dfe4776943b47558791ca89120c5de1_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0128c7e2dc824abf8e6b5ba3df4232cc_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic831591b74d94d658a1c241551842979_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideb8786f17a944249a713999b3b6e208_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf46a55a1dca41ffa4b84ec847aa7e7d_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i722cb51aca1543c3a7ae3b0a6fe127ff_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf6e5a27a774e869497e0aa2f53c5b9_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia015295d7f5a43dcaad4e1a68cefc54f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5400f99139394995bff032d46312fcac_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9845531e1544cfaa60c21e5946faa1a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7cdcd1f2024d52919c1a2b418c162c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1743be59d8b4610a3d295d501005cd0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef90bedc87e45cea6e49532d1496f6d_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3287b402551c4484b394de8276d293f9_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7662fd5ddc4846a3b1818f333fa21bc6_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a2ce0616b7406aaf58a444927e2047_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib532fb9422ed4614a1eecad8c8435a75_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc1c765754d4475a879977b61883766_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38876ff942eb4950811a685cde835ba5_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia710ad7cb9d04f4184dbd32294cd4f75_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25fca766f96443b785e425e523fbce14_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20dcb86296844dbda765eb7afdc78e2d_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i157d929ac5794703b29ad1b3d0e06f2e_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1993ccddfb034873a36b94a7f7017ddd_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4c53848f34480d9a9a1d516da71087_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b7edee30e3d480da3deca7eb3ed8837_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i908f6839346c4686938c7732821b75a8_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia717abc404b146b3a20cf3cdbee20322_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8fbc02017884ac9a57e155715db8909_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d39404482e4c219c8780425fba1375_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic64782304ba44edc84ba60d27fa2279b_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31026e003cb1415fbad582c204df9190_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b0b233fad44191b424a24fece33b51_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a4466b00cc249fb98151e07aa84fbad_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57a2012297b041c7b1efa586c301f494_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97c25d98536140f3b69ae8c88acf7a37_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586d3a14b6c740d8844f2849c4eb2582_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i443117f5e241456285fb9a55936853e7_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie01251da528b4f90a10a4142620a65cd_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bfe8df60f4743ec99ca6904a5e64756_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27fec44642f34c5099c21747e3250cb1_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412aa3432fcf467f8fd19c46b727c491_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia390d2427f664929bec44ea56be4ec81_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8baa768ee1284c7e99d6ee829ff2c08a_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e11d4f4c34c41b5be8ae617dc5e9c1d_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6fda5fb73a341449bfac9d8fb7a268f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed73e5ea20c4b98b366ff0b993278cc_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f8de01c4be45768b397e71429b87f0_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68e9b1789db54a1992eb64fc846195f1_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i569ace16f96641559bb1b2d217a5f3ee_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3982de94b47b42dea86bcede03224217_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e3610796c24f389098231002fd25b3_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i441e7039e08a47fcbf82ede9c2ebfbe6_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i324894961943456d92139b57181b5bb9_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i281e3cd9deea4daaacf98eaf97ea934e_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016776eee5714891a0386a16d5557a03_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i747469c41b2a43deb3981557e85294f3_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e1c7c7e8dd48959fd8bf1743fc8e80_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a2fceceece40e9b7f64f083218ee49_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4bdb0db58854e95a85e98d94100f662_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ed2d31b27e045ab82b125179a98301e_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9584ac8d54c6468f80de0bb9c19b14e8_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0672b25c90a4d09917d157086a6428a_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9696d83a57d4dacbe080d0f1444e529_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b1a88c0fa4b44b794e579ac382449d3_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a92fd5c525643629fe7ff73a1af3c2f_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bfe3e4294df4883a39ec285886b1913_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib37fb7ee236248a882538282edd2b353_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f48482859234f7bac2ce55a3818dc23_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebbec59e0ece4791b17dcc2fcc6131ef_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f938a541ab4334bc462b1f7fa4c89b_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d7a46d82f594dea958391e3f85c7adc_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b88bda5d09242278cca53b9ca866611_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11f87d928b364165a9ce065e74fb63ce_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4109ba0613344384a303908d2b52ff33_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39cea1d7d42a46b8aa131cde5e274282_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5523f7460fd948f08ef26a334123472d_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie01bb5db42274474b71ecf23309c444a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc6145fd3894d74b3ce85f802f90390_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f4b2747819f470683e7967d8ae774bd_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8edf9410e7d643b19bc9451e934d68de_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ce7bb1e40a34cac933a9900b74f1bbd_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ea13492db24868803369c77f57b645_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a69a34fd0c94f13b4b310835aa606ff_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ee68091377424783ed3c9953196597_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e33c4da904049bc8c9bfff387e3375d_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36ad544dbed4b9fba4cef602aef272a_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd3cc31f314437293f6c8d05caf543b_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841ed2eb0fd747d19d8bd3831cfcc965_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1267f9a793dd4838bee913c7e7f1bc85_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57cda4c770ae48fc874d0e1e0a6aa499_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce8cec453c54166a59e25d4837a056c_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0dc3d45f3f941dab28721d910f5e49f_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f0cbac43d94b8bb57a7d434308ab35_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e8d4536d8e4ea7a2ed2551f3af3104_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e8a3362cdda49a18367d18f349e957d_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c08b8a10da4041816e159343bf7063_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39103b4eef404909b321cdc17486f7ca_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc5007223004e44b9e3f6016636f4eb_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6180f4c8a3a141b0b11ef6eea2dd5c8e_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee0e58c2ebe74103acd746853588d46a_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id809ffa3e19b46f69f68ae5cd89fd702_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c0ab60765214aed9b7662351556aa75_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95dd4291b011442fb7dc8d71ff5ffe4b_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i719a66732d7f469782333e22b8bc190c_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2da2b15d204fb7b695aa3bfc830f42_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b15286f874144618839786849ea1437_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6094ef6600341388845fd981445402a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90adf511b62e43ed9a3312bbc6ec0892_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id349b0a0d08341149ec80073155e33e2_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7da5b6f21e243f1acad5577402788da_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaff25a8ee4a446eafc7e7a139993836_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61b390e9d694497896d1ac279e6a0013_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529d608738614ae0a943f58551da20f0_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06cae828408f49239c6f174bf1c334a3_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee05ee77bf344a68295fa0ac185a55f_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d86df693ac4fec81410c7eea2535c2_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd132153d9614629bc9c8135b8b92864_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e2458177a343e08824dfb1c6bd2f07_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bcfd345e66e46298c5faf33123c8744_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2da094b787c4b54b4e09b39c3f9a9f4_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9a7ebb719f437a941405e59e3f7376_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a725035e4c3410583da06507280fe59_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83d3c1f4234a402fa97cbd81b084f556_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ac66e3eb004358ab735bbc8456405e_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6b7844077b4016b45ccbe380ad3dc4_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2790d59614147c487677304230bb1ae_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8084c9e8e16045e1940be548a1af4fcc_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i501ea63e8e9f4d7d9d498ec389c88591_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i241ce185147a489fac065e3d478f8bc6_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5646a565d4a4fdf8f17b8e7a2cf4a6c_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c7a6815d0144fa3bda521f8ed93043c_D20210405-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia685c80f08574eeea6722e02543f738a_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9d069efa93465f945738a484e31e5e_D20210104-20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-07-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf1d14a3db84419db81e75d0179c01b4_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="brand"><xbrli:measure>jnj:brand</xbrli:measure></xbrli:unit><xbrli:context id="ic932039af4d240c09dba004300b0fc41_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d9a072c24d944d79f506df951a632cf_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:context id="ib832ec9b9cd74a91bcf4231b96beab4f_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f5f7c43d3a442a99a3d2ce435c696ea_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a31f7f1915d4fe7b8465e43a6596732_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ce6d2b512174db89a47812c9123ec44_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dabc10483784643822a9c5e7bb9014c_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa4ee166c8fc4dfd9a75a228d52f75b6_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6d7ce367d24bdfac85e944a0140905_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4db059902da348b3b536a571790f6347_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad119c0eadb24bf6b712a9ded64f1721_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>jnj:patient</xbrli:measure></xbrli:unit><xbrli:context id="i2a5fcff52eca4e2b8f7fd71362e00ee5_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cases"><xbrli:measure>jnj:cases</xbrli:measure></xbrli:unit><xbrli:context id="i5536e8ab75ef4a8ca62f7e1e6d81a778_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ba73cf6d5694c16922acb99ad67a259_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e4509ae1e9143f38c795c4c1718372b_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife017e4feb734f059e4eacc8da2b9534_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ba4fdb7eda4a54a9874ebb8569565b_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic69e838063cb443ba0f1e022744b19a5_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d9d11122c61482b9e49c7ba615148f0_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a055a5688e4ddfbc8c0852cec70dc5_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49377ad3634041709403a2a206d30a13_D20220301-20220322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jnj:RasmussenInstrumentsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i858a52bb013045799d07f07aaa301efb_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifce5aacbfc3a444c920acdbe2b4a1ec5_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic155bb14d5cf4a6ea37fc5c8528e6732_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec2a84c793b4a13a9cab4e12fc62921_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>jnj:claim</xbrli:measure></xbrli:unit><xbrli:context id="i888c4c1d679a40f2b81b60328c1858f4_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ef62a6d06b427d93b514f97600fe84_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb991236eb0f43e0bf871925f4f3d04a_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52eba45e53444e1298c1fcf2a2216b36_I20150430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e4e74ca66f8464690742d705f7eed8a_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefca38bcca5c426da7027dede1f04f08_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fdef417221f4a06a85755418e9c5222_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3938fca19a4ceaa24ccd83eff70370_D20220404-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73608594f8c3424eaa8ff95295134a24_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2909b6c557f9463ea81eb9118d4a4049_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i480b3ed870204b9391f1887a57cdae32_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74fe313c94e648559666a0a69c919630_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f129a7dfc034e9c9fe9ae8a3c42730f_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c3d0aaa08c34dad9c998070ad8755bb_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc12874a2f141468d294f5edf304948_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if65b6db0f8484a37b25b57a750fdd0c9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5042a6771a2743cfbea81abb2c4f0489_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedcbb46afcdc46c89062dca3aa694438_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c99f4219f554853b8e2459b665c0cb3_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38a9e37a55a9465296ff97bfeb4dbc2d_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0d4d2eea744af684d21c45ce8f9077_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if587f8e549024234943bfe0d376966d8_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15dab1b527c04e6c93a77db28d7f4dfb_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ca6c41d5964c50abb196f02b39a16f_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d93eaa25cfc46b38549e5a299d8f0e1_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbfc10f2d9fb46bea65fe6d1a1318594_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86429e3449e0476199236fd7c3b171dd_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i01b5d6689adc4498bfe63be39e352060_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY1_3a6f7ae6-0052-4c29-b5e4-c333d4ecdd4b">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZDBiM2NhNDc2ZDVjNDBhMWEyOGRhODM4MTc5NTBkMmYvdGFibGVyYW5nZTpkMGIzY2E0NzZkNWM0MGExYTI4ZGE4MzgxNzk1MGQyZl8xLTAtMS0xLTcwMDM0_cdf48052-38d7-4f2a-a6d7-4521a6657b53">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">for the quarterly period ended <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8xMjI_b34ff3b5-d0cd-4400-8abf-238819c2c14e">July 3, 2022</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6OTRkYTFkNDc1MDg0NGU1MTkwMDIwNDg5ZDMxMThkM2MvdGFibGVyYW5nZTo5NGRhMWQ0NzUwODQ0ZTUxOTAwMjA0ODlkMzExOGQzY18xLTAtMS0xLTcwMDM0_302d1806-870f-4e70-88d2-41bedd679d38">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934<br/>for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY2_9607cb8f-b3ce-4c1f-8435-ef1fceb16175">1-3215</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDU4_e67adb63-838f-483d-b3a9-fc10897ded01">Johnson &amp; Johnson</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6NTZmZmM2MzJjZTMxNDQ5NmJhZDA0ZjZhOTU0MTVmMzMvdGFibGVyYW5nZTo1NmZmYzYzMmNlMzE0NDk2YmFkMDRmNmE5NTQxNWYzM18wLTAtMS0xLTcwMDM0_a3026569-7637-4667-bfd6-9df28571c69c">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6NTZmZmM2MzJjZTMxNDQ5NmJhZDA0ZjZhOTU0MTVmMzMvdGFibGVyYW5nZTo1NmZmYzYzMmNlMzE0NDk2YmFkMDRmNmE5NTQxNWYzM18wLTItMS0xLTcwMDM0_200d6851-07a5-4f80-af19-fa9a59dc2eff">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDU5_b9fa3c39-1e55-4df9-a693-c93bbfdad9ca">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY3_f31c7409-0405-44b1-9f87-a0211c243936">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY4_91a6c4ad-d123-48fb-adce-a21a46110139">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY5_338f0cb8-512e-45ad-b529-78d0d456f49d">08933</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDYw_eaf408c8-b904-4910-adcf-3a134bd3c0b6">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDYx_61cf8b0c-b757-4181-b92b-18ebf56ee843">524-0400</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDYz_d21ddae8-0473-48d5-9399-4ce75c62eeff">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY0_e195f289-9a49-43c8-a3f9-50eba5a0e843">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6MzE5MTYzYzZjYjRlNGM3M2FhNzA0ODM2OWEzMDE4ODQvdGFibGVyYW5nZTozMTkxNjNjNmNiNGU0YzczYWE3MDQ4MzY5YTMwMTg4NF8wLTEtMS0xLTcwMDM0_bba92a9a-9d64-414f-9cdf-9c5bd4de67df">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6MzE5MTYzYzZjYjRlNGM3M2FhNzA0ODM2OWEzMDE4ODQvdGFibGVyYW5nZTozMTkxNjNjNmNiNGU0YzczYWE3MDQ4MzY5YTMwMTg4NF8xLTQtMS0xLTcwMDM0_53a91ec0-8220-4c0a-9695-fe1b6c8d947d">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6MzE5MTYzYzZjYjRlNGM3M2FhNzA0ODM2OWEzMDE4ODQvdGFibGVyYW5nZTozMTkxNjNjNmNiNGU0YzczYWE3MDQ4MzY5YTMwMTg4NF8yLTItMS0xLTcwMDM0_fe810477-1963-49b0-a560-ba3044a5bbcc">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If&#160;an&#160;emerging&#160;growth&#160;company,&#160;indicated&#160;by&#160;check&#160;mark&#160;if&#160;the&#160;registrant&#160;has&#160;elected&#160;not&#160;to&#160;use&#160;the&#160;extended&#160;transition period&#160;for&#160;complying with&#160;any&#160;new&#160;or&#160;revised&#160;financial&#160;accounting&#160;standards&#160;provided pursuant&#160;to&#160;Section&#160;13(a)&#160;of&#160;the&#160;Exchange&#160;Act. &#9744;</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDYy_d6d12213-66dd-4371-b0fa-00ad162d2bdc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i081646bd651e49ccbec8525d32cdd1ee_D20220103-20220703" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8xLTAtMS0xLTcwMDM0_1deda889-72c2-4bea-93d1-f994f861bb13">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i081646bd651e49ccbec8525d32cdd1ee_D20220103-20220703" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8xLTEtMS0xLTcwMDM0_55178f40-1d76-4f53-90d1-035ad46a4782">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i081646bd651e49ccbec8525d32cdd1ee_D20220103-20220703" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8xLTItMS0xLTcwMDM0_673cc6fd-aa0c-45f9-8b97-ba6105ea0b5d">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbb124a5ccb24559ac685f2e90cbaea3_D20220103-20220703" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8yLTAtMS0xLTcwMDM0_49f463ff-8ce4-427f-86fd-e1986fef002a">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbb124a5ccb24559ac685f2e90cbaea3_D20220103-20220703" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8yLTEtMS0xLTcwMDM0_fc9966b3-ef71-487e-bf55-8a7ddd9efcee">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbb124a5ccb24559ac685f2e90cbaea3_D20220103-20220703" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8yLTItMS0xLTcwMDM0_57636182-5884-4b35-b101-2dd38b5a0436">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3ef6f7979ef4744b07bd5c44033c0ed_D20220103-20220703" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8zLTAtMS0xLTcwMDM0_8b11a8d0-3ba2-45f4-a3fe-dbbc0d7e8ed4">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3ef6f7979ef4744b07bd5c44033c0ed_D20220103-20220703" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8zLTEtMS0xLTcwMDM0_28a640ec-750f-4b38-8556-32a8b35f3cf7">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3ef6f7979ef4744b07bd5c44033c0ed_D20220103-20220703" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8zLTItMS0xLTcwMDM0_51f86a43-0732-484d-a16b-130cfb1424d1">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if661bb2f35c84737a9a48c16676d08af_D20220103-20220703" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV80LTAtMS0xLTcwMDM0_febf1985-0675-4e9e-9121-d6920a4ab2a4">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if661bb2f35c84737a9a48c16676d08af_D20220103-20220703" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV80LTEtMS0xLTcwMDM0_d483cef9-d101-48c6-befb-8badb0b99da9">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if661bb2f35c84737a9a48c16676d08af_D20220103-20220703" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV80LTItMS0xLTcwMDM0_01d124e1-bdbd-4702-86c3-9a12545d7689">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ee5b5caea422aab835052a7bcd38f_D20220103-20220703" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV81LTAtMS0xLTcwMDM0_081ff4d8-b861-465c-aa06-aa71a4a61f81">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ee5b5caea422aab835052a7bcd38f_D20220103-20220703" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV81LTEtMS0xLTcwMDM0_60b11683-2173-4577-ba78-d962d8315d28">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ee5b5caea422aab835052a7bcd38f_D20220103-20220703" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV81LTItMS0xLTcwMDM0_eaa22e2d-d6b6-4866-a912-9ee96ec60d84">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022, <ix:nonFraction unitRef="shares" contextRef="i391bd8bf57bd4482a4a2ddc2a79b27fc_I20220722" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8xOTk3_4d62037f-ffe5-48b7-a38c-a2109e3ae062">2,629,179,895</ix:nonFraction> shares of Common Stock, $1.00 par value, were outstanding.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_10"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_16">Part I &#8212; Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_19">Item&#160;1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_22">Consolidated Balance Sheets &#8212; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_22">July</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_22"> 3, 2022 and January 2, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_28">Consolidated Statements of Earnings for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_28">Second</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_28"> Quarters Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_28">July</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_28"> 3, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_28">July</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_28"> 4, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_28">2</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">Consolidated Statements of Earnings for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">Si</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">x</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">July</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31"> 3, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">Ju</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">ly</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_31">3</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_34">Consolidated Statements of Comprehensive Income for the Fiscal Second</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_34"> Quarters </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_34">and Fiscal Six Months </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_34">Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_34">July</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_34"> 3, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_34">July</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_34"> 4, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_34">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40">Consolidated Statements of Equity for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40">Second</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40"> Quarters </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40">and Fiscal Six Months </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40">Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40">July</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40"> 3, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40">July</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40"> 4, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_40">5</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_46">Consolidated Statements of Cash Flows for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_46">Six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_46"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_46">Ju</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_46">ly</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_46"> 3, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_46">July</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_46"> 4, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_46">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_49">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_49">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_106">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_106">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_109">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_109">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_112">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_112">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_115">Part II &#8212; Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_115">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_118">Item&#160;1 - Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_118">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_121">Item&#160;2 - Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_121">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_124">Item&#160;6 - Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_124">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_127">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01b5d6689adc4498bfe63be39e352060_127">67</a></span></div></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Johnson &amp; Johnson's other publicly available documents contain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward-looking statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.&#160;Management and representatives of Johnson &amp; Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Development, Market Success and Competition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Liability, Litigation and Regulatory Activity</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union&#8217;s Medical Devices Regulation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Company&#8217;s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company&#8217;s Consumer Health Business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s ability to consummate the planned separation of the Company&#8217;s Consumer Health business on a timely basis or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company&#8217;s ability to successfully separate the Company&#8217;s Consumer Health business and realize the anticipated benefits from the planned separation; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The New Consumer Health Company&#8217;s ability to succeed as a standalone publicly traded company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Economic Conditions, Financial Markets and Operating Internationally</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of global public health crises and pandemics, including the novel coronavirus (COVID-19) pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company&#8217;s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company&#8217;s products and operations; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Supply Chain and Operations </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Interruptions and breaches of the Company&#8217;s information technology systems or those of the Company&#8217;s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. </span></div><div><span><br/></span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022, for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;I &#8212; FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions Except Share and Per Share Data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:69.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMy0yLTEtMS03MDAzNA_eb988ff8-f203-4ec0-96e8-7a182f015e39">10,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMy00LTEtMS03MDAzNA_d1af9d26-bd0b-446c-a2da-9969c8f0e6fd">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNC0yLTEtMS03MDAzNA_98f236b4-b55f-4262-9b74-f1c1f316cea1">21,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNC00LTEtMS03MDAzNA_5ee6b174-5546-4b47-baf9-f4f1458ad319">17,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, trade, less allowances $<ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNS0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjhhMDQyMDQ4M2ZlODQ5ZWNiZmVjMTYwM2E0NDg3ZTVhXzg4_3d1152c6-3001-4624-8092-1ec1586d0ed5">223</ix:nonFraction> (2021, $<ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNS0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjhhMDQyMDQ4M2ZlODQ5ZWNiZmVjMTYwM2E0NDg3ZTVhXzk4_8aecbeec-7315-4a09-bd28-8048535e9141">230</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNS0yLTEtMS03MDAzNA_06073685-50cd-4299-bbcc-84fe4ba34b24">16,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNS00LTEtMS03MDAzNA_b521e01b-c70d-4092-86cb-8f082a46b8c8">15,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNi0yLTEtMS03MDAzNA_74c3504e-fb6d-47ef-a35f-57b9bba3a93f">11,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNi00LTEtMS03MDAzNA_8e9e3c7b-b5f7-41d0-9de3-25b38e937444">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNy0yLTEtMS03MDAzNA_f0e4611a-d816-4465-8bce-6e04165e7225">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNy00LTEtMS03MDAzNA_8ea2ca32-dfae-4cf3-917c-a3988ddbd551">3,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfOS0yLTEtMS03MDAzNA_746fffa4-1c0b-4734-83a0-9f8bd70a59eb">63,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfOS00LTEtMS03MDAzNA_8ca82bca-b38e-4a35-9d8a-06c639a988b1">60,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTAtMi0xLTEtNzAwMzQ_4fcf1e4b-6982-47d2-b0e8-7071b43bda39">47,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTAtNC0xLTEtNzAwMzQ_63b1ef54-c2ea-491f-8cbb-1406fb3fb0a3">47,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTEtMi0xLTEtNzAwMzQ_0554d698-1e8e-4924-b83d-9edf879cef8d">28,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTEtNC0xLTEtNzAwMzQ_b60d0aa4-32d1-46f6-987e-c5a26e4f2b66">28,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTItMi0xLTEtNzAwMzQ_d944b6e0-29aa-4263-b040-53bb31e47ae2">18,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTItNC0xLTEtNzAwMzQ_be5fe568-4239-454a-b54e-7438f507cde5">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTMtMi0xLTEtNzAwMzQ_fd748c4a-9d4e-47e8-8d05-8039e65f9225">42,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTMtNC0xLTEtNzAwMzQ_f66b097d-7a70-4b40-b2e7-599d7d156d15">46,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTQtMi0xLTEtNzAwMzQ_7f792dc2-b97e-4e3c-9795-3257e64e294b">34,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTQtNC0xLTEtNzAwMzQ_c431dc33-c615-4255-b805-43969474e04f">35,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTUtMi0xLTEtNzAwMzQ_197ee6f7-fe2c-48f0-9012-8e6939fdfc88">9,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTUtNC0xLTEtNzAwMzQ_dd349b43-51c9-4d83-b6f6-5cc93be210f5">10,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTYtMi0xLTEtNzAwMzQ_0a744bd4-656b-44ad-9619-eb36e79f91e4">9,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTYtNC0xLTEtNzAwMzQ_182d0ec1-8540-458e-8c3d-ed5e20cf1da7">10,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTctMi0xLTEtNzAwMzQ_6d8a898e-4a85-4e8a-a3ed-f0baf9012c26">177,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTctNC0xLTEtNzAwMzQ_4385e3c1-8cf7-4cc4-bd27-5a1969bbba4b">182,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans and notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjAtMi0xLTEtNzAwMzQ_2583fcbc-0577-4744-bac9-a9a60c3ae6df">4,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjAtNC0xLTEtNzAwMzQ_3b4e41d8-f84e-4e90-90df-ca15d968d60b">3,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjEtMi0xLTEtNzAwMzQ_9ece706c-6ea9-4edc-9cff-f943c6af5dfa">9,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjEtNC0xLTEtNzAwMzQ_195ea945-82c8-4d5a-8646-b56e97803aec">11,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjItMi0xLTEtNzAwMzQ_6bc7e7b5-414f-4565-9815-a3447e048982">12,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjItNC0xLTEtNzAwMzQ_68f40775-37f0-4b8e-b6a1-5236e53f92e2">13,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjMtMi0xLTEtNzAwMzQ_cec22065-3c07-43eb-9f89-c1aaef245da0">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjMtNC0xLTEtNzAwMzQ_5d82a43e-1e91-40fb-b28c-a7c6f3040b45">12,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjQtMi0xLTEtNzAwMzQ_b5254e70-3c15-40d0-a9fe-e387be22bab4">2,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjQtNC0xLTEtNzAwMzQ_6df2c613-ea0a-4bf3-8ffb-abba32811b9c">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjUtMi0xLTEtNzAwMzQ_724cc176-6a30-46f9-b61d-2a611261d352">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjUtNC0xLTEtNzAwMzQ_dffea15d-628e-4fc0-a924-75027322d2c7">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjYtMi0xLTEtNzAwMzQ_d71ca4ef-d8b0-4e01-b267-3e6ddac340ed">44,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjYtNC0xLTEtNzAwMzQ_a76d7c28-bacf-4bbf-ba29-19b87e932cba">45,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjctMi0xLTEtNzAwMzQ_fed4b956-78bf-4651-9365-0a1ff3a7d8c6">28,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjctNC0xLTEtNzAwMzQ_3848f3ce-8a0a-4da3-8997-dbee97ed25c4">29,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjgtMi0xLTEtNzAwMzQ_254bcf3e-07d4-4d0f-9595-2a0ae72af6f7">5,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjgtNC0xLTEtNzAwMzQ_68dd2a40-c594-4098-991a-c650db34fc7d">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjktMi0xLTEtNzAwMzQ_7eb37dfe-fd4c-42ff-a2d1-710a4c0bbb31">8,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjktNC0xLTEtNzAwMzQ_8a323ac0-f90a-48cf-86e6-4296c09d19a1">8,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term taxes payable (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzAtMi0xLTEtNzAwMzQ_52f233db-4e6c-49b6-81cc-7d1c7370b977">4,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzAtNC0xLTEtNzAwMzQ_32032112-7748-4b1e-aad8-c0e3768292ef">5,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzEtMi0xLTEtNzAwMzQ_41d817ae-6230-4ab5-bd13-793bc8fc675d">10,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzEtNC0xLTEtNzAwMzQ_73c1fc44-dd84-4cf5-bcbb-254914973bc1">10,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzItMi0xLTEtNzAwMzQ_f8abc10d-2c0c-4776-aff6-46e208da1f39">101,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzItNC0xLTEtNzAwMzQ_e072a418-c04e-41c9-a404-3da45667b36f">107,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzMtMi0xLTEtNzAwMzQ_7c4222d2-48ab-49b1-882e-c9cd5ac436b6"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzMtNC0xLTEtNzAwMzQ_ad7d9161-6518-4277-a75f-bd6992ff7df7"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl8yOQ_dc8379d1-a35e-4957-9a0a-ac2505ffb76c"><ix:nonFraction unitRef="usdPerShare" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl8yOQ_f30a7d76-3cd9-4453-b8d3-757117c1881e">1.00</ix:nonFraction></ix:nonFraction> per share (authorized <ix:nonFraction unitRef="shares" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl81NA_0d931442-ae01-4bb3-9319-71af79b709af"><ix:nonFraction unitRef="shares" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl81NA_87c05330-4c8b-47e6-80b1-8c0c350aba2c">4,320,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl83Mg_8f82e53e-302b-4351-896e-5effcf79bd5d"><ix:nonFraction unitRef="shares" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl83Mg_e8e11d31-6915-4b48-9073-d7e79efe87b8">3,119,843,000</ix:nonFraction></ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMi0xLTEtNzAwMzQ_de54b06d-b45f-41e3-b2d4-286b5435107d">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtNC0xLTEtNzAwMzQ_733b9f47-7465-4d7c-b8f8-70891ee0048c">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss) (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzYtMi0xLTEtNzAwMzQ_3049f17b-175e-4ab1-88ee-e15bab6ce56b">13,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzYtNC0xLTEtNzAwMzQ_20b789cb-5030-473f-8ce9-e0f5751582e1">13,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzctMi0xLTEtNzAwMzQ_daacf693-88ad-40ae-8d24-8c8bd556c797">126,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzctNC0xLTEtNzAwMzQ_988773ff-04d9-4ff5-af19-bd05c4495eac">123,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: common stock held in treasury, at cost (<ix:nonFraction unitRef="shares" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjozODcwNmQ5OTdiOGY0ZmRkYjk5MTNhZTdkNzAwMDU0MF81MA_b83a7fb4-bb02-4190-9118-367e2de3d49e">490,811,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjozODcwNmQ5OTdiOGY0ZmRkYjk5MTNhZTdkNzAwMDU0MF81Nw_e22a4d9e-71d7-49ab-b752-065e08b33aeb">490,878,000</ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzgtMi0xLTEtNzAwMzQ_b8086d61-6f8c-43d3-b422-a49cee2bb206">39,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzgtNC0xLTEtNzAwMzQ_48659687-3433-448f-99eb-edd46518b9a2">39,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzktMi0xLTEtNzAwMzQ_a0053591-8cbb-456c-87e4-1e1a319dfe1a">76,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzktNC0xLTEtNzAwMzQ_86c63f20-ea11-4f61-8e3f-32532feb41de">74,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNDAtMi0xLTEtNzAwMzQ_888aed61-6562-4f7a-b329-ef4cdcdaf064">177,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNDAtNC0xLTEtNzAwMzQ_5dcd41f8-48d4-4477-abf2-cb29cb704457">182,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars &amp; Shares in Millions Except Per Share Amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:54.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMi0yLTEtMS03MDAzNA_4e648f65-0643-42fc-a60a-b9b003849cda">24,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMi00LTEtMS03MDAzNA_929ad856-b048-435d-980b-7340735a592d">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMi02LTEtMS03MDAzNA_327ead6c-0b16-4ebb-8102-90e6e678adf6">23,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMi04LTEtMS03MDAzNA_c303724c-363e-4a4b-82af-be87b83b05c4">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMy0yLTEtMS03MDAzNA_86f42d7e-4551-451e-8902-6e21387aa611">7,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMy00LTEtMS03MDAzNA_a127363d-0fd0-47ce-bc9e-633fea5f3555">33.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMy02LTEtMS03MDAzNA_bbf82425-4d1e-463a-b863-0921227cffc0">7,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMy04LTEtMS03MDAzNA_6dcd5316-5c89-4148-a50d-d4939e702eb8">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNC0yLTEtMS03MDAzNA_847f996c-295e-4fba-80f6-e13d9121c30e">16,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNC00LTEtMS03MDAzNA_af417422-d5b5-4348-9b36-7647962a22f4">67.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNC02LTEtMS03MDAzNA_0532ea52-9f83-4214-a664-19e1ed090a9a">15,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNC04LTEtMS03MDAzNA_57695800-5910-4a02-91e1-9b75e4a5b160">67.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNS0yLTEtMS03MDAzNA_11316bba-7408-47b5-8a1f-5a3dab73b777">6,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNS00LTEtMS03MDAzNA_bd258ec2-8eb0-4f56-b34b-ca94ac4d9be9">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNS02LTEtMS03MDAzNA_6f06e157-8af0-4b32-8623-c40ec50dfa17">6,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNS04LTEtMS03MDAzNA_5e48c1b5-a406-482b-9f91-70edb067581c">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNi0yLTEtMS03MDAzNA_4802217b-952f-4b08-b755-9c4adf5ed1f7">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNi00LTEtMS03MDAzNA_dd7def24-097d-4022-bbc7-78fc2320f36b">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNi02LTEtMS03MDAzNA_d518b368-30ea-40b7-94d2-71da780e9ebe">3,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNi04LTEtMS03MDAzNA_704d9e9c-ef0a-4d16-8ea8-42f7c220f733">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOC0yLTEtMS03MDAzNA_0e85b7f8-53bf-4afc-a41b-c6015c0bd30a">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOC00LTEtMS03MDAzNA_2a2cec33-08d8-461e-bd17-6083ff621411">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOC02LTEtMS03MDAzNA_e05c37f8-9f1c-42ca-a4d9-f22fb589b83b">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOC04LTEtMS03MDAzNA_e7bcf073-dc6a-4455-8abd-5ca18cd8afcb">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOS0yLTEtMS03MDAzNA_9aa14bfe-f748-424f-8035-db63e2ee62e8">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOS00LTEtMS03MDAzNA_c892ded7-f817-4150-b88e-64c1031c1fac">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOS02LTEtMS03MDAzNA_ff0a8fc8-2dd2-421c-aeb5-bd5df612537f">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOS04LTEtMS03MDAzNA_b03e7753-71a3-424b-9a8b-feeeb1cba643">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTAtMi0xLTEtNzAwMzQ_347c6416-036b-4fb9-b1c2-dd2ee4e6edd9">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTAtNC0xLTEtNzAwMzQ_36649ccc-020b-4aae-8c49-150b84fdd604">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTAtNi0xLTEtNzAwMzQ_c2a24fde-1956-4c7f-804e-8003bd8a17a3">488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" sign="-" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTAtOC0xLTEtNzAwMzQ_2a620989-511a-4a54-b2c6-ddee32980e1e">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 12)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTEtMi0xLTEtNzAwMzQ_61449974-4a18-491a-b53c-4d339841c392">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTEtNC0xLTEtNzAwMzQ_69a3f69f-d560-4eae-8359-9b56165eaa36">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTEtNi0xLTEtNzAwMzQ_c4f6363a-a4fd-4563-a74d-845b48a45b06">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTEtOC0xLTEtNzAwMzQ_989b4cf2-3386-45c6-8552-420ad2904d87">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTItMi0xLTEtNzAwMzQ_024a2585-9701-41fe-992a-27cc018abc8a">5,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTItNC0xLTEtNzAwMzQ_a666c69d-847f-4c84-9ced-b251bd5b8352">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTItNi0xLTEtNzAwMzQ_f21e3963-d94d-4006-89eb-bf27f3a99669">6,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTItOC0xLTEtNzAwMzQ_67717ac8-8dcf-474a-83ba-36ea3cb77acf">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTMtMi0xLTEtNzAwMzQ_95a447f2-4194-446a-9024-d8ad804349b9">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTMtNC0xLTEtNzAwMzQ_9176d953-e620-4328-98fe-cae745e69e2d">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTMtNi0xLTEtNzAwMzQ_d71478b4-61fb-4158-b707-46d29032f314">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTMtOC0xLTEtNzAwMzQ_6742cf79-7f5b-4018-bba2-4cd2b11957b7">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTQtMi0xLTEtNzAwMzQ_f4b1ef5f-bcd4-45de-8aa5-325ebd940504">4,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTQtNC0xLTEtNzAwMzQ_f0910627-042e-4806-88f8-3f211fe17df5">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTQtNi0xLTEtNzAwMzQ_b1395c79-74e4-4b6d-9272-a459d496ce45">6,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTQtOC0xLTEtNzAwMzQ_bae6150e-4812-466d-9d82-cedcd3408b7e">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS PER SHARE (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTctMi0xLTEtNzAwMzQ_b7402fbe-0616-49f1-af6b-2e84a6ab757a">1.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTctNi0xLTEtNzAwMzQ_3178c61b-6d1c-4185-b651-f73143ba83ca">2.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTgtMi0xLTEtNzAwMzQ_47597e54-1bc4-45dc-9a30-c57ba2252662">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTgtNi0xLTEtNzAwMzQ_b3d6884c-7dc6-417f-8d82-a9852dc2f9b2">2.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVG. SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMjEtMi0xLTEtNzAwMzQ_b7986135-9d2e-4f80-af08-5c0115d46b7a">2,629.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMjEtNi0xLTEtNzAwMzQ_37acdf3f-75cc-4855-ad81-80c8198bec79">2,632.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMjItMi0xLTEtNzAwMzQ_1fd56926-8f20-4703-9d5b-e25675bd2797">2,667.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMjItNi0xLTEtNzAwMzQ_efbf8a53-77a9-4a81-a7eb-36d21b094566">2,671.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_31"></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars &amp; Shares in Millions Except Per Share Amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNC0yLTEtMS03MDAzNA_3031cb88-3cec-4fba-ba0f-320836de36cd">47,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNC00LTEtMS03MDAzNA_645104ae-ff6a-4456-9bc7-66b2bed3b423">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNC02LTEtMS03MDAzNA_5a24ba74-ca7e-465b-8e87-9dff65e0ce43">45,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNC04LTEtMS03MDAzNA_2378b466-b3cb-4ec4-9afa-4dca46d80142">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNS0yLTEtMS03MDAzNA_631838ea-02ef-466f-a1f7-3c8183b613fc">15,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNS00LTEtMS03MDAzNA_dbd83933-1843-4c94-996f-c3761f3c0cad">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNS02LTEtMS03MDAzNA_35bedf5d-5071-42f5-9001-bcb47dea46d3">14,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNS04LTEtMS03MDAzNA_86c0ed0b-68d4-41c0-9547-eca852d85bd5">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNi0yLTEtMS03MDAzNA_4be54432-5b4f-45e3-9c68-229ef3374205">31,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNi00LTEtMS03MDAzNA_cf04f8b4-1d9b-4623-ba2a-4004c98d5287">67.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNi02LTEtMS03MDAzNA_c193b9b6-eec0-4781-b7af-84080d2d248b">30,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNi04LTEtMS03MDAzNA_4c8451b0-0793-428f-bc8d-b605c5d5e3b9">67.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNy0yLTEtMS03MDAzNA_d9d64f76-1e5e-4039-8f3e-b508f0aa8762">12,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNy00LTEtMS03MDAzNA_90bc475a-9935-44f8-8487-52be82f0c50b">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNy02LTEtMS03MDAzNA_ba89b460-4cb1-4e4c-bfd0-2b61de770896">11,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNy04LTEtMS03MDAzNA_86b5720f-09ef-4366-8ce9-dfebffced7fe">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOC0yLTEtMS03MDAzNA_b921f4a5-6b02-41ec-8738-212fcd1730da">7,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOC00LTEtMS03MDAzNA_859a5820-bf8c-4229-afc9-866de6d07a96">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOC02LTEtMS03MDAzNA_95e8e2e4-4996-454e-83a9-c8b484c2bb3b">6,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOC04LTEtMS03MDAzNA_f6520623-ed9d-4c52-977d-188a659d6edb">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOS0yLTEtMS03MDAzNA_2bdc6f35-7098-4db4-9992-6253b342f4a9">610</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOS00LTEtMS03MDAzNA_8aabf2f8-7888-4a1d-997b-aa8b50715fb3">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOS02LTEtMS03MDAzNA_2de078a2-2466-4590-bfd0-94b20d969deb">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOS04LTEtMS03MDAzNA_885ad57a-2400-41c7-8e74-6b96d7162950">0.0</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTAtMi0xLTEtNzAwMzQ_31cbbea6-2e1c-4291-b029-c6f1b9897857">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTAtNC0xLTEtNzAwMzQ_a25e5292-8a00-4e31-830a-09f2317012bc">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTAtNi0xLTEtNzAwMzQ_0edbdc98-0ed7-4bb0-8ee3-99f4191630df">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:InvestmentIncomeInterestPercentToSales" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTAtOC0xLTEtNzAwMzQ_d67b7e26-3f75-4724-aa77-b79f6ff3d349">0.0</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTEtMi0xLTEtNzAwMzQ_7cce758a-a45e-4ef7-9ba5-37ddc4b5243d">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTEtNC0xLTEtNzAwMzQ_c177a32e-f067-427a-a788-53c36b313ff6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTEtNi0xLTEtNzAwMzQ_3ebc4e40-4651-41bf-851c-104772cf8983">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTEtOC0xLTEtNzAwMzQ_1816324e-66df-4c2f-afcf-4c51faeb2b59">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTItMi0xLTEtNzAwMzQ_bd5f72c1-aeaa-444c-81c4-928274bb28e9">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTItNC0xLTEtNzAwMzQ_9defd876-2cea-4745-8aba-c0a3a71c4df4">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTItNi0xLTEtNzAwMzQ_83d0e934-3537-4a52-b59a-f1d857e7b387">1,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" sign="-" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTItOC0xLTEtNzAwMzQ_956112c6-b9b1-473f-9952-1412ee01af94">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTMtMi0xLTEtNzAwMzQ_bccaa2f9-24d3-499b-87e5-06072691bf62">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTMtNC0xLTEtNzAwMzQ_572c31b7-ed88-4d77-8707-ecd17341ec6d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTMtNi0xLTEtNzAwMzQ_5e7042c5-8969-4427-9c96-92221deb99cb">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTMtOC0xLTEtNzAwMzQ_414c6b1d-e346-4b3a-aea8-2c65b6b5c00f">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTQtMi0xLTEtNzAwMzQ_b7eff584-154b-4065-be16-686a70363a10">11,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTQtNC0xLTEtNzAwMzQ_e7aa435a-0999-434e-9426-f59164aecd8b">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTQtNi0xLTEtNzAwMzQ_03ba7b6f-1591-495b-abfc-25772d77211b">14,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTQtOC0xLTEtNzAwMzQ_b2935c48-ea3c-44f6-8e06-ff430e5a3b5f">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTUtMi0xLTEtNzAwMzQ_cd6adec6-1e45-4a57-80dc-340d652bd907">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTUtNC0xLTEtNzAwMzQ_e6f54372-a256-4dd3-a1b9-74d20ab6838f">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTUtNi0xLTEtNzAwMzQ_adfdff6f-34f1-407e-bc2c-e474bbf1d0b1">1,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTUtOC0xLTEtNzAwMzQ_04930020-3f1c-4b09-9093-4065979f1af3">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTYtMi0xLTEtNzAwMzQ_64323249-7f1e-47e0-994d-41177e662ff5">9,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTYtNC0xLTEtNzAwMzQ_b995eb72-b9a8-4960-9a7e-54677ff9af53">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTYtNi0xLTEtNzAwMzQ_af9d48a7-c577-4d14-bfbd-410b553eee63">12,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTYtOC0xLTEtNzAwMzQ_13d6d056-bafd-435f-988d-9cfe9d780598">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS PER SHARE (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTktMi0xLTEtNzAwMzQ_45e31af0-6c1c-46c7-b0de-f3183a9575d0">3.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTktNi0xLTEtNzAwMzQ_e5ef5994-d0be-49d8-90be-37440ad1e7a4">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjAtMi0xLTEtNzAwMzQ_33d976ad-1e35-4dc0-8d51-754ea313bea3">3.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjAtNi0xLTEtNzAwMzQ_cffcc901-8e2d-4d7a-b27b-a9d3990edd05">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVG. SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjMtMi0xLTEtNzAwMzQ_c6821bae-1542-4115-94c6-4fc282ad3f2a">2,629.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjMtNi0xLTEtNzAwMzQ_06e03ef1-781d-4c8d-afa9-155808e38196">2,632.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjQtMi0xLTEtNzAwMzQ_75f60227-8f55-4fe3-b36b-b39ced1a1bcd">2,669.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjQtNi0xLTEtNzAwMzQ_f24cc079-df03-4a80-97d9-450d56bf16aa">2,674.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See Notes to Consolidated Financial Statements</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMy0xLTEtMS03MDAzNA_f4d2016b-7639-43ca-9268-b7ea486127aa">4,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMy0zLTEtMS03MDAzNA_f58109da-9054-480a-acf6-4eec0082c771">6,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMy01LTEtMS03MDAzNA_6a796edf-5da5-43ea-8f19-aef0eb336233">9,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMy03LTEtMS03MDAzNA_bb05c2ab-1f61-4c59-b2f3-faa0d96d407c">12,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfNi0xLTEtMS03MDAzNA_9692a227-533c-48e5-831f-25430696f0c1">151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfNi0zLTEtMS03MDAzNA_b17efe36-f2c2-4341-9918-1ce16b7db43c">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfNi01LTEtMS03MDAzNA_56077629-3cbd-477b-a485-f514f3e60dcd">705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfNi03LTEtMS03MDAzNA_dee1c155-77c4-4af7-b088-183f01e30d40">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized holding gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfOS0xLTEtMS03MDAzNA_16345338-f869-4c38-bee6-ade6004f61ad">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfOS0zLTEtMS03MDAzNA_05b052dc-c4a2-4304-976f-01d22d9f5351">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfOS01LTEtMS03MDAzNA_ce8b80f6-1d72-4121-8461-ca91b95deb3b">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfOS03LTEtMS03MDAzNA_7c496297-a559-4831-b543-6c605c5ffd21">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTAtMS0xLTEtNzAwMzQ_9b5df8da-e5da-4881-b416-bb3e4660048f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTAtMy0xLTEtNzAwMzQ_c61962fb-e3d1-4dc7-8427-f0352604afc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTAtNS0xLTEtNzAwMzQ_05d8fe39-a9d0-45a0-8de7-4b39c19951e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTAtNy0xLTEtNzAwMzQ_f54276d6-eb43-433d-a38b-2ecd3f2ed4ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTItMS0xLTEtNzAwMzQ_20c72138-361f-4b54-bd30-01335a61b035">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTItMy0xLTEtNzAwMzQ_d1081362-a7d8-433c-b14a-ffe6e3f6e682">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTItNS0xLTEtNzAwMzQ_e2b49084-a5d8-483b-818a-4bcac5df1757">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTItNy0xLTEtNzAwMzQ_ac2ea034-e7ca-4c15-a364-3b2b77cc11f5">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior service cost amortization during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTUtMS0xLTEtNzAwMzQ_3f576066-fc2b-44c1-a779-d47e8920edb6">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTUtMy0xLTEtNzAwMzQ_d9557ae6-a86f-4d41-bb5b-43b1d24af908">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTUtNS0xLTEtNzAwMzQ_d7ac4b35-d7db-475d-adf3-efc29ccd87b3">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTUtNy0xLTEtNzAwMzQ_52c75016-7896-45f2-9756-52a451cf25f7">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Gain (loss) amortization during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTYtMS0xLTEtNzAwMzQ_db9fc82c-b34e-4049-857b-4128fee9d89d">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTYtMy0xLTEtNzAwMzQ_132e9927-585a-4b65-939c-629f04dc5048">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTYtNS0xLTEtNzAwMzQ_6e042979-9db9-4a45-95e2-6b9fa503d2e4">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTYtNy0xLTEtNzAwMzQ_12be176a-9b95-428f-bb0e-8c0120ba1b00">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTgtMS0xLTEtNzAwMzQ_165a94b2-7892-412a-8739-35bad7c4e60e">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTgtMy0xLTEtNzAwMzQ_367f0c96-fb23-482d-8fc9-4533cd6de402">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTgtNS0xLTEtNzAwMzQ_010ae28f-11c8-4d00-9a88-ed3579c78d1e">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTgtNy0xLTEtNzAwMzQ_954572d2-1bee-4deb-9eb0-8cdb2d394c4a">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives &amp; hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjEtMS0xLTEtNzAwMzQ_ce918500-92c1-41fa-97f3-613a7e907605">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjEtMy0xLTEtNzAwMzQ_0edee854-7529-4d8d-bd75-0c8654bd853c">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjEtNS0xLTEtNzAwMzQ_e4df90e9-d1a0-4172-b778-0729707a2fc7">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjEtNy0xLTEtNzAwMzQ_7b9b15ae-fc56-443b-b3b0-5dc6eeb84b38">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjItMS0xLTEtNzAwMzQ_24e10da7-9885-49a5-861f-c4f8778712ed">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjItMy0xLTEtNzAwMzQ_63e3640e-b582-49e5-ad64-85639ff0eacd">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjItNS0xLTEtNzAwMzQ_bf838fa5-8798-4f69-8802-d2b6a9af2ddc">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjItNy0xLTEtNzAwMzQ_98b00702-0517-467e-a94c-13c78b8f0555">343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjMtMS0xLTEtNzAwMzQ_194fd23a-dc6b-49dc-bc67-af5900d1dcca">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjMtMy0xLTEtNzAwMzQ_e9e8b1fa-d664-4713-9d82-eacefe8bc1a1">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjMtNS0xLTEtNzAwMzQ_19de76da-75fb-4a81-a7b5-f9342fb5bc58">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjMtNy0xLTEtNzAwMzQ_135613f3-5130-410e-aac2-f20780c226c5">465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjUtMS0xLTEtNzAwMzQ_cbad59ea-d4ba-4471-ba6d-82736cbd30b7">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjUtMy0xLTEtNzAwMzQ_13fbb20b-e86a-434d-8573-c143c4491853">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjUtNS0xLTEtNzAwMzQ_781059fc-6adf-40ce-90a5-2ab00edcebe1">785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjUtNy0xLTEtNzAwMzQ_82bb17b8-1e0e-44cf-9902-0c77847e8cef">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjctMS0xLTEtNzAwMzQ_99516a02-4e88-485a-bfe0-50a652eda443">4,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjctMy0xLTEtNzAwMzQ_70883de0-6aee-4e69-a7b3-801fa966c651">6,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjctNS0xLTEtNzAwMzQ_68c280c4-bf69-482c-ba98-24ff8469187a">9,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjctNy0xLTEtNzAwMzQ_b082a6ad-6900-485b-994b-01e230607737">12,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal second quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzE1OQ_18051ee9-7327-45b5-b667-dd40fa4e2b5c">533</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzE3NQ_6a98c98c-8de6-4e90-b4c3-44a0a45a15c3">90</ix:nonFraction> million; Securities: $<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzE5OQ_5f91b3f0-a16f-4ebd-9698-81981ab43669">6</ix:nonFraction> million in 2022; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzI0NA_5d12b962-c46d-4045-b3f4-78f6e2ec6cad">84</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzI2MA_b8ffa381-5c1c-46df-942d-14ad5adb0a4c">66</ix:nonFraction> million; Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzI5NQ_b014af54-8c08-4374-a5a2-baced9ce4f4a">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzMxMQ_1b6ec1c8-08a9-409f-8d50-c8b8b6bbe20d">33</ix:nonFraction> million.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal six months were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzE1OA_98af591f-d8b2-48bc-9a4c-ffbdf1aff0eb">678</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzE3NA_6aa365d3-2aa2-4b81-a575-49567617a74b">229</ix:nonFraction> million; Securities: $<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzI3NDg3NzkwNjk3NjA_cf5d72a9-2cc7-4677-8958-af21e6d7cea8">9</ix:nonFraction> million in 2022; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzIxMQ_2afb5652-6194-404f-adde-b0e3c01bb6ed">65</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzIyNw_423b8bd2-6584-40fb-b2cc-a707984c346a">132</ix:nonFraction> million; Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzI2Mg_f8d6cefb-eb80-4876-84d0-5191d8e66217">73</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzI3OA_b123f7d1-c56d-46f3-8532-589b70b19cf7">124</ix:nonFraction> million.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Second Quarter Ended July&#160;3, 2022 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, April 3, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b78141263e14aa589db463e889e3571_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS0xLTEtMS03MDAzNA_c78ec1c8-59ff-45b1-8523-99b04c9da04b">74,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ea286cb593414bad834aaf21a6fcae_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS0zLTEtMS03MDAzNA_7bcdf02a-47df-4aa9-a24c-230a42b1aeda">124,380</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id28888afdc0d41829f3f9c4f745b09bc_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS01LTEtMS03MDAzNA_b3b014c1-8b9f-4cf7-aca6-db75970c0a63">13,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd15db9229e94c4ab701152a505a8fd9_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS03LTEtMS03MDAzNA_694eefe4-d725-4d24-8aaa-1d679c956846">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ef6b87b8da34c3ab39ea64cec57d1ab_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS05LTEtMS03MDAzNA_cdbbf0c7-8aaf-42a7-8a67-1d9c1960b36d">39,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMi0xLTEtMS03MDAzNA_8c7c1c1c-ac3a-481f-80c8-df0c15dd35e9">4,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c985e9590a44414b4eb9c785af847ef_D20220404-20220703" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMi0zLTEtMS03MDAzNA_7c31eee7-b887-4c10-8f64-552a47e54b0e">4,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMy0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjgwZTg1ZTNjY2JhZDRhMDFiOTA5MzVmMDdjMjY4NWY2XzI2_83bd9f8e-7d9e-4aab-99e5-e942fc2ba28c">1.13</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMy0xLTEtMS03MDAzNA_5177d351-59f5-4cde-92d2-d29b758a19b2">2,971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c985e9590a44414b4eb9c785af847ef_D20220404-20220703" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMy0zLTEtMS03MDAzNA_1fb2ae9a-d246-42e0-a302-678239bd682d">2,971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNC0xLTEtMS03MDAzNA_be711fa1-10cd-4a2f-a2e9-6a3a566fe7e2">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c985e9590a44414b4eb9c785af847ef_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNC0zLTEtMS03MDAzNA_19fdb1b5-24bc-4cf4-a65a-7afabfc25db2">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63678c9b15dc4215981671d3417b1d43_D20220404-20220703" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNC05LTEtMS03MDAzNA_526cdda5-742b-4754-95f8-5e97609cffd0">871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNS0xLTEtMS03MDAzNA_067259d1-db32-421b-bd27-3dc864c541e0">973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63678c9b15dc4215981671d3417b1d43_D20220404-20220703" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNS05LTEtMS03MDAzNA_7449d717-3e3f-4326-80e6-0c48070136bf">973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNy0xLTEtMS03MDAzNA_aeeb933d-0cb1-481f-8722-565726362a9f">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48b106f4f9be47ecbdbf4494e08f368e_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNy01LTEtMS03MDAzNA_e2d05259-468a-48d8-9c2b-064ed281a321">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, July 3, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC0xLTEtMS03MDAzNA_fbcfe520-38c6-418d-843a-1d784c058d6d">76,357</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f63c6c6b554f82a78ab56462752f26_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC0zLTEtMS03MDAzNA_7a6d1921-fab7-45c2-86ab-2bdb6c84359e">126,216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c44097a42f4c9b8d26741faed5e548_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC01LTEtMS03MDAzNA_f54fef64-4a4a-4fc5-b4bd-df8629201460">13,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675f9b859a9642f9980e206847468603_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC03LTEtMS03MDAzNA_69e0dd75-4834-49c5-920b-5a7bd173dbda">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5d913e7414246628af7b698ff38c727_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC05LTEtMS03MDAzNA_d4c48ab1-6e31-48ce-aa4f-ff96b1f39069">39,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Six Months Ended July&#160;3, 2022</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy0xLTEtMS03MDAzNA_14a76cf7-7d2c-4951-96cd-26a558b39299">74,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b538347dc21414a92b3853037648c53_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy0zLTEtMS03MDAzNA_6b8088f1-6e4e-44a4-89c9-bed9512cf5b3">123,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i116332ccca294d499f773d00109c050b_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy01LTEtMS03MDAzNA_3b547161-ca3d-4253-b584-ce0c91c365f2">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e44d359c554d62b5eb567fbe00c74f_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy03LTEtMS03MDAzNA_760a7439-8f55-41a4-8623-4fb7034512a9">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d0890b94dec44eaa3b81bc34fb36d8c_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy05LTEtMS03MDAzNA_48b67535-100e-4b5c-acbf-c07a67fe1afb">39,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNC0xLTEtMS03MDAzNA_547d8192-4571-4f41-a1e3-ed518c1799ef">9,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2dbba5d85c4a23b5fe98df37e5b2f0_D20220103-20220703" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNC0zLTEtMS03MDAzNA_cca25dbc-496e-4f3c-aee7-f055319e2501">9,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNS0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjhhOWUzY2Q5MGZmOTQ1MzM4ZjliM2M0MmQzMGY0ZjQ1XzI2_7f1f8e5a-3e70-4061-923b-e185490f3d5b">2.19</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNS0xLTEtMS03MDAzNA_1aa80feb-725b-4139-8c72-b60ba300eca7">5,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d2dbba5d85c4a23b5fe98df37e5b2f0_D20220103-20220703" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNS0zLTEtMS03MDAzNA_319331c1-4e38-4bc8-a8ac-133aa0205070">5,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNi0xLTEtMS03MDAzNA_7ee76e70-f489-44dd-a513-d9b70e6807d0">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d2dbba5d85c4a23b5fe98df37e5b2f0_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNi0zLTEtMS03MDAzNA_4acc424c-9f7c-467b-a9d4-bc576b565c21">1,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfb8860f4a14a0a800de5dab7ad09d3_D20220103-20220703" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNi05LTEtMS03MDAzNA_fcc9e0aa-9e76-41e0-bdd4-49712c66bb39">2,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNy0xLTEtMS03MDAzNA_7aa58ad7-6087-4cde-8a85-cc2023931dfd">2,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cfb8860f4a14a0a800de5dab7ad09d3_D20220103-20220703" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNy05LTEtMS03MDAzNA_81573893-7bfb-4a6a-9e06-4038f771c49a">2,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfOS0xLTEtMS03MDAzNA_b0c883a8-1317-4f8e-8d4c-a499f7b7e720">785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30ab88c7a9b24105a98e4bce891e1382_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfOS01LTEtMS03MDAzNA_b9394b05-bfa8-49f0-88c5-14627ac06b9e">785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, July 3, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtMS0xLTEtNzAwMzQ_46e56822-80cb-40ac-a788-23da8b7b0f7b">76,357</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f63c6c6b554f82a78ab56462752f26_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtMy0xLTEtNzAwMzQ_b8becf7d-37c4-47ad-a2b5-c8fa3090730d">126,216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c44097a42f4c9b8d26741faed5e548_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtNS0xLTEtNzAwMzQ_c2bc589a-7a1d-4003-85af-c538ade094af">13,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675f9b859a9642f9980e206847468603_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtNy0xLTEtNzAwMzQ_f42ff50e-1805-4a96-9091-aa18404f224b">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5d913e7414246628af7b698ff38c727_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtOS0xLTEtNzAwMzQ_77112fe6-a057-41df-a9cf-e9badb8f0958">39,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Second Quarter Ended July&#160;4, 2021 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:37.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, April 4, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7eb101ecd248fa8113d9b3f69f69e1_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS0xLTEtMS03MDAzNA_ffc93ddf-010e-4d0f-883f-23ec153b1241">65,834</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0104c40629d42e2b32ea4a3608507a6_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS0zLTEtMS03MDAzNA_4632c691-fd54-418a-8731-846a22d9c91a">116,508</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8978590cb1f45bbb5dd3354dd289e0e_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS01LTEtMS03MDAzNA_aa78d647-4150-4d3e-b771-aec450be4968">15,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e13fe78d9384d259e35ea7a933fd95b_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS03LTEtMS03MDAzNA_64644b62-f81a-43f5-8a72-1abade22a0df">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id32639e6970348639d64a785e7a5ba93_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS05LTEtMS03MDAzNA_5fc4951b-5865-4b03-b938-f33b3b500093">38,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMy0xLTEtMS03MDAzNA_dd31e3ac-1877-48b3-84c4-270476733671">6,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447127aa6c664afab9dd53cc168aa3e2_D20210405-20210704" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMy0zLTEtMS03MDAzNA_8ac8612c-a96c-49ac-8f1c-f1c1dc865985">6,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjQ2OTNmMjY1MzQwYjRmNmZiNWMzMzYwMDBiNWI5MjBlXzI2_9c40f748-10a3-4abc-a86b-656dc41271dd">1.06</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNC0xLTEtMS03MDAzNA_b405e61e-d481-4c2b-845d-4bc6f5c4fee2">2,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i447127aa6c664afab9dd53cc168aa3e2_D20210405-20210704" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNC0zLTEtMS03MDAzNA_7266820c-9908-4173-bfc6-d6eb2643b0b2">2,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNS0xLTEtMS03MDAzNA_99869775-4a96-400e-9f07-8bd39be9dc49">662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447127aa6c664afab9dd53cc168aa3e2_D20210405-20210704" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNS0zLTEtMS03MDAzNA_df56730b-5fe0-467d-af65-e77b55b69984">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8035da5ed0409392b2294beb7ff4d0_D20210405-20210704" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNS05LTEtMS03MDAzNA_f6abb799-4a13-4346-ad08-79cc7bc69958">503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNi0xLTEtMS03MDAzNA_0b70aee7-a8a6-4c80-8bac-7abe38d57b0f">631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb8035da5ed0409392b2294beb7ff4d0_D20210405-20210704" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNi05LTEtMS03MDAzNA_ace3f71e-c967-48e8-9392-ee01bfcc1d04">631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOC0xLTEtMS03MDAzNA_2a06ba6a-9d72-4e9f-a993-5d5c93e229ed">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9d432f47f643658a371e3e1029702b_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOC01LTEtMS03MDAzNA_5d30aabd-54cc-49c7-ae60-e0134b89f23f">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, July 4, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b98f47b14654327afbb7932046478c8_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS0xLTEtMS03MDAzNA_ba59f636-a8b1-43eb-987e-c41c9dc2f3c5">69,580</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c5660480c941a989748af1c5101066_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS0zLTEtMS03MDAzNA_cca49642-d18f-463c-964b-17b4059abdc5">120,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c49da8cee9448c0a2c883ab7e653b32_I20210704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS01LTEtMS03MDAzNA_d2f1a40e-670f-43a2-a32e-df4d4bba4744">15,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d9822830ad463ba8ac40ab5c36dd39_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS03LTEtMS03MDAzNA_415a967b-cf7d-437d-9c21-606425e262d4">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab458019d3d5460183663da5dd757b6a_I20210704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS05LTEtMS03MDAzNA_337aec26-1593-43d4-8103-6ef5de34a3ed">38,594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Six Months Ended  July&#160;4, 2021</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3aba93759e44e6998ff20f017b0ca4_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy0xLTEtMS03MDAzNA_786a28f6-c50c-4cd2-9118-453c21da6392">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207dad082de3463797edacf5f0aca4ae_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy0zLTEtMS03MDAzNA_575f3bd5-119d-4bd3-9ee6-f3f6a5370489">113,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia260343fe6194304ba1526a976025d5d_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy01LTEtMS03MDAzNA_00561d85-1582-4ad8-95a2-f411fe632bb5">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb7154123a34d2fb4812c12d8a88644_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy03LTEtMS03MDAzNA_8114d528-5241-4c39-970b-a46787d1b925">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33ae55af07ea46c6bc94c11db48a7393_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy05LTEtMS03MDAzNA_21d9b5a6-40b5-4594-8d34-ac51e6f54300">38,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNS0xLTEtMS03MDAzNA_93f8d781-71ec-4c41-9c34-d05ad84afd9a">12,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i286c70d01444493ebbeeaf534a382878_D20210104-20210704" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNS0zLTEtMS03MDAzNA_65b03a6d-4dc6-4279-830a-bb400c36773a">12,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjhkZDI5MTUyNjVlYzQxYmU4MzQxYWUxNmE4ZDIyYTZlXzI2_632f9272-d83f-47fc-82d7-680b7c4ecc81">2.07</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNi0xLTEtMS03MDAzNA_bcb1f937-3aef-4362-88de-043effb0b9bc">5,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i286c70d01444493ebbeeaf534a382878_D20210104-20210704" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNi0zLTEtMS03MDAzNA_56303090-7b0b-4ce5-96bf-65c3294ca075">5,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNy0xLTEtMS03MDAzNA_fda1e346-d17a-46ac-8c87-e2fa2a40192c">1,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i286c70d01444493ebbeeaf534a382878_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNy0zLTEtMS03MDAzNA_e7d70f9f-7d7a-4e9e-a20d-7d405a817869">761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc88aabe12454cb5a6b8b3e1ffc291ca_D20210104-20210704" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNy05LTEtMS03MDAzNA_3bb1171a-3649-48a5-9dbb-5ec0d75386f3">1,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfOC0xLTEtMS03MDAzNA_071bacae-f019-4e48-b06a-0c7275b2b683">2,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc88aabe12454cb5a6b8b3e1ffc291ca_D20210104-20210704" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfOC05LTEtMS03MDAzNA_d6ceb3ee-a548-4352-be86-6bb9e73786d7">2,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTAtMS0xLTEtNzAwMzQ_51a0f263-6def-44bd-acdc-0a879f36c250">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b85e73978e94a6e9d40658f17f4dbba_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTAtNS0xLTEtNzAwMzQ_a215d3c4-2ea0-4526-8069-2767a687d3a3">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, July 4, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b98f47b14654327afbb7932046478c8_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtMS0xLTEtNzAwMzQ_2934cef7-726c-400c-bb71-adb96458b0de">69,580</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c5660480c941a989748af1c5101066_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtMy0xLTEtNzAwMzQ_3b0e9f7e-018d-4243-8478-d08735ed8be6">120,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c49da8cee9448c0a2c883ab7e653b32_I20210704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtNS0xLTEtNzAwMzQ_cb878886-443a-4aff-b296-0f63af6e120e">15,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d9822830ad463ba8ac40ab5c36dd39_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtNy0xLTEtNzAwMzQ_ff830556-04d7-40ba-91c3-c53eaf13071b">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab458019d3d5460183663da5dd757b6a_I20210704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtOS0xLTEtNzAwMzQ_73ef818d-cb49-4a43-8d40-a182e18251de">38,594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_46"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMy0yLTEtMS03MDAzNA_d68f09e4-bfc7-438c-aaf6-ace05da9fcc4">9,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMy00LTEtMS03MDAzNA_7df04efd-0ec1-41fc-a9a6-b63ac0e15079">12,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNS0yLTEtMS03MDAzNA_b7c1c4fc-c32b-4f66-8650-1d600108dc72">3,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNS00LTEtMS03MDAzNA_f91fbc1e-7d27-4ab6-8955-4c3614493330">3,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNi0yLTEtMS03MDAzNA_3235952b-b255-424b-abd5-37b3eb3540d2">644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNi00LTEtMS03MDAzNA_aec51fe3-48b3-488a-96c3-5b22e3dd5ed8">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-downs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfOS0yLTEtMS03MDAzNA_917644a4-2a06-4e6f-8af2-39ddd4c03c9f">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfOS00LTEtMS03MDAzNA_8ecd027b-2652-4c28-b457-e90359ddb6ce">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets/businesses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTEtMi0xLTEtNzAwMzQ_440756c5-9f72-4f7b-a72b-a565881d2b06">213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTEtNC0xLTEtNzAwMzQ_18331391-eea0-40d4-87b0-b67c8a800753">601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTMtMi0xLTEtNzAwMzQ_e1729035-727b-4fe4-9992-54aa697afd99">2,349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTMtNC0xLTEtNzAwMzQ_4e8da4d2-a082-4275-879e-7ddcf4c24463">685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit losses and accounts receivable allowances </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTQtMi0xLTEtNzAwMzQ_a4dc89d9-4850-4a57-a0a7-bb8444e311c2">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTQtNC0xLTEtNzAwMzQ_b2c5a5b9-d366-42bc-9cd2-e831f91052a0">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTYtMi0xLTEtNzAwMzQ_68191129-b257-4536-ba06-d8e88555fe66">1,386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTYtNC0xLTEtNzAwMzQ_747882db-d7d1-4272-b02e-5531f04a7cef">1,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTctMi0xLTEtNzAwMzQ_a8b6a2e8-51d0-4de1-9628-6b55a97f16fb">1,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTctNC0xLTEtNzAwMzQ_4797ce65-7e77-4b7d-8dc7-abb388bfd1fc">818</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTgtMi0xLTEtNzAwMzQ_d8b47f88-b692-4d58-8223-853f5f22fae4">1,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTgtNC0xLTEtNzAwMzQ_eeacaa70-c058-45b8-b860-90b989fbe58e">4,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other current and non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTktMi0xLTEtNzAwMzQ_496a57f3-aff9-4f92-8b3d-35f0e16544df">3,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTktNC0xLTEtNzAwMzQ_aeeea5f3-61dc-4077-90c6-e7c2aa3b9b10">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other current and non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjAtMi0xLTEtNzAwMzQ_b750c3a7-f5fa-4b15-ae7f-bf8d05ebfcd7">2,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjAtNC0xLTEtNzAwMzQ_a6288af0-b9b1-4cd4-bf23-2fdb77cb1ca8">1,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjItMi0xLTEtNzAwMzQ_a13d2f1f-539a-4a13-86d3-9512e8af72a1">9,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjItNC0xLTEtNzAwMzQ_ad3cd710-4b0c-4232-9d8b-1430f96f2926">9,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjUtMi0xLTEtNzAwMzQ_1fd8838b-8d66-438e-a44b-628e3bc317a3">1,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjUtNC0xLTEtNzAwMzQ_ee427aff-fbff-40f0-a957-150c5864fe83">1,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the disposal of assets/businesses, net (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjYtMi0xLTEtNzAwMzQ_f8864d15-c14a-481d-bdd1-994b0054e040">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjYtNC0xLTEtNzAwMzQ_26515739-4339-4421-8433-0623cca5b8c0">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjctMi0xLTEtNzAwMzQ_c2d61281-c8f3-4a3a-bb88-a52d2189f225">523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjctNC0xLTEtNzAwMzQ_97b4cfdf-7b77-4d22-984c-4810e9076d9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjgtMi0xLTEtNzAwMzQ_9f4fdc35-325a-4d55-9801-45db48fea253">22,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjgtNC0xLTEtNzAwMzQ_662d7f41-3673-4135-b763-21b38c5e916f">12,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjktMi0xLTEtNzAwMzQ_8db37517-21f4-40c2-b286-6d5237ab962a">17,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjktNC0xLTEtNzAwMzQ_f1effa21-39a8-43b7-8466-dc3b41ee0345">12,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzAtMi0xLTEtNzAwMzQ_9e6fee68-30a9-4563-bc17-4aeb8281c241">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzAtNC0xLTEtNzAwMzQ_1c86f513-2cbb-4078-be62-815ba77e9177">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzEtMi0xLTEtNzAwMzQ_3e2a15b4-15c4-4cad-b3a6-41080439bd95">170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzEtNC0xLTEtNzAwMzQ_aaadfec7-733f-43b9-bc65-ebb63a9bc7df">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzMtMi0xLTEtNzAwMzQ_b1131bb9-9c51-4494-b08b-6fced3657a4a">6,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzMtNC0xLTEtNzAwMzQ_73fb6dac-9955-4410-9bfc-9395d24d0492">604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzYtMi0xLTEtNzAwMzQ_c1476f64-f343-47a7-9b48-66904e40367a">5,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzYtNC0xLTEtNzAwMzQ_ee7066e0-b18b-427b-9621-cdda87378869">5,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzctMi0xLTEtNzAwMzQ_e40f4f58-dd74-4481-b9ef-faec6f1be530">2,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzctNC0xLTEtNzAwMzQ_38a9f447-54d3-416d-b526-0a6b57d71e95">2,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzgtMi0xLTEtNzAwMzQ_4d877a2f-7137-44b1-87a9-0726c85aa7ba">4,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzgtNC0xLTEtNzAwMzQ_048a231c-8763-48f3-b1ae-95e2499c8e71">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzktMi0xLTEtNzAwMzQ_09ec4e57-6a5b-4825-8936-acbbdf5112fe">2,201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzktNC0xLTEtNzAwMzQ_c3ac9e02-c273-4829-aee3-0f42ff02caa0">689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDAtMi0xLTEtNzAwMzQ_d62587b9-380f-4ae5-86f1-49b4dc8801f4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDAtNC0xLTEtNzAwMzQ_99022fb2-42ca-41c9-bc77-0f42f5a0c2ec">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDEtMi0xLTEtNzAwMzQ_54c16761-f110-435d-a08e-4195a017fa77">2,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDEtNC0xLTEtNzAwMzQ_09222c30-9bba-4e9b-a849-43c916dd7c9c">1,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDItMi0xLTEtNzAwMzQ_faa3836f-5aa1-427f-9f42-48aca9689cec">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDItNC0xLTEtNzAwMzQ_374b6763-132d-419b-a7f6-8440cdc7d0e6">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDMtMi0xLTEtNzAwMzQ_34898d04-e3a1-4cfb-aabd-f1cbfa95a574">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDMtNC0xLTEtNzAwMzQ_4674e744-8046-43fe-b705-f8c851964dac">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDQtMi0xLTEtNzAwMzQ_28845d15-20a1-4c33-9da4-066b74237130">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDQtNC0xLTEtNzAwMzQ_471773e7-da13-426f-8d07-5725c709c3f3">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDYtMi0xLTEtNzAwMzQ_bb4885f2-e2ec-4cab-9233-361b8515933f">6,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDYtNC0xLTEtNzAwMzQ_a9d175ed-8a9f-4da7-97ba-daa360270870">8,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDgtMi0xLTEtNzAwMzQ_57fc7196-01c2-43c0-a1e9-0a92d5ffe987">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDgtNC0xLTEtNzAwMzQ_e7e5339c-4446-4531-8396-8f8ab9d71de6">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease)/Increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDktMi0xLTEtNzAwMzQ_42caae08-63cc-49bd-bf82-113a33ff8978">3,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDktNC0xLTEtNzAwMzQ_6acdb451-b004-4b8b-98ce-27544f232134">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTAtMi0xLTEtNzAwMzQ_36abfb6a-da7c-4562-a23b-0b7359a14845">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3aba93759e44e6998ff20f017b0ca4_I20210103" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTAtNC0xLTEtNzAwMzQ_aaef9dd6-6266-412c-b710-021639790db5">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS, END OF PERIOD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTEtMi0xLTEtNzAwMzQ_98a915e7-b7c2-4355-bdbd-846c0cde644d">10,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b98f47b14654327afbb7932046478c8_I20210704" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTEtNC0xLTEtNzAwMzQ_c47eb27f-ee7b-4b17-928d-259f21eafee5">14,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTgtMi0xLTEtNzAwMzQ_647b3c74-dae9-44cc-a746-adc6cfb939ca">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTgtNC0xLTEtNzAwMzQ_75569aa0-bbf7-4c3e-a908-ae7bd37382f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed and noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTktMi0xLTEtNzAwMzQ_5ab82d94-788d-46ff-8a34-9298034b2479">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTktNC0xLTEtNzAwMzQ_d954cc82-f398-4ebc-b704-88f9e5fd587f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNjAtMi0xLTEtNzAwMzQ_00cf7737-a02b-427b-9269-0df90941310c">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNjAtNC0xLTEtNzAwMzQ_ea5130ee-7ea0-4287-8ef0-eba5f791629d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 1 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81Mi9mcmFnOjE3ZjczMTE3NzUzZDRhODNhZjQwMGJhM2VjNzQ5MjBkL3RleHRyZWdpb246MTdmNzMxMTc3NTNkNGE4M2FmNDAwYmEzZWM3NDkyMGRfMjg0NA_96962297-6932-46e1-8780-471b83a61026" continuedAt="i819d0b3902964bfda5ee234df03cb8ed" escape="true">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i819d0b3902964bfda5ee234df03cb8ed"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81Mi9mcmFnOjE3ZjczMTE3NzUzZDRhODNhZjQwMGJhM2VjNzQ5MjBkL3RleHRyZWdpb246MTdmNzMxMTc3NTNkNGE4M2FmNDAwYmEzZWM3NDkyMGRfMjg0OQ_38b2f4bc-4fb5-4fa1-9e5e-e4fd1ced3be4" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of July&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended July&#160;3, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81Mi9mcmFnOjE3ZjczMTE3NzUzZDRhODNhZjQwMGJhM2VjNzQ5MjBkL3RleHRyZWdpb246MTdmNzMxMTc3NTNkNGE4M2FmNDAwYmEzZWM3NDkyMGRfMjg0MA_0717119a-304c-4e78-9938-ceb4ce1c111f" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal second quarter of 2022 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal second quarter of 2022.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81Mi9mcmFnOjE3ZjczMTE3NzUzZDRhODNhZjQwMGJhM2VjNzQ5MjBkL3RleHRyZWdpb246MTdmNzMxMTc3NTNkNGE4M2FmNDAwYmEzZWM3NDkyMGRfMjgzOA_50117ffb-532e-489a-9509-357fbac47cd6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_55"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 2 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RleHRyZWdpb246ZmZhNTE1OWI4NDhjNDk4MGExYjg5NGRmOWEwOWEzNDJfMzA_01857a6a-028f-444a-a68a-1fa651dd5a43" continuedAt="ife929dd0f9a240d9912b172535503d0e" escape="true">INVENTORIES </ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ife929dd0f9a240d9912b172535503d0e"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RleHRyZWdpb246ZmZhNTE1OWI4NDhjNDk4MGExYjg5NGRmOWEwOWEzNDJfNDE_1602eb66-ed09-4c82-b069-298319015988" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:51.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMS0yLTEtMS03MDAzNA_0d8f8e91-c723-4f0a-ac49-ad857b459ffc">1,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMS00LTEtMS03MDAzNA_7ada9d68-c3c4-4f99-a8dc-31fb1a43f8a4">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMi0yLTEtMS03MDAzNA_05a552d0-a999-4e9d-9326-86fe6d832603">2,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMi00LTEtMS03MDAzNA_dae232ee-3adc-4681-afbb-644b8dcb7e13">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMy0yLTEtMS03MDAzNA_6fa3db11-95dd-46ed-9c65-797c11b4ab91">7,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMy00LTEtMS03MDAzNA_48ec1903-3e2f-4b2f-95ae-b8c86016b088">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfNC0yLTEtMS03MDAzNA_27b5774d-791b-4e73-8ed7-9f1acdc63929">11,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfNC00LTEtMS03MDAzNA_a7bb15ed-18ff-412d-9e17-dc48cfeeae8e">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 3 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMzI5ODUzNDg4NTc5OA_ea48d531-5d01-4f21-a744-64e9a61792cc" continuedAt="i2b66821067594d8dbf81694a8db319f2" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2b66821067594d8dbf81694a8db319f2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTc4OQ_fb3e8398-eb74-4769-b717-58dee37c9837" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:61.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e83abddf294b49862a285ff0526959_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMi0yLTEtMS03MDAzNA_0de3d2aa-e256-4be5-9be8-b8810caf481d">36,885</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4644c94cdbe54b26bcc9d703afd57af1_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMi00LTEtMS03MDAzNA_9f8eb1b2-8556-4664-9f94-9731dc27a255">38,572</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1e83abddf294b49862a285ff0526959_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMy0yLTEtMS03MDAzNA_71a60201-ec11-4949-a107-1c650c42b4d5">20,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4644c94cdbe54b26bcc9d703afd57af1_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMy00LTEtMS03MDAzNA_c3fd5f25-456e-4208-9512-663b809e4b09">20,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e83abddf294b49862a285ff0526959_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNC0yLTEtMS03MDAzNA_7b3f26db-eb3a-4f33-b607-8f3008d23320">16,549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4644c94cdbe54b26bcc9d703afd57af1_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNC00LTEtMS03MDAzNA_70a07de5-6ab3-4a89-83d2-31ce5033e55f">18,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a97a3c30ea42378cd8743fdde441fa_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNS0yLTEtMS03MDAzNA_219d33f1-23b1-4355-b660-004974296208">22,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa373ac3b69447baa5db15e621348bc_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNS00LTEtMS03MDAzNA_c1537c51-78eb-43db-afa2-c272a0058701">23,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a97a3c30ea42378cd8743fdde441fa_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNi0yLTEtMS03MDAzNA_45b8b630-da5a-44d4-a569-a23b81f9e56f">12,269</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fa373ac3b69447baa5db15e621348bc_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNi00LTEtMS03MDAzNA_3f646415-23bd-40e5-84dc-dfcc074ff85b">11,925</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a97a3c30ea42378cd8743fdde441fa_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNy0yLTEtMS03MDAzNA_69cb9f15-4512-4075-904a-98f79f7a65b7">10,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa373ac3b69447baa5db15e621348bc_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNy00LTEtMS03MDAzNA_e49be848-6cd7-4c45-bc3a-55a60bbceaf5">11,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a8cf9ad2e7647399248ae1419508e0f_I20220703" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfOS0yLTEtMS03MDAzNA_3ec20c1f-32d1-4096-aab2-77005f99af95">6,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f8bf96c98845fea1edfe19f545e830_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfOS00LTEtMS03MDAzNA_24014a02-3bc8-4482-a78e-cc92188dcf29">6,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0b304ee8aa140a588288dad04e0aaac_I20220703" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTAtMi0xLTEtNzAwMzQ_d329e2b7-348e-4a6a-a687-7ce58bf4a781">8,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26a9c75b7c94e1085843fc1e74cf160_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTAtNC0xLTEtNzAwMzQ_33a65379-bf26-416a-945e-c55aa219bac8">9,837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTEtMi0xLTEtNzAwMzQ_72660c5a-87f9-48f7-a077-00cc2c7c02fb">15,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTEtNC0xLTEtNzAwMzQ_0489143c-df03-43a6-93b6-eab5bbc8c435">16,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTItMi0xLTEtNzAwMzQ_35c0f90e-f0ea-4ed8-9869-1fe0e69f78a5">42,408</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTItNC0xLTEtNzAwMzQ_7bd37e98-4ce1-4834-99cc-47d68e69d780">46,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="if4bbbe18d2594f8aad55ae35a3d252da_D20220404-20220703" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfNjE1_8d324f0d-371e-498d-ba5f-51c48ac3e867">0.6</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTgwNg_1dd1cec0-8c43-4c3b-8c4c-082422888729" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of July&#160;3, 2022 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:39.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28638ba3e4b42e1a64486cf30194fd9_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMS0yLTEtMS03MDAzNA_ed790591-d8d8-4249-812a-9f168241446d">9,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b72b1c234f43a3b95f3f25252e2da2_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMS00LTEtMS03MDAzNA_783cc598-594d-42ae-ac62-aeaa1d045a84">10,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3057d1e214724cb89a838867914b6faf_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMS02LTEtMS03MDAzNA_2869c7a7-6431-475e-beae-8cf049775161">14,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMS04LTEtMS03MDAzNA_b162ab4b-f663-4def-b47a-7a7968f38d6a">35,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc23407245a4376af9e0430687579f6_D20220103-20220703" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMi0yLTEtMS03MDAzNA_30aa31e1-5cb4-4f08-a4e1-846edfc39f2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMi00LTEtMS03MDAzNA_876ba88a-279f-4ba7-a83d-eef88de514a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMi02LTEtMS03MDAzNA_8e481612-41a2-45be-b624-819667391ba1">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMi04LTEtMS03MDAzNA_330eb344-3e59-454d-a933-189949670c1c">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bc23407245a4376af9e0430687579f6_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNC0yLTEtMS03MDAzNA_1a20cb61-e44f-4486-b08f-0f3770737501">665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNC00LTEtMS03MDAzNA_5d05de24-501b-47af-b6c6-51e577813328">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNC02LTEtMS03MDAzNA_08f58749-47d0-4130-a03a-2cf5db2a3125">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNC04LTEtMS03MDAzNA_1a0bddcc-894a-4b57-8eaa-face6662cff5">1,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e542b5e6c24d51a5840e549f120d1c_I20220703" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNS0yLTEtMS03MDAzNA_341d98d5-eb2d-488f-8bed-c3df7bbc5c26">9,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709b7cc74ca74a80a4840c6c2463936a_I20220703" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNS00LTEtMS03MDAzNA_09db5b42-97bd-452b-83a4-6da5c385fdd6">10,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf76b5399fa64aeda445faded52c1175_I20220703" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNS02LTEtMS03MDAzNA_a4a13f31-95fd-49e5-9856-d2670828448b">14,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNS04LTEtMS03MDAzNA_1f70cda5-1e7e-4e9f-a9b2-1d2ed41ee6ca">34,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is <ix:nonNumeric contextRef="i48d21dab7e7140dc8981cd34ec5ca636_D20220103-20220703" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTIwNg_12d81352-045d-4b6b-ad67-2d6140b12911">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is <ix:nonNumeric contextRef="i17734f536a0942538d393c2a2be78a63_D20220103-20220703" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTMxNQ_03f34236-922a-49c5-8234-0c19c8e1098c">21</ix:nonNumeric> years. The amortization expense of amortizable intangible assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTQyMQ_719d2aba-fa78-4594-bce5-41674ab3dc5b">1.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTQyOA_320289b6-3a71-4e25-98e2-099ece674289">1.2</ix:nonFraction>&#160;billion for the fiscal second quarters ended July&#160;3, 2022 and July&#160;4, 2021, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTA5OTUxMTYyOTkyNA_aee27440-9f9f-48a6-a7ad-11338fe7cd76">2.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTA5OTUxMTYyOTkzOA_f2953f30-bc94-452a-9c84-ea0125fc4da4">2.4</ix:nonFraction>&#160;billion for the fiscal six months ended July&#160;3, 2022 and July&#160;4, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTc4OA_e638b280-81b6-43ff-bf8d-bc20313030ca" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"></td><td style="width:18.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi0wLTEtMS03MDAzNA_d403a910-8316-445f-9e84-7eb072ecee5d">4,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi0yLTEtMS03MDAzNA_dec823c2-c7bc-4abf-b0ff-f2a89a62dcce">4,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi00LTEtMS03MDAzNA_a5c892d0-dbd2-456b-bd6b-a4e3473a1ae5">4,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi02LTEtMS03MDAzNA_0bad6abe-39d4-4351-9389-6f8c1f32ccb5">3,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi04LTEtMS03MDAzNA_d34df8cf-be22-4111-b0fc-1a4c872d8fa0">2,800</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 4 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNjA0NzMxMzk2NDgyNg_0c33a63c-ba0a-4cac-8c58-92d63d53761e" continuedAt="ibdd1d3c7e711480a943b286b51173b20" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ibdd1d3c7e711480a943b286b51173b20" continuedAt="ib4d4f4d98d4946558a1411153c35700b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of July&#160;3, 2022, the cumulative amount of cash collateral received by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703" decimals="-6" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTY0Nw_54fbdfdb-233f-40b1-9686-4808074f60a7">233.0</ix:nonFraction> million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of July&#160;3, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjMxMg_58a04449-5afc-410d-a84c-a609dc94418e">46.7</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="i5b760074bfcb4cc58e6a1ae3aac3d6e3_I20220703" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjMxNg_b31cb338-bf97-4244-9ae5-867a23568dba">37.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ia1f129fa36664a10963aba1c422e6f76_I20220703" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjMyMw_c28c2d57-7872-4308-8eaa-30e008ba3702">10.0</ix:nonFraction>&#160;billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="idd623d33cd684c54b9e101ccb633f27e_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjQ5OA_c18332f7-9e42-4caf-92d3-3245be3cb88c">45.8</ix:nonFraction> billion,  $<ix:nonFraction unitRef="usd" contextRef="i3634444be4ba4cf2985688254d252758_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjUwMw_964e2b4c-8f8b-4858-b390-cd47fb2c7ad0">37.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i9480099d643c4b7cb1462c5d2ac5ecd7_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjUxMA_8aa0ee12-46a5-4d9d-85df-08128eff0524">10.0</ix:nonFraction> billion respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July&#160;3, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNDY0MA_ce489c47-5fba-49eb-a70b-8b8bf342d3e9">613</ix:nonFraction>&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNDg5OA_dc2e002b-1c08-4cd5-b123-17c3b2536be2">next 12 months</ix:nonNumeric> as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNTA1OQ_813dd2d8-cf6b-4a46-8c0f-bb77775a701f">18</ix:nonNumeric> months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="ib4d4f4d98d4946558a1411153c35700b" continuedAt="i447243875f0d41b3aa899da4d9bc99f8"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzNjY_0d6f970d-3f24-45b8-a70a-8bfd60bb546b" continuedAt="i85e1d9bd116344ba9d9bdb8049f23516" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2022 and 2021, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d3df0e7ab74f219ef244be03b7433f_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC0xLTEtMS03MDAzNA_79684ae2-2eb0-409f-aa08-39784a7a8b8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88ebdcc2bcd40839c3f8784531db588_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC0yLTEtMS03MDAzNA_0947b273-9632-473a-a676-d503661e969c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97621d82be79453e9fa3553e70d1ca31_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC0zLTEtMS03MDAzNA_a38bd3e1-1417-49a1-a984-00fb63952d4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc8308f7d14c4181a0ae28210ff4ad62_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC00LTEtMS03MDAzNA_7292467b-f783-4209-97f2-19790553f632">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dccbe17c2b340f59a7b489aff4bfbda_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC01LTEtMS03MDAzNA_53fd6eca-1005-413d-a27d-a7e1e10bd0e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65844a253fd240329a7e6e0a74622398_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC02LTEtMS03MDAzNA_45f015c7-a8fb-4160-8538-6a24a3aa8286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3261c0c12c40feacb473910d1a2350_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC03LTEtMS03MDAzNA_45d802c2-e9d8-42ed-b21e-7dde9e778bf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22373e19eea64b96965159ae548a3427_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC04LTEtMS03MDAzNA_af8180ac-bd07-4a0d-8cd4-b40b58be9792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i052c717f8d424999972ae78c20e442bb_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC05LTEtMS03MDAzNA_621f0b97-e0cf-4983-9c97-9bdfd9bd49d2">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70aee3ac261c42958695f57ef7aa8d75_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC0xMC0xLTEtNzAwMzQ_ab28e6b3-1dbf-40bb-a404-8ac072dc1ba0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d3df0e7ab74f219ef244be03b7433f_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS0xLTEtMS03MDAzNA_95cd54ce-ffec-4143-b366-388480cb6464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88ebdcc2bcd40839c3f8784531db588_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS0yLTEtMS03MDAzNA_c9a03c11-8263-4763-a3fb-5ce97587fb78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97621d82be79453e9fa3553e70d1ca31_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS0zLTEtMS03MDAzNA_8b28f7d7-e3b6-45b3-8ef5-730da9bb4dc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc8308f7d14c4181a0ae28210ff4ad62_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS00LTEtMS03MDAzNA_c1e7592c-ba9f-4366-8da2-076dbbb4b212">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dccbe17c2b340f59a7b489aff4bfbda_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS01LTEtMS03MDAzNA_b00365e5-f54b-4b19-91d3-8462dad11e01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65844a253fd240329a7e6e0a74622398_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS02LTEtMS03MDAzNA_ffd6deb9-8309-4764-9ea0-7860e3965545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3261c0c12c40feacb473910d1a2350_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS03LTEtMS03MDAzNA_41ce561f-5b20-418b-90c7-15d83a7e64c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22373e19eea64b96965159ae548a3427_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS04LTEtMS03MDAzNA_e60b3814-4d16-46ea-8cd5-7aa0050a56dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052c717f8d424999972ae78c20e442bb_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS05LTEtMS03MDAzNA_355fa998-4ee6-43c5-845f-f902ebe7287a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70aee3ac261c42958695f57ef7aa8d75_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS0xMC0xLTEtNzAwMzQ_02e5db65-5c97-49b8-9dd0-102fef905298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffbcc5181264051a6e74314d827dd4f_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtMS0xLTEtNzAwMzQ_e1fc9b69-40d3-4d88-a709-4279eb318f06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f3ae164fc04ca49438e6a4347fa265_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtMi0xLTEtNzAwMzQ_689bce9b-8c89-4925-ad0d-ba472e07803a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426ece422f5943a1808350edaeddda4a_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtMy0xLTEtNzAwMzQ_6752251b-7036-4e67-b4aa-7e8bfafcd256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e20365cb144535a9cedca9aed02546_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtNC0xLTEtNzAwMzQ_dbafbe47-5e0d-469c-a5bc-754b97b68bae">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife68bcfafe314d1496be2149a6e924e8_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtNS0xLTEtNzAwMzQ_5238b174-226f-4f39-b725-a2549d817936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c9b9a50530a45588281a4cf80ddebf3_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtNi0xLTEtNzAwMzQ_f01004d3-2722-4e55-883e-567cd52571d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aaee80239bc4e2e93981af33614099c_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtNy0xLTEtNzAwMzQ_5154e07e-2ab5-40d3-a123-228df6d39af2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if188f2ad192d44daa74ba7278a4fcc3c_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtOC0xLTEtNzAwMzQ_d1c15e47-1fd4-47e1-b857-0e07ac6e38eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae48c65d3bab4e199e770a5fcfb0a80c_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtOS0xLTEtNzAwMzQ_0b7918c3-7a24-42e6-a435-5ba787ea3784">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab75f9b509940dbbb2fb9dead6e12fe_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtMTAtMS0xLTcwMDM0_4e1177d0-e0a1-4c5b-8141-41d919da8688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffbcc5181264051a6e74314d827dd4f_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtMS0xLTEtNzAwMzQ_4df9c615-84f1-4249-a44a-deb1b4db93a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f3ae164fc04ca49438e6a4347fa265_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtMi0xLTEtNzAwMzQ_f111a7d6-a7cc-4921-b830-7a58d28a13eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426ece422f5943a1808350edaeddda4a_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtMy0xLTEtNzAwMzQ_eed717da-9fc4-419c-9202-dfc8107a055c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e20365cb144535a9cedca9aed02546_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtNC0xLTEtNzAwMzQ_b6e0b8c2-cc25-4474-a0e4-6b5dbbc63d39">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife68bcfafe314d1496be2149a6e924e8_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtNS0xLTEtNzAwMzQ_dbc4d9b2-6a46-4fab-a4f2-00d5ab8562cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c9b9a50530a45588281a4cf80ddebf3_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtNi0xLTEtNzAwMzQ_cda6ed9e-d4d8-4c7b-821d-1cbfc4e425db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aaee80239bc4e2e93981af33614099c_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtNy0xLTEtNzAwMzQ_6d3eb306-510c-4f8e-9abc-c17bf2760492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if188f2ad192d44daa74ba7278a4fcc3c_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtOC0xLTEtNzAwMzQ_19ce921b-13c4-410e-aaec-08698fd33d99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae48c65d3bab4e199e770a5fcfb0a80c_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtOS0xLTEtNzAwMzQ_9ed8b355-1947-4580-9a9b-f98f54985f5b">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab75f9b509940dbbb2fb9dead6e12fe_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtMTAtMS0xLTcwMDM0_aa4caa57-1284-4513-ac95-968d8b565c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da8d593cb89443aa125dde02cbdc486_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtMS0xLTEtNzAwMzQ_851a2a15-541b-4418-aa97-b3d632fc4142">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c67b5fa2091465ab9dc2693e5093889_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtMi0xLTEtNzAwMzQ_4b5ff7f7-f4e5-4a03-9dcd-761551335271">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1e66f130e549638c38349732d6b9df_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtMy0xLTEtNzAwMzQ_a4649936-6e1f-4225-8992-d105e87ad6e0">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada32f8e1c5a4cfc8679d5181aba3515_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtNC0xLTEtNzAwMzQ_1b91c9bc-6506-4e6b-927d-e3ad36312554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0c4df0b7052471c8b4beecb6802dc5e_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtNS0xLTEtNzAwMzQ_3c482d8b-c2c2-4078-ac92-824442b773c9">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf52c3ab707d4713b81fa73f99e93487_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtNi0xLTEtNzAwMzQ_38cfb4d0-699f-407a-b3ea-60e39d77f6c9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928ceff46ed841a39f43bd28f651f09a_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtNy0xLTEtNzAwMzQ_d0f52d11-dd56-44cb-af8e-081dc2ea74bc">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad78c3349a7f48d6a0d49345aca00641_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtOC0xLTEtNzAwMzQ_8c91bfc9-fe9b-417f-b362-a49046b751e7">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c77b30de27d45df96a8104f4525f7d1_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtOS0xLTEtNzAwMzQ_bad28f2f-8718-4a3a-92f4-62bf496307cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf04012d40344529ab914fdd97d47466_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtMTAtMS0xLTcwMDM0_5eb8cb17-335d-42dc-a394-27f0d7f310ed">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da8d593cb89443aa125dde02cbdc486_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItMS0xLTEtNzAwMzQ_0a8ccad7-0a21-4b66-86ea-2ee855ffc4f3">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c67b5fa2091465ab9dc2693e5093889_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItMi0xLTEtNzAwMzQ_c2309bf5-41a7-4034-869e-a7eb0a9e9315">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1e66f130e549638c38349732d6b9df_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItMy0xLTEtNzAwMzQ_4acfbf2b-c546-4761-a635-2facfd83fe9d">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada32f8e1c5a4cfc8679d5181aba3515_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItNC0xLTEtNzAwMzQ_88cf9174-bb55-4faa-a7ce-60a00e5ea13a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0c4df0b7052471c8b4beecb6802dc5e_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItNS0xLTEtNzAwMzQ_e91da700-bb3a-4963-a071-ad1a9f9c7038">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf52c3ab707d4713b81fa73f99e93487_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItNi0xLTEtNzAwMzQ_3996917a-578a-49d5-b448-43063072312e">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i928ceff46ed841a39f43bd28f651f09a_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItNy0xLTEtNzAwMzQ_26b6f382-7383-4cf4-8a36-a8a55f3e7f44">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad78c3349a7f48d6a0d49345aca00641_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItOC0xLTEtNzAwMzQ_c4dc0c0e-6aa0-4712-8668-5af80023b3ce">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c77b30de27d45df96a8104f4525f7d1_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItOS0xLTEtNzAwMzQ_936a6bd3-cc9c-4933-b685-cfe6ef1101ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf04012d40344529ab914fdd97d47466_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItMTAtMS0xLTcwMDM0_264868fb-8feb-4e9c-bb8c-73dbaf2c8e6f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61321ab212a84d638148bcc2c0db2529_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtMS0xLTEtNzAwMzQ_26dae329-9a0f-4aed-a6fe-9e5ea84a5862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87adb12b544400aabac91ac10b55d9d_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtMi0xLTEtNzAwMzQ_933b4642-f69b-4bc6-89fc-6fc8e6aef4e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacaa73a24dc34f44ba74aee3094334f5_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtMy0xLTEtNzAwMzQ_9f1ec105-69f8-47ff-b3b6-19c7ab29276c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee1a2a6de5a421fbaf2a6ac76876bc0_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtNC0xLTEtNzAwMzQ_c2b54d9f-eb97-49ca-af47-10deb8b36a66">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f90bd741f24c46bc4278b4e28f7162_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtNS0xLTEtNzAwMzQ_327a107c-b200-45c0-9ef5-d97ac33c94ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9177a536afa141448d3a25292e1296fd_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtNi0xLTEtNzAwMzQ_3a95cbad-6220-41b6-89d8-e04aa7e1ce96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id5df6c8fd44b4cfaa5405658069eea76_D20210405-20210704" xsi:nil="true" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtNy0xLTEtNzAwMzQ_9e5a4ec6-177b-445f-b798-1bc84b14add8"></ix:nonFraction></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328dd4d5d05a4285b0893246ff22ab9f_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtOC0xLTEtNzAwMzQ_1aa5e339-bece-4068-8916-cab1a45fc218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dcc42285b6142869767f28bbda885e9_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtOS0xLTEtNzAwMzQ_d8cbf6b2-abc5-4ec8-92c3-8339174df2e8">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5735d577994517bf90dd973a568b70_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtMTAtMS0xLTcwMDM0_aeac3b9c-e8ae-41ec-9eaf-1841197b28e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61321ab212a84d638148bcc2c0db2529_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctMS0xLTEtNzAwMzQ_e0106ae5-6bfa-4f12-9405-9b5d6664b810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87adb12b544400aabac91ac10b55d9d_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctMi0xLTEtNzAwMzQ_d5e78cfc-1a91-4257-9c5b-070bd470b6d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacaa73a24dc34f44ba74aee3094334f5_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctMy0xLTEtNzAwMzQ_c160d810-35c8-431f-910a-9dab5189d260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee1a2a6de5a421fbaf2a6ac76876bc0_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctNC0xLTEtNzAwMzQ_481a04f1-b28f-42dc-ba8c-0e2a92bb9a72">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f90bd741f24c46bc4278b4e28f7162_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctNS0xLTEtNzAwMzQ_c4738256-bda7-46be-ac02-3e005584bc51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9177a536afa141448d3a25292e1296fd_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctNi0xLTEtNzAwMzQ_522c4224-90a3-45e9-aec9-205aba9b8323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5df6c8fd44b4cfaa5405658069eea76_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctNy0xLTEtNzAwMzQ_28872f25-c7bb-4627-add2-897d04dd4fc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328dd4d5d05a4285b0893246ff22ab9f_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctOC0xLTEtNzAwMzQ_c1527d0b-2de6-4ee2-b564-d079411fa1e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dcc42285b6142869767f28bbda885e9_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctOS0xLTEtNzAwMzQ_71179a1a-9af6-4a20-a3ed-b0c922892572">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5735d577994517bf90dd973a568b70_D20210405-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctMTAtMS0xLTcwMDM0_ed6b0871-8628-4caf-9bbc-00d399a02f27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i447243875f0d41b3aa899da4d9bc99f8" continuedAt="iec48e79d2ccf4688835404c39557fb85"><ix:continuation id="i85e1d9bd116344ba9d9bdb8049f23516" continuedAt="i9ab729d6c1c34fdba9743fb62518bbab"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2022 and 2021, net of tax:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbfeb1c605d04a88a882e139f2fa2b4b_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC0xLTEtMS03MDAzNA_2165ea07-7abd-443a-addb-dd7b807a2b2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia993599e0574405f95aa489e16792d7a_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC0yLTEtMS03MDAzNA_93ce042e-5499-46de-8c6e-96a17361a273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f85ff3cb4e8499d8c86fd7dc882efb7_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC0zLTEtMS03MDAzNA_e6a5e82e-8f5e-4e67-9fd6-f592057ec106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1c9a175a9fc4cbb8ad060ba18633dbc_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC00LTEtMS03MDAzNA_9432fdc9-2fcb-451d-a1a9-4d186c5e29b9">772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea95b17407743509a8e35647b738929_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC01LTEtMS03MDAzNA_433fdbc6-28e8-498a-b4b2-dca376deb0f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc5f6a5fc5d46d49d5760c3a3f39b2c_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC02LTEtMS03MDAzNA_198e48c6-b0b0-4de0-93db-cbe0f9cc2d5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05aa739fc5bf4fa59b3b001daa07a0b4_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC03LTEtMS03MDAzNA_7d39486f-9fe1-4561-aeae-f455ad9392c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f501bd038344088354f3932536f457_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC04LTEtMS03MDAzNA_3cfeb362-4507-4f62-9bef-64819d6c8f36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5664b5dabfd740a3b6f4396883d2cda8_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC05LTEtMS03MDAzNA_4f83beb9-f104-4121-990c-b81892f85ba6">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i408e7c6bfbab44228e55381d1839fb61_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC0xMC0xLTEtNzAwMzQ_353f875f-9ca4-4aaa-99bd-1fdee9b1a768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbfeb1c605d04a88a882e139f2fa2b4b_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS0xLTEtMS03MDAzNA_3b52f650-9451-45f0-8c5d-18facd3a7447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia993599e0574405f95aa489e16792d7a_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS0yLTEtMS03MDAzNA_a2b9edcc-dfb3-4599-bf26-dcccc577ffa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f85ff3cb4e8499d8c86fd7dc882efb7_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS0zLTEtMS03MDAzNA_250ff3d6-d9eb-4c80-aca8-03920eba492f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c9a175a9fc4cbb8ad060ba18633dbc_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS00LTEtMS03MDAzNA_880cb1b9-8422-4d84-825a-c90e02eff009">772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea95b17407743509a8e35647b738929_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS01LTEtMS03MDAzNA_02a0b585-9f63-4a89-bad6-397ced331a14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc5f6a5fc5d46d49d5760c3a3f39b2c_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS02LTEtMS03MDAzNA_33879ed3-c9b5-44c3-9b6b-e219e5f4bd39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05aa739fc5bf4fa59b3b001daa07a0b4_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS03LTEtMS03MDAzNA_8831f89b-580b-431e-9573-d32a4c10d8ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f501bd038344088354f3932536f457_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS04LTEtMS03MDAzNA_8163ea6d-6bc1-4c0f-8add-abd415d4831c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5664b5dabfd740a3b6f4396883d2cda8_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS05LTEtMS03MDAzNA_13cf884b-31ed-4a2c-b43e-a42593914dfc">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i408e7c6bfbab44228e55381d1839fb61_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS0xMC0xLTEtNzAwMzQ_e4e6c663-24b4-47d3-b93b-706c7fc69a75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580cc60e6cdf496389e8435cc5955c25_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtMS0xLTEtNzAwMzQ_902ef71c-2dd6-4c28-8df3-4549a775c95f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d90fbd49d4704baf0c8e5c9ca228b_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtMi0xLTEtNzAwMzQ_8af20a91-3334-427c-bd51-e3beaebaf700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fc5113393f459a8780e466f3ff2ea9_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtMy0xLTEtNzAwMzQ_ba81bddc-d49c-4470-bc36-864a974242e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf9543b34dd4f93b96f68a4ca25eae0_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtNC0xLTEtNzAwMzQ_f004324f-73ee-4c03-b6d2-861b0d8dbc52">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d09453c094af1b92a936cdfbacd94_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtNS0xLTEtNzAwMzQ_df301e21-9a50-4b70-ae0b-98d3f83dfc12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f2db1557b74173a9cac2b055ab75cf_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtNi0xLTEtNzAwMzQ_77e2ac6e-8585-4780-9f6f-60eee18b8163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0b9936cce44a77872c14571dd9ddf5_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtNy0xLTEtNzAwMzQ_82199b74-736d-4471-bc5b-9b3c85892092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6797e39b27654b74a22b814d372e8d12_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtOC0xLTEtNzAwMzQ_33908955-ccea-43d9-b858-f921e024614a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326883f0b0fd4a0d825ea9cb59de5804_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtOS0xLTEtNzAwMzQ_eb88bb6b-1397-4cc5-944a-6b02227768e4">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a97916e3efb46e09815fb9d03aa504b_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtMTAtMS0xLTcwMDM0_e056b182-5259-44b8-be23-06d285749a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580cc60e6cdf496389e8435cc5955c25_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtMS0xLTEtNzAwMzQ_5f2230f9-944f-49c4-abb4-ee81dfbaabd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d90fbd49d4704baf0c8e5c9ca228b_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtMi0xLTEtNzAwMzQ_f0b3f2c8-105c-4eaf-a98b-c887eb5bf8ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fc5113393f459a8780e466f3ff2ea9_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtMy0xLTEtNzAwMzQ_c04acefa-b806-4b40-a02e-116cc49c59f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf9543b34dd4f93b96f68a4ca25eae0_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtNC0xLTEtNzAwMzQ_284f1c83-766a-44d7-84dc-6b727db16b28">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d09453c094af1b92a936cdfbacd94_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtNS0xLTEtNzAwMzQ_f54093bd-c4f9-4ada-9913-556a167536e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f2db1557b74173a9cac2b055ab75cf_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtNi0xLTEtNzAwMzQ_1d466f96-71dc-4c13-ba2b-9487c9d60719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0b9936cce44a77872c14571dd9ddf5_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtNy0xLTEtNzAwMzQ_3ba9de2e-2f15-474b-8afb-4dd925dd4e10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6797e39b27654b74a22b814d372e8d12_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtOC0xLTEtNzAwMzQ_470a7f89-2983-430e-b3a0-67ab744c9c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326883f0b0fd4a0d825ea9cb59de5804_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtOS0xLTEtNzAwMzQ_7d03b228-b460-4384-aaa3-b80d995f8ff8">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a97916e3efb46e09815fb9d03aa504b_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtMTAtMS0xLTcwMDM0_d5e399cc-c3e8-4318-b443-62263b804b67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide58dcad79ab45bfbe863ddffac83f2f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtMS0xLTEtNzAwMzQ_df2d45c3-8482-4a2c-bdf7-3564a9fe9e6b">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6facbdbd9a04803b321187e1f040e70_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtMi0xLTEtNzAwMzQ_976f83ac-29a4-4fd9-abb5-4c81f0ac475a">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2561de1bd5d4cfdb3e9f49ac0d0ffdb_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtMy0xLTEtNzAwMzQ_f5173133-89a6-40fa-9a72-897920e81d08">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45661dbdcb9f4e8c8661b5da47b3b783_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtNC0xLTEtNzAwMzQ_5c068980-ce53-4a3a-a960-dc422b12d903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21556e9074dd4a0f8288063ebf6e970a_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtNS0xLTEtNzAwMzQ_c112f152-58e2-4eb9-9495-671fe39fe179">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c220c5c40240a4954cd7dae60f584b_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtNi0xLTEtNzAwMzQ_2975d81e-0bb7-4800-805e-92d1f8e5c0ef">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice3fdb84972d41ab9ba4bf47ef5ce854_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtNy0xLTEtNzAwMzQ_78b7b595-1408-4ff0-82f4-eef90531da7c">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebf3885343f54fc687fd890f151c63d7_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtOC0xLTEtNzAwMzQ_508d4e10-c4d0-4ab1-bcf8-837750f577af">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i710f2081b05d404f86c62f35feb19186_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtOS0xLTEtNzAwMzQ_ffb0fb5b-de35-4797-9c6d-f4405cbef33e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8399be3fe8e44b1f94bca7aff8b41680_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtMTAtMS0xLTcwMDM0_5594d3f2-56fb-4fbe-8ab3-068da3f06a4f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide58dcad79ab45bfbe863ddffac83f2f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItMS0xLTEtNzAwMzQ_d42f4d6b-db64-41e1-9ff3-2241c1995120">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6facbdbd9a04803b321187e1f040e70_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItMi0xLTEtNzAwMzQ_88df13d1-11ca-4752-8e2b-99b7844184b1">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2561de1bd5d4cfdb3e9f49ac0d0ffdb_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItMy0xLTEtNzAwMzQ_25a0e9e6-4d63-4450-8cbe-b9fca42cdbcf">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45661dbdcb9f4e8c8661b5da47b3b783_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItNC0xLTEtNzAwMzQ_546f24c0-35b0-4a7c-b9f8-9a1f21537638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21556e9074dd4a0f8288063ebf6e970a_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItNS0xLTEtNzAwMzQ_beef195d-035e-4aa1-92d9-2865f40bc482">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19c220c5c40240a4954cd7dae60f584b_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItNi0xLTEtNzAwMzQ_5fdc525d-71cc-49fc-8a54-b1c41643f797">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice3fdb84972d41ab9ba4bf47ef5ce854_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItNy0xLTEtNzAwMzQ_a8097b83-c2a3-4cc6-8f7d-b7387d6129a7">243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf3885343f54fc687fd890f151c63d7_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItOC0xLTEtNzAwMzQ_9b32e8fb-9894-4fac-a1ad-b6bb24db95c1">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i710f2081b05d404f86c62f35feb19186_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItOS0xLTEtNzAwMzQ_ac3348f2-645a-48d1-8b60-06bc5a42103d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8399be3fe8e44b1f94bca7aff8b41680_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItMTAtMS0xLTcwMDM0_3d7e5f0f-fc33-43cd-94e8-11e307be8b4f">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84064d0beba43568502fa51c3264dd4_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtMS0xLTEtNzAwMzQ_bb21c6ec-d911-4739-927c-9e524c53893d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237ab2105da9479f82802abf0e650c17_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtMi0xLTEtNzAwMzQ_331ecd10-48fb-42ad-b209-4788864ab7d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208da50d0b9a48189368d6e10d6a4fb3_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtMy0xLTEtNzAwMzQ_e09d022d-5cc4-460b-b8cc-11e2c0c64b0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1f944b894e40ceba89ce94e11c72d7_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtNC0xLTEtNzAwMzQ_eeb77703-e760-46ba-b90b-1f7083adc9a0">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6b67f063a14008822cf81aae590318_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtNS0xLTEtNzAwMzQ_d2fddece-4a64-4d93-8498-1b427414f489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce50b6f31f149f3a70237f88868b0cd_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtNi0xLTEtNzAwMzQ_1884fd18-2dbe-4b45-a34e-261b8e26172b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f6dad62d53466ea010085927c81451_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtNy0xLTEtNzAwMzQ_9a7c549c-11b7-435c-a060-1e5227e5f784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81964c4791646ce966adfc8c90aa7a2_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtOC0xLTEtNzAwMzQ_4d2281ff-69f7-4cfd-8b94-8d8a73ba55e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5349dd1284b14193a5715e5b6427c992_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtOS0xLTEtNzAwMzQ_bbd0082c-40f6-44fd-a22a-7723b608a17a">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc891ef4689a4994ac1847e71f539d52_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtMTAtMS0xLTcwMDM0_ae283c6d-1097-4031-a311-12a3ea70c8c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84064d0beba43568502fa51c3264dd4_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctMS0xLTEtNzAwMzQ_9581519b-cf47-4d3c-97a1-127e1c51d384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237ab2105da9479f82802abf0e650c17_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctMi0xLTEtNzAwMzQ_1354fef6-28df-47ff-9431-8ff4af45baa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208da50d0b9a48189368d6e10d6a4fb3_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctMy0xLTEtNzAwMzQ_81f95e31-05a1-40e6-a900-7717f4dfa400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f1f944b894e40ceba89ce94e11c72d7_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctNC0xLTEtNzAwMzQ_b7719836-2504-4bb4-a523-2e0366d51c88">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6b67f063a14008822cf81aae590318_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctNS0xLTEtNzAwMzQ_0d1d3849-b933-40ec-8044-9633bf59b504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce50b6f31f149f3a70237f88868b0cd_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctNi0xLTEtNzAwMzQ_70e038b3-f8a7-4cbe-b4ba-e6ea8771b1fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f6dad62d53466ea010085927c81451_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctNy0xLTEtNzAwMzQ_6160bdec-103f-4d6e-ad38-546512d613c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81964c4791646ce966adfc8c90aa7a2_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctOC0xLTEtNzAwMzQ_1efe3c15-53d7-400b-8c3b-de6e93a27504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5349dd1284b14193a5715e5b6427c992_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctOS0xLTEtNzAwMzQ_f5cfe786-f633-437c-8fb8-fd828c6b375e">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc891ef4689a4994ac1847e71f539d52_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctMTAtMS0xLTcwMDM0_e7477fe0-ecde-4f1c-b358-f7940d9e65a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="iec48e79d2ccf4688835404c39557fb85" continuedAt="i02ab23ee45a045b79ad01e51059c68a0"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzNjE_cf49201c-cbbc-4726-9d62-fef510666ba1" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  July&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f13601b97f4c86a0a2ee40c14abae9_I20220703" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwOTRhZGZkYTM0NzQ2NWZhYzk2MTAxOGMwYjA0ZTQ5L3RhYmxlcmFuZ2U6ZTA5NGFkZmRhMzQ3NDY1ZmFjOTYxMDE4YzBiMDRlNDlfNC0yLTEtMS03MDAzNA_e553f0f3-d9a2-4731-9111-7dfdb1f75acc">9,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1785c3b63c8c4e48805730aed53c751b_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwOTRhZGZkYTM0NzQ2NWZhYzk2MTAxOGMwYjA0ZTQ5L3RhYmxlcmFuZ2U6ZTA5NGFkZmRhMzQ3NDY1ZmFjOTYxMDE4YzBiMDRlNDlfNC00LTEtMS03MDAzNA_d30fc998-7bc1-4a2a-a7cd-e7bb7a103709">9,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2f13601b97f4c86a0a2ee40c14abae9_I20220703" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwOTRhZGZkYTM0NzQ2NWZhYzk2MTAxOGMwYjA0ZTQ5L3RhYmxlcmFuZ2U6ZTA5NGFkZmRhMzQ3NDY1ZmFjOTYxMDE4YzBiMDRlNDlfNC02LTEtMS03MDAzNA_8c805c95-7b33-4ec3-83d2-620d28604430">1,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1785c3b63c8c4e48805730aed53c751b_I20220102" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwOTRhZGZkYTM0NzQ2NWZhYzk2MTAxOGMwYjA0ZTQ5L3RhYmxlcmFuZ2U6ZTA5NGFkZmRhMzQ3NDY1ZmFjOTYxMDE4YzBiMDRlNDlfNC04LTEtMS03MDAzNA_f520e939-23d5-491d-a09f-1c7618a0db43">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzOTQ_6a76cc93-90d3-4e3c-96bf-b3383e848869" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended  2022 and 2021: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.010%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2d946886f14b34b8cec403cb9ceeb2_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY0MmUzNmNjODZjYjRjYzVhNjc3OWMyODhkMjgxMDQzL3RhYmxlcmFuZ2U6NjQyZTM2Y2M4NmNiNGNjNWE2Nzc5YzI4OGQyODEwNDNfNC00LTEtMS03MDAzNA_53f6cbc5-7c53-43c9-88a3-f3ca179d62ed">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d77d7df0fc245a083931c66c8432fda_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY0MmUzNmNjODZjYjRjYzVhNjc3OWMyODhkMjgxMDQzL3RhYmxlcmFuZ2U6NjQyZTM2Y2M4NmNiNGNjNWE2Nzc5YzI4OGQyODEwNDNfNC02LTEtMS03MDAzNA_f5e53e64-bb6f-4d5a-8e12-a922efed8ca0">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc5d938e6594db3a5592348cbdf14b0_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY0MmUzNmNjODZjYjRjYzVhNjc3OWMyODhkMjgxMDQzL3RhYmxlcmFuZ2U6NjQyZTM2Y2M4NmNiNGNjNWE2Nzc5YzI4OGQyODEwNDNfNC03LTEtMS03MDAzNA_03069933-5230-40b2-b5ed-2dea2243ab97">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4271111bb61a42b8bc92b5628a6fa89f_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY0MmUzNmNjODZjYjRjYzVhNjc3OWMyODhkMjgxMDQzL3RhYmxlcmFuZ2U6NjQyZTM2Y2M4NmNiNGNjNWE2Nzc5YzI4OGQyODEwNDNfNC05LTEtMS03MDAzNA_c5314fe5-0740-4d05-bf11-c3ac650d2f10">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="i9ab729d6c1c34fdba9743fb62518bbab"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal second quarters ended in 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfMy0yLTEtMS03MDAzNA_3d173a34-7539-41e6-a9dd-eb2ba2074bdf">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfMy00LTEtMS03MDAzNA_f3812c08-fd4a-4614-b442-6616c12f784d">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42c0a6a0ba542ba87e204f1f199172c_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfMy04LTEtMS03MDAzNA_d3f2117f-ce24-4561-9e2f-c58b43583a39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61c7ab12f0d40a5b1d148b50984a0ae_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfMy0xMC0xLTEtNzAwMzQ_5cacf919-7373-4ead-bb58-6a5c09d49e1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b395b190b6c40bdb82d652a413b2417_D20220404-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfNC0yLTEtMS03MDAzNA_207278e9-d0a4-4510-ba26-a66bde0ac001">313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0558f0c929e482384449ccfff5a6c40_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfNC00LTEtMS03MDAzNA_366c470d-b1cf-45aa-b605-056b3085c94a">70</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id002bac7c1ae4826bb20f0839018ad2f_D20220404-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfNC04LTEtMS03MDAzNA_6e2dc5e2-c293-42bf-8d9f-9bb69d6b628f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57bf4d1498c4d5a8f38143d4bfab826_D20210405-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfNC0xMC0xLTEtNzAwMzQ_2fb0ec7f-deae-41bc-a689-48ae7df4a9f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal six months ended in 2022 and 2021</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:24.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.265%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfMy0yLTEtMS03MDAzNA_064cabb9-e1d2-42b9-bb6b-e48d132eed1c">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfMy00LTEtMS03MDAzNA_edfc58e6-db39-4713-b19a-3384cbc2f452">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07fd826f5b134e9fa417cd75e225e819_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfMy04LTEtMS03MDAzNA_48b94523-d2c3-4e53-b9b4-c0f871e1f308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2584883493814b06bf0ed930f4028c51_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfMy0xMC0xLTEtNzAwMzQ_08040cf1-50e9-42b6-b760-889fe53a6c08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10665768ac6c48af85f34ec614dbc6fc_D20220103-20220703" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfNC0yLTEtMS03MDAzNA_c0fefa19-b81f-48c5-b994-d465c0e7e70a">873</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i455ed2b8001d4cb29c1bbe414bfe1b33_D20210104-20210704" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfNC00LTEtMS03MDAzNA_bca43d47-f75b-45e8-b8cb-a20a2a7ebc7b">291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f70882583b47f7924e55453b7f672d_D20220103-20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfNC04LTEtMS03MDAzNA_3c7605a5-780f-4fc2-b523-251a5c649ea1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ebb8454e231462c9e01ddd2a9cd640e_D20210104-20210704" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfNC0xMC0xLTEtNzAwMzQ_90c100d5-006d-47e1-a79f-4c80211fe866">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i02ab23ee45a045b79ad01e51059c68a0" continuedAt="i0cdb167ba4904a5fb0602ea01c67506f"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzODM_253996b6-dc83-4346-bb99-9b89afceb535" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:25.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.464%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b9bc17484844788bb099a867ad7081_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi0yLTEtMS03MDAzNA_14e10c80-b4e4-471e-b9bb-2a9124868092">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5585c30b729c45f9bf242ad075fd7e6e_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi00LTEtMS03MDAzNA_f117e425-5d15-43e7-ba65-848803813f8e">508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5585c30b729c45f9bf242ad075fd7e6e_D20220103-20220703" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi02LTEtMS03MDAzNA_e2bc0a4f-ee7c-4e4c-8687-4c31e8493599">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ff307f7d004130a7fbc2c25929d6fb_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi04LTEtMS03MDAzNA_1ab8d8a0-a4b8-405b-b9ac-74a8ea33927b">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ff307f7d004130a7fbc2c25929d6fb_I20220703" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi0xMC0xLTEtNzAwMzQ_218bc8c3-b0a5-487a-a8dc-b829dc923851">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5174e789a11a483cb8a586d1a51f8af1_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC0yLTEtMS03MDAzNA_a63e4059-4df3-4419-8783-622f51f0f5e6">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee1a9681011c41fc91369cb2a262d523_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC00LTEtMS03MDAzNA_c93d4c28-36b9-4038-9ed7-87e52b117be4">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1a9681011c41fc91369cb2a262d523_D20220103-20220703" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC02LTEtMS03MDAzNA_0564306e-c028-4bed-836c-30e5b704b5e6">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2bb14177b1543589f7e2d2b40f3ed99_I20220703" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC04LTEtMS03MDAzNA_7b980890-e1fa-4f78-a449-a3900d06316b">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2bb14177b1543589f7e2d2b40f3ed99_I20220703" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC0xMC0xLTEtNzAwMzQ_29d8d4d8-5954-460a-bd8e-4dc3c7954941">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, there was a decrease of $<ix:nonFraction unitRef="usd" contextRef="iee1a9681011c41fc91369cb2a262d523_D20220103-20220703" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNjUzNw_87fed6da-13c1-40f2-82bc-ad952354b1c9">14</ix:nonFraction> million in the fair value reflected in net income as a result of impairments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the fiscal second quarter ended July&#160;3, 2022, the Company sold all of its shares in argenx SE for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i974d845b8fdb4e7fa0bc0da100fcb02e_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjc0ODc3OTA4MTQ0OQ_effcc9ea-cde7-421b-b101-a324744e93ca">0.6</ix:nonFraction>&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i0cdb167ba4904a5fb0602ea01c67506f" continuedAt="icb754e9f153b43ffb15973c4c6877770"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzNzg_7703f7aa-4cfd-45af-bede-6d39876d0d74" continuedAt="ic84465c9b09d4ebea7b747e0a19df0ad" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of July&#160;3, 2022 and January&#160;2, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:48.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d11cbf312f4920a063822b57fb4379_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC0yLTEtMS03MDAzNA_f7bfffe2-594e-44ae-bf38-c11f34c14d7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465262306f745bfa8f4d12d012583ba_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC00LTEtMS03MDAzNA_d18cf625-256e-4c33-919d-c20075ef67a9">1,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC02LTEtMS03MDAzNA_d296c3cb-8baf-4968-a95f-d8b3933bdebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC04LTEtMS03MDAzNA_3a8fc225-4d4c-4006-98e9-d4455cc69893">1,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820748c0ee614ffc85acb984e5a8fa84_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC0xMC0xLTEtNzAwMzQ_a679f57e-98b0-4561-8250-85b84f6dcf5b">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45c5d30ba924db5a64a324285891798_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS0yLTEtMS03MDAzNA_5b6faba4-2a42-4a8d-aaf2-223633e9b79b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58070284d45c4b4b97413c70ea4b99ac_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS00LTEtMS03MDAzNA_dd012412-d013-48d0-889e-b95a5be78a1b">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5ce1a5044744c98c6fc083f0e7beca_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS02LTEtMS03MDAzNA_4936acb4-8ba9-4a4a-9b2a-cca611b67dd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb0e6ccd8a9348ec80a99cd8c4672572_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS04LTEtMS03MDAzNA_ac56dc27-1a08-4b65-b7e6-506fa49bef90">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c147ca24594e40a66c2a2f2b084eeb_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS0xMC0xLTEtNzAwMzQ_e3896f10-cb55-4f9e-964b-81a3f7b5e6cb">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39755d463f2405bacc970b45155df96_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy0yLTEtMS03MDAzNA_478868e0-73dd-4d0a-bf16-3638e68f8827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy00LTEtMS03MDAzNA_b4c467e1-5975-4f59-8a88-54e9d7c447ce">3,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy02LTEtMS03MDAzNA_59978fad-4400-4606-ba84-4c8daeb84bad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy04LTEtMS03MDAzNA_84a3210d-55fc-40b1-b803-f0a5ba2a66bb">3,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2023f668e54901b44a7ca21bcc4c7b_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy0xMC0xLTEtNzAwMzQ_159ace14-d0cf-4a7b-be7f-afd0fc474788">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d11cbf312f4920a063822b57fb4379_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS0yLTEtMS03MDAzNA_bd4ec976-260e-4673-ae08-0844c4d3e107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465262306f745bfa8f4d12d012583ba_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS00LTEtMS03MDAzNA_2aff71e2-8ded-4d80-b88d-abd33fa8e2b8">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS02LTEtMS03MDAzNA_faf50e7d-baa8-4c8e-acba-24581ff89aeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS04LTEtMS03MDAzNA_2ffa8606-032c-481e-a646-bd95644f5802">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820748c0ee614ffc85acb984e5a8fa84_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS0xMC0xLTEtNzAwMzQ_e07a32b5-00f8-4afc-bbce-faaf00d470bc">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45c5d30ba924db5a64a324285891798_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtMi0xLTEtNzAwMzQ_2285f25c-0e55-424e-866b-77697a553765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58070284d45c4b4b97413c70ea4b99ac_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtNC0xLTEtNzAwMzQ_57d84009-698b-4e8b-9447-f7cf790bde03">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5ce1a5044744c98c6fc083f0e7beca_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtNi0xLTEtNzAwMzQ_71f39628-f66f-437d-a60d-089f9b493cdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb0e6ccd8a9348ec80a99cd8c4672572_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtOC0xLTEtNzAwMzQ_615e05a3-f5c3-4c2b-b6e1-d3a087af6253">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c147ca24594e40a66c2a2f2b084eeb_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtMTAtMS0xLTcwMDM0_866231db-7ff8-483d-836b-791c7679295f">979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39755d463f2405bacc970b45155df96_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItMi0xLTEtNzAwMzQ_1dd279ac-529f-42c3-85fa-43d767446c6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItNC0xLTEtNzAwMzQ_c130157c-3fad-4f30-b33f-099301def4a9">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItNi0xLTEtNzAwMzQ_723fd60c-c8d0-4fba-908e-51efc49db24f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItOC0xLTEtNzAwMzQ_317190a8-e43c-4c77-a552-ba443ebda109">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2023f668e54901b44a7ca21bcc4c7b_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItMTAtMS0xLTcwMDM0_5ad17202-2216-402b-83e9-cbc7c1d4bcab">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d11cbf312f4920a063822b57fb4379_I20220703" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtMi0xLTEtNzAwMzQ_dbd04832-d127-4d10-9a25-5e18de9b6988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465262306f745bfa8f4d12d012583ba_I20220703" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtNC0xLTEtNzAwMzQ_22b5ea66-3c3b-4c4a-83ce-d98fd7d9a63b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtNi0xLTEtNzAwMzQ_bda5b47c-39d1-44fe-8eac-977a01005ab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtOC0xLTEtNzAwMzQ_f4068125-eb23-48af-8753-c5f11fee3ae9">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820748c0ee614ffc85acb984e5a8fa84_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtMTAtMS0xLTcwMDM0_6d75c113-9982-4651-9b47-2d45e4fafb3c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d11cbf312f4920a063822b57fb4379_I20220703" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctMi0xLTEtNzAwMzQ_5bc90175-281f-439b-b8c6-cf85e563b2fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465262306f745bfa8f4d12d012583ba_I20220703" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctNC0xLTEtNzAwMzQ_ec19127f-dda4-48ed-887c-9b6cdfb91601">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctNi0xLTEtNzAwMzQ_24126b88-4f87-4122-a6bd-88439e9ef0c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctOC0xLTEtNzAwMzQ_d126e21c-2494-4916-b02b-24c8b728305f">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820748c0ee614ffc85acb984e5a8fa84_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctMTAtMS0xLTcwMDM0_28268e3b-506e-473d-b9d0-9e8bf73a1b80">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39755d463f2405bacc970b45155df96_I20220703" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktMi0xLTEtNzAwMzQ_73a55a8a-682a-4659-ba2d-02f4e086a943">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktNC0xLTEtNzAwMzQ_3ff31a77-e2ca-42cd-b7bd-f391d6c0a1a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktNi0xLTEtNzAwMzQ_3c51e694-8aab-47b0-90c1-cb5633d08bce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktOC0xLTEtNzAwMzQ_ed7f0a88-cb40-43c2-9880-4479b474ec5a">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktMTAtMS0xLTcwMDM0_fb5100ee-617f-4f23-be2c-c4eb97e8963b">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39755d463f2405bacc970b45155df96_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtMi0xLTEtNzAwMzQ_3338065c-fc3b-4678-8f2a-b08311779e26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtNC0xLTEtNzAwMzQ_77aebeca-44f7-4771-9ae6-fa3265b35621">21,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtNi0xLTEtNzAwMzQ_43865ef7-aedb-409f-88ce-3e182603b73f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtOC0xLTEtNzAwMzQ_f4b51f22-21eb-421d-8e9f-3adf7ad29648">21,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtMTAtMS0xLTcwMDM0_38ac2495-d986-4b66-a784-cf45bd05d9a5">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39755d463f2405bacc970b45155df96_I20220703" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItMi0xLTEtNzAwMzQ_9e0f1348-5597-47fc-92ab-adb78a5b3dd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItNC0xLTEtNzAwMzQ_c918e3c9-c0d7-4e3f-bb0f-f5bf0270106e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItNi0xLTEtNzAwMzQ_4c3cd296-3d04-40da-ad2f-a2b3a7780d0a">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItOC0xLTEtNzAwMzQ_5ce2a5d0-a3c1-40ea-b1dd-92fe0eaf7d9a">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItMTAtMS0xLTcwMDM0_702acceb-dce4-4ad0-b229-98677ac6f620">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfMi0yLTEtMS03MDAzNA_77dcc4a6-18df-4f2a-9c12-36abc1154b9c">3,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfMi00LTEtMS03MDAzNA_d85062c8-92d9-4363-beb5-e9b1fce1e6ad">1,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfMy0yLTEtMS03MDAzNA_2e7ab37e-ec8e-470d-8c62-063d630ddf5f">3,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfMy00LTEtMS03MDAzNA_78b03e89-3396-4caf-ab43-22ecde50d3f2">1,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNC0yLTEtMS03MDAzNA_3837ba64-32bc-484f-8ea8-db06f15f1326">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNC00LTEtMS03MDAzNA_f12d3a0f-8996-4443-87a3-55e4503611b4">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNi0yLTEtMS03MDAzNA_7291b7a8-1c7a-4805-ba61-affb5f9605f7">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNi00LTEtMS03MDAzNA_28537b32-5639-488a-b62f-b8723b15a74f">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNy0yLTEtMS03MDAzNA_e210c67f-ef59-4263-abe7-cc305f229b25">2,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNy00LTEtMS03MDAzNA_d7772cf2-29b4-48ad-9b5d-1e0a329372a2">1,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfOC0yLTEtMS03MDAzNA_83e17ff4-1dbd-4de7-bc84-fb13ca696fa5">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfOC00LTEtMS03MDAzNA_93a830b1-edfd-41ae-97f3-3c1124cd893a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><ix:continuation id="icb754e9f153b43ffb15973c4c6877770" continuedAt="id1af6f86e6664ff2bb5ef95777fb8fc4"><ix:continuation id="ic84465c9b09d4ebea7b747e0a19df0ad" continuedAt="ibfab2fe8cc4145b9a65987a5e9234abb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"></td><td style="width:41.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfMy0yLTEtMS03MDAzNA_dbcf25b4-0aed-4644-9822-9b7f1ffe0d06">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3aba93759e44e6998ff20f017b0ca4_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfMy00LTEtMS03MDAzNA_41906ca3-934e-404a-8833-56c28a16acc5">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNC0yLTEtMS03MDAzNA_7749ffd7-6e41-4fd7-9f1c-0d7bb83c214d">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNC00LTEtMS03MDAzNA_e4860516-03b0-458e-842a-5e010a4d0c26">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNS0yLTEtMS03MDAzNA_8e3a3ac3-6740-40f1-afe3-4b4938fbeca5">91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNS00LTEtMS03MDAzNA_67e74433-dcef-4110-a23e-9e10582c308f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNi0yLTEtMS03MDAzNA_8ccfced6-4078-4319-88f5-76e9be9b578f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNi00LTEtMS03MDAzNA_f5680f2a-049a-4991-9dca-08efc480be04">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNy0yLTEtMS03MDAzNA_4fff1e82-dc74-4e51-8f4d-5912d025127d">536</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b98f47b14654327afbb7932046478c8_I20210704" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNy00LTEtMS03MDAzNA_3b095f7f-c1da-4f06-83a1-0f20db92a34b">593</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="i616a8d8561e148bc93cfff8d5eaaf83b_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfODc3Mw_8fb27863-ac23-4226-af94-c89413cc555e">1,884</ix:nonFraction> million, which are classified as Level 1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i02b1386668dd451a99e7f7cab14f56c2_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfODg0MQ_b05bcef4-10da-433d-a4a8-e307ce4e2454">533</ix:nonFraction> million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $<ix:nonFraction unitRef="usd" contextRef="i18ceca8d5a1842a6aa3fc80736183e3d_I20220703" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfOTA5Nw_b58a9487-529a-4cf0-b8f7-28ed3cce04a4">519</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i061f4c2dadcc48f6952c7a8571f88284_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfOTExMg_9b8334da-0d2c-4a7b-9733-bf7f63b02b4b">520</ix:nonFraction> million, classified as non-current other liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $<ix:nonFraction unitRef="usd" contextRef="i4c793d1a04514fca815ddcf0b0cbcff8_I20220703" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfOTIwOQ_c1b448e0-efdb-44b9-a0d6-62088d45ed52">17</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibbdeb75dc07c40a6aeaf91aa2cb9a764_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfOTIyNA_08ed88bf-7230-4a72-a944-19eb49967abf">13</ix:nonFraction> million classified as current liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="ibfab2fe8cc4145b9a65987a5e9234abb" continuedAt="i7431dba39fb54699b09019b7a7b30a68">           (6)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7431dba39fb54699b09019b7a7b30a68">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.</ix:continuation> </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzMTY_6e661fed-596c-42ed-af7f-d50baffaf651" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of July&#160;3, 2022 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:30.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/( Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS0xLTEtMS03MDAzNA_fa88aeed-7efc-48ff-be93-49c56a6a42ed">3,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS01LTEtMS03MDAzNA_7f75a423-84ce-4dc9-8bbe-0e4363977fc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS03LTEtMS03MDAzNA_3f7128a5-f454-4bf6-9a82-d3f3d79c764b">3,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS05LTEtMS03MDAzNA_beeffbc0-8dd7-419c-87fa-6b51305f956b">3,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS0xMS0xLTEtNzAwMzQ_bce8d410-86eb-40ca-b0d7-6957cb8decc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy0xLTEtMS03MDAzNA_3099c09a-f40c-470e-a221-653bf7c47bf6">538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy01LTEtMS03MDAzNA_ae978a50-77b1-4f1b-a50e-8b5db12626e1">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy03LTEtMS03MDAzNA_c260f3a7-683f-4ab4-a6d5-9023359f5337">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy05LTEtMS03MDAzNA_9c33f8bc-635c-4f23-b9a2-9863716cb63b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy0xMS0xLTEtNzAwMzQ_752666e3-8d45-48cf-b853-3fb2b8884937">538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC0xLTEtMS03MDAzNA_3dda5a6e-71f3-40ab-b5c9-7b608d4e3969">2,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC01LTEtMS03MDAzNA_d31d4535-b313-4446-bda0-1544cd7abbb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC03LTEtMS03MDAzNA_2e0accae-f070-4d99-8e98-6e232434da59">2,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC05LTEtMS03MDAzNA_1ed20820-b621-402d-93b9-50de3bbeae9d">2,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC0xMS0xLTEtNzAwMzQ_ceefa6a9-f81c-4280-b97d-42f127ab36fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi0xLTEtMS03MDAzNA_3934e950-9fac-42ef-b450-fe9779b38385">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi01LTEtMS03MDAzNA_38204209-e2f9-4f3f-8288-fe10e0af3f11">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi03LTEtMS03MDAzNA_2a1adf74-7f9d-4a0f-b2b6-d323576ee4c7">2,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi05LTEtMS03MDAzNA_868a419b-bbba-4c81-b244-d5ed1a9305dd">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi0xMS0xLTEtNzAwMzQ_ca4b360c-bdb5-412a-9019-ba57060776bc">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7423beb705924764a8f4876d7d961b65_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy0xLTEtMS03MDAzNA_58d74cbc-28c9-474c-94d9-c87be620a7f4">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7423beb705924764a8f4876d7d961b65_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy01LTEtMS03MDAzNA_9701a290-171e-4804-8da7-f4f761e5af1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7423beb705924764a8f4876d7d961b65_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy03LTEtMS03MDAzNA_f0852b11-9406-44b9-bcdb-ccc9594812dd">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7423beb705924764a8f4876d7d961b65_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy05LTEtMS03MDAzNA_6ed8b760-d98a-4ebb-bafb-619e146e4e68">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7423beb705924764a8f4876d7d961b65_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy0xMS0xLTEtNzAwMzQ_4ba72b7c-a287-4d24-8fb7-d47f12a25f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC0xLTEtMS03MDAzNA_e34ac321-ffc4-4919-a89f-88191af8a155">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC01LTEtMS03MDAzNA_452bc320-13d5-46a7-be26-588a71415c2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC03LTEtMS03MDAzNA_1fd96959-7757-42fb-813e-505072c50594">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC05LTEtMS03MDAzNA_5e2d2735-13cc-4580-88be-3a616bb5161e">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC0xMS0xLTEtNzAwMzQ_bf671417-495c-4466-9f9b-f41a69e76f44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437b71eb938a462080e32d083a962f86_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS0xLTEtMS03MDAzNA_efb8ae27-ff1c-4009-a1ae-8a1d54e34d6e">11,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i437b71eb938a462080e32d083a962f86_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS01LTEtMS03MDAzNA_3dc7b4d0-f7c9-4913-a276-533a0e54dffc">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437b71eb938a462080e32d083a962f86_I20220703" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS03LTEtMS03MDAzNA_ae95a153-2b70-41ea-abcb-fd59a85c6c19">11,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437b71eb938a462080e32d083a962f86_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS05LTEtMS03MDAzNA_9cc867dd-47df-47e3-9869-09c1192efb43">8,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437b71eb938a462080e32d083a962f86_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS0xMS0xLTEtNzAwMzQ_10ec41c4-569b-48d8-abdc-b330b84eafb2">2,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItMS0xLTEtNzAwMzQ_b41f8efd-7e72-43ea-981c-e8c69a2b7e30">20,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItNS0xLTEtNzAwMzQ_579ee1aa-26a6-4d57-84cd-bb2dc1baa574">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItNy0xLTEtNzAwMzQ_1a3c4b6d-2ae0-40f7-810b-b0406c2bdd0f">20,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItOS0xLTEtNzAwMzQ_900fb1b6-7037-4fc6-b2dc-21105aeb210b">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItMTEtMS0xLTcwMDM0_baf59635-13b8-4615-86c5-760a8a56f3a1">18,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtMS0xLTEtNzAwMzQ_469077b1-ba63-489e-916d-0d7be7948a44">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtNS0xLTEtNzAwMzQ_1f3f7700-c997-496d-8747-a9dc58287d1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtNy0xLTEtNzAwMzQ_d6cc7d36-a223-42a1-8c3d-3a13417af783">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtOS0xLTEtNzAwMzQ_83ab3237-127e-464d-9e7a-e775c01d6a14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtMTEtMS0xLTcwMDM0_6050e17f-1976-4993-b8d8-b48a87ee42ff"><ix:nonFraction unitRef="usd" contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtMTEtMS0xLTcwMDM0_7d60b686-84ab-408e-bdd4-40d0648dae7d">3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtMS0xLTEtNzAwMzQ_13e02a27-50f8-4925-947a-4f6629263e6f">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtNS0xLTEtNzAwMzQ_6b066871-46c7-4ac1-bede-324d654d376d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtNy0xLTEtNzAwMzQ_129744b8-047c-4811-a833-5e127293f5c9">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtOS0xLTEtNzAwMzQ_617ca763-fea0-4e87-badc-d8dde7ca5862">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtMTEtMS0xLTcwMDM0_2ff3d98c-9d78-4e79-bcc8-cb56bab79d59">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf37690c3b94285af307610b22628e8_I20220703" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtMS0xLTEtNzAwMzQ_3c489346-60dc-41fa-a92a-96f8be404393">21,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbf37690c3b94285af307610b22628e8_I20220703" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtNS0xLTEtNzAwMzQ_a3f181ff-78ed-4eea-9e56-87012794a677">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf37690c3b94285af307610b22628e8_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtNy0xLTEtNzAwMzQ_e07e0505-2fe9-4f26-86a3-81a1a2e200dd">21,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf37690c3b94285af307610b22628e8_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtOS0xLTEtNzAwMzQ_8bac3ed1-a9a5-4f51-8e31-f3ecb3802437">2,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf37690c3b94285af307610b22628e8_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtMTEtMS0xLTcwMDM0_ba8b19a5-9e2c-4394-ae6d-896a6defc131">18,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtMS0xLTEtNzAwMzQ_f9f2393d-569d-472f-9e26-5f9402e48622">32,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtNS0xLTEtNzAwMzQ_9d2b21d5-34b0-4de4-9e20-c77233f74fb9">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtNy0xLTEtNzAwMzQ_d044881e-46bc-41cf-aa62-7d3a9eb9ed86">32,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtOS0xLTEtNzAwMzQ_c47ba6bf-4c52-405a-9ad6-22db16e33d9d">10,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtMTEtMS0xLTcwMDM0_feb15ea8-5380-4c2b-a43e-61b8af9f2dbc">21,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="id1af6f86e6664ff2bb5ef95777fb8fc4" continuedAt="i5ad22b627c5d45e0932cdf399c05b6cb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;2, 2022 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzMTA_21df4384-e7f7-460f-aeb4-438ee776d497" escape="true">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzNzA_40992302-8334-4063-8f27-7f9a0e09717a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of July&#160;3, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"></td><td style="width:43.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMS0yLTEtMS03MDAzNA_3b3fc926-43f1-435f-a288-bcdce5211ba0">21,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMS00LTEtMS03MDAzNA_6ad05696-3de3-4a3e-88b0-768a4e9978ec">21,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMi0yLTEtMS03MDAzNA_7f4b866f-6f0d-40bc-926b-cabfba3f6759">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMi00LTEtMS03MDAzNA_c5e9074f-d309-4677-8f42-9bf2332549e8">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMy0yLTEtMS03MDAzNA_0ffe8112-8488-4354-ba99-1fde7f702bec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMy00LTEtMS03MDAzNA_0f221806-211f-4685-9b50-2a80445423bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfNC0yLTEtMS03MDAzNA_ed7fd829-696a-4186-a511-fe7d1070ae19">21,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfNC00LTEtMS03MDAzNA_b3fa6156-ffcb-4efe-848f-a4d6218c7a1a">21,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i5ad22b627c5d45e0932cdf399c05b6cb" continuedAt="icf1da79e8edc41eca0eb5119b1703ad1"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzMjI_f55fb49b-a813-4c91-b650-c4e868e2ae06" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of July&#160;3, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.259%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35b52ff0f6ac42609c258100f987af3e_I20220703" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNC0yLTEtMS03MDAzNA_0c0243ca-2b8e-4de6-871a-4c54e74d195f">4,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if668327e01644d82befdc0a8ab72e2cb_I20220703" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNC00LTEtMS03MDAzNA_f6f4239a-530b-4bc7-903d-6d322e93cbe4">4,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0412d7e68cd949e69dd56bb1f8ec4989_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNy0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjUyYmI2NDZkZGQ2NTQ1YmZhNzUyOGEwODZhZjQ5NjE0XzQ_665f7d40-045c-4fb5-879d-09e8a84d31fa">6.73</ix:nonFraction>% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida1ae3624a844b4f875208ff051c690e_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNy0yLTEtMS03MDAzNA_1ad5fe51-1ac4-49ce-a939-28c7ea7193d2">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7607c810ff1d4ac3b1e1815bf6afca66_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNy00LTEtMS03MDAzNA_fc025dff-4dcd-4498-a793-f18a018a2340">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if214bf0473764e41a84dd8791aadae18_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfOC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjVhNzM1ZGVjOTlhMDQ4Nzc4NjI4YTQ0ZGU4MTc1ZmYyXzQ_786349b8-ce41-446c-b438-07f1ca273e05">3.375</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd688062d5f3442ab9e3d49a23df957b_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfOC0yLTEtMS03MDAzNA_875ad927-1fce-40b9-a89c-a14b3ba41d0c">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19bd93d4b6414d7c80050b05ab626367_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfOC00LTEtMS03MDAzNA_b96a22e1-650c-4c71-a4ea-084b7539673e">805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ac16b6eb33a475a8a71478faa2b6027_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphMmYyZDJkMjQ2N2Y0N2ExYThmZDA2MGFiZjU0YTYwNl80_eea0b018-d4a9-430c-bf16-3b7e75f4b2ce">0.650</ix:nonFraction>% Notes due 2024 (<ix:nonFraction unitRef="eur" contextRef="i2ac16b6eb33a475a8a71478faa2b6027_I20220703" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphMmYyZDJkMjQ2N2Y0N2ExYThmZDA2MGFiZjU0YTYwNl8zMjk4NTM0ODgzMzgw_b767d1a6-58b5-4db5-a404-1467f280f8df">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i2ac16b6eb33a475a8a71478faa2b6027_I20220703" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphMmYyZDJkMjQ2N2Y0N2ExYThmZDA2MGFiZjU0YTYwNl8zMjk4NTM0ODgzMzkw_a7aec272-79a2-4765-950d-53699090cd94">1.0408</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ad0d9d40c440198c4ccaebcefe7e24_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtMi0xLTEtNzAwMzQ_2e3b7b90-f851-41ee-b779-a0e39a898e66">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d8e76325af440aa71852c405d16386_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtNC0xLTEtNzAwMzQ_3823db86-8fca-40a3-b8e6-555bb6de3416">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie265961801c14b649e4aec89b623b822_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphNTFlYTQ3YjE1OTY0Y2NmOTcxZjQ2MmIxMTc0Y2UwN180_de113f06-105f-45c6-9025-3fb160d6a992">5.50</ix:nonFraction>% Notes due 2024 (<ix:nonFraction unitRef="gbp" contextRef="ie265961801c14b649e4aec89b623b822_I20220703" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphNTFlYTQ3YjE1OTY0Y2NmOTcxZjQ2MmIxMTc0Y2UwN18zMjk4NTM0ODgzMzgw_48883312-0e61-44e1-95ed-3f303f3ad447">500</ix:nonFraction>MM GBP <ix:nonFraction unitRef="number" contextRef="ie265961801c14b649e4aec89b623b822_I20220703" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphNTFlYTQ3YjE1OTY0Y2NmOTcxZjQ2MmIxMTc0Y2UwN18zMjk4NTM0ODgzMzg5_eeb7eeea-c625-4884-ad26-649aa0363825">1.2143</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73c4fedbb644223a20f315d7dd9f3e7_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtMi0xLTEtNzAwMzQ_6d1c7156-86cb-4722-a36b-34f33922d02f">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f34fca0ba04ca781f7befcff5614b3_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtNC0xLTEtNzAwMzQ_e44cc55e-2dc1-472c-adf4-bcdf178c2890">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c7397d924e2469bb389835fe06d5b23_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTItMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphZDJjMjhhMDQ3YzQ0M2RkYTlhYzhlMGYzOTA4ODAzM180_4884c7ca-7e47-4e1e-ba6e-669aea14e625">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c0348a7bec543bbb40b652ecc155701_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTItMi0xLTEtNzAwMzQ_c5429e73-83b6-480a-86db-99084b249ce5">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaea24750d14422d8bb195caed4c0fa2_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTItNC0xLTEtNzAwMzQ_c838ea48-5392-4b3c-88d5-a923af082335">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.550% Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d31de7560429e9f6447755677fcc3_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTMtMi0xLTEtNzU5MjY_f4c5a965-5a97-4ea6-a01d-b9feb4ee0bce">940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f8f438d45649aaa711cfeee70572f3_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTMtNC0xLTEtNzU5MzM_464297d8-d33e-4fce-9f79-d4ed5eb4cc48">872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i714604558c6448ceac87445bd3cbe601_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpkNjhmNTk3ZTE4YmI0ZDMzYTExN2Q0MGM3ZTk5Y2MxMV80_031d16c7-a588-49b6-9e56-f7849ce5f48e">2.45</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6080a0f3af3f49e9bc2edc00f7c218f5_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTUtMi0xLTEtNzAwMzQ_07d4ea5b-d2c8-43e1-be20-a56a28c7d583">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5eac34b27640f79085c03f81117a27_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTUtNC0xLTEtNzAwMzQ_ce43b156-4f4a-4d99-b8fc-7b47ed425b03">1,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8d83f40eadc482f9785a1a1e73ae1fb_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpkMDQ0NjA2OTVhZDI0MzM4YmIyMjVjM2UyYTcxMzdlNF80_3b125397-d4bd-4fea-af7f-a0f39f53b2bb">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2422ade4dd254785ba67cf1997145fef_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTYtMi0xLTEtNzAwMzQ_ec30393d-d071-43f5-82ff-4ed8954b8a09">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24356a7eaa814e15a526f1f4f1dbb4a3_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTYtNC0xLTEtNzAwMzQ_794d17ee-6d47-4fbf-a95f-06e590b42e51">899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief6fdac95f174a9db30f9dde4a867361_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoyMzU0ZWExMGZhZWM0YjU4OWUyOTM2ZTM5NmZmYzE0N180_0c9218fe-8354-4949-9844-e732f6389956">0.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932f859fe5004fcab7d388c3ef37b01b_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTgtMi0xLTEtNzAwMzQ_a7875d2a-ff45-4f12-831d-5d9f15eec615">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8500a36cb2b404fb1495e3f0cd34b1b_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTgtNC0xLTEtNzAwMzQ_ca150f4c-639f-4ba2-b959-177d98edf793">1,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10cb7e790720410393c02b3b71132200_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTktMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNDY1MzZjMDY2MzY0ZGQ3OGJiNzNhMDZmNTA3MzMwOF80_6a9242e5-c839-4a8f-b385-31b5cdc6317e">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a981ac377da4942bd8a08b6b8f69e74_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTktMi0xLTEtNzAwMzQ_a8598e7b-858d-4b37-a89a-749c7f21b958">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f8a9e2e7444c16b12a3c2edb6be775_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTktNC0xLTEtNzAwMzQ_13460fcd-3118-4e8e-81cd-d3009c810d1d">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f60341d6ee24828ac150d7fb989724d_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo1MWE2MmZmY2Y4OTI0NDA0OTNiMzkzMjA3NTJlYTg3Yl80_57057f65-a138-479f-a047-f1b7bbc9ef0e">1.150</ix:nonFraction>% Notes due 2028 (<ix:nonFraction unitRef="eur" contextRef="i4f60341d6ee24828ac150d7fb989724d_I20220703" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo1MWE2MmZmY2Y4OTI0NDA0OTNiMzkzMjA3NTJlYTg3Yl8zMjk4NTM0ODgzMzgw_33198b80-c9b1-4814-ac92-05ba21ed7373">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i4f60341d6ee24828ac150d7fb989724d_I20220703" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo1MWE2MmZmY2Y4OTI0NDA0OTNiMzkzMjA3NTJlYTg3Yl8zMjk4NTM0ODgzMzg5_da34ee2f-4e88-413c-a967-04b7644b5a6d">1.0408</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85954b0bbfb747cba4560e6bbe91083a_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtMi0xLTEtNzAwMzQ_381be91c-efa0-4757-a93f-eb901c9fade0">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd3188721d3496bbfcb0a0a1fcdeeaa_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtNC0xLTEtNzAwMzQ_73dbee5c-0da1-46e7-808e-6e64c60b79b4">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i247279ce24df4fc984684a77a1afc670_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo0ODc4ZWYwMDFmNjc0NDk5ODRkYWYwMjgwZTc0Mjg0Yl80_0438510e-4897-4d21-bd45-8a389cbf47d9">6.95</ix:nonFraction>% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd4fb1b88c34db49fc66928580f5871_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjEtMi0xLTEtNzAwMzQ_7a551b19-fbc2-4ca4-bc7f-9aa6b0ee7744">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b5a0c24ecf49209b2e36a4c3789ba6_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjEtNC0xLTEtNzAwMzQ_84457810-340f-40e6-854e-8ae18076037f">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i687f005d14ed416ba74831b5b47b4555_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjMtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoyOTM5MWZkOGE2ZjE0MjhiODA5YTAxMzg3MDZmMmE0NV80_174a449f-d6b8-41ec-9f4e-0f5d352a79c4">1.30</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7501e1e2bb74a89922e7f7a201f16ce_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjMtMi0xLTEtNzAwMzQ_0a2dabed-0c27-4c85-aba9-ec3a77b82870">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90a8017e0214944955fce66d917c85a_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjMtNC0xLTEtNzAwMzQ_3de33170-b422-428b-ad94-05b38544b81c">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idab876f881cb42b3b32ad3e26e9ec7ab_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjQtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpkMzg0NGI2ZTk0YzU0ODQyOGFmZGEyNGZmOWQ3MDRhN180_3ac11f64-2ba0-4d54-9cae-dc021ecf0e27">4.95</ix:nonFraction>% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c198d27655479abef21848a7bba761_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjQtMi0xLTEtNzAwMzQ_88454a14-10b2-4cb6-8a3e-cebb6499eff7">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ab0ee504eb41599816d24c2113bc1f_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjQtNC0xLTEtNzAwMzQ_84b9ce5c-3e5c-4372-8130-fbbab0695b36">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d05ba815c654783b44178265f82de44_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpkOThmYzRlMWFjZTk0MGE1YTA5ZDQzYTcwMzViZGI2ZF80_f299fe19-9168-43e7-ba46-0c7a3dd4fdd0">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7914f4f7746046df9a737d4fb8979c6b_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjUtMi0xLTEtNzAwMzQ_0fff6ff0-bf0d-44bf-8a69-fffc20e6fb6b">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id275d71b261a432c89901abc9e36512b_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjUtNC0xLTEtNzAwMzQ_11b0f06a-797f-4730-8cde-6f981f2f37f5">895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8dc1e5091506483785afd9d275795a46_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjplZjkzNjk3MGE0YzQ0ZDdlOTZiNTExZjFlNWMzNDkyYV80_641f26c1-ebc8-4972-8e77-daef985fcf22">1.650</ix:nonFraction>% Notes due 2035 (<ix:nonFraction unitRef="usd" contextRef="i8dc1e5091506483785afd9d275795a46_I20220703" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjplZjkzNjk3MGE0YzQ0ZDdlOTZiNTExZjFlNWMzNDkyYV8zMjk4NTM0ODgzMzc5_713596f0-56e0-4ad4-9183-2e54c4c7460c">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="i8dc1e5091506483785afd9d275795a46_I20220703" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjplZjkzNjk3MGE0YzQ0ZDdlOTZiNTExZjFlNWMzNDkyYV8zMjk4NTM0ODgzMzg4_ba50f37b-0f83-4d2c-8299-db99e0b70cf2">1.0408</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc1e5091506483785afd9d275795a46_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtMi0xLTEtNzAwMzQ_a69c99e8-5be5-4fa3-8a2f-d7fbd269c438">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d838b361e1428f9af039eded3b682a_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtNC0xLTEtNzAwMzQ_53d375a0-ad3e-4d57-91f3-8c22ca2e68c8">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60dba65131c1437481410132c5ea4df7_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjctMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoyOTkzYjcwOGVkNDg0YWVhYTBhN2ZjZDAyNGU5OTY1OF80_b35c46e1-c8b4-4b58-bae1-509a2a62b8a7">3.55</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9048cedccfb40ed8e4d52b8f5430ad1_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjctMi0xLTEtNzAwMzQ_3c61f82a-239f-4533-9fb9-7f17347f785e">885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85efca72771a40499d8082f58202a3dd_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjctNC0xLTEtNzAwMzQ_34f04c3e-bea9-449d-aa7c-1447810fc7ca">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i350a972bfcfd4efdb72b431248967d66_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNDYwODk1MWVmMmE0MzNlOTRhZTVmOTM4ZDY5YjBhZl80_e5b6b649-e14a-4624-8899-9a1fc1fea2ee">5.95</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f46a77f7992478ea4128962d4c9f391_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjgtMi0xLTEtNzAwMzQ_7c18695b-7ddf-441b-bfd8-492a71bd925d">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d3fb3a791ca414fa77eaa67cc99a07f_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjgtNC0xLTEtNzAwMzQ_7a024074-a0d2-4652-bcb6-3c5ebf397894">1,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8ccb7e446b348588dd2f9516636ffb7_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjktMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoxZWJiYzFjMjIxOGE0OTljOGNlZmZlOTNmOGEwZDM0Nl80_096018d7-6416-44d1-95bb-725235ef9744">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a17432bed1945c48370b5015ddb5642_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjktMi0xLTEtNzAwMzQ_35b7a05a-8e15-4bdb-9789-8396f6a47823">1,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65c4c72715349aba29bef207c5ed392_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjktNC0xLTEtNzAwMzQ_c30ef640-9701-4eba-99e7-17ed5c8994f8">1,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7bc27cc5ec494407a381cf8b2d1d893b_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpmYjUxMzY0NGQ5ZjY0MjAyOGM1ZWNhNzViNWM3ODdiMl80_e2cb4114-0c2a-4329-a5f6-4bf1b3d9b4de">3.40</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9fca044219d42f0971fb8ef3a32a6c4_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzAtMi0xLTEtNzAwMzQ_d2820a96-501b-4ac8-8f34-d80c474dbd3a">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b97c77efcb43fbab577c42a6fbfc7c_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzAtNC0xLTEtNzAwMzQ_0181b5a0-bc03-480f-9e99-b992c7883c58">898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfc2e3c1f9254ffba88d55ca0c4ce058_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo3MzM1MzdjM2QxYzA0ZGM0YTQzM2I4MzkwMDE3OTFjNF80_1e7e805e-809a-45b7-a54f-3509dd6f5257">5.85</ix:nonFraction>% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915b24d83829484ebf50c108621501e4_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzEtMi0xLTEtNzAwMzQ_6a2e796e-a0f3-4eaa-bbcc-886b1bdaa4c6">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec88f4e48124475a9632ff20fb8edd5_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzEtNC0xLTEtNzAwMzQ_86b026c2-b7e4-4bcf-a6e9-3b4ccc0f01a3">817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc6c33b6176b422483f5f3ef6becebff_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzItMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoxYzIyYjE5ZmE5N2E0ZDEyYmI2NDI3ZDY4NTNhYmY0Nl80_2676b3e5-b537-4e51-8ebf-8edb1f3efab6">4.50</ix:nonFraction>% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4e43d48a4c4e21bcbe809be40eca70_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzItMi0xLTEtNzAwMzQ_a1cd0a82-6520-4a50-9fef-39df9ddd60c9">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a8feaecb4246bc9b98605730a15584_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzItNC0xLTEtNzAwMzQ_5863f544-b903-42d2-b6b1-173dcbea56b2">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3d3ef2ea8d84db099d215dfe535ddcb_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzQtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphNDg4NDRkMzZhODc0ZjRiYTQ5NjNmMDk2YjMzYmZmNF80_436a8dbc-fb98-4362-860b-48d7d16aef16">2.10</ix:nonFraction>% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib006c54c03ed480e9b393694820c92c6_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzQtMi0xLTEtNzAwMzQ_de45e081-6c22-49cb-9ad4-e1a5c74ebb9f">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i575934a7cedc4cedbde5e430befc2365_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzQtNC0xLTEtNzAwMzQ_4f94873c-a530-4ffc-b67c-b02cd1acbce7">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05004c0e3cfc490cac8c08c422000ba2_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphYjhmY2U0ZmJiMjM0MWE0OGYwZjdjYTE4YzZhYWVlNF80_3d372197-22e5-4157-86f6-456091350880">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7614f062f264a8fa4c4907f54853e94_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzUtMi0xLTEtNzAwMzQ_188a4bd5-4c74-42c2-bfcf-decb0b10d90a">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea66b619cb3443197db56a50a304a6c_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzUtNC0xLTEtNzAwMzQ_a746f78b-e889-43af-aec4-9893424c98b7">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12f17d6898c04d318d57f363e7c9bf98_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo4YzkyOWE2ZTgwYTM0NTQ4YWE0YzUzZDAwZjAzMWE0NF80_8f0d1cdb-1d23-4090-8891-bf71c42b1150">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1058600fb83c4dd480871a0a2a908496_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzYtMi0xLTEtNzAwMzQ_7b0772e2-e3e4-421e-8a93-695095983917">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616df737a6e04747b5272a1cef450ed1_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzYtNC0xLTEtNzAwMzQ_b3c830f0-e291-4651-b7d5-d818c18731c5">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42d3e3e61a244a51b1d33daefe6fe819_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzctMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo1MzA1YzMwZTU4MTE0YjNmYTQwNjg4YjM2YzQ2NzkzZV80_c82cd6c3-b9ff-4889-b8e9-09318226fa53">3.70</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd5f7853d0d4ffeab0ca0c4e2369e5d_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzctMi0xLTEtNzAwMzQ_2982a540-935e-4038-9f46-872d2550a9c1">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c41e781ada48aebeffcd3857c0fabb_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzctNC0xLTEtNzAwMzQ_44b929bd-73ca-4c75-88df-db579482e463">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96f5b18cb544467e97c5f515dcf98586_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphZDg5MWUxYzA5OTc0MDFkODgxZDQ4YTRkNzBhZWM1NV80_d918c20e-d078-474e-87f9-1c5df23ca822">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f4a61e1d17435cb3f75c415b7bedea_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzgtMi0xLTEtNzAwMzQ_582331df-fd49-4dae-8cfc-87c8a02dd5b7">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81ee28385e645de81a4923e2eb9efb4_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzgtNC0xLTEtNzAwMzQ_96fedd96-633f-4e78-9765-75997bde8069">806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92f0cf689bb644bcb78bfd87f8b277ad_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzktMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoyMzhmOTY1NGM4NjE0MTgzYTIwZTdmNTMzYjc4OTdjZV80_6e5794a1-7979-44f4-aadc-313900bbc087">3.50</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a95408bdaa4b3782748bb151cab603_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzktMi0xLTEtNzAwMzQ_ee401017-2bfa-470a-a3cb-45b037536e97">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27effcd5f6a94b389235ad25b18e2bcd_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzktNC0xLTEtNzAwMzQ_d41ab992-9f8e-49a3-bc72-a23e342b50d7">677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia18fac953b8141dabab3475985def187_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpiYjkxOTVmYTRlMGQ0NGQ2OGMzM2QxODU1MzM2ZWQ5ZV80_cb85a23f-5526-4ef3-ac64-0e9228977d71">2.25</ix:nonFraction>% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78494e54f3114f17a858e621c5e6752d_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDAtMi0xLTEtNzAwMzQ_3c17fc4e-2ec6-4f56-936f-b91af3492aed">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d8d0c23c594dd8a278bdb58b5042b2_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDAtNC0xLTEtNzAwMzQ_5b2a7353-73c9-44c2-9fd7-dd734f322c81">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07459c41a6f843978c00a7b71ef76e9c_I20220703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowMzI0MDIyYTM1ZWY0ODNiODY2NjgwNmIxNjY5NDVjZV80_b3fa8be0-a8a5-4aa1-b23f-7508180fc84f">2.45</ix:nonFraction>% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7afb6fc2c7ae48c8b09189c72a0dd118_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDEtMi0xLTEtNzAwMzQ_7211cda4-2111-4929-8ea9-2b981631cbb1">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b91038961e64c0085d31120a376145e_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDEtNC0xLTEtNzAwMzQ_011faef3-c2b6-47b6-b7ed-4ac80f0c3f80">773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7696abcc3b4b91843a6ef7190f4f06_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDItMi0xLTEtNzAwMzQ_40664bed-9a99-4535-a207-87b60674489b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b7a271cb844d789cdf3dad5b732c3a_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDItNC0xLTEtNzAwMzQ_b9ea4a20-b34f-4423-b78c-6fd73ca083bd">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35b52ff0f6ac42609c258100f987af3e_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDMtMi0xLTEtNzAwMzQ_45bef02a-5470-44ef-b201-6fbfc6992abe">28,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if668327e01644d82befdc0a8ab72e2cb_I20220703" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDMtNC0xLTEtNzAwMzQ_ad802dbd-0dcd-48a7-879e-d5f3e47f9963">26,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is <ix:nonFraction unitRef="number" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTA4ODA_49bbcf1e-599b-453e-a8af-1fd0f668e941">3.04</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $<ix:nonFraction unitRef="usd" contextRef="i702f71864f5046db87e856abadec5a61_D20220103-20220403" decimals="-8" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTA5NjA_58849c13-d7d0-42bb-97bd-f29b407dc8f3">3.2</ix:nonFraction> billion at January 2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of July&#160;3, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i59e59e4d0e434ad28048bd9cc5ed9cf5_I20220703" decimals="-8" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEwMjc_66ae3bc7-2e88-4766-b7e4-1d21923d0389">3.8</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="i59e59e4d0e434ad28048bd9cc5ed9cf5_I20220703" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEwOTY_d5662661-9d8b-4aef-befd-d07312a34fa6">0.98</ix:nonFraction>% and a weighted average maturity of approximately <ix:nonNumeric contextRef="i143c1877fac245a1b05d14212b80d45f_D20220103-20220703" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTExNDg_28fbcc20-bda6-4fb0-85b2-95e8f6870bb0">two months</ix:nonNumeric>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icf1da79e8edc41eca0eb5119b1703ad1">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</ix:continuation></span></div><div id="i01b5d6689adc4498bfe63be39e352060_70"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 5 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMTk1OA_65244ca2-e888-4718-9528-8006314edc42" continuedAt="i800cd84503d949b7963fb0693df4154a" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i800cd84503d949b7963fb0693df4154a" continuedAt="ie715941205eb4aa1a3301bcb95e7ea0d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal six months quarters of 2022 and 2021 were <ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMTE4_19d2341f-a6bc-4b4b-8c17-9f03a130c01b">14.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMTI1_238dd374-eb76-4f75-9611-52d649ba66ff">11.5</ix:nonFraction>%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal quarter is primarily due to the Company reorganizing the ownership structure of certain wholly-owned international subsidiaries in the second fiscal quarter of 2021.  As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with the applicable local regulations.  Accordingly the Company recorded a local deferred tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="i0b98f47b14654327afbb7932046478c8_I20210704" decimals="-8" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5MjYxOQ_78858b4c-8057-44cb-b8c4-4e056de2e5f3">2.3</ix:nonFraction>&#160;billion which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $<ix:nonFraction unitRef="usd" contextRef="i0b98f47b14654327afbb7932046478c8_I20210704" decimals="-8" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5MjYzMw_d9b39f53-6335-4521-95f0-cffae31117d6">1.7</ix:nonFraction>&#160;billion. The net impact of this reorganization was approximately $<ix:nonFraction unitRef="usd" contextRef="i0b98f47b14654327afbb7932046478c8_I20210704" decimals="-8" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5MjY0Nw_e6490ec7-eb21-4b1c-afe4-0e4250a8c30c">0.6</ix:nonFraction>&#160;billion net benefit or a <ix:nonFraction unitRef="number" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5MjY2MQ_8156669c-c84e-4f48-bc14-48c317b42a1e">4.4</ix:nonFraction>% decrease to the effective tax rate of the fiscal six months of 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, the Company had lower income in higher tax jurisdictions, primarily in the U.S., compared to the same period in the prior year and certain one-time tax costs.  This lower income in the fiscal six months of 2022 was primarily caused by a mark to market adjustment to the Company&#8217;s investment portfolio, the impairment of the Bermekimab AD IPR&amp;D (for further information see Note 3 to the Consolidated Financial Statements), both at the U.S. statutory rate, and litigation expenses. The impact of the income mix was partially offset by incremental tax costs directly related to the planned separation of the Company&#8217;s Consumer Health business (for further information see Note 1 to the Consolidated Financial Statements)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal second quarters. Additionally, the Company&#8217;s tax rate benefited from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of July&#160;3, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMTE0Mw_2530ef08-fb59-4838-9d6c-3497d9c57e87">3.4</ix:nonFraction> billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.  In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:continuation id="ie715941205eb4aa1a3301bcb95e7ea0d">Subsequent to July 3, 2022, as part of the planned separation of the Company&#8217;s Consumer Health business the Company has recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i2daa8a32f1fc4fdf8b188540df1f7766_D20220704-20220729" decimals="-8" name="us-gaap:IncreaseDecreaseInIncomeTaxes" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5Mjc1Ng_47300d03-49bc-4b39-a73f-2dbd42ab6352">0.3</ix:nonFraction>&#160;billion in incremental tax costs due to the reorganization of certain international subsidiaries which will be recorded in the fiscal third quarter.</ix:continuation>  </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 6 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RleHRyZWdpb246YjhmNjIzNmExMDNkNGJmZWIwMjhkYjU0MmIwMGVjMjVfMTAxMQ_a10e962a-33d0-4662-bf0c-b57730cf8778" continuedAt="i5900a6dc09b3433094b385079daa7334" escape="true">PENSIONS AND OTHER BENEFIT PLANS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5900a6dc09b3433094b385079daa7334" continuedAt="ied33b6831a8c4fa195bff8ea57a380b2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RleHRyZWdpb246YjhmNjIzNmExMDNkNGJmZWIwMjhkYjU0MmIwMGVjMjVfMTAxNA_873c537f-4eb7-4fa1-817c-d205d8f9b8c9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0yLTEtMS03MDAzNA_2f8b0899-c4c0-492d-a99b-b7feeaef3b93">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy00LTEtMS03MDAzNA_04655b53-cb24-45e4-b826-d94fff3789b6">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy02LTEtMS03MDAzNA_9558dae4-771e-4a2c-b420-0bf6e15af260">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy04LTEtMS03MDAzNA_2bb3c5c5-053c-42c0-8377-f928bf76e497">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0xMC0xLTEtNzAwMzQ_e8305794-41fe-4c53-8434-cfa8725bef9e">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0xMi0xLTEtNzAwMzQ_82e8380e-6e61-4d1a-953f-064837286473">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0xNC0xLTEtNzAwMzQ_b34e1d8f-0b7b-4584-99a0-9627c572b64b">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0xNi0xLTEtNzAwMzQ_79f4df06-32e3-421f-862e-204029f2757e">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0yLTEtMS03MDAzNA_eca6bc51-9d0a-428b-9ec5-7915b4536573">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC00LTEtMS03MDAzNA_582848b4-f5e8-4322-93aa-a7347371c2d9">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC02LTEtMS03MDAzNA_b6f0d746-3ae4-48f3-bf70-9457d244f6f6">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC04LTEtMS03MDAzNA_87dbf849-818c-4b80-bcc9-f2b56865be7c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0xMC0xLTEtNzAwMzQ_8041d649-ad97-434c-a65b-c058f5d9cf11">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0xMi0xLTEtNzAwMzQ_27342646-685b-4437-8498-9c2cf41586d0">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0xNC0xLTEtNzAwMzQ_71752bb9-0134-4795-8b53-cf04887b4f55">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0xNi0xLTEtNzAwMzQ_7eb91c1c-bad9-4599-a0fb-15914579ad91">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0yLTEtMS03MDAzNA_2441c7be-e89f-42e5-922f-bdad71a96c63">693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS00LTEtMS03MDAzNA_bb8dfb05-6059-4f30-bb27-cfd2b87b9ee2">647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS02LTEtMS03MDAzNA_290c8044-31f8-4d94-8c3d-aed2647b3448">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS04LTEtMS03MDAzNA_c1fbd1b0-0592-438b-871e-b03a31e7aad4">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0xMC0xLTEtNzAwMzQ_bd6dfd34-4355-4e11-b665-b3f2b98b1e7d">1,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0xMi0xLTEtNzAwMzQ_a2a1409b-606d-460f-868d-3b0a99698931">1,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0xNC0xLTEtNzAwMzQ_b95db552-cf30-4d2b-9fbe-4ddb4e811c26">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0xNi0xLTEtNzAwMzQ_93cc2325-ca18-4e25-b1e2-080da1e6c8af">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0yLTEtMS03MDAzNA_098a2356-736a-40d2-9fb7-63972d3cfcca">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi00LTEtMS03MDAzNA_ef1bbe5c-ba0b-4687-82a0-95e0d2bdb957">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi02LTEtMS03MDAzNA_2f7254af-9e4c-4f97-8b65-98ada5532377">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi04LTEtMS03MDAzNA_97ce89a6-208a-4437-a34a-71c7e03f42d8">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0xMC0xLTEtNzAwMzQ_e71e6025-278a-4d00-8592-d48de8146c6d">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0xMi0xLTEtNzAwMzQ_7f9c8fac-1439-4e7b-add5-7282de522ace">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0xNC0xLTEtNzAwMzQ_230a977c-b9db-4982-94a0-659fd6ec79a7">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0xNi0xLTEtNzAwMzQ_6a8b9a55-29ea-4d95-b2b4-8d333cd1a178">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0yLTEtMS03MDAzNA_1cb712f7-efd4-45a0-9b8b-c754620c250e">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC00LTEtMS03MDAzNA_363a329d-4a50-48cb-b2ee-0abb6696fc1f">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC02LTEtMS03MDAzNA_91833446-1a77-49bf-93c5-f92fb3a7d531">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC04LTEtMS03MDAzNA_46b3a184-709a-4c14-aa2b-2996ad5267fa">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0xMC0xLTEtNzAwMzQ_84a5293e-1f86-40c7-845c-df32fcad73b5">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0xMi0xLTEtNzAwMzQ_9bd40b09-3e4b-4b9a-b5a2-a8307b3057e0">630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0xNC0xLTEtNzAwMzQ_ef4a030b-1633-4eec-8278-e65689f71eca">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0xNi0xLTEtNzAwMzQ_17054029-396a-4362-b61d-ddf51b0a5ba5">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0yLTEtMS03MDAzNA_62b15c66-7bd9-47eb-b67a-da36a93843d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS00LTEtMS03MDAzNA_ae7a14c7-b21b-499a-b4df-16c454ca191c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS02LTEtMS03MDAzNA_95f7a596-6d75-4f2a-a3db-3adf353637c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS04LTEtMS03MDAzNA_f1fea04f-07a3-482b-a003-8407355933f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0xMC0xLTEtNzAwMzQ_8ef14c5c-510d-43b8-8c4e-bc09d00ad748">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0xMi0xLTEtNzAwMzQ_53d301b6-4354-4e7b-9c54-8921272d0b4b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0xNC0xLTEtNzAwMzQ_cd281b03-f02b-4b2b-80ed-88582b47b2c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0xNi0xLTEtNzAwMzQ_f71385ae-a180-4e76-b589-af0f21a103a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMi0xLTEtNzAwMzQ_83c5c4df-54a1-4fb0-9afe-b97c3c9f97f4">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtNC0xLTEtNzAwMzQ_1154d58a-2284-410a-870d-91a17aedac5e">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtNi0xLTEtNzAwMzQ_332b7835-57f7-4b01-941b-f59a6a3ec582">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtOC0xLTEtNzAwMzQ_dd49a9f9-6796-46b5-b412-4633089a582a">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMTAtMS0xLTcwMDM0_106f833f-e949-4a2d-a0fc-097fb2309773">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMTItMS0xLTcwMDM0_e95f4912-8222-4942-8f68-c0f72cf22851">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMTQtMS0xLTcwMDM0_1bd840c3-a826-49fa-b0a6-da8ab116975d">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMTYtMS0xLTcwMDM0_d31e09b0-d046-4bfc-9f4d-cddd44304011">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="ied33b6831a8c4fa195bff8ea57a380b2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal six months ended July&#160;3, 2022, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i62384ef644a54697aca04106e3f0437b_D20220103-20220703" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RleHRyZWdpb246YjhmNjIzNmExMDNkNGJmZWIwMjhkYjU0MmIwMGVjMjVfNzQy_63a2e72f-a8ce-4da0-ac7f-59da4602a1cc">54</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2fc2f74ef18d4d33b92e9d7d64d48020_D20220103-20220703" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RleHRyZWdpb246YjhmNjIzNmExMDNkNGJmZWIwMjhkYjU0MmIwMGVjMjVfNzQ5_100dd9cf-3afe-446c-afe1-ec57c35f4676">10</ix:nonFraction> million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div></ix:continuation><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_76"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 7 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RleHRyZWdpb246MzNiMWFiZGQzNTI4NDExM2IwMzUwMTQ4YzExNzBkNmZfOTI0_4fe6e6a1-1c88-4d26-acb1-964695102948" continuedAt="i5af027172bc044ac89a354a060184d9e" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5af027172bc044ac89a354a060184d9e"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RleHRyZWdpb246MzNiMWFiZGQzNTI4NDExM2IwMzUwMTQ4YzExNzBkNmZfOTI2_c8e7a109-5cc5-407e-8120-ca3a432e8b31" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.991%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9717a3a8ced548948d10ecbb0f33b8c3_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC0yLTEtMS03MDAzNA_ebe50fe6-699f-41dd-818e-bba73d68f3dc">10,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2601e00af4474b03b245711113cf2975_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC00LTEtMS03MDAzNA_5ecb11a8-e26a-4528-94d4-881fde980270">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18d1e90be3564affb9df03eb62cc401e_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC02LTEtMS03MDAzNA_3f7624d9-5863-4f72-bd17-a8c1ce2b027e">2,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a55a77208474cb0a1becbbd53ec82ca_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC04LTEtMS03MDAzNA_4e4ae442-c1ef-431c-9002-b2d28b7501fa">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i116332ccca294d499f773d00109c050b_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC0xMC0xLTEtNzAwMzQ_eb2142fa-f45b-47f9-8dd0-072fd791830a">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS0yLTEtMS03MDAzNA_56077629-3cbd-477b-a485-f514f3e60dcd">705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS00LTEtMS03MDAzNA_e2b49084-a5d8-483b-818a-4bcac5df1757">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS02LTEtMS03MDAzNA_010ae28f-11c8-4d00-9a88-ed3579c78d1e">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS04LTEtMS03MDAzNA_19de76da-75fb-4a81-a7b5-f9342fb5bc58">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS0xMC0xLTEtNzAwMzQ_781059fc-6adf-40ce-90a5-2ab00edcebe1">785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f7f5277eb57456983ec4fe69703fd6a_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy0yLTEtMS03MDAzNA_36a85768-38f9-4c56-beb8-16e24b9c3950">10,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f6f63f466324af9a0ba713c475af49a_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy00LTEtMS03MDAzNA_7aeef301-1f75-489d-aa0d-de210d2d81f1">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72370e9d3ef64afc8247235db2a6256a_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy02LTEtMS03MDAzNA_7e65a463-595b-4eaa-8cfa-e1b33bf0a86f">2,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb20df11643a4db4a4501af374b8611c_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy04LTEtMS03MDAzNA_0448e772-7b8c-4042-8deb-4ddaf743aeb8">613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c44097a42f4c9b8d26741faed5e548_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy0xMC0xLTEtNzAwMzQ_ed577aa8-48d1-4a76-8af1-ada5de6e436b">13,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 8 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RleHRyZWdpb246YmYxZGY4ZjYzYmU4NDFkZGE2NjU2OTg5ZDZiNjI0ZGVfNjI0_49883bea-b4c3-479c-b3ea-76cf6ec77848" continuedAt="i1b808ccb70d2424fadcabb344ec83375" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1b808ccb70d2424fadcabb344ec83375" continuedAt="i11fde05784404eab9b83b6732fee8ab3"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RleHRyZWdpb246YmYxZGY4ZjYzYmU4NDFkZGE2NjU2OTg5ZDZiNjI0ZGVfNjEw_e44d57f8-44d8-40c9-872f-d5def580177c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:53.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMi0yLTEtMS03MDAzNA_b7402fbe-0616-49f1-af6b-2e84a6ab757a">1.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMi00LTEtMS03MDAzNA_b7e8ccf3-286b-4d14-9208-ab0a9148e0f3">2.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMi02LTEtMS03MDAzNA_2d0f3f23-71e0-47ab-b5b7-3a8a8012b7e0">3.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMi04LTEtMS03MDAzNA_d460e8d9-07e0-4f8f-aab1-5d602aff697a">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMy0yLTEtMS03MDAzNA_b7986135-9d2e-4f80-af08-5c0115d46b7a">2,629.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMy00LTEtMS03MDAzNA_94864f6c-aadf-4e67-809a-9cfa2e2126bc">2,632.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMy02LTEtMS03MDAzNA_b6799842-1631-4e5c-892d-6d12536219a4">2,629.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMy04LTEtMS03MDAzNA_060c46e6-4cf7-41b4-b87b-79b8c21bedc3">2,632.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNC0yLTEtMS03MDAzNA_692b9422-961a-484a-bb82-7469dead192c">143.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNC00LTEtMS03MDAzNA_8d185d25-3e17-4940-b45f-e16deef2f21b">141.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNC02LTEtMS03MDAzNA_bd34e761-abe1-4be4-9cc5-0ccc77553271">141.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNC04LTEtMS03MDAzNA_a5637678-232b-47ea-9b40-5cc1fb357a4b">126.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNS0yLTEtMS03MDAzNA_dbfeb1d0-6544-4dbd-b14d-629530bf1472">105.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNS00LTEtMS03MDAzNA_ce94c423-4b72-4ad7-b986-bfb9411a2ea3">102.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNS02LTEtMS03MDAzNA_d0043884-2d75-4b2c-b2cc-f341b2f41bde">102.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNS04LTEtMS03MDAzNA_ba57cb70-18ba-4908-9d5c-0c9e01da04d4">84.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNy0yLTEtMS03MDAzNA_1fd56926-8f20-4703-9d5b-e25675bd2797">2,667.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNy00LTEtMS03MDAzNA_b22a1480-4ee2-471b-baec-7c3b8e81b1b9">2,671.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNy02LTEtMS03MDAzNA_4a3f26f1-358b-4329-87d7-49d884125b29">2,669.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNy04LTEtMS03MDAzNA_c33b217c-bc93-4d51-8f01-dc1fb218e2a0">2,674.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfOC0yLTEtMS03MDAzNA_47597e54-1bc4-45dc-9a30-c57ba2252662">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfOC00LTEtMS03MDAzNA_d0c20065-2904-4e12-8ce2-ffd967f0383b">2.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfOC02LTEtMS03MDAzNA_1f7e99a6-83a6-4e42-a106-c0263db282eb">3.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfOC04LTEtMS03MDAzNA_64ce6ba9-f542-4d71-9b95-77201cbc5907">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The diluted net earnings per share calculation for both the fiscal second quarter ended July&#160;3, 2022 and July&#160;4, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i11fde05784404eab9b83b6732fee8ab3">The diluted net earnings per share calculation for the fiscal six months ended July&#160;3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. The diluted net earnings per share calculation for the fiscal six months ended July&#160;4, 2021 excluded <ix:nonFraction unitRef="shares" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RleHRyZWdpb246YmYxZGY4ZjYzYmU4NDFkZGE2NjU2OTg5ZDZiNjI0ZGVfNDYw_d6c87682-e6eb-4607-a304-b72ed869a064">14</ix:nonFraction>&#160;million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 9 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjk0Nw_bbe7f905-fd19-4b09-84e5-ea716fd1576b" continuedAt="i33b1cef996234f8d9b7ee4234871d81e" escape="true">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i33b1cef996234f8d9b7ee4234871d81e" continuedAt="ifea9c5ee371d43ccb3b06c22fc4a3953"><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjk1Nw_c368a7bf-d5e5-4eeb-9621-b062546b5396" continuedAt="i2aaa8bcbf8c1488cb1ae0f56ab54e665" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8195ff1841b44360849eba5718e01652_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS0yLTEtMS03MDAzNA_74271dcb-860c-43e5-8c16-1f72c15d6d8e">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa7ba884545448a83b114bcc5344580_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS00LTEtMS03MDAzNA_5a5f6aa4-bea6-4a3d-bcd3-387b090fc988">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8195ff1841b44360849eba5718e01652_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS02LTEtMS03MDAzNA_f9166383-000b-48b4-8aff-f539c0b4708b">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b4ebb79f86444c5878078484251d735_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS04LTEtMS03MDAzNA_f68ed932-7dcd-46f4-85a3-cde9ef39798a">1,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e5385aae254b489b7e039a2183a902_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS0xMC0xLTEtNzAwMzQ_7e340061-a667-4681-b118-59be03b2265a">1,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b4ebb79f86444c5878078484251d735_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS0xMi0xLTEtNzAwMzQ_cc00a6f2-b92f-478c-8007-c6f1a539f127">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbf0047aef3405eb9f261a53967efb1_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi0yLTEtMS03MDAzNA_4892f887-8022-479f-aa42-3f07deb7c0aa">818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26d715418394045bf2d275669c0c2d5_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi00LTEtMS03MDAzNA_ae7fb71e-53d8-447d-a8a2-dce56cea69e4">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3bbf0047aef3405eb9f261a53967efb1_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi02LTEtMS03MDAzNA_84b596be-79a5-4b55-a061-5b11a70b2986">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc6d07570ff45a8a24f52ea1dae3e62_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi04LTEtMS03MDAzNA_437cac75-25bd-470e-90bd-c44a912517fe">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee1eec7950c4ef78e937d2c4e3298f8_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi0xMC0xLTEtNzAwMzQ_b130f33c-de46-42dc-8141-74bc904cd2fd">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fc6d07570ff45a8a24f52ea1dae3e62_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi0xMi0xLTEtNzAwMzQ_e90b521f-074f-4d0f-9bf5-af69f7e62afb">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e9c8dc44154c0889a38ce4ae1cfdee_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy0yLTEtMS03MDAzNA_f6e98e6e-c264-4f52-b0b1-4ca1b3656477">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b746d1f6934a38b36cc2f177fd06bb_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy00LTEtMS03MDAzNA_894ed995-f13d-4dd8-a6de-2aba56f1543b">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38e9c8dc44154c0889a38ce4ae1cfdee_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy02LTEtMS03MDAzNA_2fc94d43-7dac-4f63-af74-9e3e0e977528">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ab60eec1f141039a0d797a3f451481_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy04LTEtMS03MDAzNA_a9939ced-246a-4d5f-b5d0-ce3b08d83e82">2,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id334e2622b5a43608b68569880f13d0a_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy0xMC0xLTEtNzAwMzQ_4f160fe7-91ca-4c08-a6f5-69800c81f3c7">2,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96ab60eec1f141039a0d797a3f451481_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy0xMi0xLTEtNzAwMzQ_951dd4a6-bc7b-4653-991d-8ed776ae7343">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c500211bc040d4855e6035ad051bf5_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS0yLTEtMS03MDAzNA_175008db-0006-4a75-9406-39596f47fd5b">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01784d325404849937b0a9daeb1c938_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS00LTEtMS03MDAzNA_7c9a83e3-35b6-4fb1-9dd4-6ee561ac5f30">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i71c500211bc040d4855e6035ad051bf5_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS02LTEtMS03MDAzNA_adff0f4c-713a-42a5-9116-8d1f199ac6ae">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2ebe5ae60c49b0a9fff97883e882ed_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS04LTEtMS03MDAzNA_8f4934fb-556a-4771-8f31-36a53d4cd420">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6d906d8c3b44108349d0c7ae0c91ca_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS0xMC0xLTEtNzAwMzQ_bd53dba4-6746-454e-8946-4a2ef6b97f6f">1,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icb2ebe5ae60c49b0a9fff97883e882ed_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS0xMi0xLTEtNzAwMzQ_0e931898-5a0a-48c3-aead-43f5397fe733">9.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0621cbfb3ca24c87b649251bb892364a_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtMi0xLTEtNzAwMzQ_ca809938-7668-421f-b415-98159d5583f3">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if398f47ba6cc4d43b6d90c700176240d_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtNC0xLTEtNzAwMzQ_456caa29-c44e-4aa5-a6c9-2b7e63189072">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0621cbfb3ca24c87b649251bb892364a_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtNi0xLTEtNzAwMzQ_74d9c592-70b5-45da-a368-2f2122ab5889">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33319c8b0e2844c1a78f06bc06b7301c_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtOC0xLTEtNzAwMzQ_b7708471-80cd-413e-b1f9-5b14181cf38d">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13a2d7df3c942ba9306523693e96af2_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtMTAtMS0xLTcwMDM0_e9f65638-2a9e-4bda-a784-acd78d157765">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i33319c8b0e2844c1a78f06bc06b7301c_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtMTItMS0xLTcwMDM0_91df2366-02e8-4e95-b9f8-b9bb0dfff128">7.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaddb3c97163a44a0a32251c19d5d0ff7_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtMi0xLTEtNzAwMzQ_1f5039b4-ec8b-4d9c-b281-a51ca01d8881">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b62bea6d6874162b043629fa713ac31_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtNC0xLTEtNzAwMzQ_c5e90971-22b0-4117-8ab0-b13eca56f01d">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaddb3c97163a44a0a32251c19d5d0ff7_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtNi0xLTEtNzAwMzQ_1b3376ec-1c59-445e-8880-0a1758e0543e">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68089e150f524c5abad75d4bc0930034_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtOC0xLTEtNzAwMzQ_9df16b39-6fc7-4aec-a847-82024cf8ccef">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9095543594314e21a7ed013540198140_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtMTAtMS0xLTcwMDM0_f90c804f-e031-4aa2-bc24-67bac3afaba0">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i68089e150f524c5abad75d4bc0930034_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtMTItMS0xLTcwMDM0_cb8974c3-a3c1-4f33-ae90-d73ef2b545d7">8.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13101093f5447d9bc000921069e8423_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtMi0xLTEtNzAwMzQ_7e436df4-d13f-4144-bdfb-8e980c1ae3f4">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a4e77c23874d21a2804eff01168460_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtNC0xLTEtNzAwMzQ_2df6050f-2fcc-4f49-8cc2-fd46db283064">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if13101093f5447d9bc000921069e8423_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtNi0xLTEtNzAwMzQ_14283857-a09d-4ab0-bd50-8c4f366c5f38">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f309ab7ce9e47f6a93a24b6c21f112f_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtOC0xLTEtNzAwMzQ_7a77deee-86fe-4816-9eea-2dda4169a93f">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff5349857aa4a3496da3c8d285390a8_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtMTAtMS0xLTcwMDM0_161b4f08-f65f-49bf-8bcc-00ff88a66a15">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f309ab7ce9e47f6a93a24b6c21f112f_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtMTItMS0xLTcwMDM0_3fb0201f-8d28-467c-ae9b-0749539a236a">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9cb7fd4ddb4911b27d35f071fa8886_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtMi0xLTEtNzAwMzQ_4640b82d-2de9-4936-b495-ade310299089">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09063562e0d4fd3a2f72663c512d14d_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtNC0xLTEtNzAwMzQ_d5def3c1-e5f9-4e07-a2be-b99b7ec4c958">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3d9cb7fd4ddb4911b27d35f071fa8886_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtNi0xLTEtNzAwMzQ_dd1b2734-fe10-4689-81a3-85f47d821446">14.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd7a688a72f4a6d9787219e5e029a38_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtOC0xLTEtNzAwMzQ_92176407-164d-4b16-9378-f9ab0d7b6df3">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de727b2f6144bfaa64c8a53dedb41bb_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtMTAtMS0xLTcwMDM0_f27e591a-f622-42ce-b5f8-923884eeba77">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5fd7a688a72f4a6d9787219e5e029a38_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtMTItMS0xLTcwMDM0_571902a0-01ff-41cc-aab4-121cb9594043">13.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce860b4fb8441f18fffa07dcef2a31b_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtMi0xLTEtNzAwMzQ_1b598185-c890-4b47-97f0-8dec526d8c8a">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed64e30f1e54509a52b4ad3abd15f77_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtNC0xLTEtNzAwMzQ_063137ee-a2f6-4448-aa9a-baa10de6a5f5">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7ce860b4fb8441f18fffa07dcef2a31b_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtNi0xLTEtNzAwMzQ_909d14b6-2e71-4b77-a849-43f34c318118">7.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53177aeb7e124a05bf7af2cd65156f97_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtOC0xLTEtNzAwMzQ_74114812-be3b-4bd2-a0d3-4950b78b8e2b">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c9d35d1483442cdb89d4315ab87c195_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtMTAtMS0xLTcwMDM0_7f56607d-2aaf-4b39-934b-1e1fb126c1d7">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i53177aeb7e124a05bf7af2cd65156f97_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtMTItMS0xLTcwMDM0_da2cfc9a-a9a4-4615-a37c-8bcec4ce462d">9.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef348574e5b40b5951363c5761b57e0_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctMi0xLTEtNzAwMzQ_e92d779a-cc73-4a12-be45-13ed2b10c96a">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944b4a698ea646128ec4f289fc31f5bb_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctNC0xLTEtNzAwMzQ_8a8d1f99-13bc-459f-a98a-1fe624165d66">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1ef348574e5b40b5951363c5761b57e0_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctNi0xLTEtNzAwMzQ_e2143727-c641-497f-a736-6f925dbf0046">9.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5876de3f5bd4a6fafa27ffe0d10a9da_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctOC0xLTEtNzAwMzQ_70a9ff9d-2853-4bda-93a4-96b41a1ed2ab">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18cce1df7be41d3addfa2391156aebb_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctMTAtMS0xLTcwMDM0_d246bfe6-4f21-4432-a72f-03832de1d24a">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia5876de3f5bd4a6fafa27ffe0d10a9da_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctMTItMS0xLTcwMDM0_01eb99e8-6da4-4f58-9ca3-c44698d76cb5">10.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f715131df5f4ce38b709e366c8634f8_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtMi0xLTEtNzAwMzQ_dd2b989a-4ca8-4a42-81fd-8fbdc58c7a39">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9fa20297e84900a134c648c79ed724_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtNC0xLTEtNzAwMzQ_ef54775c-27d1-4033-a059-5b016505a21b">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5f715131df5f4ce38b709e366c8634f8_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtNi0xLTEtNzAwMzQ_3abc1c3e-5227-4fee-a463-5f7b5cd6d019">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a293dc78794b8c84941522d362b2b3_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtOC0xLTEtNzAwMzQ_4f52f24d-9606-44cf-a11f-89a4b75893b7">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ed86e0bf67442ab4bdba01c26ab3ef_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtMTAtMS0xLTcwMDM0_8dbf4429-6044-49da-a94d-47abe02fc0a8">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i33a293dc78794b8c84941522d362b2b3_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtMTItMS0xLTcwMDM0_41c6b092-b1bf-4171-b02b-6642fa25c686">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i102548ebfc714d89b200cb8801eada1d_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktMi0xLTEtNzAwMzQ_18574359-53df-449c-9254-e9c38b01a797">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib041fceea7e145b69657ad998b398574_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktNC0xLTEtNzAwMzQ_f4b79811-ccff-4f07-9902-f705382eb0b6">387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i102548ebfc714d89b200cb8801eada1d_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktNi0xLTEtNzAwMzQ_16d7f77b-e1f5-4247-8b83-ab5a47297d29">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a72fab377cd41989bd7cb664b052786_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktOC0xLTEtNzAwMzQ_ab586870-a881-4d63-a6e2-0568381f8d32">730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7718b305fa4e98af05f13ccd09b117_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktMTAtMS0xLTcwMDM0_fd69b998-af81-463e-b548-2446cb11e8bf">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8a72fab377cd41989bd7cb664b052786_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktMTItMS0xLTcwMDM0_7d07c52c-7069-43ce-9ae0-479b774ce2b4">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6651ef9c1ac4edbb8cf6a115bf220cc_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtMi0xLTEtNzAwMzQ_1971be6d-50bb-4c1c-9287-af314cb2a866">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed1bfe39b4e4bb5bba8bbdce7bdaa1e_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtNC0xLTEtNzAwMzQ_9365ba74-4c24-4382-a2c8-b4b567e03325">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6651ef9c1ac4edbb8cf6a115bf220cc_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtNi0xLTEtNzAwMzQ_666c4cc2-0066-4a19-9b55-beebaa0377b1">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie744fe7eb10840b59f191d4ebfb373d8_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtOC0xLTEtNzAwMzQ_0284490f-9b28-48cb-b193-052239988dac">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d92d32a1fb4d1fa4667d39d0165593_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtMTAtMS0xLTcwMDM0_a44c01ca-b9df-48f1-8fd1-877e9e14d2e7">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie744fe7eb10840b59f191d4ebfb373d8_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtMTItMS0xLTcwMDM0_fc91b045-bcf0-4023-8c36-1bb5eafe83fc">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c37007b3dc425b849156d2b344eb7e_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItMi0xLTEtNzAwMzQ_ead8c018-d3bb-4156-814a-3f41c76dc8a9">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e018caf3a44821b6b23d3804a73e3f_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItNC0xLTEtNzAwMzQ_2aae79a3-c0e2-423c-9084-f3e092ece376">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67c37007b3dc425b849156d2b344eb7e_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItNi0xLTEtNzAwMzQ_284764ff-0e18-4306-a0ac-9a5a10f7bb72">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd7be7ef01a442ea8668894c4d382fa_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItOC0xLTEtNzAwMzQ_50532cc4-236c-43db-8a4b-846141f5c4d6">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1d7a7b9b2a4248887b77dba76f601f_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItMTAtMS0xLTcwMDM0_0246e4c1-e73f-4795-a759-c17667eaaccf">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd7be7ef01a442ea8668894c4d382fa_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItMTItMS0xLTcwMDM0_6293211a-f25b-410b-a3a6-26412b25c6bd">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0e407cd47704992a0317255189675b7_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtMi0xLTEtNzAwMzQ_905ac722-afd5-432b-822a-2a9a6c1df5c9">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib867ef751de5492fa15d45f7bf794438_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtNC0xLTEtNzAwMzQ_b88cba75-24ab-449b-9c99-da5a7c7c9729">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0e407cd47704992a0317255189675b7_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtNi0xLTEtNzAwMzQ_8a4aa3b7-d7e1-42c2-b989-4e7f7e94e30d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb71611308d4b42a6e9f2cd42a75c82_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtOC0xLTEtNzAwMzQ_c112d881-30a2-48df-b01c-b93bc3a1b431">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693bf3820634476c859b68b815574d1d_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtMTAtMS0xLTcwMDM0_88225e1a-7cb5-47f6-b3a1-2b707d054e90">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibeb71611308d4b42a6e9f2cd42a75c82_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtMTItMS0xLTcwMDM0_d7ef201b-578b-46b6-80fb-9df8d4379825">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78dde3c6195f4c578643c83727dcad04_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtMi0xLTEtNzAwMzQ_cc0b66ec-9900-4582-b068-6e597457cf87">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb0aaffa7084f09810c1685730156ed_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtNC0xLTEtNzAwMzQ_ec0c5760-bd5a-48f8-9ceb-110df81216ce">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i78dde3c6195f4c578643c83727dcad04_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtNi0xLTEtNzAwMzQ_0e4d1902-266e-4b02-b65c-1d066659c241">12.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id10a3f80fd7e44589ec7f14f0a2f9fe8_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtOC0xLTEtNzAwMzQ_b02c9da5-e76e-414c-9a10-10ad9d812a71">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cccfe83ac064549a7486973cb800b07_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtMTAtMS0xLTcwMDM0_dc388f83-87dc-4a51-acff-83510a1610dc">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id10a3f80fd7e44589ec7f14f0a2f9fe8_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtMTItMS0xLTcwMDM0_0e885314-3f76-4f40-af63-19642c4e2f62">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e1f5924669f4a169c42aa764613999a_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtMi0xLTEtNzAwMzQ_313f2d4e-1b02-4cb4-bde0-9f1249d95514">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81ccc7cb7a9415a99c7f89e84017979_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtNC0xLTEtNzAwMzQ_9a687e8d-6419-40a4-b158-6fbf7e0e1ce7">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e1f5924669f4a169c42aa764613999a_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtNi0xLTEtNzAwMzQ_80941b2f-6b37-4bad-b2de-63c358a860dc">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0812d79d0004274855fe19590ad7dd0_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtOC0xLTEtNzAwMzQ_238593e0-5f70-4676-ada4-964c57a827f3">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8781a8fbd8814cff8dcfd139cc582995_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtMTAtMS0xLTcwMDM0_6d104904-60cc-49ac-8770-28fb0cf10ca2">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0812d79d0004274855fe19590ad7dd0_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtMTItMS0xLTcwMDM0_e5f0688b-a1a0-4911-9609-886064dc0fff">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffbd0973fa444c9b15cf063be1c3066_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctMi0xLTEtNzAwMzQ_c8a29e37-ef97-4aaa-bef6-f3345d276904">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6d698eee9664f599005ef75c6f73674_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctNC0xLTEtNzAwMzQ_ab0dbc49-f5b4-4fb4-946f-cdeda343cfb3">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1ffbd0973fa444c9b15cf063be1c3066_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctNi0xLTEtNzAwMzQ_1f57c027-515c-4292-999a-55f1f032e703">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fee31f1267449d6b660c897312001ae_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctOC0xLTEtNzAwMzQ_660ccd99-5332-4e0d-ba13-b4ca009b0c5a">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7192a0ac28bf4f76aa87147c2805f776_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctMTAtMS0xLTcwMDM0_85ba9484-7eab-4d21-9e63-a2319b7d8df1">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2fee31f1267449d6b660c897312001ae_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctMTItMS0xLTcwMDM0_214dd1f3-b270-469d-a83a-db1ef8066e4a">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f670f752605441cb46a46a85c79ecf2_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktMi0xLTEtNzAwMzQ_b987801d-fd76-4c52-b22f-5affdf2154e6">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658570b4166140dfadfbeea24c17c0db_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktNC0xLTEtNzAwMzQ_5a7d0b46-e2fa-4a32-9646-4d899158731a">1,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7f670f752605441cb46a46a85c79ecf2_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktNi0xLTEtNzAwMzQ_342610ce-4858-42f8-8dd9-f199d869b71f">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f83165908d14fcdb9fa9d202e01a201_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktOC0xLTEtNzAwMzQ_d7dc489f-9c58-4dc6-8f25-93df3c3d58f0">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74eb8c72df8240e79e32ce252be20ff1_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktMTAtMS0xLTcwMDM0_2fe45638-9c93-44fa-aa3b-0dcd20c1a34c">3,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6f83165908d14fcdb9fa9d202e01a201_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktMTItMS0xLTcwMDM0_6e639f9b-0c9b-4a3e-b642-4e090f25d7e8">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ea4eb5ba9a4f1c803077ceebb44e5f_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtMi0xLTEtNzAwMzQ_e903c996-562c-4590-863d-67924bb263fa">2,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50ce2e3f0464c71a9c5b8e469a9fa78_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtNC0xLTEtNzAwMzQ_f9101b63-b2c0-48d0-99b6-f7b34cc48e9c">2,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03ea4eb5ba9a4f1c803077ceebb44e5f_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtNi0xLTEtNzAwMzQ_239f96c6-d137-452e-b999-fa22460ab156">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c19f4191b1d426ba5408a30686ae901_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtOC0xLTEtNzAwMzQ_b7e87a24-939b-43ae-9ac3-ba7f7e6c35a9">4,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf51f604ce94696a0c9e9f86c80dcbe_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtMTAtMS0xLTcwMDM0_f084fe8d-1763-4ba8-8733-f16107cd4a0e">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c19f4191b1d426ba5408a30686ae901_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtMTItMS0xLTcwMDM0_a2d329c3-548b-4a41-ac7e-cac10ca63fae">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228867d760f145b882a88a1d618a76f8_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtMi0xLTEtNzAwMzQ_ffe2f892-497c-4c84-9448-935fb1c1085a">3,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecaa039dee6d486891f8d14610b01fbe_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtNC0xLTEtNzAwMzQ_ec78ded2-8c33-4293-9d56-b8ff3c4d14a4">3,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i228867d760f145b882a88a1d618a76f8_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtNi0xLTEtNzAwMzQ_831292d8-648d-416c-9979-adc8604f9db2">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc23407245a4376af9e0430687579f6_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtOC0xLTEtNzAwMzQ_884c7919-5968-4910-9562-1fc66a8f5c09">7,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e3c97cc494f4d5bafd40b0e6898cdc8_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtMTAtMS0xLTcwMDM0_6ee4bd2d-2aed-4523-b1b7-7dd78d863338">7,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3bc23407245a4376af9e0430687579f6_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtMTItMS0xLTcwMDM0_7fc96131-4fb1-4b55-a87a-909d5dd73ba8">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="ifea9c5ee371d43ccb3b06c22fc4a3953" continuedAt="i174bfb125ba84357bcf10e45b220f10f"><ix:continuation id="i2aaa8bcbf8c1488cb1ae0f56ab54e665" continuedAt="ic24780dbbab849b4a7113ba1d3929a7f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04a8138535574b2f8dd29e2d2ab984bc_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtMi0xLTEtNzAwMzQ_7d272322-e3c0-485d-976a-f6f5a2855af1">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i435910ace8fa4896a65a5f676869084d_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtNC0xLTEtNzAwMzQ_2d2cbac0-a751-432e-94e8-12ed3b09fc20">2,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04a8138535574b2f8dd29e2d2ab984bc_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtNi0xLTEtNzAwMzQ_db4bbeee-56d6-4a2a-8346-7b670f1f13bc">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf527b43e5c64384a1fe49225cbe7797_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtOC0xLTEtNzAwMzQ_df764553-1186-4bfc-b5fa-5f8e995c5958">5,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f36da8c5bd4d708ddc21a066e32df1_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtMTAtMS0xLTcwMDM0_d891e270-71eb-4c29-8f2b-da3c791a71de">5,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf527b43e5c64384a1fe49225cbe7797_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtMTItMS0xLTcwMDM0_53fcfe19-0d10-4629-a0ae-04999f49c226">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i429afaa0d03d45ef928c1df6565d72ea_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctMi0xLTEtNzAwMzQ_08afe25b-b247-4b47-8506-088f832bc877">1,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84783ba4704e45429e147e9d5dc289ac_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctNC0xLTEtNzAwMzQ_9f8b683d-109f-47ed-8400-224ce6e11f72">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i429afaa0d03d45ef928c1df6565d72ea_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctNi0xLTEtNzAwMzQ_37005e3c-e9c5-40cc-b347-926aecd936b2">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96db2fb32064dcc955371ae075882e9_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctOC0xLTEtNzAwMzQ_ea4d236d-4966-45e4-a7a9-f79c37b0b469">3,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901108f0a04f4af892226bc6740b5bfa_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctMTAtMS0xLTcwMDM0_d4e42dea-b6f3-4a0a-b298-ca6fc0c8ae79">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie96db2fb32064dcc955371ae075882e9_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctMTItMS0xLTcwMDM0_1b72cdfb-cf9e-4d92-a723-639c366d9701">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f056f7919a4853bb535aacc4a0cf01_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtMi0xLTEtNzAwMzQ_203aa6d6-dbb7-44f4-8a1a-32f2136a3380">4,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be3651fc9014dafa9dde9d16bfb5921_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtNC0xLTEtNzAwMzQ_0bf7f892-da2c-4cf0-9ea7-50009c3c63cd">4,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7f056f7919a4853bb535aacc4a0cf01_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtNi0xLTEtNzAwMzQ_ad196712-d14f-4c02-bac1-de37f78334cf">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd05eff2ba4e3a9580f155f072c389_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtOC0xLTEtNzAwMzQ_ca0e676b-4d2f-408c-bf7c-390fbdf2b154">8,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b5f1820f5c48d2af430c445889e0c3_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtMTAtMS0xLTcwMDM0_f99b9cfb-d572-4101-a067-0c68674c70f3">8,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1cd05eff2ba4e3a9580f155f072c389_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtMTItMS0xLTcwMDM0_ad181669-c89f-4cbf-b8df-05acd548ac6a">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8848b6a4264e499ea3824a825f707e78_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtMi0xLTEtNzAwMzQ_25aa3ac6-fae3-49af-aa1d-702280391350">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia486efb8fecc4fc8934c3d17358c54d9_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtNC0xLTEtNzAwMzQ_ade9f9a6-50a0-4cd5-b534-38ede73a74f5">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8848b6a4264e499ea3824a825f707e78_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtNi0xLTEtNzAwMzQ_32faf980-30d4-4711-bb33-3b3981108d93">27.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2010cbe9958f446584500182486f8c58_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtOC0xLTEtNzAwMzQ_25975009-ff1b-43dc-ad5b-da94252628b4">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d43b5d1458c418aace6f6915a81d82b_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtMTAtMS0xLTcwMDM0_b6899180-f868-437f-88fd-c7dfeffc4170">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2010cbe9958f446584500182486f8c58_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtMTItMS0xLTcwMDM0_a9092820-7dfc-4169-8aeb-d4e814f6c329">27.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66216b2932674442903d1b7f700d5d93_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtMi0xLTEtNzAwMzQ_9926f1d2-ba91-45c0-b81d-aa5d777716dd">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22058af4a4044d0083e435a04e70cdc7_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtNC0xLTEtNzAwMzQ_aa287dad-672a-436c-b72e-c77e73c2003a">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i66216b2932674442903d1b7f700d5d93_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtNi0xLTEtNzAwMzQ_23518406-03be-4bc8-924d-254a2339bf1f">53.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce6642f7a9645f58eeecaec17c3aaf3_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtOC0xLTEtNzAwMzQ_4bf14cec-22f1-4681-ba34-df4c68c63040">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca44e36bd354228bdceed07ebdda5c4_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtMTAtMS0xLTcwMDM0_155796b4-5032-41be-90a2-d27160761f47">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icce6642f7a9645f58eeecaec17c3aaf3_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtMTItMS0xLTcwMDM0_aea376d5-e744-467c-97f3-5c4b2c4e23d5">17.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8375cf3203764f32b355e4b3f1eed776_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItMi0xLTEtNzAwMzQ_fad172e0-4975-47bb-9d35-ea817652914f">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87013a0ff92c4beea595abb9a8da5946_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItNC0xLTEtNzAwMzQ_059ccc70-3658-401c-a14b-aa47bcdd811c">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8375cf3203764f32b355e4b3f1eed776_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItNi0xLTEtNzAwMzQ_050b23aa-23b7-4d3c-98f6-47b146b7870b">17.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1b43f5e37d4e2abc94f7b4529f8f9b_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItOC0xLTEtNzAwMzQ_a6b751e2-5a81-474f-b652-cdf9a2dfa77a">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic461d711f25c43cea2c56556fcad7ede_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItMTAtMS0xLTcwMDM0_dbc16279-56e6-4a83-814b-8aaefb29bc75">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2b1b43f5e37d4e2abc94f7b4529f8f9b_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItMTItMS0xLTcwMDM0_a866e3c8-02a2-44bb-a486-f25e9a0520d4">10.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54580f240f0f45e792175de738dd614b_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtMi0xLTEtNzAwMzQ_38e61f03-9173-48d7-913e-4028b6338eef">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbfafce4ceb2468f82b2f231481f3145_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtNC0xLTEtNzAwMzQ_308b168f-ed4f-47fd-9644-b0ed2f698da6">888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i54580f240f0f45e792175de738dd614b_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtNi0xLTEtNzAwMzQ_ee0fb5d5-b05d-4cb8-b5f5-f8cbf68495b5">27.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff5db7fcd89445889265894b5fcd908_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtOC0xLTEtNzAwMzQ_5f500432-428d-40c3-ac95-2331077ad12a">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bd678a6f6b45f49f1ad8f99d6732f4_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtMTAtMS0xLTcwMDM0_3bda3df0-afe1-448e-9326-315688c63819">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibff5db7fcd89445889265894b5fcd908_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtMTItMS0xLTcwMDM0_6f56ba7a-0310-4cca-83f9-052f4b241981">21.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica430109af49463a9ccc4038a1739ff0_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtMi0xLTEtNzAwMzQ_cef79a3c-70a9-48fe-872b-7ad328886605">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie308e8e3be304525870ea855ce38d851_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtNC0xLTEtNzAwMzQ_77f2802a-5e52-426d-b32e-fe5066ffcbec">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica430109af49463a9ccc4038a1739ff0_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtNi0xLTEtNzAwMzQ_6dc4b770-106b-4a46-8614-5cd614050438">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119135a7bf4e4b77a3ab7bdd5088eaaa_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtOC0xLTEtNzAwMzQ_891b607b-5f60-4928-b181-3da74bc4601c">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79cb5dafd17f46df9670ff1449263941_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtMTAtMS0xLTcwMDM0_a57611fa-9cfa-443c-a97a-4b8a54ee5c0b">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i119135a7bf4e4b77a3ab7bdd5088eaaa_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtMTItMS0xLTcwMDM0_6aabf8bc-c91b-458d-916c-d301b647478e">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7278c069afed4a878b544df06a8f6fa6_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtMi0xLTEtNzAwMzQ_9286c94b-81a1-4878-a308-976b36bade10">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d3d93e645c47b28b4e7046d008ba26_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtNC0xLTEtNzAwMzQ_f2310387-002b-49bd-9660-87a7db04818d">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7278c069afed4a878b544df06a8f6fa6_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtNi0xLTEtNzAwMzQ_2423d190-09aa-4cb1-a00f-8def1562fe07">9.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856a0c7b52a545e79ff3fe227f8b6e96_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtOC0xLTEtNzAwMzQ_7c586b9c-82fd-4313-b63f-858258e0b5a3">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11c3e051f3640f48ab85ea94a59bcf9_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtMTAtMS0xLTcwMDM0_9c55fb94-d438-4b1f-a1f7-614c72a01791">601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i856a0c7b52a545e79ff3fe227f8b6e96_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtMTItMS0xLTcwMDM0_6b4bf84c-99bb-4d8d-ab18-ab548928d6b0">8.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e9ebb6fa3f46c0958ce4ca2ba73452_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctMi0xLTEtNzAwMzQ_a7c3b2fa-519b-407d-a877-9b9b40e8b294">566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f6d9bd9cfe420eb311754a66cd6704_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctNC0xLTEtNzAwMzQ_65a31b20-dd16-4992-b7b0-32d4a2f5474e">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i88e9ebb6fa3f46c0958ce4ca2ba73452_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctNi0xLTEtNzAwMzQ_92de160a-b00f-4c62-9da8-efbb2845717b">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e7322aee8f94298875960a274d7d725_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctOC0xLTEtNzAwMzQ_8b4dc59f-24ef-477a-963c-56cd447d5671">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a11268216c41a0b8530633effddd01_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctMTAtMS0xLTcwMDM0_f8ce1c33-2721-4582-be40-53d0f2ed5a8a">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e7322aee8f94298875960a274d7d725_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctMTItMS0xLTcwMDM0_7ae29ed0-310d-42a3-8a4a-7d5d71e0bf56">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeec2de848b7400c8f1cbd655a32fef5_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktMi0xLTEtNzAwMzQ_73eb8d23-af97-4c33-b35f-3033291293ed">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f3484c640948dcb33be80e3ab6ce4a_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktNC0xLTEtNzAwMzQ_1f185655-1d44-4571-8092-ca8ff15583d9">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieeec2de848b7400c8f1cbd655a32fef5_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktNi0xLTEtNzAwMzQ_1a0bc19e-8ba2-4ab7-8d8c-1368d578d322">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5608e9bbae904b85a2dc6cfcb6fb8128_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktOC0xLTEtNzAwMzQ_1637c8fb-3bbe-497d-8fe1-f875fb0f4805">3,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3768e1c0c0144fe18b8421760ec7e5e9_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktMTAtMS0xLTcwMDM0_c3d03443-4bce-43cb-8b0b-0442517ac263">2,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5608e9bbae904b85a2dc6cfcb6fb8128_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktMTItMS0xLTcwMDM0_bc2f9dbc-5cc9-4dd1-a8bc-55ba191ff6d6">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b39afcb128845be8ace8181351523cc_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtMi0xLTEtNzAwMzQ_57bdec56-a720-47cf-aeaa-12a710a3487c">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0e26bb5d8c4e45980858e3929c5f05_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtNC0xLTEtNzAwMzQ_f3ed8173-66a4-4391-a905-442d3afc10fb">778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b39afcb128845be8ace8181351523cc_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtNi0xLTEtNzAwMzQ_c0b2260b-c9f2-4956-8f7a-ce3c08b03aeb">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee6054821eb402795176964928243a9_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtOC0xLTEtNzAwMzQ_96b91247-d88c-4a2d-a505-045a9b8dd35a">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i496bda2ebfc045e592996bab0207f6cb_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtMTAtMS0xLTcwMDM0_8cc57273-c6f2-4c26-bcb5-fc7b831243d8">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idee6054821eb402795176964928243a9_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtMTItMS0xLTcwMDM0_897c0a30-01c8-4144-88f3-b8b618864e45">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb85facac1f24b5493bbfd6b7352b778_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtMi0xLTEtNzAwMzQ_4d593524-b01c-4321-8fcd-08292e20ae4c">2,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813a1577af2d4a23a4349732e1febc84_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtNC0xLTEtNzAwMzQ_6f463065-ee4b-4fb4-b6bf-b43106802d22">2,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb85facac1f24b5493bbfd6b7352b778_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtNi0xLTEtNzAwMzQ_05a3717e-64ae-406f-9655-b64b542ea6ff">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a68313ab7b046478534719e89e2face_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtOC0xLTEtNzAwMzQ_c9e65e33-56d4-41e7-ae14-524ff364cfe6">4,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f537f91aebd4a4286209578f7c5aa71_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtMTAtMS0xLTcwMDM0_918e61a2-a024-45e4-9ea8-df4e3c32ce43">4,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a68313ab7b046478534719e89e2face_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtMTItMS0xLTcwMDM0_529f5697-bf5e-496a-869b-48cdb3488a1c">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2caa599d7e6c46479b011171a2725a0f_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtMi0xLTEtNzAwMzQ_9cdb5641-a328-4514-8981-a4c7b5f3ec57">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf7e16d1d0a41ecae80c957ca6cf057_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtNC0xLTEtNzAwMzQ_92253eef-447d-4963-92b5-38a84db8f2e2">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2caa599d7e6c46479b011171a2725a0f_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtNi0xLTEtNzAwMzQ_35bf4740-28df-4cf0-a0de-f63887e1a687">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e94b02a54bf4dccb3fed8ad8526a6b3_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtOC0xLTEtNzAwMzQ_07c59eef-a1df-483c-9290-574a7fa613fd">773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8485fb4ed0e431fa60a21304c9940de_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtMTAtMS0xLTcwMDM0_fdd43a45-79bd-490a-b12b-37048c0410ca">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e94b02a54bf4dccb3fed8ad8526a6b3_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtMTItMS0xLTcwMDM0_c730777a-3f37-4b05-ba1e-f967ca3388bc">29.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4212c615c9141e8b1d901365e40d779_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtMi0xLTEtNzAwMzQ_ce3b16cc-8c82-4984-bf8b-8d86169dabaf">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d619e3e7e91444ea79bc47ca3e226eb_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtNC0xLTEtNzAwMzQ_65adf08c-269d-45a7-a5a6-e65cb7a07be3">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4212c615c9141e8b1d901365e40d779_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtNi0xLTEtNzAwMzQ_ef27fd85-bd4c-42d8-a9a0-582b3ee5bd08">38.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644925d4826546d3be77503d471f03f9_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtOC0xLTEtNzAwMzQ_c94dc07e-acea-4789-86b7-7e10989bc49c">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0383c0ed08a340a0a7e28475880e66ff_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtMTAtMS0xLTcwMDM0_4919b01a-9cb6-45ec-8136-baf0f767738b">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i644925d4826546d3be77503d471f03f9_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtMTItMS0xLTcwMDM0_6c6b9f6a-da9a-4ec0-8b80-86feb224aaed">38.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e987627024b6a9dc1bc0795ad8ce3_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtMi0xLTEtNzAwMzQ_09f356ab-9201-4e55-8e53-c25a41a67a91">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fd69b06f674ad1abfb09825949a8f1_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtNC0xLTEtNzAwMzQ_cc9621ad-6ef9-4c80-a298-265ff6d76d99">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic37e987627024b6a9dc1bc0795ad8ce3_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtNi0xLTEtNzAwMzQ_85619157-4f1a-414c-9e53-5c99b2cedf94">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5fc362f083407ebc59e3ab3a9ba67f_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtOC0xLTEtNzAwMzQ_a83f9c1c-00ef-4f98-ab1e-7f2d937c010e">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57f215e7cc34af3b9e4ed202855fba3_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtMTAtMS0xLTcwMDM0_be909def-e78a-4c70-a3b9-a410eb3e3289">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b5fc362f083407ebc59e3ab3a9ba67f_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtMTItMS0xLTcwMDM0_d6bd560e-0fbe-4a93-ac0b-088273796afa">32.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22768f5a2f114ce2ab20531d2853362f_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctMi0xLTEtNzAwMzQ_ef5b7852-1e36-46cc-a7be-adbcce3773ef">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0d44953e7140198cf5743c8f9bf9fd_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctNC0xLTEtNzAwMzQ_df5e389b-83e0-4551-8460-997c112b5f49">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i22768f5a2f114ce2ab20531d2853362f_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctNi0xLTEtNzAwMzQ_513aae0c-be48-4a00-93a1-8677d81537f6">50.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia648fc74bae7454781dfef132266663b_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctOC0xLTEtNzAwMzQ_16190937-8eb0-4e1f-a6c8-1b96ab7d6207">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df360f1333340c7b4588969e82c2f00_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctMTAtMS0xLTcwMDM0_56d62581-50f2-40f3-af0c-6b284f4ab2e5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia648fc74bae7454781dfef132266663b_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctMTItMS0xLTc1MzIw_f13f3d66-e5e1-4917-b812-177cb9fa5956">24.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i889a1f92c9a540c2bd4c73d5f7491f90_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTgtMi0xLTEtNzAwMzQ_d9fb8b17-f78d-4b84-a5ce-05366e20cc84">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf53305e3b644b48bece17159e61f8bd_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTgtNC0xLTEtNzAwMzQ_25b220d4-37bf-403f-9d62-bbe99302e871">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a42cf1a5db49bc8a0351e6d0e34b93_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTgtOC0xLTEtNzAwMzQ_827c042f-79a0-45ac-9758-d50fd1213be7">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic810c0a48e8743a59ad02500a4aeecdd_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTgtMTAtMS0xLTcwMDM0_f59edabb-d4b8-4225-abbf-34f56d45a71a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4edb2f147a48b09eddb23a0c7d5ce7_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktMi0xLTEtNzAwMzQ_864b4a23-e8ac-4046-bc6f-890f401dba1f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac357a41dcce46b8bac2ce939cdb4918_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktNC0xLTEtNzAwMzQ_5bea384e-9d71-482a-bbb5-ec523a1b6d6d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icd4edb2f147a48b09eddb23a0c7d5ce7_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktNi0xLTEtNzAwMzQ_9e9c0b59-1fc0-4205-b501-2b4a13fa9f74">59.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d140cebad34e369cd420d22831ce65_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktOC0xLTEtNzAwMzQ_58d114a1-b158-4bc4-997b-9929e7abee2b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i254bd81a5b934d1da8ed0bb423ffd265_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktMTAtMS0xLTcwMDM0_b70b6f1f-29d1-4ec1-984b-025b95cfdbbb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if9d140cebad34e369cd420d22831ce65_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktMTItMS0xLTcwMDM0_def109e4-ccfa-4422-836a-0e0057ed2886">39.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82df753eb9a14110a4457fc71fa570ca_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItMi0xLTEtNzAwMzQ_1107d5bd-cdf4-4111-b69c-537a4c5c7e57">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa982fc8c9040bd9afdbedde483a631_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItNC0xLTEtNzAwMzQ_4aa0f073-40bd-40cf-85db-ebab0e52885d">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i82df753eb9a14110a4457fc71fa570ca_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItNi0xLTEtNzAwMzQ_50103b3a-abbe-461e-8c73-52d7203989eb">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b329b805e8241389b4b59c22a25fed0_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItOC0xLTEtNzAwMzQ_b6d422f6-e4eb-49c6-a76c-54c43ff941ea">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5a3356d9fd49bc8b3e5f75cc325bd4_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItMTAtMS0xLTcwMDM0_e8e6b078-9105-416f-a967-321124a14b4a">956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2b329b805e8241389b4b59c22a25fed0_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItMTItMS0xLTcwMDM0_d60d8617-6ec7-40f9-a709-46ca91a9de7b">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ff638816b949f49434427996afdf27_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtMi0xLTEtNzAwMzQ_d5baec73-a514-452d-a85e-f6a50e957be7">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa077604d394f2e9da2c45c7c1f570d_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtNC0xLTEtNzAwMzQ_20cd9d54-2383-4832-ae73-0291e9c03185">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3ff638816b949f49434427996afdf27_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtNi0xLTEtNzAwMzQ_d1b00554-1d39-4f99-b681-658912633805">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba42deda339d4571bf02c560ebf58128_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtOC0xLTEtNzAwMzQ_fcf5fbc2-f862-4475-9b99-d7fccc68c329">1,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0c7aecba784a1ba368d125cf5ef87e_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtMTAtMS0xLTcwMDM0_abae49b9-64c8-48b2-8a8e-95fcc810f3de">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba42deda339d4571bf02c560ebf58128_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtMTItMS0xLTcwMDM0_b5eee91e-0dde-4713-9fc8-8e97e9711b4b">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb92120191540b08b3e1547d87f071c_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtMi0xLTEtNzAwMzQ_12a7ab5f-3b10-4658-a81d-7de7c495b2fe">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451bf253d3fe4d909fb3822b81e8b8e7_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtNC0xLTEtNzAwMzQ_71616049-1bd6-479e-843c-f5ce990cb898">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iecb92120191540b08b3e1547d87f071c_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtNi0xLTEtNzAwMzQ_706e4331-c659-4cd3-b3fd-d6c585697281">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i131b62957aea4245a2e4f40e80b92785_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtOC0xLTEtNzAwMzQ_f7efbeda-d233-40fa-aed3-05a7573f0508">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3edcdddf80a04d079d92e9eea316d11a_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtMTAtMS0xLTcwMDM0_795d6d62-66c3-42be-b1ff-a27f1be36999">2,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i131b62957aea4245a2e4f40e80b92785_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtMTItMS0xLTcwMDM0_674f7ab6-9899-4a03-b280-6696e7242240">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b150cb6ff444a02936a3d237e2aac00_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtMi0xLTEtNzAwMzQ_b3613aae-864d-4bd6-8f76-bf114381a550">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82ae1895ed4f4e7d8ffd5e113242fb46_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtNC0xLTEtNzAwMzQ_c31a1ffa-7eb4-496e-9d84-131663b454bc">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5b150cb6ff444a02936a3d237e2aac00_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtNi0xLTEtNzAwMzQ_d51a9924-8473-4b06-b6ce-d01818099a91">11.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58cdc6aca3145fe9c3bcad7c0f6caa3_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtOC0xLTEtNzAwMzQ_02354d56-283d-42fc-8ebc-d4fbf707b207">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a04f60e80c410ea3de2b7af02a2047_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtMTAtMS0xLTcwMDM0_e5928d42-dcaa-455e-b1c2-1ba044a0175c">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic58cdc6aca3145fe9c3bcad7c0f6caa3_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtMTItMS0xLTcwMDM0_4cdd6b10-921f-474e-9a97-2192b194515d">20.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4eea102b0f843ce9148053725724350_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjctMi0xLTEtNzAwMzQ_27e9ab41-7494-411a-84e2-a2da194b8f61">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21ebd581b69464f935e36c4077fcfe8_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjctNC0xLTEtNzAwMzQ_7de4c4af-39c5-42a0-9948-bf0e56316ad9">113</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68320c8fb7d9415da27ec1628fccc3a9_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjctOC0xLTEtNzAwMzQ_2eed43b8-77b2-425b-ace7-d474d6ac3be8">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8c3beb651f493d825692e877822643_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjctMTAtMS0xLTcwMDM0_855b2be3-62f3-4dec-8aee-e9273650ea98">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a77ac5cc2f444fdbd37f54e3f3763e8_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjgtMi0xLTEtNzAwMzQ_99fa8fca-a634-4fbb-9e1e-f1e08200ba3e">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477ed121b34f408288a548d3dd53cc95_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjgtNC0xLTEtNzAwMzQ_d5f051c3-d553-4327-8422-db8bc27cf24b">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf65e5c0ea164fe9851e44a3c5176fea_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjgtOC0xLTEtNzAwMzQ_a8ba26ce-43b9-4982-8083-96d5442f8c93">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867589638fb74338a731e3ec601b44f7_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjgtMTAtMS0xLTcwMDM0_936ad9d2-8d06-4d86-b04f-86fa440391a0">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833b35d6c2414dada6f601d238feca65_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtMi0xLTEtNzAwMzQ_eb6ba5eb-57ed-4c14-8613-13a7aae090df">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51cf983137194da19e1e0ee43f86f2e6_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtNC0xLTEtNzAwMzQ_01287374-d411-43a2-80c6-308d1816b789">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i833b35d6c2414dada6f601d238feca65_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtNi0xLTEtNzAwMzQ_9dbe3c55-5e2d-44b8-824b-62944c23c1a4">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a964d08b0e4123a5c734a55c08768b_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtOC0xLTEtNzAwMzQ_40d313b5-a0a7-485f-bf6c-2583096e8dab">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0be555378cf4bc7b2c312db80e53e0c_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtMTAtMS0xLTcwMDM0_e2fb70fa-9ea6-4c02-9a41-305b1c8e95db">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i76a964d08b0e4123a5c734a55c08768b_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtMTItMS0xLTcwMDM0_f94d0971-95b2-43ac-8d76-b7f40a573d59">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0703b43478466cb628ab8efd4070ff_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtMi0xLTEtNzAwMzQ_d7aacb09-d71e-47a1-a110-68242b28a65f">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c83561616a848de8a12e6750c8eb1d4_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtNC0xLTEtNzAwMzQ_9bbffb6d-e00e-4dc8-bb99-be2a5955b94b">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2e0703b43478466cb628ab8efd4070ff_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtNi0xLTEtNzAwMzQ_23f9829b-e86f-45f9-873c-18c05974e8fc">14.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfe7e4eb68f4542a0694c4e9160e4f3_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtOC0xLTEtNzAwMzQ_13968a78-6a1f-4978-b181-935f51f846ad">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9e9151965a452dbb603490e84ec8d3_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtMTAtMS0xLTcwMDM0_0dbd0573-a489-43c1-8624-967847dccc51">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iddfe7e4eb68f4542a0694c4e9160e4f3_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtMTItMS0xLTcwMDM0_615957e2-e5ec-490f-8fbc-2977a3684c92">6.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia064ab4c0e6f48f4be4e3fb8e412913d_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItMi0xLTEtNzAwMzQ_d28adea7-410c-4240-9849-101fb05c00ee">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4619bd414a4f4191ac0846d8ada2bd_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItNC0xLTEtNzAwMzQ_c173c8c7-9282-44df-8bb9-eb61fd10c714">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia064ab4c0e6f48f4be4e3fb8e412913d_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItNi0xLTEtNzAwMzQ_3af241d1-394e-45f1-9c06-764dbaf4883a">14.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied852099577c4b06b69b158e06bdf30b_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItOC0xLTEtNzAwMzQ_960e3e9c-5637-446d-9639-d49aca26563a">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9748a1cfe0ae4be3ac0b1f755e7a71bd_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItMTAtMS0xLTcwMDM0_28f690e9-2815-4785-8341-356aa2891716">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ied852099577c4b06b69b158e06bdf30b_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItMTItMS0xLTcwMDM0_bf67b723-a875-405a-b815-dd6fb01efea3">6.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i610bb1c1ae2941719016b00d983418c0_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtMi0xLTEtNzAwMzQ_12e1a6ca-9450-43b2-96cf-417c481ba4c6">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i545c78bcf6864df7b8f8c7f3f1874047_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtNC0xLTEtNzAwMzQ_d6962d20-112b-49dd-944f-0cbaf8f13aec">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i610bb1c1ae2941719016b00d983418c0_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtNi0xLTEtNzAwMzQ_54478965-3f3e-488a-81f2-bff9bb173869">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5687d376693949f995a3364dc24a36fb_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtOC0xLTEtNzAwMzQ_37263851-4be0-48b6-b07a-014435938e69">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie177897f7a0e4cbb9fc1ae70b3de094c_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtMTAtMS0xLTcwMDM0_e530eaf7-66c7-4e3a-84e4-3405d562efd0">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5687d376693949f995a3364dc24a36fb_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtMTItMS0xLTcwMDM0_f1bec1f6-1a03-45a5-bd29-4acff27a5f97">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2d49cc4b5f4e3fb983e82500551388_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtMi0xLTEtNzAwMzQ_17f16979-eee5-4f25-8457-50768b94f221">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0743c16b76bc4a4eb2c7f09b19fb4d77_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtNC0xLTEtNzAwMzQ_2560c6b8-a723-4c46-8044-7261d7e9c62d">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3d2d49cc4b5f4e3fb983e82500551388_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtNi0xLTEtNzAwMzQ_b31ac89e-1e02-4a86-996f-802c17409312">20.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5c01877918467fa667de5c4b5a1e4b_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtOC0xLTEtNzAwMzQ_9ae54033-1ae2-445c-849f-2e583ad27d71">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8432ba6c71b9494d954af4cdfc975370_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtMTAtMS0xLTcwMDM0_5d8d70a8-e3f4-4e67-ac2e-b9c15e8eaa55">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3b5c01877918467fa667de5c4b5a1e4b_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtMTItMS0xLTcwMDM0_4b898199-2880-4cfd-9865-8403969ae27e">20.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2e8ad7b5ad474990841305b1f44bf0_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtMi0xLTEtNzAwMzQ_f8b49fb6-28f8-4c09-8530-3120c281c187">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2297bbc16743a6af0a9162f757bafd_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtNC0xLTEtNzAwMzQ_dee0a2cf-cf3b-49e3-8e6b-c61cae6c0d43">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3c2e8ad7b5ad474990841305b1f44bf0_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtNi0xLTEtNzAwMzQ_88d84d02-b86c-44fc-a572-81beed139ee9">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63d56d230d06461fbbf797c27c6ebf04_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtOC0xLTEtNzAwMzQ_1c5f0bc8-a657-4b4f-a05c-1492eec3b9f8">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf382b886c2c4ddfb2e4f553d4f3aa6c_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtMTAtMS0xLTcwMDM0_b282c43e-11c2-45f6-9fa7-9e4777947fd3">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i63d56d230d06461fbbf797c27c6ebf04_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtMTItMS0xLTcwMDM0_613d9228-1c31-454d-8869-0866d12c8705">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i174bfb125ba84357bcf10e45b220f10f" continuedAt="i24c26d3a94314775980716f3b60cf0f1"><ix:continuation id="ic24780dbbab849b4a7113ba1d3929a7f" continuedAt="i8620e65d732e4841944f6020f1007874"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae5da5ecb6c40da849942dbc851b857_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtMi0xLTEtNzAwMzQ_9a0c698c-293a-474b-94f1-31aa0b6cad40">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i881a26ffb23941f7b130a2daf70e1cab_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtNC0xLTEtNzAwMzQ_b6d72515-66e9-43a9-9563-61fe70a09883">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6ae5da5ecb6c40da849942dbc851b857_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtNi0xLTEtNzAwMzQ_b810a2b3-3d8a-40d9-b4e4-a0ab91296cc6">62.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b81754b34f1429a95dcde81ff323530_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtOC0xLTEtNzAwMzQ_bd9221b8-a08e-4f1c-a2be-1ea18363f027">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ee23c86245486ca886b6aee57831eb_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtMTAtMS0xLTcwMDM0_1a5feedc-781f-4c8b-b9f6-34e2f981cd88">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0b81754b34f1429a95dcde81ff323530_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtMTItMS0xLTcwMDM0_6a6946ef-4193-4eba-9ab4-c6dae84f6876">62.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233aa02837fb4f0fbbc523316a35d3c5_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtMi0xLTEtNzAwMzQ_276603f2-3854-40d6-bb55-59fb7b5f1062">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8c24d1d48d4f6490558a822b6c2921_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtNC0xLTEtNzAwMzQ_e52a0a04-59bc-4e23-b940-aad116080d07">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i233aa02837fb4f0fbbc523316a35d3c5_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtNi0xLTEtNzAwMzQ_eba22c19-9160-4b1a-84e9-a1811265f9bf">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37807e01372a4baa8332eca83c82dcf5_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtOC0xLTEtNzAwMzQ_0728630f-804c-4e10-838e-72f3132c3e99">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7989fc025b464111973e629161e2434e_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtMTAtMS0xLTcwMDM0_a4e96644-3ef3-4214-ba1e-53df6d82d831">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37807e01372a4baa8332eca83c82dcf5_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtMTItMS0xLTcwMDM0_2316ba48-0f2b-4f8d-a001-0d551fce99f7">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892c07bc3d55496bb0c411f6c4597f9b_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItMi0xLTEtNzAwMzQ_10ae91b6-ec5b-4301-917e-6d6856f8b70b">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if533c4ba85374d80b615f4cc8c0ac77d_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItNC0xLTEtNzAwMzQ_fee49426-9f69-4e61-8736-444d383754d9">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i892c07bc3d55496bb0c411f6c4597f9b_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItNi0xLTEtNzAwMzQ_053e3ca5-cdbc-495f-867e-56b5527a83ca">5.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350d006de9494081b89834d206e20b85_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItOC0xLTEtNzAwMzQ_c53fabe1-fb09-4c91-82d4-025023a8329d">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c986ffb2bc4b73a03b90d4d1e6e058_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItMTAtMS0xLTcwMDM0_e822de97-3c87-4e72-b452-2f4c4d53acf4">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i350d006de9494081b89834d206e20b85_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItMTItMS0xLTcwMDM0_620fda12-e4cd-4a6a-961d-d46db8fed76d">10.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf2f6500b8d47f8bcd2e1f52815ef65_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtMi0xLTEtNzAwMzQ_deabb718-8ca1-40f3-80c3-a2b16fd110ff">896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e260586dedd4093a608d4f9e119e9f6_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtNC0xLTEtNzAwMzQ_1fcc0822-e20b-4eef-bf1d-913a7b270dc5">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5cf2f6500b8d47f8bcd2e1f52815ef65_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtNi0xLTEtNzAwMzQ_5b24112d-4e54-4463-8db7-e453a4d88539">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d07ff2062fb400eab890cf3cde739a0_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtOC0xLTEtNzAwMzQ_4ac7c48f-4897-4457-bb93-b612ce25038b">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb100c8ad50b4c32a7486560779c59c7_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtMTAtMS0xLTcwMDM0_00c9650d-e02c-4bfa-bec1-62291cd153be">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d07ff2062fb400eab890cf3cde739a0_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtMTItMS0xLTcwMDM0_c594cd45-2f5b-44c8-b875-18ec21aaec31">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb6f559d024fe9867b516d3d470c90_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtMi0xLTEtNzAwMzQ_ccc40aa5-523d-4fb5-bcc9-e1a23525d83c">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3128acda5249f7b1aa270169630b2e_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtNC0xLTEtNzAwMzQ_c580285a-22f5-4105-8ffe-bd489898dc67">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia8eb6f559d024fe9867b516d3d470c90_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtNi0xLTEtNzAwMzQ_2d326af2-c6d7-4328-b4e5-8f953fa4b574">13.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9bb08a5cb64471bdd5fa7215d3a890_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtOC0xLTEtNzAwMzQ_f1d8efcd-5e4f-4a32-9483-d899217ea31f">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0939ae8630144f4986774c9e0e93db3f_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtMTAtMS0xLTcwMDM0_65974b96-16ab-48b5-b60e-3b994d95e100">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iba9bb08a5cb64471bdd5fa7215d3a890_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtMTItMS0xLTcwMDM0_18e3da85-c2f3-434a-9048-bc6012cfdfb7">8.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ebcc5ce76814be69eea5e381ee927e1_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctMi0xLTEtNzAwMzQ_326adccb-c927-4fcc-9773-ce20176feebf">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8cdb6868c7c4eaa83b08096e087411d_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctNC0xLTEtNzAwMzQ_c84adfa6-df44-4e36-8457-21d6f729c2af">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7ebcc5ce76814be69eea5e381ee927e1_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctNi0xLTEtNzAwMzQ_2ed67d99-ebe9-4a33-bcf3-de1fe5d233c7">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d8c0890db5470dabd162468412c872_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctOC0xLTEtNzAwMzQ_9e5498bb-5199-48eb-8871-1707d3437e73">3,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if270f92cc3864c79b2464cfd5f2f9ea0_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctMTAtMS0xLTcwMDM0_886ff31d-4ade-4ab7-b41b-773a61ffdbe1">3,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i70d8c0890db5470dabd162468412c872_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctMTItMS0xLTcwMDM0_91e7924d-d5a4-475f-a657-ae339b5cb4ec">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64083077365f4393b411e13a8d829ba5_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktMi0xLTEtNzAwMzQ_326e47f3-abf9-412c-9f4c-594df4cf444c">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24bd17706c8045b28592622c702e9945_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktNC0xLTEtNzAwMzQ_d003d835-b3b3-401c-8267-d76706cce167">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64083077365f4393b411e13a8d829ba5_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktNi0xLTEtNzAwMzQ_09613a41-5e73-4a49-b147-4163280f3597">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2fa6af256364b8ba090796d8cef039e_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktOC0xLTEtNzAwMzQ_91b919d5-3fb3-4993-b312-755275c33748">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c7f3684e96430cb08ceb7f25e639b0_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktMTAtMS0xLTcwMDM0_021d29a1-f66c-4d8d-9046-b88a3aff8e40">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic2fa6af256364b8ba090796d8cef039e_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktMTItMS0xLTcwMDM0_437d1edf-f26c-45a3-adb0-876d602b4b9b">11.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821e476b1e124c3da418c0da884873ec_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtMi0xLTEtNzAwMzQ_795588a6-24c6-4b74-8b7b-97013375d51c">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9867c33d4e041e39d64aeb94ca7220f_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtNC0xLTEtNzAwMzQ_acabadfe-df1c-4dc8-b4e5-834c1e80d60a">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i821e476b1e124c3da418c0da884873ec_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtNi0xLTEtNzAwMzQ_c90c751f-9722-46f9-9562-1fcd19535293">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e9055569824947bc8a8aa2e70f9c21_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtOC0xLTEtNzAwMzQ_c2ec97c0-7b13-4563-a0c0-5defd8a57660">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa6b7234499430f8a3da6a879bb9820_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtMTAtMS0xLTcwMDM0_34863630-191d-441e-992d-fdfd2e238aef">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if7e9055569824947bc8a8aa2e70f9c21_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtMTItMS0xLTcwMDM0_91c7a3cd-9f2c-4ba8-9de2-152d4367b51a">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c551506a1274d12b61d0b0bb6a17e0e_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtMi0xLTEtNzAwMzQ_c851c9a2-a805-4f3c-91c9-2a4ed71ba3a7">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0fbf4de99a4afdab1711dbfaae9849_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtNC0xLTEtNzAwMzQ_004b8981-cda8-4526-8fd7-cd073d5d8097">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c551506a1274d12b61d0b0bb6a17e0e_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtNi0xLTEtNzAwMzQ_5bab44ea-ecfb-421e-94d9-df4ce9e65666">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee16de5d59840c5bd123a9e5601d81d_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtOC0xLTEtNzAwMzQ_8819296f-9c9f-4675-b770-e3bf88c55cfa">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f474b0d055142afacf952c297331e99_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtMTAtMS0xLTcwMDM0_bb0e8d6f-d26f-445d-a8bc-b7eb02f7a2a7">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idee16de5d59840c5bd123a9e5601d81d_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtMTItMS0xLTcwMDM0_e26f6bef-ba16-4491-bb0a-86791fadf29c">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b1abcd0990401ca49e18dbeb437c17_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtMi0xLTEtNzAwMzQ_fd7585c1-7ad2-4431-b3f3-13683b85dc3a">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3ee672bbd7141948b03208867985b7c_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtNC0xLTEtNzAwMzQ_b3ef12a4-47d1-4c7d-9e58-e3f78bd14171">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42b1abcd0990401ca49e18dbeb437c17_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtNi0xLTEtNzAwMzQ_19764d95-e2c2-4a03-9e7d-b23a9809e659">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f190476843b4d519e98652aff7a77fb_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtOC0xLTEtNzAwMzQ_24d07dc8-dfd7-42ba-ae46-4d0c39a47e4f">1,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36139166d5b482eb6fba5b9c7a5dff4_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtMTAtMS0xLTcwMDM0_dace6da1-fcfe-46cb-910d-5bbf857d915b">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f190476843b4d519e98652aff7a77fb_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtMTItMS0xLTcwMDM0_9b6d547a-71b9-4aef-8268-ed24f0922156">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2adbb26c4f4169ac3ed1446c0047a5_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtMi0xLTEtNzAwMzQ_6444fefd-5477-4e71-ad0b-2604782e83af">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8333f41594a4ea74e78b5265277e8_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtNC0xLTEtNzAwMzQ_af3b7372-459c-4f14-80a2-7f967bb969db">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifc2adbb26c4f4169ac3ed1446c0047a5_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtNi0xLTEtNzAwMzQ_4be5c10a-95ef-4eb0-a2ed-5d888f9e7d5f">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33af160294004e19b207a7f75170082d_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtOC0xLTEtNzAwMzQ_158cd0e7-28ad-4181-acae-11d95128481d">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabd6e5fadb4ace892027521ea05718_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtMTAtMS0xLTcwMDM0_682ea64a-ae6c-45a5-bdea-037f80fe6dfd">756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i33af160294004e19b207a7f75170082d_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtMTItMS0xLTcwMDM0_9282bff9-ffa1-4a13-a403-d4cfecd619d6">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381a4444cf624dc6be2aa2fa0a0a3659_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtMi0xLTEtNzAwMzQ_19cbae6e-519b-4441-bd85-218062e8c4b2">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9404903e6e74429b27dbbdf8d4ff248_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtNC0xLTEtNzAwMzQ_8d73669d-d71c-46f2-aa92-830f97bc56a8">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i381a4444cf624dc6be2aa2fa0a0a3659_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtNi0xLTEtNzAwMzQ_ac942912-6c83-4371-a2b2-cb903cf61850">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81967cf9960e417ca2396582624be8d5_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtOC0xLTEtNzAwMzQ_9701e7dc-2037-46c6-b9dc-7749f85413de">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia58cde252d1f4e799a3a302ee1c41607_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtMTAtMS0xLTcwMDM0_ac4058d7-90a6-4360-ae26-5cea2b9a2f51">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81967cf9960e417ca2396582624be8d5_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtMTItMS0xLTcwMDM0_95802fbb-ae3e-4134-b105-ebbfd54338ef">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4616b6887b354b9e96c3d430604d3c42_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctMi0xLTEtNzAwMzQ_b8ec063c-510d-4b43-b5ab-c26a0d2bd9d1">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ef0d86dacf40c98cf4e5607785cedb_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctNC0xLTEtNzAwMzQ_e1a716f9-40f4-42c0-beba-073241cdc461">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4616b6887b354b9e96c3d430604d3c42_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctNi0xLTEtNzAwMzQ_44b74663-670d-480d-b0ec-aa6977fa2f4c">8.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c58a72b8a448dd98f5ac9d8f55ad47_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctOC0xLTEtNzAwMzQ_e1451a86-3f65-408f-a6ef-c46d77995014">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f4c25c27d346e28d79fffe1ec89849_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctMTAtMS0xLTcwMDM0_5bed2b54-b73e-47c2-a065-07ab76f32502">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94c58a72b8a448dd98f5ac9d8f55ad47_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctMTItMS0xLTcwMDM0_8a69c2f6-2d71-48bc-aa47-5686dd0b4ebc">7.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9db6a1f46624828bc4b33dcc757c82e_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtMi0xLTEtNzAwMzQ_ddc9c6f5-c197-4ace-ad71-85e1cfe87833">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabdebd8234af4a4b9621fb3ecb624d8b_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtNC0xLTEtNzAwMzQ_f57d2f73-5161-451f-a203-ea65c9350c58">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia9db6a1f46624828bc4b33dcc757c82e_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtNi0xLTEtNzAwMzQ_7dc91db6-9046-4824-8287-09aaa337c8c0">28.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc179fa1a480426cb4fd0d3d966e2f9d_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtOC0xLTEtNzAwMzQ_ff370d3f-5afe-4297-abd3-88951bb98660">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331342035f8849bab17b1dd2debe6771_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtMTAtMS0xLTcwMDM0_b64a0714-e453-422e-b1ba-ecca1f749fd4">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icc179fa1a480426cb4fd0d3d966e2f9d_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtMTItMS0xLTcwMDM0_b259c8e5-4ad5-4482-b42c-030e16c9081f">27.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ed53bcf088487b9c9fb95699fb4684_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktMi0xLTEtNzAwMzQ_612e7a5e-c53f-40ac-ab46-c444333b94c6">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a8381b611d418cac230e38702d6256_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktNC0xLTEtNzAwMzQ_5f27db38-eef0-4816-a203-a47ee965e13a">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if0ed53bcf088487b9c9fb95699fb4684_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktNi0xLTEtNzAwMzQ_7d21b44f-1a2f-4369-9b56-400097511721">19.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a732ecb6ddf466da949b0e4f1047c8c_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktOC0xLTEtNzAwMzQ_7139fa8f-ca06-4918-a97e-9b9d90cd9d7e">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8467285a7fb842329b2d56b3c68bc6b2_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktMTAtMS0xLTcwMDM0_dce07b2a-22da-4fe6-b148-46e360a5514d">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0a732ecb6ddf466da949b0e4f1047c8c_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktMTItMS0xLTcwMDM0_d68b34f2-661c-41a7-bcbf-02e976151d43">18.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b0e21c3cb246bcbf7a18d3394d1fc3_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTItMS0xLTcwMDM0_4fe944e5-7e2e-42f7-bef3-b568c1b7f039">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e7b7ef58fc4d74b79a62f31f63b60a_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTQtMS0xLTcwMDM0_dc85387b-39a2-4a5e-b1ee-b379731498bc">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96b0e21c3cb246bcbf7a18d3394d1fc3_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTYtMS0xLTcwMDM0_3ade4ca6-2a2e-49ed-aeee-0c5078ee0f4c">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec84871b973443e4b3a3810d110bc6a9_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTgtMS0xLTcwMDM0_2ced5c2d-6c88-4462-a215-268c8ee63db7">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05deb876f009412dba8fee7b750b9a3f_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTEwLTEtMS03MDAzNA_64a4ecaf-18d1-4c5a-96fb-55fdee321bea">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec84871b973443e4b3a3810d110bc6a9_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTEyLTEtMS03MDAzNA_d35fbd59-5d1f-41a6-a20a-9e6a10123d43">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae486921d8e2413a95e450c0a846f660_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTItMS0xLTcwMDM0_b2aa77bd-81bd-47d4-abdd-b7d473fb5cc1">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084e1532e11242b9ab8e982e98cce345_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTQtMS0xLTcwMDM0_6a6d0433-2286-49c8-986a-df9651963c54">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iae486921d8e2413a95e450c0a846f660_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTYtMS0xLTcwMDM0_a24efda9-ac25-416b-9eb4-c5818eb2f7a4">21.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2eec65477c4cf6b0a2e012668bd440_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTgtMS0xLTcwMDM0_734aacb5-bdbf-4aec-a628-50feb0a51efc">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0bf55fd1f5940659534d3655320b2a8_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTEwLTEtMS03MDAzNA_4a081ad5-83cd-4b44-a39b-1249b37596da">728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8a2eec65477c4cf6b0a2e012668bd440_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTEyLTEtMS03MDAzNA_092b68eb-55e6-4c36-a7ba-51672da64abf">15.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53cbe5667f104372ac5709b96be56d7b_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTItMS0xLTcwMDM0_1d0f7472-711f-42a5-ac5a-48a30ffef3d6">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03d9b2307334d22bd42f69770c03cbe_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTQtMS0xLTcwMDM0_7507ff73-d173-46f2-99e0-417b79be8d47">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i53cbe5667f104372ac5709b96be56d7b_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTYtMS0xLTcwMDM0_5d721298-b4f6-49a4-8b22-46cd404af8bf">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c787a1466bc48398971fdb66dccf821_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTgtMS0xLTcwMDM0_caec1735-5f9d-4aee-9ce3-6e88631d7d7f">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a6b0b9f19b4a3aa3d549fb91013f6b_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTEwLTEtMS03MDAzNA_7bd014ca-455d-4986-8f13-fec2ab0326ab">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8c787a1466bc48398971fdb66dccf821_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTEyLTEtMS03MDAzNA_673cf3a8-6aa0-4378-aceb-9745e1a80cbe">9.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8ceb7982104bb097677e4f08cf19c8_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTItMS0xLTcwMDM0_b6584af8-f00a-4ce9-b6cf-c65fdab50db4">1,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic935596d94fb4f8cbc7662516ebd2337_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTQtMS0xLTcwMDM0_255b3f03-e232-4f05-aac4-fa92414ec989">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee8ceb7982104bb097677e4f08cf19c8_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTYtMS0xLTcwMDM0_5bce422c-8ed9-4f67-ae26-894e0e66373f">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74032420b0d54f859aa6ac4ae4cb6092_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTgtMS0xLTcwMDM0_a53a8b36-a706-49b2-9fd3-c723020fa850">3,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628c3315204b4c819f5612c6ea0f76c9_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTEwLTEtMS03MDAzNA_e5a254e3-721d-47f5-b592-e4e60d0ba566">2,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74032420b0d54f859aa6ac4ae4cb6092_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTEyLTEtMS03MDAzNA_d7f707bf-4278-4d48-bac4-4490ff25aa9b">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489d0217d95349a09e3854a159fe1e20_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTItMS0xLTcwMDM0_a949f115-9b23-4117-916d-6ab94a312947">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia852ccdace584ca893a3f9fb3926a08b_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTQtMS0xLTcwMDM0_36fb1ff1-1779-4f07-9797-0f7ae8f98cfa">2,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i489d0217d95349a09e3854a159fe1e20_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTYtMS0xLTcwMDM0_9d1eb257-2169-4190-bd52-0d079835802a">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3ea038280ba420e8b3e85334bd010be_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTgtMS0xLTcwMDM0_70011626-6107-4672-a184-d199f9298a75">4,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0579266bf5fa431e86d0cc99966caf96_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTEwLTEtMS03MDAzNA_acc97264-1e27-429d-8456-40809adc53a8">4,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3ea038280ba420e8b3e85334bd010be_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTEyLTEtMS03MDAzNA_873af6b1-4838-465c-a574-c9d25a7964b7">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf0ee75730ec4eaf8b49daa1a0982cbf_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTItMS0xLTcwMDM0_f957cfe0-3001-45e4-9d61-e0775d566109">4,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9208998ddf664f808ab029146e8a7091_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTQtMS0xLTcwMDM0_335363e1-6274-4b0b-b024-c8c10679194f">3,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf0ee75730ec4eaf8b49daa1a0982cbf_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTYtMS0xLTcwMDM0_59a1f2f3-65a3-464e-84a8-b17caece67e2">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93dc841f45e74baab367942431755f0d_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTgtMS0xLTcwMDM0_8c268f3e-95b5-4f9c-8811-7a8ffbcd2ebc">7,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abc2da8c3544d7a8631b23ee75d1876_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTEwLTEtMS03MDAzNA_5bb37aff-0976-464c-9cb1-d08c1b0ca205">7,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93dc841f45e74baab367942431755f0d_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTEyLTEtMS03MDAzNA_48f53cba-4abc-4468-a238-f8cfc165187a">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615f22ff6960415c94431ef20433e83c_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTItMS0xLTcwMDM0_2593fb7f-4f34-4592-b20b-c84ae59f414b">1,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271d0e8006734cb381410cc5d646c7e5_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTQtMS0xLTcwMDM0_88a08996-445d-41fd-a0c1-30b85af3b1cf">770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i615f22ff6960415c94431ef20433e83c_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTYtMS0xLTcwMDM0_0ac8932a-bd5b-4abb-9adb-c0b846d03ff5">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b08f5246c2483c8916b0d18a4cb899_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTgtMS0xLTcwMDM0_d4be45ef-575c-4be3-b419-1d755e5aac54">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4137bbbedc454ce4a1e326ab7eddfed0_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTEwLTEtMS03MDAzNA_ff212bc2-ea6a-4a7f-8b34-f607cb4c67cb">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04b08f5246c2483c8916b0d18a4cb899_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTEyLTEtMS03MDAzNA_9ace90b7-97ea-45b6-95ec-1146aa91975c">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46129e353ad84f39a366e43a8ac98e0a_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTItMS0xLTcwMDM0_75a40422-23ec-447b-88db-b9f70f2ac624">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a134dff79c46c1bb7e1c0967197d54_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTQtMS0xLTcwMDM0_18aaacfb-7b9d-452a-aac5-0efd11bd4de4">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46129e353ad84f39a366e43a8ac98e0a_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTYtMS0xLTcwMDM0_d7727eb0-ce06-4515-aaba-b8966df6d919">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb851f7c092f4ee3bd18823be28d76ec_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTgtMS0xLTcwMDM0_2b0249c2-1e5f-43f7-ab15-00752f343493">1,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4755679550432890b18a7d35fbe2fe_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTEwLTEtMS03MDAzNA_1f5f196b-5e8a-4c35-96fe-f7d759eec6dc">1,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb851f7c092f4ee3bd18823be28d76ec_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTEyLTEtMS03MDAzNA_1b4dc528-6f8b-4069-b0b7-f5dbed8d62b8">39.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e47d07acf0a4b3bbe3c60a9e96bf4f3_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTItMS0xLTcwMDM0_6c5443eb-fb7c-4e48-a5c2-aea242fd5643">1,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f53949a41d46ef898ac80d318d4189_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTQtMS0xLTcwMDM0_fe6cfdce-2666-41cf-ab74-1a094a4b1541">1,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e47d07acf0a4b3bbe3c60a9e96bf4f3_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTYtMS0xLTcwMDM0_d8301656-76a6-4c52-8801-37472706f1bb">38.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2284a61a0db642eb9a40b3613d8594d2_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTgtMS0xLTcwMDM0_1c458649-25c6-433d-95de-090cce5783b9">3,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1379f0be014f4ea396ebb2effecec503_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTEwLTEtMS03MDAzNA_e915502f-fc36-4fef-bec7-fdaa157d9ef8">2,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2284a61a0db642eb9a40b3613d8594d2_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTEyLTEtMS03MDAzNA_f7c1c9d8-96f4-45e9-8797-41eed91569f7">37.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426a47a9bb5049e49edcb30d41af643d_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTItMS0xLTcwMDM0_d77d5fbe-9bbf-4255-a940-b61086b82665">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie71f54f5a529400e992bcff94dd82726_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTQtMS0xLTcwMDM0_532b5643-b8e2-44d5-a478-160b81750a00">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i426a47a9bb5049e49edcb30d41af643d_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTYtMS0xLTcwMDM0_a2ddf5f2-c0bb-4899-b2b3-3c1fb58005b4">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i130828dd7fbb4e60887d19e7e530c789_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTgtMS0xLTcwMDM0_22396e01-5208-4104-81cc-f6c9e4152118">439</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90029a9516f4591902efe683175866b_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTEwLTEtMS03MDAzNA_1c0145b4-a384-4c0e-a880-709b5fa327c6">364</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i130828dd7fbb4e60887d19e7e530c789_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTEyLTEtMS03MDAzNA_df836193-e0e8-49e0-9b45-bad63f19c088">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e7b1fc93c648b8b4e52538ecb02755_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE1LTItMS0xLTcwMDM0_4a9b16fe-33c1-4040-81a4-d86ec90fded3">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea982946629432694550a8492f1df45_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE1LTQtMS0xLTcwMDM0_87ff678d-f43d-42c0-b3e5-2d03f16a105a">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba1c7b633bd48db874857a7afcde3a7_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE1LTgtMS0xLTcwMDM0_3e099d63-e9fd-4e86-ae09-ef570f9d3ae4">412</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5808bbc2a03c4b5bab9390a5f8f31033_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE1LTEwLTEtMS03MDAzNA_b5b11be8-96fe-42fa-8e7d-641f740a02e2">199</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0c50a7dcd74d0db255eeaf0c492416_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTItMS0xLTcwMDM0_add64fda-4661-4a62-b1ca-0e4fb4ea819e">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387b27c79f194d799d0479f8a64250d9_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTQtMS0xLTcwMDM0_5c918763-41c3-4278-9b03-6fdaade5fd0c">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0c50a7dcd74d0db255eeaf0c492416_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTYtMS0xLTcwMDM0_94bffbb9-e80f-4e39-979c-7aa6346a7115">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f7fbaf72f24eac8c150dc42468daee_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTgtMS0xLTcwMDM0_af3de1d7-a82d-4e97-81d3-dd01ff701bd6">850</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8419c61da6e9446b84344e772ddcae1f_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTEwLTEtMS03MDAzNA_c544f505-6048-4525-bbe9-d60b2b34a23f">563</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5f7fbaf72f24eac8c150dc42468daee_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTEyLTEtMS03MDAzNA_c8923ad9-1176-4696-929f-26810445ef86">51.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfa9586158743db9a0c50d35d5c3e89_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTItMS0xLTcwMDM0_1d3a4a69-96bc-4a4b-b807-82f11f88e1ac">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592eccbed0a44157b77b90479b36ff12_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTQtMS0xLTcwMDM0_99958ded-a883-43d1-bf53-8afab636844a">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5bfa9586158743db9a0c50d35d5c3e89_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTYtMS0xLTcwMDM0_fe4f50de-b636-4688-8b79-23b8633cf7c7">23.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0339ec3d81486890f895801d2a05b3_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTgtMS0xLTcwMDM0_83f7c6cb-b151-4d9b-b896-d8054fe7d15c">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c10bec547049118934a57af7d55e71_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTEwLTEtMS03MDAzNA_3774766a-8a11-4eb5-98fa-859972be855a">898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ida0339ec3d81486890f895801d2a05b3_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTEyLTEtMS03MDAzNA_c88933e0-c815-4ea5-b6e7-4620b59fa220">19.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30dd2aba0a4a4cd58d61a14fded9bf4e_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTItMS0xLTcwMDM0_cf7da587-7272-4b6a-a0da-5f03d8a8bbe6">620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40056c4ceeb846b4811bce1524b88e28_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTQtMS0xLTcwMDM0_5f2b0944-868b-4764-aefa-59bb0457b3e2">662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i30dd2aba0a4a4cd58d61a14fded9bf4e_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTYtMS0xLTcwMDM0_64d936ca-7f92-48eb-9c14-f18874a70052">6.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4acd16385e14790b4257cd1e30e36ad_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTgtMS0xLTcwMDM0_9cd05de8-6521-4ef5-84f3-f736bbc8eb1f">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e28b4687a6462d8f2d01ee02868bf2_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTEwLTEtMS03MDAzNA_9ca18d7d-1f70-4891-a59f-0497b46e810a">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia4acd16385e14790b4257cd1e30e36ad_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTEyLTEtMS03MDAzNA_c0f546bf-91ca-4c69-b86f-2cffe1d8c545">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406d7f79310444cba9070d2c72c8ed3d_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTItMS0xLTcwMDM0_994f6e8a-7aed-4365-bb74-36a5703f6ef5">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9ae73e21244184a996ccfa27a0e0d6_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTQtMS0xLTcwMDM0_f246b978-ca7e-4c45-8be4-33409076cb80">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i406d7f79310444cba9070d2c72c8ed3d_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTYtMS0xLTcwMDM0_cc17a102-0564-4672-9cbb-0aebfee9d300">13.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe33b178b5f24c92919e80285cf6ce87_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTgtMS0xLTcwMDM0_12d93eeb-406c-498c-bc46-60a1d4c724c6">2,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a022bc19634f4291caec90e24c1e56_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTEwLTEtMS03MDAzNA_81ee06b8-b2c2-4cf7-b182-534c418fe958">2,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibe33b178b5f24c92919e80285cf6ce87_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTEyLTEtMS03MDAzNA_be52059d-936a-49d7-8a41-e817d1689fe9">10.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fbf93a0d984f74a4c18b8438d93705_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTItMS0xLTcwMDM0_d19052b0-27e6-42f5-b4d2-3f95c18a4972">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e590252c39f4b69acea8c278aaaa6f1_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTQtMS0xLTcwMDM0_7e352860-c008-4f6a-be37-7bb6a096f375">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id8fbf93a0d984f74a4c18b8438d93705_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTYtMS0xLTcwMDM0_ddd78e94-74a2-44ea-8688-71eb487a5cde">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d89ac93d3541048345e457b838050c_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTgtMS0xLTcwMDM0_6d148417-b5c7-43df-8e37-68e8ebeabc12">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a77e4ef832546f095278c7e2e4cdd06_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTEwLTEtMS03MDAzNA_38334c2a-1b7b-491d-987a-c374a26dd78a">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic8d89ac93d3541048345e457b838050c_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTEyLTEtMS03MDAzNA_f366764f-cd2a-4c61-89f2-eec2b124d5a8">47.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53abdb7bf8da48d28acfcb3784400145_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTItMS0xLTcwMDM0_e335c732-6cff-4f62-80ba-592ef9341a5f">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1508e902d9b44570a06c0b42a8e602df_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTQtMS0xLTcwMDM0_aae17587-7549-43d3-afb8-763e0eaf6a30">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i53abdb7bf8da48d28acfcb3784400145_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTYtMS0xLTcwMDM0_52a86919-7f5a-4d97-b0e1-87bc04da6dfe">10.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b50ec6523c84e019fd0db2f7ee816f9_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTgtMS0xLTcwMDM0_ae1e33fb-f1ad-44d3-9337-aba04a4c3272">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d63678be1842828f166c73f3d5ae66_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTEwLTEtMS03MDAzNA_190de8d5-2820-4f84-af61-173b537f85f5">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3b50ec6523c84e019fd0db2f7ee816f9_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTEyLTEtMS03MDAzNA_36ce3705-5801-461a-8b58-c7b2afa59a1a">11.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia254c76d3f8f491097090592e479401a_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTItMS0xLTcwMDM0_b82e4c01-ce3d-4acc-86b2-5ff4e6c05043">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14d651799574575bfd8abdfa9223117_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTQtMS0xLTcwMDM0_d7d5737b-c09d-4423-8ff3-20e1554e94d4">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia254c76d3f8f491097090592e479401a_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTYtMS0xLTcwMDM0_0f7fa8b0-981e-4c30-99cb-f6929b7516d8">10.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaf1d0c5d9848a8b48f4bd785f69d6a_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTgtMS0xLTcwMDM0_271c3050-db78-4e65-85ac-2402091b5a31">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fbc96ca92fb42cea0ec295a49f4dfc5_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTEwLTEtMS03MDAzNA_06bc765b-6c46-4c5f-aea7-9532240ba54b">1,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8aaf1d0c5d9848a8b48f4bd785f69d6a_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTEyLTEtMS03MDAzNA_75854417-f089-45da-bf53-dd551111acca">13.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i24c26d3a94314775980716f3b60cf0f1" continuedAt="i07ceed92831c48aa92fb7991b935c5fb"><ix:continuation id="i8620e65d732e4841944f6020f1007874" continuedAt="ic0d630ad1e79457bb5e1bd0ebc003eca"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3058cd0a794324aafc2a3a3fb3d32c_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI3LTItMS0xLTcwMDM0_1dc9fd78-8a98-49d5-91df-8679eed7169a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06149290e1044e6681818593b0e3b54a_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI3LTQtMS0xLTcwMDM0_5b53ee29-bd85-4832-980d-9b8e053b9e8d">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665d8acf34544c7bc3d213e29a403a7_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI3LTgtMS0xLTcwMDM0_2e645454-a32d-4429-bf0f-c5d36c49159b">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b2aa9141884cdb897069ea96225219_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI3LTEwLTEtMS03MDAzNA_4c2adf4b-5c42-4c24-a03e-1a80e29fca51">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50642add27bf4a3c847f19d7dcc1fa55_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTItMS0xLTcwMDM0_880ff248-8faa-4146-b0bf-228b2a70a32d">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1878b6e06b6d4e8fbac6886000f181e7_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTQtMS0xLTcwMDM0_abb72520-182d-47c7-8637-3cc161401caf">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i50642add27bf4a3c847f19d7dcc1fa55_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTYtMS0xLTcwMDM0_8542422b-fa2f-4515-b2b4-545eccb717ee">25.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e1c777f67d469aa4c5d82eb4cac8d3_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTgtMS0xLTcwMDM0_fa224e72-fb83-4b9a-bbc5-8cb598b79a7e">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a597acb37e446f8a4c956653e8bab3_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTEwLTEtMS03MDAzNA_7b8ab8ad-df98-422f-894a-3e4ffd735690">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i49e1c777f67d469aa4c5d82eb4cac8d3_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTEyLTEtMS03MDAzNA_b20d0a2a-1ad7-4353-b133-e12248c6d29f">39.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c828becc5644f42afd048825810abaf_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTItMS0xLTcwMDM0_5a33ab92-c091-415b-906d-55cae04188ce">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fea4855dd1f4faabcb8e2d17b561470_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTQtMS0xLTcwMDM0_3f0dd065-36d0-40f3-a6f1-570a82246cd9">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c828becc5644f42afd048825810abaf_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTYtMS0xLTcwMDM0_5ee32ded-0d4c-4d0d-a55a-45f2e3f14287">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f53d151fe8347b498763fd23057410d_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTgtMS0xLTcwMDM0_8989a34b-0f1c-4597-90f3-27c8ce1f10ef">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be7291502c242fa9978dea11ad9818c_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTEwLTEtMS03MDAzNA_a82ec63e-e405-4001-92be-0482d83b7226">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9f53d151fe8347b498763fd23057410d_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTEyLTEtMS03MDAzNA_9e73a81f-2f1b-447e-bec8-7e2ada57ed7f">18.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc09d2d675884189bc0ba76a89d7113f_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTItMS0xLTcwMDM0_6e4ea0ec-7eda-4e20-a54e-11a9d3b0b17d">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89dd98c72cc84fe1ba6b852522d18a83_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTQtMS0xLTcwMDM0_66430c3f-b02e-4d9d-94e3-5462fd130b43">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idc09d2d675884189bc0ba76a89d7113f_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTYtMS0xLTcwMDM0_b941c7a5-db72-4c19-9b81-014bad38dd2b">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa4bd06b9544485bda39398396ffcb0_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTgtMS0xLTcwMDM0_1ea28081-c576-4ff7-aff9-a639047b8a23">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafcb61ea5b64eafb32a7afa38475c33_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTEwLTEtMS03MDAzNA_bf09965c-ae19-4550-89eb-b1f7c4ea7cfc">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4aa4bd06b9544485bda39398396ffcb0_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTEyLTEtMS03MDAzNA_e3d75fbd-6b0f-474e-963f-4f39489c501b">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d20d851bb704983b94a0bd5e2bf8063_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTItMS0xLTcwMDM0_b8661c3a-9576-420a-950d-01929ee9c349">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdee48ad66d84e4c821395f425508ec9_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTQtMS0xLTcwMDM0_691ef893-b145-4a4a-b91b-32bbc6a76ad7">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d20d851bb704983b94a0bd5e2bf8063_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTYtMS0xLTcwMDM0_479837c1-0723-4321-a81b-8e718ee3bbc5">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29866d57d1454ab78e5a90bf77a1bd34_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTgtMS0xLTcwMDM0_d83b908c-efd1-4726-86c6-1dbc823ea50f">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d781877b74c43629248df91d29e0ac3_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTEwLTEtMS03MDAzNA_abb2e4cc-7c13-494c-b013-11b088649323">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29866d57d1454ab78e5a90bf77a1bd34_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTEyLTEtMS03MDAzNA_391d9e06-6f5c-4b20-99c8-6c8a92308a29">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i287ae97dc4bb452493b5178c62898f36_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTItMS0xLTcwMDM0_3c859b49-058e-4889-b7ca-4240261f67ac">843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffbcf7aa3c2d4150a651ef9642bdc10a_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTQtMS0xLTcwMDM0_44e95bd7-4161-4af3-af11-85ea485dedfb">870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i287ae97dc4bb452493b5178c62898f36_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTYtMS0xLTcwMDM0_c26fd25d-7299-44d9-a5ea-db903499544b">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc239cfb9ce0485982b4ed133c7bd657_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTgtMS0xLTcwMDM0_95ba2dae-d015-4871-a4b0-f505289a6a68">1,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37914cd1dccc44c0996e33a397571801_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTEwLTEtMS03MDAzNA_6d920ad6-b934-47fb-9d81-ec8719b1ec26">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idc239cfb9ce0485982b4ed133c7bd657_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTEyLTEtMS03MDAzNA_dffb892a-640f-47ca-b2ad-35d174face06">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c955b2727464d82bdccca98ce299c54_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTItMS0xLTcwMDM0_189c8751-b59b-4a4e-9fdd-820bbb34e333">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0328f187daa42cebf05b6bd3a2f5dae_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTQtMS0xLTcwMDM0_5a9b5d4f-ab09-4c67-bf70-7057ae557453">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4c955b2727464d82bdccca98ce299c54_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTYtMS0xLTcwMDM0_0db48466-fff7-46e5-b9e1-1db01604e718">8.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bb153e375c54c7eafcbd065d7b6af94_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTgtMS0xLTcwMDM0_27adf4ea-b406-4085-ae9b-9e4e20717273">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f501d0f4a749579b31839d170e6acd_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTEwLTEtMS03MDAzNA_4a821d9c-2a9f-47e5-9757-a7dd3bf309f2">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0bb153e375c54c7eafcbd065d7b6af94_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTEyLTEtMS03MDAzNA_bd68b8bd-b413-427e-ab3f-eddec24e423b">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53051d91ab824126b4235ef16cb6263a_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTItMS0xLTcwMDM0_0936fd17-55b4-42c7-b49b-18d28cde72d6">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i051a1f8ff4d040a5a7eb2d6081274333_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTQtMS0xLTcwMDM0_29396b1b-03d9-4413-9f76-690a137e44cf">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53051d91ab824126b4235ef16cb6263a_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTYtMS0xLTcwMDM0_68c861c2-d165-4362-81e9-f893574b39fc">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ef09cd80ce48528fd4e15b267fa581_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTgtMS0xLTcwMDM0_fe8945f6-8b8d-44b3-ab76-211e7ccf9302">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06739f6ca36d4acf8527637cfd8a8414_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTEwLTEtMS03MDAzNA_f02e749b-5e16-426a-9ebd-5921381fff52">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i17ef09cd80ce48528fd4e15b267fa581_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTEyLTEtMS03MDAzNA_67d783e0-9467-4944-b59a-a9d893aef486">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2195e9ea8f74827888df91311e38634_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTItMS0xLTcwMDM0_cd74b344-34cb-4463-9ec2-ea2b77036e3b">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie560385a5b9746bfbc9ecf44f08e40b2_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTQtMS0xLTcwMDM0_a9e3d168-e6ec-4b04-8c4b-96aeb004a84b">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia2195e9ea8f74827888df91311e38634_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTYtMS0xLTcwMDM0_00074e2b-f4b1-43a7-9963-bf4db73f4b86">5.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c14ab77a3f4981856f2e47e937f928_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTgtMS0xLTcwMDM0_2875a69a-484d-4495-95ce-8403da58a6f3">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e2da82b9524140bea1c1e3e0376373_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTEwLTEtMS03MDAzNA_3b0ba521-67a8-4421-9416-057334d1b970">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i64c14ab77a3f4981856f2e47e937f928_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTEyLTEtMS03MDAzNA_eae1532a-a847-4d4c-bd61-9a0fbff32e24">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica029ef15f3c412ea7f79ededd61891e_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTItMS0xLTcwMDM0_422c9569-421e-4c7b-9a42-d6b07600f6fc">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38059bf51b94495b9e558db7253d6b7_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTQtMS0xLTcwMDM0_0cc1a5f3-831f-41ab-849a-9e428c95f1ae">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica029ef15f3c412ea7f79ededd61891e_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTYtMS0xLTcwMDM0_5cd15cad-a267-4322-9ce5-fb3694704715">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55223f8e057b44348303589fe6a6d634_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTgtMS0xLTcwMDM0_cf734b19-88ef-429c-9966-2a7046dfed40">541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1da4c3fbf5a45588aa47da0d8af5515_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTEwLTEtMS03MDAzNA_e5191036-bc2f-4b5f-8d28-d624e21d78b4">527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55223f8e057b44348303589fe6a6d634_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTEyLTEtMS03MDAzNA_233d1015-0b6a-4fc9-903b-5c146e805147">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22eb4caafc674003b9ed0fe8faa1adfd_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTItMS0xLTcwMDM0_c7cdc320-5868-454c-a5d6-e52d49bee07a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa53a4d85235465fb23f952022ed2de3_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTQtMS0xLTcwMDM0_7a07525a-f5e7-4e51-823c-2e4b4f8525d8">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i22eb4caafc674003b9ed0fe8faa1adfd_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTYtMS0xLTcwMDM0_d4fffbe0-0103-4cc0-ada0-474f397a3e6f">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1ebe756b1a4fdaba163f6226a73865_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTgtMS0xLTcwMDM0_279dd592-68f7-483f-9f0f-fd38bc07101a">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38c14e59526462aa00b9fdf01150b88_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTEwLTEtMS03MDAzNA_ad5164b1-68ec-4986-bcc8-47ba30e2fa82">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d1ebe756b1a4fdaba163f6226a73865_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTEyLTEtMS03MDAzNA_6a5dd3cc-091d-49f7-a039-084229035b2e">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ca4cedb5aa472d978a64ed56e29c3e_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTItMS0xLTcwMDM0_ecb7a480-ded4-4f09-a8bb-a9d1e4e70f91">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50df75de55354d31977579bd740f47d0_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTQtMS0xLTcwMDM0_cd3c28fd-a60c-4af4-8f20-696d902f2cc5">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81ca4cedb5aa472d978a64ed56e29c3e_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTYtMS0xLTcwMDM0_86653114-0849-4e3a-a334-5bb8ac70581b">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb8526f11d44a7285dcfe44fe83967c_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTgtMS0xLTcwMDM0_a1f525c1-c98a-459b-b9df-9049ad3c8626">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d92da1715d4466934af62c118acd2d_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTEwLTEtMS03MDAzNA_5fcda91e-b757-44d3-b52e-8203b55eb1df">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fb8526f11d44a7285dcfe44fe83967c_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTEyLTEtMS03MDAzNA_930974cc-4e7a-49e5-8561-3da961f25920">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0236b7aa74b24bf18b2ebaca9df2dfaa_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTItMS0xLTcwMDM0_dba7136e-8aed-4d1d-8081-1fba2054f565">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebde257fe3c43c099d64ee47d4049de_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTQtMS0xLTcwMDM0_b30a0217-edfd-446f-8211-f755ba3bf01f">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0236b7aa74b24bf18b2ebaca9df2dfaa_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTYtMS0xLTcwMDM0_d373480d-f7cd-4bb5-8a83-6fc5720e6b3b">36.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ff9ea6230d4739b53a98d08fe59cd1_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTgtMS0xLTcwMDM0_449a7425-0466-4d20-a56a-5f327d1a4582">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557f42df940c4b5ab8401d631fbf9c50_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTEwLTEtMS03MDAzNA_dfd36b9b-30cf-44ed-97a0-1e70f5edf2ad">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib4ff9ea6230d4739b53a98d08fe59cd1_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTEyLTEtMS03MDAzNA_b61d7c92-0361-43eb-9ca0-5160fb33afea">32.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf3bc11cf184431b734d51a51999f44_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTItMS0xLTcwMDM0_458a0455-018a-438f-8beb-84789bc88e8f">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05790066f2a14f93b4be920ebfa71d30_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTQtMS0xLTcwMDM0_f62b65de-97c6-46cf-b9bd-440558547b92">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icdf3bc11cf184431b734d51a51999f44_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTYtMS0xLTcwMDM0_25056d97-5f74-48f6-8888-f14f0eadfd11">8.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f0430dcadf4801885432b12fc09d25_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTgtMS0xLTcwMDM0_ed352e0c-c1ed-4fa2-b258-5fb6010feb57">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b567ecf14d4468a81aeaabef24109b_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTEwLTEtMS03MDAzNA_438808d3-1c12-44d4-b4bf-9db40ae961be">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib0f0430dcadf4801885432b12fc09d25_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTEyLTEtMS03MDAzNA_13715754-c984-4cff-855b-924ff15614fb">11.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a1a2d1f27b42d4804ea393d24ea74a_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTItMS0xLTcwMDM0_8a6ab624-5f1b-487c-b63a-e4d02bb1bf89">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d46afbf8ebf4c85a615530f2f6ca89c_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTQtMS0xLTcwMDM0_6d06060e-6533-4249-a031-15d5b6ac02b5">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i25a1a2d1f27b42d4804ea393d24ea74a_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTYtMS0xLTcwMDM0_820f6b52-d919-4ceb-92b0-92782ae863e2">18.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfa29cbf57143ac90d54acbc629ab41_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTgtMS0xLTcwMDM0_390f648f-12b8-48c5-8d8d-77029ae34b77">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b934d9eaccf40c292408c0121b1ab1f_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTEwLTEtMS03MDAzNA_1df5c14c-6101-4bc7-b5c1-d3e6a49361cd">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idbfa29cbf57143ac90d54acbc629ab41_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTEyLTEtMS03MDAzNA_cbfbcb63-cf9c-406d-9627-8639872eca7b">19.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b191b04cb24993a324572ceed1a094_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTItMS0xLTcwMDM0_b0582da2-55f0-4fa6-851e-25392e45d479">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd72d040762453daa0d7e628045ba1c_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTQtMS0xLTcwMDM0_f5bc85a6-fe3c-4db6-935b-c84d81173516">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic6b191b04cb24993a324572ceed1a094_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTYtMS0xLTcwMDM0_6001ec79-ecd3-495b-b93c-1b3850c336d5">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39d2198e5ec0432fa48695a07a06b16f_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTgtMS0xLTcwMDM0_db40afc0-f169-4352-b557-1c20031477c4">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb17e60efe244f14be98a7b086a2993b_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTEwLTEtMS03MDAzNA_e261e2ac-cf6d-4c7a-b6ed-f2f0df8061a6">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i39d2198e5ec0432fa48695a07a06b16f_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTEyLTEtMS03MDAzNA_555866c0-7e0a-44ed-b998-bf3398b648ad">9.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic801c7ed779a4b89ab0b1c8ecda3f3c1_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTItMS0xLTcwMDM0_7d608950-6774-4210-ba03-13e1d3d452fd">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2cf187fa1e34995ab2bc76d0f9990b1_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTQtMS0xLTcwMDM0_4e304176-3995-43f9-9a6b-c18a42b92953">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic801c7ed779a4b89ab0b1c8ecda3f3c1_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTYtMS0xLTcwMDM0_3a76cc5c-2771-417b-9269-b13173a4e0c9">10.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eefdcd0b36f4eab9f7efff9e9bbd8b4_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTgtMS0xLTcwMDM0_fc166634-b611-4b7d-8b87-5fdc61bc3611">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d2207e1597d44adb9a60324bef5417b_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTEwLTEtMS03MDAzNA_73a132ce-a809-49d1-a288-ec8cbe203db8">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4eefdcd0b36f4eab9f7efff9e9bbd8b4_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTEyLTEtMS03MDAzNA_56aec7fc-a4e8-460d-976c-ca2513298af5">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73303bef5d5d44fa9de21fa225eb70b0_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTItMS0xLTcwMDM0_472805ae-bf1f-474e-87b7-03b3c97c74bc">972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328e26ff5b614b91acdf8a791462b459_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTQtMS0xLTcwMDM0_b36ff4b2-1b18-4f43-9ce4-db7bfad2cee6">1,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i73303bef5d5d44fa9de21fa225eb70b0_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTYtMS0xLTcwMDM0_a14f5377-b272-4f9a-b0eb-b3124929b9c2">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be86e56935f49e082bc5a14e5f2756d_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTgtMS0xLTcwMDM0_6958c946-da51-42bf-89f0-5fdb65b43796">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fffd0e4936e44f9ab0a1b46f12c274f_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTEwLTEtMS03MDAzNA_1f00cc52-8317-4b3f-8860-482dec47346a">2,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7be86e56935f49e082bc5a14e5f2756d_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTEyLTEtMS03MDAzNA_b01a95e8-dfc2-42e9-a788-ea3daac60743">8.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic518c8578d7d45928e9c8d6d8f5afdb9_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTItMS0xLTcwMDM0_5ec49d18-0d46-4803-a7e4-082082324b7a">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib11d6a998a194ce0abd3b90c4cac5da7_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTQtMS0xLTcwMDM0_adffddc5-6fb3-4da7-b2df-05a8b637b5cc">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic518c8578d7d45928e9c8d6d8f5afdb9_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTYtMS0xLTcwMDM0_0650a327-320f-4ddb-9997-52beed98adfd">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d2a4965d144779a4ceefbf2e67dda8_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTgtMS0xLTcwMDM0_0b372c62-4bca-41fc-9fc2-abbc74effa4e">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbfb604e8334efcb004e1de36bbe2ba_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTEwLTEtMS03MDAzNA_110cf3d4-f9a1-4c07-867e-ce1f2f069cd5">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94d2a4965d144779a4ceefbf2e67dda8_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTEyLTEtMS03MDAzNA_0047fdb3-fe8d-48ad-b23c-11f75a92ca69">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a5fe4bb174446db8453acdb52d0b8d_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTItMS0xLTcwMDM0_8e3183e5-9ce2-42d2-a997-6e619c8fd020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5868064a491c4c21beda0fc35e2236f5_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTQtMS0xLTcwMDM0_71bf253f-bd64-4926-a2db-ba85a75cc892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4a5fe4bb174446db8453acdb52d0b8d_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTYtMS0xLTcwMDM0_45e08a03-72ef-4313-a6e3-50c16c694d38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcef923095ae403daa45a3cd38e272eb_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTgtMS0xLTcwMDM0_4ee222e2-6fd1-44bb-b740-2662b7afdbfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2e614016aa4c27b3a18c5a2bb1d03d_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTEwLTEtMS03MDAzNA_4b7020de-f3af-4789-a942-7c958edf1f52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcef923095ae403daa45a3cd38e272eb_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTEyLTEtMS03MDAzNA_739fa34f-513a-45bd-8c1c-88d0588b800e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d4961fbd434dfdb053a7619753dbb5_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTItMS0xLTcwMDM0_191e2833-6b95-4232-bdbf-a8212507f4d6">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5288342ca6544db84e6afa56ec57667_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTQtMS0xLTcwMDM0_dc7217dd-701e-4420-b646-6fd2f7d13415">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05d4961fbd434dfdb053a7619753dbb5_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTYtMS0xLTcwMDM0_828ffcfe-8f6e-435b-ba69-c7e0ee1d2796">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2490c0acc14641bd54b07d1a9dcba1_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTgtMS0xLTcwMDM0_878bf0a3-af59-45bb-8c28-bdeea33ae4ef">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8201a9664e94c64abb84f293366b311_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTEwLTEtMS03MDAzNA_99f90df5-eeae-4309-97a3-936782d8174d">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f2490c0acc14641bd54b07d1a9dcba1_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTEyLTEtMS03MDAzNA_ecc9e240-96b6-4754-8510-77cb7d5f4585">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA / INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a145198034434d8c34cb328adb37ee_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTItMS0xLTcwMDM0_dd33e729-b97b-481f-bb04-99d3ce0c8dd0">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa58911049db441c9be14900db7de10b_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTQtMS0xLTcwMDM0_828f00c9-999c-43c7-849f-94f939746612">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41a145198034434d8c34cb328adb37ee_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTYtMS0xLTcwMDM0_a40c8e41-b53a-4f13-a310-c5c1dc2c4edd">42.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92942d5c5a284320a4d0d4db266ef84b_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTgtMS0xLTcwMDM0_99211fb8-5555-417d-9795-7aff201c2b7b">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dbe9e6430447a283ce3f28d7a2cff3_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTEwLTEtMS03MDAzNA_23c86430-038e-4f99-ba2e-e463019e38b0">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i92942d5c5a284320a4d0d4db266ef84b_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTEyLTEtMS03MDAzNA_0a3fb888-8846-4603-b3a5-37c8b5fef85a">37.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634a6971cc2c4ab4b880a9dc1245444c_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTItMS0xLTcwMDM0_ee117213-2002-40be-9a2f-32a0d98a92fc">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9198cff7a66447b9be7b837f342aaf9_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTQtMS0xLTcwMDM0_02b4a3d5-48b1-4e68-ad25-6ead559d25ad">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i634a6971cc2c4ab4b880a9dc1245444c_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTYtMS0xLTcwMDM0_8084f844-e559-4b4c-9ec9-6d1da12f0433">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e2dbe91cf1482c865a5ed7f20252ae_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTgtMS0xLTcwMDM0_ebc6ea99-6bed-4442-97b3-0dcb6e110201">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280edb799a7541e4b978e766002ab0dd_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTEwLTEtMS03MDAzNA_408766c8-cda1-4fd0-8632-abeed78d19d7">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63e2dbe91cf1482c865a5ed7f20252ae_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTEyLTEtMS03MDAzNA_b2315ab3-6ea0-4134-969e-9ace25f7998a">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df7fc7846394d8cb6b3dfa190ddbeec_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTItMS0xLTcwMDM0_e79877e6-7708-495b-b263-2a1d880f27cc">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4358b89737469c9a4a76ab01d38b21_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTQtMS0xLTcwMDM0_21c1175f-7e3e-457a-9ecc-abcf9c81e1ba">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2df7fc7846394d8cb6b3dfa190ddbeec_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTYtMS0xLTcwMDM0_dd89f5a5-66da-4a38-9d3d-9e7ebf629529">24.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748c908553434318bab2f9e71aca0df3_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTgtMS0xLTcwMDM0_28c8ef32-6efe-42f0-9f59-fcafeff098ef">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7d57cfef704ed4a19a72497cfd1cff_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTEwLTEtMS03MDAzNA_d0008e9e-c2fb-44a0-9293-68c3a519ff9b">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i748c908553434318bab2f9e71aca0df3_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTEyLTEtMS03MDAzNA_582cde3e-b4fe-41b4-8897-17ec975c2e2c">19.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07dc3cd22e6141a9b58734901b2bcca3_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTItMS0xLTcwMDM0_4398e537-ce30-487c-b604-a7de7ee92e1c">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37d45622a2a4e2aaf861e5d5425dc36_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTQtMS0xLTcwMDM0_9faaf3eb-187d-4ed7-8c28-4939c9bcd428">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i07dc3cd22e6141a9b58734901b2bcca3_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTYtMS0xLTcwMDM0_efcbe04b-5ff7-4fde-889d-99acf66d3d65">19.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5736eee575b44f30b0528226c5b341e0_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTgtMS0xLTcwMDM0_67d90e27-e198-46f5-9948-2e6b5160deb2">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd466ee6375247868fb5aa1fe4cf6baf_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTEwLTEtMS03MDAzNA_d159b7a4-0c1c-44e2-b635-92b6713396b1">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5736eee575b44f30b0528226c5b341e0_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTEyLTEtMS03MDAzNA_f7704693-6c85-42f0-aa0c-6fb64b348a9d">17.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453e566b12f94b9ca1bf28f9a151ca35_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTItMS0xLTcwMDM0_f9db2c57-d0ee-43c0-904e-b5f0952d7473">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7771dfc5043b3bc9fe3d75e90560b_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTQtMS0xLTcwMDM0_26ec1150-0971-4925-8734-adba2d019ac6">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i453e566b12f94b9ca1bf28f9a151ca35_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTYtMS0xLTcwMDM0_2b9371f2-eb88-4811-b083-832557c0759e">15.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b54aa8f21a4defb2e212647938d507_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTgtMS0xLTcwMDM0_e33d377b-8038-489a-8686-4f1cb48a84df">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0430efa680354f9cb2e7be97ad4bbd52_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTEwLTEtMS03MDAzNA_0f24771c-d0fd-43f3-bb6b-4cb383285223">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i19b54aa8f21a4defb2e212647938d507_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTEyLTEtMS03MDAzNA_06783af4-2c8d-4b33-8e18-24ab00c26bc2">11.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01602ac9da834941912114e1dd805606_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTItMS0xLTcwMDM0_404e04e7-caf6-4a47-a66b-8d4034eedbc2">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2018aba666564bf1b4cbefc426636cd4_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTQtMS0xLTcwMDM0_2bb58aeb-b9f1-463e-92fb-9cb516d03327">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i01602ac9da834941912114e1dd805606_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTYtMS0xLTcwMDM0_2c677ffd-a722-4a70-be80-0b4410077715">17.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica2b3030232242349c0d22aa237d5dd7_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTgtMS0xLTcwMDM0_c8c7ffdb-8d5a-417c-ac05-f5180322bd7a">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10a4ac80eaa840618cb738116eeaed5d_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTEwLTEtMS03MDAzNA_540584cb-d0ee-4f97-93b4-ee252282e6d8">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ica2b3030232242349c0d22aa237d5dd7_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTEyLTEtMS03MDAzNA_91471e56-b7c3-4843-99e4-e656420f3a52">13.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46733e339864c9abf57c0d982aa4ce3_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTItMS0xLTcwMDM0_323a6d16-9657-4ebb-a85e-9edab110cedd">7,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic649a922ce584f0d9a52986e9dc716a2_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTQtMS0xLTcwMDM0_38be5e5a-80f7-4883-aa71-bd77140c6cb9">6,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia46733e339864c9abf57c0d982aa4ce3_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTYtMS0xLTcwMDM0_660f1f02-cc92-44d8-bda8-eac9b5539937">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab330b638fb84af6abe1d5d6ece91457_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTgtMS0xLTcwMDM0_3a2d23cc-6e62-494a-b511-4a573a9e8f80">13,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba7b8ae8c0741bc955d90fcc7f5d900_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTEwLTEtMS03MDAzNA_86e0773c-a0aa-43d7-8b2a-12faf47eb4f5">13,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab330b638fb84af6abe1d5d6ece91457_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTEyLTEtMS03MDAzNA_34cdf659-aa45-4ae7-b17e-99304e1e0d03">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia03b1fe2f3c84cfcb0bb12f78e27dfd3_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTItMS0xLTcwMDM0_06bc3fcf-cc2f-4f54-9723-c7bffb079d5d">6,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1878e36b1da48ddb9bb5431f67577b0_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTQtMS0xLTcwMDM0_f45925a9-b6d4-4003-a6cf-f29d051e3539">5,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia03b1fe2f3c84cfcb0bb12f78e27dfd3_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTYtMS0xLTcwMDM0_caa0c0e2-1816-4917-8104-9b28b4dbbf18">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dfc5851d11944dbb13e597eb1fd2070_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTgtMS0xLTcwMDM0_548b6b2a-1ece-4fb3-919e-9acad4b2cb0f">12,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62985e4313f041be8295862d52b0fc22_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTEwLTEtMS03MDAzNA_71eceb53-ebec-4cd7-8f76-fe0c4ff484bf">11,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4dfc5851d11944dbb13e597eb1fd2070_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTEyLTEtMS03MDAzNA_6ee41b5a-189c-4c95-94f3-f2e80367974d">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i637eadc895304441993cdbadddd0035c_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTItMS0xLTcwMDM0_83185f8c-8a33-43d1-9172-8edab73538be">13,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a3c9a671634fbba070e5002be64b8d_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTQtMS0xLTcwMDM0_a5ce2156-f52c-4235-9364-c4159f63b3d6">12,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i637eadc895304441993cdbadddd0035c_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTYtMS0xLTcwMDM0_a37b2a55-a2e6-4dba-9bd4-316adc15e5f5">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTgtMS0xLTcwMDM0_f0e7b86b-ead9-4ef8-9849-e7446d30aebd">26,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd716f176c54a4ab7a98be713399fc0_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTEwLTEtMS03MDAzNA_30785eb7-d47f-4788-9524-4caf7a45a114">24,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTEyLTEtMS03MDAzNA_7058f660-3d50-423b-8529-c1cbe2049f21">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i07ceed92831c48aa92fb7991b935c5fb" continuedAt="i7238a46d257547b19e53f9198b750e18"><ix:continuation id="ic0d630ad1e79457bb5e1bd0ebc003eca" continuedAt="ib085e6e55c814de98868511605b46163"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebdbfdd7008486e8f029ba89cadcf10_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTItMS0xLTcwMDM0_528a17ec-71c7-4c25-83ea-169886a64de1">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6daaee3c30874bc79deda2eecad2dfd6_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTQtMS0xLTcwMDM0_bb48b10b-c7a0-4953-a451-b1f486e4d2f8">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ebdbfdd7008486e8f029ba89cadcf10_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTYtMS0xLTcwMDM0_083d133f-8820-4312-822f-e9c6ffb283da">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75726cc4c32942e7a189dd026b7e9840_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTgtMS0xLTcwMDM0_e2aee550-fa6e-4ae4-adc3-097126afce11">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78908a1d4be846b8a6aced964d30ae02_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTEwLTEtMS03MDAzNA_3a92b3e4-d526-451a-97c6-489123d676d4">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75726cc4c32942e7a189dd026b7e9840_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTEyLTEtMS03MDAzNA_55e78592-ebfc-4c50-8e69-ff6f59c9c8d7">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ebc6f14333d4c1388255155e8187c1c_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTItMS0xLTcwMDM0_6aa4fa17-2b17-48cd-ace5-9bd65eb0bd49">525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia43954139ed84f7788fdfc46187abd9c_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTQtMS0xLTcwMDM0_8daf04aa-706e-4cf4-8608-05f88403f90a">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2ebc6f14333d4c1388255155e8187c1c_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTYtMS0xLTcwMDM0_93c59180-0881-44b6-83fe-1b32c2a1aa82">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a3f4ca28e54311a8fa6ffc5adf57e5_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTgtMS0xLTcwMDM0_c15ea4b4-66c2-41f7-8e49-806372a53d81">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f9cf052510468ba9fc81d28838fd23_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTEwLTEtMS03MDAzNA_6127e0de-07b6-4bf5-9468-677728e85d3c">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19a3f4ca28e54311a8fa6ffc5adf57e5_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTEyLTEtMS03MDAzNA_fe9d9e30-d022-471d-b6df-901521acfea8">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9a42189a364282ad35f4fd9c4a7727_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTItMS0xLTcwMDM0_1897e659-2671-4394-aa54-26a597f7819f">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9144df0a32e4cb08d0e4aa2404166d7_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTQtMS0xLTcwMDM0_765359f9-d2e6-4d05-a657-3b2bb0d094c3">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e9a42189a364282ad35f4fd9c4a7727_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTYtMS0xLTcwMDM0_9706ccb4-4250-4048-a507-b205ac4aefc4">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fb3c8f804914aacbb20f2e7f625263a_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTgtMS0xLTcwMDM0_641c4473-e8ac-421e-a4ce-887526e6ad68">2,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c37042917f440519d1e8bc9992f2fec_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTEwLTEtMS03MDAzNA_af3c8145-6b09-4b08-b352-8a85f7168a0e">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fb3c8f804914aacbb20f2e7f625263a_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTEyLTEtMS03MDAzNA_9afc5dd3-9c8d-4d3a-b09d-51631035a6ec">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2629a235c24645959df36f899307dc_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTItMS0xLTcwMDM0_9417f22c-9229-48cf-9d3e-28ecad9bad49">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e55ed4369874656b82f600d8374ab35_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTQtMS0xLTcwMDM0_74c670e7-02ad-4b46-b66f-6f0afa3c4b86">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c2629a235c24645959df36f899307dc_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTYtMS0xLTcwMDM0_b9feda61-e7e4-4682-a8e2-331716e07413">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c61d257b050413a9a5a10d395f54aae_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTgtMS0xLTcwMDM0_91abf0fc-d94d-439b-9e9b-e7aa7fb7f3ae">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda8eac58b0944c9aab3bf2cde640d22_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTEwLTEtMS03MDAzNA_9e53cc25-5d12-4582-8f5e-b908591a3e34">2,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c61d257b050413a9a5a10d395f54aae_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTEyLTEtMS03MDAzNA_0d2d58af-6f41-45dd-95d6-423f1f0f4b03">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc7392d00fe4b7db44b1ba0ad3f51fd_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTItMS0xLTcwMDM0_058bfbde-b55b-4604-a48a-2a587078be37">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9843005d574706b3acbf5b7281d78f_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTQtMS0xLTcwMDM0_04ae054a-4c9b-496b-9146-e453bb382dd4">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifdc7392d00fe4b7db44b1ba0ad3f51fd_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTYtMS0xLTcwMDM0_561363ec-30cb-43f3-8d87-e8308a944497">9.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab78a1c95a9c4ab192a4c1a1d997c9ca_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTgtMS0xLTcwMDM0_1a0c30cc-e929-4f79-adf6-916cb82c73f8">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776c543649cb40e19afd5abe8d84c755_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTEwLTEtMS03MDAzNA_476127fd-8538-458b-b06b-2fd322bbb951">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iab78a1c95a9c4ab192a4c1a1d997c9ca_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTEyLTEtMS03MDAzNA_540838bb-0f06-4599-83a1-deff5f6a7855">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08070e9deccd401188eddde752dc796b_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTItMS0xLTcwMDM0_62cf1c9d-1748-42e6-bdde-4d19a691ff5b">2,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097c8aa852634e928b7afcda7183e13c_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTQtMS0xLTcwMDM0_7b1ada3a-d78e-4bf9-b012-abdab3646219">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i08070e9deccd401188eddde752dc796b_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTYtMS0xLTcwMDM0_f658993d-0e04-46e5-8941-d52c2ca89071">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574c9d60d2e44b9cb58117accbb26f8e_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTgtMS0xLTcwMDM0_0eb9c69f-0e64-4c05-a59b-b80697a77e9c">4,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288b2f784c3e4914ac7711b5f2478340_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTEwLTEtMS03MDAzNA_e95ee7e4-803d-442b-a522-04a11d747ca3">4,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i574c9d60d2e44b9cb58117accbb26f8e_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTEyLTEtMS03MDAzNA_8c99b98c-01b3-43ed-aa6e-b38e09b2b5c9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d97ec6f67842ab9cadf89c6fe46eda_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTItMS0xLTcwMDM0_d764a9a6-577e-4f5e-899c-215b47fa0b0f">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84032433ba9a4c7ba7a5e2b0546f0df0_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTQtMS0xLTcwMDM0_84804183-7a8d-4e6a-8e5b-8986dc081cdd">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2d97ec6f67842ab9cadf89c6fe46eda_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTYtMS0xLTcwMDM0_9d4b196b-4193-4fa7-99be-3bd0d80c218f">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a6d6bc6ec434449b8d91b39d96f7fdd_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTgtMS0xLTcwMDM0_80897c6e-4d22-4b01-b928-cf79b8d3f849">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db29bb20ad146c98f52bdefa9efc026_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTEwLTEtMS03MDAzNA_174f5d63-2a77-44a4-bffb-e6e04e163e96">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a6d6bc6ec434449b8d91b39d96f7fdd_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTEyLTEtMS03MDAzNA_a791e6b6-cb02-43de-adb0-92f64d2c4abb">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id86625d8b1c144f6a7fcb9b8153032b9_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTItMS0xLTcwMDM0_05cb7dde-923d-40bc-96d1-8e0244fd3ba4">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia123fa54d1184c2aad6e71ad4bae91a2_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTQtMS0xLTcwMDM0_67cfd49f-d377-459a-af3a-5cb1b8e2a978">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id86625d8b1c144f6a7fcb9b8153032b9_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTYtMS0xLTcwMDM0_5d35dc54-8238-41f3-8fa0-cf8bdf38167b">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c45e5237224a03a593f86fb93b0f6e_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTgtMS0xLTcwMDM0_421bf8a9-0f40-4e00-8b28-068a5a4ecee6">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if310cab52cc8487192e4cee2584a6967_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTEwLTEtMS03MDAzNA_c6233c3f-2f29-4552-964d-d43ceee1020b">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65c45e5237224a03a593f86fb93b0f6e_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTEyLTEtMS03MDAzNA_87f7f52b-5fe9-4f9d-8480-3de18293507f">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da796b8ae144afaa39da1574f7ee62f_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTItMS0xLTcwMDM0_e30322f7-df04-4560-ae39-e56a1bbdf88a">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3333c58c0224485a25259a31b39760c_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTQtMS0xLTcwMDM0_dacd8cbd-b49b-4c87-b3ff-45cf11ac5474">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5da796b8ae144afaa39da1574f7ee62f_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTYtMS0xLTcwMDM0_d586e635-737a-4cf1-8c90-bb333e58c76a">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0ef2500d684d2499aa554260f71a9a_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTgtMS0xLTcwMDM0_cd0e2e43-6a60-4e82-8238-fdde7fbfd7ed">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af9ca056caa4bd992cb4135170e25b6_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTEwLTEtMS03MDAzNA_6fcef373-07da-48ed-bd57-6ee774008c7c">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d0ef2500d684d2499aa554260f71a9a_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTEyLTEtMS03MDAzNA_6252f8e9-0170-4495-bd27-d6f542ece02d">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief64ee8dccfd4858bca89783721cee84_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTItMS0xLTcwMDM0_142eef82-e9d9-460e-9218-9e213e043e6d">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i535b8d9ff9b64a70bf52d430da04038b_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTQtMS0xLTcwMDM0_378153a7-1408-466f-a353-e1fadc914546">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief64ee8dccfd4858bca89783721cee84_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTYtMS0xLTcwMDM0_4be84952-a370-4fb3-bf62-5eabc4ece038">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7b0bfbd8d946e583f91bdff7c13a2f_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTgtMS0xLTcwMDM0_5d329855-885c-4375-8fcc-5899e10b3c12">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d06f779d4c344b5a71fc394e5493ba1_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTEwLTEtMS03MDAzNA_9782afb9-2bff-414f-bb4d-9754b0a0b868">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b7b0bfbd8d946e583f91bdff7c13a2f_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTEyLTEtMS03MDAzNA_a338a9ab-3e0c-497a-b547-220f624b550d">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488ea6d5e23043b399c268075239f4e0_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTItMS0xLTcwMDM0_f70d2b7e-8fc6-4210-925f-2dae817670f4">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d8db5b819f845cfa20287368a74625f_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTQtMS0xLTcwMDM0_598bbb09-b89e-4734-a718-4d3231ea2a55">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i488ea6d5e23043b399c268075239f4e0_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTYtMS0xLTcwMDM0_48425de9-9ba7-4020-8e57-35484ff02909">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308a3a88c11043999761321424b73595_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTgtMS0xLTcwMDM0_2599f567-d20f-4df6-8f45-55f64d7e402f">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b8bbd849704bb8a3082cf7ddf04d68_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTEwLTEtMS03MDAzNA_b4f5924b-b6a2-428e-8602-dd3ca75b6981">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i308a3a88c11043999761321424b73595_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTEyLTEtMS03MDAzNA_e3439be6-dd81-4da0-86b6-43059a805366">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50f737a17604260939c66ca049ac180_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTItMS0xLTcwMDM0_ce59f832-acbc-40ca-846f-02a4afc84746">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff780826f8d4410fb949c193f8b1f46c_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTQtMS0xLTcwMDM0_d46b3f02-e4bc-469a-a6b9-58967c76887f">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib50f737a17604260939c66ca049ac180_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTYtMS0xLTcwMDM0_f01e6d89-1235-484b-867c-fcbea7c6cb89">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7919279ca65c431e8605adcfc55e133c_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTgtMS0xLTcwMDM0_73821357-2c99-4794-841d-7fe3f580913e">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic304b1ad72744238ab93ae9de9dbbf07_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTEwLTEtMS03MDAzNA_5aadd8d9-c3dc-4a6e-a297-b6cf764b1f2b">667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7919279ca65c431e8605adcfc55e133c_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTEyLTEtMS03MDAzNA_63651660-56b5-4627-b65b-a42a9747e35c">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9722068a2d428f869481dca29dbdfd_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTItMS0xLTcwMDM0_37a729bf-d5e5-4135-8b02-64e4865657ff">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6fccf214b6547379cc0f5be19a827a5_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTQtMS0xLTcwMDM0_e6df681c-badc-47de-8d81-09e22b22198e">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f9722068a2d428f869481dca29dbdfd_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTYtMS0xLTcwMDM0_dc3e2333-2597-4c2d-acd3-efc6a802a59a">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb2ac2edd4547409e4873be0e8e70d0_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTgtMS0xLTcwMDM0_57e19366-9bf5-4141-941c-dd0b30feeefa">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34444c4d5b245d6882f29099655768f_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTEwLTEtMS03MDAzNA_09dcf44f-b161-405d-b7c6-b23effa60d0f">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcb2ac2edd4547409e4873be0e8e70d0_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTEyLTEtMS03MDAzNA_cc1d9b9a-d694-4b39-8375-e081eddb93d1">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0963689bca64f6898d7b2bf22ef5fc4_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTItMS0xLTcwMDM0_345f8b26-72b3-4e85-88bb-0248fa615f18">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6077b503ac1a407ca0aa969ab1a53c71_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTQtMS0xLTcwMDM0_16db02d8-a28f-40b6-95b8-4278514071f7">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie0963689bca64f6898d7b2bf22ef5fc4_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTYtMS0xLTcwMDM0_308e6fd9-b85a-41b3-a86e-b544210a31a1">11.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc182ac674a40cda02a21659912b0ac_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTgtMS0xLTcwMDM0_55b5a77d-db0e-491f-bef4-3db4a7b93b57">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1100853d86db4419993b4d34aeecc26f_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTEwLTEtMS03MDAzNA_7f2e5fd5-b1ef-4c76-976f-3464e5a05a7c">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idfc182ac674a40cda02a21659912b0ac_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTEyLTEtMS03MDAzNA_799ca3b0-4a99-422f-9284-040c69cb693a">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d2f83c9f3cf4e93b4ab482d7b240b68_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTItMS0xLTcwMDM0_6249cbb6-df8d-4c0a-b8bf-eb8146a52be0">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff83048ffc448809d919aa3cc1cdbf0_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTQtMS0xLTcwMDM0_8ffc7575-1a78-411a-9006-2f01c56c5564">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4d2f83c9f3cf4e93b4ab482d7b240b68_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTYtMS0xLTcwMDM0_6a07ccca-c1fa-4fe2-b6de-fbaf51d1e6c7">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0000c4d098c643cda7e8da1a1ce56862_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTgtMS0xLTcwMDM0_a8d9287c-36e4-4727-9643-53c09c5ae7f2">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfe4776943b47558791ca89120c5de1_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTEwLTEtMS03MDAzNA_fb701cf4-0197-4d7c-9adf-93b462fe5e79">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0000c4d098c643cda7e8da1a1ce56862_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTEyLTEtMS03MDAzNA_095cd716-4d4a-4d15-85fa-033cee7eeabe">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0128c7e2dc824abf8e6b5ba3df4232cc_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTItMS0xLTcwMDM0_18f813e4-a0b2-405e-a57c-78ed4eeea071">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic831591b74d94d658a1c241551842979_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTQtMS0xLTcwMDM0_af1905d4-6e83-4ad9-b1d6-2fc44ca4d239">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0128c7e2dc824abf8e6b5ba3df4232cc_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTYtMS0xLTcwMDM0_f05fa8dc-5468-4789-a819-eeac2519a807">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb8786f17a944249a713999b3b6e208_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTgtMS0xLTcwMDM0_c7c67098-9746-4bf1-a41e-a29dfad74003">805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf46a55a1dca41ffa4b84ec847aa7e7d_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTEwLTEtMS03MDAzNA_e6bfc57d-9797-490d-92de-60cb07cee0ea">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ideb8786f17a944249a713999b3b6e208_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTEyLTEtMS03MDAzNA_6b3bbef3-5116-4e16-b6f3-359a8da36fe2">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722cb51aca1543c3a7ae3b0a6fe127ff_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTItMS0xLTcwMDM0_28b1df94-f2f2-48d6-905d-76f885addfd4">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf6e5a27a774e869497e0aa2f53c5b9_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTQtMS0xLTcwMDM0_a22fff61-e667-45a8-b909-540df78868d2">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i722cb51aca1543c3a7ae3b0a6fe127ff_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTYtMS0xLTcwMDM0_2690dd4f-0751-4c25-a228-7d3a27c37cd2">10.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia015295d7f5a43dcaad4e1a68cefc54f_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTgtMS0xLTcwMDM0_d73898d8-cdc0-4121-af53-d64cb55ff24c">630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5400f99139394995bff032d46312fcac_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTEwLTEtMS03MDAzNA_b6acd520-09e0-4a1f-99e0-c5399c07b1a1">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia015295d7f5a43dcaad4e1a68cefc54f_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTEyLTEtMS03MDAzNA_b441564c-0ace-4d01-89f5-0a90464be528">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9845531e1544cfaa60c21e5946faa1a_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTItMS0xLTcwMDM0_60866027-a705-4d68-ab5e-510c9c9615e5">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7cdcd1f2024d52919c1a2b418c162c_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTQtMS0xLTcwMDM0_e9e824e7-1ba6-4fb2-9939-7534dca7734e">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id9845531e1544cfaa60c21e5946faa1a_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTYtMS0xLTcwMDM0_f328f46f-c799-49cf-885d-ece22fcbf3b1">6.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1743be59d8b4610a3d295d501005cd0_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTgtMS0xLTcwMDM0_c2aa7a24-b1fd-4abc-8d2b-2c43ea0fe295">1,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef90bedc87e45cea6e49532d1496f6d_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTEwLTEtMS03MDAzNA_47872085-6dbe-45c2-80ba-f0b5af6effb2">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib1743be59d8b4610a3d295d501005cd0_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTEyLTEtMS03MDAzNA_277dca3b-9917-4b52-b696-5f6eb11ea9dd">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3287b402551c4484b394de8276d293f9_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTItMS0xLTcwMDM0_e3fa47ca-b9a3-4d32-9864-00386455605d">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7662fd5ddc4846a3b1818f333fa21bc6_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTQtMS0xLTcwMDM0_f30df582-db9b-4fc6-a49b-b50a18c4a6e9">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3287b402551c4484b394de8276d293f9_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTYtMS0xLTcwMDM0_1e2cab09-a1c6-4135-be5d-a2d362f7eaa0">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a2ce0616b7406aaf58a444927e2047_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTgtMS0xLTcwMDM0_e7e8f7e0-9fdf-4b6f-ba32-e2738ec963c3">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib532fb9422ed4614a1eecad8c8435a75_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTEwLTEtMS03MDAzNA_e93eb347-9dea-4c74-b66e-ef1f6babdfb7">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if7a2ce0616b7406aaf58a444927e2047_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTEyLTEtMS03MDAzNA_57a0d4f3-a7da-42fa-9dd9-5f5cd17c01db">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc1c765754d4475a879977b61883766_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTItMS0xLTcwMDM0_985ae93a-982e-45d9-a6d7-e26f621b7c4b">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38876ff942eb4950811a685cde835ba5_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTQtMS0xLTcwMDM0_6ad8d2db-f9de-4659-895e-bfc9fe615c51">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6bc1c765754d4475a879977b61883766_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTYtMS0xLTcwMDM0_877c3e77-dea9-41f5-b9e7-e7e04315def6">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia710ad7cb9d04f4184dbd32294cd4f75_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTgtMS0xLTcwMDM0_ebd7e6c4-1bdd-417f-86ea-eeb113b21f7a">2,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25fca766f96443b785e425e523fbce14_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTEwLTEtMS03MDAzNA_9649c042-e93e-4b34-9fd0-020625e58bf4">2,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia710ad7cb9d04f4184dbd32294cd4f75_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTEyLTEtMS03MDAzNA_9c892447-1ee2-4021-9a3c-34608a03f9c1">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20dcb86296844dbda765eb7afdc78e2d_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTItMS0xLTcwMDM0_422f5fdb-cc96-4b86-96d5-c993d2df3cd3">2,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157d929ac5794703b29ad1b3d0e06f2e_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTQtMS0xLTcwMDM0_07c0a9aa-d7ab-4f0e-a982-17ffd82e9d9e">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i20dcb86296844dbda765eb7afdc78e2d_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTYtMS0xLTcwMDM0_e96c8d3b-8183-4430-8b97-0a68cfe095a8">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1993ccddfb034873a36b94a7f7017ddd_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTgtMS0xLTcwMDM0_feafd4ec-14bd-4af9-93fd-72928e8524f1">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4c53848f34480d9a9a1d516da71087_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTEwLTEtMS03MDAzNA_1f82e9cc-9915-4159-b7e2-1b80a4b8fd48">4,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1993ccddfb034873a36b94a7f7017ddd_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTEyLTEtMS03MDAzNA_357cbee4-b1ed-4605-82d8-abc8c1d6edcf">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b7edee30e3d480da3deca7eb3ed8837_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTItMS0xLTcwMDM0_a667bf70-63d3-4867-9756-d86746b2eee7">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908f6839346c4686938c7732821b75a8_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTQtMS0xLTcwMDM0_fb3dff2d-f25c-4f6d-9105-aaf1764815e7">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6b7edee30e3d480da3deca7eb3ed8837_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTYtMS0xLTcwMDM0_483cdc6a-7ab0-445f-83fe-45c73ec548af">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia717abc404b146b3a20cf3cdbee20322_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTgtMS0xLTcwMDM0_d19e49d9-5934-46f8-b0eb-dc1805b2538b">871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8fbc02017884ac9a57e155715db8909_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTEwLTEtMS03MDAzNA_6dee16aa-0749-42b2-80c2-2efd3bf5ddb4">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia717abc404b146b3a20cf3cdbee20322_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTEyLTEtMS03MDAzNA_719449c6-46de-4455-a000-5ee65bff1052">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d39404482e4c219c8780425fba1375_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTItMS0xLTcwMDM0_af40f53b-2853-40af-8448-870e558c0089">702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64782304ba44edc84ba60d27fa2279b_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTQtMS0xLTcwMDM0_4eaf6527-3751-4fe3-9e9a-3fd115a19fc9">708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i21d39404482e4c219c8780425fba1375_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTYtMS0xLTcwMDM0_81ae0977-a252-411c-827d-6fab15cb4a83">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31026e003cb1415fbad582c204df9190_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTgtMS0xLTcwMDM0_bf8ec13f-6fcf-4f98-9a79-856fcc04a8a2">1,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b0b233fad44191b424a24fece33b51_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTEwLTEtMS03MDAzNA_5ce225cf-6f21-4777-8a89-069336af02e8">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31026e003cb1415fbad582c204df9190_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTEyLTEtMS03MDAzNA_69a1ffda-da56-4e87-8923-a7acf57e976d">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4466b00cc249fb98151e07aa84fbad_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTItMS0xLTcwMDM0_6bfdf9ac-3c30-4cc9-bddf-f8cc8e9e91fe">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a2012297b041c7b1efa586c301f494_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTQtMS0xLTcwMDM0_5501c7f0-90b7-4bf7-a807-e3a590c33c31">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3a4466b00cc249fb98151e07aa84fbad_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTYtMS0xLTcwMDM0_c457cde8-0ba6-45c7-a82f-3c25c62ed8f7">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97c25d98536140f3b69ae8c88acf7a37_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTgtMS0xLTcwMDM0_d395a265-764a-4b87-845c-dcabc89c0e9e">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586d3a14b6c740d8844f2849c4eb2582_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTEwLTEtMS03MDAzNA_537b19d9-c30f-46b2-a421-f97986ab3592">2,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97c25d98536140f3b69ae8c88acf7a37_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTEyLTEtMS03MDAzNA_95b029fa-26e4-43b4-928a-e8a968a151c8">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i443117f5e241456285fb9a55936853e7_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTItMS0xLTcwMDM0_5e265b0e-6246-4544-8542-e56e1e8a1570">538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01251da528b4f90a10a4142620a65cd_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTQtMS0xLTcwMDM0_abf7de89-583b-414c-b7cd-ec3e252c3c2f">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i443117f5e241456285fb9a55936853e7_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTYtMS0xLTcwMDM0_9c5b2ac6-3029-4d8e-bba2-9887b48d43fd">6.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfe8df60f4743ec99ca6904a5e64756_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTgtMS0xLTcwMDM0_62ae5f9b-cc62-445c-a39b-06b4ab0c333f">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fec44642f34c5099c21747e3250cb1_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTEwLTEtMS03MDAzNA_a1b91a9c-cb29-4481-9ce7-59bed872e95a">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9bfe8df60f4743ec99ca6904a5e64756_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTEyLTEtMS03MDAzNA_d8c8be63-2beb-483d-b1ba-fcb9ea443b59">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412aa3432fcf467f8fd19c46b727c491_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTItMS0xLTcwMDM0_1e099bc6-ed29-42c5-a78c-b3a1045d462c">756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia390d2427f664929bec44ea56be4ec81_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTQtMS0xLTcwMDM0_d4022ee9-f9f8-4d95-910d-c8610d9c591c">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i412aa3432fcf467f8fd19c46b727c491_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTYtMS0xLTcwMDM0_52ddcf61-2e20-4d5b-af53-82ce49ff8ebe">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8baa768ee1284c7e99d6ee829ff2c08a_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTgtMS0xLTcwMDM0_bb1124bd-a161-48b9-8ac9-f852629974f7">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e11d4f4c34c41b5be8ae617dc5e9c1d_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTEwLTEtMS03MDAzNA_65cbc530-f60c-4ce5-9b52-aba56ab4b891">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8baa768ee1284c7e99d6ee829ff2c08a_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTEyLTEtMS03MDAzNA_c394819d-ec9e-4502-a1df-1c1c36276f16">0.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6fda5fb73a341449bfac9d8fb7a268f_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTItMS0xLTcwMDM0_0c972253-28fc-4fcb-931d-83cd37b73903">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed73e5ea20c4b98b366ff0b993278cc_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTQtMS0xLTcwMDM0_3a5dadd1-74bd-42a4-88f8-a75af687d61f">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic6fda5fb73a341449bfac9d8fb7a268f_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTYtMS0xLTcwMDM0_4f48042c-25db-4fcb-8c89-84970472f8e8">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f8de01c4be45768b397e71429b87f0_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTgtMS0xLTcwMDM0_8c82f24a-033e-4a46-8759-693b3f0aca8c">2,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68e9b1789db54a1992eb64fc846195f1_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTEwLTEtMS03MDAzNA_6b69d2cb-a982-4351-b848-8290a08a8904">2,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i64f8de01c4be45768b397e71429b87f0_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTEyLTEtMS03MDAzNA_2d7e4ad8-170f-47b3-ab15-17f70bc59d4f">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569ace16f96641559bb1b2d217a5f3ee_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTItMS0xLTcwMDM0_46713888-7c32-4bf3-b93d-0fd9d79b037b">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3982de94b47b42dea86bcede03224217_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTQtMS0xLTcwMDM0_ed1ba9e3-cb82-43e3-b7d6-8a5b23e555c1">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i569ace16f96641559bb1b2d217a5f3ee_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTYtMS0xLTcwMDM0_50faad4b-2443-4c99-853b-f42b6814a539">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e3610796c24f389098231002fd25b3_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTgtMS0xLTcwMDM0_6e3a931e-1937-48d4-92ed-d3e2ae02de0b">1,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i441e7039e08a47fcbf82ede9c2ebfbe6_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTEwLTEtMS03MDAzNA_34e731c1-c388-4601-9526-a2c40b657133">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80e3610796c24f389098231002fd25b3_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTEyLTEtMS03MDAzNA_0b4a1e73-ae42-4bd3-9dc3-eed1334c8816">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i324894961943456d92139b57181b5bb9_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTItMS0xLTcwMDM0_6f058e78-0e3f-4481-81bc-e3720fdf1c82">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281e3cd9deea4daaacf98eaf97ea934e_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTQtMS0xLTcwMDM0_3cb8a508-63a6-4001-a92a-00fbeceb584e">716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i324894961943456d92139b57181b5bb9_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTYtMS0xLTcwMDM0_635e2a09-e019-4b19-8ab3-70ac267064a5">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016776eee5714891a0386a16d5557a03_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTgtMS0xLTcwMDM0_db6f1446-c3bb-48b1-8e03-0ea54c620cb5">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747469c41b2a43deb3981557e85294f3_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTEwLTEtMS03MDAzNA_2f857373-3cc3-412f-beb6-7fa194151e83">1,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i016776eee5714891a0386a16d5557a03_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTEyLTEtMS03MDAzNA_880edaad-31f1-4878-94c9-7e79d3eed47a">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54e1c7c7e8dd48959fd8bf1743fc8e80_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTItMS0xLTcwMDM0_2fa7d14d-dad0-46ff-9217-161501b30547">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a2fceceece40e9b7f64f083218ee49_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTQtMS0xLTcwMDM0_f9a5eb90-61ec-4c28-818a-8858584ed8e1">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54e1c7c7e8dd48959fd8bf1743fc8e80_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTYtMS0xLTcwMDM0_d366de00-db55-4dbb-a1e2-423e10b38ab4">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bdb0db58854e95a85e98d94100f662_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTgtMS0xLTcwMDM0_7a14767e-c87a-44a8-b071-d7fc0b934f10">2,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed2d31b27e045ab82b125179a98301e_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTEwLTEtMS03MDAzNA_a3cdb3a0-c20e-4502-bb19-e0225a26f829">2,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4bdb0db58854e95a85e98d94100f662_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTEyLTEtMS03MDAzNA_a34fa33e-4fa9-4464-a9cb-fae77323b2df">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9584ac8d54c6468f80de0bb9c19b14e8_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTItMS0xLTcwMDM0_d53c13bb-7aef-4327-bb8b-bd62c5c7cbe1">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0672b25c90a4d09917d157086a6428a_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTQtMS0xLTcwMDM0_0bdc9143-27a9-4767-9697-4edea0d4a9c8">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9584ac8d54c6468f80de0bb9c19b14e8_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTYtMS0xLTcwMDM0_8c843225-8fbd-4827-9d3c-fa88de2338fa">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9696d83a57d4dacbe080d0f1444e529_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTgtMS0xLTcwMDM0_145a28c0-519c-4543-b843-6ac21612da9b">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b1a88c0fa4b44b794e579ac382449d3_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTEwLTEtMS03MDAzNA_c6b5b2f6-1b32-46bd-b119-bb68dc8124cf">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9696d83a57d4dacbe080d0f1444e529_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTEyLTEtMS03MDAzNA_821d8cac-826b-4f29-8323-186bd68a4654">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a92fd5c525643629fe7ff73a1af3c2f_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTItMS0xLTcwMDM0_e4fb7aed-27ad-446c-ac63-3db02c23e779">519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfe3e4294df4883a39ec285886b1913_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTQtMS0xLTcwMDM0_511d41b9-d6c1-4d16-a5ff-ba9cf513c18f">517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a92fd5c525643629fe7ff73a1af3c2f_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTYtMS0xLTcwMDM0_192aead0-288b-4409-a2b8-5f260525002d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37fb7ee236248a882538282edd2b353_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTgtMS0xLTcwMDM0_e2e3cada-be76-4899-bdc7-45d6a8aa8831">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f48482859234f7bac2ce55a3818dc23_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTEwLTEtMS03MDAzNA_c32382e0-4908-456a-af6f-60e64a4bc084">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib37fb7ee236248a882538282edd2b353_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTEyLTEtMS03MDAzNA_dfd4df96-f109-4c52-a4a7-fbf541f9209f">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbec59e0ece4791b17dcc2fcc6131ef_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTItMS0xLTcwMDM0_93190fc9-5399-479d-96e5-a910b9e9910d">894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f938a541ab4334bc462b1f7fa4c89b_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTQtMS0xLTcwMDM0_2f306019-15b4-4bb0-965c-9de3598245c4">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebbec59e0ece4791b17dcc2fcc6131ef_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTYtMS0xLTcwMDM0_e210ce9c-d8bc-44b4-adf3-3dc64ea07e9d">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7a46d82f594dea958391e3f85c7adc_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTgtMS0xLTcwMDM0_35b03601-6c11-43c5-ba3d-9f80c4fb00a3">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b88bda5d09242278cca53b9ca866611_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTEwLTEtMS03MDAzNA_2e696e99-22b6-4e2e-8207-982c60d332e2">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d7a46d82f594dea958391e3f85c7adc_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTEyLTEtMS03MDAzNA_aab71efc-7c75-4d06-8e51-448900fbd9dc">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i7238a46d257547b19e53f9198b750e18" continuedAt="ib607ce15c8fa454cb404b1639c8580b9"><ix:continuation id="ib085e6e55c814de98868511605b46163"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f87d928b364165a9ce065e74fb63ce_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTItMS0xLTcwMDM0_0d89526f-39a6-49f3-82ee-f10e52724910">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4109ba0613344384a303908d2b52ff33_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTQtMS0xLTcwMDM0_c6c87df9-c3f3-4122-b4f1-305a912fcf4a">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11f87d928b364165a9ce065e74fb63ce_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTYtMS0xLTcwMDM0_799e056c-27e0-4eff-a0f1-6f609cf2c971">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39cea1d7d42a46b8aa131cde5e274282_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTgtMS0xLTcwMDM0_0b1bc9d2-2a00-48bd-a834-187bec28c0fb">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5523f7460fd948f08ef26a334123472d_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTEwLTEtMS03MDAzNA_dafc3ed4-d4e8-461e-b2e4-853ef0b464ff">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i39cea1d7d42a46b8aa131cde5e274282_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTEyLTEtMS03MDAzNA_96d9de95-21b8-49e1-865a-ea391449096b">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01bb5db42274474b71ecf23309c444a_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTItMS0xLTcwMDM0_314b3392-94cb-4ea8-acd6-89e13f6a72ff">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc6145fd3894d74b3ce85f802f90390_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTQtMS0xLTcwMDM0_1cc64213-4928-42e1-86d7-bcfac0d2ea49">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie01bb5db42274474b71ecf23309c444a_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTYtMS0xLTcwMDM0_11d4c3ef-f4bb-4257-b7f4-d4ac6f7f3272">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4b2747819f470683e7967d8ae774bd_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTgtMS0xLTcwMDM0_51257226-28f7-4d13-a1b9-7928f35919a3">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8edf9410e7d643b19bc9451e934d68de_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTEwLTEtMS03MDAzNA_b96de444-980f-4503-b945-9c196ab78870">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f4b2747819f470683e7967d8ae774bd_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTEyLTEtMS03MDAzNA_cbe85ee9-d9c8-41f1-bede-3a57ae8d9f4c">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce7bb1e40a34cac933a9900b74f1bbd_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTItMS0xLTcwMDM0_05809f96-8ea7-47f2-8d34-8e07f9463a77">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ea13492db24868803369c77f57b645_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTQtMS0xLTcwMDM0_09cfd999-4cd2-47d6-9dac-294839f20885">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ce7bb1e40a34cac933a9900b74f1bbd_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTYtMS0xLTcwMDM0_b286856c-34b7-408b-a4dd-8380ea0233e9">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a69a34fd0c94f13b4b310835aa606ff_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTgtMS0xLTcwMDM0_4d28483f-0f80-42e1-9415-2754c439aa17">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ee68091377424783ed3c9953196597_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTEwLTEtMS03MDAzNA_aede987f-8b89-4cc3-bf98-5b7b86961012">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a69a34fd0c94f13b4b310835aa606ff_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTEyLTEtMS03MDAzNA_a6603f66-1ce6-4531-98f1-0914cd6575db">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33c4da904049bc8c9bfff387e3375d_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTItMS0xLTcwMDM0_80403384-0a37-49d2-a9e7-79a56a121812">3,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36ad544dbed4b9fba4cef602aef272a_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTQtMS0xLTcwMDM0_ac2f9e2f-7459-466e-bb59-0ae2867c74b3">3,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e33c4da904049bc8c9bfff387e3375d_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTYtMS0xLTcwMDM0_c81fc747-09a0-4f8c-9226-a884318d635d">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd3cc31f314437293f6c8d05caf543b_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTgtMS0xLTcwMDM0_97395dc0-cdc2-4501-9573-b20f2de15eca">6,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841ed2eb0fd747d19d8bd3831cfcc965_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTEwLTEtMS03MDAzNA_08f8b163-999f-4173-9f95-8de3d99ac57f">6,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fd3cc31f314437293f6c8d05caf543b_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTEyLTEtMS03MDAzNA_c4078468-3114-4887-aaf9-106c8371b2d3">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1267f9a793dd4838bee913c7e7f1bc85_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTItMS0xLTcwMDM0_d1ab6752-9b86-46b3-8bc9-5afce5212b68">3,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57cda4c770ae48fc874d0e1e0a6aa499_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTQtMS0xLTcwMDM0_d80aaa0b-362f-47da-9abe-60c88c0c6749">3,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1267f9a793dd4838bee913c7e7f1bc85_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTYtMS0xLTcwMDM0_df85a7b4-4526-4e8d-9cfa-f5bc0da8c38c">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce8cec453c54166a59e25d4837a056c_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTgtMS0xLTcwMDM0_b343432f-3359-4791-b40c-c0375576dd1c">7,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc3d45f3f941dab28721d910f5e49f_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTEwLTEtMS03MDAzNA_d48721a4-5fad-412a-9e50-f49d63e19bfa">7,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icce8cec453c54166a59e25d4837a056c_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTEyLTEtMS03MDAzNA_a582a5c1-6c4f-4025-a779-14bd590d9afd">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f0cbac43d94b8bb57a7d434308ab35_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTItMS0xLTcwMDM0_e116f4be-256c-4dd7-b426-1bd62f2940ab">6,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27e8d4536d8e4ea7a2ed2551f3af3104_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTQtMS0xLTcwMDM0_827bc7fa-b704-48ac-9404-b862b706da25">6,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i22f0cbac43d94b8bb57a7d434308ab35_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTYtMS0xLTcwMDM0_ea82fe6a-fc20-45f9-a1b2-4dd0b87e41af">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTgtMS0xLTcwMDM0_5ec423a1-f44c-4277-ad31-bfc5416eac2c">13,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTEwLTEtMS03MDAzNA_d785815f-ace1-4b0a-a749-250f2aef78cf">13,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTEyLTEtMS03MDAzNA_523d2ef1-74c8-4c2f-83f0-675210e62a06">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTItMS0xLTcwMDM0_39e0b36e-7ede-4c74-a6f7-12720545c243">12,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e8a3362cdda49a18367d18f349e957d_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTQtMS0xLTcwMDM0_92fd4463-e027-40db-ba5f-be08ebb2e30b">11,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTYtMS0xLTcwMDM0_b44de36a-a335-48ee-9518-b118af48d827">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c08b8a10da4041816e159343bf7063_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTgtMS0xLTcwMDM0_c5fae355-c817-47e1-8ecd-ce5c85b31783">23,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39103b4eef404909b321cdc17486f7ca_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTEwLTEtMS03MDAzNA_48ddc344-520f-406c-8249-946d9beefcc7">23,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96c08b8a10da4041816e159343bf7063_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTEyLTEtMS03MDAzNA_c7dfdc0b-3e98-4486-ab7f-354b8e3c4eed">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc5007223004e44b9e3f6016636f4eb_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTItMS0xLTcwMDM0_c57df79a-1e45-4168-bc14-e343751f276d">11,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6180f4c8a3a141b0b11ef6eea2dd5c8e_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTQtMS0xLTcwMDM0_c8392d3c-3141-4f77-ac6f-ba035d3ccfa0">11,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedc5007223004e44b9e3f6016636f4eb_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTYtMS0xLTcwMDM0_01302543-ea1f-444b-92ed-2ccb79ea26e0">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee0e58c2ebe74103acd746853588d46a_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTgtMS0xLTcwMDM0_9c6db14a-ee6b-4d99-988f-5480e96fc6e3">23,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id809ffa3e19b46f69f68ae5cd89fd702_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTEwLTEtMS03MDAzNA_3d4383a7-0f92-4f7f-a856-5349f031ce17">22,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee0e58c2ebe74103acd746853588d46a_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTEyLTEtMS03MDAzNA_9f72c2b5-2d3e-479f-8fa7-5da19252f023">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTItMS0xLTcwMDM0_800a398d-ad36-496c-b85d-fba17a2f237e">24,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTQtMS0xLTcwMDM0_3d753470-b32c-4603-a562-388f31f1c547">23,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTYtMS0xLTcwMDM0_015ac2c6-9523-41ec-ba0d-2dc699a7c94e">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTgtMS0xLTcwMDM0_efaf433c-e907-42da-be96-cd96d6bf4c32">47,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTEwLTEtMS03MDAzNA_cf3a1cfd-4294-4f1d-9555-8c68c4a93a55">45,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTEyLTEtMS03MDAzNA_024a6b63-cd93-4504-9d94-733c60c7ce38">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Approximately $<ix:nonFraction unitRef="usd" contextRef="i1c0ab60765214aed9b7662351556aa75_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTkz_8d7f0c98-9077-4062-81df-239e6f556ce4">0.1</ix:nonFraction>&#160;billion in the fiscal second quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="i95dd4291b011442fb7dc8d71ff5ffe4b_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTk0MQ_ff8dca22-993e-4508-91b1-a1ce421bf1c2">0.2</ix:nonFraction>&#160;billion in the fiscal six months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Previously referred to as Medical Devices</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjk1OA_4209aba6-1f8f-49b9-96f8-a1450af71f02" continuedAt="ifd44686cb9884c2ca1c138c0789f04d2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:36.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi0yLTEtMS03MDAzNA_007c63e3-744f-4ba6-9686-a043bed92f37">784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2da2b15d204fb7b695aa3bfc830f42_D20210405-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi00LTEtMS03MDAzNA_3688d36c-3278-4329-b8a7-82b304875f39">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi02LTEtMS03MDAzNA_868c203b-2790-4dc8-ab6f-f293034a09ea">9.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi04LTEtMS03MDAzNA_853fbd43-f272-4635-a53b-c245c5c82a0e">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b15286f874144618839786849ea1437_D20210104-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi0xMC0xLTEtNzAwMzQ_6d772ebd-8fae-46e4-8563-27dbe504dba1">1,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi0xMi0xLTEtNzAwMzQ_36e17b42-c505-4ef7-bce3-8a8f423b9428">13.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy0yLTEtMS03MDAzNA_b9f264a8-ce1b-4369-9834-93f2d24ad4bd">4,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90adf511b62e43ed9a3312bbc6ec0892_D20210405-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy00LTEtMS03MDAzNA_df93318e-7bd6-488e-ac9a-87c1cfe65461">4,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy02LTEtMS03MDAzNA_9c07686d-6ac4-450e-8224-56b9be350bd2">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy04LTEtMS03MDAzNA_c8a87afe-e311-431b-826b-4245f41661d5">8,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id349b0a0d08341149ec80073155e33e2_D20210104-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy0xMC0xLTEtNzAwMzQ_c9cac312-a883-4ec4-af44-9667f14f6ad9">9,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy0xMi0xLTEtNzAwMzQ_86d48530-7ccc-42dd-a6ab-04147dc95e77">11.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC0yLTEtMS03MDAzNA_78fa3858-87c1-485b-ad3c-37532e7830f0">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7da5b6f21e243f1acad5577402788da_D20210405-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC00LTEtMS03MDAzNA_3f17b02b-cd2a-45d1-b8f3-8351352274df">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC02LTEtMS03MDAzNA_2cff0db8-50b7-4ec9-a08e-abb7aea588e6">34.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaff25a8ee4a446eafc7e7a139993836_D20220103-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC04LTEtMS03MDAzNA_7b3a22b2-d681-4202-8033-c645c5367726">2,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b390e9d694497896d1ac279e6a0013_D20210104-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC0xMC0xLTEtNzAwMzQ_1317e0db-73ab-4f2d-beb2-0115f9621690">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaaff25a8ee4a446eafc7e7a139993836_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC0xMi0xLTEtNzAwMzQ_26d75125-2732-419c-ae00-3b8eeb5b6612">22.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529d608738614ae0a943f58551da20f0_D20220404-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS0yLTEtMS03MDAzNA_7e38552c-eda3-4d94-9a35-2b86e0756e89">6,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06cae828408f49239c6f174bf1c334a3_D20210405-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS00LTEtMS03MDAzNA_86d4550d-4129-4b14-8dc4-3b9cba5c33fb">6,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i529d608738614ae0a943f58551da20f0_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS02LTEtMS03MDAzNA_13045900-6ac3-421e-831a-1559b059e502">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee05ee77bf344a68295fa0ac185a55f_D20220103-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS04LTEtMS03MDAzNA_db31d90d-73be-4641-8ab1-4c6384338dbb">12,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d86df693ac4fec81410c7eea2535c2_D20210104-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS0xMC0xLTEtNzAwMzQ_f1cc784d-4498-4af8-97fd-b0d6739d84ff">14,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifee05ee77bf344a68295fa0ac185a55f_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS0xMi0xLTEtNzAwMzQ_43a4d41f-b997-4c12-b2c5-03b1946c9f59">14.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd132153d9614629bc9c8135b8b92864_D20220404-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNi0yLTEtMS03MDAzNA_d8b4b206-2500-41be-8b18-338adda422d6">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e2458177a343e08824dfb1c6bd2f07_D20210405-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNi00LTEtMS03MDAzNA_dc7d775f-3da9-4c79-8a34-4722eedde222">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bcfd345e66e46298c5faf33123c8744_D20220103-20220703" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNi04LTEtMS03MDAzNA_49d53ce5-361b-4bc1-8718-57f2c2810bdf">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2da094b787c4b54b4e09b39c3f9a9f4_D20210104-20210704" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNi0xMC0xLTEtNzAwMzQ_e5113a3a-158a-4790-99a1-819708bb529c">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNy0yLTEtMS03MDAzNA_65961bdb-5b5a-46c0-86b7-4b540ee9566c">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2da2b15d204fb7b695aa3bfc830f42_D20210405-20210704" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNy00LTEtMS03MDAzNA_1f2b0090-4a11-4212-b1cb-481da5f950c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNy04LTEtMS03MDc5OA_893e2b00-4e28-4360-9f5c-688607b8fc52">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b15286f874144618839786849ea1437_D20210104-20210704" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNy0xMC0xLTEtNzA4MDg_044baccb-f8b1-43b1-a0ce-7cf8b662e17a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC0yLTEtMS03MDAzNA_a07de4d5-f752-46dc-a1e7-0a4687ecb400">5,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC00LTEtMS03MDAzNA_8f6e8a26-0bb1-4327-ad95-9664072f28c2">6,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC02LTEtMS03MDAzNA_ad737cc9-2a10-487e-b005-968e2993884f">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC04LTEtMS03MDAzNA_3429230a-be16-486f-8666-736ab1fdbb10">11,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC0xMC0xLTEtNzAwMzQ_99e7cc0b-0fa8-42af-897f-1d3789c01534">14,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC0xMi0xLTEtNzAwMzQ_e38d19e3-24cb-4866-ae4f-34ca7c523a45">17.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*The 2021 fiscal second  quarter and six months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfODYx_6aa644a2-5db7-4fad-9f99-35da1a1236d3">0.1</ix:nonFraction> billion in both the fiscal second quarter of 2022 and 2021 and $<ix:nonFraction unitRef="usd" contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMDg3NQ_382f207a-bdec-413a-9332-651f1ae01f81"><ix:nonFraction unitRef="usd" contextRef="i7b15286f874144618839786849ea1437_D20210104-20210704" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMDg3NQ_3fba85ca-b79d-4073-a3d2-1570993f8109">0.2</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal six months of 2022 and 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i1a2da2b15d204fb7b695aa3bfc830f42_D20210405-20210704" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjIzMw_18284545-02c7-4651-977f-1fb908f5af76"><ix:nonFraction unitRef="usd" contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjIzMw_5590edc6-5938-4246-be4b-88217c418c7e"><ix:nonFraction unitRef="usd" contextRef="i7b15286f874144618839786849ea1437_D20210104-20210704" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjIzMw_627bf815-252a-4784-a07f-40fab29a0395"><ix:nonFraction unitRef="usd" contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjIzMw_c2605bdc-f498-4adf-8503-9ec84f2a8a5e">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal second quarters and fiscal six months of 2022 and 2021, primarily for talc related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $<ix:nonFraction unitRef="usd" contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703" decimals="-8" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfOTQ5_356d5a8d-c0af-40f1-a4d4-5a281f8eaa1f">0.6</ix:nonFraction>&#160;billion in the fiscal six months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA2Mg_3b8dca50-7674-49a5-85a1-3e06cf222510">0.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i90adf511b62e43ed9a3312bbc6ec0892_D20210405-20210704" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA2OQ_30374733-bf2c-44d1-ba75-3f5bc470783c">0.8</ix:nonFraction>&#160;billion in the fiscal second quarter of 2022 and 2021, respectively. Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTA5MQ_9a38cd86-0d0d-43a1-902c-b1659e1c35ff">1.5</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="id349b0a0d08341149ec80073155e33e2_D20210104-20210704" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTEwNQ_dc7db8f8-1f05-4621-9f5b-8a269cf1a460">1.7</ix:nonFraction>&#160;billion in the fiscal six months of 2022 and 2021, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the fiscal six months of 2022, the Company recorded an intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i4a9a7ebb719f437a941405e59e3f7376_D20220103-20220703" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTIyNg_b0434c7e-cfee-4bf3-bd27-46b6ae26f4f8">0.6</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A loss of $<ix:nonFraction unitRef="usd" contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703" decimals="-8" sign="-" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTU5NQ_187d8bff-5264-4904-b04d-ba7f6464f50a">0.1</ix:nonFraction>&#160;billion and a gain of $<ix:nonFraction unitRef="usd" contextRef="i90adf511b62e43ed9a3312bbc6ec0892_D20210405-20210704" decimals="-8" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTQ0OQ_30c165a3-f0ef-40fb-8638-d324f2ae0cab">0.2</ix:nonFraction>&#160;billion related to the change in the fair value of securities in the fiscal second quarter of 2022 and 2021, respectively. A loss of $<ix:nonFraction unitRef="usd" contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703" decimals="-8" sign="-" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTQyMQ_7f1f68dc-4b13-4566-bd02-ac92442c4297"><ix:nonFraction unitRef="usd" contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703" decimals="-8" sign="-" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTQyMQ_b30e8f7d-76d0-4794-8049-fb3493faff3f">0.5</ix:nonFraction></ix:nonFraction>&#160;billion and a gain of $<ix:nonFraction unitRef="usd" contextRef="id349b0a0d08341149ec80073155e33e2_D20210104-20210704" decimals="-8" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTQzNQ_5a4ede07-f70d-4aa3-ad92-3913521a0f23">0.1</ix:nonFraction>&#160;billion related to the change in the fair value of securities in the fiscal six months of 2022 and 2021, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ib607ce15c8fa454cb404b1639c8580b9"><ix:continuation id="ifd44686cb9884c2ca1c138c0789f04d2" continuedAt="if7edf9ad388f478f8d1e355f38a28f98"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $<ix:nonFraction unitRef="usd" contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703" decimals="-8" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjQzNA_621497af-65da-48cd-8e5f-1e4cf134478f"><ix:nonFraction unitRef="usd" contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703" decimals="-8" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjQzNA_93f1dbfb-d3a8-479f-b640-9b8e3692f394">0.2</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal second quarter and fiscal six months 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal second quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $<ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-8" name="jnj:AmountPrepaidAndDueToManufacturers" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjE4Mg_ad2cd455-9a09-47bb-aa1a-28040ce82ff8">0.9</ix:nonFraction>&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjYxMQ_41673951-c187-4ea7-853d-a4a2ace78ad6"><ix:nonFraction unitRef="usd" contextRef="iaaff25a8ee4a446eafc7e7a139993836_D20220103-20220703" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjYxMQ_f142eae0-3065-4af3-8d56-a277fe2432ea">0.3</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal second quarters and fiscal six months of 2022 primarily pelvic mesh related costs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjY3MQ_5aaa8d60-89a1-4949-967d-7a21855177e6">0.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTY4MQ_2af5cdc2-871d-4d52-8d96-a3c4a8916f0d"><ix:nonFraction unitRef="usd" contextRef="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTY4MQ_ba442ba7-4bf0-4c12-bc9a-b9b22484bde6">0.1</ix:nonFraction></ix:nonFraction>&#160;billion in the fiscal six months of 2022 and 2021, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjc0Mg_cef43cf2-841d-4536-a75e-b4aab77313a2"><ix:nonFraction unitRef="usd" contextRef="ia7da5b6f21e243f1acad5577402788da_D20210405-20210704" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjc0Mg_efd782aa-82ae-490d-8093-7825b1652860">0.3</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal second quarter of 2022 and 2021 and $<ix:nonFraction unitRef="usd" contextRef="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTYwMQ_2f79dc5f-194c-48c5-bc20-c0e910a4ca14"><ix:nonFraction unitRef="usd" contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTYwMQ_af2bf537-0922-4b65-9ebc-45b7d0ff7a46">0.5</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal six months of 2022 and 2021.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="if7edf9ad388f478f8d1e355f38a28f98" continuedAt="i4db0f85f39a743b887ab9dabbdf9f752">(4)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4db0f85f39a743b887ab9dabbdf9f752"> Amounts not allocated to segments include interest income/expense and general corporate income/expense.</ix:continuation> </span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjkzNg_396f691c-b5d0-4a49-907b-8860cdc915f3" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi0yLTEtMS03MDAzNA_8b557745-5429-4f92-82dc-ccdb99a7a102">12,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e8a3362cdda49a18367d18f349e957d_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi00LTEtMS03MDAzNA_f9a604ee-d185-4002-8ee4-fd0e70ca7290">11,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi02LTEtMS03MDAzNA_88ac9658-287d-4c1d-9dff-1f7c8cf60700">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c08b8a10da4041816e159343bf7063_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi04LTEtMS03MDAzNA_ad75dc3e-95ab-45de-9a9e-3a46622f84f5">23,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39103b4eef404909b321cdc17486f7ca_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi0xMC0xLTEtNzAwMzQ_430611fd-55cf-4b54-aa22-04e78d636fc3">23,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96c08b8a10da4041816e159343bf7063_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi0xMi0xLTEtNzAwMzQ_d6738035-118b-4332-bb21-0bbcd8b53ede">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a725035e4c3410583da06507280fe59_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy0yLTEtMS03MDAzNA_54cf2669-3d74-42b6-8581-4492e88db611">6,085</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d3c1f4234a402fa97cbd81b084f556_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy00LTEtMS03MDAzNA_da997ece-fd4e-422b-8c5d-a3957fc6b931">5,668</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a725035e4c3410583da06507280fe59_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy02LTEtMS03MDAzNA_a246e9e3-e767-489c-bbd7-68f58450c3cc">7.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ac66e3eb004358ab735bbc8456405e_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy04LTEtMS03MDAzNA_6a74599d-5037-42ed-90ac-7c1c5d1c6e23">12,109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6b7844077b4016b45ccbe380ad3dc4_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy0xMC0xLTEtNzAwMzQ_476efdfc-0b21-4cf4-891e-17d2edf5020d">11,082</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1ac66e3eb004358ab735bbc8456405e_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy0xMi0xLTEtNzAwMzQ_b7ac284e-3fc1-44ab-9a41-7853ee4a363b">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2790d59614147c487677304230bb1ae_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC0yLTEtMS03MDAzNA_e952f5bb-aa1e-4cc9-9bf0-02e69e5fe069">1,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8084c9e8e16045e1940be548a1af4fcc_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC00LTEtMS03MDAzNA_37a94a78-75ca-4610-98ce-bfc53a402d09">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2790d59614147c487677304230bb1ae_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC02LTEtMS03MDAzNA_7c9d2ef8-9efd-4a2a-9399-47e125c02768">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i501ea63e8e9f4d7d9d498ec389c88591_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC04LTEtMS03MDAzNA_c5f9e802-8b05-47d6-98e4-ee4b4df7ecbc">3,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i241ce185147a489fac065e3d478f8bc6_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC0xMC0xLTEtNzAwMzQ_e2d879fc-d1ba-476a-81ea-600258772820">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i501ea63e8e9f4d7d9d498ec389c88591_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC0xMi0xLTEtNzAwMzQ_ffce9fc2-ae4f-45e1-bcb4-78f9f609bcdc">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5646a565d4a4fdf8f17b8e7a2cf4a6c_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS0yLTEtMS03MDAzNA_dffc0e13-e959-4a4f-b8dc-7fc4a3b3822b">4,202</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c7a6815d0144fa3bda521f8ed93043c_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS00LTEtMS03MDAzNA_40d5115a-9032-42a1-aa2e-78754d16db93">4,358</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id5646a565d4a4fdf8f17b8e7a2cf4a6c_D20220404-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS02LTEtMS03MDAzNA_fea6389d-98fe-456e-8897-caa665d0a73e">3.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia685c80f08574eeea6722e02543f738a_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS04LTEtMS03MDAzNA_3d9a797d-c452-4e2c-abc6-fc411f8b4dd0">8,708</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9d069efa93465f945738a484e31e5e_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS0xMC0xLTEtNzAwMzQ_3ce3f2f1-4910-4096-9463-4b8643ad1b31">8,730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia685c80f08574eeea6722e02543f738a_D20220103-20220703" decimals="3" sign="-" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS0xMi0xLTEtNzAwMzQ_47a2ba9c-b77f-4544-8930-e5f2799d44cf">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi0yLTEtMS03MDAzNA_8c21ca0a-020e-4746-ab86-e6a907dbde22">24,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi00LTEtMS03MDAzNA_ffdc12d8-3b17-4f2b-a6a8-3ba3e42745ba">23,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi02LTEtMS03MDAzNA_89593f4a-d863-4cb5-a5b3-38de73ff9b0a">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi04LTEtMS03MDAzNA_adb906c3-6cac-4462-ac65-91a337a4e01c">47,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi0xMC0xLTEtNzAwMzQ_bedb5d7a-0f8b-487d-bf07-4ec2a0ccc76c">45,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi0xMi0xLTEtNzAwMzQ_e2ef25c4-4a91-42cd-8ea8-f4592342dc5a">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 10&#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84NS9mcmFnOmQ2ZTJiZjA3Njg2ZDQxNjFhZTI0N2IwMmI0NzgwNGU1L3RleHRyZWdpb246ZDZlMmJmMDc2ODZkNDE2MWFlMjQ3YjAyYjQ3ODA0ZTVfMzcy_488e05db-912a-4a5d-930c-fb0df96a01ce" continuedAt="i359e6012719a4f2baceb8a0bc7faaa6c" escape="true">ACQUISITIONS AND DIVESTITURES</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i359e6012719a4f2baceb8a0bc7faaa6c" continuedAt="i4f148a9bec2a4b6fa9ece5648bec39a0">There were no material acquisitions or divestitures in the fiscal first quarter and fiscal second quarter of 2022. </ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i4f148a9bec2a4b6fa9ece5648bec39a0">During the first fiscal quarter of 2021, in separate transactions, the Company divested <ix:nonFraction unitRef="brand" contextRef="iaf1d14a3db84419db81e75d0179c01b4_I20210404" decimals="INF" name="jnj:NumberOfBrands" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84NS9mcmFnOmQ2ZTJiZjA3Njg2ZDQxNjFhZTI0N2IwMmI0NzgwNGU1L3RleHRyZWdpb246ZDZlMmJmMDc2ODZkNDE2MWFlMjQ3YjAyYjQ3ODA0ZTVfMzI5ODUzNDg4MzczOQ_6b6ce5ff-79a3-46c4-bb72-2da73200ff99">two</ix:nonFraction> brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="ic932039af4d240c09dba004300b0fc41_D20210104-20210404" decimals="-8" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84NS9mcmFnOmQ2ZTJiZjA3Njg2ZDQxNjFhZTI0N2IwMmI0NzgwNGU1L3RleHRyZWdpb246ZDZlMmJmMDc2ODZkNDE2MWFlMjQ3YjAyYjQ3ODA0ZTVfMzY3_6fcbebfc-d030-4958-9d7d-858d06663079">0.6</ix:nonFraction>&#160;billion.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 11 &#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfOTI0MzI_dee2a4b6-d7ed-426e-8bf5-12234bc8cea8" continuedAt="ic43f806fe7f549fcb4abda39faa49a4f" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic43f806fe7f549fcb4abda39faa49a4f" continuedAt="i6a1843bdcf004d31a09581a0fb91c83f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of  July&#160;3, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i6a1843bdcf004d31a09581a0fb91c83f" continuedAt="i606d08596f1d4dc19e92d9bd2f0c3281"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON&#8217;S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of July&#160;3, 2022, in the United States there were approximately <ix:nonFraction unitRef="claimant" contextRef="i3d9a072c24d944d79f506df951a632cf_I20220703" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDM4Nw_5ce380c3-f9f4-447e-981e-8295750825b2">190</ix:nonFraction> plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; <ix:nonFraction unitRef="claimant" contextRef="ib832ec9b9cd74a91bcf4231b96beab4f_I20220703" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDU0OQ_e11482c0-888a-40a1-ba53-b27e4ebc635e">1,900</ix:nonFraction> with respect to the PINNACLE Acetabular Cup System; <ix:nonFraction unitRef="claimant" contextRef="i4f5f7c43d3a442a99a3d2ce435c696ea_I20220703" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDYwNA_1160c99f-3cfd-4eb5-bae6-19eab539bd59">9,500</ix:nonFraction> with respect to pelvic meshes; <ix:nonFraction unitRef="claimant" contextRef="i7a31f7f1915d4fe7b8465e43a6596732_I20220703" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDYzOA_06c20faa-10e8-4917-a9db-0bf595beb198">2,100</ix:nonFraction> with respect to RISPERDAL; <ix:nonFraction unitRef="claimant" contextRef="i7ce6d2b512174db89a47812c9123ec44_I20220703" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDY2OA_a48539fb-6efd-408f-bd61-3e627e51bd24">3,000</ix:nonFraction> with respect to XARELTO; <ix:nonFraction unitRef="claimant" contextRef="i6dabc10483784643822a9c5e7bb9014c_I20220703" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDY5Ng_c578ca6b-0475-4a23-9d65-f5891cb9fce5">40,300</ix:nonFraction> with respect to body powders containing talc; <ix:nonFraction unitRef="claimant" contextRef="iaa4ee166c8fc4dfd9a75a228d52f75b6_I20220703" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDc0NQ_b929d91c-1593-4b7f-ab86-9626828f7097">10</ix:nonFraction> with respect to INVOKANA;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> <ix:nonFraction unitRef="claimant" contextRef="i6b6d7ce367d24bdfac85e944a0140905_I20220703" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDc3OQ_4d46b51b-a657-494c-b49d-ef2849d75049">4,700</ix:nonFraction> with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; and <ix:nonFraction unitRef="claimant" contextRef="i4db059902da348b3b536a571790f6347_I20220703" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTA5OTUxMTkxMzUzMA_a563ba67-6593-4596-b9e7-d1aac03234d6">1,300</ix:nonFraction> with respect to ELMIRON. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than <ix:nonFraction unitRef="patient" contextRef="iad119c0eadb24bf6b712a9ded64f1721_I20220703" decimals="0" name="jnj:Numberofpatientsinsettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjE2MQ_42751223-9ec2-47da-92bb-06e1efdf7769">10,000</ix:nonFraction> claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i606d08596f1d4dc19e92d9bd2f0c3281" continuedAt="i3e76511b6aff436a95e056122c38c66b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia  and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. In March 2022, the Court appointed a barrister to prepare a written report and recommendation on the form and mechanism of the individual case assessment process, due by August 2022, with a court hearing on those findings later that month. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately <ix:nonFraction unitRef="cases" contextRef="i2a5fcff52eca4e2b8f7fd71362e00ee5_I20210531" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTIxMzk_f4cd7bc8-ab2e-4bf6-a039-308d79f1f6c2">3,600</ix:nonFraction> Physiomesh cases (covering approximately <ix:nonFraction unitRef="claimant" contextRef="i2a5fcff52eca4e2b8f7fd71362e00ee5_I20210531" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTIxODM_057f3f7f-737e-4a4b-8fd7-f6928b8186de">4,300</ix:nonFraction> plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes <ix:nonFraction unitRef="cases" contextRef="i5536e8ab75ef4a8ca62f7e1e6d81a778_I20210930" decimals="0" name="jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTIzMjM_99cef78b-e46d-4a99-b93a-83419912d2bb">3,729</ix:nonFraction> cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of July 2022, there are approximately <ix:nonFraction unitRef="cases" contextRef="i3ba73cf6d5694c16922acb99ad67a259_I20220703" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTI4MTc_0db17471-4703-4720-8667-034938609e96">126</ix:nonFraction> active cases subject to these orders which are being reviewed and evaluated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i3e76511b6aff436a95e056122c38c66b" continuedAt="ia2eceecd168c4d3381b12b8f1d2e6baa"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="i9e4509ae1e9143f38c795c4c1718372b_D20191001-20191031" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTQ4MTE_5ddcb65b-f776-47ab-9fc9-06482b54924c">8.0</ix:nonFraction>&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $<ix:nonFraction unitRef="usd" contextRef="ife017e4feb734f059e4eacc8da2b9534_D20200101-20200131" decimals="-5" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTQ4OTM_50415800-f4ee-43da-8f24-b9f5d2fbd044">6.8</ix:nonFraction>&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp; Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $<ix:nonFraction unitRef="usd" contextRef="if1ba4fdb7eda4a54a9874ebb8569565b_D20180701-20180731" decimals="-8" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTcxNDE_7580d010-4f4c-47ea-9cf9-bc81b5bc153a">4.7</ix:nonFraction>&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No. ED 207476 (Mo. App.), reducing the overall award to  $<ix:nonFraction unitRef="usd" contextRef="ic69e838063cb443ba0f1e022744b19a5_D20200601-20200630" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTcyNDE_ed1c4360-62b1-4ab4-bc95-b7ab0430c828">2.1</ix:nonFraction>&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i7d9d11122c61482b9e49c7ba615148f0_D20210601-20210630" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTc1NjM_2028cc61-ff3c-4e46-983c-4ebdea24a5c0">2.5</ix:nonFraction>&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. Opening briefs were filed in June 2022 and briefing is to be completed by September 2022. Additionally, an industrial talc class action was filed against the Company and others in New Jersey state court in May 2022. The case was subsequently removed to federal court. In July 2022, Imerys, and LTL, filed a motion to stay the industrial talc class action. The court heard oral argument and a ruling is expected at any time. While the New Jersey Bankruptcy Court&#8217;s order effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="ia2eceecd168c4d3381b12b8f1d2e6baa" continuedAt="i74a75b3f94ef45fbb30f25db0d3ff5b9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $<ix:nonFraction unitRef="usd" contextRef="i51a055a5688e4ddfbc8c0852cec70dc5_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMjEyMTc_d8de6a84-d6d8-4bdf-b36e-40603199497f">2</ix:nonFraction>&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $<ix:nonFraction unitRef="usd" contextRef="i51a055a5688e4ddfbc8c0852cec70dc5_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMjEzMTQ_3a933a3c-9b02-42d7-a4fa-73d70c3669ce">2</ix:nonFraction>&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#8217;s insurers (the Mediation Parties) have since agreed to engage in mediation, which remains ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC)  (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#8220;talc-related claims&#8221; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i74a75b3f94ef45fbb30f25db0d3ff5b9" continuedAt="i9b6b01797e034e31b138fc43a781de27"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs&#8217; motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record.  In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action, and Plaintiff filed a notice of appeal regarding the Bankruptcy Court&#8217;s order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In July 2022, the Court denied Plaintiff's discovery motion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i9b6b01797e034e31b138fc43a781de27" continuedAt="i6a8b1e8aceb84e2f8138a8dfcfe2704e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well the Court of Common Pleas in Philadelphia, where an application is pending for mass tort designation. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MedTech</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos.  6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447);  and 9,452,276 (&#8217;276) based on Auris&#8217; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the  &#8217;056,  &#8217;447, &#8217;276 and &#8217;906 patents.  In December 2019, the USPTO  denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the  &#8217;447,  and &#8217;906 patents and denied review of the &#8217;276 patent. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris appealed, and  in April 2022, the United States Court of Appeals for the Federal Circuit vacated the decision that the &#8217;447 patent was not invalid and remanded the decision  to the USPTO for further review.  In May 2022, the United States Court of Appeals for the Federal Circuit confirmed the ruling that claim 53 of the &#8217;906 patent was not invalid, vacated the decision that the remaining claims of the &#8217;906 patent were not invalid and remanded the decision  to the USPTO for further review. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 (&#8217;234) and 9,713,537 (&#8217;537) by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. Trial is scheduled to begin in December 2022. In June 2022, DePuy filed potentially dispositive summary judgment motions that the &#8217;234 patent is invalid as anticipated and the &#8217;537 patent is not infringed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i6a8b1e8aceb84e2f8138a8dfcfe2704e" continuedAt="i3bf4c39b8e3c4025abdbbda93d4be524"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 (&#8217;180) and 10,517,583 (&#8217;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#8217;180 patent, and awarding damages in the amount of $<ix:nonFraction unitRef="usd" contextRef="i49377ad3634041709403a2a206d30a13_D20220301-20220322" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMzI5ODUzNTE2NzM1OQ_89d2887c-524f-405b-9dd8-82fede15a76d">20</ix:nonFraction>&#160;million. DePuy is challenging the verdict in its post-trial motions. In July 2022, a hearing was held on the post-trial motions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc., Janssen Oncology, Inc., and BTG International Ltd. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision. The appeal hearing has been scheduled to take place in September 2022. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In April 2021, July 2021 and April 2022, respectively, Apotex, DRL and Pharmascience initiated Statements of Claim under Section 8 of the Patented Medicines (Notice of Compliance) Regulations against Janssen seeking damages in respect of those parties generic Zytiga tablets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> Trials against Apotex and DRL are scheduled for June 2023. A trial date for the Pharmascience action has not been set.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#8217;310). The following generic drug companies are named defendants:  Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. No trial date has been set in this lawsuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Micro Labs Ltd. and Micro Labs USA Inc. (collectively, Micro) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In March 2022, the case against Micro was consolidated for all purposes, including trial, with the consolidated Delaware lawsuits. In July 2022, the parties entered into a confidential settlement agreement, and the action was dismissed. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i3bf4c39b8e3c4025abdbbda93d4be524" continuedAt="ifce7682e4c1e421a9a15f07b9e79860e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Partes Review with the United States Patent and Trademark Office, seeking to invalidate the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022, Janssen Pharmaceuticals, Inc. (JPI), Bayer Intellectual Property GmbH and Bayer AG filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Changzhou Pharmaceutical Factory, which filed an ANDA seeking approval to market generic a version of XARELTO (10 mg, 15 mg, and 20 mg) before expiration of U.S. Patent No. 9,539,218 (&#8217;218). In this lawsuit, JPI, Bayer Intellectual Property GmbH and Bayer AG are seeking an order enjoining Changzhou from marketing its generic version of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. In June 2022, the parties entered into a confidential settlement agreement, and the action was dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA/INVOKAMET/INVOKAMET XR</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788) relating to INVOKAMET. In this lawsuit, Janssen and MTPC are seeking an order enjoining DRL from marketing its generic version of INVOKAMET before the expiration of the &#8217;788 patent. In June 2022, the parties entered into a confidential settlement agreement and the lawsuit was dismissed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Sandoz stipulated to infringement of the &#8217;770 patent.  Trial against Sandoz on the issue of validity concluded in February 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Sandoz appealed the decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Apotex stipulated to validity of the &#8217;770 patent.  Trial against Apotex on the issue of infringement concluded in March 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Apotex appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of United States Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ifce7682e4c1e421a9a15f07b9e79860e" continuedAt="ie336bc7d06384e4badd254d8896586ba"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. A trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. The action has been consolidated with the November 2020 action for trial, which took place in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS (original ANDS) seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Janssen Canada initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex in response to Apotex&#8217;s Notice of Allegation of invalidity with respect to the original ANDS and in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Trial is scheduled to begin in October 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before expiration of the &#8217;693 patent.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="ie336bc7d06384e4badd254d8896586ba" continuedAt="ibac18b25d58f46f49c7c5a56c0113ed6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. The trial is scheduled to begin in July 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SYMTUZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of United States Patent Nos. 10,039,718 (the &#8217;718 patent) and 10,786,518 (the &#8217;518 patent). Janssen is seeking an order enjoining Lupin from marketing its generic version of SYMTUZA before the expiration of the &#8217;718 and &#8217;518 patents. The trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ERLEADA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of United States Patent No. 9,481,663 (the &#8217;663 patent). Janssen and SKI are seeking an order enjoining Lupin from marketing its generic version of ERLEADA before the expiration of the &#8217;663 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited (collectively, Zydus), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663 patent and United States Patent Nos. 9,884,054 (the &#8217;054 patent), 10,052,314 (the &#8217;314 patent), 10,702,508 (the &#8217;508 patent), and 10,849,888 (the &#8217;888 patent). Janssen and SKI are seeking an order enjoining Zydus from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc.  and Janssen Biotech, Inc. (collectively, Janssen), The Regents of the University of California (UC), and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Sandoz Inc. (Sandoz), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663 patent and United States Patent Nos. 8,445,507 (the &#8217;507 patent), 8,802,689 (the &#8217;689 patent), 9,338,159 (the &#8217;159 patent), and 9,987,261 (the &#8217;261 patent). Janssen, UC, and SKI are seeking an order enjoining Sandoz from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;689, &#8217;159, and &#8217;261 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and  Janssen Biotech, Inc. (collectively, Janssen), The Regents of the University of California (UC), and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States  District Court for the Districts of New Jersey and Delaware against Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively, Eugia), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of  the &#8217;663, &#8217;507, &#8217;689, &#8217;159 and &#8217;261 patents. Janssen, UC, and SKI are seeking </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ibac18b25d58f46f49c7c5a56c0113ed6" continuedAt="ib29ffc733b1e49b28d6c3f78df523892"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">an order enjoining Eugia from marketing its generic version of ERLEADA before the expiration of the &#8217;663,&#8217;507, &#8217;689, &#8217;159, and &#8217;261 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen), The Regents of the University of California (UC), and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Hetero Labs Limited Unit V and Hetero USA, Inc. (collectively, Hetero), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507,&#8217;054, &#8217;314,&#8217;508, and&#8217;888 patents. Janssen, UC, and SKI are seeking an order enjoining Hetero from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Other Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#8217; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#8217; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in response to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to <ix:nonFraction unitRef="claimant" contextRef="i858a52bb013045799d07f07aaa301efb_I20220703" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjExNDA_68421d2d-9e62-4d3a-b7fd-bf0c231d7582">3,500</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ib29ffc733b1e49b28d6c3f78df523892" continuedAt="i9037f06fe4464a0eb43a15cb2b5f50df"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $<ix:nonFraction unitRef="usd" contextRef="ifce5aacbfc3a444c920acdbe2b4a1ec5_D20191230-20200329" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjM1MDQ_aba3cbec-73e6-4bdd-9f39-d17d9f414f5e">465</ix:nonFraction>&#160;million. Johnson &amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment and directed entry of judgment for Defendants. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#8217; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $<ix:nonFraction unitRef="usd" contextRef="ic155bb14d5cf4a6ea37fc5c8528e6732_I20191031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjQ1Mjk_11b8a31d-2ca5-41d1-ac22-21730be4ce0f">4</ix:nonFraction>&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $<ix:nonFraction unitRef="usd" contextRef="icec2a84c793b4a13a9cab4e12fc62921_I20201031" decimals="-9" name="jnj:LossContingencyEstimateOfAdditionalPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjQ2Njk_bcc4d0c9-b4b9-4aa7-922b-f9377aebf281">1</ix:nonFraction>&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of  $<ix:nonFraction unitRef="usd" contextRef="icec2a84c793b4a13a9cab4e12fc62921_I20201031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjQ4MzA_e9101a4d-6563-4a7f-9eb2-2ad688bb7c28">5</ix:nonFraction>&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement is expected to be paid by the end of fiscal year 2022, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022 and initial payments were made in July 2022. In April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions. Consequently, by July 2022, the Company had settled the opioid claims advanced by all states except Washington and New Hampshire.  A trial of claims brought by the Attorney General of New Hampshire is scheduled to begin in September 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are approximately <ix:nonFraction unitRef="claim" contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjYyMzE_90806700-b8e3-40a5-bde7-472a6cfeec5d">60</ix:nonFraction> cases remaining post-settlement in various state courts. There are approximately <ix:nonFraction unitRef="claim" contextRef="i888c4c1d679a40f2b81b60328c1858f4_I20220703" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjYzMTU_3e12fcb9-2a66-4ade-8425-5733b69710a1">1,000</ix:nonFraction> remaining federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i9037f06fe4464a0eb43a15cb2b5f50df" continuedAt="i86fc4d7c359144e48f89b3cc13bd3116"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.  By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted Johnson &amp; Johnson&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder filed a notice of appeal regarding the state court&#8217;s dismissal order.   </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit. The relators&#8217; opening brief was filed in May 2022 and was accepted for filing by the First Circuit in June 2022. DePuy&#8217;s opposition brief is due in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene.  The case has been transferred to the United States District Court for the District of New Jersey. Janssen&#8217;s motion to dismiss was denied in December 2021, and discovery is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for May 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $<ix:nonFraction unitRef="usd" contextRef="ib6ef62a6d06b427d93b514f97600fe84_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNzQwNzU_f9167205-88c4-4770-8b5e-87530897fbfd">344</ix:nonFraction>&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $<ix:nonFraction unitRef="usd" contextRef="ib6ef62a6d06b427d93b514f97600fe84_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNzQyMzk_adb5e384-26cc-4aad-b02b-9a602d221d61">344</ix:nonFraction>&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $<ix:nonFraction unitRef="usd" contextRef="ibb991236eb0f43e0bf871925f4f3d04a_D20220401-20220430" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNzQ0MTE_03030e03-7416-4a32-9903-6a672c0b966b">302</ix:nonFraction>&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company's petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. The Company plans to petition for review by the United States Supreme Court.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i86fc4d7c359144e48f89b3cc13bd3116" continuedAt="i8359d9df5dd74d88b93b93b9de0e27c0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting as barred by the stay arising from the LTL Bankruptcy Case, while the State argued that the stay did not apply. In January 2022, the Court granted plaintiff&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. The temporary stay expired in May 2022. The State has proposed a scheduling order for further proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court. The 60-day stay expired in June 2022, and the State made a motion for a modified scheduling order. A motion is before the court. In June 2022, the New Mexico Supreme Court granted oral argument on the Company's Writ for Superintending Control on the issue of the State of New Mexico&#8217;s discovery obligations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to enter into negotiations to determine if they would resolve their claims through the LTL Bankruptcy Case.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products, LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i8359d9df5dd74d88b93b93b9de0e27c0" continuedAt="i4051c3343794494394066debc081f8f6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over <ix:nonFraction unitRef="claim" contextRef="i52eba45e53444e1298c1fcf2a2216b36_I20150430" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfODE4MjE_4c35bcc6-21a0-4a3c-8b14-ce7a7e8e40cf">30</ix:nonFraction> putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. This case was settled in March 2022, subject to Court approval. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022, subject to Court approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. This case was settled in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2022, defendants petitioned for rehearing en banc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i4051c3343794494394066debc081f8f6" continuedAt="i108bca31a5b34821b87e352469ee5e2b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for February 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, Janssen Pharmaceuticals, Inc. filed an arbitration demand against Emergent Biosolutions Inc. et al (&#8220;EBSI&#8221;) with the American Arbitration Association, alleging that EBSI breached the parties&#8217; Manufacturing Services Agreement for the Company&#8217;s COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i108bca31a5b34821b87e352469ee5e2b"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 12&#8212; <ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMjM5MQ_ea529f5b-436d-4f24-a9dc-34d3f3bb84f5" continuedAt="i95e27fd2582845c1a6d34324fe3cd363" escape="true">RESTRUCTURING</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i95e27fd2582845c1a6d34324fe3cd363"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal second quarter of 2022, the Company recorded a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i5e4e74ca66f8464690742d705f7eed8a_D20220404-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfNjY0_dd74f39e-d910-4b35-82f2-75bd87113b81">128</ix:nonFraction> million, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="iefca38bcca5c426da7027dede1f04f08_D20220404-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfNzUy_f0da602a-825a-423c-923e-dc6bcf3ca68b">85</ix:nonFraction> million in restructuring, $<ix:nonFraction unitRef="usd" contextRef="i7fdef417221f4a06a85755418e9c5222_D20220404-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfNzcz_eb365b41-5686-46bc-883c-dc71ba695c24">17</ix:nonFraction> million in cost of products sold and $<ix:nonFraction unitRef="usd" contextRef="i5d3938fca19a4ceaa24ccd83eff70370_D20220404-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfODE1_7a291919-7633-4424-b6ca-5df22b864e13">26</ix:nonFraction> million in other (income) expense, net.  In the fiscal six months of 2022, the Company recorded a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i73608594f8c3424eaa8ff95295134a24_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTA5OTUxMTYzMDczMA_afb5022c-eb07-41de-99fb-0a14d705b9d1">200</ix:nonFraction>&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="i2909b6c557f9463ea81eb9118d4a4049_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTY0OTI2NzQ0NDkzMA_143c0501-a2ec-486f-9b7b-63a32df98c7f">155</ix:nonFraction>&#160;million in restructuring, $<ix:nonFraction unitRef="usd" contextRef="i480b3ed870204b9391f1887a57cdae32_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTY0OTI2NzQ0NDk0NQ_ad39319f-93ac-4f8c-afc1-2b48a3c439cf"><ix:nonFraction unitRef="usd" contextRef="i480b3ed870204b9391f1887a57cdae32_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTY0OTI2NzQ0NDk0NQ_d6ee1f7e-4c01-4675-9d62-2bf10b2f57f6">33</ix:nonFraction></ix:nonFraction>&#160;million in cost of products sold and $<ix:nonFraction unitRef="usd" contextRef="i74fe313c94e648559666a0a69c919630_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTY0OTI2NzQ0NDk1OQ_6386d8c8-3ef2-4857-80c6-1985f531eebf">12</ix:nonFraction>&#160;million in other (income) expense, net. Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i6f129a7dfc034e9c9fe9ae8a3c42730f_I20220703" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfOTA5_ff4b6f5d-e421-45ab-bfa1-d90a9dfb025c">2.0</ix:nonFraction> billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In total, the Company expects the Global Supply Chain actions to generate approximately $<ix:nonFraction unitRef="usd" contextRef="i0c3d0aaa08c34dad9c998070ad8755bb_I20220703" decimals="-8" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTEzNw_bb0c663f-e546-4763-b486-4f65dd42fb39">0.6</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="i6cc12874a2f141468d294f5edf304948_I20220703" decimals="-8" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTE0Mw_dbbdb491-4e3d-4b4d-9e51-d9bc3470d278">0.8</ix:nonFraction> billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i0c3d0aaa08c34dad9c998070ad8755bb_I20220703" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTMxMQ_04e2a2ca-c896-49b4-8417-caf86c9bd73d">2.1</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="i6cc12874a2f141468d294f5edf304948_I20220703" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTMxNw_9620c184-5273-4a44-99ed-2d99a4a2a6a3">2.3</ix:nonFraction> billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMjM4OA_2b333ae8-b563-4e1a-a6ee-ce65a4210b88" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal second quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:32.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65b6db0f8484a37b25b57a750fdd0c9_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfMS0xLTEtMS03MDAzNA_0f7458e7-e027-4061-ad09-b18531312f51">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5042a6771a2743cfbea81abb2c4f0489_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfMS0yLTEtMS03MDAzNA_58741452-446a-4310-83a7-b9fcc7a000f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcbb46afcdc46c89062dca3aa694438_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfMS00LTEtMS03MDAzNA_1e07599c-098e-4bdd-b659-1c80a68c933e">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c99f4219f554853b8e2459b665c0cb3_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfMS01LTEtMS03MDAzNA_2207a5fb-0f09-457b-b789-c0e21d5ddadc">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9e37a55a9465296ff97bfeb4dbc2d_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNC0xLTEtMS03MDAzNA_123d4d62-4cfc-45cf-b4ff-10403df3d3bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c0d4d2eea744af684d21c45ce8f9077_D20220103-20220703" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNC0yLTEtMS03MDAzNA_fe8875bd-e53a-4422-a3e0-c1627171764f">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if587f8e549024234943bfe0d376966d8_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNC00LTEtMS03MDAzNA_9f716725-3822-4624-a376-5173d8bb361a">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dab1b527c04e6c93a77db28d7f4dfb_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNC01LTEtMS03MDAzNA_2daff90b-4ca4-4d10-9ad2-a19b87cd9f04">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9e37a55a9465296ff97bfeb4dbc2d_D20220103-20220703" decimals="-6" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNS0xLTEtMS03MDAzNA_ccce489d-ec6c-4d18-91d6-358a0dd5d0aa">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0d4d2eea744af684d21c45ce8f9077_D20220103-20220703" decimals="-6" sign="-" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNS0yLTEtMS03MDAzNA_8b7cbeb4-fe05-41d5-92ae-cfc7caa7d57b">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if587f8e549024234943bfe0d376966d8_D20220103-20220703" decimals="-6" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNS00LTEtMS03MDAzNA_17fce06c-573a-482d-be9d-ef02c53fdcdc">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15dab1b527c04e6c93a77db28d7f4dfb_D20220103-20220703" decimals="-6" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNS01LTEtMS03MDAzNA_c11549a4-5e3c-490a-b61b-f01384867b51">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9e37a55a9465296ff97bfeb4dbc2d_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNi0xLTEtMS03MDAzNA_6358fe9e-117d-481b-8f04-5bca48747589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c0d4d2eea744af684d21c45ce8f9077_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNi0yLTEtMS03MDAzNA_17a09de0-b60c-4a33-bff0-c36de81bb227">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if587f8e549024234943bfe0d376966d8_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNi00LTEtMS03MDAzNA_34124c90-9dfb-40d6-ae30-e0ca27003f57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15dab1b527c04e6c93a77db28d7f4dfb_D20220103-20220703" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNi01LTEtMS03MDAzNA_ba4ef742-4e7f-4c4f-b758-fb3d7174a0e4">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, July 3, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ca6c41d5964c50abb196f02b39a16f_I20220703" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfOS0xLTEtMS03MDAzNA_8a6c135c-5764-47e9-9e9f-fc2b0db6c5dc">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d93eaa25cfc46b38549e5a299d8f0e1_I20220703" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfOS0yLTEtMS03MDAzNA_b18b5ac0-88bc-4fa4-9d49-7a707513bc12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfc10f2d9fb46bea65fe6d1a1318594_I20220703" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfOS00LTEtMS03MDAzNA_be846ca5-cbaf-4911-8ef0-facb6fb48ac8">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86429e3449e0476199236fd7c3b171dd_I20220703" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfOS01LTEtMS03MDAzNA_d527310d-53f7-475c-bce1-5a4fa5d4bfca">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_106"></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Consolidated Sales</span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal six months of 2022, worldwide sales were $47.4 billion, a total increase of 4.0%, including an operational increase of 7.8% as compared to 2021 fiscal six months sales of $45.6 billion. Currency fluctuations had a negative impact of 3.8% for the fiscal six months of 2022. In the fiscal six months of 2022, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.2%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S. companies were $23.6 billion in the fiscal six months of 2022, which represented an increase of 2.5% as compared to the prior year. In the fiscal six months of 2022, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a negative 0.1%.  Sales by international companies were $23.8 billion, an increase of 5.5%, including an operational increase of 13.3%, and a negative currency impact of 7.8% as compared to the fiscal six months sales of 2021. In the fiscal six months of 2022, the net impact of acquisitions and divestitures on the international operational sales growth was a negative 0.3%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal six months of 2022, sales by companies in Europe achieved growth of 9.3%, which included an operational increase of 20.1% and a negative currency impact of 10.8%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 8.1%, which included an operational increase of 9.9%, and a negative currency impact of 1.8%. Sales by companies in the Asia-Pacific, Africa region experienced a decline of 0.2%, including an operational increase of 5.6% and a negative currency impact of 5.8%.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20220703_g1.jpg" alt="jnj-20220703_g1.jpg" style="height:268px;margin-bottom:5pt;vertical-align:text-bottom;width:355px"/><img src="jnj-20220703_g2.jpg" alt="jnj-20220703_g2.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal second quarter of 2022, worldwide sales were $24.0 billion, a total increase of 3.0%, which included operational growth of 8.0%  and a negative currency impact of 5.0% as compared to 2021 fiscal second quarter sales of $23.3 billion. In the fiscal second quarter of 2022, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.1%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S. companies were $12.2 billion in the fiscal second quarter of 2022, which represented an increase of 2.3% as compared to the prior year. In the fiscal second quarter of 2022, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a negative 0.1%.  Sales by international companies were $11.8 billion, a total increase of 3.8%, which included operational growth of 13.9% and a negative currency impact of 10.1%. In the fiscal second quarter of 2022, the net impact of acquisitions and divestitures on the international operational sales growth was a negative 0.3%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2022, sales by companies in Europe achieved growth of 7.3%, which included operational growth of 20.7% and a negative currency impact of 13.4%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 12.4%, including operational growth of 14.9% and a negative currency impact of 2.5%. Sales by companies in the Asia-Pacific, Africa region experienced a decline of 3.6%, including operational growth of 4.7% and a negative currency impact of 8.3%.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20220703_g3.jpg" alt="jnj-20220703_g3.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/><img src="jnj-20220703_g4.jpg" alt="jnj-20220703_g4.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Sales by Business Segments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health segment sales in the fiscal six months of 2022 were $7.4 billion, a decrease of 1.4% as compared to the same period a year ago, including operational growth of 1.6% and a negative currency impact of 3.0%. U.S. Consumer Health segment sales decreased by 3.5%.  International Consumer Health segment sales increased by 0.3%, including operational growth of 5.7% and a negative currency impact of 5.4%.  In the fiscal six months of 2022, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was a negative 0.6%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Consumer Health Franchise Sales* &#8212; Fiscal Six Months Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:42.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,495</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first fiscal six months of 2021, approximately $0.2 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consumer Health segment sales in the fiscal second quarter of 2022 were $3.8 billion, a decrease of 1.3% as compared to the same period a year ago, including operational growth of 2.3% offset by a negative currency impact of 3.6%. U.S. Consumer Health segment sales decreased by 3.6%. International Consumer Health segment sales increased by 0.6% including operational growth of 7.3% and a negative currency impact of 6.7%. In the fiscal second quarter of 2022, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was a negative 0.6% primarily due to the DR. CI:LABO - Sedona divestiture in Asia Pacific. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Major Consumer Health Franchise Sales* &#8212; Fiscal Second Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:43.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2021, approximately $0.1 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OTC franchise achieved operational growth of 7.5% as compared to the prior year fiscal second quarter. Growth was driven by upper respiratory and analgesic products outside the U.S. and IMODIUM in digestive health. This was partially offset by supply constraints and a softer allergy season in the U.S.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skin Health/Beauty franchise experienced an operational decline of 0.3% as compared to the prior year fiscal second quarter. The decline was driven by external supply constraints, competitive pressures, the DR. CI:LABO - Sedona divestiture in Asia Pacific and regional COVID-19 related mobility restrictions. The decline was partially offset by pricing actions coupled with new product introductions in ASPAC.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oral Care franchise experienced an operational decline of 4.0% as compared to the prior year fiscal second quarter. The decline was driven by regional COVID-19 related mobility restrictions, a divestiture primarily in the EMEA region and lapping of prior year COVID-19 related demand increases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Baby Care franchise achieved operational growth of 0.5% as compared to the prior year fiscal second quarter. Slight growth was driven by performance outside the U.S. due to price actions in the Latin America region and higher demand in the Asia Pacific region. The growth was mostly offset by supply constraints primarily in the U.S.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Women&#8217;s Health franchise achieved operational growth of 7.2% as compared to the prior year fiscal second quarter which was primarily driven by growth in the Asia Pacific region due to price increases and strong consumer demand and increased distribution in EMEA.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Wound Care/Other franchise experienced an operational decline of 7.4% as compared to the prior year fiscal second quarter primarily driven by lapping of  prior year higher demand and the professional tape divestiture partially offset by supply recovery in Canada. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after the initial announcement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment sales in the fiscal six months of 2022 were $26.2 billion, an increase of 6.5% as compared to the same period a year ago, with an operational increase of 10.8% and a negative currency impact of 4.3%. U.S. Pharmaceutical sales increased 3.6% as compared to the same period a year ago. International Pharmaceutical sales increased by 10.0%, including operational growth of 19.4% and a negative currency impact of 9.4%.  In the fiscal six months of 2022, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was a negative 0.1%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Pharmaceutical Therapeutic Area Sales** &#8212; Fiscal Six Months Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:48.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.017%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI/ SIMPONI ARIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,613</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT/rilpivirine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,475</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,519</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA/methylphenidate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA/ abiraterone acetate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA/ INVOKAMET</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1,2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,581</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal six months of 2021, approximately $0.2 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pharmaceutical segment sales in the fiscal second quarter of 2022 were $13.3 billion, an increase of 6.7% as compared to the same period a year ago, including an operational increase of 12.3% and a negative currency impact of 5.6%. U.S. Pharmaceutical sales increased 4.2% as compared to the same period a year ago. International Pharmaceutical sales increased by 9.8%, including operational growth of 22.1% and a negative currency impact of 12.3%. In the fiscal second quarter of 2022, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was a negative 0.1%. Adjustments to previous sales reserve estimates were approximately $0.1 billion unfavorable in the fiscal second quarter of 2022 and approximately $0.2 billion favorable in the fiscal second quarter of 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Pharmaceutical Therapeutic Area Sales** &#8212; Fiscal Second Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:47.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI/ SIMPONI ARIA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT/rilpivirine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA/ PREZCOBIX/ REZOLSTA/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,734</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA/ methylphenidate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,042</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,535</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA/ abiraterone acetate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA/ INVOKAMET</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1,2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,317</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2021, approximately $0.1 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunology products achieved operational growth of 8.1% as compared to the same period a year ago driven by continued strong uptake of STELARA (ustekinumab) in Crohn's disease and Ulcerative Colitis, as well as the net benefit of favorable discounts partially offset by unfavorable adjustments to previous sales reserves. Additionally, strong growth of TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(guselkumab) due to market share gains in Psoriasis and Psoriatic Arthritis was partially offset by unfavorable adjustments to previous sales reserves. This was partially offset by lower sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(infliximab) due to biosimilar competition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The latest expiring United States patent for STELARA (ustekinumab) will expire in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2021 were approximately $5.9 billion. The expiration of a product patent or loss of market exclusivity is likely to result in a reduction in sales.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease products achieved operational growth of 42.0% as compared to the same period a year ago. Growth was primarily driven by the contribution of the COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This was partially offset by lower sales of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PREZCOBIX/REZOLSTA (darunavir/cobicistat) due to increased competition and loss of exclusivity of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries outside the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience products achieved operational sales growth of 0.5% as compared to the same period a year ago. Growth of Paliperidone long-acting injectables INVEGA SUSTENNA/XEPLION (paliperidone palmitate) and INVEGA TRINZA/TREVICTA was due to new patient starts and persistence of treatment as well as the launch of INVEGA HAFYERA. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology products achieved operational sales growth of 21.9% as compared to the same period a year ago. Contributors to the growth were strong sales of DARZALEX (daratumumab) driven by share gains in all regions, continued strong market growth, and solid uptake of the subcutaneous formulation and the continued global launch uptake of ERLEADA (apalutamide). IMBRUVICA (ibrutinib) declined due to competitive pressures. The U.S. decline was partially offset by growth in all regions outside the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pulmonary Hypertension achieved operational sales growth of 0.9% as compared to the same period a year ago. Sales growth was due to demand and share gains from UPTRAVI (selexipag) partially offset by COVID-19 related market constraints and unfavorable patient mix in OPSUMIT (macitentan) as well as entrants in Other Pulmonary Hypertension.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular / Metabolism / Other products experienced an operational decline of 3.1% as compared to the same period a year ago. The growth of XARELTO (rivaroxaban) was primarily driven by volume growth and share gains from commercial access changes. The decline in sales of INVOKANA/INVOKAMET (canagliflozin) were due to continued share erosion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Starting in the second quarter of fiscal 2022, the Company updated its policy so that no end customer will be permitted direct delivery of product to a location other than the billing location. The updated policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company&#8217;s drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain unlimited contract pharmacy arrangements under policy exceptions. The Company will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy update has discount and volume implications in the current year and going forward. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech*</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment sales in the fiscal six months of 2022 were $13.9 billion, an increase of 2.3% as compared to the same period a year ago, with an operational increase of 5.9% and a negative currency impact of 3.6%. U.S. MedTech sales increased 3.5%. International MedTech sales increased by 1.2%, including an operational increase of 8.0% and a negative currency impact of 6.8%. In the fiscal six months of 2022, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a negative 0.1%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major MedTech Franchise Sales &#8212; Fiscal Six Months Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:228.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,884</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,340</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,995</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total MedTech Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,869</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,557</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Previously referred to as Medical Devices</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment sales in the fiscal second quarter of 2022 were $6.9 billion, a decrease of 1.1% as compared to the same period a year ago, which included operational growth of 3.4% offset by and a negative currency impact of 4.5%. U.S. MedTech sales increased 1.6%. International MedTech sales decreased by 3.6%, including operational growth of 5.1% offset by a negative currency impact of 8.7%. In the fiscal second quarter of 2022, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was negligible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Major MedTech Franchise Sales &#8212; Fiscal Second Quarter Ended</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:235.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,522</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,227</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total MedTech Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Previously referred to as Medical Devices</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Surgery franchise achieved operational sales growth of 1.8% as compared to the prior year fiscal second quarter. The operational growth in Advanced Surgery was primarily driven by Endocutter and Biosurgery products attributable to market expansion and the success of new products. Growth of Endocutter products was partially offset by regional COVID-19 related mobility restrictions and competitive pressures in the U.S. Growth of Biosurgery products was partially offset by strong market demand in the prior year for infection prevention products and by regional COVID-19 related mobility restrictions. Energy products growth was due to new product penetration coupled with competitive supply challenges and stocking outside the U.S. partially offset by regional COVID-19 related mobility restrictions. The operational growth in General Surgery was primarily driven by strength of the Suture portfolio and technology penetration mostly offset by regional COVID-19 related mobility restrictions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Orthopaedics franchise achieved operational sales growth of 0.5% as compared to the prior year fiscal second quarter. The operational growth in hips reflects the continued strength of the portfolio including the ACTIS stem and enabling technologies &#8211; KINCISE and VELYS Hip Navigation and momentum in the U.S. Ambulatory Surgery Center channel partially offset by the negative impact of regional COVID-19 related mobility restrictions. The operational growth in knees was primarily driven by market recovery and uptake of new products partially offset by regional COVID-19 related mobility restrictions and the timing of tenders outside the U.S. The operational growth in Trauma was driven by the uptake of new products partially offset by the negative impact of regional COVID-19 related mobility restrictions. The operational decline in Spine, Sports &amp; Other was primarily driven by continued procedural softness in Spine and regional COVID-19 related mobility restrictions partially offset by new products in Sports, Spine &amp; VELYS Digital Solutions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vision franchise achieved operational sales growth of 10.9% as compared to the prior year fiscal second quarter. The Contact Lenses/Other operational growth was primarily driven by market growth, commercial execution and new products. The growth was partially offset by the negative impact from prior year stocking. The Surgical operational growth was primarily driven by Cataract market recovery, uptake of recently launched products, timing of stocking in ASPAC partially offset by high prior year comparison in Refractive.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interventional Solutions franchise achieved operational sales growth of 5.3% as compared to the prior year fiscal second quarter was driven by market growth in the U.S., EMEA and LATAM coupled with success of new products and commercial strategies. Growth was partially offset by the negative impact of regional COVID-19 related mobility restrictions. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANALYSIS OF CONSOLIDATED EARNINGS BEFORE PROVISION FOR TAXES ON INCOME </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income for the fiscal six months of 2022 was $11.7 billion representing 24.7% of sales as compared to $14.1 billion in the fiscal six months of 2021, representing 30.9% of sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income for the fiscal second quarter of 2022 was $5.8 billion representing 24.3% of sales as compared to $6.7 billion in the fiscal second quarter of 2021, representing 28.6% of sales. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="text-align:center"><img src="jnj-20220703_g5.jpg" alt="jnj-20220703_g5.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="jnj-20220703_g6.jpg" alt="jnj-20220703_g6.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Six months Q2 2022 versus Fiscal Six months Q2 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Inflation and unfavorable mix in the MedTech segment </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commodity inflation in the Consumer Health segment</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">COVID-19 vaccine supply network related costs in the Pharmaceutical segment</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Favorable segment mix with a higher percentage of sales coming from the Pharmaceutical segment</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits in the Consumer Health segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset amortization expense included in cost of products sold for the fiscal six months of 2022 and 2021 was $2.2&#160;billion and $2.4&#160;billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q2 2022 versus Q2 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Inflation and unfavorable mix in the MedTech segment </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commodity inflation in the Consumer Health segment</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">COVID-19 vaccine supply network related costs in the Pharmaceutical segment</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits in the Consumer Health segment</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Favorable segment mix with a higher percentage of sales coming from the Pharmaceutical segment</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intangible asset amortization expense included in cost of products sold for the fiscal second quarters of 2022 and 2021 was $1.1 billion and $1.2&#160;billion, respectively. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, Marketing and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="jnj-20220703_g7.jpg" alt="jnj-20220703_g7.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="jnj-20220703_g8.jpg" alt="jnj-20220703_g8.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Six months Q2 2022 versus Fiscal Six months Q2 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased spending to support product launches in the MedTech business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher brand marketing expenses in the Consumer Health business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Q2 2022 versus Q2 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Leveraging in Pharmaceutical brand marketing expense spending</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Favorable segment mix with a higher percentage of sales coming from the Pharmaceutical segment</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased spending to support product launches in the MedTech business</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and Development Expense</span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20220703_g9.jpg" alt="jnj-20220703_g9.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="jnj-20220703_g10.jpg" alt="jnj-20220703_g10.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Six months Q2 2022 versus Fiscal Six months Q2 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">General portfolio progression in the Pharmaceutical business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased investment across all franchises in the MedTech business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q2 2022 versus Q2 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">General portfolio progression in the Pharmaceutical business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased investment across all franchises in the MedTech business</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Process Research and Development (IPR&amp;D)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fiscal six months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Interest (Income) Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (Income) Expense in the first fiscal six months of 2022 was a net interest income of $38 million as compared to interest expense of $76 million in the same period a year ago primarily due to higher rates of interest earned on cash balances and the benefit from net investment hedging. Interest (Income) Expense in the fiscal second quarter of 2022 was a net interest income of $26 million as compared to interest expense of $28 million in the same period a year ago primarily due to higher rates of interest earned on cash balances. The balance of cash, cash equivalents and current marketable securities was $32.6&#160;billion at the end of the fiscal second quarter of 2022 as compared to $25.3 billion at the end of the fiscal second quarter of 2021. The Company&#8217;s debt position was $32.6 billion as of July&#160;3, 2022 as compared to $33.5 billion the same period a year ago. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income) Expense, Net*</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Six months Q2 2022 versus Fiscal Six months Q2 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal six months of 2022 was unfavorable by $1.6 billion as compared to the prior year primarily due to the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Six Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, integration and divestiture related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Primarily related to divestiture gains of two pharmaceutical brands outside the U.S. in the fiscal six months of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q2 2022 versus Q2 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal second quarter of 2022 was unfavorable by $0.8 billion as compared to the prior year primarily due to the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Second Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before tax by segment of business for the fiscal six months were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:31.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,432&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,446&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,633&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consumer Health segment income before tax as a percent of sales in the fiscal six months of 2022 was 19.9% versus 22.8% for the same period a year ago. The decline in the income before tax as a percent of sales in the fiscal six months of 2022 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Commodity inflation </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment income before tax as a percent of sales in the fiscal six months of 2022 was 31.9% versus 38.5% for the same period a year ago. The decline in the income before tax as a percent of sales for the fiscal six months of 2022 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An IPR&amp;D charge of $0.6 billion in 2022 related to bermekimab (JnJ-77474462), an investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS) </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6 billion in 2021, primarily related to divestiture gains of two pharmaceutical brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net mark-to-market loss related to the change in the fair value of securities ($0.5 billion loss in 2022 vs. $0.1 billion gain in 2021)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $0.2 billion in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased Research &amp; Development investment for general portfolio progression </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Favorable product mix</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower intangible asset amortization expense ($1.5 billion in 2022 vs. $1.7 billion in 2021)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment income before tax as a percent of sales in the fiscal six months of 2022 was 18.9% versus 24.9% for the same period a year ago. The decline in the income before tax as a percent of sales for the fiscal six months of 2022 was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Litigation related expense of $0.3 billion in 2022 vs. income of $0.1 billion in 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Inflation and unfavorable product mix</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased investment in Research &amp; Development </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income before tax by segment of business for the fiscal second quarters were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:32.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,020&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consumer Health segment income before tax as a percent of sales in the fiscal second quarter of 2022 was 20.6% versus 22.5% for the same period a year ago. The decrease in the income before tax as a percent of sales in the fiscal second quarter of 2022 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Commodity inflation </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment income before tax as a percent of sales in the fiscal second quarter of 2022 was 33.2% versus 34.4% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal second quarter of 2021 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Net mark-to-market loss related to the change in the fair value of securities ($0.1 billion loss in 2022 vs. $0.2 billion gain in 2021)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $0.2 billion in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased Research &amp; Development investment for general portfolio progression </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower intangible asset amortization expense ($0.7 billion in 2022 vs. $0.8 billion in 2021)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Brand marketing expense leveraging</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Favorable product mix</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment income before tax as a percent of sales in the fiscal second quarter of 2022 was 16.5% versus 25.0% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal second quarter was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Litigation related expense of $0.3 billion in 2022 vs. income of $0.1 billion in 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Inflation and unfavorable product mix </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased investment in Research &amp; Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                     </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement actions across its Global Supply Chain that are intended to enable the Company to focus resources and increase investments in critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio of the future, enhance agility and drive growth. The Company expects these supply chain actions will include expanding its use of strategic collaborations, and bolstering its initiatives to reduce complexity, improving cost-competitiveness, enhancing capabilities and optimizing its network.&#160;Discussions regarding specific future actions are ongoing and are subject to all relevant consultation requirements before they are finalized. In total, the Company expects these actions to generate approximately $0.6 to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restructuring charges of approximately $2.1 to $2.3 billion by the completion of the program in December 2022. In the first fiscal six months of 2022, the Company recorded a net pre-tax charge of $200 million, which is included on the following lines of the Consolidated Statement of Earnings, $155 million in restructuring, $33 million in cost of products sold and $12 million in other (income) expense, net.  In the first fiscal six months of 2021, the Company recorded a pre-tax charge of $212 million, which is included on the following lines of the Consolidated Statement of Earnings, $109 million in restructuring, $47 million in cost of products sold and $56 million in other (income) expense, net. In the fiscal second quarter of 2022, the Company recorded a net pre-tax charge of $128 million, which is included on the following lines of the Consolidated Statement of Earnings, $85 million in restructuring, $17 million in cost of products sold and $26 million in other (income) expense, net. In the fiscal second quarter of 2021, the Company recorded a pre-tax charge of $108 million, which is included on the following lines of the Consolidated Statement of Earnings, $56 million in restructuring, $20 million in cost of products sold and $32 million in other (income) expense, net. Restructuring charges of approximately $2.0 billion have been recorded since the restructuring was announced. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;12 to the Consolidated Financial Statements for additional details related to the restructuring.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Taxes on Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rate for the fiscal six months of 2022 was 14.9% in 2022 and 11.5% in 2021. Subsequent to July 3, 2022, as part of the planned separation of the Company&#8217;s Consumer Health business the Company has recognized approximately $0.3 billion in incremental tax costs due to the reorganization of certain international subsidiaries which will be recorded in the fiscal third quarter. During fiscal year 2022, the Company is expected to incur significant additional international tax costs related to the legal separation of the Consumer Health business.</span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For discussion related to the fiscal six months of 2022 provision for taxes refer to Note&#160;5 to the Consolidated Financial Statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20220703_g11.jpg" alt="jnj-20220703_g11.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20220703_g12.jpg" alt="jnj-20220703_g12.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20220703_g13.jpg" alt="jnj-20220703_g13.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents were $11.0 billion at the end of the fiscal second quarter of 2022 as compared with $14.5 billion at the end of fiscal year 2021. The primary sources and uses of cash that contributed to the $3.5&#160;billion decrease were:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:21.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2021 Cash and cash equivalents balance</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash generated from operating activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by investing activities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by financing activities</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">effect of exchange rate and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2 2022 Cash and cash equivalents balance</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company had $21.6 billion in marketable securities at the end of the fiscal second quarter of 2022 and $17.1 billion at the end of fiscal year 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operations of $9.6&#160;billion was the result of:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts receivable and inventories </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in accounts payable and accrued liabilities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in other current and non-current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in other current and non-current liabilities and rounding</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow from operations</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities use of $6.3 billion of cash was primarily used for:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">additions to property, plant and equipment</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from the disposal of assets/businesses, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">acquisitions, net of cash acquired and other</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net purchases of investments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities use of $6.6 billion of cash was primarily used for: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dividends to shareholders </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">repurchase of common stock</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from stock options exercised/employee withholding tax on stock awards, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for financing activities</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10&#160;billion, which expires on September&#160;8, 2022.  Interest charged on borrowings under the credit line agreement is based on either Term Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreement are not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of July&#160;3, 2022, the Company's cash, cash equivalents and marketable securities was approximately $32.6 billion and approximately $32.6 billion of notes payable and long-term debt for a net neutral cash position as compared to the prior year net debt position of $8.2 billion. Considering recent market conditions and the on-going COVID-19 crisis, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's approximate $0.9 billion in contractual supply commitments associated with its development of the COVID-19 vaccine, the remaining balance to be paid on the agreement to settle opioid litigation for approximately $4.2 billion and the establishment of the $2.0 billion trust for talc related liabilities (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal second quarter of 2022, the Company paid approximately $1.7 billion to the U.S. Treasury which included $0.8 billion related to the current installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January 2, 2022),  and $0.9 billion primarily related to the normal estimated payments for the first six months of fiscal 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequent to the fiscal second quarter ended July 3, 2022, the Company sold all of its shares in argenx SE for proceeds of $0.6 billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2022, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on June 7, 2022 to shareholders of record as of May 24, 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2022, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on September 6, 2022 to shareholders of record as of August 23, 2022. The Company expects to continue the practice of paying regular quarterly cash dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic and Market Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 considerations and business continuity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered various internal and external factors in assessing the potential impact of COVID-19 on its business and financial results based upon information available at this time, as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Operating Model: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations and commercial capabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory at major distribution centers away from high-risk areas to ensure adequate and effective distribution. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business Continuity: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The robust, active business continuity plans across the Company's network have been instrumental in preparing the Company for events like COVID-19 and the ability to meet the majority of patient and consumer needs remains uninterrupted.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Workforce: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has put procedures in place to protect its essential workforce in manufacturing, distribution, commercial and research operations while ensuring appropriate remote working protocols have been established for other employees. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's high-quality credit rating allows the Company superior access to the financial capital markets for the foreseeable future. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Domestic and Foreign Legislation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess and evaluate the on-going global legislative efforts to combat the COVID-19 impact on economies and the sectors in which it participates. Currently, the recent legislative acts put in place are not expected to have a material impact on the Company&#8217;s operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal second quarter of 2022, amounts paid for services to be delivered</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9 billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the global progress on vaccine development and distribution as well as the amount of existing global supply, the Company is modifying its COVID-19 vaccine research programs and manufacturing capacity to levels that meet all customer contractual commitments which will result in incremental costs for the year. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to evaluate and monitor both its internal and external supply arrangements. The Company has established a global vaccine supply network, where, in addition to its internal manufacturing site in Leiden, the Netherlands, ten other manufacturing sites have been involved in the production of the vaccine across different countries and continents. The Company does not believe that a disruption relating to vaccine manufacturing, or the resulting delay would have a material financial impact on the Company&#8217;s consolidated financial statements or results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the long-term implications of Russia&#8217;s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal second quarter and six months of 2022, including accounts receivable or inventory reserves, was not material. As of both the 2021 fiscal year ending January 2, 2022, and the fiscal second quarter ending July 3, 2022, the business of the Company&#8217;s Ukraine subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and revenues. As of both the 2021 fiscal year ending January 2, 2022, and the fiscal second quarter ending July 3, 2022, the business of the Company&#8217;s Russian subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and represented 1% of revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In early March, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. Additionally, at the end of March, the Company made the decision to suspend supply of personal care products in Russia.  The Company continued to supply its other products throughout the second quarter as patients rely on many of the products for healthcare purposes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela and Argentina as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. Beginning in the fiscal second quarter of 2022, the Company accounted for operations in Turkey as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact on the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160;This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160; The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, as a result of the current global economic downturn, may continue to impact the Company&#8217;s businesses.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;3 &#8212; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the Company&#8217;s assessment of its sensitivity to market risk since its presentation set forth in Item&#160;7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; in its Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;4 &#8212; CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Duato and Wolk concluded that, as of the end of the period covered by this report, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal control. During the period covered by this report, there were no changes in the Company&#8217;s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company has not experienced any material impact to its internal controls over financial reporting despite the fact that many of its employees are working remotely due to the COVID-19 pandemic. The Company proactively took actions to re-evaluate and refine its financial reporting process through additional monitoring controls to provide reasonable assurance that the financial results are reported accurately and timely. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part II &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to Note 11 included in Part&#160;I, Item&#160;1, Financial Statements (unaudited) &#8212; Notes to Consolidated Financial Statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i01b5d6689adc4498bfe63be39e352060_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to Common Stock purchases by the Company during the fiscal second quarter of 2022. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal second quarter.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:497.25pt"><tr><td style="width:1.0pt"></td><td style="width:210.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:84.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:57pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Month Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avg. Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2022 through May 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2, 2022 through May 29, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 30, 2022 through July 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;During the fiscal second quarter of 2022, the Company repurchased an aggregate of 5,354,996 shares of Johnson &amp; Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;6 &#8212; EXHIBITS</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20222qex311ceocertificati.htm">Exhibit&#160;31.1  </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20222qex312cfocertificati.htm">Exhibit&#160;31.2 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20222qex321ceocertificati.htm">Exhibit&#160;32.1 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div style="text-indent:11.25pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20222qex322cfocertificati.htm">Exhibit&#160;32.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certification of Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 101: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i01b5d6689adc4498bfe63be39e352060_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:51.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JOHNSON &amp; JOHNSON<br/>(Registrant)&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: July 29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/ J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer (Principal Financial Officer)&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: July 29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/&#160;R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller (Principal Accounting Officer)&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a20222qex311ceocertificati.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie1f18c0f245a4827b0edec28d5da311f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joaquin Duato, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended July&#160;3, 2022 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joaquin Duato</font></div><div style="padding-left:288pt"><font style="color:#7d7d7d;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">__________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joaquin Duato </font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;   July&#160;29, 2022</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a20222qex312cfocertificati.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib9184e8ef7914f018a14fb515025ed6c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended July&#160;3, 2022 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joseph J. Wolk</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">______________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph J. Wolk</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July&#160;29, 2022</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a20222qex321ceocertificati.htm
<DESCRIPTION>EX-32.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibea3baf744e049ba8572b1bde55e213d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:11pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended July 3, 2022 (the&#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joaquin Duato</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;  July&#160;29, 2022</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a20222qex322cfocertificati.htm
<DESCRIPTION>EX-32.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8851324a56d6465b8ee5e62f1259f64f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.2</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended July 3, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Dated&#58;  July&#160;29, 2022</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>jnj-20220703.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a211293e-c516-4076-a852-d6c27f4cfad7,g:c2e9e48c-ca8c-4ec1-bfd7-8d90ecda38c0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20220703" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20220703">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220703_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220703_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220703_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220703_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.jnj.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>1003004 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1006007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1008009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>2103102 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>2304301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>2405401 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2106103 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillBySegmentDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
        <link:definition>2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails">
        <link:definition>2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.jnj.com/role/FairValueMeasurements">
        <link:definition>2112104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.jnj.com/role/FairValueMeasurementsTables">
        <link:definition>2313303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDerivativesBalanceSheetLocationDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
        <link:definition>2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails">
        <link:definition>2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
        <link:definition>2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.jnj.com/role/IncomeTaxes">
        <link:definition>2124105 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncomeTaxesDetails">
        <link:definition>2425416 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlans" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans">
        <link:definition>2126106 - Disclosure - Pensions and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansTables" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables">
        <link:definition>2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails">
        <link:definition>2429418 - Disclosure - Pensions and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncome" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome">
        <link:definition>2130107 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeTables" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables">
        <link:definition>2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.jnj.com/role/EarningsPerShare">
        <link:definition>2133108 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.jnj.com/role/EarningsPerShareTables">
        <link:definition>2334306 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.jnj.com/role/EarningsPerShareDetails">
        <link:definition>2435420 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreas" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas">
        <link:definition>2136109 - Disclosure - Segments of Business and Geographic Areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasTables" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables">
        <link:definition>2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
        <link:definition>2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
        <link:definition>2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
        <link:definition>2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures">
        <link:definition>2141110 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails">
        <link:definition>2443425 - Disclosure - Business Combinations and Divestitures - Schedule of Pro Forma Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.jnj.com/role/LegalProceedings">
        <link:definition>2144111 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.jnj.com/role/LegalProceedingsDetails">
        <link:definition>2445426 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.jnj.com/role/Restructuring">
        <link:definition>2146112 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.jnj.com/role/RestructuringTables">
        <link:definition>2347308 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails">
        <link:definition>2448427 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringReserveDetails" roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails">
        <link:definition>2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" abstract="false" name="LossContingencyNumberOfClaimsWithinSettlementAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RestructuringandRelatedCostExpectedFutureSavings" abstract="false" name="RestructuringandRelatedCostExpectedFutureSavings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BabyCareMember" abstract="true" name="BabyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterestExpensePercentToSales" abstract="false" name="InterestExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesDomain" abstract="true" name="LitigationSettlementByCompaniesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyEstimateOfAdditionalPossibleLoss" abstract="false" name="LossContingencyEstimateOfAdditionalPossibleLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentInProcessPercentToSales" abstract="false" name="ResearchAndDevelopmentInProcessPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SellingGeneralAndAdministrativeExpensePercentToSales" abstract="false" name="SellingGeneralAndAdministrativeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" abstract="false" name="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyReserveEstablishedWithinTrust" abstract="false" name="LossContingencyReserveEstablishedWithinTrust" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WomensHealthMember" abstract="true" name="WomensHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesByGeographicArea" abstract="false" name="PercentageChangeInSalesByGeographicArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesAxis" abstract="true" name="LitigationSettlementByCompaniesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ExcessOfFairValueOverCarryingValueOfDebt" abstract="false" name="ExcessOfFairValueOverCarryingValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CostOfGoodsSoldPercentToSales" abstract="false" name="CostOfGoodsSoldPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_PaymentsForRestructuringNet" abstract="false" name="PaymentsForRestructuringNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GrossProfitPercentToSales" abstract="false" name="GrossProfitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1300NotesDue2030Member" abstract="true" name="A1300NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" abstract="true" name="CONSUMERHEALTHAndPHARMACEUTICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInOperatingIncomeLoss" abstract="false" name="PercentageChangeInOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentImpairmentLoss" abstract="false" name="EquityFairValueAdjustmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_RISPERDALCONSTAMember" abstract="true" name="RISPERDALCONSTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.375Notesdue2023Member" abstract="true" name="A3.375Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_MedicalDevicesMember" abstract="true" name="MedicalDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_Restructuringchargepercenttosales" abstract="false" name="Restructuringchargepercenttosales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_SurgicalMeshProductsMarketingMember" abstract="true" name="SurgicalMeshProductsMarketingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NotesDuePeriodFifteenMember" abstract="true" name="NotesDuePeriodFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A6.73Debenturesdue2023Member" abstract="true" name="A6.73Debenturesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ERLEADAMember" abstract="true" name="ERLEADAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IncomeTaxExpenseBenefitPercentToSales" abstract="false" name="IncomeTaxExpenseBenefitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_SalesRevenueGoodsNetPercentToSales" abstract="false" name="SalesRevenueGoodsNetPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OpioidMember" abstract="true" name="OpioidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NumberOfBrands" abstract="false" name="NumberOfBrands" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_INVOKANAINVOKAMETMember" abstract="true" name="INVOKANAINVOKAMETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InternationalRetirementPlansMember" abstract="true" name="InternationalRetirementPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NetIncomeAttributableToParentPercentToSales" abstract="false" name="NetIncomeAttributableToParentPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SupplyChainMember" abstract="true" name="SupplyChainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ElmironMember" abstract="true" name="ElmironMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InterventionalSolutionsMember" abstract="true" name="InterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ContactLensesMember" abstract="true" name="ContactLensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTCMember" abstract="true" name="OTCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EvraAndDoxilMember" abstract="true" name="EvraAndDoxilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A0550NotesDue2025Member" abstract="true" name="A0550NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RasmussenInstrumentsLLCMember" abstract="true" name="RasmussenInstrumentsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BeautyMember" abstract="true" name="BeautyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" abstract="true" name="OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WoundCareandOtherMember" abstract="true" name="WoundCareandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InvokanaMember" abstract="true" name="InvokanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SPINEOTHERMember" abstract="true" name="SPINEOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LegalProceedingTextualsAbstract" abstract="true" name="LegalProceedingTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AmountPrepaidAndDueToManufacturers" abstract="false" name="AmountPrepaidAndDueToManufacturers" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InvestmentIncomeInterestPercentToSales" abstract="false" name="InvestmentIncomeInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_AurisHealthMember" abstract="true" name="AurisHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OralCareMember" abstract="true" name="OralCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" abstract="false" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_AssetWriteoffMember" abstract="true" name="AssetWriteoffMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherNonOperatingIncomeExpensePercentToSales" abstract="false" name="OtherNonOperatingIncomeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>jnj-20220703_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a211293e-c516-4076-a852-d6c27f4cfad7,g:c2e9e48c-ca8c-4ec1-bfd7-8d90ecda38c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15173f73-04d8-43d8-9846-5daadadabe73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_68b77bd3-5799-487d-bd90-b4a315a5fc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_15173f73-04d8-43d8-9846-5daadadabe73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_68b77bd3-5799-487d-bd90-b4a315a5fc5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4da6f65e-55d6-4eb1-9690-bdca7decacd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_15173f73-04d8-43d8-9846-5daadadabe73" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4da6f65e-55d6-4eb1-9690-bdca7decacd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ce041961-c6f6-4308-94e9-562f72d70f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_40f65a6c-81dc-4a62-a88f-6bc6ce97a490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ce041961-c6f6-4308-94e9-562f72d70f89" xlink:to="loc_us-gaap_LiabilitiesCurrent_40f65a6c-81dc-4a62-a88f-6bc6ce97a490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e2094e92-d1ec-41af-963a-ca20b9cff454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ce041961-c6f6-4308-94e9-562f72d70f89" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e2094e92-d1ec-41af-963a-ca20b9cff454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4aea565c-7df1-4ea9-8a9e-67a522fdb9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ce041961-c6f6-4308-94e9-562f72d70f89" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4aea565c-7df1-4ea9-8a9e-67a522fdb9b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_7bf5b315-f59f-4659-9c91-36133e6b7979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ce041961-c6f6-4308-94e9-562f72d70f89" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_7bf5b315-f59f-4659-9c91-36133e6b7979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_24adb4cf-1570-458d-97dd-b1aa3c0c0110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ce041961-c6f6-4308-94e9-562f72d70f89" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_24adb4cf-1570-458d-97dd-b1aa3c0c0110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c45a24d6-bbcd-4ce5-b481-1f85402c2719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ce041961-c6f6-4308-94e9-562f72d70f89" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c45a24d6-bbcd-4ce5-b481-1f85402c2719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_092ebd84-536b-4cff-a1a6-a6eea6abf703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0fe9a706-b7a0-45e8-a656-f09820fd4ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_092ebd84-536b-4cff-a1a6-a6eea6abf703" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0fe9a706-b7a0-45e8-a656-f09820fd4ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_432fb10f-991f-4f9c-9e2f-d7b5ae65e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_092ebd84-536b-4cff-a1a6-a6eea6abf703" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_432fb10f-991f-4f9c-9e2f-d7b5ae65e11f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_045811d5-10c6-4ef1-bf2a-086a0d1925d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_092ebd84-536b-4cff-a1a6-a6eea6abf703" xlink:to="loc_us-gaap_CommonStockValue_045811d5-10c6-4ef1-bf2a-086a0d1925d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_4c3d1a13-5cd6-4580-ac7e-817f74b60305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_092ebd84-536b-4cff-a1a6-a6eea6abf703" xlink:to="loc_us-gaap_TreasuryStockValue_4c3d1a13-5cd6-4580-ac7e-817f74b60305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7acbae62-a3e5-4b03-b02a-de0b5e48f33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5c751281-ba21-4f57-a877-067462068007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7acbae62-a3e5-4b03-b02a-de0b5e48f33c" xlink:to="loc_us-gaap_AssetsCurrent_5c751281-ba21-4f57-a877-067462068007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fe01ef27-1a03-410a-b5e3-2970d62e50c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7acbae62-a3e5-4b03-b02a-de0b5e48f33c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fe01ef27-1a03-410a-b5e3-2970d62e50c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_013962db-cf2f-4eee-b955-b22a79a779df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7acbae62-a3e5-4b03-b02a-de0b5e48f33c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_013962db-cf2f-4eee-b955-b22a79a779df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_503605d2-1cbf-4a10-8bb5-c42fafa13f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7acbae62-a3e5-4b03-b02a-de0b5e48f33c" xlink:to="loc_us-gaap_Goodwill_503605d2-1cbf-4a10-8bb5-c42fafa13f18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_5ac018e6-0d67-4267-968b-253e5468d1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7acbae62-a3e5-4b03-b02a-de0b5e48f33c" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_5ac018e6-0d67-4267-968b-253e5468d1b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_916a2735-c08a-4f83-bb01-964265191962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7acbae62-a3e5-4b03-b02a-de0b5e48f33c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_916a2735-c08a-4f83-bb01-964265191962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f19f2105-f716-46c4-b315-18470ef77450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bb31950f-bfed-4829-8d0c-52673d7045fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f19f2105-f716-46c4-b315-18470ef77450" xlink:to="loc_us-gaap_Liabilities_bb31950f-bfed-4829-8d0c-52673d7045fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_029de449-b984-47a9-8d34-1821478f2078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f19f2105-f716-46c4-b315-18470ef77450" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_029de449-b984-47a9-8d34-1821478f2078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a35f8bb8-3bcb-407d-be8c-4ac451d46b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f19f2105-f716-46c4-b315-18470ef77450" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a35f8bb8-3bcb-407d-be8c-4ac451d46b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5a069654-306a-4371-b40a-91f6ca411940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1085edc-6245-47ac-8ac3-7e664e7a52f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5a069654-306a-4371-b40a-91f6ca411940" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1085edc-6245-47ac-8ac3-7e664e7a52f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_5d445aaf-1155-4443-9c9f-8002ad11100f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5a069654-306a-4371-b40a-91f6ca411940" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_5d445aaf-1155-4443-9c9f-8002ad11100f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_33b235e8-82a2-4409-9175-120bc89f6f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5a069654-306a-4371-b40a-91f6ca411940" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_33b235e8-82a2-4409-9175-120bc89f6f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_51095d20-f304-4195-96da-31a48dd48103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5a069654-306a-4371-b40a-91f6ca411940" xlink:to="loc_us-gaap_InventoryNet_51095d20-f304-4195-96da-31a48dd48103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b7531f2-8cec-43a6-a0e9-42d134df6a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5a069654-306a-4371-b40a-91f6ca411940" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b7531f2-8cec-43a6-a0e9-42d134df6a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4334967b-aad4-44d2-a77e-3548f6a6df6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_1c02d227-50dc-40a5-a2cd-54751b3ffdca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4334967b-aad4-44d2-a77e-3548f6a6df6c" xlink:to="loc_us-gaap_ShortTermBorrowings_1c02d227-50dc-40a5-a2cd-54751b3ffdca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1f7db4f6-dc31-4807-ad3f-032e1e0c2d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4334967b-aad4-44d2-a77e-3548f6a6df6c" xlink:to="loc_us-gaap_AccountsPayableCurrent_1f7db4f6-dc31-4807-ad3f-032e1e0c2d17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dfe122f7-a65e-4525-8dce-2dc456136989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4334967b-aad4-44d2-a77e-3548f6a6df6c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dfe122f7-a65e-4525-8dce-2dc456136989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_b8de3048-945f-44e0-9e07-483a46cfb5fd" xlink:href="jnj-20220703.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4334967b-aad4-44d2-a77e-3548f6a6df6c" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_b8de3048-945f-44e0-9e07-483a46cfb5fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c7ce1a6f-4fe0-45dc-8f7d-2841182eea82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4334967b-aad4-44d2-a77e-3548f6a6df6c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c7ce1a6f-4fe0-45dc-8f7d-2841182eea82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_394c00be-0417-4d7e-8625-db0447a390da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4334967b-aad4-44d2-a77e-3548f6a6df6c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_394c00be-0417-4d7e-8625-db0447a390da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c23b957b-5f0c-4ca8-a8a9-33b4321aac21" xlink:href="jnj-20220703.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_3a939e06-bff0-409a-ac25-0e1ee6d625ca" xlink:href="jnj-20220703.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c23b957b-5f0c-4ca8-a8a9-33b4321aac21" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_3a939e06-bff0-409a-ac25-0e1ee6d625ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_be2e6815-c0e3-4643-ba06-882674c27520" xlink:href="jnj-20220703.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c23b957b-5f0c-4ca8-a8a9-33b4321aac21" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_be2e6815-c0e3-4643-ba06-882674c27520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_a083ea8b-21da-4130-bdb6-4089263aed5c" xlink:href="jnj-20220703.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c23b957b-5f0c-4ca8-a8a9-33b4321aac21" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_a083ea8b-21da-4130-bdb6-4089263aed5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_27cfd325-40d4-413e-8a4f-a94bb78f51ca" xlink:href="jnj-20220703.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c23b957b-5f0c-4ca8-a8a9-33b4321aac21" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_27cfd325-40d4-413e-8a4f-a94bb78f51ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_de667aa6-7381-41fd-899a-18118e296a60" xlink:href="jnj-20220703.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c23b957b-5f0c-4ca8-a8a9-33b4321aac21" xlink:to="loc_jnj_Restructuringchargepercenttosales_de667aa6-7381-41fd-899a-18118e296a60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_d458a359-947a-4bcc-944b-45c5696e0f84" xlink:href="jnj-20220703.xsd#jnj_InterestExpensePercentToSales"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c23b957b-5f0c-4ca8-a8a9-33b4321aac21" xlink:to="loc_jnj_InterestExpensePercentToSales_d458a359-947a-4bcc-944b-45c5696e0f84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_01c41f25-c1a9-421d-a302-ab344e8d6c75" xlink:href="jnj-20220703.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c23b957b-5f0c-4ca8-a8a9-33b4321aac21" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_01c41f25-c1a9-421d-a302-ab344e8d6c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_0d0d1d43-361f-42a5-8dc2-f8a181606728" xlink:href="jnj-20220703.xsd#jnj_GrossProfitPercentToSales"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c23b957b-5f0c-4ca8-a8a9-33b4321aac21" xlink:to="loc_jnj_GrossProfitPercentToSales_0d0d1d43-361f-42a5-8dc2-f8a181606728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_4269d087-dc50-4491-81a8-d01ad46a8b51" xlink:href="jnj-20220703.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_9d2c5549-89af-4e4c-9707-c245f7766777" xlink:href="jnj-20220703.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_4269d087-dc50-4491-81a8-d01ad46a8b51" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_9d2c5549-89af-4e4c-9707-c245f7766777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_ea3d4a3f-b497-4e81-8b42-da00a0535222" xlink:href="jnj-20220703.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_4269d087-dc50-4491-81a8-d01ad46a8b51" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_ea3d4a3f-b497-4e81-8b42-da00a0535222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82bf9be6-3d22-45ac-bf91-cb3d2af6b42d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_12e654aa-0b85-4370-babb-54e49c15052f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82bf9be6-3d22-45ac-bf91-cb3d2af6b42d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_12e654aa-0b85-4370-babb-54e49c15052f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_79789cb9-d306-4e86-94ad-313d6c347c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82bf9be6-3d22-45ac-bf91-cb3d2af6b42d" xlink:to="loc_us-gaap_GrossProfit_79789cb9-d306-4e86-94ad-313d6c347c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_94038d48-c68f-40e6-8bbb-632738c7ff97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82bf9be6-3d22-45ac-bf91-cb3d2af6b42d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_94038d48-c68f-40e6-8bbb-632738c7ff97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_23dd58e7-3237-4222-a938-68139dd5b11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82bf9be6-3d22-45ac-bf91-cb3d2af6b42d" xlink:to="loc_us-gaap_RestructuringCharges_23dd58e7-3237-4222-a938-68139dd5b11d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c357c033-d6f2-486d-b299-a033fb48eaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82bf9be6-3d22-45ac-bf91-cb3d2af6b42d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c357c033-d6f2-486d-b299-a033fb48eaa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2bb7f8b3-35f4-4a2d-81c3-fd3d1efc0e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82bf9be6-3d22-45ac-bf91-cb3d2af6b42d" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2bb7f8b3-35f4-4a2d-81c3-fd3d1efc0e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_58e2882a-8d00-4d54-8710-aaf7b0fb7337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82bf9be6-3d22-45ac-bf91-cb3d2af6b42d" xlink:to="loc_us-gaap_InterestExpense_58e2882a-8d00-4d54-8710-aaf7b0fb7337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e8ba1db7-611a-4e00-b353-ef9d63d3b00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82bf9be6-3d22-45ac-bf91-cb3d2af6b42d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e8ba1db7-611a-4e00-b353-ef9d63d3b00c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_abd363d4-a2e5-458e-80a8-55ff6a3aefc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c1dc86b5-2f3d-47a5-bca4-af70321d77ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abd363d4-a2e5-458e-80a8-55ff6a3aefc1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c1dc86b5-2f3d-47a5-bca4-af70321d77ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b0196e5e-3cd9-4482-8b21-cafff95c6ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abd363d4-a2e5-458e-80a8-55ff6a3aefc1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b0196e5e-3cd9-4482-8b21-cafff95c6ce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_e64bb5fc-ff8c-45e8-9fca-fc5891bc3a42" xlink:href="jnj-20220703.xsd#jnj_GrossProfitPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_39577127-a5d4-4c35-a071-afb0d703a386" xlink:href="jnj-20220703.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_e64bb5fc-ff8c-45e8-9fca-fc5891bc3a42" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_39577127-a5d4-4c35-a071-afb0d703a386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_de4762a4-1eed-4e05-85f4-89624581ffba" xlink:href="jnj-20220703.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_e64bb5fc-ff8c-45e8-9fca-fc5891bc3a42" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_de4762a4-1eed-4e05-85f4-89624581ffba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b48582ff-6163-42e3-88ad-204c4ebdbf0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d531af8b-cde6-430d-83b6-7f51c4ad0276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b48582ff-6163-42e3-88ad-204c4ebdbf0e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d531af8b-cde6-430d-83b6-7f51c4ad0276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0796c296-7981-47c5-8053-bb69a077f230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b48582ff-6163-42e3-88ad-204c4ebdbf0e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0796c296-7981-47c5-8053-bb69a077f230" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_94634b22-9493-4fa1-9f28-9a3e6c9226af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_4657af47-01e5-40ba-8724-cd20a1768782" xlink:href="jnj-20220703.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_94634b22-9493-4fa1-9f28-9a3e6c9226af" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_4657af47-01e5-40ba-8724-cd20a1768782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_8636371a-1e9f-4d82-8b0e-d85060f6eef5" xlink:href="jnj-20220703.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_94634b22-9493-4fa1-9f28-9a3e6c9226af" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_8636371a-1e9f-4d82-8b0e-d85060f6eef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18e54cba-4952-47c5-87be-96ea0a13d60a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d5865689-3564-4b8e-b740-64652d8a015d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18e54cba-4952-47c5-87be-96ea0a13d60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d5865689-3564-4b8e-b740-64652d8a015d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4c573cb2-5992-4923-b73f-094c7776606d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18e54cba-4952-47c5-87be-96ea0a13d60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4c573cb2-5992-4923-b73f-094c7776606d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_429030e9-99c1-457d-adbb-3517569df367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18e54cba-4952-47c5-87be-96ea0a13d60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_429030e9-99c1-457d-adbb-3517569df367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_51b3c81a-e3ea-45da-ae3a-1d1d5edae0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18e54cba-4952-47c5-87be-96ea0a13d60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_51b3c81a-e3ea-45da-ae3a-1d1d5edae0b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a126af86-17d4-42c3-96af-110f6bb5d927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_5877e619-34cb-4c3f-a557-c90bc37ac084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a126af86-17d4-42c3-96af-110f6bb5d927" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_5877e619-34cb-4c3f-a557-c90bc37ac084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_4ef8a73f-dd76-46bc-bc45-74bc67840482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a126af86-17d4-42c3-96af-110f6bb5d927" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_4ef8a73f-dd76-46bc-bc45-74bc67840482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3f03a6bf-c214-4365-9dae-33d0fa8f2ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_cb30f54a-e614-4739-a132-c02e31858c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3f03a6bf-c214-4365-9dae-33d0fa8f2ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_cb30f54a-e614-4739-a132-c02e31858c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09c87006-eca9-46c9-8cc3-1eef58b7eeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3f03a6bf-c214-4365-9dae-33d0fa8f2ff7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09c87006-eca9-46c9-8cc3-1eef58b7eeb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9afeb666-262e-4460-bf99-0cfce37a9062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b38dcaf0-8289-45ae-9d97-9bc23c39967e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9afeb666-262e-4460-bf99-0cfce37a9062" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b38dcaf0-8289-45ae-9d97-9bc23c39967e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a8d4916-b170-4ab4-9c6a-1f929e0de6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9afeb666-262e-4460-bf99-0cfce37a9062" xlink:to="loc_us-gaap_NetIncomeLoss_8a8d4916-b170-4ab4-9c6a-1f929e0de6ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7e89766-8f87-4711-838f-f13d65f75ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_eda23e5f-a3a9-4218-9bd0-94a7ea8b62c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7e89766-8f87-4711-838f-f13d65f75ed5" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_eda23e5f-a3a9-4218-9bd0-94a7ea8b62c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ff04f22-e605-401d-ac41-cef9f5352792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7e89766-8f87-4711-838f-f13d65f75ed5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ff04f22-e605-401d-ac41-cef9f5352792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_07e3013f-9ccb-41e1-a554-e83d85b62dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7e89766-8f87-4711-838f-f13d65f75ed5" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_07e3013f-9ccb-41e1-a554-e83d85b62dd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b7267bea-ede2-4068-89a6-7ebcc7f30960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7e89766-8f87-4711-838f-f13d65f75ed5" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b7267bea-ede2-4068-89a6-7ebcc7f30960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_59781dd7-0316-42bb-9741-98a21092be01" xlink:href="jnj-20220703.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7e89766-8f87-4711-838f-f13d65f75ed5" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_59781dd7-0316-42bb-9741-98a21092be01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a78e8d19-1545-4b4b-b434-c68809d36639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7e89766-8f87-4711-838f-f13d65f75ed5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a78e8d19-1545-4b4b-b434-c68809d36639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_567f3a0a-3005-4b71-8801-2005653fa77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7e89766-8f87-4711-838f-f13d65f75ed5" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_567f3a0a-3005-4b71-8801-2005653fa77c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_613873c6-c0b3-412b-af2b-1e7344709c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2268cbd-02af-4bd1-b676-b75339435b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_613873c6-c0b3-412b-af2b-1e7344709c0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2268cbd-02af-4bd1-b676-b75339435b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2b1897d0-e5e0-4ff5-8301-89119cc87135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_613873c6-c0b3-412b-af2b-1e7344709c0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2b1897d0-e5e0-4ff5-8301-89119cc87135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb598cd7-3652-47e2-8cec-ad9461605f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_613873c6-c0b3-412b-af2b-1e7344709c0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb598cd7-3652-47e2-8cec-ad9461605f4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc0f8e0f-540b-4d19-957f-5a69a373c08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_613873c6-c0b3-412b-af2b-1e7344709c0a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc0f8e0f-540b-4d19-957f-5a69a373c08a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0750ffc5-efc5-43e2-b0ea-70afd6387f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_NetIncomeLoss_0750ffc5-efc5-43e2-b0ea-70afd6387f83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9170b62d-d64f-49f8-aae5-847f0063ba41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9170b62d-d64f-49f8-aae5-847f0063ba41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_88499551-4a7b-4f83-9934-8068b851d3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_ShareBasedCompensation_88499551-4a7b-4f83-9934-8068b851d3ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3728402f-68f8-44bc-beac-5eb4df2cd707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_AssetImpairmentCharges_3728402f-68f8-44bc-beac-5eb4df2cd707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_0dbecaa2-3f85-48c7-987c-604593ba53ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_0dbecaa2-3f85-48c7-987c-604593ba53ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_568d688f-7e2f-43d3-8165-90f41e403ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_568d688f-7e2f-43d3-8165-90f41e403ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_03ea59d8-d381-4391-b913-84cbf722a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_03ea59d8-d381-4391-b913-84cbf722a8ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7ced69ec-c0c6-4da1-834b-54e997e6e874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7ced69ec-c0c6-4da1-834b-54e997e6e874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_53ee0582-d6fd-4778-9ef6-a9f1462e7fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_53ee0582-d6fd-4778-9ef6-a9f1462e7fcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cd7b4f50-21c2-4bc6-881a-e4d60673c65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cd7b4f50-21c2-4bc6-881a-e4d60673c65a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e40d5f78-194b-4d02-a959-97928875450b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e40d5f78-194b-4d02-a959-97928875450b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_62536891-a661-480f-be80-f9989eba8179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24165eec-1191-4ae4-a1c0-594647f48bc6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_62536891-a661-480f-be80-f9989eba8179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_f53d8de6-c768-478b-b611-d23c0eba1499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_2f3ae4fc-74e5-4301-beae-4c7e0bed5150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_f53d8de6-c768-478b-b611-d23c0eba1499" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_2f3ae4fc-74e5-4301-beae-4c7e0bed5150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_95d9a5aa-5285-42af-a183-376f83acb8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_f53d8de6-c768-478b-b611-d23c0eba1499" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_95d9a5aa-5285-42af-a183-376f83acb8f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_d73177a6-7967-46fd-a8ec-d7cf2efa7d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_d73177a6-7967-46fd-a8ec-d7cf2efa7d28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f085fd53-8f3f-446d-b128-b32322866002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f085fd53-8f3f-446d-b128-b32322866002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_7e956b08-7d8e-4746-a866-2849455431d7" xlink:href="jnj-20220703.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_7e956b08-7d8e-4746-a866-2849455431d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_fdfdfc65-3071-4499-bbaf-307e440ba55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_fdfdfc65-3071-4499-bbaf-307e440ba55a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_fe94ecc9-955f-49b7-b485-0fb34e93f6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_fe94ecc9-955f-49b7-b485-0fb34e93f6b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_60532267-44ea-476a-b934-e78646fac18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_60532267-44ea-476a-b934-e78646fac18e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_c1bc231f-1c52-4e56-bb9b-7307110c7e9b" xlink:href="jnj-20220703.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_c1bc231f-1c52-4e56-bb9b-7307110c7e9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ee74badf-8b2e-4abb-9618-fac203f3face" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ee74badf-8b2e-4abb-9618-fac203f3face" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6b2c9a8b-3d10-416d-b851-2b5be7106d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7abfcb65-fcfc-44bd-935d-6b2df97418f9" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6b2c9a8b-3d10-416d-b851-2b5be7106d2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3377c969-b0ca-478e-ab41-583bcf2fc0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_26b01463-0af2-4998-a374-b67f16c8763c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3377c969-b0ca-478e-ab41-583bcf2fc0c6" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_26b01463-0af2-4998-a374-b67f16c8763c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cd5dfa02-7299-42b1-bcc5-a04a57bfc260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3377c969-b0ca-478e-ab41-583bcf2fc0c6" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cd5dfa02-7299-42b1-bcc5-a04a57bfc260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5178f0ac-8df2-496c-8d09-09c00ec2cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3377c969-b0ca-478e-ab41-583bcf2fc0c6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5178f0ac-8df2-496c-8d09-09c00ec2cda8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04d4eafd-3f78-448f-b14a-dde8c54a69da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1251137c-5ec1-4fd6-957a-29767d86ea53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04d4eafd-3f78-448f-b14a-dde8c54a69da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1251137c-5ec1-4fd6-957a-29767d86ea53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_39e3f046-3cac-4dfe-a0af-1ef1f8694879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04d4eafd-3f78-448f-b14a-dde8c54a69da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_39e3f046-3cac-4dfe-a0af-1ef1f8694879" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_d695e8ee-79b1-45ec-9bc5-87ab82f388f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d20bb32e-72ed-4098-8990-617061a4d057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_d695e8ee-79b1-45ec-9bc5-87ab82f388f3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d20bb32e-72ed-4098-8990-617061a4d057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_3a5a90ae-8a53-4389-853a-b4a23cbc488c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_d695e8ee-79b1-45ec-9bc5-87ab82f388f3" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_3a5a90ae-8a53-4389-853a-b4a23cbc488c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1620b69b-d612-4654-a70d-357e96caf853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1756ddfb-acee-489b-9545-976ff300a149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_1620b69b-d612-4654-a70d-357e96caf853" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1756ddfb-acee-489b-9545-976ff300a149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5a51e2f7-92c2-4dc0-b61d-676acbc6aa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_1620b69b-d612-4654-a70d-357e96caf853" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5a51e2f7-92c2-4dc0-b61d-676acbc6aa6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f4a4c2d0-01f7-4038-a4a1-e12be4f570de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_79bbe373-171d-4946-92de-78b45cf4449d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f4a4c2d0-01f7-4038-a4a1-e12be4f570de" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_79bbe373-171d-4946-92de-78b45cf4449d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b43ee9a-8c41-42ee-82f6-841db2b3c084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f4a4c2d0-01f7-4038-a4a1-e12be4f570de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6b43ee9a-8c41-42ee-82f6-841db2b3c084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_d225059d-00d9-4072-bffc-762b5e06197f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_def1dfe7-6132-4c56-abf1-d7c2ff33ec33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_d225059d-00d9-4072-bffc-762b5e06197f" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_def1dfe7-6132-4c56-abf1-d7c2ff33ec33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_1fdd1132-0377-48cd-8388-825f5da75643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_d225059d-00d9-4072-bffc-762b5e06197f" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_1fdd1132-0377-48cd-8388-825f5da75643" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_fa00a7f6-69fb-4f3b-babc-c9c40d75dd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1dd3f744-fda0-4531-88a3-8f2bf963efdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_fa00a7f6-69fb-4f3b-babc-c9c40d75dd42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1dd3f744-fda0-4531-88a3-8f2bf963efdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_779c2c1a-3d42-4a42-9fbd-73e3f668e973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_fa00a7f6-69fb-4f3b-babc-c9c40d75dd42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_779c2c1a-3d42-4a42-9fbd-73e3f668e973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_00d5b560-0cc9-485e-afac-2f41f897440d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_fa00a7f6-69fb-4f3b-babc-c9c40d75dd42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_00d5b560-0cc9-485e-afac-2f41f897440d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c3e58747-34c8-4b26-bb69-39bbe2ea5aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_aa4a5e18-ffdd-4432-93f6-4c9cd3081ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c3e58747-34c8-4b26-bb69-39bbe2ea5aae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_aa4a5e18-ffdd-4432-93f6-4c9cd3081ba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c04d3502-6320-48be-9725-cd611a083c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c3e58747-34c8-4b26-bb69-39bbe2ea5aae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c04d3502-6320-48be-9725-cd611a083c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_dcb770a8-57ad-45ee-afaf-8984a94796b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c3e58747-34c8-4b26-bb69-39bbe2ea5aae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_dcb770a8-57ad-45ee-afaf-8984a94796b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c4ad3557-78f9-45a7-995c-f4886617ea8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_838e734b-cd37-4fbd-97e0-cac94e7f4faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c4ad3557-78f9-45a7-995c-f4886617ea8f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_838e734b-cd37-4fbd-97e0-cac94e7f4faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_7b486a70-025a-4cbf-99fb-5684bd95614d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c4ad3557-78f9-45a7-995c-f4886617ea8f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_7b486a70-025a-4cbf-99fb-5684bd95614d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_93d9cec9-7da6-43b5-84c9-4597f5e5f7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c4ad3557-78f9-45a7-995c-f4886617ea8f" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_93d9cec9-7da6-43b5-84c9-4597f5e5f7d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5b10908d-14f7-444c-91c4-790ef39f6064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c4ad3557-78f9-45a7-995c-f4886617ea8f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5b10908d-14f7-444c-91c4-790ef39f6064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0a8c0b36-2841-4cf2-a76c-cb272752058b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c4ad3557-78f9-45a7-995c-f4886617ea8f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0a8c0b36-2841-4cf2-a76c-cb272752058b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_c1f81eff-d2c1-4d64-9f09-2cbeb91c476d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c4ad3557-78f9-45a7-995c-f4886617ea8f" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_c1f81eff-d2c1-4d64-9f09-2cbeb91c476d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bf88089b-34b2-4df2-876f-20d25ad0ede2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_74c3e6b1-8c04-4bfe-89c1-26093799d581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bf88089b-34b2-4df2-876f-20d25ad0ede2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_74c3e6b1-8c04-4bfe-89c1-26093799d581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4af434e9-fa9a-43f7-a4be-3ef6f1716980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bf88089b-34b2-4df2-876f-20d25ad0ede2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4af434e9-fa9a-43f7-a4be-3ef6f1716980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_25c23f9c-77db-4e53-a6e9-eb3741094b31" xlink:href="jnj-20220703.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bf88089b-34b2-4df2-876f-20d25ad0ede2" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_25c23f9c-77db-4e53-a6e9-eb3741094b31" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>jnj-20220703_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a211293e-c516-4076-a852-d6c27f4cfad7,g:c2e9e48c-ca8c-4ec1-bfd7-8d90ecda38c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20220703.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended" id="ife06475160d14887ba6cf886ce82f1ce_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d2d116e8-5850-4646-96e4-6a9238f77604" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentType_d2d116e8-5850-4646-96e4-6a9238f77604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_37b76dee-7ffb-4c64-8ef1-0593e9a1c247" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentQuarterlyReport_37b76dee-7ffb-4c64-8ef1-0593e9a1c247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_42359cd2-45a2-410d-89b7-49aefbe18d1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentPeriodEndDate_42359cd2-45a2-410d-89b7-49aefbe18d1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3e0c8b14-a2b4-4df4-801b-d43fa6bddca3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentTransitionReport_3e0c8b14-a2b4-4df4-801b-d43fa6bddca3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_01ec493d-ebdb-4f14-85bd-e18f4cbebf39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityFileNumber_01ec493d-ebdb-4f14-85bd-e18f4cbebf39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d4ce835f-d496-4642-ae8c-b01c7c3b0bf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityRegistrantName_d4ce835f-d496-4642-ae8c-b01c7c3b0bf0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_15bcded1-3a82-4b07-992f-b9bbe7ebc20f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_15bcded1-3a82-4b07-992f-b9bbe7ebc20f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d1399971-d8bf-454e-827c-913a41b7fb4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityTaxIdentificationNumber_d1399971-d8bf-454e-827c-913a41b7fb4b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_af0c2848-e268-44e9-871d-91c77e89a8aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityAddressAddressLine1_af0c2848-e268-44e9-871d-91c77e89a8aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_52dc51ad-804b-4a8a-b771-c16e88cea102" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityAddressCityOrTown_52dc51ad-804b-4a8a-b771-c16e88cea102" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_830ee115-1ae3-4cb6-839c-4ec8db330929" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityAddressStateOrProvince_830ee115-1ae3-4cb6-839c-4ec8db330929" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a1358165-c093-468d-bbbc-12646e5bae6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityAddressPostalZipCode_a1358165-c093-468d-bbbc-12646e5bae6d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_55d42c24-c4ac-4e8a-9e1d-269cc369910b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_CityAreaCode_55d42c24-c4ac-4e8a-9e1d-269cc369910b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_face12e4-1ae6-4016-aeb0-ccafd377d47c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_LocalPhoneNumber_face12e4-1ae6-4016-aeb0-ccafd377d47c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_51758f9a-3fe0-4c59-ab1f-e5b43b4168af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityCurrentReportingStatus_51758f9a-3fe0-4c59-ab1f-e5b43b4168af" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f60b28d7-d35a-469b-a1d1-7669fce37998" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityInteractiveDataCurrent_f60b28d7-d35a-469b-a1d1-7669fce37998" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3290a16a-fe8c-44bd-9197-68a93de2e06e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityFilerCategory_3290a16a-fe8c-44bd-9197-68a93de2e06e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9aba50a2-683a-4fa9-873f-ee73e2c2844c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntitySmallBusiness_9aba50a2-683a-4fa9-873f-ee73e2c2844c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d003f883-0d35-49dd-a71a-18d68803fbff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityEmergingGrowthCompany_d003f883-0d35-49dd-a71a-18d68803fbff" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_473d5045-4fd3-48c9-9408-5a337c5bdce3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityShellCompany_473d5045-4fd3-48c9-9408-5a337c5bdce3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6e458c7c-5b66-4072-8728-3797759afa6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_Security12bTitle_6e458c7c-5b66-4072-8728-3797759afa6d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_10b6ad06-d24c-40cf-ae85-744e8a871ab6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_TradingSymbol_10b6ad06-d24c-40cf-ae85-744e8a871ab6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f0606ccf-5504-45fa-a884-35e2882e0479" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_SecurityExchangeName_f0606ccf-5504-45fa-a884-35e2882e0479" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c7633562-8566-4479-958f-1d7790c755e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c7633562-8566-4479-958f-1d7790c755e0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_17a9b2dd-3a46-4b14-8514-2c8113a76c81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityCentralIndexKey_17a9b2dd-3a46-4b14-8514-2c8113a76c81" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1d96fa5b-3c62-41bc-bb6c-b7a8a2e19f96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_CurrentFiscalYearEndDate_1d96fa5b-3c62-41bc-bb6c-b7a8a2e19f96" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_12a8319e-7636-4e85-96be-c7d10d3c1e67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentFiscalYearFocus_12a8319e-7636-4e85-96be-c7d10d3c1e67" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0042627e-e355-4768-a531-3ef55b57ef99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0042627e-e355-4768-a531-3ef55b57ef99" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_64ee0c4c-e18f-4afe-8aa4-7852ff3d28b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_AmendmentFlag_64ee0c4c-e18f-4afe-8aa4-7852ff3d28b1" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_43d5e52e-1926-492d-a304-4ef7391e1e8c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntitiesTable_43d5e52e-1926-492d-a304-4ef7391e1e8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_627405df-cc54-47ad-917f-71e386c9bb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_43d5e52e-1926-492d-a304-4ef7391e1e8c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_627405df-cc54-47ad-917f-71e386c9bb0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_627405df-cc54-47ad-917f-71e386c9bb0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_627405df-cc54-47ad-917f-71e386c9bb0f" xlink:to="loc_us-gaap_ClassOfStockDomain_627405df-cc54-47ad-917f-71e386c9bb0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_627405df-cc54-47ad-917f-71e386c9bb0f" xlink:to="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_57b5cd2e-c3fa-4609-a84f-158203be12f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_us-gaap_CommonStockMember_57b5cd2e-c3fa-4609-a84f-158203be12f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_5f19b8f8-2585-484a-a201-ee8a2aab0571" xlink:href="jnj-20220703.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_jnj_A0.650NotesDue2024Member_5f19b8f8-2585-484a-a201-ee8a2aab0571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_df052815-6be6-40bc-bf53-9178e916a9cc" xlink:href="jnj-20220703.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_jnj_A5.50NotesDue2024Member_df052815-6be6-40bc-bf53-9178e916a9cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_cc770579-8002-4457-ad47-9e2c28fa3382" xlink:href="jnj-20220703.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_jnj_A1.150NotesDue2028Member_cc770579-8002-4457-ad47-9e2c28fa3382" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_0e90a10d-210c-4629-9485-986cceb6d7ab" xlink:href="jnj-20220703.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_jnj_A1.650NotesDue2035Member_0e90a10d-210c-4629-9485-986cceb6d7ab" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i3eec0514bdf34d3f9f48f5b4797dd4f3_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2325e25-52d0-4fa5-8916-bf8e4eb0a0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2325e25-52d0-4fa5-8916-bf8e4eb0a0ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a70e620-ebe0-4b17-a9fb-a98c8431b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_NetIncomeLoss_3a70e620-ebe0-4b17-a9fb-a98c8431b95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_4d709aaa-b691-4953-97ff-33e75d3f0e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_DividendsCommonStockCash_4d709aaa-b691-4953-97ff-33e75d3f0e9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6bb65595-9dc1-481b-8dca-bbac22b7948f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6bb65595-9dc1-481b-8dca-bbac22b7948f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_955229d8-fa35-466d-9cc1-6e32104c4a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_955229d8-fa35-466d-9cc1-6e32104c4a37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6bd1f90b-e2af-48d4-a951-58e9fa4b132e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6bd1f90b-e2af-48d4-a951-58e9fa4b132e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f4ac7ec-eb22-4797-adb2-2be62e6f923b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5ef1255e-fb8e-4583-abfc-19ee1fbba978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_StatementTable_5ef1255e-fb8e-4583-abfc-19ee1fbba978" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12512320-64c2-409f-ae1e-db3d5fed4597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5ef1255e-fb8e-4583-abfc-19ee1fbba978" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12512320-64c2-409f-ae1e-db3d5fed4597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_12512320-64c2-409f-ae1e-db3d5fed4597_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12512320-64c2-409f-ae1e-db3d5fed4597" xlink:to="loc_us-gaap_EquityComponentDomain_12512320-64c2-409f-ae1e-db3d5fed4597_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12512320-64c2-409f-ae1e-db3d5fed4597" xlink:to="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_59358b30-864d-4544-b061-b2b79d1578a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:to="loc_us-gaap_RetainedEarningsMember_59358b30-864d-4544-b061-b2b79d1578a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a965000a-faee-4e37-ad5e-6b631c15b729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a965000a-faee-4e37-ad5e-6b631c15b729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9f057f95-4153-4017-93d8-6d0aaea757c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:to="loc_us-gaap_CommonStockMember_9f057f95-4153-4017-93d8-6d0aaea757c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_49fd2e50-43d0-4611-92d8-51c87c9f11f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:to="loc_us-gaap_TreasuryStockMember_49fd2e50-43d0-4611-92d8-51c87c9f11f4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i505348a3e98d485d8d63d57b0b15a9ff_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_5a11acd5-203a-4773-8238-f0c03eeed3d6" xlink:href="jnj-20220703.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_acdedae9-e4a9-428b-aa7f-61b6b42cb28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_5a11acd5-203a-4773-8238-f0c03eeed3d6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_acdedae9-e4a9-428b-aa7f-61b6b42cb28e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_acdedae9-e4a9-428b-aa7f-61b6b42cb28e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_10f320d0-f1af-41d2-966d-57ab7d0332c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_10f320d0-f1af-41d2-966d-57ab7d0332c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9da8aedf-33c6-4849-98c9-df5addbdf3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9da8aedf-33c6-4849-98c9-df5addbdf3c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1b2c78a0-bbdb-4554-a8d4-7ec8c6bf5d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1b2c78a0-bbdb-4554-a8d4-7ec8c6bf5d52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f5ee3627-cbd0-4ddf-b7fb-6e1a50e181a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_acdedae9-e4a9-428b-aa7f-61b6b42cb28e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f5ee3627-cbd0-4ddf-b7fb-6e1a50e181a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_29324754-6f72-40cb-ba4b-0bb60d5fd0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f5ee3627-cbd0-4ddf-b7fb-6e1a50e181a2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_29324754-6f72-40cb-ba4b-0bb60d5fd0ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d6cfe9df-dab6-4a77-a81c-c0a006d2ccdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f5ee3627-cbd0-4ddf-b7fb-6e1a50e181a2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d6cfe9df-dab6-4a77-a81c-c0a006d2ccdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7a3e1f48-016e-4594-b874-eb92d447a8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_5a11acd5-203a-4773-8238-f0c03eeed3d6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7a3e1f48-016e-4594-b874-eb92d447a8d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:href="jnj-20220703.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_5a11acd5-203a-4773-8238-f0c03eeed3d6" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629dbd81-4782-4ab6-af9d-aac78a242f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629dbd81-4782-4ab6-af9d-aac78a242f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629dbd81-4782-4ab6-af9d-aac78a242f4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629dbd81-4782-4ab6-af9d-aac78a242f4d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_629dbd81-4782-4ab6-af9d-aac78a242f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629dbd81-4782-4ab6-af9d-aac78a242f4d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_5a9b7441-dc90-4b68-a981-8ac41b48eb07" xlink:href="jnj-20220703.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:to="loc_jnj_PatentsAndTrademarksMember_5a9b7441-dc90-4b68-a981-8ac41b48eb07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_0270b9b2-4925-4387-966c-c9625f729756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_0270b9b2-4925-4387-966c-c9625f729756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_94240c81-c226-46f7-924c-1002e3ff0745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_94240c81-c226-46f7-924c-1002e3ff0745" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_41cd2453-aaf2-4ff7-be72-a8c1ed639caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_41cd2453-aaf2-4ff7-be72-a8c1ed639caa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_41cd2453-aaf2-4ff7-be72-a8c1ed639caa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_41cd2453-aaf2-4ff7-be72-a8c1ed639caa" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_41cd2453-aaf2-4ff7-be72-a8c1ed639caa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2df6fe5f-ac0e-4356-8f3e-9516c238b907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_41cd2453-aaf2-4ff7-be72-a8c1ed639caa" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2df6fe5f-ac0e-4356-8f3e-9516c238b907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_8a8ab453-42f7-449d-aaa6-4eadeb0cd614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2df6fe5f-ac0e-4356-8f3e-9516c238b907" xlink:to="loc_us-gaap_TrademarksMember_8a8ab453-42f7-449d-aaa6-4eadeb0cd614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_c5ee9e03-6e34-4cd7-bb35-6d84ddb88593" xlink:href="jnj-20220703.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2df6fe5f-ac0e-4356-8f3e-9516c238b907" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_c5ee9e03-6e34-4cd7-bb35-6d84ddb88593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fa626477-d623-413f-a28b-7022661f8539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fa626477-d623-413f-a28b-7022661f8539" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa626477-d623-413f-a28b-7022661f8539_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fa626477-d623-413f-a28b-7022661f8539" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa626477-d623-413f-a28b-7022661f8539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2993b33-833e-494b-8412-3958d0f8283e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fa626477-d623-413f-a28b-7022661f8539" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2993b33-833e-494b-8412-3958d0f8283e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_6a8a9865-f167-4356-bb9a-f84ffe3e48b1" xlink:href="jnj-20220703.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2993b33-833e-494b-8412-3958d0f8283e" xlink:to="loc_jnj_BermekimabMember_6a8a9865-f167-4356-bb9a-f84ffe3e48b1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended" id="ic96f5bc94eb94c7ca123401e9a6c626f_IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c9c14e73-aaeb-402a-a4f0-9b4e0c9b6566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c9c14e73-aaeb-402a-a4f0-9b4e0c9b6566" xlink:to="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_be97f82c-a3b9-40e2-b34d-a47cd07cab33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:to="loc_us-gaap_Goodwill_be97f82c-a3b9-40e2-b34d-a47cd07cab33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_9004a8ae-21b4-4e37-ae92-dfc9ec26dfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_9004a8ae-21b4-4e37-ae92-dfc9ec26dfbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_c210d092-dc8f-45ab-8f2d-5e8d3ac0e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_c210d092-dc8f-45ab-8f2d-5e8d3ac0e11f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_018425a9-dc34-4d52-a04f-bcb07aeaae36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_af749906-6589-40dc-b8ca-75f123dcfbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_c9c14e73-aaeb-402a-a4f0-9b4e0c9b6566" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_af749906-6589-40dc-b8ca-75f123dcfbe9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_67265c5d-662b-4a60-8b77-f653aa360d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_af749906-6589-40dc-b8ca-75f123dcfbe9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_67265c5d-662b-4a60-8b77-f653aa360d57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_67265c5d-662b-4a60-8b77-f653aa360d57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_67265c5d-662b-4a60-8b77-f653aa360d57" xlink:to="loc_us-gaap_SegmentDomain_67265c5d-662b-4a60-8b77-f653aa360d57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_67265c5d-662b-4a60-8b77-f653aa360d57" xlink:to="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_cbcf5b49-020d-49ef-9d43-0d61a64a9264" xlink:href="jnj-20220703.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:to="loc_jnj_ConsumerMember_cbcf5b49-020d-49ef-9d43-0d61a64a9264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_36e6eeb7-fdb1-43a5-b7d7-70d18d6f4a78" xlink:href="jnj-20220703.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:to="loc_jnj_PharmaceuticalMember_36e6eeb7-fdb1-43a5-b7d7-70d18d6f4a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_8e138092-85c2-4b56-bd66-224903eeeb40" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:to="loc_jnj_MedicalDevicesMember_8e138092-85c2-4b56-bd66-224903eeeb40" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="i7fdb337078614e72a4cb1299296aee1e_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b32570e7-bced-42a2-a831-6180090e416d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1497e2f5-94f1-48c3-9e1d-17805a9809e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b32570e7-bced-42a2-a831-6180090e416d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1497e2f5-94f1-48c3-9e1d-17805a9809e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7fb75594-cc2b-40e1-a0f7-c9a8ad1b39e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b32570e7-bced-42a2-a831-6180090e416d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7fb75594-cc2b-40e1-a0f7-c9a8ad1b39e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a7ceb9-90f5-47c5-b549-1be92c6a0be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b32570e7-bced-42a2-a831-6180090e416d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a7ceb9-90f5-47c5-b549-1be92c6a0be5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_be2ceddd-f6b5-4f62-bda9-b41b262dad65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a7ceb9-90f5-47c5-b549-1be92c6a0be5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_be2ceddd-f6b5-4f62-bda9-b41b262dad65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be2ceddd-f6b5-4f62-bda9-b41b262dad65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_be2ceddd-f6b5-4f62-bda9-b41b262dad65" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be2ceddd-f6b5-4f62-bda9-b41b262dad65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a0e124a-702a-4f61-8764-25229e94351a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_be2ceddd-f6b5-4f62-bda9-b41b262dad65" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a0e124a-702a-4f61-8764-25229e94351a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_fd123a6e-386d-480c-acf4-8f1da3725014" xlink:href="jnj-20220703.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a0e124a-702a-4f61-8764-25229e94351a" xlink:to="loc_jnj_PatentsAndTrademarksMember_fd123a6e-386d-480c-acf4-8f1da3725014" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_4acb0590-a8aa-4281-91a4-306338dfc203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a0e124a-702a-4f61-8764-25229e94351a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_4acb0590-a8aa-4281-91a4-306338dfc203" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i77b096e8ae1043639b431d088f6c6904_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_860c9b89-5b9b-4e99-b0dc-b2b97179beb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_860c9b89-5b9b-4e99-b0dc-b2b97179beb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b835cd19-050d-49a2-ba3e-2830492f3aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b835cd19-050d-49a2-ba3e-2830492f3aa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_8fd59aeb-0fcd-4f19-854d-4fb741f84c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_8fd59aeb-0fcd-4f19-854d-4fb741f84c07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_eb65d93c-e21e-4909-b2c6-67103eb9f13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_eb65d93c-e21e-4909-b2c6-67103eb9f13e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_18d0b593-0280-4987-b9ec-542ca0255a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_18d0b593-0280-4987-b9ec-542ca0255a88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_8b0149a6-3caf-4193-9adc-5dcc4f3d74fa" xlink:href="jnj-20220703.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_8b0149a6-3caf-4193-9adc-5dcc4f3d74fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_16499ce2-a9a7-4f29-b297-0fa591e4030d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_EquityFairValueAdjustment_16499ce2-a9a7-4f29-b297-0fa591e4030d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_ae62c6f2-ee7d-49db-92e9-7843e9a33db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_ae62c6f2-ee7d-49db-92e9-7843e9a33db2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_b78418b7-96e5-415d-ab46-32944c4e87dd" xlink:href="jnj-20220703.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_b78418b7-96e5-415d-ab46-32944c4e87dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4a378fea-7a89-4b9d-8c80-dde1b488e5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_ShortTermBorrowings_4a378fea-7a89-4b9d-8c80-dde1b488e5b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_f719f41b-71b3-494e-bc26-e83ea0a0404c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_f719f41b-71b3-494e-bc26-e83ea0a0404c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e0eab09e-472c-4c3f-b247-cf28fd02314e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_DebtInstrumentTerm_e0eab09e-472c-4c3f-b247-cf28fd02314e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_d9649f75-7e31-40fb-9eab-3946a53874d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_d9649f75-7e31-40fb-9eab-3946a53874d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_d9649f75-7e31-40fb-9eab-3946a53874d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_d9649f75-7e31-40fb-9eab-3946a53874d1" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_d9649f75-7e31-40fb-9eab-3946a53874d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0d7df606-6876-4657-bf9a-dee40624f2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_d9649f75-7e31-40fb-9eab-3946a53874d1" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0d7df606-6876-4657-bf9a-dee40624f2e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_566b4c79-02a7-432d-910f-24aa2ef064e1" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0d7df606-6876-4657-bf9a-dee40624f2e9" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_566b4c79-02a7-432d-910f-24aa2ef064e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_fc087fe8-62de-4bcb-bac6-41789e0cddd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_fc087fe8-62de-4bcb-bac6-41789e0cddd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fc087fe8-62de-4bcb-bac6-41789e0cddd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_fc087fe8-62de-4bcb-bac6-41789e0cddd4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fc087fe8-62de-4bcb-bac6-41789e0cddd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af7b1644-8ead-4e27-b039-a5189be31f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_fc087fe8-62de-4bcb-bac6-41789e0cddd4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af7b1644-8ead-4e27-b039-a5189be31f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_fe79df62-dd67-4ba3-9822-d8aac23a9f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af7b1644-8ead-4e27-b039-a5189be31f69" xlink:to="loc_us-gaap_EquitySecuritiesMember_fe79df62-dd67-4ba3-9822-d8aac23a9f03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9ee2ff4d-9ae6-4e3d-93bb-71f5765a123e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9ee2ff4d-9ae6-4e3d-93bb-71f5765a123e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9ee2ff4d-9ae6-4e3d-93bb-71f5765a123e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9ee2ff4d-9ae6-4e3d-93bb-71f5765a123e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9ee2ff4d-9ae6-4e3d-93bb-71f5765a123e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9ee2ff4d-9ae6-4e3d-93bb-71f5765a123e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_79b9ef4d-863e-4905-ba44-270912acf80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_79b9ef4d-863e-4905-ba44-270912acf80d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_d89cfcba-866e-48fb-accb-48b41f804175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_d89cfcba-866e-48fb-accb-48b41f804175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_03391859-5de6-4523-b6c6-c0b1b379d01c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:to="loc_us-gaap_InterestRateSwapMember_03391859-5de6-4523-b6c6-c0b1b379d01c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_f6b2aeda-5cab-464d-bce3-afee95a4de93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_f6b2aeda-5cab-464d-bce3-afee95a4de93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_f6b2aeda-5cab-464d-bce3-afee95a4de93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_f6b2aeda-5cab-464d-bce3-afee95a4de93" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_f6b2aeda-5cab-464d-bce3-afee95a4de93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_a4e719d7-f55d-41bd-bbdf-78ba892a561e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_f6b2aeda-5cab-464d-bce3-afee95a4de93" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_a4e719d7-f55d-41bd-bbdf-78ba892a561e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1d21fff0-a7dc-4abb-9d53-756dc680bf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_a4e719d7-f55d-41bd-bbdf-78ba892a561e" xlink:to="loc_us-gaap_CommercialPaperMember_1d21fff0-a7dc-4abb-9d53-756dc680bf5e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended" id="i7bfae1ac9cf74d18a2cdd8186ecbd1ab_FairValueMeasurementsSummaryofDerivativeActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_f410856f-eee1-44cf-b9cc-ac2375e3562a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_f410856f-eee1-44cf-b9cc-ac2375e3562a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_8d34fa28-4df8-485a-a527-d79a5f95fec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_8d34fa28-4df8-485a-a527-d79a5f95fec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_22b07b8c-daf8-4a03-8f8c-49aa7e6791ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_22b07b8c-daf8-4a03-8f8c-49aa7e6791ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_aeeb350d-7ff2-40c6-8c88-771bfebd4f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_aeeb350d-7ff2-40c6-8c88-771bfebd4f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_aeeb350d-7ff2-40c6-8c88-771bfebd4f34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_aeeb350d-7ff2-40c6-8c88-771bfebd4f34" xlink:to="loc_us-gaap_HedgingRelationshipDomain_aeeb350d-7ff2-40c6-8c88-771bfebd4f34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_aeeb350d-7ff2-40c6-8c88-771bfebd4f34" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_84d45b78-86e3-4966-adb8-999ad13fa32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:to="loc_us-gaap_FairValueHedgingMember_84d45b78-86e3-4966-adb8-999ad13fa32e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_a616fac4-cc10-49c9-8e4c-778b32ce6e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_a616fac4-cc10-49c9-8e4c-778b32ce6e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_5cc005c2-a639-44fa-9fd4-0d896a692b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:to="loc_us-gaap_CashFlowHedgingMember_5cc005c2-a639-44fa-9fd4-0d896a692b2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_07c5f25e-16bb-4dfa-820e-48f8c569caa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_07c5f25e-16bb-4dfa-820e-48f8c569caa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_07c5f25e-16bb-4dfa-820e-48f8c569caa7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_07c5f25e-16bb-4dfa-820e-48f8c569caa7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_07c5f25e-16bb-4dfa-820e-48f8c569caa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_07c5f25e-16bb-4dfa-820e-48f8c569caa7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_0224dc1b-8d4b-4b20-af5f-8ebc083009f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_InterestRateContractMember_0224dc1b-8d4b-4b20-af5f-8ebc083009f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5d2380de-db49-430a-9bb8-7b746855e1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5d2380de-db49-430a-9bb8-7b746855e1c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_5c80ab57-a0d1-47ed-a199-9d8bad2a93b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_5c80ab57-a0d1-47ed-a199-9d8bad2a93b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_d855f1fa-f99c-4d03-9f53-282e60b2b498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_InterestRateSwapMember_d855f1fa-f99c-4d03-9f53-282e60b2b498" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_453ba57c-0aba-4bd0-ab12-8868dd5204ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_453ba57c-0aba-4bd0-ab12-8868dd5204ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5118c8cb-c0ea-4ead-9891-c944e5fe1bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5118c8cb-c0ea-4ead-9891-c944e5fe1bbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5118c8cb-c0ea-4ead-9891-c944e5fe1bbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5118c8cb-c0ea-4ead-9891-c944e5fe1bbb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5118c8cb-c0ea-4ead-9891-c944e5fe1bbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5118c8cb-c0ea-4ead-9891-c944e5fe1bbb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_61f07887-9211-4bcb-983f-1b13425557d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_us-gaap_SalesMember_61f07887-9211-4bcb-983f-1b13425557d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ee563780-31d5-4870-8d8f-16fc76e287ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_us-gaap_CostOfSalesMember_ee563780-31d5-4870-8d8f-16fc76e287ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_01dc3bee-9b5c-4679-9d59-75ebb798f854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_01dc3bee-9b5c-4679-9d59-75ebb798f854" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_2f7daf79-7d1c-4c95-907d-6a4a36876749" xlink:href="jnj-20220703.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_2f7daf79-7d1c-4c95-907d-6a4a36876749" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_a2ac98ae-3ccb-4ae4-89b9-8595319f3904" xlink:href="jnj-20220703.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_a2ac98ae-3ccb-4ae4-89b9-8595319f3904" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended" id="i5a97ad5d72e649eebe70669e9813f7d3_FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_5f9d390e-f20b-4b73-9314-5ac7f0562f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_627411fc-ab19-4780-8c75-bbe9106849be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5f9d390e-f20b-4b73-9314-5ac7f0562f79" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_627411fc-ab19-4780-8c75-bbe9106849be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_da0bd2fa-2b53-431a-be01-f89335f73a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5f9d390e-f20b-4b73-9314-5ac7f0562f79" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_da0bd2fa-2b53-431a-be01-f89335f73a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_31f38799-012f-4b53-85e1-2d91c7460907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_5f9d390e-f20b-4b73-9314-5ac7f0562f79" xlink:to="loc_us-gaap_DerivativeTable_31f38799-012f-4b53-85e1-2d91c7460907" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5bc00101-adeb-4b93-92cf-3e816e1aff87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_31f38799-012f-4b53-85e1-2d91c7460907" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5bc00101-adeb-4b93-92cf-3e816e1aff87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5bc00101-adeb-4b93-92cf-3e816e1aff87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5bc00101-adeb-4b93-92cf-3e816e1aff87" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5bc00101-adeb-4b93-92cf-3e816e1aff87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7fc0febe-0a78-4c58-b082-39c84144c324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5bc00101-adeb-4b93-92cf-3e816e1aff87" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7fc0febe-0a78-4c58-b082-39c84144c324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_2ff9f665-76e8-43d7-8d8a-64984fea4df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7fc0febe-0a78-4c58-b082-39c84144c324" xlink:to="loc_us-gaap_LongTermDebtMember_2ff9f665-76e8-43d7-8d8a-64984fea4df7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_986631ef-e57f-4667-8d3a-32c12b39c0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_31f38799-012f-4b53-85e1-2d91c7460907" xlink:to="loc_us-gaap_HedgingDesignationAxis_986631ef-e57f-4667-8d3a-32c12b39c0f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_986631ef-e57f-4667-8d3a-32c12b39c0f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_986631ef-e57f-4667-8d3a-32c12b39c0f0" xlink:to="loc_us-gaap_HedgingDesignationDomain_986631ef-e57f-4667-8d3a-32c12b39c0f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ee3923b6-6948-4513-bfd5-235474acb847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_986631ef-e57f-4667-8d3a-32c12b39c0f0" xlink:to="loc_us-gaap_HedgingDesignationDomain_ee3923b6-6948-4513-bfd5-235474acb847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_295f4580-171f-459e-8f88-3081f96972a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ee3923b6-6948-4513-bfd5-235474acb847" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_295f4580-171f-459e-8f88-3081f96972a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i33abecfb68474f3587847727c9b009fb_FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4f94e916-b72c-4148-98cc-235e9f753dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5829bd57-5e15-4d2c-8900-2ef83b620c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4f94e916-b72c-4148-98cc-235e9f753dd4" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5829bd57-5e15-4d2c-8900-2ef83b620c73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4f94e916-b72c-4148-98cc-235e9f753dd4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4c486b9c-46fe-485d-812c-86abc48fdee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:to="loc_us-gaap_HedgingDesignationAxis_4c486b9c-46fe-485d-812c-86abc48fdee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4c486b9c-46fe-485d-812c-86abc48fdee7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_4c486b9c-46fe-485d-812c-86abc48fdee7" xlink:to="loc_us-gaap_HedgingDesignationDomain_4c486b9c-46fe-485d-812c-86abc48fdee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bae2814c-ba45-4930-898b-c8e776b2e300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_4c486b9c-46fe-485d-812c-86abc48fdee7" xlink:to="loc_us-gaap_HedgingDesignationDomain_bae2814c-ba45-4930-898b-c8e776b2e300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6aa4dc6c-c09a-468b-bb4e-687080e21288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bae2814c-ba45-4930-898b-c8e776b2e300" xlink:to="loc_us-gaap_NondesignatedMember_6aa4dc6c-c09a-468b-bb4e-687080e21288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6f40ab2b-3bd8-42dc-a447-3d620efc7f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6f40ab2b-3bd8-42dc-a447-3d620efc7f9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6f40ab2b-3bd8-42dc-a447-3d620efc7f9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6f40ab2b-3bd8-42dc-a447-3d620efc7f9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6f40ab2b-3bd8-42dc-a447-3d620efc7f9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ce019c7a-4525-4c80-9253-e0cb3feeab3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6f40ab2b-3bd8-42dc-a447-3d620efc7f9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ce019c7a-4525-4c80-9253-e0cb3feeab3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ddd16b96-4849-45cd-bfc4-9f706c64a5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ce019c7a-4525-4c80-9253-e0cb3feeab3d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ddd16b96-4849-45cd-bfc4-9f706c64a5e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5dc3246f-a4c5-4810-aca0-98ebbdbb197d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5dc3246f-a4c5-4810-aca0-98ebbdbb197d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5dc3246f-a4c5-4810-aca0-98ebbdbb197d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5dc3246f-a4c5-4810-aca0-98ebbdbb197d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5dc3246f-a4c5-4810-aca0-98ebbdbb197d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aa46ba99-2fc1-4cd1-9f81-51fe73c28e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5dc3246f-a4c5-4810-aca0-98ebbdbb197d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aa46ba99-2fc1-4cd1-9f81-51fe73c28e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_c0b9646d-5fa2-4cb4-8115-475cf2918c43" xlink:href="jnj-20220703.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa46ba99-2fc1-4cd1-9f81-51fe73c28e43" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_c0b9646d-5fa2-4cb4-8115-475cf2918c43" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="i3e0849ad855741ad8601399e6ebd7c6b_FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ea6dd4cd-595b-480f-bc9d-29309752091e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ff3fac18-db88-466e-85b0-8457674054ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ea6dd4cd-595b-480f-bc9d-29309752091e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ff3fac18-db88-466e-85b0-8457674054ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_9ddc72db-342c-48ce-812f-1f2f00abb7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ea6dd4cd-595b-480f-bc9d-29309752091e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_9ddc72db-342c-48ce-812f-1f2f00abb7bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a5786043-0004-4969-9bad-5c81236c10d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ea6dd4cd-595b-480f-bc9d-29309752091e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a5786043-0004-4969-9bad-5c81236c10d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_781e3dd0-3af1-4169-969b-7541c4b5313e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a5786043-0004-4969-9bad-5c81236c10d2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_781e3dd0-3af1-4169-969b-7541c4b5313e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_781e3dd0-3af1-4169-969b-7541c4b5313e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_781e3dd0-3af1-4169-969b-7541c4b5313e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_781e3dd0-3af1-4169-969b-7541c4b5313e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_85a8a61b-73b5-480f-b0f2-60ef7e6c4d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_781e3dd0-3af1-4169-969b-7541c4b5313e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_85a8a61b-73b5-480f-b0f2-60ef7e6c4d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_539b6c9c-4258-43b0-8687-33796a07cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_85a8a61b-73b5-480f-b0f2-60ef7e6c4d77" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_539b6c9c-4258-43b0-8687-33796a07cc62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_694bf12e-5e9e-4ce6-9d7b-590ae769a97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a5786043-0004-4969-9bad-5c81236c10d2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_694bf12e-5e9e-4ce6-9d7b-590ae769a97f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_694bf12e-5e9e-4ce6-9d7b-590ae769a97f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_694bf12e-5e9e-4ce6-9d7b-590ae769a97f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_694bf12e-5e9e-4ce6-9d7b-590ae769a97f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_65ba82bb-49eb-4106-ad92-1e0b1d453864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_694bf12e-5e9e-4ce6-9d7b-590ae769a97f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_65ba82bb-49eb-4106-ad92-1e0b1d453864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_9dd3beb8-0106-4936-9582-a52cb71c3fb1" xlink:href="jnj-20220703.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_65ba82bb-49eb-4106-ad92-1e0b1d453864" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_9dd3beb8-0106-4936-9582-a52cb71c3fb1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended" id="i0359676e2d464ab4851949a6d950cfdb_FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_83f6fa3a-c8f9-4e7f-b4ca-292885d920cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_83f6fa3a-c8f9-4e7f-b4ca-292885d920cc" xlink:to="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_47958141-e66c-43c8-9258-a6b087da2a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_47958141-e66c-43c8-9258-a6b087da2a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_77dd6951-c349-48da-a993-66a3eb0cd5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_77dd6951-c349-48da-a993-66a3eb0cd5dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_6832159e-dbd3-4115-b9df-08fea3cd7b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_EquityFairValueAdjustment_6832159e-dbd3-4115-b9df-08fea3cd7b29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_cc47e23e-7489-4f36-8009-7af9f13f7c95" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_cc47e23e-7489-4f36-8009-7af9f13f7c95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_1c336cf9-8392-4e9c-93ae-144fef31c505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9ef9b042-ed8e-40a9-9f99-34a53e9f9596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b629ddc2-0986-4b0a-9fb2-72f24d85766d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b629ddc2-0986-4b0a-9fb2-72f24d85766d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_b32e37e4-c897-4178-8f9f-112499c55632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_83f6fa3a-c8f9-4e7f-b4ca-292885d920cc" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_b32e37e4-c897-4178-8f9f-112499c55632" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5897e04c-10a9-472d-85e8-8f3004f658c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_b32e37e4-c897-4178-8f9f-112499c55632" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5897e04c-10a9-472d-85e8-8f3004f658c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5897e04c-10a9-472d-85e8-8f3004f658c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5897e04c-10a9-472d-85e8-8f3004f658c5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5897e04c-10a9-472d-85e8-8f3004f658c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94b16253-a01b-4783-924e-d4dac0bae096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5897e04c-10a9-472d-85e8-8f3004f658c5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94b16253-a01b-4783-924e-d4dac0bae096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_7dbf9344-f52e-4f5c-a260-936dcc572791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94b16253-a01b-4783-924e-d4dac0bae096" xlink:to="loc_us-gaap_EquitySecuritiesMember_7dbf9344-f52e-4f5c-a260-936dcc572791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_39958f83-bb39-4447-b150-205d38c47ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_b32e37e4-c897-4178-8f9f-112499c55632" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_39958f83-bb39-4447-b150-205d38c47ad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_39958f83-bb39-4447-b150-205d38c47ad9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_39958f83-bb39-4447-b150-205d38c47ad9" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_39958f83-bb39-4447-b150-205d38c47ad9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c05155af-84c5-4905-a358-bb5aabde5c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_39958f83-bb39-4447-b150-205d38c47ad9" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c05155af-84c5-4905-a358-bb5aabde5c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_3eb0f74b-e94c-415f-9193-6001f81ba78d" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c05155af-84c5-4905-a358-bb5aabde5c14" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_3eb0f74b-e94c-415f-9193-6001f81ba78d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_8bb9236c-e384-44f1-86f9-92b15d6fd62b" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c05155af-84c5-4905-a358-bb5aabde5c14" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_8bb9236c-e384-44f1-86f9-92b15d6fd62b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="if855ba8f1a684717b02fb332620a9c13_FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_4117b658-c44a-433c-945c-3fc7dbc29b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_4117b658-c44a-433c-945c-3fc7dbc29b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_b326dfbd-4ca8-4659-aade-82ffc83b5ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_b326dfbd-4ca8-4659-aade-82ffc83b5ae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_2bdd8ae4-92c2-48e7-847f-454c2c93b132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_2bdd8ae4-92c2-48e7-847f-454c2c93b132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_0a26f0ee-ac56-4cfb-b203-167cc24d8fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_0a26f0ee-ac56-4cfb-b203-167cc24d8fe0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7d735970-a24f-45df-abf4-d5d715cbfa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7d735970-a24f-45df-abf4-d5d715cbfa18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9a5687ff-34da-4caa-b064-52792e582c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9a5687ff-34da-4caa-b064-52792e582c7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_452f03c2-1aec-4bae-9d96-aeae8c5a0120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_452f03c2-1aec-4bae-9d96-aeae8c5a0120" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_52b36cff-1d76-4ef5-8670-29d367978d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_52b36cff-1d76-4ef5-8670-29d367978d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_b853c45c-ba0b-4d76-b4bb-8ba6779cfec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_b853c45c-ba0b-4d76-b4bb-8ba6779cfec9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2eb717f2-b982-4609-9e3a-9b4046404eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeAssets_2eb717f2-b982-4609-9e3a-9b4046404eab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_42aa73f7-35f6-4fa6-a5cf-a6bde7154b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_42aa73f7-35f6-4fa6-a5cf-a6bde7154b65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_6d1d5f79-cbd8-4b8e-bfd2-6776a904e5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_6d1d5f79-cbd8-4b8e-bfd2-6776a904e5cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_902ace78-bd9f-46ea-bfe2-c23c6cbb2d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeLiabilities_902ace78-bd9f-46ea-bfe2-c23c6cbb2d30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ec74477d-5883-42c0-b373-cf6da2c3b7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ec74477d-5883-42c0-b373-cf6da2c3b7a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_16e80d46-4c73-4c3b-a625-1429d0c80596" xlink:href="jnj-20220703.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_16e80d46-4c73-4c3b-a625-1429d0c80596" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_216a6669-9f82-45b2-ae8e-b9dfd44a8349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_216a6669-9f82-45b2-ae8e-b9dfd44a8349" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a11109f-55e7-48b9-9527-07ac28f04c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a11109f-55e7-48b9-9527-07ac28f04c8a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_df0bf457-3cc1-4891-84a4-dc11af8aa96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ffe0d546-5f80-47db-8ab6-d899b2a7badb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ffe0d546-5f80-47db-8ab6-d899b2a7badb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ffe0d546-5f80-47db-8ab6-d899b2a7badb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ffe0d546-5f80-47db-8ab6-d899b2a7badb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ffe0d546-5f80-47db-8ab6-d899b2a7badb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ffe0d546-5f80-47db-8ab6-d899b2a7badb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_921ac250-08eb-4da8-a5d4-fafa2fa7287c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_921ac250-08eb-4da8-a5d4-fafa2fa7287c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_b72d043b-0cdd-42c4-b603-efcf315ef721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_b72d043b-0cdd-42c4-b603-efcf315ef721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_355df89f-f4db-4046-9216-a8c5d41f2061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:to="loc_us-gaap_LongTermDebtMember_355df89f-f4db-4046-9216-a8c5d41f2061" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7c121723-7683-4b2a-9e3c-e350555f9249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7c121723-7683-4b2a-9e3c-e350555f9249" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c121723-7683-4b2a-9e3c-e350555f9249_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7c121723-7683-4b2a-9e3c-e350555f9249" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c121723-7683-4b2a-9e3c-e350555f9249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d32ae83b-895c-4adc-b4f8-ae0bcba416de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7c121723-7683-4b2a-9e3c-e350555f9249" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d32ae83b-895c-4adc-b4f8-ae0bcba416de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_8beb264c-a43e-40ea-9f7a-ef21be154685" xlink:href="jnj-20220703.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d32ae83b-895c-4adc-b4f8-ae0bcba416de" xlink:to="loc_jnj_AurisHealthMember_8beb264c-a43e-40ea-9f7a-ef21be154685" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a79ca58e-43b3-4b41-9003-44daac74500e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_InvestmentTypeAxis_a79ca58e-43b3-4b41-9003-44daac74500e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a79ca58e-43b3-4b41-9003-44daac74500e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_a79ca58e-43b3-4b41-9003-44daac74500e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a79ca58e-43b3-4b41-9003-44daac74500e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_01b9693b-a269-4ce9-9213-ecf45fc969f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_a79ca58e-43b3-4b41-9003-44daac74500e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_01b9693b-a269-4ce9-9213-ecf45fc969f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_766211d5-dff0-4b3c-80d8-6739b59953a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_01b9693b-a269-4ce9-9213-ecf45fc969f3" xlink:to="loc_us-gaap_EquitySecuritiesMember_766211d5-dff0-4b3c-80d8-6739b59953a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fc004970-bebf-4052-9d2c-7aef439327c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fc004970-bebf-4052-9d2c-7aef439327c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fc004970-bebf-4052-9d2c-7aef439327c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fc004970-bebf-4052-9d2c-7aef439327c1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fc004970-bebf-4052-9d2c-7aef439327c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fc004970-bebf-4052-9d2c-7aef439327c1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_709c323f-4a36-4624-9923-4b99a60720fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:to="loc_us-gaap_InterestRateContractMember_709c323f-4a36-4624-9923-4b99a60720fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b2a507dc-3aef-4ace-b886-fe133fe05d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b2a507dc-3aef-4ace-b886-fe133fe05d29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_a7406646-d2a4-4a12-91e0-8b20e84e52a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_a7406646-d2a4-4a12-91e0-8b20e84e52a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bc9d67fc-e5a4-49a9-a4f2-ce684df0319c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bc9d67fc-e5a4-49a9-a4f2-ce684df0319c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc9d67fc-e5a4-49a9-a4f2-ce684df0319c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bc9d67fc-e5a4-49a9-a4f2-ce684df0319c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc9d67fc-e5a4-49a9-a4f2-ce684df0319c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bc9d67fc-e5a4-49a9-a4f2-ce684df0319c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c2f3ce70-c6ae-4e07-92ac-f00f37d36146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c2f3ce70-c6ae-4e07-92ac-f00f37d36146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dbaca665-4b52-492c-a604-8d9ca8b87601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dbaca665-4b52-492c-a604-8d9ca8b87601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1bff275f-e3ca-44f9-8d1a-07e11a78f6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1bff275f-e3ca-44f9-8d1a-07e11a78f6d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a61313a8-9b5e-4888-abde-138534da3d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a61313a8-9b5e-4888-abde-138534da3d80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a61313a8-9b5e-4888-abde-138534da3d80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a61313a8-9b5e-4888-abde-138534da3d80" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a61313a8-9b5e-4888-abde-138534da3d80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_62b83e25-bc99-425d-a7c3-c706189b7f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a61313a8-9b5e-4888-abde-138534da3d80" xlink:to="loc_us-gaap_HedgingRelationshipDomain_62b83e25-bc99-425d-a7c3-c706189b7f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_13f78d91-5d48-4702-8e29-7b2b58d9eca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_62b83e25-bc99-425d-a7c3-c706189b7f6b" xlink:to="loc_us-gaap_FairValueHedgingMember_13f78d91-5d48-4702-8e29-7b2b58d9eca0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="iaccfb2e0a0e44eaf82cf623f0052ef96_FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_d9362d9e-ea4d-401c-8d91-ac7756482109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:to="loc_us-gaap_HeldToMaturitySecurities_d9362d9e-ea4d-401c-8d91-ac7756482109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_611f3b17-262e-4d0b-8a70-e28ce64fdee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_611f3b17-262e-4d0b-8a70-e28ce64fdee7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_c4341413-fb15-4f6d-8d27-a4a611ed5b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_c4341413-fb15-4f6d-8d27-a4a611ed5b1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_77cc5a86-4e14-44a3-aa63-9e3c68d5e81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_77cc5a86-4e14-44a3-aa63-9e3c68d5e81e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f54b20d9-a49a-4424-a87c-2dcbd91c63c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f54b20d9-a49a-4424-a87c-2dcbd91c63c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bb1b24e-22c9-4e59-b625-81cba30737a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bb1b24e-22c9-4e59-b625-81cba30737a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ad13387a-eb3d-45d7-a2b6-286f05677942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ad13387a-eb3d-45d7-a2b6-286f05677942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_c100a313-d74d-4fd0-b9c7-4ebccffea68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_c100a313-d74d-4fd0-b9c7-4ebccffea68d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_51541e09-46a2-4c1d-a17e-058f3d4c3629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_51541e09-46a2-4c1d-a17e-058f3d4c3629" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_0a184a5b-bbca-4bf4-952d-348eea6cf328" xlink:href="jnj-20220703.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_0a184a5b-bbca-4bf4-952d-348eea6cf328" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_d711f813-7faf-4957-ac43-0541a4a2e3ce" xlink:href="jnj-20220703.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_d711f813-7faf-4957-ac43-0541a4a2e3ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_056b7495-029d-407b-95c7-fe0d28f3d884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_056b7495-029d-407b-95c7-fe0d28f3d884" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_7b8120ba-0622-4190-9202-825e90c4765b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_056b7495-029d-407b-95c7-fe0d28f3d884" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_7b8120ba-0622-4190-9202-825e90c4765b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_7b8120ba-0622-4190-9202-825e90c4765b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_7b8120ba-0622-4190-9202-825e90c4765b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_7b8120ba-0622-4190-9202-825e90c4765b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_470c6fa3-91a5-4b52-8630-15e8fb882e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_7b8120ba-0622-4190-9202-825e90c4765b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_470c6fa3-91a5-4b52-8630-15e8fb882e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_df464cef-f1d8-4879-9379-4ccadfcfd8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_470c6fa3-91a5-4b52-8630-15e8fb882e70" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_df464cef-f1d8-4879-9379-4ccadfcfd8d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_4e3a880f-4869-4281-8944-0d533c9817eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_470c6fa3-91a5-4b52-8630-15e8fb882e70" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_4e3a880f-4869-4281-8944-0d533c9817eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a419240a-ad83-42a8-bc87-ab3dd589036e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_056b7495-029d-407b-95c7-fe0d28f3d884" xlink:to="loc_us-gaap_InvestmentTypeAxis_a419240a-ad83-42a8-bc87-ab3dd589036e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a419240a-ad83-42a8-bc87-ab3dd589036e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_a419240a-ad83-42a8-bc87-ab3dd589036e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a419240a-ad83-42a8-bc87-ab3dd589036e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_a419240a-ad83-42a8-bc87-ab3dd589036e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_8ee3829d-de39-4c47-9e5b-f49e04c135a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_CashMember_8ee3829d-de39-4c47-9e5b-f49e04c135a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_ca80d47e-620c-4639-9c9a-7a6d26dfd5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_ca80d47e-620c-4639-9c9a-7a6d26dfd5b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_fe0e5876-febe-412b-bf5f-bf77cf659c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_fe0e5876-febe-412b-bf5f-bf77cf659c41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_da6a6336-ed57-466d-b63a-79a1a8abf8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_da6a6336-ed57-466d-b63a-79a1a8abf8c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3f62ed48-0bb0-4f82-b158-39de0e107390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3f62ed48-0bb0-4f82-b158-39de0e107390" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_71fe3c1d-ab6b-4492-bfdd-f844fc96c62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_BankTimeDepositsMember_71fe3c1d-ab6b-4492-bfdd-f844fc96c62a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_4e02d45d-5aee-4142-92d5-c5a5378869b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_4e02d45d-5aee-4142-92d5-c5a5378869b2" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended" id="i59f956aef0f24bc39f1336ddc10aa401_FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0694f366-a69b-435b-aca7-3765b25e068a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0694f366-a69b-435b-aca7-3765b25e068a" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_3e25e360-89d3-4972-b68f-6f5eec17dd59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_3e25e360-89d3-4972-b68f-6f5eec17dd59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_d796fac0-47a6-46dd-afad-3416493748eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_3e25e360-89d3-4972-b68f-6f5eec17dd59" xlink:to="loc_us-gaap_ShortTermBorrowings_d796fac0-47a6-46dd-afad-3416493748eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_7b6fbf31-acaf-468d-a2d1-91dfa337faaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_7b6fbf31-acaf-468d-a2d1-91dfa337faaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_99582771-6c0e-4c78-9a9a-fc0117dbb91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_7b6fbf31-acaf-468d-a2d1-91dfa337faaa" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_99582771-6c0e-4c78-9a9a-fc0117dbb91e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41589eaf-a0b4-4115-b5bb-95dd52171fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41589eaf-a0b4-4115-b5bb-95dd52171fe3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ab8cbfc5-68d3-4743-9eb4-5d1c80b74706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ab8cbfc5-68d3-4743-9eb4-5d1c80b74706" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_fdd15d11-7689-49ad-bdec-4129dc761cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_fdd15d11-7689-49ad-bdec-4129dc761cf8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f7da8bc6-9c2a-48f4-89bb-e4bbe7a51d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0694f366-a69b-435b-aca7-3765b25e068a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f7da8bc6-9c2a-48f4-89bb-e4bbe7a51d0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e233fa3b-d518-42ae-81b7-d388652b5b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f7da8bc6-9c2a-48f4-89bb-e4bbe7a51d0a" xlink:to="loc_us-gaap_DebtInstrumentAxis_e233fa3b-d518-42ae-81b7-d388652b5b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e233fa3b-d518-42ae-81b7-d388652b5b48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e233fa3b-d518-42ae-81b7-d388652b5b48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e233fa3b-d518-42ae-81b7-d388652b5b48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e233fa3b-d518-42ae-81b7-d388652b5b48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_b0e3729a-3b1b-4a15-92dd-f623a8c2dbb4" xlink:href="jnj-20220703.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_b0e3729a-3b1b-4a15-92dd-f623a8c2dbb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_33871d21-bc69-4bfe-af14-e909d6ef48c6" xlink:href="jnj-20220703.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.375Notesdue2023Member_33871d21-bc69-4bfe-af14-e909d6ef48c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_58fe60a1-78cf-446d-924b-76e5e6b0a3be" xlink:href="jnj-20220703.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A0.650NotesDue2024Member_58fe60a1-78cf-446d-924b-76e5e6b0a3be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_d7012415-6ce5-4ff3-957e-48097f545d7f" xlink:href="jnj-20220703.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A5.50NotesDue2024Member_d7012415-6ce5-4ff3-957e-48097f545d7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_ae7c4fb2-c1a4-45dd-bed1-6cff737e4d45" xlink:href="jnj-20220703.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2.625Notesdue2025Member_ae7c4fb2-c1a4-45dd-bed1-6cff737e4d45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_62e75135-82c4-4b1b-b4e7-32a255214e6b" xlink:href="jnj-20220703.xsd#jnj_A0550NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A0550NotesDue2025Member_62e75135-82c4-4b1b-b4e7-32a255214e6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_8352b94b-1a8d-4e02-a9f0-c5aae51c4000" xlink:href="jnj-20220703.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2.45Notesdue2026Member_8352b94b-1a8d-4e02-a9f0-c5aae51c4000" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_337b9c48-56ff-4ea8-88e2-66a21c01628e" xlink:href="jnj-20220703.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2.95Notesdue2027Member_337b9c48-56ff-4ea8-88e2-66a21c01628e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_74dd0eb4-d72e-4b26-8f47-1b2b91894cce" xlink:href="jnj-20220703.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A095NotesDue2027Member_74dd0eb4-d72e-4b26-8f47-1b2b91894cce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_265f848e-f325-4d99-ba8f-c24323ca3dbf" xlink:href="jnj-20220703.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2.900Notesdue2028Member_265f848e-f325-4d99-ba8f-c24323ca3dbf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_15e3e97e-1841-4e40-9bb4-e83373924aea" xlink:href="jnj-20220703.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A1.150NotesDue2028Member_15e3e97e-1841-4e40-9bb4-e83373924aea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_bdfa39e2-aead-42de-98ad-117cc7a1f7d9" xlink:href="jnj-20220703.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A6.95Notesdue2029Member_bdfa39e2-aead-42de-98ad-117cc7a1f7d9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_9c2c091a-d0f1-4d26-b365-71558b00968b" xlink:href="jnj-20220703.xsd#jnj_A1300NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A1300NotesDue2030Member_9c2c091a-d0f1-4d26-b365-71558b00968b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_7e7a8297-3cc8-402b-acff-92ac7ba77c15" xlink:href="jnj-20220703.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_7e7a8297-3cc8-402b-acff-92ac7ba77c15" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_dd9dc79c-e57b-4779-ba24-6882e5277f9c" xlink:href="jnj-20220703.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.375Notesdue2033Member_dd9dc79c-e57b-4779-ba24-6882e5277f9c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_8951cc69-a038-4e85-8b88-6a31b9214742" xlink:href="jnj-20220703.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A1.650NotesDue2035Member_8951cc69-a038-4e85-8b88-6a31b9214742" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_934e8384-c752-4543-bafd-83bcbcd25436" xlink:href="jnj-20220703.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.55Notesdue2036Member_934e8384-c752-4543-bafd-83bcbcd25436" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_f1194c71-c963-43e3-a97d-90f11d71e6f7" xlink:href="jnj-20220703.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A5.95Notesdue2037Member_f1194c71-c963-43e3-a97d-90f11d71e6f7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_6f00e0a7-a42a-445d-abb3-30a537f39dab" xlink:href="jnj-20220703.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.625Notesdue2037Member_6f00e0a7-a42a-445d-abb3-30a537f39dab" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_1b517ca1-691b-4978-8f87-b60380ae7740" xlink:href="jnj-20220703.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.400Notesdue2038Member_1b517ca1-691b-4978-8f87-b60380ae7740" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_eef0664c-26bd-4597-9c86-0f3e458e5366" xlink:href="jnj-20220703.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_eef0664c-26bd-4597-9c86-0f3e458e5366" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_a1af5be5-1e57-4237-accc-0c448909d01e" xlink:href="jnj-20220703.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_a1af5be5-1e57-4237-accc-0c448909d01e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_bc0c51d1-1746-4807-a181-4fc52b64129f" xlink:href="jnj-20220703.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A210NotesDue2040Member_bc0c51d1-1746-4807-a181-4fc52b64129f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_57feaa26-3111-4e88-9771-5d359c466452" xlink:href="jnj-20220703.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.85Notesdue2041Member_57feaa26-3111-4e88-9771-5d359c466452" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_4d2d1246-a8b4-46f9-b46c-d3e0a2c818de" xlink:href="jnj-20220703.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.50Notesdue2043Member_4d2d1246-a8b4-46f9-b46c-d3e0a2c818de" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_bae6d85f-b7c9-41a6-b230-23b8afa382b5" xlink:href="jnj-20220703.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.70Notesdue2046Member_bae6d85f-b7c9-41a6-b230-23b8afa382b5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_d90ca951-2189-4201-bad0-7dd8e34a1cfc" xlink:href="jnj-20220703.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.75Notesdue2047Member_d90ca951-2189-4201-bad0-7dd8e34a1cfc" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_0adbc5fb-6e29-422e-84ad-1dbd7eb6dfa1" xlink:href="jnj-20220703.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.500Notesdue2048Member_0adbc5fb-6e29-422e-84ad-1dbd7eb6dfa1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_1f9c3a95-afca-47e8-8c61-8d03ceaafda4" xlink:href="jnj-20220703.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2250NotesDue2050Member_1f9c3a95-afca-47e8-8c61-8d03ceaafda4" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_a49f7d88-83c7-4279-b773-e507f8517fe4" xlink:href="jnj-20220703.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2450NotesDue2060Member_a49f7d88-83c7-4279-b773-e507f8517fe4" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_ef4a10a1-beb5-41bd-8e2b-30022530be17" xlink:href="jnj-20220703.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_ef4a10a1-beb5-41bd-8e2b-30022530be17" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_75b062de-410a-456f-bf29-a555f9a4e9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f7da8bc6-9c2a-48f4-89bb-e4bbe7a51d0a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_75b062de-410a-456f-bf29-a555f9a4e9b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_75b062de-410a-456f-bf29-a555f9a4e9b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_75b062de-410a-456f-bf29-a555f9a4e9b8" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_75b062de-410a-456f-bf29-a555f9a4e9b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3682a63e-9897-4dbe-a6e5-6b76c791703b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_75b062de-410a-456f-bf29-a555f9a4e9b8" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3682a63e-9897-4dbe-a6e5-6b76c791703b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5558f9d5-82c2-48fb-a40a-2da1c64e92e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3682a63e-9897-4dbe-a6e5-6b76c791703b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5558f9d5-82c2-48fb-a40a-2da1c64e92e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d826f788-24c5-40fd-b271-e98e05408d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5558f9d5-82c2-48fb-a40a-2da1c64e92e2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d826f788-24c5-40fd-b271-e98e05408d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9efbc13e-0d2a-43ab-924d-01856d1b0b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5558f9d5-82c2-48fb-a40a-2da1c64e92e2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9efbc13e-0d2a-43ab-924d-01856d1b0b79" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended" id="ib4c8f2df53ed4ad8bb349435caa7504b_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_4e264493-6769-4137-9d66-825455e5235e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_d3df9979-3090-4920-9dc0-cb21df484b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e264493-6769-4137-9d66-825455e5235e" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_d3df9979-3090-4920-9dc0-cb21df484b34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1f005cb2-b154-4be9-b22e-86951731c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e264493-6769-4137-9d66-825455e5235e" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1f005cb2-b154-4be9-b22e-86951731c3d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ac3cfc9f-5a27-4a90-ab5a-58f826cd14df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1f005cb2-b154-4be9-b22e-86951731c3d3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ac3cfc9f-5a27-4a90-ab5a-58f826cd14df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ac3cfc9f-5a27-4a90-ab5a-58f826cd14df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ac3cfc9f-5a27-4a90-ab5a-58f826cd14df" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ac3cfc9f-5a27-4a90-ab5a-58f826cd14df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2c0683d5-e5c2-4e36-87e9-a72814d690e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ac3cfc9f-5a27-4a90-ab5a-58f826cd14df" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2c0683d5-e5c2-4e36-87e9-a72814d690e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7f111712-9dd9-4292-b11a-0597b3483c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2c0683d5-e5c2-4e36-87e9-a72814d690e8" xlink:to="loc_us-gaap_SubsequentEventMember_7f111712-9dd9-4292-b11a-0597b3483c57" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="if06a2920b44f4bc18147a8843cb216ea_PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_564a8f2e-f833-435c-a8f3-7fc5909eea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_564a8f2e-f833-435c-a8f3-7fc5909eea5d" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_01f9ba80-e14a-4db0-ab05-966ae5e454cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_01f9ba80-e14a-4db0-ab05-966ae5e454cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_d9cbac81-2b14-4ad2-ba82-c63abd629afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_d9cbac81-2b14-4ad2-ba82-c63abd629afa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2714f0e5-a324-45de-807d-fa6344bd43e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2714f0e5-a324-45de-807d-fa6344bd43e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b7e0e817-e768-48e6-862f-e65851b41d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b7e0e817-e768-48e6-862f-e65851b41d0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ccb2e038-2287-4dfc-a4ca-83bc16b92f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ccb2e038-2287-4dfc-a4ca-83bc16b92f28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_53e91bb4-ef30-4726-ba4e-e3a699788004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_53e91bb4-ef30-4726-ba4e-e3a699788004" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_fb6b9a3b-54b5-4676-93b3-163614101283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_fb6b9a3b-54b5-4676-93b3-163614101283" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a91ec34-4659-49e7-be77-ed133e56e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_564a8f2e-f833-435c-a8f3-7fc5909eea5d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a91ec34-4659-49e7-be77-ed133e56e2db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bb5e13c5-78b8-49b8-832f-1dc27ba24479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a91ec34-4659-49e7-be77-ed133e56e2db" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bb5e13c5-78b8-49b8-832f-1dc27ba24479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bb5e13c5-78b8-49b8-832f-1dc27ba24479_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bb5e13c5-78b8-49b8-832f-1dc27ba24479" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bb5e13c5-78b8-49b8-832f-1dc27ba24479_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5a153737-8fae-415f-8f47-f1e649acfaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bb5e13c5-78b8-49b8-832f-1dc27ba24479" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5a153737-8fae-415f-8f47-f1e649acfaa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_cead955e-eabe-4b1b-88fb-5fd11b53f552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5a153737-8fae-415f-8f47-f1e649acfaa1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_cead955e-eabe-4b1b-88fb-5fd11b53f552" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5030d090-f38f-4cbf-8081-af4797cc83eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5a153737-8fae-415f-8f47-f1e649acfaa1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5030d090-f38f-4cbf-8081-af4797cc83eb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended" id="if946650667e24cfeae7456f5f1fed042_PensionsandOtherBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b95787f7-a0b8-42d8-b964-d2bb53156808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_cbf71c5d-42c0-45d7-a20a-a6bf31eaf12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b95787f7-a0b8-42d8-b964-d2bb53156808" xlink:to="loc_us-gaap_PensionContributions_cbf71c5d-42c0-45d7-a20a-a6bf31eaf12d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dca336e7-766e-431b-b423-cb06316cc6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b95787f7-a0b8-42d8-b964-d2bb53156808" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dca336e7-766e-431b-b423-cb06316cc6b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899a53f-d2c3-41ec-bc92-d62d0bb074cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dca336e7-766e-431b-b423-cb06316cc6b1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899a53f-d2c3-41ec-bc92-d62d0bb074cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c899a53f-d2c3-41ec-bc92-d62d0bb074cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899a53f-d2c3-41ec-bc92-d62d0bb074cc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c899a53f-d2c3-41ec-bc92-d62d0bb074cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_176ffbe6-3fd5-441d-aa84-3d99374be450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899a53f-d2c3-41ec-bc92-d62d0bb074cc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_176ffbe6-3fd5-441d-aa84-3d99374be450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_34c7f43f-7cc3-4f5f-a12d-3af5a237361f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_176ffbe6-3fd5-441d-aa84-3d99374be450" xlink:to="loc_us-gaap_DomesticPlanMember_34c7f43f-7cc3-4f5f-a12d-3af5a237361f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2c9bb20a-c5e3-4fd9-bd85-48da141b9119" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_34c7f43f-7cc3-4f5f-a12d-3af5a237361f" xlink:to="loc_country_US_2c9bb20a-c5e3-4fd9-bd85-48da141b9119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_1ef4a740-3e09-43bd-a5fe-15ddac3bc6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_176ffbe6-3fd5-441d-aa84-3d99374be450" xlink:to="loc_us-gaap_ForeignPlanMember_1ef4a740-3e09-43bd-a5fe-15ddac3bc6ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InternationalRetirementPlansMember_4de7b604-9698-40ff-bcf6-796674127fed" xlink:href="jnj-20220703.xsd#jnj_InternationalRetirementPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_1ef4a740-3e09-43bd-a5fe-15ddac3bc6ac" xlink:to="loc_jnj_InternationalRetirementPlansMember_4de7b604-9698-40ff-bcf6-796674127fed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="i1b3625f889ee4a618a6c89eaa73fb477_AccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_70c88ada-aec0-4782-96fa-0d713c15df60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_54218d40-4b2a-4693-a655-5a36d8580262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_70c88ada-aec0-4782-96fa-0d713c15df60" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_54218d40-4b2a-4693-a655-5a36d8580262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec3c61c9-f37c-401e-8c10-01094f5b3bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_54218d40-4b2a-4693-a655-5a36d8580262" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec3c61c9-f37c-401e-8c10-01094f5b3bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_82bd5a4d-b0f9-4dad-8b05-e3c722fe6cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_54218d40-4b2a-4693-a655-5a36d8580262" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_82bd5a4d-b0f9-4dad-8b05-e3c722fe6cd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd133f89-f8c8-4b79-880f-6588de982e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9a51b2df-00a6-49a7-8062-36ed89b32aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_70c88ada-aec0-4782-96fa-0d713c15df60" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9a51b2df-00a6-49a7-8062-36ed89b32aea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f0cd058d-b636-43bd-8564-3526b2d561c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9a51b2df-00a6-49a7-8062-36ed89b32aea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f0cd058d-b636-43bd-8564-3526b2d561c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f0cd058d-b636-43bd-8564-3526b2d561c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0cd058d-b636-43bd-8564-3526b2d561c1" xlink:to="loc_us-gaap_EquityComponentDomain_f0cd058d-b636-43bd-8564-3526b2d561c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0cd058d-b636-43bd-8564-3526b2d561c1" xlink:to="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_88d1b743-e7b3-4e8f-b2f4-1506f74a93b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_88d1b743-e7b3-4e8f-b2f4-1506f74a93b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f55919cc-27d9-4929-961c-f0fb8678480e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f55919cc-27d9-4929-961c-f0fb8678480e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4542a7e1-00a0-4388-8ebd-3c2ca7e082e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4542a7e1-00a0-4388-8ebd-3c2ca7e082e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bd505954-2b83-4c12-926a-6a4bd3b9cb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bd505954-2b83-4c12-926a-6a4bd3b9cb94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a9c9dd7a-d540-4aee-acad-4943f8107b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a9c9dd7a-d540-4aee-acad-4943f8107b69" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended" id="i14c46a07bd80474a93571cbb3beb9878_SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6526f1f8-eff4-48a8-9228-857a18953d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_04fabcb8-19c9-4d26-90cf-de5271d9c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6526f1f8-eff4-48a8-9228-857a18953d9b" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_04fabcb8-19c9-4d26-90cf-de5271d9c16b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0fdc213f-2961-422c-87f6-a517a9c88773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_04fabcb8-19c9-4d26-90cf-de5271d9c16b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0fdc213f-2961-422c-87f6-a517a9c88773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b500fc0f-52dc-4c2f-bbc2-7416772d5dfd" xlink:href="jnj-20220703.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_04fabcb8-19c9-4d26-90cf-de5271d9c16b" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b500fc0f-52dc-4c2f-bbc2-7416772d5dfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6526f1f8-eff4-48a8-9228-857a18953d9b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fb18aa48-24e5-45ef-8e74-4dd0c24a3b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fb18aa48-24e5-45ef-8e74-4dd0c24a3b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb18aa48-24e5-45ef-8e74-4dd0c24a3b97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fb18aa48-24e5-45ef-8e74-4dd0c24a3b97" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb18aa48-24e5-45ef-8e74-4dd0c24a3b97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d193fac-ec8e-4948-97b2-1f6f26b6e617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fb18aa48-24e5-45ef-8e74-4dd0c24a3b97" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d193fac-ec8e-4948-97b2-1f6f26b6e617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5eeb4e48-2d2e-4ba1-88e2-b73aef3d9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5eeb4e48-2d2e-4ba1-88e2-b73aef3d9f85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5eeb4e48-2d2e-4ba1-88e2-b73aef3d9f85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5eeb4e48-2d2e-4ba1-88e2-b73aef3d9f85" xlink:to="loc_us-gaap_SegmentDomain_5eeb4e48-2d2e-4ba1-88e2-b73aef3d9f85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5eeb4e48-2d2e-4ba1-88e2-b73aef3d9f85" xlink:to="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_eff65268-b27b-4055-9533-302ca64b5e2a" xlink:href="jnj-20220703.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:to="loc_jnj_ConsumerMember_eff65268-b27b-4055-9533-302ca64b5e2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_442d5529-80cf-43b0-bb31-b9fd668f718d" xlink:href="jnj-20220703.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:to="loc_jnj_PharmaceuticalMember_442d5529-80cf-43b0-bb31-b9fd668f718d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_7358c27e-74a4-405c-bab1-09187b03f523" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:to="loc_jnj_MedicalDevicesMember_7358c27e-74a4-405c-bab1-09187b03f523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_df618092-2b34-48c8-aed7-d7fe30b45558" xlink:href="jnj-20220703.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_df618092-2b34-48c8-aed7-d7fe30b45558" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_70fb883d-37ee-4607-b6f1-a1837f95bd24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_us-gaap_SubsegmentsAxis_70fb883d-37ee-4607-b6f1-a1837f95bd24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_70fb883d-37ee-4607-b6f1-a1837f95bd24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_70fb883d-37ee-4607-b6f1-a1837f95bd24" xlink:to="loc_us-gaap_SubsegmentsDomain_70fb883d-37ee-4607-b6f1-a1837f95bd24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_70fb883d-37ee-4607-b6f1-a1837f95bd24" xlink:to="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_5fe723ce-5ffc-4c10-ba22-cc487cbd5e93" xlink:href="jnj-20220703.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_ImmunologyMember_5fe723ce-5ffc-4c10-ba22-cc487cbd5e93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_b9a57d0e-8833-4f6b-a192-4c6a288d650e" xlink:href="jnj-20220703.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_InfectiousDiseasesMember_b9a57d0e-8833-4f6b-a192-4c6a288d650e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_2fbe2951-393f-47eb-9a75-b95d28b6f049" xlink:href="jnj-20220703.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_NeuroscienceMember_2fbe2951-393f-47eb-9a75-b95d28b6f049" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_5f7e3047-4093-45f1-98ae-708e25711566" xlink:href="jnj-20220703.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_OncologyMember_5f7e3047-4093-45f1-98ae-708e25711566" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_dacba104-9c32-4af3-b2b9-8b8cca3f7cc3" xlink:href="jnj-20220703.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_PulmonaryHypertensionMember_dacba104-9c32-4af3-b2b9-8b8cca3f7cc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_8bceeeec-e403-4e48-9d58-78884a2db4f8" xlink:href="jnj-20220703.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_8bceeeec-e403-4e48-9d58-78884a2db4f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_5462ff36-0bc2-4019-ac90-f3563a2b3e40" xlink:href="jnj-20220703.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_InterventionalSolutionsMember_5462ff36-0bc2-4019-ac90-f3563a2b3e40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_664f33bd-eaf5-4471-b2f1-a040411bd97f" xlink:href="jnj-20220703.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_OrthopaedicsMember_664f33bd-eaf5-4471-b2f1-a040411bd97f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_691d7ed9-cc23-4b19-bac4-9bd28d9f035a" xlink:href="jnj-20220703.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_SurgeryMember_691d7ed9-cc23-4b19-bac4-9bd28d9f035a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_4275b4bd-81e1-4fe4-9d36-c0528a1f6c2b" xlink:href="jnj-20220703.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_VisionMember_4275b4bd-81e1-4fe4-9d36-c0528a1f6c2b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7a48ca91-7970-4603-adfb-9d4ca453bbf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_srt_ProductOrServiceAxis_7a48ca91-7970-4603-adfb-9d4ca453bbf5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a48ca91-7970-4603-adfb-9d4ca453bbf5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7a48ca91-7970-4603-adfb-9d4ca453bbf5" xlink:to="loc_srt_ProductsAndServicesDomain_7a48ca91-7970-4603-adfb-9d4ca453bbf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7a48ca91-7970-4603-adfb-9d4ca453bbf5" xlink:to="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_fbba266e-9504-4b01-b299-91a1541c3f69" xlink:href="jnj-20220703.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OTCMember_fbba266e-9504-4b01-b299-91a1541c3f69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_dbd19eaa-139e-453f-a2c8-f0981414bccf" xlink:href="jnj-20220703.xsd#jnj_BeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_BeautyMember_dbd19eaa-139e-453f-a2c8-f0981414bccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_165e55de-3937-4c53-91a8-960449602d99" xlink:href="jnj-20220703.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OralCareMember_165e55de-3937-4c53-91a8-960449602d99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_218c4064-fc46-4d8d-94d2-4872d6d2cde6" xlink:href="jnj-20220703.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_BabyCareMember_218c4064-fc46-4d8d-94d2-4872d6d2cde6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_7bf5c003-47d4-4c17-a6e8-97139eb3db24" xlink:href="jnj-20220703.xsd#jnj_WomensHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_WomensHealthMember_7bf5c003-47d4-4c17-a6e8-97139eb3db24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_eba62d10-bb41-4813-82da-2408c48a2d8e" xlink:href="jnj-20220703.xsd#jnj_WoundCareandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_WoundCareandOtherMember_eba62d10-bb41-4813-82da-2408c48a2d8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_f515ea4b-ace2-4e94-8cfe-597263d71b51" xlink:href="jnj-20220703.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_RemicadeMember_f515ea4b-ace2-4e94-8cfe-597263d71b51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_3d148e89-a632-46f5-9d17-cb53649b5352" xlink:href="jnj-20220703.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_SimponiSimponiAriaMember_3d148e89-a632-46f5-9d17-cb53649b5352" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_be57ed33-9a1f-4159-80a3-8a977c91c2d9" xlink:href="jnj-20220703.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_StelaraMember_be57ed33-9a1f-4159-80a3-8a977c91c2d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_e6f6eb66-254a-4f69-9a98-a32bbc4dfcb1" xlink:href="jnj-20220703.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_TremfyaMember_e6f6eb66-254a-4f69-9a98-a32bbc4dfcb1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_d377c1a1-cf27-4b73-8d15-e4f6315d15a8" xlink:href="jnj-20220703.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OtherImmunologyMember_d377c1a1-cf27-4b73-8d15-e4f6315d15a8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_379d7cb1-fa15-4ab4-bc1f-9cb5c5df6cf5" xlink:href="jnj-20220703.xsd#jnj_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_COVID19Member_379d7cb1-fa15-4ab4-bc1f-9cb5c5df6cf5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_d23afdfd-65be-412a-b1da-01e3124fce45" xlink:href="jnj-20220703.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_EDURANTrilpivirineMember_d23afdfd-65be-412a-b1da-01e3124fce45" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_5b977937-e590-4c75-8a5f-9b7a8fb896aa" xlink:href="jnj-20220703.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_5b977937-e590-4c75-8a5f-9b7a8fb896aa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_8d745df6-fc38-4b3b-8763-fad56416d29b" xlink:href="jnj-20220703.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_8d745df6-fc38-4b3b-8763-fad56416d29b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_b7b57eb2-ee1c-4ced-b71a-20ef20ccd611" xlink:href="jnj-20220703.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_b7b57eb2-ee1c-4ced-b71a-20ef20ccd611" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_7b176752-6ac1-4f72-a298-617cceba1f01" xlink:href="jnj-20220703.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_7b176752-6ac1-4f72-a298-617cceba1f01" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_21f5bb70-8300-454b-bb86-a0e7fde62108" xlink:href="jnj-20220703.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_RISPERDALCONSTAMember_21f5bb70-8300-454b-bb86-a0e7fde62108" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_94aa479e-410c-4f25-a5a5-45702283653b" xlink:href="jnj-20220703.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_94aa479e-410c-4f25-a5a5-45702283653b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_7a085d63-4781-4886-805a-e8cea042817e" xlink:href="jnj-20220703.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_DARZALEXMember_7a085d63-4781-4886-805a-e8cea042817e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_a2713d5b-cb7b-4e9f-bb8b-c1718f646b45" xlink:href="jnj-20220703.xsd#jnj_ERLEADAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_ERLEADAMember_a2713d5b-cb7b-4e9f-bb8b-c1718f646b45" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_797d280d-3fe5-4c38-bd5a-d2a27c147bd9" xlink:href="jnj-20220703.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_IMBRUVICAMember_797d280d-3fe5-4c38-bd5a-d2a27c147bd9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_e9bbf80c-16dd-48f4-be85-b3313605b45e" xlink:href="jnj-20220703.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_ZYTIGAMember_e9bbf80c-16dd-48f4-be85-b3313605b45e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_19d91e68-a3a8-42c9-bd99-9126091ccf5b" xlink:href="jnj-20220703.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OtherOncologyMember_19d91e68-a3a8-42c9-bd99-9126091ccf5b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_94375471-14fb-461c-9eb1-1f204c9f738e" xlink:href="jnj-20220703.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OPSUMITMember_94375471-14fb-461c-9eb1-1f204c9f738e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_3c2d59a2-3734-4d51-8dee-7f11dde1a190" xlink:href="jnj-20220703.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_UPTRAVIMember_3c2d59a2-3734-4d51-8dee-7f11dde1a190" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_5f3e6b61-5202-487c-a44d-5aba88cd0da1" xlink:href="jnj-20220703.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_XareltoMember_5f3e6b61-5202-487c-a44d-5aba88cd0da1" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_5b30d943-31a2-40d2-a5ea-7b44b803bce6" xlink:href="jnj-20220703.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_5b30d943-31a2-40d2-a5ea-7b44b803bce6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_69fc666e-149f-4ed9-9c3c-4e0f8a2788ba" xlink:href="jnj-20220703.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OtherMember_69fc666e-149f-4ed9-9c3c-4e0f8a2788ba" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_6ed9f8c3-ff6c-4fee-8d82-4496f39db848" xlink:href="jnj-20220703.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_HIPSMember_6ed9f8c3-ff6c-4fee-8d82-4496f39db848" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_49c13e1b-995f-4a0f-939e-b826fe44291c" xlink:href="jnj-20220703.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_KNEESMember_49c13e1b-995f-4a0f-939e-b826fe44291c" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_4c782ece-907e-483e-8cb5-315b1e340354" xlink:href="jnj-20220703.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_TRAUMAMember_4c782ece-907e-483e-8cb5-315b1e340354" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_1df5e3f2-2407-4dad-baf6-7757383a2253" xlink:href="jnj-20220703.xsd#jnj_SPINEOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_SPINEOTHERMember_1df5e3f2-2407-4dad-baf6-7757383a2253" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_dbd926a2-3b6d-4025-b873-e2ac0eb7defe" xlink:href="jnj-20220703.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_ADVANCEDMember_dbd926a2-3b6d-4025-b873-e2ac0eb7defe" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_2000a8b6-9c4a-4539-942e-2f004fa84f0d" xlink:href="jnj-20220703.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_GENERALMember_2000a8b6-9c4a-4539-942e-2f004fa84f0d" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_807fee07-fbf9-40b6-a792-09ee6916dc09" xlink:href="jnj-20220703.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_807fee07-fbf9-40b6-a792-09ee6916dc09" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_3f74c2d5-1dd9-4cbb-bfa8-5bf3eecc6f34" xlink:href="jnj-20220703.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_SURGICALMember_3f74c2d5-1dd9-4cbb-bfa8-5bf3eecc6f34" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c1b3d7a7-66d0-478e-8e1e-2d5dc1e3bbe7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_srt_StatementGeographicalAxis_c1b3d7a7-66d0-478e-8e1e-2d5dc1e3bbe7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c1b3d7a7-66d0-478e-8e1e-2d5dc1e3bbe7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c1b3d7a7-66d0-478e-8e1e-2d5dc1e3bbe7" xlink:to="loc_srt_SegmentGeographicalDomain_c1b3d7a7-66d0-478e-8e1e-2d5dc1e3bbe7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c1b3d7a7-66d0-478e-8e1e-2d5dc1e3bbe7" xlink:to="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_7f363113-94fd-40ed-b6a4-50f6960023c3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:to="loc_country_CN_7f363113-94fd-40ed-b6a4-50f6960023c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a591e7ee-fcbc-478b-8785-ab8f7c674a67" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:to="loc_country_US_a591e7ee-fcbc-478b-8785-ab8f7c674a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_834668e4-388f-445d-bdaa-08899ebcf00b" xlink:href="jnj-20220703.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:to="loc_jnj_UNITEDSTATESExportsMember_834668e4-388f-445d-bdaa-08899ebcf00b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2a91312e-1319-4552-a95c-b41763663819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:to="loc_us-gaap_NonUsMember_2a91312e-1319-4552-a95c-b41763663819" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended" id="ie84ad19898314881a4b6a884c79ab133_SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5a28905f-5beb-4e18-a963-6dae490fa0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_OperatingIncomeLoss_5a28905f-5beb-4e18-a963-6dae490fa0a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_f8cefc92-2c63-4501-99cb-25fa48e8102b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_BusinessExitCosts1_f8cefc92-2c63-4501-99cb-25fa48e8102b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_69528bd0-2a4f-48c2-805a-9813640e7562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_69528bd0-2a4f-48c2-805a-9813640e7562" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_79babe09-91a8-43ff-a6d1-0ad34b47f30d" xlink:href="jnj-20220703.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_79babe09-91a8-43ff-a6d1-0ad34b47f30d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_e56583ca-2892-4c18-bbfa-ec37e88bffd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_AdjustmentForAmortization_e56583ca-2892-4c18-bbfa-ec37e88bffd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6bee4d31-2c49-4b77-9781-03d7ddfbfbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6bee4d31-2c49-4b77-9781-03d7ddfbfbcb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e81f69b5-8e35-46d0-81c5-bd46531b0a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e81f69b5-8e35-46d0-81c5-bd46531b0a7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_7d0c7324-4252-46e9-be52-ae4892b70bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_7d0c7324-4252-46e9-be52-ae4892b70bf2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_ecafc5a9-bd03-4761-a59b-781c68707bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_SuppliesExpense_ecafc5a9-bd03-4761-a59b-781c68707bec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_8f3d2b71-1619-4106-98d9-01c24d516064" xlink:href="jnj-20220703.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_8f3d2b71-1619-4106-98d9-01c24d516064" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ef90360a-04fe-426a-97cf-1b1032b2fe66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_RestructuringCharges_ef90360a-04fe-426a-97cf-1b1032b2fe66" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_5b865261-9a49-41f3-8678-c39ccb99f66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_LitigationSettlementExpense_5b865261-9a49-41f3-8678-c39ccb99f66e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d41461a6-62fb-4f98-8c50-32c3c1c412aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:to="loc_srt_ConsolidationItemsAxis_d41461a6-62fb-4f98-8c50-32c3c1c412aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d41461a6-62fb-4f98-8c50-32c3c1c412aa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_d41461a6-62fb-4f98-8c50-32c3c1c412aa" xlink:to="loc_srt_ConsolidationItemsDomain_d41461a6-62fb-4f98-8c50-32c3c1c412aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e44aa74c-fd14-4736-87ea-cfa7d9400aca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_d41461a6-62fb-4f98-8c50-32c3c1c412aa" xlink:to="loc_srt_ConsolidationItemsDomain_e44aa74c-fd14-4736-87ea-cfa7d9400aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_80414c46-759b-4b66-a5db-930f1bd02253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e44aa74c-fd14-4736-87ea-cfa7d9400aca" xlink:to="loc_us-gaap_OperatingSegmentsMember_80414c46-759b-4b66-a5db-930f1bd02253" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_95574d03-57e5-4d25-98bd-78c36f6ff929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e44aa74c-fd14-4736-87ea-cfa7d9400aca" xlink:to="loc_us-gaap_CorporateNonSegmentMember_95574d03-57e5-4d25-98bd-78c36f6ff929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9758b53e-3601-48dd-a596-55c40dd5a49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9758b53e-3601-48dd-a596-55c40dd5a49c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9758b53e-3601-48dd-a596-55c40dd5a49c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9758b53e-3601-48dd-a596-55c40dd5a49c" xlink:to="loc_us-gaap_SegmentDomain_9758b53e-3601-48dd-a596-55c40dd5a49c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9758b53e-3601-48dd-a596-55c40dd5a49c" xlink:to="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_cabbb19e-0ab2-45a0-aa86-fc9839682307" xlink:href="jnj-20220703.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:to="loc_jnj_ConsumerMember_cabbb19e-0ab2-45a0-aa86-fc9839682307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_a1041af9-7b9b-4d9b-8b1b-f7772aa102ac" xlink:href="jnj-20220703.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:to="loc_jnj_PharmaceuticalMember_a1041af9-7b9b-4d9b-8b1b-f7772aa102ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_ad2421d8-8f9c-4b99-a4f7-b5f8059281c0" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:to="loc_jnj_MedicalDevicesMember_ad2421d8-8f9c-4b99-a4f7-b5f8059281c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b091087d-eaf1-425e-9edb-30c2d9fcce2e" xlink:href="jnj-20220703.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b091087d-eaf1-425e-9edb-30c2d9fcce2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_53de40d3-22f9-4da5-8636-7194c884558f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_53de40d3-22f9-4da5-8636-7194c884558f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53de40d3-22f9-4da5-8636-7194c884558f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_53de40d3-22f9-4da5-8636-7194c884558f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53de40d3-22f9-4da5-8636-7194c884558f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8d46266-c015-44e8-9239-498eedffe523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_53de40d3-22f9-4da5-8636-7194c884558f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8d46266-c015-44e8-9239-498eedffe523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_37adb6ad-f4ea-4da6-aebd-ead3e3e9f790" xlink:href="jnj-20220703.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8d46266-c015-44e8-9239-498eedffe523" xlink:to="loc_jnj_BermekimabMember_37adb6ad-f4ea-4da6-aebd-ead3e3e9f790" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended" id="i5bcb86a94ae44d6082d0b4bebdedb6ed_SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4d3d95e4-3d27-4df5-a577-19e56164a664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_b3854022-53f1-4138-b48e-d4d12e76fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4d3d95e4-3d27-4df5-a577-19e56164a664" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_b3854022-53f1-4138-b48e-d4d12e76fbe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_613c8329-f555-4ed3-93a2-7c82a734e219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_b3854022-53f1-4138-b48e-d4d12e76fbe0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_613c8329-f555-4ed3-93a2-7c82a734e219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_80583f3c-452f-4a46-9eb9-414529b3ff3b" xlink:href="jnj-20220703.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_b3854022-53f1-4138-b48e-d4d12e76fbe0" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_80583f3c-452f-4a46-9eb9-414529b3ff3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_56841910-811a-482a-89c8-2434010763a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4d3d95e4-3d27-4df5-a577-19e56164a664" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_56841910-811a-482a-89c8-2434010763a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_09439634-241d-420c-8737-11855d5f56de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_56841910-811a-482a-89c8-2434010763a1" xlink:to="loc_srt_StatementGeographicalAxis_09439634-241d-420c-8737-11855d5f56de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_09439634-241d-420c-8737-11855d5f56de_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_09439634-241d-420c-8737-11855d5f56de" xlink:to="loc_srt_SegmentGeographicalDomain_09439634-241d-420c-8737-11855d5f56de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_09439634-241d-420c-8737-11855d5f56de" xlink:to="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b7f92f19-c26d-447c-b2da-25ac0c874e1f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:to="loc_country_US_b7f92f19-c26d-447c-b2da-25ac0c874e1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_fcf6e268-7dd2-452b-808b-515a61efe7c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:to="loc_srt_EuropeMember_fcf6e268-7dd2-452b-808b-515a61efe7c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_a5b5d497-2cd8-4aed-a796-5449b766e1db" xlink:href="jnj-20220703.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_a5b5d497-2cd8-4aed-a796-5449b766e1db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_c4207669-ae04-49f9-8e09-6bab5f88e704" xlink:href="jnj-20220703.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:to="loc_jnj_AsiaPacificAfricaMember_c4207669-ae04-49f9-8e09-6bab5f88e704" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="i934aad662f4e43478ae69d18b6e787b5_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_923cad82-cdb4-43e6-9ded-063dc8ff30bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfBrands_86a8388c-1de3-4ccd-b275-11c28ddea58b" xlink:href="jnj-20220703.xsd#jnj_NumberOfBrands"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_923cad82-cdb4-43e6-9ded-063dc8ff30bf" xlink:to="loc_jnj_NumberOfBrands_86a8388c-1de3-4ccd-b275-11c28ddea58b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_c592a347-94de-4f92-a3dd-3472c2c0ded7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_923cad82-cdb4-43e6-9ded-063dc8ff30bf" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_c592a347-94de-4f92-a3dd-3472c2c0ded7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_47f37f93-2074-4c20-a3dd-f3712800e1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_923cad82-cdb4-43e6-9ded-063dc8ff30bf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_47f37f93-2074-4c20-a3dd-f3712800e1b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ea3bdb4-75b0-4d88-a4fc-e119abd58aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_47f37f93-2074-4c20-a3dd-f3712800e1b1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ea3bdb4-75b0-4d88-a4fc-e119abd58aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8ea3bdb4-75b0-4d88-a4fc-e119abd58aad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ea3bdb4-75b0-4d88-a4fc-e119abd58aad" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8ea3bdb4-75b0-4d88-a4fc-e119abd58aad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce5d7bf3-cd81-4961-a3b8-d8e3b4714dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ea3bdb4-75b0-4d88-a4fc-e119abd58aad" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce5d7bf3-cd81-4961-a3b8-d8e3b4714dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_b1c0e9e7-4270-45c9-9823-98c6b91ce72c" xlink:href="jnj-20220703.xsd#jnj_EvraAndDoxilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce5d7bf3-cd81-4961-a3b8-d8e3b4714dcc" xlink:to="loc_jnj_EvraAndDoxilMember_b1c0e9e7-4270-45c9-9823-98c6b91ce72c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#LegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended" id="i6ef3c7292989401ea5827a067f61ae64_LegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2d11940a-14b0-4696-8779-63bb0a608e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:href="jnj-20220703.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2d11940a-14b0-4696-8779-63bb0a608e97" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_87b3d0c8-8fe6-418c-949d-1d4f18fd8f6f" xlink:href="jnj-20220703.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_87b3d0c8-8fe6-418c-949d-1d4f18fd8f6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_473a1d97-3957-42f0-8354-3ef60212d922" xlink:href="jnj-20220703.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_Numberofpatientsinsettlement_473a1d97-3957-42f0-8354-3ef60212d922" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_aba91388-780f-4703-9b8d-8acc747e53e9" xlink:href="jnj-20220703.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_aba91388-780f-4703-9b8d-8acc747e53e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_1548c268-b755-4b4e-8710-2418691a029f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_1548c268-b755-4b4e-8710-2418691a029f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_14d8b85e-4977-46be-903d-8fb2eb6a3f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_14d8b85e-4977-46be-903d-8fb2eb6a3f62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_55c7dfdb-706b-40d1-bbfb-2a0a9765cbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_55c7dfdb-706b-40d1-bbfb-2a0a9765cbc3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_fbb1cc51-0497-4725-bb49-93411d4b3141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_fbb1cc51-0497-4725-bb49-93411d4b3141" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_988c5a83-f0e2-430a-aa1e-127b75690021" xlink:href="jnj-20220703.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_988c5a83-f0e2-430a-aa1e-127b75690021" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d82300d5-0183-4f09-a8b2-55176537d556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d82300d5-0183-4f09-a8b2-55176537d556" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_8406594f-b8ef-4ef2-80a6-b835cd146afc" xlink:href="jnj-20220703.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_8406594f-b8ef-4ef2-80a6-b835cd146afc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2d11940a-14b0-4696-8779-63bb0a608e97" xlink:to="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ee2c3fcb-f0f3-4192-b5aa-c13f36a404e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_srt_LitigationCaseAxis_ee2c3fcb-f0f3-4192-b5aa-c13f36a404e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ee2c3fcb-f0f3-4192-b5aa-c13f36a404e5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ee2c3fcb-f0f3-4192-b5aa-c13f36a404e5" xlink:to="loc_srt_LitigationCaseTypeDomain_ee2c3fcb-f0f3-4192-b5aa-c13f36a404e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ee2c3fcb-f0f3-4192-b5aa-c13f36a404e5" xlink:to="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_9399b9e0-0d2e-40bf-93a6-22fd7ab83cce" xlink:href="jnj-20220703.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_DePuyASRU.S.Member_9399b9e0-0d2e-40bf-93a6-22fd7ab83cce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_c9d160aa-5f05-4bc3-b6da-ea00729943d4" xlink:href="jnj-20220703.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_RisperdalMember_c9d160aa-5f05-4bc3-b6da-ea00729943d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_ad845685-95a9-4d0d-a270-5736527506ee" xlink:href="jnj-20220703.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_BabyPowderMember_ad845685-95a9-4d0d-a270-5736527506ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_a317c042-539d-4473-83d5-5d2df207fe93" xlink:href="jnj-20220703.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_a317c042-539d-4473-83d5-5d2df207fe93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_c01111a8-7cd8-4391-80d3-a1f7c20342f4" xlink:href="jnj-20220703.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_c01111a8-7cd8-4391-80d3-a1f7c20342f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a886b5a3-71bb-44d7-97ec-7063937f9a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_us-gaap_LitigationStatusAxis_a886b5a3-71bb-44d7-97ec-7063937f9a7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a886b5a3-71bb-44d7-97ec-7063937f9a7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_a886b5a3-71bb-44d7-97ec-7063937f9a7d" xlink:to="loc_us-gaap_LitigationStatusDomain_a886b5a3-71bb-44d7-97ec-7063937f9a7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_a886b5a3-71bb-44d7-97ec-7063937f9a7d" xlink:to="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_480cc749-bbd2-473d-b3ce-3f368a5a68fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:to="loc_us-gaap_SettledLitigationMember_480cc749-bbd2-473d-b3ce-3f368a5a68fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_4f62720e-da17-49a3-b375-6deee94790c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:to="loc_us-gaap_JudicialRulingMember_4f62720e-da17-49a3-b375-6deee94790c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_757e39d1-fdcd-46c9-99de-73e4975a645c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:to="loc_us-gaap_PendingLitigationMember_757e39d1-fdcd-46c9-99de-73e4975a645c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c317af3-6056-4e2a-99a0-292cd45a2241" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_srt_ProductOrServiceAxis_8c317af3-6056-4e2a-99a0-292cd45a2241" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c317af3-6056-4e2a-99a0-292cd45a2241_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c317af3-6056-4e2a-99a0-292cd45a2241" xlink:to="loc_srt_ProductsAndServicesDomain_8c317af3-6056-4e2a-99a0-292cd45a2241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c317af3-6056-4e2a-99a0-292cd45a2241" xlink:to="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_d55ea94e-1bee-4b2c-ae08-cec989dffff2" xlink:href="jnj-20220703.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_AsrMember_d55ea94e-1bee-4b2c-ae08-cec989dffff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_c41bccb2-f4ad-4a4c-9ffd-df83ef905cf0" xlink:href="jnj-20220703.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_c41bccb2-f4ad-4a4c-9ffd-df83ef905cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_77ec6436-8364-4286-af23-c1243e728634" xlink:href="jnj-20220703.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_PelvicMeshesMember_77ec6436-8364-4286-af23-c1243e728634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_479cc258-11f4-44a6-b8a3-85817ba0a14e" xlink:href="jnj-20220703.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_RisperdalMember_479cc258-11f4-44a6-b8a3-85817ba0a14e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_7ccd2f24-a7af-4e6b-b2ed-8dd8115f3009" xlink:href="jnj-20220703.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_XareltoMember_7ccd2f24-a7af-4e6b-b2ed-8dd8115f3009" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_bb642d11-1d0f-4543-a636-cc72b5410bc9" xlink:href="jnj-20220703.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_TalcMember_bb642d11-1d0f-4543-a636-cc72b5410bc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_c6bd4f50-761d-437e-8551-8c06a7417b80" xlink:href="jnj-20220703.xsd#jnj_InvokanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_InvokanaMember_c6bd4f50-761d-437e-8551-8c06a7417b80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_8d0687dc-1efc-4965-bb18-e27906b21243" xlink:href="jnj-20220703.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_PhysiomeshMember_8d0687dc-1efc-4965-bb18-e27906b21243" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_1b370af6-d4c1-4548-82ef-19fad7835563" xlink:href="jnj-20220703.xsd#jnj_OpioidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_OpioidMember_1b370af6-d4c1-4548-82ef-19fad7835563" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_e1336a96-e871-4e72-b920-49e58565a689" xlink:href="jnj-20220703.xsd#jnj_ContactLensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_ContactLensesMember_e1336a96-e871-4e72-b920-49e58565a689" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_1f8ed51f-0727-45b1-a760-3d927ea001c1" xlink:href="jnj-20220703.xsd#jnj_ElmironMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_ElmironMember_1f8ed51f-0727-45b1-a760-3d927ea001c1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_734add84-6470-4eae-baad-8f564f291057" xlink:href="jnj-20220703.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_734add84-6470-4eae-baad-8f564f291057" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_734add84-6470-4eae-baad-8f564f291057_default" xlink:href="jnj-20220703.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_734add84-6470-4eae-baad-8f564f291057" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_734add84-6470-4eae-baad-8f564f291057_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_119e31f1-2e4d-4cdc-b71d-23d70f47da95" xlink:href="jnj-20220703.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_734add84-6470-4eae-baad-8f564f291057" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_119e31f1-2e4d-4cdc-b71d-23d70f47da95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b61637d1-652b-4beb-b5e9-4caccab2c97b" xlink:href="jnj-20220703.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_119e31f1-2e4d-4cdc-b71d-23d70f47da95" xlink:to="loc_jnj_RisperdalMember_b61637d1-652b-4beb-b5e9-4caccab2c97b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_65ba735c-13f6-4fb1-bea8-86dcdd108664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_65ba735c-13f6-4fb1-bea8-86dcdd108664" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_65ba735c-13f6-4fb1-bea8-86dcdd108664_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_65ba735c-13f6-4fb1-bea8-86dcdd108664" xlink:to="loc_us-gaap_LossContingencyNatureDomain_65ba735c-13f6-4fb1-bea8-86dcdd108664_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_70e05e59-610c-4f68-b7f0-b52a7f2377f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_65ba735c-13f6-4fb1-bea8-86dcdd108664" xlink:to="loc_us-gaap_LossContingencyNatureDomain_70e05e59-610c-4f68-b7f0-b52a7f2377f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_fbf7b062-3e88-48b5-bf11-6f9a98efeef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_70e05e59-610c-4f68-b7f0-b52a7f2377f1" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_fbf7b062-3e88-48b5-bf11-6f9a98efeef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0fcfd002-0ddb-45bb-9fc1-045b46b94dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0fcfd002-0ddb-45bb-9fc1-045b46b94dfd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0fcfd002-0ddb-45bb-9fc1-045b46b94dfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0fcfd002-0ddb-45bb-9fc1-045b46b94dfd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0fcfd002-0ddb-45bb-9fc1-045b46b94dfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0accf52b-2b01-4851-b37f-e7ede76c3f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0fcfd002-0ddb-45bb-9fc1-045b46b94dfd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0accf52b-2b01-4851-b37f-e7ede76c3f48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a4402ff4-a06e-4d1b-b4a3-f35ad62fecd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0accf52b-2b01-4851-b37f-e7ede76c3f48" xlink:to="loc_us-gaap_SubsequentEventMember_a4402ff4-a06e-4d1b-b4a3-f35ad62fecd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_87ca86db-12a2-448f-a4a3-9631395a3935" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_srt_CounterpartyNameAxis_87ca86db-12a2-448f-a4a3-9631395a3935" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87ca86db-12a2-448f-a4a3-9631395a3935_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_87ca86db-12a2-448f-a4a3-9631395a3935" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87ca86db-12a2-448f-a4a3-9631395a3935_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a96e6d8a-f3cf-4e5d-85e6-4e423ed277d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_87ca86db-12a2-448f-a4a3-9631395a3935" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a96e6d8a-f3cf-4e5d-85e6-4e423ed277d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RasmussenInstrumentsLLCMember_4ed650ba-f74c-480a-932b-f5bafbca698b" xlink:href="jnj-20220703.xsd#jnj_RasmussenInstrumentsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a96e6d8a-f3cf-4e5d-85e6-4e423ed277d8" xlink:to="loc_jnj_RasmussenInstrumentsLLCMember_4ed650ba-f74c-480a-932b-f5bafbca698b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i307bb5167741451193f0a4f4b007e489_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_4cfc2624-1a92-4eba-aa53-3d9682217fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:to="loc_us-gaap_RestructuringCharges_4cfc2624-1a92-4eba-aa53-3d9682217fee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_de46057c-d9ee-4dbc-ad79-e8727d62fc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_de46057c-d9ee-4dbc-ad79-e8727d62fc97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_a90e7760-d128-40b0-aa41-e509143c12af" xlink:href="jnj-20220703.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_a90e7760-d128-40b0-aa41-e509143c12af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_aebc31c8-c01a-4b62-a164-54cdc317ad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_aebc31c8-c01a-4b62-a164-54cdc317ad3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9594692a-b041-4c6f-aa98-4ccb08482b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9594692a-b041-4c6f-aa98-4ccb08482b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9594692a-b041-4c6f-aa98-4ccb08482b63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9594692a-b041-4c6f-aa98-4ccb08482b63" xlink:to="loc_us-gaap_SegmentDomain_9594692a-b041-4c6f-aa98-4ccb08482b63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9aefa655-b4c4-4cf9-aff1-e47322193d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9594692a-b041-4c6f-aa98-4ccb08482b63" xlink:to="loc_us-gaap_SegmentDomain_9aefa655-b4c4-4cf9-aff1-e47322193d8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_cc439543-bb3f-4519-9b80-82e0656b0176" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9aefa655-b4c4-4cf9-aff1-e47322193d8b" xlink:to="loc_jnj_MedicalDevicesMember_cc439543-bb3f-4519-9b80-82e0656b0176" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_4537e148-fc07-4f62-83e3-01b4626b89cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:to="loc_us-gaap_RestructuringPlanAxis_4537e148-fc07-4f62-83e3-01b4626b89cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_4537e148-fc07-4f62-83e3-01b4626b89cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_4537e148-fc07-4f62-83e3-01b4626b89cd" xlink:to="loc_us-gaap_RestructuringPlanDomain_4537e148-fc07-4f62-83e3-01b4626b89cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_aa9d8235-16ab-450d-975f-9ebd42474002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_4537e148-fc07-4f62-83e3-01b4626b89cd" xlink:to="loc_us-gaap_RestructuringPlanDomain_aa9d8235-16ab-450d-975f-9ebd42474002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_5e31374a-ef6e-4d5a-b5ab-d92c6500b854" xlink:href="jnj-20220703.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_aa9d8235-16ab-450d-975f-9ebd42474002" xlink:to="loc_jnj_SupplyChainMember_5e31374a-ef6e-4d5a-b5ab-d92c6500b854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_da4390ff-9796-4bd8-984c-3b7f96775d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_da4390ff-9796-4bd8-984c-3b7f96775d3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_da4390ff-9796-4bd8-984c-3b7f96775d3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da4390ff-9796-4bd8-984c-3b7f96775d3e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_da4390ff-9796-4bd8-984c-3b7f96775d3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da4390ff-9796-4bd8-984c-3b7f96775d3e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_0e944af2-eb23-4cb3-bba9-2df07ba58638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:to="loc_us-gaap_RestructuringChargesMember_0e944af2-eb23-4cb3-bba9-2df07ba58638" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_0fd6fcde-937b-4ff8-956f-28b4340e5c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:to="loc_us-gaap_CostOfSalesMember_0fd6fcde-937b-4ff8-956f-28b4340e5c2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_ccf53d44-aaeb-4bc9-a37e-f5a1cfc43ce6" xlink:href="jnj-20220703.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_ccf53d44-aaeb-4bc9-a37e-f5a1cfc43ce6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81a8d4c2-28c3-4d62-ba5a-99d8dabec4dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:to="loc_srt_RangeAxis_81a8d4c2-28c3-4d62-ba5a-99d8dabec4dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81a8d4c2-28c3-4d62-ba5a-99d8dabec4dd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_81a8d4c2-28c3-4d62-ba5a-99d8dabec4dd" xlink:to="loc_srt_RangeMember_81a8d4c2-28c3-4d62-ba5a-99d8dabec4dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_69457967-a404-4cdd-b9d7-a8681a0b84ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_81a8d4c2-28c3-4d62-ba5a-99d8dabec4dd" xlink:to="loc_srt_RangeMember_69457967-a404-4cdd-b9d7-a8681a0b84ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_03df9965-bead-4ed4-98ed-03a21e91a91e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_69457967-a404-4cdd-b9d7-a8681a0b84ae" xlink:to="loc_srt_MaximumMember_03df9965-bead-4ed4-98ed-03a21e91a91e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3072b54d-7621-4e0b-af6b-bc540157ba25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_69457967-a404-4cdd-b9d7-a8681a0b84ae" xlink:to="loc_srt_MinimumMember_3072b54d-7621-4e0b-af6b-bc540157ba25" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended" id="i37779f4aa8854ee3b3d1ca7b9396d98e_RestructuringScheduleofRestructuringReserveDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_364fe6e7-d1bb-4298-b3e7-6b2aa4c77363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_364fe6e7-d1bb-4298-b3e7-6b2aa4c77363" xlink:to="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_543bab18-d35e-4aa2-b154-943ed5d8e95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:to="loc_us-gaap_RestructuringReserve_543bab18-d35e-4aa2-b154-943ed5d8e95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_db8e99f7-91fb-45ae-97ff-66daf4fd1d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:to="loc_us-gaap_RestructuringCharges_db8e99f7-91fb-45ae-97ff-66daf4fd1d3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsForRestructuringNet_038101e1-bfe5-4d74-bf57-8f83afdbbc9f" xlink:href="jnj-20220703.xsd#jnj_PaymentsForRestructuringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:to="loc_jnj_PaymentsForRestructuringNet_038101e1-bfe5-4d74-bf57-8f83afdbbc9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_daef8873-33af-4e8a-8df7-6865932bd892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_daef8873-33af-4e8a-8df7-6865932bd892" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3ed80133-335c-4e1b-b46a-617140748975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_26d58398-b140-4bbe-9333-2ca2a7829a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_364fe6e7-d1bb-4298-b3e7-6b2aa4c77363" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_26d58398-b140-4bbe-9333-2ca2a7829a8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_d3450b26-7857-48bf-9ff9-8d242d1331e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_26d58398-b140-4bbe-9333-2ca2a7829a8f" xlink:to="loc_us-gaap_RestructuringPlanAxis_d3450b26-7857-48bf-9ff9-8d242d1331e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d3450b26-7857-48bf-9ff9-8d242d1331e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_d3450b26-7857-48bf-9ff9-8d242d1331e9" xlink:to="loc_us-gaap_RestructuringPlanDomain_d3450b26-7857-48bf-9ff9-8d242d1331e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_22553b2b-b926-4a08-8947-55c0c23873b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_d3450b26-7857-48bf-9ff9-8d242d1331e9" xlink:to="loc_us-gaap_RestructuringPlanDomain_22553b2b-b926-4a08-8947-55c0c23873b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_3a699ca5-c25f-457b-a6e3-c082c0400ccc" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_22553b2b-b926-4a08-8947-55c0c23873b5" xlink:to="loc_jnj_MedicalDevicesMember_3a699ca5-c25f-457b-a6e3-c082c0400ccc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_de6ff403-efeb-4062-9c3a-bddd0e6f4184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_26d58398-b140-4bbe-9333-2ca2a7829a8f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_de6ff403-efeb-4062-9c3a-bddd0e6f4184" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_de6ff403-efeb-4062-9c3a-bddd0e6f4184_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_de6ff403-efeb-4062-9c3a-bddd0e6f4184" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_de6ff403-efeb-4062-9c3a-bddd0e6f4184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_de6ff403-efeb-4062-9c3a-bddd0e6f4184" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_ae5c82a0-4879-411d-a95a-d303815fcb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:to="loc_us-gaap_EmployeeSeveranceMember_ae5c82a0-4879-411d-a95a-d303815fcb14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_92d4528f-77e4-4924-a0df-daca5dd7eb23" xlink:href="jnj-20220703.xsd#jnj_AssetWriteoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:to="loc_jnj_AssetWriteoffMember_92d4528f-77e4-4924-a0df-daca5dd7eb23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_5fbc5062-fce9-41fd-b6d4-7c2580b2d8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:to="loc_us-gaap_OtherRestructuringMember_5fbc5062-fce9-41fd-b6d4-7c2580b2d8de" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>jnj-20220703_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a211293e-c516-4076-a852-d6c27f4cfad7,g:c2e9e48c-ca8c-4ec1-bfd7-8d90ecda38c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_80a5f0ef-c0d2-4f26-aff2-6adb76f03b25_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_6fbf9438-376d-4ad6-8a36-18062bb55246_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_73ce72e1-4b76-4a88-a214-7797f7bff264_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_445dd05d-7d5f-4f7f-b7cb-1d6a135478f7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_35aada8c-8751-44d3-a909-c7751bcbf541_terseLabel_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_label_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_documentation_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:href="jnj-20220703.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:to="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_63e4a7b1-4ce4-4ce8-b78f-2a6802aba8c8_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20220703.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_581c1335-07c3-4c1e-993a-1be30f4bc788_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_80b2aa8b-427d-40d0-8e83-5a42f7fd196b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_7482401d-7a78-4077-90c6-bf90e2e271c4_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value (6)</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20220703.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_f4c3ddd4-5277-459f-bca6-0000a16e5660_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH (1)</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20220703.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_c312291d-ddec-4e53-80c9-948bccd38471_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20220703.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_3f801f52-83da-44c2-8796-99946fc260a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_1e26281e-68f7-4ed8-8417-5556f33437f3_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20220703.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_bc779f62-c516-46da-9d9a-a85c91e003e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_dfacee20-adec-495e-bce9-9489f9a50d9a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_79bce8d4-df54-4b8b-8ff6-9d3789a7de4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_ae48b9b9-c8d0-4a2a-80f7-dd9f56fcedeb_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_28d77261-840e-41c9-8882-c46d750b63d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_bc739f33-2fe9-4241-bc8f-4fe8182b68b9_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_8a34fcb4-879a-454c-ae0b-0c669f9bb408_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_35f78b98-e982-4a70-aaab-803608a7b0d3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_2426ad7b-712b-413b-b85e-c59d459488c1_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_label_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in operating income loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:href="jnj-20220703.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:to="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_93216224-dae3-479d-af1c-c582f0a73215_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_166bc6e4-f25b-4325-9cef-efd3085c2e1d_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply network costs</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_ba8db3ee-3b13-4795-9056-de9e39b2d077_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_492efcb1-3be0-465f-ac11-60b1d906157d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_af225037-e56a-45f4-a8a2-26fc7d5526ae_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20220703.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6e63b6bd-63b8-4537-99b7-49a2943d8c97_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b2e3428f-0264-45d6-939e-5757aeb6a069_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b16980f5-19c5-48f8-84e8-5ab62ebfe364_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_71beafb1-6538-4f3f-9579-c53c7a0fac93_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_3fbeefd8-ff36-49de-a1e6-dc3ad7ad7385_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_c685e02f-7a39-44ba-bf09-03f4221a8311_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES / OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20220703.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_02892fde-324d-4e1a-acb5-3c9a4f4b63d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_4a850451-5cc1-45c1-acff-da8f59354ba1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1690ca20-1548-4cfc-a1e9-2dcaaf5d38fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0512729e-f9af-4450-9f65-992d7cbaa00d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_c7108c09-6dec-4cdd-821b-8496e3a7953b_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_87aac2ba-d63d-4816-b23e-85e065c65abb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_ee655949-3b00-45e5-aeb2-3a144d050e3e_negatedTerseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:href="jnj-20220703.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_a5a36c1e-48cc-42e3-a7b1-ef0f1ebeb0ab_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: shares which could be repurchased under treasury stock method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20220703.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6b7a5ca2-7dc0-4f3d-9979-b050a57ba1bc_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_1fd3e9b0-b45c-412f-bed2-f2604183f5d4_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20220703.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6d27efc7-4ee1-496f-b958-d302fa88efb4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_fc05c523-0629-4b90-872d-ce25fe424d0a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange rate</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_13488691-37bd-4c65-903e-86dc58ada701_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b27ccd39-6a76-44d1-92a7-9278852370be_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6f6cacb6-cb3d-4fd0-862b-96f398d90033_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9c29a5e6-b092-40f5-a7bb-7690d546279a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_79e3c301-1f68-4100-bcf0-e098853a3468_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_a25be8e8-2232-40ff-b394-628a20755770_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_c4823aaf-913d-4b7e-8781-1faf116d62f9_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_56437a8e-8edb-4326-8090-27a9807c4ca4_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes due 2035 (1.5B Euro 1.0408)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20220703.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d3f72c5a-38f8-48cc-8e7c-f14c3ede5db1_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost/(credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_d0f03d86-b41e-44b3-b9ad-db2ad90f7e3b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_6aad7560-b033-4be8-8948-09811c4dad26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_1253ba7f-3caf-4ee8-8d43-8401e40ed40a_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20220703.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2f4ac6d9-684f-4c40-b8f9-a0aa556631c5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_733f1add-8b7a-4f6e-a34f-a571994b7cdc_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims within settlement agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_label_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_documentation_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:href="jnj-20220703.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:to="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_883bae5e-d328-497e-8c9a-0abb75a428f0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_26041464-8b3a-40af-bdd4-f040628ef4db_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_adb64181-1825-4905-ad92-1512be17d303_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_9cba3f62-fcd4-4782-8488-8fdc5042201f_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20220703.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_136f65d5-29cd-4566-9eea-808ae2b1e394_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_2abe3e93-e927-455f-9bd9-455265816aea_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_dd4c663e-81bc-48ef-bc38-3aaeb1686f12_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20220703.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_2765db3a-21a2-48e1-ba44-9650249d6c96_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20220703.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d7c577d7-5734-41ca-a79f-b33ea6c508dc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b4c58114-2321-4c7a-8e3c-db4380d955c9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_537579fe-fc02-44e3-b435-ad43f232f930_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_31c2744e-68b5-425a-8f4b-10f6896bfdcb_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20220703.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_967ea333-28db-46ea-a845-f59816da1ec8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_4dbf6df8-3e83-41f5-b776-abf4c374863d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_30068897-49e0-4d4a-b1d6-8885062c91fe_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Revenue for Reportable Segment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_649f9468-a522-43a2-8c4e-f2a3ea1ff03b_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ce9d512c-2b49-4e4a-84c0-466b78f21c22_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_d650e0cb-0972-4b42-b097-034283be7e76_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvokanaMember_2aa19a0c-01d7-4131-af39-59bbc4010cb3_terseLabel_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana</link:label>
    <link:label id="lab_jnj_InvokanaMember_label_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:label id="lab_jnj_InvokanaMember_documentation_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember" xlink:href="jnj-20220703.xsd#jnj_InvokanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvokanaMember" xlink:to="lab_jnj_InvokanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_f06e5407-b1b0-470a-95bd-54510891318d_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_dbad92d0-0951-4dc7-9684-e4572f0bed62_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_60bdb67d-837c-4400-bef9-0ca38310f17d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_56f9aeff-7fa2-4551-bab8-563578fafec0_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S.</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20220703.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7981932f-4e70-4311-ba8a-871452414cd3_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets and liabilities Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8dae8606-94d2-418b-b8da-f7175e46da6f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a16e954-1423-41ad-af80-36d14f6120fb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_9af8ad24-afb3-4d11-ac82-d9fe99903be9_terseLabel_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income percent to sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_label_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income interest percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:href="jnj-20220703.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:to="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_43b052b4-2f36-4d0a-a669-9f153b1f02b0_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b1cc2065-74f8-49c3-95b3-f117e62e8983_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for Sale Securities Maturities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3c5f0d46-d194-410f-835e-5ad38314a0d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_cdc6103b-1da5-4823-8446-a707619bf06f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_79d2e206-e2dd-466d-a1e6-9011375bd394_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_b2c9cf00-3dd6-4fff-994e-fd1beedc2396_terseLabel_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net percent to sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Operating Income Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non operating income expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:href="jnj-20220703.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:to="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_21842b89-0ca6-4d08-b4e5-f5832fd129bf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring estimated cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BeautyMember_d7656d91-f0b0-4120-83c8-a045c8b3ced4_terseLabel_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin Health/Beauty</link:label>
    <link:label id="lab_jnj_BeautyMember_label_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:label id="lab_jnj_BeautyMember_documentation_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember" xlink:href="jnj-20220703.xsd#jnj_BeautyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BeautyMember" xlink:to="lab_jnj_BeautyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3dbf63c8-8c01-4c75-b044-0f58883717e1_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 4)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_5f4385c7-bad1-40b8-98f8-39aeb344775b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fab8f304-abff-434a-a6ba-8eefb74d9922_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_a33e33b4-7a88-446f-884f-609360c7376d_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8f56b696-4081-4e2a-bff9-668762a08fbc_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_COVID19Member_9cac63c2-6ec7-453b-a0e4-578a20ca5fa1_terseLabel_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_jnj_COVID19Member_label_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_jnj_COVID19Member_documentation_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member" xlink:href="jnj-20220703.xsd#jnj_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_COVID19Member" xlink:to="lab_jnj_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_9ed74b5c-0055-4ace-9eaa-5320cf597745_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits(1)</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_20400ce7-fbe9-4240-b418-8951d11ede52_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net (Note 10)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_95d6f663-8c20-43d7-87b3-6f38f8d7ed87_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97d5fb6d-5763-461a-9343-bc1b3f0d0e6a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_327cfe48-6b1b-4ef6-b072-95d38bbba2ff_terseLabel_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL [Member]</link:label>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_label_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL [Member]</link:label>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_documentation_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:href="jnj-20220703.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:to="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfBrands_538a35c5-d74b-4062-bd2f-5b39d6de6595_terseLabel_en-US" xlink:label="lab_jnj_NumberOfBrands" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Brands</link:label>
    <link:label id="lab_jnj_NumberOfBrands_label_en-US" xlink:label="lab_jnj_NumberOfBrands" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Brands</link:label>
    <link:label id="lab_jnj_NumberOfBrands_documentation_en-US" xlink:label="lab_jnj_NumberOfBrands" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Brands</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfBrands" xlink:href="jnj-20220703.xsd#jnj_NumberOfBrands"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfBrands" xlink:to="lab_jnj_NumberOfBrands" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d44c389a-e176-4045-b4cc-427a059fd69d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99489411-5c93-41c2-ab3d-746933c73007_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_7abb98cb-bab0-4f06-be8e-708f095bfd29_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_d5aafc36-3a83-442b-bc72-529f2e48a81f_terseLabel_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member" xlink:href="jnj-20220703.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.375Notesdue2023Member" xlink:to="lab_jnj_A3.375Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_946affbe-0dc2-46d3-a143-03fdf8abb848_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6f9b597c-3e6e-481b-b732-27d208fff2a1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_b4f5aa58-bd7e-4f15-aa5c-6485413b74be_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20220703.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_881ccb31-4aa2-4fad-8f1c-bc5f32c4b641_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20220703.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_8df19d53-3400-4cad-80a0-903116c3e31b_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20220703.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_d7ccb5c1-c823-4691-b345-bab7cf368972_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_c599a32a-b080-4430-be8d-3f63439217f2_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_d0f70ee6-d17c-47a1-b96e-56f553269696_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dc5ddea-62d9-45d7-bc14-e41068626de8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_6eeaaa99-1989-4cd4-84b9-5aa0644f57be_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development in process percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">research and development in process percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:href="jnj-20220703.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_84cabdd3-261d-448b-bb64-db937d84b417_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Business Segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_06ec65d6-39b4-49b0-b984-0d70d9980310_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplyChainMember_00f49720-eace-4e5d-888f-e5f977502833_terseLabel_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:label id="lab_jnj_SupplyChainMember_label_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain [Member]</link:label>
    <link:label id="lab_jnj_SupplyChainMember_documentation_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember" xlink:href="jnj-20220703.xsd#jnj_SupplyChainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplyChainMember" xlink:to="lab_jnj_SupplyChainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_555a3e9e-1beb-4f2e-8ab7-65a99561fe5b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_76280f88-fdac-4e03-9c1f-e4c8b0db9310_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8842c60c-e7bd-4538-81ab-e18e5ad924dc_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_f4bc635f-66b1-475c-b447-0cf9c0462852_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20220703.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_cfe996f2-d548-402b-b7f4-43abbe6bae8a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fc0798cd-9f2f-4e50-85f8-c662c1cdad58_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_360edbc1-d447-4c50-8b51-c2ed6f7ed8b3_terseLabel_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_label_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing [Member]</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_documentation_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:href="jnj-20220703.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:to="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e65fc593-ee95-4bb8-9948-ae4820f05c48_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_0139666c-16fd-48a5-a0ca-d602b2855633_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Fair Value Reflected in Net Income</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_a311df54-5e66-4a6a-b3c7-92d0ee962237_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. sovereign securities(1)</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_acba42a0-973c-4ef1-8f3c-fe32f3218b36_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_213e9480-27c6-4cf6-aaa0-df64bf12188d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0fa03b2e-3694-4c1f-a07c-2fb8c7a42298_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_10f9dd1e-ce11-4419-8aef-64abc656e4f3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1a661404-a1fa-4e77-a8b2-972ea56643d0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ecd54188-2756-42b2-be98-b786bcfc914d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8663aae0-813d-481e-a5c6-9bc2ab844c34_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1300NotesDue2030Member_5a0fb632-c39b-43c4-ba27-8afcbcc108a8_terseLabel_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member" xlink:href="jnj-20220703.xsd#jnj_A1300NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1300NotesDue2030Member" xlink:to="lab_jnj_A1300NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_5abe9c0e-02e6-43d7-b1a8-913de45e7fe6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_658202fc-6dae-4e57-98dd-0a3eb237062a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_0469698d-3620-4d29-9cda-a4cdc9ea9eb0_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations (Note 6)</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_347589ef-ce33-47e2-ba94-8f54dc502dee_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c13f281e-8f53-4d5b-807a-cd7ec0471647_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_10f6e9d5-f196-4aa5-9b14-43d1ea6bb401_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_c0fbf1be-f761-4e17-877e-2aee18e92009_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5983b0b2-f919-410c-b75b-01c739585114_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_a3ccc646-9388-4e1e-b839-3b1b66d23109_totalLabel_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:href="jnj-20220703.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:to="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_154110f1-807b-43cb-a150-90d1840af572_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_d52d07f7-97a1-498b-a1d2-7feb49ad5a6e_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_8c8679ce-8df4-48db-b4da-6618ec9588d4_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular / Metabolism / Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20220703.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_166a6b44-e616-4526-8f5d-125496197c11_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f587af80-47f5-45f9-a4a0-33684c9ab73f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide income before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_83942357-e25c-4afc-93c3-068b40288148_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6ee45e6c-3ed6-4a86-b2c0-c24ae9e65bb6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6afc34b8-fcc2-4494-adc3-7f436f58af32_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_f99baa76-3d28-4bdb-b50c-e065761c4a3b_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_d8074c2f-b279-4179-843d-ac4ed0aecdef_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_14eb12a5-2d21-4586-af58-165a34bdb85a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_ea12478a-5f8a-4c21-9155-2561a821b6df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_36076dc0-496e-4b75-92e2-a71b3356eec7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_1934a072-89d8-4134-9f34-cc6995be2537_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_a51c2eb0-70d2-4de5-8cf5-df051266344b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_c4f2e9ad-65ec-441d-9e28-d52402dc84f0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_5692b9a5-21bb-4294-8287-56555835ba5b_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20220703.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_0ba24261-53e4-4aae-af32-6a87dedd0768_terseLabel_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals)</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_label_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract" xlink:href="jnj-20220703.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalProceedingTextualsAbstract" xlink:to="lab_jnj_LegalProceedingTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_de93cc67-2c31-485a-bfbf-3c4531efe00e_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20220703.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_956a4b91-4999-4c7d-9d19-9e230d1fb33e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4b687950-e4cd-4280-bde0-6e6146280f39_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_6860abea-212d-46e6-9cec-198a95bbaf0e_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20220703.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_ab006632-53a8-4330-b5a9-98fb440bb16e_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_7b52b8fc-a59b-4d9d-af60-70321a96bfb9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_54574335-dff9-41ad-bb57-f2ea044e459c_terseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20220703.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyCareMember_228c38f9-0b21-44fe-ba82-f78dcda60343_terseLabel_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care</link:label>
    <link:label id="lab_jnj_BabyCareMember_label_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:label id="lab_jnj_BabyCareMember_documentation_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember" xlink:href="jnj-20220703.xsd#jnj_BabyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyCareMember" xlink:to="lab_jnj_BabyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_2bea3195-ae30-4344-b5d1-5b114917d0f4_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20220703.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxes_0f80efc1-cc38-4c4e-8ec1-e1fd0b5726e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental tax costs related to restructuring</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_15b47adf-b4d5-4db0-b768-fd5796519113_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_6d8a30f0-d196-4aaf-a9f5-137760b4cbad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_00b77baa-8c47-4590-859a-694317be695b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_b8f5dfd5-330b-4fc3-bce2-1d2722f2ce04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled non cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_383b5e58-5f66-4540-84b8-eb4b78b7dd72_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_8754a288-13e6-4663-b15c-fb60838e5ffa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_0b7792f7-9c8c-444e-b3cf-7d07b968a34b_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_9651493b-fba2-463a-b267-838179586e7a_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b823035c-60f3-4abf-b958-af161e0b4950_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_e41203fe-f352-4608-895d-dc972afb4d5b_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_7bf78c78-cdf0-402e-af1c-d5695d7e27cf_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20220703.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_1e1f0a04-bb37-4ab6-a09c-b6f37258c8be_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20220703.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_49dfd312-3e69-422d-857e-8c1646e8cf39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income on derivatives, after tax</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_55cbe520-77f9-44e5-96b2-e8ac4aabacc0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_8d798de9-2331-4283-928f-43c0b67faa8c_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20220703.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_beafe324-3c9f-435d-b9d7-337aedc002fd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_abc0f7a0-9215-4682-b9fe-e138e529eea4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_873be5c6-b7d6-4617-aa0b-d822cfdaaa51_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_ff9067aa-eb96-4dfa-92f0-a56361cdf640_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_c5616283-57e5-40fd-85ba-5b4c142f17d5_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20220703.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_977e1c80-02cd-4ce2-89eb-bc7f4683b962_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b0f97af6-9757-4b4f-9267-8bc88769678b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daac32ed-f279-4678-8e61-870469197c20_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_354e7dfc-8af3-4734-bbe9-8ec94f2339a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_d4077357-e1e0-44e6-b45f-96374afceda5_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIMPONI / SIMPONI ARIA</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20220703.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_71a904c8-e5dc-41ef-a626-e41be758c6c4_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20220703.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ad0280ca-8b9e-4f3d-9662-84ccd27de5c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6cc902d4-ec3a-47fb-b783-a554771edd99_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0759d1e9-48c5-448b-a9e4-0d14969bf3fd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_386b4e82-77dc-4eea-856d-2d4453615ee4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_82bfa867-d96a-4548-9c3e-7de1c4edd015_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InternationalRetirementPlansMember_f4237206-1ea4-4ae8-acee-628a7a26599c_terseLabel_en-US" xlink:label="lab_jnj_InternationalRetirementPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Retirement Plans [Member]</link:label>
    <link:label id="lab_jnj_InternationalRetirementPlansMember_label_en-US" xlink:label="lab_jnj_InternationalRetirementPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Retirement Plans [Member]</link:label>
    <link:label id="lab_jnj_InternationalRetirementPlansMember_documentation_en-US" xlink:label="lab_jnj_InternationalRetirementPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Retirement Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InternationalRetirementPlansMember" xlink:href="jnj-20220703.xsd#jnj_InternationalRetirementPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InternationalRetirementPlansMember" xlink:to="lab_jnj_InternationalRetirementPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_625978c0-3d4d-417b-84b8-85c5a2124d0f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_6f2d7de8-315f-410b-896e-7bf9a98e3274_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XARELTO</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20220703.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_39b3b0f6-fb53-48b6-9c90-52ee3528785f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ad76d66-0d72-4b09-952c-a74587505114_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92527442-07a8-4179-9418-2a4491ebf516_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_5891ac22-ecbc-4abb-89d3-c90b9f39bad3_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_52bdb8dd-afa5-4b9e-bd9f-d8c2fb1c9316_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_0de3534b-11d8-4080-8d07-b953419b997d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_528b1a29-ccd5-4fe8-b278-0827ce84fce0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_171a1074-5db2-4b17-a4f2-56d8611349e2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_d7a9d3f6-7460-482f-8483-c95b91f2cd62_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20220703.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b5bfd0e7-ee3b-4db6-968e-503904a357db_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e0104f99-9093-4160-ac4b-d616020f0387_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b727919a-88a2-4319-ae41-5b92978b5346_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RasmussenInstrumentsLLCMember_db3b0f6d-9245-49d2-b1a0-4eca2e417231_terseLabel_en-US" xlink:label="lab_jnj_RasmussenInstrumentsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rasmussen Instruments, LLC</link:label>
    <link:label id="lab_jnj_RasmussenInstrumentsLLCMember_label_en-US" xlink:label="lab_jnj_RasmussenInstrumentsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rasmussen Instruments, LLC [Member]</link:label>
    <link:label id="lab_jnj_RasmussenInstrumentsLLCMember_documentation_en-US" xlink:label="lab_jnj_RasmussenInstrumentsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rasmussen Instruments, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RasmussenInstrumentsLLCMember" xlink:href="jnj-20220703.xsd#jnj_RasmussenInstrumentsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RasmussenInstrumentsLLCMember" xlink:to="lab_jnj_RasmussenInstrumentsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_b15b7146-fdf6-405e-9574-7163fe2c9ac8_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20220703.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_7bd32a2b-7198-4884-89e6-c18556cb0321_terseLabel_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense Benefit Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense benefit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:href="jnj-20220703.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:to="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_f8114c4c-0d74-4362-9407-0c54cb0fbcbf_terseLabel_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers percent to sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_label_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue Goods Net Percent To Sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_documentation_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue goods net percentage to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:href="jnj-20220703.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:to="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_cc6130ab-f16b-4fbb-8dcf-79b7cfc774a5_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2424f74c-6e66-422b-b0c0-1a1121be6248_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide effective income tax rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_96119195-4e57-4d12-b08c-395642e901be_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales/ Purchases/Other</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_64ff2412-96da-4b47-a3f4-767460394bba_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_86b3150b-bd14-4efc-b65d-c64cb7797de9_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_887cbe88-1f32-4176-aef1-85ccde56aee3_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA / abiraterone acetate</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20220703.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f968bdae-46fe-44e1-b76d-2c3d5a881f3d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d7757e1b-234c-4620-aa02-24b41f7f8767_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_c8e114a3-7bd9-4195-901b-6293733bcf10_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_1f23cf2e-63a5-4d00-bb67-850ca6ea064f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges recorded to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_a911666e-1f07-446d-b6fd-e7b719e3a5ed_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20220703.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ba4b2b60-1eea-4f8c-9ba8-b5103f1a2761_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a627a52f-4295-46ff-a1d6-166941ee359a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_712446ba-5c53-4047-964f-a3b1e345fd26_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_1bd78e84-794e-456f-b2b9-dbbc4d04bc52_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_a355f919-1d96-48da-aec9-f7188721e8ab_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_9d3cc1b9-6c89-4842-85eb-b5f30aa93a6d_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_c3dbf509-b748-41cb-a768-b4d6a044ec42_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2484dac1-84d7-4724-ae78-5dfc836af44a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_fca01a2f-38dd-4697-a51c-797f6b8a64de_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_a015cf63-2bd3-49de-a13c-09fa082d70a5_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_5f6f58d0-7e45-4b2c-be25-f4a6d1c4c853_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_d49582c7-86d2-4ff8-b32a-8d94c579d3ec_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:href="jnj-20220703.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:to="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ffd77691-7312-48de-bcea-03b6ffaefa82_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_63884b8c-c8dd-4302-ab9b-4ee3197fc231_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PHARMACEUTICAL(1)</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20220703.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_cf22f6af-6837-4999-b599-4dde0d9c2dab_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_29286ad0-9cc5-4245-a7e0-c8ca34bd944f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_059381a6-e4e4-4c42-ac5a-8ee031cc6706_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_90d3b1d6-8ac9-4e95-90d4-a18cfa59f987_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_1dda49b6-663a-4933-8ee0-4492b6f0167b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_98de069b-6d5b-434b-92e3-b43b15bb0f0c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_28e63842-eaaf-4290-85ed-63d02e14a1d0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_13360e9d-27ae-43e5-aa8d-2a82a5db74d0_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by geographic area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:href="jnj-20220703.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:to="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_f622088a-d43c-41bd-8049-90e978d73970_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20220703.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_189a627f-3016-424d-b4f4-851d998c8c6a_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-Maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_8a3373a1-8ccb-4931-aaf5-122b51c0d977_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8cbe0801-3ad8-48fe-a72a-46d5916c712a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_da3f8872-2d1d-4b53-a43e-af0bafc28791_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2ae6a772-cf2f-4d62-9d95-3a01ab8062f5_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_2f01c458-abec-48ef-b02c-44c90d715058_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REMICADE</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20220703.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6b7ef27c-9b25-40f6-a8a7-de610cb84240_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a633cba3-6a68-48cc-add6-a0f69b2f8f27_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_4f27bbd3-5747-46ef-af00-469bd339c1ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ee5a2871-099e-456b-94cc-256154668743_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_b7e4e687-27cf-4a04-889d-443f88a13c83_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum length of time for hedge exposure</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_09847bf0-52a4-4df6-844a-a5bc3515ef69_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TREMFYA</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20220703.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_0e3766ff-ced3-4f63-bc85-0611c6daca22_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2497b68b-841b-4020-9a51-c72746cc53bd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_109493ae-c205-4e08-b057-7a2a47eeda2f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_5ffc116f-b1af-4cd3-8b1f-721aa82ea588_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_72eacd85-e931-4ea5-bba0-8701922a0a51_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PaymentsForRestructuringNet_55cad7ac-7885-49b1-9117-588a2600ba14_negatedTerseLabel_en-US" xlink:label="lab_jnj_PaymentsForRestructuringNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settlements</link:label>
    <link:label id="lab_jnj_PaymentsForRestructuringNet_label_en-US" xlink:label="lab_jnj_PaymentsForRestructuringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Net</link:label>
    <link:label id="lab_jnj_PaymentsForRestructuringNet_documentation_en-US" xlink:label="lab_jnj_PaymentsForRestructuringNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsForRestructuringNet" xlink:href="jnj-20220703.xsd#jnj_PaymentsForRestructuringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PaymentsForRestructuringNet" xlink:to="lab_jnj_PaymentsForRestructuringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_4d167ffa-ba79-4b5f-93ac-605ace9aff4b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ElmironMember_a5823937-f7b3-455e-a7d5-d60b1ffa4607_terseLabel_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron</link:label>
    <link:label id="lab_jnj_ElmironMember_label_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron [Member]</link:label>
    <link:label id="lab_jnj_ElmironMember_documentation_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember" xlink:href="jnj-20220703.xsd#jnj_ElmironMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ElmironMember" xlink:to="lab_jnj_ElmironMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_8e5b0f48-c678-413c-a738-9a0c663b53e9_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4256f264-6c54-474d-863b-ee5b4dab7f91_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_46d656bb-d966-4ab8-b8d2-89a3a836fd8a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_43c70518-3ce1-4921-a00b-fe2cbcee71cb_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20220703.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_d001e61f-0d39-400b-89b3-3bd052aef64d_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_daa9d520-f532-4b41-ba5b-d9c637373fbb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d09b25af-e9a4-4aac-b903-5e7be659e4a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_953d8da1-f68c-4737-88eb-957dd12abbbc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_396429e7-922d-4cb7-a2d5-58146f43ef24_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_17f9195f-2654-47df-80a1-032390626e20_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_017f1f18-013f-4cdf-bf3e-cc44bb675680_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_7e6135e7-2d38-4e9b-9818-cb6758e75069_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_d8762524-d44b-48d7-b734-fb8a50a499b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5dc9f181-df48-4716-8efe-28e68d8ba9f7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9ac05f09-43a3-4a0e-b66f-1cbc0a287d03_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_36406ea7-c532-486b-a67a-9d26e21bbb2b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_49fc192b-0049-4561-b336-e21799c7cc0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_436f0646-7e12-4602-8f5f-f4a323a7aab9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_362fb6b8-5421-4c43-8934-0614a7870fcd_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e00afd2a-7f7a-4a7e-855b-ca1e3757c91c_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_441b7085-b842-42f1-b4e3-1edf42d1689e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cda2857b-6ead-458d-ad84-dddf5325f6ca_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, trade, less allowances $223 (2021, $230)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6adc743e-0359-47de-a4a3-8cabb360fc80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_bdd0f573-63f0-4673-af72-5c87f5925b78_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov't securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3d928c62-ea8c-4b38-88a3-6f0df22dc5c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_c592123e-38e2-4d6c-8d3d-41a6a71ee368_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20220703.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_5af7685d-2b45-4aaa-b6df-88945cf717e3_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_bac3a564-5876-4b9d-bdb0-bc3fbaac4929_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_37bea191-4223-44c6-aac9-4acbc7426241_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_146400b5-2fb9-4942-b62e-7416f3591287_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_d49b173f-ee37-45f2-b414-da9b7b55f865_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6f4f1754-cc64-46d0-a2ed-6dfb04b78fd3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4e9f9667-e183-4784-b603-7cd4894ca773_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_5313270a-3b6c-42b9-af8b-a8e60771c1a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_6681c672-72c1-43cc-90d5-2fb8c179e6d3_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20220703.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_10c4e6ce-1087-45a5-a32b-79b98f0c9603_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_fa8d43f3-bdf1-4182-81d0-a8ff3cf51670_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9f6ac678-ca7f-4b39-b238-5075dedeed2c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a12b9ec6-3164-4fce-badd-9c9cba99e5da_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_e5ddaea3-ceac-4e32-b002-3a0583ce40af_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7b9522a4-bbd0-497d-b877-7340619a86cd_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_62d56d03-2316-4b7f-af77-fb39c4837d08_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a349e6bb-4326-4945-a691-2fa77647edf5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0569533a-4bbe-4fc4-a6a4-895696c9cbb2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_198438be-264c-4995-ad4a-128fd8cfbba0_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_359e0795-fbbd-4806-a5f7-3f795e2eafc1_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20220703.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0550NotesDue2025Member_98946b33-2c63-4439-897f-f4e386a96da8_terseLabel_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member" xlink:href="jnj-20220703.xsd#jnj_A0550NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0550NotesDue2025Member" xlink:to="lab_jnj_A0550NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_f1cb01f0-2c66-40af-86af-2bcf09b58624_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, impairment loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:href="jnj-20220703.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:to="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_69b355f4-c164-4958-bc75-242fd712b5b7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6207658f-2827-4b15-a2d1-09ac7457fe60_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3a9ff27a-4ea9-4ccf-8c2d-2ab6d3d6abdb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_e237d138-4890-4db6-a223-cad45254635c_terseLabel_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_label_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_documentation_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales" xlink:href="jnj-20220703.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Restructuringchargepercenttosales" xlink:to="lab_jnj_Restructuringchargepercenttosales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_53f89f57-1a7b-4d21-afe6-64fcf5bd5f3d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Segment Operating Income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4cf04378-ef05-4ff3-9218-158201294597_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_76d5b097-cc83-4aa8-b480-d037e530c9f3_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4867235d-56b7-4094-bfa7-703bf85e4cd7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New and Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_0e5747a6-cb24-4c76-9ae3-daef8124b6bb_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7bb84b9a-6690-485e-a1a0-dfd3b8d51c82_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_3254d7c0-cede-48f4-927b-71fd9abd7aeb_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ba4aee92-430f-4b4b-b400-008725ccc7db_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Note 3)</link:label>
    <link:label id="lab_us-gaap_Goodwill_21f163a2-ba31-4be3-8aee-67c16265ff39_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Beginning of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_701f05e5-26af-4a8f-bb89-3be4c638d6f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill End of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_e904475c-c44f-4329-a6b1-f7d1a2373fec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINEOTHERMember_c5244c93-f0d2-49c4-85ef-919f9e29e432_terseLabel_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE, SPORTS &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_label_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember" xlink:href="jnj-20220703.xsd#jnj_SPINEOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINEOTHERMember" xlink:to="lab_jnj_SPINEOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_7dbe7d56-9b60-4914-8283-3037f01130c2_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_32363155-2128-4e34-a9f8-2a0e580db553_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20220703.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_fb636ebc-fdbc-4757-9905-01ce7a7f9a0a_terseLabel_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold percent to sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_label_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold Percent To Sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_documentation_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:href="jnj-20220703.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:to="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d6885763-af80-4fe8-8d2f-7336ecc29151_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0732222e-68e2-4005-ab22-ff27ee2301a7_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_306a0c43-a56d-4725-ade4-23d9edd2dc9b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a56bfb05-1c29-42a0-8fbf-ccac1c7eb870_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_f0acea4b-7558-477d-8416-cd6ad20ee4ca_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_74b2d072-afd6-426a-946a-11c564e95501_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1272e24a-19ea-45a9-a6a6-ad2373ff9bcb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_316b3ca6-67ea-4589-b147-40406d7930a8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7bfb3057-8285-4b31-a323-f08b593ce8a0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0928ca7f-0448-474a-84c0-1453df712e0c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_7b2362af-44c6-4c27-bf65-280b29b3c22e_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20220703.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1123c364-561d-4c76-907e-d0f8892fa95e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_42bbaea8-5882-443c-a6c3-3b66a17eb816_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3cc9f032-a5ef-42c5-9dd5-218a129b70c9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd6bca78-3f5a-4be7-90d7-f17a98d8be0e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_0fe8c177-3a21-4880-a4f3-06be72121b89_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6836eb0c-1009-4c4f-96b7-a5c2826bba93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_9ccdca1f-60c7-4672-9835-bd3b323e7016_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9711c764-1632-41c7-b5fd-de67d81c965f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_17e9e122-edc6-4156-993c-817bfec03d37_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_360f2f61-15dd-4d78-98e9-809f805181b8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_eb86a3be-d92c-4c8b-9f7f-3be04e4e50b5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_d96bca13-252d-473a-b168-4835d029476d_verboseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of foreign exchange contracts into earnings, period</link:label>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_label_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Reclassification of Cash Flow Hedge Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:to="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6ea116ae-65d8-4e17-924e-655efb412012_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_65157383-99ae-4dc3-89c5-ca81113dcfde_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_370ab593-9c62-4fd3-817c-31e4c9739a9b_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20220703.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_bf2cf1d1-4998-46a6-a7d3-d4f8aaa556d6_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20220703.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_2a988960-ab67-42da-a43b-bc49a0265bb4_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_c5b29185-b655-43d3-a698-4e07376e8980_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes due 2028 (750MM Euro 1.0408)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20220703.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8aac9100-3b50-43fd-b0f5-aeb4854fe3b1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_7eaecb36-3929-4dfd-aa29-f93fb06265c1_verboseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_ce9d4e0c-6ba0-4cb8-98ee-e0bc27c0a110_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_790b5278-3ab4-4d11-a0ba-ec5467ab05ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_8e4ae09a-06ba-405e-aef4-af8d0d61ccf8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_b36b1d2a-5c61-4bd7-841d-0481f9101284_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT / rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20220703.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_5593449e-42c0-4acf-915a-6dafb6d07994_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_f9e2572e-279e-4ed5-8196-f39cae517203_verboseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_d84aba44-afa5-4d60-bcee-97b12fba350e_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 1.0408)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20220703.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_4c81eeac-bffa-4029-92dd-6977330e8cfd_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of additional possible loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_label_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_documentation_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:href="jnj-20220703.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:to="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f7485256-f9db-4383-b47e-3a3426488e52_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8697f905-1602-4f04-92f9-717a5ce5e8a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_40c75171-9ba5-4a5e-b6d0-79f74afcd51e_negatedTerseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in effective tax rate (percent)</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:href="jnj-20220703.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_1f96814e-c516-412b-bace-c58362afd221_terseLabel_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount prepaid and due to manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_label_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_documentation_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:href="jnj-20220703.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:to="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WomensHealthMember_49c0fa4a-4f74-41c6-a797-098252bb920b_terseLabel_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health</link:label>
    <link:label id="lab_jnj_WomensHealthMember_label_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:label id="lab_jnj_WomensHealthMember_documentation_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember" xlink:href="jnj-20220703.xsd#jnj_WomensHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WomensHealthMember" xlink:to="lab_jnj_WomensHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0f05b226-8384-4650-b899-6c36ebada835_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3c18c241-5f5c-4e2a-8be9-231e561b97f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6fd411ea-5112-4012-8cd2-5a31412f2f95_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_57b2fca5-9a77-46c7-9100-625c4b603e99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_5e65c073-f0f6-4653-808a-60c58e385886_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20220703.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_749af055-c63b-4a02-80cf-1e21aedf51f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_78be60f8-4f2c-4cb6-9ed0-4e9f319b7bea_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20220703.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_b2730958-77b7-4cda-8604-fa3185782bbc_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_41b6a3a6-5ca6-47ab-8d77-0afe4ea1a5d4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_fae04dcb-e662-4c55-9184-98defede980b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_e82b464b-2c16-4443-94a1-07ffa316d357_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8c7ade1a-7149-4eff-8886-e65e49bf240d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_91c5ade5-e610-4f6f-9ef7-c3cdd85ebe63_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Weighted-Average Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9f6c575a-3f27-4bf5-af86-5223aad4178a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_4c1e9fe0-4cd1-4021-8b23-6ce557818855_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6bb0211a-6ef1-4368-9034-e4620fd4b144_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_2cb87517-5ec2-45c7-843a-c318cc07a973_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9ed4dc04-c356-4438-8845-1a8d69b4a854_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7095e2f2-e1c0-449c-bcdb-3affc5a6f4c9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_44056568-fbe8-4f7c-8474-3e0d399f29e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_abdc6391-2297-4f30-b377-c14a5323a1bf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OralCareMember_48833420-4c2d-443c-982a-1ebe3528abe7_terseLabel_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care</link:label>
    <link:label id="lab_jnj_OralCareMember_label_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:label id="lab_jnj_OralCareMember_documentation_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember" xlink:href="jnj-20220703.xsd#jnj_OralCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OralCareMember" xlink:to="lab_jnj_OralCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_073f7031-b3a2-4c2d-86d0-d5327f782e3f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_0c6f8220-cbf0-428f-b7a1-3b75ffb3d6ac_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_eb89a054-2070-4521-b537-0ae28590b26f_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20220703.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_1a28ad5a-0e1b-4b7c-afa8-7f6cd25890f6_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_222d472a-a55d-4e8a-9cbf-946945dc9b65_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20220703.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8cb3b296-448b-490c-8768-2d32524037c7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Profit by Segment of Business</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_449e6fef-2a05-49aa-86b9-234dc4964dc4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b0de9dc7-e4f1-43c8-aaf5-1e922e0025b6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_21125c4e-a107-4158-9035-cbcf016b89d8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_71b1431b-9678-4ba9-860f-4f18489e8fd7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_81560ce9-117d-4ac4-aa21-88fc01f78d6b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_09ee6e8f-3287-41fb-a8d1-8c87d15adf79_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_ce02a6b1-0dd4-41ab-83fa-97a06288326e_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0ae05c96-a557-483e-abb9-ce65679b6cbb_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_3e0444ed-a474-4073-b496-ad277dd79a89_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20220703.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_e1ee1aba-8a2c-4fb0-b433-e175e27378b6_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20220703.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_b7b5d2b8-df31-4bb6-b0dc-707c1c4b7949_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AssetWriteoffMember_ad1e66b6-d12a-4cc6-b8a3-556623d48ab6_terseLabel_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-offs/Sales</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_label_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_documentation_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember" xlink:href="jnj-20220703.xsd#jnj_AssetWriteoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AssetWriteoffMember" xlink:to="lab_jnj_AssetWriteoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_2e8b0f26-69a8-4514-82dc-24b8a3d61407_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c60775ed-7741-4181-8a18-464a540b07c1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_8906461b-6b49-460c-924f-2f9c1b74abad_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_171bb40d-85e2-4f72-97fc-958bd3b60b74_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_05985e4a-0c1a-4421-9ad3-a6b7b88555b1_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20220703.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_b80dba1c-2d7a-46d1-bbe8-165abe08bd9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6c6c5cff-f8aa-4edd-a26b-9f6ffbcd083f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_c3a89abe-0e57-4aa7-9791-03b77da685fd_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of the estimated fair value over the carrying value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Fair Value Over Carrying Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:href="jnj-20220703.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:to="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GrossProfitPercentToSales_2dd1f857-bda5-41e9-937d-4a7e3a5bdebd_totalLabel_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_label_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_documentation_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales" xlink:href="jnj-20220703.xsd#jnj_GrossProfitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GrossProfitPercentToSales" xlink:to="lab_jnj_GrossProfitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f77e8e9a-830e-4298-b0f2-9e72ef727179_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_61e95017-c4db-465f-bd6e-d4ef444bb416_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6a9dffb9-2784-44e1-ba47-2216181eef02_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_90524018-9bca-4670-9e31-149944b85507_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve established</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_label_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_documentation_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:href="jnj-20220703.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:to="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_2cb5129b-5941-4f76-ac3c-b0d1f2db0f57_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_3ab16aec-c2b2-41a7-bc18-240f857c2185_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_9609abb9-07a2-45c4-9349-f32ea04fa7fb_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20220703.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_340459ef-a85a-4bec-ab3e-e339b486131e_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20220703.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_0136aad2-8366-48d2-9bc4-7dabf0669b87_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_d03842b8-ef14-4f07-8b00-4cff18be8cce_terseLabel_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling marketing and administrative expenses percent to sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling general and administrative expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:href="jnj-20220703.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:to="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_6d170c01-0720-471b-872b-2f6e6a158217_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_ac59399f-3e1c-4a09-8e49-8c20216f46b4_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: common stock held in treasury, at cost (490,811,000 and 490,878,000 shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_f8117b2c-3eb5-421f-9e96-3edcf5d3a889_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_3764b142-e6d7-4975-b0ba-9d647d96b01a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_b6801502-0d08-4ff5-8d70-0877551339df_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3426eb00-a82b-4c26-aec8-413abf135116_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2955b08d-189b-4a32-98a0-33217d64b55b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7d66860d-b92e-4cb1-ae27-9ca74afc818d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_314eb811-d606-48d4-9d1d-cde84a6767dd_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0fe9f1bd-4722-4b54-8e72-039939ac0d1e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_bfa6b423-5340-42cb-8ea1-3d473b13f5eb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cd8f28ca-60e2-482d-8657-3ab92cbcf669_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_1b7978e0-8d30-44a5-bf87-7ba292ab4252_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c5df500d-6325-4e2d-8bce-9a115e0a7a11_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4cd0d80c-b828-4169-b15d-59aa3a41652e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss) (Note 7)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_49f0d2e6-ae06-4be1-ae64-8399efef29f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1ea36689-1d4f-42f2-84f5-8a103fd6da60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7abd795-8e28-466a-89b9-2a77b8950658_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7a94b59e-32c9-48f8-b02c-2ffeee989f4a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_90b9f912-1495-4b4f-96ab-4e1639f933e9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_28216739-20c7-441e-9950-c699f90f6b87_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_39493c46-e4d0-462f-9c74-696a2fa65ad8_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency, number of claimants</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20220703.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ef69c8b8-f8ea-43a6-8607-e06c8f862158_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_0747f12b-ac6b-4312-9c71-177969b71aee_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_93a8e914-0f6e-4809-9320-22ee5c33568f_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2ad3dedb-6e59-49ec-875e-57acd2bb3257_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_db224ce6-339f-4bc2-ba4f-28fd6eb0659d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation/Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d951ce10-7045-40b4-a99a-38814914c8ea_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_021d2f08-4934-4254-ba50-7a4565767ecc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3393cf90-c26f-4c9a-a973-db52f652b728_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7f8fba2a-fcc1-45ce-930e-cf6eda707aa5_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_ae86d448-ef8e-4fbf-b207-033ba1dfff4f_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by geographic area</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_1127809a-68f7-4a71-9fce-4b8d72694ff2_terseLabel_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA / INVOKAMET</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_label_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_documentation_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember" xlink:href="jnj-20220703.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVOKANAINVOKAMETMember" xlink:to="lab_jnj_INVOKANAINVOKAMETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_b80f2699-037e-476e-96c9-d9f06e774715_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20220703.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AurisHealthMember_4bdfcbad-4b92-4806-8323-bb08d9f89f4f_terseLabel_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:label id="lab_jnj_AurisHealthMember_label_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health [Member]</link:label>
    <link:label id="lab_jnj_AurisHealthMember_documentation_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember" xlink:href="jnj-20220703.xsd#jnj_AurisHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AurisHealthMember" xlink:to="lab_jnj_AurisHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_643bcdce-8d5e-45cb-bbae-1f5ca5bc020b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_136fac99-34f0-4b7f-911a-4c3b24848112_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_64e191dd-af67-425d-b03f-e1739f40db82_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c85e033a-74f7-4868-ba59-66e3cab09253_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bc5f9285-a4aa-4ab5-9b04-873dfb143d0c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_051f258c-cc4d-4f95-b6d7-096e566cfbb7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_f4a335b2-09e1-4167-b01a-700e7c7d2dae_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_80462c01-58b6-4597-95d7-204be1c17367_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_label_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Loaned or Sold under Agreements to Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:to="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_1dbf5832-2ee7-4c09-9dac-c22e4192812b_terseLabel_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_label_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due Period Fifteen Member</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_documentation_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due period fifteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember" xlink:href="jnj-20220703.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NotesDuePeriodFifteenMember" xlink:to="lab_jnj_NotesDuePeriodFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_baf2bd25-11b3-4b60-860b-e471a304bf9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_3c96061f-7043-4e23-b397-ea78739bad6f_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20220703.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_5d7e2575-64cb-42d9-bf65-faa1d30d181c_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business and Geographic Areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_2ffb8860-9886-450b-b143-1fe1737cd507_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_7317d12f-3ed7-44a5-a359-493777b10a99_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_f84a235e-3a89-4893-86e8-ffaf48078d52_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_28a99bd8-9310-49b6-8aed-70ca1eb5c2e8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_ecb9ed83-b6b8-42a9-b087-6bd5d18407d9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_a34018e2-4614-4e99-b86b-46436a088130_verboseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_4cc97c4d-ae50-4bb3-85a3-32b402bc5beb_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes due 2024 (500MM GBP 1.2143)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20220703.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02254e86-673a-4ef3-8d36-efa4561e33a5_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0c8c3496-ee96-449c-ab82-05a17b4297f0_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_01b1740e-0859-4c7e-b6a5-4d1e73ffbb40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6d1ae7ab-98ac-44b3-801d-8c64580b82bf_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_c4227bd5-a4f4-489d-8e27-5f5732f14fdc_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20220703.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_9c8db08d-c1fc-4652-b88b-3c522f1a560a_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20220703.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a2d1bb49-65e5-46e2-9d9a-44291af041f3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVG. SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_8aa22bc8-724d-4288-9d1d-cb1a8b642730_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Note 2)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_28f1890e-546a-450c-a444-4648bea28304_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0ede0d25-9376-436c-a795-d00f760f0676_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_f3e8799d-e439-45d3-9282-d2a597290da1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring (Note 12)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_afc564e1-5b70-447a-894c-77ae8edcd138_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedicalDevicesMember_eeb9c3f0-170a-4032-8522-8353b04fc94d_verboseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MedTech</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_93ccb8f3-a7ab-47a4-b644-bc37420c74f8_terseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEDTECH(3)</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_label_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_documentation_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedicalDevicesMember" xlink:to="lab_jnj_MedicalDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d2d8f3f0-2525-4986-8bfe-3b83ca9dac3b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_4c21e18e-f12b-4b26-a117-3ee1fe799829_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_58e009b5-5b81-48cb-8fcb-3ca9a165ca00_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER ONCOLOGY</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20220703.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_6531c24a-327b-4625-8051-dc60f9a20bfe_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b103b9ed-683e-4b4f-90e9-28208edde081_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_ef779b00-6198-49a0-9469-9398e4e8343e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Liability Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0bc36d61-9843-47bb-9414-0dd583f8aa65_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ad61baa-ce84-418d-9fce-03cd471f1bee_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_5fb8e453-8242-42e8-a4a1-e7dd120f8a02_terseLabel_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_label_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member" xlink:href="jnj-20220703.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.73Debenturesdue2023Member" xlink:to="lab_jnj_A6.73Debenturesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e03eaaf7-8ad4-424c-9f24-761ec5371ee2_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_2e74860f-81a6-4970-aca0-052c633f2f2c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ERLEADAMember_c511ff51-57c1-458e-809b-e11a7959e78d_terseLabel_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:label id="lab_jnj_ERLEADAMember_label_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA [Member]</link:label>
    <link:label id="lab_jnj_ERLEADAMember_documentation_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember" xlink:href="jnj-20220703.xsd#jnj_ERLEADAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ERLEADAMember" xlink:to="lab_jnj_ERLEADAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_e5043ff8-2caa-4f44-867f-a652e5c7a4d0_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20220703.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ce540050-6459-40a4-bd69-1fa3b2df659f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_922e460a-ffe2-4050-be1f-8291d2e247f6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_4a77dfdc-c814-4ddb-af4e-7bcb9296efe0_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20220703.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_a8d64ebf-ebad-463c-92a6-d2ab1993364e_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_7767cb79-8ac5-4c6d-9087-818cdd9f3b26_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on disposition of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4de89acd-fa25-4f1f-9a92-bae74e2cc9e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_4301da72-f959-42b5-9859-4eff14936e2d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_94059424-7ef8-4559-9918-4ea037427f94_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER IMMUNOLOGY</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20220703.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_4ba91249-f1d8-4794-8c26-4a42157e7ae8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_3c382107-034f-4ee8-846a-df1da38c1c65_terseLabel_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_label_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_documentation_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember" xlink:href="jnj-20220703.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RISPERDALCONSTAMember" xlink:to="lab_jnj_RISPERDALCONSTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_04d556d0-1976-43c9-afe9-6f8c3f85df8d_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20220703.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_5b5cab8f-dc32-4494-8bee-84828de343d4_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_6af593f9-d9ea-4a05-8215-074452624ecc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_77ceaa91-6409-46ed-bf44-19bcc32753e2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0ae4e0d-cc5f-45a7-9234-f9c8e39b2b97_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_284dd089-59f2-4aa7-894a-d3c2ac03aeda_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_e9cc6034-ec3c-40b2-bba8-48809d65dd58_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EvraAndDoxilMember_d77f198f-3641-4f7f-99f7-bc02de075118_terseLabel_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_label_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil [Member]</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_documentation_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember" xlink:href="jnj-20220703.xsd#jnj_EvraAndDoxilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EvraAndDoxilMember" xlink:to="lab_jnj_EvraAndDoxilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_413c6156-cd9f-4132-9e9f-f5f2e08e6846_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_f24890f3-540f-424b-9361-e248647a6b41_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ca3ee0cd-3135-47c1-b3c0-753f2eaea0fb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_d7acc5b1-a73b-4cc7-af01-0f22bca55b85_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_4521a197-f978-4d32-b3bd-46b6df392268_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_bacbdc87-36e4-4c2e-8fd8-27831be3acf9_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_c563d79a-e3ad-410c-9c3a-c93db959d088_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_15f6c40c-9bd7-4577-b919-b336964048fe_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterventionalSolutionsMember_bc06fe02-c9a2-4be1-b2c2-8a6bf3b532b9_verboseLabel_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember" xlink:href="jnj-20220703.xsd#jnj_InterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterventionalSolutionsMember" xlink:to="lab_jnj_InterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_004a251d-6506-4e26-9ae4-1779f1bed2b7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_565e59a5-88c3-4a4f-a153-8ebaf54dbbe9_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_75e2c55f-7999-438b-9158-56098b5eb763_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_c75a0510-a8f8-436d-a8ed-59b337514cef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestExpensePercentToSales_337951da-1a34-4878-b2ec-99d6544cf73d_terseLabel_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized percent to sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_label_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales" xlink:href="jnj-20220703.xsd#jnj_InterestExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestExpensePercentToSales" xlink:to="lab_jnj_InterestExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_a029b7d3-de8f-44f8-bfd0-fae4af4b779a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_985a5d4d-cafb-4962-9083-1d61b05dc650_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20220703.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a3e233d5-962c-4941-b32d-c78c7817d0ba_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_ffaa5a8f-2695-4e2f-ace0-9b665c37d8a4_terseLabel_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects</link:label>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_label_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1bfc67a0-dd35-4e8c-9566-4c8454b9c413_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares exercisable under stock option plans</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_9ad1c024-2ef2-4af3-8d06-4b0c8db27db3_verboseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_d5cba434-4131-4c0f-bee6-c9b4e5b0e528_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_e76a8369-d2d4-4d36-9f0b-d0dd808b4553_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_3e30a8d5-4083-49c6-b69e-ec70e8324a9a_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f7c2d485-d496-42ca-b071-7ca8d277d294_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_245ad8b5-2c58-42b4-9f7f-96aa343ff45f_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20220703.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e12a1dfd-f6e7-455c-ad24-4bc0261a292f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired (Note 10)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8012706d-b5e5-43e8-87f7-7e2e3f5e3f07_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_24b3da39-d845-4cb5-b8fa-c0f32b76cba6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2d73ce83-eecd-4e71-b7c0-ba19be065203_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_4437bfdb-a669-4162-9634-d22b4d44862b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_aa09c78e-c891-44d0-9478-27b9f5733cea_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_930ee4b1-719c-4e15-8c46-89001ed35c80_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_23110c90-3c59-4882-b5d5-097362e64d9b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4d4687fb-a18b-4f2c-84ae-2b3434feed9d_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (Note 3)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_483f1615-8f15-413b-9869-b57832f8626d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets - net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpioidMember_9c3fcb3d-e459-4777-aeff-4624462dd09e_terseLabel_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:label id="lab_jnj_OpioidMember_label_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">opioid [Member]</link:label>
    <link:label id="lab_jnj_OpioidMember_documentation_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember" xlink:href="jnj-20220703.xsd#jnj_OpioidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpioidMember" xlink:to="lab_jnj_OpioidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_5334ea1c-d70f-42b8-8e7a-41f9cd1e97cb_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20220703.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d33d35e8-eb09-4690-9a16-c968bbc272eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_a6f0726b-c9ce-433b-838c-80c665f340f9_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_d2e56579-e8a8-480b-86dd-c4930682e124_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20220703.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_dba73dc5-6b45-4086-ac67-dbfd558afe3e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_37b74575-6424-4631-8c44-bedcc2c195b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_3ccb80be-ae83-4bf1-a72b-c0a64e51ad98_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term taxes payable (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_31d42708-fbe6-49e1-b627-fc8f6a783825_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20220703.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ce155e50-b121-43bd-8452-c05113580bba_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_6e943beb-5ad2-4b98-acd1-cad1d1e68e7f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_7c73e378-f970-45e6-bd3e-711b872cf67d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_d4414c1f-5822-47b8-99ae-47180d9f45d5_verboseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income)/Interest expense, net</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20220703.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ab9c48e1-0884-4a54-9882-39d8aa20e062_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities(1)</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d550d5c6-f8f9-40df-8d9d-5e3189313cc9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_a39b2baa-33eb-4cb3-a3a1-a8f65e862f30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Asset Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_f453ebdb-c931-456c-be4c-9891675ab110_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_695a3b4e-3b89-4188-8095-f3495bed456c_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20220703.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_1c55c704-c003-4fd7-b053-a3bce67e7d40_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_4f7b507d-628c-4887-86f0-1c179bea5730_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_60cf5d71-87e4-4163-99cf-b24f5942d74b_verboseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20220703.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_13751e14-3f37-450b-a011-eaeb75062662_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_2b58e1a9-0bcc-4a28-88e7-ba165a9d83a5_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral already posted, aggregate fair value</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d28be91f-3e86-496c-9a4a-a728d897b273_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_0053961f-2f5e-4989-b57d-1c8f0ed9dcef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b5542a86-aa04-4b19-af6b-75cf70a7a43b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_ae48eb8f-d2eb-4c4f-81f8-7f642d92aa3c_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20220703.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_2609b227-02f9-4989-8371-853cb14c9178_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_662edbfa-54dd-4061-8145-1c2c4f0aedbc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_d9f1c1d7-00e4-41ba-8068-91af299c47ca_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_8aae5142-9547-4ead-ac41-06d3b8cf08b5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_24c52b70-6c52-4661-8c85-ee9351d0a0ec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a6045a92-5053-4237-98ee-a6c8a843cf79_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTCMember_9ddac47b-f4a0-48f8-a503-055541f5ea10_terseLabel_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_label_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_documentation_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember" xlink:href="jnj-20220703.xsd#jnj_OTCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTCMember" xlink:to="lab_jnj_OTCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_604f1fb2-2f5b-49a3-a0f1-58b90d4f6891_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e9b3344c-a118-410f-9473-ec61d5e96616_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_cbc85cfe-350a-490f-ba02-c170e91e298a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_a5affcba-3e62-4242-aade-ecf2cb0e4c00_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_d952c77e-a130-4b65-8d60-eb54cff25a11_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Excluding Acquired In Process Cost Percent To Sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense excluding acquired in process cost percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:href="jnj-20220703.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_00619fd1-9d35-418e-934b-5c45ab0567f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_0c553108-233b-4b53-98dc-092c05a7b7e1_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_5cbe4e07-1b1d-4f83-866b-fd299df03099_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_eaab74e5-1618-43dc-a716-17818d38e566_terseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:href="jnj-20220703.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_2dd8d154-cc9e-4d70-94d9-8e3e52fb93a3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_9cadc4a0-8159-45c8-9f29-852ca88c8a7c_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20220703.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_85756e67-b505-4adb-9303-566aa756862e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_04fc6865-2f5a-4a07-9442-25dbfee44d10_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_acdf6cf1-b1db-4716-b6e2-660e7802ec6f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_4fdb7a03-02e3-4c5e-bee3-152817251815_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_44d55a20-3026-4592-bd1a-3ff78c5b95bc_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6725fb55-6f49-4ab2-a037-42d819aed9c8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_20db28d7-3c49-4c15-b0c7-1d44cef4424d_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_3a350501-df9e-4c8f-8228-60c51faf4cd5_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20220703.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_2f2ba081-6d8d-4247-a015-2f938ee191a8_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:href="jnj-20220703.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:to="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_30467585-3c3f-49ca-b4c2-1504873e965b_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA / methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20220703.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_dd788bfa-d017-43cf-9ffb-97355e97708d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_3f1c308a-1ca2-4d10-a78f-28787ff573d8_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STELARA</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20220703.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_3b7120a5-97ee-4d29-9ca6-703a4450cd36_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20220703.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_ecad30aa-9168-4fb7-883b-a17e0a535a62_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_a648968a-c944-49e9-8bae-769059d48014_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dcad95dd-b751-4fe5-8f51-411db72083e1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease)/Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_c23cc07f-f58f-4a0f-9aa9-2db7425c1be7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f5032d36-626f-4a86-a418-97406b9bfbe9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_1b1c4203-fd4f-4286-ad0b-ef71357ac3cd_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20220703.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_b4596bff-d579-4b30-8334-ffadaf48bc83_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_265be067-231b-4243-97f0-32a2997a728e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_51be37d6-f272-4ab6-8ce3-76910653a878_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20220703.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_aaebc589-ee85-45f4-aae6-9f74bd0daee9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_e6ef2256-7c6a-4daf-a8e8-214825ec3ccc_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20220703.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5e8cfe96-92e3-4aef-8ac1-703cdef1deb2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_892e9128-ce7a-403a-beb2-2a69046abf5f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_422a586d-006e-445a-b8f1-14f84cbce72b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2c8a5930-c9bd-41b2-84d8-9aecbe93d45a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_471a7882-a31c-4730-b636-a575a44cff0b_totalLabel_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings percent to sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_label_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_documentation_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:href="jnj-20220703.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:to="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_85e565aa-b5e5-42db-a5d2-48246792aed2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_3199a169-0c17-40a4-b08d-b911b1509ccb_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_33a3b418-6e0c-4152-a3df-9bf9291dcff5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_2a2abddb-199e-4456-97c3-ddc9c338fe39_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_fb745e54-7623-4675-adcf-7f37d314c5a6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_c16fc1bd-6c5a-40c4-be8b-22680fe10e87_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_9f1b1aed-62dd-4d58-b993-f3fb267e23c0_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Change (as a percent)</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20220703.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_b2600087-57c0-4b33-a3d2-d92a18bc26ee_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20220703.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d1238c9e-4ac9-45f3-b5b6-62632312ec1b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_3ab3bdb2-9fe1-4903-a452-385a7e207b25_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_9fc16088-f55d-4e5f-a686-13d47a110d75_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate on non-current debt</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_997ce8dc-8714-423d-9ddd-31a58738dd88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_3f6e4fb2-9eda-431e-a993-330a532ce368_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_9cf17853-d68a-4b6c-8bd3-0a265a357c64_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bfd41b69-88d8-4d01-aa73-99466d691881_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_1993ba92-1d12-4f8d-b5f2-1ebbf97e0be3_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20220703.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0f2e0f53-ca8a-45a0-9eb0-c922ec440bcf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_8a936702-8cc2-4d70-81ef-f471abd35717_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_7b2b7967-bb0f-4c7d-81ad-8e3f9b8c5502_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20220703.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8e72e2f1-d959-4562-9f1f-5a6b7422a17a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WoundCareandOtherMember_89177348-76da-4848-bea8-05bab5e67703_terseLabel_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care/Other</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_label_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_documentation_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember" xlink:href="jnj-20220703.xsd#jnj_WoundCareandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WoundCareandOtherMember" xlink:to="lab_jnj_WoundCareandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4947d259-2db2-42b9-9397-e3ce6e457e86_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_a05b8794-ac57-4b9d-b8d7-14b3bcb19d37_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_e8891c1f-e130-48a7-a4bf-ca04ae528aaa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_ae1e3367-827d-4242-a3df-340425c770e6_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INFECTIOUS DISEASES(</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20220703.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cc6997a2-3f0a-4524-baea-121aa069cc23_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_98051819-5ae6-4cb7-a659-96c247d9a045_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost savings expected</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:href="jnj-20220703.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:to="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0067fec2-9fc9-4801-b592-32c3a6ac49ed_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_41e925c0-67d3-456e-becd-42a9a864c262_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_a319d5e6-5b74-412a-b191-aff0faef87ee_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ContactLensesMember_091a99d1-2166-4f57-a461-a6ec79e1c96e_terseLabel_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:label id="lab_jnj_ContactLensesMember_label_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses [Member]</link:label>
    <link:label id="lab_jnj_ContactLensesMember_documentation_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember" xlink:href="jnj-20220703.xsd#jnj_ContactLensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ContactLensesMember" xlink:to="lab_jnj_ContactLensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f08ea3b2-ec47-4eea-aa14-3a4fb19b5af2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>jnj-20220703_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a211293e-c516-4076-a852-d6c27f4cfad7,g:c2e9e48c-ca8c-4ec1-bfd7-8d90ecda38c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20220703.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ade48903-abb6-4815-82e4-ade2576daf18" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_43d5e52e-1926-492d-a304-4ef7391e1e8c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ade48903-abb6-4815-82e4-ade2576daf18" xlink:to="loc_dei_EntitiesTable_43d5e52e-1926-492d-a304-4ef7391e1e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_627405df-cc54-47ad-917f-71e386c9bb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_43d5e52e-1926-492d-a304-4ef7391e1e8c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_627405df-cc54-47ad-917f-71e386c9bb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_627405df-cc54-47ad-917f-71e386c9bb0f" xlink:to="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_57b5cd2e-c3fa-4609-a84f-158203be12f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_us-gaap_CommonStockMember_57b5cd2e-c3fa-4609-a84f-158203be12f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_5f19b8f8-2585-484a-a201-ee8a2aab0571" xlink:href="jnj-20220703.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_jnj_A0.650NotesDue2024Member_5f19b8f8-2585-484a-a201-ee8a2aab0571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_df052815-6be6-40bc-bf53-9178e916a9cc" xlink:href="jnj-20220703.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_jnj_A5.50NotesDue2024Member_df052815-6be6-40bc-bf53-9178e916a9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_cc770579-8002-4457-ad47-9e2c28fa3382" xlink:href="jnj-20220703.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_jnj_A1.150NotesDue2028Member_cc770579-8002-4457-ad47-9e2c28fa3382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_0e90a10d-210c-4629-9485-986cceb6d7ab" xlink:href="jnj-20220703.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f0b933ad-0631-492b-b05a-d1c7932884bf" xlink:to="loc_jnj_A1.650NotesDue2035Member_0e90a10d-210c-4629-9485-986cceb6d7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_43d5e52e-1926-492d-a304-4ef7391e1e8c" xlink:to="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d2d116e8-5850-4646-96e4-6a9238f77604" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentType_d2d116e8-5850-4646-96e4-6a9238f77604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_37b76dee-7ffb-4c64-8ef1-0593e9a1c247" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentQuarterlyReport_37b76dee-7ffb-4c64-8ef1-0593e9a1c247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_42359cd2-45a2-410d-89b7-49aefbe18d1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentPeriodEndDate_42359cd2-45a2-410d-89b7-49aefbe18d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3e0c8b14-a2b4-4df4-801b-d43fa6bddca3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentTransitionReport_3e0c8b14-a2b4-4df4-801b-d43fa6bddca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_01ec493d-ebdb-4f14-85bd-e18f4cbebf39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityFileNumber_01ec493d-ebdb-4f14-85bd-e18f4cbebf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d4ce835f-d496-4642-ae8c-b01c7c3b0bf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityRegistrantName_d4ce835f-d496-4642-ae8c-b01c7c3b0bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_15bcded1-3a82-4b07-992f-b9bbe7ebc20f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_15bcded1-3a82-4b07-992f-b9bbe7ebc20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d1399971-d8bf-454e-827c-913a41b7fb4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityTaxIdentificationNumber_d1399971-d8bf-454e-827c-913a41b7fb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_af0c2848-e268-44e9-871d-91c77e89a8aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityAddressAddressLine1_af0c2848-e268-44e9-871d-91c77e89a8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_52dc51ad-804b-4a8a-b771-c16e88cea102" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityAddressCityOrTown_52dc51ad-804b-4a8a-b771-c16e88cea102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_830ee115-1ae3-4cb6-839c-4ec8db330929" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityAddressStateOrProvince_830ee115-1ae3-4cb6-839c-4ec8db330929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a1358165-c093-468d-bbbc-12646e5bae6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityAddressPostalZipCode_a1358165-c093-468d-bbbc-12646e5bae6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_55d42c24-c4ac-4e8a-9e1d-269cc369910b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_CityAreaCode_55d42c24-c4ac-4e8a-9e1d-269cc369910b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_face12e4-1ae6-4016-aeb0-ccafd377d47c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_LocalPhoneNumber_face12e4-1ae6-4016-aeb0-ccafd377d47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_51758f9a-3fe0-4c59-ab1f-e5b43b4168af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityCurrentReportingStatus_51758f9a-3fe0-4c59-ab1f-e5b43b4168af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f60b28d7-d35a-469b-a1d1-7669fce37998" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityInteractiveDataCurrent_f60b28d7-d35a-469b-a1d1-7669fce37998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3290a16a-fe8c-44bd-9197-68a93de2e06e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityFilerCategory_3290a16a-fe8c-44bd-9197-68a93de2e06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9aba50a2-683a-4fa9-873f-ee73e2c2844c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntitySmallBusiness_9aba50a2-683a-4fa9-873f-ee73e2c2844c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d003f883-0d35-49dd-a71a-18d68803fbff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityEmergingGrowthCompany_d003f883-0d35-49dd-a71a-18d68803fbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_473d5045-4fd3-48c9-9408-5a337c5bdce3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityShellCompany_473d5045-4fd3-48c9-9408-5a337c5bdce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6e458c7c-5b66-4072-8728-3797759afa6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_Security12bTitle_6e458c7c-5b66-4072-8728-3797759afa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_10b6ad06-d24c-40cf-ae85-744e8a871ab6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_TradingSymbol_10b6ad06-d24c-40cf-ae85-744e8a871ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f0606ccf-5504-45fa-a884-35e2882e0479" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_SecurityExchangeName_f0606ccf-5504-45fa-a884-35e2882e0479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c7633562-8566-4479-958f-1d7790c755e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c7633562-8566-4479-958f-1d7790c755e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_17a9b2dd-3a46-4b14-8514-2c8113a76c81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_EntityCentralIndexKey_17a9b2dd-3a46-4b14-8514-2c8113a76c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1d96fa5b-3c62-41bc-bb6c-b7a8a2e19f96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_CurrentFiscalYearEndDate_1d96fa5b-3c62-41bc-bb6c-b7a8a2e19f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_12a8319e-7636-4e85-96be-c7d10d3c1e67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentFiscalYearFocus_12a8319e-7636-4e85-96be-c7d10d3c1e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0042627e-e355-4768-a531-3ef55b57ef99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0042627e-e355-4768-a531-3ef55b57ef99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_64ee0c4c-e18f-4afe-8aa4-7852ff3d28b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b9c7e2a2-33c3-48c6-92fb-8b6a27486cf3" xlink:to="loc_dei_AmendmentFlag_64ee0c4c-e18f-4afe-8aa4-7852ff3d28b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3e238d39-0750-43f6-98b5-4a5fafd9cc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3e238d39-0750-43f6-98b5-4a5fafd9cc0e" xlink:to="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1c57ac17-e453-4190-8df9-0220a56bb9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1c57ac17-e453-4190-8df9-0220a56bb9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_70465427-a348-422f-939d-2e5108bdbc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1c57ac17-e453-4190-8df9-0220a56bb9f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_70465427-a348-422f-939d-2e5108bdbc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ef0ded9c-723b-49d5-97fd-3e88b786c285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1c57ac17-e453-4190-8df9-0220a56bb9f0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ef0ded9c-723b-49d5-97fd-3e88b786c285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a8ef0864-03d9-4923-8ba2-8c4f668fcac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1c57ac17-e453-4190-8df9-0220a56bb9f0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a8ef0864-03d9-4923-8ba2-8c4f668fcac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fbeaf0bd-403c-42e1-b67d-235c485302dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1c57ac17-e453-4190-8df9-0220a56bb9f0" xlink:to="loc_us-gaap_InventoryNet_fbeaf0bd-403c-42e1-b67d-235c485302dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_efbb6493-8388-4f97-a6a1-261fe05f9dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1c57ac17-e453-4190-8df9-0220a56bb9f0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_efbb6493-8388-4f97-a6a1-261fe05f9dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6cc4ac1a-7bdf-40c3-833f-5777839393cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1c57ac17-e453-4190-8df9-0220a56bb9f0" xlink:to="loc_us-gaap_AssetsCurrent_6cc4ac1a-7bdf-40c3-833f-5777839393cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d8577e8d-114e-449c-a3a5-c14094d95937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d8577e8d-114e-449c-a3a5-c14094d95937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_03b118e6-b3a0-40c5-aebc-4340852a42f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_03b118e6-b3a0-40c5-aebc-4340852a42f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_11233632-56d2-47cc-b4ae-1dd2708d84f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_11233632-56d2-47cc-b4ae-1dd2708d84f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_41a1bbe8-134a-4181-be99-be6e8a27ee60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_41a1bbe8-134a-4181-be99-be6e8a27ee60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ab127c4a-3a1e-4461-bf7b-d1adeb520b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:to="loc_us-gaap_Goodwill_ab127c4a-3a1e-4461-bf7b-d1adeb520b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_fc29a157-d9c9-4042-a39a-e52bed3f8b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_fc29a157-d9c9-4042-a39a-e52bed3f8b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_722ef59c-1d4b-4323-ac03-55c069713692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_722ef59c-1d4b-4323-ac03-55c069713692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2f105615-a938-4fab-a0ef-ab14970e8023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dd172604-fa67-469e-a1b5-02ea9285ce73" xlink:to="loc_us-gaap_Assets_2f105615-a938-4fab-a0ef-ab14970e8023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3e238d39-0750-43f6-98b5-4a5fafd9cc0e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_61d5e16b-77e8-46b0-9cf8-6868feec8196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_61d5e16b-77e8-46b0-9cf8-6868feec8196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_a2e0b396-f607-4ece-9753-b696ea8cd91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_61d5e16b-77e8-46b0-9cf8-6868feec8196" xlink:to="loc_us-gaap_ShortTermBorrowings_a2e0b396-f607-4ece-9753-b696ea8cd91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0011a08e-b70a-4468-a837-6f7871972813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_61d5e16b-77e8-46b0-9cf8-6868feec8196" xlink:to="loc_us-gaap_AccountsPayableCurrent_0011a08e-b70a-4468-a837-6f7871972813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f2e17e6c-bc3f-49fd-8909-3145acd16edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_61d5e16b-77e8-46b0-9cf8-6868feec8196" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f2e17e6c-bc3f-49fd-8909-3145acd16edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_99886db1-225f-4284-aa98-71983586be4d" xlink:href="jnj-20220703.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_61d5e16b-77e8-46b0-9cf8-6868feec8196" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_99886db1-225f-4284-aa98-71983586be4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3dd6c764-7ba8-4cb6-865e-02e249ce466d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_61d5e16b-77e8-46b0-9cf8-6868feec8196" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3dd6c764-7ba8-4cb6-865e-02e249ce466d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_1991b9d2-9e92-414c-bd60-7b4653cf5caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_61d5e16b-77e8-46b0-9cf8-6868feec8196" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_1991b9d2-9e92-414c-bd60-7b4653cf5caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_36a0ca3a-a09f-433f-8b5f-7cdc841d8c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_61d5e16b-77e8-46b0-9cf8-6868feec8196" xlink:to="loc_us-gaap_LiabilitiesCurrent_36a0ca3a-a09f-433f-8b5f-7cdc841d8c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a6cd4343-722e-4cdb-8424-65010b2f9b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a6cd4343-722e-4cdb-8424-65010b2f9b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e8db4575-db2e-4677-ae15-47343917e0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e8db4575-db2e-4677-ae15-47343917e0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_95379977-6ef0-4af0-9427-732cb8476a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_95379977-6ef0-4af0-9427-732cb8476a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_a8939b05-9700-4674-9d5a-26f8419db059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_a8939b05-9700-4674-9d5a-26f8419db059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d38c13fd-1fed-49e8-a5cd-4742f4d4ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d38c13fd-1fed-49e8-a5cd-4742f4d4ebed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1a80f97f-ef83-40ac-9ac1-6fc7cbbb6fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_Liabilities_1a80f97f-ef83-40ac-9ac1-6fc7cbbb6fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_354b455b-ddd7-4dc7-bb15-62bfa43d430c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_CommitmentsAndContingencies_354b455b-ddd7-4dc7-bb15-62bfa43d430c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0619859c-30fc-42a2-8d87-f023eb5429d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0619859c-30fc-42a2-8d87-f023eb5429d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e8731014-0ac3-4065-bfae-955c94d438a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0619859c-30fc-42a2-8d87-f023eb5429d3" xlink:to="loc_us-gaap_CommonStockValue_e8731014-0ac3-4065-bfae-955c94d438a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb045775-5e51-4be2-a63c-6ce0a6d59060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0619859c-30fc-42a2-8d87-f023eb5429d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb045775-5e51-4be2-a63c-6ce0a6d59060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2d6de05a-acac-4dac-8810-8f04261c3955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0619859c-30fc-42a2-8d87-f023eb5429d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2d6de05a-acac-4dac-8810-8f04261c3955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_4edbc474-a676-48ee-8edd-b4673556feda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0619859c-30fc-42a2-8d87-f023eb5429d3" xlink:to="loc_us-gaap_TreasuryStockValue_4edbc474-a676-48ee-8edd-b4673556feda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0c53fb7a-8ad1-4ee0-8495-7108d60bd207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0619859c-30fc-42a2-8d87-f023eb5429d3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0c53fb7a-8ad1-4ee0-8495-7108d60bd207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a82df7c9-c0de-4821-b15e-ba084a418e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6f4a070-d4ef-43b3-9203-ed33ea308706" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a82df7c9-c0de-4821-b15e-ba084a418e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7e607b90-67e4-4871-b33e-9e825ea83336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_321ba793-144c-4d0d-801c-6324eac929bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7e607b90-67e4-4871-b33e-9e825ea83336" xlink:to="loc_us-gaap_AssetsCurrentAbstract_321ba793-144c-4d0d-801c-6324eac929bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_acebb904-3ddb-40b8-a3c2-c26060a4b193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_321ba793-144c-4d0d-801c-6324eac929bf" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_acebb904-3ddb-40b8-a3c2-c26060a4b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9bcea7d2-ff8d-4e6b-a21e-398b2ce1cb90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7e607b90-67e4-4871-b33e-9e825ea83336" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9bcea7d2-ff8d-4e6b-a21e-398b2ce1cb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_97397503-8397-473e-8fb9-9d0913c989b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9bcea7d2-ff8d-4e6b-a21e-398b2ce1cb90" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_97397503-8397-473e-8fb9-9d0913c989b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e9e126a8-5d24-40f0-a0a2-0dd35efb9ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9bcea7d2-ff8d-4e6b-a21e-398b2ce1cb90" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e9e126a8-5d24-40f0-a0a2-0dd35efb9ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_dcd520e1-3524-4aab-8ce8-ef6831986837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9bcea7d2-ff8d-4e6b-a21e-398b2ce1cb90" xlink:to="loc_us-gaap_CommonStockSharesIssued_dcd520e1-3524-4aab-8ce8-ef6831986837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_d2ee36ad-053e-4e59-a206-63e1ff1a5f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9bcea7d2-ff8d-4e6b-a21e-398b2ce1cb90" xlink:to="loc_us-gaap_TreasuryStockShares_d2ee36ad-053e-4e59-a206-63e1ff1a5f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7bb3e76-a0f9-4d73-aff0-6c16407a0e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7bb3e76-a0f9-4d73-aff0-6c16407a0e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_8d993718-4934-4f6b-8138-9d8d8a1f6ef9" xlink:href="jnj-20220703.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_8d993718-4934-4f6b-8138-9d8d8a1f6ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_99ad4b4e-1db2-438a-ac5c-274d3bfe9168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_99ad4b4e-1db2-438a-ac5c-274d3bfe9168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_fb9817fd-6f69-43d2-90fa-6a321f0c35bc" xlink:href="jnj-20220703.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_fb9817fd-6f69-43d2-90fa-6a321f0c35bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_79ccbf9d-d04b-4805-93b0-88e585033d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_GrossProfit_79ccbf9d-d04b-4805-93b0-88e585033d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_6b5cbcdf-62c4-46e1-a156-9d24f134a7c3" xlink:href="jnj-20220703.xsd#jnj_GrossProfitPercentToSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_GrossProfitPercentToSales_6b5cbcdf-62c4-46e1-a156-9d24f134a7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8c6d747a-4af2-4356-a259-6a1d93c1b3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8c6d747a-4af2-4356-a259-6a1d93c1b3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_67bffa80-5645-448b-952b-406457ca1a9f" xlink:href="jnj-20220703.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_67bffa80-5645-448b-952b-406457ca1a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75ad1e56-8cba-412a-a21d-174187b6d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75ad1e56-8cba-412a-a21d-174187b6d3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_a2ad9205-4012-4507-b126-0dabd361818b" xlink:href="jnj-20220703.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_a2ad9205-4012-4507-b126-0dabd361818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_fa50fbdf-67d3-41aa-b09b-fa61635d0957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_fa50fbdf-67d3-41aa-b09b-fa61635d0957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_2b78b567-3974-45e2-93c7-bf6f7db0f2d6" xlink:href="jnj-20220703.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_2b78b567-3974-45e2-93c7-bf6f7db0f2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a9eabd22-b946-4b96-9568-35a6cfd8fbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a9eabd22-b946-4b96-9568-35a6cfd8fbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_f935d586-0dc6-4a00-a9de-c45cbacad86a" xlink:href="jnj-20220703.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_f935d586-0dc6-4a00-a9de-c45cbacad86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2f51be82-3011-484d-996e-042645a6d2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_InterestExpense_2f51be82-3011-484d-996e-042645a6d2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_142673aa-58f5-470a-956c-a919cb953555" xlink:href="jnj-20220703.xsd#jnj_InterestExpensePercentToSales"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_InterestExpensePercentToSales_142673aa-58f5-470a-956c-a919cb953555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a1a9d10f-68da-47b6-99a0-35141114bed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a1a9d10f-68da-47b6-99a0-35141114bed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_dc2218b0-f74a-4609-8d9c-7f4601c4c6f1" xlink:href="jnj-20220703.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_dc2218b0-f74a-4609-8d9c-7f4601c4c6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_46bf96e3-63ac-4e02-a015-2ddf4cfe6547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_RestructuringCharges_46bf96e3-63ac-4e02-a015-2ddf4cfe6547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_f634ebb4-fbde-44fb-9312-f36e3bc0beb6" xlink:href="jnj-20220703.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_Restructuringchargepercenttosales_f634ebb4-fbde-44fb-9312-f36e3bc0beb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_835c4976-ae9a-4f9f-9490-72551351cd26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_835c4976-ae9a-4f9f-9490-72551351cd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_d3d84153-9fb4-4fde-af58-2b0deb977f62" xlink:href="jnj-20220703.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_d3d84153-9fb4-4fde-af58-2b0deb977f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4d1d6af6-d235-44e3-9f7c-7f01b7fbc3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4d1d6af6-d235-44e3-9f7c-7f01b7fbc3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_a0af1695-96e4-4533-9b64-dd5e6483c33f" xlink:href="jnj-20220703.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_a0af1695-96e4-4533-9b64-dd5e6483c33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_29677d31-5472-4d8b-a5fb-5985577606dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_NetIncomeLoss_29677d31-5472-4d8b-a5fb-5985577606dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_e237c57d-422a-4cdf-a4b1-8c92861f848c" xlink:href="jnj-20220703.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_jnj_NetIncomeAttributableToParentPercentToSales_e237c57d-422a-4cdf-a4b1-8c92861f848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b04f1453-8a3e-49ff-9317-0352a253e8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b04f1453-8a3e-49ff-9317-0352a253e8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e9b0eacb-aa4d-427e-9862-daec9ae78bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b04f1453-8a3e-49ff-9317-0352a253e8de" xlink:to="loc_us-gaap_EarningsPerShareBasic_e9b0eacb-aa4d-427e-9862-daec9ae78bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bbee9d7c-ef4e-4591-be22-301f74d3621c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b04f1453-8a3e-49ff-9317-0352a253e8de" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bbee9d7c-ef4e-4591-be22-301f74d3621c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3bc3afe1-e342-4030-91d5-7c1afe38cdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43865bc7-889d-41d5-9522-e1cc8bb3c9c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3bc3afe1-e342-4030-91d5-7c1afe38cdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a794193-54d9-4712-8095-67820315cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3bc3afe1-e342-4030-91d5-7c1afe38cdc3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a794193-54d9-4712-8095-67820315cd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63f214d4-b25d-46ac-9f1b-c041bc46f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3bc3afe1-e342-4030-91d5-7c1afe38cdc3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63f214d4-b25d-46ac-9f1b-c041bc46f0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d5bfaabf-0d39-405c-8f03-648c722c20c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1471f857-a199-4974-8598-a21cb6ac4e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d5bfaabf-0d39-405c-8f03-648c722c20c0" xlink:to="loc_us-gaap_NetIncomeLoss_1471f857-a199-4974-8598-a21cb6ac4e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6c1e4046-037e-4be9-a581-c33ace7ce6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d5bfaabf-0d39-405c-8f03-648c722c20c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6c1e4046-037e-4be9-a581-c33ace7ce6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_a8affb01-b9cc-483a-bd45-56a6207ef33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6c1e4046-037e-4be9-a581-c33ace7ce6b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_a8affb01-b9cc-483a-bd45-56a6207ef33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_8d6be441-d63e-4c22-8ecd-908b8858b154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6c1e4046-037e-4be9-a581-c33ace7ce6b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_8d6be441-d63e-4c22-8ecd-908b8858b154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_79a832f6-e39f-4a86-b968-2eccc81da2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_8d6be441-d63e-4c22-8ecd-908b8858b154" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_79a832f6-e39f-4a86-b968-2eccc81da2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_5e59a49a-3e16-495f-9eec-5f48b96dba89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_8d6be441-d63e-4c22-8ecd-908b8858b154" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_5e59a49a-3e16-495f-9eec-5f48b96dba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5194e57d-e8af-4b61-84a2-d3d30cb38fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_8d6be441-d63e-4c22-8ecd-908b8858b154" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5194e57d-e8af-4b61-84a2-d3d30cb38fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_42585cac-6951-4433-bf60-d21e865b7aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6c1e4046-037e-4be9-a581-c33ace7ce6b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_42585cac-6951-4433-bf60-d21e865b7aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_a9669f9f-ba56-49ac-bc5f-a815c45284b6" xlink:href="jnj-20220703.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_42585cac-6951-4433-bf60-d21e865b7aa4" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_a9669f9f-ba56-49ac-bc5f-a815c45284b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_b36a0e26-4571-4129-a002-91e97a6b6d80" xlink:href="jnj-20220703.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_42585cac-6951-4433-bf60-d21e865b7aa4" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_b36a0e26-4571-4129-a002-91e97a6b6d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e9009f90-23c4-4cf5-aee1-f34291ede823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_42585cac-6951-4433-bf60-d21e865b7aa4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e9009f90-23c4-4cf5-aee1-f34291ede823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_00c40cc9-26a9-4c88-98b4-4e5695869128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6c1e4046-037e-4be9-a581-c33ace7ce6b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_00c40cc9-26a9-4c88-98b4-4e5695869128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d5f059fa-b486-4236-826b-1e15a139afbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_00c40cc9-26a9-4c88-98b4-4e5695869128" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d5f059fa-b486-4236-826b-1e15a139afbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_a30118b8-1c09-4dd1-840d-7a800ac7efd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_00c40cc9-26a9-4c88-98b4-4e5695869128" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_a30118b8-1c09-4dd1-840d-7a800ac7efd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_fa1f6533-bd1d-4159-880b-0a814030fe17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_00c40cc9-26a9-4c88-98b4-4e5695869128" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_fa1f6533-bd1d-4159-880b-0a814030fe17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cfc04b91-6470-4e0f-af32-1aa37af0d9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d5bfaabf-0d39-405c-8f03-648c722c20c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cfc04b91-6470-4e0f-af32-1aa37af0d9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7a089470-eff3-45c9-8078-8453a439b72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d5bfaabf-0d39-405c-8f03-648c722c20c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7a089470-eff3-45c9-8078-8453a439b72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b78bf0d5-e91b-4ca5-a064-5fa3e637ad73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_12091684-0808-4f92-9a69-6b6d94c1b800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b78bf0d5-e91b-4ca5-a064-5fa3e637ad73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_12091684-0808-4f92-9a69-6b6d94c1b800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_88ddc64b-9acd-4f12-affb-2b67ba4ce8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b78bf0d5-e91b-4ca5-a064-5fa3e637ad73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_88ddc64b-9acd-4f12-affb-2b67ba4ce8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_451b0955-50cc-4ade-9e2e-e2470450cf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b78bf0d5-e91b-4ca5-a064-5fa3e637ad73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_451b0955-50cc-4ade-9e2e-e2470450cf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_2e21c384-7276-4fbd-8f24-4f80f45d5f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b78bf0d5-e91b-4ca5-a064-5fa3e637ad73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_2e21c384-7276-4fbd-8f24-4f80f45d5f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_484a512c-5f52-4b3f-bb9e-3f3138a04dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5ef1255e-fb8e-4583-abfc-19ee1fbba978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_484a512c-5f52-4b3f-bb9e-3f3138a04dd9" xlink:to="loc_us-gaap_StatementTable_5ef1255e-fb8e-4583-abfc-19ee1fbba978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12512320-64c2-409f-ae1e-db3d5fed4597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5ef1255e-fb8e-4583-abfc-19ee1fbba978" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12512320-64c2-409f-ae1e-db3d5fed4597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12512320-64c2-409f-ae1e-db3d5fed4597" xlink:to="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_59358b30-864d-4544-b061-b2b79d1578a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:to="loc_us-gaap_RetainedEarningsMember_59358b30-864d-4544-b061-b2b79d1578a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a965000a-faee-4e37-ad5e-6b631c15b729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a965000a-faee-4e37-ad5e-6b631c15b729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9f057f95-4153-4017-93d8-6d0aaea757c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:to="loc_us-gaap_CommonStockMember_9f057f95-4153-4017-93d8-6d0aaea757c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_49fd2e50-43d0-4611-92d8-51c87c9f11f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8de0309d-500b-4a54-968a-890f716ab3df" xlink:to="loc_us-gaap_TreasuryStockMember_49fd2e50-43d0-4611-92d8-51c87c9f11f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5ef1255e-fb8e-4583-abfc-19ee1fbba978" xlink:to="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2325e25-52d0-4fa5-8916-bf8e4eb0a0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2325e25-52d0-4fa5-8916-bf8e4eb0a0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a70e620-ebe0-4b17-a9fb-a98c8431b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_NetIncomeLoss_3a70e620-ebe0-4b17-a9fb-a98c8431b95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_4d709aaa-b691-4953-97ff-33e75d3f0e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_DividendsCommonStockCash_4d709aaa-b691-4953-97ff-33e75d3f0e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6bb65595-9dc1-481b-8dca-bbac22b7948f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_6bb65595-9dc1-481b-8dca-bbac22b7948f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_955229d8-fa35-466d-9cc1-6e32104c4a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_955229d8-fa35-466d-9cc1-6e32104c4a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6bd1f90b-e2af-48d4-a951-58e9fa4b132e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6bd1f90b-e2af-48d4-a951-58e9fa4b132e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f4ac7ec-eb22-4797-adb2-2be62e6f923b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a5fa7f77-f72a-4ceb-9592-03f5993c3f21" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f4ac7ec-eb22-4797-adb2-2be62e6f923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_52f37535-a2b4-448c-9519-4c3456182f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_e23f6c72-69b2-4d75-9aa4-bd4381c5ba0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_52f37535-a2b4-448c-9519-4c3456182f03" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_e23f6c72-69b2-4d75-9aa4-bd4381c5ba0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20220703.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_952f6f66-e232-4e4d-bb85-aa470be4f447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1752c68f-eee2-429b-9ca3-068b892e955f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_952f6f66-e232-4e4d-bb85-aa470be4f447" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1752c68f-eee2-429b-9ca3-068b892e955f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0be4ee81-4d8e-497a-bd57-9ef97d23ed67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1752c68f-eee2-429b-9ca3-068b892e955f" xlink:to="loc_us-gaap_NetIncomeLoss_0be4ee81-4d8e-497a-bd57-9ef97d23ed67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90882e8e-8db3-42d6-95ed-feb46e52dfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1752c68f-eee2-429b-9ca3-068b892e955f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90882e8e-8db3-42d6-95ed-feb46e52dfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_90b90d79-0ff1-4f49-be08-5eb397685e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90882e8e-8db3-42d6-95ed-feb46e52dfc6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_90b90d79-0ff1-4f49-be08-5eb397685e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_23a55805-7130-4f54-abec-9be53ed723b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90882e8e-8db3-42d6-95ed-feb46e52dfc6" xlink:to="loc_us-gaap_ShareBasedCompensation_23a55805-7130-4f54-abec-9be53ed723b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_50ae141d-0224-4103-813f-325fe1dabbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90882e8e-8db3-42d6-95ed-feb46e52dfc6" xlink:to="loc_us-gaap_AssetImpairmentCharges_50ae141d-0224-4103-813f-325fe1dabbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_cc91b779-1cea-4268-b81d-f3b166b508e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90882e8e-8db3-42d6-95ed-feb46e52dfc6" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_cc91b779-1cea-4268-b81d-f3b166b508e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7a442d16-e148-4d10-ace1-a6e24f8f8717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90882e8e-8db3-42d6-95ed-feb46e52dfc6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7a442d16-e148-4d10-ace1-a6e24f8f8717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b7b3b45a-3e30-49e0-a10b-316368435dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90882e8e-8db3-42d6-95ed-feb46e52dfc6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b7b3b45a-3e30-49e0-a10b-316368435dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76ee9f80-bf04-48f7-bc0f-511bee0fca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1752c68f-eee2-429b-9ca3-068b892e955f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76ee9f80-bf04-48f7-bc0f-511bee0fca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe209419-726c-46d3-ba28-aead19194ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76ee9f80-bf04-48f7-bc0f-511bee0fca6f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe209419-726c-46d3-ba28-aead19194ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1513983e-ed68-40f4-a01b-5054ab775dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76ee9f80-bf04-48f7-bc0f-511bee0fca6f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1513983e-ed68-40f4-a01b-5054ab775dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d65ad3f3-072a-4851-ae01-52347a3c5364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76ee9f80-bf04-48f7-bc0f-511bee0fca6f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d65ad3f3-072a-4851-ae01-52347a3c5364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_42484bea-2f21-40a5-8086-6b2be691e3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76ee9f80-bf04-48f7-bc0f-511bee0fca6f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_42484bea-2f21-40a5-8086-6b2be691e3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b37a026d-fc70-44e2-a0e3-1c3f5eb7cb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76ee9f80-bf04-48f7-bc0f-511bee0fca6f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b37a026d-fc70-44e2-a0e3-1c3f5eb7cb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72c869a0-7491-4b47-ba5d-3156be4422ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1752c68f-eee2-429b-9ca3-068b892e955f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72c869a0-7491-4b47-ba5d-3156be4422ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_952f6f66-e232-4e4d-bb85-aa470be4f447" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dae48144-2842-4925-abd9-dccfd5e6b5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dae48144-2842-4925-abd9-dccfd5e6b5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_753c8918-9333-49ce-ba41-d197684bb183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_753c8918-9333-49ce-ba41-d197684bb183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_064a672f-0fbc-4292-bf7b-32be6be44c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_064a672f-0fbc-4292-bf7b-32be6be44c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_be62bb7a-c25d-4855-862d-14cae73be405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_be62bb7a-c25d-4855-862d-14cae73be405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ac221dde-f021-4d93-b233-3229884de67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ac221dde-f021-4d93-b233-3229884de67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_9bd4d7f5-0e70-4a9d-ac36-369481db005a" xlink:href="jnj-20220703.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_9bd4d7f5-0e70-4a9d-ac36-369481db005a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a63db6f3-572d-4122-a195-cb084555d05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a63db6f3-572d-4122-a195-cb084555d05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fbfa12-98f4-4dbf-a2da-01d6085c8701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94789ae6-6b9a-49b4-ad27-58aae79c0af1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fbfa12-98f4-4dbf-a2da-01d6085c8701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_952f6f66-e232-4e4d-bb85-aa470be4f447" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_6a11014a-ed5a-43f0-a081-6a73b8ec2803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_6a11014a-ed5a-43f0-a081-6a73b8ec2803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_74861be6-93c9-4c13-a788-6e206f6875d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_74861be6-93c9-4c13-a788-6e206f6875d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_d2e65792-a4ca-40b8-90c9-9f075aa41c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_d2e65792-a4ca-40b8-90c9-9f075aa41c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_1c4d0219-01c6-4c8f-b829-f250882c7c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_1c4d0219-01c6-4c8f-b829-f250882c7c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_30882d69-5e36-4d42-a91e-cf8a2b2c5593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_30882d69-5e36-4d42-a91e-cf8a2b2c5593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2345dc9c-3168-4eb0-bc43-660821ec6008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2345dc9c-3168-4eb0-bc43-660821ec6008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_8fe21178-de49-435b-9d07-e6683e625fa1" xlink:href="jnj-20220703.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_8fe21178-de49-435b-9d07-e6683e625fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_e0a41c1a-d735-450d-acb4-8159adb03873" xlink:href="jnj-20220703.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_e0a41c1a-d735-450d-acb4-8159adb03873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_dad5069a-586e-4fb6-8208-f11b3c1226c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_dad5069a-586e-4fb6-8208-f11b3c1226c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c52e5c1c-c602-44de-901c-f7e56a7fd424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20dcb740-bde4-4208-a24a-2c267f0dbba4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c52e5c1c-c602-44de-901c-f7e56a7fd424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_981e9428-4b06-458e-9773-0c05f6fa5fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_952f6f66-e232-4e4d-bb85-aa470be4f447" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_981e9428-4b06-458e-9773-0c05f6fa5fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e828a60-a7fa-4737-ae54-c14a3090d646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_952f6f66-e232-4e4d-bb85-aa470be4f447" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e828a60-a7fa-4737-ae54-c14a3090d646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d6cfcdf-24d6-4803-b053-efe2fed4f6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_952f6f66-e232-4e4d-bb85-aa470be4f447" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d6cfcdf-24d6-4803-b053-efe2fed4f6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6e5ec2f-846d-4b3f-b789-1ef067e41b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_952f6f66-e232-4e4d-bb85-aa470be4f447" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6e5ec2f-846d-4b3f-b789-1ef067e41b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_1a6eb5f4-5308-4726-93e2-6c6d8370d97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_952f6f66-e232-4e4d-bb85-aa470be4f447" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_1a6eb5f4-5308-4726-93e2-6c6d8370d97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_7457e517-93df-4fef-9f94-fefbdb2e86bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_1a6eb5f4-5308-4726-93e2-6c6d8370d97a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_7457e517-93df-4fef-9f94-fefbdb2e86bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_aa9477a4-b787-4968-b64d-66c8b40bd328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_1a6eb5f4-5308-4726-93e2-6c6d8370d97a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_aa9477a4-b787-4968-b64d-66c8b40bd328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_cd7c18ef-5c3b-48de-b477-b22dbb523237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_1a6eb5f4-5308-4726-93e2-6c6d8370d97a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_cd7c18ef-5c3b-48de-b477-b22dbb523237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20220703.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dabac981-530e-4c31-9116-dc0a900a81f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_de7398e8-8ddb-49f9-a58d-388d0ebc58db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dabac981-530e-4c31-9116-dc0a900a81f5" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_de7398e8-8ddb-49f9-a58d-388d0ebc58db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20220703.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7f49f130-6e1d-4f14-8989-dd7f23ee9fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_691f1ad4-eb3b-4a53-a955-a56a576794b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f49f130-6e1d-4f14-8989-dd7f23ee9fab" xlink:to="loc_us-gaap_UseOfEstimates_691f1ad4-eb3b-4a53-a955-a56a576794b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bc957c78-8291-4d0f-b707-7459b2d6c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f49f130-6e1d-4f14-8989-dd7f23ee9fab" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bc957c78-8291-4d0f-b707-7459b2d6c5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3b79e521-8a0c-4300-96bd-0c6b65de17d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f49f130-6e1d-4f14-8989-dd7f23ee9fab" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3b79e521-8a0c-4300-96bd-0c6b65de17d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_99e2c322-3182-4365-8304-8b58c7953cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f49f130-6e1d-4f14-8989-dd7f23ee9fab" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_99e2c322-3182-4365-8304-8b58c7953cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20220703.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4d8031f2-15ae-41d5-9b54-3ee7f6e37dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7864c00f-fddc-4a2a-9a4c-919c5bf7cd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4d8031f2-15ae-41d5-9b54-3ee7f6e37dcf" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_7864c00f-fddc-4a2a-9a4c-919c5bf7cd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20220703.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_109d3b12-b264-4c88-ac72-2857f9dc4ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9c9d4398-da57-4d43-bae1-a0d8094fe1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_109d3b12-b264-4c88-ac72-2857f9dc4ec2" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9c9d4398-da57-4d43-bae1-a0d8094fe1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d3bac38b-db33-4f4d-8dd7-838648b06dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_36cda4bf-88d1-4bb0-acc3-1c03aadc0b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d3bac38b-db33-4f4d-8dd7-838648b06dbe" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_36cda4bf-88d1-4bb0-acc3-1c03aadc0b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dedbc56d-00e2-4040-aeca-253d6e3db637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d3bac38b-db33-4f4d-8dd7-838648b06dbe" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dedbc56d-00e2-4040-aeca-253d6e3db637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_aa7d7578-e33b-42cf-8171-024d3b5d7f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d3bac38b-db33-4f4d-8dd7-838648b06dbe" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_aa7d7578-e33b-42cf-8171-024d3b5d7f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c4f96032-a895-4252-bf4b-00506267dd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d3bac38b-db33-4f4d-8dd7-838648b06dbe" xlink:to="loc_us-gaap_InventoryNet_c4f96032-a895-4252-bf4b-00506267dd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4cf8d6a8-d730-484c-b73a-ed8dbedd1705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_49ab0291-af24-49d6-b6fe-4567a28f2e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4cf8d6a8-d730-484c-b73a-ed8dbedd1705" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_49ab0291-af24-49d6-b6fe-4567a28f2e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_20ed2a87-5946-4933-ae9d-2b6163a08286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_cd62328c-3ff1-46a2-92db-1db8a7a2c5ad" xlink:href="jnj-20220703.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_20ed2a87-5946-4933-ae9d-2b6163a08286" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_cd62328c-3ff1-46a2-92db-1db8a7a2c5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_fb0dd982-a154-4c8c-ad79-52c11c71e7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_20ed2a87-5946-4933-ae9d-2b6163a08286" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_fb0dd982-a154-4c8c-ad79-52c11c71e7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_40c2e1c4-acd1-4967-a361-13b65851585b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_20ed2a87-5946-4933-ae9d-2b6163a08286" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_40c2e1c4-acd1-4967-a361-13b65851585b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b39f0e3-85e6-4e8f-b3b2-f9ed483d9799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:href="jnj-20220703.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b39f0e3-85e6-4e8f-b3b2-f9ed483d9799" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629dbd81-4782-4ab6-af9d-aac78a242f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629dbd81-4782-4ab6-af9d-aac78a242f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_629dbd81-4782-4ab6-af9d-aac78a242f4d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_5a9b7441-dc90-4b68-a981-8ac41b48eb07" xlink:href="jnj-20220703.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:to="loc_jnj_PatentsAndTrademarksMember_5a9b7441-dc90-4b68-a981-8ac41b48eb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_0270b9b2-4925-4387-966c-c9625f729756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_0270b9b2-4925-4387-966c-c9625f729756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_94240c81-c226-46f7-924c-1002e3ff0745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db1e4d3f-8232-4c91-bb80-3cd27275ea9a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_94240c81-c226-46f7-924c-1002e3ff0745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_41cd2453-aaf2-4ff7-be72-a8c1ed639caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_41cd2453-aaf2-4ff7-be72-a8c1ed639caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2df6fe5f-ac0e-4356-8f3e-9516c238b907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_41cd2453-aaf2-4ff7-be72-a8c1ed639caa" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2df6fe5f-ac0e-4356-8f3e-9516c238b907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_8a8ab453-42f7-449d-aaa6-4eadeb0cd614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2df6fe5f-ac0e-4356-8f3e-9516c238b907" xlink:to="loc_us-gaap_TrademarksMember_8a8ab453-42f7-449d-aaa6-4eadeb0cd614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_c5ee9e03-6e34-4cd7-bb35-6d84ddb88593" xlink:href="jnj-20220703.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2df6fe5f-ac0e-4356-8f3e-9516c238b907" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_c5ee9e03-6e34-4cd7-bb35-6d84ddb88593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fa626477-d623-413f-a28b-7022661f8539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fa626477-d623-413f-a28b-7022661f8539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2993b33-833e-494b-8412-3958d0f8283e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fa626477-d623-413f-a28b-7022661f8539" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2993b33-833e-494b-8412-3958d0f8283e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_6a8a9865-f167-4356-bb9a-f84ffe3e48b1" xlink:href="jnj-20220703.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2993b33-833e-494b-8412-3958d0f8283e" xlink:to="loc_jnj_BermekimabMember_6a8a9865-f167-4356-bb9a-f84ffe3e48b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_5a11acd5-203a-4773-8238-f0c03eeed3d6" xlink:href="jnj-20220703.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e96ec8ec-918f-4cc0-b295-eeb5e3525161" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_5a11acd5-203a-4773-8238-f0c03eeed3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_acdedae9-e4a9-428b-aa7f-61b6b42cb28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_5a11acd5-203a-4773-8238-f0c03eeed3d6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_acdedae9-e4a9-428b-aa7f-61b6b42cb28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_acdedae9-e4a9-428b-aa7f-61b6b42cb28e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_10f320d0-f1af-41d2-966d-57ab7d0332c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_10f320d0-f1af-41d2-966d-57ab7d0332c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9da8aedf-33c6-4849-98c9-df5addbdf3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9da8aedf-33c6-4849-98c9-df5addbdf3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1b2c78a0-bbdb-4554-a8d4-7ec8c6bf5d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_02a86834-8f79-46f8-ba68-602f7e6aa71d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1b2c78a0-bbdb-4554-a8d4-7ec8c6bf5d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f5ee3627-cbd0-4ddf-b7fb-6e1a50e181a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_acdedae9-e4a9-428b-aa7f-61b6b42cb28e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f5ee3627-cbd0-4ddf-b7fb-6e1a50e181a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_29324754-6f72-40cb-ba4b-0bb60d5fd0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f5ee3627-cbd0-4ddf-b7fb-6e1a50e181a2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_29324754-6f72-40cb-ba4b-0bb60d5fd0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d6cfe9df-dab6-4a77-a81c-c0a006d2ccdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f5ee3627-cbd0-4ddf-b7fb-6e1a50e181a2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d6cfe9df-dab6-4a77-a81c-c0a006d2ccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7a3e1f48-016e-4594-b874-eb92d447a8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_5a11acd5-203a-4773-8238-f0c03eeed3d6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7a3e1f48-016e-4594-b874-eb92d447a8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bf39bbf2-4375-4cb8-91ee-dc8a05d216b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_af749906-6589-40dc-b8ca-75f123dcfbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bf39bbf2-4375-4cb8-91ee-dc8a05d216b0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_af749906-6589-40dc-b8ca-75f123dcfbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_67265c5d-662b-4a60-8b77-f653aa360d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_af749906-6589-40dc-b8ca-75f123dcfbe9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_67265c5d-662b-4a60-8b77-f653aa360d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_67265c5d-662b-4a60-8b77-f653aa360d57" xlink:to="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_cbcf5b49-020d-49ef-9d43-0d61a64a9264" xlink:href="jnj-20220703.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:to="loc_jnj_ConsumerMember_cbcf5b49-020d-49ef-9d43-0d61a64a9264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_36e6eeb7-fdb1-43a5-b7d7-70d18d6f4a78" xlink:href="jnj-20220703.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:to="loc_jnj_PharmaceuticalMember_36e6eeb7-fdb1-43a5-b7d7-70d18d6f4a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_8e138092-85c2-4b56-bd66-224903eeeb40" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_75a9bda7-3d92-47db-98ee-3d61d1f2f6a4" xlink:to="loc_jnj_MedicalDevicesMember_8e138092-85c2-4b56-bd66-224903eeeb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c9c14e73-aaeb-402a-a4f0-9b4e0c9b6566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_af749906-6589-40dc-b8ca-75f123dcfbe9" xlink:to="loc_us-gaap_GoodwillLineItems_c9c14e73-aaeb-402a-a4f0-9b4e0c9b6566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c9c14e73-aaeb-402a-a4f0-9b4e0c9b6566" xlink:to="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_be97f82c-a3b9-40e2-b34d-a47cd07cab33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:to="loc_us-gaap_Goodwill_be97f82c-a3b9-40e2-b34d-a47cd07cab33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_9004a8ae-21b4-4e37-ae92-dfc9ec26dfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_9004a8ae-21b4-4e37-ae92-dfc9ec26dfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_c210d092-dc8f-45ab-8f2d-5e8d3ac0e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_c210d092-dc8f-45ab-8f2d-5e8d3ac0e11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_018425a9-dc34-4d52-a04f-bcb07aeaae36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e8e713c1-feac-4cde-9648-94a3f553cffc" xlink:to="loc_us-gaap_Goodwill_018425a9-dc34-4d52-a04f-bcb07aeaae36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a20687ae-8fc5-4285-a262-6a5604421bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a7ceb9-90f5-47c5-b549-1be92c6a0be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a20687ae-8fc5-4285-a262-6a5604421bf8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a7ceb9-90f5-47c5-b549-1be92c6a0be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_be2ceddd-f6b5-4f62-bda9-b41b262dad65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a7ceb9-90f5-47c5-b549-1be92c6a0be5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_be2ceddd-f6b5-4f62-bda9-b41b262dad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a0e124a-702a-4f61-8764-25229e94351a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_be2ceddd-f6b5-4f62-bda9-b41b262dad65" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a0e124a-702a-4f61-8764-25229e94351a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_fd123a6e-386d-480c-acf4-8f1da3725014" xlink:href="jnj-20220703.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a0e124a-702a-4f61-8764-25229e94351a" xlink:to="loc_jnj_PatentsAndTrademarksMember_fd123a6e-386d-480c-acf4-8f1da3725014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_4acb0590-a8aa-4281-91a4-306338dfc203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a0e124a-702a-4f61-8764-25229e94351a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_4acb0590-a8aa-4281-91a4-306338dfc203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b32570e7-bced-42a2-a831-6180090e416d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a7ceb9-90f5-47c5-b549-1be92c6a0be5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b32570e7-bced-42a2-a831-6180090e416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1497e2f5-94f1-48c3-9e1d-17805a9809e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b32570e7-bced-42a2-a831-6180090e416d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1497e2f5-94f1-48c3-9e1d-17805a9809e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7fb75594-cc2b-40e1-a0f7-c9a8ad1b39e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b32570e7-bced-42a2-a831-6180090e416d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7fb75594-cc2b-40e1-a0f7-c9a8ad1b39e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_229f7877-7cb3-4e89-98ae-5690cb1aaa58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_af995941-2e09-443f-83e3-8ee6b3af4e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_229f7877-7cb3-4e89-98ae-5690cb1aaa58" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_af995941-2e09-443f-83e3-8ee6b3af4e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0219e28f-5940-481a-aad0-0e0b07704934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_229f7877-7cb3-4e89-98ae-5690cb1aaa58" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0219e28f-5940-481a-aad0-0e0b07704934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9d89b811-a2c6-4310-8ef1-58b0c83bfb41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_229f7877-7cb3-4e89-98ae-5690cb1aaa58" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9d89b811-a2c6-4310-8ef1-58b0c83bfb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_73257ccd-9e66-4b08-b68a-d39b98e9b4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_229f7877-7cb3-4e89-98ae-5690cb1aaa58" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_73257ccd-9e66-4b08-b68a-d39b98e9b4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d6418584-a2fa-4b51-a3b5-0387f7d916ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_229f7877-7cb3-4e89-98ae-5690cb1aaa58" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d6418584-a2fa-4b51-a3b5-0387f7d916ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0c12d92b-d4d0-4db8-bc00-164f13529a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ac133080-550e-43d9-af57-73ce113da25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0c12d92b-d4d0-4db8-bc00-164f13529a05" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ac133080-550e-43d9-af57-73ce113da25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2688843c-47f3-40f0-a6cd-5344261ca796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_32331048-168b-4006-99eb-8dfc075a7e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2688843c-47f3-40f0-a6cd-5344261ca796" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_32331048-168b-4006-99eb-8dfc075a7e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_6d052ad5-307f-48bb-b609-856f0e08c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2688843c-47f3-40f0-a6cd-5344261ca796" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_6d052ad5-307f-48bb-b609-856f0e08c60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_afeed336-edcb-4f7e-ad11-5d3db8f79439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2688843c-47f3-40f0-a6cd-5344261ca796" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_afeed336-edcb-4f7e-ad11-5d3db8f79439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1b2a6f0a-4a64-4495-8300-05df06aef44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2688843c-47f3-40f0-a6cd-5344261ca796" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1b2a6f0a-4a64-4495-8300-05df06aef44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e9841902-d74a-4ae6-af76-bec2a5de9507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2688843c-47f3-40f0-a6cd-5344261ca796" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e9841902-d74a-4ae6-af76-bec2a5de9507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_64184d01-f62e-439d-bd18-28b32cd67628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2688843c-47f3-40f0-a6cd-5344261ca796" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_64184d01-f62e-439d-bd18-28b32cd67628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d5089f4b-6ebd-40b3-9274-f40c79f2fe22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2688843c-47f3-40f0-a6cd-5344261ca796" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d5089f4b-6ebd-40b3-9274-f40c79f2fe22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0a981f11-ca2c-4872-92f9-9bfc7211a6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2688843c-47f3-40f0-a6cd-5344261ca796" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0a981f11-ca2c-4872-92f9-9bfc7211a6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_84f69127-f2ad-4912-963b-7b0222efb914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_84f69127-f2ad-4912-963b-7b0222efb914" xlink:to="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_d9649f75-7e31-40fb-9eab-3946a53874d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_d9649f75-7e31-40fb-9eab-3946a53874d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0d7df606-6876-4657-bf9a-dee40624f2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_d9649f75-7e31-40fb-9eab-3946a53874d1" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0d7df606-6876-4657-bf9a-dee40624f2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_566b4c79-02a7-432d-910f-24aa2ef064e1" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0d7df606-6876-4657-bf9a-dee40624f2e9" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_566b4c79-02a7-432d-910f-24aa2ef064e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_fc087fe8-62de-4bcb-bac6-41789e0cddd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_fc087fe8-62de-4bcb-bac6-41789e0cddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af7b1644-8ead-4e27-b039-a5189be31f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_fc087fe8-62de-4bcb-bac6-41789e0cddd4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af7b1644-8ead-4e27-b039-a5189be31f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_fe79df62-dd67-4ba3-9822-d8aac23a9f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af7b1644-8ead-4e27-b039-a5189be31f69" xlink:to="loc_us-gaap_EquitySecuritiesMember_fe79df62-dd67-4ba3-9822-d8aac23a9f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9ee2ff4d-9ae6-4e3d-93bb-71f5765a123e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9ee2ff4d-9ae6-4e3d-93bb-71f5765a123e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9ee2ff4d-9ae6-4e3d-93bb-71f5765a123e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_79b9ef4d-863e-4905-ba44-270912acf80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_79b9ef4d-863e-4905-ba44-270912acf80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_d89cfcba-866e-48fb-accb-48b41f804175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_d89cfcba-866e-48fb-accb-48b41f804175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_03391859-5de6-4523-b6c6-c0b1b379d01c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b29df2d-4ef2-43ab-99cc-cbe5cf90758b" xlink:to="loc_us-gaap_InterestRateSwapMember_03391859-5de6-4523-b6c6-c0b1b379d01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_f6b2aeda-5cab-464d-bce3-afee95a4de93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_f6b2aeda-5cab-464d-bce3-afee95a4de93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_a4e719d7-f55d-41bd-bbdf-78ba892a561e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_f6b2aeda-5cab-464d-bce3-afee95a4de93" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_a4e719d7-f55d-41bd-bbdf-78ba892a561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1d21fff0-a7dc-4abb-9d53-756dc680bf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_a4e719d7-f55d-41bd-bbdf-78ba892a561e" xlink:to="loc_us-gaap_CommercialPaperMember_1d21fff0-a7dc-4abb-9d53-756dc680bf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9cd3c8a4-226d-49f4-9abf-7042ec1b0a1d" xlink:to="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_860c9b89-5b9b-4e99-b0dc-b2b97179beb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_860c9b89-5b9b-4e99-b0dc-b2b97179beb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b835cd19-050d-49a2-ba3e-2830492f3aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b835cd19-050d-49a2-ba3e-2830492f3aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_8fd59aeb-0fcd-4f19-854d-4fb741f84c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_8fd59aeb-0fcd-4f19-854d-4fb741f84c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_eb65d93c-e21e-4909-b2c6-67103eb9f13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_eb65d93c-e21e-4909-b2c6-67103eb9f13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_18d0b593-0280-4987-b9ec-542ca0255a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_18d0b593-0280-4987-b9ec-542ca0255a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_8b0149a6-3caf-4193-9adc-5dcc4f3d74fa" xlink:href="jnj-20220703.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_8b0149a6-3caf-4193-9adc-5dcc4f3d74fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_16499ce2-a9a7-4f29-b297-0fa591e4030d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_EquityFairValueAdjustment_16499ce2-a9a7-4f29-b297-0fa591e4030d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_ae62c6f2-ee7d-49db-92e9-7843e9a33db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_ae62c6f2-ee7d-49db-92e9-7843e9a33db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_b78418b7-96e5-415d-ab46-32944c4e87dd" xlink:href="jnj-20220703.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_b78418b7-96e5-415d-ab46-32944c4e87dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4a378fea-7a89-4b9d-8c80-dde1b488e5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_ShortTermBorrowings_4a378fea-7a89-4b9d-8c80-dde1b488e5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_f719f41b-71b3-494e-bc26-e83ea0a0404c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_f719f41b-71b3-494e-bc26-e83ea0a0404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e0eab09e-472c-4c3f-b247-cf28fd02314e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7e37741b-e0d1-4d5f-8af2-f6f10a4478c3" xlink:to="loc_us-gaap_DebtInstrumentTerm_e0eab09e-472c-4c3f-b247-cf28fd02314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_686a052e-81b3-40b0-b925-90b4457cfb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_686a052e-81b3-40b0-b925-90b4457cfb65" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_aeeb350d-7ff2-40c6-8c88-771bfebd4f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_aeeb350d-7ff2-40c6-8c88-771bfebd4f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_aeeb350d-7ff2-40c6-8c88-771bfebd4f34" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_84d45b78-86e3-4966-adb8-999ad13fa32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:to="loc_us-gaap_FairValueHedgingMember_84d45b78-86e3-4966-adb8-999ad13fa32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_a616fac4-cc10-49c9-8e4c-778b32ce6e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_a616fac4-cc10-49c9-8e4c-778b32ce6e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_5cc005c2-a639-44fa-9fd4-0d896a692b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3730b423-867a-4a22-9348-3d15cbeb613f" xlink:to="loc_us-gaap_CashFlowHedgingMember_5cc005c2-a639-44fa-9fd4-0d896a692b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_07c5f25e-16bb-4dfa-820e-48f8c569caa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_07c5f25e-16bb-4dfa-820e-48f8c569caa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_07c5f25e-16bb-4dfa-820e-48f8c569caa7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_0224dc1b-8d4b-4b20-af5f-8ebc083009f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_InterestRateContractMember_0224dc1b-8d4b-4b20-af5f-8ebc083009f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5d2380de-db49-430a-9bb8-7b746855e1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5d2380de-db49-430a-9bb8-7b746855e1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_5c80ab57-a0d1-47ed-a199-9d8bad2a93b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_5c80ab57-a0d1-47ed-a199-9d8bad2a93b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_d855f1fa-f99c-4d03-9f53-282e60b2b498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_InterestRateSwapMember_d855f1fa-f99c-4d03-9f53-282e60b2b498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_453ba57c-0aba-4bd0-ab12-8868dd5204ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_975edb8d-1c1f-4e74-8605-4dd5f0cb0770" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_453ba57c-0aba-4bd0-ab12-8868dd5204ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5118c8cb-c0ea-4ead-9891-c944e5fe1bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5118c8cb-c0ea-4ead-9891-c944e5fe1bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5118c8cb-c0ea-4ead-9891-c944e5fe1bbb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_61f07887-9211-4bcb-983f-1b13425557d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_us-gaap_SalesMember_61f07887-9211-4bcb-983f-1b13425557d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ee563780-31d5-4870-8d8f-16fc76e287ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_us-gaap_CostOfSalesMember_ee563780-31d5-4870-8d8f-16fc76e287ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_01dc3bee-9b5c-4679-9d59-75ebb798f854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_01dc3bee-9b5c-4679-9d59-75ebb798f854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_2f7daf79-7d1c-4c95-907d-6a4a36876749" xlink:href="jnj-20220703.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_2f7daf79-7d1c-4c95-907d-6a4a36876749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_a2ac98ae-3ccb-4ae4-89b9-8595319f3904" xlink:href="jnj-20220703.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37a12d32-61a1-42c3-8fb7-1370ff4a19b4" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_a2ac98ae-3ccb-4ae4-89b9-8595319f3904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d77a095d-3f17-4c66-8111-c8c199b7c23c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_f410856f-eee1-44cf-b9cc-ac2375e3562a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_f410856f-eee1-44cf-b9cc-ac2375e3562a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_8d34fa28-4df8-485a-a527-d79a5f95fec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_8d34fa28-4df8-485a-a527-d79a5f95fec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_22b07b8c-daf8-4a03-8f8c-49aa7e6791ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_054bc93e-59a7-4d68-b34d-967c58142324" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_22b07b8c-daf8-4a03-8f8c-49aa7e6791ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b9839efa-eb6a-4786-93a8-41421c2c8474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_31f38799-012f-4b53-85e1-2d91c7460907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b9839efa-eb6a-4786-93a8-41421c2c8474" xlink:to="loc_us-gaap_DerivativeTable_31f38799-012f-4b53-85e1-2d91c7460907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5bc00101-adeb-4b93-92cf-3e816e1aff87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_31f38799-012f-4b53-85e1-2d91c7460907" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5bc00101-adeb-4b93-92cf-3e816e1aff87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7fc0febe-0a78-4c58-b082-39c84144c324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5bc00101-adeb-4b93-92cf-3e816e1aff87" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7fc0febe-0a78-4c58-b082-39c84144c324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_2ff9f665-76e8-43d7-8d8a-64984fea4df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7fc0febe-0a78-4c58-b082-39c84144c324" xlink:to="loc_us-gaap_LongTermDebtMember_2ff9f665-76e8-43d7-8d8a-64984fea4df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_986631ef-e57f-4667-8d3a-32c12b39c0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_31f38799-012f-4b53-85e1-2d91c7460907" xlink:to="loc_us-gaap_HedgingDesignationAxis_986631ef-e57f-4667-8d3a-32c12b39c0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ee3923b6-6948-4513-bfd5-235474acb847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_986631ef-e57f-4667-8d3a-32c12b39c0f0" xlink:to="loc_us-gaap_HedgingDesignationDomain_ee3923b6-6948-4513-bfd5-235474acb847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_295f4580-171f-459e-8f88-3081f96972a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ee3923b6-6948-4513-bfd5-235474acb847" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_295f4580-171f-459e-8f88-3081f96972a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_5f9d390e-f20b-4b73-9314-5ac7f0562f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_31f38799-012f-4b53-85e1-2d91c7460907" xlink:to="loc_us-gaap_DerivativeLineItems_5f9d390e-f20b-4b73-9314-5ac7f0562f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_627411fc-ab19-4780-8c75-bbe9106849be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5f9d390e-f20b-4b73-9314-5ac7f0562f79" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_627411fc-ab19-4780-8c75-bbe9106849be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_da0bd2fa-2b53-431a-be01-f89335f73a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5f9d390e-f20b-4b73-9314-5ac7f0562f79" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_da0bd2fa-2b53-431a-be01-f89335f73a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cbc762b9-56ab-490b-ba36-efe402cbcfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cbc762b9-56ab-490b-ba36-efe402cbcfc7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4c486b9c-46fe-485d-812c-86abc48fdee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:to="loc_us-gaap_HedgingDesignationAxis_4c486b9c-46fe-485d-812c-86abc48fdee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bae2814c-ba45-4930-898b-c8e776b2e300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_4c486b9c-46fe-485d-812c-86abc48fdee7" xlink:to="loc_us-gaap_HedgingDesignationDomain_bae2814c-ba45-4930-898b-c8e776b2e300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6aa4dc6c-c09a-468b-bb4e-687080e21288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bae2814c-ba45-4930-898b-c8e776b2e300" xlink:to="loc_us-gaap_NondesignatedMember_6aa4dc6c-c09a-468b-bb4e-687080e21288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6f40ab2b-3bd8-42dc-a447-3d620efc7f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6f40ab2b-3bd8-42dc-a447-3d620efc7f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ce019c7a-4525-4c80-9253-e0cb3feeab3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6f40ab2b-3bd8-42dc-a447-3d620efc7f9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ce019c7a-4525-4c80-9253-e0cb3feeab3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ddd16b96-4849-45cd-bfc4-9f706c64a5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ce019c7a-4525-4c80-9253-e0cb3feeab3d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ddd16b96-4849-45cd-bfc4-9f706c64a5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5dc3246f-a4c5-4810-aca0-98ebbdbb197d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5dc3246f-a4c5-4810-aca0-98ebbdbb197d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aa46ba99-2fc1-4cd1-9f81-51fe73c28e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5dc3246f-a4c5-4810-aca0-98ebbdbb197d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aa46ba99-2fc1-4cd1-9f81-51fe73c28e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_c0b9646d-5fa2-4cb4-8115-475cf2918c43" xlink:href="jnj-20220703.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa46ba99-2fc1-4cd1-9f81-51fe73c28e43" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_c0b9646d-5fa2-4cb4-8115-475cf2918c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4f94e916-b72c-4148-98cc-235e9f753dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0afe6b41-8c7c-4100-9077-f8d500f102b6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4f94e916-b72c-4148-98cc-235e9f753dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5829bd57-5e15-4d2c-8900-2ef83b620c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4f94e916-b72c-4148-98cc-235e9f753dd4" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5829bd57-5e15-4d2c-8900-2ef83b620c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_319dec7c-b1c7-4eeb-9f0a-be2735a82b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a5786043-0004-4969-9bad-5c81236c10d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_319dec7c-b1c7-4eeb-9f0a-be2735a82b3d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a5786043-0004-4969-9bad-5c81236c10d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_781e3dd0-3af1-4169-969b-7541c4b5313e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a5786043-0004-4969-9bad-5c81236c10d2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_781e3dd0-3af1-4169-969b-7541c4b5313e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_85a8a61b-73b5-480f-b0f2-60ef7e6c4d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_781e3dd0-3af1-4169-969b-7541c4b5313e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_85a8a61b-73b5-480f-b0f2-60ef7e6c4d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_539b6c9c-4258-43b0-8687-33796a07cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_85a8a61b-73b5-480f-b0f2-60ef7e6c4d77" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_539b6c9c-4258-43b0-8687-33796a07cc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_694bf12e-5e9e-4ce6-9d7b-590ae769a97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a5786043-0004-4969-9bad-5c81236c10d2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_694bf12e-5e9e-4ce6-9d7b-590ae769a97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_65ba82bb-49eb-4106-ad92-1e0b1d453864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_694bf12e-5e9e-4ce6-9d7b-590ae769a97f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_65ba82bb-49eb-4106-ad92-1e0b1d453864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_9dd3beb8-0106-4936-9582-a52cb71c3fb1" xlink:href="jnj-20220703.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_65ba82bb-49eb-4106-ad92-1e0b1d453864" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_9dd3beb8-0106-4936-9582-a52cb71c3fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ea6dd4cd-595b-480f-bc9d-29309752091e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a5786043-0004-4969-9bad-5c81236c10d2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ea6dd4cd-595b-480f-bc9d-29309752091e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ff3fac18-db88-466e-85b0-8457674054ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ea6dd4cd-595b-480f-bc9d-29309752091e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ff3fac18-db88-466e-85b0-8457674054ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_9ddc72db-342c-48ce-812f-1f2f00abb7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ea6dd4cd-595b-480f-bc9d-29309752091e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_9ddc72db-342c-48ce-812f-1f2f00abb7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_09d02b3e-e224-40ff-92d9-8cec85113306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_b32e37e4-c897-4178-8f9f-112499c55632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_09d02b3e-e224-40ff-92d9-8cec85113306" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_b32e37e4-c897-4178-8f9f-112499c55632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5897e04c-10a9-472d-85e8-8f3004f658c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_b32e37e4-c897-4178-8f9f-112499c55632" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5897e04c-10a9-472d-85e8-8f3004f658c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94b16253-a01b-4783-924e-d4dac0bae096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5897e04c-10a9-472d-85e8-8f3004f658c5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94b16253-a01b-4783-924e-d4dac0bae096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_7dbf9344-f52e-4f5c-a260-936dcc572791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_94b16253-a01b-4783-924e-d4dac0bae096" xlink:to="loc_us-gaap_EquitySecuritiesMember_7dbf9344-f52e-4f5c-a260-936dcc572791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_39958f83-bb39-4447-b150-205d38c47ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_b32e37e4-c897-4178-8f9f-112499c55632" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_39958f83-bb39-4447-b150-205d38c47ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c05155af-84c5-4905-a358-bb5aabde5c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_39958f83-bb39-4447-b150-205d38c47ad9" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c05155af-84c5-4905-a358-bb5aabde5c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_3eb0f74b-e94c-415f-9193-6001f81ba78d" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c05155af-84c5-4905-a358-bb5aabde5c14" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_3eb0f74b-e94c-415f-9193-6001f81ba78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_8bb9236c-e384-44f1-86f9-92b15d6fd62b" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c05155af-84c5-4905-a358-bb5aabde5c14" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_8bb9236c-e384-44f1-86f9-92b15d6fd62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_83f6fa3a-c8f9-4e7f-b4ca-292885d920cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_b32e37e4-c897-4178-8f9f-112499c55632" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_83f6fa3a-c8f9-4e7f-b4ca-292885d920cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_83f6fa3a-c8f9-4e7f-b4ca-292885d920cc" xlink:to="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_47958141-e66c-43c8-9258-a6b087da2a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_47958141-e66c-43c8-9258-a6b087da2a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_77dd6951-c349-48da-a993-66a3eb0cd5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_77dd6951-c349-48da-a993-66a3eb0cd5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_6832159e-dbd3-4115-b9df-08fea3cd7b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_EquityFairValueAdjustment_6832159e-dbd3-4115-b9df-08fea3cd7b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_cc47e23e-7489-4f36-8009-7af9f13f7c95" xlink:href="jnj-20220703.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_cc47e23e-7489-4f36-8009-7af9f13f7c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_1c336cf9-8392-4e9c-93ae-144fef31c505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_1c336cf9-8392-4e9c-93ae-144fef31c505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9ef9b042-ed8e-40a9-9f99-34a53e9f9596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9ef9b042-ed8e-40a9-9f99-34a53e9f9596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b629ddc2-0986-4b0a-9fb2-72f24d85766d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_36d14575-3312-435e-ae4d-fb24bca52c94" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b629ddc2-0986-4b0a-9fb2-72f24d85766d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_88557ad7-c3eb-49ac-b6a7-231eec39dc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_88557ad7-c3eb-49ac-b6a7-231eec39dc46" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ffe0d546-5f80-47db-8ab6-d899b2a7badb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ffe0d546-5f80-47db-8ab6-d899b2a7badb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ffe0d546-5f80-47db-8ab6-d899b2a7badb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_921ac250-08eb-4da8-a5d4-fafa2fa7287c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_921ac250-08eb-4da8-a5d4-fafa2fa7287c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_b72d043b-0cdd-42c4-b603-efcf315ef721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_b72d043b-0cdd-42c4-b603-efcf315ef721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_355df89f-f4db-4046-9216-a8c5d41f2061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbcbf975-d125-4085-a3e9-6e93c9183f86" xlink:to="loc_us-gaap_LongTermDebtMember_355df89f-f4db-4046-9216-a8c5d41f2061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7c121723-7683-4b2a-9e3c-e350555f9249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7c121723-7683-4b2a-9e3c-e350555f9249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d32ae83b-895c-4adc-b4f8-ae0bcba416de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7c121723-7683-4b2a-9e3c-e350555f9249" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d32ae83b-895c-4adc-b4f8-ae0bcba416de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_8beb264c-a43e-40ea-9f7a-ef21be154685" xlink:href="jnj-20220703.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d32ae83b-895c-4adc-b4f8-ae0bcba416de" xlink:to="loc_jnj_AurisHealthMember_8beb264c-a43e-40ea-9f7a-ef21be154685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a79ca58e-43b3-4b41-9003-44daac74500e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_InvestmentTypeAxis_a79ca58e-43b3-4b41-9003-44daac74500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_01b9693b-a269-4ce9-9213-ecf45fc969f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_a79ca58e-43b3-4b41-9003-44daac74500e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_01b9693b-a269-4ce9-9213-ecf45fc969f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_766211d5-dff0-4b3c-80d8-6739b59953a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_01b9693b-a269-4ce9-9213-ecf45fc969f3" xlink:to="loc_us-gaap_EquitySecuritiesMember_766211d5-dff0-4b3c-80d8-6739b59953a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fc004970-bebf-4052-9d2c-7aef439327c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fc004970-bebf-4052-9d2c-7aef439327c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fc004970-bebf-4052-9d2c-7aef439327c1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_709c323f-4a36-4624-9923-4b99a60720fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:to="loc_us-gaap_InterestRateContractMember_709c323f-4a36-4624-9923-4b99a60720fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b2a507dc-3aef-4ace-b886-fe133fe05d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b2a507dc-3aef-4ace-b886-fe133fe05d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_a7406646-d2a4-4a12-91e0-8b20e84e52a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2b159d71-e323-42a3-b2bc-04763d9d9732" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_a7406646-d2a4-4a12-91e0-8b20e84e52a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bc9d67fc-e5a4-49a9-a4f2-ce684df0319c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bc9d67fc-e5a4-49a9-a4f2-ce684df0319c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bc9d67fc-e5a4-49a9-a4f2-ce684df0319c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c2f3ce70-c6ae-4e07-92ac-f00f37d36146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c2f3ce70-c6ae-4e07-92ac-f00f37d36146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dbaca665-4b52-492c-a604-8d9ca8b87601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dbaca665-4b52-492c-a604-8d9ca8b87601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1bff275f-e3ca-44f9-8d1a-07e11a78f6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b59294cd-f745-416c-b5c8-aee4e2914a1a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1bff275f-e3ca-44f9-8d1a-07e11a78f6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a61313a8-9b5e-4888-abde-138534da3d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a61313a8-9b5e-4888-abde-138534da3d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_62b83e25-bc99-425d-a7c3-c706189b7f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a61313a8-9b5e-4888-abde-138534da3d80" xlink:to="loc_us-gaap_HedgingRelationshipDomain_62b83e25-bc99-425d-a7c3-c706189b7f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_13f78d91-5d48-4702-8e29-7b2b58d9eca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_62b83e25-bc99-425d-a7c3-c706189b7f6b" xlink:to="loc_us-gaap_FairValueHedgingMember_13f78d91-5d48-4702-8e29-7b2b58d9eca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_eff7af63-2d9a-4090-92f0-2f5050df4c54" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_4117b658-c44a-433c-945c-3fc7dbc29b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_4117b658-c44a-433c-945c-3fc7dbc29b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_b326dfbd-4ca8-4659-aade-82ffc83b5ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_b326dfbd-4ca8-4659-aade-82ffc83b5ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_2bdd8ae4-92c2-48e7-847f-454c2c93b132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_2bdd8ae4-92c2-48e7-847f-454c2c93b132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_0a26f0ee-ac56-4cfb-b203-167cc24d8fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_0a26f0ee-ac56-4cfb-b203-167cc24d8fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7d735970-a24f-45df-abf4-d5d715cbfa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7d735970-a24f-45df-abf4-d5d715cbfa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9a5687ff-34da-4caa-b064-52792e582c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9a5687ff-34da-4caa-b064-52792e582c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_452f03c2-1aec-4bae-9d96-aeae8c5a0120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_46324ab8-c434-49a3-b8ae-9f4a8a73e503" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_452f03c2-1aec-4bae-9d96-aeae8c5a0120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_52b36cff-1d76-4ef5-8670-29d367978d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_52b36cff-1d76-4ef5-8670-29d367978d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_b853c45c-ba0b-4d76-b4bb-8ba6779cfec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_b853c45c-ba0b-4d76-b4bb-8ba6779cfec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2eb717f2-b982-4609-9e3a-9b4046404eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeAssets_2eb717f2-b982-4609-9e3a-9b4046404eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_42aa73f7-35f6-4fa6-a5cf-a6bde7154b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_42aa73f7-35f6-4fa6-a5cf-a6bde7154b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_6d1d5f79-cbd8-4b8e-bfd2-6776a904e5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_6d1d5f79-cbd8-4b8e-bfd2-6776a904e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_902ace78-bd9f-46ea-bfe2-c23c6cbb2d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_DerivativeLiabilities_902ace78-bd9f-46ea-bfe2-c23c6cbb2d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ec74477d-5883-42c0-b373-cf6da2c3b7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ec74477d-5883-42c0-b373-cf6da2c3b7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_16e80d46-4c73-4c3b-a625-1429d0c80596" xlink:href="jnj-20220703.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_16e80d46-4c73-4c3b-a625-1429d0c80596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_216a6669-9f82-45b2-ae8e-b9dfd44a8349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_216a6669-9f82-45b2-ae8e-b9dfd44a8349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a11109f-55e7-48b9-9527-07ac28f04c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a11109f-55e7-48b9-9527-07ac28f04c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_df0bf457-3cc1-4891-84a4-dc11af8aa96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6754e1e1-cd7f-4e71-8942-cc53ce325367" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_df0bf457-3cc1-4891-84a4-dc11af8aa96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2b514c4b-4d42-4555-a075-561680902c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_056b7495-029d-407b-95c7-fe0d28f3d884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2b514c4b-4d42-4555-a075-561680902c82" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_056b7495-029d-407b-95c7-fe0d28f3d884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_7b8120ba-0622-4190-9202-825e90c4765b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_056b7495-029d-407b-95c7-fe0d28f3d884" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_7b8120ba-0622-4190-9202-825e90c4765b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_470c6fa3-91a5-4b52-8630-15e8fb882e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_7b8120ba-0622-4190-9202-825e90c4765b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_470c6fa3-91a5-4b52-8630-15e8fb882e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_df464cef-f1d8-4879-9379-4ccadfcfd8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_470c6fa3-91a5-4b52-8630-15e8fb882e70" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_df464cef-f1d8-4879-9379-4ccadfcfd8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_4e3a880f-4869-4281-8944-0d533c9817eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_470c6fa3-91a5-4b52-8630-15e8fb882e70" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_4e3a880f-4869-4281-8944-0d533c9817eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a419240a-ad83-42a8-bc87-ab3dd589036e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_056b7495-029d-407b-95c7-fe0d28f3d884" xlink:to="loc_us-gaap_InvestmentTypeAxis_a419240a-ad83-42a8-bc87-ab3dd589036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_a419240a-ad83-42a8-bc87-ab3dd589036e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_8ee3829d-de39-4c47-9e5b-f49e04c135a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_CashMember_8ee3829d-de39-4c47-9e5b-f49e04c135a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_ca80d47e-620c-4639-9c9a-7a6d26dfd5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_ca80d47e-620c-4639-9c9a-7a6d26dfd5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_fe0e5876-febe-412b-bf5f-bf77cf659c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_fe0e5876-febe-412b-bf5f-bf77cf659c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_da6a6336-ed57-466d-b63a-79a1a8abf8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_da6a6336-ed57-466d-b63a-79a1a8abf8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3f62ed48-0bb0-4f82-b158-39de0e107390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3f62ed48-0bb0-4f82-b158-39de0e107390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_71fe3c1d-ab6b-4492-bfdd-f844fc96c62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_BankTimeDepositsMember_71fe3c1d-ab6b-4492-bfdd-f844fc96c62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_4e02d45d-5aee-4142-92d5-c5a5378869b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1d83e271-7388-497d-8fda-712f0af8df9d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_4e02d45d-5aee-4142-92d5-c5a5378869b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_056b7495-029d-407b-95c7-fe0d28f3d884" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_d9362d9e-ea4d-401c-8d91-ac7756482109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:to="loc_us-gaap_HeldToMaturitySecurities_d9362d9e-ea4d-401c-8d91-ac7756482109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_611f3b17-262e-4d0b-8a70-e28ce64fdee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_611f3b17-262e-4d0b-8a70-e28ce64fdee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_c4341413-fb15-4f6d-8d27-a4a611ed5b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dd410d83-5ce5-409e-a79c-286004a4fa0e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_c4341413-fb15-4f6d-8d27-a4a611ed5b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_77cc5a86-4e14-44a3-aa63-9e3c68d5e81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_77cc5a86-4e14-44a3-aa63-9e3c68d5e81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f54b20d9-a49a-4424-a87c-2dcbd91c63c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f54b20d9-a49a-4424-a87c-2dcbd91c63c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bb1b24e-22c9-4e59-b625-81cba30737a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9365ffc9-0f2d-491a-b8e8-28e526ce5f11" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bb1b24e-22c9-4e59-b625-81cba30737a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_5e9af678-9b89-4c57-b850-693caabc7141" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ad13387a-eb3d-45d7-a2b6-286f05677942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ad13387a-eb3d-45d7-a2b6-286f05677942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_c100a313-d74d-4fd0-b9c7-4ebccffea68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_c100a313-d74d-4fd0-b9c7-4ebccffea68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_51541e09-46a2-4c1d-a17e-058f3d4c3629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_51541e09-46a2-4c1d-a17e-058f3d4c3629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_0a184a5b-bbca-4bf4-952d-348eea6cf328" xlink:href="jnj-20220703.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_0a184a5b-bbca-4bf4-952d-348eea6cf328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_d711f813-7faf-4957-ac43-0541a4a2e3ce" xlink:href="jnj-20220703.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_1e04dd2e-2938-4a8a-a017-ea3e7118b6a4" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_d711f813-7faf-4957-ac43-0541a4a2e3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_417b182d-41bb-4aa2-9f24-fdb31e7e7ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_10787091-056d-449d-b2a5-4c064dbf7df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_417b182d-41bb-4aa2-9f24-fdb31e7e7ccb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_10787091-056d-449d-b2a5-4c064dbf7df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_01f796cd-b818-4f8a-88b4-a0b533ff8c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_10787091-056d-449d-b2a5-4c064dbf7df0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_01f796cd-b818-4f8a-88b4-a0b533ff8c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8068f6de-5d08-4fe6-a5f1-3f1403d9b643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_10787091-056d-449d-b2a5-4c064dbf7df0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8068f6de-5d08-4fe6-a5f1-3f1403d9b643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_bb6ea312-6cd8-476d-aaab-c513fc86b81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_10787091-056d-449d-b2a5-4c064dbf7df0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_bb6ea312-6cd8-476d-aaab-c513fc86b81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_ad6291d2-5b8b-4e27-874b-9c061c61018c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_10787091-056d-449d-b2a5-4c064dbf7df0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_ad6291d2-5b8b-4e27-874b-9c061c61018c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_6f28c57f-606a-4852-a800-e8749f665054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_417b182d-41bb-4aa2-9f24-fdb31e7e7ccb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_6f28c57f-606a-4852-a800-e8749f665054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f2b811bb-fa53-4ba1-8848-6b8d64b7810d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_6f28c57f-606a-4852-a800-e8749f665054" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f2b811bb-fa53-4ba1-8848-6b8d64b7810d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_77c1c308-6652-4e41-8566-1cd457c312d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_6f28c57f-606a-4852-a800-e8749f665054" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_77c1c308-6652-4e41-8566-1cd457c312d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_eda9e20e-c10b-4599-9735-1a8715f2a616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_6f28c57f-606a-4852-a800-e8749f665054" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_eda9e20e-c10b-4599-9735-1a8715f2a616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_5c260566-7883-46ce-b685-4c9ecda4092b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_6f28c57f-606a-4852-a800-e8749f665054" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_5c260566-7883-46ce-b685-4c9ecda4092b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_83ba7909-90d8-4e54-b113-28b5edeb1031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f7da8bc6-9c2a-48f4-89bb-e4bbe7a51d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83ba7909-90d8-4e54-b113-28b5edeb1031" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f7da8bc6-9c2a-48f4-89bb-e4bbe7a51d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e233fa3b-d518-42ae-81b7-d388652b5b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f7da8bc6-9c2a-48f4-89bb-e4bbe7a51d0a" xlink:to="loc_us-gaap_DebtInstrumentAxis_e233fa3b-d518-42ae-81b7-d388652b5b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e233fa3b-d518-42ae-81b7-d388652b5b48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_b0e3729a-3b1b-4a15-92dd-f623a8c2dbb4" xlink:href="jnj-20220703.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_b0e3729a-3b1b-4a15-92dd-f623a8c2dbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_33871d21-bc69-4bfe-af14-e909d6ef48c6" xlink:href="jnj-20220703.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.375Notesdue2023Member_33871d21-bc69-4bfe-af14-e909d6ef48c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_58fe60a1-78cf-446d-924b-76e5e6b0a3be" xlink:href="jnj-20220703.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A0.650NotesDue2024Member_58fe60a1-78cf-446d-924b-76e5e6b0a3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_d7012415-6ce5-4ff3-957e-48097f545d7f" xlink:href="jnj-20220703.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A5.50NotesDue2024Member_d7012415-6ce5-4ff3-957e-48097f545d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_ae7c4fb2-c1a4-45dd-bed1-6cff737e4d45" xlink:href="jnj-20220703.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2.625Notesdue2025Member_ae7c4fb2-c1a4-45dd-bed1-6cff737e4d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_62e75135-82c4-4b1b-b4e7-32a255214e6b" xlink:href="jnj-20220703.xsd#jnj_A0550NotesDue2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A0550NotesDue2025Member_62e75135-82c4-4b1b-b4e7-32a255214e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_8352b94b-1a8d-4e02-a9f0-c5aae51c4000" xlink:href="jnj-20220703.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2.45Notesdue2026Member_8352b94b-1a8d-4e02-a9f0-c5aae51c4000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_337b9c48-56ff-4ea8-88e2-66a21c01628e" xlink:href="jnj-20220703.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2.95Notesdue2027Member_337b9c48-56ff-4ea8-88e2-66a21c01628e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_74dd0eb4-d72e-4b26-8f47-1b2b91894cce" xlink:href="jnj-20220703.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A095NotesDue2027Member_74dd0eb4-d72e-4b26-8f47-1b2b91894cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_265f848e-f325-4d99-ba8f-c24323ca3dbf" xlink:href="jnj-20220703.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2.900Notesdue2028Member_265f848e-f325-4d99-ba8f-c24323ca3dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_15e3e97e-1841-4e40-9bb4-e83373924aea" xlink:href="jnj-20220703.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A1.150NotesDue2028Member_15e3e97e-1841-4e40-9bb4-e83373924aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_bdfa39e2-aead-42de-98ad-117cc7a1f7d9" xlink:href="jnj-20220703.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A6.95Notesdue2029Member_bdfa39e2-aead-42de-98ad-117cc7a1f7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_9c2c091a-d0f1-4d26-b365-71558b00968b" xlink:href="jnj-20220703.xsd#jnj_A1300NotesDue2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A1300NotesDue2030Member_9c2c091a-d0f1-4d26-b365-71558b00968b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_7e7a8297-3cc8-402b-acff-92ac7ba77c15" xlink:href="jnj-20220703.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_7e7a8297-3cc8-402b-acff-92ac7ba77c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_dd9dc79c-e57b-4779-ba24-6882e5277f9c" xlink:href="jnj-20220703.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.375Notesdue2033Member_dd9dc79c-e57b-4779-ba24-6882e5277f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_8951cc69-a038-4e85-8b88-6a31b9214742" xlink:href="jnj-20220703.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A1.650NotesDue2035Member_8951cc69-a038-4e85-8b88-6a31b9214742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_934e8384-c752-4543-bafd-83bcbcd25436" xlink:href="jnj-20220703.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.55Notesdue2036Member_934e8384-c752-4543-bafd-83bcbcd25436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_f1194c71-c963-43e3-a97d-90f11d71e6f7" xlink:href="jnj-20220703.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A5.95Notesdue2037Member_f1194c71-c963-43e3-a97d-90f11d71e6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_6f00e0a7-a42a-445d-abb3-30a537f39dab" xlink:href="jnj-20220703.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.625Notesdue2037Member_6f00e0a7-a42a-445d-abb3-30a537f39dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_1b517ca1-691b-4978-8f87-b60380ae7740" xlink:href="jnj-20220703.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.400Notesdue2038Member_1b517ca1-691b-4978-8f87-b60380ae7740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_eef0664c-26bd-4597-9c86-0f3e458e5366" xlink:href="jnj-20220703.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_eef0664c-26bd-4597-9c86-0f3e458e5366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_a1af5be5-1e57-4237-accc-0c448909d01e" xlink:href="jnj-20220703.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_a1af5be5-1e57-4237-accc-0c448909d01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_bc0c51d1-1746-4807-a181-4fc52b64129f" xlink:href="jnj-20220703.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A210NotesDue2040Member_bc0c51d1-1746-4807-a181-4fc52b64129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_57feaa26-3111-4e88-9771-5d359c466452" xlink:href="jnj-20220703.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.85Notesdue2041Member_57feaa26-3111-4e88-9771-5d359c466452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_4d2d1246-a8b4-46f9-b46c-d3e0a2c818de" xlink:href="jnj-20220703.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A4.50Notesdue2043Member_4d2d1246-a8b4-46f9-b46c-d3e0a2c818de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_bae6d85f-b7c9-41a6-b230-23b8afa382b5" xlink:href="jnj-20220703.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.70Notesdue2046Member_bae6d85f-b7c9-41a6-b230-23b8afa382b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_d90ca951-2189-4201-bad0-7dd8e34a1cfc" xlink:href="jnj-20220703.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.75Notesdue2047Member_d90ca951-2189-4201-bad0-7dd8e34a1cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_0adbc5fb-6e29-422e-84ad-1dbd7eb6dfa1" xlink:href="jnj-20220703.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A3.500Notesdue2048Member_0adbc5fb-6e29-422e-84ad-1dbd7eb6dfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_1f9c3a95-afca-47e8-8c61-8d03ceaafda4" xlink:href="jnj-20220703.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2250NotesDue2050Member_1f9c3a95-afca-47e8-8c61-8d03ceaafda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_a49f7d88-83c7-4279-b773-e507f8517fe4" xlink:href="jnj-20220703.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_A2450NotesDue2060Member_a49f7d88-83c7-4279-b773-e507f8517fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_ef4a10a1-beb5-41bd-8e2b-30022530be17" xlink:href="jnj-20220703.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2577395-b588-4bb6-a437-da064bae2a00" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_ef4a10a1-beb5-41bd-8e2b-30022530be17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_75b062de-410a-456f-bf29-a555f9a4e9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f7da8bc6-9c2a-48f4-89bb-e4bbe7a51d0a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_75b062de-410a-456f-bf29-a555f9a4e9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3682a63e-9897-4dbe-a6e5-6b76c791703b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_75b062de-410a-456f-bf29-a555f9a4e9b8" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3682a63e-9897-4dbe-a6e5-6b76c791703b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5558f9d5-82c2-48fb-a40a-2da1c64e92e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3682a63e-9897-4dbe-a6e5-6b76c791703b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5558f9d5-82c2-48fb-a40a-2da1c64e92e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d826f788-24c5-40fd-b271-e98e05408d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5558f9d5-82c2-48fb-a40a-2da1c64e92e2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d826f788-24c5-40fd-b271-e98e05408d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9efbc13e-0d2a-43ab-924d-01856d1b0b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5558f9d5-82c2-48fb-a40a-2da1c64e92e2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9efbc13e-0d2a-43ab-924d-01856d1b0b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0694f366-a69b-435b-aca7-3765b25e068a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f7da8bc6-9c2a-48f4-89bb-e4bbe7a51d0a" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0694f366-a69b-435b-aca7-3765b25e068a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0694f366-a69b-435b-aca7-3765b25e068a" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_3e25e360-89d3-4972-b68f-6f5eec17dd59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_3e25e360-89d3-4972-b68f-6f5eec17dd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_d796fac0-47a6-46dd-afad-3416493748eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_3e25e360-89d3-4972-b68f-6f5eec17dd59" xlink:to="loc_us-gaap_ShortTermBorrowings_d796fac0-47a6-46dd-afad-3416493748eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_7b6fbf31-acaf-468d-a2d1-91dfa337faaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_7b6fbf31-acaf-468d-a2d1-91dfa337faaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_99582771-6c0e-4c78-9a9a-fc0117dbb91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_7b6fbf31-acaf-468d-a2d1-91dfa337faaa" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_99582771-6c0e-4c78-9a9a-fc0117dbb91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41589eaf-a0b4-4115-b5bb-95dd52171fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41589eaf-a0b4-4115-b5bb-95dd52171fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ab8cbfc5-68d3-4743-9eb4-5d1c80b74706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ab8cbfc5-68d3-4743-9eb4-5d1c80b74706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_fdd15d11-7689-49ad-bdec-4129dc761cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_860204dc-9b1c-48ce-8eec-89dcdb26a416" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_fdd15d11-7689-49ad-bdec-4129dc761cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20220703.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f4726221-6e90-4aa0-a219-5529bd758b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_46999297-f4a4-45f5-bb98-6728f1eaf797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f4726221-6e90-4aa0-a219-5529bd758b32" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_46999297-f4a4-45f5-bb98-6728f1eaf797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf119f5-38cd-4cbc-9ebb-28de45c8c03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_19501738-5dbf-4b4d-bbdd-97d3d61a65cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf119f5-38cd-4cbc-9ebb-28de45c8c03d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_19501738-5dbf-4b4d-bbdd-97d3d61a65cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4a534db4-684c-4a94-b821-d67bd2e99a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf119f5-38cd-4cbc-9ebb-28de45c8c03d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4a534db4-684c-4a94-b821-d67bd2e99a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1b4db8c5-6344-4d85-8f51-aef6c5f99dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf119f5-38cd-4cbc-9ebb-28de45c8c03d" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1b4db8c5-6344-4d85-8f51-aef6c5f99dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_233a10d2-d9a8-4f63-9853-a41a44082e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf119f5-38cd-4cbc-9ebb-28de45c8c03d" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_233a10d2-d9a8-4f63-9853-a41a44082e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_1bdf3f8c-8d87-4928-8f49-9e5de97d36f3" xlink:href="jnj-20220703.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf119f5-38cd-4cbc-9ebb-28de45c8c03d" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_1bdf3f8c-8d87-4928-8f49-9e5de97d36f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cd1fa2e2-1a07-42d2-a979-33dc2bb3e10f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf119f5-38cd-4cbc-9ebb-28de45c8c03d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cd1fa2e2-1a07-42d2-a979-33dc2bb3e10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1f005cb2-b154-4be9-b22e-86951731c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf119f5-38cd-4cbc-9ebb-28de45c8c03d" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1f005cb2-b154-4be9-b22e-86951731c3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ac3cfc9f-5a27-4a90-ab5a-58f826cd14df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1f005cb2-b154-4be9-b22e-86951731c3d3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ac3cfc9f-5a27-4a90-ab5a-58f826cd14df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2c0683d5-e5c2-4e36-87e9-a72814d690e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ac3cfc9f-5a27-4a90-ab5a-58f826cd14df" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2c0683d5-e5c2-4e36-87e9-a72814d690e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7f111712-9dd9-4292-b11a-0597b3483c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2c0683d5-e5c2-4e36-87e9-a72814d690e8" xlink:to="loc_us-gaap_SubsequentEventMember_7f111712-9dd9-4292-b11a-0597b3483c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_4e264493-6769-4137-9d66-825455e5235e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1f005cb2-b154-4be9-b22e-86951731c3d3" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_4e264493-6769-4137-9d66-825455e5235e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_d3df9979-3090-4920-9dc0-cb21df484b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e264493-6769-4137-9d66-825455e5235e" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_d3df9979-3090-4920-9dc0-cb21df484b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20220703.xsd#PensionsandOtherBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ac441fb8-1918-4162-8956-8cbbfea5c359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_053cb1cf-b631-465e-9e56-a2f2ab35b111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ac441fb8-1918-4162-8956-8cbbfea5c359" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_053cb1cf-b631-465e-9e56-a2f2ab35b111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20220703.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_97381b69-2e02-4dd1-b105-574fc27a92cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_12f36427-6564-42af-bfc0-116951e5f906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_97381b69-2e02-4dd1-b105-574fc27a92cb" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_12f36427-6564-42af-bfc0-116951e5f906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8d64762d-5c4d-49a5-a93b-5c17d62e20a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a91ec34-4659-49e7-be77-ed133e56e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8d64762d-5c4d-49a5-a93b-5c17d62e20a6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a91ec34-4659-49e7-be77-ed133e56e2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bb5e13c5-78b8-49b8-832f-1dc27ba24479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a91ec34-4659-49e7-be77-ed133e56e2db" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bb5e13c5-78b8-49b8-832f-1dc27ba24479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5a153737-8fae-415f-8f47-f1e649acfaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bb5e13c5-78b8-49b8-832f-1dc27ba24479" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5a153737-8fae-415f-8f47-f1e649acfaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_cead955e-eabe-4b1b-88fb-5fd11b53f552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5a153737-8fae-415f-8f47-f1e649acfaa1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_cead955e-eabe-4b1b-88fb-5fd11b53f552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5030d090-f38f-4cbf-8081-af4797cc83eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5a153737-8fae-415f-8f47-f1e649acfaa1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5030d090-f38f-4cbf-8081-af4797cc83eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_564a8f2e-f833-435c-a8f3-7fc5909eea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1a91ec34-4659-49e7-be77-ed133e56e2db" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_564a8f2e-f833-435c-a8f3-7fc5909eea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_564a8f2e-f833-435c-a8f3-7fc5909eea5d" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_01f9ba80-e14a-4db0-ab05-966ae5e454cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_01f9ba80-e14a-4db0-ab05-966ae5e454cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_d9cbac81-2b14-4ad2-ba82-c63abd629afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_d9cbac81-2b14-4ad2-ba82-c63abd629afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2714f0e5-a324-45de-807d-fa6344bd43e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2714f0e5-a324-45de-807d-fa6344bd43e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b7e0e817-e768-48e6-862f-e65851b41d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b7e0e817-e768-48e6-862f-e65851b41d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ccb2e038-2287-4dfc-a4ca-83bc16b92f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ccb2e038-2287-4dfc-a4ca-83bc16b92f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_53e91bb4-ef30-4726-ba4e-e3a699788004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_53e91bb4-ef30-4726-ba4e-e3a699788004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_fb6b9a3b-54b5-4676-93b3-163614101283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c3ffdbb2-8590-43c9-b865-3e74e0123ef4" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_fb6b9a3b-54b5-4676-93b3-163614101283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8afcdf11-1794-4d4a-8623-eee9e8276535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dca336e7-766e-431b-b423-cb06316cc6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8afcdf11-1794-4d4a-8623-eee9e8276535" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dca336e7-766e-431b-b423-cb06316cc6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899a53f-d2c3-41ec-bc92-d62d0bb074cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dca336e7-766e-431b-b423-cb06316cc6b1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899a53f-d2c3-41ec-bc92-d62d0bb074cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_176ffbe6-3fd5-441d-aa84-3d99374be450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899a53f-d2c3-41ec-bc92-d62d0bb074cc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_176ffbe6-3fd5-441d-aa84-3d99374be450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_34c7f43f-7cc3-4f5f-a12d-3af5a237361f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_176ffbe6-3fd5-441d-aa84-3d99374be450" xlink:to="loc_us-gaap_DomesticPlanMember_34c7f43f-7cc3-4f5f-a12d-3af5a237361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2c9bb20a-c5e3-4fd9-bd85-48da141b9119" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_34c7f43f-7cc3-4f5f-a12d-3af5a237361f" xlink:to="loc_country_US_2c9bb20a-c5e3-4fd9-bd85-48da141b9119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_1ef4a740-3e09-43bd-a5fe-15ddac3bc6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_176ffbe6-3fd5-441d-aa84-3d99374be450" xlink:to="loc_us-gaap_ForeignPlanMember_1ef4a740-3e09-43bd-a5fe-15ddac3bc6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InternationalRetirementPlansMember_4de7b604-9698-40ff-bcf6-796674127fed" xlink:href="jnj-20220703.xsd#jnj_InternationalRetirementPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_1ef4a740-3e09-43bd-a5fe-15ddac3bc6ac" xlink:to="loc_jnj_InternationalRetirementPlansMember_4de7b604-9698-40ff-bcf6-796674127fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b95787f7-a0b8-42d8-b964-d2bb53156808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dca336e7-766e-431b-b423-cb06316cc6b1" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b95787f7-a0b8-42d8-b964-d2bb53156808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_cbf71c5d-42c0-45d7-a20a-a6bf31eaf12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_b95787f7-a0b8-42d8-b964-d2bb53156808" xlink:to="loc_us-gaap_PensionContributions_cbf71c5d-42c0-45d7-a20a-a6bf31eaf12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20220703.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5d1f388d-01ed-4d7f-a043-937cf48a273d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_fac5ee1f-c0d2-4e9a-bca7-4082e0ce5eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5d1f388d-01ed-4d7f-a043-937cf48a273d" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_fac5ee1f-c0d2-4e9a-bca7-4082e0ce5eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="jnj-20220703.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f581ae99-3596-49c6-8eea-9916a2b38b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c72e7f52-d5e9-472a-9ec2-5073ee71dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f581ae99-3596-49c6-8eea-9916a2b38b13" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c72e7f52-d5e9-472a-9ec2-5073ee71dee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cce1333d-323d-4109-8b25-59348eff2830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9a51b2df-00a6-49a7-8062-36ed89b32aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cce1333d-323d-4109-8b25-59348eff2830" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9a51b2df-00a6-49a7-8062-36ed89b32aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f0cd058d-b636-43bd-8564-3526b2d561c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9a51b2df-00a6-49a7-8062-36ed89b32aea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f0cd058d-b636-43bd-8564-3526b2d561c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0cd058d-b636-43bd-8564-3526b2d561c1" xlink:to="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_88d1b743-e7b3-4e8f-b2f4-1506f74a93b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_88d1b743-e7b3-4e8f-b2f4-1506f74a93b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f55919cc-27d9-4929-961c-f0fb8678480e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f55919cc-27d9-4929-961c-f0fb8678480e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4542a7e1-00a0-4388-8ebd-3c2ca7e082e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4542a7e1-00a0-4388-8ebd-3c2ca7e082e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bd505954-2b83-4c12-926a-6a4bd3b9cb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bd505954-2b83-4c12-926a-6a4bd3b9cb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a9c9dd7a-d540-4aee-acad-4943f8107b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c39fbf1-71a2-47c4-9125-3369fad45fc4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a9c9dd7a-d540-4aee-acad-4943f8107b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_70c88ada-aec0-4782-96fa-0d713c15df60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9a51b2df-00a6-49a7-8062-36ed89b32aea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_70c88ada-aec0-4782-96fa-0d713c15df60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_54218d40-4b2a-4693-a655-5a36d8580262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_70c88ada-aec0-4782-96fa-0d713c15df60" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_54218d40-4b2a-4693-a655-5a36d8580262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec3c61c9-f37c-401e-8c10-01094f5b3bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_54218d40-4b2a-4693-a655-5a36d8580262" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec3c61c9-f37c-401e-8c10-01094f5b3bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_82bd5a4d-b0f9-4dad-8b05-e3c722fe6cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_54218d40-4b2a-4693-a655-5a36d8580262" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_82bd5a4d-b0f9-4dad-8b05-e3c722fe6cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd133f89-f8c8-4b79-880f-6588de982e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_54218d40-4b2a-4693-a655-5a36d8580262" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd133f89-f8c8-4b79-880f-6588de982e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20220703.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_781148e6-ef86-449c-b264-002d1f42a023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c23e267f-bf40-4545-96ce-0caeee87e44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_781148e6-ef86-449c-b264-002d1f42a023" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c23e267f-bf40-4545-96ce-0caeee87e44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20220703.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a95d7fe6-36d7-46d0-9857-f927eba804c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_dc34e72c-76ce-4815-a7f9-0f99105ec447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a95d7fe6-36d7-46d0-9857-f927eba804c9" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_dc34e72c-76ce-4815-a7f9-0f99105ec447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d71d4221-e31f-4cd8-ba7f-e35bce2e2f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_c2c5dd24-5705-45d4-8715-b6b9ff2794d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d71d4221-e31f-4cd8-ba7f-e35bce2e2f68" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_c2c5dd24-5705-45d4-8715-b6b9ff2794d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e0f5126f-9683-4512-a81b-cc1a3b4032c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c2c5dd24-5705-45d4-8715-b6b9ff2794d0" xlink:to="loc_us-gaap_EarningsPerShareBasic_e0f5126f-9683-4512-a81b-cc1a3b4032c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c00bb583-5119-40d8-8022-bcdd9eae19b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c2c5dd24-5705-45d4-8715-b6b9ff2794d0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c00bb583-5119-40d8-8022-bcdd9eae19b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c5c7e254-877c-4f4f-bffd-f06d4a15b603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c2c5dd24-5705-45d4-8715-b6b9ff2794d0" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c5c7e254-877c-4f4f-bffd-f06d4a15b603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_ef79bffa-b614-4e83-a10d-63753c5acea1" xlink:href="jnj-20220703.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c2c5dd24-5705-45d4-8715-b6b9ff2794d0" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_ef79bffa-b614-4e83-a10d-63753c5acea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_65cc9674-ebac-472c-8760-977ede8aa958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c2c5dd24-5705-45d4-8715-b6b9ff2794d0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_65cc9674-ebac-472c-8760-977ede8aa958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6288e31b-3c57-48d3-9d4d-299a56558105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c2c5dd24-5705-45d4-8715-b6b9ff2794d0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6288e31b-3c57-48d3-9d4d-299a56558105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c6ee15d0-6c20-43e1-847b-18edabcb13b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d71d4221-e31f-4cd8-ba7f-e35bce2e2f68" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c6ee15d0-6c20-43e1-847b-18edabcb13b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20220703.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ff9d17ed-f66f-4ff8-913a-5e87afd46625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_bb570788-1d5c-4d0f-a820-0ad07d9cda72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ff9d17ed-f66f-4ff8-913a-5e87afd46625" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_bb570788-1d5c-4d0f-a820-0ad07d9cda72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20220703.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5b756d8a-987b-4df0-bb7a-a180ddf5bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_69c67661-70f2-4d5f-9447-5ae234dde0e9" xlink:href="jnj-20220703.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5b756d8a-987b-4df0-bb7a-a180ddf5bbf4" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_69c67661-70f2-4d5f-9447-5ae234dde0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6f935360-ba22-4edb-a452-754e286e25d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5b756d8a-987b-4df0-bb7a-a180ddf5bbf4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6f935360-ba22-4edb-a452-754e286e25d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_d5d83997-73df-4c17-bd0c-b592826ccb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5b756d8a-987b-4df0-bb7a-a180ddf5bbf4" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_d5d83997-73df-4c17-bd0c-b592826ccb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ebd9c503-5039-4140-a89f-7b7a6218867b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ebd9c503-5039-4140-a89f-7b7a6218867b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fb18aa48-24e5-45ef-8e74-4dd0c24a3b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fb18aa48-24e5-45ef-8e74-4dd0c24a3b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d193fac-ec8e-4948-97b2-1f6f26b6e617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fb18aa48-24e5-45ef-8e74-4dd0c24a3b97" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d193fac-ec8e-4948-97b2-1f6f26b6e617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5eeb4e48-2d2e-4ba1-88e2-b73aef3d9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5eeb4e48-2d2e-4ba1-88e2-b73aef3d9f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5eeb4e48-2d2e-4ba1-88e2-b73aef3d9f85" xlink:to="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_eff65268-b27b-4055-9533-302ca64b5e2a" xlink:href="jnj-20220703.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:to="loc_jnj_ConsumerMember_eff65268-b27b-4055-9533-302ca64b5e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_442d5529-80cf-43b0-bb31-b9fd668f718d" xlink:href="jnj-20220703.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:to="loc_jnj_PharmaceuticalMember_442d5529-80cf-43b0-bb31-b9fd668f718d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_7358c27e-74a4-405c-bab1-09187b03f523" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:to="loc_jnj_MedicalDevicesMember_7358c27e-74a4-405c-bab1-09187b03f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_df618092-2b34-48c8-aed7-d7fe30b45558" xlink:href="jnj-20220703.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2867feff-682e-4a5e-8ecb-2da240efb30f" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_df618092-2b34-48c8-aed7-d7fe30b45558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_70fb883d-37ee-4607-b6f1-a1837f95bd24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_us-gaap_SubsegmentsAxis_70fb883d-37ee-4607-b6f1-a1837f95bd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_70fb883d-37ee-4607-b6f1-a1837f95bd24" xlink:to="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_5fe723ce-5ffc-4c10-ba22-cc487cbd5e93" xlink:href="jnj-20220703.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_ImmunologyMember_5fe723ce-5ffc-4c10-ba22-cc487cbd5e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_b9a57d0e-8833-4f6b-a192-4c6a288d650e" xlink:href="jnj-20220703.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_InfectiousDiseasesMember_b9a57d0e-8833-4f6b-a192-4c6a288d650e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_2fbe2951-393f-47eb-9a75-b95d28b6f049" xlink:href="jnj-20220703.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_NeuroscienceMember_2fbe2951-393f-47eb-9a75-b95d28b6f049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_5f7e3047-4093-45f1-98ae-708e25711566" xlink:href="jnj-20220703.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_OncologyMember_5f7e3047-4093-45f1-98ae-708e25711566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_dacba104-9c32-4af3-b2b9-8b8cca3f7cc3" xlink:href="jnj-20220703.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_PulmonaryHypertensionMember_dacba104-9c32-4af3-b2b9-8b8cca3f7cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_8bceeeec-e403-4e48-9d58-78884a2db4f8" xlink:href="jnj-20220703.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_8bceeeec-e403-4e48-9d58-78884a2db4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_5462ff36-0bc2-4019-ac90-f3563a2b3e40" xlink:href="jnj-20220703.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_InterventionalSolutionsMember_5462ff36-0bc2-4019-ac90-f3563a2b3e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_664f33bd-eaf5-4471-b2f1-a040411bd97f" xlink:href="jnj-20220703.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_OrthopaedicsMember_664f33bd-eaf5-4471-b2f1-a040411bd97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_691d7ed9-cc23-4b19-bac4-9bd28d9f035a" xlink:href="jnj-20220703.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_SurgeryMember_691d7ed9-cc23-4b19-bac4-9bd28d9f035a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_4275b4bd-81e1-4fe4-9d36-c0528a1f6c2b" xlink:href="jnj-20220703.xsd#jnj_VisionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_311a1fe5-9c67-40dc-8d11-09b457ef9a66" xlink:to="loc_jnj_VisionMember_4275b4bd-81e1-4fe4-9d36-c0528a1f6c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7a48ca91-7970-4603-adfb-9d4ca453bbf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_srt_ProductOrServiceAxis_7a48ca91-7970-4603-adfb-9d4ca453bbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7a48ca91-7970-4603-adfb-9d4ca453bbf5" xlink:to="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_fbba266e-9504-4b01-b299-91a1541c3f69" xlink:href="jnj-20220703.xsd#jnj_OTCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OTCMember_fbba266e-9504-4b01-b299-91a1541c3f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_dbd19eaa-139e-453f-a2c8-f0981414bccf" xlink:href="jnj-20220703.xsd#jnj_BeautyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_BeautyMember_dbd19eaa-139e-453f-a2c8-f0981414bccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_165e55de-3937-4c53-91a8-960449602d99" xlink:href="jnj-20220703.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OralCareMember_165e55de-3937-4c53-91a8-960449602d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_218c4064-fc46-4d8d-94d2-4872d6d2cde6" xlink:href="jnj-20220703.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_BabyCareMember_218c4064-fc46-4d8d-94d2-4872d6d2cde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_7bf5c003-47d4-4c17-a6e8-97139eb3db24" xlink:href="jnj-20220703.xsd#jnj_WomensHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_WomensHealthMember_7bf5c003-47d4-4c17-a6e8-97139eb3db24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_eba62d10-bb41-4813-82da-2408c48a2d8e" xlink:href="jnj-20220703.xsd#jnj_WoundCareandOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_WoundCareandOtherMember_eba62d10-bb41-4813-82da-2408c48a2d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_f515ea4b-ace2-4e94-8cfe-597263d71b51" xlink:href="jnj-20220703.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_RemicadeMember_f515ea4b-ace2-4e94-8cfe-597263d71b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_3d148e89-a632-46f5-9d17-cb53649b5352" xlink:href="jnj-20220703.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_SimponiSimponiAriaMember_3d148e89-a632-46f5-9d17-cb53649b5352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_be57ed33-9a1f-4159-80a3-8a977c91c2d9" xlink:href="jnj-20220703.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_StelaraMember_be57ed33-9a1f-4159-80a3-8a977c91c2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_e6f6eb66-254a-4f69-9a98-a32bbc4dfcb1" xlink:href="jnj-20220703.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_TremfyaMember_e6f6eb66-254a-4f69-9a98-a32bbc4dfcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_d377c1a1-cf27-4b73-8d15-e4f6315d15a8" xlink:href="jnj-20220703.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OtherImmunologyMember_d377c1a1-cf27-4b73-8d15-e4f6315d15a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_379d7cb1-fa15-4ab4-bc1f-9cb5c5df6cf5" xlink:href="jnj-20220703.xsd#jnj_COVID19Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_COVID19Member_379d7cb1-fa15-4ab4-bc1f-9cb5c5df6cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_d23afdfd-65be-412a-b1da-01e3124fce45" xlink:href="jnj-20220703.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_EDURANTrilpivirineMember_d23afdfd-65be-412a-b1da-01e3124fce45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_5b977937-e590-4c75-8a5f-9b7a8fb896aa" xlink:href="jnj-20220703.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_5b977937-e590-4c75-8a5f-9b7a8fb896aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_8d745df6-fc38-4b3b-8763-fad56416d29b" xlink:href="jnj-20220703.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_8d745df6-fc38-4b3b-8763-fad56416d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_b7b57eb2-ee1c-4ced-b71a-20ef20ccd611" xlink:href="jnj-20220703.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_b7b57eb2-ee1c-4ced-b71a-20ef20ccd611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_7b176752-6ac1-4f72-a298-617cceba1f01" xlink:href="jnj-20220703.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_7b176752-6ac1-4f72-a298-617cceba1f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_21f5bb70-8300-454b-bb86-a0e7fde62108" xlink:href="jnj-20220703.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_RISPERDALCONSTAMember_21f5bb70-8300-454b-bb86-a0e7fde62108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_94aa479e-410c-4f25-a5a5-45702283653b" xlink:href="jnj-20220703.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_94aa479e-410c-4f25-a5a5-45702283653b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_7a085d63-4781-4886-805a-e8cea042817e" xlink:href="jnj-20220703.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_DARZALEXMember_7a085d63-4781-4886-805a-e8cea042817e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_a2713d5b-cb7b-4e9f-bb8b-c1718f646b45" xlink:href="jnj-20220703.xsd#jnj_ERLEADAMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_ERLEADAMember_a2713d5b-cb7b-4e9f-bb8b-c1718f646b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_797d280d-3fe5-4c38-bd5a-d2a27c147bd9" xlink:href="jnj-20220703.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_IMBRUVICAMember_797d280d-3fe5-4c38-bd5a-d2a27c147bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_e9bbf80c-16dd-48f4-be85-b3313605b45e" xlink:href="jnj-20220703.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_ZYTIGAMember_e9bbf80c-16dd-48f4-be85-b3313605b45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_19d91e68-a3a8-42c9-bd99-9126091ccf5b" xlink:href="jnj-20220703.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OtherOncologyMember_19d91e68-a3a8-42c9-bd99-9126091ccf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_94375471-14fb-461c-9eb1-1f204c9f738e" xlink:href="jnj-20220703.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OPSUMITMember_94375471-14fb-461c-9eb1-1f204c9f738e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_3c2d59a2-3734-4d51-8dee-7f11dde1a190" xlink:href="jnj-20220703.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_UPTRAVIMember_3c2d59a2-3734-4d51-8dee-7f11dde1a190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_5f3e6b61-5202-487c-a44d-5aba88cd0da1" xlink:href="jnj-20220703.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_XareltoMember_5f3e6b61-5202-487c-a44d-5aba88cd0da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_5b30d943-31a2-40d2-a5ea-7b44b803bce6" xlink:href="jnj-20220703.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_5b30d943-31a2-40d2-a5ea-7b44b803bce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_69fc666e-149f-4ed9-9c3c-4e0f8a2788ba" xlink:href="jnj-20220703.xsd#jnj_OtherMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_OtherMember_69fc666e-149f-4ed9-9c3c-4e0f8a2788ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_6ed9f8c3-ff6c-4fee-8d82-4496f39db848" xlink:href="jnj-20220703.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_HIPSMember_6ed9f8c3-ff6c-4fee-8d82-4496f39db848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_49c13e1b-995f-4a0f-939e-b826fe44291c" xlink:href="jnj-20220703.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_KNEESMember_49c13e1b-995f-4a0f-939e-b826fe44291c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_4c782ece-907e-483e-8cb5-315b1e340354" xlink:href="jnj-20220703.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_TRAUMAMember_4c782ece-907e-483e-8cb5-315b1e340354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_1df5e3f2-2407-4dad-baf6-7757383a2253" xlink:href="jnj-20220703.xsd#jnj_SPINEOTHERMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_SPINEOTHERMember_1df5e3f2-2407-4dad-baf6-7757383a2253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_dbd926a2-3b6d-4025-b873-e2ac0eb7defe" xlink:href="jnj-20220703.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_ADVANCEDMember_dbd926a2-3b6d-4025-b873-e2ac0eb7defe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_2000a8b6-9c4a-4539-942e-2f004fa84f0d" xlink:href="jnj-20220703.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_GENERALMember_2000a8b6-9c4a-4539-942e-2f004fa84f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_807fee07-fbf9-40b6-a792-09ee6916dc09" xlink:href="jnj-20220703.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_807fee07-fbf9-40b6-a792-09ee6916dc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_3f74c2d5-1dd9-4cbb-bfa8-5bf3eecc6f34" xlink:href="jnj-20220703.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37fabc23-440e-4ef8-af0d-828a62dce838" xlink:to="loc_jnj_SURGICALMember_3f74c2d5-1dd9-4cbb-bfa8-5bf3eecc6f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c1b3d7a7-66d0-478e-8e1e-2d5dc1e3bbe7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_srt_StatementGeographicalAxis_c1b3d7a7-66d0-478e-8e1e-2d5dc1e3bbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c1b3d7a7-66d0-478e-8e1e-2d5dc1e3bbe7" xlink:to="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_7f363113-94fd-40ed-b6a4-50f6960023c3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:to="loc_country_CN_7f363113-94fd-40ed-b6a4-50f6960023c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a591e7ee-fcbc-478b-8785-ab8f7c674a67" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:to="loc_country_US_a591e7ee-fcbc-478b-8785-ab8f7c674a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_834668e4-388f-445d-bdaa-08899ebcf00b" xlink:href="jnj-20220703.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:to="loc_jnj_UNITEDSTATESExportsMember_834668e4-388f-445d-bdaa-08899ebcf00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2a91312e-1319-4552-a95c-b41763663819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fa22a477-82b0-4b04-95d6-238189ccc1ed" xlink:to="loc_us-gaap_NonUsMember_2a91312e-1319-4552-a95c-b41763663819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6526f1f8-eff4-48a8-9228-857a18953d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3f169d51-eaaa-4244-a6f7-a9dc7f4e3a5b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_6526f1f8-eff4-48a8-9228-857a18953d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_04fabcb8-19c9-4d26-90cf-de5271d9c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6526f1f8-eff4-48a8-9228-857a18953d9b" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_04fabcb8-19c9-4d26-90cf-de5271d9c16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0fdc213f-2961-422c-87f6-a517a9c88773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_04fabcb8-19c9-4d26-90cf-de5271d9c16b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0fdc213f-2961-422c-87f6-a517a9c88773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b500fc0f-52dc-4c2f-bbc2-7416772d5dfd" xlink:href="jnj-20220703.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_04fabcb8-19c9-4d26-90cf-de5271d9c16b" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b500fc0f-52dc-4c2f-bbc2-7416772d5dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a4d44c47-9078-412d-9cc5-aad1bdf0b1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a4d44c47-9078-412d-9cc5-aad1bdf0b1f7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d41461a6-62fb-4f98-8c50-32c3c1c412aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:to="loc_srt_ConsolidationItemsAxis_d41461a6-62fb-4f98-8c50-32c3c1c412aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e44aa74c-fd14-4736-87ea-cfa7d9400aca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_d41461a6-62fb-4f98-8c50-32c3c1c412aa" xlink:to="loc_srt_ConsolidationItemsDomain_e44aa74c-fd14-4736-87ea-cfa7d9400aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_80414c46-759b-4b66-a5db-930f1bd02253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e44aa74c-fd14-4736-87ea-cfa7d9400aca" xlink:to="loc_us-gaap_OperatingSegmentsMember_80414c46-759b-4b66-a5db-930f1bd02253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_95574d03-57e5-4d25-98bd-78c36f6ff929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e44aa74c-fd14-4736-87ea-cfa7d9400aca" xlink:to="loc_us-gaap_CorporateNonSegmentMember_95574d03-57e5-4d25-98bd-78c36f6ff929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9758b53e-3601-48dd-a596-55c40dd5a49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9758b53e-3601-48dd-a596-55c40dd5a49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9758b53e-3601-48dd-a596-55c40dd5a49c" xlink:to="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_cabbb19e-0ab2-45a0-aa86-fc9839682307" xlink:href="jnj-20220703.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:to="loc_jnj_ConsumerMember_cabbb19e-0ab2-45a0-aa86-fc9839682307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_a1041af9-7b9b-4d9b-8b1b-f7772aa102ac" xlink:href="jnj-20220703.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:to="loc_jnj_PharmaceuticalMember_a1041af9-7b9b-4d9b-8b1b-f7772aa102ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_ad2421d8-8f9c-4b99-a4f7-b5f8059281c0" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:to="loc_jnj_MedicalDevicesMember_ad2421d8-8f9c-4b99-a4f7-b5f8059281c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b091087d-eaf1-425e-9edb-30c2d9fcce2e" xlink:href="jnj-20220703.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_850b7460-1ee8-4452-9191-2a04d1792e9a" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b091087d-eaf1-425e-9edb-30c2d9fcce2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_53de40d3-22f9-4da5-8636-7194c884558f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_53de40d3-22f9-4da5-8636-7194c884558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8d46266-c015-44e8-9239-498eedffe523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_53de40d3-22f9-4da5-8636-7194c884558f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8d46266-c015-44e8-9239-498eedffe523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_37adb6ad-f4ea-4da6-aebd-ead3e3e9f790" xlink:href="jnj-20220703.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8d46266-c015-44e8-9239-498eedffe523" xlink:to="loc_jnj_BermekimabMember_37adb6ad-f4ea-4da6-aebd-ead3e3e9f790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b5a1338b-046f-45d8-8d0e-6c5813a7a932" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5a28905f-5beb-4e18-a963-6dae490fa0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_OperatingIncomeLoss_5a28905f-5beb-4e18-a963-6dae490fa0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_f8cefc92-2c63-4501-99cb-25fa48e8102b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_BusinessExitCosts1_f8cefc92-2c63-4501-99cb-25fa48e8102b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_69528bd0-2a4f-48c2-805a-9813640e7562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_69528bd0-2a4f-48c2-805a-9813640e7562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_79babe09-91a8-43ff-a6d1-0ad34b47f30d" xlink:href="jnj-20220703.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_79babe09-91a8-43ff-a6d1-0ad34b47f30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_e56583ca-2892-4c18-bbfa-ec37e88bffd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_AdjustmentForAmortization_e56583ca-2892-4c18-bbfa-ec37e88bffd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6bee4d31-2c49-4b77-9781-03d7ddfbfbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6bee4d31-2c49-4b77-9781-03d7ddfbfbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e81f69b5-8e35-46d0-81c5-bd46531b0a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e81f69b5-8e35-46d0-81c5-bd46531b0a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_7d0c7324-4252-46e9-be52-ae4892b70bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_7d0c7324-4252-46e9-be52-ae4892b70bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_ecafc5a9-bd03-4761-a59b-781c68707bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_SuppliesExpense_ecafc5a9-bd03-4761-a59b-781c68707bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_8f3d2b71-1619-4106-98d9-01c24d516064" xlink:href="jnj-20220703.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_8f3d2b71-1619-4106-98d9-01c24d516064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ef90360a-04fe-426a-97cf-1b1032b2fe66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_RestructuringCharges_ef90360a-04fe-426a-97cf-1b1032b2fe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_5b865261-9a49-41f3-8678-c39ccb99f66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a35e183b-4bea-4069-b35d-c0a2fff491ab" xlink:to="loc_us-gaap_LitigationSettlementExpense_5b865261-9a49-41f3-8678-c39ccb99f66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b41e3b28-a413-401e-b914-9bb475ed35cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_56841910-811a-482a-89c8-2434010763a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b41e3b28-a413-401e-b914-9bb475ed35cb" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_56841910-811a-482a-89c8-2434010763a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_09439634-241d-420c-8737-11855d5f56de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_56841910-811a-482a-89c8-2434010763a1" xlink:to="loc_srt_StatementGeographicalAxis_09439634-241d-420c-8737-11855d5f56de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_09439634-241d-420c-8737-11855d5f56de" xlink:to="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b7f92f19-c26d-447c-b2da-25ac0c874e1f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:to="loc_country_US_b7f92f19-c26d-447c-b2da-25ac0c874e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_fcf6e268-7dd2-452b-808b-515a61efe7c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:to="loc_srt_EuropeMember_fcf6e268-7dd2-452b-808b-515a61efe7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_a5b5d497-2cd8-4aed-a796-5449b766e1db" xlink:href="jnj-20220703.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_a5b5d497-2cd8-4aed-a796-5449b766e1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_c4207669-ae04-49f9-8e09-6bab5f88e704" xlink:href="jnj-20220703.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c4fdb8b4-f4a9-4d48-b81a-6ef385f2d8f7" xlink:to="loc_jnj_AsiaPacificAfricaMember_c4207669-ae04-49f9-8e09-6bab5f88e704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4d3d95e4-3d27-4df5-a577-19e56164a664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_56841910-811a-482a-89c8-2434010763a1" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4d3d95e4-3d27-4df5-a577-19e56164a664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_b3854022-53f1-4138-b48e-d4d12e76fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4d3d95e4-3d27-4df5-a577-19e56164a664" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_b3854022-53f1-4138-b48e-d4d12e76fbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_613c8329-f555-4ed3-93a2-7c82a734e219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_b3854022-53f1-4138-b48e-d4d12e76fbe0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_613c8329-f555-4ed3-93a2-7c82a734e219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_80583f3c-452f-4a46-9eb9-414529b3ff3b" xlink:href="jnj-20220703.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_b3854022-53f1-4138-b48e-d4d12e76fbe0" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_80583f3c-452f-4a46-9eb9-414529b3ff3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20220703.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f17fd37d-c039-4e8e-aaa8-8233f538f167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_28169c6d-8536-4122-8d98-6da7600e22ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f17fd37d-c039-4e8e-aaa8-8233f538f167" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_28169c6d-8536-4122-8d98-6da7600e22ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_84e5d698-a8c0-41a5-b3d3-76d95102bb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_47f37f93-2074-4c20-a3dd-f3712800e1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_84e5d698-a8c0-41a5-b3d3-76d95102bb8f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_47f37f93-2074-4c20-a3dd-f3712800e1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ea3bdb4-75b0-4d88-a4fc-e119abd58aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_47f37f93-2074-4c20-a3dd-f3712800e1b1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ea3bdb4-75b0-4d88-a4fc-e119abd58aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce5d7bf3-cd81-4961-a3b8-d8e3b4714dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ea3bdb4-75b0-4d88-a4fc-e119abd58aad" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce5d7bf3-cd81-4961-a3b8-d8e3b4714dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_b1c0e9e7-4270-45c9-9823-98c6b91ce72c" xlink:href="jnj-20220703.xsd#jnj_EvraAndDoxilMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce5d7bf3-cd81-4961-a3b8-d8e3b4714dcc" xlink:to="loc_jnj_EvraAndDoxilMember_b1c0e9e7-4270-45c9-9823-98c6b91ce72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_923cad82-cdb4-43e6-9ded-063dc8ff30bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_47f37f93-2074-4c20-a3dd-f3712800e1b1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_923cad82-cdb4-43e6-9ded-063dc8ff30bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfBrands_86a8388c-1de3-4ccd-b275-11c28ddea58b" xlink:href="jnj-20220703.xsd#jnj_NumberOfBrands"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_923cad82-cdb4-43e6-9ded-063dc8ff30bf" xlink:to="loc_jnj_NumberOfBrands_86a8388c-1de3-4ccd-b275-11c28ddea58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_c592a347-94de-4f92-a3dd-3472c2c0ded7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_923cad82-cdb4-43e6-9ded-063dc8ff30bf" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_c592a347-94de-4f92-a3dd-3472c2c0ded7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20220703.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5d3816c0-4db1-4dde-830f-965827c45761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_03b730cf-cd91-40d7-823b-6e927a789c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5d3816c0-4db1-4dde-830f-965827c45761" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_03b730cf-cd91-40d7-823b-6e927a789c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cc5a0b5b-ddb2-45eb-8387-22c62b852e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cc5a0b5b-ddb2-45eb-8387-22c62b852e6e" xlink:to="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ee2c3fcb-f0f3-4192-b5aa-c13f36a404e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_srt_LitigationCaseAxis_ee2c3fcb-f0f3-4192-b5aa-c13f36a404e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ee2c3fcb-f0f3-4192-b5aa-c13f36a404e5" xlink:to="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_9399b9e0-0d2e-40bf-93a6-22fd7ab83cce" xlink:href="jnj-20220703.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_DePuyASRU.S.Member_9399b9e0-0d2e-40bf-93a6-22fd7ab83cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_c9d160aa-5f05-4bc3-b6da-ea00729943d4" xlink:href="jnj-20220703.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_RisperdalMember_c9d160aa-5f05-4bc3-b6da-ea00729943d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_ad845685-95a9-4d0d-a270-5736527506ee" xlink:href="jnj-20220703.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_BabyPowderMember_ad845685-95a9-4d0d-a270-5736527506ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_a317c042-539d-4473-83d5-5d2df207fe93" xlink:href="jnj-20220703.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_a317c042-539d-4473-83d5-5d2df207fe93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_c01111a8-7cd8-4391-80d3-a1f7c20342f4" xlink:href="jnj-20220703.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1c54d424-ac85-476c-a96f-ac48fc8da2d5" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_c01111a8-7cd8-4391-80d3-a1f7c20342f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a886b5a3-71bb-44d7-97ec-7063937f9a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_us-gaap_LitigationStatusAxis_a886b5a3-71bb-44d7-97ec-7063937f9a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_a886b5a3-71bb-44d7-97ec-7063937f9a7d" xlink:to="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_480cc749-bbd2-473d-b3ce-3f368a5a68fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:to="loc_us-gaap_SettledLitigationMember_480cc749-bbd2-473d-b3ce-3f368a5a68fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_4f62720e-da17-49a3-b375-6deee94790c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:to="loc_us-gaap_JudicialRulingMember_4f62720e-da17-49a3-b375-6deee94790c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_757e39d1-fdcd-46c9-99de-73e4975a645c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_748ec8c4-d830-4943-b4b5-7a40fe30924c" xlink:to="loc_us-gaap_PendingLitigationMember_757e39d1-fdcd-46c9-99de-73e4975a645c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c317af3-6056-4e2a-99a0-292cd45a2241" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_srt_ProductOrServiceAxis_8c317af3-6056-4e2a-99a0-292cd45a2241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8c317af3-6056-4e2a-99a0-292cd45a2241" xlink:to="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_d55ea94e-1bee-4b2c-ae08-cec989dffff2" xlink:href="jnj-20220703.xsd#jnj_AsrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_AsrMember_d55ea94e-1bee-4b2c-ae08-cec989dffff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_c41bccb2-f4ad-4a4c-9ffd-df83ef905cf0" xlink:href="jnj-20220703.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_c41bccb2-f4ad-4a4c-9ffd-df83ef905cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_77ec6436-8364-4286-af23-c1243e728634" xlink:href="jnj-20220703.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_PelvicMeshesMember_77ec6436-8364-4286-af23-c1243e728634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_479cc258-11f4-44a6-b8a3-85817ba0a14e" xlink:href="jnj-20220703.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_RisperdalMember_479cc258-11f4-44a6-b8a3-85817ba0a14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_7ccd2f24-a7af-4e6b-b2ed-8dd8115f3009" xlink:href="jnj-20220703.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_XareltoMember_7ccd2f24-a7af-4e6b-b2ed-8dd8115f3009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_bb642d11-1d0f-4543-a636-cc72b5410bc9" xlink:href="jnj-20220703.xsd#jnj_TalcMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_TalcMember_bb642d11-1d0f-4543-a636-cc72b5410bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_c6bd4f50-761d-437e-8551-8c06a7417b80" xlink:href="jnj-20220703.xsd#jnj_InvokanaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_InvokanaMember_c6bd4f50-761d-437e-8551-8c06a7417b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_8d0687dc-1efc-4965-bb18-e27906b21243" xlink:href="jnj-20220703.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_PhysiomeshMember_8d0687dc-1efc-4965-bb18-e27906b21243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_1b370af6-d4c1-4548-82ef-19fad7835563" xlink:href="jnj-20220703.xsd#jnj_OpioidMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_OpioidMember_1b370af6-d4c1-4548-82ef-19fad7835563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_e1336a96-e871-4e72-b920-49e58565a689" xlink:href="jnj-20220703.xsd#jnj_ContactLensesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_ContactLensesMember_e1336a96-e871-4e72-b920-49e58565a689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_1f8ed51f-0727-45b1-a760-3d927ea001c1" xlink:href="jnj-20220703.xsd#jnj_ElmironMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89554cc8-7efb-4a32-8c2d-caa341a5bf10" xlink:to="loc_jnj_ElmironMember_1f8ed51f-0727-45b1-a760-3d927ea001c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_734add84-6470-4eae-baad-8f564f291057" xlink:href="jnj-20220703.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_734add84-6470-4eae-baad-8f564f291057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_119e31f1-2e4d-4cdc-b71d-23d70f47da95" xlink:href="jnj-20220703.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_734add84-6470-4eae-baad-8f564f291057" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_119e31f1-2e4d-4cdc-b71d-23d70f47da95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b61637d1-652b-4beb-b5e9-4caccab2c97b" xlink:href="jnj-20220703.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_119e31f1-2e4d-4cdc-b71d-23d70f47da95" xlink:to="loc_jnj_RisperdalMember_b61637d1-652b-4beb-b5e9-4caccab2c97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_65ba735c-13f6-4fb1-bea8-86dcdd108664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_65ba735c-13f6-4fb1-bea8-86dcdd108664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_70e05e59-610c-4f68-b7f0-b52a7f2377f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_65ba735c-13f6-4fb1-bea8-86dcdd108664" xlink:to="loc_us-gaap_LossContingencyNatureDomain_70e05e59-610c-4f68-b7f0-b52a7f2377f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_fbf7b062-3e88-48b5-bf11-6f9a98efeef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_70e05e59-610c-4f68-b7f0-b52a7f2377f1" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_fbf7b062-3e88-48b5-bf11-6f9a98efeef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0fcfd002-0ddb-45bb-9fc1-045b46b94dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0fcfd002-0ddb-45bb-9fc1-045b46b94dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0accf52b-2b01-4851-b37f-e7ede76c3f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0fcfd002-0ddb-45bb-9fc1-045b46b94dfd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0accf52b-2b01-4851-b37f-e7ede76c3f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a4402ff4-a06e-4d1b-b4a3-f35ad62fecd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0accf52b-2b01-4851-b37f-e7ede76c3f48" xlink:to="loc_us-gaap_SubsequentEventMember_a4402ff4-a06e-4d1b-b4a3-f35ad62fecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_87ca86db-12a2-448f-a4a3-9631395a3935" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_srt_CounterpartyNameAxis_87ca86db-12a2-448f-a4a3-9631395a3935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a96e6d8a-f3cf-4e5d-85e6-4e423ed277d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_87ca86db-12a2-448f-a4a3-9631395a3935" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a96e6d8a-f3cf-4e5d-85e6-4e423ed277d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RasmussenInstrumentsLLCMember_4ed650ba-f74c-480a-932b-f5bafbca698b" xlink:href="jnj-20220703.xsd#jnj_RasmussenInstrumentsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a96e6d8a-f3cf-4e5d-85e6-4e423ed277d8" xlink:to="loc_jnj_RasmussenInstrumentsLLCMember_4ed650ba-f74c-480a-932b-f5bafbca698b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2d11940a-14b0-4696-8779-63bb0a608e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_706398e8-c40b-4728-a626-4815b4fc9e35" xlink:to="loc_us-gaap_LossContingenciesLineItems_2d11940a-14b0-4696-8779-63bb0a608e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:href="jnj-20220703.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2d11940a-14b0-4696-8779-63bb0a608e97" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_87b3d0c8-8fe6-418c-949d-1d4f18fd8f6f" xlink:href="jnj-20220703.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_87b3d0c8-8fe6-418c-949d-1d4f18fd8f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_473a1d97-3957-42f0-8354-3ef60212d922" xlink:href="jnj-20220703.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_Numberofpatientsinsettlement_473a1d97-3957-42f0-8354-3ef60212d922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_aba91388-780f-4703-9b8d-8acc747e53e9" xlink:href="jnj-20220703.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_aba91388-780f-4703-9b8d-8acc747e53e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_1548c268-b755-4b4e-8710-2418691a029f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_1548c268-b755-4b4e-8710-2418691a029f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_14d8b85e-4977-46be-903d-8fb2eb6a3f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_14d8b85e-4977-46be-903d-8fb2eb6a3f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_55c7dfdb-706b-40d1-bbfb-2a0a9765cbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_55c7dfdb-706b-40d1-bbfb-2a0a9765cbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_fbb1cc51-0497-4725-bb49-93411d4b3141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_fbb1cc51-0497-4725-bb49-93411d4b3141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_988c5a83-f0e2-430a-aa1e-127b75690021" xlink:href="jnj-20220703.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_988c5a83-f0e2-430a-aa1e-127b75690021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d82300d5-0183-4f09-a8b2-55176537d556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d82300d5-0183-4f09-a8b2-55176537d556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_8406594f-b8ef-4ef2-80a6-b835cd146afc" xlink:href="jnj-20220703.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_24a86bc8-36dc-4150-a51b-2504edd1c172" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_8406594f-b8ef-4ef2-80a6-b835cd146afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20220703.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_95004936-99a2-412f-aa93-f04e4e17cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ab76ee52-0525-4d85-a218-fd24e79affb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_95004936-99a2-412f-aa93-f04e4e17cf30" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ab76ee52-0525-4d85-a218-fd24e79affb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20220703.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ead53947-8129-4dcd-a9b9-cc99513280b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e7349fad-9eb4-4e2b-99d2-880546da6b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ead53947-8129-4dcd-a9b9-cc99513280b2" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e7349fad-9eb4-4e2b-99d2-880546da6b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5bc06e93-212e-4c35-8590-94cee9fcb6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5bc06e93-212e-4c35-8590-94cee9fcb6ea" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9594692a-b041-4c6f-aa98-4ccb08482b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9594692a-b041-4c6f-aa98-4ccb08482b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9aefa655-b4c4-4cf9-aff1-e47322193d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9594692a-b041-4c6f-aa98-4ccb08482b63" xlink:to="loc_us-gaap_SegmentDomain_9aefa655-b4c4-4cf9-aff1-e47322193d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_cc439543-bb3f-4519-9b80-82e0656b0176" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9aefa655-b4c4-4cf9-aff1-e47322193d8b" xlink:to="loc_jnj_MedicalDevicesMember_cc439543-bb3f-4519-9b80-82e0656b0176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_4537e148-fc07-4f62-83e3-01b4626b89cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:to="loc_us-gaap_RestructuringPlanAxis_4537e148-fc07-4f62-83e3-01b4626b89cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_aa9d8235-16ab-450d-975f-9ebd42474002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_4537e148-fc07-4f62-83e3-01b4626b89cd" xlink:to="loc_us-gaap_RestructuringPlanDomain_aa9d8235-16ab-450d-975f-9ebd42474002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_5e31374a-ef6e-4d5a-b5ab-d92c6500b854" xlink:href="jnj-20220703.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_aa9d8235-16ab-450d-975f-9ebd42474002" xlink:to="loc_jnj_SupplyChainMember_5e31374a-ef6e-4d5a-b5ab-d92c6500b854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_da4390ff-9796-4bd8-984c-3b7f96775d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_da4390ff-9796-4bd8-984c-3b7f96775d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da4390ff-9796-4bd8-984c-3b7f96775d3e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_0e944af2-eb23-4cb3-bba9-2df07ba58638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:to="loc_us-gaap_RestructuringChargesMember_0e944af2-eb23-4cb3-bba9-2df07ba58638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_0fd6fcde-937b-4ff8-956f-28b4340e5c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:to="loc_us-gaap_CostOfSalesMember_0fd6fcde-937b-4ff8-956f-28b4340e5c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_ccf53d44-aaeb-4bc9-a37e-f5a1cfc43ce6" xlink:href="jnj-20220703.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_21053bd6-de03-44cd-913b-0e4fd10f4672" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_ccf53d44-aaeb-4bc9-a37e-f5a1cfc43ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81a8d4c2-28c3-4d62-ba5a-99d8dabec4dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:to="loc_srt_RangeAxis_81a8d4c2-28c3-4d62-ba5a-99d8dabec4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_69457967-a404-4cdd-b9d7-a8681a0b84ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_81a8d4c2-28c3-4d62-ba5a-99d8dabec4dd" xlink:to="loc_srt_RangeMember_69457967-a404-4cdd-b9d7-a8681a0b84ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_03df9965-bead-4ed4-98ed-03a21e91a91e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_69457967-a404-4cdd-b9d7-a8681a0b84ae" xlink:to="loc_srt_MaximumMember_03df9965-bead-4ed4-98ed-03a21e91a91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3072b54d-7621-4e0b-af6b-bc540157ba25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_69457967-a404-4cdd-b9d7-a8681a0b84ae" xlink:to="loc_srt_MinimumMember_3072b54d-7621-4e0b-af6b-bc540157ba25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66d52e5f-7706-4750-a52a-a19164cc7e5f" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_4cfc2624-1a92-4eba-aa53-3d9682217fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:to="loc_us-gaap_RestructuringCharges_4cfc2624-1a92-4eba-aa53-3d9682217fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_de46057c-d9ee-4dbc-ad79-e8727d62fc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_de46057c-d9ee-4dbc-ad79-e8727d62fc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_a90e7760-d128-40b0-aa41-e509143c12af" xlink:href="jnj-20220703.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_a90e7760-d128-40b0-aa41-e509143c12af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_aebc31c8-c01a-4b62-a164-54cdc317ad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bce29ac2-183f-4484-b6eb-e4d4bc206369" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_aebc31c8-c01a-4b62-a164-54cdc317ad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20220703.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_136c8c28-cec8-464b-9f60-d230e32f11ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_26d58398-b140-4bbe-9333-2ca2a7829a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_136c8c28-cec8-464b-9f60-d230e32f11ad" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_26d58398-b140-4bbe-9333-2ca2a7829a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_d3450b26-7857-48bf-9ff9-8d242d1331e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_26d58398-b140-4bbe-9333-2ca2a7829a8f" xlink:to="loc_us-gaap_RestructuringPlanAxis_d3450b26-7857-48bf-9ff9-8d242d1331e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_22553b2b-b926-4a08-8947-55c0c23873b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_d3450b26-7857-48bf-9ff9-8d242d1331e9" xlink:to="loc_us-gaap_RestructuringPlanDomain_22553b2b-b926-4a08-8947-55c0c23873b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_3a699ca5-c25f-457b-a6e3-c082c0400ccc" xlink:href="jnj-20220703.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_22553b2b-b926-4a08-8947-55c0c23873b5" xlink:to="loc_jnj_MedicalDevicesMember_3a699ca5-c25f-457b-a6e3-c082c0400ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_de6ff403-efeb-4062-9c3a-bddd0e6f4184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_26d58398-b140-4bbe-9333-2ca2a7829a8f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_de6ff403-efeb-4062-9c3a-bddd0e6f4184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_de6ff403-efeb-4062-9c3a-bddd0e6f4184" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_ae5c82a0-4879-411d-a95a-d303815fcb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:to="loc_us-gaap_EmployeeSeveranceMember_ae5c82a0-4879-411d-a95a-d303815fcb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_92d4528f-77e4-4924-a0df-daca5dd7eb23" xlink:href="jnj-20220703.xsd#jnj_AssetWriteoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:to="loc_jnj_AssetWriteoffMember_92d4528f-77e4-4924-a0df-daca5dd7eb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_5fbc5062-fce9-41fd-b6d4-7c2580b2d8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_be46793a-1ad1-4a45-bcd7-be28e31d253d" xlink:to="loc_us-gaap_OtherRestructuringMember_5fbc5062-fce9-41fd-b6d4-7c2580b2d8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_364fe6e7-d1bb-4298-b3e7-6b2aa4c77363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_26d58398-b140-4bbe-9333-2ca2a7829a8f" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_364fe6e7-d1bb-4298-b3e7-6b2aa4c77363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_364fe6e7-d1bb-4298-b3e7-6b2aa4c77363" xlink:to="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_543bab18-d35e-4aa2-b154-943ed5d8e95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:to="loc_us-gaap_RestructuringReserve_543bab18-d35e-4aa2-b154-943ed5d8e95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_db8e99f7-91fb-45ae-97ff-66daf4fd1d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:to="loc_us-gaap_RestructuringCharges_db8e99f7-91fb-45ae-97ff-66daf4fd1d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsForRestructuringNet_038101e1-bfe5-4d74-bf57-8f83afdbbc9f" xlink:href="jnj-20220703.xsd#jnj_PaymentsForRestructuringNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:to="loc_jnj_PaymentsForRestructuringNet_038101e1-bfe5-4d74-bf57-8f83afdbbc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_daef8873-33af-4e8a-8df7-6865932bd892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_daef8873-33af-4e8a-8df7-6865932bd892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3ed80133-335c-4e1b-b46a-617140748975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_ffa10147-fcac-48ad-8800-0d7a51905817" xlink:to="loc_us-gaap_RestructuringReserve_3ed80133-335c-4e1b-b46a-617140748975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>jnj-20220703_g1.jpg
<TEXT>
begin 644 jnj-20220703_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_9^UBPTO36\-6#QB01W.L17=K*;A;P/;3K+*PC6.1U5X/D>OV2_9ZM?B+9?
M+P/9?&#48[SQ;#X/TQ/%-W%<+,D^HBUC%RZR)\KAI=Y##@YR.M 'R;_P55_X
M+6Z)_P $Y-4;P!\,OV2?'GQM\8V&B+K?BC2_!MK,EAX9TQBXCN-2OH[><6ID
M\N1D0QGY(V=B@*%^@_X(]?\ !9;X _\ !87X1ZYXT^&'A/4O"GB?PC=P6_B_
MP;JURD\EEYZNT$\4Z!1/!)Y4JARJ,&B<,@&TM](_%+QO\'/V;OAKXT^/OQ#E
MTOP_H6FZ?-KOC+63;I&9DM[5$::8@ S2"""*)<Y8K'&@Z**_*/\ X-__ -AC
MXK?L6_L#?M"_\%!_%/@J;PEXH^,NBW_B'P1X/:+RY=%T:UM[VYT_<G'EO*]R
M6"8XBC@/!9E !]'>,O\ @N]X=O=)^./Q<_9Q_9PF^(7PL_9RU2+3_B;XS3Q@
MEA=7<P<BZ_L:S-M*FH+;J"[O-<6BN!F,R @GW/XD?\%0_P!F'P3^PMHO[?WA
M:ZUKQEX4\6V5JW@;1/">DO=:OXBOKG<(=.MK4?,UUN217C./+\F4M@1MC\0_
M^"(JB7_@VS_;NNYV+/);ZOO=CDDC0X2,GZFOO?\ X-%+E_'/_!(7P\?&.D6]
MXW@SXG:_;^$[F[MU=[&.14DD:!F!,99KRZ0E<9$C@\$B@"7]@_\ X.@_A?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAM?%::=9?&'2M7T6W\/Z_H"7;1K?ZL\-WYB.+-4?RC;^>DBJD6Z-C&/W%HH
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MX@_9@\1?#+_A4=MI]I\7_''BC4=-;3K&+3M.CTU7L#;74KZA)-&)94"*%4E
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M\*;\;:3JNGQZ?#9W<7V65-5>XN8Y;26VA$;,?+=9BK>66) KZ=T;]DK]NO\
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MH6W^*-C>_$'X8>++32H- \8>&EU9)+JVT;_1 ]I+!8 DQ)*)I/)F#+(L@DB
M/W*E,HB8P(K.%.Q7;:">P)P<#WP:^(OV"_\ @M#I'[:W[?\ \6O^">FH_LYW
MWA+Q-\((-1;7-9_X2:._LKR2SU&&Q=8,01/M9I0ZLRJ=HY4$X'V_7\^G_!,C
MX3?$OXU?\'(7[;G@3X<?M$Z_\,OM$OB@ZIXA\):=93:JT'_"06H$-O)>Q30V
MY+E&:0PN^U"J%&;>H!_0717X^_\ !%'_ (*%_ML?M0_';]IS_@D9^T]^TCJ5
M[XZ^%-WJ]MX,^,>F:-8IJ<,=EJ;:;,\L3PM;SE93;R)YD;$K)*K,WR%<O_@A
MM_P5 _:T\5?M#_M0?L<?\%7OVI]5E\<?";2+N[M+Q],TRQM[+3["2:+4[R'R
M+./>\>;:9&?S%:.3<$PI) /V6KRW]L?]LW]G7]@GX#:K^T?^T_\ $"#P]X9T
MLK$)"ADN+ZY<'R[6VA7YIIGVG"+T"LS%55F&-_P3V\.?M"Z'^R9X3U3]J?XJ
MZ]XL\<Z_8+K&LS>(;&RMY],^T@2QZ=Y=E;PQ@V\;)$[;26D61LX8*/PX_P"#
MU?XG^.=?_:Z^!_[.M_JT]MX1M?!<FM1('*PO?7=_+:RR,.C-'%:Q8)SM$K8Q
MO.0#]:/V9/\ @H3^W7^V?\*;/]HSX ?\$W-)TOX?:Y!]L\)W7Q3^,IT36=;L
M6YCN8K"TTF^CB60?,GG7$892&!*,K'J/V0_^"F=O^U-^U-XV_8^\1?LN^.OA
MMXS^'/AJUU/Q?9>-&M-@DN)VCA6SDM998[RW94:1;E652"HVYW!??+R_^'G[
M/_PKA-T/[)\,^%]*@MHQ;VDDJVEK$JQ(-D2LVQ5"Y(&% ). ":\%^!W[>G_!
M+/\ :1_:,D\8_L\_M)>"_%_Q$?PI_95Y+X:OGNKC^R8IS<!9A&I"Q1RN[!WP
M%,K#(W\@'U!17X3> /\ @L_^T/\ MY?L[_M+_MB_#[]K#Q#\/?$7@C63!^SK
M\*?"^B0W$5U!:HMQNOXWM9CJ$UXC+$R.X2-M_EJO!'>_M\_\%\_VH[+]B[]E
M/PO\%O#S?#?XQ_M+W$=IXGU*]T3=)X52"^BTZ[>VM;Q2 \UT[&(RJ^R*-N"S
M(X /V<HK\I_B/_P4#^/G_!,[_@N=\*/^"=WCGXY>(OB5\)/C=X3TU[23QT;:
M?5O#^MW5Y>V43PW4$,32PR3VL&Z*3<J_:&*; @4X_P"RM^VW^U[_ ,%0_P#@
MLM^TA^R9J_Q_\4_"CX=_!"PU32_">@>"([6VN[K4(-16P35+N>:"1[@$K),L
M&1%AX058!S( ?KA17XU_\$'/V\O^"A7_  4%_8E_:"^.?[1G[:WB>_UGP38W
MVE:#_9_@GP]9VUG=)9K=PW]O-!IZ&29=CQO#,)(]DBMC+#;Y!_P2N_:7_P"#
M@?\ X+(?L%^/F^#O[>/AWPGXF\*?$***+QKXD\-VT,^K1/:V[_V7')9696RB
MAP\[RB":69KB.,&-%<L ?OG17YV_M3_&S_@HCX1_;D^'?P&^+VOZGX%_9JL/
MA:UY\5/V@_#FHZ9I,<FNK;2[I)[N\CD6SA^T1Q(EM$L<K-<A][1J8Z\B_P"#
M<K_@H_\ M3?MM>./VD?V1OC[\=-3\867PSUE8? ?Q#N+&W@UH6,US?6P\XB!
M8Y7 MXI4:2(L&=PVY=JJ ?K?7&_M#?$[7/@K\"_%WQA\.^#XO$%UX5\/W6K?
MV++J?V/[9';QF62-9O+D".8T?;E=I;:"5!++^+O_  1:_:2_X*U?\%;;G]IG
MX,>//^"FOB/PU!\.;K3[7P[KVC^#=%BU-;N:358X%,J6:JML3:!IPJ"9RD0C
MEA7S!)ZE_P $4O\ @JW\?O\ @I!_P2Y_:2^'?[5VK1:O\0OA)X4U&SU#Q#':
M1P/J5C>:;>_9VF2)5C\Y)+2Y1G15#*L9(W;F8 ^T/^"/7_!5KP?_ ,%>OV=/
M$'[0_@KX/ZGX+MM \:S^')-,U35([N2:2.SM+DS!XT4!2+H+MQG*$YYKT;_@
MHO\ MCG_ ()__L8>.OVO1\(]6\='P7I\-Q_PC&BS>5-=^9<Q0;FDV2>5%'YO
MF22;'V1QNVTXQ7\]'_!*S7OVU?@__P &]/[0'[4_[,O[8.H?#:T^'/Q9_M"V
MT?P_X?M9;G6;U[;1(9Q=7-PKE+=89(_+CA5"9/,,C2*41?T/^,?_  4U_;*\
M?_\ !KEI'_!4;P1\:;OPA\6M.TZR-[K&B:18/!J4Z>)DT.X::WN;>6-1+'OF
MVQJFV0C;A1L(!^C7["7[4S?MM?LA^ OVK&^%NK>"CXWT-=0/AC6VW7%E\[IC
M?M3S(VV;XY-J[XW1]J[L#UJOQD^._P#P77_:8_93_P"#=_X*?M<:CXHMO$?Q
MR^+_ )VDZ=XDU73+=8K65;B[,VHO;Q(D+F*&&-$3:$,DB,RNJLK?37@#X2?\
M%A_V=O\ @J1X!T/0/C#K/Q;_ &9_$O@0'XEZ]XWU'2O/TC7(K>X#SVJ1)#/%
MYDJ6K+%$CPXN)5(78&0 ^\_$MQXEM-!NKCP?I-C?ZFD>;.SU+4'M()7ST>9(
MIFC&,\B-_I7YO?LB_P#!P=X^_;8_; \??L/?!3_@GY>'QU\-[?5)O$<6K_$Z
MUM[4"PU"'3[@12_9&WGSYT"\#*Y/&,5^E]?S.?\ !)K]J2V_8R_X+N?ML_M%
MZO\ !'QQX\TCPWHOQ N]>TWX?VMC/?65E'XML9);PQ7=W;"2*,(-PB9Y!N#;
M"JNR@'[!?LO?\%SO@=\9_P!N;5_^":GQY^"OB[X._&G3)'2V\.>*YK2ZL]48
M6XN0EK>6LK*[-;GSDW*JNF-K,WRU]PU^ '_!+[X>ZA_P7C_X+>Z__P %E[+7
M-&\&>!?A=K^GK9^ GU/S_$,[V^GB"P>=$79'#(R/*\NY@3&\"!]K2+]=_M[?
M\%7/$7_#Y;P)_P $LM&^-EW\,/ &F^&Y->^+7C+1H%.JW\SV4MS:Z7;2M%*;
M6(@6SR2QKYK"5E5HPF6 /U$HK\;OAA_P6Q_;%^!7[%7[9VN>//#FK?$#4_V>
MO$:Q?!KXA>)/#;VB^*M$O]5?3[*ZNO+BACN3:CRIY'C"&6-QG!!<^-?M,_M^
M_P#!2S]GS_@A1\%/^"K'@_\ X*!>,)?B7\2O'ILO%UK>Z1HEQI+V-P=3:."T
MLIK!XK5XA81 ,BY)>;=D;54 _3+_ (*\_P#!6E_^"4OAWX;:^G[*GBOXH?\
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MEW']CQ:G+93W$,<8NH?+%WM>13(/*C&X@D5X;^Q1^UE_P51_; _X+*?M,_\
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M?^#@SX$_M,_#/46T[PY\0O#VI2_&:TLIPC7EIH\$,,R3H,&2WOH+JQT^08(
M.2077/Z@?M$?!C2/VC?@'XU_9_\ $'B'5-(L?&WA6_T*\U31;CRKNTBNK=X&
MEA?!"R*')&01D<@C(KQ#_@F3_P $UD_X)W?"32OAQK_[0>M_$V]\/:%_8'AG
M5];TN&S&D:,+J6Z%G!%&7(W2RYDD9V9U@MD^58$4 'U#7P1_P7H_X(G^'/\
M@L!\"]'3PAXJLO#/Q1\#-<2^"]=U"-C:744P7SK"[V N(G:.-ED56:)ER%8,
MZM][T4 ?&/[*?[:'[:_P\^!6B?#+]M;_ ()S_%E_B3X:TB*PU75O 0TG6=)\
M220H(Q>V]R+^/R6F"^8T5P(MC.5W'%?(O_!L_P#\$=_VT?V"?B;\8?C/^V)\
M-M)\+Z?\1-'@L=(\.'7K>\OU07,LKF86C20QJ4=1@2EL\%1C-?L110!^'_\
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M=;L;?4K=DM7L9HG99WAD26RD6+= \QBEC\S#KC'[)44 ?&/QG_: _;9\0_\
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MM621 [(NYU_86B@#\D?^#6[_ ()W_MV_\$ZH/C7X6_;._9IO?!B>-M1TK4M
MU,>*M&U&WE^SB[26!A8WLTB2?OT8$IL(#?," #^MU%% !1110 4444 %%%%
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M[9;2ZEN(4DF@>!71UDM9@T89A@ ACGCX4_X.7?\ E--^PC_V-VE?^I'94?\
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M@K8+XC\$>(?M*,T5V8((I;B.:'?Y<CF50;>4)*RLH !]3?LE?M?_  D_;(\
M:AXR^&4E]9:AX>UVYT'QGX3UN%8=4\-:Q;-LN-/O(E9@DJ'HRLT;J5='96!/
MJ=?CS\-OB]JW[+G_  =Z^.?@+X7N&@\-_M"?#BTO-:TF,[8#JEEHQNHKS:./
M,"V-TN>_VN0GDY'[#4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >7?MO?L]_\-9?L=?%']F9+R.VF\=^
M M5T2SNY<[;>XN+62.&4X[)(R,?]VOA__@UL\3Z_X2_X)07?P!\4^$;^+QK\
M&?B)XE\.>*/"),4=]!?+=->_9\2NB*S&ZV*SNJ%E.6 !(_3&O+=/_9(^&?AC
M]IJ^_:M^'-UJ'AGQ)XBL8K/Q[:Z.\:V/BV*"-TM7OH71@;BWWGR[F(QS;?W;
ML\>$ !^9_P#P;O?L&_\ !03_ ()Y?'#]IKXA_M1?L9>(-)L/B=<V>K>%!I_C
M#PY>O.]K<:G,;1A%J9\N9Q>QA&8B+*MND08)\=_X)1_\$I_^"GO[(W_!,_\
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M$WQMTF[U3P])X&N;%K_2-7DO?MO]FW-O=7$+)$7DN$2X7>@7R=Y4E]OZPT4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ;W;\W=G\\9EFN8YQB7B,;5=2;ZM_@ELEY*R"BBBN\\\**** "BBB@ HHHH
M**** /JS]C'_ (+ ?M7_ +(LUIX;N_$#^-O!\.U&\,^([IG,$8[6UP<R08'
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M=.NXKBWN(ED@G@D#I(C#*LK#@@@@@C@@U_*O\%_^"DWBSX4_\$MOB9_P;O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#R?7[$Z;K=U9;<".=MH_P!G.1^F*IUU'Q2TPP:K%J:+\MQ'M8_[2_\
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MY_9BOYK\7LSCB^(*>$B]*,-?\4]7_P"2\I_3G@YE<L)P[4QDEK6GI_AAHO\
MR;F"BBBOR<_7 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/
MB=:W4_@F_N]/TXW=S9P-<6]LK[3*R G8#@X)&0..I%?&_BSXX>.O$Y:""_\
M[.MCTAL258CG[S_>/!P<$ ^E?<]?%_[4/PJ;X9?$F>;3[79I>K%KFP*CY4)/
M[R(?[K'@?W66OT+@.O@IXF>&K13EO%ORW7:_5?,_.>/\-C(8>&*H2:BO=DEY
M[/O;H_D>;DDG)-%%%?K1^0A1110 5SOQ"^(%KX*L?)MMDNHSIFWA;D1C_GHP
M]/0=S["I?'OCNQ\$:<'(6:^G4FTM2>W3S']$!S_O$8'1BOB^HZC?:O?2ZEJ5
MRTT\S[I)'/)/]/IT%>YE.5/%2]K57N+\?^!W^X\'-\V6$C[*D_??X?\ ![??
MV&7EY=:A=R7U]</+-,Y>661LLS'J2:CHHK[-))61\4VV[L],^#O[7GQ]^!T:
M6'@OQQ-)IT?32-37[1; >BJW,8_W"M?0/@__ (*XWJ0K#X^^#44LF!ON='U0
MHI/?$<BMC_ONOC*BOF<UX,X8SFHZF*PT7)[R5XM^KBU?YW/J,IXVXIR6FJ>%
MQ4E!;1=I)>BDG;Y6/O<_\%:/@]Y61\-/$N_'W2;?&?KYG]*Y7QA_P5QO7A>#
MP!\&XHY,?)<ZQJA=0?>*-5S_ -]U\945X]#PQX-HSYG0<O6<K?<FOQ/:K^*7
M&M>'*L0H^D(7^]I_@>F?&/\ :\^/GQRCDT_QIXWECTV3[VCZ8OV>V(]&5>9!
M_OEJ\SHHK[7!X'!9=05'"TXP@ND4DOPZ^9\/C<?CLRKNMBZDJDWUDVW^/3R"
MLOQGX+\-_$#P]-X8\5Z<+BTFY&#AXG&=LB-_"XR<'T)!!!(.I172TI*S.5-Q
M=T?&OQF^"'B7X0:L!=YN]*N)"+'4T3"OWV./X'QV[X)!(!QQ-?>VMZ'H_B72
M+C0?$&FQ7EE=1[+BVF&5<=>W((.""""" 000#7RE\=_V>=9^%%V^MZ,9;[0)
M9,173#,EL2>(YL#&>P< !N.A.VH3<7:7WEN*DKQ^X\VHHHK0S"BBOJS_ ((_
M?L92_M=?M8:?=>)-+\[P?X)>+6/$K21YCG*OFWM#V/FR+R#UCCE[XK@S3,<-
ME&7U<9B':%--O]$O-O1>;/0RK+<3G&8TL%AU>=1I+R[M^26K\D?K!_P22_9;
MD_96_8J\-^'M<TXV_B'Q*#K_ (C21,/'/<(ICA8'D&.!84([.KGO7TQ117\7
MYECZ^:9A5Q=9^]4DY/YO;T6R\C^VLLR^AE67TL'1^&G%17R6_J]WYA1117$=
MP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!\/?M]_\%3-4^!G_  4*^"G_  3#^&'B'PQX
M4\4?%NQFU35/B!XVM'N;+1K$?:DMK>WMUFA$][=3VDL$?F2JB,8\I,7"5S__
M  3U_:5_X*8ZG#^SWK7QYU[PI\3?AQ\9]#OAJGBVV\-/I>M^%M5@L;J\B2X$
M$C6MU;SK:NBR+% 4?Y6R2F^__P %KO\ @B5\!?\ @L'X3L8QX]C\'_%[P3IA
M;POXF@ F"VLSN4MKZW!#O;/+%*4D&&C=9&3</,C?\Z_^#>7_ (*L_MM?LN?M
M&_#/_@D]^V_X4GU#P3X\T3S?@_XCN8 L]C;M'/);F*91B[LI6@EB&\&6&3Y2
MRA&C4 ^N/^"Q7QL_X+\_"WX0^,_VT/V2_&_PY^&WPP^'HENV\'7NEPZCXFU?
M2H9-DFHW+7=M+;0[@#,MM$R2) 1O<S9B'UA_P1M_;8^)?_!0W_@G)\.?VLOC
M!X(M]!\2>([6\BU6WL8GCM;F6UO)K4W4"N2RQR^3Y@4D[2Q4%@ Q\T_X+Z_L
M+_MJ_MX?L2>(_A=^R-^T8?#H72WN-;^'QT:(KXS2%O.%E]NSYMJS%%"J/W<C
M!4DVJS,.,_X-;OVU?B_^VE_P2]M;KXT:791ZC\-O%UQX*T^^T_3(K..]L;6S
MLIK<F&%4C1XTNA"=BJ"(58_,6- 'JO\ P7+_ ."HK?\ !)W]AJ^^/OACP]8Z
MQXSUS68= \#:7J18VS7\T<LIGG5"&:**&&60JI&Y@B;EW[A\^^,?^"F_[3?_
M  3N_;L_9C_9]_:O^-[_ !+\%_M(>%;2+5M4U;P_IVG7/A?Q'+)%$'M&L+>!
M6T]IKF!#%<"66-27,[;2K>$_\'O6B>([C]ESX'>([5)#I%IX_P!2MKY@/D%S
M+8JT /OLAN,?0UYG_P '/FD:[XI_:Z_8-\,>"T=]5U"RM[?2EAY9IY+_ $M(
M@N.^\C% ']!=%%% !7'?''X4V7Q=\!7'AV3:E[%^^TRX;_EG, < G^ZPRI]C
MGJ!78T5OAL36PF(C6I.THNZ9ABL-1QF'E0JJ\9*S1^=VJ:9J&BZE/I&JVCP7
M-K*T5Q#(,,CJ<$'\:@KZC_:V_9^?Q5:2?$[P;9%M2MHO^)G:Q+S<Q*.) .[J
M.H[J/4 'Y<K]]R3.*&=8%5Z>DMI+L_\ +L^WS/Y[SW)L1DF/="IK'>+[K_/N
MN_E8*Q?'/C?3O ^F"YG19KR93]BLR?O]M[XY" _BQ&!CEE?XS\9Z;X)TO[==
MJ);B4$6EIG!D;U..0H[GOT'J/%-:UK4O$.IRZOJ]R99YFR['H!T  [ #@ <
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M\$;OB%H/C3X,_M6?MS^-K&?QO\'/AU+X<^'G@CPWI4<-IX;DF:?S[VYN3<7
MU"[(G8(RB.&,;2(V<;Z_1BB@#X,_8^_8&_X+ ?LHIXB^&>K?\%7=%^)?@[5[
MN>;2=<^)OP\O-5\1Z+YA)S!.=217(SPLQEB5E#+&%W1MU7Q1_P"".WPVB_X)
M+>(/^"6'[*GQ0UCX<V6K:8L:^-!FYOKN[-Y'=7,]X4:(S?:FC:.8*4'ERE%
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MLBI7V7^P?^PC/=3V7QN^-FC;($VSZ!H-U'S(>JW$RGHO=4/7ACQ@-U7['O\
MP3NT[P!+:?$OXZ6L%]K:8EL-"R)(+%NH>4])91V RBGGYC@CZOK\&X]\285H
M3R[*)Z/2=1=>ZAY=Y?\ @/<_?N /#&=&<,RSB&JUA3?3M*?GVC_X%V"BBBOP
MT_> HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^"OC#_R5
MSQ3_ -C'??\ I0]<Y71_&'_DKGBG_L8[[_TH>N<K^DL#_N5+_#'\D?S+CO\
M?:O^*7YL^K_V%/\ DD>H_P#8QS?^D]O7M->+?L*?\DCU'_L8YO\ TGMZ]IK\
M+XG_ .1_B/\ %^B/WOA?_DG\-_A"BBBO!/?"OA3_ (*EVTG[-G[7O[,O_!0!
M+V[C\*Z9\25\$?%/3UO)%LI+/6H6M-/U6YBW>6397OE8E*E@+@#/RKM^ZZ\B
M_;X_97T7]MO]C/XD?LJZW+%#_P )IX5N;+3KN;.VSOP/-L[GCG]U<QPR\?\
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M5T/Q!XTMM M(M/WM#"!<3JY>XN)HYUC4(5)@E:66(;6?A/VP?V&/VEOVCO\
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M-#>$>8L<C-Q@KM:I/%G_  4MU/P'^RYXR_:^UC]GF;7_  5X9^&T/C32M:\
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MMCIDI$2)(((X]P")^N7BSPGX>\<^&[SPCXKTQ+S3[^$Q7-N[,N1U!5E(9&!
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MF&6-N8WEM;1+HH?F4705@&4@?4] !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>jnj-20220703_g10.jpg
<TEXT>
begin 644 jnj-20220703_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHKY3^,?[2?QJ\*_%'7/#F@>-/(L[._>.VA_LZV?8HQ@9:,D
M_B:]C)LDQ6>5Y4J$HIQ5_>;76W1,\;.L\PF14(U<1&34G;W4GTOU:/JRBOBW
M_AK/]H'_ *'_ /\ *5:?_&J/^&L_V@?^A_\ _*5:?_&J^C_XA]G7_/RG]\O_
M ) ^:_XB+DG_ #[J?='_ .3/M*BOBW_AK/\ :!_Z'_\ \I5I_P#&J/\ AK/]
MH'_H?_\ RE6G_P :H_XA]G7_ #\I_?+_ .0#_B(N2?\ /NI]T?\ Y,^TJ*^+
M?^&L_P!H'_H?_P#RE6G_ ,:H_P"&L_V@?^A__P#*5:?_ !JC_B'V=?\ /RG]
M\O\ Y /^(BY)_P ^ZGW1_P#DS[2HKXM_X:S_ &@?^A__ /*5:?\ QJC_ (:S
M_:!_Z'__ ,I5I_\ &J/^(?9U_P _*?WR_P#D _XB+DG_ #[J?='_ .3/M*BO
MBW_AK/\ :!_Z'_\ \I5I_P#&J/\ AK/]H'_H?_\ RE6G_P :H_XA]G7_ #\I
M_?+_ .0#_B(N2?\ /NI]T?\ Y,^TJ*^+?^&L_P!H'_H?_P#RE6G_ ,:H_P"&
ML_V@?^A__P#*5:?_ !JC_B'V=?\ /RG]\O\ Y /^(BY)_P ^ZGW1_P#DS[2H
MKXM_X:S_ &@?^A__ /*5:?\ QJC_ (:S_:!_Z'__ ,I5I_\ &J/^(?9U_P _
M*?WR_P#D _XB+DG_ #[J?='_ .3/M*BOBW_AK/\ :!_Z'_\ \I5I_P#&J/\
MAK/]H'_H?_\ RE6G_P :H_XA]G7_ #\I_?+_ .0#_B(N2?\ /NI]T?\ Y,^T
MJ*H>%;VYU+PQINHWLN^:XL(9)7V@;F9 2<#@<GM5^OAIQ<)N+Z'WD)JI!277
M4****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYB,D"?8YI=R@XSF-& Y]:P?^&L_V?O\ H?\ _P I5W_\:KR7]O/_ )'30O\
ML%O_ .C#7@]?IN2<%Y7F65TL35G-2DKNSC;=KK%_F?EV><;9KEF;5<+2A!QB
MTE=2OLGK:2_(^TO^&L_V?O\ H?\ _P I5W_\:H_X:S_9^_Z'_P#\I5W_ /&J
M^+:*]7_B'V2_\_*GWQ_^0/)_XB+G?_/NG]TO_DS[2_X:S_9^_P"A_P#_ "E7
M?_QJC_AK/]G[_H?_ /RE7?\ \:KXMHH_XA]DO_/RI]\?_D _XB+G?_/NG]TO
M_DS[2_X:S_9^_P"A_P#_ "E7?_QJC_AK/]G[_H?_ /RE7?\ \:KXMHH_XA]D
MO_/RI]\?_D _XB+G?_/NG]TO_DS[2_X:S_9^_P"A_P#_ "E7?_QJC_AK/]G[
M_H?_ /RE7?\ \:KXMHH_XA]DO_/RI]\?_D _XB+G?_/NG]TO_DS[2_X:S_9^
M_P"A_P#_ "E7?_QJC_AK/]G[_H?_ /RE7?\ \:KXMHH_XA]DO_/RI]\?_D _
MXB+G?_/NG]TO_DS[2_X:S_9^_P"A_P#_ "E7?_QJC_AK/]G[_H?_ /RE7?\
M\:KXMHH_XA]DO_/RI]\?_D _XB+G?_/NG]TO_DS[2_X:S_9^_P"A_P#_ "E7
M?_QJC_AK/]G[_H?_ /RE7?\ \:KXMHH_XA]DO_/RI]\?_D _XB+G?_/NG]TO
M_DS[2_X:S_9^_P"A_P#_ "E7?_QJNP\%>.O"OQ$T0>(_!VJ?;+,RM&)O(>/Y
MEZC#J#W]*_/VOK[]BS_DB<?_ &%+C_V6OGN)N%,NR;+?K%"<W+F2]YJVM^T4
M?1\+\6YEG>9_5Z\(*/*W[J:>EN\GW['K5%%%?GQ^B!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?#/[0G_ "6SQ+_V%'_I7W-7PS^T)_R6SQ+_
M -A1_P"E?H'AY_R,JW^#_P!N1^=^(W_(LH_X_P#VUG&T445^N'X^%%%% '%_
MM"? #X7_ +4/P?UKX&_&/0/[1T#7;<1W<*R%)(V5@\<T;CE)$=5=6]5&01D'
M\]O@K\7/C]_P2%^*WBKX;_&&ZO/B)\ S\0[+0[CXBW!SJWAV]ET?3'MS=+N.
M^V6UDM8/3_1\IL.V%_OG]I+X8_%+XD^%M&G^"WQ"L/#?B7PYXEMM8TZZU;37
MNK2Z$:2QR6LR)(C".6*9T9E.Y0<@9P1X!XC_ &0OVA?VK+[QW\,/VC[/PQX:
M\!ZY\3]+U[Q';:!>7%]/XCBL](T=$MH))H81;VS3V@\R0AY-T<D:@ "5_GLV
MP]:IB(U</%JM'X9+9JS]V7]V^]]4G>+N?1Y/B*-/#SI8F:=&7Q1>Z=X^]'KS
M6VMHVK25D?4OQ+TGXBZYX+O=*^%/C33?#VN3Q%;+5]5T-M1BMB01N\A9X=Y'
M!&7QQR&'%?)G_!+/Q]\>OA_\5?BQ^PO^TQI^CWWBGP3J<7B%/&FB6GE+XDAU
M1Y)GNK@8&9BV/FP.,QX_= M[C\3M*_;LMOC7%KWP7\5_#.[\!RZ9'%=>'_%=
ME>P7T%R&.Z6.XM]X<$$?*R@#&,9^8ZWP-^ $OPV\8>+/C#XX\0P:WXX\<S6I
M\0:I:6)MK:"VM8S':V5M$7=DAB5G.6=G>261R0"J)V5:=6OCZ=6"E'D;3O\
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MQ_PL?_A4'_"::?\ \)/_ &?]N_L3[0//\C.-^W]<=<<XQS0!T%%%% !1110
M4444 %%%% 'Z">!_^1+T?_L%V_\ Z+6M2LOP/_R)>C_]@NW_ /1:UJ5_-.(_
MCS]7^9_3V'_W>'HOR"BBBL38**** "BBB@ HHHH ^7_V\_\ D=-"_P"P6_\
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M17KGC!1110 5]??L6?\ )$X_^PI<?^RU\@U]??L6?\D3C_["EQ_[+7Q?'O\
MR(O^WX_DS[?P_P#^1\_\$OS1ZU1117XN?MH4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7PS^T)_P EL\2_]A1_Z5]S5\,_M"?\EL\2_P#84?\
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M,D&R0@ ./EW=5ZBCXD>&_&_BC0H+#P#\1&\,7L>HP3RZ@NEQ7GFP(V9(-DA
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M_P#R/G_@E^:/6J***_%S]M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^&?VA/^2V>)?\ L*/_ $K[FKX9_:$_Y+9XE_["C_TK] \//^1E6_P?
M^W(_._$;_D64?\?_ +:SC:***_7#\?"BBB@ HHHH *Y__A57PX_X6/\ \+?_
M .$+T_\ X2?^S_L/]M_9QY_D9SLW?IGKCC..*Z"B@ HHHH **** "BBB@ HH
MHH _03P/_P B7H__ &"[?_T6M:E9?@?_ )$O1_\ L%V__HM:U*_FG$?QY^K_
M #/Z>P_^[P]%^04445B;!1110 4444 %%%% 'R_^WG_R.FA?]@M__1AKP>O>
M/V\_^1TT+_L%O_Z,->#U^]\*?\D]A_1_FS^?N+O^2CQ'JO\ TE!1117T)\X%
M%%% !1110!\/_MG?\$G_ /A:'Q'M/B'^SS-I^C_VQJ"KXFTRY.R"WW'+WD('
MXEHAU)RN,D5]0?LV_LV_#C]E[X<6_P //AY8>DFIZG,H\_4)\8,LA'Y!1PHX
M'<GT"B@ HHHH **** "BBB@ KZ^_8L_Y(G'_ -A2X_\ 9:^0:^OOV+/^2)Q_
M]A2X_P#9:^+X]_Y$7_;\?R9]OX?_ /(^?^"7YH]:HHHK\7/VT**** "BBB@
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M%WOP3U71]+TW]G/P_:WGV+4M*^T_\)+>?8I+^ZBF?>K00K#%Y*"/#F1BY<J
MA^=?^'B?[!$'_!5/X<_$[X=_$O[-X"T'X+3^%K:6U\&ZK"EI=&\/D6J6YM1(
M$$94!@GEJ."PQ7V'\7_V!(_'GB;XI:GX ^+,GA;3OC9HEIIGQ)L5T1;N2X2"
M%[9IK.0RHMK-):R-"Y=)E.%<(&!+>+A\3B\?1JJA54W&<K\LELX/EL[Z+GM;
M75)[ZW]S$8;"9?6I/$4734J<;<T7NIKFNK:RY+WTTNMM+>A:#^TYX!U#]EG1
M?VL-9CN++0]9\)6&N16:)YMR?M<,;PVL:#F6=WE2)$49>1E4#)%;GP5/Q6N/
MA]:ZO\:3;0^(-1EDO+G2[)5,6DQR.6BL0Z_ZYH8RJ/*?]8X=AM4JJ^!7WB;X
M6>&?"ES\7M1MI+7X'_LY:-)#X6LK<>8-:U/3H# ]R@8XECM AM8,G#W)FD_Y
M8PO72_"']MGQ!XE^*GP_^%7QC^%UGX8N_BMX(E\2^!Y-/UQKT$0I'-/87(:"
M+9<1P2QR;DW(W[Q<C8I?UJ6-@JL56GK9)6O9MM+F\DY:1O:^K5[JWCU<#-TI
M.C#2[;O:Z25^5=VHZSMMHG:SO]!T445ZQY 4444 ?H)X'_Y$O1_^P7;_ /HM
M:U*R_ __ ")>C_\ 8+M__1:UJ5_-.(_CS]7^9_3V'_W>'HOR"BBBL38****
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M<UEJ[M)6>UK'7#.L0L%4P\XQ?-&,4^2":2MN^6[T5DV[K=.Y\^_'GQ9\,/\
M@HC^Q_\ &GX*_LU_$"UUW5K2RU+PW=I'#+"L&L11[EMV:5$W*T@5?-7<A!)#
M'!KR_P"'WQ3^%?C'_@B)<>&?%PB@N-"^$4O@G7O#ES'B]M]=MK$V"V!@/SK=
M/<(GEQXWL9(RN<@U]F>'?!WA'PA]M_X1+PKINE_VE?R7VH_V=8QP?:KI\;YY
M-@&^1L#+MEC@9-47^$OPJD\;CXFR?#/P\WB0*%'B!M%@-\ !@#S]GF8QQ][I
M3JX"O5J>U<ES.#A+1VLW=-*[VUTOK?=$TLPH4J?LHQ?+&:G'57NE9INR6NEG
M;2VS/.O^"?7PJ\:_ ;]B+X9_"SXGL8M;T/PC;1ZK#-)DVDA!D,#'I^Z#",XX
M^3CBH_@]')^T?\3%_:@U="WA71UGL_A1:./EN(W!CN=<(/\ %<#,5N>UL&<'
M%VRCUWQ#X?T7Q9H-[X7\2:;%>Z=J5I):W]G.NZ.>&12KQL.ZLI(([@U/965E
MIEE#IVG6D5O;V\2QP001A$C11A551P    !P *ZH814X4Z2?N02^;6BOZ;^M
MGT.2>+=2=2JU[\V[]DGJ[>NWI=:WT_*SQIK'C&#]C+XH?M"RVY_X7QIG[5HM
M-#U IG4HKU-3M+>WTV)_O_9_L+NBP [&BD;@ACG]6*Y6\^!OP7U'XA1?%J_^
M$WAN?Q1"ZO%XAET6!KU'5#&KB8KO#*A9 V<A6*@@$BNJKGR[+YX*4G*5[I+U
MLY/F?]Y\VOHM3IS+,:>.C%1C:S;]+J*Y5_=CRZ>KT"BBBO4/*"OK[]BS_DB<
M?_84N/\ V6OD&OK[]BS_ )(G'_V%+C_V6OB^/?\ D1?]OQ_)GV_A_P#\CY_X
M)?FCUJBBBOQ<_;0HHHH **** "BBB@ HHHH **** "BBB@ HKYCUW_@D_P#L
MW^(-;O-?O?'?Q.2:^NI+B9(/B'>(BL[%B%4'"C)X Z"JO_#H?]F;_H?_ (I_
M^''O?\: /J:BOEG_ (=#_LS?]#_\4_\ PX][_C1_PZ'_ &9O^A_^*?\ X<>]
M_P : /J:OAG]H3_DMGB7_L*/_2O0/^'0_P"S-_T/_P 4_P#PX][_ (T?\.A_
MV9O^A_\ BG_X<>]_QKZ#A[/?[!Q,ZWL^?F5K7MU3[,^=XCR#_6#"PH^TY.5W
MO;FZ-=T>&T5[E_PZ'_9F_P"A_P#BG_X<>]_QH_X=#_LS?]#_ /%/_P ./>_X
MU]=_Q$?_ *A?_)__ +0^/_XAK_U%?^2?_;GAM%>Y?\.A_P!F;_H?_BG_ .''
MO?\ &C_AT/\ LS?]#_\ %/\ \./>_P"-'_$1_P#J%_\ )_\ [0/^(:_]17_D
MG_VYX;17N7_#H?\ 9F_Z'_XI_P#AQ[W_ !H_X=#_ +,W_0__ !3_ /#CWO\
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M\1'_ .H7_P G_P#M _XAK_U%?^2?_;GAM%>Y?\.A_P!F;_H?_BG_ .''O?\
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MV+/^2)Q_]A2X_P#9:\S_ .'0_P"S-_T/_P 4_P#PX][_ (T?\.A_V9O^A_\
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M/6OCKQ-!//H/@^358O[2O888GEEE2W!\SRU2-R7("\8SD@4 =C1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>jnj-20220703_g11.jpg
<TEXT>
begin 644 jnj-20220703_g11.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M%%% !1110 4444 %17]_8Z58SZIJEY%;6UM"TMQ<3R!$BC4$LS,>%  ))/
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MX_:9\ M5^'S:#XMFT.?3KW5AJ$%R5ABF66&Y$,._Y9E#IL!1N,L"#7T;\/\
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MXET/Q9_PA_Q3^%GB:'Q+\)OB!%9B=M'U.)T?RIHLJ9[.;RHUFAW#<$4YR@H
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M%+&P974C(((X((YS3Z* "BBB@ HHHH **** "OD#_@OQ_P H;/VA/^R?S?\
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M;- 'QS_P<>_'[4_@I_P< _L<^-/BS>O!\-?!*>'M?$MP?]&MI3XCF_M&X&>
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MYI6:25MH7,CLS,3EB22: -+_ ()VJT?_  >+_'177!/_  DY /O%;$?I3?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXD?MCZ5XVN["]\6?#'PWH\?B:V^$NMK+=WL-]K#ZAE5L?,#M"=(#R, )%AA
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M]KO_ +>/_3Y/7[_5^ /_  :;?\I3/VN_^WC_ -/D]?O]0 5\Y_M_?MO?$/\
M8KN/ FH>!/V4?'GQ@3Q3J5]8WWAOX;:4+O5+416XF2[",0ODJ5,;[BO,R8.0
M%;Z,J)[*SDNX]0DM(FGBC=(IVC!=%8J64-U )521WVCT% 'Y@+^W]X-.O:UX
MIN?^#:S]HJZU+Q#JSZGK5]??!_3+B6[NW1$>5FDF8Y(C7.."03U))^J/^"6W
MQAT?XW?#3X@^,-&_8RU?X$)%\39K67P)XAT!-,U .FD:6?M=Q;Q_NT>4,I4I
MPT:QMDDDGZ5U/5-,T6QDU/6-1@M+:( RW%S,L:("<#+,0!R0/QI;2UL(6EN[
M&VA0W<@EGEB0 S-L5 [$?>.Q47)[*!T H FHHHH ***\"_;Y_;Y\'_L#>#]!
M\8^,? 6HZ]%KVHRVD46G7,<1A*1[RS%^H/3BJA"=2:A!7;T26[?9$SG"G!SF
M[):MO9+NSWVBOS?_ .(D'X%?]&\^)O\ P;6_^%'_ !$@_ K_ *-Y\3?^#:W_
M ,*]3^P,]_Z!:G_@N7^1Y7^L&0_]!=+_ ,&0_P S](**_-__ (B0?@5_T;SX
MF_\ !M;_ .%'_$2#\"O^C>?$W_@VM_\ "C^P,]_Z!:G_ (+E_D'^L&0_]!=+
M_P &0_S/T@HK\W_^(D'X%?\ 1O/B;_P;6_\ A1_Q$@_ K_HWGQ-_X-K?_"C^
MP,]_Z!:G_@N7^0?ZP9#_ -!=+_P9#_,_2"BOS?\ ^(D'X%?]&\^)O_!M;_X4
M?\1(/P*_Z-Y\3?\ @VM_\*/[ SW_ *!:G_@N7^0?ZP9#_P!!=+_P9#_,_2"B
MOS?_ .(D'X%?]&\^)O\ P;6_^%'_ !$@_ K_ *-Y\3?^#:W_ ,*/[ SW_H%J
M?^"Y?Y!_K!D/_072_P#!D/\ ,_2"BOS?_P"(D'X%?]&\^)O_  ;6_P#A1_Q$
M@_ K_HWGQ-_X-K?_  H_L#/?^@6I_P""Y?Y!_K!D/_072_\ !D/\S](**_-_
M_B)!^!7_ $;SXF_\&UO_ (4?\1(/P*_Z-Y\3?^#:W_PH_L#/?^@6I_X+E_D'
M^L&0_P#072_\&0_S/T@HK\W_ /B)!^!7_1O/B;_P;6_^%?9'[%W[6'AW]M'X
M'V_QP\+^$[S1;2XU&XM%L;^=)) 8F +93C!S7+BLOQ^!2>)HRA?;FBXW]+I'
M7A<QR_'-K#5HSMORR4K>MFSUBBBBN,[ HHHH **** "BBB@#E?B/\"O@C\8I
M[2Y^+GP<\*^*I+!'6QD\1^'K:^:W5R"PC,R-L!*KG&,X&>E<U_PQ%^Q?_P!&
MB?"__P ('3O_ (S7I]% 'F'_  Q%^Q?_ -&B?"__ ,('3O\ XS5K0?V0?V3/
M"VMVGB7PQ^R]\.M-U+3[E+BPU"P\$V$,]M,C!DDCD2(,CJP!# @@@$5Z+10
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MVM[236GWG\N7]GWO_/NU']GWO_/NU?T[?\*0^"W_ $2'PO\ ^""V_P#B*/\
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M""V_^(H_X4A\%O\ HD/A?_P06W_Q%'_$9<]_Z!Z?_DW_ ,D'_$%<A_Z"*O\
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M]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110 4444 %%%% !1110
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MR)Y;.J@()-X4*N%'4_\ !1:PL=4\7?LVZ9J=G%<6US^T9817%O/&'25&T'7
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M4 #+$G   ["NCK\?/^"E'[/&C?L>?"/]E7_@H)\*/B5XZ_X6S_PN/P/HVO\
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MUW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@
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MXXD?=U^6OTFK\P?^"7__ "L)?\% O^N/@O\ ]-YH [#]N;]L[_@I_P#L0?\
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M_*4S]KO_ +>/_3Y/7[_5^ /_  :;?\I3/VN_^WC_ -/D]?O]0 4444 %%%%
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ML/!FJ:M=P100+ L\5G<74,)FVH&'F.\>[JC#BOK>B@#YS_X)U_\ !-+X*_\
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MX=_9/\:>'/#?CR^M/(T+Q#XKL)+NSTUF(#7!@C_ULB+DHK?)OVE@R@JWP?\
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MWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\ T8]\0/\
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M^P[\2OV3_"W[)'C30]0\=>&WTVTU;4-<M)(;5V=&WNJ#<1\O0>M 'X6T444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>jnj-20220703_g12.jpg
<TEXT>
begin 644 jnj-20220703_g12.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M5^(/_![S_P FL_ __LH&H_\ I"* //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\
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MAQ>> /%NK>$G\6:)\/\ 6_$>@C3;+3KK3-8CMH]4U-[4-(\8MDG411(0]Q/
M#M3<R@'[DT5^3_Q/_P""H_\ P4O_ ."2?_!('6/CY_P51\/^&/$'Q\UGXCW.
M@?#32;(V8M)[>6!9()[T::5C*1"&]D(CVLZ"WC=D>1F7B_VK?^"GW_!23_@F
M/^Q;^S1_P4@^+_Q[M/BQHWQ;DTT_$GX:ZGX/TW3;?3EU'3CJ44>E7-E#'/$\
M422Q;KE[@.ZJQ !*T ?LI17Y5_\ !P3_ ,%;OVF?V(?V1O@O^V?^P?\ $_21
MH?Q.NH(TLM>\-07D-S9W-@;ZVNT+8>-RF R[F4@K@*02W@/_  5 _P""K/\
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M_ __ +*!J/\ Z0B@#S__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\
MV\?^GR>OW^H **** "BBB@ HHHH **** ,;Q]\1?A_\ "GPK<^.OBAXYT?PW
MHED%-YK&O:E%:6L&2%&^65E1<D@#)Y) K^;7_@V!^-'PK^''_!;;XR>.OB1X
M[TWPYHOC'P7XDMO#.JZ_=+96^H7$WB#3KF*&.28JID>&*1U7.2$.!FOZ8Z*
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M]OI&F6]K')*TLB6T*QAG;JQ"@9)[GJ: /YLK'4/AY_P1*_X.#OBUXB_X*1_
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M2=<F\1Z=J<&DZG=I;W$UE':3"2X2.0AGC0@[W (3(W$9&?/O^"#'Q1^&B?\
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M*#Q!'!X/\83^%O$-IXF\.7.E7=GJL%M:W$]N]M=(DJ-&+I(VW*/G5]NY=K,
M=^?B-\/1\0A\)#X[T;_A*SHQU<>&/[4B_M Z>)?)-Y]FW>9Y'FD1^;MV;_ES
MGBMFOAC_ ()E'_AI?]N_]JG_ (*!7G[_ $UO&EM\*/AY,_(32?#Z$7TL+=&B
MN-2N)WR."8..F3]ST %%%% !1110 4444 %%%% !7X@_\'O/_)K/P/\ ^R@:
MC_Z0BOV^K\0?^#WG_DUGX'_]E U'_P!(10!Y_P#\&FW_ "E,_:[_ .WC_P!/
MD]?O]7X _P#!IM_RE,_:[_[>/_3Y/7[_ % !1110 4444 %%%% !1110 5_/
MY^WGX@UO6?\ @\G^#FE?%&1FT72;CPW;^$TNS^[6)K"6:/R\\?\ (0EFQC^/
MWK^@.OCO_@IM_P $5_V:/^"FGC/P9\:?%GC/Q5X ^)OP^GB?PK\1/ MW%#?P
M)%/Y\44GF(XD6.;,L9&UXW9BK89E8 _,'_@X$A@C_P"#H']C*2*)%:0_#UI6
M50"Q_P"$TO@"?7@ ?04__@[=_P"4E_[(_P!$_P#3S;5]R_$W_@VL_9>^./[3
M/A#]KSXU?M6?'#7_ !_X3LK!AXD?Q19Q76H:E:7<EQ#?2,+0B#9NBC2&V6&-
M%MT."Y=G[?\ X*"?\$%OV<?^"DWQN\)?'KX__M)_&.SU?P-I\%KX6M?#.J:+
M;V]B8Y%E,V)M*EDDD>51(QD=AGA0JX4 'Q__ ,'$'_!-K]M+QQ^U[HO_  5"
M_P""7_Q,O[GXJ?"[PC8P>*/!GAR\QK=G:"6\:VO[2(Y%S'*ANH9+4@^:L+!4
MEW2(+G["'_!3@?\ !2__ ((D?MI^,?B%\)M-\,_%70_A?XC'Q0O]%@>*U\17
M3^%I[:VU(Q,3Y,Y@L%@DC' -LK# <(GZ ?$S_@G7KWBK]I6']KWX:_MI?$SP
M5X\C^'>G>#[Z[TV#2+BPUFTM+J]N1-?6,]DT$TS/>N0\:P^7L_=[5=U;Q_XG
M_P#!.SX&?\$YO^"/?[5_A+X5ZGJVLZQXS^%GCCQ'X[\9>(Y(6O\ 7=4GT:\,
MDTGDQQQ1("2$BC140$\%F9F /C+_ (-0/#?A'6_^"'W[1=IXJTVU>RU/QUXD
ML]8DFB7]]:?\(UIP:-R>J!9)>#P-[>IKX^_X(L^,_C]H/_! ;_@H##\.9]02
MRM-)TV337MBP$?VB":+6'0CH18)$6(Z* >U>Y_\ !LC^P'JW[:/_  2J^+6@
M>&?VP?B5\+E\1_$[4_#?B^T\&W5G-:ZSI+Z/IA,4D%Y!*+>7]_,OVFV,,K)(
M4=I%5 G[,?L-_P#!-K]E7_@GY^RD/V._@=X+:Y\)W8N7\1OXB9+NX\03W$8B
MN)KT[%25I(U6,J$5 B*@4 8H _'[_@GU::);?\&<'QLFD2(^>GB:2XR!_K_M
M-NL9/O\ +'CZ"L3]@C]A#XA?\%3?^#8CPW^RUJWQ4M/#?B2T^-^J7OP0/B&X
M:.TU6>UM[J5M/) +;'\W5R"H;8T6[:0A%?HA%_P;T?!'P[\!O&7[%WPO_:L^
M*/A;X"^/?%"ZYXA^%FGR:;,J2;X9'M;74)[1[J"V=K>#=&7=B(R-_P [Y]W^
M+W_!+[]GOXA_LN?#W]D3X<:WXE^%WA3X7^(=/UGP9<_#C44M-0TVYLDG$+QS
MS1S?.9)VDD=U=I&+;R=[$@'Y4?\ !#;_ (*._MI_#7_@H9X-_P""1O\ P5D^
M$>H7WCGPS:ZE;?"[QCXA0G6=$(T^222VDN4)74+&XMK=O+GR^62([Y%"&+M?
MAFW[+EC_ ,%1/VLO _\ P25TW4[_ ,<Z[X9UZ^_:"^)/C_6WO/#?A]FN7DO+
M/1].A\J:^NY+QF7S)IQ# 4DV%T!C?]"_A%_P2T\&^&?VU+3_ (*#?M _'7Q1
M\6?BGH?A'_A&/"&L^)--TVP@T+3B9BYAM]/MH$:XD^TW >9\_+.ZJJ X'B_@
MG_@V;_X)Y>"OVP/&/[7$/B+XDW \;7E[<:SX 'C VNAS"[E,UQ;RK;1QW%Q;
M-)\WV>69XCC:ZNH  !\@?\&/TLA_9^^/D)<[%\8Z,RKG@$VEQD_H/RKC/^#*
M'_DLO[5'^[X<_P#2C5Z_2/\ X)R?\$)_V=O^"7<GCZ;]F']H3XN6[>.HO+5-
M2\0V<\&C[=WES06QM/LTUP@8JLMS%-A> !EMTO\ P3#_ ."%7[-7_!)KXC>)
M_B)^S5\>/BOJ?_"96D,'B71O&6J:1=VEZ86E:&0F#389D=&FE(*2*#O.X,,"
M@#OO^"SFN_$?PU_P2C_:"USX3R7,>MV_PKU<PS69(EA@-NPN9$(Y5E@,K CD
M;<CD5^3W_!(^TT2W_P"#1O\ ::FD2(^>GC62XR!_KQI=HL9/O\L6/PK]]-4T
MO3-<TRYT76M.@O+.\@>"[M+J(213Q.I5D=6!#*02"#P0<5\"0?\ !OA\$?!_
MP;^(7[)7P1_:F^)O@;X'_%+Q -7\6_"[1SIL\<<A\KS8;*]N;22YM8)5MX$=
M"TA*QXW ,00#XD_X(M:U\0]5_P"#3/\ :<LO&LMPVFZ=X>^(]MX1$^=JZ<=
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MQI7@KP=9VD/@>X\/70AO_#S6T/D12V\TBR!F\LLK^:KB3<2X9L, #P?XI_\
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M_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@
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M/]H?Z/\ 9MG^J^;9C]]0!]X4444 %%%% !1110 4444 %%%% !1110 4444
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M^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O]0 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\0?\
M@]Y_Y-9^!_\ V4#4?_2$5^WU?B#_ ,'O/_)K/P/_ .R@:C_Z0B@#S_\ X--O
M^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=Q\1- @N-3:7Q[=ZDMY+XBU)]1N7U+4'G3Y)6FOVNI"R?(2WR97% 'L5%%%
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M]YC[_P ^Z@#U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME))NR[DS;C!M*[['6?\ #S_]@'_HZ?PO_P!_Y/\ XBC_ (>?_L _]'3^%_\
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M-IG[1?\ #S_]@'_HZ?PO_P!_Y/\ XBC_ (>?_L _]'3^%_\ O_)_\17XN_\
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M#'U,CQ,<#?VSA+DL[/FMI9Z6=S\N?^&A_CK_ -%@\3?^#ZX_^+H_X:'^.O\
MT6#Q-_X/KC_XNO5?^'4G_!0/_HU_Q-_X#I_\71_PZD_X*!_]&O\ B;_P'3_X
MNOWW^TO"+^6C_P""W_\ (G\^?V;XQ?S5O_!B_P#DCRK_ (:'^.O_ $6#Q-_X
M/KC_ .+H_P"&A_CK_P!%@\3?^#ZX_P#BZ]5_X=2?\% _^C7_ !-_X#I_\71_
MPZD_X*!_]&O^)O\ P'3_ .+H_M+PB_EH_P#@M_\ R(?V;XQ?S5O_  8O_DCR
MK_AH?XZ_]%@\3?\ @^N/_BZ/^&A_CK_T6#Q-_P"#ZX_^+KU7_AU)_P % _\
MHU_Q-_X#I_\ %T?\.I/^"@?_ $:_XF_\!T_^+H_M+PB_EH_^"W_\B']F^,7\
MU;_P8O\ Y(\J_P"&A_CK_P!%@\3?^#ZX_P#BZ/\ AH?XZ_\ 18/$W_@^N/\
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M::\*P^!OVC?@?X2\>:-;W:W5OI7C#P[;:E;Q3J"!*D=PCJK@$C< #AB.A(H
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M_@DW^U5^S1^U=^QG8R>%/#7Q"^+^G_#;XK_#C19'CT?Q%:ZB&,%Y]C!\I+V
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M&M8\ ^*;/QK?6T?A]1?VL7V:VLH)4M5C,4CAG:)I9&(9Y&*J  ?O!17YN?\
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MOAVZUR7P/>Z)K'BOQ)+<0P27]];RK=ZEY<4<DDW[Z4[(&=,1A$\P", _7-%
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M7]E%.T<,@6YM"P#;!LE6)B&$>3S?_!:7_@FO\=?^"EO[+&D?L?\ P-\6^"/
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MOQ!_X/>?^36?@?\ ]E U'_TA% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\
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MUGT:\N6FD>&..6-UN(RSHHR\94*6R^=M?<-% !7PC<?\$\OVRYO^"Q47_!5
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'!&<F@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>jnj-20220703_g13.jpg
<TEXT>
begin 644 jnj-20220703_g13.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MP7X_Y0V?M"?]D_F_]'14 ?QA4444 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^
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MQFU_X:OO$/PH?7;Z2XDBBMI-,\N"UGN"&:".6!D5HI/.D(< H7_I15510B*
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M"]GX<N+BZU60:Q(X:,JOEI"T4JS"XD=(!$&D,@12U?T-T4 ?A/\ L^_!A_\
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M?('_  7X_P"4-G[0G_9/YO\ T=%0!_&%1110!^_W_!IM_P I3/VN_P#MX_\
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MDW]O/]I;]LI?C'X<_8\_X)L:E\'E^*EUH4OBCQ-/\9+V]73K'15E-M!%'%8
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M/&_CF"P\7?$DZD/!&BR6\K/JG]GVZW%YM94*)Y<3*YWLN<X7)XH ^1-8M_\
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M'15]?U\@?\%^/^4-G[0G_9/YO_1T5 '\85%%% '[_?\ !IM_RE,_:[_[>/\
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MX%?]&\^)O_!M;_X4?\1(/P*_Z-Y\3?\ @VM_\*_'NBC_ (@UD7_014_\E_\
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M^F_"+_DE)?\ 7R7Y1/Y<\8O^2MC_ ->H_G(****_43\J"BBB@ HHHH ****
M"BBB@ HHHH *=#_K5_WA3:=#_K5_WA6&*_W6I_A?Y'1A/][I_P")?F?T5?\
M!,'_ ),!^%?_ &*T?_HQZ]XKP?\ X)@_\F _"O\ [%:/_P!&/7O%?PT?W@%?
M('_!?C_E#9^T)_V3^;_T=%7U_7R!_P %^/\ E#9^T)_V3^;_ -'14 ?QA444
M4 ?O]_P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\
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MCW1117]JG\/!1110 4444 %%%% !1110 4444 %%%% !7[L_\$'O^4?>F?\
M8S:E_P"AK7X35^[/_!![_E'WIG_8S:E_Z&M?B'C3_NV"]9_E$_=/!'_>\;_A
MA^<C[+HHHK\"/Z$/R+_X.2?^2N_#G_L6+K_TI%?F?7Z8?\')/_)7?AS_ -BQ
M=?\ I2*_,^OZ;\(O^24E_P!?)?E$_ESQB_Y*V/\ UZC^<@HHHK]1/RH****
M"BBB@ HHHH **** "BBB@ IT/^M7_>%-IT/^M7_>%88K_=:G^%_D=&$_WNG_
M (E^9_15_P $P?\ DP'X5_\ 8K1_^C'KWBO!_P#@F#_R8#\*_P#L5H__ $8]
M>\5_#1_> 5\@?\%^/^4-G[0G_9/YO_1T5?7]?('_  7X_P"4-G[0G_9/YO\
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M>#_B1/I/@ >%/&%UK-E8JNG:?->6-G/<0INM(;V:[50'(BD\V!%6.%*^MS!
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M_/NU']OY%_T%4_\ P9'_ ##_ %?S[_H$J_\ @N?^1#14W]GWO_/NU']GWO\
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MHHH _?[_ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H
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MV_\ B*/^%(?!;_HD/A?_ ,$%M_\ $5U%% '+_P#"D/@M_P!$A\+_ /@@MO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ?PZ//JUU'':6\$<-U;YN$MUFN71B1LFMN4WY/Z0:+;ZK::3;VVN:G'>WB1
M7-U#;>2LK]V";FVCVR?K7XJ?MZ_!GQS\+_B=_P $]?'?QJTX6_Q)^*/[8UGX
MV^)$1;<;74[ZYTTIIX;NEE:):V">J6:GN:^NOVM_C=J/QY_X+4_"7_@E]XHU
M>]MOAW!\(]2^(OC'1;6\DMX_%=S]HFLK*PNC&5:6UA,,MPT&?+E;8) ZIMH
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M=%7U_7R!_P %^/\ E#9^T)_V3^;_ -'14 ?QA4444 ?O]_P:;?\ *4S]KO\
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M /!0*7QW\&?B?\(KOX8?&OX2ZO\ V9\2OAOJ%^MS]F?<R+=VLX"_:+9V1AN
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MIU\@_P#!07X96?\ P49\7Z-_P3MTN!;OP1IOB72O$?Q^U4#=!!I]I-'?66@
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MQJ5G$;*RDHZYV;6^GJ* /F/P)^Q1\1/B/^VYHW[?O[7>H>&F\2>!_"=UX?\
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MQG\.M6TKXZR:<FJ^&=+N+Z*?0X[)1% T4[P%;IA%N#*R1!V((,8XKT/_ (+
M?L8_'7_@HA^Q3XI_8O\ A#XG\*>'+7QJ+%=8\3>(I;F62TCMKZ"["0VT,>'+
MM;JI=I!M!;",2"/J:B@#Y(\"_ [_ (*P^%?V??#_ .SYX=^.WP-\)R:'X:L]
M$@\;V'@S5-6NX(H(%@6>*SN+J&$S;4##S'>/=U1AQ75_\$Z_^":7P5_X)T>#
M?$<'@GQ#K7B[QMX]UIM9^)/Q*\63K-JWB74&+L9)64 )&K22%(EX7S&)+,S.
MWT910!P7[3NB?M&>)?@=K_AW]D_QIX<\-^/+ZT\C0O$/BNPDN[/368@-<&"/
M_6R(N2BM\F_:6#*"K?!_PJ_8,_X. O@G\.$^&GPU_P""B7P*L+??-/<:G+\*
MKBYOKN\F8O-?7$T[N;BYDD9I'DDW%F//'%?I;10!\P_M2_\ !/'4OCQ\-?@[
MK&@?%N:'XO? ;6+#6O OQ$\06S71O[R*%(;V#4$5E=[>_C4K.(V5E)1USLVL
M[P)^Q1\1/B/^VYHW[?O[7>H>&F\2>!_"=UX?^&/@SPC/<76G^'UNS_I^HO=W
M,4,ES=SIB$8ABCBA!7$C,9!].44 ?G?X^_8F_P""Y6L_M3>)OVE_ 7[;?P,T
MN34H6TWPQIFJ?#N\OQX<TC>'^QVSR2#:965))Y0 T[I'N^2*&./Z:_85^#W[
M;'PQ\-^)-9_;P_:9TCXD>+M:U:/^S6\+Z%_9FDZ3IL40$<$-MU,S2O</),Q+
M.&B4G$2@>[44 ?&7A;]AK]K#1O\ @KUK/_!2R^U[X>MH>M_"R'P!+X.BU"^^
MU6]BE_%>?;1<FW"23;HV_=&-5(8+O&-Y^S:** "BBB@ KY _X+\?\H;/VA/^
MR?S?^CHJ^OZ^0/\ @OQ_RAL_:$_[)_-_Z.BH _C"HHHH _?[_@TV_P"4IG[7
M?_;Q_P"GR>OW^K^3W_@EW_P6%^&W_!'O_@H'^T5\2/B1\'=<\8P>,=<O]-MK
M;0[^&![=XM6GE+L91@@@XP*_03_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S
M^RS_ -&/?$#_ ,**Q_PH_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS
M_P!&/?$#_P **Q_PH_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CW
MQ _\**Q_PH_XC>?V6?\ HQ[X@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_P
MHK'_  H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\
M*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^
M(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_
M *,>^('_ (45C_A0!^WU%?B#_P 1O/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[
MX@?^%%8_X4 ?M]17X@_\1O/[+/\ T8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X
M45C_ (4 ?M]17X@_\1O/[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^
M% '[?45^(/\ Q&\_LL_]&/?$#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M
M]17X@_\ $;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/
M_$;S^RS_ -&/?$#_ ,**Q_PH_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;
MS^RS_P!&/?$#_P **Q_PH_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/
M_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\ A16/^% '[?45^(/_ !&\_LL_]&/?
M$#_PHK'_  H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"
MBL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q&\_LL_\ 1CWQ _\ "BL?
M\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_P#$;S^RS_T8]\0/_"BL?\*/^(WG
M]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1O/[+/_1CWQ _\**Q_P */^(WG]EG
M_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\ T8]\0/\ PHK'_"C_ (C>?V6?^C'O
MB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A
M16/^% '[?5\@?\%^/^4-G[0G_9/YO_1T5? '_$;S^RS_ -&/?$#_ ,**Q_PK
MQ/\ X*.?\':7[/'[;G[#OQ*_9/\ "W[)'C30]0\=>&WTVTU;4-<M)(;5V=&W
1NJ#<1\O0>M 'X6T444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jnj-20220703_g2.jpg
<TEXT>
begin 644 jnj-20220703_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^@@T?Q1XWF,-U%%/)Y<%U=Z?+;Q-!;L?O21RS!0"1N )K[-_X*9_\%0O#O\
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M2W7DW%_)+/!;W&I1RLBK>)PZHY*-A>F;?_!7_P#8=^+7_!0SP#\5?AK\:O\
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M_@UINC^/],L/$-C9:B=0AU74YK>;3TO)HH[B:&*XDWQ/)$K)<C#[PJG[)HH
M_+O_ (*#_P#!/_Q)_P %C/VP_@'X[L?V3_$7PUT'X6>)3JWC[XF>.;2SL-1U
M2QBEBEBT2SMX9Y)[@M)&S>=*$A@#LT;2,[(W#?M6_L#?M_>/O^#DOX:_\%%O
M W['^N:G\)_!%E9:7J.O1^+O#T4UP%MKV%[F&VEU))C$K72G#(LA"-A,X!_7
MVB@#\XO^"P/[(O[2?_!5;X=?$+]F+7_V5?&>B^#O"'A&;6?A=K,7B+P[N\4>
M-E+QVK,O]I>9;6D4+2)B81^:+R5F\MK>(2=-_P &^7@[_@I)\ /V,=/_ &1/
M^"C'[-^H^%[_ .'P-IX+\4OXLT?4X-0TC(,%FXLKV:6.6WRT:[D$9A2(!MRD
M'[WHH \$_P""GWAWXQ?$']@CXM?!KX#?!+5_'?BGQY\.M;\-:/I>E:MIMD(9
M[ZPFM4GFEU"ZMXUB0RAFVEGPI 4FOGO_ (+-_P#!.SX@?\%AO^":=OX!M/A#
M=>"/BIH>L6&M>$](\5:EI[R65T"L5W;R7%E<3PF)[>6<?+)AGBB8C@5]_P!%
M 'YU?\%:?^"?WQ;U#_@B'-_P2R_8)_9VU;QC>+H'AS1M$EMM9TC3[>WBT[4K
M&[EN+E[Z\@)DE%K(Q,:N6DER<9)K@/\ @G)_P2U_:)\1_P#!!'Q+_P $D_VS
M/@IJWPV\1:C8ZU%;ZW<ZUI.I61N)]0:_L;A#I][.[".8Q%T=4R(F /(-?JI1
M0!^%^L?\$[/^"EOBO_@ACX8_X(>#]D+5;/QUI7Q&DCU#Q]<Z[IW_  BPT3^V
M;G51J2W2W!F<;ITC\@0>?\K$Q@C:>Z_X+??\$</VLOB1_P $NOV=/^"=/[!G
MP/U#XAS?"J\MI=8UY_$&D:7 P@T^:WDD87U["WF333M*%1651D%@0 ?V6HH
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M$_B"&UCO=1;)/FRK:0PP!N<?NXD7@<4 ;U%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\]?\%4?
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M?V>_V\OA5^QWJVM?#OX5:5X>L_$^K6GC/0(FGDM]5OKNY>UANM0AFEC2.[0
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M0VB:MXJUF>&2WN]:N[>TEECM8S!*T81W\Z5D65U0DAOFC_@G'^QQ_P %:?\
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M-A;7#1I ]W.\WF210R0PP%XC'YL;0G8LV\9_;2B@#\>_^#EW_@G%_P %(?\
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MH\?>*/VGO ?[3/[=OQ/N#=>,/B=\:]NLW;L6*Q6]DEQ#;J3TBB%^Z(O1550
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MNXM#K'AV_;3DM5G2WFGC6Z@=H+9F\IV=6:<[2H3=^IM% 'Y=_P#!'S_@F/\
MM"_ K]N3]I;_ (*T?M)_#&\T'Q!\6=7UH> /AFFHV4^JVVCW6H_;\73K/]EC
MN9?(LXUC\X!"DGF,F[CYP_X),_\ !+[_ (*:_LC?LF_MR_"WXT_L2ZU::Y\<
M_ <EI\.[6R\<>&KA;N\DMM6M?(E==3VP$'489"[X79%+@EPB2?NG10!^2/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,?UEUV6F_P#)7'_B'B^*L0\+A6X86+T6SG;[4O+M'IN]=BBBBOTH_,@HHHH
M**** "BBB@ HHHH **** "I;*RN]1O(M/T^UDGGGE6."&)"SR.QP%4#DDD@
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MX[A#F^JW\E.G?_TK\C\P*FT_3[[5K^#2M,M9)[FYF6*W@B7+2.Q 50!U))
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M6_$JT^"OBWXO:8WC:^A$UKX(T=9=2UJ2$X_??8+-);D1<C]X8PGO7I*L'4.
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MH9I,^;&KMN.37LES^S9^TQX5_9P\&?LS? []J^+P[#X:\%Z?H&I?$'6_"?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY?%"*O\ XGK+_P F;/XGXIS6.=\18G&Q^&<G;_"M(_\ DJ04445[QX 4444
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M  43_8J\/?MO?L^7O@!T@M_$NF;KWPAJLHQ]GO O^J9NHBE V/UQ\KX)1:_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUP\4(D,(P9 =AQ@_)SG*I)RD[MGUT(1IQ48JR1_0_17S3_P1Y_9Y\;?LP?\
M!-7X1_"SXH:[JNI>+#X4BU7Q7=ZW>R7%T-1OB;R:&220ECY+3>0.>%A %>K_
M +3'[0GA?]F7X3W?Q*\0:5=ZM>/<PZ?X:\,Z7M-]X@U:X?R[33K52<&6:4A0
M3A47=(Y5$=A)1W]%?BE_P;M_M#_M*?M(_P#!9']LSQ;^U3XE@O/%>FK%HUW8
MZ;<O)I^F+9:I<VJVEF' (@C$6U20&?EVR[L3^UM !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[5/HLX\T_C+7ZQEGC-P]BDEC*4Z,O_ X_>K2_P#)3\CS3P4XCPK;P56%:/\
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M^D\7>$_A+X?AU;P_J(F>:WTIY);4P1VS/\T,-U:WJS_9R2(W@?: 3(6^HO\
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M'_A!YQ=ZC<I''\_^D9OP+7*[^#NZ<U_1K7@W[,7_  3/_8T_8Z^.7Q"_:/\
MV>_A9/HGC#XI7TUYXWU.7Q!?7:W\TMS)=.PBGF>.',TKMB-5 S@< "O>: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUIXOMO"U^VN:3>6+V>LW*0/;V,Z7$*-!-*MU;E%D"[_.3;G<*N^*OVP/V8O
MFI^--&\=?&O0M#N?AUI$&J^-HM9NOLG]D6,Q<0W,IE"CRI#'($<9#E"%)/%
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MVAOC]^T1\4?VD_"7Q=^(T=Y8_"WXT7W@GPG]@T6VMI!9Q6=K<I<SL$(EN/\
M2=N0%C^3/E\\4_\ @FI^V#\3?B[\*/C5\5?VK_BOI"V/PX^.GBOP99WW]GP:
M=:P:9I-V+>*XF(Y,\F26.X(25"H#U /KZBO*]%_;;_96UOPWXR\4CXS:;I]O
M\/#$/'5OK\4VF7>@^:@> W5K=I'/")5(,19 )>B;C7(?'S]KGP[XJ_9,^-_B
M_P#9A^*R6/C;X9>#=2O+NWU+09([[0[Z+3WO;876GWT<<B+*BJR&1 KHVY=P
M% 'T'17R)\'?^"FO@G1]"_9A^#7QFU34=1^(?QJ^%%GXCU'58M#E6V0II5M-
M<3DP0^49)+FXC7R8]H19"S;%"!^9_8K_ ."F/A+3-4^)/PU_;:_:DT$>);+]
MICQ#X&\#K>V$%B7L8)X+>PA=;>,)'OD9T668CS9"RAB0% !]PT444 %%%% !
M1110 4444 %%%?SD?MP_\GJ?%_\ [*CX@_\ 3E/7V_!'!O\ KEBJU'V_LO9Q
M3OR\U[NUOBC;\3X7CKC3_4O"4:_L/:^TDXVYN6UE>_PRO^!_1O17\N]?LK_P
M;P?\F5^)_P#LJ-[_ .FW3:^@XN\,/]5<F>/^M^TM)+E]GR[^?/+\CY[@[Q2_
MULSI9?\ 4_9WC*7-[3FVZ6Y(_F?>=%%%?E!^MA1110 45\A?MJ?'[]IGP'_P
M4._9O_9:^#?Q:LM!\/\ QFLO&)\0RWOAF"^FLGT;3K>[@:V+%,>8TS*X??P!
MMV\Y^<O'_P#P5,_;,M_@+\<-"NO&GAS2O&?[/G[1_A7P3JGCGPYX=C_LWQ1I
M.IZQ86S9@NWG6SND@NG$ZJ[A'"E2N<  _4JBO*OAO^W'^R)\7+#QMJOP]_:$
M\,ZA:?#B(3>.;HWXABT:W,3S+<S/*%46[1Q2.MP"8G6-RKD*<-T']N+]E#7]
M,\3:N/C3IFF0^#=%M]9\3CQ)#-I,FG:;<*S6]])'>I$_V:4(^R< QN48*Q((
MH ]7HKY[TO\ X*O_ /!.#651M._;(\$/YJ:&\"MJFQIAK SIPC# &0S#/"Y*
M8.\)@XL77_!47_@G]9Z-XHUV;]J;PR8?!EY%;>(XHI)9)[5I8GEB<0*AEFB>
M*.219HU:-DB=PQ5&( /?**\U\5?M@?LV^$/"_AOQC?\ Q4L[VP\8Z+)K'A5M
M MI]4EU;38X4GDOH(;..622V2*6)WG"F-!+'N8;US=NOVH?@%#\-_#GQ:L/B
M;8:KH/C&*.3P?=: DFI2:\LD+3K]B@M5DENSY*O*5B1R$1V("JQ !WM%>;Z1
M^UW^S?XC^$VC?&_PI\5]/UKPWXBNGM?#]WH<4M]-J=TGF>9:V]M CSS7">3/
MO@2,R)Y$NY5\ML4O"_[;_P"R=XUTSP=K7A;XYZ)>V?Q UF;1_!]S%(^S4=2A
M\SS;!25 2Z3R9=UN^V5?*?*C:V #U6BOG?\ :D_X*<?LP?LQ_L_?$OXZ7GBB
M37I/A?>)I?B#P[I5E<->0:O-&KVME.GEEK?S1)$WFNNQ8W#DD8SN7'[0'P\\
M8_M0_#OPAX/_ &M['3IM4\,:S?/\)FT:$WGB2%6A6._9ID%S9I:LDH  59C.
M<YV+0![917FEO^V)^S1<_%'3_@W%\6M/_M[6-3N]-T:-X9EM=2O[4,;JQMKL
MH+>XNH0DGF6\<C2Q^6^Y!M;$?AS]L[]F'Q;\2K#X2>'OB[87&MZOJ.HZ?H:"
M"=;;5KS3]POK6SNF06]W/;F.02Q0R.\1BD#*-C8 /3Z*^9?^"?/QT^-OQ:^+
M/[2O@;XQ^/4UZ#X=?'*3P_X3:/2;>T^R::=%TN\6 B%09")+J4[Y"SG/7  '
MTU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '%_'7_ )%&V_["2?\ HN2O)Z]8^.OQ#^#WPT\(VVN_&S6/L6E2ZDD%O+]G
MN),W!CD95Q K-]Q)#DC''KBO)_\ AK/_ ()^?]#_ /\ E*U7_P"-5]OD5+,I
MY>G1PE6I&[]Z%-RCZ774^%S^KEL,Q:KXNC3E9>[.I&,O6SZ&EX._Y&[2O^PE
M!_Z,6O>J\%\'?M._L.Z_XNTK0O"7C?SM5O=2@@TR+^S=37?</(JQKEXPHRY4
M98@>O%>]5Y?$<,7"M3]O0G2=G93BXMZ]+[GK<-U,'.A4^KUZ=575W3DI):;.
MVS"BBBOG#Z0*\Q_;4_9TM_VN_P!D3XE_LOSZT--/C[P1J6APZD5+"TFN+=XX
MYB!RP1V5BO<*1WKTZB@#XU_X)[?M4ZY\&_V6O G[*W[5OP)^)/A7XG?#CPK8
M^&-7T^P^&VL:KI^L&Q@2UCO]/U"QM9;6X@G2)9?]8K1%RLBIMR:7Q+F^-OPI
M_P""J/P\_;'^)WPF\22?#CQ'\"-2\$7<?A[3)];E\':T^KPZC')>16,<C)'=
M6\44+RQ*\23VR(TA79(WVO10!^4'B']EKXN^"?!?AWQ,WP6\97FC^-_^"DMO
M\4=)\-67@N^NYO#_ (8\S8][=VT4+M8I))&]X8Y0C(+M0R+()%7M_BI\);#Q
ME\?_ -M^U^,/P.^,<G@OQSK'PM.D:WX#\(:M#J$DMF+2WEU;2IHK5S<3:;<+
M!=MY*RMMLR0KJ"*_2BB@#\JOC%X#_;KUW]AKXI^$?B18>(/B_9?#WXX> O$/
M@[QY9_#B72_$OC71+'4M)O+XS::D:/>7-G#"T(GCC'VD0$*I9"*WOBKK7C;X
MQ_M&_M>?$KPA^SK\5F\/_$#]CO3M&\%7U_\ ##5;=M9OHUU]3;);R0">*<M>
M0@6\T<<V&W&,(5=OTWHH _.;P=\/?&</Q5_X)O7T_P "O&D4'P_^'FKV?BZ>
M7X?ZBL?AJ>;PK;V4<5XQM\6;-=1F/$FWE0WW<-7E'B3X;_M)^&? OQ'^,_A+
M]FKXHZUI_@O_ (*":G\1-7\&:/HFIZ1K'B7PE<Z.=/>\TG(@DNY$FN&N$CB<
M%VMSG&5)_7"B@#\M/VQ/AI\-_C;^P9\6_B?^S+^PY\8;74_B?X_^'<NM_P#"
M7>%-?O/$/BLZ1K]A-/-+IUWY]S%;VUA"R++(L?G!'4!E2)I/U#LKFSFT]-2M
M;>2.*:,3!7M7CDP1GYHV4.&]5(# \$9XJQ10!^=/_!._]DOX,^/_ -H#]K3Q
MQ^U'^Q+%J$^N?'_4M;\(ZQ\2/@Y*SZAHIL;*))+26^L\R1F:*<B-"6.=P7#
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M"X;NSUV*%K5E@1;^.XDN(9Y=3$DUN'GD9I+591$?UQHH ^1_^":_A_QAX?\
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MH'BOP[\-++Q%J%IIOB4:C:W&FZB+F)8VF2.&2"YCDMW62%D P\;([JV1F_\
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M+PK^S?X5N?A[X]^'>D_&+X7?M&>(OB=X%DEU.^N]#U6UU>[U![G2;Z3[)%-
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20220703_g3.jpg
<TEXT>
begin 644 jnj-20220703_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQO\ &/XP7LB>$O"+ZR-.M+6SB#M-J%_=B&=K:V412X*032.8G"H=K8=^P?\
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M:SRVH2XEAVM(JJ&.8B<@#K7L%?AC;?\ !5+X@_\ !+3_ (-AOV;_ !5\#(+
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M?&VJ>(+>Q\,>$=&O[&6PLM(MK<.+F-;&XGB62:>YN [,YE86\8;"+$!]B44
M?/?_  4X^('[=_@;]E+6[;_@G#\ &\=_%36@=/T2277=,L;;01(K;]1E.H7$
M*3&,#]W$N[=(R%AL#9_*_P#8[^%O_!U?\+]%\(_LG7'[*/@OX<_#/4_$MM#X
M[\::'XBT&36HK2ZNT.J:L]RNK37$UZZ/-*\ZJ\Y<Y3#!,?NI10!^;G_!0O\
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M[FZM/"NM>(=,EAUN&26Y\V&&ZM+F:!#)'-"Z-*Z8>!D<(&#C[A_X)I?M%?\
M!6;XX>#?"/@+]LG]AZ/X3S^%[&&'QSX[USQ7:WLGB>2&(H%L+&#<T#S.$DEE
ME<QHHD6/>SJT?VW10!^''_!4K_@EO^T3_P %/_A3I+^+?^";NO>&/VHK;Q3%
MIUO\8=+U?1;?P]K^@I=-&+_5GAN_,1Q:*C^4;?[0DBJD6Z,^6/VL^&GA?5/
M_P ./#_@K6_$D^LWNCZ):65YJ]UGS;Z6*%(WG?)/S.RECR>6K;HH _(OXO\
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MS_@AU^V#X\_X(!_$_P#X)A?M/?"27X:_$.Z\>R^*/!&I:EXATS4+"YN%%I)
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M7Q+I\VMZU+9P6[73QZY>0H3' B1KB.-%^51]W/4DT ?;_P"VA_P7MT3]C?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&:&XB6>WE61&&5=&R"/8B@!U%%% !1110 4444 %%%% !1110 4444 %%%%
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M/K-Z7N;:.WGFM&2XDM;1Q9SS6\+@R)<D.LOR(>]_X(\_LJ:U8_!W]F']K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1T?PR6TEY>?=;HKT445[1XP4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'UW_P $EO\ @HWJ_P"Q/\7D\&^.]5ED^&WBF\1-?MFRPTR<X5+^->Q7
M@2 ??C'0LB5^\EA?V.J6,.IZ9>17-M<Q++;W$$@=)4895E8<,""""."#7\L%
M?KW_ ,$#?V]W\>^#Y/V+OBAKA?6/#]LUQX(N;F7+76GKS)9Y/5H<[D')\HD
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MWA6YTC5[%OWEO<+\LB'.V2-A\LD;8X=20?6N9K][?VK?V/\ X._M?^ SX/\
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MX",7/E*\NR-R8MTA=D9DC9/QE\-_\$[/A[\-_P#@[:\->'/^"?O@J/PGX1\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTI?=:/WCZ***_!#^@0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Y+X^:-\0/$7P*\:^'_A-J+V?BJ_
M\):E;^&;N.Y\EH-0>UD6W<2?\LR)2AW=L9[5UM% 'Y&_MC>.OVJ/VOKGX6_
MC]IS_@EMXQN/B3J7P;\?:!J_A.?4M"FT35-5N+728X[^UU#[>8H[:.:-;@N^
MR>'Y?+21U!/*?&[_ (-H/BGXK_X(-^ _V&O#_CK1[[XT?#OQ%=>+[.X:Y9-.
MO+Z[:7[5I4<KJ"D9BDC5964!I;9&;RTD;;^SM% 'XW_M/?\ !.C]LG_@L%XB
M_8Q\"?'?]FO7?A?HGP,TJ27XX:UXKU"P9;V[VZ8DEEI:VMQ,]SYQTZ0B<JL2
M)<(2Q93&?JIO&7_!:W_A]R/!Z^!M _X8]_X1W<=4\NQ\S?\ V;N\SS-WVO[7
M_:/[ORL>5Y'S;<_O*^YJ* /QW_X.C_\ @GS_ ,%!O^"G"_"CP!^QU^R!K/B"
MV\"7^M7.L:]?>+_#UA;3_:4LTA6!;C44F;_42%M\:8^7&<G'ZT_#'Q1XE\8^
M";'7_%_PSU?PAJ,T*_:M URZLIKBV?:,JSV5Q/"PSD960]*WZ* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K\^?^"L'_)Q.B_]B5;?^E=Y7Z#5^?/_  5@_P"3
MB=%_[$JV_P#2N\K]*\*/^2NC_@G^2/S'Q<_Y(Z?^.'YGS#7T]_P2?_Y.)UK_
M +$JY_\ 2NSKYAKZ>_X)/_\ )Q.M?]B5<_\ I79U^[<=_P#)(8S_  ?JC\#X
M"_Y+'!?XU^3/T&HHHK^/S^R@HHHH ^7/^"R_[3/QH_8Q_P""=_CO]J?X ^(K
M2Q\3>#VTR2SAU/3([NTNEN-3M+21)8VPW$=P[*4=2&"D[AE3Z FC_'KP;\7O
M"6EW_P"U!9:Y8S?VA?>(O#&H^%+>*[O=+@M6C,UHUL P>*]N=.W9#!DD9<!B
MIKQ+_@X)\$^/?BK_ ,$G?BA\(OA5\,O$_C#Q+XC&CP:1H'A3PU=ZG<W+1:Q8
MSR?);1OL58HI&+/A<*1G) /5^"T_8_\  7QY\+>-_P!F?]BK7]*\:ZY#)X:E
MU;3/@;JGAJTM=(GFM[N[FO[R?3H(@D8LE:)'8LTK"- #*S* >HQ?MM_LIS?#
MZP^*\?QLTC_A&]2\5?\ ",VNM'S!;C6/M7V3[!(Y3$4_VC]SL?:?,^7KQ67K
MW_!17]ASPU\6#\"M9_:@\(Q^+QXKL/#+:!'J0DN$U>]S]FLF" A97("X)&UG
M16VET!_.3QUI'Q?\+_L8^/\ ]DO_ (9@^+.H^,-"_;97Q9<II?PVU*:RN=!F
M\?0ZK#J-K=B'R+V-K5@QCMWDFCPQDC1$9Q]7?LS^"/&6K_\ !1O]L;Q/!X \
M4^&X_&^C^#(O!WC+6/!=[:6MU)::+-!*\%S-"L<IM[ATRJL>>1G!( /HFT_;
M'_9FO?B'IWPO@^+FGC5=8U:YTK1'EAF2RU34;??]HL;6\9!;7-U$8Y ]O%(T
MJ&*0,H*-CB/'?_!5S_@F_P##+4+G3?'/[9W@/3Y++Q.WAZ^9]:5X[74D6%GA
ME=,K$$^T0!Y&(1&D568-Q7Q5X,^!GQM^+W_!)_X-?\$X-6^"OC#PO\:_AO\
M$;PM:ZGJ5YX8O4L-&?1M<BN;KQ!!JC1"UGBEL8II(Y(I6>62Z\H#?O LZ5)X
M/\9Z7_P4E_9\?X-:]XL\1>.?B-?Z7HNEZ5X.NKN/5KJX\)Z9#:6_VM(C!"T=
MPXD+2R(MN)/.8HN7 !^AGQH_:N_9]_9[LGU'XN?$>WTN"#3#J=[)%9W%V+'3
MPQ4WUS]GCD^RV@((-S+LB!!!?@UW.AZYHOB?1;/Q+X:UBUU#3M1M8[FPO[&X
M66&Y@D4.DL;J2KHRD,&!((((K\MM%^&/CS]ASXVR?"3]LG]GWXU?%3P+X[^
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M>S\,^#;6'PQ9W-NQ=+E-+1WOKF&(L$-U+?W<FG,>&8Z7$A; KG[S_@L/\)?
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M25K\Z=OERJY\;DW"N!P6:4J\,7S.+O;V;5_GS.QOT445^:'ZB%%%% !UZU\
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MQD^_$X7ZMJOI6D:5H6GQ:3H>F6]G:P@B&VM(5CCC!.<*J@ <DGCUH L4444
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M9XU8M"7C(=0X&Y2",CFM.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-WK#V\7DP-=2HH><QQ#8A<G:O P*WJ** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20220703_g4.jpg
<TEXT>
begin 644 jnj-20220703_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(\8^*+:,"+6_%]L;JXBL8I!Q+-;F\MQ.>?+%F(VVETH ^CO^"JW_  7#T/\
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M2W^HV_B"3P]H&GSVOBHZ?#!=3J;:ZMYEC>2QN$D580G^D*54!&"#:_X)T?\
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MIOAZU\4:K9^-- B,TEOJM[>7+6D5U?PS2QI'=( 9(XF=D;"@8)P_VH?V"O\
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MURRE^&VB0W&ZTCU#4[22Y#; ?DN+&POI;,%L,8M0+<AP:^U_^"K7_!-G2/\
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M_:%_:#\:R>(O&/B7Q+I\VMZU+9P6[73QZY>0H3' B1KB.-%^51]W/4DUP_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?,F:63,E>HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%([I&ADD<*JC+,QP /6N3UWX_?
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M>#3XFLLK&/%&@0)#J"#IF6W^6*?ZIY1QV8U^1<0>#V<8"+JY;-5X+[+]V?\
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MW5W.D-M!&,M)(S!54>Y) _&OL7P!X+L/AWX.L?!VG,CBUCS=3QCBXN&YDEZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[ ^0D5T=1LE)_O17!\T_A,*^(?B__P $:OVH_@%XVM[GQ;I-MXA\$QRF6_\
M$_AR8LL4"#<5EB8"6%F "[MK(I8'<0#7VF2>(O"N>R5.E6Y*CVC-<K?DG=Q;
M\E)L^(SSPWXLR&+J5J//36\X/F2\VK*27FXI>9RG[+/PX;PGX-?QEJ=N4O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+"^!O%&I?#CP)K'@[Q5X)N+=/$_A/6YTG:**X\SR)X9T"B:-C%(IRJ,C)@J
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M+3_A%?B'\*[B._U.&Y:WC:=KN":=%\L3F6/:1"RJBN#-N K[:HH ^&OV&/\
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MK%'[YX(Y#3JU\1F]17Y/W</)M7F_6S2]),6BBBOYY/Z,"BBB@ HHHH ****
M"@@,"K#(/4&BB@#\O_VY_@1%\"OCM>V>C60AT36U_M#1U1<)$KD^9"/38^X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWNEWLVFZG9RV]S;RM%<6\\91XG4X964\J0000>0145?N"::NC\*::=F%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#OVH?!]_XX_9]^*.F>*=(L-:NM'O-3T>7?'#?6Y"S1988++N4YP5(92"002
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M!_H1R#R.:NU3U^;7K?1;J?PMIMG>:BL)-G:ZA>O;02R=E>5(Y6C7U8(Q'H:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>jnj-20220703_g5.jpg
<TEXT>
begin 644 jnj-20220703_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /%OBU^U]_PJ[X@ZAX$_P"%>?;OL/E?Z5_:
MWE;]\22?=\IL8WXZGIFN<_X;^_ZI-_Y7O_M%><_M:?\ )P/B#_MT_P#22&O.
M:_9LKX3X?Q.64*M2C>4H1;?-/5N*;VD?B>:\7<0X;-*]&G6M&,Y)+EAHE)I;
MQOL?1G_#?W_5)O\ RO?_ &BC_AO[_JDW_E>_^T5\YT5W_P"IO#?_ #X_\FG_
M /)'!_KKQ-_S_P#_ "6'_P B?1G_  W]_P!4F_\ *]_]HH_X;^_ZI-_Y7O\
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ME"$U+F32=^]UO\]SAQ$)4L1.$H\K3:MVL]OEL%%%%;&(5]&?L _\S;_VX?\
MMQ7SG7T9^P#_ ,S;_P!N'_MQ7S'&7_)-U_\ MW_TN)]3P5_R4U#_ +>_](D?
M1E%%%?A1^]A1110 4444 %%%% !1110 5\Y_\-_?]4F_\KW_ -HKZ,K\YZ^[
MX*R;+<W]O];I\W+RVU:M?FOLUV1\#QQG69Y/]7^J5.7FY[Z1=[<MMT^[V/HS
M_AO[_JDW_E>_^T4?\-_?]4F_\KW_ -HKYSHK[K_4WAO_ )\?^33_ /DCX+_7
M7B;_ )__ /DL/_D3Z,_X;^_ZI-_Y7O\ [11_PW]_U2;_ ,KW_P!HKYSHH_U-
MX;_Y\?\ DT__ )(/]=>)O^?_ /Y+#_Y$^C/^&_O^J3?^5[_[11_PW]_U2;_R
MO?\ VBOG.BC_ %-X;_Y\?^33_P#D@_UUXF_Y_P#_ )+#_P"1/HS_ (;^_P"J
M3?\ E>_^T4?\-_?]4F_\KW_VBOG.BC_4WAO_ )\?^33_ /D@_P!=>)O^?_\
MY+#_ .1/HS_AO[_JDW_E>_\ M%'_  W]_P!4F_\ *]_]HKYSHH_U-X;_ .?'
M_DT__D@_UUXF_P"?_P#Y+#_Y$^C/^&_O^J3?^5[_ .T4?\-_?]4F_P#*]_\
M:*^<Z*/]3>&_^?'_ )-/_P"2#_77B;_G_P#^2P_^1/HS_AO[_JDW_E>_^T4?
M\-_?]4F_\KW_ -HKYSHH_P!3>&_^?'_DT_\ Y(/]=>)O^?\ _P"2P_\ D3Z,
M_P"&_O\ JDW_ )7O_M%'_#?W_5)O_*]_]HKYSHH_U-X;_P"?'_DT_P#Y(/\
M77B;_G__ .2P_P#D3[U^$OC_ /X6C\/M/\=_V3]A^W>;_HOG^;LV2O'][:N<
M[,]!UQ71UYS^R7_R;]X?_P"WO_TKFKT:OQG-*-+#9G7I4U:,9R279*32W/VS
M*J]7$Y70K5'>4H1;?=N*;VTW"BBBN [PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ^+?VM/^3@?$'_;I_P"DD-><UZ-^UI_R<#X@_P"W3_TDAKSFOZ)R
M3_D2X;_KW#_TE'\WYY_R.\5_U\G_ .E,****],\L*^3/C[^T%\2O#^@ZQX ^
M./P6\8VXT[XT>&KCPKXDTCPZ^I6.KZ2/$^FSP -8B0PSJ@:(12JC.4CP7>3;
M7UG45W966H1""_M(IT65)%2:,, Z.'1L'NK*K ]00".17+BJ%2O3Y83Y=&NZ
M=U;5?Y-'5A,13P]12G#FU3[-6=]'^=TSYF_X)_?LX^*OAK\6_C?^T9K?@&3P
M7IOQ9\66=]H'@J<QB>RMK6&1&NYTB9DAFNI99)FB!)3Y0QW94<OK6E?$"7_@
MLCIGQ^A^#_C!_!%K\%7\(S^)E\.S^0NI'5)+G&W;YABV%1YH79DYSM^:OL:B
MN;^S*<:%.E"5E"7/ZN[D_DVWHOE8ZO[4JRQ%2K.*;G'DZZ*RBO.Z26K^=SRC
M]IO]HKXB?L^7OA>\\*_LO>,?B+HVKWLT'B"[\%+'/=Z*JJABD-JQ#3JY9\E6
M4((SDDLH//Z#X&\3?M&_M&>"_P!I7QI\,]4\(Z/\.M)U2/PEI_B$0IJ=_>ZC
M'%#-<2Q1/(+:&."-D5';S'>9BR1B-/,]WHKHGAI5:MYS;C=-1LK)JS6MK[J^
M^_EH<T,5&E2M""4K-.5W=IW3TO;9VVV\]3S7P;\:OB?XD_:8\8_!/6OV==:T
MCPOX<TFRNM&^(MS>JUEKLTR*9+>*/8"K1EF4G<W^K;<$RF[S[X=?MG_'_P"(
MNG:CX7F_8!^(OAKQG;7$MO;V^OO;+H>X,52=M2\Q0\/1F\J-Y,9"))QGZ+HH
MEA\0VK5GN^D=GLMOL[)]>MQQQ&'2=Z*>BZRW2U>_VMVNG2R//?V4?@!I/[+?
M[/'A;X#:/J7VU/#^GE+F]$/EBYNI9'GN)53)V*\TLC!<G:& R<9KT*BBNBE2
MA1I1IP5E%)+T6QSU:M2O5E4F[RDVV_-ZL****LS"OHS]@'_F;?\ MP_]N*^<
MZ^C/V ?^9M_[</\ VXKYCC+_ ))NO_V[_P"EQ/J>"O\ DIJ'_;W_ *1(^C**
M**_"C]["BBB@ HHHH **** "BBB@ K\YZ_1BOSGK].\./^8K_MS_ -O/RWQ*
M_P"87_N)_P"V!1117Z<?EH5'=W=K86LM]?7,<,$$;2332N%6- ,EB3P  ,DF
MI*H>*O#>E^,O#&I>$-<C9[+5;":SO$1MK-%*A1P#V.UCS2=[:;CC;F5]CYTT
MC_@H5XB^(/B'0]=^"G[,WBCQ9X(UKPWK>K:;JUI=64%_K$&GW=A;M<V5K/<(
M6A)NVVK*8I9?D*)C[WN'@+XP^$?B/\'='^.7AJ'4Y-$US0X-6L8QI<LEV8)H
MUD0&WC5I"^&&44$YS7YO?#_XC?&/_@C7\?O!?PD_:^\[Q/\ !K2_#VOZ7\/O
MB'H5D9;C3;&\O]*ED_M"%265()(K=. 2/M6$:4!8U_3#X;W7@.^\ :-?_"Z\
ML;CPY/IL,NAW&F3"2WDM64-&T; D,A4@@@]*\/*<;7Q4IQJRM./Q0:2<79:J
MV\6[V=W=6UW/>SC!8?"1A*E"].5^6:;:DKO1WVDE:ZLK.^FQYW^R)^V5X$_;
M(LO&FI^ _!^OZ/#X)\9W'AN^A\26:VUS)=01QM*3"&9HP&D*[7PWRG(4\#U/
MQ#X@T/PGH%]XI\3ZM;V&FZ;:276H7UW*$BMX(U+O(['A55022>@%?(G_  22
M 'C']J? _P";I/$__H45>M^.5_X:E^+LGP?MOWO@#P1J$,_CJ8<QZWJR;9K?
M1P>C0PYCN+D=&8P0G<#.@WP6,K5<OA4GK.3:72[NU]R2N_+S.?'8*A2S&=.&
ME.*3?6RLG\VV[+S?1%[]BW]L7P-^V]\,-5^+7PZ\.ZEIVE:?XKOM%MQJJA);
MD6^S$^P<QAPX.QOF7H>:[7XV_%WPO\!?A-KWQ@\90W<VGZ!I[W,MKI\/F7-V
M_"QV\*9&^:61DC1<C<[J,C.:^8O^")W_ ";Q\1?^R[>)_P#T;%7U_J&EZ9JT
M<<6J:?!<I#/'/$L\0<)*C!D< ]&5@"#U! (K3+JV(Q660J2:YY1WMI?O;]#/
M,J&&PF:SIQB^2,MKZV[7_4^,/%7_  6AL/ OAJ[\:>-O^"<7[3FCZ/I\!GO]
M6U7X9BWMK:(=7DEDG"(ON2!7V-X4UV3Q1X6TWQ+-HMWIKZCI\-TVG:@JK/:F
M1 YBD"EE#KG:P!(R#@GK7@G[>2_\+5\3_"G]C^W_ 'D7C_QO'J?BB$_=;0=&
MVW]TK8Y"R3K90>_GD5]%TL#];6)JPJU.>,;+9+6UWMY./WCQWU-X:E.E3Y)2
MN_B;]V]EOYJ7W(****],\L**** /M+]DO_DW[P__ -O?_I7-7HU><_LE_P#)
MOWA__M[_ /2N:O1J_G?._P#D=8G_ *^3_P#2F?T?D?\ R),+_P!>X?\ I*"B
MBBO+/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XM_:T_Y.!\0?]NG_
M *20UYS7HW[6G_)P/B#_ +=/_22&O.:_HG)/^1+AO^O</_24?S?GG_([Q7_7
MR?\ Z4PHHHKTSRPHHHH **** "BBB@ HHHH **** "BBB@ KZ,_8!_YFW_MP
M_P#;BOG.OHS]@'_F;?\ MP_]N*^8XR_Y)NO_ -N_^EQ/J>"O^2FH?]O?^D2/
MHRBBBOPH_>PHHHH **** "BBB@ HHHH *_.>OT8K\YZ_3O#C_F*_[<_]O/RW
MQ*_YA?\ N)_[8%%%%?IQ^6A6+\2#XQ'P[U\_#L ^(/[%NO["#;,?;/);R<^9
M\G^LV_>^7UXK:HI27-%H<7RR3L?%_P 2/C_K'Q3\9>&M#^(7['WCNY\4ZC\&
MO%NEZM\.K[PTS07=Y/=: #$MZ2;-K4LC@W'F[44H6"LZ*WL/[ WP%\2?L:_L
M/^"/@C\1-6?4]5\+Z-,^K2:=#)<XEEN);EX8E12\HC,OE+M7+!!@<XKVI[*R
MDO8]1DM(FN(HGCBG,8+HCE2RANH!*(2.A*+GH*EKSZ& =+%/$3ES2M9.UM'R
MWO;=MQ79=DKL]&OF'M<*L/"'+"]VKMZKFM:^R2D^[[MV1\@?\$N_#/Q'^'_C
MGX]P_$OX2>*/#:^-_C=K?BOPS/K&C21Q7>G7++Y;%QE8Y,+DQN5;D8S@XZGX
M@_\ !'W_ ()Q?%/QWK/Q,\>_LU6NH:YX@U2?4=8OV\1:G&;BYFD:260JERJK
MN=B<* !G@ 5]+44J658186-"M%5%&[7,D]W?KZCJYMC'BY8BC-TW))/EDULD
MNC\CX>_X(\?\$^O"O[+NE>,?BIXM^!5SX:\<S>+];TK2KR[O9S))X=:>"2VC
M6-I3&4)B4ARN\[>6ZU],?LJ?&GXG?'KX5GQY\6_V>-9^&.K#5[JT'AG7;U9Y
MS#$^U+C<J)\KC.!M['!92KMZ3158++Z>7TH4J+M&*=U9:MVU>FZ\M[Z]"<=F
M-3,:TZM97G)JSN_=2OHM=GY[6TZGA7PO\%>+O&G[<_Q%^/'C'PS?V.E^&?#V
MG^#/ LE]:O$MW$V-0U*[B#@;T>:2U@$B_*39, 3BO=:**ZJ%%4(M)WNVW\W?
M\-EY)'+7KNO)-JUDDODK?CN_-L****V, HHHH ^TOV2_^3?O#_\ V]_^E<U>
MC5YS^R7_ ,F_>'_^WO\ ]*YJ]&K^=\[_ .1UB?\ KY/_ -*9_1^1_P#(DPO_
M %[A_P"DH****\L]4**** "BBB@ HHHH **** "BBB@ HHHH **** /BW]K3
M_DX'Q!_VZ?\ I)#7G->C?M:?\G ^(/\ MT_])(:\YK^B<D_Y$N&_Z]P_])1_
M-^>?\CO%?]?)_P#I3"BBBO3/+"BBB@ HHHH **** "BBB@ HHHH **** "OH
MS]@'_F;?^W#_ -N*^<Z^C/V ?^9M_P"W#_VXKYCC+_DFZ_\ V[_Z7$^IX*_Y
M*:A_V]_Z1(^C****_"C]["BBB@ HHHH **** "BBB@ K\YZ_1BOSGK].\./^
M8K_MS_V\_+?$K_F%_P"XG_M@4445^G'Y:%%%% !1110 4444 %%%% !1110
M4444 %%%% 'VE^R7_P F_>'_ /M[_P#2N:O1J\Y_9+_Y-^\/_P#;W_Z5S5Z-
M7\[YW_R.L3_U\G_Z4S^C\C_Y$F%_Z]P_])04445Y9ZH4444 %%%% !1110 4
M444 %%%% !1110 4444 ?%O[6G_)P/B#_MT_])(:\YKT;]K3_DX'Q!_VZ?\
MI)#7G-?T3DG_ ")<-_U[A_Z2C^;\\_Y'>*_Z^3_]*84445Z9Y84444 %%%%
M!1110 4444 %%%% !1110 5]&?L _P#,V_\ ;A_[<5\YU]&?L _\S;_VX?\
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M?VM/^3@?$'_;I_Z20UYS7HW[6G_)P/B#_MT_])(:\YK^B<D_Y$N&_P"O</\
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MS##AAR.X'H% !1110 4444 %%%% 'VE^R7_R;]X?_P"WO_TKFKT:O.?V2_\
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MY9ZH4444 %%%% !1110 4444 %%%% !1110 4444 ?%O[6G_ "<#X@_[=/\
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MIG]'Y'_R),+_ ->X?^DH****\L]4**** "BBB@ HHHH **** "BBB@ HHHH
M**** /BW]K3_ ).!\0?]NG_I)#7G->C?M:?\G ^(/^W3_P!)(:\YK^B<D_Y$
MN&_Z]P_])1_-^>?\CO%?]?)_^E,****],\L*^#_V@O%'[7_[)?\ P4&^&/QX
M^*WB3PKX]^'WQ#UZV^'ME%8>&&L+KPG+?RAD,&Z:9CYKQJ\DF]O-6WV%4VQ$
M?6?[1NC_ +1^M?#U8?V6/&GA?1/%,.I0R^=XPTN:ZLKFV7=YD#"%E>,ME?G&
M2 I  +;EX^W^ ?QA^,_BKP;XP_:PUCPH8? VKKK6D>&/!D%RUK/K"1/%#>SW
M%SAV6)99&CA5% D8.SR;5 \K,:=7$N-.FI*47&2DOAWUOKKIT:]-3U\MJTL+
MS5*CBXR4HN+^+;2VFEWLT_70]8\<>-_"OPW\(ZAXZ\;:S%I^E:9;F>\NI02%
M4< !0"78DA51069F"J"2!7C_ .R%\#_$&C^-_B#^UG\4-!?3/&'Q9U.UG?1Y
M\>9HNCV<(@T^RDQD"?R\RS;3@2RE.1&&/*?M9_L[?M\?&+XUZ1XR^"WQV^'V
M@>%O#6V?0] \0>&[B^+W^T9O9P&"/+&=PB&"L>=X'F89>E_9K^$G[>&@_$J;
MQ=^UI^TQX<\3Z/;:3)!I/A_PCX=.G1?:G=";BX8Y:7;&K*J9V@R%L;@I"E5J
MUL?%2HRM%^Z_=M>UG+XK[-I*W5]U8C2I4<ODX5H\TU[R][FM>ZBO=MNDWKT7
M9W][KYU_;Q7_ (6KXG^%/[(%N/,B\?\ C>/4_%$)^ZV@Z-MO[I6QR%DG6R@]
M_/(KT#]G+PC^T[X3/C#_ (:5^+6B^*_M_BZZN?!W]CZ.MI_9NCMCR;67:J[W
M7G).]O61\\5M!^!GB9_VPO$'[2GB_5+":R3P19>&O!=C;.YEM(3<276H2S!E
M"J\LHM5&PM\ELN<$X&^(]IB\,H*+7,TFG;2-];V;W2MOU1AAO9X3%2FYI\B;
M35]96]VUTMF[[=&'QT_9F@^*OQ0\"?'CPGXJCT'QK\/+B^_L34KK3#>VL]K>
M0>1<VMQ LL32(RA&4K(C(Z @D%E;R3PG^SY8^ +2^_8C^&WC"^U'4/&>MWOC
M/XZ^-47[/-Y6H3$RQ1B,G[/->M&;>-58M%;032;_ #%C9_J'Q)<Z[9>';^[\
M+:5!?:G%9ROIUE<W/D1SSA28XWD"MY:EL MM; ).#C%<G\ ?A%<_"7P;,GB;
M6$U?Q5KU\VJ^,M>2,J-0U&155V13RD,:)'!#'D[(88UR2"3-;!4JF(YHQU=W
M)Z[62LNEY))-[\J>JT*HXZM3PW+*6BLHK3>[:;ZVBVVE>W,UH]3P5O\ @I!X
M=\&^"-6^*V@_"2RMO@WX+^)$7@&[UR#5?*NH-DL5HU_#:+!Y?V*.>2.(+YH<
MH&<*-H1OK.OB3Q3_ ,$S?BEJOPB\5_L::9KWAX?"[QA\7!XMO-=EOIUU2STU
M[J*]FTM+40F-Y//A").9@/+<EDW*%;[;K/+98]N2Q"TLNB7O7ES)6^RERV?K
MJ:9G'+U&+PSUN^K?NVCRMWVDWS77IH%%%%>J>2%?1G[ /_,V_P#;A_[<5\YU
M]&?L _\ ,V_]N'_MQ7S'&7_)-U_^W?\ TN)]3P5_R4U#_M[_ -(D?1E%%%?A
M1^]A1110 4444 %%%% !1110 5^<]?HQ7YSU^G>''_,5_P!N?^WGY;XE?\PO
M_<3_ -L"BBBOTX_+0K,\6:IJ'AS0;WQ%H7@R\UV_A@'DZ7IDMO'<79!X17N)
M(HAC<3\[J!SWX.G7DWQP_:=\3?!+XF:)X./[,'Q%\6:'J]BTL_BOP7HZ:A!I
M\X<J(9H5<3+\H#;PI'S #=AMN->K3HT^:;LMKVOO\G^.G<VH4JE:IRP5WO:]
MKV^:_#7L?/G_  36^.WA?XB?M@_'G2_BO\%M<^'WQOUN_L]3\0^']:DCEC;0
M[2&.SL?LTD?RN$1D:1QD2/<AD9DPJ?5/Q*\9?#O]G#X*ZIXNU73$M]"T#3F,
M>FV<&Y[ER=L=M$@R9)II66-%&6>20#DM7F/PI^"^O>//VU-9_;G\6>!KOPQ$
MOPZ@\&^&=(U,1_;[NW^V->SWURD;,(<OY4<418R!4<N$+!!XQXR_:P_:D\2?
M'F;QAXG_ ."9GQ7U[PWX7OB? .FQM9P1><%*MJEPCR$M<$,RQ(>($+'F1R4\
M2A7GE^"Y:EW)RGRRY6VTW?FDHKJW=Z+F=MKZ>[7H0S''<U*RBHPYH\Z2NDER
MQ<GTV6KY5?>VOM'_  3!_9B\0_LD?L7^%/A/XTMX[?7I/M&JZ[90N#'97-W,
MTYMEQQB)62(D$@M&Q!P17T!7AOP^_:0_:/\ $O[._C/XZ^+OV0-9T76=(6Y?
MPI\-9M21]5U5(858%Y%4I&TLI=515<A4!^<N%'HOPO\ B-XA\8?!?1/BEX_^
M&NJ>%-3U#0XK_5/"LZ-=W>FRL@9[<B)-TCJ>,! Q[J#E1Z6!EA:6'IT*5TE%
M6NFM%IK=+7RWZV/,Q\<55Q%2O6LY2D[V:?O/72S>GFM.ESYE_P""20 \8_M3
MX'_-TGB?_P!"BJ#XN_LE?M >&/$W[3>E_";P)'XDL?VB?#MK;:1J3ZO;6\>@
M7K6$NG71O1,ZR-"$E$Z- DK'#(4! +7_ /@EWX9^(_P_\<_'N'XE_"3Q1X;7
MQO\ &[6_%?AF?6-&DCBN].N67RV+C*QR87)C<JW(QG!Q]%_'CQ_XO\!>!A_P
MK;PJ^L^*-9O(],\-V30NUNEW+G%Q=,@_=6T*J\TC$@E8RJY=T4^9A,+1KY1#
MVMURN3TWUYELUU4M-.JL>IC,56H9Q/V-GS*"UVTY9;IK9QUUZ.YXE:^!]%A^
M'WAC]AR3Q3$_@#X2^"]+B^,/B.YD$4%U!:V<?DZ4S$X19DC%S= G"6NR-N+H
M%?6/A%^UA\"_C3KMKX3\ ^([H7M_H":WHMKJ>B75@=3TIG"+>VOVB-//@W%?
MF3. Z$@!T+<-\>OV1]=U'_@G[X__ &:/A9K<M]XG\2>%M1\_6K^18Y]<U:X5
MI)IIW^ZIN)"5/\$:.$ "(H'D7PD\&_$/XP_M6?LU>-=!^&OB7P[I?P?^%&I6
MOCR;7] N=/2.]N[&WLX]+0SH@N'CDB>4F+?&%56W?.FZ_:XG!5X0C#XN5=7I
MS<O*G_<C[SWOJ]"/987&X>=24_AY^RUY>;F:_P"GDO=6UM%J?;]%%%>^?/!1
M110!]I?LE_\ )OWA_P#[>_\ TKFKT:O.?V2_^3?O#_\ V]_^E<U>C5_.^=_\
MCK$_]?)_^E,_H_(_^1)A?^O</_24%%%%>6>J%%%% !1110 4444 %%%% !11
M10 4444 %%%% 'Q;^UI_R<#X@_[=/_22&O.:]&_:T_Y.!\0?]NG_ *20UYS7
M]$Y)_P B7#?]>X?^DH_F_//^1WBO^OD__2F%%%%>F>6%%%% !1110 4444 %
M%%% !1110 4444 %?1G[ /\ S-O_ &X?^W%?.=?1G[ /_,V_]N'_ +<5\QQE
M_P DW7_[=_\ 2XGU/!7_ "4U#_M[_P!(D?1E%%%?A1^]A1110 4444 %%%%
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M-O\ VX?^W%?,<9?\DW7_ .W?_2XGU/!7_)34/^WO_2)'T91117X4?O84444
M%%%% !1110 4444 %?G/7Z,5^<]?IWAQ_P Q7_;G_MY^6^)7_,+_ -Q/_; H
MHHK]./RT**** "BBB@ HHHH **** "BBB@ HHHH **** /M+]DO_ )-^\/\
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M -*84445Z9Y84444 %%%% !1110 4444 %%%% !1110 5]&?L _\S;_VX?\
MMQ7SG7T9^P#_ ,S;_P!N'_MQ7S'&7_)-U_\ MW_TN)]3P5_R4U#_ +>_](D?
M1E%%%?A1^]A1110 4444 %%%% !1110 5^<]?HQ7YSU^G>''_,5_VY_[>?EO
MB5_S"_\ <3_VP****_3C\M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M[2_9+_Y-^\/_ /;W_P"E<U>C5YS^R7_R;]X?_P"WO_TKFKT:OYWSO_D=8G_K
MY/\ ]*9_1^1_\B3"_P#7N'_I*"BBBO+/5"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#XM_:T_P"3@?$'_;I_Z20UYS7HW[6G_)P/B#_MT_\ 22&O.:_H
MG)/^1+AO^O</_24?S?GG_([Q7_7R?_I3"BBBO3/+"BBB@ HHHH **** "BBB
M@ HHHH **** "OHS]@'_ )FW_MP_]N*^<Z^C/V ?^9M_[</_ &XKYCC+_DFZ
M_P#V[_Z7$^IX*_Y*:A_V]_Z1(^C****_"C]["BBB@ HHHH **** "BBB@ K\
MYZ_1BOSGK].\./\ F*_[<_\ ;S\M\2O^87_N)_[8%%%%?IQ^6A1110 4444
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M/K=/FY;VUDK7M?9KLMS\S=G[3/\ T8U\4_\ P7V7_P DT;/VF?\ HQKXI_\
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MBLC4^6?^&^_VF?\ I&#\4_\ P.LO_BJ/^&^_VF?^D8/Q3_\  ZR_^*KZFHH
MJZ%J%UJVB6>JWNERV,US:QRS64Y!>W9E!,;8XRI.#CN*M444 %%%% !1110
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MIUBWA;3O&5S*FE^'7FMI+BYNM3E@7S&M[9895Q$ T\IAC4KYH9?F_1OVY/\
M@JQ^P/\ MZ?"3]FO_@I1-\,_B)\._CSK3Z%X1\>_#?1;C3KG0]:POEVUQ!*Q
M#1,SH.<DJQ<2?NGC(!^F%%%% !1110 4444 %%%% !116#\4OB=X#^"OPUU_
MXO\ Q1\2V^C>&_"^CW.J:[JMT3Y=I:01M)+(V 20$4G !)Z $G% &]17Q/\
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M?[$NO^$+;X@6%C+<Z)I_CC1)KRPU65$++:.8;JW:W,A&T3;F"E@2I -?.?\
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M#+[X<W^I,MII'BJ&<07275RJDI90+F\>0#>;8 *IE94H ^PJ*_+SXN_MP_\
M!8G_ ()A_'OX6^)/^"@U[\(OB9\&?BKX[L_".IZI\-="O-.O?".IWC-Y!59W
M8S08#MEM[.L+*3&Y3S/N_P#;6^*'QP^"G[+_ (U^+O[/GA+POK/B/PSX:O\
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M(-9U'X674]S<$9$%N':3Y+>",^7#"N$1=QP7>1W /O[X#?!7P'^SA\$_"7P
M^%VG-:>'/!?AVST718)&W.MM;0K$A=L#<Y"@LW5F))ZU\V>(_AA9?\% _P!O
MGP+\9VMUF^%7[-VHZE-H>HD9C\4>-9D^RR- >CVNF1K(IE7A[R5HP3]ED!I?
M&/\ 9-_X*H>+OV#=,_9Y\"?MN^%D^*>N7MS+\2_BAJ^BW,8FMY9F<V>EV]J8
M_L,?E%+<.I5UCC9E(FD,J\+\,OV+/^"Y.BIX7^%_BK_@H#\'-"^&^F7-C::M
MI'PX^%C:9?)HL+H);.QE)*VCM K1)(H#1[@RD%0: /T&HHHH **** "BBB@
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MDFV?7M3E\V:"W) )MX$$5O&3C<(=^%+E1X-^T#^Q?_P6D^(/[86I_M*_"/\
M;(^"FA:78V\NG?#[P]KO@&\U+_A'K%V/F2(6<+]KG4()IP-Q51&A6/*GW?\
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M ,$Z_P!OZY_X*SW/_!4GP)X^^$%E,WPU7P3:>"]875+M$L1,)S,US$D):8R
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MC!)(CG+IR>.37=44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>jnj-20220703_g6.jpg
<TEXT>
begin 644 jnj-20220703_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\6^+7[7W_  J[X@ZAX$_X5Y]N^P^5_I7]K>5O
MWQ))]WRFQC?CJ>F:YS_AO[_JDW_E>_\ M%?14.$^(,31C5IT;QDDT^:&J:NM
MY'S=?B[A[#5Y4:E:THMIKEGHT[/:-MSZ,HKYS_X;^_ZI-_Y7O_M%'_#?W_5)
MO_*]_P#:*U_U-XD_Y\?^30_^2,O]=>&?^?\ _P"2S_\ D3Z,HKYS_P"&_O\
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MG_)P/B#_ +=/_22&O.:]&_:T_P"3@?$'_;I_Z20UYS7]$Y)_R)<-_P!>X?\
MI*/YOSS_ )'>*_Z^3_\ 2F%%%%>F>6%%%1W=W:V%K+?7US'#!!&TDTTKA5C0
M#)8D\  #))H#<DHKYETC_@H5XB^(/B'0]=^"G[,WBCQ9X(UKPWK>K:;JUI=6
M4%_K$&GW=A;M<V5K/<(6A)NVVK*8I9?D*)C[W8?%+]N;X;?#C]FSPO\ M+:3
MX$\8>*K3QJ+$>%/"_AC0S<:SJ3W41G6..V+ [UA621QGY1&W7C/#',<'*,I<
MVB5[V>VFJTU6JVONNZ.Z668V,HQ<-9.UKJ]]='KH]'O;9]F>U45\=Z?_ ,%?
MK%O&'AOPAXJ_X)^_M%^&3XJ\26>AZ7J/BCX?I86AO+F39&C2S7 4?Q,1R=J,
M<<&OL2M,+C<+C+^QE>V^C7YI$8K XK!<OMHVOMJG^3845XUJO[6U]KOBCQ;X
M9^ 7P6UCX@?\('>FQ\57NFZE:6L"7ZQK+)I]LT[C[3=1HR%T^2-#(JF0-E5Z
M_P#9W_:$^&/[47PETSXS_"35I;K2-3#J8KJ$Q7-G/&Q26VGC/,<L;@JRGTR"
M5()JGB\/5J>SC+77YV=G;H[/1VVZDU,)B*5/VDHZ:?*ZNKK=76JO:_0[:BBB
MN@Y@HHHH *^C/V ?^9M_[</_ &XKYSKZ,_8!_P"9M_[</_;BOF.,O^2;K_\
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M ,I5I_\ &J\YHH_L3)?^@:G_ . 1_P @_MS._P#H*J?^!R_S/1O^&L_V@?\
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MA1117G'I!1110 4444 %%%% !1110 4444 %%%% !1110!\6_M:?\G ^(/\
MMT_])(:\YKT;]K3_ ).!\0?]NG_I)#7G-?T3DG_(EPW_ %[A_P"DH_F_//\
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M-^\/_P#;W_Z5S5Z-7G/[)?\ R;]X?_[>_P#TKFKT:OYWSO\ Y'6)_P"OD_\
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M7PK\ :#\-/%GP?T?PY'!X;&F6FGC2TFDVBV=;I6CW%M^"&89SGGK7BE?1G[
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M<R);Z7%JUPT5E;NYP;BY9?G\F-<N50;WVA%P6W#Y=\*?M ?MX_L__MR_#_\
M9H_:BU?P9XY\,?%BQU5] U_PEH,VG7.DW5A;_:)DDB:60-"%9%R22?,#;AL*
MMQXG&T\+.,9Q=FTKI:)R=E?U>FB=NMCMPV!J8JG*4)1NDW9O5J*N[>BUU:OK
M:Y]C45Y+^T-!^V%XLU./P;^S!KGA3PG!#9"XU'Q?XLTR34/-E9F"6MM:QR(
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M=.2:DG9KK?L6Z*^8?@O_ ,%*]0^-OQ/T;X=Z1^P1^T'HMGK=SLA\6>)OA_\
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M]>7,E;[*7+9^NIEF<<O48O#/6[ZM^[:/*W?:3?-=>F@4445ZIY(5]&?L _\
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ME?\ ,+_W$_\ ; HHHK]./RT**** "BBB@ HHHH **** "BBB@ HHHH ****
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M</\ TE!1117EGJA1110 4444 %%%% !1110 4444 %%%% !1110!\6_M:?\
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M@PU&-*G6M&*22Y8:)*RWB?-U^$>'L37E6J4;RDVV^:>K;N]I6W/S-V?M,_\
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M  .LO_BJ^IJ*\(]\^6?^&^_VF?\ I&#\4_\ P.LO_BJ/^&^_VF?^D8/Q3_\
M ZR_^*KZFHH ^6?^&^_VF?\ I&#\4_\ P.LO_BJ/^&^_VF?^D8/Q3_\  ZR_
M^*KZFHH ^6?^&^_VF?\ I&#\4_\ P.LO_BJ/^&^_VF?^D8/Q3_\  ZR_^*KZ
MFHH ^6?^&^_VF?\ I&#\4_\ P.LO_BJ/^&^_VF?^D8/Q3_\  ZR_^*KZFHH
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M37Z944?ZY<2?\_\ _P EA_\ (A_J5PS_ ,^/_)I__)'YF[/VF?\ HQKXI_\
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MJ.M7 A2RF@TJ W<D[N0$"LLA8L>,'-? W[)WQ4C_ ."_7QV;1?V\O"X^%_\
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M_:A^-EK\2OB7=7EY?:YK]O:_V?ITDKR,+>VMH$0_9;>.%88\*I)822D,\C9
M/D;_ ()+?\I9/^"AO_91O"'_ *:KFOT2KXW_ &$/V%_VI/V8/VV?C]^T[\2O
M$W@+5-&^/GB'3M5O-*T2ZO4N?#YL;:>&&-&E@VW@=9$#$^3@J6&?N5]D4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 <5\2?V<O@9\7O$6F^-/B%\+])O_$&B@C0_$RV_D:KI@.=WV:]B*W%OG)SY
M<BYR<]:["PLH=-L8=.MWE:.")8T:>=Y9"%  +.Y+.W'+,22>22:EHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N%LOV9?@-H_Q+N?C'X9^&6G:'XHU"9)=8UOPZ'TZ?5F4Y7[<UJT?VX#
M)PMQY@&3Q7=44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>jnj-20220703_g7.jpg
<TEXT>
begin 644 jnj-20220703_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS_\ _)8?_(GT9_PW]_U2;_RO?_:*/^&_O^J3?^5[_P"T5\YT4?ZF\-_\^/\
MR:?_ ,D'^NO$W_/_ /\ )8?_ ")]&?\ #?W_ %2;_P KW_VBC_AO[_JDW_E>
M_P#M%?.=%'^IO#?_ #X_\FG_ /)!_KKQ-_S_ /\ R6'_ ,B?1G_#?W_5)O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_B'V2_\ /RI]\?\ Y /^(BYW_P ^Z?W2_P#DS[2_X:S_ &?O^A__ /*5=_\
MQJC_ (:S_9^_Z'__ ,I5W_\ &J^+:*/^(?9+_P _*GWQ_P#D _XB+G?_ #[I
M_=+_ .3/M+_AK/\ 9^_Z'_\ \I5W_P#&J/\ AK/]G[_H?_\ RE7?_P :KXMH
MH_XA]DO_ #\J??'_ .0#_B(N=_\ /NG]TO\ Y,^WO#W[2GP4\5:W;>'=!\:>
M?>7DHBMH?[.N5WL>@RT8 _$UW5?#'[/O_):_#7_85CK[GKX7BK),)D>+ITJ$
MI-2C?WFGU:Z)'WO">>8O/<'4JXB,4XRM[J:Z)]6PHHHKY<^J"BBB@ HHHH *
M*** "BBB@ HHHH **** "O)/VU?^2*-_V%;?_P!FKUNO)/VU?^2*-_V%;?\
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MI:U:RO O_(D:-_V"K?\ ]%+6K7\TXC^//U?YG].X;_=H>B_(****Q-PHHHH
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M[)"=R!Y #\YKO-3TO3-:T^;2-9TZ"[M+F,QW%K=0K)'*A&"K*P(8$=C7E8;
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M"BBBOSX_1 HHHH **** "BBB@ HHHH **** "BBB@ KR3]M7_DBC?]A6W_\
M9J];KR3]M7_DBC?]A6W_ /9J]GAW_D>X;_''\SQ.)/\ D0XG_ _R/D*BBBOZ
M#/YV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _0/P+_P B1HW_
M &"K?_T4M:M97@7_ )$C1O\ L%6__HI:U:_FG$?QY^K_ #/Z=PW^[0]%^044
M45B;A1110 4444 %%%% 'R]^WE_R.^A_]@I__1IKPBO=_P!O+_D=]#_[!3_^
MC37A%?O?"G_)/8?T?YL_G[B[_DH\1ZK_ -)04445]"?.!1110 4444 %%%%
M!1110 4444 %%%% !1110!V/[/O_ "6OPU_V%8Z^YZ^&/V??^2U^&O\ L*QU
M]SU^2>(?_(RH_P"#]6?L'AS_ ,BRM_C_ /;4%%%%?GQ^B!1110 4444 %%%%
M !1110 4444 %%%% !7DG[:O_)%&_P"PK;_^S5ZW7DG[:O\ R11O^PK;_P#L
MU>SP[_R/<-_CC^9XG$G_ "(<3_@?Y'R%1117]!G\[!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?H'X%_Y$C1O^P5;_ /HI:U:RO O_ ")&C?\
M8*M__12UJU_-.(_CS]7^9_3N&_W:'HOR"BBBL3<**** "BBB@ HHHH ^7OV\
MO^1WT/\ [!3_ /HTUX17N_[>7_([Z'_V"G_]&FO"*_>^%/\ DGL/Z/\ -G\_
M<7?\E'B/5?\ I*"BBBOH3YP**** "BBB@ HHHH **** "BBB@ HHHH ****
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M5*C!^;..#3M,\3^&M:\/IXLT?Q#8W>E2P&>+4[:[22W>(9)<2*2I48/.<<4
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M_P#:2_9M^''[4/PXN/AY\0[#UDTS4X5'GZ?/C EC)_)E/##@]B/0** /P_\
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M^T-\0]6U#1_[8T_R=,\,HY3[1 W(GND/YQH>1G<<9 K[@HHH **** "BBB@
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M8UH<\=GMY^?H^GD<U6E*C/DENM_+R]5U\PHHHK0S"BBB@#] _ O_ ")&C?\
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M5'0_&/\ ;X\*_#'Q/\0=%\.?#76/%%I\(M&L]4^)VH:9<PQ_V5!<(TRI"DC
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M%&_["MO_ .S5ZW7DG[:O_)%&_P"PK;_^S5[/#O\ R/<-_CC^9XG$G_(AQ/\
M@?Y'R%1117]!G\[!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?H
M'X%_Y$C1O^P5;_\ HI:U:RO O_(D:-_V"K?_ -%+6K7\TXC^//U?YG].X;_=
MH>B_(****Q-PHHHH **** "BBB@#Y>_;R_Y'?0_^P4__ *-->$5[O^WE_P C
MOH?_ &"G_P#1IKPBOWOA3_DGL/Z/\V?S]Q=_R4>(]5_Z2@HHHKZ$^<"BBB@
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MR3V']'^;/Y^XN_Y*/$>J_P#24%%%%?0GS@4444 %%%% !1110 4444 %%%%
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M?_@OLO\ Y)K],J*/]<N)/^?_ /Y+#_Y$/]2N&?\ GQ_Y-/\ ^2/S-V?M,_\
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M_@OLO_DFC9^TS_T8U\4__!?9?_)-?IE11_KEQ)_S_P#_ "6'_P B'^I7#/\
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MRMRI8?9W)]X_;&^,_P"V9#^UI\+?V9/V*?''@&VO/$5I=ZO\1E\8^#[K4O\
MA'O#]NP3^T0]O?6^))IW2V@@<?O765PX6"4@ ^I:*^:=5T__ (*?^.OCUXJT
M3P#\9/A=X+\ >'(=-LM)U#Q)\)=0U;4/$%\UC%/>7*>7K%G%#;+),L:$>:2\
M<R$@QY/S%_P3#_;*_P""M7_!3']G3XA?&/PS\=O@7X3U?P9\4-8\':?I%_\
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MZ+JTEDU^UG>#6KA7EMH+F20&2 *RPLQQC8>*\:_MI_\ !2#4/^"TMS_P2_\
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M-/\ B5X>\*W7A+Q-I'B-YH=-\7>'IY1.MG// DDEK-!<JL\4ZQ2C[R/&P*E
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M?&GQ&_BC4-"\;QW:KX2\2SQ+%>:G:);(POHKC9%*UG(UOMDC.V<(^Q*VG?\
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MD8))$<Y=.3QR:[JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>jnj-20220703_g8.jpg
<TEXT>
begin 644 jnj-20220703_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\KW_ -HH_P!3>)/^?'_DT/\ Y(/]=>&?^?\ _P"2S_\ D3Z,HKYS_P"&_O\
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M9'+B<=@L%;ZQ5C"^W-)*]M[7:O:YZ-17G/\ PUG^S]_T/_\ Y2KO_P"-4?\
M#6?[/W_0_P#_ )2KO_XU75_8F=?] U3_ , E_D<G]N9)_P!!5/\ \#C_ )GH
MU%><_P##6?[/W_0__P#E*N__ (U1_P -9_L_?]#_ /\ E*N__C5']B9U_P!
MU3_P"7^0?VYDG_053_\  X_YGHU%><_\-9_L_?\ 0_\ _E*N_P#XU1_PUG^S
M]_T/_P#Y2KO_ .-4?V)G7_0-4_\  )?Y!_;F2?\ 053_ / X_P"9Z-17G/\
MPUG^S]_T/_\ Y2KO_P"-4?\ #6?[/W_0_P#_ )2KO_XU1_8F=?\ 0-4_\ E_
MD']N9)_T%4__  ./^9Z-17G/_#6?[/W_ $/_ /Y2KO\ ^-4?\-9_L_?]#_\
M^4J[_P#C5']B9U_T#5/_  "7^0?VYDG_ $%4_P#P./\ F>C45YS_ ,-9_L_?
M]#__ .4J[_\ C5'_  UG^S]_T/\ _P"4J[_^-4?V)G7_ $#5/_ )?Y!_;F2?
M]!5/_P #C_F>C45YS_PUG^S]_P!#_P#^4J[_ /C5'_#6?[/W_0__ /E*N_\
MXU1_8F=?] U3_P  E_D']N9)_P!!5/\ \#C_ )GHU%><_P##6?[/W_0__P#E
M*N__ (U1_P -9_L_?]#_ /\ E*N__C5']B9U_P! U3_P"7^0?VYDG_053_\
M X_YGHU%9WA+Q;X?\=>'[?Q3X5U#[5876_R)_*=-VUV1OE<!AAE(Y':M&O-G
M"=*;A-6:T:>C36Z:/2IU(58*<&FFKIK5-/9I]@HHHJ2PHHHH **** "BBB@
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MI;^1U=%%<X/C!\*V^)Z_!6/XA:._BXZ:^H-X;COT:]2U1D4S/$#N1,R( S
MYXS@T2G&%N9VOH$83G?E5[:_(Z.BBBJ)"BBB@ HHHH ^TOV2_P#DW[P__P!O
M?_I7-7HU><_LE_\ )OWA_P#[>_\ TKFKT:OYWSO_ )'6)_Z^3_\ 2F?T?D?_
M "),+_U[A_Z2@HHHKRSU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+
M?VM/^3@?$'_;I_Z20UYS7HW[6G_)P/B#_MT_])(:\YK^B<D_Y$N&_P"O</\
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M/%/Q-U&#3]%UGQ3;:)<ZM=W(BAL'N$E\J61F& AE1$))4*)-Q.%(/P#_ ,%
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M_I7-7HU?SOG?_(ZQ/_7R?_I3/Z/R/_D287_KW#_TE!1117EGJA1110 4444
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MPGX%T2'PSX(\+Z=HVFV^?(T_2K*.W@CSUVQQ@*/P%:-?/_\ P\D_9P_X:/\
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M@ HHHH **** "BBB@ HHHH **** /BW]K3_DX'Q!_P!NG_I)#7G->C?M:?\
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M2 $B$D?+N. /3D5T%% '/^%O&&O:_P##B#QMJ?@+4-+U&73VN'\.W3J;F*0
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M:GJ<RCS]0GQ@RR$?D%'"C@=R?0* "BBB@ HHHH **** /M+]DO\ Y-^\/_\
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M%% !1110 4444 %%%% 'VE^R7_R;]X?_ .WO_P!*YJ]&KSG]DO\ Y-^\/_\
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MCP=IUV/AIIFKK]G:&.9,76NW2OCRGDA7RX8WP8H"[OM>=DB\?,L'3Q,HN/\
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MULK7MJ<=3 U*U&;I))7DVO.,7)Q7E"/I=WM?0^OZ***]L\(**** /M+]DO\
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M )'>*_Z^3_\ 2F%%%%>F>6%%%% !1110 4444 %%%% !1110 4444 %?1G[
M/_,V_P#;A_[<5\YU]&?L _\ ,V_]N'_MQ7S'&7_)-U_^W?\ TN)]3P5_R4U#
M_M[_ -(D?1E%%%?A1^]A1110 4444 %%%% !1110 5^<]?HQ7YSU^G>''_,5
M_P!N?^WGY;XE?\PO_<3_ -L"BBBOTX_+0HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^TOV2_^3?O#_\ V]_^E<U>C5YS^R7_ ,F_>'_^WO\ ]*YJ]&K^
M=\[_ .1UB?\ KY/_ -*9_1^1_P#(DPO_ %[A_P"DH****\L]4**** "BBB@
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M]IG_ *,:^*?_ (+[+_Y)HV?M,_\ 1C7Q3_\ !?9?_)-?IE11_KEQ)_S_ /\
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M/_/C_P FG_\ )'YF[/VF?^C&OBG_ ."^R_\ DFC9^TS_ -&-?%/_ ,%]E_\
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M];_L#QE\8M>T-]7GUO75&9M/T>T$T4*QP#'F7<[2*V]!'"RL): /MJBOA/\
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M7@3PS&NJ^+/@9IMM?2:GI>B[@9?^)J2%N+J&,[I9$41 H[)'(JA6^A/VL?\
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M  <#:'\(]<_;L^!^@_!72/!>A:9+X@L?@9XATB^N/$%UH<2&8_;+L.B)J#0
MR-;0E50_NP\CK\_V%^P]^UUIW[='[%'@;]K[X=^$O[//C?PN-0M]"U.]*K;7
MBEXY;9YUC8[%GC=/-$9)4!]G.V@#V2BOC#_@FA^W'^U-^T_^V!^U-\ ?VE?#
MG@[24^"WBS1-(\.V?@XW$L9ANH+N9I);BXVO.[*D//EQ*,$!!R3]GT %%%%
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MD1O+2,R2)';Q6\:;R3,SI)&K_2G_  4F_9,_X*5_M3?$7PF/V7?VC?AAX/\
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M[,_PJM9(O#W@?P[:Z1IAG(,LJ0QA3-(0 #)(VZ1R ,L['O7PEX,_83_X+]>
M_'OBSXFZ%_P4#^ SZ[XSU(7.L:G??"V[N)A#'N%M8Q,\I,5I;J[+%"OR@O)(
M=TLLLC_9_P"R)\,_VE_A+\ HM&_:A^-EK\2OB7=7EY?:YK]O:_V?ITDKR,+>
MVMH$0_9;>.%88\*I)822D,\C9 /D;_@DM_RED_X*&_\ 91O"'_IJN:_1*OC?
M]A#]A?\ :D_9@_;9^/W[3OQ*\3> M4T;X^>(=.U6\TK1+J]2Y\/FQMIX88T:
M6#;>!UD0,3Y."I89^Y7V10 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>jnj-20220703_g9.jpg
<TEXT>
begin 644 jnj-20220703_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"&_O\ JDW_ )7O_M%'_#?W_5)O_*]_]HKYSHH_U-X;_P"?'_DT_P#Y(/\
M77B;_G__ .2P_P#D3Z,_X;^_ZI-_Y7O_ +11_P -_?\ 5)O_ "O?_:*^<Z*/
M]3>&_P#GQ_Y-/_Y(/]=>)O\ G_\ ^2P_^1/HS_AO[_JDW_E>_P#M%'_#?W_5
M)O\ RO?_ &BOG.BC_4WAO_GQ_P"33_\ D@_UUXF_Y_\ _DL/_D3Z,_X;^_ZI
M-_Y7O_M%'_#?W_5)O_*]_P#:*^<Z*/\ 4WAO_GQ_Y-/_ .2#_77B;_G_ /\
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MAQ!1110 5]??L6?\D3C_ .PI<?\ LM?(-?7W[%G_ "1./_L*7'_LM?%\>_\
M(B_[?C^3/M_#_P#Y'S_P2_-'K5%%%?BY^VA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?#/[0G_);/$O\ V%'_ *5]S5\,_M"?\EL\2_\ 84?^
ME?H'AY_R,JW^#_VY'YWXC?\ (LH_X_\ VUG&T445^N'X^%%%% !1110 4444
M %%%% !1110 4444 %%%% 'Z">!_^1+T?_L%V_\ Z+6M2LOP/_R)>C_]@NW_
M /1:UJ5_-.(_CS]7^9_3V'_W>'HOR"BBBL38**** "BBB@ HHHH ^7_V\_\
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M?#8^)=1\*W4"+K4$61"+F&XAFB>2-2RI.J+,JL5#@8 ZSX4?"7P#\$O!-O\
M#[X;:$+#3;>669E:9Y9;B>5S)-/-+(6>::1V9WD<EF9B237+@LIEAJE'1+V?
M/JMY*6R?YN_5*USKQV;PQ5*MJW[7DT>T7'=K\E;HW>QTE%%%>^?/!1110 5]
M??L6?\D3C_["EQ_[+7R#7U]^Q9_R1./_ +"EQ_[+7Q?'O_(B_P"WX_DS[?P_
M_P"1\_\ !+\T>M4445^+G[:%%%% !1110 4444 %%%% !1110 4444 %%%%
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M>)?^PH_]*^YJ^&?VA/\ DMGB7_L*/_2OT#P\_P"1E6_P?^W(_._$;_D64?\
M'_[:SC:***_7#\?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]!/ _\
MR)>C_P#8+M__ $6M:E9?@?\ Y$O1_P#L%V__ *+6M2OYIQ'\>?J_S/Z>P_\
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MX^%%%% !1110 4444 %%%% !1110 4444 %%%% 'Z">!_P#D2]'_ .P7;_\
MHM:U*R_ _P#R)>C_ /8+M_\ T6M:E?S3B/X\_5_F?T]A_P#=X>B_(****Q-@
MHHHH **** "BBB@#Y?\ V\_^1TT+_L%O_P"C#7@]>\?MY_\ (Z:%_P!@M_\
MT8:\'K][X4_Y)[#^C_-G\_<7?\E'B/5?^DH****^A/G HHHH **** "BBB@
MHHHH **** "BBB@ KZ^_8L_Y(G'_ -A2X_\ 9:^0:^OOV+/^2)Q_]A2X_P#9
M:^+X]_Y$7_;\?R9]OX?_ /(^?^"7YH]:HHHK\7/VT**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KX9_:$_Y+9XE_P"PH_\ 2ON:OAG]H3_DMGB7
M_L*/_2OT#P\_Y&5;_!_[<C\[\1O^191_Q_\ MK.-HHHK]</Q\**** "BBB@
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MGP3=02Z9>RZMH<<;330Q!6>U82 CRY1\K'KCI6I\</AUXY^)WA*U\/\ P_\
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M-%<=\;_#WQI\2^$[6P^!'Q#TSPSK":S:37=_JNDB]CDL5DS<0!"1AW3Y0_\
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M/+_TCU/3)F'GZ?/C)BD _,,.&'([@?A_7T!_P3;_ .&C_P#AH^P_X9Y_V?\
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M_P#Z,->#U^]\*?\ )/8?T?YL_G[B[_DH\1ZK_P!)04445]"?.!1110 4444
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M/2:***] \X**** /T$\#_P#(EZ/_ -@NW_\ 1:UJ5E^!_P#D2]'_ .P7;_\
MHM:U*_FG$?QY^K_,_I[#_P"[P]%^04445B;!1110 4444 %%%% 'R_\ MY_\
MCIH7_8+?_P!&&O!Z]X_;S_Y'30O^P6__ *,->#U^]\*?\D]A_1_FS^?N+O\
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MRU\7Q[_R(O\ M^/Y,^W\/_\ D?/_  2_-'K5%%%?BY^VA1110 4444 %%%%
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MMS=&NZ/#:*]R_P"'0_[,W_0__%/_ ,./>_XT?\.A_P!F;_H?_BG_ .''O?\
M&OKO^(C_ /4+_P"3_P#VA\?_ ,0U_P"HK_R3_P"W/#:*]R_X=#_LS?\ 0_\
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M /V@?\0U_P"HK_R3_P"W/#:*]R_X=#_LS?\ 0_\ Q3_\./>_XT?\.A_V9O\
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M\.A_V9O^A_\ BG_X<>]_QH_X=#_LS?\ 0_\ Q3_\./>_XT?\1'_ZA?\ R?\
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M^*WQWC_: ^,7P_TGQ?JNG^'(]&\-VGB73(;VVT.(S2RW,MK'*K+'-<%XEEE
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M-M?!G@^Q\*?\()8^%--AT/[&UI_8T5C&MI]G92K1>2!LV$$@KC!!(Q6'X3^
M'P(\!:W'XF\#?!/PCHNI0JRPZAI/ANUMIXPP*L!)'&& ()!P>0<5UU% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952787344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  03,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Johnson & Johnson<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,629,179,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952937024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,983<span></span>
</td>
<td class="nump">$ 14,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">21,585<span></span>
</td>
<td class="nump">17,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, trade, less allowances $223 (2021, $230)</a></td>
<td class="nump">16,139<span></span>
</td>
<td class="nump">15,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 2)</a></td>
<td class="nump">11,437<span></span>
</td>
<td class="nump">10,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">3,703<span></span>
</td>
<td class="nump">3,701<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">63,847<span></span>
</td>
<td class="nump">60,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment at cost</a></td>
<td class="nump">47,144<span></span>
</td>
<td class="nump">47,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(28,790)<span></span>
</td>
<td class="num">(28,717)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">18,354<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (Note 3)</a></td>
<td class="nump">42,408<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="nump">34,166<span></span>
</td>
<td class="nump">35,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">9,514<span></span>
</td>
<td class="nump">10,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">9,435<span></span>
</td>
<td class="nump">10,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">177,724<span></span>
</td>
<td class="nump">182,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">4,305<span></span>
</td>
<td class="nump">3,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,765<span></span>
</td>
<td class="nump">11,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">12,607<span></span>
</td>
<td class="nump">13,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">13,447<span></span>
</td>
<td class="nump">12,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">2,717<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income (Note 5)</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">44,821<span></span>
</td>
<td class="nump">45,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 4)</a></td>
<td class="nump">28,292<span></span>
</td>
<td class="nump">29,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">5,015<span></span>
</td>
<td class="nump">7,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employee related obligations (Note 6)</a></td>
<td class="nump">8,553<span></span>
</td>
<td class="nump">8,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable (Note 5)</a></td>
<td class="nump">4,162<span></span>
</td>
<td class="nump">5,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">10,524<span></span>
</td>
<td class="nump">10,686<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">101,367<span></span>
</td>
<td class="nump">107,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss) (Note 7)</a></td>
<td class="num">(13,843)<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">126,216<span></span>
</td>
<td class="nump">123,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost (490,811,000 and 490,878,000 shares)</a></td>
<td class="nump">39,136<span></span>
</td>
<td class="nump">39,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">76,357<span></span>
</td>
<td class="nump">74,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 177,724<span></span>
</td>
<td class="nump">$ 182,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744951366128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">490,811,000<span></span>
</td>
<td class="nump">490,878,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744950674768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 24,020<span></span>
</td>
<td class="nump">$ 23,312<span></span>
</td>
<td class="nump">$ 47,446<span></span>
</td>
<td class="nump">$ 45,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesRevenueGoodsNetPercentToSales', window );">Sales to customers percent to sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 7,919<span></span>
</td>
<td class="nump">$ 7,587<span></span>
</td>
<td class="nump">$ 15,517<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CostOfGoodsSoldPercentToSales', window );">Cost of products sold percent to sales</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="nump">32.70%<span></span>
</td>
<td class="nump">32.10%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 16,101<span></span>
</td>
<td class="nump">$ 15,725<span></span>
</td>
<td class="nump">$ 31,929<span></span>
</td>
<td class="nump">$ 30,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GrossProfitPercentToSales', window );">Gross Profit Percent To Sales</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">67.50%<span></span>
</td>
<td class="nump">67.30%<span></span>
</td>
<td class="nump">67.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">$ 6,226<span></span>
</td>
<td class="nump">$ 6,073<span></span>
</td>
<td class="nump">$ 12,164<span></span>
</td>
<td class="nump">$ 11,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales', window );">Selling marketing and administrative expenses percent to sales</a></td>
<td class="nump">25.90%<span></span>
</td>
<td class="nump">26.10%<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
<td class="nump">25.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">$ 3,703<span></span>
</td>
<td class="nump">$ 3,394<span></span>
</td>
<td class="nump">$ 7,165<span></span>
</td>
<td class="nump">$ 6,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales', window );">Research and development expense percent to sales</a></td>
<td class="nump">15.40%<span></span>
</td>
<td class="nump">14.60%<span></span>
</td>
<td class="nump">15.10%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentInProcessPercentToSales', window );">In-process research and development percent to sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (64)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (86)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InvestmentIncomeInterestPercentToSales', window );">Interest income percent to sales</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net of portion capitalized</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InterestExpensePercentToSales', window );">Interest expense, net of portion capitalized percent to sales</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="num">$ (488)<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="num">$ (1,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherNonOperatingIncomeExpensePercentToSales', window );">Other (income) expense, net percent to sales</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (Note 12)</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Restructuringchargepercenttosales', window );">Restructuring charge percent to sales</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 5,840<span></span>
</td>
<td class="nump">$ 6,662<span></span>
</td>
<td class="nump">$ 11,702<span></span>
</td>
<td class="nump">$ 14,091<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales', window );">Earnings before provision for taxes on income percent to sales</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">28.60%<span></span>
</td>
<td class="nump">24.70%<span></span>
</td>
<td class="nump">30.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income (Note 5)</a></td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 1,739<span></span>
</td>
<td class="nump">$ 1,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxExpenseBenefitPercentToSales', window );">Provision for taxes on income percent to sales</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 4,814<span></span>
</td>
<td class="nump">$ 6,278<span></span>
</td>
<td class="nump">$ 9,963<span></span>
</td>
<td class="nump">$ 12,475<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_NetIncomeAttributableToParentPercentToSales', window );">Net earnings percent to sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">27.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (per share)</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (per share)</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>AVG. SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">2,629.6<span></span>
</td>
<td class="nump">2,632.5<span></span>
</td>
<td class="nump">2,629.4<span></span>
</td>
<td class="nump">2,632.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">2,667.9<span></span>
</td>
<td class="nump">2,671.6<span></span>
</td>
<td class="nump">2,669.2<span></span>
</td>
<td class="nump">2,674.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CostOfGoodsSoldPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CostOfGoodsSoldPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_GrossProfitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross profit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_GrossProfitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeTaxExpenseBenefitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax expense benefit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeTaxExpenseBenefitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InterestExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InterestExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InvestmentIncomeInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment income interest percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InvestmentIncomeInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NetIncomeAttributableToParentPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income Attributable to Parent Percent to Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NetIncomeAttributableToParentPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonOperatingIncomeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other non operating income expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonOperatingIncomeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense excluding acquired in process cost percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentInProcessPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>research and development in process percent to sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentInProcessPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Restructuringchargepercenttosales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring charge percent to sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Restructuringchargepercenttosales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesRevenueGoodsNetPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales revenue goods net percentage to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesRevenueGoodsNetPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling general and administrative expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SellingGeneralAndAdministrativeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947628688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 4,814<span></span>
</td>
<td class="nump">$ 6,278<span></span>
</td>
<td class="nump">$ 9,963<span></span>
</td>
<td class="nump">$ 12,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service cost amortization during period</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss) amortization during period</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to earnings</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="num">(343)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(277)<span></span>
</td>
<td class="num">(465)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="num">(785)<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 4,728<span></span>
</td>
<td class="nump">$ 6,506<span></span>
</td>
<td class="nump">$ 9,178<span></span>
</td>
<td class="nump">$ 12,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952685744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign Currency Translation</a></td>
<td class="nump">$ 533<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
<td class="nump">$ 678<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Securities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee Benefit Plans</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives &amp; Hedges</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744954431168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jan. 03, 2021</a></td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="nump">$ 113,890<span></span>
</td>
<td class="num">$ (15,242)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (38,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">12,475<span></span>
</td>
<td class="nump">12,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(5,450)<span></span>
</td>
<td class="num">(5,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">1,204<span></span>
</td>
<td class="num">(761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,069)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jul. 04, 2021</a></td>
<td class="nump">69,580<span></span>
</td>
<td class="nump">120,154<span></span>
</td>
<td class="num">(15,100)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,594)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Apr. 04, 2021</a></td>
<td class="nump">65,834<span></span>
</td>
<td class="nump">116,508<span></span>
</td>
<td class="num">(15,328)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">6,278<span></span>
</td>
<td class="nump">6,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,791)<span></span>
</td>
<td class="num">(2,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jul. 04, 2021</a></td>
<td class="nump">69,580<span></span>
</td>
<td class="nump">120,154<span></span>
</td>
<td class="num">(15,100)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,594)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jan. 02, 2022</a></td>
<td class="nump">74,023<span></span>
</td>
<td class="nump">123,060<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(39,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">9,963<span></span>
</td>
<td class="nump">9,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(5,758)<span></span>
</td>
<td class="num">(5,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">1,464<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jul. 03, 2022</a></td>
<td class="nump">76,357<span></span>
</td>
<td class="nump">126,216<span></span>
</td>
<td class="num">(13,843)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(39,136)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Apr. 03, 2022</a></td>
<td class="nump">74,709<span></span>
</td>
<td class="nump">124,380<span></span>
</td>
<td class="num">(13,757)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(39,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">4,814<span></span>
</td>
<td class="nump">4,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,971)<span></span>
</td>
<td class="num">(2,971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">864<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jul. 03, 2022</a></td>
<td class="nump">$ 76,357<span></span>
</td>
<td class="nump">$ 126,216<span></span>
</td>
<td class="num">$ (13,843)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (39,136)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952676400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947483280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 9,963<span></span>
</td>
<td class="nump">$ 12,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="nump">3,513<span></span>
</td>
<td class="nump">3,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="num">(2,349)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(1,386)<span></span>
</td>
<td class="num">(1,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(1,257)<span></span>
</td>
<td class="num">(818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accrued liabilities</a></td>
<td class="num">(1,170)<span></span>
</td>
<td class="num">(4,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other current and non-current assets</a></td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in other current and non-current liabilities</a></td>
<td class="num">(2,456)<span></span>
</td>
<td class="num">(1,150)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH FLOWS FROM OPERATING ACTIVITIES</a></td>
<td class="nump">9,560<span></span>
</td>
<td class="nump">9,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(1,470)<span></span>
</td>
<td class="num">(1,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net (Note 10)</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note 10)</a></td>
<td class="num">(523)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(22,048)<span></span>
</td>
<td class="num">(12,264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">17,634<span></span>
</td>
<td class="nump">12,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (primarily licenses and milestones)</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED BY INVESTING ACTIVITIES</a></td>
<td class="num">(6,273)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="num">(5,758)<span></span>
</td>
<td class="num">(5,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(2,550)<span></span>
</td>
<td class="num">(2,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="nump">4,371<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="num">(2,201)<span></span>
</td>
<td class="num">(689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(2,132)<span></span>
</td>
<td class="num">(1,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED BY FINANCING ACTIVITIES</a></td>
<td class="num">(6,646)<span></span>
</td>
<td class="num">(8,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(145)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease)/Increase in cash and cash equivalents</a></td>
<td class="num">(3,504)<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash equivalents, beginning of period</a></td>
<td class="nump">14,487<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">10,983<span></span>
</td>
<td class="nump">14,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed and noncontrolling interests</a></td>
<td class="num">(98)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions</a></td>
<td class="nump">$ 523<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744955978400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of July&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended July&#160;3, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal second quarter of 2022 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal second quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139745058649024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">INVENTORIES <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952043232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of July&#160;3, 2022 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $1.2&#160;billion for the fiscal second quarters ended July&#160;3, 2022 and July&#160;4, 2021, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $2.2&#160;billion and $2.4&#160;billion for the fiscal six months ended July&#160;3, 2022 and July&#160;4, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744955883904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of July&#160;3, 2022, the cumulative amount of cash collateral received by the Company under the CSA amounted to $233.0 million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of July&#160;3, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $46.7&#160;billion, $37.2&#160;billion and $10.0&#160;billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion,  $37.4 billion and $10.0 billion respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July&#160;3, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $613&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2022 and 2021, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2022 and 2021, net of tax:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  July&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,010)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended  2022 and 2021: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.277%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal second quarters ended in 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal six months ended in 2022 and 2021</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:24.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair  </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:25.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.464%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, there was a decrease of $14 million in the fair value reflected in net income as a result of impairments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the fiscal second quarter ended July&#160;3, 2022, the Company sold all of its shares in argenx SE for proceeds of $0.6&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of July&#160;3, 2022 and January&#160;2, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $519 million and $520 million, classified as non-current other liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $17 million and $13 million classified as current liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of July&#160;3, 2022 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:30.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/( Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;2, 2022 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of July&#160;3, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of July&#160;3, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.0408)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500MM GBP 1.2143)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.550% Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.0408)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.0408)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is 3.04%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $3.2 billion at January 2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of July&#160;3, 2022 includes $3.8&#160;billion of commercial paper which has a weighted average interest rate of 0.98% and a weighted average maturity of approximately two months.</span></div>Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952013744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal six months quarters of 2022 and 2021 were 14.9% and 11.5%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal quarter is primarily due to the Company reorganizing the ownership structure of certain wholly-owned international subsidiaries in the second fiscal quarter of 2021.  As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with the applicable local regulations.  Accordingly the Company recorded a local deferred tax benefit of approximately $2.3&#160;billion which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $1.7&#160;billion. The net impact of this reorganization was approximately $0.6&#160;billion net benefit or a 4.4% decrease to the effective tax rate of the fiscal six months of 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, the Company had lower income in higher tax jurisdictions, primarily in the U.S., compared to the same period in the prior year and certain one-time tax costs.  This lower income in the fiscal six months of 2022 was primarily caused by a mark to market adjustment to the Company&#8217;s investment portfolio, the impairment of the Bermekimab AD IPR&amp;D (for further information see Note 3 to the Consolidated Financial Statements), both at the U.S. statutory rate, and litigation expenses. The impact of the income mix was partially offset by incremental tax costs directly related to the planned separation of the Company&#8217;s Consumer Health business (for further information see Note 1 to the Consolidated Financial Statements)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal second quarters. Additionally, the Company&#8217;s tax rate benefited from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of July&#160;3, 2022, the Company had approximately $3.4 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.  In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div>Subsequent to July 3, 2022, as part of the planned separation of the Company&#8217;s Consumer Health business the Company has recognized approximately $0.3&#160;billion in incremental tax costs due to the reorganization of certain international subsidiaries which will be recorded in the fiscal third quarter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744951972368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and Other Benefit Plans</a></td>
<td class="text">PENSIONS AND OTHER BENEFIT PLANS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal six months ended July&#160;3, 2022, the Company contributed $54 million and $10 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744956807536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,843)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952045664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:53.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,669.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The diluted net earnings per share calculation for both the fiscal second quarter ended July&#160;3, 2022 and July&#160;4, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. </span></div>The diluted net earnings per share calculation for the fiscal six months ended July&#160;3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. The diluted net earnings per share calculation for the fiscal six months ended July&#160;4, 2021 excluded 14&#160;million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744955873296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business and Geographic Areas</a></td>
<td class="text">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA / INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Approximately $0.1&#160;billion in the fiscal second quarter of 2021 and $0.2&#160;billion in the fiscal six months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Previously referred to as Medical Devices</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:36.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.904%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*The 2021 fiscal second  quarter and six months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $0.1 billion in both the fiscal second quarter of 2022 and 2021 and $0.2&#160;billion in both the fiscal six months of 2022 and 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Litigation expense of $0.1&#160;billion in both the fiscal second quarters and fiscal six months of 2022 and 2021, primarily for talc related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6&#160;billion in the fiscal six months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal second quarter of 2022 and 2021, respectively. Intangible amortization expense of $1.5&#160;billion and $1.7&#160;billion in the fiscal six months of 2022 and 2021, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the fiscal six months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A loss of $0.1&#160;billion and a gain of $0.2&#160;billion related to the change in the fair value of securities in the fiscal second quarter of 2022 and 2021, respectively. A loss of $0.5&#160;billion and a gain of $0.1&#160;billion related to the change in the fair value of securities in the fiscal six months of 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $0.2&#160;billion in both the fiscal second quarter and fiscal six months 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal second quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $0.3&#160;billion in both the fiscal second quarters and fiscal six months of 2022 primarily pelvic mesh related costs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.2 billion and $0.1&#160;billion in the fiscal six months of 2022 and 2021, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.3&#160;billion in both the fiscal second quarter of 2022 and 2021 and $0.5&#160;billion in both the fiscal six months of 2022 and 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest income/expense and general corporate income/expense. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,085&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,668&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744955838736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">ACQUISITIONS AND DIVESTITURESThere were no material acquisitions or divestitures in the fiscal first quarter and fiscal second quarter of 2022. During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744955883904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">LEGAL PROCEEDINGS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of  July&#160;3, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON&#8217;S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of July&#160;3, 2022, in the United States there were approximately 190 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 1,900 with respect to the PINNACLE Acetabular Cup System; 9,500 with respect to pelvic meshes; 2,100 with respect to RISPERDAL; 3,000 with respect to XARELTO; 40,300 with respect to body powders containing talc; 10 with respect to INVOKANA;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> 4,700 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; and 1,300 with respect to ELMIRON. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia  and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. In March 2022, the Court appointed a barrister to prepare a written report and recommendation on the form and mechanism of the individual case assessment process, due by August 2022, with a court hearing on those findings later that month. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of July 2022, there are approximately 126 active cases subject to these orders which are being reviewed and evaluated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp; Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No. ED 207476 (Mo. App.), reducing the overall award to  $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. Opening briefs were filed in June 2022 and briefing is to be completed by September 2022. Additionally, an industrial talc class action was filed against the Company and others in New Jersey state court in May 2022. The case was subsequently removed to federal court. In July 2022, Imerys, and LTL, filed a motion to stay the industrial talc class action. The court heard oral argument and a ruling is expected at any time. While the New Jersey Bankruptcy Court&#8217;s order effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#8217;s insurers (the Mediation Parties) have since agreed to engage in mediation, which remains ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC)  (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#8220;talc-related claims&#8221; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs&#8217; motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record.  In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action, and Plaintiff filed a notice of appeal regarding the Bankruptcy Court&#8217;s order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In July 2022, the Court denied Plaintiff's discovery motion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well the Court of Common Pleas in Philadelphia, where an application is pending for mass tort designation. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MedTech</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos.  6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447);  and 9,452,276 (&#8217;276) based on Auris&#8217; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the  &#8217;056,  &#8217;447, &#8217;276 and &#8217;906 patents.  In December 2019, the USPTO  denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the  &#8217;447,  and &#8217;906 patents and denied review of the &#8217;276 patent. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris appealed, and  in April 2022, the United States Court of Appeals for the Federal Circuit vacated the decision that the &#8217;447 patent was not invalid and remanded the decision  to the USPTO for further review.  In May 2022, the United States Court of Appeals for the Federal Circuit confirmed the ruling that claim 53 of the &#8217;906 patent was not invalid, vacated the decision that the remaining claims of the &#8217;906 patent were not invalid and remanded the decision  to the USPTO for further review. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 (&#8217;234) and 9,713,537 (&#8217;537) by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. Trial is scheduled to begin in December 2022. In June 2022, DePuy filed potentially dispositive summary judgment motions that the &#8217;234 patent is invalid as anticipated and the &#8217;537 patent is not infringed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 (&#8217;180) and 10,517,583 (&#8217;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#8217;180 patent, and awarding damages in the amount of $20&#160;million. DePuy is challenging the verdict in its post-trial motions. In July 2022, a hearing was held on the post-trial motions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc., Janssen Oncology, Inc., and BTG International Ltd. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision. The appeal hearing has been scheduled to take place in September 2022. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In April 2021, July 2021 and April 2022, respectively, Apotex, DRL and Pharmascience initiated Statements of Claim under Section 8 of the Patented Medicines (Notice of Compliance) Regulations against Janssen seeking damages in respect of those parties generic Zytiga tablets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> Trials against Apotex and DRL are scheduled for June 2023. A trial date for the Pharmascience action has not been set.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#8217;310). The following generic drug companies are named defendants:  Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. No trial date has been set in this lawsuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Micro Labs Ltd. and Micro Labs USA Inc. (collectively, Micro) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In March 2022, the case against Micro was consolidated for all purposes, including trial, with the consolidated Delaware lawsuits. In July 2022, the parties entered into a confidential settlement agreement, and the action was dismissed. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Partes Review with the United States Patent and Trademark Office, seeking to invalidate the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022, Janssen Pharmaceuticals, Inc. (JPI), Bayer Intellectual Property GmbH and Bayer AG filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Changzhou Pharmaceutical Factory, which filed an ANDA seeking approval to market generic a version of XARELTO (10 mg, 15 mg, and 20 mg) before expiration of U.S. Patent No. 9,539,218 (&#8217;218). In this lawsuit, JPI, Bayer Intellectual Property GmbH and Bayer AG are seeking an order enjoining Changzhou from marketing its generic version of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. In June 2022, the parties entered into a confidential settlement agreement, and the action was dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA/INVOKAMET/INVOKAMET XR</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788) relating to INVOKAMET. In this lawsuit, Janssen and MTPC are seeking an order enjoining DRL from marketing its generic version of INVOKAMET before the expiration of the &#8217;788 patent. In June 2022, the parties entered into a confidential settlement agreement and the lawsuit was dismissed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Sandoz stipulated to infringement of the &#8217;770 patent.  Trial against Sandoz on the issue of validity concluded in February 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Sandoz appealed the decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Apotex stipulated to validity of the &#8217;770 patent.  Trial against Apotex on the issue of infringement concluded in March 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Apotex appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of United States Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. A trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. The action has been consolidated with the November 2020 action for trial, which took place in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS (original ANDS) seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Janssen Canada initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex in response to Apotex&#8217;s Notice of Allegation of invalidity with respect to the original ANDS and in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Trial is scheduled to begin in October 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before expiration of the &#8217;693 patent.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. The trial is scheduled to begin in July 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SYMTUZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of United States Patent Nos. 10,039,718 (the &#8217;718 patent) and 10,786,518 (the &#8217;518 patent). Janssen is seeking an order enjoining Lupin from marketing its generic version of SYMTUZA before the expiration of the &#8217;718 and &#8217;518 patents. The trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ERLEADA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of United States Patent No. 9,481,663 (the &#8217;663 patent). Janssen and SKI are seeking an order enjoining Lupin from marketing its generic version of ERLEADA before the expiration of the &#8217;663 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited (collectively, Zydus), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663 patent and United States Patent Nos. 9,884,054 (the &#8217;054 patent), 10,052,314 (the &#8217;314 patent), 10,702,508 (the &#8217;508 patent), and 10,849,888 (the &#8217;888 patent). Janssen and SKI are seeking an order enjoining Zydus from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc.  and Janssen Biotech, Inc. (collectively, Janssen), The Regents of the University of California (UC), and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Sandoz Inc. (Sandoz), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663 patent and United States Patent Nos. 8,445,507 (the &#8217;507 patent), 8,802,689 (the &#8217;689 patent), 9,338,159 (the &#8217;159 patent), and 9,987,261 (the &#8217;261 patent). Janssen, UC, and SKI are seeking an order enjoining Sandoz from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;689, &#8217;159, and &#8217;261 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and  Janssen Biotech, Inc. (collectively, Janssen), The Regents of the University of California (UC), and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States  District Court for the Districts of New Jersey and Delaware against Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively, Eugia), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of  the &#8217;663, &#8217;507, &#8217;689, &#8217;159 and &#8217;261 patents. Janssen, UC, and SKI are seeking </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">an order enjoining Eugia from marketing its generic version of ERLEADA before the expiration of the &#8217;663,&#8217;507, &#8217;689, &#8217;159, and &#8217;261 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen), The Regents of the University of California (UC), and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Hetero Labs Limited Unit V and Hetero USA, Inc. (collectively, Hetero), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507,&#8217;054, &#8217;314,&#8217;508, and&#8217;888 patents. Janssen, UC, and SKI are seeking an order enjoining Hetero from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Other Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#8217; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#8217; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in response to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment and directed entry of judgment for Defendants. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#8217; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of  $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement is expected to be paid by the end of fiscal year 2022, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022 and initial payments were made in July 2022. In April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions. Consequently, by July 2022, the Company had settled the opioid claims advanced by all states except Washington and New Hampshire.  A trial of claims brought by the Attorney General of New Hampshire is scheduled to begin in September 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are approximately 60 cases remaining post-settlement in various state courts. There are approximately 1,000 remaining federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.  By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted Johnson &amp; Johnson&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder filed a notice of appeal regarding the state court&#8217;s dismissal order.   </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit. The relators&#8217; opening brief was filed in May 2022 and was accepted for filing by the First Circuit in June 2022. DePuy&#8217;s opposition brief is due in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene.  The case has been transferred to the United States District Court for the District of New Jersey. Janssen&#8217;s motion to dismiss was denied in December 2021, and discovery is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for May 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company's petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. The Company plans to petition for review by the United States Supreme Court.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting as barred by the stay arising from the LTL Bankruptcy Case, while the State argued that the stay did not apply. In January 2022, the Court granted plaintiff&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. The temporary stay expired in May 2022. The State has proposed a scheduling order for further proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court. The 60-day stay expired in June 2022, and the State made a motion for a modified scheduling order. A motion is before the court. In June 2022, the New Mexico Supreme Court granted oral argument on the Company's Writ for Superintending Control on the issue of the State of New Mexico&#8217;s discovery obligations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to enter into negotiations to determine if they would resolve their claims through the LTL Bankruptcy Case.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products, LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. This case was settled in March 2022, subject to Court approval. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022, subject to Court approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. This case was settled in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2022, defendants petitioned for rehearing en banc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for February 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, Janssen Pharmaceuticals, Inc. filed an arbitration demand against Emergent Biosolutions Inc. et al (&#8220;EBSI&#8221;) with the American Arbitration Association, alleging that EBSI breached the parties&#8217; Manufacturing Services Agreement for the Company&#8217;s COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952067488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">RESTRUCTURING<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal second quarter of 2022, the Company recorded a net pre-tax charge of $128 million, which is included on the following lines of the Consolidated Statement of Earnings, $85 million in restructuring, $17 million in cost of products sold and $26 million in other (income) expense, net.  In the fiscal six months of 2022, the Company recorded a net pre-tax charge of $200&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $155&#160;million in restructuring, $33&#160;million in cost of products sold and $12&#160;million in other (income) expense, net. Total project costs of approximately $2.0 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.1 billion to $2.3 billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal second quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:32.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, July 3, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947404512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of July&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended July&#160;3, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New and Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal second quarter of 2022 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal second quarter of 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952045664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952704640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of July&#160;3, 2022 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952800064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2022 and 2021, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2022 and 2021, net of tax:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal second quarters ended in 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal six months ended in 2022 and 2021</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:24.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  July&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,010)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended  2022 and 2021: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.010%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.277%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:25.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.464%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of July&#160;3, 2022 and January&#160;2, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $519 million and $520 million, classified as non-current other liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $17 million and $13 million classified as current liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.</span></div>           (6)    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of July&#160;3, 2022 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:30.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/( Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available for Sale Securities Maturities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of July&#160;3, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial Liabilities not Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of July&#160;3, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.0408)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500MM GBP 1.2143)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.550% Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.0408)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.0408)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744955873296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744952051520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,843)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744955874112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:53.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,669.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744956181168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Sales By Segment Of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA / INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Approximately $0.1&#160;billion in the fiscal second quarter of 2021 and $0.2&#160;billion in the fiscal six months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Previously referred to as Medical Devices</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating Profit by Segment of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:36.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.904%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*The 2021 fiscal second  quarter and six months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $0.1 billion in both the fiscal second quarter of 2022 and 2021 and $0.2&#160;billion in both the fiscal six months of 2022 and 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Litigation expense of $0.1&#160;billion in both the fiscal second quarters and fiscal six months of 2022 and 2021, primarily for talc related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6&#160;billion in the fiscal six months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal second quarter of 2022 and 2021, respectively. Intangible amortization expense of $1.5&#160;billion and $1.7&#160;billion in the fiscal six months of 2022 and 2021, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the fiscal six months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A loss of $0.1&#160;billion and a gain of $0.2&#160;billion related to the change in the fair value of securities in the fiscal second quarter of 2022 and 2021, respectively. A loss of $0.5&#160;billion and a gain of $0.1&#160;billion related to the change in the fair value of securities in the fiscal six months of 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $0.2&#160;billion in both the fiscal second quarter and fiscal six months 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal second quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $0.3&#160;billion in both the fiscal second quarters and fiscal six months of 2022 primarily pelvic mesh related costs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.2 billion and $0.1&#160;billion in the fiscal six months of 2022 and 2021, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.3&#160;billion in both the fiscal second quarter of 2022 and 2021 and $0.5&#160;billion in both the fiscal six months of 2022 and 2021.</span></div>(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Second Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,085&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,668&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744955883904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal second quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:32.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, July 3, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947611232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 1,696<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">2,324<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,417<span></span>
</td>
<td class="nump">6,508<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 11,437<span></span>
</td>
<td class="nump">$ 10,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744946182560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">$ 15,570<span></span>
</td>
<td class="nump">$ 16,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets - net</a></td>
<td class="nump">42,408<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">6,794<span></span>
</td>
<td class="nump">6,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased In-Process Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">8,776<span></span>
</td>
<td class="nump">9,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">36,885<span></span>
</td>
<td class="nump">38,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(20,336)<span></span>
</td>
<td class="num">(20,088)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">16,549<span></span>
</td>
<td class="nump">18,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">22,558<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(12,269)<span></span>
</td>
<td class="num">(11,925)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">10,289<span></span>
</td>
<td class="nump">$ 11,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947455888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill By Segment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 03, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">$ 35,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(1,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">34,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">9,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">9,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">10,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">10,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">14,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">$ 14,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744951330672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744956763040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 03, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947332816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Accumulated other comprehensive income on derivatives, after tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss', window );">Reclassification of foreign exchange contracts into earnings, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">next 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Maximum length of time for hedge exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate on non-current debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt', window );">Excess of the estimated fair value over the carrying value of debt</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,305<span></span>
</td>
<td class="nump">$ 3,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral already posted, aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,700<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,200<span></span>
</td>
<td class="nump">37,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember', window );">Equity Investments without readily determinable value | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentImpairmentLoss', window );">Equity, fair value adjustment, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of fair value over carrying value of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfFairValueOverCarryingValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744945573104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="num">(241)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(39)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947442736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">$ 3,097<span></span>
</td>
<td class="nump">$ 1,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term Debt | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">9,035<span></span>
</td>
<td class="nump">9,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability</a></td>
<td class="num">$ (1,010)<span></span>
</td>
<td class="num">$ (142)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744954414560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947340784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">313<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract | Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744946179792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 9,435<span></span>
</td>
<td class="nump">$ 10,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, end of period</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments with readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, beginning of period</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, end of period</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, beginning of period</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, end of period</a></td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744945362128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">$ 3,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">21,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">3,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(3,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,285)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total Net Asset</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total Gross Liabilities</a></td>
<td class="nump">3,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(2,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,855)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total Net Liabilities</a></td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value (6)</a></td>
<td class="num">(88)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">$ 593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">3,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">21,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947915888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">$ 21,123<span></span>
</td>
<td class="nump">$ 19,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">10,983<span></span>
</td>
<td class="nump">14,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">21,585<span></span>
</td>
<td class="nump">$ 17,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and current marketable securities, Carrying Amount</a></td>
<td class="nump">32,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss', window );">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue', window );">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</a></td>
<td class="nump">32,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">11,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">11,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">8,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">3,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">3,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">3,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Non-U.S. sovereign securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">2,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">2,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">21,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">21,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">18,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Non-U.S. sovereign securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">20,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">20,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 18,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744956591184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 03, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 21,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">21,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">21,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 21,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744940781200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 03, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 03, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 4,305,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,766,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">28,292,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,985,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">4,305,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">28,292,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">4,304,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 26,781,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 263,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 802,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.0408)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">1.0408<span></span>
</td>
<td class="nump">1.0408<span></span>
</td>
<td class="nump">1.0408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.0408) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 774,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.0408) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 766,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500MM GBP 1.2143)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">1.2143<span></span>
</td>
<td class="nump">1.2143<span></span>
</td>
<td class="nump">1.2143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500MM GBP 1.2143) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 605,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500MM GBP 1.2143) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 647,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 749,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">745,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">940,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 872,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,995,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,950,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 911,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 899,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,423,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,264,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,462,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.0408)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">1.0408<span></span>
</td>
<td class="nump">1.0408<span></span>
</td>
<td class="nump">1.0408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.0408) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 776,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.0408) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 735,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 298,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 372,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,646,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,404,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 498,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 554,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 855,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">895,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.0408) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,554,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">1.0408<span></span>
</td>
<td class="nump">1.0408<span></span>
</td>
<td class="nump">1.0408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.0408) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 885,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 848,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 993,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,181,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,381,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,328,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 992,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 898,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 697,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 817,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 546,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 876,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 647,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 297,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 312,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 506,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,975,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,830,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 863,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 806,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 677,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 864,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 599,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,108,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">773,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744951333872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 29, 2022</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Worldwide effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.90%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax benefit, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent', window );">Decrease in effective tax rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Incremental tax costs related to restructuring</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947936256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">$ 327<span></span>
</td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">$ 680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(693)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
<td class="num">(1,392)<span></span>
</td>
<td class="num">(1,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947680496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 03, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947576608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 74,709<span></span>
</td>
<td class="nump">$ 65,834<span></span>
</td>
<td class="nump">$ 74,023<span></span>
</td>
<td class="nump">$ 63,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="num">(785)<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">76,357<span></span>
</td>
<td class="nump">69,580<span></span>
</td>
<td class="nump">76,357<span></span>
</td>
<td class="nump">69,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Foreign Currency Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(10,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Investment Gain (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(2,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(13,757)<span></span>
</td>
<td class="num">(15,328)<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="num">(785)<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (13,843)<span></span>
</td>
<td class="num">$ (15,100)<span></span>
</td>
<td class="num">$ (13,843)<span></span>
</td>
<td class="num">$ (15,100)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744945461632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings per share</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding &#8212; basic</a></td>
<td class="nump">2,629.6<span></span>
</td>
<td class="nump">2,632.5<span></span>
</td>
<td class="nump">2,629.4<span></span>
</td>
<td class="nump">2,632.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Potential shares exercisable under stock option plans</a></td>
<td class="nump">143.7<span></span>
</td>
<td class="nump">141.9<span></span>
</td>
<td class="nump">141.8<span></span>
</td>
<td class="nump">126.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares which could be repurchased under treasury stock method</a></td>
<td class="num">(105.4)<span></span>
</td>
<td class="num">(102.8)<span></span>
</td>
<td class="num">(102.0)<span></span>
</td>
<td class="num">(84.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding &#8212; diluted</a></td>
<td class="nump">2,667.9<span></span>
</td>
<td class="nump">2,671.6<span></span>
</td>
<td class="nump">2,669.2<span></span>
</td>
<td class="nump">2,674.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744867525312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 24,020<span></span>
</td>
<td class="nump">$ 23,312<span></span>
</td>
<td class="nump">$ 47,446<span></span>
</td>
<td class="nump">$ 45,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 12,197<span></span>
</td>
<td class="nump">11,919<span></span>
</td>
<td class="nump">$ 23,611<span></span>
</td>
<td class="nump">23,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 11,823<span></span>
</td>
<td class="nump">11,393<span></span>
</td>
<td class="nump">$ 23,835<span></span>
</td>
<td class="nump">22,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,805<span></span>
</td>
<td class="nump">3,854<span></span>
</td>
<td class="nump">$ 7,391<span></span>
</td>
<td class="nump">7,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,687<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
<td class="nump">$ 3,244<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,118<span></span>
</td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">$ 4,147<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | OTC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,482<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">$ 2,943<span></span>
</td>
<td class="nump">2,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | OTC [Member] | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | OTC [Member] | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 818<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="nump">$ 1,609<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Skin Health/Beauty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
<td class="nump">$ 2,138<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Skin Health/Beauty | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 629<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Skin Health/Beauty | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Oral Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 394<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Oral Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Oral Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">$ 447<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Baby Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">$ 730<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Baby Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Baby Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Women's Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Women's Health | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Women's Health | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Wound Care/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Wound Care/Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Wound Care/Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 13,317<span></span>
</td>
<td class="nump">12,480<span></span>
</td>
<td class="nump">$ 26,186<span></span>
</td>
<td class="nump">24,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 7,159<span></span>
</td>
<td class="nump">6,869<span></span>
</td>
<td class="nump">$ 13,791<span></span>
</td>
<td class="nump">13,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,158<span></span>
</td>
<td class="nump">5,611<span></span>
</td>
<td class="nump">$ 12,395<span></span>
</td>
<td class="nump">11,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 4,411<span></span>
</td>
<td class="nump">4,231<span></span>
</td>
<td class="nump">$ 8,530<span></span>
</td>
<td class="nump">8,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,853<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">$ 5,354<span></span>
</td>
<td class="nump">5,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,559<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
<td class="nump">$ 3,176<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | REMICADE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(27.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | REMICADE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(27.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | REMICADE | U.S. Exports</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(53.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | REMICADE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(17.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 566<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">$ 1,137<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | STELARA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,599<span></span>
</td>
<td class="nump">2,274<span></span>
</td>
<td class="nump">$ 4,887<span></span>
</td>
<td class="nump">4,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | STELARA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,731<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
<td class="nump">$ 3,110<span></span>
</td>
<td class="nump">2,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | STELARA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="nump">$ 1,777<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | TREMFYA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">24.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | TREMFYA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 382<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | TREMFYA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">38.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(59.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(50.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,316<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">$ 2,613<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">29.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="nump">$ 876<span></span>
</td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">$ 1,737<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">56.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">$ 1,001<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">$ 881<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">$ 724<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(20.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES(</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(62.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,734<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">$ 3,475<span></span>
</td>
<td class="nump">3,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 896<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="nump">$ 1,739<span></span>
</td>
<td class="nump">1,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 837<span></span>
</td>
<td class="nump">963<span></span>
</td>
<td class="nump">$ 1,735<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">$ 2,102<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 691<span></span>
</td>
<td class="nump">645<span></span>
</td>
<td class="nump">$ 1,352<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(19.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(28.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 292<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(21.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 4,042<span></span>
</td>
<td class="nump">3,535<span></span>
</td>
<td class="nump">$ 7,992<span></span>
</td>
<td class="nump">7,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">$ 3,261<span></span>
</td>
<td class="nump">2,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,362<span></span>
</td>
<td class="nump">2,073<span></span>
</td>
<td class="nump">$ 4,731<span></span>
</td>
<td class="nump">4,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | DARZALEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">1,433<span></span>
</td>
<td class="nump">$ 3,842<span></span>
</td>
<td class="nump">2,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | DARZALEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,021<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="nump">$ 1,974<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">32.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | DARZALEX | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="nump">$ 1,868<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">45.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ERLEADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">49.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ERLEADA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">$ 439<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ERLEADA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | IMBRUVICA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 970<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">$ 2,008<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(13.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | IMBRUVICA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="nump">$ 719<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(23.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | IMBRUVICA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">$ 1,044<span></span>
</td>
<td class="nump">1,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="nump">$ 1,006<span></span>
</td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(25.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="nump">$ 1,695<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 560<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">$ 1,132<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">$ 881<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">26.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(18.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(36.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 972<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">$ 1,882<span></span>
</td>
<td class="nump">2,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">$ 453<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(24.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(42.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">$ 517<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(17.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(19.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,898<span></span>
</td>
<td class="nump">6,978<span></span>
</td>
<td class="nump">$ 13,869<span></span>
</td>
<td class="nump">13,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,351<span></span>
</td>
<td class="nump">3,299<span></span>
</td>
<td class="nump">$ 6,576<span></span>
</td>
<td class="nump">6,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,547<span></span>
</td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">$ 7,293<span></span>
</td>
<td class="nump">7,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,049<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">$ 2,141<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Interventional Solutions | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Interventional Solutions | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">$ 1,123<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,157<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
<td class="nump">$ 4,345<span></span>
</td>
<td class="nump">4,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,338<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="nump">$ 2,627<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 820<span></span>
</td>
<td class="nump">904<span></span>
</td>
<td class="nump">$ 1,719<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | HIPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | HIPS | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | HIPS | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | KNEES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | KNEES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | KNEES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | TRAUMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="nump">$ 1,444<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | TRAUMA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="nump">$ 939<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | TRAUMA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | SPINE, SPORTS &amp; OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 724<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="nump">$ 1,436<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | SPINE, SPORTS &amp; OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | SPINE, SPORTS &amp; OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,450<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">$ 4,884<span></span>
</td>
<td class="nump">4,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">$ 1,913<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,458<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">$ 2,971<span></span>
</td>
<td class="nump">2,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | ADVANCED</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">$ 2,302<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | ADVANCED | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 454<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">$ 871<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | ADVANCED | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 702<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="nump">$ 1,431<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | GENERAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,294<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">$ 2,582<span></span>
</td>
<td class="nump">2,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | GENERAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | GENERAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 756<span></span>
</td>
<td class="nump">779<span></span>
</td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,241<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">$ 2,498<span></span>
</td>
<td class="nump">2,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">$ 1,017<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
<td class="nump">1,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | CONTACT LENSES / OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="nump">$ 1,804<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | CONTACT LENSES / OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 374<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">$ 774<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | CONTACT LENSES / OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 519<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">$ 1,030<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | SURGICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | SURGICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | SURGICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember', window );">CONSUMER HEALTH and PHARMACEUTICAL [Member] | OTC [Member] | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ERLEADAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ERLEADAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINEOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINEOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744954365392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Worldwide income before tax</a></td>
<td class="nump">$ 5,840<span></span>
</td>
<td class="nump">$ 6,662<span></span>
</td>
<td class="nump">$ 11,702<span></span>
</td>
<td class="nump">$ 14,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(12.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AmountPrepaidAndDueToManufacturers', window );">Amount prepaid and due to manufacturers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">In-process research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 6,345<span></span>
</td>
<td class="nump">6,906<span></span>
</td>
<td class="nump">$ 12,432<span></span>
</td>
<td class="nump">14,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(8.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CONSUMER HEALTH (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 784<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="nump">1,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(9.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | PHARMACEUTICAL(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 4,420<span></span>
</td>
<td class="nump">4,294<span></span>
</td>
<td class="nump">$ 8,344<span></span>
</td>
<td class="nump">9,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on disposition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Unrealized gain (loss) on securities</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supply network costs</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 1,141<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">$ 2,618<span></span>
</td>
<td class="nump">3,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(34.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AmountPrepaidAndDueToManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Prepaid and Due to Manufacturers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AmountPrepaidAndDueToManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in operating income loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947560112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 24,020<span></span>
</td>
<td class="nump">$ 23,312<span></span>
</td>
<td class="nump">$ 47,446<span></span>
</td>
<td class="nump">$ 45,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 12,197<span></span>
</td>
<td class="nump">11,919<span></span>
</td>
<td class="nump">$ 23,611<span></span>
</td>
<td class="nump">23,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 6,085<span></span>
</td>
<td class="nump">5,668<span></span>
</td>
<td class="nump">$ 12,109<span></span>
</td>
<td class="nump">11,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember', window );">Western Hemisphere, excluding U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 1,536<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">$ 3,018<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember', window );">Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 4,202<span></span>
</td>
<td class="nump">$ 4,358<span></span>
</td>
<td class="nump">$ 8,708<span></span>
</td>
<td class="nump">$ 8,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesByGeographicArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by geographic area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesByGeographicArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744951974752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details) - Evra and Doxil<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($) </div>
<div>brand</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_NumberOfBrands', window );">Number Of Brands | brand</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on disposition of assets | $</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfBrands">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Brands</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfBrands</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744946469376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2022 </div>
<div>claim </div>
<div>claimant </div>
<div>patient </div>
<div>cases</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>cases</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>cases </div>
<div>claimant</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jnj_RasmussenInstrumentsLLCMember', window );">Rasmussen Instruments, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">XARELTO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_InvokanaMember', window );">Invokana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpioidMember', window );">Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember', window );">Contact Lenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ElmironMember', window );">Elmiron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss', window );">Loss contingency, estimate of additional possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement', window );">Number of claims within settlement agreement | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyReserveEstablishedWithinTrust', window );">Reserve established | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Judicial Ruling | Damages from Product Defects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Litigation contingency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember', window );">Surgical Mesh Products Marketing | Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="nump">$ 302.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalProceedingTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal Proceeding Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalProceedingTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Additional Possible Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyEstimateOfAdditionalPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Claims within Settlement Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyReserveEstablishedWithinTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reserve Established within Trust</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyReserveEstablishedWithinTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jnj_RasmussenInstrumentsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jnj_RasmussenInstrumentsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_InvokanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_InvokanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpioidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpioidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ContactLensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ElmironMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ElmironMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744947666736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring charges recorded to date</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostExpectedFutureSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Future Savings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostExpectedFutureSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139744940685024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Reserve (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech | Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech | Asset Write-offs/Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PaymentsForRestructuringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Restructuring, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PaymentsForRestructuringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>jnj-20220703_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20220703"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20220703.xsd" xlink:type="simple"/>
    <context id="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i081646bd651e49ccbec8525d32cdd1ee_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ifbb124a5ccb24559ac685f2e90cbaea3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id3ef6f7979ef4744b07bd5c44033c0ed_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if661bb2f35c84737a9a48c16676d08af_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i554ee5b5caea422aab835052a7bcd38f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i391bd8bf57bd4482a4a2ddc2a79b27fc_I20220722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id586f19507c64de598ca1e8367cecfee_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0b78141263e14aa589db463e889e3571_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="if9ea286cb593414bad834aaf21a6fcae_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="id28888afdc0d41829f3f9c4f745b09bc_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ibd15db9229e94c4ab701152a505a8fd9_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i2ef6b87b8da34c3ab39ea64cec57d1ab_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i0c985e9590a44414b4eb9c785af847ef_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i63678c9b15dc4215981671d3417b1d43_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i48b106f4f9be47ecbdbf4494e08f368e_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie2f63c6c6b554f82a78ab56462752f26_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="if6c44097a42f4c9b8d26741faed5e548_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i675f9b859a9642f9980e206847468603_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ia5d913e7414246628af7b698ff38c727_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i4b538347dc21414a92b3853037648c53_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i116332ccca294d499f773d00109c050b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic7e44d359c554d62b5eb567fbe00c74f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5d0890b94dec44eaa3b81bc34fb36d8c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0d2dbba5d85c4a23b5fe98df37e5b2f0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7cfb8860f4a14a0a800de5dab7ad09d3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i30ab88c7a9b24105a98e4bce891e1382_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9a7eb101ecd248fa8113d9b3f69f69e1_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie0104c40629d42e2b32ea4a3608507a6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic8978590cb1f45bbb5dd3354dd289e0e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0e13fe78d9384d259e35ea7a933fd95b_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id32639e6970348639d64a785e7a5ba93_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i447127aa6c664afab9dd53cc168aa3e2_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibb8035da5ed0409392b2294beb7ff4d0_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idd9d432f47f643658a371e3e1029702b_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0b98f47b14654327afbb7932046478c8_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i18c5660480c941a989748af1c5101066_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i8c49da8cee9448c0a2c883ab7e653b32_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i70d9822830ad463ba8ac40ab5c36dd39_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="iab458019d3d5460183663da5dd757b6a_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i9e3aba93759e44e6998ff20f017b0ca4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i207dad082de3463797edacf5f0aca4ae_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia260343fe6194304ba1526a976025d5d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="icdb7154123a34d2fb4812c12d8a88644_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i33ae55af07ea46c6bc94c11db48a7393_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i286c70d01444493ebbeeaf534a382878_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idc88aabe12454cb5a6b8b3e1ffc291ca_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2b85e73978e94a6e9d40658f17f4dbba_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if1e83abddf294b49862a285ff0526959_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i4644c94cdbe54b26bcc9d703afd57af1_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie7a97a3c30ea42378cd8743fdde441fa_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i9fa373ac3b69447baa5db15e621348bc_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6a8cf9ad2e7647399248ae1419508e0f_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i96f8bf96c98845fea1edfe19f545e830_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib0b304ee8aa140a588288dad04e0aaac_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="id26a9c75b7c94e1085843fc1e74cf160_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if4bbbe18d2594f8aad55ae35a3d252da_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id28638ba3e4b42e1a64486cf30194fd9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i44b72b1c234f43a3b95f3f25252e2da2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3057d1e214724cb89a838867914b6faf_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3bc23407245a4376af9e0430687579f6_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i80e542b5e6c24d51a5840e549f120d1c_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i709b7cc74ca74a80a4840c6c2463936a_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="idf76b5399fa64aeda445faded52c1175_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i48d21dab7e7140dc8981cd34ec5ca636_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i17734f536a0942538d393c2a2be78a63_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic46b61746c914b54a3d85958237e5f97_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i5b760074bfcb4cc58e6a1ae3aac3d6e3_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ia1f129fa36664a10963aba1c422e6f76_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="idd623d33cd684c54b9e101ccb633f27e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3634444be4ba4cf2985688254d252758_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9480099d643c4b7cb1462c5d2ac5ecd7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i99d3df0e7ab74f219ef244be03b7433f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie88ebdcc2bcd40839c3f8784531db588_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i97621d82be79453e9fa3553e70d1ca31_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="icc8308f7d14c4181a0ae28210ff4ad62_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5dccbe17c2b340f59a7b489aff4bfbda_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i65844a253fd240329a7e6e0a74622398_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7c3261c0c12c40feacb473910d1a2350_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i22373e19eea64b96965159ae548a3427_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i052c717f8d424999972ae78c20e442bb_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i70aee3ac261c42958695f57ef7aa8d75_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1ffbcc5181264051a6e74314d827dd4f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib2f3ae164fc04ca49438e6a4347fa265_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i426ece422f5943a1808350edaeddda4a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if5e20365cb144535a9cedca9aed02546_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ife68bcfafe314d1496be2149a6e924e8_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4c9b9a50530a45588281a4cf80ddebf3_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5aaee80239bc4e2e93981af33614099c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if188f2ad192d44daa74ba7278a4fcc3c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iae48c65d3bab4e199e770a5fcfb0a80c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5ab75f9b509940dbbb2fb9dead6e12fe_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5da8d593cb89443aa125dde02cbdc486_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1c67b5fa2091465ab9dc2693e5093889_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7d1e66f130e549638c38349732d6b9df_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iada32f8e1c5a4cfc8679d5181aba3515_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if0c4df0b7052471c8b4beecb6802dc5e_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ibf52c3ab707d4713b81fa73f99e93487_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i928ceff46ed841a39f43bd28f651f09a_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iad78c3349a7f48d6a0d49345aca00641_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2c77b30de27d45df96a8104f4525f7d1_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibf04012d40344529ab914fdd97d47466_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i61321ab212a84d638148bcc2c0db2529_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib87adb12b544400aabac91ac10b55d9d_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iacaa73a24dc34f44ba74aee3094334f5_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4ee1a2a6de5a421fbaf2a6ac76876bc0_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib4f90bd741f24c46bc4278b4e28f7162_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9177a536afa141448d3a25292e1296fd_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id5df6c8fd44b4cfaa5405658069eea76_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i328dd4d5d05a4285b0893246ff22ab9f_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1dcc42285b6142869767f28bbda885e9_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibb5735d577994517bf90dd973a568b70_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="icbfeb1c605d04a88a882e139f2fa2b4b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia993599e0574405f95aa489e16792d7a_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3f85ff3cb4e8499d8c86fd7dc882efb7_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic1c9a175a9fc4cbb8ad060ba18633dbc_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2ea95b17407743509a8e35647b738929_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iccc5f6a5fc5d46d49d5760c3a3f39b2c_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i05aa739fc5bf4fa59b3b001daa07a0b4_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i22f501bd038344088354f3932536f457_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5664b5dabfd740a3b6f4396883d2cda8_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i408e7c6bfbab44228e55381d1839fb61_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i580cc60e6cdf496389e8435cc5955c25_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6e8d90fbd49d4704baf0c8e5c9ca228b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i96fc5113393f459a8780e466f3ff2ea9_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8bf9543b34dd4f93b96f68a4ca25eae0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if53d09453c094af1b92a936cdfbacd94_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i26f2db1557b74173a9cac2b055ab75cf_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iaf0b9936cce44a77872c14571dd9ddf5_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i6797e39b27654b74a22b814d372e8d12_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i326883f0b0fd4a0d825ea9cb59de5804_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1a97916e3efb46e09815fb9d03aa504b_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ide58dcad79ab45bfbe863ddffac83f2f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if6facbdbd9a04803b321187e1f040e70_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id2561de1bd5d4cfdb3e9f49ac0d0ffdb_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i45661dbdcb9f4e8c8661b5da47b3b783_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i21556e9074dd4a0f8288063ebf6e970a_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i19c220c5c40240a4954cd7dae60f584b_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ice3fdb84972d41ab9ba4bf47ef5ce854_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iebf3885343f54fc687fd890f151c63d7_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i710f2081b05d404f86c62f35feb19186_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8399be3fe8e44b1f94bca7aff8b41680_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic84064d0beba43568502fa51c3264dd4_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i237ab2105da9479f82802abf0e650c17_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i208da50d0b9a48189368d6e10d6a4fb3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4f1f944b894e40ceba89ce94e11c72d7_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ibd6b67f063a14008822cf81aae590318_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ifce50b6f31f149f3a70237f88868b0cd_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib0f6dad62d53466ea010085927c81451_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib81964c4791646ce966adfc8c90aa7a2_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5349dd1284b14193a5715e5b6427c992_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idc891ef4689a4994ac1847e71f539d52_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ie2f13601b97f4c86a0a2ee40c14abae9_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i1785c3b63c8c4e48805730aed53c751b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6d2d946886f14b34b8cec403cb9ceeb2_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8d77d7df0fc245a083931c66c8432fda_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idfc5d938e6594db3a5592348cbdf14b0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4271111bb61a42b8bc92b5628a6fa89f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib42c0a6a0ba542ba87e204f1f199172c_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id61c7ab12f0d40a5b1d148b50984a0ae_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2b395b190b6c40bdb82d652a413b2417_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie0558f0c929e482384449ccfff5a6c40_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id002bac7c1ae4826bb20f0839018ad2f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia57bf4d1498c4d5a8f38143d4bfab826_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i07fd826f5b134e9fa417cd75e225e819_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2584883493814b06bf0ed930f4028c51_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i10665768ac6c48af85f34ec614dbc6fc_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i455ed2b8001d4cb29c1bbe414bfe1b33_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if8f70882583b47f7924e55453b7f672d_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7ebb8454e231462c9e01ddd2a9cd640e_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia2b9bc17484844788bb099a867ad7081_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5585c30b729c45f9bf242ad075fd7e6e_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic6ff307f7d004130a7fbc2c25929d6fb_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i5174e789a11a483cb8a586d1a51f8af1_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iee1a9681011c41fc91369cb2a262d523_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia2bb14177b1543589f7e2d2b40f3ed99_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i974d845b8fdb4e7fa0bc0da100fcb02e_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i53d11cbf312f4920a063822b57fb4379_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ie465262306f745bfa8f4d12d012583ba_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i820748c0ee614ffc85acb984e5a8fa84_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic45c5d30ba924db5a64a324285891798_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i58070284d45c4b4b97413c70ea4b99ac_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7c5ce1a5044744c98c6fc083f0e7beca_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="idb0e6ccd8a9348ec80a99cd8c4672572_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i02c147ca24594e40a66c2a2f2b084eeb_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib39755d463f2405bacc970b45155df96_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ib9b36b292cb1493bb900a69e5bd34765_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i1f2023f668e54901b44a7ca21bcc4c7b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i616a8d8561e148bc93cfff8d5eaaf83b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i02b1386668dd451a99e7f7cab14f56c2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i18ceca8d5a1842a6aa3fc80736183e3d_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i061f4c2dadcc48f6952c7a8571f88284_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4c793d1a04514fca815ddcf0b0cbcff8_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ibbdeb75dc07c40a6aeaf91aa2cb9a764_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="icd657c60f1a24c10a33422ab5ee9af4a_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i5e49767d9045405dbabb0ebdd3457dc3_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="iab0ec69a90244ff8a111f44c89663546_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i00d9e4015c714d518f4373cf0ad3530b_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7423beb705924764a8f4876d7d961b65_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i808ec468ce6c44538860a6822a475fbf_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i437b71eb938a462080e32d083a962f86_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i504a09c1cadb41b2bc01218b05dd9585_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i489821c51d7e4e6692905fc0dd2b650e_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="idbf37690c3b94285af307610b22628e8_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i35b52ff0f6ac42609c258100f987af3e_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="if668327e01644d82befdc0a8ab72e2cb_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i0412d7e68cd949e69dd56bb1f8ec4989_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ida1ae3624a844b4f875208ff051c690e_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7607c810ff1d4ac3b1e1815bf6afca66_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="if214bf0473764e41a84dd8791aadae18_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="idd688062d5f3442ab9e3d49a23df957b_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i19bd93d4b6414d7c80050b05ab626367_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i2ac16b6eb33a475a8a71478faa2b6027_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ib5ad0d9d40c440198c4ccaebcefe7e24_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i10d8e76325af440aa71852c405d16386_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ie265961801c14b649e4aec89b623b822_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ic73c4fedbb644223a20f315d7dd9f3e7_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ic9f34fca0ba04ca781f7befcff5614b3_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i2c7397d924e2469bb389835fe06d5b23_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i8c0348a7bec543bbb40b652ecc155701_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ieaea24750d14422d8bb195caed4c0fa2_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i517d31de7560429e9f6447755677fcc3_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i15f8f438d45649aaa711cfeee70572f3_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i714604558c6448ceac87445bd3cbe601_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i6080a0f3af3f49e9bc2edc00f7c218f5_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i8f5eac34b27640f79085c03f81117a27_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ie8d83f40eadc482f9785a1a1e73ae1fb_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i2422ade4dd254785ba67cf1997145fef_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i24356a7eaa814e15a526f1f4f1dbb4a3_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ief6fdac95f174a9db30f9dde4a867361_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i932f859fe5004fcab7d388c3ef37b01b_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ia8500a36cb2b404fb1495e3f0cd34b1b_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i10cb7e790720410393c02b3b71132200_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i3a981ac377da4942bd8a08b6b8f69e74_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i51f8a9e2e7444c16b12a3c2edb6be775_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i4f60341d6ee24828ac150d7fb989724d_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i85954b0bbfb747cba4560e6bbe91083a_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i9fd3188721d3496bbfcb0a0a1fcdeeaa_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i247279ce24df4fc984684a77a1afc670_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7dd4fb1b88c34db49fc66928580f5871_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i51b5a0c24ecf49209b2e36a4c3789ba6_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i687f005d14ed416ba74831b5b47b4555_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ib7501e1e2bb74a89922e7f7a201f16ce_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ib90a8017e0214944955fce66d917c85a_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="idab876f881cb42b3b32ad3e26e9ec7ab_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="if6c198d27655479abef21848a7bba761_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i16ab0ee504eb41599816d24c2113bc1f_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i9d05ba815c654783b44178265f82de44_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7914f4f7746046df9a737d4fb8979c6b_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="id275d71b261a432c89901abc9e36512b_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i8dc1e5091506483785afd9d275795a46_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="id9d838b361e1428f9af039eded3b682a_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i60dba65131c1437481410132c5ea4df7_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ia9048cedccfb40ed8e4d52b8f5430ad1_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i85efca72771a40499d8082f58202a3dd_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i350a972bfcfd4efdb72b431248967d66_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i3f46a77f7992478ea4128962d4c9f391_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i8d3fb3a791ca414fa77eaa67cc99a07f_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="id8ccb7e446b348588dd2f9516636ffb7_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i1a17432bed1945c48370b5015ddb5642_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="id65c4c72715349aba29bef207c5ed392_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7bc27cc5ec494407a381cf8b2d1d893b_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="if9fca044219d42f0971fb8ef3a32a6c4_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="id8b97c77efcb43fbab577c42a6fbfc7c_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ibfc2e3c1f9254ffba88d55ca0c4ce058_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i915b24d83829484ebf50c108621501e4_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ibec88f4e48124475a9632ff20fb8edd5_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ibc6c33b6176b422483f5f3ef6becebff_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="icd4e43d48a4c4e21bcbe809be40eca70_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i53a8feaecb4246bc9b98605730a15584_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ia3d3ef2ea8d84db099d215dfe535ddcb_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ib006c54c03ed480e9b393694820c92c6_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i575934a7cedc4cedbde5e430befc2365_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i05004c0e3cfc490cac8c08c422000ba2_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ia7614f062f264a8fa4c4907f54853e94_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7ea66b619cb3443197db56a50a304a6c_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i12f17d6898c04d318d57f363e7c9bf98_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i1058600fb83c4dd480871a0a2a908496_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i616df737a6e04747b5272a1cef450ed1_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i42d3e3e61a244a51b1d33daefe6fe819_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i3bd5f7853d0d4ffeab0ca0c4e2369e5d_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i30c41e781ada48aebeffcd3857c0fabb_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i96f5b18cb544467e97c5f515dcf98586_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i58f4a61e1d17435cb3f75c415b7bedea_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ie81ee28385e645de81a4923e2eb9efb4_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i92f0cf689bb644bcb78bfd87f8b277ad_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="if0a95408bdaa4b3782748bb151cab603_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i27effcd5f6a94b389235ad25b18e2bcd_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ia18fac953b8141dabab3475985def187_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i78494e54f3114f17a858e621c5e6752d_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i17d8d0c23c594dd8a278bdb58b5042b2_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i07459c41a6f843978c00a7b71ef76e9c_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7afb6fc2c7ae48c8b09189c72a0dd118_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i5b91038961e64c0085d31120a376145e_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="icd7696abcc3b4b91843a6ef7190f4f06_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i33b7a271cb844d789cdf3dad5b732c3a_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i702f71864f5046db87e856abadec5a61_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i59e59e4d0e434ad28048bd9cc5ed9cf5_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i143c1877fac245a1b05d14212b80d45f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2daa8a32f1fc4fdf8b188540df1f7766_D20220704-20220729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-07-29</endDate>
        </period>
    </context>
    <context id="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i68813d26799a432b89daecc2918201f0_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i98c6a26c3964431798d06c23223c6509_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i62384ef644a54697aca04106e3f0437b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2fc2f74ef18d4d33b92e9d7d64d48020_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9717a3a8ced548948d10ecbb0f33b8c3_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2601e00af4474b03b245711113cf2975_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i18d1e90be3564affb9df03eb62cc401e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4a55a77208474cb0a1becbbd53ec82ca_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2f7f5277eb57456983ec4fe69703fd6a_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i0f6f63f466324af9a0ba713c475af49a_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i72370e9d3ef64afc8247235db2a6256a_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ieb20df11643a4db4a4501af374b8611c_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i8195ff1841b44360849eba5718e01652_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ieaa7ba884545448a83b114bcc5344580_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5b4ebb79f86444c5878078484251d735_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i18e5385aae254b489b7e039a2183a902_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3bbf0047aef3405eb9f261a53967efb1_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie26d715418394045bf2d275669c0c2d5_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7fc6d07570ff45a8a24f52ea1dae3e62_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7ee1eec7950c4ef78e937d2c4e3298f8_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i38e9c8dc44154c0889a38ce4ae1cfdee_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i25b746d1f6934a38b36cc2f177fd06bb_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i96ab60eec1f141039a0d797a3f451481_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id334e2622b5a43608b68569880f13d0a_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i71c500211bc040d4855e6035ad051bf5_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib01784d325404849937b0a9daeb1c938_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="icb2ebe5ae60c49b0a9fff97883e882ed_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5b6d906d8c3b44108349d0c7ae0c91ca_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0621cbfb3ca24c87b649251bb892364a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if398f47ba6cc4d43b6d90c700176240d_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i33319c8b0e2844c1a78f06bc06b7301c_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib13a2d7df3c942ba9306523693e96af2_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iaddb3c97163a44a0a32251c19d5d0ff7_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6b62bea6d6874162b043629fa713ac31_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i68089e150f524c5abad75d4bc0930034_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9095543594314e21a7ed013540198140_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if13101093f5447d9bc000921069e8423_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i40a4e77c23874d21a2804eff01168460_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1f309ab7ce9e47f6a93a24b6c21f112f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ieff5349857aa4a3496da3c8d285390a8_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3d9cb7fd4ddb4911b27d35f071fa8886_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id09063562e0d4fd3a2f72663c512d14d_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5fd7a688a72f4a6d9787219e5e029a38_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5de727b2f6144bfaa64c8a53dedb41bb_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7ce860b4fb8441f18fffa07dcef2a31b_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iaed64e30f1e54509a52b4ad3abd15f77_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i53177aeb7e124a05bf7af2cd65156f97_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5c9d35d1483442cdb89d4315ab87c195_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1ef348574e5b40b5951363c5761b57e0_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i944b4a698ea646128ec4f289fc31f5bb_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia5876de3f5bd4a6fafa27ffe0d10a9da_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if18cce1df7be41d3addfa2391156aebb_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5f715131df5f4ce38b709e366c8634f8_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2f9fa20297e84900a134c648c79ed724_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i33a293dc78794b8c84941522d362b2b3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i66ed86e0bf67442ab4bdba01c26ab3ef_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i102548ebfc714d89b200cb8801eada1d_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib041fceea7e145b69657ad998b398574_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8a72fab377cd41989bd7cb664b052786_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0b7718b305fa4e98af05f13ccd09b117_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id6651ef9c1ac4edbb8cf6a115bf220cc_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7ed1bfe39b4e4bb5bba8bbdce7bdaa1e_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ie744fe7eb10840b59f191d4ebfb373d8_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i43d92d32a1fb4d1fa4667d39d0165593_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i67c37007b3dc425b849156d2b344eb7e_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i88e018caf3a44821b6b23d3804a73e3f_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i6bd7be7ef01a442ea8668894c4d382fa_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2b1d7a7b9b2a4248887b77dba76f601f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if0e407cd47704992a0317255189675b7_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib867ef751de5492fa15d45f7bf794438_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibeb71611308d4b42a6e9f2cd42a75c82_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i693bf3820634476c859b68b815574d1d_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i78dde3c6195f4c578643c83727dcad04_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0eb0aaffa7084f09810c1685730156ed_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id10a3f80fd7e44589ec7f14f0a2f9fe8_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1cccfe83ac064549a7486973cb800b07_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8e1f5924669f4a169c42aa764613999a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie81ccc7cb7a9415a99c7f89e84017979_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id0812d79d0004274855fe19590ad7dd0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8781a8fbd8814cff8dcfd139cc582995_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1ffbd0973fa444c9b15cf063be1c3066_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic6d698eee9664f599005ef75c6f73674_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2fee31f1267449d6b660c897312001ae_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7192a0ac28bf4f76aa87147c2805f776_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7f670f752605441cb46a46a85c79ecf2_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i658570b4166140dfadfbeea24c17c0db_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i6f83165908d14fcdb9fa9d202e01a201_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i74eb8c72df8240e79e32ce252be20ff1_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i03ea4eb5ba9a4f1c803077ceebb44e5f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie50ce2e3f0464c71a9c5b8e469a9fa78_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9c19f4191b1d426ba5408a30686ae901_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ibaf51f604ce94696a0c9e9f86c80dcbe_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i228867d760f145b882a88a1d618a76f8_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iecaa039dee6d486891f8d14610b01fbe_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1e3c97cc494f4d5bafd40b0e6898cdc8_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i04a8138535574b2f8dd29e2d2ab984bc_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i435910ace8fa4896a65a5f676869084d_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibf527b43e5c64384a1fe49225cbe7797_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie1f36da8c5bd4d708ddc21a066e32df1_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i429afaa0d03d45ef928c1df6565d72ea_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i84783ba4704e45429e147e9d5dc289ac_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ie96db2fb32064dcc955371ae075882e9_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i901108f0a04f4af892226bc6740b5bfa_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id7f056f7919a4853bb535aacc4a0cf01_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8be3651fc9014dafa9dde9d16bfb5921_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic1cd05eff2ba4e3a9580f155f072c389_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i72b5f1820f5c48d2af430c445889e0c3_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8848b6a4264e499ea3824a825f707e78_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia486efb8fecc4fc8934c3d17358c54d9_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2010cbe9958f446584500182486f8c58_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6d43b5d1458c418aace6f6915a81d82b_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i66216b2932674442903d1b7f700d5d93_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i22058af4a4044d0083e435a04e70cdc7_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="icce6642f7a9645f58eeecaec17c3aaf3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iaca44e36bd354228bdceed07ebdda5c4_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8375cf3203764f32b355e4b3f1eed776_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i87013a0ff92c4beea595abb9a8da5946_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2b1b43f5e37d4e2abc94f7b4529f8f9b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic461d711f25c43cea2c56556fcad7ede_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i54580f240f0f45e792175de738dd614b_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ifbfafce4ceb2468f82b2f231481f3145_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibff5db7fcd89445889265894b5fcd908_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie9bd678a6f6b45f49f1ad8f99d6732f4_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ica430109af49463a9ccc4038a1739ff0_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie308e8e3be304525870ea855ce38d851_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i119135a7bf4e4b77a3ab7bdd5088eaaa_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i79cb5dafd17f46df9670ff1449263941_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7278c069afed4a878b544df06a8f6fa6_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i68d3d93e645c47b28b4e7046d008ba26_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i856a0c7b52a545e79ff3fe227f8b6e96_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia11c3e051f3640f48ab85ea94a59bcf9_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i88e9ebb6fa3f46c0958ce4ca2ba73452_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i24f6d9bd9cfe420eb311754a66cd6704_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3e7322aee8f94298875960a274d7d725_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i19a11268216c41a0b8530633effddd01_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ieeec2de848b7400c8f1cbd655a32fef5_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id1f3484c640948dcb33be80e3ab6ce4a_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5608e9bbae904b85a2dc6cfcb6fb8128_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3768e1c0c0144fe18b8421760ec7e5e9_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3b39afcb128845be8ace8181351523cc_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4c0e26bb5d8c4e45980858e3929c5f05_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idee6054821eb402795176964928243a9_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i496bda2ebfc045e592996bab0207f6cb_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="icb85facac1f24b5493bbfd6b7352b778_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i813a1577af2d4a23a4349732e1febc84_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2a68313ab7b046478534719e89e2face_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7f537f91aebd4a4286209578f7c5aa71_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2caa599d7e6c46479b011171a2725a0f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0cf7e16d1d0a41ecae80c957ca6cf057_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9e94b02a54bf4dccb3fed8ad8526a6b3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie8485fb4ed0e431fa60a21304c9940de_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib4212c615c9141e8b1d901365e40d779_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4d619e3e7e91444ea79bc47ca3e226eb_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i644925d4826546d3be77503d471f03f9_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0383c0ed08a340a0a7e28475880e66ff_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic37e987627024b6a9dc1bc0795ad8ce3_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib7fd69b06f674ad1abfb09825949a8f1_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9b5fc362f083407ebc59e3ab3a9ba67f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if57f215e7cc34af3b9e4ed202855fba3_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i22768f5a2f114ce2ab20531d2853362f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8a0d44953e7140198cf5743c8f9bf9fd_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia648fc74bae7454781dfef132266663b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9df360f1333340c7b4588969e82c2f00_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i889a1f92c9a540c2bd4c73d5f7491f90_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ibf53305e3b644b48bece17159e61f8bd_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ie6a42cf1a5db49bc8a0351e6d0e34b93_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic810c0a48e8743a59ad02500a4aeecdd_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="icd4edb2f147a48b09eddb23a0c7d5ce7_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iac357a41dcce46b8bac2ce939cdb4918_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if9d140cebad34e369cd420d22831ce65_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i254bd81a5b934d1da8ed0bb423ffd265_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i82df753eb9a14110a4457fc71fa570ca_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="idaa982fc8c9040bd9afdbedde483a631_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2b329b805e8241389b4b59c22a25fed0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5b5a3356d9fd49bc8b3e5f75cc325bd4_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if3ff638816b949f49434427996afdf27_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ibfa077604d394f2e9da2c45c7c1f570d_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iba42deda339d4571bf02c560ebf58128_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ieb0c7aecba784a1ba368d125cf5ef87e_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iecb92120191540b08b3e1547d87f071c_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i451bf253d3fe4d909fb3822b81e8b8e7_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i131b62957aea4245a2e4f40e80b92785_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3edcdddf80a04d079d92e9eea316d11a_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5b150cb6ff444a02936a3d237e2aac00_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i82ae1895ed4f4e7d8ffd5e113242fb46_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic58cdc6aca3145fe9c3bcad7c0f6caa3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i03a04f60e80c410ea3de2b7af02a2047_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia4eea102b0f843ce9148053725724350_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib21ebd581b69464f935e36c4077fcfe8_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i68320c8fb7d9415da27ec1628fccc3a9_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ied8c3beb651f493d825692e877822643_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7a77ac5cc2f444fdbd37f54e3f3763e8_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i477ed121b34f408288a548d3dd53cc95_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idf65e5c0ea164fe9851e44a3c5176fea_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i867589638fb74338a731e3ec601b44f7_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i833b35d6c2414dada6f601d238feca65_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i51cf983137194da19e1e0ee43f86f2e6_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i76a964d08b0e4123a5c734a55c08768b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib0be555378cf4bc7b2c312db80e53e0c_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2e0703b43478466cb628ab8efd4070ff_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8c83561616a848de8a12e6750c8eb1d4_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iddfe7e4eb68f4542a0694c4e9160e4f3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6f9e9151965a452dbb603490e84ec8d3_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia064ab4c0e6f48f4be4e3fb8e412913d_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0c4619bd414a4f4191ac0846d8ada2bd_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ied852099577c4b06b69b158e06bdf30b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9748a1cfe0ae4be3ac0b1f755e7a71bd_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i610bb1c1ae2941719016b00d983418c0_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i545c78bcf6864df7b8f8c7f3f1874047_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5687d376693949f995a3364dc24a36fb_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie177897f7a0e4cbb9fc1ae70b3de094c_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3d2d49cc4b5f4e3fb983e82500551388_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0743c16b76bc4a4eb2c7f09b19fb4d77_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3b5c01877918467fa667de5c4b5a1e4b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8432ba6c71b9494d954af4cdfc975370_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3c2e8ad7b5ad474990841305b1f44bf0_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3e2297bbc16743a6af0a9162f757bafd_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i63d56d230d06461fbbf797c27c6ebf04_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iaf382b886c2c4ddfb2e4f553d4f3aa6c_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i6ae5da5ecb6c40da849942dbc851b857_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i881a26ffb23941f7b130a2daf70e1cab_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0b81754b34f1429a95dcde81ff323530_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i09ee23c86245486ca886b6aee57831eb_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i233aa02837fb4f0fbbc523316a35d3c5_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3d8c24d1d48d4f6490558a822b6c2921_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i37807e01372a4baa8332eca83c82dcf5_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7989fc025b464111973e629161e2434e_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i892c07bc3d55496bb0c411f6c4597f9b_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if533c4ba85374d80b615f4cc8c0ac77d_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i350d006de9494081b89834d206e20b85_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i87c986ffb2bc4b73a03b90d4d1e6e058_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5cf2f6500b8d47f8bcd2e1f52815ef65_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5e260586dedd4093a608d4f9e119e9f6_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9d07ff2062fb400eab890cf3cde739a0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="icb100c8ad50b4c32a7486560779c59c7_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia8eb6f559d024fe9867b516d3d470c90_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ifc3128acda5249f7b1aa270169630b2e_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iba9bb08a5cb64471bdd5fa7215d3a890_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0939ae8630144f4986774c9e0e93db3f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7ebcc5ce76814be69eea5e381ee927e1_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia8cdb6868c7c4eaa83b08096e087411d_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i70d8c0890db5470dabd162468412c872_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if270f92cc3864c79b2464cfd5f2f9ea0_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i64083077365f4393b411e13a8d829ba5_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i24bd17706c8045b28592622c702e9945_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic2fa6af256364b8ba090796d8cef039e_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id5c7f3684e96430cb08ceb7f25e639b0_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i821e476b1e124c3da418c0da884873ec_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if9867c33d4e041e39d64aeb94ca7220f_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if7e9055569824947bc8a8aa2e70f9c21_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5aa6b7234499430f8a3da6a879bb9820_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9c551506a1274d12b61d0b0bb6a17e0e_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4c0fbf4de99a4afdab1711dbfaae9849_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idee16de5d59840c5bd123a9e5601d81d_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0f474b0d055142afacf952c297331e99_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i42b1abcd0990401ca49e18dbeb437c17_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia3ee672bbd7141948b03208867985b7c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0f190476843b4d519e98652aff7a77fb_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic36139166d5b482eb6fba5b9c7a5dff4_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ifc2adbb26c4f4169ac3ed1446c0047a5_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i02a8333f41594a4ea74e78b5265277e8_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i33af160294004e19b207a7f75170082d_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3dabd6e5fadb4ace892027521ea05718_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i381a4444cf624dc6be2aa2fa0a0a3659_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib9404903e6e74429b27dbbdf8d4ff248_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i81967cf9960e417ca2396582624be8d5_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia58cde252d1f4e799a3a302ee1c41607_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i4616b6887b354b9e96c3d430604d3c42_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i84ef0d86dacf40c98cf4e5607785cedb_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i94c58a72b8a448dd98f5ac9d8f55ad47_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i87f4c25c27d346e28d79fffe1ec89849_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia9db6a1f46624828bc4b33dcc757c82e_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iabdebd8234af4a4b9621fb3ecb624d8b_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="icc179fa1a480426cb4fd0d3d966e2f9d_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i331342035f8849bab17b1dd2debe6771_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if0ed53bcf088487b9c9fb95699fb4684_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i53a8381b611d418cac230e38702d6256_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0a732ecb6ddf466da949b0e4f1047c8c_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8467285a7fb842329b2d56b3c68bc6b2_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i96b0e21c3cb246bcbf7a18d3394d1fc3_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i11e7b7ef58fc4d74b79a62f31f63b60a_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iec84871b973443e4b3a3810d110bc6a9_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i05deb876f009412dba8fee7b750b9a3f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iae486921d8e2413a95e450c0a846f660_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i084e1532e11242b9ab8e982e98cce345_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8a2eec65477c4cf6b0a2e012668bd440_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if0bf55fd1f5940659534d3655320b2a8_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i53cbe5667f104372ac5709b96be56d7b_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic03d9b2307334d22bd42f69770c03cbe_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8c787a1466bc48398971fdb66dccf821_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i54a6b0b9f19b4a3aa3d549fb91013f6b_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iee8ceb7982104bb097677e4f08cf19c8_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic935596d94fb4f8cbc7662516ebd2337_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i74032420b0d54f859aa6ac4ae4cb6092_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i628c3315204b4c819f5612c6ea0f76c9_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i489d0217d95349a09e3854a159fe1e20_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia852ccdace584ca893a3f9fb3926a08b_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id3ea038280ba420e8b3e85334bd010be_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0579266bf5fa431e86d0cc99966caf96_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibf0ee75730ec4eaf8b49daa1a0982cbf_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9208998ddf664f808ab029146e8a7091_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i93dc841f45e74baab367942431755f0d_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8abc2da8c3544d7a8631b23ee75d1876_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i615f22ff6960415c94431ef20433e83c_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i271d0e8006734cb381410cc5d646c7e5_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i04b08f5246c2483c8916b0d18a4cb899_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4137bbbedc454ce4a1e326ab7eddfed0_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i46129e353ad84f39a366e43a8ac98e0a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia7a134dff79c46c1bb7e1c0967197d54_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ifb851f7c092f4ee3bd18823be28d76ec_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6f4755679550432890b18a7d35fbe2fe_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7e47d07acf0a4b3bbe3c60a9e96bf4f3_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia9f53949a41d46ef898ac80d318d4189_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2284a61a0db642eb9a40b3613d8594d2_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1379f0be014f4ea396ebb2effecec503_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i426a47a9bb5049e49edcb30d41af643d_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie71f54f5a529400e992bcff94dd82726_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i130828dd7fbb4e60887d19e7e530c789_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib90029a9516f4591902efe683175866b_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i10e7b1fc93c648b8b4e52538ecb02755_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ifea982946629432694550a8492f1df45_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1ba1c7b633bd48db874857a7afcde3a7_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5808bbc2a03c4b5bab9390a5f8f31033_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idc0c50a7dcd74d0db255eeaf0c492416_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i387b27c79f194d799d0479f8a64250d9_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if5f7fbaf72f24eac8c150dc42468daee_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8419c61da6e9446b84344e772ddcae1f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5bfa9586158743db9a0c50d35d5c3e89_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i592eccbed0a44157b77b90479b36ff12_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ida0339ec3d81486890f895801d2a05b3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i29c10bec547049118934a57af7d55e71_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i30dd2aba0a4a4cd58d61a14fded9bf4e_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i40056c4ceeb846b4811bce1524b88e28_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia4acd16385e14790b4257cd1e30e36ad_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i28e28b4687a6462d8f2d01ee02868bf2_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i406d7f79310444cba9070d2c72c8ed3d_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2f9ae73e21244184a996ccfa27a0e0d6_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibe33b178b5f24c92919e80285cf6ce87_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i01a022bc19634f4291caec90e24c1e56_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id8fbf93a0d984f74a4c18b8438d93705_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7e590252c39f4b69acea8c278aaaa6f1_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic8d89ac93d3541048345e457b838050c_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8a77e4ef832546f095278c7e2e4cdd06_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i53abdb7bf8da48d28acfcb3784400145_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1508e902d9b44570a06c0b42a8e602df_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3b50ec6523c84e019fd0db2f7ee816f9_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if5d63678be1842828f166c73f3d5ae66_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia254c76d3f8f491097090592e479401a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia14d651799574575bfd8abdfa9223117_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8aaf1d0c5d9848a8b48f4bd785f69d6a_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1fbc96ca92fb42cea0ec295a49f4dfc5_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="icb3058cd0a794324aafc2a3a3fb3d32c_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i06149290e1044e6681818593b0e3b54a_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7665d8acf34544c7bc3d213e29a403a7_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i11b2aa9141884cdb897069ea96225219_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i50642add27bf4a3c847f19d7dcc1fa55_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1878b6e06b6d4e8fbac6886000f181e7_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i49e1c777f67d469aa4c5d82eb4cac8d3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i77a597acb37e446f8a4c956653e8bab3_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0c828becc5644f42afd048825810abaf_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4fea4855dd1f4faabcb8e2d17b561470_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9f53d151fe8347b498763fd23057410d_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4be7291502c242fa9978dea11ad9818c_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idc09d2d675884189bc0ba76a89d7113f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i89dd98c72cc84fe1ba6b852522d18a83_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i4aa4bd06b9544485bda39398396ffcb0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iaafcb61ea5b64eafb32a7afa38475c33_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7d20d851bb704983b94a0bd5e2bf8063_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="icdee48ad66d84e4c821395f425508ec9_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i29866d57d1454ab78e5a90bf77a1bd34_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1d781877b74c43629248df91d29e0ac3_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i287ae97dc4bb452493b5178c62898f36_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iffbcf7aa3c2d4150a651ef9642bdc10a_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idc239cfb9ce0485982b4ed133c7bd657_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i37914cd1dccc44c0996e33a397571801_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i4c955b2727464d82bdccca98ce299c54_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib0328f187daa42cebf05b6bd3a2f5dae_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0bb153e375c54c7eafcbd065d7b6af94_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie7f501d0f4a749579b31839d170e6acd_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i53051d91ab824126b4235ef16cb6263a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i051a1f8ff4d040a5a7eb2d6081274333_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i17ef09cd80ce48528fd4e15b267fa581_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i06739f6ca36d4acf8527637cfd8a8414_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia2195e9ea8f74827888df91311e38634_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie560385a5b9746bfbc9ecf44f08e40b2_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i64c14ab77a3f4981856f2e47e937f928_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic6e2da82b9524140bea1c1e3e0376373_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ica029ef15f3c412ea7f79ededd61891e_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if38059bf51b94495b9e558db7253d6b7_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i55223f8e057b44348303589fe6a6d634_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic1da4c3fbf5a45588aa47da0d8af5515_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i22eb4caafc674003b9ed0fe8faa1adfd_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iaa53a4d85235465fb23f952022ed2de3_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8d1ebe756b1a4fdaba163f6226a73865_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib38c14e59526462aa00b9fdf01150b88_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i81ca4cedb5aa472d978a64ed56e29c3e_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i50df75de55354d31977579bd740f47d0_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9fb8526f11d44a7285dcfe44fe83967c_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia0d92da1715d4466934af62c118acd2d_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0236b7aa74b24bf18b2ebaca9df2dfaa_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ibebde257fe3c43c099d64ee47d4049de_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib4ff9ea6230d4739b53a98d08fe59cd1_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i557f42df940c4b5ab8401d631fbf9c50_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="icdf3bc11cf184431b734d51a51999f44_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i05790066f2a14f93b4be920ebfa71d30_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib0f0430dcadf4801885432b12fc09d25_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i25b567ecf14d4468a81aeaabef24109b_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i25a1a2d1f27b42d4804ea393d24ea74a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4d46afbf8ebf4c85a615530f2f6ca89c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idbfa29cbf57143ac90d54acbc629ab41_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6b934d9eaccf40c292408c0121b1ab1f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic6b191b04cb24993a324572ceed1a094_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1cd72d040762453daa0d7e628045ba1c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i39d2198e5ec0432fa48695a07a06b16f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ifb17e60efe244f14be98a7b086a2993b_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic801c7ed779a4b89ab0b1c8ecda3f3c1_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id2cf187fa1e34995ab2bc76d0f9990b1_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i4eefdcd0b36f4eab9f7efff9e9bbd8b4_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9d2207e1597d44adb9a60324bef5417b_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i73303bef5d5d44fa9de21fa225eb70b0_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i328e26ff5b614b91acdf8a791462b459_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7be86e56935f49e082bc5a14e5f2756d_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3fffd0e4936e44f9ab0a1b46f12c274f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic518c8578d7d45928e9c8d6d8f5afdb9_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib11d6a998a194ce0abd3b90c4cac5da7_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i94d2a4965d144779a4ceefbf2e67dda8_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2dbfb604e8334efcb004e1de36bbe2ba_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic4a5fe4bb174446db8453acdb52d0b8d_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5868064a491c4c21beda0fc35e2236f5_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibcef923095ae403daa45a3cd38e272eb_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2d2e614016aa4c27b3a18c5a2bb1d03d_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i05d4961fbd434dfdb053a7619753dbb5_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia5288342ca6544db84e6afa56ec57667_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1f2490c0acc14641bd54b07d1a9dcba1_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic8201a9664e94c64abb84f293366b311_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i41a145198034434d8c34cb328adb37ee_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iaa58911049db441c9be14900db7de10b_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i92942d5c5a284320a4d0d4db266ef84b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i13dbe9e6430447a283ce3f28d7a2cff3_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i634a6971cc2c4ab4b880a9dc1245444c_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic9198cff7a66447b9be7b837f342aaf9_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i63e2dbe91cf1482c865a5ed7f20252ae_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i280edb799a7541e4b978e766002ab0dd_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2df7fc7846394d8cb6b3dfa190ddbeec_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6a4358b89737469c9a4a76ab01d38b21_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i748c908553434318bab2f9e71aca0df3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6d7d57cfef704ed4a19a72497cfd1cff_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i07dc3cd22e6141a9b58734901b2bcca3_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib37d45622a2a4e2aaf861e5d5425dc36_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5736eee575b44f30b0528226c5b341e0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ifd466ee6375247868fb5aa1fe4cf6baf_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i453e566b12f94b9ca1bf28f9a151ca35_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9ac7771dfc5043b3bc9fe3d75e90560b_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i19b54aa8f21a4defb2e212647938d507_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0430efa680354f9cb2e7be97ad4bbd52_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i01602ac9da834941912114e1dd805606_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2018aba666564bf1b4cbefc426636cd4_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ica2b3030232242349c0d22aa237d5dd7_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i10a4ac80eaa840618cb738116eeaed5d_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia46733e339864c9abf57c0d982aa4ce3_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic649a922ce584f0d9a52986e9dc716a2_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iab330b638fb84af6abe1d5d6ece91457_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8ba7b8ae8c0741bc955d90fcc7f5d900_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia03b1fe2f3c84cfcb0bb12f78e27dfd3_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib1878e36b1da48ddb9bb5431f67577b0_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i4dfc5851d11944dbb13e597eb1fd2070_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i62985e4313f041be8295862d52b0fc22_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i637eadc895304441993cdbadddd0035c_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i02a3c9a671634fbba070e5002be64b8d_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3bd716f176c54a4ab7a98be713399fc0_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i4ebdbfdd7008486e8f029ba89cadcf10_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6daaee3c30874bc79deda2eecad2dfd6_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i75726cc4c32942e7a189dd026b7e9840_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i78908a1d4be846b8a6aced964d30ae02_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2ebc6f14333d4c1388255155e8187c1c_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia43954139ed84f7788fdfc46187abd9c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i19a3f4ca28e54311a8fa6ffc5adf57e5_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i58f9cf052510468ba9fc81d28838fd23_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3e9a42189a364282ad35f4fd9c4a7727_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id9144df0a32e4cb08d0e4aa2404166d7_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8fb3c8f804914aacbb20f2e7f625263a_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6c37042917f440519d1e8bc9992f2fec_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9c2629a235c24645959df36f899307dc_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7e55ed4369874656b82f600d8374ab35_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8c61d257b050413a9a5a10d395f54aae_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ibda8eac58b0944c9aab3bf2cde640d22_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ifdc7392d00fe4b7db44b1ba0ad3f51fd_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0f9843005d574706b3acbf5b7281d78f_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iab78a1c95a9c4ab192a4c1a1d997c9ca_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i776c543649cb40e19afd5abe8d84c755_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i08070e9deccd401188eddde752dc796b_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i097c8aa852634e928b7afcda7183e13c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i574c9d60d2e44b9cb58117accbb26f8e_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i288b2f784c3e4914ac7711b5f2478340_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia2d97ec6f67842ab9cadf89c6fe46eda_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i84032433ba9a4c7ba7a5e2b0546f0df0_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0a6d6bc6ec434449b8d91b39d96f7fdd_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4db29bb20ad146c98f52bdefa9efc026_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id86625d8b1c144f6a7fcb9b8153032b9_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia123fa54d1184c2aad6e71ad4bae91a2_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i65c45e5237224a03a593f86fb93b0f6e_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if310cab52cc8487192e4cee2584a6967_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5da796b8ae144afaa39da1574f7ee62f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib3333c58c0224485a25259a31b39760c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i6d0ef2500d684d2499aa554260f71a9a_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5af9ca056caa4bd992cb4135170e25b6_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ief64ee8dccfd4858bca89783721cee84_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i535b8d9ff9b64a70bf52d430da04038b_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0b7b0bfbd8d946e583f91bdff7c13a2f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7d06f779d4c344b5a71fc394e5493ba1_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i488ea6d5e23043b399c268075239f4e0_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4d8db5b819f845cfa20287368a74625f_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i308a3a88c11043999761321424b73595_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i68b8bbd849704bb8a3082cf7ddf04d68_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib50f737a17604260939c66ca049ac180_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iff780826f8d4410fb949c193f8b1f46c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i7919279ca65c431e8605adcfc55e133c_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic304b1ad72744238ab93ae9de9dbbf07_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0f9722068a2d428f869481dca29dbdfd_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if6fccf214b6547379cc0f5be19a827a5_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ifcb2ac2edd4547409e4873be0e8e70d0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia34444c4d5b245d6882f29099655768f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ie0963689bca64f6898d7b2bf22ef5fc4_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6077b503ac1a407ca0aa969ab1a53c71_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idfc182ac674a40cda02a21659912b0ac_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1100853d86db4419993b4d34aeecc26f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i4d2f83c9f3cf4e93b4ab482d7b240b68_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9ff83048ffc448809d919aa3cc1cdbf0_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0000c4d098c643cda7e8da1a1ce56862_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3dfe4776943b47558791ca89120c5de1_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i0128c7e2dc824abf8e6b5ba3df4232cc_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic831591b74d94d658a1c241551842979_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ideb8786f17a944249a713999b3b6e208_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="idf46a55a1dca41ffa4b84ec847aa7e7d_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i722cb51aca1543c3a7ae3b0a6fe127ff_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ibaf6e5a27a774e869497e0aa2f53c5b9_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia015295d7f5a43dcaad4e1a68cefc54f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5400f99139394995bff032d46312fcac_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id9845531e1544cfaa60c21e5946faa1a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="icc7cdcd1f2024d52919c1a2b418c162c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib1743be59d8b4610a3d295d501005cd0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6ef90bedc87e45cea6e49532d1496f6d_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3287b402551c4484b394de8276d293f9_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7662fd5ddc4846a3b1818f333fa21bc6_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if7a2ce0616b7406aaf58a444927e2047_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib532fb9422ed4614a1eecad8c8435a75_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i6bc1c765754d4475a879977b61883766_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i38876ff942eb4950811a685cde835ba5_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia710ad7cb9d04f4184dbd32294cd4f75_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i25fca766f96443b785e425e523fbce14_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i20dcb86296844dbda765eb7afdc78e2d_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i157d929ac5794703b29ad1b3d0e06f2e_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1993ccddfb034873a36b94a7f7017ddd_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6a4c53848f34480d9a9a1d516da71087_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i6b7edee30e3d480da3deca7eb3ed8837_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i908f6839346c4686938c7732821b75a8_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia717abc404b146b3a20cf3cdbee20322_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib8fbc02017884ac9a57e155715db8909_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i21d39404482e4c219c8780425fba1375_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ic64782304ba44edc84ba60d27fa2279b_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i31026e003cb1415fbad582c204df9190_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i90b0b233fad44191b424a24fece33b51_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i3a4466b00cc249fb98151e07aa84fbad_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i57a2012297b041c7b1efa586c301f494_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i97c25d98536140f3b69ae8c88acf7a37_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i586d3a14b6c740d8844f2849c4eb2582_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i443117f5e241456285fb9a55936853e7_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie01251da528b4f90a10a4142620a65cd_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9bfe8df60f4743ec99ca6904a5e64756_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i27fec44642f34c5099c21747e3250cb1_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i412aa3432fcf467f8fd19c46b727c491_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia390d2427f664929bec44ea56be4ec81_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8baa768ee1284c7e99d6ee829ff2c08a_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3e11d4f4c34c41b5be8ae617dc5e9c1d_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic6fda5fb73a341449bfac9d8fb7a268f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i9ed73e5ea20c4b98b366ff0b993278cc_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i64f8de01c4be45768b397e71429b87f0_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i68e9b1789db54a1992eb64fc846195f1_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i569ace16f96641559bb1b2d217a5f3ee_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3982de94b47b42dea86bcede03224217_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i80e3610796c24f389098231002fd25b3_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i441e7039e08a47fcbf82ede9c2ebfbe6_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i324894961943456d92139b57181b5bb9_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i281e3cd9deea4daaacf98eaf97ea934e_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i016776eee5714891a0386a16d5557a03_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i747469c41b2a43deb3981557e85294f3_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i54e1c7c7e8dd48959fd8bf1743fc8e80_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie1a2fceceece40e9b7f64f083218ee49_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib4bdb0db58854e95a85e98d94100f662_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0ed2d31b27e045ab82b125179a98301e_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9584ac8d54c6468f80de0bb9c19b14e8_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia0672b25c90a4d09917d157086a6428a_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib9696d83a57d4dacbe080d0f1444e529_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0b1a88c0fa4b44b794e579ac382449d3_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8a92fd5c525643629fe7ff73a1af3c2f_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4bfe3e4294df4883a39ec285886b1913_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ib37fb7ee236248a882538282edd2b353_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8f48482859234f7bac2ce55a3818dc23_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iebbec59e0ece4791b17dcc2fcc6131ef_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i79f938a541ab4334bc462b1f7fa4c89b_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i4d7a46d82f594dea958391e3f85c7adc_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0b88bda5d09242278cca53b9ca866611_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i11f87d928b364165a9ce065e74fb63ce_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4109ba0613344384a303908d2b52ff33_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i39cea1d7d42a46b8aa131cde5e274282_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5523f7460fd948f08ef26a334123472d_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ie01bb5db42274474b71ecf23309c444a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4cc6145fd3894d74b3ce85f802f90390_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5f4b2747819f470683e7967d8ae774bd_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8edf9410e7d643b19bc9451e934d68de_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2ce7bb1e40a34cac933a9900b74f1bbd_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i01ea13492db24868803369c77f57b645_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i8a69a34fd0c94f13b4b310835aa606ff_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ie2ee68091377424783ed3c9953196597_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i2e33c4da904049bc8c9bfff387e3375d_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia36ad544dbed4b9fba4cef602aef272a_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i5fd3cc31f314437293f6c8d05caf543b_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i841ed2eb0fd747d19d8bd3831cfcc965_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1267f9a793dd4838bee913c7e7f1bc85_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i57cda4c770ae48fc874d0e1e0a6aa499_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="icce8cec453c54166a59e25d4837a056c_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if0dc3d45f3f941dab28721d910f5e49f_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i22f0cbac43d94b8bb57a7d434308ab35_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i27e8d4536d8e4ea7a2ed2551f3af3104_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i4e8a3362cdda49a18367d18f349e957d_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i96c08b8a10da4041816e159343bf7063_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i39103b4eef404909b321cdc17486f7ca_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iedc5007223004e44b9e3f6016636f4eb_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6180f4c8a3a141b0b11ef6eea2dd5c8e_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iee0e58c2ebe74103acd746853588d46a_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id809ffa3e19b46f69f68ae5cd89fd702_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i1c0ab60765214aed9b7662351556aa75_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i95dd4291b011442fb7dc8d71ff5ffe4b_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i719a66732d7f469782333e22b8bc190c_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i1a2da2b15d204fb7b695aa3bfc830f42_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7b15286f874144618839786849ea1437_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic6094ef6600341388845fd981445402a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i90adf511b62e43ed9a3312bbc6ec0892_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="id349b0a0d08341149ec80073155e33e2_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ia7da5b6f21e243f1acad5577402788da_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iaaff25a8ee4a446eafc7e7a139993836_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i61b390e9d694497896d1ac279e6a0013_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i529d608738614ae0a943f58551da20f0_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i06cae828408f49239c6f174bf1c334a3_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ifee05ee77bf344a68295fa0ac185a55f_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i57d86df693ac4fec81410c7eea2535c2_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ibd132153d9614629bc9c8135b8b92864_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib6e2458177a343e08824dfb1c6bd2f07_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i6bcfd345e66e46298c5faf33123c8744_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ib2da094b787c4b54b4e09b39c3f9a9f4_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i4a9a7ebb719f437a941405e59e3f7376_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3a725035e4c3410583da06507280fe59_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i83d3c1f4234a402fa97cbd81b084f556_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic1ac66e3eb004358ab735bbc8456405e_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i3b6b7844077b4016b45ccbe380ad3dc4_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ic2790d59614147c487677304230bb1ae_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i8084c9e8e16045e1940be548a1af4fcc_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="i501ea63e8e9f4d7d9d498ec389c88591_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i241ce185147a489fac065e3d478f8bc6_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="id5646a565d4a4fdf8f17b8e7a2cf4a6c_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0c7a6815d0144fa3bda521f8ed93043c_D20210405-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="ia685c80f08574eeea6722e02543f738a_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="ifd9d069efa93465f945738a484e31e5e_D20210104-20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-04</endDate>
        </period>
    </context>
    <context id="iaf1d14a3db84419db81e75d0179c01b4_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic932039af4d240c09dba004300b0fc41_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3d9a072c24d944d79f506df951a632cf_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ib832ec9b9cd74a91bcf4231b96beab4f_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i4f5f7c43d3a442a99a3d2ce435c696ea_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7a31f7f1915d4fe7b8465e43a6596732_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i7ce6d2b512174db89a47812c9123ec44_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i6dabc10483784643822a9c5e7bb9014c_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="iaa4ee166c8fc4dfd9a75a228d52f75b6_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i6b6d7ce367d24bdfac85e944a0140905_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i4db059902da348b3b536a571790f6347_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="iad119c0eadb24bf6b712a9ded64f1721_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i2a5fcff52eca4e2b8f7fd71362e00ee5_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i5536e8ab75ef4a8ca62f7e1e6d81a778_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3ba73cf6d5694c16922acb99ad67a259_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i9e4509ae1e9143f38c795c4c1718372b_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="ife017e4feb734f059e4eacc8da2b9534_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="if1ba4fdb7eda4a54a9874ebb8569565b_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ic69e838063cb443ba0f1e022744b19a5_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7d9d11122c61482b9e49c7ba615148f0_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i51a055a5688e4ddfbc8c0852cec70dc5_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i49377ad3634041709403a2a206d30a13_D20220301-20220322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jnj:RasmussenInstrumentsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-22</endDate>
        </period>
    </context>
    <context id="i858a52bb013045799d07f07aaa301efb_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ifce5aacbfc3a444c920acdbe2b4a1ec5_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ic155bb14d5cf4a6ea37fc5c8528e6732_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="icec2a84c793b4a13a9cab4e12fc62921_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i888c4c1d679a40f2b81b60328c1858f4_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="ib6ef62a6d06b427d93b514f97600fe84_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ibb991236eb0f43e0bf871925f4f3d04a_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i52eba45e53444e1298c1fcf2a2216b36_I20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="i5e4e74ca66f8464690742d705f7eed8a_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="iefca38bcca5c426da7027dede1f04f08_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i7fdef417221f4a06a85755418e9c5222_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i5d3938fca19a4ceaa24ccd83eff70370_D20220404-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i73608594f8c3424eaa8ff95295134a24_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i2909b6c557f9463ea81eb9118d4a4049_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i480b3ed870204b9391f1887a57cdae32_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i74fe313c94e648559666a0a69c919630_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i6f129a7dfc034e9c9fe9ae8a3c42730f_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i0c3d0aaa08c34dad9c998070ad8755bb_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i6cc12874a2f141468d294f5edf304948_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="if65b6db0f8484a37b25b57a750fdd0c9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5042a6771a2743cfbea81abb2c4f0489_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iedcbb46afcdc46c89062dca3aa694438_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4c99f4219f554853b8e2459b665c0cb3_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i38a9e37a55a9465296ff97bfeb4dbc2d_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i0c0d4d2eea744af684d21c45ce8f9077_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="if587f8e549024234943bfe0d376966d8_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i15dab1b527c04e6c93a77db28d7f4dfb_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i69ca6c41d5964c50abb196f02b39a16f_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i3d93eaa25cfc46b38549e5a299d8f0e1_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="idbfc10f2d9fb46bea65fe6d1a1318594_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i86429e3449e0476199236fd7c3b171dd_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="brand">
        <measure>jnj:brand</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="patient">
        <measure>jnj:patient</measure>
    </unit>
    <unit id="cases">
        <measure>jnj:cases</measure>
    </unit>
    <unit id="claim">
        <measure>jnj:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV80LTEtMS0xLTcwMDM0_d6eb2da0-026f-4021-891b-f5400f9ee9e0">0000200406</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV81LTEtMS0xLTcwMDM0_55b6af1b-df68-4642-9507-d3c0c7629e46">--01-01</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV85LTEtMS0xLTcwMDM0_9541b481-cade-4610-b6b3-322e34dcb3b0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV8xMC0xLTEtMS03MDAzNA_8ecd8193-ad3e-49d5-b4f4-a5412c7ff489">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83L2ZyYWc6YWI5Y2FkOGFlZmJmNGE1YTg0Mzg3NWFkZmU0ODE0OTMvdGFibGU6YTIyOWYwODQwYWE2NGY1ZTk3N2U0NjI4NWViMmVkNTkvdGFibGVyYW5nZTphMjI5ZjA4NDBhYTY0ZjVlOTc3ZTQ2Mjg1ZWIyZWQ1OV8xMS0xLTEtMS03MDAzNA_016152d0-d882-4d22-96d3-de0002383a66">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY1_3a6f7ae6-0052-4c29-b5e4-c333d4ecdd4b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZDBiM2NhNDc2ZDVjNDBhMWEyOGRhODM4MTc5NTBkMmYvdGFibGVyYW5nZTpkMGIzY2E0NzZkNWM0MGExYTI4ZGE4MzgxNzk1MGQyZl8xLTAtMS0xLTcwMDM0_cdf48052-38d7-4f2a-a6d7-4521a6657b53">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8xMjI_b34ff3b5-d0cd-4400-8abf-238819c2c14e">2022-07-03</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6OTRkYTFkNDc1MDg0NGU1MTkwMDIwNDg5ZDMxMThkM2MvdGFibGVyYW5nZTo5NGRhMWQ0NzUwODQ0ZTUxOTAwMjA0ODlkMzExOGQzY18xLTAtMS0xLTcwMDM0_302d1806-870f-4e70-88d2-41bedd679d38">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY2_9607cb8f-b3ce-4c1f-8435-ef1fceb16175">1-3215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDU4_e67adb63-838f-483d-b3a9-fc10897ded01">Johnson &amp; Johnson</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6NTZmZmM2MzJjZTMxNDQ5NmJhZDA0ZjZhOTU0MTVmMzMvdGFibGVyYW5nZTo1NmZmYzYzMmNlMzE0NDk2YmFkMDRmNmE5NTQxNWYzM18wLTAtMS0xLTcwMDM0_a3026569-7637-4667-bfd6-9df28571c69c">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6NTZmZmM2MzJjZTMxNDQ5NmJhZDA0ZjZhOTU0MTVmMzMvdGFibGVyYW5nZTo1NmZmYzYzMmNlMzE0NDk2YmFkMDRmNmE5NTQxNWYzM18wLTItMS0xLTcwMDM0_200d6851-07a5-4f80-af19-fa9a59dc2eff">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDU5_b9fa3c39-1e55-4df9-a693-c93bbfdad9ca">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY3_f31c7409-0405-44b1-9f87-a0211c243936">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY4_91a6c4ad-d123-48fb-adce-a21a46110139">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY5_338f0cb8-512e-45ad-b529-78d0d456f49d">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDYw_eaf408c8-b904-4910-adcf-3a134bd3c0b6">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDYx_61cf8b0c-b757-4181-b92b-18ebf56ee843">524-0400</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDYz_d21ddae8-0473-48d5-9399-4ce75c62eeff">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDY0_e195f289-9a49-43c8-a3f9-50eba5a0e843">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6MzE5MTYzYzZjYjRlNGM3M2FhNzA0ODM2OWEzMDE4ODQvdGFibGVyYW5nZTozMTkxNjNjNmNiNGU0YzczYWE3MDQ4MzY5YTMwMTg4NF8wLTEtMS0xLTcwMDM0_bba92a9a-9d64-414f-9cdf-9c5bd4de67df">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6MzE5MTYzYzZjYjRlNGM3M2FhNzA0ODM2OWEzMDE4ODQvdGFibGVyYW5nZTozMTkxNjNjNmNiNGU0YzczYWE3MDQ4MzY5YTMwMTg4NF8xLTQtMS0xLTcwMDM0_53a91ec0-8220-4c0a-9695-fe1b6c8d947d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6MzE5MTYzYzZjYjRlNGM3M2FhNzA0ODM2OWEzMDE4ODQvdGFibGVyYW5nZTozMTkxNjNjNmNiNGU0YzczYWE3MDQ4MzY5YTMwMTg4NF8yLTItMS0xLTcwMDM0_fe810477-1963-49b0-a560-ba3044a5bbcc">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8yMDYy_d6d12213-66dd-4371-b0fa-00ad162d2bdc">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="i081646bd651e49ccbec8525d32cdd1ee_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8xLTAtMS0xLTcwMDM0_1deda889-72c2-4bea-93d1-f994f861bb13">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i081646bd651e49ccbec8525d32cdd1ee_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8xLTEtMS0xLTcwMDM0_55178f40-1d76-4f53-90d1-035ad46a4782">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i081646bd651e49ccbec8525d32cdd1ee_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8xLTItMS0xLTcwMDM0_673cc6fd-aa0c-45f9-8b97-ba6105ea0b5d">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ifbb124a5ccb24559ac685f2e90cbaea3_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8yLTAtMS0xLTcwMDM0_49f463ff-8ce4-427f-86fd-e1986fef002a">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifbb124a5ccb24559ac685f2e90cbaea3_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8yLTEtMS0xLTcwMDM0_fc9966b3-ef71-487e-bf55-8a7ddd9efcee">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifbb124a5ccb24559ac685f2e90cbaea3_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8yLTItMS0xLTcwMDM0_57636182-5884-4b35-b101-2dd38b5a0436">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id3ef6f7979ef4744b07bd5c44033c0ed_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8zLTAtMS0xLTcwMDM0_8b11a8d0-3ba2-45f4-a3fe-dbbc0d7e8ed4">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id3ef6f7979ef4744b07bd5c44033c0ed_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8zLTEtMS0xLTcwMDM0_28a640ec-750f-4b38-8556-32a8b35f3cf7">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id3ef6f7979ef4744b07bd5c44033c0ed_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV8zLTItMS0xLTcwMDM0_51f86a43-0732-484d-a16b-130cfb1424d1">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if661bb2f35c84737a9a48c16676d08af_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV80LTAtMS0xLTcwMDM0_febf1985-0675-4e9e-9121-d6920a4ab2a4">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if661bb2f35c84737a9a48c16676d08af_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV80LTEtMS0xLTcwMDM0_d483cef9-d101-48c6-befb-8badb0b99da9">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if661bb2f35c84737a9a48c16676d08af_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV80LTItMS0xLTcwMDM0_01d124e1-bdbd-4702-86c3-9a12545d7689">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i554ee5b5caea422aab835052a7bcd38f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV81LTAtMS0xLTcwMDM0_081ff4d8-b861-465c-aa06-aa71a4a61f81">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i554ee5b5caea422aab835052a7bcd38f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV81LTEtMS0xLTcwMDM0_60b11683-2173-4577-ba78-d962d8315d28">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i554ee5b5caea422aab835052a7bcd38f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGFibGU6ZmNkOGY0NTM0MmMzNDdlOGFkZmIwZTIyNTVmMmI2N2EvdGFibGVyYW5nZTpmY2Q4ZjQ1MzQyYzM0N2U4YWRmYjBlMjI1NWYyYjY3YV81LTItMS0xLTcwMDM0_eaa22e2d-d6b6-4866-a912-9ee96ec60d84">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i391bd8bf57bd4482a4a2ddc2a79b27fc_I20220722"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8xL2ZyYWc6ZjUzOTI5MzdjZDg3NGQ0MGE1MWU1OGJkZTU5MjZjMjQvdGV4dHJlZ2lvbjpmNTM5MjkzN2NkODc0ZDQwYTUxZTU4YmRlNTkyNmMyNF8xOTk3_4d62037f-ffe5-48b7-a38c-a2109e3ae062"
      unitRef="shares">2629179895</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMy0yLTEtMS03MDAzNA_eb988ff8-f203-4ec0-96e8-7a182f015e39"
      unitRef="usd">10983000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMy00LTEtMS03MDAzNA_d1af9d26-bd0b-446c-a2da-9969c8f0e6fd"
      unitRef="usd">14487000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNC0yLTEtMS03MDAzNA_98f236b4-b55f-4262-9b74-f1c1f316cea1"
      unitRef="usd">21585000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNC00LTEtMS03MDAzNA_5ee6b174-5546-4b47-baf9-f4f1458ad319"
      unitRef="usd">17121000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNS0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjhhMDQyMDQ4M2ZlODQ5ZWNiZmVjMTYwM2E0NDg3ZTVhXzg4_3d1152c6-3001-4624-8092-1ec1586d0ed5"
      unitRef="usd">223000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNS0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjhhMDQyMDQ4M2ZlODQ5ZWNiZmVjMTYwM2E0NDg3ZTVhXzk4_8aecbeec-7315-4a09-bd28-8048535e9141"
      unitRef="usd">230000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNS0yLTEtMS03MDAzNA_06073685-50cd-4299-bbcc-84fe4ba34b24"
      unitRef="usd">16139000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNS00LTEtMS03MDAzNA_b521e01b-c70d-4092-86cb-8f082a46b8c8"
      unitRef="usd">15283000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNi0yLTEtMS03MDAzNA_74c3504e-fb6d-47ef-a35f-57b9bba3a93f"
      unitRef="usd">11437000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNi00LTEtMS03MDAzNA_8e9e3c7b-b5f7-41d0-9de3-25b38e937444"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNy0yLTEtMS03MDAzNA_f0e4611a-d816-4465-8bce-6e04165e7225"
      unitRef="usd">3703000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNy00LTEtMS03MDAzNA_8ea2ca32-dfae-4cf3-917c-a3988ddbd551"
      unitRef="usd">3701000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfOS0yLTEtMS03MDAzNA_746fffa4-1c0b-4734-83a0-9f8bd70a59eb"
      unitRef="usd">63847000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfOS00LTEtMS03MDAzNA_8ca82bca-b38e-4a35-9d8a-06c639a988b1"
      unitRef="usd">60979000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTAtMi0xLTEtNzAwMzQ_4fcf1e4b-6982-47d2-b0e8-7071b43bda39"
      unitRef="usd">47144000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTAtNC0xLTEtNzAwMzQ_63b1ef54-c2ea-491f-8cbb-1406fb3fb0a3"
      unitRef="usd">47679000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTEtMi0xLTEtNzAwMzQ_0554d698-1e8e-4924-b83d-9edf879cef8d"
      unitRef="usd">28790000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTEtNC0xLTEtNzAwMzQ_b60d0aa4-32d1-46f6-987e-c5a26e4f2b66"
      unitRef="usd">28717000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTItMi0xLTEtNzAwMzQ_d944b6e0-29aa-4263-b040-53bb31e47ae2"
      unitRef="usd">18354000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTItNC0xLTEtNzAwMzQ_be5fe568-4239-454a-b54e-7438f507cde5"
      unitRef="usd">18962000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTMtMi0xLTEtNzAwMzQ_fd748c4a-9d4e-47e8-8d05-8039e65f9225"
      unitRef="usd">42408000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTMtNC0xLTEtNzAwMzQ_f66b097d-7a70-4b40-b2e7-599d7d156d15"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTQtMi0xLTEtNzAwMzQ_7f792dc2-b97e-4e3c-9795-3257e64e294b"
      unitRef="usd">34166000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTQtNC0xLTEtNzAwMzQ_c431dc33-c615-4255-b805-43969474e04f"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTUtMi0xLTEtNzAwMzQ_197ee6f7-fe2c-48f0-9012-8e6939fdfc88"
      unitRef="usd">9514000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTUtNC0xLTEtNzAwMzQ_dd349b43-51c9-4d83-b6f6-5cc93be210f5"
      unitRef="usd">10223000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTYtMi0xLTEtNzAwMzQ_0a744bd4-656b-44ad-9619-eb36e79f91e4"
      unitRef="usd">9435000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTYtNC0xLTEtNzAwMzQ_182d0ec1-8540-458e-8c3d-ed5e20cf1da7"
      unitRef="usd">10216000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTctMi0xLTEtNzAwMzQ_6d8a898e-4a85-4e8a-a3ed-f0baf9012c26"
      unitRef="usd">177724000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMTctNC0xLTEtNzAwMzQ_4385e3c1-8cf7-4cc4-bd27-5a1969bbba4b"
      unitRef="usd">182018000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjAtMi0xLTEtNzAwMzQ_2583fcbc-0577-4744-bac9-a9a60c3ae6df"
      unitRef="usd">4305000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjAtNC0xLTEtNzAwMzQ_3b4e41d8-f84e-4e90-90df-ca15d968d60b"
      unitRef="usd">3766000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjEtMi0xLTEtNzAwMzQ_9ece706c-6ea9-4edc-9cff-f943c6af5dfa"
      unitRef="usd">9765000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjEtNC0xLTEtNzAwMzQ_195ea945-82c8-4d5a-8646-b56e97803aec"
      unitRef="usd">11055000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjItMi0xLTEtNzAwMzQ_6bc7e7b5-414f-4565-9815-a3447e048982"
      unitRef="usd">12607000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjItNC0xLTEtNzAwMzQ_68f40775-37f0-4b8e-b6a1-5236e53f92e2"
      unitRef="usd">13612000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjMtMi0xLTEtNzAwMzQ_cec22065-3c07-43eb-9f89-c1aaef245da0"
      unitRef="usd">13447000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjMtNC0xLTEtNzAwMzQ_5d82a43e-1e91-40fb-b28c-a7c6f3040b45"
      unitRef="usd">12095000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjQtMi0xLTEtNzAwMzQ_b5254e70-3c15-40d0-a9fe-e387be22bab4"
      unitRef="usd">2717000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjQtNC0xLTEtNzAwMzQ_6df2c613-ea0a-4bf3-8ffb-abba32811b9c"
      unitRef="usd">3586000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjUtMi0xLTEtNzAwMzQ_724cc176-6a30-46f9-b61d-2a611261d352"
      unitRef="usd">1980000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjUtNC0xLTEtNzAwMzQ_dffea15d-628e-4fc0-a924-75027322d2c7"
      unitRef="usd">1112000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjYtMi0xLTEtNzAwMzQ_d71ca4ef-d8b0-4e01-b267-3e6ddac340ed"
      unitRef="usd">44821000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjYtNC0xLTEtNzAwMzQ_a76d7c28-bacf-4bbf-ba29-19b87e932cba"
      unitRef="usd">45226000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjctMi0xLTEtNzAwMzQ_fed4b956-78bf-4651-9365-0a1ff3a7d8c6"
      unitRef="usd">28292000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjctNC0xLTEtNzAwMzQ_3848f3ce-8a0a-4da3-8997-dbee97ed25c4"
      unitRef="usd">29985000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjgtMi0xLTEtNzAwMzQ_254bcf3e-07d4-4d0f-9595-2a0ae72af6f7"
      unitRef="usd">5015000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjgtNC0xLTEtNzAwMzQ_68dd2a40-c594-4098-991a-c650db34fc7d"
      unitRef="usd">7487000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjktMi0xLTEtNzAwMzQ_7eb37dfe-fd4c-42ff-a2d1-710a4c0bbb31"
      unitRef="usd">8553000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMjktNC0xLTEtNzAwMzQ_8a323ac0-f90a-48cf-86e6-4296c09d19a1"
      unitRef="usd">8898000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzAtMi0xLTEtNzAwMzQ_52f233db-4e6c-49b6-81cc-7d1c7370b977"
      unitRef="usd">4162000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzAtNC0xLTEtNzAwMzQ_32032112-7748-4b1e-aad8-c0e3768292ef"
      unitRef="usd">5713000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzEtMi0xLTEtNzAwMzQ_41d817ae-6230-4ab5-bd13-793bc8fc675d"
      unitRef="usd">10524000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzEtNC0xLTEtNzAwMzQ_73c1fc44-dd84-4cf5-bcbb-254914973bc1"
      unitRef="usd">10686000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzItMi0xLTEtNzAwMzQ_f8abc10d-2c0c-4776-aff6-46e208da1f39"
      unitRef="usd">101367000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzItNC0xLTEtNzAwMzQ_e072a418-c04e-41c9-a404-3da45667b36f"
      unitRef="usd">107995000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzMtMi0xLTEtNzAwMzQ_7c4222d2-48ab-49b1-882e-c9cd5ac436b6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzMtNC0xLTEtNzAwMzQ_ad7d9161-6518-4277-a75f-bd6992ff7df7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl8yOQ_dc8379d1-a35e-4957-9a0a-ac2505ffb76c"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl8yOQ_f30a7d76-3cd9-4453-b8d3-757117c1881e"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl81NA_0d931442-ae01-4bb3-9319-71af79b709af"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl81NA_87c05330-4c8b-47e6-80b1-8c0c350aba2c"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl83Mg_8f82e53e-302b-4351-896e-5effcf79bd5d"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNmFhMGZlMzgzYWI0ODRkYTk4NzU2YTRmOWIzNThhZl83Mg_e8e11d31-6915-4b48-9073-d7e79efe87b8"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtMi0xLTEtNzAwMzQ_de54b06d-b45f-41e3-b2d4-286b5435107d"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzUtNC0xLTEtNzAwMzQ_733b9f47-7465-4d7c-b8f8-70891ee0048c"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzYtMi0xLTEtNzAwMzQ_3049f17b-175e-4ab1-88ee-e15bab6ce56b"
      unitRef="usd">-13843000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzYtNC0xLTEtNzAwMzQ_20b789cb-5030-473f-8ce9-e0f5751582e1"
      unitRef="usd">-13058000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzctMi0xLTEtNzAwMzQ_daacf693-88ad-40ae-8d24-8c8bd556c797"
      unitRef="usd">126216000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzctNC0xLTEtNzAwMzQ_988773ff-04d9-4ff5-af19-bd05c4495eac"
      unitRef="usd">123060000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjozODcwNmQ5OTdiOGY0ZmRkYjk5MTNhZTdkNzAwMDU0MF81MA_b83a7fb4-bb02-4190-9118-367e2de3d49e"
      unitRef="shares">490811000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjozODcwNmQ5OTdiOGY0ZmRkYjk5MTNhZTdkNzAwMDU0MF81Nw_e22a4d9e-71d7-49ab-b752-065e08b33aeb"
      unitRef="shares">490878000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzgtMi0xLTEtNzAwMzQ_b8086d61-6f8c-43d3-b422-a49cee2bb206"
      unitRef="usd">39136000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzgtNC0xLTEtNzAwMzQ_48659687-3433-448f-99eb-edd46518b9a2"
      unitRef="usd">39099000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzktMi0xLTEtNzAwMzQ_a0053591-8cbb-456c-87e4-1e1a319dfe1a"
      unitRef="usd">76357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfMzktNC0xLTEtNzAwMzQ_86c63f20-ea11-4f61-8e3f-32532feb41de"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNDAtMi0xLTEtNzAwMzQ_888aed61-6562-4f7a-b329-ef4cdcdaf064"
      unitRef="usd">177724000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yMi9mcmFnOjM5MTUzMzdmZjYwOTRjYmNiMmYzMjU3NmYzMWU1OGY0L3RhYmxlOjJlOWQxM2FiOTEwNTRjOWU4NzgwMTQ4NTI5ZmI5MmE3L3RhYmxlcmFuZ2U6MmU5ZDEzYWI5MTA1NGM5ZTg3ODAxNDg1MjlmYjkyYTdfNDAtNC0xLTEtNzAwMzQ_5dcd41f8-48d4-4477-abf2-cb29cb704457"
      unitRef="usd">182018000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMi0yLTEtMS03MDAzNA_4e648f65-0643-42fc-a60a-b9b003849cda"
      unitRef="usd">24020000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMi00LTEtMS03MDAzNA_929ad856-b048-435d-980b-7340735a592d"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMi02LTEtMS03MDAzNA_327ead6c-0b16-4ebb-8102-90e6e678adf6"
      unitRef="usd">23312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMi04LTEtMS03MDAzNA_c303724c-363e-4a4b-82af-be87b83b05c4"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMy0yLTEtMS03MDAzNA_86f42d7e-4551-451e-8902-6e21387aa611"
      unitRef="usd">7919000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMy00LTEtMS03MDAzNA_a127363d-0fd0-47ce-bc9e-633fea5f3555"
      unitRef="number">0.330</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMy02LTEtMS03MDAzNA_bbf82425-4d1e-463a-b863-0921227cffc0"
      unitRef="usd">7587000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMy04LTEtMS03MDAzNA_6dcd5316-5c89-4148-a50d-d4939e702eb8"
      unitRef="number">0.325</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:GrossProfit
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNC0yLTEtMS03MDAzNA_847f996c-295e-4fba-80f6-e13d9121c30e"
      unitRef="usd">16101000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNC00LTEtMS03MDAzNA_af417422-d5b5-4348-9b36-7647962a22f4"
      unitRef="number">0.670</jnj:GrossProfitPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNC02LTEtMS03MDAzNA_0532ea52-9f83-4214-a664-19e1ed090a9a"
      unitRef="usd">15725000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNC04LTEtMS03MDAzNA_57695800-5910-4a02-91e1-9b75e4a5b160"
      unitRef="number">0.675</jnj:GrossProfitPercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNS0yLTEtMS03MDAzNA_11316bba-7408-47b5-8a1f-5a3dab73b777"
      unitRef="usd">6226000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNS00LTEtMS03MDAzNA_bd258ec2-8eb0-4f56-b34b-ca94ac4d9be9"
      unitRef="number">0.259</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNS02LTEtMS03MDAzNA_6f06e157-8af0-4b32-8623-c40ec50dfa17"
      unitRef="usd">6073000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNS04LTEtMS03MDAzNA_5e48c1b5-a406-482b-9f91-70edb067581c"
      unitRef="number">0.261</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNi0yLTEtMS03MDAzNA_4802217b-952f-4b08-b755-9c4adf5ed1f7"
      unitRef="usd">3703000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNi00LTEtMS03MDAzNA_dd7def24-097d-4022-bbc7-78fc2320f36b"
      unitRef="number">0.154</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNi02LTEtMS03MDAzNA_d518b368-30ea-40b7-94d2-71da780e9ebe"
      unitRef="usd">3394000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfNi04LTEtMS03MDAzNA_704d9e9c-ef0a-4d16-8ea8-42f7c220f733"
      unitRef="number">0.146</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOC0yLTEtMS03MDAzNA_0e85b7f8-53bf-4afc-a41b-c6015c0bd30a"
      unitRef="usd">64000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOC00LTEtMS03MDAzNA_2a2cec33-08d8-461e-bd17-6083ff621411"
      unitRef="number">-0.003</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOC02LTEtMS03MDAzNA_e05c37f8-9f1c-42ca-a4d9-f22fb589b83b"
      unitRef="usd">12000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOC04LTEtMS03MDAzNA_e7bcf073-dc6a-4455-8abd-5ca18cd8afcb"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InterestExpense
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOS0yLTEtMS03MDAzNA_9aa14bfe-f748-424f-8035-db63e2ee62e8"
      unitRef="usd">38000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOS00LTEtMS03MDAzNA_c892ded7-f817-4150-b88e-64c1031c1fac"
      unitRef="number">0.002</jnj:InterestExpensePercentToSales>
    <us-gaap:InterestExpense
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOS02LTEtMS03MDAzNA_ff0a8fc8-2dd2-421c-aeb5-bd5df612537f"
      unitRef="usd">40000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfOS04LTEtMS03MDAzNA_b03e7753-71a3-424b-9a8b-feeeb1cba643"
      unitRef="number">0.002</jnj:InterestExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTAtMi0xLTEtNzAwMzQ_347c6416-036b-4fb9-b1c2-dd2ee4e6edd9"
      unitRef="usd">-273000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTAtNC0xLTEtNzAwMzQ_36649ccc-020b-4aae-8c49-150b84fdd604"
      unitRef="number">0.011</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTAtNi0xLTEtNzAwMzQ_c2a24fde-1956-4c7f-804e-8003bd8a17a3"
      unitRef="usd">488000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTAtOC0xLTEtNzAwMzQ_2a620989-511a-4a54-b2c6-ddee32980e1e"
      unitRef="number">-0.021</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:RestructuringCharges
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTEtMi0xLTEtNzAwMzQ_61449974-4a18-491a-b53c-4d339841c392"
      unitRef="usd">85000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTEtNC0xLTEtNzAwMzQ_69a3f69f-d560-4eae-8359-9b56165eaa36"
      unitRef="number">0.004</jnj:Restructuringchargepercenttosales>
    <us-gaap:RestructuringCharges
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTEtNi0xLTEtNzAwMzQ_c4f6363a-a4fd-4563-a74d-845b48a45b06"
      unitRef="usd">56000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTEtOC0xLTEtNzAwMzQ_989b4cf2-3386-45c6-8552-420ad2904d87"
      unitRef="number">0.002</jnj:Restructuringchargepercenttosales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTItMi0xLTEtNzAwMzQ_024a2585-9701-41fe-992a-27cc018abc8a"
      unitRef="usd">5840000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTItNC0xLTEtNzAwMzQ_a666c69d-847f-4c84-9ced-b251bd5b8352"
      unitRef="number">0.243</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTItNi0xLTEtNzAwMzQ_f21e3963-d94d-4006-89eb-bf27f3a99669"
      unitRef="usd">6662000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTItOC0xLTEtNzAwMzQ_67717ac8-8dcf-474a-83ba-36ea3cb77acf"
      unitRef="number">0.286</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTMtMi0xLTEtNzAwMzQ_95a447f2-4194-446a-9024-d8ad804349b9"
      unitRef="usd">1026000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTMtNC0xLTEtNzAwMzQ_9176d953-e620-4328-98fe-cae745e69e2d"
      unitRef="number">0.043</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTMtNi0xLTEtNzAwMzQ_d71478b4-61fb-4158-b707-46d29032f314"
      unitRef="usd">384000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTMtOC0xLTEtNzAwMzQ_6742cf79-7f5b-4018-bba2-4cd2b11957b7"
      unitRef="number">0.017</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTQtMi0xLTEtNzAwMzQ_f4b1ef5f-bcd4-45de-8aa5-325ebd940504"
      unitRef="usd">4814000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTQtNC0xLTEtNzAwMzQ_f0910627-042e-4806-88f8-3f211fe17df5"
      unitRef="number">0.200</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTQtNi0xLTEtNzAwMzQ_b1395c79-74e4-4b6d-9272-a459d496ce45"
      unitRef="usd">6278000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTQtOC0xLTEtNzAwMzQ_bae6150e-4812-466d-9d82-cedcd3408b7e"
      unitRef="number">0.269</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:EarningsPerShareBasic
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTctMi0xLTEtNzAwMzQ_b7402fbe-0616-49f1-af6b-2e84a6ab757a"
      unitRef="usdPerShare">1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTctNi0xLTEtNzAwMzQ_3178c61b-6d1c-4185-b651-f73143ba83ca"
      unitRef="usdPerShare">2.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTgtMi0xLTEtNzAwMzQ_47597e54-1bc4-45dc-9a30-c57ba2252662"
      unitRef="usdPerShare">1.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMTgtNi0xLTEtNzAwMzQ_b3d6884c-7dc6-417f-8d82-a9852dc2f9b2"
      unitRef="usdPerShare">2.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMjEtMi0xLTEtNzAwMzQ_b7986135-9d2e-4f80-af08-5c0115d46b7a"
      unitRef="shares">2629600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMjEtNi0xLTEtNzAwMzQ_37acdf3f-75cc-4855-ad81-80c8198bec79"
      unitRef="shares">2632500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMjItMi0xLTEtNzAwMzQ_1fd56926-8f20-4703-9d5b-e25675bd2797"
      unitRef="shares">2667900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8yOC9mcmFnOjRjM2VjMzQzNzVjMjQ3OGNiZjM5MjJkZGEzY2NiYTRmL3RhYmxlOjcxZTg1ZmVmZjgwNTQ4ODU5MmEzM2EwODAxNGNiZjI1L3RhYmxlcmFuZ2U6NzFlODVmZWZmODA1NDg4NTkyYTMzYTA4MDE0Y2JmMjVfMjItNi0xLTEtNzAwMzQ_efbf8a53-77a9-4a81-a7eb-36d21b094566"
      unitRef="shares">2671600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNC0yLTEtMS03MDAzNA_3031cb88-3cec-4fba-ba0f-320836de36cd"
      unitRef="usd">47446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNC00LTEtMS03MDAzNA_645104ae-ff6a-4456-9bc7-66b2bed3b423"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNC02LTEtMS03MDAzNA_5a24ba74-ca7e-465b-8e87-9dff65e0ce43"
      unitRef="usd">45633000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNC04LTEtMS03MDAzNA_2378b466-b3cb-4ec4-9afa-4dca46d80142"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNS0yLTEtMS03MDAzNA_631838ea-02ef-466f-a1f7-3c8183b613fc"
      unitRef="usd">15517000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNS00LTEtMS03MDAzNA_dbd83933-1843-4c94-996f-c3761f3c0cad"
      unitRef="number">0.327</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNS02LTEtMS03MDAzNA_35bedf5d-5071-42f5-9001-bcb47dea46d3"
      unitRef="usd">14650000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNS04LTEtMS03MDAzNA_86c0ed0b-68d4-41c0-9547-eca852d85bd5"
      unitRef="number">0.321</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNi0yLTEtMS03MDAzNA_4be54432-5b4f-45e3-9c68-229ef3374205"
      unitRef="usd">31929000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNi00LTEtMS03MDAzNA_cf04f8b4-1d9b-4623-ba2a-4004c98d5287"
      unitRef="number">0.673</jnj:GrossProfitPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNi02LTEtMS03MDAzNA_c193b9b6-eec0-4781-b7af-84080d2d248b"
      unitRef="usd">30983000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNi04LTEtMS03MDAzNA_4c8451b0-0793-428f-bc8d-b605c5d5e3b9"
      unitRef="number">0.679</jnj:GrossProfitPercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNy0yLTEtMS03MDAzNA_d9d64f76-1e5e-4039-8f3e-b508f0aa8762"
      unitRef="usd">12164000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNy00LTEtMS03MDAzNA_90bc475a-9935-44f8-8487-52be82f0c50b"
      unitRef="number">0.256</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNy02LTEtMS03MDAzNA_ba89b460-4cb1-4e4c-bfd0-2b61de770896"
      unitRef="usd">11505000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfNy04LTEtMS03MDAzNA_86b5720f-09ef-4366-8ce9-dfebffced7fe"
      unitRef="number">0.252</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOC0yLTEtMS03MDAzNA_b921f4a5-6b02-41ec-8738-212fcd1730da"
      unitRef="usd">7165000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOC00LTEtMS03MDAzNA_859a5820-bf8c-4229-afc9-866de6d07a96"
      unitRef="number">0.151</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOC02LTEtMS03MDAzNA_95e8e2e4-4996-454e-83a9-c8b484c2bb3b"
      unitRef="usd">6572000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOC04LTEtMS03MDAzNA_f6520623-ed9d-4c52-977d-188a659d6edb"
      unitRef="number">0.144</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOS0yLTEtMS03MDAzNA_2bdc6f35-7098-4db4-9992-6253b342f4a9"
      unitRef="usd">610000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOS00LTEtMS03MDAzNA_8aabf2f8-7888-4a1d-997b-aa8b50715fb3"
      unitRef="number">0.013</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOS02LTEtMS03MDAzNA_2de078a2-2466-4590-bfd0-94b20d969deb"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfOS04LTEtMS03MDAzNA_885ad57a-2400-41c7-8e74-6b96d7162950"
      unitRef="number">0.0</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTAtMi0xLTEtNzAwMzQ_31cbbea6-2e1c-4291-b029-c6f1b9897857"
      unitRef="usd">86000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTAtNC0xLTEtNzAwMzQ_a25e5292-8a00-4e31-830a-09f2317012bc"
      unitRef="number">-0.002</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTAtNi0xLTEtNzAwMzQ_0edbdc98-0ed7-4bb0-8ee3-99f4191630df"
      unitRef="usd">27000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTAtOC0xLTEtNzAwMzQ_d67b7e26-3f75-4724-aa77-b79f6ff3d349"
      unitRef="number">0.0</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InterestExpense
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTEtMi0xLTEtNzAwMzQ_7cce758a-a45e-4ef7-9ba5-37ddc4b5243d"
      unitRef="usd">48000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTEtNC0xLTEtNzAwMzQ_c177a32e-f067-427a-a788-53c36b313ff6"
      unitRef="number">0.001</jnj:InterestExpensePercentToSales>
    <us-gaap:InterestExpense
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTEtNi0xLTEtNzAwMzQ_3ebc4e40-4651-41bf-851c-104772cf8983"
      unitRef="usd">103000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTEtOC0xLTEtNzAwMzQ_1816324e-66df-4c2f-afcf-4c51faeb2b59"
      unitRef="number">0.002</jnj:InterestExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTItMi0xLTEtNzAwMzQ_bd5f72c1-aeaa-444c-81c4-928274bb28e9"
      unitRef="usd">-171000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTItNC0xLTEtNzAwMzQ_9defd876-2cea-4745-8aba-c0a3a71c4df4"
      unitRef="number">0.004</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTItNi0xLTEtNzAwMzQ_83d0e934-3537-4a52-b59a-f1d857e7b387"
      unitRef="usd">1370000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTItOC0xLTEtNzAwMzQ_956112c6-b9b1-473f-9952-1412ee01af94"
      unitRef="number">-0.030</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:RestructuringCharges
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTMtMi0xLTEtNzAwMzQ_bccaa2f9-24d3-499b-87e5-06072691bf62"
      unitRef="usd">155000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTMtNC0xLTEtNzAwMzQ_572c31b7-ed88-4d77-8707-ecd17341ec6d"
      unitRef="number">0.003</jnj:Restructuringchargepercenttosales>
    <us-gaap:RestructuringCharges
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTMtNi0xLTEtNzAwMzQ_5e7042c5-8969-4427-9c96-92221deb99cb"
      unitRef="usd">109000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTMtOC0xLTEtNzAwMzQ_414c6b1d-e346-4b3a-aea8-2c65b6b5c00f"
      unitRef="number">0.002</jnj:Restructuringchargepercenttosales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTQtMi0xLTEtNzAwMzQ_b7eff584-154b-4065-be16-686a70363a10"
      unitRef="usd">11702000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTQtNC0xLTEtNzAwMzQ_e7aa435a-0999-434e-9426-f59164aecd8b"
      unitRef="number">0.247</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTQtNi0xLTEtNzAwMzQ_03ba7b6f-1591-495b-abfc-25772d77211b"
      unitRef="usd">14091000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTQtOC0xLTEtNzAwMzQ_b2935c48-ea3c-44f6-8e06-ff430e5a3b5f"
      unitRef="number">0.309</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTUtMi0xLTEtNzAwMzQ_cd6adec6-1e45-4a57-80dc-340d652bd907"
      unitRef="usd">1739000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTUtNC0xLTEtNzAwMzQ_e6f54372-a256-4dd3-a1b9-74d20ab6838f"
      unitRef="number">0.037</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTUtNi0xLTEtNzAwMzQ_adfdff6f-34f1-407e-bc2c-e474bbf1d0b1"
      unitRef="usd">1616000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTUtOC0xLTEtNzAwMzQ_04930020-3f1c-4b09-9093-4065979f1af3"
      unitRef="number">0.036</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTYtMi0xLTEtNzAwMzQ_64323249-7f1e-47e0-994d-41177e662ff5"
      unitRef="usd">9963000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTYtNC0xLTEtNzAwMzQ_b995eb72-b9a8-4960-9a7e-54677ff9af53"
      unitRef="number">0.210</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTYtNi0xLTEtNzAwMzQ_af9d48a7-c577-4d14-bfbd-410b553eee63"
      unitRef="usd">12475000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTYtOC0xLTEtNzAwMzQ_13d6d056-bafd-435f-988d-9cfe9d780598"
      unitRef="number">0.273</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTktMi0xLTEtNzAwMzQ_45e31af0-6c1c-46c7-b0de-f3183a9575d0"
      unitRef="usdPerShare">3.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMTktNi0xLTEtNzAwMzQ_e5ef5994-d0be-49d8-90be-37440ad1e7a4"
      unitRef="usdPerShare">4.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjAtMi0xLTEtNzAwMzQ_33d976ad-1e35-4dc0-8d51-754ea313bea3"
      unitRef="usdPerShare">3.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjAtNi0xLTEtNzAwMzQ_cffcc901-8e2d-4d7a-b27b-a9d3990edd05"
      unitRef="usdPerShare">4.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjMtMi0xLTEtNzAwMzQ_c6821bae-1542-4115-94c6-4fc282ad3f2a"
      unitRef="shares">2629400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjMtNi0xLTEtNzAwMzQ_06e03ef1-781d-4c8d-afa9-155808e38196"
      unitRef="shares">2632000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjQtMi0xLTEtNzAwMzQ_75f60227-8f55-4fe3-b36b-b39ced1a1bcd"
      unitRef="shares">2669200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zMS9mcmFnOjlhZjhmNGQ2NzJiYjRlOWU5YmZiYzFiODA2N2U5OTMxL3RhYmxlOmMwOTM3YjNkZmU5YzRmNjE4NTgxNGEyNDc1MTkyN2Y0L3RhYmxlcmFuZ2U6YzA5MzdiM2RmZTljNGY2MTg1ODE0YTI0NzUxOTI3ZjRfMjQtNi0xLTEtNzAwMzQ_f24cc079-df03-4a80-97d9-450d56bf16aa"
      unitRef="shares">2674000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMy0xLTEtMS03MDAzNA_f4d2016b-7639-43ca-9268-b7ea486127aa"
      unitRef="usd">4814000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMy0zLTEtMS03MDAzNA_f58109da-9054-480a-acf6-4eec0082c771"
      unitRef="usd">6278000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMy01LTEtMS03MDAzNA_6a796edf-5da5-43ea-8f19-aef0eb336233"
      unitRef="usd">9963000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMy03LTEtMS03MDAzNA_bb05c2ab-1f61-4c59-b2f3-faa0d96d407c"
      unitRef="usd">12475000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfNi0xLTEtMS03MDAzNA_9692a227-533c-48e5-831f-25430696f0c1"
      unitRef="usd">-151000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfNi0zLTEtMS03MDAzNA_b17efe36-f2c2-4341-9918-1ce16b7db43c"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfNi01LTEtMS03MDAzNA_56077629-3cbd-477b-a485-f514f3e60dcd"
      unitRef="usd">-705000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfNi03LTEtMS03MDAzNA_dee1c155-77c4-4af7-b088-183f01e30d40"
      unitRef="usd">141000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfOS0xLTEtMS03MDAzNA_16345338-f869-4c38-bee6-ade6004f61ad"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfOS0zLTEtMS03MDAzNA_05b052dc-c4a2-4304-976f-01d22d9f5351"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfOS01LTEtMS03MDAzNA_ce8b80f6-1d72-4121-8461-ca91b95deb3b"
      unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfOS03LTEtMS03MDAzNA_7c496297-a559-4831-b543-6c605c5ffd21"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTAtMS0xLTEtNzAwMzQ_9b5df8da-e5da-4881-b416-bb3e4660048f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTAtMy0xLTEtNzAwMzQ_c61962fb-e3d1-4dc7-8427-f0352604afc8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTAtNS0xLTEtNzAwMzQ_05d8fe39-a9d0-45a0-8de7-4b39c19951e1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTAtNy0xLTEtNzAwMzQ_f54276d6-eb43-433d-a38b-2ecd3f2ed4ac"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTItMS0xLTEtNzAwMzQ_20c72138-361f-4b54-bd30-01335a61b035"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTItMy0xLTEtNzAwMzQ_d1081362-a7d8-433c-b14a-ffe6e3f6e682"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTItNS0xLTEtNzAwMzQ_e2b49084-a5d8-483b-818a-4bcac5df1757"
      unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTItNy0xLTEtNzAwMzQ_ac2ea034-e7ca-4c15-a364-3b2b77cc11f5"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTUtMS0xLTEtNzAwMzQ_3f576066-fc2b-44c1-a779-d47e8920edb6"
      unitRef="usd">20000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTUtMy0xLTEtNzAwMzQ_d9557ae6-a86f-4d41-bb5b-43b1d24af908"
      unitRef="usd">41000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTUtNS0xLTEtNzAwMzQ_d7ac4b35-d7db-475d-adf3-efc29ccd87b3"
      unitRef="usd">73000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTUtNy0xLTEtNzAwMzQ_52c75016-7896-45f2-9756-52a451cf25f7"
      unitRef="usd">82000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTYtMS0xLTEtNzAwMzQ_db9fc82c-b34e-4049-857b-4128fee9d89d"
      unitRef="usd">-86000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTYtMy0xLTEtNzAwMzQ_132e9927-585a-4b65-939c-629f04dc5048"
      unitRef="usd">-275000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTYtNS0xLTEtNzAwMzQ_6e042979-9db9-4a45-95e2-6b9fa503d2e4"
      unitRef="usd">-303000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTYtNy0xLTEtNzAwMzQ_12be176a-9b95-428f-bb0e-8c0120ba1b00"
      unitRef="usd">-549000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTgtMS0xLTEtNzAwMzQ_165a94b2-7892-412a-8739-35bad7c4e60e"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTgtMy0xLTEtNzAwMzQ_367f0c96-fb23-482d-8fc9-4533cd6de402"
      unitRef="usd">-234000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTgtNS0xLTEtNzAwMzQ_010ae28f-11c8-4d00-9a88-ed3579c78d1e"
      unitRef="usd">-230000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMTgtNy0xLTEtNzAwMzQ_954572d2-1bee-4deb-9eb0-8cdb2d394c4a"
      unitRef="usd">-467000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjEtMS0xLTEtNzAwMzQ_ce918500-92c1-41fa-97f3-613a7e907605"
      unitRef="usd">145000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjEtMy0xLTEtNzAwMzQ_0edee854-7529-4d8d-bd75-0c8654bd853c"
      unitRef="usd">400000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjEtNS0xLTEtNzAwMzQ_e4df90e9-d1a0-4172-b778-0729707a2fc7"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjEtNy0xLTEtNzAwMzQ_7b9b15ae-fc56-443b-b3b0-5dc6eeb84b38"
      unitRef="usd">-122000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjItMS0xLTEtNzAwMzQ_24e10da7-9885-49a5-861f-c4f8778712ed"
      unitRef="usd">126000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjItMy0xLTEtNzAwMzQ_63e3640e-b582-49e5-ad64-85639ff0eacd"
      unitRef="usd">270000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjItNS0xLTEtNzAwMzQ_bf838fa5-8798-4f69-8802-d2b6a9af2ddc"
      unitRef="usd">227000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjItNy0xLTEtNzAwMzQ_98b00702-0517-467e-a94c-13c78b8f0555"
      unitRef="usd">343000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjMtMS0xLTEtNzAwMzQ_194fd23a-dc6b-49dc-bc67-af5900d1dcca"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjMtMy0xLTEtNzAwMzQ_e9e8b1fa-d664-4713-9d82-eacefe8bc1a1"
      unitRef="usd">130000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjMtNS0xLTEtNzAwMzQ_19de76da-75fb-4a81-a7b5-f9342fb5bc58"
      unitRef="usd">-277000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjMtNy0xLTEtNzAwMzQ_135613f3-5130-410e-aac2-f20780c226c5"
      unitRef="usd">-465000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjUtMS0xLTEtNzAwMzQ_cbad59ea-d4ba-4471-ba6d-82736cbd30b7"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjUtMy0xLTEtNzAwMzQ_13fbb20b-e86a-434d-8573-c143c4491853"
      unitRef="usd">228000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjUtNS0xLTEtNzAwMzQ_781059fc-6adf-40ce-90a5-2ab00edcebe1"
      unitRef="usd">-785000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjUtNy0xLTEtNzAwMzQ_82bb17b8-1e0e-44cf-9902-0c77847e8cef"
      unitRef="usd">142000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjctMS0xLTEtNzAwMzQ_99516a02-4e88-485a-bfe0-50a652eda443"
      unitRef="usd">4728000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjctMy0xLTEtNzAwMzQ_70883de0-6aee-4e69-a7b3-801fa966c651"
      unitRef="usd">6506000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjctNS0xLTEtNzAwMzQ_68c280c4-bf69-482c-ba98-24ff8469187a"
      unitRef="usd">9178000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOjJkMmQ2NWMxYmEzMDQ5NGRhZDk1YTg4ZGZiMzAwMzA4L3RhYmxlcmFuZ2U6MmQyZDY1YzFiYTMwNDk0ZGFkOTVhODhkZmIzMDAzMDhfMjctNy0xLTEtNzAwMzQ_b082a6ad-6900-485b-994b-01e230607737"
      unitRef="usd">12617000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzE1OQ_18051ee9-7327-45b5-b667-dd40fa4e2b5c"
      unitRef="usd">533000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzE3NQ_6a98c98c-8de6-4e90-b4c3-44a0a45a15c3"
      unitRef="usd">-90000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzE5OQ_5f91b3f0-a16f-4ebd-9698-81981ab43669"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzI0NA_5d12b962-c46d-4045-b3f4-78f6e2ec6cad"
      unitRef="usd">-84000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzI2MA_b8ffa381-5c1c-46df-942d-14ad5adb0a4c"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzI5NQ_b014af54-8c08-4374-a5a2-baced9ce4f4a"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmMzYzRkYTk2N2E3YjRkMTlhOTgyMTNhNjBhOThkNTU0XzMxMQ_1b6ec1c8-08a9-409f-8d50-c8b8b6bbe20d"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzE1OA_98af591f-d8b2-48bc-9a4c-ffbdf1aff0eb"
      unitRef="usd">678000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzE3NA_6aa365d3-2aa2-4b81-a575-49567617a74b"
      unitRef="usd">229000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzI3NDg3NzkwNjk3NjA_cf5d72a9-2cc7-4677-8958-af21e6d7cea8"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzIxMQ_2afb5652-6194-404f-adde-b0e3c01bb6ed"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzIyNw_423b8bd2-6584-40fb-b2cc-a707984c346a"
      unitRef="usd">-132000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzI2Mg_f8d6cefb-eb80-4876-84d0-5191d8e66217"
      unitRef="usd">-73000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF8zNC9mcmFnOjA0NGIwZTM5YWNmNDRhZTlhNTA0NDA3M2M4YjRlNjA4L3RhYmxlOmVlOGQ3NTcyZjY5MTRiYTA4ODk1ZGYzMGVmNTVlNmFkL3RhYmxlcmFuZ2U6ZWU4ZDc1NzJmNjkxNGJhMDg4OTVkZjMwZWY1NWU2YWRfMi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOmRhYjViYzViMjEyMjRjMjZhNDA5YWU5YTFhY2ZhNzBlXzI3OA_b123f7d1-c56d-46f3-8532-589b70b19cf7"
      unitRef="usd">-124000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b78141263e14aa589db463e889e3571_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS0xLTEtMS03MDAzNA_c78ec1c8-59ff-45b1-8523-99b04c9da04b"
      unitRef="usd">74709000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9ea286cb593414bad834aaf21a6fcae_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS0zLTEtMS03MDAzNA_7bcdf02a-47df-4aa9-a24c-230a42b1aeda"
      unitRef="usd">124380000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id28888afdc0d41829f3f9c4f745b09bc_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS01LTEtMS03MDAzNA_b3b014c1-8b9f-4cf7-aca6-db75970c0a63"
      unitRef="usd">-13757000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd15db9229e94c4ab701152a505a8fd9_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS03LTEtMS03MDAzNA_694eefe4-d725-4d24-8aaa-1d679c956846"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ef6b87b8da34c3ab39ea64cec57d1ab_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMS05LTEtMS03MDAzNA_cdbbf0c7-8aaf-42a7-8a67-1d9c1960b36d"
      unitRef="usd">-39034000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMi0xLTEtMS03MDAzNA_8c7c1c1c-ac3a-481f-80c8-df0c15dd35e9"
      unitRef="usd">4814000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c985e9590a44414b4eb9c785af847ef_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMi0zLTEtMS03MDAzNA_7c31eee7-b887-4c10-8f64-552a47e54b0e"
      unitRef="usd">4814000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMy0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjgwZTg1ZTNjY2JhZDRhMDFiOTA5MzVmMDdjMjY4NWY2XzI2_83bd9f8e-7d9e-4aab-99e5-e942fc2ba28c"
      unitRef="usdPerShare">1.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMy0xLTEtMS03MDAzNA_5177d351-59f5-4cde-92d2-d29b758a19b2"
      unitRef="usd">2971000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0c985e9590a44414b4eb9c785af847ef_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfMy0zLTEtMS03MDAzNA_1fb2ae9a-d246-42e0-a302-678239bd682d"
      unitRef="usd">2971000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNC0xLTEtMS03MDAzNA_be711fa1-10cd-4a2f-a2e9-6a3a566fe7e2"
      unitRef="usd">864000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i0c985e9590a44414b4eb9c785af847ef_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNC0zLTEtMS03MDAzNA_19fdb1b5-24bc-4cf4-a65a-7afabfc25db2"
      unitRef="usd">-7000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i63678c9b15dc4215981671d3417b1d43_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNC05LTEtMS03MDAzNA_526cdda5-742b-4754-95f8-5e97609cffd0"
      unitRef="usd">871000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNS0xLTEtMS03MDAzNA_067259d1-db32-421b-bd27-3dc864c541e0"
      unitRef="usd">973000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i63678c9b15dc4215981671d3417b1d43_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNS05LTEtMS03MDAzNA_7449d717-3e3f-4326-80e6-0c48070136bf"
      unitRef="usd">973000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNy0xLTEtMS03MDAzNA_aeeb933d-0cb1-481f-8722-565726362a9f"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i48b106f4f9be47ecbdbf4494e08f368e_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfNy01LTEtMS03MDAzNA_e2d05259-468a-48d8-9c2b-064ed281a321"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC0xLTEtMS03MDAzNA_fbcfe520-38c6-418d-843a-1d784c058d6d"
      unitRef="usd">76357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2f63c6c6b554f82a78ab56462752f26_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC0zLTEtMS03MDAzNA_7a6d1921-fab7-45c2-86ab-2bdb6c84359e"
      unitRef="usd">126216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6c44097a42f4c9b8d26741faed5e548_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC01LTEtMS03MDAzNA_f54fef64-4a4a-4fc5-b4bd-df8629201460"
      unitRef="usd">-13843000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i675f9b859a9642f9980e206847468603_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC03LTEtMS03MDAzNA_69e0dd75-4834-49c5-920b-5a7bd173dbda"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia5d913e7414246628af7b698ff38c727_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmIzNjY1NmI1MDJkODRmMTBiNWU3MjJiZjI1OTc1YjM5L3RhYmxlcmFuZ2U6YjM2NjU2YjUwMmQ4NGYxMGI1ZTcyMmJmMjU5NzViMzlfOC05LTEtMS03MDAzNA_d4c48ab1-6e31-48ce-aa4f-ff96b1f39069"
      unitRef="usd">-39136000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy0xLTEtMS03MDAzNA_14a76cf7-7d2c-4951-96cd-26a558b39299"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b538347dc21414a92b3853037648c53_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy0zLTEtMS03MDAzNA_6b8088f1-6e4e-44a4-89c9-bed9512cf5b3"
      unitRef="usd">123060000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i116332ccca294d499f773d00109c050b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy01LTEtMS03MDAzNA_3b547161-ca3d-4253-b584-ce0c91c365f2"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7e44d359c554d62b5eb567fbe00c74f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy03LTEtMS03MDAzNA_760a7439-8f55-41a4-8623-4fb7034512a9"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d0890b94dec44eaa3b81bc34fb36d8c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMy05LTEtMS03MDAzNA_48b67535-100e-4b5c-acbf-c07a67fe1afb"
      unitRef="usd">-39099000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNC0xLTEtMS03MDAzNA_547d8192-4571-4f41-a1e3-ed518c1799ef"
      unitRef="usd">9963000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d2dbba5d85c4a23b5fe98df37e5b2f0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNC0zLTEtMS03MDAzNA_cca25dbc-496e-4f3c-aee7-f055319e2501"
      unitRef="usd">9963000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNS0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjhhOWUzY2Q5MGZmOTQ1MzM4ZjliM2M0MmQzMGY0ZjQ1XzI2_7f1f8e5a-3e70-4061-923b-e185490f3d5b"
      unitRef="usdPerShare">2.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNS0xLTEtMS03MDAzNA_1aa80feb-725b-4139-8c72-b60ba300eca7"
      unitRef="usd">5758000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0d2dbba5d85c4a23b5fe98df37e5b2f0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNS0zLTEtMS03MDAzNA_319331c1-4e38-4bc8-a8ac-133aa0205070"
      unitRef="usd">5758000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNi0xLTEtMS03MDAzNA_7ee76e70-f489-44dd-a513-d9b70e6807d0"
      unitRef="usd">1464000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i0d2dbba5d85c4a23b5fe98df37e5b2f0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNi0zLTEtMS03MDAzNA_4acc424c-9f7c-467b-a9d4-bc576b565c21"
      unitRef="usd">-1049000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i7cfb8860f4a14a0a800de5dab7ad09d3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNi05LTEtMS03MDAzNA_fcc9e0aa-9e76-41e0-bdd4-49712c66bb39"
      unitRef="usd">2513000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNy0xLTEtMS03MDAzNA_7aa58ad7-6087-4cde-8a85-cc2023931dfd"
      unitRef="usd">2550000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7cfb8860f4a14a0a800de5dab7ad09d3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfNy05LTEtMS03MDAzNA_81573893-7bfb-4a6a-9e06-4038f771c49a"
      unitRef="usd">2550000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfOS0xLTEtMS03MDAzNA_b0c883a8-1317-4f8e-8d4c-a499f7b7e720"
      unitRef="usd">-785000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i30ab88c7a9b24105a98e4bce891e1382_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfOS01LTEtMS03MDAzNA_b9394b05-bfa8-49f0-88c5-14627ac06b9e"
      unitRef="usd">-785000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtMS0xLTEtNzAwMzQ_46e56822-80cb-40ac-a788-23da8b7b0f7b"
      unitRef="usd">76357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2f63c6c6b554f82a78ab56462752f26_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtMy0xLTEtNzAwMzQ_b8becf7d-37c4-47ad-a2b5-c8fa3090730d"
      unitRef="usd">126216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6c44097a42f4c9b8d26741faed5e548_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtNS0xLTEtNzAwMzQ_c2bc589a-7a1d-4003-85af-c538ade094af"
      unitRef="usd">-13843000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i675f9b859a9642f9980e206847468603_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtNy0xLTEtNzAwMzQ_f42ff50e-1805-4a96-9091-aa18404f224b"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia5d913e7414246628af7b698ff38c727_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjEyMTFjZmFjOGY2OTQ3M2Y5MTVjYjdhYzUzZmI0ZDhiL3RhYmxlcmFuZ2U6MTIxMWNmYWM4ZjY5NDczZjkxNWNiN2FjNTNmYjRkOGJfMTAtOS0xLTEtNzAwMzQ_77112fe6-a057-41df-a9cf-e9badb8f0958"
      unitRef="usd">-39136000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a7eb101ecd248fa8113d9b3f69f69e1_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS0xLTEtMS03MDAzNA_ffc93ddf-010e-4d0f-883f-23ec153b1241"
      unitRef="usd">65834000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0104c40629d42e2b32ea4a3608507a6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS0zLTEtMS03MDAzNA_4632c691-fd54-418a-8731-846a22d9c91a"
      unitRef="usd">116508000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8978590cb1f45bbb5dd3354dd289e0e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS01LTEtMS03MDAzNA_aa78d647-4150-4d3e-b771-aec450be4968"
      unitRef="usd">-15328000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e13fe78d9384d259e35ea7a933fd95b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS03LTEtMS03MDAzNA_64644b62-f81a-43f5-8a72-1abade22a0df"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id32639e6970348639d64a785e7a5ba93_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMS05LTEtMS03MDAzNA_5fc4951b-5865-4b03-b938-f33b3b500093"
      unitRef="usd">-38466000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMy0xLTEtMS03MDAzNA_dd31e3ac-1877-48b3-84c4-270476733671"
      unitRef="usd">6278000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i447127aa6c664afab9dd53cc168aa3e2_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfMy0zLTEtMS03MDAzNA_8ac8612c-a96c-49ac-8f1c-f1c1dc865985"
      unitRef="usd">6278000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjQ2OTNmMjY1MzQwYjRmNmZiNWMzMzYwMDBiNWI5MjBlXzI2_9c40f748-10a3-4abc-a86b-656dc41271dd"
      unitRef="usdPerShare">1.06</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNC0xLTEtMS03MDAzNA_b405e61e-d481-4c2b-845d-4bc6f5c4fee2"
      unitRef="usd">2791000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i447127aa6c664afab9dd53cc168aa3e2_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNC0zLTEtMS03MDAzNA_7266820c-9908-4173-bfc6-d6eb2643b0b2"
      unitRef="usd">2791000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNS0xLTEtMS03MDAzNA_99869775-4a96-400e-9f07-8bd39be9dc49"
      unitRef="usd">662000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i447127aa6c664afab9dd53cc168aa3e2_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNS0zLTEtMS03MDAzNA_df56730b-5fe0-467d-af65-e77b55b69984"
      unitRef="usd">159000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ibb8035da5ed0409392b2294beb7ff4d0_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNS05LTEtMS03MDAzNA_f6abb799-4a13-4346-ad08-79cc7bc69958"
      unitRef="usd">503000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNi0xLTEtMS03MDAzNA_0b70aee7-a8a6-4c80-8bac-7abe38d57b0f"
      unitRef="usd">631000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibb8035da5ed0409392b2294beb7ff4d0_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfNi05LTEtMS03MDAzNA_ace3f71e-c967-48e8-9392-ee01bfcc1d04"
      unitRef="usd">631000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOC0xLTEtMS03MDAzNA_2a06ba6a-9d72-4e9f-a993-5d5c93e229ed"
      unitRef="usd">228000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idd9d432f47f643658a371e3e1029702b_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOC01LTEtMS03MDAzNA_5d30aabd-54cc-49c7-ae60-e0134b89f23f"
      unitRef="usd">228000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b98f47b14654327afbb7932046478c8_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS0xLTEtMS03MDAzNA_ba59f636-a8b1-43eb-987e-c41c9dc2f3c5"
      unitRef="usd">69580000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18c5660480c941a989748af1c5101066_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS0zLTEtMS03MDAzNA_cca49642-d18f-463c-964b-17b4059abdc5"
      unitRef="usd">120154000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c49da8cee9448c0a2c883ab7e653b32_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS01LTEtMS03MDAzNA_d2f1a40e-670f-43a2-a32e-df4d4bba4744"
      unitRef="usd">-15100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70d9822830ad463ba8ac40ab5c36dd39_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS03LTEtMS03MDAzNA_415a967b-cf7d-437d-9c21-606425e262d4"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab458019d3d5460183663da5dd757b6a_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOmFmNDA3YzZmZWU1YTRhYTFiZTY5ZGU1NGJhZDRjNTNiL3RhYmxlcmFuZ2U6YWY0MDdjNmZlZTVhNGFhMWJlNjlkZTU0YmFkNGM1M2JfOS05LTEtMS03MDAzNA_337aec26-1593-43d4-8103-6ef5de34a3ed"
      unitRef="usd">-38594000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9e3aba93759e44e6998ff20f017b0ca4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy0xLTEtMS03MDAzNA_786a28f6-c50c-4cd2-9118-453c21da6392"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i207dad082de3463797edacf5f0aca4ae_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy0zLTEtMS03MDAzNA_575f3bd5-119d-4bd3-9ee6-f3f6a5370489"
      unitRef="usd">113890000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia260343fe6194304ba1526a976025d5d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy01LTEtMS03MDAzNA_00561d85-1582-4ad8-95a2-f411fe632bb5"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdb7154123a34d2fb4812c12d8a88644_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy03LTEtMS03MDAzNA_8114d528-5241-4c39-970b-a46787d1b925"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33ae55af07ea46c6bc94c11db48a7393_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMy05LTEtMS03MDAzNA_21d9b5a6-40b5-4594-8d34-ac51e6f54300"
      unitRef="usd">-38490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNS0xLTEtMS03MDAzNA_93f8d781-71ec-4c41-9c34-d05ad84afd9a"
      unitRef="usd">12475000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i286c70d01444493ebbeeaf534a382878_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNS0zLTEtMS03MDAzNA_65b03a6d-4dc6-4279-830a-bb400c36773a"
      unitRef="usd">12475000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNi0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjhkZDI5MTUyNjVlYzQxYmU4MzQxYWUxNmE4ZDIyYTZlXzI2_632f9272-d83f-47fc-82d7-680b7c4ecc81"
      unitRef="usdPerShare">2.07</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNi0xLTEtMS03MDAzNA_bcb1f937-3aef-4362-88de-043effb0b9bc"
      unitRef="usd">5450000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i286c70d01444493ebbeeaf534a382878_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNi0zLTEtMS03MDAzNA_56303090-7b0b-4ce5-96bf-65c3294ca075"
      unitRef="usd">5450000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNy0xLTEtMS03MDAzNA_fda1e346-d17a-46ac-8c87-e2fa2a40192c"
      unitRef="usd">1204000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i286c70d01444493ebbeeaf534a382878_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNy0zLTEtMS03MDAzNA_e7d70f9f-7d7a-4e9e-a20d-7d405a817869"
      unitRef="usd">-761000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="idc88aabe12454cb5a6b8b3e1ffc291ca_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfNy05LTEtMS03MDAzNA_3bb1171a-3649-48a5-9dbb-5ec0d75386f3"
      unitRef="usd">1965000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfOC0xLTEtMS03MDAzNA_071bacae-f019-4e48-b06a-0c7275b2b683"
      unitRef="usd">2069000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="idc88aabe12454cb5a6b8b3e1ffc291ca_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfOC05LTEtMS03MDAzNA_d6ceb3ee-a548-4352-be86-6bb9e73786d7"
      unitRef="usd">2069000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTAtMS0xLTEtNzAwMzQ_51a0f263-6def-44bd-acdc-0a879f36c250"
      unitRef="usd">142000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2b85e73978e94a6e9d40658f17f4dbba_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTAtNS0xLTEtNzAwMzQ_a215d3c4-2ea0-4526-8069-2767a687d3a3"
      unitRef="usd">142000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b98f47b14654327afbb7932046478c8_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtMS0xLTEtNzAwMzQ_2934cef7-726c-400c-bb71-adb96458b0de"
      unitRef="usd">69580000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18c5660480c941a989748af1c5101066_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtMy0xLTEtNzAwMzQ_3b0e9f7e-018d-4243-8478-d08735ed8be6"
      unitRef="usd">120154000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c49da8cee9448c0a2c883ab7e653b32_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtNS0xLTEtNzAwMzQ_cb878886-443a-4aff-b296-0f63af6e120e"
      unitRef="usd">-15100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70d9822830ad463ba8ac40ab5c36dd39_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtNy0xLTEtNzAwMzQ_ff830556-04d7-40ba-91c3-c53eaf13071b"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab458019d3d5460183663da5dd757b6a_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80MC9mcmFnOjIzOTc5Mzc0NjYxYTRkZWNiZGI2MTlmZDM4ZjY0YWY4L3RhYmxlOjYyNjkzOWVmMjM3ZDRjYTU4YzQ1NDY2ZGE1MDZiNzY0L3RhYmxlcmFuZ2U6NjI2OTM5ZWYyMzdkNGNhNThjNDU0NjZkYTUwNmI3NjRfMTEtOS0xLTEtNzAwMzQ_73ef818d-cb49-4a43-8d40-a182e18251de"
      unitRef="usd">-38594000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMy0yLTEtMS03MDAzNA_d68f09e4-bfc7-438c-aaf6-ace05da9fcc4"
      unitRef="usd">9963000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMy00LTEtMS03MDAzNA_7df04efd-0ec1-41fc-a9a6-b63ac0e15079"
      unitRef="usd">12475000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNS0yLTEtMS03MDAzNA_b7c1c4fc-c32b-4f66-8650-1d600108dc72"
      unitRef="usd">3513000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNS00LTEtMS03MDAzNA_f91fbc1e-7d27-4ab6-8955-4c3614493330"
      unitRef="usd">3733000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNi0yLTEtMS03MDAzNA_3235952b-b255-424b-abd5-37b3eb3540d2"
      unitRef="usd">644000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNi00LTEtMS03MDAzNA_aec51fe3-48b3-488a-96c3-5b22e3dd5ed8"
      unitRef="usd">661000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfOS0yLTEtMS03MDAzNA_917644a4-2a06-4e6f-8af2-39ddd4c03c9f"
      unitRef="usd">747000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfOS00LTEtMS03MDAzNA_8ecd027b-2652-4c28-b457-e90359ddb6ce"
      unitRef="usd">26000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTEtMi0xLTEtNzAwMzQ_440756c5-9f72-4f7b-a72b-a565881d2b06"
      unitRef="usd">213000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTEtNC0xLTEtNzAwMzQ_18331391-eea0-40d4-87b0-b67c8a800753"
      unitRef="usd">601000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTMtMi0xLTEtNzAwMzQ_e1729035-727b-4fe4-9992-54aa697afd99"
      unitRef="usd">-2349000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTMtNC0xLTEtNzAwMzQ_4e8da4d2-a082-4275-879e-7ddcf4c24463"
      unitRef="usd">-685000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTQtMi0xLTEtNzAwMzQ_a4dc89d9-4850-4a57-a0a7-bb8444e311c2"
      unitRef="usd">-3000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTQtNC0xLTEtNzAwMzQ_b2c5a5b9-d366-42bc-9cd2-e831f91052a0"
      unitRef="usd">-52000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTYtMi0xLTEtNzAwMzQ_68191129-b257-4536-ba06-d8e88555fe66"
      unitRef="usd">1386000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTYtNC0xLTEtNzAwMzQ_747882db-d7d1-4272-b02e-5531f04a7cef"
      unitRef="usd">1566000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTctMi0xLTEtNzAwMzQ_a8b6a2e8-51d0-4de1-9628-6b55a97f16fb"
      unitRef="usd">1257000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTctNC0xLTEtNzAwMzQ_4797ce65-7e77-4b7d-8dc7-abb388bfd1fc"
      unitRef="usd">818000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTgtMi0xLTEtNzAwMzQ_d8b47f88-b692-4d58-8223-853f5f22fae4"
      unitRef="usd">-1170000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTgtNC0xLTEtNzAwMzQ_eeacaa70-c058-45b8-b860-90b989fbe58e"
      unitRef="usd">-4050000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTktMi0xLTEtNzAwMzQ_496a57f3-aff9-4f92-8b3d-35f0e16544df"
      unitRef="usd">-3527000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMTktNC0xLTEtNzAwMzQ_aeeea5f3-61dc-4077-90c6-e7c2aa3b9b10"
      unitRef="usd">-1415000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjAtMi0xLTEtNzAwMzQ_b750c3a7-f5fa-4b15-ae7f-bf8d05ebfcd7"
      unitRef="usd">-2456000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjAtNC0xLTEtNzAwMzQ_a6288af0-b9b1-4cd4-bf23-2fdb77cb1ca8"
      unitRef="usd">-1150000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjItMi0xLTEtNzAwMzQ_a13d2f1f-539a-4a13-86d3-9512e8af72a1"
      unitRef="usd">9560000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjItNC0xLTEtNzAwMzQ_ad3cd710-4b0c-4232-9d8b-1430f96f2926"
      unitRef="usd">9388000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjUtMi0xLTEtNzAwMzQ_1fd8838b-8d66-438e-a44b-628e3bc317a3"
      unitRef="usd">1470000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjUtNC0xLTEtNzAwMzQ_ee427aff-fbff-40f0-a957-150c5864fe83"
      unitRef="usd">1490000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjYtMi0xLTEtNzAwMzQ_f8864d15-c14a-481d-bdd1-994b0054e040"
      unitRef="usd">314000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjYtNC0xLTEtNzAwMzQ_26515739-4339-4421-8433-0623cca5b8c0"
      unitRef="usd">654000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjctMi0xLTEtNzAwMzQ_c2d61281-c8f3-4a3a-bb88-a52d2189f225"
      unitRef="usd">523000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjctNC0xLTEtNzAwMzQ_97b4cfdf-7b77-4d22-984c-4810e9076d9c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjgtMi0xLTEtNzAwMzQ_9f4fdc35-325a-4d55-9801-45db48fea253"
      unitRef="usd">22048000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjgtNC0xLTEtNzAwMzQ_662d7f41-3673-4135-b763-21b38c5e916f"
      unitRef="usd">12264000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjktMi0xLTEtNzAwMzQ_8db37517-21f4-40c2-b286-6d5237ab962a"
      unitRef="usd">17634000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMjktNC0xLTEtNzAwMzQ_f1effa21-39a8-43b7-8466-dc3b41ee0345"
      unitRef="usd">12453000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzAtMi0xLTEtNzAwMzQ_9e6fee68-30a9-4563-bc17-4aeb8281c241"
      unitRef="usd">-10000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzAtNC0xLTEtNzAwMzQ_1c86f513-2cbb-4078-be62-815ba77e9177"
      unitRef="usd">441000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzEtMi0xLTEtNzAwMzQ_3e2a15b4-15c4-4cad-b3a6-41080439bd95"
      unitRef="usd">170000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzEtNC0xLTEtNzAwMzQ_aaadfec7-733f-43b9-bc65-ebb63a9bc7df"
      unitRef="usd">398000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzMtMi0xLTEtNzAwMzQ_b1131bb9-9c51-4494-b08b-6fced3657a4a"
      unitRef="usd">-6273000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzMtNC0xLTEtNzAwMzQ_73fb6dac-9955-4410-9bfc-9395d24d0492"
      unitRef="usd">-604000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzYtMi0xLTEtNzAwMzQ_c1476f64-f343-47a7-9b48-66904e40367a"
      unitRef="usd">5758000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzYtNC0xLTEtNzAwMzQ_ee7066e0-b18b-427b-9621-cdda87378869"
      unitRef="usd">5450000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzctMi0xLTEtNzAwMzQ_e40f4f58-dd74-4481-b9ef-faec6f1be530"
      unitRef="usd">2550000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzctNC0xLTEtNzAwMzQ_38a9f447-54d3-416d-b526-0a6b57d71e95"
      unitRef="usd">2069000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzgtMi0xLTEtNzAwMzQ_4d877a2f-7137-44b1-87a9-0726c85aa7ba"
      unitRef="usd">4371000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzgtNC0xLTEtNzAwMzQ_048a231c-8763-48f3-b1ae-95e2499c8e71"
      unitRef="usd">498000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzktMi0xLTEtNzAwMzQ_09ec4e57-6a5b-4825-8936-acbbdf5112fe"
      unitRef="usd">2201000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfMzktNC0xLTEtNzAwMzQ_c3ac9e02-c273-4829-aee3-0f42ff02caa0"
      unitRef="usd">689000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDAtMi0xLTEtNzAwMzQ_d62587b9-380f-4ae5-86f1-49b4dc8801f4"
      unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDAtNC0xLTEtNzAwMzQ_99022fb2-42ca-41c9-bc77-0f42f5a0c2ec"
      unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDEtMi0xLTEtNzAwMzQ_54c16761-f110-435d-a08e-4195a017fa77"
      unitRef="usd">2132000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDEtNC0xLTEtNzAwMzQ_09222c30-9bba-4e9b-a849-43c916dd7c9c"
      unitRef="usd">1451000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDItMi0xLTEtNzAwMzQ_faa3836f-5aa1-427f-9f42-48aca9689cec"
      unitRef="usd">820000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDItNC0xLTEtNzAwMzQ_374b6763-132d-419b-a7f6-8440cdc7d0e6"
      unitRef="usd">543000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDMtMi0xLTEtNzAwMzQ_34898d04-e3a1-4cfb-aabd-f1cbfa95a574"
      unitRef="usd">813000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDMtNC0xLTEtNzAwMzQ_4674e744-8046-43fe-b705-f8c851964dac"
      unitRef="usd">130000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDQtMi0xLTEtNzAwMzQ_28845d15-20a1-4c33-9da4-066b74237130"
      unitRef="usd">-11000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDQtNC0xLTEtNzAwMzQ_471773e7-da13-426f-8d07-5725c709c3f3"
      unitRef="usd">83000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDYtMi0xLTEtNzAwMzQ_bb4885f2-e2ec-4cab-9233-361b8515933f"
      unitRef="usd">-6646000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDYtNC0xLTEtNzAwMzQ_a9d175ed-8a9f-4da7-97ba-daa360270870"
      unitRef="usd">-8404000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDgtMi0xLTEtNzAwMzQ_57fc7196-01c2-43c0-a1e9-0a92d5ffe987"
      unitRef="usd">-145000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDgtNC0xLTEtNzAwMzQ_e7e5339c-4446-4531-8396-8f8ab9d71de6"
      unitRef="usd">-33000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDktMi0xLTEtNzAwMzQ_42caae08-63cc-49bd-bf82-113a33ff8978"
      unitRef="usd">-3504000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNDktNC0xLTEtNzAwMzQ_6acdb451-b004-4b8b-98ce-27544f232134"
      unitRef="usd">347000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTAtMi0xLTEtNzAwMzQ_36abfb6a-da7c-4562-a23b-0b7359a14845"
      unitRef="usd">14487000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9e3aba93759e44e6998ff20f017b0ca4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTAtNC0xLTEtNzAwMzQ_aaef9dd6-6266-412c-b710-021639790db5"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTEtMi0xLTEtNzAwMzQ_98a915e7-b7c2-4355-bdbd-846c0cde644d"
      unitRef="usd">10983000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0b98f47b14654327afbb7932046478c8_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTEtNC0xLTEtNzAwMzQ_c47eb27f-ee7b-4b17-928d-259f21eafee5"
      unitRef="usd">14332000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTgtMi0xLTEtNzAwMzQ_647b3c74-dae9-44cc-a746-adc6cfb939ca"
      unitRef="usd">621000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTgtNC0xLTEtNzAwMzQ_75569aa0-bbf7-4c3e-a908-ae7bd37382f9"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTktMi0xLTEtNzAwMzQ_5ab82d94-788d-46ff-8a34-9298034b2479"
      unitRef="usd">98000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNTktNC0xLTEtNzAwMzQ_d954cc82-f398-4ebc-b704-88f9e5fd587f"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNjAtMi0xLTEtNzAwMzQ_00cf7737-a02b-427b-9269-0df90941310c"
      unitRef="usd">523000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF80Ni9mcmFnOjg0ZTcyODNiZDQ4ZjQ2ZTU5MTE1MjFjYjM4NzAyNTAxL3RhYmxlOmU2NDRjY2UwYWJiNTQ0NmY5MzU3ZDEwNmY5OWY2MzMzL3RhYmxlcmFuZ2U6ZTY0NGNjZTBhYmI1NDQ2ZjkzNTdkMTA2Zjk5ZjYzMzNfNjAtNC0xLTEtNzAwMzQ_ea5130ee-7ea0-4287-8ef0-eba5f791629d"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81Mi9mcmFnOjE3ZjczMTE3NzUzZDRhODNhZjQwMGJhM2VjNzQ5MjBkL3RleHRyZWdpb246MTdmNzMxMTc3NTNkNGE4M2FmNDAwYmEzZWM3NDkyMGRfMjg0NA_96962297-6932-46e1-8780-471b83a61026">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp;amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of July&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended July&#160;3, 2022, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal second quarter of 2022 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal second quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81Mi9mcmFnOjE3ZjczMTE3NzUzZDRhODNhZjQwMGJhM2VjNzQ5MjBkL3RleHRyZWdpb246MTdmNzMxMTc3NTNkNGE4M2FmNDAwYmEzZWM3NDkyMGRfMjg0OQ_38b2f4bc-4fb5-4fa1-9e5e-e4fd1ced3be4">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of July&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended July&#160;3, 2022, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81Mi9mcmFnOjE3ZjczMTE3NzUzZDRhODNhZjQwMGJhM2VjNzQ5MjBkL3RleHRyZWdpb246MTdmNzMxMTc3NTNkNGE4M2FmNDAwYmEzZWM3NDkyMGRfMjg0MA_0717119a-304c-4e78-9938-ceb4ce1c111f">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal second quarter of 2022 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal second quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81Mi9mcmFnOjE3ZjczMTE3NzUzZDRhODNhZjQwMGJhM2VjNzQ5MjBkL3RleHRyZWdpb246MTdmNzMxMTc3NTNkNGE4M2FmNDAwYmEzZWM3NDkyMGRfMjgzOA_50117ffb-532e-489a-9509-357fbac47cd6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RleHRyZWdpb246ZmZhNTE1OWI4NDhjNDk4MGExYjg5NGRmOWEwOWEzNDJfMzA_01857a6a-028f-444a-a68a-1fa651dd5a43">INVENTORIES &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RleHRyZWdpb246ZmZhNTE1OWI4NDhjNDk4MGExYjg5NGRmOWEwOWEzNDJfNDE_1602eb66-ed09-4c82-b069-298319015988">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMS0yLTEtMS03MDAzNA_0d8f8e91-c723-4f0a-ac49-ad857b459ffc"
      unitRef="usd">1696000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMS00LTEtMS03MDAzNA_7ada9d68-c3c4-4f99-a8dc-31fb1a43f8a4"
      unitRef="usd">1592000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMi0yLTEtMS03MDAzNA_05a552d0-a999-4e9d-9326-86fe6d832603"
      unitRef="usd">2324000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMi00LTEtMS03MDAzNA_dae232ee-3adc-4681-afbb-644b8dcb7e13"
      unitRef="usd">2287000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMy0yLTEtMS03MDAzNA_6fa3db11-95dd-46ed-9c65-797c11b4ab91"
      unitRef="usd">7417000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfMy00LTEtMS03MDAzNA_48ec1903-3e2f-4b2f-95ae-b8c86016b088"
      unitRef="usd">6508000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfNC0yLTEtMS03MDAzNA_27b5774d-791b-4e73-8ed7-9f1acdc63929"
      unitRef="usd">11437000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81NS9mcmFnOmZmYTUxNTliODQ4YzQ5ODBhMWI4OTRkZjlhMDlhMzQyL3RhYmxlOjQxNmMxMjU2YjdhZTRmY2RhZjEyNDg5MWI5ZjExNzczL3RhYmxlcmFuZ2U6NDE2YzEyNTZiN2FlNGZjZGFmMTI0ODkxYjlmMTE3NzNfNC00LTEtMS03MDAzNA_a7bb15ed-18ff-412d-9e17-dc48cfeeae8e"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMzI5ODUzNDg4NTc5OA_ea48d531-5d01-4f21-a744-64e9a61792cc">INTANGIBLE ASSETS AND GOODWILL&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of July&#160;3, 2022 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $1.2&#160;billion for the fiscal second quarters ended July&#160;3, 2022 and July&#160;4, 2021, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $2.2&#160;billion and $2.4&#160;billion for the fiscal six months ended July&#160;3, 2022 and July&#160;4, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTc4OQ_fb3e8398-eb74-4769-b717-58dee37c9837">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.&lt;/span&gt;&lt;/div&gt;</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if1e83abddf294b49862a285ff0526959_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMi0yLTEtMS03MDAzNA_0de3d2aa-e256-4be5-9be8-b8810caf481d"
      unitRef="usd">36885000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4644c94cdbe54b26bcc9d703afd57af1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMi00LTEtMS03MDAzNA_9f8eb1b2-8556-4664-9f94-9731dc27a255"
      unitRef="usd">38572000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if1e83abddf294b49862a285ff0526959_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMy0yLTEtMS03MDAzNA_71a60201-ec11-4949-a107-1c650c42b4d5"
      unitRef="usd">20336000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4644c94cdbe54b26bcc9d703afd57af1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMy00LTEtMS03MDAzNA_c3fd5f25-456e-4208-9512-663b809e4b09"
      unitRef="usd">20088000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if1e83abddf294b49862a285ff0526959_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNC0yLTEtMS03MDAzNA_7b3f26db-eb3a-4f33-b607-8f3008d23320"
      unitRef="usd">16549000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4644c94cdbe54b26bcc9d703afd57af1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNC00LTEtMS03MDAzNA_70a07de5-6ab3-4a89-83d2-31ce5033e55f"
      unitRef="usd">18484000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie7a97a3c30ea42378cd8743fdde441fa_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNS0yLTEtMS03MDAzNA_219d33f1-23b1-4355-b660-004974296208"
      unitRef="usd">22558000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9fa373ac3b69447baa5db15e621348bc_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNS00LTEtMS03MDAzNA_c1537c51-78eb-43db-afa2-c272a0058701"
      unitRef="usd">23011000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie7a97a3c30ea42378cd8743fdde441fa_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNi0yLTEtMS03MDAzNA_45b8b630-da5a-44d4-a569-a23b81f9e56f"
      unitRef="usd">12269000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9fa373ac3b69447baa5db15e621348bc_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNi00LTEtMS03MDAzNA_3f646415-23bd-40e5-84dc-dfcc074ff85b"
      unitRef="usd">11925000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie7a97a3c30ea42378cd8743fdde441fa_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNy0yLTEtMS03MDAzNA_69cb9f15-4512-4075-904a-98f79f7a65b7"
      unitRef="usd">10289000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9fa373ac3b69447baa5db15e621348bc_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfNy00LTEtMS03MDAzNA_e49be848-6cd7-4c45-bc3a-55a60bbceaf5"
      unitRef="usd">11086000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6a8cf9ad2e7647399248ae1419508e0f_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfOS0yLTEtMS03MDAzNA_3ec20c1f-32d1-4096-aab2-77005f99af95"
      unitRef="usd">6794000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i96f8bf96c98845fea1edfe19f545e830_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfOS00LTEtMS03MDAzNA_24014a02-3bc8-4482-a78e-cc92188dcf29"
      unitRef="usd">6985000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib0b304ee8aa140a588288dad04e0aaac_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTAtMi0xLTEtNzAwMzQ_d329e2b7-348e-4a6a-a687-7ce58bf4a781"
      unitRef="usd">8776000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id26a9c75b7c94e1085843fc1e74cf160_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTAtNC0xLTEtNzAwMzQ_33a65379-bf26-416a-945e-c55aa219bac8"
      unitRef="usd">9837000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTEtMi0xLTEtNzAwMzQ_72660c5a-87f9-48f7-a077-00cc2c7c02fb"
      unitRef="usd">15570000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTEtNC0xLTEtNzAwMzQ_0489143c-df03-43a6-93b6-eab5bbc8c435"
      unitRef="usd">16822000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTItMi0xLTEtNzAwMzQ_35c0f90e-f0ea-4ed8-9869-1fe0e69f78a5"
      unitRef="usd">42408000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmJiNTY3MzY0YWFmNjQ0NmY5YzU1ZDI5OTk3ZGM2NjhiL3RhYmxlcmFuZ2U6YmI1NjczNjRhYWY2NDQ2ZjljNTVkMjk5OTdkYzY2OGJfMTItNC0xLTEtNzAwMzQ_7bd37e98-4ce1-4834-99cc-47d68e69d780"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="if4bbbe18d2594f8aad55ae35a3d252da_D20220404-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfNjE1_8d324f0d-371e-498d-ba5f-51c48ac3e867"
      unitRef="usd">600000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTgwNg_1dd1cec0-8c43-4c3b-8c4c-082422888729">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of July&#160;3, 2022 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="id28638ba3e4b42e1a64486cf30194fd9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMS0yLTEtMS03MDAzNA_ed790591-d8d8-4249-812a-9f168241446d"
      unitRef="usd">9810000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i44b72b1c234f43a3b95f3f25252e2da2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMS00LTEtMS03MDAzNA_783cc598-594d-42ae-ac62-aeaa1d045a84"
      unitRef="usd">10580000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3057d1e214724cb89a838867914b6faf_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMS02LTEtMS03MDAzNA_2869c7a7-6431-475e-beae-8cf049775161"
      unitRef="usd">14856000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMS04LTEtMS03MDAzNA_b162ab4b-f663-4def-b47a-7a7968f38d6a"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3bc23407245a4376af9e0430687579f6_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMi0yLTEtMS03MDAzNA_30aa31e1-5cb4-4f08-a4e1-846edfc39f2f"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMi00LTEtMS03MDAzNA_876ba88a-279f-4ba7-a83d-eef88de514a3"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMi02LTEtMS03MDAzNA_8e481612-41a2-45be-b624-819667391ba1"
      unitRef="usd">195000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfMi04LTEtMS03MDAzNA_330eb344-3e59-454d-a933-189949670c1c"
      unitRef="usd">195000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i3bc23407245a4376af9e0430687579f6_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNC0yLTEtMS03MDAzNA_1a20cb61-e44f-4486-b08f-0f3770737501"
      unitRef="usd">-665000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNC00LTEtMS03MDAzNA_5d05de24-501b-47af-b6c6-51e577813328"
      unitRef="usd">-545000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNC02LTEtMS03MDAzNA_08f58749-47d0-4130-a03a-2cf5db2a3125"
      unitRef="usd">-65000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNC04LTEtMS03MDAzNA_1a0bddcc-894a-4b57-8eaa-face6662cff5"
      unitRef="usd">-1275000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i80e542b5e6c24d51a5840e549f120d1c_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNS0yLTEtMS03MDAzNA_341d98d5-eb2d-488f-8bed-c3df7bbc5c26"
      unitRef="usd">9145000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i709b7cc74ca74a80a4840c6c2463936a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNS00LTEtMS03MDAzNA_09db5b42-97bd-452b-83a4-6da5c385fdd6"
      unitRef="usd">10035000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idf76b5399fa64aeda445faded52c1175_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNS02LTEtMS03MDAzNA_a4a13f31-95fd-49e5-9856-d2670828448b"
      unitRef="usd">14986000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmQ4NTJhY2IwNWUwNjQyM2E4N2MyOTY2MzVkZGRhYmQ5L3RhYmxlcmFuZ2U6ZDg1MmFjYjA1ZTA2NDIzYTg3YzI5NjYzNWRkZGFiZDlfNS04LTEtMS03MDAzNA_1f70cda5-1e7e-4e9f-a9b2-1d2ed41ee6ca"
      unitRef="usd">34166000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i48d21dab7e7140dc8981cd34ec5ca636_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTIwNg_12d81352-045d-4b6b-ad67-2d6140b12911">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i17734f536a0942538d393c2a2be78a63_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTMxNQ_03f34236-922a-49c5-8234-0c19c8e1098c">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTQyMQ_719d2aba-fa78-4594-bce5-41674ab3dc5b"
      unitRef="usd">1100000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTQyOA_320289b6-3a71-4e25-98e2-099ece674289"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTA5OTUxMTYyOTkyNA_aee27440-9f9f-48a6-a7ad-11338fe7cd76"
      unitRef="usd">2200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTA5OTUxMTYyOTkzOA_f2953f30-bc94-452a-9c84-ea0125fc4da4"
      unitRef="usd">2400000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RleHRyZWdpb246MDU2NmQ2ZmFhMzBlNDkxZjgzMThlY2FmMDJmMDM4YzRfMTc4OA_e638b280-81b6-43ff-bf8d-bc20313030ca">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi0wLTEtMS03MDAzNA_d403a910-8316-445f-9e84-7eb072ecee5d"
      unitRef="usd">4400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi0yLTEtMS03MDAzNA_dec823c2-c7bc-4abf-b0ff-f2a89a62dcce"
      unitRef="usd">4400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi00LTEtMS03MDAzNA_a5c892d0-dbd2-456b-bd6b-a4e3473a1ae5"
      unitRef="usd">4200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi02LTEtMS03MDAzNA_0bad6abe-39d4-4351-9389-6f8c1f32ccb5"
      unitRef="usd">3400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF81OC9mcmFnOjA1NjZkNmZhYTMwZTQ5MWY4MzE4ZWNhZjAyZjAzOGM0L3RhYmxlOmM1YWY2OWI0MDRmYjQxNDNhYWJiYzc5MzIxNzE5OWZhL3RhYmxlcmFuZ2U6YzVhZjY5YjQwNGZiNDE0M2FhYmJjNzkzMjE3MTk5ZmFfMi04LTEtMS03MDAzNA_d34df8cf-be22-4111-b0fc-1a4c872d8fa0"
      unitRef="usd">2800000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNjA0NzMxMzk2NDgyNg_0c33a63c-ba0a-4cac-8c58-92d63d53761e">FAIR VALUE MEASUREMENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of July&#160;3, 2022, the cumulative amount of cash collateral received by the Company under the CSA amounted to $233.0 million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of July&#160;3, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $46.7&#160;billion, $37.2&#160;billion and $10.0&#160;billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion,  $37.4 billion and $10.0 billion respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of July&#160;3, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $613&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net investment hedge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  July&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended  2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal second quarters ended in 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal six months ended in 2022 and 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="33" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity investments without readily determinable market values, there was a decrease of $14 million in the fair value reflected in net income as a result of impairments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the fiscal second quarter ended July&#160;3, 2022, the Company sold all of its shares in argenx SE for proceeds of $0.6&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of July&#160;3, 2022 and January&#160;2, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $519 million and $520 million, classified as non-current other liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $17 million and $13 million classified as current liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of July&#160;3, 2022 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain/( Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other sovereign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the fiscal year ended January&#160;2, 2022 the carrying amount was approximately the same as the estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of July&#160;3, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of July&#160;3, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.0408)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500MM GBP 1.2143)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.550% Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.0408)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.0408)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average effective interest rate on non-current debt is 3.04%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the estimated fair value over the carrying value of debt was $3.2 billion at January 2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The current debt balance as of July&#160;3, 2022 includes $3.8&#160;billion of commercial paper which has a weighted average interest rate of 0.98% and a weighted average maturity of approximately two months.&lt;/span&gt;&lt;/div&gt;Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTY0Nw_54fbdfdb-233f-40b1-9686-4808074f60a7"
      unitRef="usd">233000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjMxMg_58a04449-5afc-410d-a84c-a609dc94418e"
      unitRef="usd">46700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5b760074bfcb4cc58e6a1ae3aac3d6e3_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjMxNg_b31cb338-bf97-4244-9ae5-867a23568dba"
      unitRef="usd">37200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia1f129fa36664a10963aba1c422e6f76_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjMyMw_c28c2d57-7872-4308-8eaa-30e008ba3702"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idd623d33cd684c54b9e101ccb633f27e_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjQ5OA_c18332f7-9e42-4caf-92d3-3245be3cb88c"
      unitRef="usd">45800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3634444be4ba4cf2985688254d252758_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjUwMw_964e2b4c-8f8b-4858-b390-cd47fb2c7ad0"
      unitRef="usd">37400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9480099d643c4b7cb1462c5d2ac5ecd7_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjUxMA_8aa0ee12-46a5-4d9d-85df-08128eff0524"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNDY0MA_ce489c47-5fba-49eb-a70b-8b8bf342d3e9"
      unitRef="usd">613000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNDg5OA_dc2e002b-1c08-4cd5-b123-17c3b2536be2">next 12 months</us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNTA1OQ_813dd2d8-cf6b-4a46-8c0f-bb77775a701f">P18M</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzNjY_0d6f970d-3f24-45b8-a70a-8bfd60bb546b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal second quarters ended in 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal six months ended in 2022 and 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="33" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i99d3df0e7ab74f219ef244be03b7433f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC0xLTEtMS03MDAzNA_79684ae2-2eb0-409f-aa08-39784a7a8b8d"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ie88ebdcc2bcd40839c3f8784531db588_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC0yLTEtMS03MDAzNA_0947b273-9632-473a-a676-d503661e969c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i97621d82be79453e9fa3553e70d1ca31_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC0zLTEtMS03MDAzNA_a38bd3e1-1417-49a1-a984-00fb63952d4d"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="icc8308f7d14c4181a0ae28210ff4ad62_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC00LTEtMS03MDAzNA_7292467b-f783-4209-97f2-19790553f632"
      unitRef="usd">-241000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5dccbe17c2b340f59a7b489aff4bfbda_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC01LTEtMS03MDAzNA_53fd6eca-1005-413d-a27d-a7e1e10bd0e6"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i65844a253fd240329a7e6e0a74622398_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC02LTEtMS03MDAzNA_45f015c7-a8fb-4160-8538-6a24a3aa8286"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i7c3261c0c12c40feacb473910d1a2350_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC03LTEtMS03MDAzNA_45d802c2-e9d8-42ed-b21e-7dde9e778bf2"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i22373e19eea64b96965159ae548a3427_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC04LTEtMS03MDAzNA_af8180ac-bd07-4a0d-8cd4-b40b58be9792"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i052c717f8d424999972ae78c20e442bb_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC05LTEtMS03MDAzNA_621f0b97-e0cf-4983-9c97-9bdfd9bd49d2"
      unitRef="usd">-6000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i70aee3ac261c42958695f57ef7aa8d75_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOC0xMC0xLTEtNzAwMzQ_ab28e6b3-1dbf-40bb-a404-8ac072dc1ba0"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i99d3df0e7ab74f219ef244be03b7433f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS0xLTEtMS03MDAzNA_95cd54ce-ffec-4143-b366-388480cb6464"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie88ebdcc2bcd40839c3f8784531db588_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS0yLTEtMS03MDAzNA_c9a03c11-8263-4763-a3fb-5ce97587fb78"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i97621d82be79453e9fa3553e70d1ca31_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS0zLTEtMS03MDAzNA_8b28f7d7-e3b6-45b3-8ef5-730da9bb4dc2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="icc8308f7d14c4181a0ae28210ff4ad62_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS00LTEtMS03MDAzNA_c1e7592c-ba9f-4366-8da2-076dbbb4b212"
      unitRef="usd">241000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5dccbe17c2b340f59a7b489aff4bfbda_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS01LTEtMS03MDAzNA_b00365e5-f54b-4b19-91d3-8462dad11e01"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i65844a253fd240329a7e6e0a74622398_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS02LTEtMS03MDAzNA_ffd6deb9-8309-4764-9ea0-7860e3965545"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7c3261c0c12c40feacb473910d1a2350_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS03LTEtMS03MDAzNA_41ce561f-5b20-418b-90c7-15d83a7e64c6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i22373e19eea64b96965159ae548a3427_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS04LTEtMS03MDAzNA_e60b3814-4d16-46ea-8cd5-7aa0050a56dd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i052c717f8d424999972ae78c20e442bb_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS05LTEtMS03MDAzNA_355fa998-4ee6-43c5-845f-f902ebe7287a"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i70aee3ac261c42958695f57ef7aa8d75_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfOS0xMC0xLTEtNzAwMzQ_02e5db65-5c97-49b8-9dd0-102fef905298"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i1ffbcc5181264051a6e74314d827dd4f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtMS0xLTEtNzAwMzQ_e1fc9b69-40d3-4d88-a709-4279eb318f06"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ib2f3ae164fc04ca49438e6a4347fa265_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtMi0xLTEtNzAwMzQ_689bce9b-8c89-4925-ad0d-ba472e07803a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i426ece422f5943a1808350edaeddda4a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtMy0xLTEtNzAwMzQ_6752251b-7036-4e67-b4aa-7e8bfafcd256"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if5e20365cb144535a9cedca9aed02546_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtNC0xLTEtNzAwMzQ_dbafbe47-5e0d-469c-a5bc-754b97b68bae"
      unitRef="usd">44000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ife68bcfafe314d1496be2149a6e924e8_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtNS0xLTEtNzAwMzQ_5238b174-226f-4f39-b725-a2549d817936"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i4c9b9a50530a45588281a4cf80ddebf3_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtNi0xLTEtNzAwMzQ_f01004d3-2722-4e55-883e-567cd52571d0"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5aaee80239bc4e2e93981af33614099c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtNy0xLTEtNzAwMzQ_5154e07e-2ab5-40d3-a123-228df6d39af2"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if188f2ad192d44daa74ba7278a4fcc3c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtOC0xLTEtNzAwMzQ_d1c15e47-1fd4-47e1-b857-0e07ac6e38eb"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="iae48c65d3bab4e199e770a5fcfb0a80c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtOS0xLTEtNzAwMzQ_0b7918c3-7a24-42e6-a435-5ba787ea3784"
      unitRef="usd">40000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5ab75f9b509940dbbb2fb9dead6e12fe_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTMtMTAtMS0xLTcwMDM0_4e1177d0-e0a1-4c5b-8141-41d919da8688"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1ffbcc5181264051a6e74314d827dd4f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtMS0xLTEtNzAwMzQ_4df9c615-84f1-4249-a44a-deb1b4db93a7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib2f3ae164fc04ca49438e6a4347fa265_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtMi0xLTEtNzAwMzQ_f111a7d6-a7cc-4921-b830-7a58d28a13eb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i426ece422f5943a1808350edaeddda4a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtMy0xLTEtNzAwMzQ_eed717da-9fc4-419c-9202-dfc8107a055c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if5e20365cb144535a9cedca9aed02546_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtNC0xLTEtNzAwMzQ_b6e0b8c2-cc25-4474-a0e4-6b5dbbc63d39"
      unitRef="usd">44000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ife68bcfafe314d1496be2149a6e924e8_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtNS0xLTEtNzAwMzQ_dbc4d9b2-6a46-4fab-a4f2-00d5ab8562cb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4c9b9a50530a45588281a4cf80ddebf3_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtNi0xLTEtNzAwMzQ_cda6ed9e-d4d8-4c7b-821d-1cbfc4e425db"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5aaee80239bc4e2e93981af33614099c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtNy0xLTEtNzAwMzQ_6d3eb306-510c-4f8e-9abc-c17bf2760492"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if188f2ad192d44daa74ba7278a4fcc3c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtOC0xLTEtNzAwMzQ_19ce921b-13c4-410e-aaec-08698fd33d99"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iae48c65d3bab4e199e770a5fcfb0a80c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtOS0xLTEtNzAwMzQ_9ed8b355-1947-4580-9a9b-f98f54985f5b"
      unitRef="usd">40000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5ab75f9b509940dbbb2fb9dead6e12fe_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTQtMTAtMS0xLTcwMDM0_aa4caa57-1284-4513-ac95-968d8b565c3f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i5da8d593cb89443aa125dde02cbdc486_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtMS0xLTEtNzAwMzQ_851a2a15-541b-4418-aa97-b3d632fc4142"
      unitRef="usd">-17000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i1c67b5fa2091465ab9dc2693e5093889_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtMi0xLTEtNzAwMzQ_4b5ff7f7-f4e5-4a03-9dcd-761551335271"
      unitRef="usd">-6000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i7d1e66f130e549638c38349732d6b9df_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtMy0xLTEtNzAwMzQ_a4649936-6e1f-4225-8992-d105e87ad6e0"
      unitRef="usd">42000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iada32f8e1c5a4cfc8679d5181aba3515_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtNC0xLTEtNzAwMzQ_1b91c9bc-6506-4e6b-927d-e3ad36312554"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="if0c4df0b7052471c8b4beecb6802dc5e_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtNS0xLTEtNzAwMzQ_3c482d8b-c2c2-4078-ac92-824442b773c9"
      unitRef="usd">-39000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ibf52c3ab707d4713b81fa73f99e93487_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtNi0xLTEtNzAwMzQ_38cfb4d0-699f-407a-b3ea-60e39d77f6c9"
      unitRef="usd">11000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i928ceff46ed841a39f43bd28f651f09a_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtNy0xLTEtNzAwMzQ_d0f52d11-dd56-44cb-af8e-081dc2ea74bc"
      unitRef="usd">14000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iad78c3349a7f48d6a0d49345aca00641_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtOC0xLTEtNzAwMzQ_8c91bfc9-fe9b-417f-b362-a49046b751e7"
      unitRef="usd">104000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i2c77b30de27d45df96a8104f4525f7d1_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtOS0xLTEtNzAwMzQ_bad28f2f-8718-4a3a-92f4-62bf496307cf"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ibf04012d40344529ab914fdd97d47466_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMTgtMTAtMS0xLTcwMDM0_5eb8cb17-335d-42dc-a394-27f0d7f310ed"
      unitRef="usd">2000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5da8d593cb89443aa125dde02cbdc486_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItMS0xLTEtNzAwMzQ_0a8ccad7-0a21-4b66-86ea-2ee855ffc4f3"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1c67b5fa2091465ab9dc2693e5093889_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItMi0xLTEtNzAwMzQ_c2309bf5-41a7-4034-869e-a7eb0a9e9315"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7d1e66f130e549638c38349732d6b9df_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItMy0xLTEtNzAwMzQ_4acfbf2b-c546-4761-a635-2facfd83fe9d"
      unitRef="usd">69000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iada32f8e1c5a4cfc8679d5181aba3515_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItNC0xLTEtNzAwMzQ_88cf9174-bb55-4faa-a7ce-60a00e5ea13a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if0c4df0b7052471c8b4beecb6802dc5e_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItNS0xLTEtNzAwMzQ_e91da700-bb3a-4963-a071-ad1a9f9c7038"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibf52c3ab707d4713b81fa73f99e93487_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItNi0xLTEtNzAwMzQ_3996917a-578a-49d5-b448-43063072312e"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i928ceff46ed841a39f43bd28f651f09a_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItNy0xLTEtNzAwMzQ_26b6f382-7383-4cf4-8a36-a8a55f3e7f44"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iad78c3349a7f48d6a0d49345aca00641_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItOC0xLTEtNzAwMzQ_c4dc0c0e-6aa0-4712-8668-5af80023b3ce"
      unitRef="usd">119000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2c77b30de27d45df96a8104f4525f7d1_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItOS0xLTEtNzAwMzQ_936a6bd3-cc9c-4933-b685-cfe6ef1101ba"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibf04012d40344529ab914fdd97d47466_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjItMTAtMS0xLTcwMDM0_264868fb-8feb-4e9c-bb8c-73dbaf2c8e6f"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i61321ab212a84d638148bcc2c0db2529_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtMS0xLTEtNzAwMzQ_26dae329-9a0f-4aed-a6fe-9e5ea84a5862"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ib87adb12b544400aabac91ac10b55d9d_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtMi0xLTEtNzAwMzQ_933b4642-f69b-4bc6-89fc-6fc8e6aef4e1"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iacaa73a24dc34f44ba74aee3094334f5_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtMy0xLTEtNzAwMzQ_9f1ec105-69f8-47ff-b3b6-19c7ab29276c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4ee1a2a6de5a421fbaf2a6ac76876bc0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtNC0xLTEtNzAwMzQ_c2b54d9f-eb97-49ca-af47-10deb8b36a66"
      unitRef="usd">102000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ib4f90bd741f24c46bc4278b4e28f7162_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtNS0xLTEtNzAwMzQ_327a107c-b200-45c0-9ef5-d97ac33c94ec"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i9177a536afa141448d3a25292e1296fd_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtNi0xLTEtNzAwMzQ_3a95cbad-6220-41b6-89d8-e04aa7e1ce96"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="id5df6c8fd44b4cfaa5405658069eea76_D20210405-20210704"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtNy0xLTEtNzAwMzQ_9e5a4ec6-177b-445f-b798-1bc84b14add8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i328dd4d5d05a4285b0893246ff22ab9f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtOC0xLTEtNzAwMzQ_1aa5e339-bece-4068-8916-cab1a45fc218"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i1dcc42285b6142869767f28bbda885e9_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtOS0xLTEtNzAwMzQ_d8cbf6b2-abc5-4ec8-92c3-8339174df2e8"
      unitRef="usd">99000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ibb5735d577994517bf90dd973a568b70_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjUtMTAtMS0xLTcwMDM0_aeac3b9c-e8ae-41ec-9eaf-1841197b28e4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i61321ab212a84d638148bcc2c0db2529_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctMS0xLTEtNzAwMzQ_e0106ae5-6bfa-4f12-9405-9b5d6664b810"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib87adb12b544400aabac91ac10b55d9d_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctMi0xLTEtNzAwMzQ_d5e78cfc-1a91-4257-9c5b-070bd470b6d0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iacaa73a24dc34f44ba74aee3094334f5_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctMy0xLTEtNzAwMzQ_c160d810-35c8-431f-910a-9dab5189d260"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4ee1a2a6de5a421fbaf2a6ac76876bc0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctNC0xLTEtNzAwMzQ_481a04f1-b28f-42dc-ba8c-0e2a92bb9a72"
      unitRef="usd">60000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib4f90bd741f24c46bc4278b4e28f7162_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctNS0xLTEtNzAwMzQ_c4738256-bda7-46be-ac02-3e005584bc51"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9177a536afa141448d3a25292e1296fd_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctNi0xLTEtNzAwMzQ_522c4224-90a3-45e9-aec9-205aba9b8323"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id5df6c8fd44b4cfaa5405658069eea76_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctNy0xLTEtNzAwMzQ_28872f25-c7bb-4627-add2-897d04dd4fc7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i328dd4d5d05a4285b0893246ff22ab9f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctOC0xLTEtNzAwMzQ_c1527d0b-2de6-4ee2-b564-d079411fa1e2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1dcc42285b6142869767f28bbda885e9_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctOS0xLTEtNzAwMzQ_71179a1a-9af6-4a20-a3ed-b0c922892572"
      unitRef="usd">286000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibb5735d577994517bf90dd973a568b70_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjc3ZGNlZGM5ZTg3ZjRjZDA4ZmI5Mzk1MTkwY2IyZmM3L3RhYmxlcmFuZ2U6NzdkY2VkYzllODdmNGNkMDhmYjkzOTUxOTBjYjJmYzdfMjctMTAtMS0xLTcwMDM0_ed6b0871-8628-4caf-9bbc-00d399a02f27"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="icbfeb1c605d04a88a882e139f2fa2b4b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC0xLTEtMS03MDAzNA_2165ea07-7abd-443a-addb-dd7b807a2b2f"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ia993599e0574405f95aa489e16792d7a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC0yLTEtMS03MDAzNA_93ce042e-5499-46de-8c6e-96a17361a273"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i3f85ff3cb4e8499d8c86fd7dc882efb7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC0zLTEtMS03MDAzNA_e6a5e82e-8f5e-4e67-9fd6-f592057ec106"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ic1c9a175a9fc4cbb8ad060ba18633dbc_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC00LTEtMS03MDAzNA_9432fdc9-2fcb-451d-a1a9-4d186c5e29b9"
      unitRef="usd">-772000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i2ea95b17407743509a8e35647b738929_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC01LTEtMS03MDAzNA_433fdbc6-28e8-498a-b4b2-dca376deb0f6"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="iccc5f6a5fc5d46d49d5760c3a3f39b2c_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC02LTEtMS03MDAzNA_198e48c6-b0b0-4de0-93db-cbe0f9cc2d5d"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i05aa739fc5bf4fa59b3b001daa07a0b4_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC03LTEtMS03MDAzNA_7d39486f-9fe1-4561-aeae-f455ad9392c0"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i22f501bd038344088354f3932536f457_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC04LTEtMS03MDAzNA_3cfeb362-4507-4f62-9bef-64819d6c8f36"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5664b5dabfd740a3b6f4396883d2cda8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC05LTEtMS03MDAzNA_4f83beb9-f104-4121-990c-b81892f85ba6"
      unitRef="usd">-6000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i408e7c6bfbab44228e55381d1839fb61_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOC0xMC0xLTEtNzAwMzQ_353f875f-9ca4-4aaa-99bd-1fdee9b1a768"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="icbfeb1c605d04a88a882e139f2fa2b4b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS0xLTEtMS03MDAzNA_3b52f650-9451-45f0-8c5d-18facd3a7447"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia993599e0574405f95aa489e16792d7a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS0yLTEtMS03MDAzNA_a2b9edcc-dfb3-4599-bf26-dcccc577ffa0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3f85ff3cb4e8499d8c86fd7dc882efb7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS0zLTEtMS03MDAzNA_250ff3d6-d9eb-4c80-aca8-03920eba492f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic1c9a175a9fc4cbb8ad060ba18633dbc_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS00LTEtMS03MDAzNA_880cb1b9-8422-4d84-825a-c90e02eff009"
      unitRef="usd">772000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2ea95b17407743509a8e35647b738929_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS01LTEtMS03MDAzNA_02a0b585-9f63-4a89-bad6-397ced331a14"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iccc5f6a5fc5d46d49d5760c3a3f39b2c_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS02LTEtMS03MDAzNA_33879ed3-c9b5-44c3-9b6b-e219e5f4bd39"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i05aa739fc5bf4fa59b3b001daa07a0b4_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS03LTEtMS03MDAzNA_8831f89b-580b-431e-9573-d32a4c10d8ae"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i22f501bd038344088354f3932536f457_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS04LTEtMS03MDAzNA_8163ea6d-6bc1-4c0f-8add-abd415d4831c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5664b5dabfd740a3b6f4396883d2cda8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS05LTEtMS03MDAzNA_13cf884b-31ed-4a2c-b43e-a42593914dfc"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i408e7c6bfbab44228e55381d1839fb61_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfOS0xMC0xLTEtNzAwMzQ_e4e6c663-24b4-47d3-b93b-706c7fc69a75"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i580cc60e6cdf496389e8435cc5955c25_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtMS0xLTEtNzAwMzQ_902ef71c-2dd6-4c28-8df3-4549a775c95f"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i6e8d90fbd49d4704baf0c8e5c9ca228b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtMi0xLTEtNzAwMzQ_8af20a91-3334-427c-bd51-e3beaebaf700"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i96fc5113393f459a8780e466f3ff2ea9_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtMy0xLTEtNzAwMzQ_ba81bddc-d49c-4470-bc36-864a974242e6"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i8bf9543b34dd4f93b96f68a4ca25eae0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtNC0xLTEtNzAwMzQ_f004324f-73ee-4c03-b6d2-861b0d8dbc52"
      unitRef="usd">89000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if53d09453c094af1b92a936cdfbacd94_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtNS0xLTEtNzAwMzQ_df301e21-9a50-4b70-ae0b-98d3f83dfc12"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i26f2db1557b74173a9cac2b055ab75cf_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtNi0xLTEtNzAwMzQ_77e2ac6e-8585-4780-9f6f-60eee18b8163"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="iaf0b9936cce44a77872c14571dd9ddf5_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtNy0xLTEtNzAwMzQ_82199b74-736d-4471-bc5b-9b3c85892092"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i6797e39b27654b74a22b814d372e8d12_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtOC0xLTEtNzAwMzQ_33908955-ccea-43d9-b858-f921e024614a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i326883f0b0fd4a0d825ea9cb59de5804_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtOS0xLTEtNzAwMzQ_eb88bb6b-1397-4cc5-944a-6b02227768e4"
      unitRef="usd">80000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i1a97916e3efb46e09815fb9d03aa504b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTMtMTAtMS0xLTcwMDM0_e056b182-5259-44b8-be23-06d285749a81"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i580cc60e6cdf496389e8435cc5955c25_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtMS0xLTEtNzAwMzQ_5f2230f9-944f-49c4-abb4-ee81dfbaabd7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6e8d90fbd49d4704baf0c8e5c9ca228b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtMi0xLTEtNzAwMzQ_f0b3f2c8-105c-4eaf-a98b-c887eb5bf8ad"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i96fc5113393f459a8780e466f3ff2ea9_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtMy0xLTEtNzAwMzQ_c04acefa-b806-4b40-a02e-116cc49c59f3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8bf9543b34dd4f93b96f68a4ca25eae0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtNC0xLTEtNzAwMzQ_284f1c83-766a-44d7-84dc-6b727db16b28"
      unitRef="usd">89000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if53d09453c094af1b92a936cdfbacd94_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtNS0xLTEtNzAwMzQ_f54093bd-c4f9-4ada-9913-556a167536e5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i26f2db1557b74173a9cac2b055ab75cf_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtNi0xLTEtNzAwMzQ_1d466f96-71dc-4c13-ba2b-9487c9d60719"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iaf0b9936cce44a77872c14571dd9ddf5_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtNy0xLTEtNzAwMzQ_3ba9de2e-2f15-474b-8afb-4dd925dd4e10"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6797e39b27654b74a22b814d372e8d12_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtOC0xLTEtNzAwMzQ_470a7f89-2983-430e-b3a0-67ab744c9c60"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i326883f0b0fd4a0d825ea9cb59de5804_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtOS0xLTEtNzAwMzQ_7d03b228-b460-4384-aaa3-b80d995f8ff8"
      unitRef="usd">80000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1a97916e3efb46e09815fb9d03aa504b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTQtMTAtMS0xLTcwMDM0_d5e399cc-c3e8-4318-b443-62263b804b67"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ide58dcad79ab45bfbe863ddffac83f2f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtMS0xLTEtNzAwMzQ_df2d45c3-8482-4a2c-bdf7-3564a9fe9e6b"
      unitRef="usd">-34000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="if6facbdbd9a04803b321187e1f040e70_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtMi0xLTEtNzAwMzQ_976f83ac-29a4-4fd9-abb5-4c81f0ac475a"
      unitRef="usd">-58000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="id2561de1bd5d4cfdb3e9f49ac0d0ffdb_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtMy0xLTEtNzAwMzQ_f5173133-89a6-40fa-9a72-897920e81d08"
      unitRef="usd">65000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i45661dbdcb9f4e8c8661b5da47b3b783_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtNC0xLTEtNzAwMzQ_5c068980-ce53-4a3a-a960-dc422b12d903"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i21556e9074dd4a0f8288063ebf6e970a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtNS0xLTEtNzAwMzQ_c112f152-58e2-4eb9-9495-671fe39fe179"
      unitRef="usd">-57000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i19c220c5c40240a4954cd7dae60f584b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtNi0xLTEtNzAwMzQ_2975d81e-0bb7-4800-805e-92d1f8e5c0ef"
      unitRef="usd">28000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ice3fdb84972d41ab9ba4bf47ef5ce854_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtNy0xLTEtNzAwMzQ_78b7b595-1408-4ff0-82f4-eef90531da7c"
      unitRef="usd">48000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iebf3885343f54fc687fd890f151c63d7_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtOC0xLTEtNzAwMzQ_508d4e10-c4d0-4ab1-bcf8-837750f577af"
      unitRef="usd">-9000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i710f2081b05d404f86c62f35feb19186_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtOS0xLTEtNzAwMzQ_ffb0fb5b-de35-4797-9c6d-f4405cbef33e"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i8399be3fe8e44b1f94bca7aff8b41680_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMTgtMTAtMS0xLTcwMDM0_5594d3f2-56fb-4fbe-8ab3-068da3f06a4f"
      unitRef="usd">5000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ide58dcad79ab45bfbe863ddffac83f2f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItMS0xLTEtNzAwMzQ_d42f4d6b-db64-41e1-9ff3-2241c1995120"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if6facbdbd9a04803b321187e1f040e70_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItMi0xLTEtNzAwMzQ_88df13d1-11ca-4752-8e2b-99b7844184b1"
      unitRef="usd">-59000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id2561de1bd5d4cfdb3e9f49ac0d0ffdb_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItMy0xLTEtNzAwMzQ_25a0e9e6-4d63-4450-8cbe-b9fca42cdbcf"
      unitRef="usd">102000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i45661dbdcb9f4e8c8661b5da47b3b783_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItNC0xLTEtNzAwMzQ_546f24c0-35b0-4a7c-b9f8-9a1f21537638"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i21556e9074dd4a0f8288063ebf6e970a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItNS0xLTEtNzAwMzQ_beef195d-035e-4aa1-92d9-2865f40bc482"
      unitRef="usd">-111000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i19c220c5c40240a4954cd7dae60f584b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItNi0xLTEtNzAwMzQ_5fdc525d-71cc-49fc-8a54-b1c41643f797"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ice3fdb84972d41ab9ba4bf47ef5ce854_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItNy0xLTEtNzAwMzQ_a8097b83-c2a3-4cc6-8f7d-b7387d6129a7"
      unitRef="usd">-243000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iebf3885343f54fc687fd890f151c63d7_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItOC0xLTEtNzAwMzQ_9b32e8fb-9894-4fac-a1ad-b6bb24db95c1"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i710f2081b05d404f86c62f35feb19186_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItOS0xLTEtNzAwMzQ_ac3348f2-645a-48d1-8b60-06bc5a42103d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8399be3fe8e44b1f94bca7aff8b41680_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjItMTAtMS0xLTcwMDM0_3d7e5f0f-fc33-43cd-94e8-11e307be8b4f"
      unitRef="usd">25000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ic84064d0beba43568502fa51c3264dd4_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtMS0xLTEtNzAwMzQ_bb21c6ec-d911-4739-927c-9e524c53893d"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i237ab2105da9479f82802abf0e650c17_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtMi0xLTEtNzAwMzQ_331ecd10-48fb-42ad-b209-4788864ab7d2"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i208da50d0b9a48189368d6e10d6a4fb3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtMy0xLTEtNzAwMzQ_e09d022d-5cc4-460b-b8cc-11e2c0c64b0e"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4f1f944b894e40ceba89ce94e11c72d7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtNC0xLTEtNzAwMzQ_eeb77703-e760-46ba-b90b-1f7083adc9a0"
      unitRef="usd">222000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ibd6b67f063a14008822cf81aae590318_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtNS0xLTEtNzAwMzQ_d2fddece-4a64-4d93-8498-1b427414f489"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ifce50b6f31f149f3a70237f88868b0cd_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtNi0xLTEtNzAwMzQ_1884fd18-2dbe-4b45-a34e-261b8e26172b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ib0f6dad62d53466ea010085927c81451_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtNy0xLTEtNzAwMzQ_9a7c549c-11b7-435c-a060-1e5227e5f784"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ib81964c4791646ce966adfc8c90aa7a2_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtOC0xLTEtNzAwMzQ_4d2281ff-69f7-4cfd-8b94-8d8a73ba55e9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i5349dd1284b14193a5715e5b6427c992_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtOS0xLTEtNzAwMzQ_bbd0082c-40f6-44fd-a22a-7723b608a17a"
      unitRef="usd">191000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="idc891ef4689a4994ac1847e71f539d52_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjUtMTAtMS0xLTcwMDM0_ae283c6d-1097-4031-a311-12a3ea70c8c6"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic84064d0beba43568502fa51c3264dd4_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctMS0xLTEtNzAwMzQ_9581519b-cf47-4d3c-97a1-127e1c51d384"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i237ab2105da9479f82802abf0e650c17_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctMi0xLTEtNzAwMzQ_1354fef6-28df-47ff-9431-8ff4af45baa8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i208da50d0b9a48189368d6e10d6a4fb3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctMy0xLTEtNzAwMzQ_81f95e31-05a1-40e6-a900-7717f4dfa400"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4f1f944b894e40ceba89ce94e11c72d7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctNC0xLTEtNzAwMzQ_b7719836-2504-4bb4-a523-2e0366d51c88"
      unitRef="usd">-68000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibd6b67f063a14008822cf81aae590318_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctNS0xLTEtNzAwMzQ_0d1d3849-b933-40ec-8044-9633bf59b504"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ifce50b6f31f149f3a70237f88868b0cd_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctNi0xLTEtNzAwMzQ_70e038b3-f8a7-4cbe-b4ba-e6ea8771b1fb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib0f6dad62d53466ea010085927c81451_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctNy0xLTEtNzAwMzQ_6160bdec-103f-4d6e-ad38-546512d613c7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib81964c4791646ce966adfc8c90aa7a2_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctOC0xLTEtNzAwMzQ_1efe3c15-53d7-400b-8c3b-de6e93a27504"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5349dd1284b14193a5715e5b6427c992_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctOS0xLTEtNzAwMzQ_f5cfe786-f633-437c-8fb8-fd828c6b375e"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="idc891ef4689a4994ac1847e71f539d52_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjA5NWI5N2QxOGZhMzQyMjdiNzA3Y2Y0ODI5NGI2Y2YyL3RhYmxlcmFuZ2U6MDk1Yjk3ZDE4ZmEzNDIyN2I3MDdjZjQ4Mjk0YjZjZjJfMjctMTAtMS0xLTcwMDM0_e7477fe0-ecde-4f1c-b358-f7940d9e65a9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzNjE_cf49201c-cbbc-4726-9d62-fef510666ba1">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  July&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie2f13601b97f4c86a0a2ee40c14abae9_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwOTRhZGZkYTM0NzQ2NWZhYzk2MTAxOGMwYjA0ZTQ5L3RhYmxlcmFuZ2U6ZTA5NGFkZmRhMzQ3NDY1ZmFjOTYxMDE4YzBiMDRlNDlfNC0yLTEtMS03MDAzNA_e553f0f3-d9a2-4731-9111-7dfdb1f75acc"
      unitRef="usd">9035000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1785c3b63c8c4e48805730aed53c751b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwOTRhZGZkYTM0NzQ2NWZhYzk2MTAxOGMwYjA0ZTQ5L3RhYmxlcmFuZ2U6ZTA5NGFkZmRhMzQ3NDY1ZmFjOTYxMDE4YzBiMDRlNDlfNC00LTEtMS03MDAzNA_d30fc998-7bc1-4a2a-a7cd-e7bb7a103709"
      unitRef="usd">9793000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ie2f13601b97f4c86a0a2ee40c14abae9_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwOTRhZGZkYTM0NzQ2NWZhYzk2MTAxOGMwYjA0ZTQ5L3RhYmxlcmFuZ2U6ZTA5NGFkZmRhMzQ3NDY1ZmFjOTYxMDE4YzBiMDRlNDlfNC02LTEtMS03MDAzNA_8c805c95-7b33-4ec3-83d2-620d28604430"
      unitRef="usd">-1010000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i1785c3b63c8c4e48805730aed53c751b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwOTRhZGZkYTM0NzQ2NWZhYzk2MTAxOGMwYjA0ZTQ5L3RhYmxlcmFuZ2U6ZTA5NGFkZmRhMzQ3NDY1ZmFjOTYxMDE4YzBiMDRlNDlfNC04LTEtMS03MDAzNA_f520e939-23d5-491d-a09f-1c7618a0db43"
      unitRef="usd">-142000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzOTQ_6a76cc93-90d3-4e3c-96bf-b3383e848869">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended  2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i6d2d946886f14b34b8cec403cb9ceeb2_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY0MmUzNmNjODZjYjRjYzVhNjc3OWMyODhkMjgxMDQzL3RhYmxlcmFuZ2U6NjQyZTM2Y2M4NmNiNGNjNWE2Nzc5YzI4OGQyODEwNDNfNC00LTEtMS03MDAzNA_53f6cbc5-7c53-43c9-88a3-f3ca179d62ed"
      unitRef="usd">73000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i8d77d7df0fc245a083931c66c8432fda_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY0MmUzNmNjODZjYjRjYzVhNjc3OWMyODhkMjgxMDQzL3RhYmxlcmFuZ2U6NjQyZTM2Y2M4NmNiNGNjNWE2Nzc5YzI4OGQyODEwNDNfNC02LTEtMS03MDAzNA_f5e53e64-bb6f-4d5a-8e12-a922efed8ca0"
      unitRef="usd">-21000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="idfc5d938e6594db3a5592348cbdf14b0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY0MmUzNmNjODZjYjRjYzVhNjc3OWMyODhkMjgxMDQzL3RhYmxlcmFuZ2U6NjQyZTM2Y2M4NmNiNGNjNWE2Nzc5YzI4OGQyODEwNDNfNC03LTEtMS03MDAzNA_03069933-5230-40b2-b5ed-2dea2243ab97"
      unitRef="usd">102000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i4271111bb61a42b8bc92b5628a6fa89f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY0MmUzNmNjODZjYjRjYzVhNjc3OWMyODhkMjgxMDQzL3RhYmxlcmFuZ2U6NjQyZTM2Y2M4NmNiNGNjNWE2Nzc5YzI4OGQyODEwNDNfNC05LTEtMS03MDAzNA_c5314fe5-0740-4d05-bf11-c3ac650d2f10"
      unitRef="usd">-37000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfMy0yLTEtMS03MDAzNA_3d173a34-7539-41e6-a9dd-eb2ba2074bdf"
      unitRef="usd">202000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfMy00LTEtMS03MDAzNA_f3812c08-fd4a-4614-b442-6616c12f784d"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ib42c0a6a0ba542ba87e204f1f199172c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfMy04LTEtMS03MDAzNA_d3f2117f-ce24-4561-9e2f-c58b43583a39"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="id61c7ab12f0d40a5b1d148b50984a0ae_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfMy0xMC0xLTEtNzAwMzQ_5cacf919-7373-4ead-bb58-6a5c09d49e1b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i2b395b190b6c40bdb82d652a413b2417_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfNC0yLTEtMS03MDAzNA_207278e9-d0a4-4510-ba26-a66bde0ac001"
      unitRef="usd">313000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ie0558f0c929e482384449ccfff5a6c40_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfNC00LTEtMS03MDAzNA_366c470d-b1cf-45aa-b605-056b3085c94a"
      unitRef="usd">-70000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="id002bac7c1ae4826bb20f0839018ad2f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfNC04LTEtMS03MDAzNA_6e2dc5e2-c293-42bf-8d9f-9bb69d6b628f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ia57bf4d1498c4d5a8f38143d4bfab826_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjg3MTY2MWE2MGM3ZDRlMTBiMTNmMzk1N2UzODM2ZTUwL3RhYmxlcmFuZ2U6ODcxNjYxYTYwYzdkNGUxMGIxM2YzOTU3ZTM4MzZlNTBfNC0xMC0xLTEtNzAwMzQ_2fb0ec7f-deae-41bc-a689-48ae7df4a9f8"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfMy0yLTEtMS03MDAzNA_064cabb9-e1d2-42b9-bb6b-e48d132eed1c"
      unitRef="usd">270000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfMy00LTEtMS03MDAzNA_edfc58e6-db39-4713-b19a-3384cbc2f452"
      unitRef="usd">164000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i07fd826f5b134e9fa417cd75e225e819_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfMy04LTEtMS03MDAzNA_48b94523-d2c3-4e53-b9b4-c0f871e1f308"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i2584883493814b06bf0ed930f4028c51_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfMy0xMC0xLTEtNzAwMzQ_08040cf1-50e9-42b6-b760-889fe53a6c08"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i10665768ac6c48af85f34ec614dbc6fc_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfNC0yLTEtMS03MDAzNA_c0fefa19-b81f-48c5-b994-d465c0e7e70a"
      unitRef="usd">873000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i455ed2b8001d4cb29c1bbe414bfe1b33_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfNC00LTEtMS03MDAzNA_bca43d47-f75b-45e8-b8cb-a20a2a7ebc7b"
      unitRef="usd">291000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="if8f70882583b47f7924e55453b7f672d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfNC04LTEtMS03MDAzNA_3c7605a5-780f-4fc2-b523-251a5c649ea1"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i7ebb8454e231462c9e01ddd2a9cd640e_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjZkNGMxN2Q3MjMwYzRkMzQ5N2ZkZWE3OTkxY2U3YmY2L3RhYmxlcmFuZ2U6NmQ0YzE3ZDcyMzBjNGQzNDk3ZmRlYTc5OTFjZTdiZjZfNC0xMC0xLTEtNzAwMzQ_90c100d5-006d-47e1-a79f-4c80211fe866"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzODM_253996b6-dc83-4346-bb99-9b89afceb535">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ia2b9bc17484844788bb099a867ad7081_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi0yLTEtMS03MDAzNA_14e10c80-b4e4-471e-b9bb-2a9124868092"
      unitRef="usd">1884000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i5585c30b729c45f9bf242ad075fd7e6e_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi00LTEtMS03MDAzNA_f117e425-5d15-43e7-ba65-848803813f8e"
      unitRef="usd">-508000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i5585c30b729c45f9bf242ad075fd7e6e_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi02LTEtMS03MDAzNA_e2bc0a4f-ee7c-4e4c-8687-4c31e8493599"
      unitRef="usd">-36000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ic6ff307f7d004130a7fbc2c25929d6fb_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi04LTEtMS03MDAzNA_1ab8d8a0-a4b8-405b-b9ac-74a8ea33927b"
      unitRef="usd">1340000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic6ff307f7d004130a7fbc2c25929d6fb_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfMi0xMC0xLTEtNzAwMzQ_218bc8c3-b0a5-487a-a8dc-b829dc923851"
      unitRef="usd">1340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i5174e789a11a483cb8a586d1a51f8af1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC0yLTEtMS03MDAzNA_a63e4059-4df3-4419-8783-622f51f0f5e6"
      unitRef="usd">500000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="iee1a9681011c41fc91369cb2a262d523_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC00LTEtMS03MDAzNA_c93d4c28-36b9-4038-9ed7-87e52b117be4"
      unitRef="usd">-14000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="iee1a9681011c41fc91369cb2a262d523_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC02LTEtMS03MDAzNA_0564306e-c028-4bed-836c-30e5b704b5e6"
      unitRef="usd">35000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ia2bb14177b1543589f7e2d2b40f3ed99_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC04LTEtMS03MDAzNA_7b980890-e1fa-4f78-a449-a3900d06316b"
      unitRef="usd">521000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia2bb14177b1543589f7e2d2b40f3ed99_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjY4YjdiOWQ1MzhiMDQyNzZiYzMwZTAwZmY5OTJhMDJiL3RhYmxlcmFuZ2U6NjhiN2I5ZDUzOGIwNDI3NmJjMzBlMDBmZjk5MmEwMmJfNC0xMC0xLTEtNzAwMzQ_29d8d4d8-5954-460a-bd8e-4dc3c7954941"
      unitRef="usd">521000000</us-gaap:OtherAssetsNoncurrent>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="iee1a9681011c41fc91369cb2a262d523_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfNjUzNw_87fed6da-13c1-40f2-82bc-ad952354b1c9"
      unitRef="usd">-14000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i974d845b8fdb4e7fa0bc0da100fcb02e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMjc0ODc3OTA4MTQ0OQ_effcc9ea-cde7-421b-b101-a324744e93ca"
      unitRef="usd">600000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzNzg_7703f7aa-4cfd-45af-bede-6d39876d0d74">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of July&#160;3, 2022 and January&#160;2, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $519 million and $520 million, classified as non-current other liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $17 million and $13 million classified as current liabilities as of July&#160;3, 2022 and January&#160;2, 2022, respectively.&lt;/span&gt;&lt;/div&gt;           (6)    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i53d11cbf312f4920a063822b57fb4379_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC0yLTEtMS03MDAzNA_f7bfffe2-594e-44ae-bf38-c11f34c14d7c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie465262306f745bfa8f4d12d012583ba_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC00LTEtMS03MDAzNA_d18cf625-256e-4c33-919d-c20075ef67a9"
      unitRef="usd">1314000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC02LTEtMS03MDAzNA_d296c3cb-8baf-4968-a95f-d8b3933bdebf"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC04LTEtMS03MDAzNA_3a8fc225-4d4c-4006-98e9-d4455cc69893"
      unitRef="usd">1314000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i820748c0ee614ffc85acb984e5a8fa84_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNC0xMC0xLTEtNzAwMzQ_a679f57e-98b0-4561-8250-85b84f6dcf5b"
      unitRef="usd">540000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ic45c5d30ba924db5a64a324285891798_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS0yLTEtMS03MDAzNA_5b6faba4-2a42-4a8d-aaf2-223633e9b79b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i58070284d45c4b4b97413c70ea4b99ac_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS00LTEtMS03MDAzNA_dd012412-d013-48d0-889e-b95a5be78a1b"
      unitRef="usd">1979000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7c5ce1a5044744c98c6fc083f0e7beca_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS02LTEtMS03MDAzNA_4936acb4-8ba9-4a4a-9b2a-cca611b67dd4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="idb0e6ccd8a9348ec80a99cd8c4672572_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS04LTEtMS03MDAzNA_ac56dc27-1a08-4b65-b7e6-506fa49bef90"
      unitRef="usd">1979000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i02c147ca24594e40a66c2a2f2b084eeb_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNS0xMC0xLTEtNzAwMzQ_e3896f10-cb55-4f9e-964b-81a3f7b5e6cb"
      unitRef="usd">796000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ib39755d463f2405bacc970b45155df96_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy0yLTEtMS03MDAzNA_478868e0-73dd-4d0a-bf16-3638e68f8827"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy00LTEtMS03MDAzNA_b4c467e1-5975-4f59-8a88-54e9d7c447ce"
      unitRef="usd">3293000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy02LTEtMS03MDAzNA_59978fad-4400-4606-ba84-4c8daeb84bad"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy04LTEtMS03MDAzNA_84a3210d-55fc-40b1-b803-f0a5ba2a66bb"
      unitRef="usd">3293000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i1f2023f668e54901b44a7ca21bcc4c7b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfNy0xMC0xLTEtNzAwMzQ_159ace14-d0cf-4a7b-be7f-afd0fc474788"
      unitRef="usd">1336000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i53d11cbf312f4920a063822b57fb4379_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS0yLTEtMS03MDAzNA_bd4ec976-260e-4673-ae08-0844c4d3e107"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie465262306f745bfa8f4d12d012583ba_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS00LTEtMS03MDAzNA_2aff71e2-8ded-4d80-b88d-abd33fa8e2b8"
      unitRef="usd">1513000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS02LTEtMS03MDAzNA_faf50e7d-baa8-4c8e-acba-24581ff89aeb"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS04LTEtMS03MDAzNA_2ffa8606-032c-481e-a646-bd95644f5802"
      unitRef="usd">1513000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i820748c0ee614ffc85acb984e5a8fa84_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfOS0xMC0xLTEtNzAwMzQ_e07a32b5-00f8-4afc-bbce-faaf00d470bc"
      unitRef="usd">881000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ic45c5d30ba924db5a64a324285891798_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtMi0xLTEtNzAwMzQ_2285f25c-0e55-424e-866b-77697a553765"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i58070284d45c4b4b97413c70ea4b99ac_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtNC0xLTEtNzAwMzQ_57d84009-698b-4e8b-9447-f7cf790bde03"
      unitRef="usd">1540000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7c5ce1a5044744c98c6fc083f0e7beca_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtNi0xLTEtNzAwMzQ_71f39628-f66f-437d-a60d-089f9b493cdb"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="idb0e6ccd8a9348ec80a99cd8c4672572_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtOC0xLTEtNzAwMzQ_615e05a3-f5c3-4c2b-b6e1-d3a087af6253"
      unitRef="usd">1540000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i02c147ca24594e40a66c2a2f2b084eeb_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTAtMTAtMS0xLTcwMDM0_866231db-7ff8-483d-836b-791c7679295f"
      unitRef="usd">979000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ib39755d463f2405bacc970b45155df96_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItMi0xLTEtNzAwMzQ_1dd279ac-529f-42c3-85fa-43d767446c6a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItNC0xLTEtNzAwMzQ_c130157c-3fad-4f30-b33f-099301def4a9"
      unitRef="usd">3053000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItNi0xLTEtNzAwMzQ_723fd60c-c8d0-4fba-908e-51efc49db24f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItOC0xLTEtNzAwMzQ_317190a8-e43c-4c77-a552-ba443ebda109"
      unitRef="usd">3053000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i1f2023f668e54901b44a7ca21bcc4c7b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTItMTAtMS0xLTcwMDM0_5ad17202-2216-402b-83e9-cbc7c1d4bcab"
      unitRef="usd">1860000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i53d11cbf312f4920a063822b57fb4379_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtMi0xLTEtNzAwMzQ_dbd04832-d127-4d10-9a25-5e18de9b6988"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ie465262306f745bfa8f4d12d012583ba_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtNC0xLTEtNzAwMzQ_22b5ea66-3c3b-4c4a-83ce-d98fd7d9a63b"
      unitRef="usd">47000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtNi0xLTEtNzAwMzQ_bda5b47c-39d1-44fe-8eac-977a01005ab8"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtOC0xLTEtNzAwMzQ_f4068125-eb23-48af-8753-c5f11fee3ae9"
      unitRef="usd">47000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i820748c0ee614ffc85acb984e5a8fa84_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTUtMTAtMS0xLTcwMDM0_6d75c113-9982-4651-9b47-2d45e4fafb3c"
      unitRef="usd">24000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i53d11cbf312f4920a063822b57fb4379_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctMi0xLTEtNzAwMzQ_5bc90175-281f-439b-b8c6-cf85e563b2fc"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ie465262306f745bfa8f4d12d012583ba_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctNC0xLTEtNzAwMzQ_ec19127f-dda4-48ed-887c-9b6cdfb91601"
      unitRef="usd">44000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i2b2bfe8cd32e41c598eab72737d45a8e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctNi0xLTEtNzAwMzQ_24126b88-4f87-4122-a6bd-88439e9ef0c9"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ic46b61746c914b54a3d85958237e5f97_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctOC0xLTEtNzAwMzQ_d126e21c-2494-4916-b02b-24c8b728305f"
      unitRef="usd">44000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i820748c0ee614ffc85acb984e5a8fa84_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTctMTAtMS0xLTcwMDM0_28268e3b-506e-473d-b9d0-9e8bf73a1b80"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib39755d463f2405bacc970b45155df96_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktMi0xLTEtNzAwMzQ_73a55a8a-682a-4659-ba2d-02f4e086a943"
      unitRef="usd">1340000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktNC0xLTEtNzAwMzQ_3ff31a77-e2ca-42cd-b7bd-f391d6c0a1a3"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktNi0xLTEtNzAwMzQ_3c51e694-8aab-47b0-90c1-cb5633d08bce"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktOC0xLTEtNzAwMzQ_ed7f0a88-cb40-43c2-9880-4479b474ec5a"
      unitRef="usd">1340000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMTktMTAtMS0xLTcwMDM0_fb5100ee-617f-4f23-be2c-c4eb97e8963b"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib39755d463f2405bacc970b45155df96_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtMi0xLTEtNzAwMzQ_3338065c-fc3b-4678-8f2a-b08311779e26"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtNC0xLTEtNzAwMzQ_77aebeca-44f7-4771-9ae6-fa3265b35621"
      unitRef="usd">21123000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtNi0xLTEtNzAwMzQ_43865ef7-aedb-409f-88ce-3e182603b73f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtOC0xLTEtNzAwMzQ_f4b51f22-21eb-421d-8e9f-3adf7ad29648"
      unitRef="usd">21123000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjAtMTAtMS0xLTcwMDM0_38ac2495-d986-4b66-a784-cf45bd05d9a5"
      unitRef="usd">19727000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib39755d463f2405bacc970b45155df96_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItMi0xLTEtNzAwMzQ_9e0f1348-5597-47fc-92ab-adb78a5b3dd3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i57eb94e827d94cdeb85f1fa0ed4a6818_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItNC0xLTEtNzAwMzQ_c918e3c9-c0d7-4e3f-bb0f-f5bf0270106e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib9b36b292cb1493bb900a69e5bd34765_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItNi0xLTEtNzAwMzQ_4c3cd296-3d04-40da-ad2f-a2b3a7780d0a"
      unitRef="usd">536000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItOC0xLTEtNzAwMzQ_5ce2a5d0-a3c1-40ea-b1dd-92fe0eaf7d9a"
      unitRef="usd">536000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjFhYzExZTEwYWU2OTRiYWM5Yjc1NWM4ODA5NzNlMzRiL3RhYmxlcmFuZ2U6MWFjMTFlMTBhZTY5NGJhYzliNzU1Yzg4MDk3M2UzNGJfMjItMTAtMS0xLTcwMDM0_702acceb-dce4-4ad0-b229-98677ac6f620"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfMi0yLTEtMS03MDAzNA_77dcc4a6-18df-4f2a-9c12-36abc1154b9c"
      unitRef="usd">3340000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfMi00LTEtMS03MDAzNA_d85062c8-92d9-4363-beb5-e9b1fce1e6ad"
      unitRef="usd">1360000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfMy0yLTEtMS03MDAzNA_2e7ab37e-ec8e-470d-8c62-063d630ddf5f"
      unitRef="usd">3226000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfMy00LTEtMS03MDAzNA_78b03e89-3396-4caf-ab43-22ecde50d3f2"
      unitRef="usd">1285000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNC0yLTEtMS03MDAzNA_3837ba64-32bc-484f-8ea8-db06f15f1326"
      unitRef="usd">114000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNC00LTEtMS03MDAzNA_f12d3a0f-8996-4443-87a3-55e4503611b4"
      unitRef="usd">75000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNi0yLTEtMS03MDAzNA_7291b7a8-1c7a-4805-ba61-affb5f9605f7"
      unitRef="usd">3097000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNi00LTEtMS03MDAzNA_28537b32-5639-488a-b62f-b8723b15a74f"
      unitRef="usd">1888000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNy0yLTEtMS03MDAzNA_e210c67f-ef59-4263-abe7-cc305f229b25"
      unitRef="usd">2993000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfNy00LTEtMS03MDAzNA_d7772cf2-29b4-48ad-9b5d-1e0a329372a2"
      unitRef="usd">1855000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfOC0yLTEtMS03MDAzNA_83e17ff4-1dbd-4de7-bc84-fb13ca696fa5"
      unitRef="usd">104000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjk1NmJiNGMzNmYyZDQ3MWRhYmFiODYyNjBiNTRiN2JlL3RhYmxlcmFuZ2U6OTU2YmI0YzM2ZjJkNDcxZGFiYWI4NjI2MGI1NGI3YmVfOC00LTEtMS03MDAzNA_93a830b1-edfd-41ae-97f3-3c1124cd893a"
      unitRef="usd">33000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3cf9dba1d9014bdcba643daa09edd4f1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfMy0yLTEtMS03MDAzNA_dbcf25b4-0aed-4644-9822-9b7f1ffe0d06"
      unitRef="usd">533000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9e3aba93759e44e6998ff20f017b0ca4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfMy00LTEtMS03MDAzNA_41906ca3-934e-404a-8833-56c28a16acc5"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNC0yLTEtMS03MDAzNA_7749ffd7-6e41-4fd7-9f1c-0d7bb83c214d"
      unitRef="usd">-88000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNC00LTEtMS03MDAzNA_e4860516-03b0-458e-842a-5e010a4d0c26"
      unitRef="usd">8000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNS0yLTEtMS03MDAzNA_8e3a3ac3-6740-40f1-afe3-4b4938fbeca5"
      unitRef="usd">91000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNS00LTEtMS03MDAzNA_67e74433-dcef-4110-a23e-9e10582c308f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNi0yLTEtMS03MDAzNA_8ccfced6-4078-4319-88f5-76e9be9b578f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNi00LTEtMS03MDAzNA_f5680f2a-049a-4991-9dca-08efc480be04"
      unitRef="usd">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNy0yLTEtMS03MDAzNA_4fff1e82-dc74-4e51-8f4d-5912d025127d"
      unitRef="usd">536000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0b98f47b14654327afbb7932046478c8_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjUyYzg3NzAyZGRjNDQzOTFhNmI5MTBlNDcxYWIyMDU5L3RhYmxlcmFuZ2U6NTJjODc3MDJkZGM0NDM5MWE2YjkxMGU0NzFhYjIwNTlfNy00LTEtMS03MDAzNA_3b095f7f-c1da-4f06-83a1-0f20db92a34b"
      unitRef="usd">593000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i616a8d8561e148bc93cfff8d5eaaf83b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfODc3Mw_8fb27863-ac23-4226-af94-c89413cc555e"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i02b1386668dd451a99e7f7cab14f56c2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfODg0MQ_b05bcef4-10da-433d-a4a8-e307ce4e2454"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i18ceca8d5a1842a6aa3fc80736183e3d_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfOTA5Nw_b58a9487-529a-4cf0-b8f7-28ed3cce04a4"
      unitRef="usd">519000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i061f4c2dadcc48f6952c7a8571f88284_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfOTExMg_9b8334da-0d2c-4a7b-9733-bf7f63b02b4b"
      unitRef="usd">520000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4c793d1a04514fca815ddcf0b0cbcff8_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfOTIwOQ_c1b448e0-efdb-44b9-a0d6-62088d45ed52"
      unitRef="usd">17000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibbdeb75dc07c40a6aeaf91aa2cb9a764_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfOTIyNA_08ed88bf-7230-4a72-a944-19eb49967abf"
      unitRef="usd">13000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzMTY_6e661fed-596c-42ed-af7f-d50baffaf651">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of July&#160;3, 2022 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain/( Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other sovereign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS0xLTEtMS03MDAzNA_fa88aeed-7efc-48ff-be93-49c56a6a42ed"
      unitRef="usd">3337000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS01LTEtMS03MDAzNA_7f75a423-84ce-4dc9-8bbe-0e4363977fc7"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS03LTEtMS03MDAzNA_3f7128a5-f454-4bf6-9a82-d3f3d79c764b"
      unitRef="usd">3337000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS05LTEtMS03MDAzNA_beeffbc0-8dd7-419c-87fa-6b51305f956b"
      unitRef="usd">3337000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="icd657c60f1a24c10a33422ab5ee9af4a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMS0xMS0xLTEtNzAwMzQ_bce8d410-86eb-40ca-b0d7-6957cb8decc6"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy0xLTEtMS03MDAzNA_3099c09a-f40c-470e-a221-653bf7c47bf6"
      unitRef="usd">538000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy01LTEtMS03MDAzNA_ae978a50-77b1-4f1b-a50e-8b5db12626e1"
      unitRef="usd">1000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy03LTEtMS03MDAzNA_c260f3a7-683f-4ab4-a6d5-9023359f5337"
      unitRef="usd">537000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy05LTEtMS03MDAzNA_9c33f8bc-635c-4f23-b9a2-9863716cb63b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5e49767d9045405dbabb0ebdd3457dc3_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMy0xMS0xLTEtNzAwMzQ_752666e3-8d45-48cf-b853-3fb2b8884937"
      unitRef="usd">538000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC0xLTEtMS03MDAzNA_3dda5a6e-71f3-40ab-b5c9-7b608d4e3969"
      unitRef="usd">2112000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC01LTEtMS03MDAzNA_d31d4535-b313-4446-bda0-1544cd7abbb0"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC03LTEtMS03MDAzNA_2e0accae-f070-4d99-8e98-6e232434da59"
      unitRef="usd">2112000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC05LTEtMS03MDAzNA_1ed20820-b621-402d-93b9-50de3bbeae9d"
      unitRef="usd">2112000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iab0ec69a90244ff8a111f44c89663546_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNC0xMS0xLTEtNzAwMzQ_ceefa6a9-f81c-4280-b97d-42f127ab36fb"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi0xLTEtMS03MDAzNA_3934e950-9fac-42ef-b450-fe9779b38385"
      unitRef="usd">2443000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi01LTEtMS03MDAzNA_38204209-e2f9-4f3f-8288-fe10e0af3f11"
      unitRef="usd">8000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi03LTEtMS03MDAzNA_2a1adf74-7f9d-4a0f-b2b6-d323576ee4c7"
      unitRef="usd">2435000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi05LTEtMS03MDAzNA_868a419b-bbba-4c81-b244-d5ed1a9305dd"
      unitRef="usd">240000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i00d9e4015c714d518f4373cf0ad3530b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNi0xMS0xLTEtNzAwMzQ_ca4b360c-bdb5-412a-9019-ba57060776bc"
      unitRef="usd">2203000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i7423beb705924764a8f4876d7d961b65_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy0xLTEtMS03MDAzNA_58d74cbc-28c9-474c-94d9-c87be620a7f4"
      unitRef="usd">1968000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i7423beb705924764a8f4876d7d961b65_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy01LTEtMS03MDAzNA_9701a290-171e-4804-8da7-f4f761e5af1f"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i7423beb705924764a8f4876d7d961b65_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy03LTEtMS03MDAzNA_f0852b11-9406-44b9-bcdb-ccc9594812dd"
      unitRef="usd">1968000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7423beb705924764a8f4876d7d961b65_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy05LTEtMS03MDAzNA_6ed8b760-d98a-4ebb-bafb-619e146e4e68"
      unitRef="usd">1968000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i7423beb705924764a8f4876d7d961b65_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfNy0xMS0xLTEtNzAwMzQ_4ba72b7c-a287-4d24-8fb7-d47f12a25f30"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC0xLTEtMS03MDAzNA_e34ac321-ffc4-4919-a89f-88191af8a155"
      unitRef="usd">1047000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC01LTEtMS03MDAzNA_452bc320-13d5-46a7-be26-588a71415c2d"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC03LTEtMS03MDAzNA_1fd96959-7757-42fb-813e-505072c50594"
      unitRef="usd">1047000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC05LTEtMS03MDAzNA_5e2d2735-13cc-4580-88be-3a616bb5161e"
      unitRef="usd">1047000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i808ec468ce6c44538860a6822a475fbf_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOC0xMS0xLTEtNzAwMzQ_bf671417-495c-4466-9f9b-f41a69e76f44"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i437b71eb938a462080e32d083a962f86_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS0xLTEtMS03MDAzNA_efb8ae27-ff1c-4009-a1ae-8a1d54e34d6e"
      unitRef="usd">11445000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i437b71eb938a462080e32d083a962f86_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS01LTEtMS03MDAzNA_3dc7b4d0-f7c9-4913-a276-533a0e54dffc"
      unitRef="usd">9000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i437b71eb938a462080e32d083a962f86_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS03LTEtMS03MDAzNA_ae95a153-2b70-41ea-abcb-fd59a85c6c19"
      unitRef="usd">11436000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i437b71eb938a462080e32d083a962f86_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS05LTEtMS03MDAzNA_9cc867dd-47df-47e3-9869-09c1192efb43"
      unitRef="usd">8704000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i437b71eb938a462080e32d083a962f86_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfOS0xMS0xLTEtNzAwMzQ_10ec41c4-569b-48d8-abdc-b330b84eafb2"
      unitRef="usd">2741000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItMS0xLTEtNzAwMzQ_b41f8efd-7e72-43ea-981c-e8c69a2b7e30"
      unitRef="usd">20919000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItNS0xLTEtNzAwMzQ_579ee1aa-26a6-4d57-84cd-bb2dc1baa574"
      unitRef="usd">45000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItNy0xLTEtNzAwMzQ_1a3c4b6d-2ae0-40f7-810b-b0406c2bdd0f"
      unitRef="usd">20874000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItOS0xLTEtNzAwMzQ_900fb1b6-7037-4fc6-b2dc-21105aeb210b"
      unitRef="usd">2251000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib7bccd30febf43d0a4d2c381c7afc0b5_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTItMTEtMS0xLTcwMDM0_baf59635-13b8-4615-86c5-760a8a56f3a1"
      unitRef="usd">18623000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtMS0xLTEtNzAwMzQ_469077b1-ba63-489e-916d-0d7be7948a44"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtNS0xLTEtNzAwMzQ_1f3f7700-c997-496d-8747-a9dc58287d1d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtNy0xLTEtNzAwMzQ_d6cc7d36-a223-42a1-8c3d-3a13417af783"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtOS0xLTEtNzAwMzQ_83ab3237-127e-464d-9e7a-e775c01d6a14"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtMTEtMS0xLTcwMDM0_6050e17f-1976-4993-b8d8-b48a87ee42ff"
      unitRef="usd">3000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i504a09c1cadb41b2bc01218b05dd9585_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTMtMTEtMS0xLTcwMDM0_7d60b686-84ab-408e-bdd4-40d0648dae7d"
      unitRef="usd">3000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtMS0xLTEtNzAwMzQ_13e02a27-50f8-4925-947a-4f6629263e6f"
      unitRef="usd">247000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtNS0xLTEtNzAwMzQ_6b066871-46c7-4ac1-bede-324d654d376d"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtNy0xLTEtNzAwMzQ_129744b8-047c-4811-a833-5e127293f5c9"
      unitRef="usd">246000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtOS0xLTEtNzAwMzQ_617ca763-fea0-4e87-badc-d8dde7ca5862"
      unitRef="usd">28000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i489821c51d7e4e6692905fc0dd2b650e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTQtMTEtMS0xLTcwMDM0_2ff3d98c-9d78-4e79-bcc8-cb56bab79d59"
      unitRef="usd">218000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idbf37690c3b94285af307610b22628e8_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtMS0xLTEtNzAwMzQ_3c489346-60dc-41fa-a92a-96f8be404393"
      unitRef="usd">21169000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idbf37690c3b94285af307610b22628e8_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtNS0xLTEtNzAwMzQ_a3f181ff-78ed-4eea-9e56-87012794a677"
      unitRef="usd">46000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idbf37690c3b94285af307610b22628e8_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtNy0xLTEtNzAwMzQ_e07e0505-2fe9-4f26-86a3-81a1a2e200dd"
      unitRef="usd">21123000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idbf37690c3b94285af307610b22628e8_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtOS0xLTEtNzAwMzQ_8bac3ed1-a9a5-4f51-8e31-f3ecb3802437"
      unitRef="usd">2279000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idbf37690c3b94285af307610b22628e8_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTUtMTEtMS0xLTcwMDM0_ba8b19a5-9e2c-4394-ae6d-896a6defc131"
      unitRef="usd">18844000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtMS0xLTEtNzAwMzQ_f9f2393d-569d-472f-9e26-5f9402e48622"
      unitRef="usd">32614000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtNS0xLTEtNzAwMzQ_9d2b21d5-34b0-4de4-9e20-c77233f74fb9"
      unitRef="usd">55000000</jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtNy0xLTEtNzAwMzQ_d044881e-46bc-41cf-aa62-7d3a9eb9ed86"
      unitRef="usd">32559000000</jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtOS0xLTEtNzAwMzQ_c47ba6bf-4c52-405a-9ad6-22db16e33d9d"
      unitRef="usd">10983000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmUwNjc2YmJmYTM4NDRlMTE5MDk5N2IzMGYwY2ViNDhiL3RhYmxlcmFuZ2U6ZTA2NzZiYmZhMzg0NGUxMTkwOTk3YjMwZjBjZWI0OGJfMTYtMTEtMS0xLTcwMDM0_feb15ea8-5380-4c2b-a43e-61b8af9f2dbc"
      unitRef="usd">21585000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzMTA_21df4384-e7f7-460f-aeb4-438ee776d497">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzNzA_40992302-8334-4063-8f27-7f9a0e09717a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of July&#160;3, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMS0yLTEtMS03MDAzNA_3b3fc926-43f1-435f-a288-bcdce5211ba0"
      unitRef="usd">21155000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMS00LTEtMS03MDAzNA_6ad05696-3de3-4a3e-88b0-768a4e9978ec"
      unitRef="usd">21109000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMi0yLTEtMS03MDAzNA_7f4b866f-6f0d-40bc-926b-cabfba3f6759"
      unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMi00LTEtMS03MDAzNA_c5e9074f-d309-4677-8f42-9bf2332549e8"
      unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMy0yLTEtMS03MDAzNA_0ffe8112-8488-4354-ba99-1fde7f702bec"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfMy00LTEtMS03MDAzNA_0f221806-211f-4685-9b50-2a80445423bd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfNC0yLTEtMS03MDAzNA_ed7fd829-696a-4186-a511-fe7d1070ae19"
      unitRef="usd">21169000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOjQ5ZjgxMzllOTQxYjQ3MmM5OWI2NzI4NDMxM2ExZDYwL3RhYmxlcmFuZ2U6NDlmODEzOWU5NDFiNDcyYzk5YjY3Mjg0MzEzYTFkNjBfNC00LTEtMS03MDAzNA_b3fa6156-ffcb-4efe-848f-a4d6218c7a1a"
      unitRef="usd">21123000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEzMjI_f55fb49b-a813-4c91-b650-c4e868e2ae06">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of July&#160;3, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.0408)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500MM GBP 1.2143)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.550% Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.0408)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.0408)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="i35b52ff0f6ac42609c258100f987af3e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNC0yLTEtMS03MDAzNA_0c0243ca-2b8e-4de6-871a-4c54e74d195f"
      unitRef="usd">4305000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="if668327e01644d82befdc0a8ab72e2cb_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNC00LTEtMS03MDAzNA_f6f4239a-530b-4bc7-903d-6d322e93cbe4"
      unitRef="usd">4304000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0412d7e68cd949e69dd56bb1f8ec4989_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNy0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjUyYmI2NDZkZGQ2NTQ1YmZhNzUyOGEwODZhZjQ5NjE0XzQ_665f7d40-045c-4fb5-879d-09e8a84d31fa"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ida1ae3624a844b4f875208ff051c690e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNy0yLTEtMS03MDAzNA_1ad5fe51-1ac4-49ce-a939-28c7ea7193d2"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7607c810ff1d4ac3b1e1815bf6afca66_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNy00LTEtMS03MDAzNA_fc025dff-4dcd-4498-a793-f18a018a2340"
      unitRef="usd">263000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if214bf0473764e41a84dd8791aadae18_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfOC0wLTEtMS03MDAzNC90ZXh0cmVnaW9uOjVhNzM1ZGVjOTlhMDQ4Nzc4NjI4YTQ0ZGU4MTc1ZmYyXzQ_786349b8-ce41-446c-b438-07f1ca273e05"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idd688062d5f3442ab9e3d49a23df957b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfOC0yLTEtMS03MDAzNA_875ad927-1fce-40b9-a89c-a14b3ba41d0c"
      unitRef="usd">802000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i19bd93d4b6414d7c80050b05ab626367_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfOC00LTEtMS03MDAzNA_b96a22e1-650c-4c71-a4ea-084b7539673e"
      unitRef="usd">805000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2ac16b6eb33a475a8a71478faa2b6027_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphMmYyZDJkMjQ2N2Y0N2ExYThmZDA2MGFiZjU0YTYwNl80_eea0b018-d4a9-430c-bf16-3b7e75f4b2ce"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2ac16b6eb33a475a8a71478faa2b6027_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphMmYyZDJkMjQ2N2Y0N2ExYThmZDA2MGFiZjU0YTYwNl8zMjk4NTM0ODgzMzgw_b767d1a6-58b5-4db5-a404-1467f280f8df"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i2ac16b6eb33a475a8a71478faa2b6027_I20220703"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphMmYyZDJkMjQ2N2Y0N2ExYThmZDA2MGFiZjU0YTYwNl8zMjk4NTM0ODgzMzkw_a7aec272-79a2-4765-950d-53699090cd94"
      unitRef="number">1.0408</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib5ad0d9d40c440198c4ccaebcefe7e24_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtMi0xLTEtNzAwMzQ_2e3b7b90-f851-41ee-b779-a0e39a898e66"
      unitRef="usd">774000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i10d8e76325af440aa71852c405d16386_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTAtNC0xLTEtNzAwMzQ_3823db86-8fca-40a3-b8e6-555bb6de3416"
      unitRef="usd">766000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie265961801c14b649e4aec89b623b822_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphNTFlYTQ3YjE1OTY0Y2NmOTcxZjQ2MmIxMTc0Y2UwN180_de113f06-105f-45c6-9025-3fb160d6a992"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie265961801c14b649e4aec89b623b822_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphNTFlYTQ3YjE1OTY0Y2NmOTcxZjQ2MmIxMTc0Y2UwN18zMjk4NTM0ODgzMzgw_48883312-0e61-44e1-95ed-3f303f3ad447"
      unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ie265961801c14b649e4aec89b623b822_I20220703"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphNTFlYTQ3YjE1OTY0Y2NmOTcxZjQ2MmIxMTc0Y2UwN18zMjk4NTM0ODgzMzg5_eeb7eeea-c625-4884-ad26-649aa0363825"
      unitRef="number">1.2143</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic73c4fedbb644223a20f315d7dd9f3e7_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtMi0xLTEtNzAwMzQ_6d1c7156-86cb-4722-a36b-34f33922d02f"
      unitRef="usd">605000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic9f34fca0ba04ca781f7befcff5614b3_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTEtNC0xLTEtNzAwMzQ_e44cc55e-2dc1-472c-adf4-bcdf178c2890"
      unitRef="usd">647000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2c7397d924e2469bb389835fe06d5b23_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTItMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphZDJjMjhhMDQ3YzQ0M2RkYTlhYzhlMGYzOTA4ODAzM180_4884c7ca-7e47-4e1e-ba6e-669aea14e625"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8c0348a7bec543bbb40b652ecc155701_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTItMi0xLTEtNzAwMzQ_c5429e73-83b6-480a-86db-99084b249ce5"
      unitRef="usd">749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ieaea24750d14422d8bb195caed4c0fa2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTItNC0xLTEtNzAwMzQ_c838ea48-5392-4b3c-88d5-a923af082335"
      unitRef="usd">745000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i517d31de7560429e9f6447755677fcc3_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTMtMi0xLTEtNzU5MjY_f4c5a965-5a97-4ea6-a01d-b9feb4ee0bce"
      unitRef="usd">940000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i15f8f438d45649aaa711cfeee70572f3_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTMtNC0xLTEtNzU5MzM_464297d8-d33e-4fce-9f79-d4ed5eb4cc48"
      unitRef="usd">872000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i714604558c6448ceac87445bd3cbe601_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpkNjhmNTk3ZTE4YmI0ZDMzYTExN2Q0MGM3ZTk5Y2MxMV80_031d16c7-a588-49b6-9e56-f7849ce5f48e"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6080a0f3af3f49e9bc2edc00f7c218f5_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTUtMi0xLTEtNzAwMzQ_07d4ea5b-d2c8-43e1-be20-a56a28c7d583"
      unitRef="usd">1995000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8f5eac34b27640f79085c03f81117a27_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTUtNC0xLTEtNzAwMzQ_ce43b156-4f4a-4d99-b8fc-7b47ed425b03"
      unitRef="usd">1950000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie8d83f40eadc482f9785a1a1e73ae1fb_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpkMDQ0NjA2OTVhZDI0MzM4YmIyMjVjM2UyYTcxMzdlNF80_3b125397-d4bd-4fea-af7f-a0f39f53b2bb"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2422ade4dd254785ba67cf1997145fef_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTYtMi0xLTEtNzAwMzQ_ec30393d-d071-43f5-82ff-4ed8954b8a09"
      unitRef="usd">911000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i24356a7eaa814e15a526f1f4f1dbb4a3_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTYtNC0xLTEtNzAwMzQ_794d17ee-6d47-4fbf-a95f-06e590b42e51"
      unitRef="usd">899000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ief6fdac95f174a9db30f9dde4a867361_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoyMzU0ZWExMGZhZWM0YjU4OWUyOTM2ZTM5NmZmYzE0N180_0c9218fe-8354-4949-9844-e732f6389956"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i932f859fe5004fcab7d388c3ef37b01b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTgtMi0xLTEtNzAwMzQ_a7875d2a-ff45-4f12-831d-5d9f15eec615"
      unitRef="usd">1423000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia8500a36cb2b404fb1495e3f0cd34b1b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTgtNC0xLTEtNzAwMzQ_ca150f4c-639f-4ba2-b959-177d98edf793"
      unitRef="usd">1264000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i10cb7e790720410393c02b3b71132200_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTktMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNDY1MzZjMDY2MzY0ZGQ3OGJiNzNhMDZmNTA3MzMwOF80_6a9242e5-c839-4a8f-b385-31b5cdc6317e"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3a981ac377da4942bd8a08b6b8f69e74_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTktMi0xLTEtNzAwMzQ_a8598e7b-858d-4b37-a89a-749c7f21b958"
      unitRef="usd">1496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i51f8a9e2e7444c16b12a3c2edb6be775_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMTktNC0xLTEtNzAwMzQ_13460fcd-3118-4e8e-81cd-d3009c810d1d"
      unitRef="usd">1462000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4f60341d6ee24828ac150d7fb989724d_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo1MWE2MmZmY2Y4OTI0NDA0OTNiMzkzMjA3NTJlYTg3Yl80_57057f65-a138-479f-a047-f1b7bbc9ef0e"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4f60341d6ee24828ac150d7fb989724d_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo1MWE2MmZmY2Y4OTI0NDA0OTNiMzkzMjA3NTJlYTg3Yl8zMjk4NTM0ODgzMzgw_33198b80-c9b1-4814-ac92-05ba21ed7373"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i4f60341d6ee24828ac150d7fb989724d_I20220703"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo1MWE2MmZmY2Y4OTI0NDA0OTNiMzkzMjA3NTJlYTg3Yl8zMjk4NTM0ODgzMzg5_da34ee2f-4e88-413c-a967-04b7644b5a6d"
      unitRef="number">1.0408</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i85954b0bbfb747cba4560e6bbe91083a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtMi0xLTEtNzAwMzQ_381be91c-efa0-4757-a93f-eb901c9fade0"
      unitRef="usd">776000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9fd3188721d3496bbfcb0a0a1fcdeeaa_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjAtNC0xLTEtNzAwMzQ_73dbee5c-0da1-46e7-808e-6e64c60b79b4"
      unitRef="usd">735000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i247279ce24df4fc984684a77a1afc670_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo0ODc4ZWYwMDFmNjc0NDk5ODRkYWYwMjgwZTc0Mjg0Yl80_0438510e-4897-4d21-bd45-8a389cbf47d9"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7dd4fb1b88c34db49fc66928580f5871_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjEtMi0xLTEtNzAwMzQ_7a551b19-fbc2-4ca4-bc7f-9aa6b0ee7744"
      unitRef="usd">298000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i51b5a0c24ecf49209b2e36a4c3789ba6_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjEtNC0xLTEtNzAwMzQ_84457810-340f-40e6-854e-8ae18076037f"
      unitRef="usd">372000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i687f005d14ed416ba74831b5b47b4555_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjMtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoyOTM5MWZkOGE2ZjE0MjhiODA5YTAxMzg3MDZmMmE0NV80_174a449f-d6b8-41ec-9f4e-0f5d352a79c4"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib7501e1e2bb74a89922e7f7a201f16ce_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjMtMi0xLTEtNzAwMzQ_0a2dabed-0c27-4c85-aba9-ec3a77b82870"
      unitRef="usd">1646000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib90a8017e0214944955fce66d917c85a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjMtNC0xLTEtNzAwMzQ_3de33170-b422-428b-ad94-05b38544b81c"
      unitRef="usd">1404000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idab876f881cb42b3b32ad3e26e9ec7ab_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjQtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpkMzg0NGI2ZTk0YzU0ODQyOGFmZGEyNGZmOWQ3MDRhN180_3ac11f64-2ba0-4d54-9cae-dc021ecf0e27"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if6c198d27655479abef21848a7bba761_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjQtMi0xLTEtNzAwMzQ_88454a14-10b2-4cb6-8a3e-cebb6499eff7"
      unitRef="usd">498000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i16ab0ee504eb41599816d24c2113bc1f_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjQtNC0xLTEtNzAwMzQ_84b9ce5c-3e5c-4372-8130-fbbab0695b36"
      unitRef="usd">554000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9d05ba815c654783b44178265f82de44_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpkOThmYzRlMWFjZTk0MGE1YTA5ZDQzYTcwMzViZGI2ZF80_f299fe19-9168-43e7-ba46-0c7a3dd4fdd0"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7914f4f7746046df9a737d4fb8979c6b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjUtMi0xLTEtNzAwMzQ_0fff6ff0-bf0d-44bf-8a69-fffc20e6fb6b"
      unitRef="usd">855000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id275d71b261a432c89901abc9e36512b_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjUtNC0xLTEtNzAwMzQ_11b0f06a-797f-4730-8cde-6f981f2f37f5"
      unitRef="usd">895000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8dc1e5091506483785afd9d275795a46_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjplZjkzNjk3MGE0YzQ0ZDdlOTZiNTExZjFlNWMzNDkyYV80_641f26c1-ebc8-4972-8e77-daef985fcf22"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8dc1e5091506483785afd9d275795a46_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjplZjkzNjk3MGE0YzQ0ZDdlOTZiNTExZjFlNWMzNDkyYV8zMjk4NTM0ODgzMzc5_713596f0-56e0-4ad4-9183-2e54c4c7460c"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i8dc1e5091506483785afd9d275795a46_I20220703"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjplZjkzNjk3MGE0YzQ0ZDdlOTZiNTExZjFlNWMzNDkyYV8zMjk4NTM0ODgzMzg4_ba50f37b-0f83-4d2c-8299-db99e0b70cf2"
      unitRef="number">1.0408</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8dc1e5091506483785afd9d275795a46_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtMi0xLTEtNzAwMzQ_a69c99e8-5be5-4fa3-8a2f-d7fbd269c438"
      unitRef="usd">1554000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id9d838b361e1428f9af039eded3b682a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjYtNC0xLTEtNzAwMzQ_53d375a0-ad3e-4d57-91f3-8c22ca2e68c8"
      unitRef="usd">1370000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i60dba65131c1437481410132c5ea4df7_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjctMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoyOTkzYjcwOGVkNDg0YWVhYTBhN2ZjZDAyNGU5OTY1OF80_b35c46e1-c8b4-4b58-bae1-509a2a62b8a7"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia9048cedccfb40ed8e4d52b8f5430ad1_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjctMi0xLTEtNzAwMzQ_3c61f82a-239f-4533-9fb9-7f17347f785e"
      unitRef="usd">885000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i85efca72771a40499d8082f58202a3dd_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjctNC0xLTEtNzAwMzQ_34f04c3e-bea9-449d-aa7c-1447810fc7ca"
      unitRef="usd">848000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i350a972bfcfd4efdb72b431248967d66_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowNDYwODk1MWVmMmE0MzNlOTRhZTVmOTM4ZDY5YjBhZl80_e5b6b649-e14a-4624-8899-9a1fc1fea2ee"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3f46a77f7992478ea4128962d4c9f391_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjgtMi0xLTEtNzAwMzQ_7c18695b-7ddf-441b-bfd8-492a71bd925d"
      unitRef="usd">993000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8d3fb3a791ca414fa77eaa67cc99a07f_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjgtNC0xLTEtNzAwMzQ_7a024074-a0d2-4652-bcb6-3c5ebf397894"
      unitRef="usd">1181000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id8ccb7e446b348588dd2f9516636ffb7_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjktMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoxZWJiYzFjMjIxOGE0OTljOGNlZmZlOTNmOGEwZDM0Nl80_096018d7-6416-44d1-95bb-725235ef9744"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1a17432bed1945c48370b5015ddb5642_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjktMi0xLTEtNzAwMzQ_35b7a05a-8e15-4bdb-9789-8396f6a47823"
      unitRef="usd">1381000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id65c4c72715349aba29bef207c5ed392_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMjktNC0xLTEtNzAwMzQ_c30ef640-9701-4eba-99e7-17ed5c8994f8"
      unitRef="usd">1328000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7bc27cc5ec494407a381cf8b2d1d893b_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpmYjUxMzY0NGQ5ZjY0MjAyOGM1ZWNhNzViNWM3ODdiMl80_e2cb4114-0c2a-4329-a5f6-4bf1b3d9b4de"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if9fca044219d42f0971fb8ef3a32a6c4_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzAtMi0xLTEtNzAwMzQ_d2820a96-501b-4ac8-8f34-d80c474dbd3a"
      unitRef="usd">992000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id8b97c77efcb43fbab577c42a6fbfc7c_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzAtNC0xLTEtNzAwMzQ_0181b5a0-bc03-480f-9e99-b992c7883c58"
      unitRef="usd">898000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibfc2e3c1f9254ffba88d55ca0c4ce058_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo3MzM1MzdjM2QxYzA0ZGM0YTQzM2I4MzkwMDE3OTFjNF80_1e7e805e-809a-45b7-a54f-3509dd6f5257"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i915b24d83829484ebf50c108621501e4_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzEtMi0xLTEtNzAwMzQ_6a2e796e-a0f3-4eaa-bbcc-886b1bdaa4c6"
      unitRef="usd">697000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibec88f4e48124475a9632ff20fb8edd5_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzEtNC0xLTEtNzAwMzQ_86b026c2-b7e4-4bcf-a6e9-3b4ccc0f01a3"
      unitRef="usd">817000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc6c33b6176b422483f5f3ef6becebff_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzItMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoxYzIyYjE5ZmE5N2E0ZDEyYmI2NDI3ZDY4NTNhYmY0Nl80_2676b3e5-b537-4e51-8ebf-8edb1f3efab6"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icd4e43d48a4c4e21bcbe809be40eca70_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzItMi0xLTEtNzAwMzQ_a1cd0a82-6520-4a50-9fef-39df9ddd60c9"
      unitRef="usd">540000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i53a8feaecb4246bc9b98605730a15584_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzItNC0xLTEtNzAwMzQ_5863f544-b903-42d2-b6b1-173dcbea56b2"
      unitRef="usd">546000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia3d3ef2ea8d84db099d215dfe535ddcb_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzQtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphNDg4NDRkMzZhODc0ZjRiYTQ5NjNmMDk2YjMzYmZmNF80_436a8dbc-fb98-4362-860b-48d7d16aef16"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib006c54c03ed480e9b393694820c92c6_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzQtMi0xLTEtNzAwMzQ_de45e081-6c22-49cb-9ad4-e1a5c74ebb9f"
      unitRef="usd">876000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i575934a7cedc4cedbde5e430befc2365_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzQtNC0xLTEtNzAwMzQ_4f94873c-a530-4ffc-b67c-b02cd1acbce7"
      unitRef="usd">647000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05004c0e3cfc490cac8c08c422000ba2_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzUtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphYjhmY2U0ZmJiMjM0MWE0OGYwZjdjYTE4YzZhYWVlNF80_3d372197-22e5-4157-86f6-456091350880"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia7614f062f264a8fa4c4907f54853e94_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzUtMi0xLTEtNzAwMzQ_188a4bd5-4c74-42c2-bfcf-decb0b10d90a"
      unitRef="usd">297000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7ea66b619cb3443197db56a50a304a6c_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzUtNC0xLTEtNzAwMzQ_a746f78b-e889-43af-aec4-9893424c98b7"
      unitRef="usd">312000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i12f17d6898c04d318d57f363e7c9bf98_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzYtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo4YzkyOWE2ZTgwYTM0NTQ4YWE0YzUzZDAwZjAzMWE0NF80_8f0d1cdb-1d23-4090-8891-bf71c42b1150"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1058600fb83c4dd480871a0a2a908496_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzYtMi0xLTEtNzAwMzQ_7b0772e2-e3e4-421e-8a93-695095983917"
      unitRef="usd">496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i616df737a6e04747b5272a1cef450ed1_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzYtNC0xLTEtNzAwMzQ_b3c830f0-e291-4651-b7d5-d818c18731c5"
      unitRef="usd">506000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i42d3e3e61a244a51b1d33daefe6fe819_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzctMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjo1MzA1YzMwZTU4MTE0YjNmYTQwNjg4YjM2YzQ2NzkzZV80_c82cd6c3-b9ff-4889-b8e9-09318226fa53"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3bd5f7853d0d4ffeab0ca0c4e2369e5d_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzctMi0xLTEtNzAwMzQ_2982a540-935e-4038-9f46-872d2550a9c1"
      unitRef="usd">1975000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i30c41e781ada48aebeffcd3857c0fabb_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzctNC0xLTEtNzAwMzQ_44b929bd-73ca-4c75-88df-db579482e463"
      unitRef="usd">1830000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i96f5b18cb544467e97c5f515dcf98586_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzgtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjphZDg5MWUxYzA5OTc0MDFkODgxZDQ4YTRkNzBhZWM1NV80_d918c20e-d078-474e-87f9-1c5df23ca822"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i58f4a61e1d17435cb3f75c415b7bedea_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzgtMi0xLTEtNzAwMzQ_582331df-fd49-4dae-8cfc-87c8a02dd5b7"
      unitRef="usd">863000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie81ee28385e645de81a4923e2eb9efb4_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzgtNC0xLTEtNzAwMzQ_96fedd96-633f-4e78-9765-75997bde8069"
      unitRef="usd">806000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i92f0cf689bb644bcb78bfd87f8b277ad_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzktMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjoyMzhmOTY1NGM4NjE0MTgzYTIwZTdmNTMzYjc4OTdjZV80_6e5794a1-7979-44f4-aadc-313900bbc087"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if0a95408bdaa4b3782748bb151cab603_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzktMi0xLTEtNzAwMzQ_ee401017-2bfa-470a-a3cb-45b037536e97"
      unitRef="usd">743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i27effcd5f6a94b389235ad25b18e2bcd_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfMzktNC0xLTEtNzAwMzQ_d41ab992-9f8e-49a3-bc72-a23e342b50d7"
      unitRef="usd">677000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia18fac953b8141dabab3475985def187_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDAtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjpiYjkxOTVmYTRlMGQ0NGQ2OGMzM2QxODU1MzM2ZWQ5ZV80_cb85a23f-5526-4ef3-ac64-0e9228977d71"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i78494e54f3114f17a858e621c5e6752d_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDAtMi0xLTEtNzAwMzQ_3c17fc4e-2ec6-4f56-936f-b91af3492aed"
      unitRef="usd">864000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i17d8d0c23c594dd8a278bdb58b5042b2_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDAtNC0xLTEtNzAwMzQ_5b2a7353-73c9-44c2-9fd7-dd734f322c81"
      unitRef="usd">599000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i07459c41a6f843978c00a7b71ef76e9c_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDEtMC0xLTEtNzAwMzQvdGV4dHJlZ2lvbjowMzI0MDIyYTM1ZWY0ODNiODY2NjgwNmIxNjY5NDVjZV80_b3fa8be0-a8a5-4aa1-b23f-7508180fc84f"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7afb6fc2c7ae48c8b09189c72a0dd118_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDEtMi0xLTEtNzAwMzQ_7211cda4-2111-4929-8ea9-2b981631cbb1"
      unitRef="usd">1108000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5b91038961e64c0085d31120a376145e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDEtNC0xLTEtNzAwMzQ_011faef3-c2b6-47b6-b7ed-4ac80f0c3f80"
      unitRef="usd">773000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icd7696abcc3b4b91843a6ef7190f4f06_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDItMi0xLTEtNzAwMzQ_40664bed-9a99-4535-a207-87b60674489b"
      unitRef="usd">10000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i33b7a271cb844d789cdf3dad5b732c3a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDItNC0xLTEtNzAwMzQ_b9ea4a20-b34f-4423-b78c-6fd73ca083bd"
      unitRef="usd">10000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i35b52ff0f6ac42609c258100f987af3e_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDMtMi0xLTEtNzAwMzQ_45bef02a-5470-44ef-b201-6fbfc6992abe"
      unitRef="usd">28292000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if668327e01644d82befdc0a8ab72e2cb_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RhYmxlOmE0YjMzZGM5ZTcwNDRlYjdhYTkzYWQ5OWFiOGU3ZGVjL3RhYmxlcmFuZ2U6YTRiMzNkYzllNzA0NGViN2FhOTNhZDk5YWI4ZTdkZWNfNDMtNC0xLTEtNzAwMzQ_ad802dbd-0dcd-48a7-879e-d5f3e47f9963"
      unitRef="usd">26781000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTA4ODA_49bbcf1e-599b-453e-a8af-1fd0f668e941"
      unitRef="number">0.0304</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="i702f71864f5046db87e856abadec5a61_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTA5NjA_58849c13-d7d0-42bb-97bd-f29b407dc8f3"
      unitRef="usd">3200000000</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="i59e59e4d0e434ad28048bd9cc5ed9cf5_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEwMjc_66ae3bc7-2e88-4766-b7e4-1d21923d0389"
      unitRef="usd">3800000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i59e59e4d0e434ad28048bd9cc5ed9cf5_I20220703"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTEwOTY_d5662661-9d8b-4aef-befd-d07312a34fa6"
      unitRef="number">0.0098</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm
      contextRef="i143c1877fac245a1b05d14212b80d45f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF82NC9mcmFnOjQ3NTUxMGNlZjFlODQ0MGU4YzQwZTc0MGIzMWM1OWFlL3RleHRyZWdpb246NDc1NTEwY2VmMWU4NDQwZThjNDBlNzQwYjMxYzU5YWVfMTExNDg_28fbcc20-bda6-4fb0-85b2-95e8f6870bb0">P2M</us-gaap:DebtInstrumentTerm>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMTk1OA_65244ca2-e888-4718-9528-8006314edc42">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The worldwide effective income tax rates for the fiscal six months quarters of 2022 and 2021 were 14.9% and 11.5%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal quarter is primarily due to the Company reorganizing the ownership structure of certain wholly-owned international subsidiaries in the second fiscal quarter of 2021.  As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with the applicable local regulations.  Accordingly the Company recorded a local deferred tax benefit of approximately $2.3&#160;billion which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $1.7&#160;billion. The net impact of this reorganization was approximately $0.6&#160;billion net benefit or a 4.4% decrease to the effective tax rate of the fiscal six months of 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Additionally, the Company had lower income in higher tax jurisdictions, primarily in the U.S., compared to the same period in the prior year and certain one-time tax costs.  This lower income in the fiscal six months of 2022 was primarily caused by a mark to market adjustment to the Company&#x2019;s investment portfolio, the impairment of the Bermekimab AD IPR&amp;amp;D (for further information see Note 3 to the Consolidated Financial Statements), both at the U.S. statutory rate, and litigation expenses. The impact of the income mix was partially offset by incremental tax costs directly related to the planned separation of the Company&#x2019;s Consumer Health business (for further information see Note 1 to the Consolidated Financial Statements)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal second quarters. Additionally, the Company&#x2019;s tax rate benefited from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of July&#160;3, 2022, the Company had approximately $3.4 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.  In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;Subsequent to July 3, 2022, as part of the planned separation of the Company&#x2019;s Consumer Health business the Company has recognized approximately $0.3&#160;billion in incremental tax costs due to the reorganization of certain international subsidiaries which will be recorded in the fiscal third quarter.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMTE4_19d2341f-a6bc-4b4b-8c17-9f03a130c01b"
      unitRef="number">0.149</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMTI1_238dd374-eb76-4f75-9611-52d649ba66ff"
      unitRef="number">0.115</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i0b98f47b14654327afbb7932046478c8_I20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5MjYxOQ_78858b4c-8057-44cb-b8c4-4e056de2e5f3"
      unitRef="usd">2300000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i0b98f47b14654327afbb7932046478c8_I20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5MjYzMw_d9b39f53-6335-4521-95f0-cffae31117d6"
      unitRef="usd">1700000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i0b98f47b14654327afbb7932046478c8_I20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5MjY0Nw_e6490ec7-eb21-4b1c-afe4-0e4250a8c30c"
      unitRef="usd">600000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5MjY2MQ_8156669c-c84e-4f48-bc14-48c317b42a1e"
      unitRef="number">-0.044</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMTE0Mw_2530ef08-fb59-4838-9d6c-3497d9c57e87"
      unitRef="usd">3400000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="i2daa8a32f1fc4fdf8b188540df1f7766_D20220704-20220729"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83MC9mcmFnOjM5MjU5YmQyOTQ3YjRmNTY5Y2E5ODZmNTgwMmE0YzY4L3RleHRyZWdpb246MzkyNTliZDI5NDdiNGY1NjljYTk4NmY1ODAyYTRjNjhfMzI5ODUzNDg5Mjc1Ng_47300d03-49bc-4b39-a73f-2dbd42ab6352"
      unitRef="usd">300000000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RleHRyZWdpb246YjhmNjIzNmExMDNkNGJmZWIwMjhkYjU0MmIwMGVjMjVfMTAxMQ_a10e962a-33d0-4662-bf0c-b57730cf8778">PENSIONS AND OTHER BENEFIT PLANS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Company Contributions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal six months ended July&#160;3, 2022, the Company contributed $54 million and $10 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RleHRyZWdpb246YjhmNjIzNmExMDNkNGJmZWIwMjhkYjU0MmIwMGVjMjVfMTAxNA_873c537f-4eb7-4fa1-817c-d205d8f9b8c9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0yLTEtMS03MDAzNA_2f8b0899-c4c0-492d-a99b-b7feeaef3b93"
      unitRef="usd">319000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy00LTEtMS03MDAzNA_04655b53-cb24-45e4-b826-d94fff3789b6"
      unitRef="usd">327000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy02LTEtMS03MDAzNA_9558dae4-771e-4a2c-b420-0bf6e15af260"
      unitRef="usd">80000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy04LTEtMS03MDAzNA_2bb3c5c5-053c-42c0-8377-f928bf76e497"
      unitRef="usd">77000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0xMC0xLTEtNzAwMzQ_e8305794-41fe-4c53-8434-cfa8725bef9e"
      unitRef="usd">640000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0xMi0xLTEtNzAwMzQ_82e8380e-6e61-4d1a-953f-064837286473"
      unitRef="usd">680000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0xNC0xLTEtNzAwMzQ_b34e1d8f-0b7b-4584-99a0-9627c572b64b"
      unitRef="usd">160000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMy0xNi0xLTEtNzAwMzQ_79f4df06-32e3-421f-862e-204029f2757e"
      unitRef="usd">154000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0yLTEtMS03MDAzNA_eca6bc51-9d0a-428b-9ec5-7915b4536573"
      unitRef="usd">229000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC00LTEtMS03MDAzNA_582848b4-f5e8-4322-93aa-a7347371c2d9"
      unitRef="usd">193000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC02LTEtMS03MDAzNA_b6f0d746-3ae4-48f3-bf70-9457d244f6f6"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC04LTEtMS03MDAzNA_87dbf849-818c-4b80-bcc9-f2b56865be7c"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0xMC0xLTEtNzAwMzQ_8041d649-ad97-434c-a65b-c058f5d9cf11"
      unitRef="usd">459000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0xMi0xLTEtNzAwMzQ_27342646-685b-4437-8498-9c2cf41586d0"
      unitRef="usd">386000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0xNC0xLTEtNzAwMzQ_71752bb9-0134-4795-8b53-cf04887b4f55"
      unitRef="usd">53000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNC0xNi0xLTEtNzAwMzQ_7eb91c1c-bad9-4599-a0fb-15914579ad91"
      unitRef="usd">41000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0yLTEtMS03MDAzNA_2441c7be-e89f-42e5-922f-bdad71a96c63"
      unitRef="usd">693000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS00LTEtMS03MDAzNA_bb8dfb05-6059-4f30-bb27-cfd2b87b9ee2"
      unitRef="usd">647000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS02LTEtMS03MDAzNA_290c8044-31f8-4d94-8c3d-aed2647b3448"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS04LTEtMS03MDAzNA_c1fbd1b0-0592-438b-871e-b03a31e7aad4"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0xMC0xLTEtNzAwMzQ_bd6dfd34-4355-4e11-b665-b3f2b98b1e7d"
      unitRef="usd">1392000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0xMi0xLTEtNzAwMzQ_a2a1409b-606d-460f-868d-3b0a99698931"
      unitRef="usd">1327000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0xNC0xLTEtNzAwMzQ_b95db552-cf30-4d2b-9fbe-4ddb4e811c26"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNS0xNi0xLTEtNzAwMzQ_93cc2325-ca18-4e25-b1e2-080da1e6c8af"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0yLTEtMS03MDAzNA_098a2356-736a-40d2-9fb7-63972d3cfcca"
      unitRef="usd">-46000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi00LTEtMS03MDAzNA_ef1bbe5c-ba0b-4687-82a0-95e0d2bdb957"
      unitRef="usd">-45000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi02LTEtMS03MDAzNA_2f7254af-9e4c-4f97-8b65-98ada5532377"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi04LTEtMS03MDAzNA_97ce89a6-208a-4437-a34a-71c7e03f42d8"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0xMC0xLTEtNzAwMzQ_e71e6025-278a-4d00-8592-d48de8146c6d"
      unitRef="usd">-92000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0xMi0xLTEtNzAwMzQ_7f9c8fac-1439-4e7b-add5-7282de522ace"
      unitRef="usd">-90000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0xNC0xLTEtNzAwMzQ_230a977c-b9db-4982-94a0-659fd6ec79a7"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfNi0xNi0xLTEtNzAwMzQ_6a8b9a55-29ea-4d95-b2b4-8d333cd1a178"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0yLTEtMS03MDAzNA_1cb712f7-efd4-45a0-9b8b-c754620c250e"
      unitRef="usd">-167000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC00LTEtMS03MDAzNA_363a329d-4a50-48cb-b2ee-0abb6696fc1f"
      unitRef="usd">-316000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC02LTEtMS03MDAzNA_91833446-1a77-49bf-93c5-f92fb3a7d531"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC04LTEtMS03MDAzNA_46b3a184-709a-4c14-aa2b-2996ad5267fa"
      unitRef="usd">-37000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0xMC0xLTEtNzAwMzQ_84a5293e-1f86-40c7-845c-df32fcad73b5"
      unitRef="usd">-329000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0xMi0xLTEtNzAwMzQ_9bd40b09-3e4b-4b9a-b5a2-a8307b3057e0"
      unitRef="usd">-630000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0xNC0xLTEtNzAwMzQ_ef4a030b-1633-4eec-8278-e65689f71eca"
      unitRef="usd">-61000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOC0xNi0xLTEtNzAwMzQ_17054029-396a-4362-b61d-ddf51b0a5ba5"
      unitRef="usd">-75000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0yLTEtMS03MDAzNA_62b15c66-7bd9-47eb-b67a-da36a93843d0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS00LTEtMS03MDAzNA_ae7a14c7-b21b-499a-b4df-16c454ca191c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS02LTEtMS03MDAzNA_95f7a596-6d75-4f2a-a3db-3adf353637c4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS04LTEtMS03MDAzNA_f1fea04f-07a3-482b-a003-8407355933f0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0xMC0xLTEtNzAwMzQ_8ef14c5c-510d-43b8-8c4e-bc09d00ad748"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0xMi0xLTEtNzAwMzQ_53d301b6-4354-4e7b-9c54-8921272d0b4b"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0xNC0xLTEtNzAwMzQ_cd281b03-f02b-4b2b-80ed-88582b47b2c3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfOS0xNi0xLTEtNzAwMzQ_f71385ae-a180-4e76-b589-af0f21a103a6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMi0xLTEtNzAwMzQ_83c5c4df-54a1-4fb0-9afe-b97c3c9f97f4"
      unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5654886106c447ecae5a5b1a06bf67c6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtNC0xLTEtNzAwMzQ_1154d58a-2284-410a-870d-91a17aedac5e"
      unitRef="usd">144000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i68813d26799a432b89daecc2918201f0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtNi0xLTEtNzAwMzQ_332b7835-57f7-4b01-941b-f59a6a3ec582"
      unitRef="usd">134000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ibe2203779831431fa77f27a48dfc9a4f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtOC0xLTEtNzAwMzQ_dd49a9f9-6796-46b5-b412-4633089a582a"
      unitRef="usd">126000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if187a93253e44c62a4c70185ce8a9c9f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMTAtMS0xLTcwMDM0_106f833f-e949-4a2d-a0fc-097fb2309773"
      unitRef="usd">-55000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="idba8914da7c442a595b6ea0289b85e77_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMTItMS0xLTcwMDM0_e95f4912-8222-4942-8f68-c0f72cf22851"
      unitRef="usd">280000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i98c6a26c3964431798d06c23223c6509_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMTQtMS0xLTcwMDM0_1bd840c3-a826-49fa-b0a6-da8ab116975d"
      unitRef="usd">267000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3f0e7fcabbbc45b88552ca45968c9cd8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RhYmxlOjg2NzU5ZTYxZGRhMzQ2ZDU4MTc3MDAyZmEyZjZlODFhL3RhYmxlcmFuZ2U6ODY3NTllNjFkZGEzNDZkNTgxNzcwMDJmYTJmNmU4MWFfMTAtMTYtMS0xLTcwMDM0_d31e09b0-d046-4bfc-9f4d-cddd44304011"
      unitRef="usd">251000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:PensionContributions
      contextRef="i62384ef644a54697aca04106e3f0437b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RleHRyZWdpb246YjhmNjIzNmExMDNkNGJmZWIwMjhkYjU0MmIwMGVjMjVfNzQy_63a2e72f-a8ce-4da0-ac7f-59da4602a1cc"
      unitRef="usd">54000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="i2fc2f74ef18d4d33b92e9d7d64d48020_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83My9mcmFnOmI4ZjYyMzZhMTAzZDRiZmViMDI4ZGI1NDJiMDBlYzI1L3RleHRyZWdpb246YjhmNjIzNmExMDNkNGJmZWIwMjhkYjU0MmIwMGVjMjVfNzQ5_100dd9cf-3afe-446c-afe1-ec57c35f4676"
      unitRef="usd">10000000</us-gaap:PensionContributions>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RleHRyZWdpb246MzNiMWFiZGQzNTI4NDExM2IwMzUwMTQ4YzExNzBkNmZfOTI0_4fe6e6a1-1c88-4d26-acb1-964695102948">ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RleHRyZWdpb246MzNiMWFiZGQzNTI4NDExM2IwMzUwMTQ4YzExNzBkNmZfOTI2_c8e7a109-5cc5-407e-8120-ca3a432e8b31">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9717a3a8ced548948d10ecbb0f33b8c3_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC0yLTEtMS03MDAzNA_ebe50fe6-699f-41dd-818e-bba73d68f3dc"
      unitRef="usd">-10017000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2601e00af4474b03b245711113cf2975_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC00LTEtMS03MDAzNA_5ecb11a8-e26a-4528-94d4-881fde980270"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18d1e90be3564affb9df03eb62cc401e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC02LTEtMS03MDAzNA_3f7624d9-5863-4f72-bd17-a8c1ce2b027e"
      unitRef="usd">-2702000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a55a77208474cb0a1becbbd53ec82ca_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC04LTEtMS03MDAzNA_4e4ae442-c1ef-431c-9002-b2d28b7501fa"
      unitRef="usd">-336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i116332ccca294d499f773d00109c050b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNC0xMC0xLTEtNzAwMzQ_eb2142fa-f45b-47f9-8dd0-072fd791830a"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS0yLTEtMS03MDAzNA_56077629-3cbd-477b-a485-f514f3e60dcd"
      unitRef="usd">-705000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS00LTEtMS03MDAzNA_e2b49084-a5d8-483b-818a-4bcac5df1757"
      unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS02LTEtMS03MDAzNA_010ae28f-11c8-4d00-9a88-ed3579c78d1e"
      unitRef="usd">-230000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS04LTEtMS03MDAzNA_19de76da-75fb-4a81-a7b5-f9342fb5bc58"
      unitRef="usd">-277000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNS0xMC0xLTEtNzAwMzQ_781059fc-6adf-40ce-90a5-2ab00edcebe1"
      unitRef="usd">-785000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f7f5277eb57456983ec4fe69703fd6a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy0yLTEtMS03MDAzNA_36a85768-38f9-4c56-beb8-16e24b9c3950"
      unitRef="usd">-10722000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f6f63f466324af9a0ba713c475af49a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy00LTEtMS03MDAzNA_7aeef301-1f75-489d-aa0d-de210d2d81f1"
      unitRef="usd">-36000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72370e9d3ef64afc8247235db2a6256a_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy02LTEtMS03MDAzNA_7e65a463-595b-4eaa-8cfa-e1b33bf0a86f"
      unitRef="usd">-2472000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb20df11643a4db4a4501af374b8611c_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy04LTEtMS03MDAzNA_0448e772-7b8c-4042-8deb-4ddaf743aeb8"
      unitRef="usd">-613000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6c44097a42f4c9b8d26741faed5e548_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83Ni9mcmFnOjMzYjFhYmRkMzUyODQxMTNiMDM1MDE0OGMxMTcwZDZmL3RhYmxlOjgyYmFkZTMwNmE2MTRiODhiZGZlYjhmNThmNDkwZGUxL3RhYmxlcmFuZ2U6ODJiYWRlMzA2YTYxNGI4OGJkZmViOGY1OGY0OTBkZTFfNy0xMC0xLTEtNzAwMzQ_ed577aa8-48d1-4a76-8af1-ada5de6e436b"
      unitRef="usd">-13843000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RleHRyZWdpb246YmYxZGY4ZjYzYmU4NDFkZGE2NjU2OTg5ZDZiNjI0ZGVfNjI0_49883bea-b4c3-479c-b3ea-76cf6ec77848">EARNINGS PER SHARE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,669.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The diluted net earnings per share calculation for both the fiscal second quarter ended July&#160;3, 2022 and July&#160;4, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#x2019;s stock. &lt;/span&gt;&lt;/div&gt;The diluted net earnings per share calculation for the fiscal six months ended July&#160;3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#x2019;s stock. The diluted net earnings per share calculation for the fiscal six months ended July&#160;4, 2021 excluded 14&#160;million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RleHRyZWdpb246YmYxZGY4ZjYzYmU4NDFkZGE2NjU2OTg5ZDZiNjI0ZGVfNjEw_e44d57f8-44d8-40c9-872f-d5def580177c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,669.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMi0yLTEtMS03MDAzNA_b7402fbe-0616-49f1-af6b-2e84a6ab757a"
      unitRef="usdPerShare">1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMi00LTEtMS03MDAzNA_b7e8ccf3-286b-4d14-9208-ab0a9148e0f3"
      unitRef="usdPerShare">2.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMi02LTEtMS03MDAzNA_2d0f3f23-71e0-47ab-b5b7-3a8a8012b7e0"
      unitRef="usdPerShare">3.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMi04LTEtMS03MDAzNA_d460e8d9-07e0-4f8f-aab1-5d602aff697a"
      unitRef="usdPerShare">4.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMy0yLTEtMS03MDAzNA_b7986135-9d2e-4f80-af08-5c0115d46b7a"
      unitRef="shares">2629600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMy00LTEtMS03MDAzNA_94864f6c-aadf-4e67-809a-9cfa2e2126bc"
      unitRef="shares">2632500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMy02LTEtMS03MDAzNA_b6799842-1631-4e5c-892d-6d12536219a4"
      unitRef="shares">2629400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfMy04LTEtMS03MDAzNA_060c46e6-4cf7-41b4-b87b-79b8c21bedc3"
      unitRef="shares">2632000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNC0yLTEtMS03MDAzNA_692b9422-961a-484a-bb82-7469dead192c"
      unitRef="shares">143700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNC00LTEtMS03MDAzNA_8d185d25-3e17-4940-b45f-e16deef2f21b"
      unitRef="shares">141900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNC02LTEtMS03MDAzNA_bd34e761-abe1-4be4-9cc5-0ccc77553271"
      unitRef="shares">141800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNC04LTEtMS03MDAzNA_a5637678-232b-47ea-9b40-5cc1fb357a4b"
      unitRef="shares">126000000.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNS0yLTEtMS03MDAzNA_dbfeb1d0-6544-4dbd-b14d-629530bf1472"
      unitRef="shares">105400000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNS00LTEtMS03MDAzNA_ce94c423-4b72-4ad7-b986-bfb9411a2ea3"
      unitRef="shares">102800000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNS02LTEtMS03MDAzNA_d0043884-2d75-4b2c-b2cc-f341b2f41bde"
      unitRef="shares">102000000.0</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNS04LTEtMS03MDAzNA_ba57cb70-18ba-4908-9d5c-0c9e01da04d4"
      unitRef="shares">84000000.0</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNy0yLTEtMS03MDAzNA_1fd56926-8f20-4703-9d5b-e25675bd2797"
      unitRef="shares">2667900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNy00LTEtMS03MDAzNA_b22a1480-4ee2-471b-baec-7c3b8e81b1b9"
      unitRef="shares">2671600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNy02LTEtMS03MDAzNA_4a3f26f1-358b-4329-87d7-49d884125b29"
      unitRef="shares">2669200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfNy04LTEtMS03MDAzNA_c33b217c-bc93-4d51-8f01-dc1fb218e2a0"
      unitRef="shares">2674000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfOC0yLTEtMS03MDAzNA_47597e54-1bc4-45dc-9a30-c57ba2252662"
      unitRef="usdPerShare">1.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfOC00LTEtMS03MDAzNA_d0c20065-2904-4e12-8ce2-ffd967f0383b"
      unitRef="usdPerShare">2.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfOC02LTEtMS03MDAzNA_1f7e99a6-83a6-4e42-a106-c0263db282eb"
      unitRef="usdPerShare">3.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RhYmxlOjgwOGZkYmJkOGE2YTRkZGU4ZWEwZTI0N2I3Njg0ZmFjL3RhYmxlcmFuZ2U6ODA4ZmRiYmQ4YTZhNGRkZThlYTBlMjQ3Yjc2ODRmYWNfOC04LTEtMS03MDAzNA_64ce6ba9-f542-4d71-9b95-77201cbc5907"
      unitRef="usdPerShare">4.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF83OS9mcmFnOmJmMWRmOGY2M2JlODQxZGRhNjY1Njk4OWQ2YjYyNGRlL3RleHRyZWdpb246YmYxZGY4ZjYzYmU4NDFkZGE2NjU2OTg5ZDZiNjI0ZGVfNDYw_d6c87682-e6eb-4607-a304-b72ed869a064"
      unitRef="shares">14000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjk0Nw_bbe7f905-fd19-4b09-84e5-ea716fd1576b">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA / INVOKAMET&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDTECH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Approximately $0.1&#160;billion in the fiscal second quarter of 2021 and $0.2&#160;billion in the fiscal six months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of  PROCRIT / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Previously referred to as Medical Devices&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*The 2021 fiscal second  quarter and six months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.1 billion in both the fiscal second quarter of 2022 and 2021 and $0.2&#160;billion in both the fiscal six months of 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Litigation expense of $0.1&#160;billion in both the fiscal second quarters and fiscal six months of 2022 and 2021, primarily for talc related costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Divestiture gains of $0.6&#160;billion in the fiscal six months of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal second quarter of 2022 and 2021, respectively. Intangible amortization expense of $1.5&#160;billion and $1.7&#160;billion in the fiscal six months of 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In the fiscal six months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A loss of $0.1&#160;billion and a gain of $0.2&#160;billion related to the change in the fair value of securities in the fiscal second quarter of 2022 and 2021, respectively. A loss of $0.5&#160;billion and a gain of $0.1&#160;billion related to the change in the fair value of securities in the fiscal six months of 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;COVID-19 Vaccine supply network related costs of $0.2&#160;billion in both the fiscal second quarter and fiscal six months 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal second quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Litigation expense of $0.3&#160;billion in both the fiscal second quarters and fiscal six months of 2022 primarily pelvic mesh related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.2 billion and $0.1&#160;billion in the fiscal six months of 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.3&#160;billion in both the fiscal second quarter of 2022 and 2021 and $0.5&#160;billion in both the fiscal six months of 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Amounts not allocated to segments include interest income/expense and general corporate income/expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <jnj:SalesBySegmentOfBusinessTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjk1Nw_c368a7bf-d5e5-4eeb-9621-b062546b5396">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA / INVOKAMET&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDTECH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Approximately $0.1&#160;billion in the fiscal second quarter of 2021 and $0.2&#160;billion in the fiscal six months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of  PROCRIT / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Previously referred to as Medical Devices&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8195ff1841b44360849eba5718e01652_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS0yLTEtMS03MDAzNA_74271dcb-860c-43e5-8c16-1f72c15d6d8e"
      unitRef="usd">663000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaa7ba884545448a83b114bcc5344580_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS00LTEtMS03MDAzNA_5a5f6aa4-bea6-4a3d-bcd3-387b090fc988"
      unitRef="usd">675000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8195ff1841b44360849eba5718e01652_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS02LTEtMS03MDAzNA_f9166383-000b-48b4-8aff-f539c0b4708b"
      unitRef="number">-0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b4ebb79f86444c5878078484251d735_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS04LTEtMS03MDAzNA_f68ed932-7dcd-46f4-85a3-cde9ef39798a"
      unitRef="usd">1333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18e5385aae254b489b7e039a2183a902_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS0xMC0xLTEtNzAwMzQ_7e340061-a667-4681-b118-59be03b2265a"
      unitRef="usd">1274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5b4ebb79f86444c5878078484251d735_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNS0xMi0xLTEtNzAwMzQ_cc00a6f2-b92f-478c-8007-c6f1a539f127"
      unitRef="number">0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bbf0047aef3405eb9f261a53967efb1_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi0yLTEtMS03MDAzNA_4892f887-8022-479f-aa42-3f07deb7c0aa"
      unitRef="usd">818000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie26d715418394045bf2d275669c0c2d5_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi00LTEtMS03MDAzNA_ae7fb71e-53d8-447d-a8a2-dce56cea69e4"
      unitRef="usd">752000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3bbf0047aef3405eb9f261a53967efb1_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi02LTEtMS03MDAzNA_84b596be-79a5-4b55-a061-5b11a70b2986"
      unitRef="number">0.088</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fc6d07570ff45a8a24f52ea1dae3e62_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi04LTEtMS03MDAzNA_437cac75-25bd-470e-90bd-c44a912517fe"
      unitRef="usd">1609000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ee1eec7950c4ef78e937d2c4e3298f8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi0xMC0xLTEtNzAwMzQ_b130f33c-de46-42dc-8141-74bc904cd2fd"
      unitRef="usd">1425000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7fc6d07570ff45a8a24f52ea1dae3e62_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNi0xMi0xLTEtNzAwMzQ_e90b521f-074f-4d0f-9bf5-af69f7e62afb"
      unitRef="number">0.129</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38e9c8dc44154c0889a38ce4ae1cfdee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy0yLTEtMS03MDAzNA_f6e98e6e-c264-4f52-b0b1-4ca1b3656477"
      unitRef="usd">1482000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25b746d1f6934a38b36cc2f177fd06bb_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy00LTEtMS03MDAzNA_894ed995-f13d-4dd8-a6de-2aba56f1543b"
      unitRef="usd">1426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i38e9c8dc44154c0889a38ce4ae1cfdee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy02LTEtMS03MDAzNA_2fc94d43-7dac-4f63-af74-9e3e0e977528"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96ab60eec1f141039a0d797a3f451481_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy04LTEtMS03MDAzNA_a9939ced-246a-4d5f-b5d0-ce3b08d83e82"
      unitRef="usd">2943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id334e2622b5a43608b68569880f13d0a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy0xMC0xLTEtNzAwMzQ_4f160fe7-91ca-4c08-a6f5-69800c81f3c7"
      unitRef="usd">2699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i96ab60eec1f141039a0d797a3f451481_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNy0xMi0xLTEtNzAwMzQ_951dd4a6-bc7b-4653-991d-8ed776ae7343"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71c500211bc040d4855e6035ad051bf5_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS0yLTEtMS03MDAzNA_175008db-0006-4a75-9406-39596f47fd5b"
      unitRef="usd">629000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib01784d325404849937b0a9daeb1c938_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS00LTEtMS03MDAzNA_7c9a83e3-35b6-4fb1-9dd4-6ee561ac5f30"
      unitRef="usd">659000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i71c500211bc040d4855e6035ad051bf5_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS02LTEtMS03MDAzNA_adff0f4c-713a-42a5-9116-8d1f199ac6ae"
      unitRef="number">-0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb2ebe5ae60c49b0a9fff97883e882ed_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS04LTEtMS03MDAzNA_8f4934fb-556a-4771-8f31-36a53d4cd420"
      unitRef="usd">1173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b6d906d8c3b44108349d0c7ae0c91ca_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS0xMC0xLTEtNzAwMzQ_bd53dba4-6746-454e-8946-4a2ef6b97f6f"
      unitRef="usd">1293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icb2ebe5ae60c49b0a9fff97883e882ed_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOS0xMi0xLTEtNzAwMzQ_0e931898-5a0a-48c3-aead-43f5397fe733"
      unitRef="number">-0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0621cbfb3ca24c87b649251bb892364a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtMi0xLTEtNzAwMzQ_ca809938-7668-421f-b415-98159d5583f3"
      unitRef="usd">497000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if398f47ba6cc4d43b6d90c700176240d_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtNC0xLTEtNzAwMzQ_456caa29-c44e-4aa5-a6c9-2b7e63189072"
      unitRef="usd">511000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0621cbfb3ca24c87b649251bb892364a_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtNi0xLTEtNzAwMzQ_74d9c592-70b5-45da-a368-2f2122ab5889"
      unitRef="number">-0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33319c8b0e2844c1a78f06bc06b7301c_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtOC0xLTEtNzAwMzQ_b7708471-80cd-413e-b1f9-5b14181cf38d"
      unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib13a2d7df3c942ba9306523693e96af2_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtMTAtMS0xLTcwMDM0_e9f65638-2a9e-4bda-a784-acd78d157765"
      unitRef="usd">1040000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i33319c8b0e2844c1a78f06bc06b7301c_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAtMTItMS0xLTcwMDM0_91df2366-02e8-4e95-b9f8-b9bb0dfff128"
      unitRef="number">-0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaddb3c97163a44a0a32251c19d5d0ff7_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtMi0xLTEtNzAwMzQ_1f5039b4-ec8b-4d9c-b281-a51ca01d8881"
      unitRef="usd">1126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b62bea6d6874162b043629fa713ac31_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtNC0xLTEtNzAwMzQ_c5e90971-22b0-4117-8ab0-b13eca56f01d"
      unitRef="usd">1170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaddb3c97163a44a0a32251c19d5d0ff7_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtNi0xLTEtNzAwMzQ_1b3376ec-1c59-445e-8880-0a1758e0543e"
      unitRef="number">-0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68089e150f524c5abad75d4bc0930034_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtOC0xLTEtNzAwMzQ_9df16b39-6fc7-4aec-a847-82024cf8ccef"
      unitRef="usd">2138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9095543594314e21a7ed013540198140_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtMTAtMS0xLTcwMDM0_f90c804f-e031-4aa2-bc24-67bac3afaba0"
      unitRef="usd">2333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i68089e150f524c5abad75d4bc0930034_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEtMTItMS0xLTcwMDM0_cb8974c3-a3c1-4f33-ae90-d73ef2b545d7"
      unitRef="number">-0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if13101093f5447d9bc000921069e8423_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtMi0xLTEtNzAwMzQ_7e436df4-d13f-4144-bdfb-8e980c1ae3f4"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40a4e77c23874d21a2804eff01168460_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtNC0xLTEtNzAwMzQ_2df6050f-2fcc-4f49-8cc2-fd46db283064"
      unitRef="usd">165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if13101093f5447d9bc000921069e8423_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtNi0xLTEtNzAwMzQ_14283857-a09d-4ab0-bd50-8c4f366c5f38"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f309ab7ce9e47f6a93a24b6c21f112f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtOC0xLTEtNzAwMzQ_7a77deee-86fe-4816-9eea-2dda4169a93f"
      unitRef="usd">313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieff5349857aa4a3496da3c8d285390a8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtMTAtMS0xLTcwMDM0_161b4f08-f65f-49bf-8bcc-00ff88a66a15"
      unitRef="usd">328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1f309ab7ce9e47f6a93a24b6c21f112f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMtMTItMS0xLTcwMDM0_3fb0201f-8d28-467c-ae9b-0749539a236a"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d9cb7fd4ddb4911b27d35f071fa8886_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtMi0xLTEtNzAwMzQ_4640b82d-2de9-4936-b495-ade310299089"
      unitRef="usd">224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id09063562e0d4fd3a2f72663c512d14d_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtNC0xLTEtNzAwMzQ_d5def3c1-e5f9-4e07-a2be-b99b7ec4c958"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3d9cb7fd4ddb4911b27d35f071fa8886_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtNi0xLTEtNzAwMzQ_dd1b2734-fe10-4689-81a3-85f47d821446"
      unitRef="number">-0.141</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fd7a688a72f4a6d9787219e5e029a38_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtOC0xLTEtNzAwMzQ_92176407-164d-4b16-9378-f9ab0d7b6df3"
      unitRef="usd">447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5de727b2f6144bfaa64c8a53dedb41bb_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtMTAtMS0xLTcwMDM0_f27e591a-f622-42ce-b5f8-923884eeba77"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5fd7a688a72f4a6d9787219e5e029a38_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQtMTItMS0xLTcwMDM0_571902a0-01ff-41cc-aab4-121cb9594043"
      unitRef="number">-0.130</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ce860b4fb8441f18fffa07dcef2a31b_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtMi0xLTEtNzAwMzQ_1b598185-c890-4b47-97f0-8dec526d8c8a"
      unitRef="usd">394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaed64e30f1e54509a52b4ad3abd15f77_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtNC0xLTEtNzAwMzQ_063137ee-a2f6-4448-aa9a-baa10de6a5f5"
      unitRef="usd">426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7ce860b4fb8441f18fffa07dcef2a31b_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtNi0xLTEtNzAwMzQ_909d14b6-2e71-4b77-a849-43f34c318118"
      unitRef="number">-0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53177aeb7e124a05bf7af2cd65156f97_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtOC0xLTEtNzAwMzQ_74114812-be3b-4bd2-a0d3-4950b78b8e2b"
      unitRef="usd">760000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c9d35d1483442cdb89d4315ab87c195_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtMTAtMS0xLTcwMDM0_7f56607d-2aaf-4b39-934b-1e1fb126c1d7"
      unitRef="usd">843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i53177aeb7e124a05bf7af2cd65156f97_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUtMTItMS0xLTcwMDM0_da2cfc9a-a9a4-4615-a37c-8bcec4ce462d"
      unitRef="number">-0.097</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ef348574e5b40b5951363c5761b57e0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctMi0xLTEtNzAwMzQ_e92d779a-cc73-4a12-be45-13ed2b10c96a"
      unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i944b4a698ea646128ec4f289fc31f5bb_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctNC0xLTEtNzAwMzQ_8a8d1f99-13bc-459f-a98a-1fe624165d66"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1ef348574e5b40b5951363c5761b57e0_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctNi0xLTEtNzAwMzQ_e2143727-c641-497f-a736-6f925dbf0046"
      unitRef="number">-0.091</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5876de3f5bd4a6fafa27ffe0d10a9da_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctOC0xLTEtNzAwMzQ_70a9ff9d-2853-4bda-93a4-96b41a1ed2ab"
      unitRef="usd">173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if18cce1df7be41d3addfa2391156aebb_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctMTAtMS0xLTcwMDM0_d246bfe6-4f21-4432-a72f-03832de1d24a"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia5876de3f5bd4a6fafa27ffe0d10a9da_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTctMTItMS0xLTcwMDM0_01eb99e8-6da4-4f58-9ca3-c44698d76cb5"
      unitRef="number">-0.103</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f715131df5f4ce38b709e366c8634f8_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtMi0xLTEtNzAwMzQ_dd2b989a-4ca8-4a42-81fd-8fbdc58c7a39"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f9fa20297e84900a134c648c79ed724_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtNC0xLTEtNzAwMzQ_ef54775c-27d1-4033-a059-5b016505a21b"
      unitRef="usd">290000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5f715131df5f4ce38b709e366c8634f8_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtNi0xLTEtNzAwMzQ_3abc1c3e-5227-4fee-a463-5f7b5cd6d019"
      unitRef="number">-0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33a293dc78794b8c84941522d362b2b3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtOC0xLTEtNzAwMzQ_4f52f24d-9606-44cf-a11f-89a4b75893b7"
      unitRef="usd">557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66ed86e0bf67442ab4bdba01c26ab3ef_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtMTAtMS0xLTcwMDM0_8dbf4429-6044-49da-a94d-47abe02fc0a8"
      unitRef="usd">583000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i33a293dc78794b8c84941522d362b2b3_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTgtMTItMS0xLTcwMDM0_41c6b092-b1bf-4171-b02b-6642fa25c686"
      unitRef="number">-0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i102548ebfc714d89b200cb8801eada1d_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktMi0xLTEtNzAwMzQ_18574359-53df-449c-9254-e9c38b01a797"
      unitRef="usd">375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib041fceea7e145b69657ad998b398574_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktNC0xLTEtNzAwMzQ_f4b79811-ccff-4f07-9902-f705382eb0b6"
      unitRef="usd">387000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i102548ebfc714d89b200cb8801eada1d_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktNi0xLTEtNzAwMzQ_16d7f77b-e1f5-4247-8b83-ab5a47297d29"
      unitRef="number">-0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a72fab377cd41989bd7cb664b052786_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktOC0xLTEtNzAwMzQ_ab586870-a881-4d63-a6e2-0568381f8d32"
      unitRef="usd">730000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b7718b305fa4e98af05f13ccd09b117_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktMTAtMS0xLTcwMDM0_fd69b998-af81-463e-b548-2446cb11e8bf"
      unitRef="usd">776000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a72fab377cd41989bd7cb664b052786_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTktMTItMS0xLTcwMDM0_7d07c52c-7069-43ce-9ae0-479b774ce2b4"
      unitRef="number">-0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6651ef9c1ac4edbb8cf6a115bf220cc_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtMi0xLTEtNzAwMzQ_1971be6d-50bb-4c1c-9287-af314cb2a866"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ed1bfe39b4e4bb5bba8bbdce7bdaa1e_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtNC0xLTEtNzAwMzQ_9365ba74-4c24-4382-a2c8-b4b567e03325"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id6651ef9c1ac4edbb8cf6a115bf220cc_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtNi0xLTEtNzAwMzQ_666c4cc2-0066-4a19-9b55-beebaa0377b1"
      unitRef="number">0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie744fe7eb10840b59f191d4ebfb373d8_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtOC0xLTEtNzAwMzQ_0284490f-9b28-48cb-b193-052239988dac"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43d92d32a1fb4d1fa4667d39d0165593_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtMTAtMS0xLTcwMDM0_a44c01ca-b9df-48f1-8fd1-877e9e14d2e7"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie744fe7eb10840b59f191d4ebfb373d8_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEtMTItMS0xLTcwMDM0_fc91b045-bcf0-4023-8c36-1bb5eafe83fc"
      unitRef="number">0.081</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67c37007b3dc425b849156d2b344eb7e_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItMi0xLTEtNzAwMzQ_ead8c018-d3bb-4156-814a-3f41c76dc8a9"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88e018caf3a44821b6b23d3804a73e3f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItNC0xLTEtNzAwMzQ_2aae79a3-c0e2-423c-9084-f3e092ece376"
      unitRef="usd">227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67c37007b3dc425b849156d2b344eb7e_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItNi0xLTEtNzAwMzQ_284764ff-0e18-4306-a0ac-9a5a10f7bb72"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bd7be7ef01a442ea8668894c4d382fa_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItOC0xLTEtNzAwMzQ_50532cc4-236c-43db-8a4b-846141f5c4d6"
      unitRef="usd">452000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b1d7a7b9b2a4248887b77dba76f601f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItMTAtMS0xLTcwMDM0_0246e4c1-e73f-4795-a759-c17667eaaccf"
      unitRef="usd">446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6bd7be7ef01a442ea8668894c4d382fa_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjItMTItMS0xLTcwMDM0_6293211a-f25b-410b-a3a6-26412b25c6bd"
      unitRef="number">0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0e407cd47704992a0317255189675b7_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtMi0xLTEtNzAwMzQ_905ac722-afd5-432b-822a-2a9a6c1df5c9"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib867ef751de5492fa15d45f7bf794438_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtNC0xLTEtNzAwMzQ_b88cba75-24ab-449b-9c99-da5a7c7c9729"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if0e407cd47704992a0317255189675b7_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtNi0xLTEtNzAwMzQ_8a4aa3b7-d7e1-42c2-b989-4e7f7e94e30d"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibeb71611308d4b42a6e9f2cd42a75c82_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtOC0xLTEtNzAwMzQ_c112d881-30a2-48df-b01c-b93bc3a1b431"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i693bf3820634476c859b68b815574d1d_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtMTAtMS0xLTcwMDM0_88225e1a-7cb5-47f6-b3a1-2b707d054e90"
      unitRef="usd">452000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibeb71611308d4b42a6e9f2cd42a75c82_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMtMTItMS0xLTcwMDM0_d7ef201b-578b-46b6-80fb-9df8d4379825"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78dde3c6195f4c578643c83727dcad04_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtMi0xLTEtNzAwMzQ_cc0b66ec-9900-4582-b068-6e597457cf87"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eb0aaffa7084f09810c1685730156ed_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtNC0xLTEtNzAwMzQ_ec0c5760-bd5a-48f8-9ceb-110df81216ce"
      unitRef="usd">153000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i78dde3c6195f4c578643c83727dcad04_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtNi0xLTEtNzAwMzQ_0e4d1902-266e-4b02-b65c-1d066659c241"
      unitRef="number">-0.127</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id10a3f80fd7e44589ec7f14f0a2f9fe8_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtOC0xLTEtNzAwMzQ_b02c9da5-e76e-414c-9a10-10ad9d812a71"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cccfe83ac064549a7486973cb800b07_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtMTAtMS0xLTcwMDM0_dc388f83-87dc-4a51-acff-83510a1610dc"
      unitRef="usd">268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id10a3f80fd7e44589ec7f14f0a2f9fe8_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjUtMTItMS0xLTcwMDM0_0e885314-3f76-4f40-af63-19642c4e2f62"
      unitRef="number">-0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e1f5924669f4a169c42aa764613999a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtMi0xLTEtNzAwMzQ_313f2d4e-1b02-4cb4-bde0-9f1249d95514"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie81ccc7cb7a9415a99c7f89e84017979_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtNC0xLTEtNzAwMzQ_9a687e8d-6419-40a4-b158-6fbf7e0e1ce7"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8e1f5924669f4a169c42aa764613999a_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtNi0xLTEtNzAwMzQ_80941b2f-6b37-4bad-b2de-63c358a860dc"
      unitRef="number">0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0812d79d0004274855fe19590ad7dd0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtOC0xLTEtNzAwMzQ_238593e0-5f70-4676-ada4-964c57a827f3"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8781a8fbd8814cff8dcfd139cc582995_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtMTAtMS0xLTcwMDM0_6d104904-60cc-49ac-8770-28fb0cf10ca2"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id0812d79d0004274855fe19590ad7dd0_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjYtMTItMS0xLTcwMDM0_e5f0688b-a1a0-4911-9609-886064dc0fff"
      unitRef="number">-0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ffbd0973fa444c9b15cf063be1c3066_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctMi0xLTEtNzAwMzQ_c8a29e37-ef97-4aaa-bef6-f3345d276904"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6d698eee9664f599005ef75c6f73674_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctNC0xLTEtNzAwMzQ_ab0dbc49-f5b4-4fb4-946f-cdeda343cfb3"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1ffbd0973fa444c9b15cf063be1c3066_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctNi0xLTEtNzAwMzQ_1f57c027-515c-4292-999a-55f1f032e703"
      unitRef="number">-0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fee31f1267449d6b660c897312001ae_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctOC0xLTEtNzAwMzQ_660ccd99-5332-4e0d-ba13-b4ca009b0c5a"
      unitRef="usd">361000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7192a0ac28bf4f76aa87147c2805f776_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctMTAtMS0xLTcwMDM0_85ba9484-7eab-4d21-9e63-a2319b7d8df1"
      unitRef="usd">393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2fee31f1267449d6b660c897312001ae_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjctMTItMS0xLTcwMDM0_214dd1f3-b270-469d-a83a-db1ef8066e4a"
      unitRef="number">-0.080</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f670f752605441cb46a46a85c79ecf2_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktMi0xLTEtNzAwMzQ_b987801d-fd76-4c52-b22f-5affdf2154e6"
      unitRef="usd">1687000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i658570b4166140dfadfbeea24c17c0db_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktNC0xLTEtNzAwMzQ_5a7d0b46-e2fa-4a32-9646-4d899158731a"
      unitRef="usd">1751000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7f670f752605441cb46a46a85c79ecf2_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktNi0xLTEtNzAwMzQ_342610ce-4858-42f8-8dd9-f199d869b71f"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f83165908d14fcdb9fa9d202e01a201_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktOC0xLTEtNzAwMzQ_d7dc489f-9c58-4dc6-8f25-93df3c3d58f0"
      unitRef="usd">3244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74eb8c72df8240e79e32ce252be20ff1_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktMTAtMS0xLTcwMDM0_2fe45638-9c93-44fa-aa3b-0dcd20c1a34c"
      unitRef="usd">3362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6f83165908d14fcdb9fa9d202e01a201_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjktMTItMS0xLTcwMDM0_6e639f9b-0c9b-4a3e-b642-4e090f25d7e8"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03ea4eb5ba9a4f1c803077ceebb44e5f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtMi0xLTEtNzAwMzQ_e903c996-562c-4590-863d-67924bb263fa"
      unitRef="usd">2118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie50ce2e3f0464c71a9c5b8e469a9fa78_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtNC0xLTEtNzAwMzQ_f9101b63-b2c0-48d0-99b6-f7b34cc48e9c"
      unitRef="usd">2103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i03ea4eb5ba9a4f1c803077ceebb44e5f_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtNi0xLTEtNzAwMzQ_239f96c6-d137-452e-b999-fa22460ab156"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c19f4191b1d426ba5408a30686ae901_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtOC0xLTEtNzAwMzQ_b7e87a24-939b-43ae-9ac3-ba7f7e6c35a9"
      unitRef="usd">4147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaf51f604ce94696a0c9e9f86c80dcbe_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtMTAtMS0xLTcwMDM0_f084fe8d-1763-4ba8-8733-f16107cd4a0e"
      unitRef="usd">4133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c19f4191b1d426ba5408a30686ae901_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzAtMTItMS0xLTcwMDM0_a2d329c3-548b-4a41-ac7e-cac10ca63fae"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i228867d760f145b882a88a1d618a76f8_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtMi0xLTEtNzAwMzQ_ffe2f892-497c-4c84-9448-935fb1c1085a"
      unitRef="usd">3805000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecaa039dee6d486891f8d14610b01fbe_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtNC0xLTEtNzAwMzQ_ec78ded2-8c33-4293-9d56-b8ff3c4d14a4"
      unitRef="usd">3854000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i228867d760f145b882a88a1d618a76f8_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtNi0xLTEtNzAwMzQ_831292d8-648d-416c-9979-adc8604f9db2"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bc23407245a4376af9e0430687579f6_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtOC0xLTEtNzAwMzQ_884c7919-5968-4910-9562-1fc66a8f5c09"
      unitRef="usd">7391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e3c97cc494f4d5bafd40b0e6898cdc8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtMTAtMS0xLTcwMDM0_6ee4bd2d-2aed-4523-b1b7-7dd78d863338"
      unitRef="usd">7495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3bc23407245a4376af9e0430687579f6_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzEtMTItMS0xLTcwMDM0_7fc96131-4fb1-4b55-a87a-909d5dd73ba8"
      unitRef="number">-0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04a8138535574b2f8dd29e2d2ab984bc_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtMi0xLTEtNzAwMzQ_7d272322-e3c0-485d-976a-f6f5a2855af1"
      unitRef="usd">2853000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i435910ace8fa4896a65a5f676869084d_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtNC0xLTEtNzAwMzQ_2d2cbac0-a751-432e-94e8-12ed3b09fc20"
      unitRef="usd">2748000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i04a8138535574b2f8dd29e2d2ab984bc_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtNi0xLTEtNzAwMzQ_db4bbeee-56d6-4a2a-8346-7b670f1f13bc"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf527b43e5c64384a1fe49225cbe7797_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtOC0xLTEtNzAwMzQ_df764553-1186-4bfc-b5fa-5f8e995c5958"
      unitRef="usd">5354000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1f36da8c5bd4d708ddc21a066e32df1_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtMTAtMS0xLTcwMDM0_d891e270-71eb-4c29-8f2b-da3c791a71de"
      unitRef="usd">5161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibf527b43e5c64384a1fe49225cbe7797_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzYtMTItMS0xLTcwMDM0_53fcfe19-0d10-4629-a0ae-04999f49c226"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i429afaa0d03d45ef928c1df6565d72ea_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctMi0xLTEtNzAwMzQ_08afe25b-b247-4b47-8506-088f832bc877"
      unitRef="usd">1559000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84783ba4704e45429e147e9d5dc289ac_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctNC0xLTEtNzAwMzQ_9f8b683d-109f-47ed-8400-224ce6e11f72"
      unitRef="usd">1483000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i429afaa0d03d45ef928c1df6565d72ea_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctNi0xLTEtNzAwMzQ_37005e3c-e9c5-40cc-b347-926aecd936b2"
      unitRef="number">0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie96db2fb32064dcc955371ae075882e9_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctOC0xLTEtNzAwMzQ_ea4d236d-4966-45e4-a7a9-f79c37b0b469"
      unitRef="usd">3176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i901108f0a04f4af892226bc6740b5bfa_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctMTAtMS0xLTcwMDM0_d4e42dea-b6f3-4a0a-b298-ca6fc0c8ae79"
      unitRef="usd">2984000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie96db2fb32064dcc955371ae075882e9_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzctMTItMS0xLTcwMDM0_1b72cdfb-cf9e-4d92-a723-639c366d9701"
      unitRef="number">0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7f056f7919a4853bb535aacc4a0cf01_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtMi0xLTEtNzAwMzQ_203aa6d6-dbb7-44f4-8a1a-32f2136a3380"
      unitRef="usd">4411000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8be3651fc9014dafa9dde9d16bfb5921_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtNC0xLTEtNzAwMzQ_0bf7f892-da2c-4cf0-9ea7-50009c3c63cd"
      unitRef="usd">4231000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id7f056f7919a4853bb535aacc4a0cf01_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtNi0xLTEtNzAwMzQ_ad196712-d14f-4c02-bac1-de37f78334cf"
      unitRef="number">0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1cd05eff2ba4e3a9580f155f072c389_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtOC0xLTEtNzAwMzQ_ca0e676b-4d2f-408c-bf7c-390fbdf2b154"
      unitRef="usd">8530000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72b5f1820f5c48d2af430c445889e0c3_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtMTAtMS0xLTcwMDM0_f99b9cfb-d572-4101-a067-0c68674c70f3"
      unitRef="usd">8145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic1cd05eff2ba4e3a9580f155f072c389_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMzgtMTItMS0xLTcwMDM0_ad181669-c89f-4cbf-b8df-05acd548ac6a"
      unitRef="number">0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8848b6a4264e499ea3824a825f707e78_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtMi0xLTEtNzAwMzQ_25aa3ac6-fae3-49af-aa1d-702280391350"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia486efb8fecc4fc8934c3d17358c54d9_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtNC0xLTEtNzAwMzQ_ade9f9a6-50a0-4cd5-b534-38ede73a74f5"
      unitRef="usd">540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8848b6a4264e499ea3824a825f707e78_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtNi0xLTEtNzAwMzQ_32faf980-30d4-4711-bb33-3b3981108d93"
      unitRef="number">-0.274</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2010cbe9958f446584500182486f8c58_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtOC0xLTEtNzAwMzQ_25975009-ff1b-43dc-ad5b-da94252628b4"
      unitRef="usd">749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d43b5d1458c418aace6f6915a81d82b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtMTAtMS0xLTcwMDM0_b6899180-f868-437f-88fd-c7dfeffc4170"
      unitRef="usd">1029000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2010cbe9958f446584500182486f8c58_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDAtMTItMS0xLTcwMDM0_a9092820-7dfc-4169-8aeb-d4e814f6c329"
      unitRef="number">-0.271</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66216b2932674442903d1b7f700d5d93_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtMi0xLTEtNzAwMzQ_9926f1d2-ba91-45c0-b81d-aa5d777716dd"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22058af4a4044d0083e435a04e70cdc7_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtNC0xLTEtNzAwMzQ_aa287dad-672a-436c-b72e-c77e73c2003a"
      unitRef="usd">93000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i66216b2932674442903d1b7f700d5d93_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtNi0xLTEtNzAwMzQ_23518406-03be-4bc8-924d-254a2339bf1f"
      unitRef="number">-0.530</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icce6642f7a9645f58eeecaec17c3aaf3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtOC0xLTEtNzAwMzQ_4bf14cec-22f1-4681-ba34-df4c68c63040"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaca44e36bd354228bdceed07ebdda5c4_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtMTAtMS0xLTcwMDM0_155796b4-5032-41be-90a2-d27160761f47"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icce6642f7a9645f58eeecaec17c3aaf3_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDEtMTItMS0xLTcwMDM0_aea376d5-e744-467c-97f3-5c4b2c4e23d5"
      unitRef="number">-0.175</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8375cf3203764f32b355e4b3f1eed776_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItMi0xLTEtNzAwMzQ_fad172e0-4975-47bb-9d35-ea817652914f"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87013a0ff92c4beea595abb9a8da5946_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItNC0xLTEtNzAwMzQ_059ccc70-3658-401c-a14b-aa47bcdd811c"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8375cf3203764f32b355e4b3f1eed776_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItNi0xLTEtNzAwMzQ_050b23aa-23b7-4d3c-98f6-47b146b7870b"
      unitRef="number">-0.172</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b1b43f5e37d4e2abc94f7b4529f8f9b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItOC0xLTEtNzAwMzQ_a6b751e2-5a81-474f-b652-cdf9a2dfa77a"
      unitRef="usd">437000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic461d711f25c43cea2c56556fcad7ede_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItMTAtMS0xLTcwMDM0_dbc16279-56e6-4a83-814b-8aaefb29bc75"
      unitRef="usd">487000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2b1b43f5e37d4e2abc94f7b4529f8f9b_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDItMTItMS0xLTcwMDM0_a866e3c8-02a2-44bb-a486-f25e9a0520d4"
      unitRef="number">-0.103</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54580f240f0f45e792175de738dd614b_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtMi0xLTEtNzAwMzQ_38e61f03-9173-48d7-913e-4028b6338eef"
      unitRef="usd">647000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbfafce4ceb2468f82b2f231481f3145_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtNC0xLTEtNzAwMzQ_308b168f-ed4f-47fd-9644-b0ed2f698da6"
      unitRef="usd">888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i54580f240f0f45e792175de738dd614b_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtNi0xLTEtNzAwMzQ_ee0fb5d5-b05d-4cb8-b5f5-f8cbf68495b5"
      unitRef="number">-0.272</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibff5db7fcd89445889265894b5fcd908_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtOC0xLTEtNzAwMzQ_5f500432-428d-40c3-ac95-2331077ad12a"
      unitRef="usd">1310000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9bd678a6f6b45f49f1ad8f99d6732f4_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtMTAtMS0xLTcwMDM0_3bda3df0-afe1-448e-9326-315688c63819"
      unitRef="usd">1665000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibff5db7fcd89445889265894b5fcd908_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDMtMTItMS0xLTcwMDM0_6f56ba7a-0310-4cca-83f9-052f4b241981"
      unitRef="number">-0.214</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica430109af49463a9ccc4038a1739ff0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtMi0xLTEtNzAwMzQ_cef79a3c-70a9-48fe-872b-7ad328886605"
      unitRef="usd">301000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie308e8e3be304525870ea855ce38d851_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtNC0xLTEtNzAwMzQ_77f2802a-5e52-426d-b32e-fe5066ffcbec"
      unitRef="usd">290000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ica430109af49463a9ccc4038a1739ff0_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtNi0xLTEtNzAwMzQ_6dc4b770-106b-4a46-8614-5cd614050438"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i119135a7bf4e4b77a3ab7bdd5088eaaa_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtOC0xLTEtNzAwMzQ_891b607b-5f60-4928-b181-3da74bc4601c"
      unitRef="usd">588000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79cb5dafd17f46df9670ff1449263941_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtMTAtMS0xLTcwMDM0_a57611fa-9cfa-443c-a97a-4b8a54ee5c0b"
      unitRef="usd">545000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i119135a7bf4e4b77a3ab7bdd5088eaaa_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDUtMTItMS0xLTcwMDM0_6aabf8bc-c91b-458d-916c-d301b647478e"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7278c069afed4a878b544df06a8f6fa6_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtMi0xLTEtNzAwMzQ_9286c94b-81a1-4878-a308-976b36bade10"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68d3d93e645c47b28b4e7046d008ba26_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtNC0xLTEtNzAwMzQ_f2310387-002b-49bd-9660-87a7db04818d"
      unitRef="usd">294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7278c069afed4a878b544df06a8f6fa6_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtNi0xLTEtNzAwMzQ_2423d190-09aa-4cb1-a00f-8def1562fe07"
      unitRef="number">-0.097</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i856a0c7b52a545e79ff3fe227f8b6e96_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtOC0xLTEtNzAwMzQ_7c586b9c-82fd-4313-b63f-858258e0b5a3"
      unitRef="usd">549000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia11c3e051f3640f48ab85ea94a59bcf9_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtMTAtMS0xLTcwMDM0_9c55fb94-d438-4b1f-a1f7-614c72a01791"
      unitRef="usd">601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i856a0c7b52a545e79ff3fe227f8b6e96_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDYtMTItMS0xLTcwMDM0_6b4bf84c-99bb-4d8d-ab18-ab548928d6b0"
      unitRef="number">-0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88e9ebb6fa3f46c0958ce4ca2ba73452_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctMi0xLTEtNzAwMzQ_a7c3b2fa-519b-407d-a877-9b9b40e8b294"
      unitRef="usd">566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24f6d9bd9cfe420eb311754a66cd6704_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctNC0xLTEtNzAwMzQ_65a31b20-dd16-4992-b7b0-32d4a2f5474e"
      unitRef="usd">584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i88e9ebb6fa3f46c0958ce4ca2ba73452_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctNi0xLTEtNzAwMzQ_92de160a-b00f-4c62-9da8-efbb2845717b"
      unitRef="number">-0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e7322aee8f94298875960a274d7d725_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctOC0xLTEtNzAwMzQ_8b4dc59f-24ef-477a-963c-56cd447d5671"
      unitRef="usd">1137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19a11268216c41a0b8530633effddd01_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctMTAtMS0xLTcwMDM0_f8ce1c33-2721-4582-be40-53d0f2ed5a8a"
      unitRef="usd">1146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3e7322aee8f94298875960a274d7d725_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDctMTItMS0xLTcwMDM0_7ae29ed0-310d-42a3-8a4a-7d5d71e0bf56"
      unitRef="number">-0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieeec2de848b7400c8f1cbd655a32fef5_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktMi0xLTEtNzAwMzQ_73eb8d23-af97-4c33-b35f-3033291293ed"
      unitRef="usd">1731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1f3484c640948dcb33be80e3ab6ce4a_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktNC0xLTEtNzAwMzQ_1f185655-1d44-4571-8092-ca8ff15583d9"
      unitRef="usd">1496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieeec2de848b7400c8f1cbd655a32fef5_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktNi0xLTEtNzAwMzQ_1a0bc19e-8ba2-4ab7-8d8c-1368d578d322"
      unitRef="number">0.157</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5608e9bbae904b85a2dc6cfcb6fb8128_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktOC0xLTEtNzAwMzQ_1637c8fb-3bbe-497d-8fe1-f875fb0f4805"
      unitRef="usd">3110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3768e1c0c0144fe18b8421760ec7e5e9_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktMTAtMS0xLTcwMDM0_c3d03443-4bce-43cb-8b0b-0442517ac263"
      unitRef="usd">2827000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5608e9bbae904b85a2dc6cfcb6fb8128_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNDktMTItMS0xLTcwMDM0_bc2f9dbc-5cc9-4dd1-a8bc-55ba191ff6d6"
      unitRef="number">0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b39afcb128845be8ace8181351523cc_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtMi0xLTEtNzAwMzQ_57bdec56-a720-47cf-aeaa-12a710a3487c"
      unitRef="usd">868000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c0e26bb5d8c4e45980858e3929c5f05_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtNC0xLTEtNzAwMzQ_f3ed8173-66a4-4391-a905-442d3afc10fb"
      unitRef="usd">778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3b39afcb128845be8ace8181351523cc_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtNi0xLTEtNzAwMzQ_c0b2260b-c9f2-4956-8f7a-ce3c08b03aeb"
      unitRef="number">0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idee6054821eb402795176964928243a9_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtOC0xLTEtNzAwMzQ_96b91247-d88c-4a2d-a505-045a9b8dd35a"
      unitRef="usd">1777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i496bda2ebfc045e592996bab0207f6cb_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtMTAtMS0xLTcwMDM0_8cc57273-c6f2-4c26-bcb5-fc7b831243d8"
      unitRef="usd">1595000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idee6054821eb402795176964928243a9_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTAtMTItMS0xLTcwMDM0_897c0a30-01c8-4144-88f3-b8b618864e45"
      unitRef="number">0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb85facac1f24b5493bbfd6b7352b778_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtMi0xLTEtNzAwMzQ_4d593524-b01c-4321-8fcd-08292e20ae4c"
      unitRef="usd">2599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i813a1577af2d4a23a4349732e1febc84_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtNC0xLTEtNzAwMzQ_6f463065-ee4b-4fb4-b6bf-b43106802d22"
      unitRef="usd">2274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icb85facac1f24b5493bbfd6b7352b778_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtNi0xLTEtNzAwMzQ_05a3717e-64ae-406f-9655-b64b542ea6ff"
      unitRef="number">0.143</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a68313ab7b046478534719e89e2face_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtOC0xLTEtNzAwMzQ_c9e65e33-56d4-41e7-ae14-524ff364cfe6"
      unitRef="usd">4887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f537f91aebd4a4286209578f7c5aa71_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtMTAtMS0xLTcwMDM0_918e61a2-a024-45e4-9ea8-df4e3c32ce43"
      unitRef="usd">4422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2a68313ab7b046478534719e89e2face_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTEtMTItMS0xLTcwMDM0_529f5697-bf5e-496a-869b-48cdb3488a1c"
      unitRef="number">0.105</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2caa599d7e6c46479b011171a2725a0f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtMi0xLTEtNzAwMzQ_9cdb5641-a328-4514-8981-a4c7b5f3ec57"
      unitRef="usd">382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cf7e16d1d0a41ecae80c957ca6cf057_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtNC0xLTEtNzAwMzQ_92253eef-447d-4963-92b5-38a84db8f2e2"
      unitRef="usd">325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2caa599d7e6c46479b011171a2725a0f_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtNi0xLTEtNzAwMzQ_35bf4740-28df-4cf0-a0de-f63887e1a687"
      unitRef="number">0.177</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e94b02a54bf4dccb3fed8ad8526a6b3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtOC0xLTEtNzAwMzQ_07c59eef-a1df-483c-9290-574a7fa613fd"
      unitRef="usd">773000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8485fb4ed0e431fa60a21304c9940de_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtMTAtMS0xLTcwMDM0_fdd43a45-79bd-490a-b12b-37048c0410ca"
      unitRef="usd">599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9e94b02a54bf4dccb3fed8ad8526a6b3_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTMtMTItMS0xLTcwMDM0_c730777a-3f37-4b05-ba1e-f967ca3388bc"
      unitRef="number">0.291</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4212c615c9141e8b1d901365e40d779_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtMi0xLTEtNzAwMzQ_ce3b16cc-8c82-4984-bf8b-8d86169dabaf"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d619e3e7e91444ea79bc47ca3e226eb_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtNC0xLTEtNzAwMzQ_65adf08c-269d-45a7-a5a6-e65cb7a07be3"
      unitRef="usd">155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib4212c615c9141e8b1d901365e40d779_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtNi0xLTEtNzAwMzQ_ef27fd85-bd4c-42d8-a9a0-582b3ee5bd08"
      unitRef="number">0.383</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i644925d4826546d3be77503d471f03f9_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtOC0xLTEtNzAwMzQ_c94dc07e-acea-4789-86b7-7e10989bc49c"
      unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0383c0ed08a340a0a7e28475880e66ff_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtMTAtMS0xLTcwMDM0_4919b01a-9cb6-45ec-8136-baf0f767738b"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i644925d4826546d3be77503d471f03f9_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTQtMTItMS0xLTcwMDM0_6c6b9f6a-da9a-4ec0-8b80-86feb224aaed"
      unitRef="number">0.386</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic37e987627024b6a9dc1bc0795ad8ce3_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtMi0xLTEtNzAwMzQ_09f356ab-9201-4e55-8e53-c25a41a67a91"
      unitRef="usd">597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7fd69b06f674ad1abfb09825949a8f1_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtNC0xLTEtNzAwMzQ_cc9621ad-6ef9-4c80-a298-265ff6d76d99"
      unitRef="usd">479000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic37e987627024b6a9dc1bc0795ad8ce3_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtNi0xLTEtNzAwMzQ_85619157-4f1a-414c-9e53-5c99b2cedf94"
      unitRef="number">0.244</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b5fc362f083407ebc59e3ab3a9ba67f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtOC0xLTEtNzAwMzQ_a83f9c1c-00ef-4f98-ab1e-7f2d937c010e"
      unitRef="usd">1187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if57f215e7cc34af3b9e4ed202855fba3_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtMTAtMS0xLTcwMDM0_be909def-e78a-4c70-a3b9-a410eb3e3289"
      unitRef="usd">897000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9b5fc362f083407ebc59e3ab3a9ba67f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTUtMTItMS0xLTcwMDM0_d6bd560e-0fbe-4a93-ac0b-088273796afa"
      unitRef="number">0.323</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22768f5a2f114ce2ab20531d2853362f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctMi0xLTEtNzAwMzQ_ef5b7852-1e36-46cc-a7be-adbcce3773ef"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a0d44953e7140198cf5743c8f9bf9fd_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctNC0xLTEtNzAwMzQ_df5e389b-83e0-4551-8460-997c112b5f49"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i22768f5a2f114ce2ab20531d2853362f_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctNi0xLTEtNzAwMzQ_513aae0c-be48-4a00-93a1-8677d81537f6"
      unitRef="number">-0.501</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia648fc74bae7454781dfef132266663b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctOC0xLTEtNzAwMzQ_16190937-8eb0-4e1f-a6c8-1b96ab7d6207"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9df360f1333340c7b4588969e82c2f00_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctMTAtMS0xLTcwMDM0_56d62581-50f2-40f3-af0c-6b284f4ab2e5"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia648fc74bae7454781dfef132266663b_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTctMTItMS0xLTc1MzIw_f13f3d66-e5e1-4917-b812-177cb9fa5956"
      unitRef="number">-0.248</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i889a1f92c9a540c2bd4c73d5f7491f90_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTgtMi0xLTEtNzAwMzQ_d9fb8b17-f78d-4b84-a5ce-05366e20cc84"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf53305e3b644b48bece17159e61f8bd_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTgtNC0xLTEtNzAwMzQ_25b220d4-37bf-403f-9d62-bbe99302e871"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6a42cf1a5db49bc8a0351e6d0e34b93_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTgtOC0xLTEtNzAwMzQ_827c042f-79a0-45ac-9758-d50fd1213be7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic810c0a48e8743a59ad02500a4aeecdd_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTgtMTAtMS0xLTcwMDM0_f59edabb-d4b8-4225-abbf-34f56d45a71a"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd4edb2f147a48b09eddb23a0c7d5ce7_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktMi0xLTEtNzAwMzQ_864b4a23-e8ac-4046-bc6f-890f401dba1f"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac357a41dcce46b8bac2ce939cdb4918_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktNC0xLTEtNzAwMzQ_5bea384e-9d71-482a-bbb5-ec523a1b6d6d"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icd4edb2f147a48b09eddb23a0c7d5ce7_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktNi0xLTEtNzAwMzQ_9e9c0b59-1fc0-4205-b501-2b4a13fa9f74"
      unitRef="number">-0.592</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9d140cebad34e369cd420d22831ce65_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktOC0xLTEtNzAwMzQ_58d114a1-b158-4bc4-997b-9929e7abee2b"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i254bd81a5b934d1da8ed0bb423ffd265_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktMTAtMS0xLTcwMDM0_b70b6f1f-29d1-4ec1-984b-025b95cfdbbb"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if9d140cebad34e369cd420d22831ce65_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNTktMTItMS0xLTcwMDM0_def109e4-ccfa-4422-836a-0e0057ed2886"
      unitRef="number">-0.390</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82df753eb9a14110a4457fc71fa570ca_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItMi0xLTEtNzAwMzQ_1107d5bd-cdf4-4111-b69c-537a4c5c7e57"
      unitRef="usd">415000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaa982fc8c9040bd9afdbedde483a631_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItNC0xLTEtNzAwMzQ_4aa0f073-40bd-40cf-85db-ebab0e52885d"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i82df753eb9a14110a4457fc71fa570ca_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItNi0xLTEtNzAwMzQ_50103b3a-abbe-461e-8c73-52d7203989eb"
      unitRef="number">-0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b329b805e8241389b4b59c22a25fed0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItOC0xLTEtNzAwMzQ_b6d422f6-e4eb-49c6-a76c-54c43ff941ea"
      unitRef="usd">876000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b5a3356d9fd49bc8b3e5f75cc325bd4_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItMTAtMS0xLTcwMDM0_e8e6b078-9105-416f-a967-321124a14b4a"
      unitRef="usd">956000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2b329b805e8241389b4b59c22a25fed0_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjItMTItMS0xLTcwMDM0_d60d8617-6ec7-40f9-a709-46ca91a9de7b"
      unitRef="number">-0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3ff638816b949f49434427996afdf27_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtMi0xLTEtNzAwMzQ_d5baec73-a514-452d-a85e-f6a50e957be7"
      unitRef="usd">901000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfa077604d394f2e9da2c45c7c1f570d_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtNC0xLTEtNzAwMzQ_20cd9d54-2383-4832-ae73-0291e9c03185"
      unitRef="usd">575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if3ff638816b949f49434427996afdf27_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtNi0xLTEtNzAwMzQ_d1b00554-1d39-4f99-b681-658912633805"
      unitRef="number">0.568</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba42deda339d4571bf02c560ebf58128_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtOC0xLTEtNzAwMzQ_fcf5fbc2-f862-4475-9b99-d7fccc68c329"
      unitRef="usd">1737000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb0c7aecba784a1ba368d125cf5ef87e_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtMTAtMS0xLTcwMDM0_abae49b9-64c8-48b2-8a8e-95fcc810f3de"
      unitRef="usd">1060000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iba42deda339d4571bf02c560ebf58128_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjMtMTItMS0xLTcwMDM0_b5eee91e-0dde-4713-9fc8-8e97e9711b4b"
      unitRef="number">0.639</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecb92120191540b08b3e1547d87f071c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtMi0xLTEtNzAwMzQ_12a7ab5f-3b10-4658-a81d-7de7c495b2fe"
      unitRef="usd">1316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i451bf253d3fe4d909fb3822b81e8b8e7_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtNC0xLTEtNzAwMzQ_71616049-1bd6-479e-843c-f5ce990cb898"
      unitRef="usd">1018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iecb92120191540b08b3e1547d87f071c_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtNi0xLTEtNzAwMzQ_706e4331-c659-4cd3-b3fd-d6c585697281"
      unitRef="number">0.293</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i131b62957aea4245a2e4f40e80b92785_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtOC0xLTEtNzAwMzQ_f7efbeda-d233-40fa-aed3-05a7573f0508"
      unitRef="usd">2613000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3edcdddf80a04d079d92e9eea316d11a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtMTAtMS0xLTcwMDM0_795d6d62-66c3-42be-b1ff-a27f1be36999"
      unitRef="usd">2016000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i131b62957aea4245a2e4f40e80b92785_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjQtMTItMS0xLTcwMDM0_674f7ab6-9899-4a03-b280-6696e7242240"
      unitRef="number">0.296</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b150cb6ff444a02936a3d237e2aac00_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtMi0xLTEtNzAwMzQ_b3613aae-864d-4bd6-8f76-bf114381a550"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82ae1895ed4f4e7d8ffd5e113242fb46_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtNC0xLTEtNzAwMzQ_c31a1ffa-7eb4-496e-9d84-131663b454bc"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5b150cb6ff444a02936a3d237e2aac00_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtNi0xLTEtNzAwMzQ_d51a9924-8473-4b06-b6ce-d01818099a91"
      unitRef="number">-0.115</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic58cdc6aca3145fe9c3bcad7c0f6caa3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtOC0xLTEtNzAwMzQ_02354d56-283d-42fc-8ebc-d4fbf707b207"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03a04f60e80c410ea3de2b7af02a2047_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtMTAtMS0xLTcwMDM0_e5928d42-dcaa-455e-b1c2-1ba044a0175c"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic58cdc6aca3145fe9c3bcad7c0f6caa3_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjYtMTItMS0xLTcwMDM0_4cdd6b10-921f-474e-9a97-2192b194515d"
      unitRef="number">-0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4eea102b0f843ce9148053725724350_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjctMi0xLTEtNzAwMzQ_27e9ab41-7494-411a-84e2-a2da194b8f61"
      unitRef="usd">499000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib21ebd581b69464f935e36c4077fcfe8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjctNC0xLTEtNzAwMzQ_7de4c4af-39c5-42a0-9948-bf0e56316ad9"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68320c8fb7d9415da27ec1628fccc3a9_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjctOC0xLTEtNzAwMzQ_2eed43b8-77b2-425b-ace7-d474d6ac3be8"
      unitRef="usd">881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied8c3beb651f493d825692e877822643_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjctMTAtMS0xLTcwMDM0_855b2be3-62f3-4dec-8aee-e9273650ea98"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a77ac5cc2f444fdbd37f54e3f3763e8_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjgtMi0xLTEtNzAwMzQ_99fa8fca-a634-4fbb-9e1e-f1e08200ba3e"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i477ed121b34f408288a548d3dd53cc95_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjgtNC0xLTEtNzAwMzQ_d5f051c3-d553-4327-8422-db8bc27cf24b"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf65e5c0ea164fe9851e44a3c5176fea_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjgtOC0xLTEtNzAwMzQ_a8ba26ce-43b9-4982-8083-96d5442f8c93"
      unitRef="usd">1001000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i867589638fb74338a731e3ec601b44f7_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNjgtMTAtMS0xLTcwMDM0_936ad9d2-8d06-4d86-b04f-86fa440391a0"
      unitRef="usd">264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i833b35d6c2414dada6f601d238feca65_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtMi0xLTEtNzAwMzQ_eb6ba5eb-57ed-4c14-8613-13a7aae090df"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51cf983137194da19e1e0ee43f86f2e6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtNC0xLTEtNzAwMzQ_01287374-d411-43a2-80c6-308d1816b789"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i833b35d6c2414dada6f601d238feca65_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtNi0xLTEtNzAwMzQ_9dbe3c55-5e2d-44b8-824b-62944c23c1a4"
      unitRef="number">-0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76a964d08b0e4123a5c734a55c08768b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtOC0xLTEtNzAwMzQ_40d313b5-a0a7-485f-bf6c-2583096e8dab"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0be555378cf4bc7b2c312db80e53e0c_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtMTAtMS0xLTcwMDM0_e2fb70fa-9ea6-4c02-9a41-305b1c8e95db"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i76a964d08b0e4123a5c734a55c08768b_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzAtMTItMS0xLTcwMDM0_f94d0971-95b2-43ac-8d76-b7f40a573d59"
      unitRef="number">-0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e0703b43478466cb628ab8efd4070ff_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtMi0xLTEtNzAwMzQ_d7aacb09-d71e-47a1-a110-68242b28a65f"
      unitRef="usd">215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c83561616a848de8a12e6750c8eb1d4_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtNC0xLTEtNzAwMzQ_9bbffb6d-e00e-4dc8-bb99-be2a5955b94b"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2e0703b43478466cb628ab8efd4070ff_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtNi0xLTEtNzAwMzQ_23f9829b-e86f-45f9-873c-18c05974e8fc"
      unitRef="number">-0.147</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddfe7e4eb68f4542a0694c4e9160e4f3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtOC0xLTEtNzAwMzQ_13968a78-6a1f-4978-b181-935f51f846ad"
      unitRef="usd">454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f9e9151965a452dbb603490e84ec8d3_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtMTAtMS0xLTcwMDM0_0dbd0573-a489-43c1-8624-967847dccc51"
      unitRef="usd">486000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iddfe7e4eb68f4542a0694c4e9160e4f3_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzEtMTItMS0xLTcwMDM0_615957e2-e5ec-490f-8fbc-2977a3684c92"
      unitRef="number">-0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia064ab4c0e6f48f4be4e3fb8e412913d_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItMi0xLTEtNzAwMzQ_d28adea7-410c-4240-9849-101fb05c00ee"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c4619bd414a4f4191ac0846d8ada2bd_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItNC0xLTEtNzAwMzQ_c173c8c7-9282-44df-8bb9-eb61fd10c714"
      unitRef="usd">262000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia064ab4c0e6f48f4be4e3fb8e412913d_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItNi0xLTEtNzAwMzQ_3af241d1-394e-45f1-9c06-764dbaf4883a"
      unitRef="number">-0.143</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied852099577c4b06b69b158e06bdf30b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItOC0xLTEtNzAwMzQ_960e3e9c-5637-446d-9639-d49aca26563a"
      unitRef="usd">473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9748a1cfe0ae4be3ac0b1f755e7a71bd_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItMTAtMS0xLTcwMDM0_28f690e9-2815-4785-8341-356aa2891716"
      unitRef="usd">505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ied852099577c4b06b69b158e06bdf30b_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzItMTItMS0xLTcwMDM0_bf67b723-a875-405a-b815-dd6fb01efea3"
      unitRef="number">-0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i610bb1c1ae2941719016b00d983418c0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtMi0xLTEtNzAwMzQ_12e1a6ca-9450-43b2-96cf-417c481ba4c6"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i545c78bcf6864df7b8f8c7f3f1874047_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtNC0xLTEtNzAwMzQ_d6962d20-112b-49dd-944f-0cbaf8f13aec"
      unitRef="usd">368000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i610bb1c1ae2941719016b00d983418c0_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtNi0xLTEtNzAwMzQ_54478965-3f3e-488a-81f2-bff9bb173869"
      unitRef="number">-0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5687d376693949f995a3364dc24a36fb_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtOC0xLTEtNzAwMzQ_37263851-4be0-48b6-b07a-014435938e69"
      unitRef="usd">724000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie177897f7a0e4cbb9fc1ae70b3de094c_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtMTAtMS0xLTcwMDM0_e530eaf7-66c7-4e3a-84e4-3405d562efd0"
      unitRef="usd">748000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5687d376693949f995a3364dc24a36fb_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzQtMTItMS0xLTcwMDM0_f1bec1f6-1a03-45a5-bd29-4acff27a5f97"
      unitRef="number">-0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d2d49cc4b5f4e3fb983e82500551388_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtMi0xLTEtNzAwMzQ_17f16979-eee5-4f25-8457-50768b94f221"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0743c16b76bc4a4eb2c7f09b19fb4d77_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtNC0xLTEtNzAwMzQ_2560c6b8-a723-4c46-8044-7261d7e9c62d"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3d2d49cc4b5f4e3fb983e82500551388_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtNi0xLTEtNzAwMzQ_b31ac89e-1e02-4a86-996f-802c17409312"
      unitRef="number">-0.202</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b5c01877918467fa667de5c4b5a1e4b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtOC0xLTEtNzAwMzQ_9ae54033-1ae2-445c-849f-2e583ad27d71"
      unitRef="usd">242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8432ba6c71b9494d954af4cdfc975370_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtMTAtMS0xLTcwMDM0_5d8d70a8-e3f4-4e67-ac2e-b9c15e8eaa55"
      unitRef="usd">303000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3b5c01877918467fa667de5c4b5a1e4b_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzUtMTItMS0xLTcwMDM0_4b898199-2880-4cfd-9865-8403969ae27e"
      unitRef="number">-0.203</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c2e8ad7b5ad474990841305b1f44bf0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtMi0xLTEtNzAwMzQ_f8b49fb6-28f8-4c09-8530-3120c281c187"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e2297bbc16743a6af0a9162f757bafd_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtNC0xLTEtNzAwMzQ_dee0a2cf-cf3b-49e3-8e6b-c61cae6c0d43"
      unitRef="usd">505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3c2e8ad7b5ad474990841305b1f44bf0_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtNi0xLTEtNzAwMzQ_88d84d02-b86c-44fc-a572-81beed139ee9"
      unitRef="number">-0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63d56d230d06461fbbf797c27c6ebf04_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtOC0xLTEtNzAwMzQ_1c5f0bc8-a657-4b4f-a05c-1492eec3b9f8"
      unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf382b886c2c4ddfb2e4f553d4f3aa6c_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtMTAtMS0xLTcwMDM0_b282c43e-11c2-45f6-9fa7-9e4777947fd3"
      unitRef="usd">1051000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i63d56d230d06461fbbf797c27c6ebf04_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfNzYtMTItMS0xLTcwMDM0_613d9228-1c31-454d-8869-0866d12c8705"
      unitRef="number">-0.081</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ae5da5ecb6c40da849942dbc851b857_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtMi0xLTEtNzAwMzQ_9a0c698c-293a-474b-94f1-31aa0b6cad40"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i881a26ffb23941f7b130a2daf70e1cab_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtNC0xLTEtNzAwMzQ_b6d72515-66e9-43a9-9563-61fe70a09883"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6ae5da5ecb6c40da849942dbc851b857_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtNi0xLTEtNzAwMzQ_b810a2b3-3d8a-40d9-b4e4-a0ab91296cc6"
      unitRef="number">-0.625</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b81754b34f1429a95dcde81ff323530_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtOC0xLTEtNzAwMzQ_bd9221b8-a08e-4f1c-a2be-1ea18363f027"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09ee23c86245486ca886b6aee57831eb_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtMTAtMS0xLTcwMDM0_1a5feedc-781f-4c8b-b9f6-34e2f981cd88"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0b81754b34f1429a95dcde81ff323530_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODAtMTItMS0xLTcwMDM0_6a6946ef-4193-4eba-9ab4-c6dae84f6876"
      unitRef="number">-0.625</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i233aa02837fb4f0fbbc523316a35d3c5_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtMi0xLTEtNzAwMzQ_276603f2-3854-40d6-bb55-59fb7b5f1062"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d8c24d1d48d4f6490558a822b6c2921_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtNC0xLTEtNzAwMzQ_e52a0a04-59bc-4e23-b940-aad116080d07"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i233aa02837fb4f0fbbc523316a35d3c5_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtNi0xLTEtNzAwMzQ_eba22c19-9160-4b1a-84e9-a1811265f9bf"
      unitRef="number">0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37807e01372a4baa8332eca83c82dcf5_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtOC0xLTEtNzAwMzQ_0728630f-804c-4e10-838e-72f3132c3e99"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7989fc025b464111973e629161e2434e_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtMTAtMS0xLTcwMDM0_a4e96644-3ef3-4214-ba1e-53df6d82d831"
      unitRef="usd">158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i37807e01372a4baa8332eca83c82dcf5_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODEtMTItMS0xLTcwMDM0_2316ba48-0f2b-4f8d-a001-0d551fce99f7"
      unitRef="number">0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i892c07bc3d55496bb0c411f6c4597f9b_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItMi0xLTEtNzAwMzQ_10ae91b6-ec5b-4301-917e-6d6856f8b70b"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if533c4ba85374d80b615f4cc8c0ac77d_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItNC0xLTEtNzAwMzQ_fee49426-9f69-4e61-8736-444d383754d9"
      unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i892c07bc3d55496bb0c411f6c4597f9b_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItNi0xLTEtNzAwMzQ_053e3ca5-cdbc-495f-867e-56b5527a83ca"
      unitRef="number">-0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i350d006de9494081b89834d206e20b85_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItOC0xLTEtNzAwMzQ_c53fabe1-fb09-4c91-82d4-025023a8329d"
      unitRef="usd">174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87c986ffb2bc4b73a03b90d4d1e6e058_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItMTAtMS0xLTcwMDM0_e822de97-3c87-4e72-b452-2f4c4d53acf4"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i350d006de9494081b89834d206e20b85_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODItMTItMS0xLTcwMDM0_620fda12-e4cd-4a6a-961d-d46db8fed76d"
      unitRef="number">-0.109</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cf2f6500b8d47f8bcd2e1f52815ef65_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtMi0xLTEtNzAwMzQ_deabb718-8ca1-40f3-80c3-a2b16fd110ff"
      unitRef="usd">896000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e260586dedd4093a608d4f9e119e9f6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtNC0xLTEtNzAwMzQ_1fcc0822-e20b-4eef-bf1d-913a7b270dc5"
      unitRef="usd">842000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5cf2f6500b8d47f8bcd2e1f52815ef65_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtNi0xLTEtNzAwMzQ_5b24112d-4e54-4463-8db7-e453a4d88539"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d07ff2062fb400eab890cf3cde739a0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtOC0xLTEtNzAwMzQ_4ac7c48f-4897-4457-bb93-b612ce25038b"
      unitRef="usd">1739000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb100c8ad50b4c32a7486560779c59c7_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtMTAtMS0xLTcwMDM0_00c9650d-e02c-4bfa-bec1-62291cd153be"
      unitRef="usd">1613000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9d07ff2062fb400eab890cf3cde739a0_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODUtMTItMS0xLTcwMDM0_c594cd45-2f5b-44c8-b875-18ec21aaec31"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8eb6f559d024fe9867b516d3d470c90_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtMi0xLTEtNzAwMzQ_ccc40aa5-523d-4fb5-bcc9-e1a23525d83c"
      unitRef="usd">837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc3128acda5249f7b1aa270169630b2e_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtNC0xLTEtNzAwMzQ_c580285a-22f5-4105-8ffe-bd489898dc67"
      unitRef="usd">963000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia8eb6f559d024fe9867b516d3d470c90_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtNi0xLTEtNzAwMzQ_2d326af2-c6d7-4328-b4e5-8f953fa4b574"
      unitRef="number">-0.130</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba9bb08a5cb64471bdd5fa7215d3a890_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtOC0xLTEtNzAwMzQ_f1d8efcd-5e4f-4a32-9483-d899217ea31f"
      unitRef="usd">1735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0939ae8630144f4986774c9e0e93db3f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtMTAtMS0xLTcwMDM0_65974b96-16ab-48b5-b60e-3b994d95e100"
      unitRef="usd">1906000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iba9bb08a5cb64471bdd5fa7215d3a890_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODYtMTItMS0xLTcwMDM0_18e3da85-c2f3-434a-9048-bc6012cfdfb7"
      unitRef="number">-0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ebcc5ce76814be69eea5e381ee927e1_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctMi0xLTEtNzAwMzQ_326adccb-c927-4fcc-9773-ce20176feebf"
      unitRef="usd">1734000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8cdb6868c7c4eaa83b08096e087411d_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctNC0xLTEtNzAwMzQ_c84adfa6-df44-4e36-8457-21d6f729c2af"
      unitRef="usd">1804000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7ebcc5ce76814be69eea5e381ee927e1_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctNi0xLTEtNzAwMzQ_2ed67d99-ebe9-4a33-bcf3-de1fe5d233c7"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70d8c0890db5470dabd162468412c872_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctOC0xLTEtNzAwMzQ_9e5498bb-5199-48eb-8871-1707d3437e73"
      unitRef="usd">3475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if270f92cc3864c79b2464cfd5f2f9ea0_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctMTAtMS0xLTcwMDM0_886ff31d-4ade-4ab7-b41b-773a61ffdbe1"
      unitRef="usd">3519000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i70d8c0890db5470dabd162468412c872_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODctMTItMS0xLTcwMDM0_91e7924d-d5a4-475f-a657-ae339b5cb4ec"
      unitRef="number">-0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64083077365f4393b411e13a8d829ba5_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktMi0xLTEtNzAwMzQ_326e47f3-abf9-412c-9f4c-594df4cf444c"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24bd17706c8045b28592622c702e9945_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktNC0xLTEtNzAwMzQ_d003d835-b3b3-401c-8267-d76706cce167"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i64083077365f4393b411e13a8d829ba5_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktNi0xLTEtNzAwMzQ_09613a41-5e73-4a49-b147-4163280f3597"
      unitRef="number">0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2fa6af256364b8ba090796d8cef039e_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktOC0xLTEtNzAwMzQ_91b919d5-3fb3-4993-b312-755275c33748"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5c7f3684e96430cb08ceb7f25e639b0_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktMTAtMS0xLTcwMDM0_021d29a1-f66c-4d8d-9046-b88a3aff8e40"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic2fa6af256364b8ba090796d8cef039e_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfODktMTItMS0xLTcwMDM0_437d1edf-f26c-45a3-adb0-876d602b4b9b"
      unitRef="number">-0.113</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i821e476b1e124c3da418c0da884873ec_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtMi0xLTEtNzAwMzQ_795588a6-24c6-4b74-8b7b-97013375d51c"
      unitRef="usd">123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9867c33d4e041e39d64aeb94ca7220f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtNC0xLTEtNzAwMzQ_acabadfe-df1c-4dc8-b4e5-834c1e80d60a"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i821e476b1e124c3da418c0da884873ec_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtNi0xLTEtNzAwMzQ_c90c751f-9722-46f9-9562-1fcd19535293"
      unitRef="number">-0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7e9055569824947bc8a8aa2e70f9c21_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtOC0xLTEtNzAwMzQ_c2ec97c0-7b13-4563-a0c0-5defd8a57660"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aa6b7234499430f8a3da6a879bb9820_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtMTAtMS0xLTcwMDM0_34863630-191d-441e-992d-fdfd2e238aef"
      unitRef="usd">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if7e9055569824947bc8a8aa2e70f9c21_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTAtMTItMS0xLTcwMDM0_91c7a3cd-9f2c-4ba8-9de2-152d4367b51a"
      unitRef="number">-0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c551506a1274d12b61d0b0bb6a17e0e_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtMi0xLTEtNzAwMzQ_c851c9a2-a805-4f3c-91c9-2a4ed71ba3a7"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c0fbf4de99a4afdab1711dbfaae9849_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtNC0xLTEtNzAwMzQ_004b8981-cda8-4526-8fd7-cd073d5d8097"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c551506a1274d12b61d0b0bb6a17e0e_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtNi0xLTEtNzAwMzQ_5bab44ea-ecfb-421e-94d9-df4ce9e65666"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idee16de5d59840c5bd123a9e5601d81d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtOC0xLTEtNzAwMzQ_8819296f-9c9f-4675-b770-e3bf88c55cfa"
      unitRef="usd">318000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f474b0d055142afacf952c297331e99_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtMTAtMS0xLTcwMDM0_bb0e8d6f-d26f-445d-a8bc-b7eb02f7a2a7"
      unitRef="usd">332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idee16de5d59840c5bd123a9e5601d81d_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTEtMTItMS0xLTcwMDM0_e26f6bef-ba16-4491-bb0a-86791fadf29c"
      unitRef="number">-0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42b1abcd0990401ca49e18dbeb437c17_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtMi0xLTEtNzAwMzQ_fd7585c1-7ad2-4431-b3f3-13683b85dc3a"
      unitRef="usd">691000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3ee672bbd7141948b03208867985b7c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtNC0xLTEtNzAwMzQ_b3ef12a4-47d1-4c7d-9e58-e3f78bd14171"
      unitRef="usd">645000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i42b1abcd0990401ca49e18dbeb437c17_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtNi0xLTEtNzAwMzQ_19764d95-e2c2-4a03-9e7d-b23a9809e659"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f190476843b4d519e98652aff7a77fb_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtOC0xLTEtNzAwMzQ_24d07dc8-dfd7-42ba-ae46-4d0c39a47e4f"
      unitRef="usd">1352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic36139166d5b482eb6fba5b9c7a5dff4_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtMTAtMS0xLTcwMDM0_dace6da1-fcfe-46cb-910d-5bbf857d915b"
      unitRef="usd">1234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0f190476843b4d519e98652aff7a77fb_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTMtMTItMS0xLTcwMDM0_9b6d547a-71b9-4aef-8268-ed24f0922156"
      unitRef="number">0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc2adbb26c4f4169ac3ed1446c0047a5_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtMi0xLTEtNzAwMzQ_6444fefd-5477-4e71-ad0b-2604782e83af"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02a8333f41594a4ea74e78b5265277e8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtNC0xLTEtNzAwMzQ_af3b7372-459c-4f14-80a2-7f967bb969db"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifc2adbb26c4f4169ac3ed1446c0047a5_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtNi0xLTEtNzAwMzQ_4be5c10a-95ef-4eb0-a2ed-5d888f9e7d5f"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33af160294004e19b207a7f75170082d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtOC0xLTEtNzAwMzQ_158cd0e7-28ad-4181-acae-11d95128481d"
      unitRef="usd">749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dabd6e5fadb4ace892027521ea05718_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtMTAtMS0xLTcwMDM0_682ea64a-ae6c-45a5-bdea-037f80fe6dfd"
      unitRef="usd">756000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i33af160294004e19b207a7f75170082d_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTQtMTItMS0xLTcwMDM0_9282bff9-ffa1-4a13-a403-d4cfecd619d6"
      unitRef="number">-0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i381a4444cf624dc6be2aa2fa0a0a3659_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtMi0xLTEtNzAwMzQ_19cbae6e-519b-4441-bd85-218062e8c4b2"
      unitRef="usd">1054000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9404903e6e74429b27dbbdf8d4ff248_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtNC0xLTEtNzAwMzQ_8d73669d-d71c-46f2-aa92-830f97bc56a8"
      unitRef="usd">1024000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i381a4444cf624dc6be2aa2fa0a0a3659_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtNi0xLTEtNzAwMzQ_ac942912-6c83-4371-a2b2-cb903cf61850"
      unitRef="number">0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81967cf9960e417ca2396582624be8d5_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtOC0xLTEtNzAwMzQ_9701e7dc-2037-46c6-b9dc-7749f85413de"
      unitRef="usd">2102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia58cde252d1f4e799a3a302ee1c41607_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtMTAtMS0xLTcwMDM0_ac4058d7-90a6-4360-ae26-5cea2b9a2f51"
      unitRef="usd">1989000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i81967cf9960e417ca2396582624be8d5_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTUtMTItMS0xLTcwMDM0_95802fbb-ae3e-4134-b105-ebbfd54338ef"
      unitRef="number">0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4616b6887b354b9e96c3d430604d3c42_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctMi0xLTEtNzAwMzQ_b8ec063c-510d-4b43-b5ab-c26a0d2bd9d1"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84ef0d86dacf40c98cf4e5607785cedb_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctNC0xLTEtNzAwMzQ_e1a716f9-40f4-42c0-beba-073241cdc461"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4616b6887b354b9e96c3d430604d3c42_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctNi0xLTEtNzAwMzQ_44b74663-670d-480d-b0ec-aa6977fa2f4c"
      unitRef="number">-0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94c58a72b8a448dd98f5ac9d8f55ad47_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctOC0xLTEtNzAwMzQ_e1451a86-3f65-408f-a6ef-c46d77995014"
      unitRef="usd">128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87f4c25c27d346e28d79fffe1ec89849_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctMTAtMS0xLTcwMDM0_5bed2b54-b73e-47c2-a065-07ab76f32502"
      unitRef="usd">139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i94c58a72b8a448dd98f5ac9d8f55ad47_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTctMTItMS0xLTcwMDM0_8a69c2f6-2d71-48bc-aa47-5686dd0b4ebc"
      unitRef="number">-0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9db6a1f46624828bc4b33dcc757c82e_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtMi0xLTEtNzAwMzQ_ddc9c6f5-c197-4ace-ad71-85e1cfe87833"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabdebd8234af4a4b9621fb3ecb624d8b_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtNC0xLTEtNzAwMzQ_f57d2f73-5161-451f-a203-ea65c9350c58"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia9db6a1f46624828bc4b33dcc757c82e_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtNi0xLTEtNzAwMzQ_7dc91db6-9046-4824-8287-09aaa337c8c0"
      unitRef="number">-0.280</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc179fa1a480426cb4fd0d3d966e2f9d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtOC0xLTEtNzAwMzQ_ff370d3f-5afe-4297-abd3-88951bb98660"
      unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i331342035f8849bab17b1dd2debe6771_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtMTAtMS0xLTcwMDM0_b64a0714-e453-422e-b1ba-ecca1f749fd4"
      unitRef="usd">173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icc179fa1a480426cb4fd0d3d966e2f9d_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTgtMTItMS0xLTcwMDM0_b259c8e5-4ad5-4482-b42c-030e16c9081f"
      unitRef="number">-0.271</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0ed53bcf088487b9c9fb95699fb4684_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktMi0xLTEtNzAwMzQ_612e7a5e-c53f-40ac-ab46-c444333b94c6"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53a8381b611d418cac230e38702d6256_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktNC0xLTEtNzAwMzQ_5f27db38-eef0-4816-a203-a47ee965e13a"
      unitRef="usd">155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if0ed53bcf088487b9c9fb95699fb4684_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktNi0xLTEtNzAwMzQ_7d21b44f-1a2f-4369-9b56-400097511721"
      unitRef="number">-0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a732ecb6ddf466da949b0e4f1047c8c_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktOC0xLTEtNzAwMzQ_7139fa8f-ca06-4918-a97e-9b9d90cd9d7e"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8467285a7fb842329b2d56b3c68bc6b2_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktMTAtMS0xLTcwMDM0_dce07b2a-22da-4fe6-b148-46e360a5514d"
      unitRef="usd">312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0a732ecb6ddf466da949b0e4f1047c8c_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfOTktMTItMS0xLTcwMDM0_d68b34f2-661c-41a7-bcbf-02e976151d43"
      unitRef="number">-0.184</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96b0e21c3cb246bcbf7a18d3394d1fc3_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTItMS0xLTcwMDM0_4fe944e5-7e2e-42f7-bef3-b568c1b7f039"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11e7b7ef58fc4d74b79a62f31f63b60a_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTQtMS0xLTcwMDM0_dc85387b-39a2-4a5e-b1ee-b379731498bc"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i96b0e21c3cb246bcbf7a18d3394d1fc3_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTYtMS0xLTcwMDM0_3ade4ca6-2a2e-49ed-aeee-0c5078ee0f4c"
      unitRef="number">0.118</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec84871b973443e4b3a3810d110bc6a9_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTgtMS0xLTcwMDM0_2ced5c2d-6c88-4462-a215-268c8ee63db7"
      unitRef="usd">186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05deb876f009412dba8fee7b750b9a3f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTEwLTEtMS03MDAzNA_64a4ecaf-18d1-4c5a-96fb-55fdee321bea"
      unitRef="usd">158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iec84871b973443e4b3a3810d110bc6a9_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAxLTEyLTEtMS03MDAzNA_d35fbd59-5d1f-41a6-a20a-9e6a10123d43"
      unitRef="number">0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae486921d8e2413a95e450c0a846f660_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTItMS0xLTcwMDM0_b2aa77bd-81bd-47d4-abdd-b7d473fb5cc1"
      unitRef="usd">292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i084e1532e11242b9ab8e982e98cce345_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTQtMS0xLTcwMDM0_6a6d0433-2286-49c8-986a-df9651963c54"
      unitRef="usd">373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iae486921d8e2413a95e450c0a846f660_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTYtMS0xLTcwMDM0_a24efda9-ac25-416b-9eb4-c5818eb2f7a4"
      unitRef="number">-0.218</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a2eec65477c4cf6b0a2e012668bd440_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTgtMS0xLTcwMDM0_734aacb5-bdbf-4aec-a628-50feb0a51efc"
      unitRef="usd">615000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0bf55fd1f5940659534d3655320b2a8_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTEwLTEtMS03MDAzNA_4a081ad5-83cd-4b44-a39b-1249b37596da"
      unitRef="usd">728000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a2eec65477c4cf6b0a2e012668bd440_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAyLTEyLTEtMS03MDAzNA_092b68eb-55e6-4c36-a7ba-51672da64abf"
      unitRef="number">-0.155</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53cbe5667f104372ac5709b96be56d7b_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTItMS0xLTcwMDM0_1d0f7472-711f-42a5-ac5a-48a30ffef3d6"
      unitRef="usd">393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic03d9b2307334d22bd42f69770c03cbe_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTQtMS0xLTcwMDM0_7507ff73-d173-46f2-99e0-417b79be8d47"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i53cbe5667f104372ac5709b96be56d7b_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTYtMS0xLTcwMDM0_5d721298-b4f6-49a4-8b22-46cd404af8bf"
      unitRef="number">-0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c787a1466bc48398971fdb66dccf821_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTgtMS0xLTcwMDM0_caec1735-5f9d-4aee-9ce3-6e88631d7d7f"
      unitRef="usd">800000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54a6b0b9f19b4a3aa3d549fb91013f6b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTEwLTEtMS03MDAzNA_7bd014ca-455d-4986-8f13-fec2ab0326ab"
      unitRef="usd">886000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8c787a1466bc48398971fdb66dccf821_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTAzLTEyLTEtMS03MDAzNA_673cf3a8-6aa0-4378-aceb-9745e1a80cbe"
      unitRef="number">-0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee8ceb7982104bb097677e4f08cf19c8_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTItMS0xLTcwMDM0_b6584af8-f00a-4ce9-b6cf-c65fdab50db4"
      unitRef="usd">1679000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic935596d94fb4f8cbc7662516ebd2337_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTQtMS0xLTcwMDM0_255b3f03-e232-4f05-aac4-fa92414ec989"
      unitRef="usd">1462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee8ceb7982104bb097677e4f08cf19c8_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTYtMS0xLTcwMDM0_5bce422c-8ed9-4f67-ae26-894e0e66373f"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74032420b0d54f859aa6ac4ae4cb6092_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTgtMS0xLTcwMDM0_a53a8b36-a706-49b2-9fd3-c723020fa850"
      unitRef="usd">3261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i628c3315204b4c819f5612c6ea0f76c9_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTEwLTEtMS03MDAzNA_e5a254e3-721d-47f5-b592-e4e60d0ba566"
      unitRef="usd">2839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i74032420b0d54f859aa6ac4ae4cb6092_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA2LTEyLTEtMS03MDAzNA_d7f707bf-4278-4d48-bac4-4490ff25aa9b"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i489d0217d95349a09e3854a159fe1e20_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTItMS0xLTcwMDM0_a949f115-9b23-4117-916d-6ab94a312947"
      unitRef="usd">2362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia852ccdace584ca893a3f9fb3926a08b_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTQtMS0xLTcwMDM0_36fb1ff1-1779-4f07-9797-0f7ae8f98cfa"
      unitRef="usd">2073000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i489d0217d95349a09e3854a159fe1e20_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTYtMS0xLTcwMDM0_9d1eb257-2169-4190-bd52-0d079835802a"
      unitRef="number">0.140</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3ea038280ba420e8b3e85334bd010be_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTgtMS0xLTcwMDM0_70011626-6107-4672-a184-d199f9298a75"
      unitRef="usd">4731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0579266bf5fa431e86d0cc99966caf96_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTEwLTEtMS03MDAzNA_acc97264-1e27-429d-8456-40809adc53a8"
      unitRef="usd">4266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id3ea038280ba420e8b3e85334bd010be_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA3LTEyLTEtMS03MDAzNA_873af6b1-4838-465c-a574-c9d25a7964b7"
      unitRef="number">0.109</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf0ee75730ec4eaf8b49daa1a0982cbf_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTItMS0xLTcwMDM0_f957cfe0-3001-45e4-9d61-e0775d566109"
      unitRef="usd">4042000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9208998ddf664f808ab029146e8a7091_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTQtMS0xLTcwMDM0_335363e1-6274-4b0b-b024-c8c10679194f"
      unitRef="usd">3535000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibf0ee75730ec4eaf8b49daa1a0982cbf_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTYtMS0xLTcwMDM0_59a1f2f3-65a3-464e-84a8-b17caece67e2"
      unitRef="number">0.143</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93dc841f45e74baab367942431755f0d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTgtMS0xLTcwMDM0_8c268f3e-95b5-4f9c-8811-7a8ffbcd2ebc"
      unitRef="usd">7992000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8abc2da8c3544d7a8631b23ee75d1876_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTEwLTEtMS03MDAzNA_5bb37aff-0976-464c-9cb1-d08c1b0ca205"
      unitRef="usd">7105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i93dc841f45e74baab367942431755f0d_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTA4LTEyLTEtMS03MDAzNA_48f53cba-4abc-4468-a238-f8cfc165187a"
      unitRef="number">0.125</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i615f22ff6960415c94431ef20433e83c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTItMS0xLTcwMDM0_2593fb7f-4f34-4592-b20b-c84ae59f414b"
      unitRef="usd">1021000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i271d0e8006734cb381410cc5d646c7e5_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTQtMS0xLTcwMDM0_88a08996-445d-41fd-a0c1-30b85af3b1cf"
      unitRef="usd">770000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i615f22ff6960415c94431ef20433e83c_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTYtMS0xLTcwMDM0_0ac8932a-bd5b-4abb-9adb-c0b846d03ff5"
      unitRef="number">0.326</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04b08f5246c2483c8916b0d18a4cb899_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTgtMS0xLTcwMDM0_d4be45ef-575c-4be3-b419-1d755e5aac54"
      unitRef="usd">1974000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4137bbbedc454ce4a1e326ab7eddfed0_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTEwLTEtMS03MDAzNA_ff212bc2-ea6a-4a7f-8b34-f607cb4c67cb"
      unitRef="usd">1461000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i04b08f5246c2483c8916b0d18a4cb899_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEwLTEyLTEtMS03MDAzNA_9ace90b7-97ea-45b6-95ec-1146aa91975c"
      unitRef="number">0.351</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46129e353ad84f39a366e43a8ac98e0a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTItMS0xLTcwMDM0_75a40422-23ec-447b-88db-b9f70f2ac624"
      unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7a134dff79c46c1bb7e1c0967197d54_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTQtMS0xLTcwMDM0_18aaacfb-7b9d-452a-aac5-0efd11bd4de4"
      unitRef="usd">663000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i46129e353ad84f39a366e43a8ac98e0a_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTYtMS0xLTcwMDM0_d7727eb0-ce06-4515-aaba-b8966df6d919"
      unitRef="number">0.455</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb851f7c092f4ee3bd18823be28d76ec_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTgtMS0xLTcwMDM0_2b0249c2-1e5f-43f7-ab15-00752f343493"
      unitRef="usd">1868000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f4755679550432890b18a7d35fbe2fe_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTEwLTEtMS03MDAzNA_1f5f196b-5e8a-4c35-96fe-f7d759eec6dc"
      unitRef="usd">1337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifb851f7c092f4ee3bd18823be28d76ec_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTExLTEyLTEtMS03MDAzNA_1b4dc528-6f8b-4069-b0b7-f5dbed8d62b8"
      unitRef="number">0.397</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e47d07acf0a4b3bbe3c60a9e96bf4f3_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTItMS0xLTcwMDM0_6c5443eb-fb7c-4e48-a5c2-aea242fd5643"
      unitRef="usd">1986000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9f53949a41d46ef898ac80d318d4189_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTQtMS0xLTcwMDM0_fe6cfdce-2666-41cf-ab74-1a094a4b1541"
      unitRef="usd">1433000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7e47d07acf0a4b3bbe3c60a9e96bf4f3_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTYtMS0xLTcwMDM0_d8301656-76a6-4c52-8801-37472706f1bb"
      unitRef="number">0.386</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2284a61a0db642eb9a40b3613d8594d2_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTgtMS0xLTcwMDM0_1c458649-25c6-433d-95de-090cce5783b9"
      unitRef="usd">3842000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1379f0be014f4ea396ebb2effecec503_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTEwLTEtMS03MDAzNA_e915502f-fc36-4fef-bec7-fdaa157d9ef8"
      unitRef="usd">2798000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2284a61a0db642eb9a40b3613d8594d2_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTEyLTEyLTEtMS03MDAzNA_f7c1c9d8-96f4-45e9-8797-41eed91569f7"
      unitRef="number">0.373</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i426a47a9bb5049e49edcb30d41af643d_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTItMS0xLTcwMDM0_d77d5fbe-9bbf-4255-a940-b61086b82665"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie71f54f5a529400e992bcff94dd82726_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTQtMS0xLTcwMDM0_532b5643-b8e2-44d5-a478-160b81750a00"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i426a47a9bb5049e49edcb30d41af643d_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTYtMS0xLTcwMDM0_a2ddf5f2-c0bb-4899-b2b3-3c1fb58005b4"
      unitRef="number">0.206</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i130828dd7fbb4e60887d19e7e530c789_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTgtMS0xLTcwMDM0_22396e01-5208-4104-81cc-f6c9e4152118"
      unitRef="usd">439000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib90029a9516f4591902efe683175866b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTEwLTEtMS03MDAzNA_1c0145b4-a384-4c0e-a880-709b5fa327c6"
      unitRef="usd">364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i130828dd7fbb4e60887d19e7e530c789_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE0LTEyLTEtMS03MDAzNA_df836193-e0e8-49e0-9b45-bad63f19c088"
      unitRef="number">0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10e7b1fc93c648b8b4e52538ecb02755_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE1LTItMS0xLTcwMDM0_4a9b16fe-33c1-4040-81a4-d86ec90fded3"
      unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifea982946629432694550a8492f1df45_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE1LTQtMS0xLTcwMDM0_87ff678d-f43d-42c0-b3e5-2d03f16a105a"
      unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ba1c7b633bd48db874857a7afcde3a7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE1LTgtMS0xLTcwMDM0_3e099d63-e9fd-4e86-ae09-ef570f9d3ae4"
      unitRef="usd">412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5808bbc2a03c4b5bab9390a5f8f31033_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE1LTEwLTEtMS03MDAzNA_b5b11be8-96fe-42fa-8e7d-641f740a02e2"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc0c50a7dcd74d0db255eeaf0c492416_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTItMS0xLTcwMDM0_add64fda-4661-4a62-b1ca-0e4fb4ea819e"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i387b27c79f194d799d0479f8a64250d9_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTQtMS0xLTcwMDM0_5c918763-41c3-4278-9b03-6fdaade5fd0c"
      unitRef="usd">302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idc0c50a7dcd74d0db255eeaf0c492416_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTYtMS0xLTcwMDM0_94bffbb9-e80f-4e39-979c-7aa6346a7115"
      unitRef="number">0.495</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5f7fbaf72f24eac8c150dc42468daee_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTgtMS0xLTcwMDM0_af3de1d7-a82d-4e97-81d3-dd01ff701bd6"
      unitRef="usd">850000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8419c61da6e9446b84344e772ddcae1f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTEwLTEtMS03MDAzNA_c544f505-6048-4525-bbe9-d60b2b34a23f"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if5f7fbaf72f24eac8c150dc42468daee_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE2LTEyLTEtMS03MDAzNA_c8923ad9-1176-4696-929f-26810445ef86"
      unitRef="number">0.511</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bfa9586158743db9a0c50d35d5c3e89_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTItMS0xLTcwMDM0_1d3a4a69-96bc-4a4b-b807-82f11f88e1ac"
      unitRef="usd">349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i592eccbed0a44157b77b90479b36ff12_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTQtMS0xLTcwMDM0_99958ded-a883-43d1-bf53-8afab636844a"
      unitRef="usd">454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5bfa9586158743db9a0c50d35d5c3e89_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTYtMS0xLTcwMDM0_fe4f50de-b636-4688-8b79-23b8633cf7c7"
      unitRef="number">-0.231</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida0339ec3d81486890f895801d2a05b3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTgtMS0xLTcwMDM0_83f7c6cb-b151-4d9b-b896-d8054fe7d15c"
      unitRef="usd">719000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29c10bec547049118934a57af7d55e71_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTEwLTEtMS03MDAzNA_3774766a-8a11-4eb5-98fa-859972be855a"
      unitRef="usd">898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ida0339ec3d81486890f895801d2a05b3_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE4LTEyLTEtMS03MDAzNA_c88933e0-c815-4ea5-b6e7-4620b59fa220"
      unitRef="number">-0.199</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30dd2aba0a4a4cd58d61a14fded9bf4e_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTItMS0xLTcwMDM0_cf7da587-7272-4b6a-a0da-5f03d8a8bbe6"
      unitRef="usd">620000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40056c4ceeb846b4811bce1524b88e28_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTQtMS0xLTcwMDM0_5f2b0944-868b-4764-aefa-59bb0457b3e2"
      unitRef="usd">662000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i30dd2aba0a4a4cd58d61a14fded9bf4e_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTYtMS0xLTcwMDM0_64d936ca-7f92-48eb-9c14-f18874a70052"
      unitRef="number">-0.063</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4acd16385e14790b4257cd1e30e36ad_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTgtMS0xLTcwMDM0_9cd05de8-6521-4ef5-84f3-f736bbc8eb1f"
      unitRef="usd">1288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e28b4687a6462d8f2d01ee02868bf2_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTEwLTEtMS03MDAzNA_9ca18d7d-1f70-4891-a59f-0497b46e810a"
      unitRef="usd">1342000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia4acd16385e14790b4257cd1e30e36ad_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTE5LTEyLTEtMS03MDAzNA_c0f546bf-91ca-4c69-b86f-2cffe1d8c545"
      unitRef="number">-0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i406d7f79310444cba9070d2c72c8ed3d_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTItMS0xLTcwMDM0_994f6e8a-7aed-4365-bb74-36a5703f6ef5"
      unitRef="usd">970000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f9ae73e21244184a996ccfa27a0e0d6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTQtMS0xLTcwMDM0_f246b978-ca7e-4c45-8be4-33409076cb80"
      unitRef="usd">1116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i406d7f79310444cba9070d2c72c8ed3d_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTYtMS0xLTcwMDM0_cc17a102-0564-4672-9cbb-0aebfee9d300"
      unitRef="number">-0.131</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe33b178b5f24c92919e80285cf6ce87_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTgtMS0xLTcwMDM0_12d93eeb-406c-498c-bc46-60a1d4c724c6"
      unitRef="usd">2008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01a022bc19634f4291caec90e24c1e56_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTEwLTEtMS03MDAzNA_81ee06b8-b2c2-4cf7-b182-534c418fe958"
      unitRef="usd">2241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibe33b178b5f24c92919e80285cf6ce87_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIwLTEyLTEtMS03MDAzNA_be52059d-936a-49d7-8a41-e817d1689fe9"
      unitRef="number">-0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8fbf93a0d984f74a4c18b8438d93705_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTItMS0xLTcwMDM0_d19052b0-27e6-42f5-b4d2-3f95c18a4972"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e590252c39f4b69acea8c278aaaa6f1_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTQtMS0xLTcwMDM0_7e352860-c008-4f6a-be37-7bb6a096f375"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id8fbf93a0d984f74a4c18b8438d93705_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTYtMS0xLTcwMDM0_ddd78e94-74a2-44ea-8688-71eb487a5cde"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8d89ac93d3541048345e457b838050c_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTgtMS0xLTcwMDM0_6d148417-b5c7-43df-8e37-68e8ebeabc12"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a77e4ef832546f095278c7e2e4cdd06_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTEwLTEtMS03MDAzNA_38334c2a-1b7b-491d-987a-c374a26dd78a"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic8d89ac93d3541048345e457b838050c_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIyLTEyLTEtMS03MDAzNA_f366764f-cd2a-4c61-89f2-eec2b124d5a8"
      unitRef="number">-0.470</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53abdb7bf8da48d28acfcb3784400145_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTItMS0xLTcwMDM0_e335c732-6cff-4f62-80ba-592ef9341a5f"
      unitRef="usd">486000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1508e902d9b44570a06c0b42a8e602df_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTQtMS0xLTcwMDM0_aae17587-7549-43d3-afb8-763e0eaf6a30"
      unitRef="usd">542000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i53abdb7bf8da48d28acfcb3784400145_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTYtMS0xLTcwMDM0_52a86919-7f5a-4d97-b0e1-87bc04da6dfe"
      unitRef="number">-0.102</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b50ec6523c84e019fd0db2f7ee816f9_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTgtMS0xLTcwMDM0_ae1e33fb-f1ad-44d3-9337-aba04a4c3272"
      unitRef="usd">1006000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5d63678be1842828f166c73f3d5ae66_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTEwLTEtMS03MDAzNA_190de8d5-2820-4f84-af61-173b537f85f5"
      unitRef="usd">1130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3b50ec6523c84e019fd0db2f7ee816f9_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTIzLTEyLTEtMS03MDAzNA_36ce3705-5801-461a-8b58-c7b2afa59a1a"
      unitRef="number">-0.110</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia254c76d3f8f491097090592e479401a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTItMS0xLTcwMDM0_b82e4c01-ce3d-4acc-86b2-5ff4e6c05043"
      unitRef="usd">505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia14d651799574575bfd8abdfa9223117_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTQtMS0xLTcwMDM0_d7d5737b-c09d-4423-8ff3-20e1554e94d4"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia254c76d3f8f491097090592e479401a_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTYtMS0xLTcwMDM0_0f7fa8b0-981e-4c30-99cb-f6929b7516d8"
      unitRef="number">-0.103</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aaf1d0c5d9848a8b48f4bd785f69d6a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTgtMS0xLTcwMDM0_271c3050-db78-4e65-85ac-2402091b5a31"
      unitRef="usd">1044000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fbc96ca92fb42cea0ec295a49f4dfc5_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTEwLTEtMS03MDAzNA_06bc765b-6c46-4c5f-aea7-9532240ba54b"
      unitRef="usd">1201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8aaf1d0c5d9848a8b48f4bd785f69d6a_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI0LTEyLTEtMS03MDAzNA_75854417-f089-45da-bf53-dd551111acca"
      unitRef="number">-0.131</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb3058cd0a794324aafc2a3a3fb3d32c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI3LTItMS0xLTcwMDM0_1dc9fd78-8a98-49d5-91df-8679eed7169a"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06149290e1044e6681818593b0e3b54a_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI3LTQtMS0xLTcwMDM0_5b53ee29-bd85-4832-980d-9b8e053b9e8d"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7665d8acf34544c7bc3d213e29a403a7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI3LTgtMS0xLTcwMDM0_2e645454-a32d-4429-bf0f-c5d36c49159b"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11b2aa9141884cdb897069ea96225219_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI3LTEwLTEtMS03MDAzNA_4c2adf4b-5c42-4c24-a03e-1a80e29fca51"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50642add27bf4a3c847f19d7dcc1fa55_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTItMS0xLTcwMDM0_880ff248-8faa-4146-b0bf-228b2a70a32d"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1878b6e06b6d4e8fbac6886000f181e7_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTQtMS0xLTcwMDM0_abb72520-182d-47c7-8637-3cc161401caf"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i50642add27bf4a3c847f19d7dcc1fa55_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTYtMS0xLTcwMDM0_8542422b-fa2f-4515-b2b4-545eccb717ee"
      unitRef="number">-0.257</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49e1c777f67d469aa4c5d82eb4cac8d3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTgtMS0xLTcwMDM0_fa224e72-fb83-4b9a-bbc5-8cb598b79a7e"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77a597acb37e446f8a4c956653e8bab3_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTEwLTEtMS03MDAzNA_7b8ab8ad-df98-422f-894a-3e4ffd735690"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i49e1c777f67d469aa4c5d82eb4cac8d3_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI4LTEyLTEtMS03MDAzNA_b20d0a2a-1ad7-4353-b133-e12248c6d29f"
      unitRef="number">-0.394</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c828becc5644f42afd048825810abaf_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTItMS0xLTcwMDM0_5a33ab92-c091-415b-906d-55cae04188ce"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fea4855dd1f4faabcb8e2d17b561470_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTQtMS0xLTcwMDM0_3f0dd065-36d0-40f3-a6f1-570a82246cd9"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0c828becc5644f42afd048825810abaf_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTYtMS0xLTcwMDM0_5ee32ded-0d4c-4d0d-a55a-45f2e3f14287"
      unitRef="number">0.075</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f53d151fe8347b498763fd23057410d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTgtMS0xLTcwMDM0_8989a34b-0f1c-4597-90f3-27c8ce1f10ef"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4be7291502c242fa9978dea11ad9818c_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTEwLTEtMS03MDAzNA_a82ec63e-e405-4001-92be-0482d83b7226"
      unitRef="usd">302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9f53d151fe8347b498763fd23057410d_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTI5LTEyLTEtMS03MDAzNA_9e73a81f-2f1b-447e-bec8-7e2ada57ed7f"
      unitRef="number">-0.180</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc09d2d675884189bc0ba76a89d7113f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTItMS0xLTcwMDM0_6e4ea0ec-7eda-4e20-a54e-11a9d3b0b17d"
      unitRef="usd">560000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89dd98c72cc84fe1ba6b852522d18a83_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTQtMS0xLTcwMDM0_66430c3f-b02e-4d9d-94e3-5462fd130b43"
      unitRef="usd">595000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idc09d2d675884189bc0ba76a89d7113f_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTYtMS0xLTcwMDM0_b941c7a5-db72-4c19-9b81-014bad38dd2b"
      unitRef="number">-0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4aa4bd06b9544485bda39398396ffcb0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTgtMS0xLTcwMDM0_1ea28081-c576-4ff7-aff9-a639047b8a23"
      unitRef="usd">1132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaafcb61ea5b64eafb32a7afa38475c33_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTEwLTEtMS03MDAzNA_bf09965c-ae19-4550-89eb-b1f7c4ea7cfc"
      unitRef="usd">1168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4aa4bd06b9544485bda39398396ffcb0_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMyLTEyLTEtMS03MDAzNA_e3d75fbd-6b0f-474e-963f-4f39489c501b"
      unitRef="number">-0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d20d851bb704983b94a0bd5e2bf8063_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTItMS0xLTcwMDM0_b8661c3a-9576-420a-950d-01929ee9c349"
      unitRef="usd">284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdee48ad66d84e4c821395f425508ec9_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTQtMS0xLTcwMDM0_691ef893-b145-4a4a-b91b-32bbc6a76ad7"
      unitRef="usd">275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7d20d851bb704983b94a0bd5e2bf8063_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTYtMS0xLTcwMDM0_479837c1-0723-4321-a81b-8e718ee3bbc5"
      unitRef="number">0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29866d57d1454ab78e5a90bf77a1bd34_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTgtMS0xLTcwMDM0_d83b908c-efd1-4726-86c6-1dbc823ea50f"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d781877b74c43629248df91d29e0ac3_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTEwLTEtMS03MDAzNA_abb2e4cc-7c13-494c-b013-11b088649323"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29866d57d1454ab78e5a90bf77a1bd34_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTMzLTEyLTEtMS03MDAzNA_391d9e06-6f5c-4b20-99c8-6c8a92308a29"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i287ae97dc4bb452493b5178c62898f36_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTItMS0xLTcwMDM0_3c859b49-058e-4889-b7ca-4240261f67ac"
      unitRef="usd">843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffbcf7aa3c2d4150a651ef9642bdc10a_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTQtMS0xLTcwMDM0_44e95bd7-4161-4af3-af11-85ea485dedfb"
      unitRef="usd">870000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i287ae97dc4bb452493b5178c62898f36_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTYtMS0xLTcwMDM0_c26fd25d-7299-44d9-a5ea-db903499544b"
      unitRef="number">-0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc239cfb9ce0485982b4ed133c7bd657_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTgtMS0xLTcwMDM0_95ba2dae-d015-4871-a4b0-f505289a6a68"
      unitRef="usd">1695000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37914cd1dccc44c0996e33a397571801_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTEwLTEtMS03MDAzNA_6d920ad6-b934-47fb-9d81-ec8719b1ec26"
      unitRef="usd">1731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idc239cfb9ce0485982b4ed133c7bd657_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM0LTEyLTEtMS03MDAzNA_dffb892a-640f-47ca-b2ad-35d174face06"
      unitRef="number">-0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c955b2727464d82bdccca98ce299c54_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTItMS0xLTcwMDM0_189c8751-b59b-4a4e-9fdd-820bbb34e333"
      unitRef="usd">265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0328f187daa42cebf05b6bd3a2f5dae_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTQtMS0xLTcwMDM0_5a9b5d4f-ab09-4c67-bf70-7057ae557453"
      unitRef="usd">290000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4c955b2727464d82bdccca98ce299c54_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTYtMS0xLTcwMDM0_0db48466-fff7-46e5-b9e1-1db01604e718"
      unitRef="number">-0.087</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bb153e375c54c7eafcbd065d7b6af94_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTgtMS0xLTcwMDM0_27adf4ea-b406-4085-ae9b-9e4e20717273"
      unitRef="usd">538000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7f501d0f4a749579b31839d170e6acd_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTEwLTEtMS03MDAzNA_4a821d9c-2a9f-47e5-9757-a7dd3bf309f2"
      unitRef="usd">562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0bb153e375c54c7eafcbd065d7b6af94_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM2LTEyLTEtMS03MDAzNA_bd68b8bd-b413-427e-ab3f-eddec24e423b"
      unitRef="number">-0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53051d91ab824126b4235ef16cb6263a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTItMS0xLTcwMDM0_0936fd17-55b4-42c7-b49b-18d28cde72d6"
      unitRef="usd">173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i051a1f8ff4d040a5a7eb2d6081274333_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTQtMS0xLTcwMDM0_29396b1b-03d9-4413-9f76-690a137e44cf"
      unitRef="usd">172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i53051d91ab824126b4235ef16cb6263a_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTYtMS0xLTcwMDM0_68c861c2-d165-4362-81e9-f893574b39fc"
      unitRef="number">0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17ef09cd80ce48528fd4e15b267fa581_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTgtMS0xLTcwMDM0_fe8945f6-8b8d-44b3-ab76-211e7ccf9302"
      unitRef="usd">343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06739f6ca36d4acf8527637cfd8a8414_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTEwLTEtMS03MDAzNA_f02e749b-5e16-426a-9ebd-5921381fff52"
      unitRef="usd">351000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i17ef09cd80ce48528fd4e15b267fa581_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM3LTEyLTEtMS03MDAzNA_67d783e0-9467-4944-b59a-a9d893aef486"
      unitRef="number">-0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2195e9ea8f74827888df91311e38634_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTItMS0xLTcwMDM0_cd74b344-34cb-4463-9ec2-ea2b77036e3b"
      unitRef="usd">438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie560385a5b9746bfbc9ecf44f08e40b2_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTQtMS0xLTcwMDM0_a9e3d168-e6ec-4b04-8c4b-96aeb004a84b"
      unitRef="usd">463000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia2195e9ea8f74827888df91311e38634_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTYtMS0xLTcwMDM0_00074e2b-f4b1-43a7-9963-bf4db73f4b86"
      unitRef="number">-0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64c14ab77a3f4981856f2e47e937f928_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTgtMS0xLTcwMDM0_2875a69a-484d-4495-95ce-8403da58a6f3"
      unitRef="usd">881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6e2da82b9524140bea1c1e3e0376373_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTEwLTEtMS03MDAzNA_3b0ba521-67a8-4421-9416-057334d1b970"
      unitRef="usd">913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i64c14ab77a3f4981856f2e47e937f928_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTM4LTEyLTEtMS03MDAzNA_eae1532a-a847-4d4c-bd61-9a0fbff32e24"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica029ef15f3c412ea7f79ededd61891e_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTItMS0xLTcwMDM0_422c9569-421e-4c7b-9a42-d6b07600f6fc"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if38059bf51b94495b9e558db7253d6b7_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTQtMS0xLTcwMDM0_0cc1a5f3-831f-41ab-849a-9e428c95f1ae"
      unitRef="usd">268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ica029ef15f3c412ea7f79ededd61891e_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTYtMS0xLTcwMDM0_5cd15cad-a267-4322-9ce5-fb3694704715"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55223f8e057b44348303589fe6a6d634_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTgtMS0xLTcwMDM0_cf734b19-88ef-429c-9966-2a7046dfed40"
      unitRef="usd">541000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1da4c3fbf5a45588aa47da0d8af5515_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTEwLTEtMS03MDAzNA_e5191036-bc2f-4b5f-8d28-d624e21d78b4"
      unitRef="usd">527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i55223f8e057b44348303589fe6a6d634_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQwLTEyLTEtMS03MDAzNA_233d1015-0b6a-4fc9-903b-5c146e805147"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22eb4caafc674003b9ed0fe8faa1adfd_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTItMS0xLTcwMDM0_c7cdc320-5868-454c-a5d6-e52d49bee07a"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa53a4d85235465fb23f952022ed2de3_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTQtMS0xLTcwMDM0_7a07525a-f5e7-4e51-823c-2e4b4f8525d8"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i22eb4caafc674003b9ed0fe8faa1adfd_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTYtMS0xLTcwMDM0_d4fffbe0-0103-4cc0-ada0-474f397a3e6f"
      unitRef="number">0.262</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d1ebe756b1a4fdaba163f6226a73865_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTgtMS0xLTcwMDM0_279dd592-68f7-483f-9f0f-fd38bc07101a"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib38c14e59526462aa00b9fdf01150b88_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTEwLTEtMS03MDAzNA_ad5164b1-68ec-4986-bcc8-47ba30e2fa82"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8d1ebe756b1a4fdaba163f6226a73865_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQxLTEyLTEtMS03MDAzNA_6a5dd3cc-091d-49f7-a039-084229035b2e"
      unitRef="number">0.235</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81ca4cedb5aa472d978a64ed56e29c3e_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTItMS0xLTcwMDM0_ecb7a480-ded4-4f09-a8bb-a9d1e4e70f91"
      unitRef="usd">328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50df75de55354d31977579bd740f47d0_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTQtMS0xLTcwMDM0_cd3c28fd-a60c-4af4-8f20-696d902f2cc5"
      unitRef="usd">313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i81ca4cedb5aa472d978a64ed56e29c3e_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTYtMS0xLTcwMDM0_86653114-0849-4e3a-a334-5bb8ac70581b"
      unitRef="number">0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb8526f11d44a7285dcfe44fe83967c_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTgtMS0xLTcwMDM0_a1f525c1-c98a-459b-b9df-9049ad3c8626"
      unitRef="usd">653000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0d92da1715d4466934af62c118acd2d_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTEwLTEtMS03MDAzNA_5fcda91e-b757-44d3-b52e-8203b55eb1df"
      unitRef="usd">618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9fb8526f11d44a7285dcfe44fe83967c_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQyLTEyLTEtMS03MDAzNA_930974cc-4e7a-49e5-8561-3da961f25920"
      unitRef="number">0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0236b7aa74b24bf18b2ebaca9df2dfaa_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTItMS0xLTcwMDM0_dba7136e-8aed-4d1d-8081-1fba2054f565"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibebde257fe3c43c099d64ee47d4049de_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTQtMS0xLTcwMDM0_b30a0217-edfd-446f-8211-f755ba3bf01f"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0236b7aa74b24bf18b2ebaca9df2dfaa_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTYtMS0xLTcwMDM0_d373480d-f7cd-4bb5-8a83-6fc5720e6b3b"
      unitRef="number">-0.362</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4ff9ea6230d4739b53a98d08fe59cd1_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTgtMS0xLTcwMDM0_449a7425-0466-4d20-a56a-5f327d1a4582"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i557f42df940c4b5ab8401d631fbf9c50_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTEwLTEtMS03MDAzNA_dfd36b9b-30cf-44ed-97a0-1e70f5edf2ad"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib4ff9ea6230d4739b53a98d08fe59cd1_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ0LTEyLTEtMS03MDAzNA_b61d7c92-0361-43eb-9ca0-5160fb33afea"
      unitRef="number">-0.323</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdf3bc11cf184431b734d51a51999f44_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTItMS0xLTcwMDM0_458a0455-018a-438f-8beb-84789bc88e8f"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05790066f2a14f93b4be920ebfa71d30_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTQtMS0xLTcwMDM0_f62b65de-97c6-46cf-b9bd-440558547b92"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icdf3bc11cf184431b734d51a51999f44_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTYtMS0xLTcwMDM0_25056d97-5f74-48f6-8888-f14f0eadfd11"
      unitRef="number">-0.081</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0f0430dcadf4801885432b12fc09d25_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTgtMS0xLTcwMDM0_ed352e0c-c1ed-4fa2-b258-5fb6010feb57"
      unitRef="usd">108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25b567ecf14d4468a81aeaabef24109b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTEwLTEtMS03MDAzNA_438808d3-1c12-44d4-b4bf-9db40ae961be"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib0f0430dcadf4801885432b12fc09d25_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ1LTEyLTEtMS03MDAzNA_13715754-c984-4cff-855b-924ff15614fb"
      unitRef="number">-0.117</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25a1a2d1f27b42d4804ea393d24ea74a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTItMS0xLTcwMDM0_8a6ab624-5f1b-487c-b63a-e4d02bb1bf89"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d46afbf8ebf4c85a615530f2f6ca89c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTQtMS0xLTcwMDM0_6d06060e-6533-4249-a031-15d5b6ac02b5"
      unitRef="usd">95000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i25a1a2d1f27b42d4804ea393d24ea74a_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTYtMS0xLTcwMDM0_820f6b52-d919-4ceb-92b0-92782ae863e2"
      unitRef="number">-0.187</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbfa29cbf57143ac90d54acbc629ab41_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTgtMS0xLTcwMDM0_390f648f-12b8-48c5-8d8d-77029ae34b77"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b934d9eaccf40c292408c0121b1ab1f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTEwLTEtMS03MDAzNA_1df5c14c-6101-4bc7-b5c1-d3e6a49361cd"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idbfa29cbf57143ac90d54acbc629ab41_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ2LTEyLTEtMS03MDAzNA_cbfbcb63-cf9c-406d-9627-8639872eca7b"
      unitRef="number">-0.198</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6b191b04cb24993a324572ceed1a094_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTItMS0xLTcwMDM0_b0582da2-55f0-4fa6-851e-25392e45d479"
      unitRef="usd">757000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cd72d040762453daa0d7e628045ba1c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTQtMS0xLTcwMDM0_f5bc85a6-fe3c-4db6-935b-c84d81173516"
      unitRef="usd">780000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic6b191b04cb24993a324572ceed1a094_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTYtMS0xLTcwMDM0_6001ec79-ecd3-495b-b93c-1b3850c336d5"
      unitRef="number">-0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39d2198e5ec0432fa48695a07a06b16f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTgtMS0xLTcwMDM0_db40afc0-f169-4352-b557-1c20031477c4"
      unitRef="usd">1429000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb17e60efe244f14be98a7b086a2993b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTEwLTEtMS03MDAzNA_e261e2ac-cf6d-4c7a-b6ed-f2f0df8061a6"
      unitRef="usd">1579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i39d2198e5ec0432fa48695a07a06b16f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTQ5LTEyLTEtMS03MDAzNA_555866c0-7e0a-44ed-b998-bf3398b648ad"
      unitRef="number">-0.095</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic801c7ed779a4b89ab0b1c8ecda3f3c1_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTItMS0xLTcwMDM0_7d608950-6774-4210-ba03-13e1d3d452fd"
      unitRef="usd">215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2cf187fa1e34995ab2bc76d0f9990b1_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTQtMS0xLTcwMDM0_4e304176-3995-43f9-9a6b-c18a42b92953"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic801c7ed779a4b89ab0b1c8ecda3f3c1_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTYtMS0xLTcwMDM0_3a76cc5c-2771-417b-9269-b13173a4e0c9"
      unitRef="number">-0.109</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4eefdcd0b36f4eab9f7efff9e9bbd8b4_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTgtMS0xLTcwMDM0_fc166634-b611-4b7d-8b87-5fdc61bc3611"
      unitRef="usd">453000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d2207e1597d44adb9a60324bef5417b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTEwLTEtMS03MDAzNA_73a132ce-a809-49d1-a288-ec8cbe203db8"
      unitRef="usd">486000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4eefdcd0b36f4eab9f7efff9e9bbd8b4_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUwLTEyLTEtMS03MDAzNA_56aec7fc-a4e8-460d-976c-ca2513298af5"
      unitRef="number">-0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73303bef5d5d44fa9de21fa225eb70b0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTItMS0xLTcwMDM0_472805ae-bf1f-474e-87b7-03b3c97c74bc"
      unitRef="usd">972000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i328e26ff5b614b91acdf8a791462b459_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTQtMS0xLTcwMDM0_b36ff4b2-1b18-4f43-9ce4-db7bfad2cee6"
      unitRef="usd">1021000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i73303bef5d5d44fa9de21fa225eb70b0_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTYtMS0xLTcwMDM0_a14f5377-b272-4f9a-b0eb-b3124929b9c2"
      unitRef="number">-0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7be86e56935f49e082bc5a14e5f2756d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTgtMS0xLTcwMDM0_6958c946-da51-42bf-89f0-5fdb65b43796"
      unitRef="usd">1882000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fffd0e4936e44f9ab0a1b46f12c274f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTEwLTEtMS03MDAzNA_1f00cc52-8317-4b3f-8860-482dec47346a"
      unitRef="usd">2065000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7be86e56935f49e082bc5a14e5f2756d_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUxLTEyLTEtMS03MDAzNA_b01a95e8-dfc2-42e9-a788-ea3daac60743"
      unitRef="number">-0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic518c8578d7d45928e9c8d6d8f5afdb9_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTItMS0xLTcwMDM0_5ec49d18-0d46-4803-a7e4-082082324b7a"
      unitRef="usd">609000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib11d6a998a194ce0abd3b90c4cac5da7_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTQtMS0xLTcwMDM0_adffddc5-6fb3-4da7-b2df-05a8b637b5cc"
      unitRef="usd">569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic518c8578d7d45928e9c8d6d8f5afdb9_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTYtMS0xLTcwMDM0_0650a327-320f-4ddb-9997-52beed98adfd"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94d2a4965d144779a4ceefbf2e67dda8_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTgtMS0xLTcwMDM0_0b372c62-4bca-41fc-9fc2-abbc74effa4e"
      unitRef="usd">1117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dbfb604e8334efcb004e1de36bbe2ba_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTEwLTEtMS03MDAzNA_110cf3d4-f9a1-4c07-867e-ce1f2f069cd5"
      unitRef="usd">1158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i94d2a4965d144779a4ceefbf2e67dda8_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTUzLTEyLTEtMS03MDAzNA_0047fdb3-fe8d-48ad-b23c-11f75a92ca69"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4a5fe4bb174446db8453acdb52d0b8d_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTItMS0xLTcwMDM0_8e3183e5-9ce2-42d2-a997-6e619c8fd020"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5868064a491c4c21beda0fc35e2236f5_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTQtMS0xLTcwMDM0_71bf253f-bd64-4926-a2db-ba85a75cc892"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic4a5fe4bb174446db8453acdb52d0b8d_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTYtMS0xLTcwMDM0_45e08a03-72ef-4313-a6e3-50c16c694d38"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcef923095ae403daa45a3cd38e272eb_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTgtMS0xLTcwMDM0_4ee222e2-6fd1-44bb-b740-2662b7afdbfe"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d2e614016aa4c27b3a18c5a2bb1d03d_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTEwLTEtMS03MDAzNA_4b7020de-f3af-4789-a942-7c958edf1f52"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibcef923095ae403daa45a3cd38e272eb_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU0LTEyLTEtMS03MDAzNA_739fa34f-513a-45bd-8c1c-88d0588b800e"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05d4961fbd434dfdb053a7619753dbb5_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTItMS0xLTcwMDM0_191e2833-6b95-4232-bdbf-a8212507f4d6"
      unitRef="usd">609000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5288342ca6544db84e6afa56ec57667_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTQtMS0xLTcwMDM0_dc7217dd-701e-4420-b646-6fd2f7d13415"
      unitRef="usd">569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i05d4961fbd434dfdb053a7619753dbb5_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTYtMS0xLTcwMDM0_828ffcfe-8f6e-435b-ba69-c7e0ee1d2796"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f2490c0acc14641bd54b07d1a9dcba1_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTgtMS0xLTcwMDM0_878bf0a3-af59-45bb-8c28-bdeea33ae4ef"
      unitRef="usd">1117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8201a9664e94c64abb84f293366b311_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTEwLTEtMS03MDAzNA_99f90df5-eeae-4309-97a3-936782d8174d"
      unitRef="usd">1158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1f2490c0acc14641bd54b07d1a9dcba1_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU1LTEyLTEtMS03MDAzNA_ecc9e240-96b6-4754-8510-77cb7d5f4585"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41a145198034434d8c34cb328adb37ee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTItMS0xLTcwMDM0_dd33e729-b97b-481f-bb04-99d3ce0c8dd0"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa58911049db441c9be14900db7de10b_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTQtMS0xLTcwMDM0_828f00c9-999c-43c7-849f-94f939746612"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i41a145198034434d8c34cb328adb37ee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTYtMS0xLTcwMDM0_a40c8e41-b53a-4f13-a310-c5c1dc2c4edd"
      unitRef="number">-0.429</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92942d5c5a284320a4d0d4db266ef84b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTgtMS0xLTcwMDM0_99211fb8-5555-417d-9795-7aff201c2b7b"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13dbe9e6430447a283ce3f28d7a2cff3_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTEwLTEtMS03MDAzNA_23c86430-038e-4f99-ba2e-e463019e38b0"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i92942d5c5a284320a4d0d4db266ef84b_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU3LTEyLTEtMS03MDAzNA_0a3fb888-8846-4603-b3a5-37c8b5fef85a"
      unitRef="number">-0.371</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i634a6971cc2c4ab4b880a9dc1245444c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTItMS0xLTcwMDM0_ee117213-2002-40be-9a2f-32a0d98a92fc"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9198cff7a66447b9be7b837f342aaf9_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTQtMS0xLTcwMDM0_02b4a3d5-48b1-4e68-ad25-6ead559d25ad"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i634a6971cc2c4ab4b880a9dc1245444c_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTYtMS0xLTcwMDM0_8084f844-e559-4b4c-9ec9-6d1da12f0433"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63e2dbe91cf1482c865a5ed7f20252ae_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTgtMS0xLTcwMDM0_ebc6ea99-6bed-4442-97b3-0dcb6e110201"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i280edb799a7541e4b978e766002ab0dd_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTEwLTEtMS03MDAzNA_408766c8-cda1-4fd0-8632-abeed78d19d7"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i63e2dbe91cf1482c865a5ed7f20252ae_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU4LTEyLTEtMS03MDAzNA_b2315ab3-6ea0-4134-969e-9ace25f7998a"
      unitRef="number">0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2df7fc7846394d8cb6b3dfa190ddbeec_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTItMS0xLTcwMDM0_e79877e6-7708-495b-b263-2a1d880f27cc"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a4358b89737469c9a4a76ab01d38b21_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTQtMS0xLTcwMDM0_21c1175f-7e3e-457a-9ecc-abcf9c81e1ba"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2df7fc7846394d8cb6b3dfa190ddbeec_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTYtMS0xLTcwMDM0_dd89f5a5-66da-4a38-9d3d-9e7ebf629529"
      unitRef="number">-0.249</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i748c908553434318bab2f9e71aca0df3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTgtMS0xLTcwMDM0_28c8ef32-6efe-42f0-9f59-fcafeff098ef"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d7d57cfef704ed4a19a72497cfd1cff_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTEwLTEtMS03MDAzNA_d0008e9e-c2fb-44a0-9293-68c3a519ff9b"
      unitRef="usd">310000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i748c908553434318bab2f9e71aca0df3_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTU5LTEyLTEtMS03MDAzNA_582cde3e-b4fe-41b4-8897-17ec975c2e2c"
      unitRef="number">-0.199</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07dc3cd22e6141a9b58734901b2bcca3_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTItMS0xLTcwMDM0_4398e537-ce30-487c-b604-a7de7ee92e1c"
      unitRef="usd">93000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib37d45622a2a4e2aaf861e5d5425dc36_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTQtMS0xLTcwMDM0_9faaf3eb-187d-4ed7-8c28-4939c9bcd428"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i07dc3cd22e6141a9b58734901b2bcca3_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTYtMS0xLTcwMDM0_efcbe04b-5ff7-4fde-889d-99acf66d3d65"
      unitRef="number">-0.195</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5736eee575b44f30b0528226c5b341e0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTgtMS0xLTcwMDM0_67d90e27-e198-46f5-9948-2e6b5160deb2"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd466ee6375247868fb5aa1fe4cf6baf_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTEwLTEtMS03MDAzNA_d159b7a4-0c1c-44e2-b635-92b6713396b1"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5736eee575b44f30b0528226c5b341e0_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY1LTEyLTEtMS03MDAzNA_f7704693-6c85-42f0-aa0c-6fb64b348a9d"
      unitRef="number">-0.172</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i453e566b12f94b9ca1bf28f9a151ca35_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTItMS0xLTcwMDM0_f9db2c57-d0ee-43c0-904e-b5f0952d7473"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ac7771dfc5043b3bc9fe3d75e90560b_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTQtMS0xLTcwMDM0_26ec1150-0971-4925-8734-adba2d019ac6"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i453e566b12f94b9ca1bf28f9a151ca35_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTYtMS0xLTcwMDM0_2b9371f2-eb88-4811-b083-832557c0759e"
      unitRef="number">-0.156</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19b54aa8f21a4defb2e212647938d507_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTgtMS0xLTcwMDM0_e33d377b-8038-489a-8686-4f1cb48a84df"
      unitRef="usd">320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0430efa680354f9cb2e7be97ad4bbd52_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTEwLTEtMS03MDAzNA_0f24771c-d0fd-43f3-bb6b-4cb383285223"
      unitRef="usd">360000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i19b54aa8f21a4defb2e212647938d507_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY2LTEyLTEtMS03MDAzNA_06783af4-2c8d-4b33-8e18-24ab00c26bc2"
      unitRef="number">-0.111</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01602ac9da834941912114e1dd805606_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTItMS0xLTcwMDM0_404e04e7-caf6-4a47-a66b-8d4034eedbc2"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2018aba666564bf1b4cbefc426636cd4_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTQtMS0xLTcwMDM0_2bb58aeb-b9f1-463e-92fb-9cb516d03327"
      unitRef="usd">293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i01602ac9da834941912114e1dd805606_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTYtMS0xLTcwMDM0_2c677ffd-a722-4a70-be80-0b4410077715"
      unitRef="number">-0.172</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica2b3030232242349c0d22aa237d5dd7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTgtMS0xLTcwMDM0_c8c7ffdb-8d5a-417c-ac05-f5180322bd7a"
      unitRef="usd">517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10a4ac80eaa840618cb738116eeaed5d_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTEwLTEtMS03MDAzNA_540584cb-d0ee-4f97-93b4-ee252282e6d8"
      unitRef="usd">598000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ica2b3030232242349c0d22aa237d5dd7_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTY3LTEyLTEtMS03MDAzNA_91471e56-b7c3-4843-99e4-e656420f3a52"
      unitRef="number">-0.135</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia46733e339864c9abf57c0d982aa4ce3_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTItMS0xLTcwMDM0_323a6d16-9657-4ebb-a85e-9edab110cedd"
      unitRef="usd">7159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic649a922ce584f0d9a52986e9dc716a2_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTQtMS0xLTcwMDM0_38be5e5a-80f7-4883-aa71-bd77140c6cb9"
      unitRef="usd">6869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia46733e339864c9abf57c0d982aa4ce3_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTYtMS0xLTcwMDM0_660f1f02-cc92-44d8-bda8-eac9b5539937"
      unitRef="number">0.042</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab330b638fb84af6abe1d5d6ece91457_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTgtMS0xLTcwMDM0_3a2d23cc-6e62-494a-b511-4a573a9e8f80"
      unitRef="usd">13791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ba7b8ae8c0741bc955d90fcc7f5d900_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTEwLTEtMS03MDAzNA_86e0773c-a0aa-43d7-8b2a-12faf47eb4f5"
      unitRef="usd">13315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iab330b638fb84af6abe1d5d6ece91457_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcwLTEyLTEtMS03MDAzNA_34cdf659-aa45-4ae7-b17e-99304e1e0d03"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia03b1fe2f3c84cfcb0bb12f78e27dfd3_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTItMS0xLTcwMDM0_06bc3fcf-cc2f-4f54-9723-c7bffb079d5d"
      unitRef="usd">6158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1878e36b1da48ddb9bb5431f67577b0_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTQtMS0xLTcwMDM0_f45925a9-b6d4-4003-a6cf-f29d051e3539"
      unitRef="usd">5611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia03b1fe2f3c84cfcb0bb12f78e27dfd3_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTYtMS0xLTcwMDM0_caa0c0e2-1816-4917-8104-9b28b4dbbf18"
      unitRef="number">0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dfc5851d11944dbb13e597eb1fd2070_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTgtMS0xLTcwMDM0_548b6b2a-1ece-4fb3-919e-9acad4b2cb0f"
      unitRef="usd">12395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62985e4313f041be8295862d52b0fc22_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTEwLTEtMS03MDAzNA_71eceb53-ebec-4cd7-8f76-fe0c4ff484bf"
      unitRef="usd">11266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4dfc5851d11944dbb13e597eb1fd2070_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcxLTEyLTEtMS03MDAzNA_6ee41b5a-189c-4c95-94f3-f2e80367974d"
      unitRef="number">0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i637eadc895304441993cdbadddd0035c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTItMS0xLTcwMDM0_83185f8c-8a33-43d1-9172-8edab73538be"
      unitRef="usd">13317000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02a3c9a671634fbba070e5002be64b8d_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTQtMS0xLTcwMDM0_a5ce2156-f52c-4235-9364-c4159f63b3d6"
      unitRef="usd">12480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i637eadc895304441993cdbadddd0035c_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTYtMS0xLTcwMDM0_a37b2a55-a2e6-4dba-9bd4-316adc15e5f5"
      unitRef="number">0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTgtMS0xLTcwMDM0_f0e7b86b-ead9-4ef8-9849-e7446d30aebd"
      unitRef="usd">26186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bd716f176c54a4ab7a98be713399fc0_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTEwLTEtMS03MDAzNA_30785eb7-d47f-4788-9524-4caf7a45a114"
      unitRef="usd">24581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie2f241249beb4e2c8e6f20cfdee65fc7_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTcyLTEyLTEtMS03MDAzNA_7058f660-3d50-423b-8529-c1cbe2049f21"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ebdbfdd7008486e8f029ba89cadcf10_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTItMS0xLTcwMDM0_528a17ec-71c7-4c25-83ea-169886a64de1"
      unitRef="usd">525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6daaee3c30874bc79deda2eecad2dfd6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTQtMS0xLTcwMDM0_bb48b10b-c7a0-4953-a451-b1f486e4d2f8"
      unitRef="usd">475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4ebdbfdd7008486e8f029ba89cadcf10_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTYtMS0xLTcwMDM0_083d133f-8820-4312-822f-e9c6ffb283da"
      unitRef="number">0.105</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75726cc4c32942e7a189dd026b7e9840_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTgtMS0xLTcwMDM0_e2aee550-fa6e-4ae4-adc3-097126afce11"
      unitRef="usd">1019000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78908a1d4be846b8a6aced964d30ae02_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTEwLTEtMS03MDAzNA_3a92b3e4-d526-451a-97c6-489123d676d4"
      unitRef="usd">909000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i75726cc4c32942e7a189dd026b7e9840_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg1LTEyLTEtMS03MDAzNA_55e78592-ebfc-4c50-8e69-ff6f59c9c8d7"
      unitRef="number">0.121</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ebc6f14333d4c1388255155e8187c1c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTItMS0xLTcwMDM0_6aa4fa17-2b17-48cd-ace5-9bd65eb0bd49"
      unitRef="usd">525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia43954139ed84f7788fdfc46187abd9c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTQtMS0xLTcwMDM0_8daf04aa-706e-4cf4-8608-05f88403f90a"
      unitRef="usd">572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ebc6f14333d4c1388255155e8187c1c_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTYtMS0xLTcwMDM0_93c59180-0881-44b6-83fe-1b32c2a1aa82"
      unitRef="number">-0.081</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19a3f4ca28e54311a8fa6ffc5adf57e5_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTgtMS0xLTcwMDM0_c15ea4b4-66c2-41f7-8e49-806372a53d81"
      unitRef="usd">1123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58f9cf052510468ba9fc81d28838fd23_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTEwLTEtMS03MDAzNA_6127e0de-07b6-4bf5-9468-677728e85d3c"
      unitRef="usd">1086000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i19a3f4ca28e54311a8fa6ffc5adf57e5_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg2LTEyLTEtMS03MDAzNA_fe9d9e30-d022-471d-b6df-901521acfea8"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e9a42189a364282ad35f4fd9c4a7727_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTItMS0xLTcwMDM0_1897e659-2671-4394-aa54-26a597f7819f"
      unitRef="usd">1049000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9144df0a32e4cb08d0e4aa2404166d7_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTQtMS0xLTcwMDM0_765359f9-d2e6-4d05-a657-3b2bb0d094c3"
      unitRef="usd">1046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3e9a42189a364282ad35f4fd9c4a7727_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTYtMS0xLTcwMDM0_9706ccb4-4250-4048-a507-b205ac4aefc4"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fb3c8f804914aacbb20f2e7f625263a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTgtMS0xLTcwMDM0_641c4473-e8ac-421e-a4ce-887526e6ad68"
      unitRef="usd">2141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c37042917f440519d1e8bc9992f2fec_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTEwLTEtMS03MDAzNA_af3c8145-6b09-4b08-b352-8a85f7168a0e"
      unitRef="usd">1995000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8fb3c8f804914aacbb20f2e7f625263a_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg3LTEyLTEtMS03MDAzNA_9afc5dd3-9c8d-4d3a-b09d-51631035a6ec"
      unitRef="number">0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c2629a235c24645959df36f899307dc_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTItMS0xLTcwMDM0_9417f22c-9229-48cf-9d3e-28ecad9bad49"
      unitRef="usd">1338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e55ed4369874656b82f600d8374ab35_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTQtMS0xLTcwMDM0_74c670e7-02ad-4b46-b66f-6f0afa3c4b86"
      unitRef="usd">1323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c2629a235c24645959df36f899307dc_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTYtMS0xLTcwMDM0_b9feda61-e7e4-4682-a8e2-331716e07413"
      unitRef="number">0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c61d257b050413a9a5a10d395f54aae_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTgtMS0xLTcwMDM0_91abf0fc-d94d-439b-9e9b-e7aa7fb7f3ae"
      unitRef="usd">2627000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibda8eac58b0944c9aab3bf2cde640d22_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTEwLTEtMS03MDAzNA_9e53cc25-5d12-4582-8f5e-b908591a3e34"
      unitRef="usd">2572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8c61d257b050413a9a5a10d395f54aae_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTg5LTEyLTEtMS03MDAzNA_0d2d58af-6f41-45dd-95d6-423f1f0f4b03"
      unitRef="number">0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdc7392d00fe4b7db44b1ba0ad3f51fd_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTItMS0xLTcwMDM0_058bfbde-b55b-4604-a48a-2a587078be37"
      unitRef="usd">820000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f9843005d574706b3acbf5b7281d78f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTQtMS0xLTcwMDM0_04ae054a-4c9b-496b-9146-e453bb382dd4"
      unitRef="usd">904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifdc7392d00fe4b7db44b1ba0ad3f51fd_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTYtMS0xLTcwMDM0_561363ec-30cb-43f3-8d87-e8308a944497"
      unitRef="number">-0.093</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab78a1c95a9c4ab192a4c1a1d997c9ca_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTgtMS0xLTcwMDM0_1a0c30cc-e929-4f79-adf6-916cb82c73f8"
      unitRef="usd">1719000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i776c543649cb40e19afd5abe8d84c755_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTEwLTEtMS03MDAzNA_476127fd-8538-458b-b06b-2fd322bbb951"
      unitRef="usd">1768000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iab78a1c95a9c4ab192a4c1a1d997c9ca_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkwLTEyLTEtMS03MDAzNA_540838bb-0f06-4599-83a1-deff5f6a7855"
      unitRef="number">-0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08070e9deccd401188eddde752dc796b_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTItMS0xLTcwMDM0_62cf1c9d-1748-42e6-bdde-4d19a691ff5b"
      unitRef="usd">2157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i097c8aa852634e928b7afcda7183e13c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTQtMS0xLTcwMDM0_7b1ada3a-d78e-4bf9-b012-abdab3646219"
      unitRef="usd">2227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i08070e9deccd401188eddde752dc796b_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTYtMS0xLTcwMDM0_f658993d-0e04-46e5-8941-d52c2ca89071"
      unitRef="number">-0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i574c9d60d2e44b9cb58117accbb26f8e_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTgtMS0xLTcwMDM0_0eb9c69f-0e64-4c05-a59b-b80697a77e9c"
      unitRef="usd">4345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i288b2f784c3e4914ac7711b5f2478340_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTEwLTEtMS03MDAzNA_e95ee7e4-803d-442b-a522-04a11d747ca3"
      unitRef="usd">4340000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i574c9d60d2e44b9cb58117accbb26f8e_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkxLTEyLTEtMS03MDAzNA_8c99b98c-01b3-43ed-aa6e-b38e09b2b5c9"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2d97ec6f67842ab9cadf89c6fe46eda_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTItMS0xLTcwMDM0_d764a9a6-577e-4f5e-899c-215b47fa0b0f"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84032433ba9a4c7ba7a5e2b0546f0df0_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTQtMS0xLTcwMDM0_84804183-7a8d-4e6a-8e5b-8986dc081cdd"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia2d97ec6f67842ab9cadf89c6fe46eda_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTYtMS0xLTcwMDM0_9d4b196b-4193-4fa7-99be-3bd0d80c218f"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a6d6bc6ec434449b8d91b39d96f7fdd_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTgtMS0xLTcwMDM0_80897c6e-4d22-4b01-b928-cf79b8d3f849"
      unitRef="usd">465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4db29bb20ad146c98f52bdefa9efc026_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTEwLTEtMS03MDAzNA_174f5d63-2a77-44a4-bffb-e6e04e163e96"
      unitRef="usd">442000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0a6d6bc6ec434449b8d91b39d96f7fdd_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTkzLTEyLTEtMS03MDAzNA_a791e6b6-cb02-43de-adb0-92f64d2c4abb"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id86625d8b1c144f6a7fcb9b8153032b9_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTItMS0xLTcwMDM0_05cb7dde-923d-40bc-96d1-8e0244fd3ba4"
      unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia123fa54d1184c2aad6e71ad4bae91a2_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTQtMS0xLTcwMDM0_67cfd49f-d377-459a-af3a-5cb1b8e2a978"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id86625d8b1c144f6a7fcb9b8153032b9_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTYtMS0xLTcwMDM0_5d35dc54-8238-41f3-8fa0-cf8bdf38167b"
      unitRef="number">-0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65c45e5237224a03a593f86fb93b0f6e_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTgtMS0xLTcwMDM0_421bf8a9-0f40-4e00-8b28-068a5a4ecee6"
      unitRef="usd">312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if310cab52cc8487192e4cee2584a6967_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTEwLTEtMS03MDAzNA_c6233c3f-2f29-4552-964d-d43ceee1020b"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i65c45e5237224a03a593f86fb93b0f6e_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk0LTEyLTEtMS03MDAzNA_87f7f52b-5fe9-4f9d-8480-3de18293507f"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5da796b8ae144afaa39da1574f7ee62f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTItMS0xLTcwMDM0_e30322f7-df04-4560-ae39-e56a1bbdf88a"
      unitRef="usd">388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3333c58c0224485a25259a31b39760c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTQtMS0xLTcwMDM0_dacd8cbd-b49b-4c87-b3ff-45cf11ac5474"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5da796b8ae144afaa39da1574f7ee62f_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTYtMS0xLTcwMDM0_d586e635-737a-4cf1-8c90-bb333e58c76a"
      unitRef="number">-0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d0ef2500d684d2499aa554260f71a9a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTgtMS0xLTcwMDM0_cd0e2e43-6a60-4e82-8238-fdde7fbfd7ed"
      unitRef="usd">777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5af9ca056caa4bd992cb4135170e25b6_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTEwLTEtMS03MDAzNA_6fcef373-07da-48ed-bd57-6ee774008c7c"
      unitRef="usd">747000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6d0ef2500d684d2499aa554260f71a9a_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk1LTEyLTEtMS03MDAzNA_6252f8e9-0170-4495-bd27-d6f542ece02d"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief64ee8dccfd4858bca89783721cee84_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTItMS0xLTcwMDM0_142eef82-e9d9-460e-9218-9e213e043e6d"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i535b8d9ff9b64a70bf52d430da04038b_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTQtMS0xLTcwMDM0_378153a7-1408-466f-a353-e1fadc914546"
      unitRef="usd">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ief64ee8dccfd4858bca89783721cee84_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTYtMS0xLTcwMDM0_4be84952-a370-4fb3-bf62-5eabc4ece038"
      unitRef="number">0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b7b0bfbd8d946e583f91bdff7c13a2f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTgtMS0xLTcwMDM0_5d329855-885c-4375-8fcc-5899e10b3c12"
      unitRef="usd">417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d06f779d4c344b5a71fc394e5493ba1_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTEwLTEtMS03MDAzNA_9782afb9-2bff-414f-bb4d-9754b0a0b868"
      unitRef="usd">395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0b7b0bfbd8d946e583f91bdff7c13a2f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk3LTEyLTEtMS03MDAzNA_a338a9ab-3e0c-497a-b547-220f624b550d"
      unitRef="number">0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i488ea6d5e23043b399c268075239f4e0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTItMS0xLTcwMDM0_f70d2b7e-8fc6-4210-925f-2dae817670f4"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d8db5b819f845cfa20287368a74625f_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTQtMS0xLTcwMDM0_598bbb09-b89e-4734-a718-4d3231ea2a55"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i488ea6d5e23043b399c268075239f4e0_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTYtMS0xLTcwMDM0_48425de9-9ba7-4020-8e57-35484ff02909"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i308a3a88c11043999761321424b73595_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTgtMS0xLTcwMDM0_2599f567-d20f-4df6-8f45-55f64d7e402f"
      unitRef="usd">271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68b8bbd849704bb8a3082cf7ddf04d68_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTEwLTEtMS03MDAzNA_b4f5924b-b6a2-428e-8602-dd3ca75b6981"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i308a3a88c11043999761321424b73595_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk4LTEyLTEtMS03MDAzNA_e3439be6-dd81-4da0-86b6-43059a805366"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib50f737a17604260939c66ca049ac180_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTItMS0xLTcwMDM0_ce59f832-acbc-40ca-846f-02a4afc84746"
      unitRef="usd">349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff780826f8d4410fb949c193f8b1f46c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTQtMS0xLTcwMDM0_d46b3f02-e4bc-469a-a6b9-58967c76887f"
      unitRef="usd">350000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib50f737a17604260939c66ca049ac180_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTYtMS0xLTcwMDM0_f01e6d89-1235-484b-867c-fcbea7c6cb89"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7919279ca65c431e8605adcfc55e133c_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTgtMS0xLTcwMDM0_73821357-2c99-4794-841d-7fe3f580913e"
      unitRef="usd">688000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic304b1ad72744238ab93ae9de9dbbf07_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTEwLTEtMS03MDAzNA_5aadd8d9-c3dc-4a6e-a297-b6cf764b1f2b"
      unitRef="usd">667000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7919279ca65c431e8605adcfc55e133c_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMTk5LTEyLTEtMS03MDAzNA_63651660-56b5-4627-b65b-a42a9747e35c"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f9722068a2d428f869481dca29dbdfd_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTItMS0xLTcwMDM0_37a729bf-d5e5-4135-8b02-64e4865657ff"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6fccf214b6547379cc0f5be19a827a5_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTQtMS0xLTcwMDM0_e6df681c-badc-47de-8d81-09e22b22198e"
      unitRef="usd">447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0f9722068a2d428f869481dca29dbdfd_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTYtMS0xLTcwMDM0_dc3e2333-2597-4c2d-acd3-efc6a802a59a"
      unitRef="number">0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcb2ac2edd4547409e4873be0e8e70d0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTgtMS0xLTcwMDM0_57e19366-9bf5-4141-941c-dd0b30feeefa"
      unitRef="usd">939000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia34444c4d5b245d6882f29099655768f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTEwLTEtMS03MDAzNA_09dcf44f-b161-405d-b7c6-b23effa60d0f"
      unitRef="usd">897000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifcb2ac2edd4547409e4873be0e8e70d0_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAxLTEyLTEtMS03MDAzNA_cc1d9b9a-d694-4b39-8375-e081eddb93d1"
      unitRef="number">0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0963689bca64f6898d7b2bf22ef5fc4_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTItMS0xLTcwMDM0_345f8b26-72b3-4e85-88bb-0248fa615f18"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6077b503ac1a407ca0aa969ab1a53c71_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTQtMS0xLTcwMDM0_16db02d8-a28f-40b6-95b8-4278514071f7"
      unitRef="usd">263000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie0963689bca64f6898d7b2bf22ef5fc4_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTYtMS0xLTcwMDM0_308e6fd9-b85a-41b3-a86e-b544210a31a1"
      unitRef="number">-0.118</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfc182ac674a40cda02a21659912b0ac_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTgtMS0xLTcwMDM0_55b5a77d-db0e-491f-bef4-3db4a7b93b57"
      unitRef="usd">505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1100853d86db4419993b4d34aeecc26f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTEwLTEtMS03MDAzNA_7f2e5fd5-b1ef-4c76-976f-3464e5a05a7c"
      unitRef="usd">545000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idfc182ac674a40cda02a21659912b0ac_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAyLTEyLTEtMS03MDAzNA_799ca3b0-4a99-422f-9284-040c69cb693a"
      unitRef="number">-0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d2f83c9f3cf4e93b4ab482d7b240b68_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTItMS0xLTcwMDM0_6249cbb6-df8d-4c0a-b8bf-eb8146a52be0"
      unitRef="usd">696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ff83048ffc448809d919aa3cc1cdbf0_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTQtMS0xLTcwMDM0_8ffc7575-1a78-411a-9006-2f01c56c5564"
      unitRef="usd">710000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4d2f83c9f3cf4e93b4ab482d7b240b68_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTYtMS0xLTcwMDM0_6a07ccca-c1fa-4fe2-b6de-fbaf51d1e6c7"
      unitRef="number">-0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0000c4d098c643cda7e8da1a1ce56862_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTgtMS0xLTcwMDM0_a8d9287c-36e4-4727-9643-53c09c5ae7f2"
      unitRef="usd">1444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dfe4776943b47558791ca89120c5de1_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTEwLTEtMS03MDAzNA_fb701cf4-0197-4d7c-9adf-93b462fe5e79"
      unitRef="usd">1443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0000c4d098c643cda7e8da1a1ce56862_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjAzLTEyLTEtMS03MDAzNA_095cd716-4d4a-4d15-85fa-033cee7eeabe"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0128c7e2dc824abf8e6b5ba3df4232cc_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTItMS0xLTcwMDM0_18f813e4-a0b2-405e-a57c-78ed4eeea071"
      unitRef="usd">418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic831591b74d94d658a1c241551842979_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTQtMS0xLTcwMDM0_af1905d4-6e83-4ad9-b1d6-2fc44ca4d239"
      unitRef="usd">434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0128c7e2dc824abf8e6b5ba3df4232cc_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTYtMS0xLTcwMDM0_f05fa8dc-5468-4789-a819-eeac2519a807"
      unitRef="number">-0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ideb8786f17a944249a713999b3b6e208_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTgtMS0xLTcwMDM0_c7c67098-9746-4bf1-a41e-a29dfad74003"
      unitRef="usd">805000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf46a55a1dca41ffa4b84ec847aa7e7d_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTEwLTEtMS03MDAzNA_e6bfc57d-9797-490d-92de-60cb07cee0ea"
      unitRef="usd">838000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ideb8786f17a944249a713999b3b6e208_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA1LTEyLTEtMS03MDAzNA_6b3bbef3-5116-4e16-b6f3-359a8da36fe2"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i722cb51aca1543c3a7ae3b0a6fe127ff_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTItMS0xLTcwMDM0_28b1df94-f2f2-48d6-905d-76f885addfd4"
      unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaf6e5a27a774e869497e0aa2f53c5b9_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTQtMS0xLTcwMDM0_a22fff61-e667-45a8-b909-540df78868d2"
      unitRef="usd">343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i722cb51aca1543c3a7ae3b0a6fe127ff_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTYtMS0xLTcwMDM0_2690dd4f-0751-4c25-a228-7d3a27c37cd2"
      unitRef="number">-0.106</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia015295d7f5a43dcaad4e1a68cefc54f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTgtMS0xLTcwMDM0_d73898d8-cdc0-4121-af53-d64cb55ff24c"
      unitRef="usd">630000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5400f99139394995bff032d46312fcac_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTEwLTEtMS03MDAzNA_b6acd520-09e0-4a1f-99e0-c5399c07b1a1"
      unitRef="usd">646000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia015295d7f5a43dcaad4e1a68cefc54f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA2LTEyLTEtMS03MDAzNA_b441564c-0ace-4d01-89f5-0a90464be528"
      unitRef="number">-0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9845531e1544cfaa60c21e5946faa1a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTItMS0xLTcwMDM0_60866027-a705-4d68-ab5e-510c9c9615e5"
      unitRef="usd">724000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc7cdcd1f2024d52919c1a2b418c162c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTQtMS0xLTcwMDM0_e9e824e7-1ba6-4fb2-9939-7534dca7734e"
      unitRef="usd">777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id9845531e1544cfaa60c21e5946faa1a_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTYtMS0xLTcwMDM0_f328f46f-c799-49cf-885d-ece22fcbf3b1"
      unitRef="number">-0.068</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1743be59d8b4610a3d295d501005cd0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTgtMS0xLTcwMDM0_c2aa7a24-b1fd-4abc-8d2b-2c43ea0fe295"
      unitRef="usd">1436000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ef90bedc87e45cea6e49532d1496f6d_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTEwLTEtMS03MDAzNA_47872085-6dbe-45c2-80ba-f0b5af6effb2"
      unitRef="usd">1484000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib1743be59d8b4610a3d295d501005cd0_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA3LTEyLTEtMS03MDAzNA_277dca3b-9917-4b52-b696-5f6eb11ea9dd"
      unitRef="number">-0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3287b402551c4484b394de8276d293f9_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTItMS0xLTcwMDM0_e3fa47ca-b9a3-4d32-9864-00386455605d"
      unitRef="usd">992000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7662fd5ddc4846a3b1818f333fa21bc6_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTQtMS0xLTcwMDM0_f30df582-db9b-4fc6-a49b-b50a18c4a6e9"
      unitRef="usd">1035000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3287b402551c4484b394de8276d293f9_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTYtMS0xLTcwMDM0_1e2cab09-a1c6-4135-be5d-a2d362f7eaa0"
      unitRef="number">-0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7a2ce0616b7406aaf58a444927e2047_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTgtMS0xLTcwMDM0_e7e8f7e0-9fdf-4b6f-ba32-e2738ec963c3"
      unitRef="usd">1913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib532fb9422ed4614a1eecad8c8435a75_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTEwLTEtMS03MDAzNA_e93eb347-9dea-4c74-b66e-ef1f6babdfb7"
      unitRef="usd">1933000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if7a2ce0616b7406aaf58a444927e2047_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjA5LTEyLTEtMS03MDAzNA_57a0d4f3-a7da-42fa-9dd9-5f5cd17c01db"
      unitRef="number">-0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bc1c765754d4475a879977b61883766_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTItMS0xLTcwMDM0_985ae93a-982e-45d9-a6d7-e26f621b7c4b"
      unitRef="usd">1458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38876ff942eb4950811a685cde835ba5_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTQtMS0xLTcwMDM0_6ad8d2db-f9de-4659-895e-bfc9fe615c51"
      unitRef="usd">1487000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6bc1c765754d4475a879977b61883766_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTYtMS0xLTcwMDM0_877c3e77-dea9-41f5-b9e7-e7e04315def6"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia710ad7cb9d04f4184dbd32294cd4f75_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTgtMS0xLTcwMDM0_ebd7e6c4-1bdd-417f-86ea-eeb113b21f7a"
      unitRef="usd">2971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25fca766f96443b785e425e523fbce14_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTEwLTEtMS03MDAzNA_9649c042-e93e-4b34-9fd0-020625e58bf4"
      unitRef="usd">2961000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia710ad7cb9d04f4184dbd32294cd4f75_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEwLTEyLTEtMS03MDAzNA_9c892447-1ee2-4021-9a3c-34608a03f9c1"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20dcb86296844dbda765eb7afdc78e2d_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTItMS0xLTcwMDM0_422f5fdb-cc96-4b86-96d5-c993d2df3cd3"
      unitRef="usd">2450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i157d929ac5794703b29ad1b3d0e06f2e_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTQtMS0xLTcwMDM0_07c0a9aa-d7ab-4f0e-a982-17ffd82e9d9e"
      unitRef="usd">2522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i20dcb86296844dbda765eb7afdc78e2d_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTYtMS0xLTcwMDM0_e96c8d3b-8183-4430-8b97-0a68cfe095a8"
      unitRef="number">-0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1993ccddfb034873a36b94a7f7017ddd_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTgtMS0xLTcwMDM0_feafd4ec-14bd-4af9-93fd-72928e8524f1"
      unitRef="usd">4884000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a4c53848f34480d9a9a1d516da71087_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTEwLTEtMS03MDAzNA_1f82e9cc-9915-4159-b7e2-1b80a4b8fd48"
      unitRef="usd">4894000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1993ccddfb034873a36b94a7f7017ddd_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjExLTEyLTEtMS03MDAzNA_357cbee4-b1ed-4605-82d8-abc8c1d6edcf"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b7edee30e3d480da3deca7eb3ed8837_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTItMS0xLTcwMDM0_a667bf70-63d3-4867-9756-d86746b2eee7"
      unitRef="usd">454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i908f6839346c4686938c7732821b75a8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTQtMS0xLTcwMDM0_fb3dff2d-f25c-4f6d-9105-aaf1764815e7"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6b7edee30e3d480da3deca7eb3ed8837_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTYtMS0xLTcwMDM0_483cdc6a-7ab0-445f-83fe-45c73ec548af"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia717abc404b146b3a20cf3cdbee20322_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTgtMS0xLTcwMDM0_d19e49d9-5934-46f8-b0eb-dc1805b2538b"
      unitRef="usd">871000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8fbc02017884ac9a57e155715db8909_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTEwLTEtMS03MDAzNA_6dee16aa-0749-42b2-80c2-2efd3bf5ddb4"
      unitRef="usd">864000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia717abc404b146b3a20cf3cdbee20322_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjEzLTEyLTEtMS03MDAzNA_719449c6-46de-4455-a000-5ee65bff1052"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21d39404482e4c219c8780425fba1375_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTItMS0xLTcwMDM0_af40f53b-2853-40af-8448-870e558c0089"
      unitRef="usd">702000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic64782304ba44edc84ba60d27fa2279b_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTQtMS0xLTcwMDM0_4eaf6527-3751-4fe3-9e9a-3fd115a19fc9"
      unitRef="usd">708000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i21d39404482e4c219c8780425fba1375_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTYtMS0xLTcwMDM0_81ae0977-a252-411c-827d-6fab15cb4a83"
      unitRef="number">-0.009</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31026e003cb1415fbad582c204df9190_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTgtMS0xLTcwMDM0_bf8ec13f-6fcf-4f98-9a79-856fcc04a8a2"
      unitRef="usd">1431000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90b0b233fad44191b424a24fece33b51_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTEwLTEtMS03MDAzNA_5ce225cf-6f21-4777-8a89-069336af02e8"
      unitRef="usd">1421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i31026e003cb1415fbad582c204df9190_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE0LTEyLTEtMS03MDAzNA_69a1ffda-da56-4e87-8923-a7acf57e976d"
      unitRef="number">0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a4466b00cc249fb98151e07aa84fbad_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTItMS0xLTcwMDM0_6bfdf9ac-3c30-4cc9-bddf-f8cc8e9e91fe"
      unitRef="usd">1156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57a2012297b041c7b1efa586c301f494_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTQtMS0xLTcwMDM0_5501c7f0-90b7-4bf7-a807-e3a590c33c31"
      unitRef="usd">1168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3a4466b00cc249fb98151e07aa84fbad_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTYtMS0xLTcwMDM0_c457cde8-0ba6-45c7-a82f-3c25c62ed8f7"
      unitRef="number">-0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97c25d98536140f3b69ae8c88acf7a37_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTgtMS0xLTcwMDM0_d395a265-764a-4b87-845c-dcabc89c0e9e"
      unitRef="usd">2302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i586d3a14b6c740d8844f2849c4eb2582_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTEwLTEtMS03MDAzNA_537b19d9-c30f-46b2-a421-f97986ab3592"
      unitRef="usd">2286000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i97c25d98536140f3b69ae8c88acf7a37_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE1LTEyLTEtMS03MDAzNA_95b029fa-26e4-43b4-928a-e8a968a151c8"
      unitRef="number">0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i443117f5e241456285fb9a55936853e7_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTItMS0xLTcwMDM0_5e265b0e-6246-4544-8542-e56e1e8a1570"
      unitRef="usd">538000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie01251da528b4f90a10a4142620a65cd_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTQtMS0xLTcwMDM0_abf7de89-583b-414c-b7cd-ec3e252c3c2f"
      unitRef="usd">576000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i443117f5e241456285fb9a55936853e7_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTYtMS0xLTcwMDM0_9c5b2ac6-3029-4d8e-bba2-9887b48d43fd"
      unitRef="number">-0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bfe8df60f4743ec99ca6904a5e64756_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTgtMS0xLTcwMDM0_62ae5f9b-cc62-445c-a39b-06b4ab0c333f"
      unitRef="usd">1042000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27fec44642f34c5099c21747e3250cb1_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTEwLTEtMS03MDAzNA_a1b91a9c-cb29-4481-9ce7-59bed872e95a"
      unitRef="usd">1069000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9bfe8df60f4743ec99ca6904a5e64756_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE3LTEyLTEtMS03MDAzNA_d8c8be63-2beb-483d-b1ba-fcb9ea443b59"
      unitRef="number">-0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i412aa3432fcf467f8fd19c46b727c491_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTItMS0xLTcwMDM0_1e099bc6-ed29-42c5-a78c-b3a1045d462c"
      unitRef="usd">756000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia390d2427f664929bec44ea56be4ec81_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTQtMS0xLTcwMDM0_d4022ee9-f9f8-4d95-910d-c8610d9c591c"
      unitRef="usd">779000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i412aa3432fcf467f8fd19c46b727c491_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTYtMS0xLTcwMDM0_52ddcf61-2e20-4d5b-af53-82ce49ff8ebe"
      unitRef="number">-0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8baa768ee1284c7e99d6ee829ff2c08a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTgtMS0xLTcwMDM0_bb1124bd-a161-48b9-8ac9-f852629974f7"
      unitRef="usd">1540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e11d4f4c34c41b5be8ae617dc5e9c1d_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTEwLTEtMS03MDAzNA_65cbc530-f60c-4ce5-9b52-aba56ab4b891"
      unitRef="usd">1540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8baa768ee1284c7e99d6ee829ff2c08a_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE4LTEyLTEtMS03MDAzNA_c394819d-ec9e-4502-a1df-1c1c36276f16"
      unitRef="number">0.0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6fda5fb73a341449bfac9d8fb7a268f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTItMS0xLTcwMDM0_0c972253-28fc-4fcb-931d-83cd37b73903"
      unitRef="usd">1294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ed73e5ea20c4b98b366ff0b993278cc_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTQtMS0xLTcwMDM0_3a5dadd1-74bd-42a4-88f8-a75af687d61f"
      unitRef="usd">1354000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic6fda5fb73a341449bfac9d8fb7a268f_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTYtMS0xLTcwMDM0_4f48042c-25db-4fcb-8c89-84970472f8e8"
      unitRef="number">-0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64f8de01c4be45768b397e71429b87f0_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTgtMS0xLTcwMDM0_8c82f24a-033e-4a46-8759-693b3f0aca8c"
      unitRef="usd">2582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68e9b1789db54a1992eb64fc846195f1_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTEwLTEtMS03MDAzNA_6b69d2cb-a982-4351-b848-8290a08a8904"
      unitRef="usd">2608000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i64f8de01c4be45768b397e71429b87f0_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjE5LTEyLTEtMS03MDAzNA_2d7e4ad8-170f-47b3-ab15-17f70bc59d4f"
      unitRef="number">-0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i569ace16f96641559bb1b2d217a5f3ee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTItMS0xLTcwMDM0_46713888-7c32-4bf3-b93d-0fd9d79b037b"
      unitRef="usd">496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3982de94b47b42dea86bcede03224217_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTQtMS0xLTcwMDM0_ed1ba9e3-cb82-43e3-b7d6-8a5b23e555c1"
      unitRef="usd">467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i569ace16f96641559bb1b2d217a5f3ee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTYtMS0xLTcwMDM0_50faad4b-2443-4c99-853b-f42b6814a539"
      unitRef="number">0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80e3610796c24f389098231002fd25b3_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTgtMS0xLTcwMDM0_6e3a931e-1937-48d4-92ed-d3e2ae02de0b"
      unitRef="usd">1017000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i441e7039e08a47fcbf82ede9c2ebfbe6_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTEwLTEtMS03MDAzNA_34e731c1-c388-4601-9526-a2c40b657133"
      unitRef="usd">939000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i80e3610796c24f389098231002fd25b3_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIxLTEyLTEtMS03MDAzNA_0b4a1e73-ae42-4bd3-9dc3-eed1334c8816"
      unitRef="number">0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i324894961943456d92139b57181b5bb9_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTItMS0xLTcwMDM0_6f058e78-0e3f-4481-81bc-e3720fdf1c82"
      unitRef="usd">745000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i281e3cd9deea4daaacf98eaf97ea934e_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTQtMS0xLTcwMDM0_3cb8a508-63a6-4001-a92a-00fbeceb584e"
      unitRef="usd">716000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i324894961943456d92139b57181b5bb9_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTYtMS0xLTcwMDM0_635e2a09-e019-4b19-8ab3-70ac267064a5"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i016776eee5714891a0386a16d5557a03_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTgtMS0xLTcwMDM0_db6f1446-c3bb-48b1-8e03-0ea54c620cb5"
      unitRef="usd">1481000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i747469c41b2a43deb3981557e85294f3_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTEwLTEtMS03MDAzNA_2f857373-3cc3-412f-beb6-7fa194151e83"
      unitRef="usd">1389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i016776eee5714891a0386a16d5557a03_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIyLTEyLTEtMS03MDAzNA_880edaad-31f1-4878-94c9-7e79d3eed47a"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54e1c7c7e8dd48959fd8bf1743fc8e80_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTItMS0xLTcwMDM0_2fa7d14d-dad0-46ff-9217-161501b30547"
      unitRef="usd">1241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1a2fceceece40e9b7f64f083218ee49_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTQtMS0xLTcwMDM0_f9a5eb90-61ec-4c28-818a-8858584ed8e1"
      unitRef="usd">1183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i54e1c7c7e8dd48959fd8bf1743fc8e80_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTYtMS0xLTcwMDM0_d366de00-db55-4dbb-a1e2-423e10b38ab4"
      unitRef="number">0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4bdb0db58854e95a85e98d94100f662_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTgtMS0xLTcwMDM0_7a14767e-c87a-44a8-b071-d7fc0b934f10"
      unitRef="usd">2498000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ed2d31b27e045ab82b125179a98301e_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTEwLTEtMS03MDAzNA_a3cdb3a0-c20e-4502-bb19-e0225a26f829"
      unitRef="usd">2328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib4bdb0db58854e95a85e98d94100f662_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjIzLTEyLTEtMS03MDAzNA_a34fa33e-4fa9-4464-a9cb-fae77323b2df"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9584ac8d54c6468f80de0bb9c19b14e8_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTItMS0xLTcwMDM0_d53c13bb-7aef-4327-bb8b-bd62c5c7cbe1"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0672b25c90a4d09917d157086a6428a_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTQtMS0xLTcwMDM0_0bdc9143-27a9-4767-9697-4edea0d4a9c8"
      unitRef="usd">352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9584ac8d54c6468f80de0bb9c19b14e8_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTYtMS0xLTcwMDM0_8c843225-8fbd-4827-9d3c-fa88de2338fa"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9696d83a57d4dacbe080d0f1444e529_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTgtMS0xLTcwMDM0_145a28c0-519c-4543-b843-6ac21612da9b"
      unitRef="usd">774000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b1a88c0fa4b44b794e579ac382449d3_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTEwLTEtMS03MDAzNA_c6b5b2f6-1b32-46bd-b119-bb68dc8124cf"
      unitRef="usd">723000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib9696d83a57d4dacbe080d0f1444e529_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI1LTEyLTEtMS03MDAzNA_821d8cac-826b-4f29-8323-186bd68a4654"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a92fd5c525643629fe7ff73a1af3c2f_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTItMS0xLTcwMDM0_e4fb7aed-27ad-446c-ac63-3db02c23e779"
      unitRef="usd">519000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bfe3e4294df4883a39ec285886b1913_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTQtMS0xLTcwMDM0_511d41b9-d6c1-4d16-a5ff-ba9cf513c18f"
      unitRef="usd">517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a92fd5c525643629fe7ff73a1af3c2f_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTYtMS0xLTcwMDM0_192aead0-288b-4409-a2b8-5f260525002d"
      unitRef="number">0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib37fb7ee236248a882538282edd2b353_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTgtMS0xLTcwMDM0_e2e3cada-be76-4899-bdc7-45d6a8aa8831"
      unitRef="usd">1030000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f48482859234f7bac2ce55a3818dc23_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTEwLTEtMS03MDAzNA_c32382e0-4908-456a-af6f-60e64a4bc084"
      unitRef="usd">1003000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib37fb7ee236248a882538282edd2b353_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI2LTEyLTEtMS03MDAzNA_dfd4df96-f109-4c52-a4a7-fbf541f9209f"
      unitRef="number">0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebbec59e0ece4791b17dcc2fcc6131ef_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTItMS0xLTcwMDM0_93190fc9-5399-479d-96e5-a910b9e9910d"
      unitRef="usd">894000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79f938a541ab4334bc462b1f7fa4c89b_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTQtMS0xLTcwMDM0_2f306019-15b4-4bb0-965c-9de3598245c4"
      unitRef="usd">868000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iebbec59e0ece4791b17dcc2fcc6131ef_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTYtMS0xLTcwMDM0_e210ce9c-d8bc-44b4-adf3-3dc64ea07e9d"
      unitRef="number">0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d7a46d82f594dea958391e3f85c7adc_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTgtMS0xLTcwMDM0_35b03601-6c11-43c5-ba3d-9f80c4fb00a3"
      unitRef="usd">1804000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b88bda5d09242278cca53b9ca866611_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTEwLTEtMS03MDAzNA_2e696e99-22b6-4e2e-8207-982c60d332e2"
      unitRef="usd">1725000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4d7a46d82f594dea958391e3f85c7adc_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjI3LTEyLTEtMS03MDAzNA_aab71efc-7c75-4d06-8e51-448900fbd9dc"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11f87d928b364165a9ce065e74fb63ce_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTItMS0xLTcwMDM0_0d89526f-39a6-49f3-82ee-f10e52724910"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4109ba0613344384a303908d2b52ff33_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTQtMS0xLTcwMDM0_c6c87df9-c3f3-4122-b4f1-305a912fcf4a"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i11f87d928b364165a9ce065e74fb63ce_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTYtMS0xLTcwMDM0_799e056c-27e0-4eff-a0f1-6f609cf2c971"
      unitRef="number">0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39cea1d7d42a46b8aa131cde5e274282_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTgtMS0xLTcwMDM0_0b1bc9d2-2a00-48bd-a834-187bec28c0fb"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5523f7460fd948f08ef26a334123472d_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTEwLTEtMS03MDAzNA_dafc3ed4-d4e8-461e-b2e4-853ef0b464ff"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i39cea1d7d42a46b8aa131cde5e274282_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMwLTEyLTEtMS03MDAzNA_96d9de95-21b8-49e1-865a-ea391449096b"
      unitRef="number">0.121</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie01bb5db42274474b71ecf23309c444a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTItMS0xLTcwMDM0_314b3392-94cb-4ea8-acd6-89e13f6a72ff"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cc6145fd3894d74b3ce85f802f90390_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTQtMS0xLTcwMDM0_1cc64213-4928-42e1-86d7-bcfac0d2ea49"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie01bb5db42274474b71ecf23309c444a_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTYtMS0xLTcwMDM0_11d4c3ef-f4bb-4257-b7f4-d4ac6f7f3272"
      unitRef="number">0.136</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f4b2747819f470683e7967d8ae774bd_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTgtMS0xLTcwMDM0_51257226-28f7-4d13-a1b9-7928f35919a3"
      unitRef="usd">451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8edf9410e7d643b19bc9451e934d68de_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTEwLTEtMS03MDAzNA_b96de444-980f-4503-b945-9c196ab78870"
      unitRef="usd">386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5f4b2747819f470683e7967d8ae774bd_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMxLTEyLTEtMS03MDAzNA_cbe85ee9-d9c8-41f1-bede-3a57ae8d9f4c"
      unitRef="number">0.170</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ce7bb1e40a34cac933a9900b74f1bbd_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTItMS0xLTcwMDM0_05809f96-8ea7-47f2-8d34-8e07f9463a77"
      unitRef="usd">347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01ea13492db24868803369c77f57b645_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTQtMS0xLTcwMDM0_09cfd999-4cd2-47d6-9dac-294839f20885"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ce7bb1e40a34cac933a9900b74f1bbd_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTYtMS0xLTcwMDM0_b286856c-34b7-408b-a4dd-8380ea0233e9"
      unitRef="number">0.105</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a69a34fd0c94f13b4b310835aa606ff_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTgtMS0xLTcwMDM0_4d28483f-0f80-42e1-9415-2754c439aa17"
      unitRef="usd">694000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2ee68091377424783ed3c9953196597_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTEwLTEtMS03MDAzNA_aede987f-8b89-4cc3-bf98-5b7b86961012"
      unitRef="usd">602000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a69a34fd0c94f13b4b310835aa606ff_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjMyLTEyLTEtMS03MDAzNA_a6603f66-1ce6-4531-98f1-0914cd6575db"
      unitRef="number">0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e33c4da904049bc8c9bfff387e3375d_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTItMS0xLTcwMDM0_80403384-0a37-49d2-a9e7-79a56a121812"
      unitRef="usd">3351000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia36ad544dbed4b9fba4cef602aef272a_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTQtMS0xLTcwMDM0_ac2f9e2f-7459-466e-bb59-0ae2867c74b3"
      unitRef="usd">3299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2e33c4da904049bc8c9bfff387e3375d_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTYtMS0xLTcwMDM0_c81fc747-09a0-4f8c-9226-a884318d635d"
      unitRef="number">0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fd3cc31f314437293f6c8d05caf543b_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTgtMS0xLTcwMDM0_97395dc0-cdc2-4501-9573-b20f2de15eca"
      unitRef="usd">6576000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i841ed2eb0fd747d19d8bd3831cfcc965_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTEwLTEtMS03MDAzNA_08f8b163-999f-4173-9f95-8de3d99ac57f"
      unitRef="usd">6353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5fd3cc31f314437293f6c8d05caf543b_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM1LTEyLTEtMS03MDAzNA_c4078468-3114-4887-aaf9-106c8371b2d3"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1267f9a793dd4838bee913c7e7f1bc85_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTItMS0xLTcwMDM0_d1ab6752-9b86-46b3-8bc9-5afce5212b68"
      unitRef="usd">3547000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57cda4c770ae48fc874d0e1e0a6aa499_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTQtMS0xLTcwMDM0_d80aaa0b-362f-47da-9abe-60c88c0c6749"
      unitRef="usd">3679000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1267f9a793dd4838bee913c7e7f1bc85_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTYtMS0xLTcwMDM0_df85a7b4-4526-4e8d-9cfa-f5bc0da8c38c"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icce8cec453c54166a59e25d4837a056c_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTgtMS0xLTcwMDM0_b343432f-3359-4791-b40c-c0375576dd1c"
      unitRef="usd">7293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0dc3d45f3f941dab28721d910f5e49f_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTEwLTEtMS03MDAzNA_d48721a4-5fad-412a-9e50-f49d63e19bfa"
      unitRef="usd">7204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icce8cec453c54166a59e25d4837a056c_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM2LTEyLTEtMS03MDAzNA_a582a5c1-6c4f-4025-a779-14bd590d9afd"
      unitRef="number">0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22f0cbac43d94b8bb57a7d434308ab35_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTItMS0xLTcwMDM0_e116f4be-256c-4dd7-b426-1bd62f2940ab"
      unitRef="usd">6898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27e8d4536d8e4ea7a2ed2551f3af3104_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTQtMS0xLTcwMDM0_827bc7fa-b704-48ac-9404-b862b706da25"
      unitRef="usd">6978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i22f0cbac43d94b8bb57a7d434308ab35_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTYtMS0xLTcwMDM0_ea82fe6a-fc20-45f9-a1b2-4dd0b87e41af"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTgtMS0xLTcwMDM0_5ec423a1-f44c-4277-ad31-bfc5416eac2c"
      unitRef="usd">13869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTEwLTEtMS03MDAzNA_d785815f-ace1-4b0a-a749-250f2aef78cf"
      unitRef="usd">13557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjM3LTEyLTEtMS03MDAzNA_523d2ef1-74c8-4c2f-83f0-675210e62a06"
      unitRef="number">0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTItMS0xLTcwMDM0_39e0b36e-7ede-4c74-a6f7-12720545c243"
      unitRef="usd">12197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e8a3362cdda49a18367d18f349e957d_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTQtMS0xLTcwMDM0_92fd4463-e027-40db-ba5f-be08ebb2e30b"
      unitRef="usd">11919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTYtMS0xLTcwMDM0_b44de36a-a335-48ee-9518-b118af48d827"
      unitRef="number">0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96c08b8a10da4041816e159343bf7063_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTgtMS0xLTcwMDM0_c5fae355-c817-47e1-8ecd-ce5c85b31783"
      unitRef="usd">23611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39103b4eef404909b321cdc17486f7ca_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTEwLTEtMS03MDAzNA_48ddc344-520f-406c-8249-946d9beefcc7"
      unitRef="usd">23030000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i96c08b8a10da4041816e159343bf7063_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQwLTEyLTEtMS03MDAzNA_c7dfdc0b-3e98-4486-ab7f-354b8e3c4eed"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedc5007223004e44b9e3f6016636f4eb_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTItMS0xLTcwMDM0_c57df79a-1e45-4168-bc14-e343751f276d"
      unitRef="usd">11823000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6180f4c8a3a141b0b11ef6eea2dd5c8e_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTQtMS0xLTcwMDM0_c8392d3c-3141-4f77-ac6f-ba035d3ccfa0"
      unitRef="usd">11393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iedc5007223004e44b9e3f6016636f4eb_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTYtMS0xLTcwMDM0_01302543-ea1f-444b-92ed-2ccb79ea26e0"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee0e58c2ebe74103acd746853588d46a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTgtMS0xLTcwMDM0_9c6db14a-ee6b-4d99-988f-5480e96fc6e3"
      unitRef="usd">23835000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id809ffa3e19b46f69f68ae5cd89fd702_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTEwLTEtMS03MDAzNA_3d4383a7-0f92-4f7f-a856-5349f031ce17"
      unitRef="usd">22603000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee0e58c2ebe74103acd746853588d46a_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQxLTEyLTEtMS03MDAzNA_9f72c2b5-2d3e-479f-8fa7-5da19252f023"
      unitRef="number">0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTItMS0xLTcwMDM0_800a398d-ad36-496c-b85d-fba17a2f237e"
      unitRef="usd">24020000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTQtMS0xLTcwMDM0_3d753470-b32c-4603-a562-388f31f1c547"
      unitRef="usd">23312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTYtMS0xLTcwMDM0_015ac2c6-9523-41ec-ba0d-2dc699a7c94e"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTgtMS0xLTcwMDM0_efaf433c-e907-42da-be96-cd96d6bf4c32"
      unitRef="usd">47446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTEwLTEtMS03MDAzNA_cf3a1cfd-4294-4f1d-9555-8c68c4a93a55"
      unitRef="usd">45633000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjE0MTZlZWQ5MWE0NzQ3NWY5NWY4ZmVlYjlkNDFmY2Y1L3RhYmxlcmFuZ2U6MTQxNmVlZDkxYTQ3NDc1Zjk1ZjhmZWViOWQ0MWZjZjVfMjQyLTEyLTEtMS03MDAzNA_024a6b63-cd93-4504-9d94-733c60c7ce38"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c0ab60765214aed9b7662351556aa75_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTkz_8d7f0c98-9077-4062-81df-239e6f556ce4"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95dd4291b011442fb7dc8d71ff5ffe4b_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTk0MQ_ff8dca22-993e-4508-91b1-a1ce421bf1c2"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjk1OA_4209aba6-1f8f-49b9-96f8-a1450af71f02">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*The 2021 fiscal second  quarter and six months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.1 billion in both the fiscal second quarter of 2022 and 2021 and $0.2&#160;billion in both the fiscal six months of 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Litigation expense of $0.1&#160;billion in both the fiscal second quarters and fiscal six months of 2022 and 2021, primarily for talc related costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Divestiture gains of $0.6&#160;billion in the fiscal six months of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal second quarter of 2022 and 2021, respectively. Intangible amortization expense of $1.5&#160;billion and $1.7&#160;billion in the fiscal six months of 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In the fiscal six months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A loss of $0.1&#160;billion and a gain of $0.2&#160;billion related to the change in the fair value of securities in the fiscal second quarter of 2022 and 2021, respectively. A loss of $0.5&#160;billion and a gain of $0.1&#160;billion related to the change in the fair value of securities in the fiscal six months of 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;COVID-19 Vaccine supply network related costs of $0.2&#160;billion in both the fiscal second quarter and fiscal six months 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal second quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Litigation expense of $0.3&#160;billion in both the fiscal second quarters and fiscal six months of 2022 primarily pelvic mesh related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.2 billion and $0.1&#160;billion in the fiscal six months of 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.3&#160;billion in both the fiscal second quarter of 2022 and 2021 and $0.5&#160;billion in both the fiscal six months of 2022 and 2021.&lt;/span&gt;&lt;/div&gt;(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi0yLTEtMS03MDAzNA_007c63e3-744f-4ba6-9686-a043bed92f37"
      unitRef="usd">784000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1a2da2b15d204fb7b695aa3bfc830f42_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi00LTEtMS03MDAzNA_3688d36c-3278-4329-b8a7-82b304875f39"
      unitRef="usd">866000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi02LTEtMS03MDAzNA_868c203b-2790-4dc8-ab6f-f293034a09ea"
      unitRef="number">-0.095</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi04LTEtMS03MDAzNA_853fbd43-f272-4635-a53b-c245c5c82a0e"
      unitRef="usd">1470000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7b15286f874144618839786849ea1437_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi0xMC0xLTEtNzAwMzQ_6d772ebd-8fae-46e4-8563-27dbe504dba1"
      unitRef="usd">1708000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMi0xMi0xLTEtNzAwMzQ_36e17b42-c505-4ef7-bce3-8a8f423b9428"
      unitRef="number">-0.139</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy0yLTEtMS03MDAzNA_b9f264a8-ce1b-4369-9834-93f2d24ad4bd"
      unitRef="usd">4420000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i90adf511b62e43ed9a3312bbc6ec0892_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy00LTEtMS03MDAzNA_df93318e-7bd6-488e-ac9a-87c1cfe65461"
      unitRef="usd">4294000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy02LTEtMS03MDAzNA_9c07686d-6ac4-450e-8224-56b9be350bd2"
      unitRef="number">0.029</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy04LTEtMS03MDAzNA_c8a87afe-e311-431b-826b-4245f41661d5"
      unitRef="usd">8344000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id349b0a0d08341149ec80073155e33e2_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy0xMC0xLTEtNzAwMzQ_c9cac312-a883-4ec4-af44-9667f14f6ad9"
      unitRef="usd">9463000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfMy0xMi0xLTEtNzAwMzQ_86d48530-7ccc-42dd-a6ab-04147dc95e77"
      unitRef="number">-0.118</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC0yLTEtMS03MDAzNA_78fa3858-87c1-485b-ad3c-37532e7830f0"
      unitRef="usd">1141000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia7da5b6f21e243f1acad5577402788da_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC00LTEtMS03MDAzNA_3f17b02b-cd2a-45d1-b8f3-8351352274df"
      unitRef="usd">1746000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC02LTEtMS03MDAzNA_2cff0db8-50b7-4ec9-a08e-abb7aea588e6"
      unitRef="number">-0.347</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaaff25a8ee4a446eafc7e7a139993836_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC04LTEtMS03MDAzNA_7b3a22b2-d681-4202-8033-c645c5367726"
      unitRef="usd">2618000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i61b390e9d694497896d1ac279e6a0013_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC0xMC0xLTEtNzAwMzQ_1317e0db-73ab-4f2d-beb2-0115f9621690"
      unitRef="usd">3375000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="iaaff25a8ee4a446eafc7e7a139993836_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNC0xMi0xLTEtNzAwMzQ_26d75125-2732-419c-ae00-3b8eeb5b6612"
      unitRef="number">-0.224</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i529d608738614ae0a943f58551da20f0_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS0yLTEtMS03MDAzNA_7e38552c-eda3-4d94-9a35-2b86e0756e89"
      unitRef="usd">6345000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i06cae828408f49239c6f174bf1c334a3_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS00LTEtMS03MDAzNA_86d4550d-4129-4b14-8dc4-3b9cba5c33fb"
      unitRef="usd">6906000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i529d608738614ae0a943f58551da20f0_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS02LTEtMS03MDAzNA_13045900-6ac3-421e-831a-1559b059e502"
      unitRef="number">-0.081</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifee05ee77bf344a68295fa0ac185a55f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS04LTEtMS03MDAzNA_db31d90d-73be-4641-8ab1-4c6384338dbb"
      unitRef="usd">12432000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i57d86df693ac4fec81410c7eea2535c2_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS0xMC0xLTEtNzAwMzQ_f1cc784d-4498-4af8-97fd-b0d6739d84ff"
      unitRef="usd">14546000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="ifee05ee77bf344a68295fa0ac185a55f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNS0xMi0xLTEtNzAwMzQ_43a4d41f-b997-4c12-b2c5-03b1946c9f59"
      unitRef="number">-0.145</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibd132153d9614629bc9c8135b8b92864_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNi0yLTEtMS03MDAzNA_d8b4b206-2500-41be-8b18-338adda422d6"
      unitRef="usd">237000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib6e2458177a343e08824dfb1c6bd2f07_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNi00LTEtMS03MDAzNA_dc7d775f-3da9-4c79-8a34-4722eedde222"
      unitRef="usd">244000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6bcfd345e66e46298c5faf33123c8744_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNi04LTEtMS03MDAzNA_49d53ce5-361b-4bc1-8718-57f2c2810bdf"
      unitRef="usd">360000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib2da094b787c4b54b4e09b39c3f9a9f4_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNi0xMC0xLTEtNzAwMzQ_e5113a3a-158a-4790-99a1-819708bb529c"
      unitRef="usd">455000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:BusinessExitCosts1
      contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNy0yLTEtMS03MDAzNA_65961bdb-5b5a-46c0-86b7-4b540ee9566c"
      unitRef="usd">268000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i1a2da2b15d204fb7b695aa3bfc830f42_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNy00LTEtMS03MDAzNA_1f2b0090-4a11-4212-b1cb-481da5f950c8"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNy04LTEtMS03MDc5OA_893e2b00-4e28-4360-9f5c-688607b8fc52"
      unitRef="usd">370000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i7b15286f874144618839786849ea1437_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfNy0xMC0xLTEtNzA4MDg_044baccb-f8b1-43b1-a0ce-7cf8b662e17a"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC0yLTEtMS03MDAzNA_a07de4d5-f752-46dc-a1e7-0a4687ecb400"
      unitRef="usd">5840000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC00LTEtMS03MDAzNA_8f6e8a26-0bb1-4327-ad95-9664072f28c2"
      unitRef="usd">6662000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC02LTEtMS03MDAzNA_ad737cc9-2a10-487e-b005-968e2993884f"
      unitRef="number">-0.123</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC04LTEtMS03MDAzNA_3429230a-be16-486f-8666-736ab1fdbb10"
      unitRef="usd">11702000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC0xMC0xLTEtNzAwMzQ_99e7cc0b-0fa8-42af-897f-1d3789c01534"
      unitRef="usd">14091000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjdhYjc5OTI5NmNhZDQxY2Q4NTQzOWU4ZDhlYmQyYzJkL3RhYmxlcmFuZ2U6N2FiNzk5Mjk2Y2FkNDFjZDg1NDM5ZThkOGViZDJjMmRfOC0xMi0xLTEtNzAwMzQ_e38d19e3-24cb-4866-ae4f-34ca7c523a45"
      unitRef="number">-0.170</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfODYx_6aa644a2-5db7-4fad-9f99-35da1a1236d3"
      unitRef="usd">100000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMDg3NQ_382f207a-bdec-413a-9332-651f1ae01f81"
      unitRef="usd">200000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i7b15286f874144618839786849ea1437_D20210104-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMDg3NQ_3fba85ca-b79d-4073-a3d2-1570993f8109"
      unitRef="usd">200000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:LitigationSettlementExpense
      contextRef="i1a2da2b15d204fb7b695aa3bfc830f42_D20210405-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjIzMw_18284545-02c7-4651-977f-1fb908f5af76"
      unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i719a66732d7f469782333e22b8bc190c_D20220404-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjIzMw_5590edc6-5938-4246-be4b-88217c418c7e"
      unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7b15286f874144618839786849ea1437_D20210104-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjIzMw_627bf815-252a-4784-a07f-40fab29a0395"
      unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="idc99a13c450a4c1e9d9c3301c1089c9e_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjIzMw_c2605bdc-f498-4adf-8503-9ec84f2a8a5e"
      unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfOTQ5_356d5a8d-c0af-40f1-a4d4-5a281f8eaa1f"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AdjustmentForAmortization
      contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA2Mg_3b8dca50-7674-49a5-85a1-3e06cf222510"
      unitRef="usd">700000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i90adf511b62e43ed9a3312bbc6ec0892_D20210405-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA2OQ_30374733-bf2c-44d1-ba75-3f5bc470783c"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTA5MQ_9a38cd86-0d0d-43a1-902c-b1659e1c35ff"
      unitRef="usd">1500000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="id349b0a0d08341149ec80073155e33e2_D20210104-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTEwNQ_dc7db8f8-1f05-4621-9f5b-8a269cf1a460"
      unitRef="usd">1700000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4a9a7ebb719f437a941405e59e3f7376_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTIyNg_b0434c7e-cfee-4bf3-bd27-46b6ae26f4f8"
      unitRef="usd">600000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTU5NQ_187d8bff-5264-4904-b04d-ba7f6464f50a"
      unitRef="usd">-100000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i90adf511b62e43ed9a3312bbc6ec0892_D20210405-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTQ0OQ_30c165a3-f0ef-40fb-8638-d324f2ae0cab"
      unitRef="usd">200000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTQyMQ_7f1f68dc-4b13-4566-bd02-ac92442c4297"
      unitRef="usd">-500000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTQyMQ_b30e8f7d-76d0-4794-8049-fb3493faff3f"
      unitRef="usd">-500000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="id349b0a0d08341149ec80073155e33e2_D20210104-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTQzNQ_5a4ede07-f70d-4aa3-ad92-3913521a0f23"
      unitRef="usd">100000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:SuppliesExpense
      contextRef="ic6094ef6600341388845fd981445402a_D20220404-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjQzNA_621497af-65da-48cd-8e5f-1e4cf134478f"
      unitRef="usd">200000000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i9dcf3bf9c7d547d9909ebf520ba06121_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjQzNA_93f1dbfb-d3a8-479f-b640-9b8e3692f394"
      unitRef="usd">200000000</us-gaap:SuppliesExpense>
    <jnj:AmountPrepaidAndDueToManufacturers
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjE4Mg_ad2cd455-9a09-47bb-aa1a-28040ce82ff8"
      unitRef="usd">900000000</jnj:AmountPrepaidAndDueToManufacturers>
    <us-gaap:LitigationSettlementExpense
      contextRef="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjYxMQ_41673951-c187-4ea7-853d-a4a2ace78ad6"
      unitRef="usd">300000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iaaff25a8ee4a446eafc7e7a139993836_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMjYxMQ_f142eae0-3065-4af3-8d56-a277fe2432ea"
      unitRef="usd">300000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjY3MQ_5aaa8d60-89a1-4949-967d-7a21855177e6"
      unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTY4MQ_2af5cdc2-871d-4d52-8d96-a3c4a8916f0d"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTY4MQ_ba442ba7-4bf0-4c12-bc9a-b9b22484bde6"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:AdjustmentForAmortization
      contextRef="if03ec701bed74775a8ea0a945b1b1509_D20220404-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjc0Mg_cef43cf2-841d-4536-a75e-b4aab77313a2"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ia7da5b6f21e243f1acad5577402788da_D20210405-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjc0Mg_efd782aa-82ae-490d-8093-7825b1652860"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ie194ccf0b4234bb787d5694b94649aa0_D20210104-20210704"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTYwMQ_2f79dc5f-194c-48c5-bc20-c0e910a4ca14"
      unitRef="usd">500000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i7c9fdeca34074a0cac3f8ecd0ee78b8c_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMTA5OTUxMTYzMTYwMQ_af2bf537-0922-4b65-9ebc-45b7d0ff7a46"
      unitRef="usd">500000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RleHRyZWdpb246ZTYxNGIxM2FmYjViNGJkYTg4YmVlNzViYzEwMjcyMWZfMjkzNg_396f691c-b5d0-4a49-907b-8860cdc915f3">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Second Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi0yLTEtMS03MDAzNA_8b557745-5429-4f92-82dc-ccdb99a7a102"
      unitRef="usd">12197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e8a3362cdda49a18367d18f349e957d_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi00LTEtMS03MDAzNA_f9a604ee-d185-4002-8ee4-fd0e70ca7290"
      unitRef="usd">11919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ieaeda5eb3f3845e0ae5ff05bf5fc90d1_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi02LTEtMS03MDAzNA_88ac9658-287d-4c1d-9dff-1f7c8cf60700"
      unitRef="number">0.023</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96c08b8a10da4041816e159343bf7063_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi04LTEtMS03MDAzNA_ad75dc3e-95ab-45de-9a9e-3a46622f84f5"
      unitRef="usd">23611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39103b4eef404909b321cdc17486f7ca_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi0xMC0xLTEtNzAwMzQ_430611fd-55cf-4b54-aa22-04e78d636fc3"
      unitRef="usd">23030000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i96c08b8a10da4041816e159343bf7063_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMi0xMi0xLTEtNzAwMzQ_d6738035-118b-4332-bb21-0bbcd8b53ede"
      unitRef="number">0.025</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a725035e4c3410583da06507280fe59_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy0yLTEtMS03MDAzNA_54cf2669-3d74-42b6-8581-4492e88db611"
      unitRef="usd">6085000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83d3c1f4234a402fa97cbd81b084f556_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy00LTEtMS03MDAzNA_da997ece-fd4e-422b-8c5d-a3957fc6b931"
      unitRef="usd">5668000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i3a725035e4c3410583da06507280fe59_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy02LTEtMS03MDAzNA_a246e9e3-e767-489c-bbd7-68f58450c3cc"
      unitRef="number">0.073</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1ac66e3eb004358ab735bbc8456405e_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy04LTEtMS03MDAzNA_6a74599d-5037-42ed-90ac-7c1c5d1c6e23"
      unitRef="usd">12109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b6b7844077b4016b45ccbe380ad3dc4_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy0xMC0xLTEtNzAwMzQ_476efdfc-0b21-4cf4-891e-17d2edf5020d"
      unitRef="usd">11082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ic1ac66e3eb004358ab735bbc8456405e_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfMy0xMi0xLTEtNzAwMzQ_b7ac284e-3fc1-44ab-9a41-7853ee4a363b"
      unitRef="number">0.093</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2790d59614147c487677304230bb1ae_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC0yLTEtMS03MDAzNA_e952f5bb-aa1e-4cc9-9bf0-02e69e5fe069"
      unitRef="usd">1536000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8084c9e8e16045e1940be548a1af4fcc_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC00LTEtMS03MDAzNA_37a94a78-75ca-4610-98ce-bfc53a402d09"
      unitRef="usd">1367000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ic2790d59614147c487677304230bb1ae_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC02LTEtMS03MDAzNA_7c9d2ef8-9efd-4a2a-9399-47e125c02768"
      unitRef="number">0.124</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i501ea63e8e9f4d7d9d498ec389c88591_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC04LTEtMS03MDAzNA_c5f9e802-8b05-47d6-98e4-ee4b4df7ecbc"
      unitRef="usd">3018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i241ce185147a489fac065e3d478f8bc6_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC0xMC0xLTEtNzAwMzQ_e2d879fc-d1ba-476a-81ea-600258772820"
      unitRef="usd">2791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i501ea63e8e9f4d7d9d498ec389c88591_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNC0xMi0xLTEtNzAwMzQ_ffce9fc2-ae4f-45e1-bcb4-78f9f609bcdc"
      unitRef="number">0.081</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5646a565d4a4fdf8f17b8e7a2cf4a6c_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS0yLTEtMS03MDAzNA_dffc0e13-e959-4a4f-b8dc-7fc4a3b3822b"
      unitRef="usd">4202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c7a6815d0144fa3bda521f8ed93043c_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS00LTEtMS03MDAzNA_40d5115a-9032-42a1-aa2e-78754d16db93"
      unitRef="usd">4358000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="id5646a565d4a4fdf8f17b8e7a2cf4a6c_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS02LTEtMS03MDAzNA_fea6389d-98fe-456e-8897-caa665d0a73e"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia685c80f08574eeea6722e02543f738a_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS04LTEtMS03MDAzNA_3d9a797d-c452-4e2c-abc6-fc411f8b4dd0"
      unitRef="usd">8708000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd9d069efa93465f945738a484e31e5e_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS0xMC0xLTEtNzAwMzQ_3ce3f2f1-4910-4096-9463-4b8643ad1b31"
      unitRef="usd">8730000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ia685c80f08574eeea6722e02543f738a_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNS0xMi0xLTEtNzAwMzQ_47a2ba9c-b77f-4544-8930-e5f2799d44cf"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi0yLTEtMS03MDAzNA_8c21ca0a-020e-4746-ab86-e6a907dbde22"
      unitRef="usd">24020000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41610869852e471f9cbe543d5c0bade8_D20210405-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi00LTEtMS03MDAzNA_ffdc12d8-3b17-4f2b-a6a8-3ba3e42745ba"
      unitRef="usd">23312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="id586f19507c64de598ca1e8367cecfee_D20220404-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi02LTEtMS03MDAzNA_89593f4a-d863-4cb5-a5b3-38de73ff9b0a"
      unitRef="number">0.030</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi04LTEtMS03MDAzNA_adb906c3-6cac-4462-ac65-91a337a4e01c"
      unitRef="usd">47446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c24e85f2617419894dcb76063c6ef4a_D20210104-20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi0xMC0xLTEtNzAwMzQ_bedb5d7a-0f8b-487d-bf07-4ec2a0ccc76c"
      unitRef="usd">45633000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84Mi9mcmFnOmU2MTRiMTNhZmI1YjRiZGE4OGJlZTc1YmMxMDI3MjFmL3RhYmxlOjM3ZjdmMzU4YjE1YTQxMjNiZjdiYjFkNDVjMmQyN2Y4L3RhYmxlcmFuZ2U6MzdmN2YzNThiMTVhNDEyM2JmN2JiMWQ0NWMyZDI3ZjhfNi0xMi0xLTEtNzAwMzQ_e2ef25c4-4a91-42cd-8ea8-f4592342dc5a"
      unitRef="number">0.040</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84NS9mcmFnOmQ2ZTJiZjA3Njg2ZDQxNjFhZTI0N2IwMmI0NzgwNGU1L3RleHRyZWdpb246ZDZlMmJmMDc2ODZkNDE2MWFlMjQ3YjAyYjQ3ODA0ZTVfMzcy_488e05db-912a-4a5d-930c-fb0df96a01ce">ACQUISITIONS AND DIVESTITURESThere were no material acquisitions or divestitures in the fiscal first quarter and fiscal second quarter of 2022. During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion.</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <jnj:NumberOfBrands
      contextRef="iaf1d14a3db84419db81e75d0179c01b4_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84NS9mcmFnOmQ2ZTJiZjA3Njg2ZDQxNjFhZTI0N2IwMmI0NzgwNGU1L3RleHRyZWdpb246ZDZlMmJmMDc2ODZkNDE2MWFlMjQ3YjAyYjQ3ODA0ZTVfMzI5ODUzNDg4MzczOQ_6b6ce5ff-79a3-46c4-bb72-2da73200ff99"
      unitRef="brand">2</jnj:NumberOfBrands>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ic932039af4d240c09dba004300b0fc41_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84NS9mcmFnOmQ2ZTJiZjA3Njg2ZDQxNjFhZTI0N2IwMmI0NzgwNGU1L3RleHRyZWdpb246ZDZlMmJmMDc2ODZkNDE2MWFlMjQ3YjAyYjQ3ODA0ZTVfMzY3_6fcbebfc-d030-4958-9d7d-858d06663079"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfOTI0MzI_dee2a4b6-d7ed-426e-8bf5-12234bc8cea8">LEGAL PROCEEDINGS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of  July&#160;3, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Company&#x2019;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#x2019;s balance sheet, is not expected to have a material adverse effect on the Company&#x2019;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#x2019;s results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;PRODUCT LIABILITY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of July&#160;3, 2022, in the United States there were approximately 190 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 1,900 with respect to the PINNACLE Acetabular Cup System; 9,500 with respect to pelvic meshes; 2,100 with respect to RISPERDAL; 3,000 with respect to XARELTO; 40,300 with respect to body powders containing talc; 10 with respect to INVOKANA;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; 4,700 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; and 1,300 with respect to ELMIRON. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp;amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp;amp; Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson arising out of Ethicon&#x2019;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#x2019;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#x2019;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia  and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. In March 2022, the Court appointed a barrister to prepare a written report and recommendation on the form and mechanism of the individual case assessment process, due by August 2022, with a court hearing on those findings later that month. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#x2019;s pelvic mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of July 2022, there are approximately 126 active cases subject to these orders which are being reviewed and evaluated. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;Claims have also been filed against Ethicon and Johnson &amp;amp; Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Ethicon and Johnson &amp;amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp;amp; Johnson; and JPI&#x2019;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp;amp; Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp;amp; Johnson Consumer Inc. and Johnson &amp;amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham v. Johnson &amp;amp; Johnson, et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;No. ED 207476 (Mo. App.), reducing the overall award to  $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, Johnson &amp;amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#x2019;s direct parent, Johnson &amp;amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#x2019;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#x2019; compensation statute or act (the Talc-Related Liabilities). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, notwithstanding the Company&#x2019;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp;amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. Opening briefs were filed in June 2022 and briefing is to be completed by September 2022. Additionally, an industrial talc class action was filed against the Company and others in New Jersey state court in May 2022. The case was subsequently removed to federal court. In July 2022, Imerys, and LTL, filed a motion to stay the industrial talc class action. The court heard oral argument and a ruling is expected at any time. While the New Jersey Bankruptcy Court&#x2019;s order effectively stays all of the Company&#x2019;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#x2019; Committee (TCC), and the Future Claimants&#x2019; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#x2019;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#x2019;s insurers (the Mediation Parties) have since agreed to engage in mediation, which remains ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#x2019;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC)  (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#x201c;talc-related claims&#x201d; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2021, several of the Company&#x2019;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2018, a securities class action lawsuit was filed against Johnson &amp;amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp;amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and that purchasers of Johnson &amp;amp; Johnson&#x2019;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs&#x2019; motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#x2019;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record.  In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action, and Plaintiff filed a notice of appeal regarding the Bankruptcy Court&#x2019;s order.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp;amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Baby Powder, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2020, a report was delivered to the Company&#x2019;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp;amp; Johnson&#x2019;s motion to dismiss pending a decision on Plaintiff&#x2019;s motion for discovery. In July 2022, the Court denied Plaintiff's discovery motion. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp;amp; Johnson Savings Plan against Johnson &amp;amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp;amp; Johnson stock as a Johnson &amp;amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#x2019; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#x2019; motion was complete. In February 2021, the Court granted Defendants&#x2019; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#x2019;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#x2019;S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp;amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#x2019;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well the Court of Common Pleas in Philadelphia, where an application is pending for mass tort designation. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;INTELLECTUAL PROPERTY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain subsidiaries of Johnson &amp;amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#x2019;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos.  6,522,906 (&#x2019;906); 6,800,056 (&#x2019;056); 8,142,447 (&#x2019;447);  and 9,452,276 (&#x2019;276) based on Auris&#x2019; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the  &#x2019;056,  &#x2019;447, &#x2019;276 and &#x2019;906 patents.  In December 2019, the USPTO  denied review of the &#x2019;056 patent. In February and March 2020, the USPTO instituted review of the  &#x2019;447,  and &#x2019;906 patents and denied review of the &#x2019;276 patent. In March 2021, the USPTO ruled that the challenged claims of the &#x2019;447 and &#x2019;906 patents are not invalid. Auris appealed, and  in April 2022, the United States Court of Appeals for the Federal Circuit vacated the decision that the &#x2019;447 patent was not invalid and remanded the decision  to the USPTO for further review.  In May 2022, the United States Court of Appeals for the Federal Circuit confirmed the ruling that claim 53 of the &#x2019;906 patent was not invalid, vacated the decision that the remaining claims of the &#x2019;906 patent were not invalid and remanded the decision  to the USPTO for further review. Auris filed a request for reexamination of the &#x2019;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in January 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 (&#x2019;234) and 9,713,537 (&#x2019;537) by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. Trial is scheduled to begin in December 2022. In June 2022, DePuy filed potentially dispositive summary judgment motions that the &#x2019;234 patent is invalid as anticipated and the &#x2019;537 patent is not infringed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 (&#x2019;180) and 10,517,583 (&#x2019;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#x2019;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#x2019;180 patent, and awarding damages in the amount of $20&#160;million. DePuy is challenging the verdict in its post-trial motions. In July 2022, a hearing was held on the post-trial motions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes lawsuits the Company&#x2019;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp;amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#x2019;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#x2019;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZYTIGA &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in January 2019, Janssen Inc., Janssen Oncology, Inc., and BTG International Ltd. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#x2019;s Laboratories Ltd. and Dr. Reddy&#x2019;s Laboratories, Inc. (collectively, DRL) in response to those parties&#x2019; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#x2019;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#x2019;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision. The appeal hearing has been scheduled to take place in September 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In April 2021, July 2021 and April 2022, respectively, Apotex, DRL and Pharmascience initiated Statements of Claim under Section 8 of the Patented Medicines (Notice of Compliance) Regulations against Janssen seeking damages in respect of those parties generic Zytiga tablets.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt; Trials against Apotex and DRL are scheduled for June 2023. A trial date for the Pharmascience action has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#x2019;310). The following generic drug companies are named defendants:  Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#x2019;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. No trial date has been set in this lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2022, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Micro Labs Ltd. and Micro Labs USA Inc. (collectively, Micro) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#x2019;310 patent. In March 2022, the case against Micro was consolidated for all purposes, including trial, with the consolidated Delaware lawsuits. In July 2022, the parties entered into a confidential settlement agreement, and the action was dismissed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#x2019;310 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Partes Review with the United States Patent and Trademark Office, seeking to invalidate the &#x2019;310 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2022, Janssen Pharmaceuticals, Inc. (JPI), Bayer Intellectual Property GmbH and Bayer AG filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Changzhou Pharmaceutical Factory, which filed an ANDA seeking approval to market generic a version of XARELTO (10 mg, 15 mg, and 20 mg) before expiration of U.S. Patent No. 9,539,218 (&#x2019;218). In this lawsuit, JPI, Bayer Intellectual Property GmbH and Bayer AG are seeking an order enjoining Changzhou from marketing its generic version of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#x2019;218 patent. In June 2022, the parties entered into a confidential settlement agreement, and the action was dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVOKANA/INVOKAMET/INVOKAMET XR&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, Janssen Pharmaceuticals, Inc., Janssen Research &amp;amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET before expiration of MTPC&#x2019;s United States Patent No. 7,943,788 (&#x2019;788) relating to INVOKAMET. In this lawsuit, Janssen and MTPC are seeking an order enjoining DRL from marketing its generic version of INVOKAMET before the expiration of the &#x2019;788 patent. In June 2022, the parties entered into a confidential settlement agreement and the lawsuit was dismissed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of Canadian Patent No. 2,659,770 (&#x2019;770). Sandoz stipulated to infringement of the &#x2019;770 patent.  Trial against Sandoz on the issue of validity concluded in February 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Sandoz appealed the decision. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the &#x2019;770 patent. Apotex stipulated to validity of the &#x2019;770 patent.  Trial against Apotex on the issue of infringement concluded in March 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Apotex appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of United States Patent No. 9,439,906 (&#x2019;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#x2019;s favor. Teva has appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent. A trial is scheduled to begin in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#x2019;629) and 2,655,335 (&#x2019;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#x2019;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#x2019;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#x2019;335 patent and that the claims of the &#x2019;335 patent are not invalid. Teva Canada appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#x2019;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. The action has been consolidated with the November 2020 action for trial, which took place in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#x2019;s filing of an ANDS (original ANDS) seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022, Janssen Canada initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex in response to Apotex&#x2019;s Notice of Allegation of invalidity with respect to the original ANDS and in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA TRINZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of United States Patent No. 10,143,693 (&#x2019;693) relating to INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(546 mg). Trial is scheduled to begin in October 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(819 mg) before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#x2019;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. The trial is scheduled to begin in July 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of United States Patent Nos. 10,039,718 (the &#x2019;718 patent) and 10,786,518 (the &#x2019;518 patent). Janssen is seeking an order enjoining Lupin from marketing its generic version of SYMTUZA before the expiration of the &#x2019;718 and &#x2019;518 patents. The trial is scheduled to begin in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ERLEADA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of United States Patent No. 9,481,663 (the &#x2019;663 patent). Janssen and SKI are seeking an order enjoining Lupin from marketing its generic version of ERLEADA before the expiration of the &#x2019;663 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited (collectively, Zydus), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#x2019;663 patent and United States Patent Nos. 9,884,054 (the &#x2019;054 patent), 10,052,314 (the &#x2019;314 patent), 10,702,508 (the &#x2019;508 patent), and 10,849,888 (the &#x2019;888 patent). Janssen and SKI are seeking an order enjoining Zydus from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Aragon Pharmaceuticals, Inc.  and Janssen Biotech, Inc. (collectively, Janssen), The Regents of the University of California (UC), and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Sandoz Inc. (Sandoz), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#x2019;663 patent and United States Patent Nos. 8,445,507 (the &#x2019;507 patent), 8,802,689 (the &#x2019;689 patent), 9,338,159 (the &#x2019;159 patent), and 9,987,261 (the &#x2019;261 patent). Janssen, UC, and SKI are seeking an order enjoining Sandoz from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;507, &#x2019;689, &#x2019;159, and &#x2019;261 patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Aragon Pharmaceuticals, Inc. and  Janssen Biotech, Inc. (collectively, Janssen), The Regents of the University of California (UC), and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States  District Court for the Districts of New Jersey and Delaware against Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively, Eugia), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of  the &#x2019;663, &#x2019;507, &#x2019;689, &#x2019;159 and &#x2019;261 patents. Janssen, UC, and SKI are seeking &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;an order enjoining Eugia from marketing its generic version of ERLEADA before the expiration of the &#x2019;663,&#x2019;507, &#x2019;689, &#x2019;159, and &#x2019;261 patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen), The Regents of the University of California (UC), and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Hetero Labs Limited Unit V and Hetero USA, Inc. (collectively, Hetero), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;507,&#x2019;054, &#x2019;314,&#x2019;508, and&#x2019;888 patents. Janssen, UC, and SKI are seeking an order enjoining Hetero from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;507, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#x2019; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#x2019; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in response to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;GOVERNMENT PROCEEDINGS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp;amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Wholesale Price (AWP) Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;amp;J AWP Defendants were ultimately dismissed. The J&amp;amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp;amp; Johnson and ALZA Corporation. All other cases have been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Opioid Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in 2014 and continuing to the present, Johnson &amp;amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp;amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Johnson &amp;amp; Johnson, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp;amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#x2019;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp;amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp;amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#x2019;s judgment and directed entry of judgment for Defendants. In October 2019 Johnson &amp;amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp;amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#x2019; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of  $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement is expected to be paid by the end of fiscal year 2022, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022 and initial payments were made in July 2022. In April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions. Consequently, by July 2022, the Company had settled the opioid claims advanced by all states except Washington and New Hampshire.  A trial of claims brought by the Attorney General of New Hampshire is scheduled to begin in September 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There are approximately 60 cases remaining post-settlement in various state courts. There are approximately 1,000 remaining federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp;amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp;amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Johnson &amp;amp; Johnson received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From June 2017 through December 2019, the Company&#x2019;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.  By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted Johnson &amp;amp; Johnson&#x2019;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder filed a notice of appeal regarding the state court&#x2019;s dismissal order.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp;amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#x2019;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#x2019; motion to dismiss with prejudice, unsealed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint, and denied the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators&#x2019; request for leave to file a further amended complaint. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#x2019;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#x2019; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#x2019; second amended complaint; the District Court denied DePuy&#x2019;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#x2019;s July 2021 ruling. In November 2021, the District Court granted DePuy&#x2019;s motion for reconsideration and dismissed the case with prejudice. The District Court&#x2019;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#x2019;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#x2019; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#x2019;s dismissal of the case to the First Circuit. The relators&#x2019; opening brief was filed in May 2022 and was accepted for filing by the First Circuit in June 2022. DePuy&#x2019;s opposition brief is due in August 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research &amp;amp; Development, LLC, and Johnson &amp;amp; Johnson (collectively, Janssen) were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene.  The case has been transferred to the United States District Court for the District of New Jersey. Janssen&#x2019;s motion to dismiss was denied in December 2021, and discovery is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2012, Johnson &amp;amp; Johnson was contacted by the California Attorney General&#x2019;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp;amp; Johnson&#x2019;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp;amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp;amp; Johnson and Ethicon settled the Washington case. In October 2019, Johnson &amp;amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for May 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#x2019;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#x2019;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company's petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. The Company plans to petition for review by the United States Supreme Court.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp;amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;by failing to disclose alleged health risks associated with female consumers&#x2019; use of talc contained in JOHNSON&#x2019;S Baby Powder and JOHNSON&#x2019;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp;amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#x2019;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp;amp; Johnson and JJCI&#x2019;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#x2019;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting as barred by the stay arising from the LTL Bankruptcy Case, while the State argued that the stay did not apply. In January 2022, the Court granted plaintiff&#x2019;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. The temporary stay expired in May 2022. The State has proposed a scheduling order for further proceedings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#x2019;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#x2019;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#x2019;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court. The 60-day stay expired in June 2022, and the State made a motion for a modified scheduling order. A motion is before the court. In June 2022, the New Mexico Supreme Court granted oral argument on the Company's Writ for Superintending Control on the issue of the State of New Mexico&#x2019;s discovery obligations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to enter into negotiations to determine if they would resolve their claims through the LTL Bankruptcy Case.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2016, Johnson &amp;amp; Johnson and Janssen Products, LP were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Daubert&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April and September 2017, Johnson &amp;amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, Johnson &amp;amp; Johnson received a subpoena from the United States Attorney&#x2019;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hospitals. Johnson &amp;amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp;amp; Johnson to cooperate with these inquiries by producing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GENERAL LITIGATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp;amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. This case was settled in March 2022, subject to Court approval. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re REMICADE Antitrust Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022, subject to Court approval.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decision. This case was settled in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#x2019;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#x2019;s decision. In February 2022, defendants petitioned for rehearing en banc. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#x2019;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2019, a class action antitrust complaint was filed against Janssen R&amp;amp;D Ireland (Janssen) and Johnson &amp;amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#x2019; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#x201c;Opt-Out&#x201d; complaints containing allegations similar to the original complaint. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#x2019;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#x2019;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#x2019;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, Johnson &amp;amp; Johnson received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp;amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp;amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp;amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp;amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp;amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp;amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp;amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#x2019; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2022, Janssen Pharmaceuticals, Inc. filed an arbitration demand against Emergent Biosolutions Inc. et al (&#x201c;EBSI&#x201d;) with the American Arbitration Association, alleging that EBSI breached the parties&#x2019; Manufacturing Services Agreement for the Company&#x2019;s COVID-19 vaccine.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in May 2021, multiple &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;putative &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;class actions were filed in state and federal courts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(California, Florida, New York, and New Jersey)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; against various Johnson &amp;amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and the affirmative promotion of those products as &#x201c;safe&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; and, in at least one case, alleging a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strict liability manufacturing defect and failure to warn &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;claims, asserting that the named plaintiffs&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; suffered unspecified injuries as a result of alleged exposure to benzene.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson (subsequently substituted by Johnson &amp;amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i3d9a072c24d944d79f506df951a632cf_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDM4Nw_5ce380c3-f9f4-447e-981e-8295750825b2"
      unitRef="claimant">190</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ib832ec9b9cd74a91bcf4231b96beab4f_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDU0OQ_e11482c0-888a-40a1-ba53-b27e4ebc635e"
      unitRef="claimant">1900</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i4f5f7c43d3a442a99a3d2ce435c696ea_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDYwNA_1160c99f-3cfd-4eb5-bae6-19eab539bd59"
      unitRef="claimant">9500</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i7a31f7f1915d4fe7b8465e43a6596732_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDYzOA_06c20faa-10e8-4917-a9db-0bf595beb198"
      unitRef="claimant">2100</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i7ce6d2b512174db89a47812c9123ec44_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDY2OA_a48539fb-6efd-408f-bd61-3e627e51bd24"
      unitRef="claimant">3000</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i6dabc10483784643822a9c5e7bb9014c_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDY5Ng_c578ca6b-0475-4a23-9d65-f5891cb9fce5"
      unitRef="claimant">40300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="iaa4ee166c8fc4dfd9a75a228d52f75b6_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDc0NQ_b929d91c-1593-4b7f-ab86-9626828f7097"
      unitRef="claimant">10</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i6b6d7ce367d24bdfac85e944a0140905_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNDc3OQ_4d46b51b-a657-494c-b49d-ef2849d75049"
      unitRef="claimant">4700</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i4db059902da348b3b536a571790f6347_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTA5OTUxMTkxMzUzMA_a563ba67-6593-4596-b9e7-d1aac03234d6"
      unitRef="claimant">1300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="iad119c0eadb24bf6b712a9ded64f1721_I20220703"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjE2MQ_42751223-9ec2-47da-92bb-06e1efdf7769"
      unitRef="patient">10000</jnj:Numberofpatientsinsettlement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i2a5fcff52eca4e2b8f7fd71362e00ee5_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTIxMzk_f4cd7bc8-ab2e-4bf6-a039-308d79f1f6c2"
      unitRef="cases">3600</us-gaap:LossContingencyPendingClaimsNumber>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i2a5fcff52eca4e2b8f7fd71362e00ee5_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTIxODM_057f3f7f-737e-4a4b-8fd7-f6928b8186de"
      unitRef="claimant">4300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement
      contextRef="i5536e8ab75ef4a8ca62f7e1e6d81a778_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTIzMjM_99cef78b-e46d-4a99-b93a-83419912d2bb"
      unitRef="cases">3729</jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i3ba73cf6d5694c16922acb99ad67a259_I20220703"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTI4MTc_0db17471-4703-4720-8667-034938609e96"
      unitRef="cases">126</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i9e4509ae1e9143f38c795c4c1718372b_D20191001-20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTQ4MTE_5ddcb65b-f776-47ab-9fc9-06482b54924c"
      unitRef="usd">8000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ife017e4feb734f059e4eacc8da2b9534_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTQ4OTM_50415800-f4ee-43da-8f24-b9f5d2fbd044"
      unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="if1ba4fdb7eda4a54a9874ebb8569565b_D20180701-20180731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTcxNDE_7580d010-4f4c-47ea-9cf9-bc81b5bc153a"
      unitRef="usd">4700000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="ic69e838063cb443ba0f1e022744b19a5_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTcyNDE_ed1c4360-62b1-4ab4-bc95-b7ab0430c828"
      unitRef="usd">2100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i7d9d11122c61482b9e49c7ba615148f0_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMTc1NjM_2028cc61-ff3c-4e46-983c-4ebdea24a5c0"
      unitRef="usd">2500000000</us-gaap:PaymentsForLegalSettlements>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i51a055a5688e4ddfbc8c0852cec70dc5_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMjEyMTc_d8de6a84-d6d8-4bdf-b36e-40603199497f"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i51a055a5688e4ddfbc8c0852cec70dc5_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMjEzMTQ_3a933a3c-9b02-42d7-a4fa-73d70c3669ce"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i49377ad3634041709403a2a206d30a13_D20220301-20220322"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfMzI5ODUzNTE2NzM1OQ_89d2887c-524f-405b-9dd8-82fede15a76d"
      unitRef="usd">20000000</us-gaap:LossContingencyDamagesAwardedValue>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i858a52bb013045799d07f07aaa301efb_I20220703"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjExNDA_68421d2d-9e62-4d3a-b7fd-bf0c231d7582"
      unitRef="claimant">3500</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ifce5aacbfc3a444c920acdbe2b4a1ec5_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjM1MDQ_aba3cbec-73e6-4bdd-9f39-d17d9f414f5e"
      unitRef="usd">465000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ic155bb14d5cf4a6ea37fc5c8528e6732_I20191031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjQ1Mjk_11b8a31d-2ca5-41d1-ac22-21730be4ce0f"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:LossContingencyEstimateOfAdditionalPossibleLoss
      contextRef="icec2a84c793b4a13a9cab4e12fc62921_I20201031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjQ2Njk_bcc4d0c9-b4b9-4aa7-922b-f9377aebf281"
      unitRef="usd">1000000000</jnj:LossContingencyEstimateOfAdditionalPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="icec2a84c793b4a13a9cab4e12fc62921_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjQ4MzA_e9101a4d-6563-4a7f-9eb2-2ad688bb7c28"
      unitRef="usd">5000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i87d0bf7de5034cf18c716d0889d4a6f2_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjYyMzE_90806700-b8e3-40a5-bde7-472a6cfeec5d"
      unitRef="claim">60</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i888c4c1d679a40f2b81b60328c1858f4_I20220703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNjYzMTU_3e12fcb9-2a66-4ade-8425-5733b69710a1"
      unitRef="claim">1000</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ib6ef62a6d06b427d93b514f97600fe84_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNzQwNzU_f9167205-88c4-4770-8b5e-87530897fbfd"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ib6ef62a6d06b427d93b514f97600fe84_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNzQyMzk_adb5e384-26cc-4aad-b02b-9a602d221d61"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ibb991236eb0f43e0bf871925f4f3d04a_D20220401-20220430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfNzQ0MTE_03030e03-7416-4a32-9903-6a672c0b966b"
      unitRef="usd">302000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i52eba45e53444e1298c1fcf2a2216b36_I20150430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF84OC9mcmFnOmRhZTI0MzBmY2RkZDQ1OTU4MzYyM2Y4MzM1MWU1ODEwL3RleHRyZWdpb246ZGFlMjQzMGZjZGRkNDU5NTgzNjIzZjgzMzUxZTU4MTBfODE4MjE_4c35bcc6-21a0-4a3c-8b14-ce7a7e8e40cf"
      unitRef="claim">30</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMjM5MQ_ea529f5b-436d-4f24-a9dc-34d3f3bb84f5">RESTRUCTURING&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal second quarter of 2022, the Company recorded a net pre-tax charge of $128 million, which is included on the following lines of the Consolidated Statement of Earnings, $85 million in restructuring, $17 million in cost of products sold and $26 million in other (income) expense, net.  In the fiscal six months of 2022, the Company recorded a net pre-tax charge of $200&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $155&#160;million in restructuring, $33&#160;million in cost of products sold and $12&#160;million in other (income) expense, net. Total project costs of approximately $2.0 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.1 billion to $2.3 billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal second quarter of 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, July 3, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents gain on sale of assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i5e4e74ca66f8464690742d705f7eed8a_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfNjY0_dd74f39e-d910-4b35-82f2-75bd87113b81"
      unitRef="usd">128000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iefca38bcca5c426da7027dede1f04f08_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfNzUy_f0da602a-825a-423c-923e-dc6bcf3ca68b"
      unitRef="usd">85000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7fdef417221f4a06a85755418e9c5222_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfNzcz_eb365b41-5686-46bc-883c-dc71ba695c24"
      unitRef="usd">17000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i5d3938fca19a4ceaa24ccd83eff70370_D20220404-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfODE1_7a291919-7633-4424-b6ca-5df22b864e13"
      unitRef="usd">26000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i73608594f8c3424eaa8ff95295134a24_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTA5OTUxMTYzMDczMA_afb5022c-eb07-41de-99fb-0a14d705b9d1"
      unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2909b6c557f9463ea81eb9118d4a4049_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTY0OTI2NzQ0NDkzMA_143c0501-a2ec-486f-9b7b-63a32df98c7f"
      unitRef="usd">155000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i480b3ed870204b9391f1887a57cdae32_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTY0OTI2NzQ0NDk0NQ_ad39319f-93ac-4f8c-afc1-2b48a3c439cf"
      unitRef="usd">33000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i480b3ed870204b9391f1887a57cdae32_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTY0OTI2NzQ0NDk0NQ_d6ee1f7e-4c01-4675-9d62-2bf10b2f57f6"
      unitRef="usd">33000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i74fe313c94e648559666a0a69c919630_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTY0OTI2NzQ0NDk1OQ_6386d8c8-3ef2-4857-80c6-1985f531eebf"
      unitRef="usd">12000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i6f129a7dfc034e9c9fe9ae8a3c42730f_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfOTA5_ff4b6f5d-e421-45ab-bfa1-d90a9dfb025c"
      unitRef="usd">2000000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i0c3d0aaa08c34dad9c998070ad8755bb_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTEzNw_bb0c663f-e546-4763-b486-4f65dd42fb39"
      unitRef="usd">600000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i6cc12874a2f141468d294f5edf304948_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTE0Mw_dbbdb491-4e3d-4b4d-9e51-d9bc3470d278"
      unitRef="usd">800000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i0c3d0aaa08c34dad9c998070ad8755bb_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTMxMQ_04e2a2ca-c896-49b4-8417-caf86c9bd73d"
      unitRef="usd">2100000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i6cc12874a2f141468d294f5edf304948_I20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMTMxNw_9620c184-5273-4a44-99ed-2d99a4a2a6a3"
      unitRef="usd">2300000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RleHRyZWdpb246ZDhmNDM0NTk2YzZhNDVmZjllNmEyNDM0ZTcxNjRmOWZfMjM4OA_2b333ae8-b563-4e1a-a6ee-ce65a4210b88">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal second quarter of 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, July 3, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents gain on sale of assets&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="if65b6db0f8484a37b25b57a750fdd0c9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfMS0xLTEtMS03MDAzNA_0f7458e7-e027-4061-ad09-b18531312f51"
      unitRef="usd">112000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5042a6771a2743cfbea81abb2c4f0489_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfMS0yLTEtMS03MDAzNA_58741452-446a-4310-83a7-b9fcc7a000f1"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iedcbb46afcdc46c89062dca3aa694438_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfMS00LTEtMS03MDAzNA_1e07599c-098e-4bdd-b659-1c80a68c933e"
      unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i4c99f4219f554853b8e2459b665c0cb3_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfMS01LTEtMS03MDAzNA_2207a5fb-0f09-457b-b789-c0e21d5ddadc"
      unitRef="usd">137000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i38a9e37a55a9465296ff97bfeb4dbc2d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNC0xLTEtMS03MDAzNA_123d4d62-4cfc-45cf-b4ff-10403df3d3bd"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0c0d4d2eea744af684d21c45ce8f9077_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNC0yLTEtMS03MDAzNA_fe8875bd-e53a-4422-a3e0-c1627171764f"
      unitRef="usd">-11000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if587f8e549024234943bfe0d376966d8_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNC00LTEtMS03MDAzNA_9f716725-3822-4624-a376-5173d8bb361a"
      unitRef="usd">211000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i15dab1b527c04e6c93a77db28d7f4dfb_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNC01LTEtMS03MDAzNA_2daff90b-4ca4-4d10-9ad2-a19b87cd9f04"
      unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <jnj:PaymentsForRestructuringNet
      contextRef="i38a9e37a55a9465296ff97bfeb4dbc2d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNS0xLTEtMS03MDAzNA_ccce489d-ec6c-4d18-91d6-358a0dd5d0aa"
      unitRef="usd">23000000</jnj:PaymentsForRestructuringNet>
    <jnj:PaymentsForRestructuringNet
      contextRef="i0c0d4d2eea744af684d21c45ce8f9077_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNS0yLTEtMS03MDAzNA_8b7cbeb4-fe05-41d5-92ae-cfc7caa7d57b"
      unitRef="usd">-35000000</jnj:PaymentsForRestructuringNet>
    <jnj:PaymentsForRestructuringNet
      contextRef="if587f8e549024234943bfe0d376966d8_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNS00LTEtMS03MDAzNA_17fce06c-573a-482d-be9d-ef02c53fdcdc"
      unitRef="usd">214000000</jnj:PaymentsForRestructuringNet>
    <jnj:PaymentsForRestructuringNet
      contextRef="i15dab1b527c04e6c93a77db28d7f4dfb_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNS01LTEtMS03MDAzNA_c11549a4-5e3c-490a-b61b-f01384867b51"
      unitRef="usd">202000000</jnj:PaymentsForRestructuringNet>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i38a9e37a55a9465296ff97bfeb4dbc2d_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNi0xLTEtMS03MDAzNA_6358fe9e-117d-481b-8f04-5bca48747589"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i0c0d4d2eea744af684d21c45ce8f9077_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNi0yLTEtMS03MDAzNA_17a09de0-b60c-4a33-bff0-c36de81bb227"
      unitRef="usd">24000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="if587f8e549024234943bfe0d376966d8_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNi00LTEtMS03MDAzNA_34124c90-9dfb-40d6-ae30-e0ca27003f57"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i15dab1b527c04e6c93a77db28d7f4dfb_D20220103-20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfNi01LTEtMS03MDAzNA_ba4ef742-4e7f-4c4f-b758-fb3d7174a0e4"
      unitRef="usd">24000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="i69ca6c41d5964c50abb196f02b39a16f_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfOS0xLTEtMS03MDAzNA_8a6c135c-5764-47e9-9e9f-fc2b0db6c5dc"
      unitRef="usd">89000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i3d93eaa25cfc46b38549e5a299d8f0e1_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfOS0yLTEtMS03MDAzNA_b18b5ac0-88bc-4fa4-9d49-7a707513bc12"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="idbfc10f2d9fb46bea65fe6d1a1318594_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfOS00LTEtMS03MDAzNA_be846ca5-cbaf-4911-8ef0-facb6fb48ac8"
      unitRef="usd">22000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i86429e3449e0476199236fd7c3b171dd_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxYjVkNjY4OWFkYzQ0OThiZmU2M2JlMzllMzUyMDYwL3NlYzowMWI1ZDY2ODlhZGM0NDk4YmZlNjNiZTM5ZTM1MjA2MF85MS9mcmFnOmQ4ZjQzNDU5NmM2YTQ1ZmY5ZTZhMjQzNGU3MTY0ZjlmL3RhYmxlOmM4YmI3MjFiMzk1OTRjMGRiMDU4OTI5YjQxMGU3ZGY0L3RhYmxlcmFuZ2U6YzhiYjcyMWIzOTU5NGMwZGIwNTg5MjliNDEwZTdkZjRfOS01LTEtMS03MDAzNA_d527310d-53f7-475c-bce1-5a4fa5d4bfca"
      unitRef="usd">111000000</us-gaap:RestructuringReserve>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M.([]"NF .QK&'2A4>Z@7H_3Q[DQ<=A&:X&D?X3-C"9DIO70@' T3[DFE$C>
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MK-O+K> @VQK ][<2%FY_8U\D'EX<K_\"4$L#!!0    ( -&!_53S=*DOY (
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M&NJ-6O'2E"@-(B3 !>.2?JN?MN/-I>4_4I<6D&\4I@44&85I 4W1@<K<O0?
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M$56'50T4+\H6XI$KW9"4KPO=E((P /U]QKG:#$R ILV-?P-02P,$%     @
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ME:5M.=1E3VT@L;Q0:K-VQ)$''9DDBTV2):>:T=/#/^CA:_78^81ESR=DK4]
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MWZYINJ)5 Q#_?V",__S0/+1Z>&YZ_A]02P,$%     @ T8']5&BM/.NM @
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MMV+[&9IX+BQ?)KAR7[2M;?N1A[*UTJ)HP.8&!2OKE3PT>=@#&)YN0-@ PJ>
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M^N<\[WJ@FOO*<=L1LDF#7A E>+.?^"XCOW]H-/G;*.P%5X=&TRXC_[(UJA.
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M$G,M8K+4\ _F2!=$KLB,%VMR ?-<D&/R?7E./OWRF?Q"DIQ\2](4YJ X[6N
M8!3UH^IU7\O7T9;7A>2;S/6Z(/,\%O'A^#Y W^&G+_B_TDZ%_]JF7\B '1$Z
MH!3!,WO+<-\.]SK@L)T[F=7'VMPY7?Y*+GZ[^F-)+FZNOI&KZ_G-]'9Q^4\R
MG=TN?BQN%_,EYK52JX]K-:%\4FQX),YZ$*N%4 ^B-_G[W[QP\ _,Y ]2=N
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M$8#G*RGURX5YP>X[J\G_ %!+ P04    " #1@?U4KC8=BSD&  "@#P  &0
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M%4X&EL2.FN0$])FVMD4+K@NIR921+PP8K_F&N =.R62K6'18U5H)[!-VI;Q
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M>>"L^W;6Z[-IELE&O"SK9JVV:,EU)LLE$XN%3'FZ)36D=WI#9X\IMVXN4E[
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M4ZM_"6L.+'1Y\U'\<?GV]VOQ[OKR]O>/U^^NW_]V*WY;2W&5;[9Q]BCJ$K2
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MNIEB];DK#W*YAR*VQO?V[-0]X"3K5@)VFN#-O+9'3Y]</''!Z;*I]#35W4?
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M;N?DT'8K</BE.I'J8-O ,81%%085&NUF***^05I=<\<*!%W)?F=JGUEVM:W
MR%O2%AXMVH#!$<+_H&OZ_^E2R>L^O[4-3I)<#R6PW5"X1G-"-:&3>E>!69=?
M/UE(,^2L!H\)2BP1 !DW9 0GW9+/#>\#>$X9/!6H%C1[TNA">T69NG4_R1ZH
MR(&NH;P[J#W$OG301VX,'TI#;XN/%Q<M?.)\^,DM IIM3#4R?98\6%#.M;D]
MAGN(7$@R-R" \\]&=<>?__:+O1XVSPZ''@;9OFGRK!+ ;<V]?84VN-O,PVZD
MF"!,Q7"7%UKFFZ6."\+$K&7^U9Q&KN5IW=91IJ(TE1:=N^8<+762T6W!,4YL
MK3PKY:'%"A9I6NXTN$S]SD.L.S_T.?>I%O(EQT)BX_+#E=C@%+$D(X5I9VO#
M.8;M<[\#DA)@5R6'(9U=T-_NL(J4G!$& 6R<;TL=9>H2W$K>5?HS#.S QMSC
MQ(P/D9EP]WB0"2AQ:<!(<7&T9TNM',9_?MU[+RT;=ZOGN]%:D#5TP\>1*"<A
M%X+AB2^ZMZBO-._=(LK=4.*GIEOL7)-%%G;M',T'HLR%;F/I?$HBH S<LW9]
MQLTN\(FRR_V=(&7J+<8'#.V=<X*J'6: X'2I@*"!SP4ZH!07J;L9V8"*E@SO
M#>"-@?%! *I2+):M'.+8W49OI/^D]BCA=,C\OEAEBPLFI=E])_3QUN4)V;V2
M*V*7X>D>-:P.M]"S=/FZVYZNL.^T7QE09&D)T4GV[.E(^70M3"_1-7(5PV#!
MQ4X>2]RDR?,&?%\Z--WNA0T,=_/3?P%02P,$%     @ T8']5(%*AI+[!
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M)<%.V1*LDW&K)-.J[$>G,O1J>B$/2NBE1+C,1>/<F.A/2B/M05,D[_,C,E?
MC-^N.TJ$6O,<W35QT9T7',E+T'F1*Y/>GW6EI<[W0)D],M'X*+=VJZJ:R6=?
MXO&-:7<,X;6W)#I[Z2O4!]_/C!."M.VCW\_V+7/9=HK_W=M^>\_T@4O'<T^A
M<3@>!J#;'M8:5M6^;U")J0OYSY+:/FKG0.M[1?KN#+=!_T=B\1]02P,$%
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MC/;48!*H0685;A]JB@XW108*MHFI)U'$![!I[$)TPD!"[0T7TPT2 D^-A%9
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M; (1T(F5-G$D!"\)$31$8FOCRZNS\^%%;_1!G7X ,"-]C)DVVC!$X$&RD M
MSXCZ-ONK!M1R:T&H@8:+:V/3W%;R0F<IS$2'S&+&=27$8%$4K[.\O$_KZ:I(
M*X3#.2+@NBSR>HX?&U5M!">,8O>Q/O -<3, >@)7/U/_T,OTFC3X6$++Q)+M
M0#4M['5\ZU]Q+/#*^D=2TB^]4?]L,FQS%0 G")']NEKB6RH4<?9]";[[6XPB
M[*>O_MZHR;X\R\6[X3]ZDNCMY7F_]578@C3)-Y)*H0#-K0LOV@\36_8;TB_/
ML@]_FYR35W,'!A5%\L*&JW;7J&B]IV/:XA1@;9%.S"#[!5Z\+CQW8@1(K".;
M,;DE@&F\T*+45H@:;FS)%HT,$D %@:"R:,!N.^Q4^-9'H"=X.I(14)U1X2'+
M:'YYFOM.NP$4BEX#L$5$(G,_TJL4A>MTZFX!&$;A)HGCPPU#A)%!?SB5\9T
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MF6H90T=,=&WJXWZA_=Q!*(?;;%KV,>UN/U0B^2QTUV*]RY^X%7?/?+BL$ A
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M+2M6B/O;5M^J_JI"C81JTHT#GO.$=BN2 _"PA<<H1O'ML_=0)6(.!=,\KY<
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MY+37THVD)&3$"C];YASS[ZD!64A"VVE9%?= %QOX%'!N2KTP/3WGZ3!7R[8
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M%P_O"@A&[D3A8+C#Q^RK<O)^JW;L@<G_&WL%")WI[[5\!5_6;2U>EH_^T]U
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MU!( "#EC0XLH43GPB)@ADZ$>BFNX]%"L2TCF2FN.1W<5";H%KA57(D?2(4"
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M5]Y3D=SM6I\.1UM709RT%^G"R_L:A)]OA=W;[DY]D:^2]]/SA?RC] L<8Z&
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M+W=O<FMS:&5E=',O<VAE970R-"YX;6R=5VMOVS84_2L77E#8@!I+LB3+;1+
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M8YD;M+&DI+AN*)-J8,FV)= 0@(O^)E3)V269L<P(K?B'+@^;!<O)AZYE[M+
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MRE-YN! 1-O$T /?G.19;GQ"#]F='I_\!4$L#!!0    ( -&!_53H*/C^D0,
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M3CO.WSO\X+@VK\;@,IDK]>0F5]DXB)P@%)A:Q\#HL\(9"N&(2,;SEC/8AW3
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M:WH<T?@ FM]KVM'!\0N,S^WZ7U!+ P04    " #1@?U4T0H+N<45  #4-
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MBB3-R^4?>H,/P\[E:;^K.L->YW^AT!<M-E6]6&*WY'^Y1?VR^17($>89\:V
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M+0O0?6F,/V[8P.D]7OP+4$L#!!0    ( -&!_534P%0ABP(  -4&   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*U574_;,!3]*U:&)I VDC@?!99&
M@E8P)B%5,+:':0]N<MM:.'9FNPW\^]E)B HU90][2?QQS_$YMN]UU@CYH%8
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MIVUQF1 EQ;DV4.\7C,G=C1Z@;GW/_@=02P,$%     @ T8']5!R!_5'4 P
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MG)HV5T!#D,D \WXAA'[O) F*_QKZ_P)02P,$%     @ T8']5-#[4L22 P
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MY+*;+"NBX$ZP;S33>>S=>BB#-=DR_22JS]#D&5F^5##EGJAJ:@,/I5NE1=&
MC8."\OI-]LTY' $P/@/ #0 [W[60<SDGFB21%!62MMJPV8&+ZM#&'.7VHRRU
M-+O4X'3RP#7A&[IB@*9*@5:(\ S="Y%5E#'T'OU;@*:%D)K^)NY0/^[-WZ$
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MH4W3<,/<=&F0ML#LKX70AXGM'&W?3_X 4$L#!!0    ( -&!_51DLR6P& 8
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MF%=!Z@9X?RF$>C[1#NJM0/-_ %!+ P04    " #1@?U4&>KL[ED-  #8H0
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M'8BC..[1Y_@I\*&'#_K,^;_3I_]\^@-G)-V52CS?\!&^#T^X%O +*,^73.=
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M;"]W;W)K<VAE971S+W-H965T-# N>&ULM5AM;]LV$/XKA%8,*=!$+WY+,MM
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M=S3!^BBJSELU4'QM6DNW7"F>F\<5T 2$%L#W*>?J?J --/W/^7]02P,$%
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MN!NZ,H&9;!R:$)DC=[=N@,'V)JYIW E=D4!5-@HE)^9R[/;5#2),J..+6DT
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MG*%.I>BIS5_X<%-/6RIKP^  CH7S*V+X*@Y)BU]4UH;A )P+Y^#<J/0<JAK
MQ(H8[H:N3("R$*^(423H4-$!)MY"A;NA*Q-@*YP'6V,S=*CJ 1-K![@ONEJ!
MN<(7:0$+20MF5-:&,>H]8XRP!2Q4E,;$2\WX>+IZ@,M"H@ZP4-$!9DMB3 !4
M!  5S2E^=?=1_2U_^$MU0BP^SM13ELK:,"K 8='\(AF^@B/2>AB5M6$X@.6B
M.2PW*C]'BBK9.K*EI]^9X+((N"R:\0S5D1DZ4CP03'KL&>Z'KDX KF@><(U^
MI*&"NM9A(%8+<6]TU0)W12_2$1:15LBHK UC!- 6$7:$10HR8YZ(H?B(NHH
MS2*BCK#.SN#YLJ$O7;?!AYLJ9]5[0'CS=/;:V[LD*ZV4W];FUV=-P;1X>N#Y
MTYLJW[?/#+_)JRK?M2_O>;SE1?.%^N^W>5Y]>],\AOSXV/G+_P-02P,$%
M  @ T8']5/W_J7.Y @  A@@  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&ULM99=3]LP%(;_BI6A":2-?/2;M9$H%=HF54)TL&LW/6DLG+BSG0;^_8Z=
MU'20=ES 36([/N_['.<XSK@2\D%E )H\YKQ0$R_3>G/A^RK)(*?J7&R@P">I
MD#G5V)5K7VTDT)4-RKD?!4'?SRDKO'ALQVYD/!:EYJR &TE4F>=4/DV!BVKB
MA=YNX):M,VT&_'B\H6M8@+[;W$CL^4YEQ7(H%!,%D9!.O,OP8AK: #OCGD&E
M]MK$I+(4XL%T?JPF7F"(@$.BC03%VQ:N@'.CA!Q_&E'/>9K _?9._=HFC\DL
MJ8(KP7^SE<XFWM C*TAIR?6MJ+Y#DU#/Z"6"*WLE53,W\$A2*BWR)A@)<E;4
M=_K8+,1>0!0="(B:@,ARUT:6<D8UC<=25$2:V:AF&C95&XUPK#!O9:$E/F48
MI^-KRB2YI[P$,@>J2@FXY%J1KV2!!; J.1"1DLLM99PNL8-U0!84&PM(2LDT
M T7F5.^:IS/0.%6=D1/""C)GG./:J[&OD=4X^DG#-:VYH@-</TM^3H+.%Q(%
M443N%C-R>G+VKXR/J;I\(Y=O9'4[!W2OA-)D2A5K9:ICN^VQ9H-<J U-8.+A
M#E @M^#%GS^%_>#;$;*.(^L<4X]G^ HJIC-<-E$ >0(JVQ!KD;X5,5MN&T=A
MV.N-_6V+=]=Y=__K35,-TED3G4E1KC.2XJ:Q(ZT+5LOV]FC";CM*SZ'TWHCR
M[.Q@-!2'67JO6()VE+Y#Z1]%^24TY;C%EYHH5^UMSOU7SOA.^J-V]X%S'QRM
MU.>=V68Y^(!*'3JRX7M4ZK!M58(#JS)RWJ./J=31FRLU#)Z_G<$'U6HC_(9B
M#?>^Y.'[E&NC\^(;$G5> /A[IXHYH>=4KEFA"(<4XX+S =++^M"K.UIL[$&S
M%!J/+=O,\$<!I)F SU,A]*YCSB[WZQ'_!5!+ P04    " #1@?U4\RL<W4 =
M  #CP $ &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6RUG6V3V\:1@/\*
M2W>^\E4E*^(=2&15)9[VO=0YYXHKN<^T1$M;6>WJN)2=5-V//W)%+GH&0&,&
M>.0/B60/GUET [-\T(W!JU\?#G][?+_?'S=__W!W__C-B_?'X\??O7SY^.;]
M_L/N\>;AX_[^]%]^?CA\V!U/?SV\>_GX\;#?O7WZT(>[E_EV6[_\L+N]?_'Z
MU=._^^'P^M7#I^/=[?W^A\/F\=.'#[O#/_ZXOWOX]9L7V8OKO_CS[;OWQ_._
M>/GZU<?=N_V/^^-?/OYP./WMY3/E[>V'_?WC[</]YK#_^9L7?\A^)WE7GC_Q
M-.2OM_M?']6?-^=C^>GAX6_GO_S'VV]>;,\_TOYN_^9X9NQ.__?+_MO]W=T9
M=?I!_O="??$\Z?F#^L]7^G=/1W\ZFI]VC_MO'^[^Y_;M\?TW+]H7F[?[GW>?
M[HY_?OCUW_>7(ZK.O#</=X]/_[OY]3)V^V+SYM/C\>'#Y<.GG^##[?WG_]_]
M_1()]8$\G_A ?OE 'ON!XO*!(O8#Y>4#9>P'JLL'G@[]Y>=C?PJ<VQUWKU\=
M'G[=',ZC3[3S'YZB__3I4[QN[\]GRH_'P^F_WIX^=WS]W>[VL/GK[N[3?O/]
M?O?XZ; _G0;'Q\UO-]_=WN_NW]SN[C;_=;O[Z?;N]GB[?]S</QRO ]]N=L>-
M^OS7;G_<W=X]_NNKE\?33W;FOWQS^2G^^/FGR"=^BO_\='>SV1:_V>3;/-_\
MY4>W^?J?QS#?IF#D+W_>?/TO_]06=?G[,9A+@?W;'W\XP[*Z&&7)#&MW?V+E
MUO&]/"7N.7OY<_;R)VXQE;VQ'(V%_S.F',><5Z/?/7[<O=E_\^*TW#SN#[_L
M7[P^'^SV]V-)(&&.A D$\W)1/.>BL.BOO_UT.)PNG8W;_W0<2\'G3]=/GSZO
MW[^\+HMMM7WZY]7+7W2 S8E2 TS"9'@015/7P4%XX2N?PU>:I_*?'NY_.Q?"
MDCR+29@C80+!O#14SVFHS+,X)@V?"94Z"?(V[_+14]F<+37*)$RJP:F<=UT;
M7I!>$.OG(-;V4K ['/YQ>_]N\X</#Y_N1V-H E)/91+F2)A ,"\+S7,6&N:7
M8T/F@H0Y$B80S,M%^YR+=M4OQW:PI$S^<C0G2@TP"1,(Y@6X>PYPM_K79T>>
MYR3,D3"!8%X:LFWO4]O5OT OB+C?H/9\J9%&:4+1_%@K=\W,6,OC\?;#[G@R
MT5Y#1^-M8E+/?)3F4)I0-#\AO8YFD(]FJ)"B-(?2A*+Y&>FE-%MGI9>/![]Y
MR_&5"/52E"84S0]S+Z_9>GO-4'U%:0ZE"47SD]$K;+;>8;,1_:N;-AL_\5&+
M16E"T?Q8]Z:;V:I;WS3%5^<HGX+]Z33!YNVG_?DN9S$:=-1Z49I#:4+1_*ST
MYIO9ZAMU!:#:B](<2A.*YB>C5]_,=M\?CT]?46_OC_L3_K@YG/ZZ^7KWN-EM
M/NX/;TXY&J^8?*:V:H7:WFSKI@@7I[AQ+G*<V$>S-%J]QV:FGTTO*)O_VT3<
M5[/IR6<U:KDH32B:7WCJ/3??KEYB<E(VOT5I#J4)1?.3T8MP;HMP5#*RX3>>
MRQVV\/N./5MRI%'#I6A^I%7!U?0U<WF*O1UA3Y%\6;#E6+8>^R7D-^_E-R_6
MKU&DAGZ+TAQ*$XKF)Z-7Y-RTOKADE"-65HRO4:C_HC2A:'ZD>__-;?\M;HJF
M^FKSIX?CC(_9G.1S'[5DE"84S<](;\EYO7XA0N48I3F4)A3-3T8OQ[GI>TM]
M[$+-<E^@BM.U%BY-L2-=]$BQCVEIS'J'S6V''5U2XHS,)B>?UVCY%Z4)1?-S
MU)MSOKX$G*-ZC-(<2A.*YO<"]GI<K"\#7Q#ZVTZ['2\"V[,EMP2B[DO1_$CW
M[EO8[CNU-,7:F(U/O210FD-I0M'\1/7J7-C%X:A+ E5CE.90FE T/QFJ6=FN
M"T<E8]CMVTYU++,MRVS/\I?PWJ+WWL+VWNU-76V#]:G<?-U4V^^_W\BGP\,F
MN]F6VW;T2Z?-3KX>4&=&:4+1_"SUSEQ4ZQ<G5)=1FD-I0M'\9/2Z7-A%Y86&
M=J$&%:YM'?I9Y#@7.4[LHUD:K=YG"]MGSZ?K*5:/Q\.G\[-;O]G\?)IKLWL2
MLM/WH,L34*,!0TO %UI6J'@UXQ4&A\XL%,U/0"_'A2W'WST<]K?O[C?[O[]Y
MO[M_MW\Z7T?C_9F3E2I"GQ?_\ R-'.AB!XI]"$M#U+MI85=UHW\)QMU3L&=+
M/G%1C45I0M'\9[)ZC2W75WE+M,J+TAQ*$XKF)Z,WW7)]E;<<5GF;9KR=TYXM
M.=*HJE(T/]*]JI9VE3=EN8J]SV!/F7R9H&J+TH2B^<GKU;9<7_4MT:HO2G,H
M32B:GPSU5._ZJF\YK/H.'RJ^1!HU6)0F%,V/=&^PI5WUK6[&EJS3]^_3DG7>
MO2"[R;.R&!4GFYQ\-:!BB]*$HODYZL6V7%\'+M$Z,$IS*$THFI^,WIO++U('
MOE"#NP)5>),A;IB+&R;VH2P-56^XI6VXL[<8SONBC 8++?ZB-'>A9?K9I^OM
MBFT8_R^ASV6OSZ6MS]%W&"Z<X'[ >>$/3\_(@2YVH-B'L#!$56^JE5UPC?SU
M%W=_P9XK];1%:0ZE"47SL]8K;96M_H58H05:E.90FE T/QF]]5:V]48E(Q]\
M5Z\G:H+V;,F11A65HOF1[A6ULJNO\8M5[-T%>\+DBP056I0F%,U/72^T5;E^
MQ4*KMBC-H32A:'XRU&95P&Y5PR=]Z[(97['8W:K8[:J^A+E6O;E6=DDVOZGS
ML,NJ&@TWJJ\HS:$TH6A^1GI]K=8_XUNA!5Z4YE":4#0_&;T@5U_D&=\+->S_
MSNL\O)T0/=)%CQ3[F);&K)?:RI;:T24ETL_0^B]*<RA-*)J_CV%OU?7Z^F^-
MRC)*<RA-*)J?C%Z6Z_7UWWJD_EMVH]]V[-F2(XV:,$7S(]V;<&V;\-32%&MC
M-C[YDD!%&J4)1?,3U8MTO;[66Z-JC-(<2A.*YB>C5^-Z?:WW@JB\]6G\_I$]
M6W*D4>^E:'ZD>^^M;>_=WE0+OSG9X.2+ 15FE"84S4^1V@)Z?:FW9G>!9K>!
M9O>!_A*N7/>N7-NEWJAD-(.5J2O']T>Q9TN.-"K"%,V/="_"M2W"$RM3]!<G
MM%Z,TAQ*$XKFYZF7[WK]P\(U:MDHS:$TH6C^/O6]93?K'Q9N1AX6;L8?%K9G
M2XTT2A.*YD>Z5^C&5NC\I@R7IWHTVFC-&:4YE"84S4](;]K-^H>"&]2F49I#
M:4+1_&3T-MW89>F%=[$OU*"'+2_#>]B1XUSD.+&/9FFT>MUM;-T=6TOB),P&
M)Y_0J">C-*%H?HIZ3V[6/]7;H$:,TAQ*$XKF)Z,WXL8N(4<EHQY\R\FZ;OS^
MD#U=<JA1WZ5H?JC5FX]LWYU8FF(MS*8G7Q+L*Y'8=R)]"5MN>EMNVO7K$ZK$
M*,VA-*%H?C)Z)6[L>G14,KJ1]6EB%UU[NN10H\)+T?R7@?7"V]K"F]]TX?K4
MC(7;QJ2>^RC-H32A:'Y">B]NU_=AMZ@3HS2'TH2B^<GHG;BUJ\\+->Q"#;6I
M"S4L<IR+'"?VT2R-5B^MK2VM8VM)G(;9X.03&BT,HS2A:'Z*>E-NR_6K"^K$
M*,VA-*%H?C)Z)V[7]TRWPY[I+AM_-Y(]6W*D4>&E:'ZD>^%MYWJF1U>F6 NS
MZ<E7!&K+*$THFI^GWI;;]9W4+:K$*,VA-*%H?C+4BX+M G)4,MIA+:P;;W*T
M9TN.-/N^X"_ANVWON^W<GER1$H:6@5&:0VE"T?PW./=6W*UOMNY0(T9I#J4)
M1?.3T1MQ9U>*%TK8A1KN&3F0L,AQ+G*<V$>S-%J]LG9S&V8ME3 ;G'Q"H\5=
ME"84S4]1[\G=^E;I#C5BE.90FE T/QF]$7=V[3@J&>7P7G.9C[\-R9XN.=2H
M[U(T/]2][W9SO=*K+,RF)U\2J"VC-*%H?IYZ6^[6-TQWJ!*C-(?2A*+YR>B5
MN%O?,'U!>.M37H_O-6I/EQQJ5'@IFA_J7G@[6WCSFV[[U6>>MTBUHS%'B\$H
MS:$TH6A^5GHY[M;W1W>H&*,TA]*$HOGOA-[V9GS^\Q>PL2MV4,,*WZ$=-\Y%
MCI.9PUD<L$P%;*[1>6)5B7R-MHU//;=9G&-Q@N&";.4J6^N[H*\,+"6H*K,X
MP7!!2@J5DO4O2+HR?$7KQK<NGIDP/>"H#V.X(."E"KBMQ-:*%2MK,W.D7R.H
M5K,XP7!!RBJ5LO7MU5<&EA+4H%F<8+@@);5*R?HFZRO#7[;J\8?)9B9,#SBJ
MR1@N"'BC FZ;<G:3#?9R;&-?[S8#3[\X4,UF<8+A@ERU*E?KVZVO#"PEJ&.S
M.,%P04HZE1*["+U8[+HQ$<NRL,X6.]#%#I29(UH:LTS)<&;+\/(7OLV0DT_N
M"R[JE6_LW(+A@C0HQ<YLQ8[>E/T*FG_O6_1(%SU29@YC<:"4W69V<3CZ5V3D
MO0E[NO23F!5A%"<8+LB>$N%L?=WXRL!2PJHRBA,,%Z1$J7*VOGI\9?AO@INX
M-6'/EQYOUG,I7!!OY;F974).6<"B;U78<Z9?,JP7HSC!<$$*E1=GZZO+5P:6
M$M:<49Q@N" ERIRS]37F*\-;Q8KQY\%GYDN/-VN_%"Z(M[+?S"XTU\-&F&X\
MYJP!HSC'X@3#!6E1!IRMKS1?&5A*T%HSBQ,,YZ<D5X*=?YEJ<SY:':Z?'Q!_
M^B<+EZTEGW*+/B4S![XXM$J:<UN:QQ:A2.VSR<G7 (IS+$XP7) H)>TY4)+.
M61-'<8[%"88+4J),/ =*TOFP))UW[?@7)GN^]'BSFDWA@G@KS<YMS9Y8JZ(-
MS\:G7QVLI*,XP7!!MI2DYT Q.F>E&\4Y%B<8+DB)DNX<*$;GPV)T,;&QZ<Q\
MZ?%FC9K"!?%61IW/U:*+X#95L1V/.5MV1G&.Q0F&"]*BQ#L'RLXY*]THSK$X
MP7!!2I1TYU^F[)R/%XG#MRM'CG.1XV3F<)8&K%!*7-A*/+:T1'J;34X^LU&<
M8W&"X8)$*<$NUN_D=65@*6%5&L4)A@M2HE2Z6/]>Y2O#Z\FKRXEZG3UA>L!9
M4:9P0<"5*!>V*$\L5M'B9N/3+P]6LU&<8+@@6TJSBQ)8L5B71G&.Q0F&"U*B
M7+I8OT?8E>%W$6_'G_^<F3 ]X*PI4[@@X,J4"]N4RZ=;3:=0GR+^Z= O6\5X
MY-DZ-8IS+$XP7) ;9=7%^NW!K@PL):Q1HSC!<$%*E%$77^1URU=LH%OE8'>>
MV($N=J#,'-'BF"GE+6SEG5QB8C6.+4&C.,?B!,/YV2J5;Y?K]P*[,JB4H#C'
MX@3#!2E19EVN?_WRE:&_%)53Y3=[OO1XL]I,X8)X*VTN;6VV%JQHE;/G2+]$
M6/%&<8+A@I0I\2Z!7O&2M6L4YUB<8+@@)<JN2[N('9>2<K!J5=6$R=GSI<>;
M56<*%\1;J7-IJW-Y4S1!U\"$Q=F@].N -6P4)Q@NR(LR[!)H "]9L49QCL4)
MA@M2HL2ZM,O52RWN@CT_&>5)U^G"&RQ6L4-=_%"9.:[%D5/^6]K^.[K(1'J<
MC4X_Q]E",XH3#!=D2EEW"71WEZQ:HSC'X@3#^2FIE%I7Z]^V?&5X6\Q7$\^=
MV/,EQQO%"88+XJV\N;*]>6JQBG8XFY]\>: XQ^($PP7I4MI= 8W?%:O5*,ZQ
M.,%P04J45E= X_>%4>D5:^+-J3/SI<>;=68*%\1;.7-E.W-V4X?/^Q;5YNOL
MIOKCDOT*[-G2+Q96P%&<8+@@>4K *Z /O&+=&\4Y%B<8+DB)<N\*Z .O1C8E
MF[P)94^8'G#6K"E<$'!EUM67,>L+-FQ'K0=>'3G0Q0Z4F2-:'#/EU)7MU-:N
M2N/!&KZ%*GM^^G(0,%:349Q@N"#X2I,KNS@=OY?2!12QEU+L2!<]4F8.8VF@
M:B6O]5P?=O17DVB_LJ=,_F6(XAR+$PP79%#I< TT:->L\J(XQ^($PP4I4<I;
M PW:]4B#=M%,+/?VA.D!9X66P@4!5T);VT);W%3A':%Z/.ALK1C%.18G&"Y(
MB_+>N@26)M9F49QC<8+A@I0HFZWM<O+2;_(7;/"]NZ@&W^0C![K8@3)S1(MC
MIG2SMG5S;'6)O%5CD]-/;E9349Q@N"!12E-KH+.Z9CNK49QC<8+A@I0H"Z[7
MOW[YRO"*8^W$K69[OO1XL^)+X8)X*_&M;?&=6*OBW8TM':,XQ^($P_G9:I1]
M-T!7=L/J-(IS+$XP7) 2I=,-T)7=#+NRVW*B*]N>+SW>K"M3N"#>RI4;VY6K
MP:9(Q>A;XV<XZ9<!:]0H3C!<D!9EU W0>=VP-HWB'(L3#!>D1-ET8U>1EZK;
M!1N(5C5\2"URH(L=*#-'M#AF2G<;6W?'5I=(=;/)Z2<W6])%<8+A@D0IQVZ
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MQ^C5#2-9>4[\3!@C27EY0$&$: '@W^\(86\WQ0#-/S/6_P)02P,$%     @
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MI34P]QLA]&%C'32/9OP+4$L#!!0    ( -&!_51FZQJSN 4  -DH   9
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M+:%HZ\ <Q)RJJ[E;YEF?948S#HXG&I\E1C,ZR[-LS@IFXM^O BO8R15R[$%
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MCH6'R$N%L X7RFHD(U],LURV2J/9"L(HT6PP65(6:%;[@GUH%!%M"FP?+L#
MLF/V_%@U=H-C.7G(<_)7D5F*R"S5;PN2G!R/CO]V]&/ZB]RT4 <0BXM87(+A
M6*2(-E18!W#AP<*#59!07(+A6'B(T%0(!W"AK+Z1)^[;S<MEZV]DDZ=C8:%D
M=K1"DF@Z3*7!945TFP+;@ MPG1B-T !81287F^VA""N6M2B16JK?!A3R<6WH
MHEY"_WL/]?NPN 3#K0.FB4S48+]/8_T^*"YB<0F&8^$AFE-#_#XMK%D<--]
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M]L'-[9N,KXLG$Q]YEO%5\7+)@AE+\@;B^SGGV>N;O(/=X[/C_P%02P,$%
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M&3MW\24<(Y:6$9_UC$-[P:XWF]^V6T%0,S@@HPN5495/VD&L]X.R$_R8B[4
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M,&W P.) I,?E&E]MO$(.UP&VIH<J!)LI7HG83/%< V+/&S#"T+[:6!Q@8*N
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M_RGKD[7KO_ZEH+_GK:F[]WPV_+=Q]0I02P$"% ,4    " #1@?U4!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( -&!_51O[N#][P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -&!_5297)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MT8']5)SCW#I-!P  DC,  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -&!_51LMJ-]*P<  $0>   8
M          " @9$/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #1@?U4\W2I+^0"  #J"   &               @('R%@  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ T8']5 =_#[;%!P  XR@
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M965T."YX;6Q02P$"% ,4    " #1@?U4WAL^D:<(  !S)0  &
M    @(&Y-   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MT8']5*XV'8LY!@  H \  !D              ("!ECT  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #1@?U4\#_MZWD"  !:!0  &0
M            @($&1   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( -&!_51,]5W=&@<  $L1   9              " @;9&  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ T8']5)*Z:4RG%P
MZ5,  !D              ("!!TX  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #1@?U41AN[_)T&  "G#P  &0              @('E
M90  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -&!_52!
M2H:2^P0  'D+   9              " @;EL  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ T8']5%@T* TI!   @ D  !D
M     ("!ZW$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -&!_510%.3\S@8  (T0   9              "
M@8ZZ  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ T8']
M5(L]SV80!@  =1   !D              ("!D\$  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #1@?U4K7NF#GP"  !B!0  &0
M        @(':QP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( -&!_52<EC]PT@4  +D-   9              " @8W*  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ T8']5$Z+O5C5#0  @C0
M !D              ("!EM   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #1@?U4Z"CX_I$#   >"   &0              @(&BW@
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -&!_51^>L"R
M[P(  %L&   9              " @6KB  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ T8']5!O/_(HU P  >@<  !D
M ("!D.4  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #1
M@?U4T0H+N<45  #4-   &0              @('\Z   >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -&!_50U\C@>H ,  )L'   9
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M970S-"YX;6Q02P$"% ,4    " #1@?U4:VX-N54"   #!@  &0
M    @($Z$@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M -&!_51DLR6P& 8  !8D   9              " @<84 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ T8']5!GJ[.Y9#0  V*$  !D
M             ("!%1L! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #1@?U4 3#09^4"  #D"   &0              @(&E* $ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -&!_53^%?%8(@,
M  P*   9              " @<$K 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ T8']5 W$(UX9!   "Q4  !D              ("!
M&B\! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #1@?U4
M7<Q'P30$   Z%0  &0              @(%J,P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -&!_51.?-W4_0H  /5I   9
M      " @=4W 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ T8']5 HOLAK4"0  @EX  !D              ("!"4,! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #1@?U4_?^I<[D"  "&"
M&0              @($430$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( -&!_53S*QS=0!T  ./  0 9              " @010 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ T8']5+=P-M:[
M P  6Q   !D              ("!>VT! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " #1@?U4AMCN\.D$  #8&   &0
M@(%M<0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( -&!
M_52H6>!9A0(  $ '   9              " @8UV 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ T8']5&;K&K.X!0  V2@  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( -&!_51)*H9-= (  &<%   9
M  " @8W5 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
MT8']5)BJ,7%F$0  E3P! !D              ("!.-@! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " #1@?U4U7@0$U<%  #^*@  &0
M            @('5Z0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( -&!_51Q*_E.M04  .TO   9              " @6/O 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ T8']5$[IN>]Z P
MYQ8   T              ( !3_4! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #1@?U4EXJ[',     3 @  "P              @ 'T^ $ 7W)E;',O+G)E
M;'-02P$"% ,4    " #1@?U4VAPK#FD$   %)@  #P              @ '=
M^0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ T8']5/,@BWGI 0  $B(
M !H              ( !<_X! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ T8']5+)H2=C5 0  OR$  !,              ( !E  "
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $$ 00"^$0  F@("

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1036</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>180</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1008009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124105 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Pensions and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlans</Role>
      <ShortName>Pensions and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - Segments of Business and Geographic Areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</Role>
      <ShortName>Segments of Business and Geographic Areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2141110 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2146112 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</Role>
      <ShortName>Pensions and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables</Role>
      <ShortName>Segments of Business and Geographic Areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2347308 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Restructuring</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill By Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails</Role>
      <ShortName>Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2425416 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Pensions and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/LegalProceedings</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="jnj-20220703.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="jnj-20220703.htm">jnj-20220703.htm</File>
    <File>a20222qex311ceocertificati.htm</File>
    <File>a20222qex312cfocertificati.htm</File>
    <File>a20222qex321ceocertificati.htm</File>
    <File>a20222qex322cfocertificati.htm</File>
    <File>jnj-20220703.xsd</File>
    <File>jnj-20220703_cal.xml</File>
    <File>jnj-20220703_def.xml</File>
    <File>jnj-20220703_lab.xml</File>
    <File>jnj-20220703_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20220703_g1.jpg</File>
    <File>jnj-20220703_g10.jpg</File>
    <File>jnj-20220703_g11.jpg</File>
    <File>jnj-20220703_g12.jpg</File>
    <File>jnj-20220703_g13.jpg</File>
    <File>jnj-20220703_g2.jpg</File>
    <File>jnj-20220703_g3.jpg</File>
    <File>jnj-20220703_g4.jpg</File>
    <File>jnj-20220703_g5.jpg</File>
    <File>jnj-20220703_g6.jpg</File>
    <File>jnj-20220703_g7.jpg</File>
    <File>jnj-20220703_g8.jpg</File>
    <File>jnj-20220703_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1759">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "jnj-20220703.htm": {
   "axisCustom": 0,
   "axisStandard": 34,
   "contextCount": 1036,
   "dts": {
    "calculationLink": {
     "local": [
      "jnj-20220703_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20220703_def.xml"
     ]
    },
    "inline": {
     "local": [
      "jnj-20220703.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20220703_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20220703_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20220703.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 647,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 41,
   "keyStandard": 268,
   "memberCustom": 111,
   "memberStandard": 61,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20220703",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.jnj.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Inventories",
     "role": "http://www.jnj.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Measurements",
     "role": "http://www.jnj.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124105 - Disclosure - Income Taxes",
     "role": "http://www.jnj.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Pensions and Other Benefit Plans",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlans",
     "shortName": "Pensions and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Accumulated Other Comprehensive Income",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome",
     "shortName": "Accumulated Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Earnings Per Share",
     "role": "http://www.jnj.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - Segments of Business and Geographic Areas",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas",
     "shortName": "Segments of Business and Geographic Areas",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141110 - Disclosure - Acquisitions and Divestitures",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Legal Proceedings",
     "role": "http://www.jnj.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146112 - Disclosure - Restructuring",
     "role": "http://www.jnj.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Inventories (Tables)",
     "role": "http://www.jnj.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables",
     "shortName": "Pensions and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.jnj.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables",
     "shortName": "Segments of Business and Geographic Areas (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347308 - Disclosure - Restructuring (Tables)",
     "role": "http://www.jnj.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Inventories (Details)",
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i3cf9dba1d9014bdcba643daa09edd4f1_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails",
     "shortName": "Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "ib42c0a6a0ba542ba87e204f1f199172c_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
     "shortName": "Fair Value Measurements - Summary of Derivative Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i580cc60e6cdf496389e8435cc5955c25_D20220103-20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
     "shortName": "Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "ie2f13601b97f4c86a0a2ee40c14abae9_I20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i6d2d946886f14b34b8cec403cb9ceeb2_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i6d2d946886f14b34b8cec403cb9ceeb2_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Earnings",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "shortName": "Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:SalesRevenueGoodsNetPercentToSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i974d845b8fdb4e7fa0bc0da100fcb02e_I20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i35b52ff0f6ac42609c258100f987af3e_I20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425416 - Disclosure - Income Taxes (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "ifae3472d85ae4ebabd628e3ed5ce9c96_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i62384ef644a54697aca04106e3f0437b_D20220103-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Pensions and Other Benefit Plans (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
     "shortName": "Pensions and Other Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i62384ef644a54697aca04106e3f0437b_D20220103-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i0b78141263e14aa589db463e889e3571_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i9717a3a8ced548948d10ecbb0f33b8c3_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.jnj.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInOperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesByGeographicArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "iaf1d14a3db84419db81e75d0179c01b4_I20210404",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfBrands",
      "reportCount": 1,
      "unique": true,
      "unitRef": "brand",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "iaf1d14a3db84419db81e75d0179c01b4_I20210404",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfBrands",
      "reportCount": 1,
      "unique": true,
      "unitRef": "brand",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Legal Proceedings (Details)",
     "role": "http://www.jnj.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i87d0bf7de5034cf18c716d0889d4a6f2_I20220703",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.jnj.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i5e4e74ca66f8464690742d705f7eed8a_D20220404-20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)",
     "role": "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
     "shortName": "Restructuring - Schedule of Restructuring Reserve (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i4c99f4219f554853b8e2459b665c0cb3_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i9e3aba93759e44e6998ff20f017b0ca4_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Equity",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i207dad082de3463797edacf5f0aca4ae_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "id586f19507c64de598ca1e8367cecfee_D20220404-20220703",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220703.htm",
      "contextRef": "i8f1becac5031429aa7d4e48fa7cb6f7f_D20220103-20220703",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 180,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "CHINA"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.650% Notes Due 2024 [Member]",
        "label": "0.650% Notes Due 2024 [Member]",
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.0408)",
        "verboseLabel": "0.650% Notes Due May 2024"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0550NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.550 Notes due 2025",
        "label": "0.550 Notes due 2025 [Member]",
        "terseLabel": "0.55% Notes due 2025"
       }
      }
     },
     "localname": "A0550NotesDue2025Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A095NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "terseLabel": "0.95% Notes due 2027"
       }
      }
     },
     "localname": "A095NotesDue2027Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.150% Notes Due 2028 [Member]",
        "label": "1.150% Notes Due 2028 [Member]",
        "terseLabel": "1.150% Notes due 2028 (750MM Euro 1.0408)",
        "verboseLabel": "1.150% Notes Due November 2028"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.650% Notes Due 2035 [Member]",
        "label": "1.650% Notes Due 2035 [Member]",
        "terseLabel": "1.650% Notes due 2035 (1.5B Euro 1.0408)",
        "verboseLabel": "1.650% Notes Due May 2035"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1300NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.300% Notes due 2030",
        "label": "1.300% Notes due 2030 [Member]",
        "terseLabel": "1.30% Notes due 2030"
       }
      }
     },
     "localname": "A1300NotesDue2030Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2026 [Member]",
        "label": "2.45% Notes due 2026 [Member]",
        "terseLabel": "2.45% Notes due 2026"
       }
      }
     },
     "localname": "A2.45Notesdue2026Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.625Notesdue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.625 Notes due 2025 [Member]",
        "label": "2.625 Notes due 2025 [Member]",
        "terseLabel": "2.625% Notes due 2025"
       }
      }
     },
     "localname": "A2.625Notesdue2025Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.900Notesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.900% Notes due 2028 [Member]",
        "label": "2.900% Notes due 2028 [Member]",
        "terseLabel": "2.90%\u00a0Notes due 2028"
       }
      }
     },
     "localname": "A2.900Notesdue2028Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Notes due 2027 [Member]",
        "label": "2.95% Notes due 2027 [Member]",
        "terseLabel": "2.95% Notes due 2027"
       }
      }
     },
     "localname": "A2.95Notesdue2027Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A210NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "terseLabel": "2.10% Notes due 2040"
       }
      }
     },
     "localname": "A210NotesDue2040Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2250NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "terseLabel": "2.25% Notes due 2050"
       }
      }
     },
     "localname": "A2250NotesDue2050Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2450NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "terseLabel": "2.45% Notes due 2060"
       }
      }
     },
     "localname": "A2450NotesDue2060Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.375Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes due 2023 [Member]",
        "label": "3.375% Notes due 2023 [Member]",
        "terseLabel": "3.375% Notes due 2023"
       }
      }
     },
     "localname": "A3.375Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.400Notesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.400% Notes due 2038 [Member]",
        "label": "3.400% Notes due 2038 [Member]",
        "terseLabel": "3.40%\u00a0Notes due 2038"
       }
      }
     },
     "localname": "A3.400Notesdue2038Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.500Notesdue2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.500% Notes due 2048 [Member]",
        "label": "3.500% Notes due 2048 [Member]",
        "terseLabel": "3.50% Notes due 2048"
       }
      }
     },
     "localname": "A3.500Notesdue2048Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2036 [Member]",
        "label": "3.55% Notes due 2036 [Member]",
        "terseLabel": "3.55% Notes due 2036"
       }
      }
     },
     "localname": "A3.55Notesdue2036Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.625Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2037 [Member]",
        "label": "3.625% Notes due 2037 [Member]",
        "terseLabel": "3.625% Notes due 2037"
       }
      }
     },
     "localname": "A3.625Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.70Notesdue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes due 2046 [Member]",
        "label": "3.70% Notes due 2046 [Member]",
        "terseLabel": "3.70% Notes due 2046"
       }
      }
     },
     "localname": "A3.70Notesdue2046Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.75Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.75% Notes due 2047 [Member]",
        "label": "3.75% Notes due 2047 [Member]",
        "terseLabel": "3.75% Notes due 2047"
       }
      }
     },
     "localname": "A3.75Notesdue2047Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.375Notesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Notes due 2033 [Member]",
        "label": "4.375% Notes due 2033 [Member]",
        "terseLabel": "4.375% Notes due 2033"
       }
      }
     },
     "localname": "A4.375Notesdue2033Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Debentures due 2040 [Member]",
        "label": "4.50% Debentures due 2040 [Member]",
        "terseLabel": "4.50% Debentures due 2040"
       }
      }
     },
     "localname": "A4.50Debenturesdue2040Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Notes due 2043 [Member]",
        "label": "4.50% Notes due 2043 [Member]",
        "terseLabel": "4.50% Notes due 2043"
       }
      }
     },
     "localname": "A4.50Notesdue2043Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.85Notesdue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.85% Notes due 2041 [Member]",
        "label": "4.85% Notes due 2041 [Member]",
        "terseLabel": "4.85% Notes due 2041"
       }
      }
     },
     "localname": "A4.85Notesdue2041Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Debentures due 2033 [Member]",
        "label": "4.95% Debentures due 2033 [Member]",
        "terseLabel": "4.95% Debentures due 2033"
       }
      }
     },
     "localname": "A4.95Debenturesdue2033Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Notes Due 2024 [Member]",
        "label": "5.50% Notes Due 2024 [Member]",
        "terseLabel": "5.50% Notes due 2024 (500MM GBP 1.2143)",
        "verboseLabel": "5.50% Notes Due November 2024"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.85% Debentures due 2038 [Member]",
        "label": "5.85% Debentures due 2038 [Member]",
        "terseLabel": "5.85% Debentures due 2038"
       }
      }
     },
     "localname": "A5.85Debenturesdue2038Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.95Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes due 2037 [Member]",
        "label": "5.95% Notes due 2037 [Member]",
        "terseLabel": "5.95% Notes due 2037"
       }
      }
     },
     "localname": "A5.95Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.73Debenturesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.73% Debentures due 2023 [Member]",
        "label": "6.73% Debentures due 2023 [Member]",
        "terseLabel": "6.73% Debentures due 2023"
       }
      }
     },
     "localname": "A6.73Debenturesdue2023Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.95Notesdue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.95% Notes due 2029 [Member]",
        "label": "6.95% Notes due 2029 [Member]",
        "terseLabel": "6.95% Notes due 2029"
       }
      }
     },
     "localname": "A6.95Notesdue2029Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ADVANCEDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVANCED [Member]",
        "label": "ADVANCED [Member]",
        "terseLabel": "ADVANCED"
       }
      }
     },
     "localname": "ADVANCEDMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.",
        "label": "Accrued Rebates Returns And Promotions",
        "verboseLabel": "Accrued rebates, returns and promotions"
       }
      }
     },
     "localname": "AccruedRebatesReturnsAndPromotions",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AmountPrepaidAndDueToManufacturers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Prepaid and Due to Manufacturers",
        "label": "Amount Prepaid and Due to Manufacturers",
        "terseLabel": "Amount prepaid and due to manufacturers"
       }
      }
     },
     "localname": "AmountPrepaidAndDueToManufacturers",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AsiaPacificAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia-Pacific, Africa [Member]",
        "label": "Asia-Pacific, Africa [Member]",
        "terseLabel": "Asia-Pacific, Africa"
       }
      }
     },
     "localname": "AsiaPacificAfricaMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASR.",
        "label": "ASR [Member]",
        "terseLabel": "ASR"
       }
      }
     },
     "localname": "AsrMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AssetWriteoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-off [Member]",
        "label": "Asset Write-off [Member]",
        "terseLabel": "Asset Write-offs/Sales"
       }
      }
     },
     "localname": "AssetWriteoffMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AurisHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auris Health",
        "label": "Auris Health [Member]",
        "terseLabel": "Auris Health"
       }
      }
     },
     "localname": "AurisHealthMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Care [Member]",
        "label": "Baby Care [Member]",
        "terseLabel": "Baby Care"
       }
      }
     },
     "localname": "BabyCareMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyPowderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Powder [Member]",
        "label": "Baby Powder [Member]",
        "terseLabel": "Baby Powder"
       }
      }
     },
     "localname": "BabyPowderMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BeautyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beauty [Member]",
        "label": "Beauty [Member]",
        "terseLabel": "Skin Health/Beauty"
       }
      }
     },
     "localname": "BeautyMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BermekimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bermekimab [Member]",
        "label": "bermekimab [Member]",
        "terseLabel": "bermekimab"
       }
      }
     },
     "localname": "BermekimabMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONCERTA/Methylphenidate [Member]",
        "label": "CONCERTA/Methylphenidate [Member]",
        "terseLabel": "CONCERTA / methylphenidate"
       }
      }
     },
     "localname": "CONCERTAMethylphenidateMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONSUMERHEALTHAndPHARMACEUTICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONSUMER HEALTH and PHARMACEUTICAL",
        "label": "CONSUMER HEALTH and PHARMACEUTICAL [Member]",
        "terseLabel": "CONSUMER HEALTH and PHARMACEUTICAL [Member]"
       }
      }
     },
     "localname": "CONSUMERHEALTHAndPHARMACEUTICALMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONTACT LENSES/OTHER [Member]",
        "label": "CONTACT LENSES/OTHER [Member]",
        "terseLabel": "CONTACT LENSES / OTHER"
       }
      }
     },
     "localname": "CONTACTLENSESOTHERMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular/Metabolism/Other [Member]",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "terseLabel": "Cardiovascular / Metabolism / Other"
       }
      }
     },
     "localname": "CardiovascularMetabolismOtherMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Total cash, cash equivalents and current marketable securities, Unrecognized Loss"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ConsumerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer.",
        "label": "Consumer [Member]",
        "terseLabel": "CONSUMER HEALTH (1)"
       }
      }
     },
     "localname": "ConsumerMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ContactLensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contact Lenses",
        "label": "Contact Lenses [Member]",
        "terseLabel": "Contact Lenses"
       }
      }
     },
     "localname": "ContactLensesMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CostOfGoodsSoldPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods sold percent to sales.",
        "label": "Cost Of Goods Sold Percent To Sales",
        "terseLabel": "Cost of products sold percent to sales"
       }
      }
     },
     "localname": "CostOfGoodsSoldPercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_DARZALEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARZALEX [Member]",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX"
       }
      }
     },
     "localname": "DARZALEXMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DePuyASRU.S.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy ASR U.S. [Member]",
        "label": "DePuy ASR U.S. [Member]",
        "terseLabel": "DePuy ASR U.S."
       }
      }
     },
     "localname": "DePuyASRU.S.Member",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EDURANTrilpivirineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EDURANT/rilpivirine [Member]",
        "label": "EDURANT/rilpivirine [Member]",
        "terseLabel": "EDURANT / rilpivirine"
       }
      }
     },
     "localname": "EDURANTrilpivirineMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ERLEADAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ERLEADA",
        "label": "ERLEADA [Member]",
        "terseLabel": "ERLEADA"
       }
      }
     },
     "localname": "ERLEADAMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "label": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "negatedTerseLabel": "Decrease in effective tax rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ElmironMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elmiron",
        "label": "Elmiron [Member]",
        "terseLabel": "Elmiron"
       }
      }
     },
     "localname": "ElmironMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityFairValueAdjustmentImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Impairment Loss",
        "label": "Equity, Fair Value Adjustment, Impairment Loss",
        "terseLabel": "Equity, fair value adjustment, impairment loss"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentImpairmentLoss",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "terseLabel": "Equity Investment [Roll Forward]"
       }
      }
     },
     "localname": "EquityInvestmentRollForward",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "terseLabel": "Sales/ Purchases/Other"
       }
      }
     },
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments with Readily Determinable Value [Member]",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments with readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments without Readily Determinable Value [Member]",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments without readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EvraAndDoxilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evra and Doxil",
        "label": "Evra and Doxil [Member]",
        "terseLabel": "Evra and Doxil"
       }
      }
     },
     "localname": "EvraAndDoxilMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExcessOfFairValueOverCarryingValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of fair value over carrying value of debt.",
        "label": "Excess Of Fair Value Over Carrying Value Of Debt",
        "terseLabel": "Excess of the estimated fair value over the carrying value of debt"
       }
      }
     },
     "localname": "ExcessOfFairValueOverCarryingValueOfDebt",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "terseLabel": "Changes in estimated fair value (6)"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_GENERALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GENERAL [Member]",
        "label": "GENERAL [Member]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "GENERALMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GrossProfitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross profit percent to sales.",
        "label": "Gross Profit Percent To Sales",
        "totalLabel": "Gross Profit Percent To Sales"
       }
      }
     },
     "localname": "GrossProfitPercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_HIPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIPS [Member]",
        "label": "HIPS [Member]",
        "terseLabel": "HIPS"
       }
      }
     },
     "localname": "HIPSMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IMBRUVICAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMBRUVICA [Member]",
        "label": "IMBRUVICA [Member]",
        "terseLabel": "IMBRUVICA"
       }
      }
     },
     "localname": "IMBRUVICAMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "terseLabel": "INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA"
       }
      }
     },
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVOKANAINVOKAMETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVOKANA/INVOKAMET [Member]",
        "label": "INVOKANA/INVOKAMET [Member]",
        "terseLabel": "INVOKANA / INVOKAMET"
       }
      }
     },
     "localname": "INVOKANAINVOKAMETMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales",
        "totalLabel": "Earnings before provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_IncomeTaxExpenseBenefitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense benefit percent to sales.",
        "label": "Income Tax Expense Benefit Percent To Sales",
        "terseLabel": "Provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitPercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Diseases [Member]",
        "label": "Infectious Diseases [Member]",
        "terseLabel": "Infectious Diseases"
       }
      }
     },
     "localname": "InfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterestExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense percent to sales.",
        "label": "Interest Expense Percent To Sales",
        "terseLabel": "Interest expense, net of portion capitalized percent to sales"
       }
      }
     },
     "localname": "InterestExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Expense Net Member.",
        "label": "Interest Income Expense Net Member",
        "verboseLabel": "Interest (income)/Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InternationalRetirementPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Retirement Plans",
        "label": "International Retirement Plans [Member]",
        "terseLabel": "International Retirement Plans [Member]"
       }
      }
     },
     "localname": "InternationalRetirementPlansMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Solutions [Member]",
        "label": "Interventional Solutions [Member]",
        "verboseLabel": "Interventional Solutions"
       }
      }
     },
     "localname": "InterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InvestmentIncomeInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income interest percent to sales.",
        "label": "Investment Income Interest Percent To Sales",
        "terseLabel": "Interest income percent to sales"
       }
      }
     },
     "localname": "InvestmentIncomeInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InvokanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invokana [Member]",
        "label": "Invokana [Member]",
        "terseLabel": "Invokana"
       }
      }
     },
     "localname": "InvokanaMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_KNEESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KNEES [Member]",
        "label": "KNEES [Member]",
        "terseLabel": "KNEES"
       }
      }
     },
     "localname": "KNEESMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalProceedingTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Proceeding Textuals Abstract.",
        "label": "Legal Proceeding (Textuals) [Abstract]",
        "terseLabel": "Legal Proceeding (Textuals)"
       }
      }
     },
     "localname": "LegalProceedingTextualsAbstract",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Axis]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesAxis",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Domain]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesDomain",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LossContingencyEstimateOfAdditionalPossibleLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Additional Possible Loss",
        "label": "Loss Contingency, Estimate of Additional Possible Loss",
        "terseLabel": "Loss contingency, estimate of additional possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfAdditionalPossibleLoss",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Claims within Settlement Agreement",
        "label": "Loss Contingency, Number of Claims within Settlement Agreement",
        "terseLabel": "Number of claims within settlement agreement"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimsWithinSettlementAgreement",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyReserveEstablishedWithinTrust": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reserve Established within Trust",
        "label": "Loss Contingency, Reserve Established within Trust",
        "terseLabel": "Reserve established"
       }
      }
     },
     "localname": "LossContingencyReserveEstablishedWithinTrust",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_MedicalDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Devices [Member]",
        "label": "Medical Devices [Member]",
        "terseLabel": "MEDTECH(3)",
        "verboseLabel": "MedTech"
       }
      }
     },
     "localname": "MedicalDevicesMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NetIncomeAttributableToParentPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income Attributable to Parent Percent to Sales",
        "label": "Net Income Attributable to Parent Percent to Sales",
        "totalLabel": "Net earnings percent to sales"
       }
      }
     },
     "localname": "NetIncomeAttributableToParentPercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neuroscience [Member]",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NotesDuePeriodFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes due period fifteen.",
        "label": "Notes Due Period Fifteen Member",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "NotesDuePeriodFifteenMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NumberOfBrands": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Brands",
        "label": "Number Of Brands",
        "terseLabel": "Number Of Brands"
       }
      }
     },
     "localname": "NumberOfBrands",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_Numberofpatientsinsettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "terseLabel": "Number of patients in settlement"
       }
      }
     },
     "localname": "Numberofpatientsinsettlement",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_OPSUMITMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPSUMIT [Member]",
        "label": "OPSUMIT [Member]",
        "terseLabel": "OPSUMIT"
       }
      }
     },
     "localname": "OPSUMITMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTC [Member]",
        "label": "OTC [Member]",
        "terseLabel": "OTC [Member]"
       }
      }
     },
     "localname": "OTCMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTHER NEUROSCIENCE [Member]",
        "label": "OTHER NEUROSCIENCE [Member]",
        "terseLabel": "OTHER NEUROSCIENCE"
       }
      }
     },
     "localname": "OTHERNEUROSCIENCEMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "label": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "terseLabel": "Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI"
       }
      }
     },
     "localname": "OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpioidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid",
        "label": "opioid [Member]",
        "terseLabel": "Opioid"
       }
      }
     },
     "localname": "OpioidMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OralCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Care [Member]",
        "label": "Oral Care [Member]",
        "terseLabel": "Oral Care"
       }
      }
     },
     "localname": "OralCareMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OrthopaedicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orthopaedics [Member]",
        "label": "Orthopaedics [Member]",
        "terseLabel": "Orthopaedics"
       }
      }
     },
     "localname": "OrthopaedicsMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "negatedTerseLabel": "Prior service cost amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "negatedTerseLabel": "Gain (loss) amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "OTHER IMMUNOLOGY"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense Net [Member]",
        "label": "Other Income Expense Net [Member]",
        "terseLabel": "Other (income) expense",
        "verboseLabel": "Other Income Expense Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Infectious Diseases [Member]",
        "label": "Other Infectious Diseases [Member]",
        "terseLabel": "OTHER INFECTIOUS DISEASES("
       }
      }
     },
     "localname": "OtherInfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherNonOperatingIncomeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non operating income expense percent to sales.",
        "label": "Other Non Operating Income Expense Percent To Sales",
        "terseLabel": "Other (income) expense, net percent to sales"
       }
      }
     },
     "localname": "OtherNonOperatingIncomeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "OTHER ONCOLOGY"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "terseLabel": "PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA"
       }
      }
     },
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And Trademarks [Member]",
        "label": "Patents And Trademarks [Member]",
        "terseLabel": "Patents And Trademarks"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PaymentsForRestructuringNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Restructuring, Net",
        "label": "Payments for Restructuring, Net",
        "negatedTerseLabel": "Cash settlements"
       }
      }
     },
     "localname": "PaymentsForRestructuringNet",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_PelvicMeshesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pelvic meshes.",
        "label": "Pelvic Meshes [Member]",
        "terseLabel": "Pelvic Meshes"
       }
      }
     },
     "localname": "PelvicMeshesMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PercentageChangeInOperatingIncomeLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in operating income loss.",
        "label": "Percentage Change in Operating Income Loss",
        "terseLabel": "Percentage Change in Operating Income Loss"
       }
      }
     },
     "localname": "PercentageChangeInOperatingIncomeLoss",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesByGeographicArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by geographic area.",
        "label": "Percentage Change In Sales By Geographic Area",
        "terseLabel": "Percentage Change In Sales By Geographic Area"
       }
      }
     },
     "localname": "PercentageChangeInSalesByGeographicArea",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by segment of business.",
        "label": "Percentage Change In Sales By Segment Of Business",
        "terseLabel": "Percent Change (as a percent)"
       }
      }
     },
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical.",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "PHARMACEUTICAL(1)"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PhysiomeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physiomesh [Member]",
        "label": "Physiomesh [Member]",
        "terseLabel": "Physiomesh"
       }
      }
     },
     "localname": "PhysiomeshMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Acetabular cup system.",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "terseLabel": "Pinnacle Acetabular Cup System"
       }
      }
     },
     "localname": "PinnacleAcetabularCupSystemMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability contingency number of claimant.",
        "label": "Product Liability Contingency Number Of Claimant",
        "terseLabel": "Product liability contingency, number of claimants"
       }
      }
     },
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_PulmonaryHypertensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pulmonary Hypertension [Member]",
        "label": "Pulmonary Hypertension [Member]",
        "terseLabel": "Pulmonary Hypertension"
       }
      }
     },
     "localname": "PulmonaryHypertensionMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased In-Process Research And Development [Member]",
        "label": "Purchased In-Process Research And Development [Member]",
        "terseLabel": "Purchased In-Process Research And Development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RISPERDALCONSTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RISPERDAL CONSTA [Member]",
        "label": "RISPERDAL CONSTA [Member]",
        "terseLabel": "RISPERDAL CONSTA"
       }
      }
     },
     "localname": "RISPERDALCONSTAMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RasmussenInstrumentsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rasmussen Instruments, LLC",
        "label": "Rasmussen Instruments, LLC [Member]",
        "terseLabel": "Rasmussen Instruments, LLC"
       }
      }
     },
     "localname": "RasmussenInstrumentsLLCMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member]",
        "label": "Remicade [Member]",
        "terseLabel": "REMICADE"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense excluding acquired in process cost percent to sales.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost Percent To Sales",
        "terseLabel": "Research and development expense percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ResearchAndDevelopmentInProcessPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "research and development in process percent to sales",
        "label": "Research and development in process percent to sales",
        "terseLabel": "In-process research and development percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessPercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RestructuringandRelatedCostExpectedFutureSavings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Expected Future Savings",
        "label": "Restructuring and Related Cost, Expected Future Savings",
        "terseLabel": "Cost savings expected"
       }
      }
     },
     "localname": "RestructuringandRelatedCostExpectedFutureSavings",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_Restructuringchargepercenttosales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring charge percent to sales",
        "label": "Restructuring charge percent to sales",
        "terseLabel": "Restructuring charge percent to sales"
       }
      }
     },
     "localname": "Restructuringchargepercenttosales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RisperdalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risperdal.",
        "label": "Risperdal [Member]",
        "terseLabel": "Risperdal"
       }
      }
     },
     "localname": "RisperdalMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPINEOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINE &amp; OTHER [Member]",
        "label": "SPINE &amp; OTHER [Member]",
        "terseLabel": "SPINE, SPORTS &amp; OTHER"
       }
      }
     },
     "localname": "SPINEOTHERMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SURGICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SURGICAL [Member]",
        "label": "SURGICAL [Member]",
        "terseLabel": "SURGICAL"
       }
      }
     },
     "localname": "SURGICALMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales by segment of business.",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "terseLabel": "Sales By Segment Of Business"
       }
      }
     },
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SalesRevenueGoodsNetPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales revenue goods net percentage to sales.",
        "label": "Sales Revenue Goods Net Percent To Sales",
        "terseLabel": "Sales to customers percent to sales"
       }
      }
     },
     "localname": "SalesRevenueGoodsNetPercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SellingGeneralAndAdministrativeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling general and administrative expense percent to sales.",
        "label": "Selling General And Administrative Expense Percent To Sales",
        "terseLabel": "Selling marketing and administrative expenses percent to sales"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "negatedTerseLabel": "Less: shares which could be repurchased under treasury stock method"
       }
      }
     },
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_SimponiSimponiAriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi/Simponi Aria [Member]",
        "label": "Simponi/Simponi Aria [Member]",
        "terseLabel": "SIMPONI / SIMPONI ARIA"
       }
      }
     },
     "localname": "SimponiSimponiAriaMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StelaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stelara [Member]",
        "label": "Stelara [Member]",
        "terseLabel": "STELARA"
       }
      }
     },
     "localname": "StelaraMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SupplyChainMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Chain",
        "label": "Supply Chain [Member]",
        "terseLabel": "Supply Chain"
       }
      }
     },
     "localname": "SupplyChainMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery [Member]",
        "label": "Surgery [Member]",
        "terseLabel": "Surgery"
       }
      }
     },
     "localname": "SurgeryMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgicalMeshProductsMarketingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Mesh Products Marketing",
        "label": "Surgical Mesh Products Marketing [Member]",
        "terseLabel": "Surgical Mesh Products Marketing"
       }
      }
     },
     "localname": "SurgicalMeshProductsMarketingMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TRAUMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRAUMA [Member]",
        "label": "TRAUMA [Member]",
        "terseLabel": "TRAUMA"
       }
      }
     },
     "localname": "TRAUMAMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TalcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Talc [Member]",
        "label": "Talc [Member]",
        "terseLabel": "Talc"
       }
      }
     },
     "localname": "TalcMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfaya",
        "label": "Tremfya [Member]",
        "terseLabel": "TREMFYA"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UNITEDSTATESExportsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES Exports [Member]",
        "label": "UNITED STATES Exports [Member]",
        "terseLabel": "U.S. Exports"
       }
      }
     },
     "localname": "UNITEDSTATESExportsMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UPTRAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPTRAVI [Member]",
        "label": "UPTRAVI [Member]",
        "terseLabel": "UPTRAVI"
       }
      }
     },
     "localname": "UPTRAVIMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision[Member]",
        "label": "Vision [Member]",
        "terseLabel": "Vision"
       }
      }
     },
     "localname": "VisionMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Hemisphere, excluding U.S. [Member]",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "terseLabel": "Western Hemisphere, excluding U.S."
       }
      }
     },
     "localname": "WesternHemisphereExcludingUSMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WomensHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Women's Health [Member]",
        "label": "Women's Health [Member]",
        "terseLabel": "Women's Health"
       }
      }
     },
     "localname": "WomensHealthMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WoundCareandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care and Other [Member]",
        "label": "Wound Care and Other [Member]",
        "terseLabel": "Wound Care/Other"
       }
      }
     },
     "localname": "WoundCareandOtherMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XareltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xarelto [Member]",
        "label": "Xarelto [Member]",
        "terseLabel": "XARELTO"
       }
      }
     },
     "localname": "XareltoMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ZYTIGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYTIGA [Member]",
        "label": "ZYTIGA [Member]",
        "terseLabel": "ZYTIGA / abiraterone acetate"
       }
      }
     },
     "localname": "ZYTIGAMember",
     "nsuri": "http://www.jnj.com/20220703",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r132",
      "r186",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r206",
      "r210",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r132",
      "r186",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r206",
      "r210",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r58",
      "r130",
      "r131",
      "r333",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r305",
      "r307",
      "r308",
      "r309",
      "r332",
      "r352",
      "r449",
      "r454",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r671",
      "r674",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r305",
      "r307",
      "r308",
      "r309",
      "r332",
      "r352",
      "r449",
      "r454",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r671",
      "r674",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r213",
      "r307",
      "r308",
      "r361",
      "r362",
      "r619",
      "r670",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r213",
      "r307",
      "r308",
      "r361",
      "r362",
      "r619",
      "r670",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r287",
      "r305",
      "r307",
      "r308",
      "r309",
      "r332",
      "r352",
      "r390",
      "r449",
      "r454",
      "r457",
      "r458",
      "r459",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r671",
      "r674",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r287",
      "r305",
      "r307",
      "r308",
      "r309",
      "r332",
      "r352",
      "r390",
      "r449",
      "r454",
      "r457",
      "r458",
      "r459",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r671",
      "r674",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r130",
      "r131",
      "r333",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r214",
      "r215",
      "r361",
      "r363",
      "r673",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r361",
      "r363",
      "r673",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r605"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r219",
      "r220"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, trade, less allowances $223 (2021, $230)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r23",
      "r630",
      "r656"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued taxes on income (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r25",
      "r630",
      "r656"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term taxes payable (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r68",
      "r74",
      "r83",
      "r84",
      "r85",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r283"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r74",
      "r83",
      "r84",
      "r85",
      "r86",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r74",
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r71",
      "r73",
      "r74",
      "r658",
      "r679",
      "r682"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss) (Note 7)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r70",
      "r74",
      "r83",
      "r84",
      "r85",
      "r133",
      "r134",
      "r135",
      "r509",
      "r601",
      "r675",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r62",
      "r74",
      "r83",
      "r84",
      "r85",
      "r509",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r116",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r32",
      "r221",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r116",
      "r268",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense of amortizable intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "negatedTerseLabel": "Accumulated other comprehensive income on derivatives, after tax"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r116",
      "r281"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r19",
      "r126",
      "r194",
      "r201",
      "r208",
      "r244",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r325",
      "r327",
      "r328",
      "r506",
      "r510",
      "r574",
      "r603",
      "r605",
      "r628",
      "r655"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r39",
      "r126",
      "r244",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r325",
      "r327",
      "r328",
      "r506",
      "r510",
      "r574",
      "r603",
      "r605"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r226",
      "r251"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Available-for-sale Securities - Carrying Amount"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r229",
      "r232",
      "r650"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r229",
      "r231",
      "r649"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r229",
      "r233",
      "r651"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r229",
      "r233",
      "r647"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r229",
      "r230",
      "r648"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r225",
      "r227",
      "r251",
      "r633"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale Securities",
        "verboseLabel": "Available-for-sale Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-Sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r522",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits(1)"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r445",
      "r450",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r445",
      "r450",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r499",
      "r500",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Business Exit Costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "verboseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r13",
      "r118"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Carrying Amount"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r112",
      "r118",
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "periodStartLabel": "Cash and Cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r112",
      "r581"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease)/Increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r124",
      "r126",
      "r155",
      "r159",
      "r160",
      "r162",
      "r164",
      "r172",
      "r173",
      "r174",
      "r244",
      "r314",
      "r319",
      "r320",
      "r321",
      "r327",
      "r328",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r574",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral already posted, aggregate fair value"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r48",
      "r636",
      "r662"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued Amount",
        "verboseLabel": "Common Stock, Par Value $1.00"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r605"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock \u2014 par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r79",
      "r81",
      "r82",
      "r92",
      "r640",
      "r666"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r91",
      "r101",
      "r639",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r391",
      "r439",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities(1)"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r97",
      "r619"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r391",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross Currency Interest Rate Contract",
        "verboseLabel": "Cross currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r21",
      "r23",
      "r24",
      "r125",
      "r132",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r596",
      "r629",
      "r631",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r329",
      "r346",
      "r347",
      "r594",
      "r596",
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46",
      "r125",
      "r132",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale and Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Available for Sale Securities Maturities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r127",
      "r478",
      "r487",
      "r488",
      "r489"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax benefit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r466",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r367",
      "r406",
      "r433",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r367",
      "r407",
      "r434",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost/(credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r367",
      "r405",
      "r432",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r367",
      "r372",
      "r404",
      "r431",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r402",
      "r429",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "verboseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "auth_ref": [
      "r368",
      "r409",
      "r436"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "negatedLabel": "Curtailments and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r370",
      "r403",
      "r430",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r116",
      "r189"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization of property and intangibles"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r52",
      "r60",
      "r526"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r53",
      "r54",
      "r58",
      "r571"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Total Net Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r532",
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r51",
      "r58",
      "r59",
      "r526",
      "r616"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total Gross Assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r51",
      "r58",
      "r59",
      "r526",
      "r616"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total Gross Liabilities",
        "verboseLabel": "Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]",
        "verboseLabel": "Financial assets and liabilities at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r58",
      "r523",
      "r527",
      "r534",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r520",
      "r523",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r520",
      "r523",
      "r534",
      "r541",
      "r542",
      "r547",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r53",
      "r54",
      "r58",
      "r571"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total Net Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r52",
      "r56",
      "r60",
      "r526"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r514",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r513",
      "r515",
      "r516",
      "r520",
      "r521",
      "r530",
      "r534",
      "r545",
      "r546",
      "r550",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.",
        "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)",
        "verboseLabel": "Reclassification of foreign exchange contracts into earnings, period"
       }
      }
     },
     "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r445",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r444",
      "r448",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan [Member]"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "NET EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r93",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r153",
      "r155",
      "r162",
      "r163",
      "r164",
      "r168",
      "r169",
      "r557",
      "r558",
      "r641",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (per share)",
        "verboseLabel": "Basic net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r93",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r155",
      "r162",
      "r163",
      "r164",
      "r168",
      "r169",
      "r557",
      "r558",
      "r641",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (per share)",
        "verboseLabel": "Diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Worldwide effective income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r635",
      "r663"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Employee-related Liabilities",
        "verboseLabel": "Employee related obligations (Note 6)"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r83",
      "r84",
      "r85",
      "r133",
      "r134",
      "r135",
      "r139",
      "r147",
      "r149",
      "r171",
      "r245",
      "r356",
      "r357",
      "r460",
      "r461",
      "r462",
      "r480",
      "r481",
      "r556",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r601",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Changes in Fair Value Reflected in Net Income"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r9",
      "r22",
      "r569"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Available-for-sale Securities, Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r242",
      "r654",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r338",
      "r346",
      "r347",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r562",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r562",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r562",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "verboseLabel": "Financial Liabilities not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r338",
      "r346",
      "r347",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r439",
      "r563",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r338",
      "r346",
      "r347",
      "r562",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r338",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r338",
      "r391",
      "r393",
      "r398",
      "r439",
      "r563",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets and liabilities Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r338",
      "r346",
      "r347",
      "r391",
      "r393",
      "r398",
      "r439",
      "r563",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r338",
      "r346",
      "r347",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r439",
      "r563",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r338",
      "r346",
      "r347",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r439",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r522",
      "r530",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Liabilities"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Finite-Lived Intangible Assets, Weighted-Average Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r17",
      "r274"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r269",
      "r271",
      "r274",
      "r278",
      "r620",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r274",
      "r624"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r269",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r274",
      "r620"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets with definite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign exchange rate"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r58",
      "r391",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Forward foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r444",
      "r448",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan [Member]"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain (loss) on disposition of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Net gain on sale of assets/businesses"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r16",
      "r254",
      "r255",
      "r262",
      "r266",
      "r605",
      "r627"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill End of Period",
        "periodStartLabel": "Goodwill Beginning of Period",
        "terseLabel": "Goodwill (Note 3)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r256",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, related to acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Currency translation/Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r96",
      "r126",
      "r194",
      "r200",
      "r204",
      "r207",
      "r210",
      "r244",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r323",
      "r325",
      "r327",
      "r328",
      "r574"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r520",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r222",
      "r234",
      "r248",
      "r250"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Held-to-maturity Securities - Carrying Amount"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r236",
      "r238"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held-to-maturity Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r235",
      "r237",
      "r633"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Held-to-maturity Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-Maturity Securities [Member]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r116",
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r89",
      "r194",
      "r200",
      "r204",
      "r207",
      "r210",
      "r625",
      "r637",
      "r645",
      "r668"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings before provision for taxes on income",
        "verboseLabel": "Worldwide income before tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r445",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r285",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r470",
      "r472",
      "r474",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r469",
      "r473",
      "r477",
      "r485",
      "r490",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r148",
      "r149",
      "r192",
      "r467",
      "r486",
      "r491",
      "r669"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income (Note 5)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Decrease in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxes": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.",
        "label": "Increase (Decrease) in Income Taxes",
        "terseLabel": "Incremental tax costs related to restructuring"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Decrease in other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Decrease in other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r164",
      "r456"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Potential shares exercisable under stock option plans"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r270",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets with indefinite lives:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r270",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r267",
      "r272"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Total intangible assets - net",
        "verboseLabel": "Intangible assets, net (Note 3)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r87",
      "r188",
      "r593",
      "r595",
      "r643"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net of portion capitalized"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r58",
      "r391",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r252"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r38",
      "r605"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories (Note 2)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r38",
      "r252"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "verboseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r34",
      "r252"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Goods in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r99",
      "r187"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r126",
      "r202",
      "r244",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r323",
      "r325",
      "r327",
      "r328",
      "r507",
      "r510",
      "r511",
      "r574",
      "r603",
      "r604"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r126",
      "r244",
      "r574",
      "r605",
      "r632",
      "r660"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r44",
      "r126",
      "r244",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r323",
      "r325",
      "r327",
      "r328",
      "r507",
      "r510",
      "r511",
      "r574",
      "r603",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-Current Debt",
        "verboseLabel": "Long-term debt (Note 4)"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Non-Current Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate on non-current debt"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Product Liability Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r303",
      "r304",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r303",
      "r304",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Litigation contingency"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r305",
      "r307",
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r304",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Maximum length of time for hedge exposure"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r6",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "verboseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH USED BY FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH USED BY INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r112",
      "r114",
      "r117"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r77",
      "r80",
      "r85",
      "r90",
      "r117",
      "r126",
      "r138",
      "r142",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r161",
      "r194",
      "r200",
      "r204",
      "r207",
      "r210",
      "r244",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r323",
      "r325",
      "r327",
      "r328",
      "r558",
      "r574",
      "r638",
      "r664"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net earnings",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r2",
      "r136",
      "r137",
      "r140",
      "r141",
      "r150",
      "r151",
      "r152",
      "r223",
      "r224",
      "r246",
      "r247",
      "r482",
      "r483",
      "r484",
      "r555",
      "r559",
      "r560",
      "r561",
      "r575",
      "r576",
      "r577",
      "r598",
      "r599",
      "r600",
      "r602",
      "r621",
      "r622",
      "r623",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New and Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net cash paid for acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "verboseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed and noncontrolling interests"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r194",
      "r200",
      "r204",
      "r207",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "verboseLabel": "Total Segment Operating Income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Non Current Other Assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]",
        "terseLabel": "Derivatives &amp; hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r61",
      "r71",
      "r578",
      "r579",
      "r582"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r65",
      "r66",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r63",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Derivatives &amp; Hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r63",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r71",
      "r75"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r64",
      "r71",
      "r531",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "verboseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r64",
      "r71",
      "r531",
      "r536",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r61",
      "r72",
      "r580",
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r78",
      "r81",
      "r83",
      "r84",
      "r86",
      "r91",
      "r356",
      "r583",
      "r588",
      "r590",
      "r639",
      "r665"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net change",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r69",
      "r72",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r71",
      "r75",
      "r76",
      "r241"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r65",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r66",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Customer relationships and other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "terseLabel": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title.",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the information about other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.",
        "label": "Other Investment Not Readily Marketable [Table]",
        "terseLabel": "Other Investment Not Readily Marketable [Table]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r417",
      "r420",
      "r424",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "verboseLabel": "Other Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r290",
      "r291",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r103",
      "r106"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other (primarily licenses and milestones)"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired (Note 10)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r390",
      "r392",
      "r398",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r439",
      "r441",
      "r442",
      "r443",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pensions and Other Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Contribution to pension plans"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r364",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r417",
      "r420",
      "r424",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r450",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net (Note 10)"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "verboseLabel": "Proceeds from short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r14",
      "r282"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r284",
      "r605",
      "r652",
      "r661"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r94",
      "r249"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Credit losses and accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Repayment of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r463",
      "r618",
      "r711"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "In-process research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r289",
      "r291",
      "r294",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r290",
      "r293",
      "r297",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring charges recorded to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r290",
      "r293",
      "r297",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring estimated cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r116",
      "r288",
      "r295",
      "r297"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring (Note 12)",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r295",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r291",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Reserve balance ending",
        "periodStartLabel": "Reserve balance beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r291",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Settled non cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r357",
      "r605",
      "r659",
      "r678",
      "r682"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r133",
      "r134",
      "r135",
      "r139",
      "r147",
      "r149",
      "r245",
      "r460",
      "r461",
      "r462",
      "r480",
      "r481",
      "r556",
      "r675",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r420",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r444",
      "r448",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r420",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r444",
      "r448",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r417",
      "r420",
      "r424",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r417",
      "r420",
      "r424",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r185",
      "r186",
      "r199",
      "r205",
      "r206",
      "r213",
      "r214",
      "r217",
      "r360",
      "r361",
      "r619"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Sales",
        "terseLabel": "Sales to customers",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r74",
      "r588",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r423",
      "r424",
      "r427",
      "r428",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r523",
      "r534",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r269",
      "r273",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r35",
      "r36",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r291",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r95",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r88",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r194",
      "r197",
      "r203",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r194",
      "r197",
      "r203",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Operating Profit by Segment of Business"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities that an institution sells and agrees to repurchase at a specified date for a specified price, net of any reductions or offsets.",
        "label": "Securities Loaned or Sold under Agreements to Repurchase [Member]",
        "terseLabel": "U.S. reverse repurchase agreements"
       }
      }
     },
     "localname": "SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r217",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r293",
      "r300",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "verboseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r194",
      "r198",
      "r204",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r216",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments of Business and Geographic Areas"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]",
        "verboseLabel": "Sales by segment of business"
       }
      }
     },
     "localname": "SegmentReportingInformationRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments, Geographical Areas [Abstract]",
        "verboseLabel": "Sales by geographic area"
       }
      }
     },
     "localname": "SegmentsGeographicalAreasAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, marketing and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r20",
      "r605",
      "r629",
      "r657"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Current Debt",
        "verboseLabel": "Loans and notes payable"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Non-U.S. sovereign securities(1)"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r4",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r217",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r286",
      "r293",
      "r300",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Statement, Business Segments"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r124",
      "r126",
      "r155",
      "r159",
      "r160",
      "r162",
      "r164",
      "r172",
      "r173",
      "r174",
      "r244",
      "r314",
      "r319",
      "r320",
      "r321",
      "r327",
      "r328",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r574",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r83",
      "r84",
      "r85",
      "r133",
      "r134",
      "r135",
      "r139",
      "r147",
      "r149",
      "r171",
      "r245",
      "r356",
      "r357",
      "r460",
      "r461",
      "r462",
      "r480",
      "r481",
      "r556",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r601",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r171",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r27",
      "r28",
      "r356",
      "r357",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r84",
      "r126",
      "r133",
      "r134",
      "r135",
      "r139",
      "r147",
      "r244",
      "r245",
      "r357",
      "r460",
      "r461",
      "r462",
      "r480",
      "r481",
      "r503",
      "r504",
      "r512",
      "r556",
      "r574",
      "r583",
      "r584",
      "r590",
      "r601",
      "r676",
      "r677"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r591",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r591",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r591",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supply network costs"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r49",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock Amount"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r49",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "verboseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r49",
      "r358",
      "r359"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "verboseLabel": "Less: common stock held in treasury, at cost (490,811,000 and 490,878,000 shares)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r356",
      "r357",
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r290",
      "r291",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r391",
      "r646",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Gov't securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r464",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r154",
      "r164"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Average shares outstanding \u2014 diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "AVG. SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r153",
      "r164"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Average shares outstanding \u2014 basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6284393-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r712": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r713": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r714": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r715": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r716": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r717": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r718": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0000200406-22-000071-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-22-000071-xbrl.zip
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MG_[H8)@7*RL.@@TIMZL:2GSA00C"$ZEWNB2Y!9[QKD"51\%;\M4OW8<5WAX
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M!QF$0J-\0K,,W9DK-VR6B#!AIJ##RG\&&LI&: "I,!)U%DFVF; )#M#D$+H
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MKO>S=C9G0<#I$W.>%U OH%Y /<>0T7F*H)Z=(5Z[J3A=WJ+<4Q1PD!Q$PED
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M@::L+X?2^V>GY^?O/SB;)SX_]/"S,SN_^-RIO1A>#*[I9VE$F2T&(+0R]]1
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M?_[ZBR]_]^Z)L$Q7DVDVGYT[QAS&DWU,F)4'_J\V V\=EH\_GN^/6^B<.H^
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MZU'M\R@6,V=X%(,^,=5DCIQ7:;28!=L./0&/:E\.9U?T6E+,2C*NQ[%AHKU
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MU?_((_Y[GH'7!E,)HU9&;ZK1<]1KDJ"FU"UF"1P;/,H&MR2!3HZ4U&"TAEI
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M(ATZB[EVG.L7',.:S=9RTO13B_ZV]?_(BY=;@D O8Q@54*^*9;@65>FB5I7
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M85<<11QHHZ;/!E#$$5$/[^]P%?,<$]P#_M=-"](,8,%8)EA!EVER:5.N"'#
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MP=[MH0YWY<&\Q,$B6)?YR&W*9*)E!$C)$O G$B+C.*EX282XYJ65XB6!0KP
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M2)9H$D5Q9' B?Y1L5(.)AW(PG@,3J54I$0E'.(HY8E98) @ER$2"8LFDHA+
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M62:4Z<T:^8KM;CIHDQC9-*_ T$J=6]O?QWH5(Q]@DG23N^5@\ Q]!F];7HX
MG$?]I8"7 180_OFUMIM(?CK=;&)_2Z/EH_POQVO/HY#JR+-^-8FW385E*K?^
MU12TA <Z^6@9:4J]31HJ5ZR]HBB'DG74 $#&V!P[I\ G+>5%X[8F2E4((,/!
MP5>![7[+BMRS;6F_^V6:39G U\L'A1YENLG+<9Y.S:R+"/E5>L4KDW:NO2F:
MXDR8?\^R/JCD$CY]KF'VX\@.='C@$E5]DF11!GI<<M1TH&>\!%,M(-_D:1_W
M*34;M.=UX+#L9\<EK#F_QSH&<KY07O2G4C#&72]AX8VF1NFHKOL[ Q?< EJ
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MPSDI._R@6L/5U/I"S'ZALZK-#/_?\RP^CB=.U8-VZ*XL[3YTF0C5PD-%A;(
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M%=9:<'%:<&<.T6#.F0$T@XAU/IN@#*DD- @,69K$0MLT,1NO:=*(Q??2Z^M
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MN"J;+UH5*1W;6''$"$L1XQ%'(B$<R9"QV&*6B,05K:*-"#_ZL),Z)+*Z8KQ
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M8H0E2')LD&$B%#;&U/JSR>@F7R&1_1TR7MX5>:_GX@!IUE_&HL_O&CQ]@@"
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M03 U[4DO4?PE!.SBHOA%^3XDC/=JRI<809!6&CC&)BE?SL 2)Q)]#H$2K5#
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M12 T12 LX+1"4?^-@'O=-2*DQ-(X!<J[I/XE,Z"H-4!%,-19F=Z+2?VKV>M
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MK_7.Y_'0#(9IELWPR^XXG(PZ@WX>Y7!0-0&Y.F98@ASS$J!_3'L69-KM7#'
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M*8%YS,!&FPD-LIS3$(+(E3K).I,SGWTMC*8I&'YPAU%A- ^(X:G2G=0+C[@
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M/";Z_6Q\^S./MM*O"%ONA5#:>,>85C8&06V@.E!.D$!_4;9V^:&CX=5&_1#
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MD#.PGB) F%)N!+;)4"R)+:L+\<4GMA2(/S3$:US/IP7&5!!(-K_*7,^!Q<Q
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MZX0$$[E&R&/OG%G;Q$TZBERB&BN7I5 0/D>$URA(T$'9G'[DA6"0UI>"]HI
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M 4^TE5P9K"U9VR3K6N)F^ Q+K&#>0)Z[Y5Z O  @UXUX'"TQ09N$7": D8#
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MG!9I\Y LPU,BJ Y"2T292B^3^DE*B =IN$U"I[",Y9<[]=J!/#JF.;; E>#
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M;++>N0=FG8C<L1@"R=UAI,;-</"6P,[<@3QOR[T >0% KAOQD@BA"'*@-5+
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M]D:E9]6,*8<,<4I18V40G%I*;A8XI=#PLDB>NM_&DX@-0P&$1$GR4$/ 4!+
M1^:9M89)5AVR6$_;J1EQU8+[.?,,B;Q6A"B*C$^JQQIE'$/&<D>%]U07GK&T
M:*^W,V"8&RVD!1>E3VA//[0C& 1*Y(,'(HAGI9U!D38/R3*,9<EHQMI3SYE
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ME^SEL;P[_-(^]Q\[KSI'G8.CX\[VV_3][S^F^WSJG.S2SO&;ZYKJ224,45&
MX\@!<YZ QE@!X]01[(V@FN1#IM?VY"HADA(BF8.X(4CZ7 :*9->XH%++X(V+
M/"*3A(T)1=PLK;BI)WYQR2.UG@/&.O?^\!1T" (BC<)P*A%3>FT38[JN= G)
M%GGS0"%9(A!E- :!-:.(68,Y$49+@0CWW-\L<$I(=EDD3SWQ"R$NL%=)\G!%
M@!FO0'-#(#*,TT:@Q%I>)7X1-ETGNR1^-1;W=X"]\U9BSC"AAC+__]G[TJ:V
MDF7;OZ(@;MS7'4'1-0_=+QQ!&^Q#OT9XP-W7_N*H$82%Q-5@#+_^9>TM"9#
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M1%*D=8@(<P9KV&%GG%]Y)5:Y6! 7;]G:F3>0YVZZ%R _ I!G@M$DPPP;C!2
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M(20(:(R<2RHG0(G(&JR1C<H%IIBFR:P GC4E](\%POE+8.<7"5F[95VK79T
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MFCJAY>*=/-AY/3[LM$Z:!U^^-0^_['_>W3[^LOL>A.UGOGVZR;_\FP\]K9_
MO],=N-_,8:>-3[1Y^)Y^.7P#POS/-CSOQY>#O=/MW?WV9PH">.,O^+<-"N!#
MVC[= B7PZ12$.6_N>K&S_C5:KH-@!(F ">*)DES_B"/)H[&2*$.]GSZ(0!T
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MN,JY6CP9#X_'1R (!8\/C\=IRL"2Y)(3D?E_0!Q'@30/'H7D/58\)2U<E93
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M^/:9_@/]:<.SPF'S;?/;]L;^X>>#;Z<[T(Z=W3\//A_\=?CY-*2=U_C'5)D
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M8L@MV>,DT!<?Z5$[<IY=BW3[A^T2LJ@;M@/!MIM&[;TANXM,6U>Q39H% ,=
M\9K\(960F;!MU/:/VB5D4#=J!T)M)^Z5)IBBG&16.<4H<@+F4!F&#K4N*ML"
ML+:A+XOE-FP?/N1=<O9T@[5GL':SIBDDBCQRBF41.2/_2C)GC&,:B^-<JJ!B
MKI5*;9:JI\@N/6NZS5(-!>6N2+TR:$)2+$9?MUQ6B@7C-(LEFUR$X"*T6:J^
MX[ST;.EF@7N&[:4L:6G &5<"<R4'!IG@#<%%<I]3P"*CRZ:L;5R>F^I;EG13
MGF_G>%SG6*F\RZLUJW^:D)T8Q9/))!_&TZIBFR=Y>CR:X'$>3=_CN^FWJE=W
MVJ27XN3M'*M[CI42GK\']>I;Y5)?T6:KY[L;H:3 0.$5.DA&.0$NQ"@C3T&2
M+]]4^%;;M__M4H:U- FSDIYYY(4!4KNB*9GYFC3B +4SR]O/]>IQZ4Y#\D>!
M=:@"J$'(H 'H9(C4#EY@%#QHG7QJ6*\\UN/N3)L*8$"R8JK42(B&.5\B,Z4&
MZY@+9-&P[CG6&!&M0@DI*BA0=V2F 3HK[D'1"TTS=_6Q[BQ<^R(RC>J:&5\<
M UNJ@E P3/AHR:WSTIK8L.XYUI!SW3[$I*P1I"AU"A4-1FN<-2'R'F/=\+T1
MOMTL[5@]M.0+R\%;!CXBPP*6"9YR<*&NCIDJ /;->B,-W3MRM*%X'I(%421$
M(%I!6A<@2U>L,++'Z#:+O!RDN^+7TJ+@-K(@.6>@(Z?0N6B6O,6H5/20FT7N
M.]9>6(N:AM^" @2 2^1U:W*GLI#>E-1C ;"&]7*P[N9UH]<Q8&*&1G$&(M3X
M.3F6.5!,ED7,WO0=ZUNL&5X?F:13,=&51&$IQ(*HB0ZC'3<^9[179X%\F(Y_
M.!SO__]KA$1N7NQ0V.@&H35NR9&B3FOK[H>:@E#K'1,A.@@"J$^YVA\[4#2[
M<PDB)5U*0"CQ&@DZ';CS2H(I14H,OC2[L^IL=9.=!0VD62G/0HZ9 3>.[(XP
M+&(02*1%*5S?[<ZCQUJD2'%AY=D(PMIX:VR1+H2$SNGL>XQUP_=F^':BP>1B
M*"9(AB%J1D;2,2^C8HZ0%A92D9GP]=]<JM#(O:/YG:"MTDE;ZSUH84/QO&8V
M*]3&!<M[3&XSR,M9<>GF/F/&J(*/+#LDBRQR9#YC8<*!$-X&Z?+RMBE<(M=-
M2'4E/[E2";UW(*3Z+<4&5]JS^VN=:YJS__NF6UP94[WT5,9653@($QTOI3!F
M+KC!K)D)!1D4(9FO'IH/.AEC(#C!6U5ASW%>>@ICPWDH.'>67I+.UL42F4 O
M&$AMF8\Z,'KD(0'],*GAW'><EYZZV' >"LZ=U:)(/":RP$SI6'6Q1&%><&0^
M8=#"^21-P[GO."\]9;'5_/<,VVZJ(CB!G'QI%J0K\XW1 KK(>);H90@>K5S;
M,)<ELAJQO2!VZ9F*S0 /A>277?TLJYS4AH54MV4P(3.,7#*5.=?:08AZ>:5
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MY#<*R%]?JLY(12;043$'3BYVJ4K%LKJE-_J2?39A;4/!I5#\;VU6[:'Q+89
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M"^>@).&83('8#J 9*LA,&A%<II]6AH9US[$.O)B$R<BD%1B3D0CF3M?Y32=
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M+(G&A- ,]LJ3+0J1JXJAN$R#YR( 8)WZ%2%&B/;.YGH;V4LC^])$L- >8Q;
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M\]RMQ5J+M19K+;8J+=;6Z]IZW>-:KSMS@D[;E-ZR(X%X:<U.A^BYL)I))ZI
MF0\LN&A8+$YG;520);8IO4<P!/1JS>[J(:"A?B/4N^MV.0HOI"TL)00&CH90
MYVRDP-_$5((GE,7:!O0IYF^4K_*Z73/T=TE_5T8<A#3!.0;%649_2(8FU"&
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M1.#.JK 0>&%%A\*E)1O>3"_/M(%[?L$]K=C+K<#=0'PS$(^&6Z**U?O*5.+
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M['1N)4X@6J^20$YV"A02+$*G1"<[\!C(OG5-G-S' 5L[67_[,8H X#)GN:3
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M+YKTJH(@K0$"KN=.1ZZ*$T)8O*RXJD'X(2 \YA/,H$+-,X$"R"!YSX(KD=D
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M,4<X'6T]@S)AR(D1E2'+,#K-,*!G.2JT-CCI+*_I% ::\_4I0]AS=%S8S*4
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M.E<@@Q,2P&JR890L1?)J7:9TR;")AM%[PNA8UT 3N#11LAJ/9A!B86BR9RI
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MOS.DJ[7GG13>,BEKWTJA+='5FLJJ#?=":>[<<##+Q+2 7^BJ:-[5&73-LD9
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M1^>,$SRS'"#';#PS1@*-^ >ME1I'(/7(+X ON/V^?FK;^QO'7YP#U>5X$X]
M8%OOWX$6E$8J"-@F/BDL<5ID4@X" 7=>"<F+U^A'CNWN\;>,DJ]QII;[\5*L
MYCO!H['''+^F",$O$9>K]N;I07?PA:)>DW/3N1,Y_-91BQOFZXC)?)T'2<E1
MLTK)^0M-#ISMU>/85)+Y"]<?*4=WM"DN^.,<INN<CU%XM '[AWOGFY_W#S9W
M5S_OK[W&[_B[N[F&?W^YP;;6_L37O^/]-U@;A7N'!T=;AQN?MX[6/VVN;7W8
M>OGGT?[;C8^;AP<?]@[?T,TC?/WR[\/-P^88Q*?-5^\<H\DJ[H@0Y12$4ISX
M3 /Q4B,F0S9:FW;*B[24.A4#M5X :HFFM8"DVJ)PU4) .UWGK_6MG8WMK9W.
MZM9:9WOWC_77G=_7M]9?;.QV_OK/ZM:]I_#\>'RM%)XHA%=&,&=0*3AFI<_9
M)">U$X9Z_I"9E$4#]H\;0H*2:BN==OYJ_&4(G/%>1B4Y/)V8E9\(L)UPD.)9
M+VUG',YX$&4,PR;K\RGC:6OUG=$B2*%+\S&O2=E-Q# =2$1>%4VVW@3;QL<#
M2N:2>WJQGR["+2.->6'^M/E:Q&L*L[NX^JML;4C?R((;L>J+2T9_'Q\,&BG,
M?J_7',]I[(G1_O[UFT>GCMS@??>8G/9/?I7-*:GFF.W77'!4Q8-RI+?G3H;I
MUXL7O\7N$+_Y_-?N<?/@S8=^&]]KG$!>,J9;QWJ;//'1VU^3J9?I**%Z7#YE
M_,WCMY>;MUJ'C4?O";ZL-/OFVW3YKN^AA7^G3WYOL&I94E['^A/&JL \FK'^
MG'D5!A[-6!_3O#[U_2J7+;<WNNL/RE_]L*C*+2[E;.+::RJLC$XAS:;$BKU1
MA947(S-V9Q1J>35.C5P_1DOW!B6T%GY:NI\ZFR/WYN24W'!W/6@=,'.CI[V^
MA,I=UML^SN5^_970_E6(ZQ.>BL:!\L7.?.JS43?&C3?&XHC#7]:*.3EH@E>;
M(R_SU]21:5;^1K,QRY6_V7Q<COH\]6F 9AK84Y^&NAOJ;JB[H>Z&NAMNM1N>
M0CWNG33XIQM2$U*H5;AK%>Z;5_!U28#FT4B7('GGH^(FB11E2#;8BSP=^)*G
M\Z-2OFNCL-789"D6RWAOELCEO!3MO6O0<E2T]_ ]W_K\!N^W]VG_Y>N#S<^O
M^/[:&]C<#6)S;?5\_VC]?/]PO[>]]N*@7;1W>VU/;.WV<$PO/NR_7/^\M;;_
M86OW_:>MS^'CYMJ?1WN[?QYM'>&]WK[(F^?TO!3LW=RAY;Z?MU;?\6P\-=:2
M (&6AF>1N%)KU.N<4NFQY&TII<BF;@Q:BV[/+V2EDF",8E0% )V"2]))SQQ5
M/BL=U/C('5!Y[9&["MF?"EG:@BP%):67@@3/@8!,0+SABD0+N%6%-M8KA"S_
MUB'?"MD%@*PRAHG(E;;6@>#>V.A2"-PRPRG+M&K9AX0L;T'62FEP?8!HS1(!
MQP/QP"FA*%\3DRYS19=6S-0]ARIBYQ>Q/B$,A=;6" :"9:=UYMJ!B3D@AG-5
ML@^)6&CS8N]%D$$2*D4@P)$<&UP\DBTWOC1:!ZM+B]&*V,5%;&9&.RNX% D@
M*.X@:,H,VK'&H27[HYIW%;$_%;&?-EOM9Y(15&J+E)AE5+(!&;(! 21D9S0O
M_:5L6EI14+7L F,V>F<L@^@TFK+<22N]2HYR-(J,3%K_H'I,Q>Q/QFRK[9OA
MB%I#$U%),0*1.6*ER(0J0'7+C8)R"DI59KS(F+4F*,=5$%8!,F-DR)&JP 7G
M(BA);=6S#XK9B0:Z A*+!D'J=6E*98!8ZRBQBNL@-?<*2D5:53&[P)@5F2:=
M@_/>!Y#>&"EY<""M,L&&:*J>?5C,MO2LMAEBIHH(G@2:LRP3HW@BQ4/(;>9:
M:N3&3$[6%7G@OHRWB;)?WW%[KF/&%RV+[AYF;SWTG236-1.W>!)K!G'IB]6L
M(NN6(@LI1CLPG4(I>"]+^RKJ4&(93VP*DFC+I <IE"R6 >=3!Z:OEQH_E654
MS,Y/8+IB]NZ8;4>FI>$&C >293($T( C5CA7"L*@':]9X-$BR[#?J@53,;L
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M2Z5LH(%'66,Y\P?D=BS')9V]9HE($0T!T)$XXSB)(4D5DE,VP=**EE,W9:E
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M3J!VYIDSSIV7QMBE%3Y5YY@*XOE5QT((9H/Q-'$#$)C3)E/E _[3@K(PFU!
M5<>W O%VVPNH-350G/RT=#1A(A'/LBW% X$9%K(P<6G%JEIK:(&1[)EP/.J8
M1;# O;."*HE*V(IDE<NUG\FC@WGS;Z= /7S<7-ND[Y+-2BHTH+FS2+M]4=;:
M '$A:A.9U%K)XNU'OE61_LB0?DOB/:7>KL1[]F#>N IFRV)&\:P(Y<D02%82
M;[/!'][3B+N8E6/[>BIW_SVBN&;[U])B,V(R^' >28QF2C@ 1YW@7++ ;)21
MYJQK:;'')?S6)R(!+$LJK >24(61XH(@GAM&'"ZSHRP:8UB3GU1K#BTRT)57
MO+0>C\IH8/B:@E#<9E?R4H-@M;;88P-Z.U 09+(4)3GAN+@$&-/$.'R%QFH*
MI;P8@GV4B#A/AZ$KT'^"Q3*E5J\6R\RQW%;:7@BM4B L2$L 9"*HIRFACFEI
M$I4@4JDS-AF^KZ<&YA;$M]'6AAJ;F*19<@C2>1>UC. #M8)2 ?74P&-#>#N.
M8&-FR@M+5 Z:@$.L.P.HLG$](62#VSR7TD-,U%J""PQT9&P2A;FT(!@DSIQ.
MD3(A@3)K&- :27AL0)^()&1+@Z&02:*"E00>3GS@Y1@![GGA,@IW6I N1#TW
M\-B0?DM>/J5:K[Q\]F!N11*"-U9#.2X@ H(YBW)PP%(2M4B9>PDRZM([<!+*
M]># 3RHUMCUPO<YS-TBUPEB]1[U'K3!6*XS-J;&3F2BFC!59EJ;9%GD/I1:M
M&F63 2[JR:*YHT";$_%$G4"HF(%$)C(!!D!\S)Z89 T-S"6186FE!AD6&LE
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M9C1JC",L)\6!*1F50E-FZG3A"N3Y=DI,J96K4V+F0&YK9,Y :*Y)4, (6(U
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MVV@\/?(^'72I\[#?181; _U\GTGO["TVB-;;Z@H@</0"I;7IL$LF(EFDL^X
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M-Z:)-L<.9<2F5.J\MWWM,<"M-W;/H(\T;SBF7FHEMD&NG7N;3$M*PXUVDO^
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M$C4>9):OU)\_/OO\=_;E?#G__N6[TV. ]MF3;LKZ(1OSE\;/I[E^CS+O+75
MK'$)K&;0806T<RE%N8PVW6Y\)R3<I-\8Z2\=C+W,;F_'^_HPGRUHH:8Q"F E
MG#!S@WEX*P3)N6&L4D)Z>)37YRA_G^W[W_RL;Y[=\L3H4:2"]C7V-7XHU_@[
M0*87 ?EM;>Z^QK[&OL9_?8TG('_TI?FG_?')9B^'[9/?__%IX.O9OWG2A)P?
M3ACF^+I,C'_\A\^^^.1);?+S_NG\EC_U'__;)^W+WWP3&O[--WYEJM\-?_T6
M\R\^^_2/7_[];_D;Z[]\ONE@7MWOC>LU13J1R/R;C[_YR^GVA^F3@G_>[;=@
M8[[8=^W3?[,_?_'PH__T._WND]_#R7MX^NM_/[_DQ^NA>/79>+4"Z?EN/_<K
M_^WO89__>OXJ7W[VAW>_.LY/'IVO/&XL[,,Q)C=A2L7KP- Y^73WYV?CJXAA
M?D]O[ZV(/'*-N9$I$\YX,:F$@GF0YU#'_(Z_]W-JY"*AN9L+J[,51'+#1AK5
MRMG/D1Q#SZD5BIV%<2DWY?#TFD*1PLL\/;T??WEX/V_]\T78I_:'+_J[WWSR
MX_;)%W_XU/[\[B>_?WI'G[[IQU^_-U\_\>L6G[BM3P_V5U_^Z]U_';YZ K[N
M5OGZ)W_]Y==/7SIQIK_Z&O%K27__R^$U_H-?8Y%_Z#O_JQ>KKU/(-_):,;PF
MBC?R8N6UIG0SKS47W:_UK;_6\AK+MWL]/W3M\T.J='_UTC[Z^)_>_/S5^Q_^
MSS<_^?C]CW[YBU<_??\7;][[Q9M?;)GN?8U]C2W3O66Z#UWCS-93L]2KY\JA
MS;A'E6/S*@E=4MEMP >K?'STT_?.VH#50LTJ:Q4]&?",8D%Y(!":A7ECK7%X
M>,R[@GF_'(N@Q3R&1U+&41PI6&PV2NA8S7<3\ $Y/FT"]MQ*3)@@YZ[ 9 J:
M,D'&T4NPH"*K&V&#?&L@O[05X3*CO%L1K@[RJ::'X#Q]G8":3(,<FH(O35 +
MYHI1<UU[,W(\RG*Y3?';UMB:3T!)[#3=,(YJFEIM77 ,BI0H[";@ U)\V@3L
MJYL(E\96D [S3E:84"^A'D.A3"/$LK:O;W-\QR!K[Y&JY,B)9892(MFG?>ZI
M"&'W+>EQ0)#/VGS1TNB]52CS" :NXN Z,A#W.%2P-I&'Q\O%\C;)QW:L+S3+
MV[&^/LFG/;Z6E7-?*^B4@+L;J#E#S<VZ\,A2#N59;XWNK=%]-6<E$IF%*%2&
M\PC#O:;Y=YB-4J.:=C+_<$?<F[-D?BPY!QH12!*OW$$&]Y0@Z?#B:6#(\>&Q
M;&'?.P:9FM3(#1M+FS:--:0D)C%ZKE$C[FS^ 4$^S>;W%"W8/&N3>IVN2J09
M='  LX:35 DME GRQ8.%&^2C@/QLS'&A4:8=:EP)WQ,[/$.+&"LJZ*01V/%I
MKY>"H2#&G(;Z6#H>%Z?_-K]'X?<90UPDE!Z02C1V,R&*O<[_5(FMCK3S^ <D
M^32/'TJ43&%)ZO,RQ!A 2#J4. @I5NJJJZR^M][<,<E%14<-,3EG1D0MU'.<
M9SOVR,1])_(/2/)9(M^F!<Z9&:@/ H[(X(8=$K61VSR3A=8"JW3QLLV-\E%0
M?EXE[S*[O)WJJP%\DK^/,_!Q8X$PH@,/:6 A((26$HXZ+?%8-?5G!+F_/X!W
M'_Y6Y;Y6&Z_&&HI7FCBP9O=0I[,R<N6D94:<.X-_N$/N_?,MF\&ZHF?H-<TS
MCN;QIE@ZY)8EY2%>@C\\RL5'W.XV."[((Q'5Z9E(HL)-@F=,@VN5&JR6LD6Y
MCPCR:09_],[*<6D"9EV;@!"D4 9F;B14$C>=(%\<;&R0C]TV=*%5WFU#5P?Y
MQ"*'1)VJ):AME>(T#9 \+7+*GE(L*VZTA\?T3"Y_M^,?%N*7I/%3:"'DUM=:
MOB"XUD(1MQARC\%EI_&/"/%I&K\F&N8=87B8UKCJM,:Q,8280J3)<-2U\KKL
M?OP[)EE*57F:<_7I7A>R0*ZA<<.>>TBRT_@')/DLC=\EQGD8%Z J93K6)8)S
MBA!GB,0MD=7!$V7=DZZWAO)+M]U<9IBW9WU]E$\;\F,8S3!"Y]J +1MHQ@:-
M<W,9O96\K'(XRKZ;YT5^=8MN[VOL:VR1JPN-8GG6*'[8__CY9U_43_KO:_].
MZV?[&OL:]WR-/4WW#ROB[>ZB;YEA2'7$D5.8X4?C,L1KBQU'BH*ISR_L$OSA
MPI)?GI7@6S?W@@)2#8'#()!0:>EW8!X-,8SQ\"B7)QAVG^"!2>XQAR2Y]=8X
M*%D.:YQ..Z)V'7G7X ](\FD-'D>M06*$E1 "GH\M^, &BF3%8PFMKJ5>'#?)
M]T+RLYG""\WR[OB]%K\GECAY9,38)KIKG)WSM,3-"W1.9-Q$$NG#8WY&KV/S
M>Z/\GEMB;:&,$4..P^?%IG,F&NJ@VGHAM2O)X>U-NF\/\]/B/%LME64 BY:)
M>2K@K@2>,=8>4R#QM4AWWNX-^OV"7GU^2Q5K*3A7BE98<LJA%*U):]DKLV\-
M]+/:_;R_.OVP!CW$"NS#P'M%R#$JUH:)O"_2,QYIAF>3_O9=\@NM^G;)KX;P
M2<U^'L5<&R>(8PVH<!5P*0E0>HUHUNN:HBW/E.SW$-XM"^G]L%N37N#&F'3/
M(Z5YPD4>72473Y@;-2[3_(5= SC<,?>KLQI K96#68(4J0$/3^"U*G2T2"FF
M)E37&-Y6_;UCDL<T95&L-DN1=>W%,8LE8-9,P6/?-8 #DGQ: ZA)0I1D$*?#
M HSS9LD8';RQZ/R_5G-Y>)QW=)-\8R2_L%WX0KN\VX6O3O*IN&VCF&W$I===
M@"G*6HRS<-8UW<.>UC9SI-?G6EQ[$N^P%+_ 'KNI>Q!+U3-S06\M#2L14R,3
MW96 FT/\M!(PL$D?M4'J/("-(B@+01/5B*4;X?BJ$G!QR6^#?ES0@Y):7[J+
MR#QXF>K"57OH2LUI[$K K8%^5@G(20N[9L!L#BPKP,ZA [DJ-TU]/C2+= U[
MCN_62'^A8WZA6=^.^?5A/JD)H'1J)@EJ7,J:Q 8:>+KG-0>,=;3A,\:6@XWQ
M_8 G 2[5Y-N5SF^K'-R]UE1[R8+L/6OOECH)]JZQ=+Q.,6![,F_K\*MGE8*5
MDVBU.M1Y0X%'K:"E$-0^35;)HW?_.F398O]W#+I);9XERVIEZTM4>+HT07,/
M4ACQ2II]&_2W!_I9(4'8VK ,;3 #=\H@JU4Q8LNC1*W1GD"7L$&_-=!?&+%<
M:-5WQ')UED]+";WETE2A>]>59Z09J\S0I74</;5(5&? 0A<%+!OBXUKK$IK4
M(!J:)YY_,&^8(V?A&:Y*B;N2<&N$GU82M"=6<8>$$W.6[B!2$+"$THBI]$*3
M\'>X[.&A.P9]Q!*&QEI),M>B/B'G.EH:<6C_NLUX5Q)N"/2S2H(L24?"I1_6
M^OS@!9S180;AEG&,YAT7Z?,@V*3?&.DO]<LO,^O;+[\^S">5!,5>-'*#EFP&
MV24-L#R#;.M$ZJDZ][I6_)Q/['\OCOFU!PO:)W]ZRR#J6Z@F?//.7_V%??6^
M38 _^_QIM.'=^4[WS]>_>GC\R4<?_N3-SS]^[]6/7OVN?_F;/W_ZA]_TWW_2
M[,N_JJ@]O9N'TJC:U]C7N(5K[ KJUE+[KD.WS$$H3"\^I\&D-)UZ[$@F3:*Z
M;2VUXSETOWVN.MJY# +SH;#<<-#!%9)RF_\=S#S].=HK5^\8Y,@S#"LEY"J!
MDT=)&G.,M83853GM,:H#@GQ:_6PA4!-*X.0$'+""Q%R@E;SN;.VXQJ@N;\O>
M(!\%Y&<S+!<:Y2W;<"U\3Y>8:9YWB1%2+Q-?8P5'+M,B9XH2!B5=4Y#/+#';
M_-XHO\\(+,5A:X N9<KLXA8T%,U-:A^!M.]-9@<D^:RPB:ZH+0&-98AUZ:01
M1BAK&6&J1(7EX;%L_:0[!KFE.F.J+-PU,X7J82+L99+=,ZE?J:JY07Y9:'PF
MAA:Q136$D7,%;M+6U$0&%S&R,:1S>'B4+4Y\:R2_L&IYH5G>5<OKDWQ2M60J
M#7L;,.(B.1F!-0\@);<<HK/K$C#%U^=6^0=1MCQ>^G[KH5UOZVK$SB4[=HQ<
MJ<TH5&IH)L)2J->=QS_:$;<<E9/\0=&4IEN28=["#.R%0;PX: DX0X[4$JZ^
MC+A5E.Z8Y+&$&&:$V;@'QD[:,EMWY6IE@CMV(O^ ))\F\JV:6QL=VL 5==1O
M5)2(*W8)TV&Q1?)6-KPUDE\8=EQHEW?8<7623S5*-=22<$PC'"-P'@J:<@0<
MM:$F2E'IX3%>U"NY(3ZP.2Y=0THIJT16+E[%Q"SV-?)0(^YT_@$A/DWGU]BK
MEAJ@.!)PR@06YA]3ZZ.)I9)SF!#SUCN[8Y*36?82B5F5*0RQ:8ZS25'W"??.
MYQ^1Y+-\/K%DRA0 =4TCS0@)5&.#T4:+/9)8'Q/E="Y/NE$^-LHO]*PO-,S;
ML[X^RF=C2+48U08ZGO84F8"V/EWK%!O3DW#T"I)?GP?)6]!L"YK=W/GVDFV,
M-25,(1O&P@VC9VS!@_O\F])#W]G\PYUO;\ZWFTC"JA;!)"3@017FB:<0C7LK
MZ$96YO&6<;<>W"_)7,/PP:VK&MMHYE@0FP^SKL*ZL_D')/DTFQ\"NZ@@U#9]
M%$XQ@XQ6YA]#H9::!-TDWQ?)SZ]3O,PL[[[\:_%[MN'<G+D;]#H<.*Z< 3==
M&H.U:\\IY_SP&)YI'-K\WBB_S[3S]HZY]=32M+NA)I\ DVE/.6"3K[5#=R+_
M6"2?)O)%4*/F 5IU .>2P$L)T,F'R#R>Z["'1\(]ZGK')(?!A3VT,*TQ1QM6
MAZ98HQ8BG([V3N0?D.2S1+Y[Z-(FRBW.#\RIS4#9Z^2Y>XBC6%SA,='NS+\U
ME%^8R+_0,.]$_O51/DGD]TEP]C[ #?-$61$FW0:2B^*P-J+6AT=^?1X?_R :
M\[>>V+?6$WO_PW]]\[_>>_6+7_[BXS<??KADQ?[WFW_^V?L??3@_^_IK_Y>]
MMVV.[#CN/;\* Z]V;S#'E56959GR!B*X,N.:L9(HT93CRF\V,NM!9EQ95%"T
MGC[]5H&4+9^&5X1ZV'/04S,D!@,,#AI]^E?Y_,\//OC\LT]^\B_K<Y]_]O$_
M?_+#SS_:6F/[&OL:6VML:XV=.FZCZ&A>6U -2]O&2#M*\^Z42L6RJYJG<_9^
M?%'5'*VP<$4HUN+T]=+T]=)(@"E+<N%6DST\9MVUD#LFV5+ON43W5I!023RD
M&&3Y^\)>ZJYJGI#D8U734Q\8GP2@&P+5TF &W0(]C2(S""<L.$F^OBEZDWP6
MDI_-OUQIEG=5\U;\'BPQ:LEKB3/T6*<EMI FOQ-B7]DS":NNJ0^/95<U[X??
MYVHA.*DM62@Y-4;M*IFCC5&LE.%[Q])KP_Q8\HS40ED#Q&VU',W#VL Z99@?
MKDF-2J>GC8B)=Z7DCD&O*6-2S+FQD\3N>;BQ:RW&;0S:.Y9>&^@7%=%FM>>V
MI,KJZ$"Y.BB&!NP^A$M3Y"5P]&'<2X[OA_1G7?(KK?IVR6^&\'&DR>?Y3,6@
MH*^5IWTL >\94[=((VB,R'DI .<3 ;QURK9.V>WD%&JTYAYSI4&8U6KJ#6D:
MNS /O+UOY(3'W,\N:@"9B$8?TS.A,D.27A"L!8>8YSV<OJFDM:0]Y:L#DCV#
M?5Z20S1)*4V*6<FH6YDO!'&.TU$II<NN 9R0Y N=LI&\I!*!6"O00 ()%J$,
MS<5=LS9?FX.VFL)K(_FE:@K7V>7=A'ESD@\VF;QSQ6"@/(,.ZA[ 8I\FNHG(
M6(4!'JL'\S+RV#IEIX7X!>8X39]KGLA1YY6HH_IDU,HHC"4$B7N\Z8P0'W/]
MR%);Z 6B6 -"F8YUM0Z(31FCD&![>"QT]8[U3?*)25X;U7/G,0TR6>VB$]C"
M$;L%+BA[O.F$)%\D\_.,@RW3*M9]LZV P5LW"*D,":/G-A;*?'4F<*-\;L_Z
M2L.\/>O;HWQ,ZD>)/H;"&(9 A@F,YNUJ5$>O+:.V)_F RZ'CK5.V=<I>W?GV
M$E=%T&AMEQXY4JO9>S2+P\+\G3+K;;+YNRGA;1U^/[](]:-6GQY,!YZ6"^:M
MQNG&"$-$"3EVJ>1Q]20$WCT)=PRZ3^^%-*3Y2BA$<3HQI;FW(8W&B'2C9/\&
M_>V!?JP$2"LI9VW0RMI8DD<$,XT@*0PM7CF;/($>-^AW _KS <MU1GTW']V*
MX"^..X=TGLP8(5=)0&E5Y:-'J#X/[GDS47@M.7AS=?)P\WL6?I_9 XB:2QVJ
M.73"4BTFS2QQHNQ=&N]Y@->&^<5J\A*PEU;G_4ME=0EG<)U_+85T"!.FUB?F
M'V+8\P!W#+JM4E&/'!L.ZD75DJ40>\=*\R:7/0_PVD"_*"%8G?'4],M!@^5I
MT', ZS$#USX-NTZ?C'&YY"K;I-\-Z<]O$;S.JF^7_&8('TL'+"$.]PENZC!M
M,X%C8.CNHS&E)&M;$3^SXN3]F0<XFSS:*871OGEHGWWR3S_]^+-_^.A''_SP
MTY_\TQ8^V]?8U]C"9UOX[%0>W#/"9QFS9Y'BB<FU:ZZI40HY4$N5XAYZ.ITO
M5R\JH2Z]AIPJ\)K))J<$SN908[;0HC=M2RYIJR7=,<A"?80FN5D=%*K*_&/I
M5)<B,RAOOF>>3@CRL=+9T0JN/>X4!@'%&L"[&X22(F%M=1[7#X]E9T]?&\@O
M;,R\TBKOQLR;@WP<>2(OE'."7)9%EOG&0Z]@EK6487%0?7B49PJ>[T1V?D/\
MMK>D4F6Q$EV,2%I3&6Q5V_R#K5'9(T\GA/A8SNQ(C"89TL@\3;(,L-P'3"O<
M2E'E@/3PB'%O=+ICDJ7,HSIRC:4ERCU**SK&Z-BK_,66U#WR=":2+^J5['W&
MP4S@914[2HU@84(=BGG)(T4.JU<X[6KE:T/YA9[UE89Y>]:W1_E0MY3I0M<X
M,L16<+K6OKQJ*L!9<FO!J7M=VL*7=<OW8J/3^9+X6\+L=IU7VM;"YS%#ST@2
M)QOD*;5:"Y<J\:]M@=[.RNU/N%]>9/-;JUKS8*BH!=:8/=@ZZH0[UM&E2$H/
MCWGK'MTSR-ZZ-XF);)"1:XXX//7J:_!!=C;_C" ?L_F#2XNC)&#,TU-A'&!Q
M.I;=,E=-'*8K^O H5P\M;9#/'7-<:95WS'%SD \6N4R+C/,>@H:UW4 BP;R-
M!8*:64KS)M8UOB1O+FWR5C [+<4OV7!0L>@P-)) ,5>GT4)+37/N<>A6,#LC
MQ<=T_ABIS)LV@&WM,(C3N9YN5@(19717R3FL=/Z6/;ICDE/"1-,)XR%"ZN98
M'%N+T]WNN13<Z?P3DGR1SO=,%@H2=.(T48X='-V@USK]K#5MV%9EKER]7VRC
M?&[7^DK#O%WKVZ-\2.=[9*W2&<C:?#.=:W"*%4(*'7/5(#BF;UW>7&[MW1)F
M6\+LU1UP+UE($GKCY'6$Z:M(<:TZ7#GK_(.RT,[FG^Z ^]^7"TDP]F+<H?(,
M/2A8G5$'9:A$E%)RI9I7U+&;\^^89$XF2= S8B.4:C5.\Y:DA-ARY+S3^2<D
M^9C.Y[&4Y9+ ?,$&(,'\33I_[3GMFKECLDDR;Y)?&\DO74ARG5W>0<?-2;[(
MYT=TH@%H<2SU$@5USM,ZAZ"%$4M<ZB7ZS'[RW9Y_6HI?LB#,2HJKF-[:JLHU
M4U(/G<:TP:N:L_/Y)Z3XF,\OF'28#*@6)KN* J:E3Y2U::A-6UEJ8UO]]YY)
M%LHE"EL9+A33DO]MG#W5+%ZSQYW//R')E^O%:P_%HT&,S8!&S^!( I1[RL&8
MD=K#8\(]^/K:4'ZA:WVE8=ZN]>U1/N3SVSQX$XT(.2^Q;K0"7GU B%U+1L9&
M:?K6\N;2++\7_?EGDQ0[L;#8IY__X\>???"3CW_^V:?_],-//O[)#S_>HF+[
M&OL:6U1LBXJ=.BC3/'VVB#55CY27^2^&TE)2:CAJVH7+DWER,R";'MS!DYMA
MF!)UAM+CZI<<TY/K8TF+9:GH982DTY/;6N[WC#)B+U[Z8!F56B$O:CF.A",G
MGZ'YKER>$N6?'?,KPDF*0U*+0*L=P;'/-ZEH24@J:V9:+UNL-LFOE.3GQ0^N
ML\M;J_UF_/[BO_*;K'6JEB':,L7:&UB?_(;*H4COX4E.#/&9/:^;X%=*\*4M
M[G6U&Z#/(YLH=?)D23 TQ. UF^ZJY2E9_N5_93G6WKC&MG:A"1#E"!9QND_3
MJYXHY]2\K 3IU6-(&^7SHARX=9>21PA*&)N;C+X\;0ZNEL8N6YX2Y8]_OQH0
M)L[IQ__PT9]^\M'_F\FH5QLPW2@$JFR@>3@PC]9[BNC]J2=PV^6[@?E9S_I*
MT[P]Z]LA_,<#PBWQ\,8*/&.@5;!\:NN='/=L\P2.Z9N"97ES)H.\5<6VJMCM
MQ(@Z2=:(37HD3*;<B4,-)I1'SF&G\\]WTOWQ(IWOT:P4;R XWU!IM.0/&OA\
MKZ3A7"L^/$:].IV_9Z;/BW(0ZL@I=L1(:U&G2U>)\_]IG!+Q3N>?$N5#.C];
M;H'2]"6CK,[G*J"2#=K0S*@Y5::'Q[3E#UX=RB]5%KO.,N]VR=NC?,CL6Z0^
MFBE8C3RCC^PS\'""RH+2/8YB$^7X7&9_2XN=%N.7##!8[+UFIE(JU9$]S _,
ML#-G\484=E+_E!@?DOHED5EU!F\^@&RM^LE1@,/H\XXR]E$?'C->/1N\43XO
MRB/X6(E?'*P4,BLG:BGS]+?#C+YD)_5/B?)%4I\L""XU(DGU:9WFC)23.LR0
M23T5UMQL;>&[.JF_83ZW>WVE;=[N]3N ^9C>#QH]3T\:F/N,E6O*8,5M:7*7
MV"R3^5@5NC>7IGGKBVU]L5=WQ+U(E:AZYYS+FJY,)5KE$M0UKX^VXCNO?[XC
M[D\7>7UL810J$0JN^F4T!EM]""26PAA]I)8?'I->G0S<+0CG1;F&U-1C"B7-
MF"/&Z9[$L5;-AOF92?G.ZY\2Y4->OW H8RT,:3C?4!X15'L PN)%O4NC\O!(
M>2N:O#:47QAX7&F9=^!Q>Y0/>7UN)6)4 :>Q2G1&(![CA+JV>=MLR+=AQV6Y
M?4N,G1;CE^3U:Y%B2#E[)4DJ6G TS[G5.B3BSNN?$N-#7K]:K],6,_#0MO+Z
M';3V!+F+Y(2MM#(QEG#U,KZ-\GE19K+LP76@.EDR2XUI27YBP#2R[[S^*5&^
MR.L7;P&ISM"8><*LDD$&)AB]1O.08C:?,._)FU<'\TOS^M?9YNU>OP.8CWG]
M7%(=R02RV8R04Q&PVAVT$'<T"3.">GC49[KVWZ7,V)^_U[>O7GZ"]"S20/L:
M^QKORS7NJ\Q6GK6*G_YZ?:=?_O%[K:+M:^QKW/,U]J3=WZR7]W[W&KU$V*/+
M=%V+RBK1N0<MN91.(T@=J%5N4X@?7W[U;_;U?#A_^/H',VR"]N63,.OZ)CO[
M\+* )5Y.WV66E?6'$8(!U:[@N0ZHF4<SY]!\;2S],!?=787W2WK5Q*M_5&DX
M#:E>2\Z1,7=O,:5RFSK])OUMDGXHXD=F3R,DZ#%%F(<X@UFE^=+32$B]JBS9
MS \I[TG;NR']>5&0Z\SZ%@6Y&<+'XKW73C%6D-YT(IP+6(\91*F'GG,J:17O
MZ<VVU7=#\*6M+A12I!@\-)ZVFM4LSX/<.E7/0>-M*OC;5K]-T _E?5N+6?UI
M).!IA9A'T-$2U!)3B&&8<'AX3!_&?+4T[B;]O*3G*#4EY&F+G:J@#LX8:^X6
M1LE5;U/@WZ2_3=(OJO^=+3+U!"7BTK\9#,X:H5//H04WSOGA,7XH:5OUNV']
M6;_\2L.^_?+;07PAUE=&"66-V,<B0(T$? 771!K&B&RF?CK/_+YJC>]&K._]
M[F]Z@2]#HFWZ**4M]0&UH#T)DR'KZ-CCC<3ZMB_SUH[!=%%+6$LQ!R+#FO@"
M0BR@F!MD<R5+&'6-"<4/T_49QMW)>%[29W ::VU6.PM5$TV6A@Y/&K,%\5U+
M>'VD'VH)*0_',1"PE)6(#)/TH@5F6&I=ADH=MD@/UTO];=+/0OJS,<N59GW'
M+#=#^%!+T(;=(Q>(F"?"J &\<8300E%)+"':4\2R1XCNAN!+6]U2MY D2G"C
M&+IXZL(IT1I)"=_.Y^]:PJL"_2@!& )BCAGR=+6 <HE@* 0-58=&%2O\\$@?
MEK37[-TQZ8'+]+^S#QY&";OD%FI5U9RK#<V[EO#Z2+^H)=B\HR5F@NEZ3=:C
M-A#B#!0DJ+6ZRHJ+]?E"V*S?"^O/^N57&O;ME]\.XF,M04JRD1V!),DTV%S!
MN!!4;9&M:*:G17SA^EK"7OQS(GG 72G]CIZ,C]![X9)"K]278@UI,T,+*K'Z
MV)6$5W8(TD4E82B7.GJ -(,7(.X$VC)"#Z5PXSQ#&5U^3*#=JWS'I&L,HBJM
MC9QI2!#S$!4I]QFT!L5=27A]I!\K"8E33ATAQ^GBD >'>8^GLR,50RZ*2F-U
M.G+:*PKNAO1G(Y8KS?J.6&Z&\'$J00U'' DRVU('I0Y")N!8EDQ9SZ7'ITK"
M7OMU-P0_8ZM3JT(XIK-6R,T\S=.;(B4LS".T74EX?: ?*@E28Y:1.B@[ PVM
M((((Q60,KRUVKP^/Y4/=NSKOF?3IA=?83&IBHC9O?D[H,2WCW5#*KB2\0M(O
M*@GLGHJ- 6LZ=!GU"EH=H87IF'NH%@,OUC%LO_QN6'_6+[_2L&^__'80'RL)
M)&,IMAO0/+*!* M83 )#ZJB8>9[6J\<G/K-CZ/V92FA?_.XM8ZAOH9KPYV?^
MY@_LF^=M\OOE5T]S$3^8SW3_:OVKA\=_^.BS?_GH1Q__K_]X63P]=Z>2Q=K7
MV-=X#=?8]=(MW_:]CX\CCQC'R)H#(5>EU?@U8J"4NJ2Z"Z6OR\=;0=HG1U$G
M3</+ !J)@-;<N,?@,#UVZZR#D-;<Z8<S#C^1B[=)?\NDQX(M= DAET35DR!A
MJ)5;IEQ+Y[UF[90P'VJA(K;JW7E&:FL/!(X&%BI""BYL(SG6\?!8RM43&1OE
MLZ#\;,;E2KN],RXW _A0"0U615.T-4GE*^GBH-:F-9X 4VXAC<$/CRD^L_QA
M$_Q*"7YFTH(\R. X36^DB:LH9@\-Q:9IGN?[KH2^/M /E=!&WHG[ "Y<8?XE
M@1,J8"O,G<TJ/ZDF:[EZ)>HF_;RD$Z;B[KU58JJ=#/O3LJ[26QN]A5T)?7VD
M7U1"QX@8O4;HEE<E90;;XC/8'CF4ZE3S?/N-;O(.L>^&]6?]\BL-^_;+;P?Q
ML1*J5KL&7S(E?>U9] S*O0(B93-%G79\>N;\YDP,;WVVK<]V.U\F8]2>.%D3
M&DDMY=PIF5A5Z<%N4RS8[LI+3KH_7-0#"MN\0S%"3'UU?!0'D>;@.DH8T6J.
M,S#1?'7#QQ[_/B_*5@P3M3&*UNFKH,^ !&O07*:=:TR[&G!*E _5@.E6FM7A
M4'RM>.=H:U\+0^BC(7JCUB?*.6^%M;M!^7F%M>L,\XXZ;@;PH1K02HFE>X#:
MUQ('QK5PR0UFJ)AS&[G-L./AD?CZ[LM-\%D(OC3&PX5QE&E^XZ#>DS<4B<E[
ME%9RK[L:\/I /U0#XII8UAH!.P^@- J83]I#*!Q'HD2:5H90LFS2[Y?T/*@P
MYZ+,@5(4#3Y]N-(2CTG[Z+L:\/I(OZ@&X."!FAVXR]J7FA@TCPZCM,+:>\VM
M+M93*IOU>V']6;_\2L.^_?+;07RL!J!3JQP%\A '"EG!5W%@<//>I.7H\O"8
M],V9&-X3 UMA[58;)CN5%HK5$8P\N?=4<S#MT_ -&FD/#KRR0_"/%X6"7)DH
M=8?AI0)U$C">(8QUBQ1'XTQ/,8O*[E6\8])-!R<E-<)&N0]1L2JA)91&*+H5
MUEX?Z8<ZPNBYCE8[Q)PS$-8!YH5@"6O1/-Z1"9_ZE]+69[H;TI_?+WF=6=\1
MR\T0/E82) 7,G*%DFPC/T 5$ D(J5&()>:#[C%=DSQ7<#\'/#/E%(<OSV&Z>
M*7:?1CMXRIB:L%+;>]]?(>B'2@)68LFD$+E.T%-JH-PZ! VU=BZ27)<:JFS=
MXWLF'5/1$;P'I$'=DN;N'OL8O?;*(>U*PNLC_7+ONR)SB -&39/UT0=XKP7&
M$KWETG1&8VN'8M&KJX:;];.P_JQ??J5AWW[Y[2 ^5A)&J5BUR2H"+OV-KB!K
M$2IA[VT"GG64:;#+J;2/M\+::176/O[L1Q]_] \?O;/']O#XP19WV]?8U]CB
M;EO<[41^XS/S6C$;%5-W#J1]_M>JI] (;61*;<]KG<^##!=EV%9*6^V!,._C
M (K,8$H!/&.0[!)SYAD$[M+,/:/<"PZFP<9QWOO05:/7,6;HUR26F/>\UBE1
M/M19.45?71/@TB,0M8DR%8&)J0L6#A;"PR/J1OEN4'Y^7NLZP[RS.3<#^%!E
MM=C:X!&77)L#B2IX] 2IXG"6$-AIVN)PUU76ZZ*45\3N<U67(%%:*\.=>@XB
MI:'VTCF%6N1&NFW;#+^0XN,P5ESELH# ,0C0JI$)U@HCUWD8(T=$>7BD=+D\
M^WN-5]]CKEQ#B&K*F >QHH;81\^R%LA(SGZ;:N;FZH5<78X^U8 T;2!8$@*J
MH8.)!"A!G8>E6&I^>$SY4O)P9X*^9Y_S2M.U?<[;476L(+8A*<^H$'KHTUYI
M#Z!.#&XMIX%:Y\U\\CK/I"2ZE<FV,MGM_/+0B^.HFFHF<9DG'$=.TJN'6)AW
MIOM\)QU>9+K)U'%-2J<93\.\66'ZY4;0)/>J8;3>TCSG<$LDW#'*HYM*5,IY
MODDQ*S$'$](XL,W@8&>Z3XGR<4])&2,7:3 H-:!8 WCJ\Y:M#0>8#0.OM9+A
M,L2^'Y1?ZNRD;Q_WZ6G^YA;]C[]MPOK[>O;._J2]Q)MQPUH\I^2-I+D4$BY6
M;-36DY6=93SE$7C(,J8>5&> !EW'/ *[9+#Y(>B#2QC:DBUQ1L++,8W-U??#
M%4L0]QHMI$K.;JY)@_&0D29,-YJ9V%R]D*N++..\=8C>Y1M9)8K#0'IID E'
MH6 A]KC*Z&\I?[_M_7/V?C<P;JV9&YW;K88Z8\#2:BO40O/(W+N-4&=42)AW
M=N=\YW:\R.[,EVBFT0QF:(] EB,X5H/0:3AU$]2^M&[WZLH[1CE)\5AJT8%*
MK4P'.=#\BUBFR*'=2$QFH_Q"E(]]C%51R@QM".M\$\MTQ7Q&HWD-IK;.HX6U
M*B?L"?2[0?G9FO*5AGG7E&\&\*&/4<G'<%?H$@903PI:M$(QRXFR%42>MEBO
MUYT_,<'O<;_5X%&&VRAQQ.EZ5:DXK6^E2%F:];XSC*>D^)!AM)%:QU; )*X,
MHQ80; E:"SA&">@M/SS*,Q[U[F/\?K@20JT9F^6N1-F%$E$O);96K>/8&<93
M<G6185S*IX-G$)(#R5JLQ.#>%5H.J]^?+*;Q\,C/+%;:F:#O6U/].M.U?<[;
M477L8ZRB,5E30"P9*&L&C3H@9IDGXEJ6+M->,;[7&U:W$LIW5D+YY,?_]V<_
M_^=/?OC1UB/9U]C7V'HD6X_D1-[;,_T7/DQ9,K(42LW55OJP)6Y<4_^/$91=
MQSN1'T<7=3QLR<BR@F:OL.3AP244D#@0ATA'6\E_NKJU\\2IPXVRQEZK]Q:,
M"+EX*:ZKE.<ICX%QU_%.B?*ACJ<ZC^/6VQK23#"/9 0?G$!LF.>4A<A62?Y,
M<V4;Y>^"\O_QLJ3*E99YW8?Y(T^N=W;E5BC_XKC"924L6X?%+5 6 ?&B$)-+
M3JF.4LM2"7LFM_)_;HS/BO%+FN0LI*2]IB9(DD7#D(ETP!8ML*==TCLEQH>2
MGJ0):J[3I49&H*;^M L>F@2FT4M#GLYUP>U<WS'*42L&[Y5INLV**)K(N-@H
MC;D7W%7$4Z)\445,I5#)V:8_C1/F[@PJ:UB!54OT+KR&(&4O;WAU,+_0O;[2
M-F_W^AW ?%F\G,=PZ@&J($^8C:>KW<MTM6-PUF'SOJVAHS>7IOF=.-A;?V7K
MK]RNK3^T>92Y!2.CVEA:1D-:BAWJ@_K.[)_OD..+S'Z=#J:Q%"BQ1""?GHN%
M9L C3,MEXM[SP^,\[^Y8M.&]1WE>@'.E^:.Z4'821*\=.9*+]"@[LW]*E(\3
M.B-Z4"*8WJ;#C$((K,_0@]4]$!=/:T0ZYZLG=#;*YPX]KK3,._2X/<J'S'ZF
MIBE7@S)T6F7I#EJ18*!((2OSO%XH/[,^[KO''9OB\QKD"6YMF)-P1RH:G"*7
M^9&>0D_9VM[I_/H0/V3]M;; K0MDCBM1.!B$1H)14G:O$WD<#X_X890M?7C'
MI,?E7SME*98IQR8CMH"]A[B\N!'W3N?71_I%44"KH;32 $<):X4(@K$."*1E
MWOLN&)8RXH?I^OWMF_5S^^976O;MF[\#G"_* F$P91^@2\N&:E9PR0-B':-C
MD\JT)NG?7.;,WHEWOMO\MVK7S1*)N951-*W9/JIN.@^P%FN)TZ%M>_OH"4^X
M3WY_41-0I3&=$H-BO0&EO":A"\&T3SSOV/S<F.>;EJW:=<<HQZ'62^H1(Q$*
MF6JN=5@L%GIH-]H^N@.3M\GYH6 PXO1BM A4*WWZ,<0@WB?GB<(\N'-U6>T-
M'R+>\VK#^R3]A6')E89[AR6WA_E0,J@5BV&($#@34"X1M+I#L.ZC=VWI:<_P
M'@9X51B_9)]B3\FQB/,\UZM&1>T2HG =N7:YT0:!;;#?)N.'F@'&IJEWAWE<
M5R"5"EXI0PZ&C>9A36O58OPPA-U>?,>D![0)L%?4G&A07&FHM2RKS_N/G?.N
M&;P^TB]J!K**0-D%/-8XG?-1P%$B<)J..LKHRFL!Y(>1SJ2<M%G_'ISS*RW[
M=L[? <['FH%WCH&U@:9LTW2W F*$T 5+PRPZ@5[+T9[9Y_I>C!)L";3O+('V
M+[_X_)/_^=$[>V@/CQ_\W0>G?&+,OY@?[%]]^>O^@=7^]7Q_J\3M:^QK;)6X
MK1)WZHBVR?"AR4)3H5%6VSK*4M*6IJF$O<O[A%[N'R_JQ@TU</0 L?2\=O0Q
M.+4(:2C/^VFDY6E'WXY7[Y?DTEE#Y%B3#O*LTP\SJ;&(S5]YX!XE.R7)A\IP
MZ8FCY  U! $:,V3UG@H4]VQ!\TB%'Q[CSCR]-I)?*F)QG5W>F:?;DWPH"[?6
MBG0EF#<O E&W-1XJ4+ [23&N;4;.&-]<=I[OLO!I,7Z!0:[29%IA32TQ3<,K
MB;BO:6!)$CC4K1%W2HP/E=_<D(2P@',M2[5U@"R#G*5+]VY><;K6:9=][YAD
ML5(Z]2$I,N41E*=;74N/G6IKX49EWTWR"TF^E(B3E*A& _3B0(H-=%IBJ&G9
MZ+P,MBV]Q\WR*V/YA<[UE99Y.]?O@.5C67>DG$NF ;7%IU$P!-$1H?<:'2,U
M-GEXI'+5+-@K+NN>+YF_%>)NMS BF;=IXX8T(VE1K([JJ0C-2R/MK/X)#[D_
M763U>THSYD@1<AUCY0(C2/ E*Q7[T$1H/.81)U?/B.S1]?.BC!RD:XA-G::+
M$BSDNF;737J>'QT[K7]*E ]I?;..Y4GLD4E7%B&!#1<H.?70;61+X>&1MPK%
MJT/YI;M?KK/,._2X/<J'O#[/HS<K*I3!MI9&%/#09_11O 9JEMOH3_VDU^3U
M-\;GM<C).?2:.:8JU /J:*%Y'*5WP3QTCWN]/L8/2?]IK:?S/1P&6@.B::XU
MI0)+VG.58E-\ZJ?Y,(3M>]\QZ8-;3KF(=Q2*$F5@SC,B&ZFQ];S'O5XAZ1=%
M =30NK09/DD,,\H6FJYY1L R#_I4AO#27,$/,6TE]M?&^DOEFZ^S[-LY?P<X
M'^L"*=>^&J1@;?P!RF@@S@*U>+1AK(9+\1&W1MQ9Z@);(^Y6VM:1J9;<TI!!
MBD%+T+"2R524 MJN"ISOB L750&7U78RS[9YSLW8Q&H%R1Z!QZ">:^! Z>&1
M ^\NACM&&:EEQJ+*A;BPCR;F;9C&F!#+K@J<$N5#5:"5QB45AQITI1EB AEC
M.9<=F:DK-9HHY\ME$QOE<Z/\4FWJZRSS#CQNC_*A*A!&&28>0 67HF.:[VEU
M&%FC>F',39ZJ M<LCMD8G]<BB]G %BJO@9VUOH\FRMZ*\'P)M&R[*O#Z&#]4
M!6+!R34':%X$IK/-(&P5(H48%)TMX5-5@"ZE9+;!OAO2<7C57*>K/9QB[19Z
MC<I&.JB-RKLJ\/I(OZ@*A.S3(6.'O&0>J?( ZU9 .<7)NQN3/RV)"GM:X+6Q
M_D+G_$K+OIWS=X#SL2I06)C6%-\(HD#<#'QP@M:8<?ZR6NU,&LW?5@7^_+W^
M_/+E)TS/HD^TK[&O\;Y<XPG(O_O:_%?]\>F(6";BBU__^],XR[,?>=*]FV\.
M#%-\4R;&?_^;+W_[Q9.,WE?]5_-+?M?__O=?M*__]<_NZ%]\X3<GPP_"?WZ)
M^6^__-6_?_W??\E?'#;+RDR3=G-+&]=CBG20 ?R+M__Z'Z?;;Z85!/^JV_\&
M&_/!_L!^]7O[XV\?_NZ__$S_]L6OX? <'G_\=_-#?KY>%!]\.3Y8SOM\MI_[
MD?_RY["O?CE_E*^__,T/OCG.#R^=;VQ\I!IS2Z:4D$IAE5 PC^0YU!$&?N.C
MS*_I[:,5!80R7[Q-HR2LTTEY"DZ*SJ!4$T_GU?^[[R,YAAG(MI)B7W/N2C3R
M#&?'?%:+%#I^GQI:3L$:]J)K8M*YH[?0O8:0^C*B_]<3)/_YXOVJ]:\68;^R
MW_RV_^#/[_Q]^^*WO_F5_?$'7_SZZ1E]^J*___:Y^?85OV[QP4H^O;"_^?1_
MWOTWX9M7P+=5]&^_\[>??O/TJ8/M_N9SB=X(__>?#F_P;_P<B?Q-7_G_]V#U
M#8?\2A[K2G.F^$H>K+Q1YE?S6'/1_5C?^F,M;[!\M\=SZW:=K<[\G46(/_W\
M'S_^[(-/?_+#3W_TZ?_\Q17ZP]\U.[*OL:]QS]?8D@5_L_[P^]UV_1*1-$^!
MI;9@,YY(D<Q&C98L#4\MQ;I[$L^78$T7/8G8JHY6!,14UHX-!L6EE#9=P!F6
MSLA59V3(90]0W"_)(2-IU-#7(LN>L^#\S9H\].1,MEL23TGRH261G5/O4<&;
M,)"D""JA@;KTP,FU2WMXC%=W))Z8Y)=Z..G;QWUZF/_'=F6^5P'VG+DM/8=$
M3%2+U]0BI@F344AVHS6@^P!\X0%X;/+J>=X^)K 4GWJRYU$XPH#*+>5*BJS^
M\*A7=WV<^ !\[TE&]&BF2"A"M;EH"5F[:8Z1(^K6>STER1=-7$OKM0URX$IK
MDV><5(?4 4W"/)9'-<:'Q^N[-4_,\GOBS.PIVNO5-=_OIL"7J&N&3/-@:;'X
M(%M: 66@MM)JQ6&\U35/:![H(F<E$L:()"### @I@P<?$*-,ZU_"\O\>'LO5
MBGR[O?>\)*,4\;RV?>=&7<9\&K)(GH]OH&#?8[3G)/DHKNE>IE\> &6%;*46
MD)P*I'D>9Z2 U<8,V:[./F^2S]VH?Z5=WHWZMR?Y,$4K3)%B]/ERB@.(D<&C
M$S!QK]4+EMX?'B._N61Y3]&>%N,7&&32CK64,G)IE-6,*C>)W:E:E99V#O64
M&!]RJ)/>2+U$&"X)R-7 O3)(=5;QHE:61"Y?+9ZY43XORJ48:[$E;MV)\I#)
MLG+.G+JX>=I)U%.B?)%$+2XV_VO0QNKMB-,PBY)!ZC1&*XFSAF63]P:\UP;S
M"]WK*VWS=J_? <S'.5B/H05;&_"LK6V6G, Q)>@X+;;4W*+.4#GIF\N:R-Z:
M]2K5,7?1][OVKU6)XC/,Y$PT*-IH@42F8<-@;F-G]<]WQ/%%5I\M)7.-2U(/
M@9 =-.0&S-5Z6 7]ND*/K>5]SRC3Z$;"W!H.&F9>77IL6)PS4@D[K7]*E ]I
M_33"6J[,D'(+0&$DL#P0UA(TF>Y*KDTGRG&C?#<H/QMW7&F8TPXW;@7P<5-6
M[RFVWB TJD M-#!>.[-XQ)X&4I3R\%C>7*U4O0$^"\"7ME@'IX:,HTNBXJ12
M<AHMIL"%,+2=T3\ERH>,OJBH)7(( R?*K&6ZU4NINM3I4./ T,>2>[DZ";A1
M/B_*Y+U$10ZQ1HK#5(NT;HC65%#JSNB?$N6+C/[TGGO-J4-?$=#:.PH:O</T
MJF*3Y"7&_/"8PEY&^]I@?F%&_TK;O#/Z[P#F8T9?>TDF." .=" J'6:L)%!Z
MM&9<>BO3,J.<;-_5G[_7MR_?_")AR]<@GK&OL:_Q&JYQ7Q6V\JQ9_.F__^K?
MOORU??7'#_[QC[^9CZO_^K?S_/M>RVG[&OL:]WR-/7#W-VM#O=]-1R_(-[2U
M%BVV7%B$4-1K<"O91%M!3+LB?[X0Y<=_O*C(YTY/*U)F1-(,J,< QM0!T;0E
M#XZEK25W5Y?Q=O_@>5&>R#:56F*M0J.C6W;AR#$V%).T*_*G1/E0D<^94JAI
M@(?8@9HV4.H)F'(<#5/PI]6SNE?/OC:47Y@XO-(R[\3A[5$^U.9="6LQ7KOL
MEC0*ZI)X0PA(;BU):]$GRF\N"WI[T.ZT%+^DEF=&WD)V92(2]F9)DTK2/$;U
ML-=5OC[$#S5[[!8E3*8KEPPT1@$;0\%RTD!KK">FM<(.T]:XN&/2EZ*RY_EB
M8,\S$AN>HA4;EH0*UW2C.;Q-^MLD_:*D[R.H9JY@'==^.PX@VAT<1ZGSKI<Z
MZA/K>8_IO3;67SJF=YUEW[[Y.\#Y6-3OJ14>WB![&$"%.FB><3>-I"1:.>#T
MSL^VK?).:HCO1GWO_6Y<>HFN0(NA":/[]%3FL38C60O>N$<?$G+:58'SG7%_
MNJ@*N.2,-1GH4W 2PWHO- BH47O7FD@?'J/<LS;K>X]R;;V36,NY"76J$C$I
M#XK3?Y5>=5<%3HGRL2J@V(?H4A(@!C(R<$6'%-UK7FGA5B;*98_YW W*SP8>
M5QKF/:=W,X /M0 J\VZ5BA!*3$ I(IA,@*47E-[3TNZ: #]3"]@ OU* +VUQ
MU.F1-2YM'N)D7J2S:?!1BJ&W1'M.[Y0H'W+^:WQ'@U3HHR%0B1DDUPS8?'I7
MJ1N'L9IM[GE_TWN/,K8B**5XH4HI1XTD;2BV&5D%JUMY[YPH7\[IN<<9%568
MMGG:9:4*'N9[B!Y$,FE:!;P-\^N#^84I_2MM\T[IOP.8CRG]-,_?>?QFR(,K
MD,< JE4@5S&-*8A%?7@,5Z7TW_Z8WGO<WW^M\-[[7;1\2>0AQ;J65LF=.$ZS
MYHQ%:HZB,E+>"?WSG7#A(J&?JK Z*026#B2BX*4:4*00,XY<K#X\"EWMK.S^
M@_.B/(;74<Q2C8V0@V7&/C13]%8Q[!W0YT3YD- GZLJ^]($Q(Y MX;V!",)/
MLHJMM^$3Y;(G=EX;RB^-.ZZSS#ONN#W*A]1^C7FTR U*5 6BIF"38FBN(9&N
M%K$S-1)MBM_Z"&U,6H=K[6$>W2K1J3=,J19OF6^TDWPW_[Y-Q \I_VFJ+3;K
MT +R=+P+@I$'&!QXGM.6+<MJ_<U[+.^>24]%D6K#5FLEJJL=O*=D20L7E("[
MS?_UD7Y1$<A-8["6P3414!D.V@2AUXF].O:ZE/OPPY(N#?IF_=RLOW@$]RK+
MOGWS=X#SL2;0QG#1:)#IJ<V_&GBT!HD;%AHV;VU>C3<G\<YOW>;?OOC=6T91
MWT)=X,_/_,T?V#?/VT3XRZ^>!@U^,)_I_M7Z5P^/G_[TGW[^XT\^_X]7Q=-3
M=RK!J'V-?8W7<(U=^-S"9M^[^$)59H\E%LK49!5':C65VJ-J9=H5S_/Y;_&B
MXHFB,^QB!&?U-??004=K(#&X>Z(9?J?IO>6==KECE#VD* .E-#.*M?L([-E;
MLCBX6=\5SU.B_+/CUD!U;C3 /"A0S05\E  E<+'.7(@7RKHKGJ\-Y9>*)UQG
MF7=6Y?8H'RJ>H3D)Y0QC"1Y1[@RN'=<$1)BHTIII>GB4-^4<.95-\=M>X^N.
MG'HJ/'&MI2_UH[5%LA7/-G3/,9V3XD-1,Q9K@[J!4\A 01BL3R];^Q(0+C@/
MZ#7ZD+::T1VCW,O@@"T,LD+*13VA)&U80L]6VYYC.B7*%U5+,HG8M$(T766.
M:9)751JLM)9\I* CKCFF+4/XVF!^H7=]I6W>WO4[@/E8L_26Q<7;M,QK*#&6
M/H/F-*"W>:,B=8K)'Q[IS66?_WM1LSQ?.G]+D]W,8>$4>!HZ-)=(&+-/&+@/
MS-5SS,EV7O]\9URZR.L'37E,)Q.8G>8)5\L\ZV;L@=*BU-9+;*O)JNRQZSM&
M>8)L.&0,:I-78RO=YWT/@K%02GMAR3E1/N3UHR;-C@XAM37^,#T6'25#UF"8
M2B>J:SEJV9N.[P;E9P./*PWSEB:[&<"';'Z6*AEKA(:988G9@&!76'J#7,B3
M+EWS\&9K"]X-P,_H&94^@M8FH782CC(:=62/N0QCP9W2/R7*AY3^Z*+$(X.X
MM&F+/8'YM,41L9=:AZ80'Q[3]0(!&^7SHAQRF4=VKI9R(ZMCTEQR*G4T,2&D
MG=(_)<H7*?T18B\K*.:.2[X[&VCW!JP1D^ 8@Q?,?/48TH;YW"G]*VWS3NF_
M YB/*?U<6I'4 RCELG0&:;6T&IBVZ69;'R1/8TB74?*6)MO29*_NA'O)[K2(
MREV[R2@DL8@\":FFZ;(FR6DWZI_PA*.+A'YM*U,P3[5$U6?DD=-T5FJ$;M'+
MO&6Y/Y4L=S/1/:/<.8<D;.Q:*/OP.E\#@V@$Z10\[H3^*5$^)/1->VJ8!7KN
M2T5U'KQ2R4&S=0^!9A"Y4+Y>$GFC?.ZXXTK+O...VZ-\;-0/H5"/#H,<@9(5
M4)VFV0<U+VE^=$4=?)9&HDWQ6S;(F2HN,?-B\UZKH' >L5/IFLK0*#NK?TJ*
MCXWZ4MBR&I#0RNHK@W+M(!12,Q;+(ST\BFP]HCM&N>8>FTETY4@XO>EN6*<A
M[B&M[/Y>.').E"^R^LF#&T>$7$PFS/,])<P0N*1$#6?H%!X>IY>U87YE,+_0
MN[[2-F_O^AW ?+%#W#IRB@8S)BY ;6T/:GD2;6'X&"GV2$OZ][)UYKUHU#^;
MN-@I9<6^%03ZZ>>???3/GVQQL7V-?8TM+K;%Q<X=C%F(V@?R2)4P=BNC:&^]
M3>,OBGW7+$_GO_WL]Q<U2XJQ*F>%&81UH%I\.FX4H64/)8<P\FI\CM=/+NQ0
M[+PHCR2!U0?/R'NEUEP[LS0OD=-\(91=LSPERH>:9:@5;9[&( D'$)J#D*Z&
M28HR(1]H?>D$[O:#NT'YV:3*E89Y#R'=#.!#I9)K0Z[6P.+JCTPQ@M;.,#QE
MI7GH%N2'1WQ#&^![ ?B9V7Z.,0WI@8L3)9(4$HN.GBVW_%=W,&];_&Y0/I0K
MZRB)'!5$^K3%4>MJ.L@0;6*<V^B-PL,CTRY7WC'*%9M136,ZUD;3H18S*LU"
M$QO,R+M<>4J4+\J5G5'G>9O!:YPP.P]8$ATS1H[4([8B3A/F>"GUN6%^I3 _
M/]U_G6G>CO7M$#X6*6-*#=?>PN#9@$95T) <N"+E+H&1RAH]RB=">$N*;4FQ
MF_DJ,7:G:C9J+O-BR;6W,+H,,[0VVL[FG^^@^\/E!%*IK:88@"4+$%,%XY:A
M<VRDWGLHMA10][3T_9)LQLFH"<?$E'GX]%F4%[2]Q=:WHM@Y23XD\XN%PI$-
M!O<"-$,0D)@JQ$Y.2\Z"FSP\TM8CNAN2GPTYKC3+.^2X&;^'7'ZC&09X#_ 4
M#E*M :Q9 "HTDA9+/8]5C'M&[& 3_$H)OK3%TK![+YP=C48S-\QIY!BSE229
M=S+_E"Q?+ G1UE@C9%FK?B0-T!$&C);$:R@8<'K5B!OE.T;9DU2<?MATI3/E
M:!:"ZV@C(')PD9W,/R7*%\E\:XQY30)G69/]*BNM7V>P7-Q2Z'&8Q#5[M%F^
M%Y:?=:ROM,S;L;X=P1<R8L:MI5HA*+9)\+3)%I)"$(I10V*/J\_MN8FC=\?P
M[LC?8F*W"CJP&M7>G%>_06Q:Q#+UQKE'K6DWYI_PG/OC12J_5R]&$J#U1D C
M*)BX+[%$[-1+&(H/CRGN;MX[1IE#&X5;9TY,+:&6LM83MD)A4&EAY_)/B?+/
MCKJ J2[!6K <9LAA@T!&#) U-PUQQ%IYHKSE#NX'Y>=CCNL,\XXY;@;P(9DO
M.7-"I!5B*%!/!I82 ;N+U1)8\&D7H6Z [P7@2UNLPX5C'HB-R$H4;G5THM$E
M:2YUY_)/B?(AEV\X.')%J"H&Q.K@V@9H(+5IIR7'_/ X<=\HWR_*%IK&9EB0
M)\LY:YI.68X5<1[G+>Z%W^=$^2*7SZ,V4^S@:\TWS0@)G&,'B2$Y<W=L8\*,
M.T:^&YB?=:RO-,W;L;X=PL=DOJ:@A>H,BWN9]E@[@W!&2!/LC".RQC4H]^9,
MLS7ONX38B87$/OW\'S_^[(.?_OQ'/_[T)Q]]]HL/_O$7/_WXL\\__LD_??+I
M3[:NV+[&OL;6%=NZ8B?RYYY9W1A3]F)6R"/Y0/'8YU-A,TJ/;=A?VZ&\@[-W
MX-F%B_)E<RN8\HS%K#>@A@TD" (.MQB8!F=>31HG<NLVR6^[9;)[ZY'+Z*E2
MJD&U9>J=2IOP:NN[>GE*D@_52T_!YMTIT-M8FQ?R (F(, JS6_(1<#P\IC--
M3F^2OP>M]BOM\M9JOSW)QYFD5!)):!/=.DEVYVF=)4$>E4L,/?O:3YB>FTG:
MJY!.B_%+##*-H=UR3*%12>J<3*4%&9VUMK^V1'D;Y'>#\:&$2:3S$(X,@7*>
MKG4,8)P->*18&AKQFF#8%<Q[)IFG5TW3["J%2L[F0@%;3C.\&EHY[ KF*4F^
MJ&!.EWIZ5>J00AW3N9ZQLA8+@*O!EZ?'':T]/)9=P'QM++_0N;[2,F_G^AVP
M?"QE>L96JD8(*:]%H]U!ZV29)ZG#4[+1;77LGV73Z-87V_IBM]-";2-Y1:P#
MA2BASU"T,1JCJ@[Z:WN4M\/R#@XYO-P6PF*!>(8>N+HGDPP0[VO/0!'U*M)E
MS-#C3(.7F^2W79_CHB'D/%U3I*')R;O&T'U8P9;V3-(Y23YD]4>.GKGU&6[4
M#)1G]#'#D)7?#\S"5%Q7$N'JB89-\KD#CROM\@X\;D_R(:L?.7!N6H!'(2 9
M&63^@C%/Y]"72!SBPZ.\N50T^>Y1QZ;XO/;8PPB40JOS5I-,QVR>WBDZQE&#
MMK@UQLY)\2&IWUOBV$.%BJM?9E@$CRP3:L_SWHWN7!X>,5R="=PHGQ?ER,ZY
M]&F+:<TEB0E:-_,^(F%0WUG]4Z)\D=6?@;$$:0FP8EQS200S2AJ@S2E8UXS>
M)\QQ"P:^-IA?FM:_SC9O[_H=P'Q,ZV,JR(5I30Q/_[J. <+LH)'&0,[3S?:E
M_OG,B-([<;!WC_Y6&KN9OV)HL>&(Q2FV><)1MZ2IQ?EGH=VJ?\(C+EXD]<6R
M>8XT8PUT("D5/">#3BU$=_0ANGL0[IODZ:)F&_-.=Q]4A2TC<PHCCEQ-M.ZD
M_BE)/B3U<PMY_NZ0.26@2+J441&0&WNV.G'FAT>]NCRW23YWV'&E7=YAQ^U)
M/BJ.Q3"R<X2FJ#/H6+U$T<-\4R1:EYQZG$&'7!5T;(S/:Y";#XM:?7!!2E8U
M-":K7G-4<]JM^N?$^)#53SHQ)AF T66ZUI5!FC0H)<S;V!-Y65G]O-> WS'*
MV351TVZU#@HU:J0@-6!$1W,<.ZM_2I0OLOK8QEH77"'/FP7DM8 O)<&6>C;2
ME+&VA\<8PH;YE<'\0O?Z2MN\W>MW /,QJS_OGE?/">K0"A1R \VQP/2L54KL
MU<K*ZNN;R[37NVS6__/W^O/+]QM,SR(/M*^QK_&^7..^RFSE6;OX0_NJ??'E
M[^RW]=]_95]]\'<?_+A_;?[EK[[X[;_-OWSZ];_VK[[7 MN^QK[&/5]C3^#]
MS7)Z[W<;TDL&[[*CH@>J'DDU68K$)<X?O:$%W8-W)PQ8^*)&[X$E-HO /,)J
M#\X@C!TB)XV=N%%9-7J^6B9Y=Q2>%V6LK<0V42UY,IR:66BEYRB!V UWD?Z<
M*!\G[]B?&BQ@R2("-<^@B1VJ4!/$DACS:K>Y.HVX43YW&O%*R[S3B+='^5"E
MSR%@KT6AUY: E-<RH0DU>A(.-:7<UF*_-Y<H[]&[TU+\ H.<M$54Z=QKH!2'
MD61E"\7"9#N/VQ3IQY=?_9M]/1_.'[[^P3QHH'WYM!UA?9-MK5^,^"^/.M84
M;-0  [,")8[@S 6PQA 24BF5'A[Q0XI[5/Z.21^.T],.??1(-'!)7H@5#Y(M
M3M-]H\F\3?K;)/VBP-]CQAZM0AVY =5BX+DW&'&$-B1DM+Q8Y[)9?VVLO] W
MO]*R;]_\'>!\+/$SL^0\37?IP;[1UG15 1\IJ7@F6=J:^N:R'7[/[;U2.;[W
MNXWI)54!"5A+;Z6HD8N:!\<J,XZU-%+%714XW1GW\]]?5 5*RT&4 ^2RI'^F
MWPENTR1AZMA2(XYC=23B'OBY8Y1;7-I=91CV1#J=%(]>2VYAJ.JD>E<%3HGR
MH2I /07"DB'-6PB4AH):=J@H1M$U*J>),NU)@=>&\DNK M=9YAUYW![E0U4@
M6<FU<H58"L*$>LWN907'A"49]5!U27F]N<PB[-F]TV+\DF'Z&1.VVH*G/*B;
MZR@S2!S:U;V)TY[=.R7&A\S_J)AS3@2><8W[E ;BLF0V6\WH->6EJTE[S\X]
MHZQM\=F1M30B:SZ=LI B>1^\3O8]NW=*E"]2^]/N8HJU@TE0(&T(%D6@5ZG>
M8TC-9<(L>XOE:X/YA>[UE;9YN]?O .:+Q'ZV7LNH,'UI <IA+<W*%:I%GI2K
MV."'QWP6_WIW^5\KR/=^ERY?X*Z4E$):ODGCZ:X,T]8C#HN1NY?@8:?USW?"
M_>%RRTZ)$M@Z^, !5*B#%"\P;VVJ6FHAKP^/6K9\\!VCG*+TF,?@&7Z2*UIM
M0ZPH4HY.K+=)Z^^.H[?)^2'GOWS001X!':<?,RB!UD[0O/BPMCK!G_J-YNW=
MI+\RTE\8EEQIN'=8<GN8#UG_M0R-4RG@L<0)LQIXZ Z>,))&=:WQX9&NTA/9
M%)_77A?ODCMG33Q(>Y#HE>>+HO.(A7/;LP"O#_%#12 K2U7*T(P1*/H T1%6
M1< S.Z6B3_9:9'OF=TQZ&F.TT)?B6Z=UT'LP=,H#8XV%;J3GMTE_FZ1?BOV-
M$&KE")*P 'F:K$L.0!+GLTPE4;:'Q_AAR'O9[6MC_:6^^766??OF[P#G8\G
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M613M-\9O6X(M*L7&:U!"*,5@U$*CYC'G/H1N-!VU#?(+,3X4.%4CXG !GK^
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M3)3/N\)2%JM*(;;4 LTX:0;*.(D&*S4A2K'T\ BX6SQO#>87NM<7VN;M7G\
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M:5Z_E5K'Z$$KP+3*-09SCB$:T7PD5A$V'ZFA:&/\VDM2%0PC1D  @DEQBQU
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M6M^D^OU>S[5'^%_?JGT_2?9__.SO/__LQS_YSI:]ZBO(\]C]'B_B&1=I&<V
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M]!D,!3*4P$OFTR.G>3]-L*<UU'\DA+>BV%84N]Y^D"@%"XLU+33F!]RK@0T
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MES!D<* N>>U6F4\RE_DO:5G20KE>''ELE(\=>5QHF7?D<7V43ZH"&7IOHZ0
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MY#IYK7C D41LI;7<F":2\/20OA!)"!I;:[%#3-*42U8M,M9%)+'7VF,O56Y
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MEG,9;?(J*DN8,89I)IM8R88A>#%6HARSE#J*@M2@3\,F(8T90U[FXA4FE:*
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MI28$\\0XYG)_?6>P] Q)V&7$N:3(>BF0(98Q97G$Q&_M<-6"KS:#:38*ST,
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M#HP#6/!LEQ<Y;%4SR%&W)KJ2($LJ[6>U_2S:C\ !\LZ-IU;= #0[.K^HS'W
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M'CPQT=!@7* )>T8U^4:+4"H;@,Z+T01V8=0'* $JWX] TPKMTE8=B[,*53-
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M3SFW:UZR2!XKR"%32KWP:%+2L)0F,I/I]!2TPYNTJJF:L4*U6J%$7JMM%3_
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M#/\?>U_:W+:1K?U76+FW[BM5D0H @EM<-U6T)#O*:(LD)]?^XFH #0DV27
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MPH.7D!]#&3FZ\HY+_2MI,X%;KX+@5PR$@^ ^!-U&.D0=4*5:%.2:'29AI=R
MR&!Q6!1E& 2XRB:!HI!?\TFL1-N4:\=4XAV &GFCF $Q)"WH+ 0+$<N"H7'6
M3DUGXZS#*6+%N%A.U-*:'B-B0<H/E^IJ-**-]&ZDN:+L--70R#34TDTEJBL
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MUKGCLKJ#M:W,9UI14TMZJFM)7T^CWZJV]_=4+9P.3J9G+F::?[G*EW4[\)7
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MUR)*."FP"#.TIP/V%EK3A:N0:/#I3*_?8>D([63E0HM]HL!:U!/1L8\^0R5
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M_:$<Q;T@")[W_SON?_SEO8RZ_5X4^IU>?]COA+#IG>$0B"")!WXD^J->'(3
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MDT'6$WLR<$TUWBWS6:3BITP-@ ?]1;U3,SP#;\PTACF!#+WHUSA/F))1X6P
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M\Q_94_S#Z>SZ#HO[' WGI[^;2=ZC08+,"[R4 +4737D7@],-;(6SF/MCW =
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M?GPAY\ PACQR@%& FQT0\F+O)/MR,?#I^,"X@,.X?H-RXK" ]7VOYX?_Z^&
M4(F.U<A8_8F/<S =]@!_(?=WN-9G-D8&TK.]LHG?;]3R?2K -7@")>P*"?,P
MB T<X\ B@4BS1 DPH /6=AHG(>YHB?!#5Z /9@D^Y'H1F#1 ?1^@C(317<0'
M@*(,S!\G#QT(%A2Y"_AQ$6& X1;7,Q"+H>3#\&" R*_"QV48<L@VWL#S!<F-
MF8@?H/P"^SS@VX(PJ/=1J#E73$O[%9Z$4<$+0=9A>>!B=5*&89R,7>6,"*+:
M2O,#J+ H[<-*""L:FFHB3)SZB3?R,0[B\)'XHJK\"M-1BB\ANTY_^=E'@>=
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M\AQ #]94K)08*R>=\Y_$5W_WW(C!(BG^BGF>J=@N8,K)[W<_J4H'EH[\]5X
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M;ZX5^%6Y[_QY 9?^K=Q=_'9U<7V_#U/*_#K0 KT0=3G[CFHUYOUQ3_HTAF=
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M&',\=5)LU\';0^L;H1LURRS;&KLL+?;(Q3XX?*V:;:T9;R1\Y<?7:M8LPO>
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M8'.C(!E3YGDN!)EV$M*=:UL1+F5#E+1ST-S#+BQ2F8R,U[$()*Y8S<">',)
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MZ!T@K;1!3)[O6XF.M:^*=&^*1CXO4URZ;#9%)-\<D0R#>N8H%7V;Q<%)<6:
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M175AU-WH0>#9H4)4%/;((G<3NS\'J=/+<S;I]3>79<P.RV%SQC!*%-:/>-Z
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M+@HY(&!@CG!*>27,;E[]L:U#(2V/*GYJ+*C"(T:@'7R';(0UD?Z2_KC\)OP
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M;!I,>3 =IGS3B_Q[^,\@'0W_]7]02P,$%     @ T8']5/4O3.U#%P  2?H
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M, G0OP6_W9<U].G;V%B_&;GQ&VVQT5+-^%D *]V\%;=_E([Q&2#R#7@A?("
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MT-X1X+OE\2L+]B=?2LNZYO#O]L".?CYTI\J>7 QN@ 'L9C.]HW^IO.6M!-P
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M3-92 W(T%T4SDEP\73-IF,X">(KT], 9N!@U)"5**+31%MXZ[6$;81\JTMY
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MVR?/8SO4-6+^IM2FS\OWBUF^6?'@M;5<6 BZYGZ2(TA.G^6TE"++A"U(9S9
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M/_>[X21;=-X21UQQEJP^SL%)5Z#4$*\N5F-NW99J<W1[7\$<3OOY)H.D;R6
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M"C?)62-;U^=O!7!,!XT[L^1V,L!0(FJ8;;*&^.NB^^VG>:_2EC> I:QS"4R
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M$DDTQ>O4O/G$CA"?OJ[TR4D/R=>O<)HFP\^+R/A[3-6D&Y9ANHB5WUC%$OL
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MUX,Q8CI(CW[V^<-"9,%,I+*TEW*SFGM!K$ /7R6>,K*7P8D&S&[Y^ -7@%V
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MXA77$]]*%AZD8#=[TZFZ33;^5GK)+ZJ9Z0?Y\471Z)V$*\11#1CKL?_R=I0
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MP-6.<CK++X/VSDWIL;^2+S9UUI@F7KU:^7/ LE^PZO>45W;S_EBLBN:I<?M
M!=NOVW?S#JXC8H<@'? GAO^F51CZVK!6RYF2K@,NY T>WU&!NAM)T*^HWO>K
M9X=KU<6G"S+U^YN_"ZP6<WQA4]V')@GUA+9\-,V0(<R3O6'?#R&#']ZM:8O$
MR$$'"F0]AN<]'R]>?EO;CRU.\D4>N#4B'>^R7>9!Q>UT&!.)!F"Y9_"#4R;\
M]&8;K@$XQVQX .T @T;.L._FIBH/7,QD1:3)UV0.>_@T-_C99H2>RSZ^U^3G
M-0RNF0S>XJ)YNO<GI>:)XB#F1 QM/S90LSPP6*;BN,FQBG'YH]_OQ2&RHD5(
M0J J%TXV>NN(0"3M@--VJ!==FQO#P["E>7OXV;=0\:3"V6FN]IZ>#Q[W@XYV
M['@SKPK(?:9J$'8B3SMC[D\A8#5[H6__F;E:XCI HV0I<K#4-MYAMF*,<9;P
M_!Q0VK:F:2KM9164$M8$F=8]GI7UUM [F<;4"('.DP0CR0V]/,5>3G$UG"[]
MT&(\!6 %9PIV<1TF[ )9=T_\/3:I$^<B]JMVKJ&^KME%H.?F_.4#Y?/))HP:
MC6BIL<^ZRT06FB<G-?V3)VL.B14 Q9#(Y#0QS5L=S :RIB/O_QFIS>JRI=WU
MI*Y-#OU8>.0D,;BMO9^JR7D;FNSXF7SE<OYF(=C%U0T+#5QO.-/!/(=13:]-
MF']2SB.PG=K2$PB">L:.J+;;PC$:=?7OFP9W#KI2C!T:9V+LW@E69.DI25]B
M"KD+'T#@WSEC4@F 5>]X-R0JOY%'^$F$*Z@T0FW 0B7K#C^ 8F)*<XV%*R91
MRF/<8U(K;Y)*P!HIWU;2]DI7H>[+/)RIZZ-G\D^8)_.>D[NQ$KDA"O(M)CV?
ML;0PS:2+@/EMQ&U%R2AE,(L:\:VW_!BG?HF?NR/'U>]J48*4^>>=>1YYK(.4
M5/EN!/Y?'Z: 7(?N[ 5WI]\GA#HE$#:UHH+7B/<(_N52<96WV&<XL<!,\<O
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M>.E; 4MN&[]864=(_.-BH^P@R9)^-*/ !=]/:RT%;IP=, A7LD"^^M7DKQ$
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M:<NT!2AZRV,=,C6V/JE+EN<$M2T?;C!F_.":VT+VM HYE5Q#7AA@89/1(IJ
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MZ>LMIM>;+[Y3<CQJ\97UAV.5@K4;-F>@$N6[17GB_B<B(Q.RS6:O-.O]/&/
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M>&NAU3X26+KU_-9R:\8RV+*I20U?\J L0<+W96!%E+%DHJ-&)&0(_J8M;'T
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M<FMG6Y*+[-M*%;];K4M6C&_V#_IX1L+BCB0A;[!#P*>7^#@D#T.6XJ12* #
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M]AK)/]^\4$5;N_'.7<[C\($8DW/GRK7^K66___\*T@PY#-L(@$#V0#7C-_=
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M;Z#[SG$I]-;N5;VT28\/S9%2D1,W)>V?6?S,FA5<;>>*I%_\N\\GBQO!"1,
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MPBKMDPE+9P-KLM,+WASIY=C"YK]#^%&V>]#\YF048%2)%/&>$ZW+,1J3LOW
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M&!_^D7!6G"H$+?RW/[C\O_VOF;AP[C]02P,$%     @ T8']5/6\OU"-/
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MRJKJFMJZ]_4-;>T=G5W='WL^#0P.#8^,CHU/S.()<_,_%GXN+I$V-K>VR;_
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MN;S[_]L%]" _9 !IXW@XA1NVA:DOF45/"-!-/.)1*W(,8 ![@;A)-[#$MC*
M.JE-+!]VSM:0BJ+X:$S(Y6$=8- _="AT8?UA$_4P5__QB5]X6DN23_AKD[>V
M7F>USB;^4+C8T/#,Q<A/(M3&E;T >5?7ETWXXV829R>V=CT2"2><CX E:(N3
MFI/C27#]_J ICH6V@8E;[QH' PUR"&9IYXK5Z4;-:?#CYB=NE(?$^"%\7!?-
MRU9*)ZW\I@0:'5$-Y,;!;^NY62,8O8DI_7.%$64:Q8-F\?[NF+*6TKRF+'),
M%+F-=+,8&H6ZN2^@+4<@4OS(G=<@MC/;+3OVN8(J6TUM3?)%X/[S@FR]^](7
M$A9"KTC1N;HI9E0$2'N%8 "S#&!59=;T6%\7FH=Z!Q93DV3=_I9@-FS+YW@S
M3E/&WF=/[\^/8XZ3PCGJ+^[<R96KG@\[YSDQ7$X)L0H_J,!J86/D(B57(^X(
MOYX3/^E+.5?^!GJIWP8NT&2"AW BSX\@36=5>,S*O<G92$S!SY'VA9;&R3CG
M/A;62Y8F%=SW,UT$^;65P4;2&3K/(^*YF84X;0WDQ5&4>XFI5+N=X&Y1,;<A
MI@FOD:_LHI.4)-_5R?+.YD%.P+7$[G;.TEQY!<>-DH*FZ>@;&SN$P$2"2)BR
MQ\W)E1KMM;QZE?O9V X&< #)3T3':9^VM9D &QA ^TB6DU3UH-*TG!)&.M[)
MQEQBZKZ!RXL*6;\P?,/$RL/A2_)VHZ/7$@HD--]/DX._R>4EY.DFR+V"?#-C
M90 ?L_(9P)@RC@'HEWE;P9G8-V?"=/<5$7\&D#=2H[!3S$<-W<5^IN>T,X#&
M]OX('7U!JV.M^H)76?Y5.%4(N$0&L"]"=+JU&$'H0#MG_Y"2YB)K%GY_1=!,
M$MT?[L/Y&U8C_@:KUBBJ-W.;-QE ZJ N WAGSP!^MCM!X$5S+T0R?M@Z*IK:
M?C$V7ONJ/E5>@7JV$QS:-5YN^]RR;>#A(9<!:XN6GF4OE8\4D[_H_ W5XY1_
M@6I'!D!Z"]8F;*/P4#?LYD8Q#DJ_L('"'UU ;:ZAIU3HE_]!!;"_ZP_[9_?_
M0]T;(>R(Y38LGYH.'L;IC;Y5=:K:Q?\(82?K=?OK\S2%37)+"^T1;"Z^FP$X
MFZ30,EO"XM]?4^ZIQ)5>??&]/NU7=FW=JF XE(?DY_[R!\H:LU=NHVZM*"=S
M7197L7S=7#\"&1$G:*X/_$<B1.Q;Y6( ,E4=6+(@:A$>8-T.JY:E9O;Q,P/$
MG $41CR87: FEJ"B&("?X4*$%.IC90K( ,@C=ZJ9([R/T/ZMY0ZJ6O8#))H!
MU$!::3XS_EWG62F&%T9].T)NET9+)V5$=:OY:1KQ#3O:#QOH'.3<G)S!=/:E
MX(B7X G3QT%_4LS2)E[V@RII?Z_>>_#1[8 21##9$7HY+""P,9GB7I,V C';
M0A:UUXI0%LAIH"O)!&\67>U%YT'JOB/BXI&:>'M?URL-P]6C#=4-? 45/3ZG
MI./:-%V>]3^[,L]YV(,-P1G' -Q4)D3(I2TD7#MD0KNO75*,*%E/@IF,-AGZ
MOG)R@)OA-4JWDB3X)[B.Q?#YWQJ<@)S2E33M[Q&[#V30P]3;1][$)3EHV95!
M8TQNEM+&4<$4W/67^+5P2;.X?#/(69MGQ09P0:?%:>VM>YOV/IX3U1FIVRH=
MS;)XY?J9QBF%6;,D-1S$)[W#JM=Z.%!]R*56FJ_QH^WLM"&;.ZG[2*S0A@>5
MOZ\;)]D"I5J"%10>^J!81$HX'LVV= <1K>659Q=J@K\49)CFT?!>].#36NU;
M^U4E88$\82D=JPKDE5IP5+B9".]$\:Y1.96?';)V@I(<,U9$OCG$G"M,QN,0
MMW6@"G*LHET1KF7$,S-LV'U-SOB^1&T-$J\8+EDKX/0;$L<;+Q??LE>U-8G=
M/NZ^?"%N,3(>FAX>H3*I/<!;67>[(!_"XG#DDU#Q*PR YY&9>TC9RJ#5O7-D
MC47+0CV5-\9^IQ:,NG#\:3XA;BOYG[-#K+VG^HPQ+U'^0@P@N@2/BH95LK_?
M/$IB $F$(:HY%Z7LU<])_[6,BH^VLO9RYZD;"M]@'BI[Z8,M MHGF%5*!EB3
M!V)6Z<H-]<00LG9R+7J\X9QK3TV6=_DOI[M7R-NIFYV^G#,>\6AFYN1<E<?3
M+-I\I(GZ63%-(JZWUMRK'WXW"GIM<L*=&Z.8-VS0AI.I7&";\8TC/VTZ%?G(
MX<NQE]5)V\W/IQ3\AT6=FW,$A.3KBS\^-X7;VD_5#(PWKO;G%.L+6H<N1 N:
M7V!G"O15#B<3O54,F>CMB*4_LALJQ?XYEUAO7I$"-[=1SVCGF:@0$IM'C4R0
M*S5E7E[M^5>!9#$ ?]B.A)H*A1U+3SP]L[T.K4-3D[-%:)%,)09BQ'NT]6C8
M7$[[+NP+NN\[$UAD)*6&48MRS!RV*["P)T%!M:O!JJH</&/UC:I9*G'N:M.@
M;&3[58<?(QY)&3*B].4#N.AC$]9Z"5>,5+]0'2E!])X(=C!16Q110D#'KJP3
M(A?7UPJ'7"G'7LHTU9*:1%37QOV5EY\2DW4 ]3M=X3R.X",B,\5*<CS'A\0U
M^1>,@7[3'4YFF"GODX79]H_W/OEL?[-M[Y&JJ-1E^ LX\0HL)1O6ADV4W,,
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MZIJ?M"C%1KF\K2+J&Q\O16M- #N/Z-P9%#[JT4'L3!ZZ0C8)Y686(Z8215?
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MGB829K"MN*@*G!XQ9186TZ287=@]<?HT\4>TOXOR_,*OM#AS9-<<$QF^>/C
MJ\Q6YO&F=@MP$N0#A V'F[X\Z.0T#5I\M2U.3;:=FCCUN6/#2//TI/D%42=.
MT)'8-YLH(HS;UR+AZ229O#I<3OBV%><K?/.J;A;?\;7# HE;/:5)(61?VLNF
M:Z4.8&P'#J *O5X227OFMXZA*GFI#=8O?5T_>%-VZ,6HESX  "?^0R_X_[E
M&>/_%U!+ P04    " #1@?U4%B',8C99  #\;P  %    &IN:BTR,#(R,#<P
M,U]G,3$N:G!G[+P+.)3ONR_^"CE'SA%3#B&D<JH<)A62-$DY,PDYI>G@5,:,
MR#F$4"I3(4I"3CED<A9)SHR8@Y"0=Y+Q9D[[[;?VWFOM]?U>___::^V]__]]
M7>MUW6-<\[SO<]_/?3^?^W,_SS.XXUP*(''"RL8*X-G$ YR'?P#N#V"+A0_F
M@B_@"\ 7#W<2. ILXOES_7G=].?BX_WSRL_'Q\NWF7_SYG^(@) @+ *;-PN*
M" H)_[G@=Z(BPJ)__OCSD'^Z=1,_+R^_L,!F >'_Z8O['M@JR'.%)X:71P78
MM)6'=RL/MQU P#KR_T,]'N"_7CR;>/GX-PO :HC #6HD8/5Y>6&E^6&-X4^C
MX,\!OJW\DCOW66R6LO<24+DJO?]6QE-!U2.5+3)G!D U_0O78H2$9>7DMRFH
M[]+0U-IM8&AD?.#@H:/'+*VLC]N<<#A[SM')V<75V\?WHI]_0.#UD-"P\(@;
M-V-OQ\4G)"8E9V;=R\[)O?\@[UE!8='SXI(7+]]45=?4UKVM;VAM:^_H[.K^
MT#,X-#PR.C8^0:+29K[.SLU_6_A._[GZ:XVQ#OW>^&,7#\#+\]^NO[5K*VS7
MIC\^$/AC%\^F\#\-MO+Q[]RW6=+"7L#KJI3*_EN"TD<RGE:V"*GJGP%E+EP;
M$)95,Z"JT_^8]@_+_FV&Q?R[+/OOAOVS721 E)<'=A[O5@ )0.L,!#N!"UQ&
M0=KERQ_H9*IU:_ID8[NR(!>XK=JN$,=L+J.)G7(N2EH[^-2YP-E7,6QF(4U[
M21RZ/<D1?L %;,*X0$]\/1?H*N$"L7;$62U"#9G=A%_X>9/->2+^'O&W#1/M
MB)07A%^Y&%9)$(%UDX@O^<^F_]GT/YO^_[1I:0\7""9#QN$<83?F5LX'SB'V
M*U,'+L!_LFG,@ ML^A;\PF/A$*[\59?AH/;+):L;M;&KH>;9;"VG;@2(3O]]
MU&]9B OX<#!L)1D OP,)CB)JC-G;R]O%63KE1&A9YKW]8021# ;4L8KT&8U<
MH"Z=;8Y"$T<@7BZP^2&^QP$91&1&<(&AKVM,]F%^:?M_%DL\WKO(N?]E8&Z&
MFYO;D<$O[J@=QY(-^:KTE:4!(340>!$TAX*T7FW,=Y!YH.L, )1+PAB479^9
M>WKU6>#&Z[SW[@'*,C$[C1JQMV-D4BMM-<=C:Z-.?:%$6P(8+M!R@ M0GG(!
M6!'*<V+5VMBR.*C@XF1;10\K??+%U;U;=,"LJ$WGS $@>'4YC_15[YS;W<+,
MPK%FIU4\K'L_*Y2^PI(2X0C/T$TX0ON81[ZC+];2+Y=>+W1]8'/<.M%@1M6U
M7_F'K$FC@Z;#Z)'1@GQM!H$CO  /K@+8SY(<8BC3]9:=2J&;9D&.,1$AY8+?
M]$]XI]N/O#86] [;GCAPQH8@[[U]C_0/E6CS!\^(.W [.>-XT(-P:UJ"G4D,
MPB<026AE4R2]S:ZJ&2H#9PY# ?ZURMN8UUS=)RV#KOH)D);ONGWIR8\:'NQ4
MK]:9#[I=;L\%8K)AT]UQ1M\0H /Z-AFTQHRG. X9(!4C:!N#& 3KZ'!(-1$O
MMO"S]-.%ZIK<]3,>43D:CZI;"H3I8H7U/@!;]QE1B1A(AG836-+Z#!7XB6VL
MG?#K.0^L]R +0T4GXHS!5(B^GHC5]A5/W)P:A0N^_&O"\M%I%Z/Y&/=3.0/=
M)9#\I0-C\#V+L"XN^,OID ::)8V@$%HPT4B)7T8@OF/K1=+KK#+H@DC2I4GF
M$1.78_JIY34#L5[K,M?&34Z\C,;5.[4A04<4I%N7@*3 -BDV;V%M&T5>%)>*
MH'.T U&\@0J&4)WL5AWP\#%!KZSE.I-B!\:5@2M.\[\[L/.P$T[!_;_A3"$J
M42S9=8K>$A)LI"DGA(/SM([UV_,C2X88D1;UJ4>N\42CA]?YC$6JE_>UO'.Y
MY1L@KK'I);ZE%0V>)4S:<H0&F'Y8"1#Y/ET>NKS2AI=XA#+/I:$%2-,V12B9
M8=E/C"JJ1WAA.VOR@7.M8H#P$T1Y32_K"E3@!R(IY7?,#0/-E8=#(_$"$/KT
MZ/Q@2"*VMW&XNC8S+(:/H^5N=<ZI<:_,[P)87RRL;W]$%<,:_EV W<6.72M/
M6\?SFRL&34LKS*=RM ,X,E4C>K=S)3TM O@"HD3!HY?>3.H]-,Y2%3=@MVSS
M_K&!Z4!-KK;@*\J7$72_+BY0[13/LGX!&?6?INNU()+RY<"17(9?HH&@*3(X
M\M+*INJ,#\VS>S(O6F^[Z"VEAG,&E,196[,XPKV%L-_07,!/[/H,XP$H<@["
MDL13+GZ>'RH/]2JQN.8H_]S%JUZBC3C[X.CS]_9O>S>)12F"7&!FOK4\&;_5
M- BL>^^IG7!FU%SYNVRM\IYX<G9%X]LZMWNW'CZ]>^S;1X&I:9[Y'3@7?(L*
MDE*(K,/#D<81G&<>QEY^!Q51]?@B5EL.=98*Q(>R1=Y+5,L:@0&.ZY\<!WS3
MC![GVX3US&:[M!E<"R9AD1PQP<_$H/([>''<;I;; #(H=+ Z,CTYPR-BW68$
M*Y]76T S>1#,E^DN9A5Y=_3GODLY_D6]OFG7+ '<;5PG'G3#;,&-(\&S>G>0
MH)V)^$1"^[326^B,H5*S?C-1LN.%HG9WF?I^M\2S)+54S0CY#QH/E84$C[LR
M\X@[B91,-'A.?-*$$0=[["L6QX[F'(IXV+I!C.,HNT;D*>JZG0)3W\47E)AG
MEY'&77NOZJ"QO_5MLCL_N]WA29YB9^(I)8@:.#KU.<(:]'(X1%\PCQBWP/2-
M*%!=%VLU]DM/.*#A=3'-[O"489.30VV1*%V]P$#_N$J2ZMVNBFTR2;MY-NHM
M<9=@9\$@3:E R,"O+Q!B'$U</U+I^5#3/CJ!ZCLV'HJ0@"Y^,.][8:':)WKS
MMN-0PKD,];@<YT_>)@6^PMN?83.X -]SV(@Z?,LE).5%OAC$!:C(+:PPR(LJ
MLA*?KU0W'(SU,VY;J\^?=D=+U\3T?W2^_\6P0NSJOHSSSFD[LHOX 62X?WD/
M"MKAQY(E,E+8-4C*8X)"LS%NY*9'77*3%V@N4KJ@5^UAKJT5RK0H[KLA;2>Z
M6\5FW:U/^=O V?CTK]T7IEU@-69@-6HYDUP /(.:6'&!LD 48^6SXLRGK/)W
M<^^8!P/-@:&=5>;*;ATZ))T.RZGVWH#ZI@\7WVZRF&VR:3AXGY?1T#3$J&27
MX81P'02!'^:&V#"Z=&W>M>FVX@77J+@J=_+BH3O+M634FSIT'FW.\?<9PU\Z
M'>=<$HK&:.O+H?2V<^P*/&6)? M1&48,&8S0IIR[G4<=E)\S'G,[^M#)MO60
M'!K*>3EO8OI<E9\4C40W2T*$KF8#*.HY5$I#MV&@8X8IT)TA*'C-?Z6HXDA[
MU_;!]F?Z1GW-%SH]MO;N_K"[)*/A$(L"<^YL).4IH::?)27%< 6MEQ%,S8AU
MVS<-(TUXN?BU8%5W\)=<[:JU;NKLX*>BBF_?@XUFKIY!/%'5F"F'-'-9,BL<
M$5NF-.<CXLT*#*X.T"Q(_26><I,_;KH4+#\)J@6+/EE@C%UP>_@[Y63_M<S&
M-VXIH;7JW@Y&0]H [J<]FH &7=&0KBR<(_E^LE-QRBQ+2)TJACP#I=-?.^LV
M*R]L,*7\SJ?SG>F_<47B1;:7G,2.PTYZ^R7#2GE;H+H_C.(([CT\>8BWD)7X
M+B+I9N^,TRUS4_^*@)^+J_YY'MGK"4TGQQ 7456/C>2]([6>9_))?'IS,N;D
M[_Z*!( M :705ZFHUG($)$?%I+*<Q)X3Z:IN]8--B"+V0OE\767^QC7I:ZII
M(N$Z\[/\!6>NJ\2.CZV^H!-/L]]RX,34,M6\'9)YP1EGM+5/RT?>QPK1 IJ$
MJP+RE:H:P%<;*9-'BPRG1W]K1+A:$2)KU2]<*4$^X0+Q>7II6!,8K:P_-^^"
M:.3VYIW50[04%SK_ZS0#:$TD^NV-G F?NX?E5RM,@A>R#BO><YI#L:2U.<)3
M]%:XV,*T$B!5Y%( K5%/:#%?K;ZN'LJFRP8KBQU9.5X7&:!G671/;N<3*<7C
M34-J ]T%_8G\O]WVXOK(<#)+1_+B*;6>ZG",[^.,FYO4T9?C"X+$R&WB24/^
MHZ2P8K7,@*02$=TCV@;)(S_S0X)T[(^=S-AS]O<3*YX59&T"2X9)G5_J8P:P
M#.%'7&?MA4*:#T(=]+V%M:[G?C2%E&E;5WMIV91C)*?GCOE)G' \\"0C\63M
MYP]$V.X8%+[E>),EG&GV0U)E6&=ZPM)CVLKM0W4)3:@]*240OF.SS1D728/K
MZDT_+7A/%.!&-ZMI]E@(E.'VX";(6_"!?'#(5G(0$7OPI.LG\$J>_<_-8V<R
MP(U]F*)6AIR8J%TQNS2X)<VTT[GGX8>IN 7T ",=\\(UP*BVH?-9'4SR5#P\
M"I7/].\XO:UU4]CF@R;7KC[R^<R?I_DL6OB_R6]>C@B="VA>8C]%+A'ZN$#!
ML_+RQ:_BD%X7ZVD5XS87>(,WYJ0E1R/O[(;;(_%$RA#F]PF_Y7 N@$%L8/.)
M^%)0@"-FQ 7N/<>-X1GPPXH_+*YO_',7L&A%9+7G*X&8A/(F-QH;UWMBL+K7
M9D^-+NI,PW'=Y1VIMJ9ONK_J^+\4D;T  )E!J\4,.RB=J8EO\> "ES IB.H]
M&4P[**UUO:7A%BC79B?00MB*,1 [@A%W[>(?^5'V==)6>J@E$K]O<B>_Z3OS
MR;LMT6Q56-L'1.@0+^,4B%HR9E[&ZK#+8&I-3E-H?D'?'%!03]=]73YC4],7
M>7(D9+3V(6IX5\#73*H]-2+C*/5PC1TQ8FR2"#K9]I9#>L4L">-CT! 3X9IZ
MO8,C-?JK7!Y*H#+N<2X7!$3R/QXIX^2=1S2M>KO5%Z4>G]I_Y/G>Z0N;V0FP
M"DI(RFTBB";$Y.]GWS%7YK1-:T,W9LJ\9_JC?QW':C^/D#L,EG6T!5UQN84)
M0I)B?LO:%XI(]JM/ME?*?[V4W1'AQ)(1;VV F7$L9TL<% "'DQFT5N1)8B'H
M-9R'\U"KB<VNJL%9#RFFY-PV%^GLB)BR#^Z7_;]DBYZ+9D,U@R&EVA_61,SV
M3RNF/!/[2#_R<G7KT'6>G*YWA[C J:$U-ZN*$1VO^EOT9L7$V(+S7WV4Q0UX
M6+/P9#].](=3(Q>H,68I23$UL0Z0ZJNIP.EMP=;O1TF7W^UZ8%93^U*J7>[D
MF&SJ?JVW=5]F^;J%]:VHMOP??JU )NLMS;M!O>7KS#VX4=?^^#4!T.C6S=&;
MH_5!_C_;_$P/I;X;R]YY.JRQXUW&*9'?J#J34R;ED!876)*#3=S,?D*D$-&;
MD1AD++E2+WD-$T\4T6O2VUSYXO6[IQ:&2S?#RLVFVD<K;$NTW]RX+G:K_5+'
M\58PB$'HKJ)OOIM4^JVMISY)V4WQ6T:/5#QI,<<]]MOQ;DI^-0]K"M_BS06"
M^F^CJXDLN46&+?N%^7:EBWKQ>0? 8Y^A&<_//PPFE8YTBLMXN*-*CC+N63-5
M-F>(?BH1<>MQTI29K(5G92-'+4*\'2Z^PI=&!.*:7+Q?$N,-UM_1A0/"1:Z%
M?--HKLJ3NV^%RE%+$DUY=/GDWNX=A&_^P)/=T<!V'I@).<$J8,W@+  7EC&)
M6-\W[+OX8!3B&VYS)BI. 9/"V8+[S" 5[ILXJKO\HPBC>R_W4^L(S<N;[P7?
M&_Y'ILUN:HEE:%W81;*ZS?LXGPC@,?(D^ABT0#^C6'Y;-@^3^ L3JZQ";/!_
M9=@86QPHNZX?@ L3S5EW4$2J>W=G^MW3W"]7/KTXI6T[_#1OTGXH^(?JVT3K
MJ]O!TE<E^G'GK3\>-%4^:%ZC8V\M&B2Z[Z6*YEE+>6&!PP*!P)_")!9%38"9
MW DD"<T('L LIZ<9IKHYY[6UZ7_1<;K6<OVI&ZGM0&HW1JO8 ?%@_:BHY.XZ
MUC8ZG=R*KQJ[;;Z7TTV0"4%L72!L1=#XY')A^@<NM]L5N73X?+@:&JF37#'1
M(107^_M367V&C,>4-.?7P&%$OP!+8IY&:+L']_X,'X!1LIGQ,#1 ;9^.F)ML
M:6C*]:\E?:F",@<C)$?/A'WR3=92.WQ[Y9SZ->UJ>( 5(/U6,GB4"T!:=<L'
MF::XJ>E#@QSE!=?.!.4B"D(.:EW3">$"D@%AX;F20F67=ZD<+-SK7F"@V6GI
MDWUBSHAW_77I=U>KK%?M=P,W/-X-JL4<L[TO>_CUH;VB6P37GHBW(R!#),.-
MOMZR?'1FA26CRK@]]!4TOM5TM1DI- T5L_DOAU##=6='GW#"IG(6F7$VJ)ZO
MMK%Q'WZO<,3LH2IPDBJ;Q;SHSG*@/R=0VX>QO'XESOC+[F4OZFNC Y\%J$I*
MN.]\&RVQWR);@"[,R2QY(C[?Q1'CA2H#0 S#C5UZK^Q._N[!7Z6HK0'F<B,^
M/PN'O6HJFW5:]1,BCN6[7^X11!ORM(3VQ\(!8X7T08V/N=+#6_4FYSF" ?28
MF3:T'"M\YJ%@U]+",_>E,99Q:9_4%\64R'U)2RK)QT14NHD7)_<WG:K(=F ?
ML95V:/^,4F@XE!UR]>[[-;YP&8G!7QW#R)K<4]$>-SR=2,>TYV[<^-0W_NG+
M:MH]'N68AA[_,%O:P1W!AUVM]$CC6[<]])]V,%V>>A3I1$.U]\?GE2_!];M
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M0]"Z!119XER4\U(CVY?0*V<T^-!;K71.LE[S:[6G??DG%&0DU;:!C"52FKA
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M? (]$\LZ"HK-%9>1(;_V+#+J*G+B\EID;W7U@Q_RGWQKI5(NKE;N.O_[_4&
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MU0#=R7CI\@0JZ<Z<*OW,)%9IU*B@U*4\"F5U'2+K WS['5A?/E.U;>9(K"-
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M5T>)GY)G'1V>ZZKSZ=PAA8J)4#UW<6>WF=C-7>J\4\_QA58"0.>)35A0-@3
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MB0_0^02NHINC:743_<CYSFTN8<GTEY+5)FP/>D.DAQ./N""1BJ2?(8&F6MU
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MG(G.BT9NPVJQ+5^]:AZ_'ML_M&@WWK9OG3%[A/_'@PERE<\[/\_R0YJP6U>
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MH/T5A9&'6;F5"TM%@>-P9[^@#*SE2ZT7%RA"_:LG___V!%L+/[$'6H\RLVX
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MGG&6((\"^*^R0=P>VR9;E5[?P+*/['<F&(FRK]+S/C"]BX'GX9$UQ(^1]4H
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M?9_)$(RF-QWB/^7Y<GUFZ.2^!?LI)"V391_.NS1%HEE>Z0_2!C<7>KD'WFK
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M3=S6<>\')I'EV)"!V;.MFTSZ1TOB=QJD;H]]^3C+5E_T7!6RD$WBJ/)+!+I
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M*=/TP**\1.&SUHWD&7QIY";OPJNWNXXXO+H?PY.+X;Q;+_((M)J9'P8OKSI
MOT'+3E@8!0NTE[I(<_PXHZ+80RK-_U+/E0+36$V?A\JGA'<>_OWQ0B$AG>;D
MY.#4>>V:[[:M1U6H$GN>7TQ"M%P2"D<H(>R_HWG;^M80VXEC0H(^H3;Z'XF5
M#;^P,?H H[A9C)]W%RG!LX,:P?8N%-+<LF!VCXN/JQ)TZ:77H4>1KZQE>KR7
MRK+)7R\XVY0<RM#>B^HY4R'ZNTH@RN?>@$?K L8OA2;.28',T%1BA$"V&D*R
M3\ZU*=1&,IH+7]J6E05^R;]2)Z!'';G7(GJ4DLE\=)"O2_J @K:C>4043\Y,
M\)$ V]+)(#'$(OX"',W.\XN!JWWC2-C6X-DHK\$D1MBWKB'D@U#SBS& &D&Y
M?*(H+4CR?:E[B==J6I_6D\J[?$9=*N(VP5VF&O?<^/?!-81(0LW#ET"KD;D6
M$UO%+^Z@%7>5JZ.W.#I7S)7X";KQJN_/+:,FJM!J7X]^3A04ATB-=)A8B/27
M-;D$3'M_FKD\4]+;:/9STTG-6\GU85WA%L?X1<9T2'^1BE6&,A8Y&X=AZ'X(
M!*+]IP>K'07:,Z:9#<1$='FW79Q)EWFC^(Y#3=*52/W<"W8=_NK.L#%1U]4Z
M01C"O:Y-@3T43'*F6N[1I9HN@&:XD?W(1%I0B4=59=/ 5<>?WR,#S;;P:M80
MEQW'7-2"#XCUKM0N:+"7K?@YS<J]4V8Y8G,NP_Z&BE@P):JZ"U<#)5Q.=Y[G
M*##8]>^K]B<M6<K8[8]VBQLC;.!78JX#R@0J!O3'+*@QYG+.2%Y@89*JDX*I
M@/RO)"VEHZ'EWJ;G)KR3MIK_EFXIVJ2Y\?I#QW#->,0<[+W&ISB_1@!&CBD.
M=# XU-YN%')2S<1?T0DO^>2H6P Z\GIZ0K?V2^TO#4\<-2;UR@ /7(:&;*!!
M:'$7CA;(B8=601]FYQJ")ZN!!<M_%K#=VB,[G()3\(!DN^>D6K_YL_L6_?M-
MIC_D+ED&2=P>]SM7?S/8]_7>VK\@"V[[(8"GBG8#5#ONO@.N=7IA54^F;,$S
MN-/WPI9=%'FJ,U*USV'3DQ=LL)UR/"6C$Z%9MVSXS-/N1&-=VF:M!O3C_L</
MW-1>"GVDW/"'79.8'F@I$',L7J\9Q2AVLG^(MPN>ZA-U@6*8N$YDC!-^^#:N
M_%7C%R<7YW<V)R[&6Z:+G7TE]#WN4N8GP"LI6"!NQA[L(F@U\L/)Q"A J@G%
M=/Z]LJ  Q#6<_O:S>$I\[LYYUNG*%,.V=V=(FVY9]NC\-<!6I>;XA^-$I_@5
M%']'N%657P^Q(M"%UCN0&>-4X [)5\Y]IL]*0E)$TN,94;5DS-+ I#91V$_#
M>)%>G4+M5>3<@SQ,$W_>U2L/=FRJ<\&T6<@,*A/&609.E_RK1ITCNZ9W?Q@P
M[9:PU1^03]9Q1X!$2 /V(-94.GC.?^S9%38.QLC1MT/0+%P[2=W;8@N4SN0J
MWB3'.+R15G:5_/"A,G5W4O33@M**[XA]85XX#-!J3'&SHX^6<H+J0%*2L?-A
M++7Y -NO9 J(=^K*C?9=Q%N_.CT]\=0R\"N56Z>AN;&_I>R(OE68T/\^+(/*
MAD',12*D:\^3LQ2(MG.=>;L:V=@$"R4KK@G^)#M119L\Q:4C7+L!QLR+P%B_
MK"#C>"O/I;D \HG1[Q^ 1G6/$11X%IV\AH!9KH?_Z!JB@RA/D)K[8QDRJ6I3
MCA<OGG72HW>RU.Y\BU(A9#^V#A#?=^5+M\2U#.SC@X'IYWWR^6\H-TA1N%K,
M?"]K<0PWE9S*(2%#&D_Z.'ZU4@_ZJR4FXJ=,B&->^OF+ATVWO]O^&#A(8=!C
MFRT$_:8T2CN6MLHR(,8OK"'@B3-+D6H2VQZ/A;*\4\V'BQWK#0GW#>:/O"%/
M[=JV*O'[G@3"HGGDB4!LS .D,H,C]]-C@2TQ'5AI'U^=#I)L2HQ*>E<DL_>@
MOG::37EYY@5;OYM<^S&F=5I(5'CCK3.1+=_X,$YCO'P,&[+K=M@_.)DN; #=
M\S(9=)Z.3M<4(R-?"4.CT>>)L)>-BE'Z'7P_UQ_ONXA[0?X=&;J&T/,?6T.,
M$8E\L\.(T)@.( $#7D2&TZN0"\@I8H+Z?@@7QD)'-RLWLJW;%V5F4%)D<5BP
M0WB5*R,&OH$^VH4:[0=R:0[TGKJP>+:%% .Y"_937&@<]L">_'K@&D9(,*:"
M79 '4=9#YKX%=B\=H9.PO!GE6F5:'FD[)#(#H&@<$6UQO7/I)TK#C9A/8101
MEY+H-*3@74P"9J4OR!4#AW(X[+U7@)4) P?9;VN(@;EL1#D71@FM]G@W=BVG
ME$WDR29PQB ==Y Z-?UPONMYC<J)5R/9Z/B5-KDDRU/95O;CY/Y$=*:8;?>-
M])U<Q:Y)O=<@*M(8V.9=DQFLT&"2&1 6*!Q=F7U?XY%):L:!D<P[<M'GNC6E
M?OW>Q[TW;AH',.9)8R9]3(\^EB1,A/G4Q)O5T_-_KJ4XT:I25^^0=H;3EVF8
M14/ U5-H&<GIXA=@&$STF ?C)ZP?X4T-X'1+ DD(<AWG^G2L(3;ZEOO?'+H[
M(4FX7SN;=3'[I]*=@>JKQPO54K4NB0GXW+- JV.3/!@(FS\#/9[ I#Y\,1Q$
M2LP0H-Y IQF])Z>ZPRP=A_.MJ\DY(V:7C3WNG_SEL&U7CX'?^K4V+#9Z00/\
MN)YC^A;TAD<MWL+0<^$:B^]DC$1%\;3,G@9)G@P8_)"]P[BP[/BC[/OB$E1_
M,^LE#$]1@XF-(4CBK6!#"L#O!6^F\HG@<BN]>C'ZKHW^TBF3_A9.@..)CE\=
M>S[L#=V\^AR9+]@E&*979_)DN5/!K?Y(P2A%AF<ZY2_$\V:?#-F[W.%D&GTF
M>5*!?8JMK'_>:/J]]NLZHUX%+8N[6O(T1[DW%92%:Q7K>A3LPY\9(:@!K1;D
ME$<8*9X9@RW97#"%BZ.=GN!38XUM#:;J3#@F8%*JD]6V?LU,]-OLZS]BS3,-
MEJ=Y:I<;TJ?G+X"!EN"GFR/&*%I,&SQ2-I1AU?;-S]W&D@-;9^9P>6L(5<(^
M",4!(*^7O/-09-!M_5OR,JIVJH&')_."-&(7YA>NX;)#LPIOQ.MF?@\..C<<
M;K&>'6X&M!XG6!#&&G"=V/ U1 VZK5>GC:+<O GJ-#>;&FTR^4ESS==T5*$M
MC8?NTWUL:6@?N'%CW78;Z1W0#/<N800E3F%4KB?G7.LA;H'4>YB9G2YZ':L#
MLY<S34VS._L']_?$#5UIL))_]3O74L[JK[^EOV]X'(84B-9R-:$J#@'L2R$<
MX'D/EOL*=N$#V)W41'RHE]>!; .-#^?4,E*VE7:4>-PJD7Y\P[S(0\3'T%R(
M,[^&2(_!7$-SY2W6%U#^^B3R(_V_]R3B/Y]WQ.]@82&=S(6L]8N)KM\E0;NC
M2?'-*MK$ IZI_Z9VA@[EL_E8F<23WFDR6-/6^_V#\\:->4?.8/MPP?WPVT?A
M*0,[IX@@P6<<>.[T!:9%#IA);=X$%J6#Q2R7F*1R/]Y13D]ITOFE(2!8R$K.
M^_5Q<1M1Y(Y;);_W'.42XA$=Y+=0,EX"[8\WSD?*)-S3.9UPY>EHUIW;%@.^
M40]M6G6Z-643M]W@*7*1_Y80\ )7N7Y)1/)Z65XTVY*1T4 PXUG5L>^57GLY
M\Z<!<,=J#K[;'M<?DZ42]_[;7T8TJ1,VI$]_=(6FU&!585E]273R(DSZ?1<A
MW3XJ%Q<WN0/"+YBV(V,$V\!!+W5Y,*=];V6C@U9=739G\8Z&Z/?'UU)ML!/4
MJOE9F,STD9)PE1X\!6H70/Y>RSW%,^17";;\J/'QU<YBN(@[@<+?"]806[X_
M[<MTR/JR(<!BM+>#L?EQ5ZQ)5VSD%\R-E+%GG'<IK;BM=W'0KLP%>9CW[0T9
M[M\?NQ\M"=V>R3;(2/EZ\DG[UZ TQ]Z.?%NEM',[SQZY8C]0?5:D-8,(VOG3
MKE,YFD2!J)T7>Z1]!CQQ.?,D5C6]WE^!RG0T/$4]KO#-XOW-I:QRX=^9&R50
M;Q:_-] A7<5Y2ZX[_BIDQ #&0CEB$!F<8I+: <E1&LWG@6(<#Q-$,/;1N^BP
M4%UD,V$_OT%Z4Z4,'MSD_S0Q#CWZ^:P([ DWK*]T00;'\!Y@;A[W,H%.D22C
M8@Z9%*&-%R5Y9A#^CPOG5>6)7G]?3J:^6V3?UNKXNF4-Z\1O+@^_-AL3.HF@
M,TI9,))-7]@'-G+Z((W\L?+J;(^'=PU\6A2S4W@:V6X6+M<];@MW<-U,9<-5
M+%6VCZOL1'YRTA6:IH]B&=2%*7#(_!(+&)_F%'X2:/C\Z>PL4Q$NCL*;WWVK
M9U,9O2WG=:[K??>LGG>=<0[YZX/VZ>+_L70YO"TFSJ#:+(NWH\AATML.]4>M
MIA#/^63S^\?2B_-O)#P>)\TD3['Z(,U5GBR)4\(/)^CPO-@ZG43U$/'.0[@N
M2EQFL\EG5/MWSG"8RM*WHE1F\D&WH+K$JOS$)O=C&3W3OF'M5@AY,(G*D^WA
M]#P3B,LK\N2/A!0SGP^R(#^\3/-&+B'O^S/DGMYI?N/\Z'+38*/ZB0F*#BZW
M^6=^N'D"9PZR8D=RHOE_-=WGFO.4&L%OR053BUN\"6IUPWB[P ,)IQ]QANV"
MZVSRXA)_EFILC2Y0;M5\6,UC<Z4$,.J_B![-Y)B"*?,!#&(";L-T#7@O7>M1
M.NNM97MV[X?W2?O3?J<YE7_0TQ/2N*V5N V)YW=;(?"5W"U JT&3+'<'WI%-
M6L"Q+5G#E6RWJ<R.I)(I5)Q@9V7\4/.'QGL.HT['3SK0T)D*.R\'<E\(Q^?O
MYJNQI0G;;1FG73'1LIYL**MZQOYH9H>HG@/UWL78[*"H.)4]H_HO+;=N$0Y,
MK;)"$+SP!OQ(#(.!C,*2O"W6BT;'XL6(E]AGJ@Q+6 ;!%R#[P(#0EU=JW^?>
M2-+Y4U<@*G=.5[ISFW?L<['5-40"!3Q-ER<,$4'LX7V<B_PR"\RD#UVFC+2=
M+8>2G[^[8KN?(M=^=_4VCN:,?_GXV,]K-IL_^2ZK7\QIGYW5%?JZ ' T(3;W
M,N\!=)H=S)D9YDGS4T'L1=_0=@L94,.E;W,]"Z?W/L:^,6U!PV3&S[3))"!.
MK%M[NNZQKF7+^L(IE:<@/J6X$(JDTA]BR-36/DG(K7VKK4C[HGC(DY;5!UD#
MD\=WF>3M,)0FO3@1TO0)$R3>%+ @\V& SX1'NI\KQ9. ^_PX1)%*V,&>YLF)
M<YI :LJPRVYQU)8?ZL)@_<!^KL2[ 9<K9Y(RZK(XSF6W.F+3W<53C*LZ"9\Q
MK_L67-C/!&)>X 7.$HB)M4 Y>?[C<L4'[]O;5<I_K=*".H9\56A>FKEF=VK*
M7EU\%?74_8RMY$..NQPB]LKSO;J2*4^%'B-'WAK\%Z66 #H4T&[],MAV?TB#
MSI-#PCPPE:W!^%D_I63N5H&;J1FFJ?'V'&[L+,7NNK<W<>O1+F%"!-#ACWG3
MQU=:[4#R=,N MG",_\OU1I.F.8YKB )U" YMT?(IT+GU$Z6"'LR*&WTK!LR'
M([,8@M^<#T= EBEQS$.0&,H2$<A=QC"M>2>6N?IKB/X4_)$U1%L\E:<KQ/D3
MOW[N+'82<"?^,5J,14'G'.#/HMBJ??-5:X@3A]EP?!330X'/D>.SZT>!-.[S
M,X ?U.;M -/*32#W+R'_)>2_A/R_"?F?'.W\3QJ'D +Q&1@HKD P71&.@JP8
MR$=K"$D! GK2.@B9=60ZI?=^K"\9_Y@I:E 7NS/VT=%-'MKAF+6Q_P502P,$
M%     @ T8']5%N(\B^A5P  VG(  !0   !J;FHM,C R,C W,#-?9S$S+FIP
M9^R\!UA37;<NNI#>#!T!(4I71)2J@$1%FH@4%1"4?"B(@!!1$-"0I2"]"7Z"
M@!(1%! QTD5*I"N(2)$2E#1L%$D0PY*TN_S_O??=Y_\\YSGG[GOVW><^__*9
M/+*898PYQGC'>->:"7^23P%D#MH[V0,"ZP2 /^!_ /\;L'Y? .94(! (P)<
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MY!2)2J//?OST^<O7.>;R]Y4?K%7HY]HOO00 08%_O7ZKERRLU[I?-A#]I9?
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M./I?*,F YNA&HPX^ &UQY<@@641F'T<AF27/O..'XN+A"JZ7];W[C#7Y:\!
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M=<B7N6/#$YNOS8E]TQ=<ENS J4+PTL(,B*"\J,+TI2(3U5B'(2_K<7 ]!T&
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M_^M./H'=Y",?^ ?E%<#_2O(E.(_4M\F[ICL-1TY?L?*6/Z<T_O1Q1&][VB-
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M*Y4_*H3"U'P/WSMXX]EW0?%]YR\I(G'$O?KW$&_ %"+#&?5_M7>E04ULVSJ
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MI(]-OFGKJ'SO]N+UE=<R,]'B1W&M3?X#4$L#!!0    ( -&!_501LTN-\8$
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M2)_*>5;7LU/#Z )=YOJM,5%936.*%F-;M'\E^W\F6/S_E&3_3;#_+A<1(B[
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MTA8YQAF[8#-.D_J//O7HU7]>R).J-XZ]8#-7?#]68J.*SH-P16?HNES1(H8
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M!(WT)R-VD=;_<O-T4LX5WYR6C=H,/]SB'7;0?G^6F9K\P.Y#2IJB?X*Y.P^
M3O\=< 3OYP#*$FFNG2L-:Z>/#BSN>"V7%^"E-G6]-?_'T>^[FF;Y),5#=KR4
M\=WW]2-TP6035/EEQ!]K'F0[YOE(#4#_^K3C^_" KG-B%>AZ$E@R)2P93K^
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MA]<J)9@/+\1(R6]\-Q!]%GNL9LG.ZJ'$GM ,20D2\C7VWY++B5-F*148SKK
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M/UAI=C354'DU*L&UZ>Y!V,/AZ J/!3L#=/W,!7;[4M[P[D6?=NR9_4\EAK&
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M3]RFG<43K]Y]MQ9_M4.OZ)+L>3MG+2M3,^@9_$<>))/4DMT/^@B);N-IR*P
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M;FOI6EG=.21]9$=KE\KI_EMF$8Y(0O^TGB-C&2(:-YGO]24 S[E5_9-U=:T
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M8T]6Y/UVKCS^6BV'QK>'KW]GRG$^N_N9E?J?L4R/#9KGR'D4X3&,6$\9=&Q
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M#UW5[(NU6S\J_'XEJ^0+'PJS2S87Q&1IWYIKO?.LG6($+Q.YQ;UHR1#&T<R
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MI^;B=J>K327[13:C)L7./W:[/:?7"]J3_=]>]_K_M'\W ?;$_P502P,$%
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MD?^/-/M?%?O?]")#) 4%0.<)RD#@$"XG-V$?Y/]/K10^M]F]%L6'5"ZT3>/
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MJGEB(_GSB*"[H6'WSZJ]WX7>0$>V]!AF5"A'48\5S2W"FG+"N5G8@]CO+48
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MJPDB-1:(E0^6)_@0L=#8+[,724_](Q?)R79?U[/0]H*HE_.5:8_F3Q(8)^&
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M1A]V[4)-[(W',OUZGQP$IZH=[TMN=S-.\P!59&%*&/TMUIDS#'649NF;A8
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M-;=ZI=F?I78&O%*8F_E'S5X=MWEG^M#P)>_I-T&:*#1A;_T/V7SNMQTW,!)
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MKJ@"0<.U-T#$3+]T%395ES=EW'6MI257RT]LBG'*1MKR0;244N++C-I7MU[
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MLW/,Y*9!H*X(F8UI^O/.Q(_8U-32DFS?UB$!\S/"YOQ:-5(OSR3B-QVN2!6
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M/)(,[ R8^%A_9\*DCXG@M)[,S1D>Z<S\':@T/-+04:'8VV%AVN@W.++&R%S
M*1>8]M5 F*_ ! '6AG6PC;D9Z?#4+MVO:RY-K>I_)>(P)/<'LJ$6PH>?MC16
M9P-T^A5,CQWF#GRNJOI!C03C8JXYA=FCQ!+&"@8U-*IA8LZ7?#!<[:O&*QWA
MWR/A_(<ZQ#L<+BWBF*WPG2Q$5/&OT;Y36S)5JG!5_!)]!V:ENFN@;8\N0/F
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M&DGF?K&]=?NZV=%O&[S%$K1,@)-NBBQC'1 %09\5X-%M)):;VG%L.?< *>"
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MA,Q(:URG/K%?J>8.I8=.&U*_6L4E:E"&F9 7H^J,2JHQ@N4:7B3:"<9(H]S
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M8/'([3^C&HQ_ T,3J)[QHYTG@%(+40H?JC:]\'+!CB5CI6H!3R)RD1[:&IT
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M[^0TADY;XHLV!VH1W3BPC,65C_K[-!/(,E]JH@QWPK^_FPA/6WK_2,'DW>R
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M(7&3]2A)0&K[5$3?I!5-#NP+GL:RTT-UJJI>6[<[NS])5?Q\3;*&"3$8?RT
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M8J_C<#HF8<*VG4_A_$VR!.5K[%F[1)6Q+9/#\X<C_I;=-K(#B'#4K:F#>,>
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M<L)T#N*+'VD?U=(=OJ\4S<EBHB+\A!9<O!"T3<X7;U0Z,=;P6YG;KFW8^[R
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MI/F8%ZO^*/I^_K,+K9K#YU?GXN%ZO;4TKUL>]?EF@<WMSJ6EX^-FL$#2Q)5
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M2)*GWT3_DJ8/@?:,>HVR^QNHVV#HO?"2Y(:XX6!"4TLC+#* 7KB0ZJR@3;N
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M;PU=D?YB1>ZIK^6T:3K(&R9"L!>RA C60K%'>A 4]+>6C>CAX*FSOVN)C+W
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M6X.R1TY&*/TTX-.+>631_D3A8&!+#-Z3>^1%(T;L-BDBB@&93,'P;ZYR HX
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MWIQ?ZU0OGGTQIKIQS_,VLI@!X=S:E:WW)&I76C]0-GX#JOK$KLH,ZW9U^&@
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M[KZR*TU4W&QST_Q.R_;R5<-U7&!5UKM;_(@CY5:5P:N31EM*(ZP@SP_M0$(
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M9,%<^@R,C,?_3,9,!7.!<IN>BV3# \T]<7;WD7OD^Z;#"PJ+?J!&T6KD!9U
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MJ::F9M3!'>>Q<MQ=*:MFQ_7-K(7+AEV'KK_ 4 A<X*[RC/Z&%IV'"SROXHS
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MHF$?0[DI8VL$&1N!@FTO#D/>''@R5Y+Z_?UO!_(5CQ[(8,^[1P,MH"T$W-8
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MYP=5G _S9T^HFCF?^)'(V_7T<8[H#WZ-CV'A$QXSB!A\B0UK]TP+IJ(2S[1
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MY[V_7^_/G#FL0=8$L-OX@M$%@&T'&W #^@>P?@$"9V][WW(&G 'H8&.- /K
M#K;M8_MUQ_;!P;[]RLG!P<[!Q<G%]1?BWK43(FXNKIV\.W?Q;!_0.SY>'K[M
M/[:9_.^/[N!D9^?DX>;BYODO'ZS/@-!.-C>V-7:V \ .(39V(396$P"#9.3\
MBWALP+\<;#O8.3BYN"$Q>*$%%;LA\=G9(:$Y(8FALZ'0>8!#B%-8]MA9+A&+
MF]P'?$2//TI\O5/NW(=ZL2O=9'GU6_?#=O'L$9?8*ZEP4%'IT&$-S1-:VB=U
M],\;7#"\:&1L>=7*VN::K9W3;6<75S?W.[Y^_@\" H."'S\)CXB,BHY)2GZ6
MDIKV_$5Z=LZ;W+=Y[_(+2LO**RJK/GZJ;FAL:FYI;?O2WM/[HZ]_8'!HF#@Y
M-3TS.S>_\).RLKJV3MT -[>V]6(#V-G^]?B[>@E!>NW8]@'WMEYL.P*V%PAQ
M<,H>XQ(^:\%]TT?DP/%'.T7/);[^4+]+3OT*6>S6_6Z>/?(:1 7*MFI_T>P_
MIUC8_Y%F_Z;8O^LU#/"QLT'.8Q<"X "#GAVC!/Q/H1*3*9MF.&C)Y-$[RFQ@
M=C>/WF-DD!S-QKM.559=\FOVKYC&5&+IB1=8P/MB/+/3,<LT,B>VTZV[ +O7
MZ&!E-U[53.U44W_]C-BBQ8-GMX:#3\&S(J59 #^#!5S-8 '*!$9V NB]O/6&
ML.G( DABJYEB-/&MC$;TZA0+.(AA ?*H8\QJBA:=!;" +S=90!OF KH1C>X[
MR +:-UB 6PY3BL;,UV+:X&D&R#D#V$]O?A;0E4!/1]/_0)?4FK( . M8N89>
M4>S&D F$=2/\2AT+&%9B 1%,%E  G4]99G8C3G8;_NFJL$6L"+J+!=!38?3H
M-5>ZU@;CBC<=BZ;&P(EX_,]D]$P("RBW^>9GP7Q+)M!!2+@\B+BW%IL(J]NR
M*D2R@ .A>_]#5471^;5:+$ /ON(.R7CV_Z=ZOA[>D\>HR+9=U#-,H=9<G%W9
M\!JJTW?2WML2W%?03E:C1TMJ,<**6<#:E?YBE+3=84UGL=*[C.$GN3K'DL=R
M-SE%+6S3PT4MSG#^=U*0(JD0LH\%?DG9FP64V10/)*&&\2L&4LR&2A9 TPS1
M/<4"Y$:UP*G-+$5A=%ND")-[$R9K82#&X$*?^@L+)(.21YW1VT.)*"-/37@W
M+!(D[S#%*+#(<JRX0VR;JA_C1.@5YO"XLMD)(W:3^]W?)#@N7.R034G[A7GE
ML>I+701/TTR8#2Q LM:"AJ"+]4;&ZXD&;K3J[>EGR@<>D64!(J?A%J5]1;D1
M'FJ;"W,FD@8/)2!G\STYT)9UV2>ZZ>;1\9[T!P,O<@/$7%V]!BK6'M@\^%F'
MS."-:)[,U(GW/77_[=*;S92^M;X6:I_#$"*'EC$!;RV$/3V!VU^93&0!4;JJ
M1:#E=1W#*#^8\%F>3D]?:J 7FV&8[8'T@S&!F?*&LH\%(F.FZ7#:/?HI"IR4
MK+9D\Q94;#ZQQ< _<:'P;944YYQ.R1F1IWSF..!9VIGF*M7 P1AJU/)$#ZE1
MXQE9+,!#+6*9LD@-ZL^N+>O_94-S=X0?^36\HIW()VXQ_7SF_+66DYSG2E.O
M2(#6U=QT>,UY;1:089_, LQZ>HIC"R5%%2_?,;:,J;9OKEH903<T6S1<R3I0
M>[C7Y]Z3S(Q@(X55@@?]5\@&29%F/(\O>_LX[POLH:[1%$S((TV0.U(71N2'
MD[2V8K,C$C\K6"LY77EK]#+\3/M)%RL]7]HA%E!_L9:?=@%YLX\%N!"DD0<H
MWHUJT9*G$T9&&O34RR^.K_3*;?2OR"HK23V28]\_$\!Y"W_.Z-5\K\=[,,OA
MQ,$?JB3YBC!*FMJ^X\=U$_.7BKHO7)2^Y)$5AKME%F&-A\$G"AY@R@4>W^&*
M);M^WI"1J>UW<E1;[^AW"5'P>EK9WY.:C$DU2;G\FG+MDU/^+??VEWTODV8J
M%TFGEOT+2<X>U^/VW1.[UR=W1>"GZBK!E6I56?; X==RB%NH!>( \A8+"*MT
M0_/@QJ:*3U'/@\63\(A@TQ']?*19C\:UEI=MV ^_5/L-;;(&3QAB5N1NI,C?
MP)0X1RM&OW[F[&#\GGL?+#=(B^2#!6V(:DLIDPC!A7'1IV1'\+X9/VC3D&J^
MPU^YX[EI<19&-'3G __K?E?Y6GG>Q)<)%AT6\"NX?__M\FWJ""ISB^K6>F2K
MK$G)*J_K:T_%,"&TFCI?_3: P(=2 .6F%!L[I2:QC9XH5<NS%*Y,,6H*>N=^
M4[[8%.W]8J=C_N#YXRP0IOR@-H^ZCY%5P@*<X4.*GQ%EU+QWN6/+$6L2Q!\E
M!^[F.+1U:M!V3;]*->3%$'?4V57?6RG4U56PLC-5+ODVC*V=:6J).R82KQCX
M=HE6.,]T4\J.&6R"7@ &^V\%QCE0G'D^7HI9;\T"M@YY6./3?6"MF$)ZU\*H
M%JW\M/BTJ(7!+2_H!?A7NL\\#7:1!XCQ:Y+>3W6-J'M+;AUOP#BE.[0+J#_O
M?CC7_QY-+&(!KLM;,*CZI02P@);"+W!OM4WI-3B-$\Z,UR2*;7D9U0<Y.J?T
M-/6]_/&F9&G*<WA1?!.3YOK2,WWF1<5U5:6S+:H*_LI+695)](1R_.\,WT%E
MOHR!P<^CH79A18!*!C;6#6O#E*6:0(WA<"B%!4P+*C(/'($6ZRTP>J _N_Z3
M7'+^Q(3]GSS^7^!157N:9HP4I5A7>1+'N%NR0F>FLY7=T&4E-B$RCU4EV"F:
M8S:-L+)E>BJ>'SUHK4/+PHG'E%XZ:!B;9_SDS8\<=%!>7TDT+*0A:%;M=/V/
MPJ@XR[CB7V^K%?O>9\<HSW05\"AE/_R[M&(V8L.\F ,QA>1TP=ICY1D5Z.D8
M+4:X)PN@WJ$&!C -/WI36E=U+\NS@$0!1;K@BMXYB.D6'_/!7SALJD\MDS@I
MRHU; A\F!)_".6N=O#26XV4D/Y*QT1H) KA<I\(%N::MNV2@_X ^W\]'V4+&
M[[Y=T14/.C'0[R\VEI+Z>G<8L^=0M[.1V,&XHP)/I:6XJTL+V7_LWCEM<^1P
MN/':YDT]!\E?F7T5B.GNOB=-EHT_KKP\66%69AW0S0RXM)G!W,6@:8.%1&PS
M/AY"/RY5$WMUQ=_2;2G.F=1'$_E?;X4H>UR[?:$F\X#+19?J5-N#;H\4],Q;
M'UR]O]6?0MF! %6>OJ!LP1XSCZ(Y[.ABZ)U=D\[D)>:YGX97D^:D'FQ&J(8;
MIHN[7/:MFL5^>%?BO=3N\_KR,P7G7;Y;-9_@R9[S.&L=?,7A#J$K19,9+X-T
MYHNR:W\EV>$SNS!0W4C E)LU= DNX/@8+^&NB+U@H\4 3+*RAA@;*$A53;U'
M$LJLU!SABVI4/N#Z]5[]^?L^V_B%)$<[ZP!&-F#8="'@P#%,26C$\O.F2J9%
MUR(*&A7JXDLCT]VE.EQ2)V<#^&K&2GNZ9D^BGVOU^UEU<3H&8N\6:I3W=%=4
M%Y8/XQV\-Y0-=/UWWCP=F[-GO7^E;NM$LM%(=@5N ZWZ':5+OXQGO$;ZDC,<
M&.ET_3S0OB%=K)B9,#7ST;:8KJ^26/C%PWOG&6230AK;8%*D[/$,W,TR1@G:
MX[3)E *A&1L%(YM@8B7+W'T[O2=,]4[%*DWTJ$K<#4EZJX^C.K<%Z1CN77'Z
M?+R6$&AAC.,5LB/@[G36Y1 ,"FBG]38"WI'!I=.\3.*I-U5IGHX))']:2FHD
M.^T$\CQ807$B(N&[]8[1#Z1]#DY]'7JR@IPY]CWK5TL?K".!)/#14GG)_=XK
M3B.AH,/7-GY8./R84K*T>%8R8%.SVM/QZ_M$H?:/=S,2*WG=CAT=]GB\>7;,
MX;;MB(6?H?-"(/@"%"LW"M$,T8I"6T=.*+;EMJ<B*SPSQJX/._O2D#+WDP6H
M;P7P,TF"!MNH]5K&7Z-6F!IJ'+%R:AY-Y4$S)#T:E,=8P)^;!(W @_YR.G(-
MG0''?*QA&NL:%K" 'G,(<JXI?N,4M7:-]RMV=2![%;\&?:_I/'@=]-:,,^+5
MI\ZB+JG#QL<8_;)X'M/RDDC1ETFN&6 -=9&11.>E2""/4FQ:X8)#A%;.7L*8
MR;M6JJF.29#G5. 1U['2<8>!8\1]8<#=J;BMMR\*%H+[7W!5Y/RTWG@08%[4
M/_"@5R715(JOL/"0[+.PG?LG8NC?(<CA0T=V,\7H-\CB=!$:M8XLK\=)20O3
MY9_$"'0(X.0DT3'?<O(7+.L5:A-6OO7F5GQ;FC;N2%'I$45\3X@@<-+%(+1<
M$DV6Y#_.KW^F6T-;X[FG&BGUXDQE]([#.B?T^0NX!()M$E.F%EUV^VM4617X
MI*1,+@]58ITKA[-:/-*Z.V;S"PE^:W<L:LISO!84/>HVOE>1-R990$-7K"'4
MUL,1%-Z+%)YYNQ>]%4%^'FL?3>S?QY#8JX5?-U0G?6K[)B!@< T,IR@2-QH0
MN\8"5R<CX\NQ@FZ5)M7+5_N]IRK#U,XXM.T]'7DE4&S%D"XT<*Z[5JV0V8N2
M(L^F>3OE#:)Z4?)5'TK+HPS%:@_-'+X0\XK3RAQ@?PB(]4* TKU6:((@ KW1
MQAWTR)(EEV2&A+YQ\^G,=1RSE4^VQ0^3OKAE/G+[,JQ>'O>H4WM6+#>Y0[S]
MT[/;I.*Z$?H61^E/H6\YCV>1)18V/<QUG(/9NW)/ITL4@01W['Q:OJ]SJ*=T
M<VZ3ZTRJHGG;U&"8X)2U1P(C"S[],%"*V4129P%&<L7>45O8N#5XY-;X!_)<
MPT(Q&#9BG&4J>#%U8;])QX>]1YMZ3O+$=)7O47QHA+VLJ69@2L5%IAQ^4#11
M,V(92<DCU=.DD-H4_[F'2#3-D@[O]N_4N\E/3<P'*WND,H)V<LBUK'!9UW-S
MN*:OB]UHWVO&<=MFUFQI@ (C"C8(QJ)$04$6P*D#A8H[Z%1/V(TTRN?JT5-;
MU)')*&J<=+AC5-N:[D$4D<@+PMP;D8OJR,8<.C>P4!<TY*CS5D_X65$1J</]
MD&&[L77 INVO!!/-SY:?+PO%C_5M8L7W!C6W_!Q9K_X)(;/@O*1M?/8 _J<^
M)\' H*<K0 ]FPX>!T?5-Q2CTRO$<IF ?YGV@+Y3%[01H-![93JI-RM9^"P-1
MX.^1S9^'P>"QW\?%LD;\RNE&]%/XBTD?17J4#WP"G;@B)FJ!^.ZZ^OX?<?T7
M8MOBGD!L"FMXTSCM6<!\;K'=[U,P6F,2G@"WV<3T?O3>< M6:X.@;-/H-I[]
M5]H,H:Y )8B@#Y4@2XA)KZ.0XS(M"-VV_)H%#$*#S9H[=B=V'+1D&BW!<^A#
M=$8S8<5B\K0-,RDL1@G[6N^>LOBD81QW(R$RF 4D/'WIS169/7:'J_OVH.O*
M3?<37/4C-5[JC^/6-"L,#AV<['G@%&ML5.&'5*=Y#C(;\56.CXAP&;H9!1?K
M.Q$ :DZ.02%Z73),I?ITSUA@8/-A[;NY#>*WCV89N<0_FXZAL@#PH!6A5;EK
M4(V8.4<ZL#'7O$Q<\1?OJPK-?[7ZAG8H(Z!S-@.Q_X-WQH, WW32$;BSX%#[
MU&1=9$LC&=%X:-)4IW]60E-B3=GY@?H7;[E+TX:I*:;52W]DMLF<$?SF4?MC
MK4[=KG>V1S-3A[?&Y/G7@#U5YD6)[4]N%"KOD! :'$B)^&R5EY!U)/=3>B7&
MX^)/ALI21:FWC6]_LXMH@3.YP1)_.*!__%=I=_"8P\*#U"BPE[F+NV0^O2H>
M?N=JSWJ(1Q($% A1O\S/ZN#F';[+/^9^YED<,?_@I5_)")-7&>V4!V6\.DJE
M8GW:/-I/Z594QWZ'7P/W."VRWF2%U6TT8GA0XH'P*\Q!<D*C)[MQS4YS!_=A
MW=U&Y>L.;:\FIG)M*68/D;NF4AXA/2>*%:_MR8U_W^<W6*);/#A6]=6RZM0%
MGP'VGBCG=:=G'5S3)3]2MD(&^L=M-I\&Q1]RW=VB5*,H[H4CE>,S<8:G:2?N
MZ*!R:"=!0<O>Y==9PV9<[O'[*!?W[D5]@>U_NK/$Z2RC#GX;+<+LDLPC.;Q&
MNI9^!$.S"9I9^9-G;_I]&/EV\*ETQ(DHDXV9N!V[PZ2O">=I+HQ+D3'AM5)Y
MTG(-,I*]:X7ZLG\,+U2Z<SBW 94_@-L3ODN'2S*@&:D_EFB?L&.>R=:MJG&J
M[%!U=W'Y.Z?RY^TF)C@Q\_C:)'NY6?FYDR7?+EV]*5&?ZU91X.V@LF'G[5_3
MT[GO.FAT]=G;-\OR:^XA50'VIQ^4#7GX=3V'>WLB)@Q),[23=LPN& =3%D2W
MZ!VD.'YZ,P;>0@O<\7'$/4UT;)3?*HH7T1J"YK[+?/%5/CX\,S-6\.O]BH^8
MDDAMT"GORQND)HC.#@SNL2&HED3FZKM+56W$-!7LVBBNOH;4?6UM56"?9:3H
M62PUP@*,@[>./&ZZ):MCD7.9GNA9N!QD1T.'N__<@AJZ@ZO$=@X/,KOP*W9T
M319P\]KBKV#0B1K* I(&B%@:3RO"=V Z"T)A;>T)(-P:54_LHL<JHQ-8@.=9
M U&;N=;Y1P:BYFQ_CQR-:'=8P!=1;QH/),92WZ+_;_NO70(0VPU^IC;3-;H)
MLR+;Q (>,0W;KEH8H,]BOM7_([[_0MSSL$?HZ8O=^"4QJ(IEIU9X*'_&K\B[
M$:@\52R@V\2N@MX;Q=1E(&;1EXGXL=?S^/T0<A>Y]U=;QNPSRR,=3,-006:]
M&0O(,0TT",&39EB '"X2@D=0%G2_K3V #R&:;2J^9R:LNJYNB*._&$:M([:,
M(2R%>[+Y^3_8CV;_\*?B36Y=HK$ !6PC@BKV%#>'_:(+E;O$%!@95<1XW(C9
MW ,U>QAS>+N@=25T[XA1>O5WJ3:9V@?Y1HE %8.T'"KL7_P"]T1L'H#PW$U[
M-".]+DL:8OM+BNY#[Q*)AD_K1[, =GK"'^^R8YB/X9EA_XCOOY#@=_@.R"F)
MT$QT&)J)#%3O]-O\9N7-/"%ZT!;^*S.S$5VCWXV"PL#Z(/&O'=-!J$JC/]V"
M,<(P+.!".CEF _V;F5$;#9@5LYL,V&S7W*\CD#X)0C_Q:\^@#ABZ:_4?!M0V
M;R>:'A13'N0!1K@3]M,B,6%H@VF"B(!:F71H%R(I$'*<W&'X!,.6QAT)7U$I
M9L(9%1!B16!@V?\WMT__ X*]0OT&L(NPO]EX8/6R'+BZCG[!.!7! AY$9M,A
M/Q69-ORU8]+P?P;8OUC ;U9F+(?#I[,:M^"=F*Y1!RC69.3ZT M*4(?=$IG[
MCYPNT/KG?/_SL(V7IP@R+UQ%UV^5404%T-.V]G0T[0X4_W@]^/G_BZ/U?T#_
M0X:8?^QSZ80_)WL$W)6PJ8J2A,0K\M\XC3*:A-'CWK& Q^NN2S+[H& HK0(A
ML_R $@"%1$7]]8[=7Y/8;P6TZO<2NT1>IB?<(TPES :^-((LM,\,A$TCPZ%"
MO;:7OO2/V/XKH1Z!?]Y/+*W]S<R(3NV$J:X^INO:+RG&L$SL"N2-#UI_[1H]
M1T8M?CH &JV61"$F&@-/;&J8?S;S!@XZDQ0B.,\"3J#A/@'T9X$)5BS@S2O(
M^_-F+_\CQY^"_2G=^5!_ZEOTY";XYEX+%L#]LVM0]R04$,[>%!9 >@>E !UD
M[/YKS/G7I/Q;"?7ZO<@.$0F;,D1\*^PK13N9>5X;0X:W;?) E7I>?7/PWSG5
M0BY,8KS![4-U$ 2.Z,G2]?'K"9=Z96_._129.J!43Q]*X#EY^A$PKQM$L2&V
M-D V(H#74!J]:VA2_%D5OZZJ40[:>5*W.#Q?ER\N,=&!$P5C]B#*TYK0PY&3
MIUN;X%$!S \+Z;=5D/%Z?-,&$O",8S,)BN]ACNCZD^B)W/>V]G9(3D8._;RP
M=HY08$"S>&EH'_M,Y4<G4L/%T)0:28#!D5WJ!Y<&X4WC K&3 H\FE>WKA$,N
M5,=:1EQJ(#\TNC?^D+VKXLCC*0PWB*DGT\^064 4Z<B:$<GTJ\[+XX]YS[$=
M/$,8 V1"W[%;QW1T(SV),"'PLIJ,FYY\64VW2X76L3NIJQ&/B$#R?I]Z<[:Y
MX;3S%.P3I!'Q8FW *S"I??E"UH_1QH*S]XK9&R!6C!-QVZPNQW3VZ#H1X;L#
M'>%2\RB%#[7=;RNUA.ZD#AA3EW=RO.!X2#H,Z,[MNS+//$K.BT(>$X_W4Q,>
M='1;M9>*JK /*0\)B+J]O6KX:- W[5?\DLIP8XIKN'\7?^N4JDC3<.ALHNJG
M+%7K_G7YRL"'\FT*5ZZ^J]\L>\I_ZA(%'E&!%<R+U4#O'AQ;N/+9-=:RLL9(
M=5PVZ?K%-_D6C[_Y- .HJ-_RXA,Z'*=!#HA"[79#:7_7M7V+<"MU,^^2^>"*
MWE=9+-RD=5'ABOF[^@Y7=NZ>"C^T9."I)KT]":TZW+$:'21A#R??/7]9B=U6
MK<!8%-CW7GMB8-7ZP''J:N_V[OU7C9SU0 ^JS72\CK*6 25AVX!1M9Y$@IA[
MU98*=7:2W[%]ZZ3G[2C7XRH%QF(2\*/:$[UK>#$0<9V\A#K:C32Z&?2FP\LU
M]FI%K9%JEFS2;>%#AZ_>H ^U<I7Z)(U)'3)8ZEBSXE=LUML[4 N'Q?JI"5US
M7+ \XQ)I65Z[K?S+CXE&5VIESK:*,N!-CK"^<@W*B922H=&%TG,N">95U8:/
M<O9V1+,-VVS;YXCMD<=78H?2E J"O:,TI%T-$IK2]:I< _),A%*5:1[/DL3C
M_._]-$Z96'WI8U;67QZJ;^P08-97G/<A,"XZB.]G]W&!HGW[A.KGM+,[N340
M5SK%^'&Y>0Z#)?GN:+[*KQG]DR?U+]C0ZA^UG%[P]%[R+AHP+ZV+\0AP^*)[
MA>L"PKPQ3*F,-V<6_CN4RR.-^7 PCWTON9DIH_[FD[#RCC=!>2\'P@WE??<G
M'1)[]G3OY;/8\8__-E6R@&;\OXR5X;^5(N4N%N"N-FQ";%VJ(T].3<*:($1P
M;:WS^!X9U&N]XP?B8)W/R3G)@[ .:#B$X 2,!?!O$S\#SP(NLP!RW&8Q5?"]
M5]?0 Q3.=7QL-<2<>XE3; Y"&]XD!?(4]37HXTT1)$+8\TUPU@MU0;@99N^Q
MB]RS$O<:$T<%S_P_TJY76<"P"=43]*&9T[4_@D$4@<9^4W7+<$-,7E?<+B?%
M%6?=HQ-4N>\0G&G\EZ4)-#6DX5\M-4M\=_;E_UZ:/T%57-P>MED 7>2F@@EL
MF)L:0R8[WR@#O1LVOD\+]7EY6> UXFCJ F$X(F6N 1L)$X67H8DW036S?OB'
M=0Y<KQ[!"[:TBC6\SGQ%OG=<@--/E,VZXWRW'TG!CQ]^L2*L^< QA6<G?KXO
MD"G8S?_J?F#+R>S><]TJ&N%D1D2"!V=8PRU["<^^FT)9/!SL7N-F$JV:=V*
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M?UZ%R])O">3V-R$ZL) BBBZY;O1O#VV0_?^:$7R1>A0;DOJ$F>1"%C2.1?"
M>?Z,S =EH1E+E4:S3I7+Y?M"[WF,LH"_29G"GW>4V[[Z7D=Y6%QM-GN1ZYQM
MATPZ'5=UJ&,EYG*6\+[\FCK[ :]BS'^A$3D&S?]7EI\1\U,]MVC=K;)N/W;$
M?F^)IU.JQZ$V-:^OKYZ/[',VJF_UL7[W]Q %-J;V%"V8[L.H07O@H]"E74O<
MA8$!C3@!\"0RW:9I.2Y+KAMS5=WC$D+G<N+M,GVI+T+Q30.6IPX(E9^;R'G/
M/5QNTX"N""!5T;8#Y: FF@=YE?$!Z?Z:;@'R3YH)V<\[RE-PR43]-XNXG34?
MV\)^S4JX)/'2]ARV^NK.]R'IJ(+*N]!D*AZ,IGD&XC;.@R>AX9E<239XBRU<
M4"U<Q(OHAHANV%V(SBOCJ#()5(W2J@K@GSW.WZ T597XYAN8\E O"H)C$!I2
M&YFCKI+GZ*+J302R,18\A(U 2KT+;(>QHQM<R;1)>..B;?&2)D/^^DYIY[ K
ME^Y''F%C TZL'.)?N<@"@L&LWB8;IDQM&3FURO/MS_MG.IS003>\LL/,B %/
MC/8F&OH+?%H794/%T"<9#]$3.; J=#1\H@ N I]()Y M3#V(E8^*0?L+ID[$
M'RAALO_,<TK+\Q;3@3^Z?-%'31,WC]RP>M ^FG^3&J X#K_K'<<"*F_#*_(:
M"$/)U$.4UH>>6%T#]X!"^@6$!*BW>(4%/ EII"Z)T,Z?KEO'R:<'F+CM]Z$-
MV%[7OJ:PG_VGG?)LI@T4V&$8<'%J(*;<#*#?!ATF\$#@?>D3'48_=(W(:>9]
M%8*[$9IQEN/7\]**;)OY2[\<;WD2]*;65W9_:_*J.%U$D-H.L:A UU]"NYI%
M(23HZI21"<23=307TKQ?5SIO09P%<%68%'J>77I=F:B8Y#>0^$I8*OZ-ROV[
MO(EX[5>"O3K*JR9,'@4HPZ &&_8,U8;?WL'SWN=F2&Q)F.R*SU(B$QXS]P>B
MFYB<N$^FW';X\O@2EZJA=V=FE4KVW)--5K%Q6^7:I3=#._,31K;%/H0)8/4.
M(P]2Q.O5G@K/]W?ZOZ/#8XGC^<10LRL1QSY-O:]A#N*COGV6_M AL.LS_\M#
MP-:OF,T-YBXH@SDEP6U)SC'2_%C L/U$7<5X)O/%P8Q);[Z?=]\NG^L[P.-<
M_@S+OU*MH\T>?#&2Q^3 .J9BN0DS+/@9+;#D!QLR(5(3)@6C4(?[18S(1(IN
MKT&.NWRCRLI/G=C/?'B7""7$=,)<JDV$PN';HZ]DB@U0KO.$*D6ZF!.5FU&G
M)XSJ1).O1./VTL^# 90YNU#>!KW3H'?VJ/N CDQ%^ JI9']*E-N+3.Z3"M<^
M)F^8[=UBISYFE.,40"R3AY.( 0]J+4%1;V<3XTS6;(UG*H C5WOYMT!O?:.>
MX7%>#^]CPO8CL=&[V95%(]3&)69&7P&A-PV0&-H1U!A3V7L8/26^)$6S=%CH
M!9>)!^,])CW5F])EGE/)8&'#QC%ND[YR@IR!+T?DTFJV<+SLA3BET.C5#9('
M99DI( S"R=Z.##Q2BH@-VX/B(W_+4(Q28^ZX(^E/:OG$]5AXK[.X3EAUR]:3
M>SM6# 4&?^0<#LH]U\:VY62 Q'O0[M&O,W+P-]4B$.4V2_KDU 86T(+86[ZX
MAUR9.:7\PM*$O-CIJ=#<V9^GPCNK65?:>'AROV30I6/Y"(WC=$(.:A1#MDH8
MA%'70".:)E1'C ^"KA01(J$UTWU-;2>X0<3%^N1=GP_N%^^H_!AF+9OMXK=O
M.N76I-F8[FWVM8:_&>R4N2?3FI;9Z&*@!Y:. ',F[4.E&E'BW;_\30.LJA4[
MRLO#3B392@%).PYI \G?=UQ68@^. 3'4<XS7:*\$\-!<PS2C$"<!SET I<A8
MQVH,4ZPD+6!BNK_6L/A:LW)3=?Q:\K=*:F)[F]TIM^P'@_I[VYSSF5 *U.NC
MU)"B#%P1?.(%G&R^4U>'>9#R-/S@!W+ 9&2XQN9=#8*$?3.^J_1C>:IM_-/7
M$O&#!>T4XZ,V':J2VMS#&C8M^')J%13$L>#<5)?0$,017H%_0A! RA)-\GK7
M&$Z37LE!H>A)TCD%!LUPG[YS2HRQW>C%]I4V<MM/#F?><2@-M:!/G<<IH>O/
M,#G :OBP&M$T+XRIC%2B,#;"4 INP4YEMFAW.\\Q3=SL_0^5D[F\G_BE;KXP
M3F);GQ&;80$5C"J2%X%=L]B,JC! E_6D[&AHL<\4,:.T1&O.1!0>EG4N]^7O
MJ[%_L7/XX&B]R8ZK#SWFX*"L&5W49G* +NI-O350&T0SO#,N_0',(,+%'=UD
M=,A[PHF?UEK)G5^/M\D]O?KQ4Y:1;EM#Y>I[;J,<X/G@=^Z19S;M<$[F4=0(
M"]@']R)$Z^TE8YH2(O,FM!KKC G&H9<"918J/,VN#RK4]A _,;^O&-O)-26-
M;BIN?/L>M=%\""'.R(>[HT$5\:4:J(<L4*I(-*BU1T/&7(,F4L%Y5_M2T%FM
M?LPBKZHR:<::UZ-P8$!.^9YLJOK^/9_E'WWW:G%C7[.+ 0,FYIIAH+)K$WQH
M8"* Y/Z&;@W")SUAK?D3G4XM3,[WH'[^$,)VOKH\U135'_#8[J--ZC#O"WFN
MBSM*&[[ZQ$?&4+"DO.WOBW[ )\JKX&03"+"BQ7$B"WK2WD\:6ZU12OTH,<(=
M\0^MU$=>=\>UUS/\?/$J"ISW/DKMFGT(-YC'0@AI!$'=@'P9"_GR4'F-X# [
M-0\,(M.F%#\W_2 MT6].XB-D8#@RLX[HGV40?^3MAQH<+N*G]-(['E,AE78I
ME[/P^\CC8/*$=QQ&P \6B^9#&GD7!?HV#1O@\E_?J8R[%/ @N:6T^? <-U]<
M'L<.]3:NAUI*V'06<!<CMAT_NCY3\WH[MN-/Y#-N3WJO0:P5Q;NI*UHRM'.F
M^%VZK5/5^_<5#Q/*';02Y9-JXX0EOB*4RSNJVM 3:1BR.7Q$K15=4=5L!AY$
M0Q'Q>7S/XTE\H[3, *)7]^:$]HRI<M.P0N,!U<]/H4;,E7HDX^QXNX7DP2-L
M&REB%+-ZQ/ R]16D?0SR(MCY#M5"$-95G< "=%E*?%=8[>DBCRQQ3UO(!J<N
M)ID,*1X(K(T_H94J\>SL"V>^E5V6/"GY-&U(<M-:'YH#]+\>D9&MQT87B%B=
M_)$EFU:?1A#P7C]H;RK7;/YM?[5)8<J5*^V<G5-M7*MW :OCI;E :+@!RA'I
MP/B(GO@ )U^")Z!YD1#NY>2J PTHZA-=S0CI(=#0LD]/<MXFW7_YB?^I%N_]
M!=^67!ZSC:C69=YT/JAU:#:40/- FH-$LB450<$V$X96&QS%^Y&&1 P_XN=[
M6[#&\F-E^2%/#Y6Y ^.*0=>>-T1MG!>8O!0;MUOP:C8N%-+^*K.'!0BC[Z)!
MQ;0&[#!Z$NQMC4:Z$[$D:0>_#$O.TO9>XQJG<U^MSI@#*F;[DCSF#__=W[7\
M*QGI-DH%G>>J'[9_&[JX F?R+88L"@[:3\'"D5[2NAYYS&Y)/%WA@\.^T>BG
M&6]+;G?!%YT^[H-$J$-]'&C..@V)A$;>8B2AW=%1Z"H\7>3\?)K.7).'YB<P
MDZS?+,[O_B:PT3PRI#74-?B%CN.KYAF^Y7WO+[G<FCQ^J9SM&[K^6U*@%U0H
MEEO9)BWWM%1^;WZ>O%<+/E*-3JDB!.@^X*[<!M<3Z>J+> '\1"H+V+&LI_4S
M.G?<#<-./ZT6]6L]NNG EUL]K]PEB=/[9>/%YUQTQ6Z9(D_2].BW\9!T#'HP
MGH&!3[Q"<<"Y/'%<@:6$ZWUHYQ 6<,+3K%GDPL?*'_Z\"TE"_F^;Y708Z;SW
MBKXFR,<E[(1;HNM-T;=9 *B41[(O"K2$^E=I'HF=W%6?Q=FMF& ^4 Z3 &\M
M7M';CXOOT)=NEU/Q=A42:MM_TE;>_#9?0>$9<?AM3%@ 09H%>*I)H.NM4/O=
MQ"7O>SCR5I*UZC,/,\>R/T4V_#%:-UW]DO*17[1JP\OYZ0FVJ<JG !@DH['5
M@]-FI,-=X:"*,Z85+QA80^UFU"+9)F%L;A&3LZL-&$$DS];5K8KN1U./CBC>
MMV^+)W0JY0:4NTG=G[897&/;_,("N*687[7$865',J!(U005)J^2JUK,AI*H
M<&'0LLFGR6SD+D?;D?(A"K-4D;]6^?9M75=>W0C<(\AN-F[IK0EH%X8Z=0[,
M\/4,@LKFL+A!#]UU4BK#ZJ9 YDT?MZ2%=$T<O71D:+@]/XZ^^L7WV&;>G>VO
M6=^@H'%1$M(;,]C1@BXUK"_V;I14!C<N>FI=I8A'NWR\F=?@'!T=,R[1E?6U
M8#$UZ6BD>^/TH^_;E06U"WF3\9P%W#:#YKDRK1:H4/+_U,((T*7?!GJUVI/'
MOLZ>-AYN'U*=>D%,5SAZ\F+O89DSER_;G#K#738P*TB7A%0]Z$ I8W[+:T9O
MF;RU6;")5Z3D5D5XY8)!N>X!U6UG5(K7"S=5BV.%V=3D+8PGV)(?1OJPW?\T
MJ@?-&6%'T/4ZT"2'!@_:-,*ED))@S=0R1R#^$B6AR=2P!3&B!Z,YY#9G]HV>
MZ/[B.6TBI9(X.WH4?<PV8+>^ST-!*1;P.&T+U0JC!LI 0'FX8BL4(0BI!96<
MB4Q,A2%=%(X C<0;U&1 ]H9J1(-9] .]$Z4?*1)UM1G6=15 ,U_BN<2H QQM
M4L*GM ^?O;0[F 4\A94-T,5$J%E@4 #9MPE1X=V8\&3K8)E7_[CL &YOX&7F
MAD-Z7\N0;-G'ND\7B_;^*-T<O_KM!>>)]YT T@="ZPTCE7DT,R9!1H\LWDD>
ML6:\=C;C,/%F 3(E5S9LDLR4GL*GQD-U*72%TX7KD[4Y5"5&# MPA4)?<7EI
M\37S*[P,$2YE0AZ/*IDU>7&^*CC\1^3QL=&.1[.=LM.5 '"XH.!PP0J>;+$<
M!DTP7:1=9#'F;F8381_]&'G1LM]+%RL$9CB65J<3[Q[5&AF6<K$.GYF1O%'?
MO6NE_9/M;O9'%%@CKQJH!".M3B#B2%YER,.,C II8T]!"[EC8$Y+F>+0;3=!
MPXI>.5O1]MK3T\42BDNE[!.(#Z1,1AY=6IEVW63R:(,)]K&>6%HC[@:M_T"O
MB5$,NHP:?L.';ELR0DQ;LH7B_TOW=@[STJV@]VS@R==(K=XC=STU/>6(K0TM
MO6K)!N'?35R=#BEX2K^RCI8WESQ=_RSLU< G%!26'Q1C_>$CB@TPLCD+&$J^
MUJT!@0A'&7+QP)-:TS>!\;.1II2 R+QGERM]NW88*11]OU[0);HHFK,LU_(Y
M_XQ@JH6_JB538#!(]VC1S5ZTTP1.SFV+PQ.A!(.1C+S.Z#WNP6WO4/RQB#H*
M%I,S+!B/]3@=6@B[]8ZYV=CI;CAKM1+1@I?Y<3DEUQ]M6&O?3M+>_8=+=9(\
M(L4Y<)'Y#?U!L GVF"#"/,H<EM&@J$6L$YX2]A21)FS[Q_V^K_$J*WLK7^YY
MU;4\_>CZ+L6,G:N?5.02[KS;;"02EF"0,1B@TR1,!&QM9 %D<^PC$0_'HWW#
M+*!)\EL.N?1G2$;8\?U5 CW(5/(%Y,>;UP\<F0I;EOO(32"PX7A 0>H]4)&H
M]A#&6SY;3IX+HY]RS9Y_?W$DT[/X];4_:FYXW1?=XU74E-R/N_M_Y&63*=C2
M=O$RIP0L2;U%=>EQ,*J0*AC1]8Z1%R@%NGG?FOWSIOZ5K]_NKM6$6,(&G59B
M[".OE'QH^?KF?S5SKM%0KU\<GW(JE^0:G5R&4,IECMPJ,KK);1I1N4ZS)(PT
MIOC+E,F@R6TJ$3I&$J(D)C5NF>9'1-*)E-L<F8MR'<R<-'YE?N;\.B__+\Z+
M_ZO_BV<]KYZU]E[[N_?^[+6>Y\$8YY/Q:?BZ2)GNMD-8%1E*XB_37L>?N"KF
M>3?7L098V>E(%3UO#D9'=Y]5\;7[^:P+*4&F.:Z$I;6^RE=<D?<^_O<36W&7
M3+\Z=!SGM:)(EPAYK1Y.)ZVS*[QBK;X"(H_'PWM'QL%#S]\&-_0-+.V- 'O;
MQC:"F7S(7P#G,!L=74U@3!2YE#R.2NC+-&+7,QQN!)SV:S<IWWGS4BI!H0W@
MWV3<3OM& LW\18($@5O&2':JX::,C.>6[Z<O3.\LD=*JC4C2%&8:7$J$&*=C
M@_!>P1,?(:($0EMR$R6FB3$D:BTTJ?."5.<-)+UY&K\6.1,#]\Y^C">EE< 3
MJ7J)].R@'7Z8RB]*Z@?6VN'<YN4(..:J"_;-\'"L#5IS$R[>3^4*C)LVO\CU
M?#N+S+N]?4*CT-^242+V1&V@V,(:S2:/P]23VD\) $LKR8!0BZ!))KU<4>X7
M!7&[!)ZK7W[%_%614( Y5#B*2;!N-XU5VV&7>=L(&?4SC0QD]LM.E)W-DI66
M2MQ,XU/O@I/ZXL&"4F8]Y!M")[H,*'VOS$_;>>YAZ>?8G,YY3AC,[ /0C?CL
M8=C7"ZPD4]SP&.4P6#Q^W;\+T%Y8[,<\F^7>X9SM"\Y=Y2 VRAK;>;[I * <
M\E!,XJZ3HOZQ<Q_TI![-]1<@YW+$?OO[1<0O'SA(<B).K#I1(4<H?J/7?37=
M_TYW+N[A/CM^S(XR.PO#8\N R$+L+UT!XZA"IFX2#ZB/2)'H'A]8 [<1UL(Z
M\KGIH),YT>HY%51S67^O[>N6XAYB@(]U7X"Z6ID%/#HK,\630IY,*VY%N5'<
M(GT!T2C$2C+^*%3[[35'1W;@_3<]'<:K>/J#+!64NN*QJQ=+HW(C3CK:MRB4
ML-Y&2S4Y,#.D/OJG$9T!_OPPCF_E&<K,)9/)%)L*F0I8&#Z.LXN>2XP_7S,6
MW$W:<6#+(<T:5FA9O%.0;]N5<)N&9)<ZJ 1&'37I&= >5E\*3Y7X &/2+G4Y
MZ#?F'=[,SO^]>^^GCO3"F*V%GQF!:BC3VJX"^Z^.,GTS.<(\%+I'%7GB(<M&
M)I/BY)@18^<5)0NL' F<P:@[%G#C9T?;]'Z8,K6]QT?+((O)7G '('H@:91.
M071VZ+*13&](ABI%&DSWA#T"LSMNA:"'C8,SPEV.LVU*=M\QL0XZJ-36/HE0
MB%M1@B',O \JEB-$5\'#<H3W8+ZD2H[(;^R""N6(E2_5<W+$\ '^TJN%D0_2
M(V(UT;0D=Z&]D9L.BW;==))^PR#%,6XWW3?U3;_3Z29R9:;WAIY-9@KNMKF;
M%%B4%B$/W(:?@^+@ZA'9_)-*0*TNGJ)E)2FMFE^$73.K\@A7%I!)FXAHSC2V
MLKFIU1&ZO[C)-,;(L L^437@K':?VF8*$/X$,GQ=&]3$B;@TA5A7OT2S.SDC
MJTJ$CE@$7IHUM ;NK^-32;O%2S(--']C>L>N>5V?6^T)C0["S^J\T*)C;,;K
M:W*$$BMW-2 2WI+FPX:$);VGBH\N0WIM/PMN+S?L$);V_$C5VO)$<8+ (27N
M09O0(B/ F<J]5#S0<>L/Y487;QO7/0YS,[4  :2Z]LFVWQLA![=OWEM;7!G5
MD,.=YE[.4]%VZ',K-<FR\UF]Y:&R-@*!4$94C0,&9"=!^A5[;$:).MLCJGSJ
MDMFUQN<-5=3?;N@%F/CVFM1-(=9RSD)7T9$DS5DD"_D*!6Y'=Z*40Z;N;@?9
M!9LC:6S'*M>P%O$2[;%Z39ZCXL6L^>F>,:S&A(FISQT[[%W\BO+V95-J&Q:(
M8EYWV3@$1*"Y> &>1E'B?R_[>)9M(X2=QYTA5IV9_GHX\<*C6?W43\F$+4:/
MW'_I^D^F!CU.>O GG3]FJ'4%DPQ6/O$:EE(I.(&JA7OS9A*-8TBV8:7$5WD\
MM;L[?]BL,FM7T.4GDU$YXS=33_DB7,@P;7F*%A870+.&FDHPX[<A(L>6? .E
M:5F^1*=4CKHC.2+BNRB>F+AGQO]\TC#'^-D)0R0 /:$<X]H@9T;:,E[[-XX2
MUAZ^M\B\YZRWK+KR'O]TVRLLG6,$T9R/\Z/QZRE1$CVPW*>/33+@,FEL+V>O
MC1,/" 6O7_ZPN)[C.1AKSQDQ<8I47-9L@&7\BPC\LFQ.;7.HD2-.X<&MDYT0
M\B7'YJY'22!8/H[9XU5432]JR V&,&'IV?7=%JM^/75"NU7O6I2K9M('Y'I+
M@%^.KJ?"ZJ8Y]%GUOEQ(3D(W2FYGUR?;ZE0+J]WO1#'TK?KWQ41&5[>_J=+I
MBUTPIX]2B<SOMBAZB=3;7HZ '+%X'8H+1 /X+ZAJ20;3P!IG&$G7:( F KQ*
M8*N5 A@F< 9B&E**;#':MU6-$@M&Y\/SG)QK<3VV.N@S21_QZUW,*&[0[Q0_
M,9K_I?.F/5X##%IPI?M)(BK.A;&RA/WNJCUY-SRL3^/>7- L^K[5]5(R&2O3
M6X93F0!'4G0 "YDS..W,NVA^ ?"TMQ,U?$5J(<:+LB6)(>+!>E3R(B":<^PP
MU&<(_'W2_\AU[=]G%]8=OJ'ZKY:T-O0VSQ^&_WK7X>?:U9L)CP9=K7+$-6YM
MH1"=":BP+@?[]XURKC Q!*VC_2&I*MR36T?F E+=IHJ/*$TR9A9K''AN'ZP6
MBSRL#2T()\S'YN<]ONPH1[!SGSE?GWGKI=5M.O"_?BV_48Z(("5W2QQ(US=C
MVZV</"3$\<YXM"9AU>+L)V_CT<R+5M5N0SFI'AKO<+N=8Z.?_[MW_Z\++1_Y
M&U!+ P04    " #1@?U4%9("Y:XZ   E3@  $P   &IN:BTR,#(R,#<P,U]G
M."YJ<&?MO D\E'W_+WY)4E3V74V%B*1""IDD^XU$)L0D24B6[,9,D7T+X8X[
MRDZ8[$(F>V7+.O8QHY)EF+&,8;9SN9_G_,_ON>_G.:_G.?]S7K_?.:_GZO6Y
M,N::Z_OYO+^?Y?WY7M_!&F/- KQ&>H9Z -L>-N .^ ]@K0"'M>]YW'4"G #P
M8&-- CK 'K;=8_>\9_?8R[Y[YMB[EWWO/HY]^WX7S@/[0>'<MV\_]_X#7+L'
M^--!;JZ#NR]V;_*7C^[A8&?GX.+<Q\GU+Q^LCP#??K8';!OL;"> /7QL['QL
MK'8  NK(\;MZ;,!?#[8]['LY]G&":G"#%]3P@NJSLX-*<X :@^^&@.\#>_DX
M^(^?T]XG8.[ ><)+\/S3I#?[I:Y6M C=&"!)*]_U#CW )2PB*B8N<U)6[I2\
MBNH%M8N7U'6NZ>KI&Q@:65C>M(+=LK9QO.=TW_F!B^MC'U\__X# H+!GX1&1
M4=$QR2DO4M/2?WV9D9.;EU]06%1<4EE575-;5_^^H;6MO:.SZ]/G+X-#PR.C
MV+'Q"3QA[MOW'_,_%Q;):^L;FY0MZO;.KEUL #O;?S_^KEU\H%U[=N> <]<N
MMCW^NQ?P[>4X?FX?O[8YIX.7P(GS3_<+7DUZ4]%R0$KY!DGHKO< E["T"EZ&
MO&O:[Y;]<X:%_B]9]O\9]C_LF@ .LK.!D\?.!T !!CTG1@[XM_Q;_BW_EO\2
MTF1+P!)#6 !7(^'PFUDS*BS[$8TGE9G**/ON@>,WW$(4=*K-%2]DS$/Q&,QB
M"NI[, NHA@U<QVL=:Q^(M_'Q$),>^A%1_+;L&V(:>0:_K!IH7FPS&.M2;OUS
MJ&KBPM3.^9CM?J8$C5FLQH1A:+H0$@ZW:8A9^\ ")A3@FVK1T/DNI@D/TZ";
MX8O/WF8!+""YGP4D:<7E-#]F 1%,%E!BP@)25YD#^G2U+<8-#SH:18F!#L](
MLX!LR+8*=/L8"[ +<&:B6,"W*E#,<N70O[& _Z"N.0LXQ& !EIDL0 ''R$G\
M#Z-"L?9BX'U8P/9I4 1^?E&8AU(]5G?R<-OV+( HB&I#H49.LH O6RS@02[#
MA&"V368!*3J@ECR;V C4/ M@&D.9U_YG9LJQ (N %"8"]>TKJ%[8?T4[A7[B
M "TH"VA=9XZR@!ACFA)-Z1,+2&<!T-YU1/_._4RO[[3YRQ6WZV?$^M;H*A6B
M,;??Q9=OYVRY* IX^/G>J<^6ZO$R;\,O/3:%57Y/'K^PZ65\+TA5T-R>;S5<
MT/P*Q]\(#-2[S9K9C]L Q_PNO\H"XF%6$NSQG?#%C7P-CVYA8@CZGC?!:^RT
M4'.%U=GFJ4$CR@S6E?+^Y_#?^>BNV<XT*.KK+J@OWF*8JG;PL9=8!KLE"_@H
MP]27I?PP9 ':X"O211;P\I^\AS[EI"\+N#(")1U /4<]NI>](63& M@3M[/B
M=0/[Z:K9RR#4H!\P;Y2S .H(A#2*JMIB\(#H&C6R@#E+U%UG^,8A"Q8 I&]S
M_EN#_P,:. <8=S1#R-A((MT";Z=#M!*QI4?3"TTF[9*:86P18@;?_,K$UYT/
M#&8^&\D8*,PU>91Q6=[WN!67ITM!><:("L6%PB67D_?N?Y(?V0FXB2&F*6<[
MA++  O*>8W_#YB)'L]<\M<!@K#-C2$<T_<#D>)MM\^,Q2U/0C1<HM?GL-8T.
M%/8S"UCX12XG9J/_M%Q.;F-CS;N:M)V='Q?OA%Y(=LGW?"O.EMR>!0#W4JX\
M,M1%=.>A6JXVZ9(YV]6/-I(L*/?)^K&:?&4!'K8CU=,V@XM?N!EW#VFMM$Z7
M/RQSKK_Z-<5OTLI"L)(>+@ )GM$205PGH3MPX0TBG1 N0_4',\<'[HR<MF%"
M3EZKRSAW8CL&.<>A&?;UQ_L'CF>I+R\.^2]5C3Q803>,N#:6S]]$",L>$I)/
MJC,93;QY/ZU?/W>9=D1(Z!OF(-1U&CK'K/+$5>&>H)OT\<&*VF5G-$-\?8]D
M)?J0FS^G?>[;1ON==3HO?77/EZL]!A<W2T9377WG>CE]<;D;(2'FJ:Y"#XS3
M<JJ((T'E67%RZ#2D%@MH,3M!U7[K5J?%P4A"RB&ND.J>/2JH(\/C$<IY^HQL
M%^F#5M\=7$15^Y]_65*0VQ\OL0?,9GPKV55;79@(>/5J"X-G+KV%Z$_3;]MA
M%&?T^<?E17WID(ZYIID7M?BI>ZRX16KOG#[D63O,QZ5OS6;2KK9A!9T_,O#A
M(48L\O5;R_"<C>;,56?W5S5551KR<CD-?6=W)QN="[T#V<Y$$=M8P".%>?4=
M90H;Z*9US"DHA=#L&(?YEHD&WP%GU4NK,!3SK> -"_! +?"#^3M&@92[]2<O
M0O<%,41W3QIMB=LQH+= *>MK.'[,#Q$F 45\JBL(6^CZ_D97\#J;+FQD,UZV
M;>=F7R/:-6WTP@5/36QZ>DJIN39_J/7TV),20#K9$T K4E$T'R3H5P((I\>S
M2EQTCZ_P&[$6QMS[RWWWX^ULK.I"9R5.>G,,+M=KTYJ2=>[PA7H7V\>?DNLS
M5*N9^5%-VESL^,+GKKB,=APM>OU\G^''(R;>6?NI>%(FX7Z5[QOZ17)'%D8F
M1=W^]L_\\K([28='HU<<#W%]XMEWGM;"F7#H=N'^ZLRJX, D45-S=X5\3-+(
M@.[CL#G.UEIJ%H;#D1J>BXE-R-@)"WBDL>$V7*.GJZQY9>5:3Q3[66 ^;G;@
M5*?P#[_FIZ*F_M]AM1BIW)P8^6@P_I[LBM8@(QDL:;@FZ"ZJ.S#5(-7 _F6P
M_)QDX%D #2QN@^_?#KS=QFF )7-4EMD,)@$CYPVD/@LX\8L2(SB2F1P:(X<^
MO7DU1N[UGG\@/+$H-[/MBQ!>U&0A,UG'_K%]/,T&]?DC-8PY#=U(%E_/8$9_
MAGXSCF !:$]P1',Z+@OU:56(!<!E64 ^Z"8*0YKO2H[*DV;2YY0.NMKS8J6<
M*T<>GJQJNN9>.F 4+LD^1G3LA9?"HSD[I? SS<@C3Q#:C%A?QC.)^UKCW^I2
MLI6_L0#KNE5$<Y-EWY?#B]^OTA?[9IQ_^(-.%X4390&S\2A(DP@IA=*\WF1&
M<C,F43#Y="UJY!MKL4<JDQ+=#'EK:/7Q&]8W#IRH,V63(M[2>\$1'Q+,Y%HB
M>Q,F*9>I'C1-YI>)D:):ZG<"4:EU0I$9'[3WO(L:P/^NY_P>XP;1S]]$OWG9
M8OBUH$L00;H3OHR'(+(<,M>8+;@(W==DF[^(.XQN4NGEF/ZV90.<4UPXV5MF
M+!7F]8.H*W=+05WAL<TJ7<!XSNP9J.MO4 ZF6(#QC:I1+7DZ-UDU.T[%S;GI
M@$>1O7Z@XE2#:P^5Z]?,;OT[;&?U7Y6T)\;Z>)UK(YRMM_INEFX"4;GY)@!>
M-A>L%.T]/O.3YF1[Z+0I1"C62#6P9L2[VWK"S];&RAO%_:.AYN48M8V22ZU@
M 7O7R-#6_G"<*',_5=F,JD,PIL$//,BH"_4-+KY'ZAC]6#MP.S;*483O?+'6
M7?D+4DDQWZ]BQE+7/(@FLR$>3"Z97+HJU3R/KDB&15;;*7<U^$?3_8L"ZK33
M3=5]A%VD)/8_^QA20'!^KB<=UA,N:-"ILZ80K(%P ]V[!DZ7\Z ZVSV@7@O0
MH=VBFXC$4B UVY-:+=\?]C$P%_Q76$!!,#)HB^3KK%<Z=TK-E'S=;W'TK6[E
M$"S'_>V"TZRCR]4:4:-S1B4W'L-^9B7"R)=];*I3:NLN:,D$=.-QRW@2S)+L
M][9 ICG\M4N/X]##V:FM,Z9CQ!SM%.DAHVYQN6[-9+;/KNM*U),\RQT$R+@4
M18E4V(H2M^WR0!M2XF%VE>$M"5]^K-S_;?+,Q7:CSWS'GMM<.#8;0T:)(4<A
M-;+16IJ]<SP"8 96UE)8FI$@?2!KL0TYNET\L1Z:ZGX#?_2JS6R$4S0/[W''
MG@2C$#6:(OTV=8!<U3*1&,\\1]_;1'W49>46(M(65#/1CQC]%)WY<OQL=+.>
M9T71Q5LMI_WQCCQ1K03RHI<IV?3<UKW43)B_BV+@#2-:T,*MN L*!](O&KXU
M[+RQE3,]B"CY7%>H[#Z),L:8@%$UH7GE/S<%<_:"K,2*)PPGCE1#=@2Q@' M
M=A>WDJ5:FZSLDKK(V_2&Z0]E7\QD7HI);.T]5$7]PK'8VM1-D:=NTBZC6@Q4
M6$"TNM9;)\93PDUJ?FY EME>MZC8DI]#"PU^T2(9%;6B.=-C)B*_OCY2>)BW
M^<M.Y-PJD7M6:1RC_U73@JQF'F8VX)LM./D@7;UF^E.,!&>](:+XWGW1_4[7
MKAI>SS%IQQM 03[4<H4I$*!L3LTD9$]H4()'TKHI3VJIQ#>W$.?KOYX!\Y7O
MIWM?5:14FZ*>19=9G9)].15?\J;MPK@HY-=>W$@%U#KL1LV+V9VWIGU:0=5I
M@T$/^HL_8T<]<3<S/#],R9])(#6DIP[;!G>XE5RV8')ITZZZ9O.R -=^ -5R
MJ5H"P]OVVJWA7I84M93)]^[]^V$/GV?G3]M87AW_):FL/4GP)?-ZQ:=G#6\0
M--SR6YH5LP\BI!IO2_&EFK_&4:'V)([2ZSBZ)A:A-7%S)M,YG,]0<N_#!_OO
MM>D9L U=G&EL@G?9'_$8WV)RF[]&?K6_..F!A\?@N/))R)=E4T?>V2P]G^KP
MK"V?_ZZ7)N'U/50[:3S5VW+^*BH"3>9F<MNZD=/QHZ-#33PDWVKT45>KPBV3
MHMNW>]Q+I1W:3$\X:)SZ;GZW3^V8C/Q80\#XR$#=3>V.,DO%_%<[2B@W#4R2
M50)_P3[!&G/+]\,I WT[T[9OM]0:JI$H!VQ[6O-^DD<H:O9#K<(LCFMAPF@1
M7G4-FQ'J4FNX9^KVA?K%H8M7U"Y97K^U=C4A %W4S(4<1.V%/J@B'"?!NT9W
M5NDGD,<RKY$YDSQ44/>:8R4(C,4S).6V@F^//+OV-=_';A(/H68QXC+1HXK7
M<*2>2MM ^Z"5]80:E1Q-Y]5ME-9,8^""W?L7/T<BCN;9N$WH]5IO!BM'GBZT
M>4$6_):!_.)ONI0S#7$QUQ4B'CUFKBL(@,)&2?]S[>Q#W<-LJZV"Y'P2QTSM
MM8^']VWCZ D5T,TUU(X%-'<-NLWO@/J=Q J:ZP8ZEX!GX!\)PO8/E7/#XX\\
M><,4I/LG;JO]7IP3?]#7F?H!Z)UM*.,4V _:O_R^VQ7R74Y]D5ZQ>-[F&I;O
M&KGC4IS(->_\%VK7#UR3]I$1N<QAO&N//81V XF#<D"=S/@?,'G)B#KQA,*B
M*3V/A]6M92=?/>C*C-9GAD%F')(O2M(XPS5A>(PD]5%W!Y-WM&SSB+)YG?4R
MVOW>(<F!=[-A#/6PYX&";'^A77\5N![R(W3] HA+)',*UN>[X;S,S@*4/1CU
M*&('HDL,]5D-SIP&422$F'&@/IOH,&? %](A8F#^P.NO.OS'>_U^O]\V=\[M
MGOPC(>L@>7B$(LY_;Y9!]2@QVL%!0":"'DKLWB4J7#OE*?EN#3X36N\+;&<F
M;A\WCK6MMS+X;C%B?8NW;0PK1JJBW*<>(IFU9ZS&(H41\E]]0/[#!U<<?:/U
M,D^;[8;B;%AW7&?,C?/'8'(7SVLFCO3Z^UAYYYL^OO'"PLUY;%#5M?7PN13#
ME<87FF9X,^X G$YVVU%ETFCVVX4Z(^%YLY'3@X0#3RZQY3X7>G1%,V$8QT75
M:45R#!PG]8=J*A4^F'!O1L1#C2H39O:O8Q]Z/<DE">7"08K6]AGJS$-] /9\
MSME$%K#CSP*>9?;"WX5@_+2Z,1OK6BNKZ3-OTS2G1K'O-=>^?V]^E?B(M!K6
M)(7GJ64!K3)X.S5CYB FF6;.[*M(X*FQTU+K/_E1[=.8F%^WY,&,;E0H9M^W
M$=-&V5;XP9JEVX'$ !^)QZ?2_5:5D3TKTWW+\YI8$UU9TTPKET.619DN'T P
MWQX#FRU@5VC&%&,6D((DL0#&![!8W![Y.3(/K833,[<B60 1[#.-?J#UT/.(
M5:;^K>S?/3)[8!M"CSZ+V5R![!B!?+2I:N2_,]._)UJ*C#+HMUF$-CBYV3N&
MAP)[@]2(+BQ EIW 0_,!G</ K<]M1U8:Y*IG))@?P')FJ+^.#&0!4DTP!B*;
M^:(5](%?UEIW>6D3E++-*-8TI,DC!#U$J#HM6[][=TC,E\W7BBZ%!MWM0]D,
MMB!E3U-.+;PU4X%4&$%_C&_$[0_ Z-8-^_3J3;_^4-D0I_)8K^VY_N;BX?W?
MKG/.LH 8.HQ@)DE-WNI@*HV6JQXQ,Z]W6?5XE*<H/7CN6PI#G>W)1:$-.%V@
MD#)"?442Z++"<;E7']+OT)+$EE/T\4LRYV_;3M49ND<^9 'B/L>$9^->HAZN
M4D_BVE%/,7Q$*/[Z _'(J*9S!$5M]PVSJFM.68/^4,72,1;0=>_B0<Z+Q[ 3
MD'=JRX?PF'&+-C<""Q#I\"BB+IG7=1 7GPPL#+S[,0,&V9O/(XGLWR6?!$>&
M-SF@W5C X6/DVL)911WC8:>A"3Q=PV?QT=WG>ZY))Z9[?3SZ6XRFXMRA8#C5
MBS.^!LKF*FZ?>R8+RX.?++1X+/B$_[@THC$!V/@&T]8%'C.%R1$?T/2+89T3
MV4]J#BF9IYNY19*(0\7O8ZX<X$W6LNL"@KSE2'5QJD04OOWHA6$Z1Y%+4%Q#
M\&UHY*-7)CTW (-G26LK%]F'DNPX!-GZJ;:=XA0,B< CX8K<,ZSR0<_N<CFD
MK<ZTX,<I0/JJP;:_)-O"I]S6F;/8&A80R1LP:4$2?I._>'Z!Z,D\TN"K=LZ
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MO:=+VL]$$JW+42TV2%6$"98.DM.]M-%F$;HZJ3^LQZ].ZRSU5=XT;HJ:8O%
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M/G.%E7NQW< $(X:YQPW%AW+%16%(EO 8I&C#P*9'E+I08CA2[*?ZJRJ=P+P
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M.FL+=GN_!1/@8$R@OM$,P!6T@X [LE)(<,B(H+O3X+]@"(U:-#^*'U65IC"
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M&@]:TS0IC^\MR.3D?<W$#LBV[_DHL,U^4&[:3[;G_[93DAIL)%2HW/1Y(\L
MXC ETG"H9$5YW%$F<?A\[X_&&O>P;[H=@G'J9NNJ@P?M0IPS"TW#GT)"&))L
M#PX)KD*WOB\>]SKNEK!T?T&N-O:ZI>59TU%%<ARQ:B6 JDT)($<2KP0CWSO:
M2(N9VMKE/Z+J2JN967]O5I)3^"[Z25:\-#YJ6)%J@1BO55QN*%F0X.]G #1C
M2D+18J*GC4DF[32Q9O"D\I*Y>Z36EU#8,>G ^1=T@O!KZOMJ1<H165H& 6](
M]U^$[?C4%]N27]/C,=.9C5P4_ RXB1QD57K^1H/>M4%"!=6P&2O@;W6TK*&L
M+/J%JJ/G@X>3ZU\,--]V:H9^-6FOMXSJ,)7)M'E[.UNNK;--9I#@.V!M.6RL
MX-/K$!#;=/=PJF7Z]4NG7F1E9,W&EQ?&QUT9<_9[G]Q@FLT$[!6CDT-7V(F-
MXS.NF43;=L0N-4LS?4@H+2!;(2:K0-QE70)8MK607)D,.L\;)2);.E01<(?C
M4O60V[W:.'F'KLY#":^JSGPX%">7D(K]&.3<!;V''JNZ0B]#/J2+$5YH[TO1
M';!/#(#LG5=C2^KW$7^\QZS9"(BM=KW]U+=VEO6EEF_#905]:Q[NV"25/K^*
M$I^&VB<25T[&IT>FGM5+["ZP(9>-T0--)>FQT$<ENQ"CHC;* S2.:3K2,+1)
M6ZF:.+FA+5UF[?SFY+L8U5>O]90,6"]:.N,;S5[F/'M.0I$IQ)(6B!!-IQ=^
MECA\DZ2?TZQP 'N#DIKKF'2J@Y[ WJS\Y656%.] IRO*?9[[>#O'MSM!ELE,
MH$GZJ<1I>AX1^F-!TY0)I.M?A=^AQV$<^/?XIY!3^AA"_H)0P9N,7NU#%95]
M*K*#*T6$'D6KYCL:\U/AJ0\<="_)&CP[:ANB^_2I=4>,TJF\1+,"W@<3Q7V-
M7WP_#C^6*T%W!UQOLALHN_0J)^LZZKCK>+7-JDG&+ ,FN_DME(#BI*":1)&"
MWLB]UL;O< O7%GUK"RX*BI7[ORA0_=&^MUWO 8&UZ %-C/(6MU^3U85T9+Q%
MS,HF-=_D1/(!W$&3Q_?JPTZ.GMJC^V"7N<%VD(;K6&L^Q:3DV<9-!,3?EGPP
MONTT]*FV($71.)+ '_;S@8".#WO16\255U^O"#R\V-;=(\OE_%%U9EYD$_4"
M5A'Z"1.ML5+R@L8Z<RX] /E.IBIC;/')T<%G QOOW2,#G,EA_=CG'K W2D_G
M+[+T5&4:BF&O'W<Q-+9:NN53]<HFS95>L>Y\[^PQH_[(Q*J&M-@%Y%D%> +Z
MCI8,F,'GUX/^6QUGWIY[SC@%EZ<$ST3[-=FP4H(SES1*0J1#H (W%_P6SBWT
M&6.Z8EQ>;+O"J[9-OZJN[=9WLQF]Y>1KYC@6G64INB6@[-6D>:_OPKT0"[,F
M-D%.S;W.,ZL4&5PP7&4:/;Y$_D0<?J',HZ5XI8H$"XENB$$_^M B2A5/<LE]
M>OS[&Q1KGDI;>.M >D2ZR5''2K2/PQ>KP Y?<9XKC:(-!I,+;2JC4QXQ&(H
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ME;(2K$]M./E=;FTG6T2!'."CW?"\0UNHEE2!;4FYXWK,ITY!54%WW31*-"#
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ML!O<*.*9(6?;$7B%*3+M+#.!YUN>Y>Z/GRL['%$5+_;9EY"NLG/LQD8)GW^
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MM_Y&,:@/.N=L>F9<YG)Y%(O^U">)2"; <8*F/J@)H7*7T(25IHNSX.=(?N1
MDD12,46M;>?)BSKC6ZOI976E(.4F)GX\^FW[,#QS^_#%PZ\A[Q@<%/YI4YJP
M%SZT"34^3("T1"NU\N?#%3\,PD_CHY^TG^OBW;UZO2IB9LU_YM69BJ9=<FR%
M/ :QZKIL?:Y$?HJZ;(=&THH"]4P7F&(9]"2;\3;HOD9E9PV[^'DK[QDS?(/H
MU Y/70/L^C%TZ5CNL_LX&9[R+(-#KYY-(GIPE=CE=/#O+.F)""'$YP-5[6X\
M(_[Y_%R.4_N(RA+RC:>LLT1]\US'VM])?8T=RWEU)XBV;D3-_?CU%J!9 O;
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M4BWP<>-+U\KZ4#UNRO(]\D]FR5>&2>@ &$RM  :OAH[,=/-74[8H%70;Z"K
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M777MHIY;RG)X><91LW:2@3\3^U,$31DU]A>C[_]3P7P1_1=02P,$%     @
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M*I( ^I$?,.G'(O1"MS!4NXE=GO%APDXWY30N"Z-YRLVYU)X2!R;JH<R9EN+
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MO9#BX]NON4GL_?8B9]0DM9P;DZ>J'Q93'\LD0M!'@<F[I0)213P88N$CA?W
M4^RAR HZL>->^ZF=.'8I0'^O]/7E/;@XO_L,?O[R[6]WX.?;;U_!MYO+V_/[
MJ^M?P/G%_=5O5_=7EW>.P;OV2V%'H_T W#-=&BXL#P468INTQ'=&<OT9^PDL
MA0<KZ3L,R'5&K*L(7/N)APVY=09D)\;6?816,7CUB6A%GU=U^+RF3J[_\3XK
M$UP?$LU75 1(\Q;3#":T/TLY":!(E$R2Q N93!QB\RRF')MUN)!R81*^5-*:
M?H"F-J5ENH$#Y,=W%[L'LF>&6FLC6MMQ2U1KF<%]!NYZ@=,I6K!C6(>+(ES
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MDKT8.>HC^0A%L;:E35ZS,K7GJ(",13%4@:0>0A)%";>-/'&;>FP;SDOI-4O
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M,0(E0RPF+!8B#MRBSVVG=GFEA@XK7X\EGV8%^"II/I^99)[V@>762V)'7'W
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MVKP=BK$R36QD,WA(B%,9)2I&+):1U_IV2'1C$\GWSZHN5:9MB;,7"QBL*@/
M2LVKW_23*LFM.QT7P%^KDWI65Z>$2AOP=4$DOP1+5?=;%D &:EI ' V?;<FK
M;P9.P.2&;90YF;QH[9JFR:^1#A%<R@PH\Q6Z5^_*NI@W<XO&?(A^58O[)7MZ
MF(IK,\F?Q&F*(T4E3');=3Q5&62,F+\RDK!,\ARYB;]'FV.3]"UL4.$V'ADH
MD=OP^RUV8,%[!#LY]D"[7O?$:\\J_,J4>H24A:=VJ"BS+<55Y5M;9Z(H*>8O
MX'Y+,3/X0P6A^;'5%I?F^*3A0M7\3-N)7O.\M4,EON?EO5J^U.OY&ALR"6%0
MHE1 %',)280HI$;'<R+SE.;.DKWSY+$)<PW.HYS9#D_GA;6S]3W+9XVK0X3M
M+@,>!=BZ,C%4P3171OQ*FAVSNJT$V<[UPY4,.P9SI\37T0NZK2W\3<WD:O%8
M3WFV[FO]2L6$VHHR&J91C&TPG(0<:01)%DO3B8(([)5DJ[VYL2F210M7"[C&
MVYAI^DWYS[#L-H</QUW/>K:F[;=#VGK8RG6C)=!\^$QC@TYPW0S?G[$ZWM4U
MI\=R^MU\&VRQ=ENVN$PFLB[0_FESJH^P-,U3%D,B!+=[O[&9A>H,QDG"LUA$
MDN9>P1YNS8Y-7;:H00/V%;# P1L+_:>+,GLX=86;](0GN/=UP4#<=LCOX4-5
ML 0?3HT.G.'#AXC#%!]>=_O)E533R8?YJLQY9$8Z$[:=]VS%WME:ZO/5A BN
M(A+%,&620$2T@BQ/&$189C3&(H\3)[?G7$-CDZ0**VB M8O@#-1PW13H++OM
MFA.2LYY5IBM=SJ+BRL41&2F4^/E^\?T7\XA*0<P/6^$X^^!!I,+5O+4X.%_?
MS7NQI33*P)2W+V^9Z6BA;A^46OVZ7#P_3>?W98;IB62IMN5B8")C"1'/4LA0
M:O1!1YQID9"<.AV+]FET;#*QK3ER95<?:]R@! [6R.N4W)YNBU,?N#DMH9GM
M64S"D.KMK_BP%,A;<6IR4%_%AX1]3\7KWH["=#K4I'%6J%FM89(PA5EN9$IH
M6PQ8X@1223/CT$0QXR3"B<XF<W5O;W04*F\03H.+5H.K":6_,?9)%86MB;XY
M4\<:<#V%RK]/'&6K'YX'$K'62+<KT#S/>.W"O;^>=:8OE+KY QA6ZSH3=*!\
MW9_DORGV33U.!9/K9,N)CF*!,@+-A<+,T)2&/$K,3TC02.9Q%F7$=5=L]]%C
M<[:^??CMYMWU^P_NNT)[5)W?&.M.0,]RL@;686MLCP3WO;'N9 RT.>9.BM?N
MV'&[6[;']FX8;'_L.-#F!MF)*[H>,Q#V>)1ZKZH_;^9?GLS<TQYK>,>>IBLV
MN^;%RDY&)YCG2B>Y@)0G&421QI 1ED.I<!P)3E""(M]:QZZ-^[RHPU17J<(C
M"ANH4A7!*X,L9U/&I[,Z6G->E?%56BNQJG/?,?$_S]-B:L=0=8><VKSDT]6S
M ?<7W\,(SGWGYISUTQ\]J^@:-'BSAOV3[90-<E!#!W^LP0<]C.#+6+!S",X-
M#WP$P9>0P],'WD\(/^]L>'4?JB*8-J#USG2>FC"<IH*S%&*&[?*Y$)!):<30
M***11DV,2'JMD77#,39/SKRB6;A)9EL'7#[3#$3K:TXWKX!%+O:GFE=5+']I
MRC#33@<N!YA[MJ$8S034@2J?6:C+X[I)XY?5@UK:)-=+]6">6^Y3BL6CVNY;
M%O_US&93_6)4^;KXFY+&%?JL5E_T'?OQU<):S)OYFNX65;:FC3^"C$9R6W(K
MRU$.$3837*:CR);G,[]-J8B55QJRO@&/36P;=H'_8(]/?P4/I4F>'F3O_>PF
MU6/JO9XUO305[-@**F/KP(TKXZ\6#^#C;/$G* W=">M8']CZIH0]?CG59B98
M)EFP4PE#QM4F+5H/SNY0W13H<]$[W$&_*T.1O_\!&JS=;E^JWQ9S]?(;6_ZW
M6GU\GLMUS*E2&4M('L.(4@51ACFDR#CJ28;C#&%,<N156.MX,V/[*I0HP6,)
M$VB+T^]S<(),-Q&_G**>I;=BIT((2H@]Q.NVLQ!(V4XT,J@>M1NZKR)GKNXX
M]MF/Z>/SXR<UOU\]&+V9/MJ#JFIZ/Z\B9L2+_93:+VFI2A.>*Z3,T(=)+C1$
M+$*0$"HA0C;HQ=9])7ZBX-?^Z-2B@@]F)7Z[4KDR%@"]6%;.)% _GLJB8YXB
MXMDKCNK2']=]RTY-\Z<-S1;\%:CA@S7^?;\OH"9UXRZ46'FV/JR*=:/F0-XZ
M/L9_H_ANJ1[U"ZN_S!$E*.<Z@EG"$$128T@08I!E7*19G"F-J>L^\<Z3QZ95
M=]\^_/;QG]?N&Z2[/)W?).YL?<_J4>/JL$6\RX#[#G%G)@;:("[QL9?3)^V]
M]H6/6MNR+;Q[_6"[PD=A-C>%CU_0S:_:S-HVP7^;'[:52-<*I-(<8ZVA4#*%
M2.,4<D$R&.$X%E@RP1*O(G0>;8]-HVKH@)G9Q2;:%?Q6)A]5_M5)?'K!S8?J
MB=N>%? LK3W,XCHP%<A;\FEY4$^I R7[7E*71W2MJ;EBMK+ ![:<3^?WZX6,
M!-&<8\*-DQ1SB*(D@I1E,11YDB,L1)9RZ5<Q\U@S8].E-4JPANE;W?(HEVZ2
M<SE#/:O+ 3D]J$D["<'*21YM9.!BD6V&'I:";+VZV\BO2RM]4T]6;.;W-W.]
M6#Z6+NFGS;'@.**(IDQ!D4091"HBD$=9#G-FIE&Y4I(E7KN/+HV.3176E< V
MH$$#]04GLYTZP$T\0M/:LY0$8-1;6GPH"B0T3DT.*CL^).R+D->]'=-&3+]/
MI9K+XMWB\7$Q+\L0V.6@2::UB&.L(8]MKEIA)E"$QQKF2<P8213+"%F?8KKS
MR!=QHCVGH;)[8.EN "$JESWE&C-X8E/IF0OB%+]N*G,170/E>UA#O (5R*IR
M2!4J$#"YPQDF0J5S.-7,L D<SAA[D++AW/479K\VLE/LI%BM_>S<Z("0)(/*
M)I)!1A0@YRR")(]BFB0L,A.83@FM3S0X-C]E-^6Q1=PY3]59KMT$(R2#/0O'
M8;[H?K-5N5(3.G_SJ>9>)R7S&>-/9ED^=U^'Q,GLI4PM\W&Q_*9LHAEA$V/-
M[S^KU23+!),Y$S G1ET0Y3&D<9Q#XW2P!$<19S'R\#[.-#=FYZ-0J]6L7$IT
M%)1SU)[?;KJ4J8&67FN494S #LXK8)"&(<LCOW$8TH;*:=R1/+\DQN<I:4M<
MW'+W<,F*SYNPDZ#8X?)NKIC5@NNYM']\^)_GZ7<CQ::=[:(%DC'.M6:0LYS:
MW#@:TM3H)XXR\P90IC7RJNEVIKVQ.6*E5-HPX_*'!N(+%HO.4>[FD 4DLF=!
MO9!#;W_,D9E [MBYU@;UQAQ-WW?&7&_S]\4^S!ZGR\6\GFJPC"0I37.H<YY"
ME&4V!Y_,H,01CXW((!PY'2(\>/+89*,&Y^XK[/)TWI7J;'W/8[W&U2%R9Y<!
M=_^H,Q,#>43G7@4OS^>HL2V^SN[U@WDW1V$V_9GC%W2L2[LINGIK^O*YJ&NM
M$Y7Q2","!<X)1'$JC-:D!%(6"8Q3GJ7**4JPO9FQ"4^C FT%T[/X['$NW3R2
MRQGJ69P.R E8J-Z-A%#E9(\W,FP-V59##PK'ME_=<>ZR792N/QLHR;!.,()8
M9 BB'$E(S%B'RH@!DHSGFL9^V5H.VO!YGP=*RK*S._*5K:/%_BW^.3I=T\Z5
M42QQACF'DF(,$>,$<B(32"A+&4FQEL2K6L1%? XRXVNP"6Z*XKG*-?#L&\EX
M2*7CO.X2@OJ>R36Y";^0?M+T4%.U@^</.SD[9=[!=.SDA?X3L,_J>;DHQ%09
MB.LAG8H\RF("4Z%BB&@20Q9%'&J5""Z4RF/AM*1S_/%C&\]-A.ZSD2.TG9^4
M749&SV.W":[#].P((>YSM,N(&6BBYD>0U[3MM/TM<[<C-PTV@3L-N#F+:[FJ
MZ]E6>U;6[@INMP._*3:SU537A2(F,HIBA6,-(YE2B*QR$<I3F'(990E3&B.O
M>&:71L<F:K_/ES5"<%_FR9B5Y4_,M[GH&";@1+V;!Q.:T)Z%<0MWI^KT&G$S
M$4G(TZGN' 4[DNK0Y,#G4-U).#Q\ZG%OQQ-AS4VW)_.Z/;!"?=$-[VPB&:,R
M2R*HLS2!B*,8<I;9R9+ :6[^7W/NEY+]?*,=@@IZ5J,M4'O06U23A,)B]3S\
M=9YP-P4*1.*KQ!LTJ6S.MP*>\W)F)]3QKO,-#GNJRYF @\-<[G=VTYRWS\5T
MK@H;;\FG\]+C?;>8VQAMTZSYJ9C*,BVH#=2NDNZ^&(?(YB9F&BIJS\,S)B"G
M40HSE7.%,ZH0\\KPT0'#V/RC+5XC1PW ?GK4I3/<!*IGBGM6K#5ZT(!O@[0W
MG.]8< 4V-H33L L(#"1J71 ,JG(74+0O>Y<\JN.)-C/;+X,3W]F,?U]TJ:W7
M/Z;%A&:I))+%4&,B(#).%B1$<4BS7,HX89QSX76,[51+H],TB\]Z!?7RJ\7H
M>TSM)*MNLA6$J[[7J+UH\C][=HZ"4 ?.3K8S["FS<^8>'"T[>\.%@E"5BTLI
M1@E5.:1)(B$2/(<LD1G,2(RP1JG2">JD J,LSK=!UZT WQYWGF-];$7UW,GH
M/KC[*)&W]_#7&<:M9>].7-4]L'@OH/!Z+F\?%LO5G5H^WLQM!9!R,C6)[;8\
MS31,<+EK+S4DD?G"1VF2T@@G6"61;XRQ6]-C&^AW"UNS0QCL5^5_@6I$R]H0
M6E%51:W3G9:+ED5CT?(=6RYM2MIN.];N/>8F(?WT0]_^0TG^?JCR5<E^"1U:
M[* !/FSDLA]A 8.8'1L>/)[9CY!CH<V>3^B<?6=:I6;Z:MZGVR<S*UHL/RVJ
M3.6ECQT9G8MU3& 4I^7)=PVY3A44 B'.<9YAXB5S9UL<F[IM 0.+&-20P1IS
MISG->=[=Q"HHFSUKU*5$=DGFXT9.N+P^9]H;.L6/F_E'LOTXWAANP_RSL:GR
M$B:YPG&:F5E2(E,"D:(<4F($2%BU(2K/(DPG3VHY74CC^RU7W3?,MXWZ#)/]
MIOO\JM>.T?>Z&K>ZG\YM B:[4E#!N'R_O,&\)#E.L@1!:;0=(B)SR/,40<T)
MRR*&*.6H9O[#W'%K,#3OZX:'8UT9'ZH?OMTT/AR#/0O\B9B$+=9^(Q$..>DQ
M!J'1V*M''QP:[A)W<.0N/SF7:CIY7T>Y_=>S44.UG+U4V9DFF134.(TQE/8P
M"\IC#(G2"B9$82()9U0[G9EK:6-L?N(:)MC@K-.+N4E&&YOM.A&(HY[%P9\>
M9U%P(."($A1*_'R_^/Z+N;L2 ?/#=NRW/7.0 >]@U'J4NUS:,>516;VN2HR_
MK11&F8@R'5&(4I;:XAP*<HPUC 47D:WE(Z/4[[S*T79\7MZ!SJS4ZUA5%6'/
M F['N71S 2[FI^?!7>&[ FN"^BAIULI!J"Q%1]L8-C51FYD'^8A:+_8;\X7Y
MT'RSA;++Y8<4HP@KED-1Q@@2S"'#.8-4VH7MF'.>.!VWV'GJV#[9=NM@6JRF
M@LUVLY1[K.CLTM8^G#N3,<#F5 <>G(?P4;O;AJRYH3%<S=^V0W7W68,,S:/P
MUT/Q^#^&K>5JPX*W1?P^_!"S9ZFDO7 Q-_VT7X;[K4U/IJ[EOY[K1>+KN;QC
M/R:(:A'3A,,H0M16VHLA3U,,S7C.*16Y$)'7&81^X8Y-+&Q\]B]51+VMZ;FX
MGY>!]C=S<"V,[_4\LS'+X,N[FS!U70/UN9M_,9Z>[%GI'&JZ;NVU=;LKB\'&
MY"NP-AJ\69O]DUV9LY:#ANGK,J_]UW0-VTD]5W0-!'84]5S#$N]:S35PJQ=\
MJ;;;D)\7JV^*R>GL9;O25/I#*,4ZP@C#7,7&C<11 HG.--2(I4G*<L:X5SX3
MQW;']NVH9&>+&QC@H$8.&LNF7;827;O"XTL0EN!!)/UB;KO)L3M3(775H=7A
M!=*=BJ-*YW%[-\FZF4NEI_/I2GTRNBEOYBOS%DWML\M)="6DT_G]KXN%_',Z
MFYDI<*(YY@1F*(DA$BB%A*;(UDM#+"=YI(7T6^;RA3"^%;"M!; T 6QM )41
M?N+EW2EN*M8GT3W+V7F&P9L-?K V(. AWZ[<!1(X[^8'5;JNY.Q+7N?GA"FR
MUIBQOC<XQ'0U45'$M$P8S'7.H!$X!4F6<2A8K-(\RP6-A9_:G6]T?/JVJ3&F
M@A1@.\*SFX"%Y:YGR3HLS/:FN212 PXH4>[L]%2Q[4B#KUJ][30!YRJYM=S9
MU<VRD]1-4/Y;9EX5H6X?E%J9F>>UE%,;1<9FVS*2Q=L7\Y>G1<%FORX7ST^%
M>42E?O::\L3>LY)?GNK#>D4UL40QSR.204Z0F5@F.H8<J13&2FJ4R!@3JGPF
MEL/ 'MN\=&T *"T G\VEG>:@ W6ZJ_,WMJ[L.[3"OQ<[>(5#DAK,EQP$], >
MZ) =<>BW#MIZQZ@5(>PYHN*;$FKZW2X??%:K>I-\(B1+2)9SB!63$&5$0B8)
M@E)*FPXGTU@PS^"5EN;&Y^&NT8+E!NX56"V9-'_,;'H$-ILM_K2]6H!_2Y(4
MO#'#*KXR/Z?1:1?.OQ\< U\"<=MW_,N:U&\-4IDVGW!PO::SS)3S;JG,$ %V
M#7\3+1,P1,:!K5"1,FU-#1LPXV#T0=R,RST=CWR+!R6?9^J+_GAZ?E\=:<9,
MBARE"D9I1NT)4@498BDD@G&>XD@+OZ-5[DV/S0]=([=Q]A_;%[^X7=3_EQU*
M9<J$;D?+W?O(3:;Z8;[OJ!]WTL.?6?<F+-1Y=O>&ASWK[DW(P3EX_R=T4[C?
M;^^699#8BW'Y?ET8MV5N?<$ZORZ7,M)9GD*<Z@@B;'YB.D]@)DBN,YID/"<^
MHM;:VMAT[/>?;W\&!N1_KCJG-&UGUTV.@G'6LP+]?@O60,MPF2W4'O*T.Y$2
M2&7:VQI46)S,WM<2MYLNS(EC#[>O7C:!*]423RII0@1.H&(V419/"23$^$18
M1U(GB129<#HXY-3:V.2CPK@--BLNRY=UE&!'AR84;3TKB#=CW;/KM#$1.MG.
MT;9>)_=.F]DG4_&TWN1?#N+OTV*Z*;(FC!,1)V;6E!*50"2Q@$2F$J*889;'
M2J78R<'8?_#8Q*#"YE[K8(>D]E%^B>D]#^@*5H=2#SOFNQ=YZ$K#0.4=*GAA
MZSH<,[FEHL/.Y8/5<C@&LEG%X>B_=W-([NSBITU-51=QGV1FPH)))F'"4693
M$S/(L4WO12C*A,[C7'FE)MYO8&Q*L\7GYV@<$.?F6UQ"1\_JLX76PP3DE-V!
MG(>#QP_J+YPR;M]%.'F=_V'%;76^=ZQ0=^8!=>%'SD3*,HQ@1G)LYA!40BYY
M!+E(-6=,()HX!9VW-3*V,=RH$FF! HO4_0#C22K;1W0H@GH>U?O<A*N?Z4+
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MS#*:(D25K<P00<2$AC3.&,22:8YEE%/J)']GVAF; FY@@C5./S_J%)UNWE,
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M:Z,?TFK(QQF[GQ"1,ZEB!O,848B4UI 0@HW?D"E$N4Y0Y)2&[N#)8QO9&W#
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M^?PKN'YW=_/WF[N;#[=^RN31#V[ZU ^[/:N4 5W%!JQA _X"WECD8#K_"6S
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M!H> >V@FJI&^5< (71]? R,V:.5N?Z; NV%PM?<WA\!W)'=T^T8?OL.GW]]
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MY-SEP]\SWM26]+8+5Y6BN%_Y_=?5\N5YMGB\VJW=:6PQ</WDT42H;RKL#(2
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MB_HLGOVT%P*E@7FODO!O8!\<#^H[BY(]]X5 :R3R\T3-B?_ZX.@@P+.WCL:
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M(P&1(AEDN2A@1'*9Y3E7C!5N'IV'%-/S^.J@*KT<9ULI':OG>$R&'<L-#/#
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M_?[SW<]@);^9H?1_6V$!W>C@&O3N-SV6WNCPH _MEVXT +4*^N4'1@GP8K0
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M<D5-7<\Z'_]!)$*3FOX@))EVHQ'!.<1,29@RG')JVN"D[&$A'TU4O.U>E\W
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MK6MQ4C]1IG=NMA6]*3, _IJMOX+91D$PUQJ6_^%:?<!SJNQ\JC'@'YBFMRK
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M*"/(1(]+A2'*-!$0$NN_21J9NL2%(LBI"-;A"%.C@;H,UH???OO]DT\AK",
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M%BF#B/,"4A7%,%))PCC-,H:=FHI:CSPU:V-/\,KU;$0'6]F=/03W^; ]I!D
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M:",S>&-F#,31^4(>ET^+G=$7'.J1HK4;L<U&>B,>V$J^26HQTK>_%P';LWF
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M"LJQ&71JW%'+#"NAP5;J)@X-_&$$!Y7DCH?L5C-@N5L1&->AMRT"0.J^>^&
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M.K"ZB'5-A>HZ5TUM5ET:MGE1=BYZGV_H<KUY*?C>LPKE,XF#. ,^5>,'?(P
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M<;%CX28E[7& ?<ON(ZUB]QFXPZ]EQ]];<5M(?UVN^#[_EC.^8IN%( F*>(1
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MDC_][2^[W\C_J*:G?_O+_P-02P,$%     @ T8']5&O1?*,*KP  Y+ ' !0
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MP/_,O^'"77*1DK6$5@^.,0%*:4MNN;+@423A2I#2B5U \,#G[X0"]110T$*
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M0.8<0;'H(,@D( E#@7)0D?OF+VWV(;#'AM![0>(NR ;33A?@>\1=\#%AL%E
M*2Z3YV@B!,$1I'=1).2)&.TKK3_NV^5C3%DC-71P3W0KSTRNQYOE1G1Y$UC_
MALO-T,*)M]);S6H_2&]KW1H%V"5Z\)EY+I-W/K;NS;(#66.?EFT0\'#:OXDZ
MNC!:]Z9@/CM??UPLI__ /$&/7)C@0&=!NY 5!H%1W,UREAJ)+;+9PV'K+CEC
MFZVA,764^/O$TNO5ZIP8R2EKP9"#U)61$"*XA ZPF#H$S]&OK9-A#Y#2;=Z^
M*88.$'L7^/DF?WS!RB0+1&E"!J;)EBK4G@3##/F;R$OA01?9^GS;0D:WZ?IC
M<'.LN!MB9ICDT[6KN5J4JTNM(]-.6S^R9<+I^S0W2C5=7!]?+W>-*"6=T3%9
M<,X3HG@=I**% ,)2<C&2#Y-:W[<^0,KQE\N?<7Z./]%^JN5B]2/_-EU_?'&^
M6M-RR^O&G370I?]RO4%'2RRB-732%D_AK940"AV\)G&CF T,1>M [0 RQW6O
M6R#G_MWSL+H:,9JK[0#>A5GM K#AL38(K24;%#,D$M_[Q>:;$Y>]EY8[4%[2
M:5W(DCLN'44.+KO B\'BOV.H=EMI7#^Z)7@&D&P74?]J_:9L>*G70[C\/$VX
M>D?'_\3[D%54M4=U%%#+RB DG4!8E64LZ+EI'^P_1,VXOO001JB1Y$>V-;>X
MJ*3?V0P4-CI>!Z.98LAHROJVGY4 )DC!"TN2A+>#F7ETD7&]Y=86IIT\.S N
MFSD@ORT79;J>6)]2+"2+S&K?6%>?A<G(2#ZHG6929MO:U[FU_+B%)D.8CT-E
M.V*I2,7W+;+O8-M$G6+*!8Q(=' :Y!"X-G1P"E5J<WN;Y ZVXL$%QGTVU]I.
MM)%C!W5#[W!3]O07G.,RS.I<EGPVG4^K>-;3SW@YQ6SBDLE6V5#?*-<CD1@*
M0GNR?#Q[F3CYYKRQ^=B-LG$?U0UA60;0R-@!T4X<W=U'-I82' -ME :E7*PB
MK'?#]'>; @^^[&"/#EE[W =VS8.FH:7?@:?SEE1$!-0)U"\I/)PM-H-_+EF[
MR2>D_SR?;AJ$D.4F9W]5O;V)U2%SI.WC4JP37$2H6=4,W"KN;#3D\K?/ AU,
M[KC/](;)!IU&=R,;P2/8O+,W@PC9"W(R%>-D^36S$+DPP'*(61KNN(L[6,9F
M!(U<QMO:7HZCJ&Z-Z#6#DQ(T*W4DJ;&Y3C@- 2+SL<ZRX$;JS+QN?;/['9)V
M0]X3RXVW4T*7%N^:E3N;143KHC86I+<4-VD4%$37M_W%%)LC*R*;@ZW: XON
MAI\GDQX?3N =6*<ZGGVUOF"HBNWZH4[P2.:4Q!.],J"BIUA;&P=2!Y-*=B6F
MULTY'J)E-SP]J31Y$[&//YFU;H^'6+F;Y/5D1K6KQW0BQ@)C$'Q&2$J3DYE"
M=B;L8(AV6VTWQ#R9]/D (N["]%QP<95Z$47SB$Z 9)R#<BJ#]P:A/HM6!/\L
ML/7-W!T2=H/-DTJH'R/DD1V=.Z3? 3LG@JTD/TV[4IN-LE -92+$<Y^BUU+?
M[6GP@#UY9)'=\/!DLNOM!-J!]=@T\_AU,:_3J<-Z\\2X2NL*YS65ECDCA][E
M0-Q$.D=]8'2.<L4Y5Q%SZ[X]CU.T&Y:>5$J]H0KZ<&6N&'JSE:$[^R4G(;B+
M#(JM(ZH-\^"R3V +_9DGE4SA.QB@?=;<#4-/)H4^F+@[,$\4-*Z7YVE]OB2^
M7GP,RP_$@S*QT&$KP<C:^@69@,"X!I%S4:F@T6J 5,\].G:#T5/+=A\G[O&3
M.C?TIPW]GR[POUZL+IQ[(Q7&J*#$VM! E0A><@%%$H<QL8AQQT3.XPOM5MKX
ME-+.#07;@6&Y:5EV5>@[G9\3;Y=&=#%?/<>R6.*MYM6OOI ,27/3>5A^?4V"
M73W0G,5)G92OU<#HR<867\ KS\ *K3D=VRF+UET1!F1G-R0_J31V+\H?N=SJ
M #%L9_JNCR&S4UQ+\"76*F>R!Z%H!R*RC-%;6XS8P<8.1-YN>'XR:?4>E-A!
MI=@U>Y=N[W.<8ZU^5)EG$XJ!+&0M%<'*D*W^+N/1EIAD;%T:]@ IN^'NB:7?
MCQ?ZZ-FQK2S<O2MGH7#C232F-H'0DAB*1D'.&HUR,DFY2[G73HOMAI,GE'1O
M+> .O,=?<7UC=R?"&VNSY$"!D "5782@R?_5WFEMK6$FM[[C^X: W1#SI/+M
MAPMX9)_JFO!OVSA>]&N[ WH4TB9M239"A#I8KD#M)00N>>$,+TZY71[ [+'D
M;DAY,IGXH83=@3]S]>#ZJIW+M:PB4X63@007ZK-X7TJ-LRTPJ4406J++K3NA
M/$3+;FAZ4KGX)F+OHH/%74Z>A]4T3=!'AB&1_0RJ;@6+X)T1D ,F']"ZF%N/
M$]U*R+C/QMMH^3O0V5_@'3@V=YEX.9V=KS%/8D3TF5QX+(H$HSV'B&)S_5WJ
MNU,C>&L7YP%2QGTS?A+D'"+T#K#S-YQ^^$AT/R,S%C[@K^=G$9=ORD4[ES?G
MZ]4ZS#?%R=<-'"D0# 4YH%3DUC')P%=K;1.G+TN7\MU'?4>#:E\:=T/;D[@J
M/(F:NCCZ=N7PPD+S8+WB7E)PD3THRP4X1I&HL4XPR77*MO5MXEX$CGM4#HN6
M Z&YO^+Z-8^7QOX>CQ,CB^ J*XA"TQXW=4)AX1$24SPF90I+K>OX]B1QW*.X
M!V0V45XS; [?NFS+U*=ON3BJB]FV3Q^JH=EW.6G?1O\R55$G1MY;^QJD6<<2
M0BS LB2CQG2J$XTD&.62%2()EMJW9]Z+Q+:Y4TYVNSAM(7!/_-;''DY[5Q]*
MIDC;1J%HW51__]SI*9KI-T?'XRG5?>1^1%7ANEV1ZG<FSE'P-%W46>.UE22^
MQ(O?KR5G$D?%E*& C$)P%=%#T(Y#DC(DM E-'*20]2BJQ^XS?#IPGEC#';B#
M#W'\TV))OL;\8O1 ^OI^&>8K8J_J?)XW?YMM$/"7,)U7Z5S<[K_%- NKU;1,
M4[CZV?!E$EPH)3(.T:<$RLD ,2L-V@1#YS$6*0<933\P7^,:[5-C=<>M,AIP
M.MY,SSZ'Z:Q>"A&KM4SQ':;SY<6XJ_SW\XNW8-<JVS9^[>(JZ5IO+IN(2G'(
MIF;YDJ"0$U,&SUQT3KO(M3K1?FK,VKA'3:=;:DSX=+RK_CHGT<_J8(!_7\QJ
MN'ME4M[,;TEH.5W1MUYN*H8O='<]'-CZX*0HAB)Q7T %9\C.& <"4TJ.YR!2
M:Z=_*%[Z/(I&!>Z.F^ND*.IX-U66[YW"UUJJ19W/WKQX3:=[K6-X4VYD<RT(
MC=H'Y0-(Y(9B.5W (R;013F22([!G3*V.8J9/L^AI["?3HNC\5\:[B*/:[U=
MLOV8WB::>X6U0@C)^24/PG!P*@C(,DN6HG0EGLJYVY?V<1M@/_5=,QA*.J@C
M>XCOEUBF<\Q7U;@S"@\/4XH2VND4$ABO.2@E9>W1PR +CO62VH9PJEW3BJ<^
M=]/(L= H@!GY<<!CJOBM?F$Q#_.\^:G?%L0>KJ?+3<;TMI3J% C2UO*RB7_M
MQ/>"V)A6H2W*L[,JLG]<HFN;L[O8F)W@C?'U,5D,NI[-)+^8Z( .CNNDM'!J
MIW>K_7#49^ T#LKO/N;O0D%[06Y\=_![PGO8-2Z7KO'.XB5WAH1T%:[>D^FU
M *,T=?(/R4Y;7ON_DAEF3(#GZ&TPT63'CMRSI^>JSP"MZWW;.?3&W[N[N#Z7
M(GKV71%M\=G1$\W%,Q"R3CU(14- Y%"D$B21C$ZT+C0=B)4^7=-1=U]/X#EZ
M*YT@[EM./V]:ZZ_^UWF83<O7S2B[?\?\X283M(NJ&$N*I>1!F.!)+,Z!=_6E
M.&I2GC.>B];EB4/S-.ZPJ&[COA$ TWFZ_D58??QIMOAC(X3OW*<7(JF:D:P+
MT[X$B,K1L2RD 2=,!(Y<!RY]*'>GG0UZ!AW 0J\1VQCXW./L&1HL3W&O/,AX
MJ/U4773 $ZN#5'/-KK(,-CC&0K)8FK]/;$9\KY'14]P?30#R- *;K?QO^'V@
M-JO40;&U0T;,O#[^TAZ<8Q%8<+R^:BC(6S]8:DE_KR',4]PFK6#2\475;?=W
MDDIB*GH.1EE66U$6"$4*X"%(&PK+/K3NK+<+7>-"NK<Z[;VTU 'RMK!S4V,4
MF/.5"RQ%@M*TKQVSCLX<+8.2/MKFSU,>(6?< /64.&NEDV;P&N5MW<71\A'7
M9-EGPSZT^W:I$[ZZ>X3'D9[@U<E#9*0TH.>13O"@(3"C0)<@T9 %R[9UMOC$
M3_ >L^+;GA',[EQ;U%W(!:N3YA4PQUSM<RJ S+J'>K?@5>*1_/$3'L4[DOVT
MGOOM@\1]3NHA=-QQ&N+02N,J N=R3D9%8CR1%UVX@/HR!D0T-@:5T,53!5M'
ML/&T'A(. ?M38:#C;;#715CE6VD>F=<:-*N/P$)&\"@04)#WI>B+A9VR('8?
MVI]61#:4G1],VYVC?/=<265<H.!)TBEGA36TO6.F.$74GM>.%:6S+IWFTYY<
M1#@4SH?3]Q/JS?+J/\^GZZ\-H\3+#QPJ%MQ&;_N([]UZD7[_2$<^Z>-BQ9MB
M$Z>"YJ*^;]$"5)0%8O0(LD@N76 J-Y]MMA-AQUK&ZT7>UP3U1",Y+%HCE.AJ
M%T$G(<22@'M$7F(,WK8NU/B6@FYBKD98N&N9CI!W!^?H-?47$JD6=C&O._39
ME^F*(D"2BA0,C$JU9Y8O$) CY"C)3F)6VK<^&Q\EJ!,L':#IAT!SM-@[P- =
M'EXNSN@,GKB,3#*?R:%D=-H'K< ;%\!Y5BPW@7AIG3O?2D@GF#E>T7?;QAXM
M]0Z@\Q;7H=:.7O7 _05K9[V)]E*[*!DX4]LF:Z4@,L,ABFA]YMJZT'[$WS9*
M1FY4?;R*[TWX.UK>':#F64KG9^>SZE(^%!=<,A:\(2FQ "4@V6B4%D(FDVVB
MD3QQ':UH[>3M3-S(K:R;8VL8K70 -V+D;#'?N(^7#/C"M"U>PV9$EF+<@I?9
M@<DL! Q6V^9M&N\1,6Z.JSU\CI-R!S!Y7ZNQSY=?;[.@?,D"-0,E,_UB. <O
MB 7-D[/)%\Y+ZQSJ%C+&31.UA\JQDNX +-=^X<]T'&\&2DZ"+L$6:Z'8S8@:
MC."U%\!DT=[+5'L*#Q5L75/1R551PPCK, %W 9&[^0HZ1&?G]?9J:R7B Q-)
M P48&H4&+>K&*$'3'N,&8G&H,++ L/7+@S:4=Q*X'8B?>W \N3(/AO"GS=4G
M"6#9IG_OMZV'9; ,#<6\&)%8B'2J!U\B_>*24Y)'KUM/L#I@7-X3@=7AHNW
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MA8U'-WHX08+OR7GS!RFT*W!N>1#JK48ZU3/PQ LHM(HV,=/$5=:%I<U(^<'
M^:1Z2.RE]7UZ2.RC@@[@],A+<M*TRHG7,7F*1!0%J[-#"YWX,;$ZO\67UOW
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M%^TMWR^>X_MEF*\N&)L($9F-+@%Y\R29P*KS1W]5/@2+%.]Q'.X$&):WCJ]
M6A\9'8'DJ;SEOA'>ZGF8A7G"=Q\1;V*CMN^Y=UQMD#?=AW!ZBG?=T3OIL03
M: (HZPQX&0A?A'J>1'+*#C9.=]!WW1=1BN1%.NL],"X*J*AITVART43V/%EE
MF&_>:/<."1V_D-Y']P^;O?T%W8$'O&T/7EP]QL089QQ"QEI76AL6"G+G)3IN
MD(=27&O /$1++]'6 0I>#"#M3E%SF;^S);&"$8$%2SN(W :(S F0GK81IXBP
M?4+J86K&14X;;>\ H0-$WP&(:EO"JXDPUWG\XHLQ&JQ!XD!F6V\1 QCEG2H8
M*&!J;73N4]$?: [1[Y8>D$<(NP.X7.9L7^)J^F%^LY>\,T9R+(#:DCDVIG(A
M TB1N(@D&E9:OV7:3DDO>9'C3ZD&DNX2+Y?;"%%Z(:,!XQ7A7G,)L60-0FKR
M\T**Y.X-CI@>SJ<6>OXN= X0>@?@N6( \[/5)4\W68TK^^EU4=HQX+86(6N/
M-0_A0#+'BS?>BM#^ZNV[9/4&J4/T?W](1%-E=(&O^RT/=?%9>H90!*M>H26O
M4'(%.B1;F#:BV-8/*0^=^G:"/.7QQ]BQ,NX*)C=MF,MMOD*<SJ;KKQ,CK.*\
MI/I>P=<,!@.7K(88T7-FG/*Q?1O1W6CK)7H_$ 0/@JJA1KJXY-F,-LG7#'S3
M(.C6B*B[UUR3'%C,H@00=7<JR0-$I-BV."^E+E92L#* .W4 J;UXZ&V0> I]
M/97KDW?I(^;S&2[*JU(PK6]WC%W-%^L;#R+<]R!6K;OE-B%FF(:Z[>5TBKN9
M%),U(GK0ILZ6]K178I &")&*"?IN:5Y%\5^DYRX+!4U4O)X]"11GK!;&6MKL
M63-6.!/-G[S_=\_=/1$[8L_=?>#1@3O\0,)")>5,K$^_3:FM>70&QT4"1[*G
M;Y6,.'Q"IZ>+JKYPLUMV<1\E=@G%RT1'#"@<5XGVN]*T\R7Y_=Y%2 ZM-5&@
M9,/GHSO.+NZEYUVSB_L(O0/P_+H@C^G*T[IZ<1F"RLDD2,P'$@Y1'Z-",,XR
MQU!PT7SFYQ8R>H/,(?J]V^_A2&%W@)='6]29HEB((H*,V8$2.4&=CP(R&\&0
M_(SB6W=Z^.].DT>>@<T4VA4XMS1J2<BX3[4_K!:T<>NL+R^T!&0IRH(8HFP]
M+?2)=IK<2^O[=)K<1P4=P.GQWG0Y9T[>@R''H?:FTRE#+$F!+Y:99%30V+Q*
M\^@&@>/TF]Q+[WLU"-Q'"5VDMA]ML9)KV8PIM-M2;5SP_['WKMM-)<FZZ*N<
M%XA:>;^,<?ZXP%7%V10PL.E>:_WQR$LD:+>16)),%_WT.U*V?)7-E)13<ZK/
M[M%% 04YX_)E9$1D9 1G$%(@63F,,<?(O6UMH?YOHZ3]3L]6ZAR!M7OY+31Y
MJ28&[T&4Q&D+9TY[S''0O*"523A4K=NA'FNCI&W4OE6CI&UT,.*>$XF1P58F
M@RY!$!M1U5?*)"JK4Q&>N_082KWTG!BH+=)62NS8<V(;B8[ TG1\ ::*5^BY
M@;@:E,F5HSV44JW303K?M<S-6VO]WWX"O<:5>RIY5-!=L_)^>O=[M",OM!,^
M9FU!8]V!N>83/0E.8'$R4@"5;.N#\J=$C24T:(>$9\'60BW'6VKPI*$L]E]1
M\,(W#U0XT)7K0]0'2.XS5FL9>;*@$",=[ZS6M0@K=7"B?9;IWZ0^(&CK#%,2
M&&.JSGOSX&,@GR8Y+J1)G&5QR./^_R_U =L@=L#Z@&W@,2I'84."U3J.=)PQ
MD*%0#, K+\9'L%KQ5"N+N>RO1';'>Y)_AUJ!K3"TS3W)-@H=%3@W)&L=[?E@
M.!$O8\U?L *1%0&&8;%HDLJVO^?Y1W5/LI76M[DGV48%(X!3Y]DJTD>3:KV%
MT/659V3@C+,@I?4F,)N2:7W"MQQZ,\S=R598V'7HS1:*&0'>7LJ^&J]BX0(I
MSO,(*J$!GVT$[5E :WSPMO48\'WO4/X=*A#V.5E;J7.\R+S9RD;'ZD[7(MS:
M:X&S.M':"^#((L]*2V?^[[")[=6^U1W*-CH8\1V*SUE&C Y8Y4!Y20+23M3F
M?2E:GF2)_"&4_IWN4+928L<[E&TD.HI*@HYI50PF9Y7(%'L=;_R'Y#,(+YFW
M6C#/#Q%K[GB+\N]07] ZZMQ3R2,X)GMK:SK-M:EI*;*$Q!WDZ%SM&H'@=/5I
ME:[M]YE6H749:K\<C24\:8?!0_6YW1X0(]@>!VM?2F=>LB)'D*I>N;F$]0%$
M 5Y$82S$:&/K8&E4/6Z';@V]SY89)4B.YN;TZNO7,/\Q*R>))#A9_E@=])B7
ML]/_N:)?WETG-K\_W?[+_=RB[BF!0]RE,I^9B!(!A2#'B94"7F0/!,'D-.=2
MLM8OAON\2[V)/M9R?3=;?L20)Y<__@SS?Y",R5>\=ABC%"@M*DC.6PIOK -7
M/.TX+I3W26LC6^=)N](VXGO,;="RT?]HK9H1>!*W OOUQ\EB@<M7]52XKE(E
M^I&I!)R%VA-&Y-K-J'(C*4HI1KND^]I;CXD9%E3]Z/[Q*X8FBA@3HE9L+&Z.
ME/Q^2B['U7Q.,?.O83%9?)K.X@+GWZO@WDR_72WKB)9IFEQ.;D+F.RFLYVBK
MR$U]%!(8C[5)46U$JQ"RRB&Q&)#YWHQ]8UY&8B3W@]IS !Y2[R/ _[5W=%:9
MGBPGMS-';8[%2Z6@:(&@BDX0A&'@I<DI:2NLYXW1NYF2D6!O4)3,FJML!,#K
M<$RM-KGT7KM"\HE1TB:O[S8CUXSPH[-T2=F06[=N[$C:L"'Y08[Y/I1T'-A[
M%[[>OO9DFFL="KC5 RC/- 19&X1''4+,J!-O?<VY%8&C=S>WA\CV,-Q17P-?
MB3[)3?QSLOQRP]MKI&]\G4PK=S?ICI6=EQA9L2H">E7?%6B*"[F78!CCQ?$8
MK'M4D;WQJG2'3X\>:+N"8'8XC8P1<+.KY4\X=#'Z>K4'*)VBS5LX.%,\^2RT
MA[,IV8BX*^9^^O71G[-]P:ZM7H[CW+V[3'"RF!)D(+^%.%)H"T25 @@OG-/9
M"Y;2X8_=D5SWC\7[VTU=(S."'V>7E[_-YO\,\WQ!P1)7VFJ0D@M04B,$5!E*
M%"JF6CSCNPR)?^$3HS]%=]3I"]9L5P&/P&3=B>4NX'Y'L?VJ"'EYH:ROPSLY
MH"$KK&1RM1.,@V B<S8'$5SK:J27*1H&74V5/NM- SOCZ1O.)[-\M@SS92]9
MM[\_>]K?9:!6E]D7UN9LO.:09&T0Y'* X*NO:4)U0U/6N?6IN#.QPSAN?6+Q
M,'H;&4SO6+DM1+HP3@I>)\'DF"6Y%5Q#]+D <P6#3-E&T3HK]RPQPWAB_<-L
M7[F/S,M:/*YN*ZLB'OI3BTE5UEFXQ-=7-:?^807CBY2412$1K'*T98HTX!CS
M8 ,YL%P6F[S>P17;EHYANJ/T :^#:V7\_AM/DL)G<FZ=]"1&]*F.)T;@%$MC
MD3QIUKILH('_IH\!;3UH8,^#\72:!_;>/!8?F1* V2&H>FWMB_<@5= 2Z:>Z
M>5% O]Z;.28D'D9O(P'I*M"_OK:^M]NB$;7^50#SSH"*+! C48 51:CLM#6F
M=3N7C81T I<])G#M+^]C*3;^C?;(-$W"Y36W87H[*8OV5%C>%36VK33>]K.]
ME!GOQ?LA:HR=T]J&;"G.K$\)?4@03; @)$=,TN>DCJG&^';M>\]F%IOF>-]_
MM':_Z\#MT[=[DP^N,^-8"OFL1M:!EX%LNJ]-G L#4<CC8+FHI)OWN^Z-FY&4
M2>V+R&>K](95_PCBF$U,K^HJ2D&6M3*@BV.@;([@0C20G?=1!!M#;OTX\#E:
M1@+"@;$RZT%Q(P7@>H1,3+%X<ILRK^WPF:N7WNC!H)?)<R>+:WWF/$_-L"!L
MH^T.$-I!]", T<I)OG./[_E.ZZX%@H<D- /FZF&1@X.@LX(22A E6.%L+Y?^
M+] T/D#MHOM-T4HK18P%6*^>8R9:D9F2$5C*&91(BEP0)@%+*I)K+%:TKF9_
MD:!A*YKZA%03%8P 3V]GT\_G./_Z&N.ZH8K4.A?G"Q1%QELQLN6T20P$EVAC
M\"*8:0VBIU0,6W74$W+V%/8(X/+KU6(RQ<7BWL7)=4?%Q 6W0H(U3H*B@QX\
MREJN1XZCUL4+U?J:]!E2AC4Y8_7-&ZAMI.BK/YWCNBPU2Q'0D?5U7B=0(5,,
MK@H=Z<AHWP;%36Y=IO13H@;VJUJHO@.<=M?#P-?W)U?SR>(/#)?++[?%QAB%
M475XGJR7(%ASV3;0$2YX1$[!C>MR'_]DX?$!80^ES5I)< 1VY>Z2I)K@U?8(
MUJ>@ZQV8C'5[* Z>O@R*(H20K-*,M38D3ZD8U@D:Z5FVI[)&![=788F?9_/)
MOU;RN=E C$=O/&W%((RO?33K4P=.440J2I=$_ZVTG]KV,ZJ&[BRYG]Y?A-'>
M2A@!K)Y[+FV,X#Q3P%)HAZE(9[QCV8&QTD?MO9:A]3#Y,;YP;ZWOCF_5MQ#^
M""#T8M?\DAA3WC*@P[V0T=8"?!W'9 ,6);T4Y%(V!M+>PR]Z&^8VTL.QF0)'
M!<8-W?7KNS^?+:=XA6(8)8*$*&("IJR1V6=OF[?:.M)A%UMI?9MA%]NH8 1P
M>F&,@F4^$0\DG2 -*",4>%]YBMX'PZQ@)33WMHYPI,56&G_B;S41_PB ]/)@
M\RB"9I9"9TG[BSA*"-$Y P6YE 69SLT?C.P_7?X _50;PZF=$D;1$[[KP)=@
M%3-&&<@B*&*,DS'GR,!%P= IU"*TGO'4<A+/ ;K"-\99'XH9!>+N=9N[_>D?
M$YP365]^O,7O>+GR'FI;8V-+ M25+Q\\!%4$)#1.Y<(D]ZWK%+I1-LS[D9&[
M_STH=5Q@?5"B_(3#]16M]L+7[MS%*EW'NR6(.M4\-BH4GM/N;.W.;47@2,H'
M&V+D.1@V5]>XT+AJ@;A8R8S?G -)%)F0HJUD H)"9FGWA@2%L2)MEH;W5Y;^
ME)R1(*T]#)X#W)X:&2V\Q TS.884C"'Y1(KCE:<XGB(D!2[[%%QTUK#6.;@7
MR!E)K<4@\-I%(Z.%E[QAAL=2A-6%/.44:ILM3WSP ,PBY\&Z8G)OS<6?DC.2
MZ\]!X+6+1D8!K^WG<UU?Y1DNN0P.?-1DI9TCT<6,P*734N4@LVM]2[4;I<.\
M%AYYW'$ I8\@\;>!C?5<0Q&=1*'K%"!?A_%F"#9)2)89[GRTQ;1^F_0L,6/)
M'_>'A%D?:AD!ONX.EVN.UD> +):\"0XZ*P?*,@&.CA2P441-_P%3\PO\S90,
MBZQ&:G[N[-U=YB- SKW#X):AM[?=#8W5"CER2-F6VMV0@_.*0OFD*3*20DO3
M.FG\(D'#]$0XFB-T7Q6."H]WI\!UIX#;U]+*2*%"=)"47.67)$1' ;HO*KA@
M)6K6NL+MYU2-Y>S<&P(=_+,]]#'>0./-M.Y-7%QWK3BYZU-QH3BWT>C*GZ*]
M*64"KW0"69+-,0D?S4%&9CY+X5BPUP8A70*$-LH:/QCO/1*\SV24PN02,Z@4
MZG!;[2$$\GF=*"4Y&77 0UC GY YEOJ!P\.R@=I&@<V;4HGU)?9&GM_-EFMO
M!O/)XL;!N?<'5GOTOAA$S)G$K,C#28(B-K3@5#V8M$HB>1EY\P*\7A@92]U"
M+_@>7O7_/CM@;0Y^W!<%"\(4A@@A:4,6H42(@DG@QJ94&Y\5;!Z;]\7,L 75
MQ[ 3]H; *';#XZ<*OWU_-[FPV4I=JX2#4'4GYP(A%@599\MUBB5PU_,KD4K'
ML%4]/6-P;\&/(+(_^4[26'4.G<UKR^0[;FI3@[M?7?B@C;.E0$W?5E\I0&1&
M@1;6"]1.I.8-;KK2-NP53L\@ZT5!(P#>^OGRJ]G7.+E.NM6D'!EHDA_];#$A
MM87KQI<W5OI":5&8)!^%!TR@8A5A]@8"!G1)!\9%Z]-Y!S*'38?V#,>^U38"
M9-Y)\-8I>%_N?G/E/E]H$6OW[P(\6_(2L&APAJR^\%D:ZZW+K/7YVH6NL43W
M_24\&^ED5#A;D7_+V.^U1/UN]T1'XJG)LAA8;6A&K$45([@8C+4^%4RM'Z!T
MHVPLD79_6&NFE^W1YJ_1-L7/-7@Y[PMTBPN!T7);!$3O*/@WS->^,0%\K,VK
MZ!\,K4L='M,PED"U9R!M)^O=#=1L&2X/<1#>.^!%(+>A6)"ZD.$M@<YVG4H=
M999)8EI%T[K,L"MM8PE #WP@[J:;41V*MRP\-,#71[W)/.MB/:28';F4#B&6
M+( LKPF>-I).K<=!=*-L++%H?WAKII<Q'HKW[H@N/!,AH740LR=Q&:2 NB")
M2\AD4HPBR_Y*6.\1,I9XLG](;2OU$9R1FZK*ZWB>3]-97.#\>\W<7)>!?\0T
MFR9B\[K<[6/-W-3Q9+^&Q>3.K;S.06.R2EF;0;O:S$\D!E%:":F8'$22T8;F
MEW%],-()NN[XH#N\U@<?M5D;!6X2PS\[B.&A%%ZM7OR_F9XNEI.OU;#?W<5P
M@XYE5:]A2 XJU5Y.1FC@BF)ZEAQ[,G9L8^?&ONGL!'-_/# ?G6Y'X)CNNN6?
MV?$?KN;I2UC0@2>X"<:8.IBM!H4Z"@A8_2:?2U8J.-F\U7)?O'0K>6/'LQ%&
MI?Q_OTUPALOEY?5#O L;..>,7#ZMT8)RD62BA05F0Q*N,)7<(1[YM^&FVT8X
MPL+CD0!@/*%C/YY@+BP6I2W(E#C)PI.*5%"0$^>AN!!\\VF7P_G__ COHX97
M>]-IK3T/WGP5%E_J/[5@YGNXK+\5IGG3?.7&HS>W_W OPS?WY/\0XS=%U%PE
M52^R5'5$M(; K 9MN'',,Y%<;QF''L9OGJ4OF*\N\7VI<C^9YD?BOW[?Q;2)
M5GD-C$(.4,Q&.G*2A3KRC(X<F9UK/4FS$V$C:?.R+TX>&\WV2AF!2_QF6F;S
MKS</#&_:4/^H5S&WQ5D_KN=S1,<%BP&8$20XOGI+6)^A"HV>)66-;GW/VI&T
M8='6 RB>="IMKZ$1 &\UMNS\2YB>X]=OLWF8_WCS]1MMW7KBO")R)LOZ1!]7
M#LCGZ>1?F-],3\-\2K['8MTN'1?ORUTC]<7-^VME63(E2/ \W/3!<48RX!I=
MB<X)M*TO/GIC9N@F]3U ;]/XNL%Q,((-\0=>YB51OES)]4GK_ER440D+%%ZO
M)IVE^%+:.A<@A5Q2R2ZW/NQ?IFA8:(X$-D]Z?S33X0@0>5N[359@\:!V^X8?
MA3(XQRCZ='5"A7"K$%0!RUK*Y!VWV-HI^!E-PU:0CA.53?4X EQN&KU#AXY0
M+$#(J[O'X" F9R%$F;-VGDDSDOE8O6'O$)[H7G(?'7(V3MTARRQ16 Y6.K+1
MWF9P)0>P7!06BLO%M\Y='N.HJVWTOOVHJVV4, )8U9VV'C6(*%W=6AEE/=B5
M!8\Z0E$>F4I<ZM#:3;O[^IA@LK]>'[>^WTW((X#'V>P[KI[[/GSRMFX('&H=
M@44P@B50ACCRR9-,@LFUM4/6L7D6[R6"ACW%>@91.U6, 5>W]+^=A2GF]_.S
MV67^-"4-G7R>XW7R_GSV$;_=7-C?L$EG/6IGZ_R1B!2NBPBQZ$(_6)N*T3ZI
MUEV;=R1UV#<Z?6/Q .H; 4I?S>8U%%KBQBV7@PE&2@.8M:4M9S)$(TF /O#@
M0BPN-9\@\Q)!PS[FZ?L(;::*$>#JS]D4?UQ?0OYV-<UK+F0Q FN73!8C U7K
MDB+7#J3/M&\XL]*WSOYNIF38ISL](ZF!\$< H5_#]!_GDZ^T';[-%I/E[914
M7E FGBF:,1&4\J*^ LE0G%)U[FHRHG4MUV9*AGV-TS.$&@A_!!#Z='8^7Y5*
M_#B9YM^K=SFM$KM-K#&1E<Z@ ]:C6@GP(FM(.FAIG3,^MBY+>)&@8=_B] RH
M=JH8 :XVY_#>WE9_:?2A&%L[E+L: M.)'9UF8+Q,(<1D>7,?_B<D#>NK]Y_]
M;*F1$0"L7E6=S_Y\<E7UZC(L%I,RP7Q;-).SXJSF^71"7?M((]11]R"<84P%
M50)KG5SO3MVP.:^FH-APF=B#AD:,O8OLI1&9J,>@ZO[D"59M[T.R5AOE!&>M
M'Y,\1\O0TP7ZT7U'B&VEB!$\8WV.CY.4KKY>7=::^4_3^>VEZQ^SRSR9?JYW
ML1>&\R(CMR H= &56007+ ,4+J%1)2.V3D#L3NVPN=F!0=E8F?L^PN@5N'?O
M#&N3,SHD)!2*I"FD-N019V$AJ$#<8M:Q^?30GQ(UK*LW, QW4\T(3MWG6S'>
MRHNLOBX490,K@LR^YX'<%70D+]3"D P+;QU5_)RJ88U>GQY>8XV,$&,/$\TG
M7V?S9;79KV:+Y>H%T86UB2)P5_O=<05*!0DA&%D;2R7CLD;'6\<6V](XK"?8
M&B,_@6!3A8W ,_P)?W<NQ:H+4/4KPF5E>#4?KA;,X7GXZZ)H%07+=>9TG:2D
MA(+@+)TC.45RBY,AW@^+TFZ$#VLZAX5N#ZH=A<O8N:,RBY%'H1"$( $KU!YB
M[5#A>(I!,BMMZ!NT>[6\[LV!/# NFRAH%*WZ'^VP1WR2E_309[Z5)D>F<J:(
M3'CIH'9IAL H2L,@T7+NHFE>%+<CJ<,"LT]?\Q"Z&X$#NEF$)\M783[_,9E^
MOH[<0N92.AL H\QUR@$%;2*:&A<6IFO_6]7Z7JX384,/73L 1#K=JNRCKQ&
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MEZ'V#8?@"ZN=P@-JGA1[''L^9Q$V+3]L"_8^#,+>0AP>!_X^"_;6X;71)^5
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M01#V&-Z'5/?8X7VOQ_/+3$LDL4K#*I>R%F:*VNF[@"F:>.<V9]W:D6A"^,!
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M<TV&7A=\\L(8Q0T"(M=UHA=ZB*MW[<9K"C9XDKGUO=VSQ P[/*LO"+61_0A
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ME$^F#LL+X#TW043I(F]])][6Y-SY@!WD6@L@'O4225:@+5I UNAKN0/QCDF
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M$&/D'H&%*&CC!$;1J*M=3;V3WC@AV:-TQN;RYP>KCB+\WD4ULR9R&KIS])=
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MM)80T?A!G:N?7:0?.B82Z'(*[L[ H7FDC]_?-FRN&5->$?U<U5$4QAMPUE(
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M._Q!_27@.O_G?_P_4$L! A0#%     @ T8']5'.?B1.I!P  \B   !X
M         ( !     &$R,#(R,G%E>#,Q,6-E;V-E<G1I9FEC871I+FAT;5!+
M 0(4 Q0    ( -&!_52WF+'1I0<  *,D   >              "  >4'  !A
M,C R,C)Q97@S,3)C9F]C97)T:69I8V%T:2YH=&U02P$"% ,4    " #1@?U4
M2"-W20$&  #7)P  '@              @ '&#P  83(P,C(R<65X,S(Q8V5O
M8V5R=&EF:6-A=&DN:'1M4$L! A0#%     @ T8']5,0+7;'W!0  P"<  !X
M             ( ! Q8  &$R,#(R,G%E>#,R,F-F;V-E<G1I9FEC871I+FAT
M;5!+ 0(4 Q0    ( -&!_52*9@27OSD$ (M:/0 0              "  38<
M  !J;FHM,C R,C W,#,N:'1M4$L! A0#%     @ T8']5/4O3.U#%P  2?H
M !               ( !(U8$ &IN:BTR,#(R,#<P,RYX<V102P$"% ,4
M" #1@?U447O&0$\D  "N9 $ %               @ &4;00 :FYJ+3(P,C(P
M-S S7V-A;"YX;6Q02P$"% ,4    " #1@?U4O7CK^G1\  "T'@4 %
M        @ $5D@0 :FYJ+3(P,C(P-S S7V1E9BYX;6Q02P$"% ,4    " #1
M@?U40%WG14>3  #"J   $P              @ &[#@4 :FYJ+3(P,C(P-S S
M7V<Q+FIP9U!+ 0(4 Q0    ( -&!_53UO+]0C3P  ,Q/   4
M  "  3.B!0!J;FHM,C R,C W,#-?9S$P+FIP9U!+ 0(4 Q0    ( -&!_506
M(<QB-ED  /QO   4              "  ?+>!0!J;FHM,C R,C W,#-?9S$Q
M+FIP9U!+ 0(4 Q0    ( -&!_523+X]! VH  #J!   4              "
M 5HX!@!J;FHM,C R,C W,#-?9S$R+FIP9U!+ 0(4 Q0    ( -&!_51;B/(O
MH5<  -IR   4              "  8^B!@!J;FHM,C R,C W,#-?9S$S+FIP
M9U!+ 0(4 Q0    ( -&!_501LTN-\8$  $Z3   3              "  6+Z
M!@!J;FHM,C R,C W,#-?9S(N:G!G4$L! A0#%     @ T8']5&6B^N>_BP
MC)\  !,              ( !A'P' &IN:BTR,#(R,#<P,U]G,RYJ<&=02P$"
M% ,4    " #1@?U4^N37*6IT  "8A0  $P              @ %T" @ :FYJ
M+3(P,C(P-S S7V<T+FIP9U!+ 0(4 Q0    ( -&!_52*AD_^*$H  #9@   3
M              "  0]]" !J;FHM,C R,C W,#-?9S4N:G!G4$L! A0#%
M  @ T8']5-TZ07&B/0  +5   !,              ( !:,<( &IN:BTR,#(R
M,#<P,U]G-BYJ<&=02P$"% ,4    " #1@?U45A'68PY+  !38@  $P
M        @ $[!0D :FYJ+3(P,C(P-S S7V<W+FIP9U!+ 0(4 Q0    ( -&!
M_505D@+EKCH  "5.   3              "  7I0"0!J;FHM,C R,C W,#-?
M9S@N:G!G4$L! A0#%     @ T8']5,%(&AE"20  MUT  !,
M ( !68L) &IN:BTR,#(R,#<P,U]G.2YJ<&=02P$"% ,4    " #1@?U4HBOC
M>'DR 0#H7 P %               @ ',U D :FYJ+3(P,C(P-S S7VQA8BYX
M;6Q02P$"% ,4    " #1@?U4:]%\HPJO  #DL < %               @ %W
M!PL :FYJ+3(P,C(P-S S7W!R92YX;6Q02P4&     !< %P %!@  L[8+

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
